Compounds > dasatinib
Page last updated: 2024-12-10

dasatinib

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3062316
CHEMBL ID1421
CHEBI ID49375
SCHEMBL ID8226
MeSH IDM0470497

Synonyms (124)

Synonym
n-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
unii-x78ug0a0rn
x78ug0a0rn ,
dasatinib [usan:inn]
HY-10181
c22h26cln7o2s
AB01273956-01
AB01273956-02
sprycel
nsc-732517
dasatinib ,
bms-354825
1n1 ,
D03658
302962-49-8
dasatinib (jan/inn)
n-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
BCB03_000715
NCGC00181129-01
anhydrous dasatinib
dasatinib anhydrous
bms dasatinib
dasatinib (anh.)
dasatinib (anhydrous)
anh. dasatinib
DB01254
5-thiazolecarboxamide, monohydrate
nsc732517
d-3307
sprycel (bristol meyers)
bms354825
5-thiazolecarboxamide, n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-
bms 354825
n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-n-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
chembl1421 ,
cid_3062316
n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide
bdbm13216
dasatinibum
CHEBI:49375 ,
nsc-759877
bms-354825 hydrate
EC-000.2122
FT-0650671
n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
KINOME_3650
n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide
NCGC00181129-02
NCGC00181129-05
NCGC00181129-03
cas-302962-49-8
dtxsid4040979 ,
dtxcid2020979
tox21_112736
nsc759877
BCP9000589
pharmakon1600-01502275
dasatinib (bms-354825) ,
MLS004774145
DASATINIB - BMS-354825
HMS3265C19
HMS3244A06
HMS3265C20
HMS2043N05
HMS3265D19
HMS3244A05
HMS3265D20
HMS3244B05
BCPP000263
302962-49-8 pound not863127-77-9
dasatinib,bms-354825
MLS003915609
smr002529551
CS-0100
S1021
AKOS015902363
AM20080877
5-thiazolecarboxamide, n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-
BRD-K49328571-001-07-7
bms 35482513
gtpl5678
bms 345825
dasatinib [who-dd]
dasatinib [mi]
dasatinib [inn]
MLS006010904
ZBNZXTGUTAYRHI-UHFFFAOYSA-N
SCHEMBL8226
tox21_112736_1
NCGC00181129-06
n-(2-chloro-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]thiazole-5-carboxamide
mfcd11046566
Q-101345
AC-22749
AB01273956_03
EX-A401
GS-6548
SR-00000000554-5
sr-00000000554
HMS3654K05
NCGC00181129-12
SW208076-5
NCGC00181129-07
Q419940
BCP01797
BRD-K49328571-001-05-1
SB17284
n-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl}amino)-1,3-thiazole-5-carboxamide
AR-270/43507994
n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide
HMS3744C11
CCG-264779
NCGC00181129-14
nsc-800087
nsc800087
NCGC00481571-01
NCGC00181129-22
EN300-123025
D5949
PA-3062316
dtxcid50157977
l01xe06
Z1546610486

Research Excerpts

Overview

Dasatinib is a small-molecule kinase inhibitor used for the treatment of imatinib-resistant chronic myelogenous leukemia (CML) Dasatinib has been recently studied for its anti-fibrotic effects in a variety of fibrous diseases.

ExcerptReferenceRelevance
"Dasatinib is a small-molecule kinase inhibitor used for the treatment of imatinib-resistant chronic myelogenous leukemia (CML). "( The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Bennett, KL; Bürckstümmer, T; Colinge, J; Ellmeier, W; Hantschel, O; Kneidinger, M; Rix, U; Schmidt, U; Schütze, G; Superti-Furga, G; Valent, P, 2007)		2.02
"Dasatinib is an orally active nonselective tyrosine kinase inhibitor used to treat certain types of adult leukemia. "( Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.
Clavel, CM; Dyson, PJ; Griffioen, AW; Nowak-Sliwinska, P; Păunescu, E, 2015)		2.14
"Dasatinib is a multitarget inhibitor of many tyrosine kinases has recently studied for its anti-fibrotic effects in a variety of fibrous diseases."( Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt/β-catenin and TGF-β/smads pathways.
Abdelhamid, AM; Zaafan, MA, 2022)		2.89
"Dasatinib is a promising therapy for ORC by correcting autophagy impairment, attenuating lipogenesis, apoptosis and macrophage infiltration by inducing antifibrotic activity."( Enhanced Autophagic Flux, Suppressed Apoptosis and Reduced Macrophage Infiltration by Dasatinib in Kidneys of Obese Mice.
El-Gamal, R; El-Nablaway, M; Elhadidy, MG; Elsayed, HRH; Elshaer, MMA; Hamed, S; Hassan, ATAE; Othman, BH; Rabei, MR; Sedky, MK, 2022)		1.67
"Dasatinib is a second-generation multityrosine kinase inhibitor used in the first-line and second-line treatment of Philadelphia chromosome-positive leukaemia. "( Dasatinib-induced Crohn's-like colitis.
Campora, M; Carlin, L; Caserta, L; Fassan, M; Grillo, F; Mastracci, L; Mazza, F; Mescoli, C; Remo, A, 2023)		3.8
"Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on acid-reducing agents (ARAs)."( Vitamin C Improves Dasatinib Concentrations Under Hypochlorhydric Conditions of the Simulated Stomach Duodenum Model.
Aburub, A; Fadda, HM; Moghrabi, FS, 2022)		1.77
"Dasatinib is an aminopyrimidine used as an inhibitor of multiple tyrosine kinases in two different formulations an immediate-release tablet and a powder for oral suspension. "( Investigational Study of DASATINIB N-Oxide Impurity in Different Diluents.
Kolli, D; Prasad Ketha, NVD, 2023)		2.66
"Dasatinib is a potent second-generation tyrosine kinase inhibitor (TKI) used in the first- and second-line treatment of chronic myeloid leukemia (CML). "( Dasatinib-induced Chylothorax in Chronic Myeloid Leukemia.
Alhuraiji, A; Ali, S; Almohammad, R; Alqattan, Y; Kayali, N, 2022)		3.61
"Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling. "( Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
De Lavallade, H; Dillon, R; Green, A; Harrington, P; Harrison, C; Hussain, F; Kordasti, S; McLornan, DP; Ong, M; Radia, D; Raj, K; Rousselot, P; Verde, A, 2023)		2.56
"Dasatinib (Sprycel®) is a tyrosine kinase inhibitor for treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia."( Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects.
Chen, J; Chen, X; Cheng, Y; Cui, Y; Deng, Q; Liu, G; Liu, Z; Qu, D; Ren, Q; Su, Z; Wang, W; Wang, Y; Xue, J; Yang, H; Yang, W; Yu, S; Zhao, Y; Zhou, Y, 2023)		2.64
"Dasatinib is a BCR::ABL1 tyrosine kinase inhibitor approved as frontline therapy at a 100 mg daily for chronic myeloid leukemia in chronic phase (CML-CP). "( Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
Alvarado, Y; Borthakur, G; Garcia-Manero, G; Gener-Ricos, G; Haddad, FG; Issa, GC; Jabbour, E; Kantarjian, H; Masarova, L; Sasaki, K; Skinner, J, 2023)		2.77
"Dasatinib 50 mg daily is an effective and safe treatment for newly diagnosed CML-CP."( Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
Alvarado, Y; Borthakur, G; Garcia-Manero, G; Gener-Ricos, G; Haddad, FG; Issa, GC; Jabbour, E; Kantarjian, H; Masarova, L; Sasaki, K; Skinner, J, 2023)		2.77
"Dasatinib is a tyrosine kinase inhibitor, and its influence on the osteogenic differentiation of mesenchymal stem cells is a controversial topic."( Dasatinib regulates the proliferation and osteogenic differentiation of PDLSCs through Erk and EID3 signals.
Hao, X; Jia, L; Sun, S; Wen, Y; Zhang, Y, 2023)		3.07
"Dasatinib (DST) is a tyrosine kinase inhibitor with established antiproliferative activity in Triple-negative breast cancer. "( Fucoidan-mediated targeted delivery of dasatinib-loaded nanoparticles amplifies apoptosis and endows cytotoxic potential in triple-negative breast cancer.
Aalhate, M; Chatterjee, E; Gupta, U; Guru, SK; Kumar, R; Mahajan, S; Maji, I; Saren, BN; Singh, PK, 2024)		3.15
"Dasatinib is a novel tyrosine-kinase inhibitor approved for CML with Philadelphia (Ph) chromosome and the most common adverse effects of dasatinib are peripheral edema and pleural effusion, which sometimes impose the interruption or reduction of dosage of dasatinib treatment, accompanied by diuretic and steroid use."( The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama, R; Harada, K; Ishikawa, J, 2020)		1.55
"Dasatinib is a second-generation potent and efficacious oral tyrosine kinase inhibitor frequently used for imatinib-resistant or intolerant BCR-ABL-positive chronic myeloid leukemia and for Philadelphia chromosome-positive acute lymphocytic leukemia. "( Dasatinib-induced Chylothorax in Chronic Myelogenous Leukemia in Pediatric Patient: Report of a Case and Review of Literature.
Adams, R; Diaz, E; Graham, R; Hickman, K; Ngwube, A, 2020)		3.44
"Dasatinib is a second-generation tyrosine kinase inhibitor that, when used as frontline therapy, produces more and faster cytogenetic and molecular responses compared with imatinib. "( Long-term results of frontline dasatinib in chronic myeloid leukemia.
Borthakur, G; Cortes, JE; DellaSala, S; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Luthra, R; Maiti, A; Masarova, L; Nogueras-González, GM; O'Brien, S; Patel, KP; Poku, R; Ravandi, F; Skinner, J; Verstovsek, S, 2020)		2.29
"Dasatinib is an oral, once-daily tyrosine kinase inhibitor used in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. "( Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib.
Becker, G; Bilger, K; Levêque, D; Natarajan-Amé, S, 2020)		2.25
"Dasatinib is a tyrosine kinase inhibitor for the treatment of BCR-ABL-positive chronic myeloid leukaemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL). "( Dasatinib-induced chylothorax: report of a case and review of the literature.
Chen, B; Cheng, D; Li, W; Wang, Q; Wu, Z, 2020)		3.44
"Dasatinib is a small molecule tyrosine kinase inhibitor with multiple targets including kit, PDGFR, and SRC. "( A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Li, J; Li, Y; Liu, X; Shen, L; Wu, X; Zhang, B; Zhang, X; Zhou, Y, 2020)		2.23
"Dasatinib is a multi-target kinase inhibitor, whose targets include BCR-ABL, SRC family kinases, and various cancer kinases. "( Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.
Bang, G; Cho, E; Choi, KM; Chung, YH; Han, EH; Kim, B; Kim, E; Kim, JH; Kim, JY; Lee, SJ; Park, SG, 2020)		2.25
"Dasatinib is a targeted cancer therapy, while programmed death ligand 1 (PD-L1) inhibitors are a form of immune checkpoint therapy used to treat various types of cancers. "( Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo.
Al Moustafa, AE; Al-Asmakh, M; Bawadi, H; Gupta, I; Hamdan, M; Jabeen, A; Kheraldine, H; Rizeq, B, 2021)		3.51
"Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) developed for treatment of patients with chronic myeloid leukemia (CML). "( Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report.
Ikejiri, F; Inoue, M; Ishihara, S; Ishimura, N; Kawashima, K; Kinoshita, Y; Mishima, Y; Moriyama, I; Okada, T; Onishi, C; Oshima, N; Shibagaki, K; Suzumiya, J, 2021)		2.33
"Dasatinib is a Src inhibitor that inhibits Src phosphorylation and suppresses Src-associated cell migration and angiogenesis."( Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.
Chao, WT; Cheng, CC; Hsu, YH; Lai, YS; Liu, YH; Shih, JH, 2021)		1.65
"Dasatinib is a multi-target protein tyrosine kinase inhibitor. "( Dasatinib inhibits proliferation of liver cancer cells, but activation of Akt/mTOR compromises dasatinib as a cancer drug.
Chi, F; Dong, X; Jia, Y; Liu, C; Mu, X; Pei, J; Qin, K; Xu, J; Yu, B; Zhang, C; Zhang, H; Zhu, X, 2021)		3.51
"Dasatinib is a second-generation tyrosine kinase inhibitor with higher central nervous system (CNS) penetration compared with imatinib and nilotinib in in vitro studies. "( A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Gong, B; Gong, X; Li, L; Li, Y; Lin, D; Liu, B; Liu, K; Mi, Y; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhou, C, 2021)		2.4
"Dasatinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor approved for patients with chronic myeloid leukaemia (CML). "( Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Bergeron, A; Bouchet, S; Busque, L; Cayssials, E; Cayuela, JM; Charbonnier, A; Coiteux, V; Cony-Makhoul, P; Dartigeas, C; Dubruille, V; Escoffre-Barbe, M; Etienne, G; Gardembas, M; Guerci, A; Guilhot, F; Guilhot, J; Huguet, F; Legros, L; Mahon, FX; Molimard, M; Mollica, L; Nicolini, FE; Réa, D; Rousselot, P; Roy, L, 2021)		3.51
"Dasatinib is an inhibitor of Src that has anti-tumour effects on many haematological and solid cancers. "( Anti-growth and pro-apoptotic effects of dasatinib on human oral cancer cells through multi-targeted mechanisms.
Bishop-Bailey, D; Choi, JS; Jang, BC; Park, JW; Park, NS; Park, YK; Shin, YM; Yadav, AK, 2021)		2.33
"Dasatinib is a first-line pharmacotherapeutic treatment for chronic myeloid leukemia (CML). "( cAMP Signaling Pathway Prevents Dasatinib-Induced Vascular Hyperpermeability.
Aoyama, T; Imai, S; Kashiwagi, H; Kuriyama, H; Sato, Y; Sugawara, M; Takekuma, Y, 2021)		2.35
"Dasatinib is a potent Src/Abl inhibitor and has demonstrated to have anti-proliferative and anti-invasive activity in many preclinical models."( Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.
Arcaroli, J; Bagby, S; Cross, B; Eckhardt, SG; Fenton, H; Gajdos, C; McCarter, M; Messersmith, WA; Pitts, TM; Purkey, A; Quackenbush, KS; Scott, AJ; Song, EK; Tan, AC, 2017)		1.47
"Dasatinib is a second generation ABL kinase inhibitor used in the management of chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). "( Pepsi® or Coke®? Influence of acid on dasatinib absorption.
Knoebel, RW; Larson, RA, 2018)		2.19
"Dasatinib is a dual Src/Abl tyrosine kinase inhibitor approved for frontline and second line treatment of chronic phase chronic myelogenous leukemia. "( Dasatinib-induced pulmonary arterial hypertension - A rare late complication.
Dhar, V; Ibrahim, U; Odaimi, M; Saqib, A, 2019)		3.4
"Dasatinib is a potent BCR-ABL1 and Src family tyrosine kinase inhibitor. "( Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
Alvarado, Y; Borthakur, G; Bose, P; Burger, J; Cortes, J; Estrov, Z; Ferrajoli, A; Jabbour, E; Jain, N; Kantarjian, HM; Naqvi, K; Paul, S; Pemmaraju, N; Skinner, J; Takahashi, K; Thompson, P; Yilmaz, M, 2018)		2.22
"Dasatinib is a competitive inhibitor of Src kinase, which has shown promise in treatment of pancreatic cancer."( Mechanism Comparison of Gemcitabine and Dasatinib-Resistant Pancreatic Cancer by Integrating mRNA and miRNA Expression Profiles.
Chen, B; Chen, Z; Shi, K; Zhao, L, 2018)		1.47
"Dasatinib is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia (CML). "( Recurrent and Fixed Neutrophilic Dermatosis Associated With Dasatinib.
Bergman, JC; Hull, PR; Keating, MM; Ly, TY, )		1.82
"Dasatinib (DAS) is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukemia and in the management of ulcerative colitis (UC). "( Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats.
Abanmy, NO; Alzoman, NZ; Maher, HM; Shehata, SM, 2018)		2.17
"Dasatinib is a new selective tyrosine kinase inhibitor that targets certain kinases involved in cellular growth and development. "( Dasatinib induces gene expression of CYP1A1, CYP1B1, and cardiac hypertrophy markers (BNP, β-MHC) in rat cardiomyocyte H9c2 cells.
Alsaad, AMS, 2018)		3.37
"Dasatinib is an oral available short-acting inhibitor of multiple tyrosine kinases. "( Dasatinib.
Hochhaus, A; Lindauer, M, )		3.02
"Dasatinib is a highly effective second-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML). "( Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
Hu, J; Huang, X; Jiang, Q; Jin, J; Li, J; Liu, T; Meng, F; Shen, Z; Wang, J; Wu, D, 2019)		2.17
"Dasatinib is a promising anti-BCSC drug that could be used in combination with paclitaxel to overcome chemoresistance in TNBC."( Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Ali, S; Bakdounes, K; Dai, M; Hachim, IY; Jean-Claude, B; Khadang, B; Lebrun, JJ; Moamer, A; Raffa, FA; Tian, J, 2018)		3.37
"Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) and it could be used as a second-line treatment for patients with chronic myeloid leukemia (CML). "( Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China.
Bao, Y; Chen, LF; Li, DJ; Li, WM; Meng, L; Ren, HB; Yuan, GL; Zhong, ZD; Zou, P, 2018)		2.21
"Dasatinib is a second-generation tyrosine kinase inhibitor that is indicated for the treatment of patients with chronic myeloid leukemia. "( Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report.
Fujimoto, S; Fukuda, A; Minakawa, A; Ochiai, S; Sato, Y, 2019)		3.4
"Dasatinib is a potent tyrosine-kinase inhibitor which is used for chronic myeloid leukemia treatment. "( Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Bakanay, SM; Dilek, I; Kucuksahin, O; Maral, S, 2020)		2.21
"Dasatinib is an Src family kinase inhibitor with modest activity in advanced breast cancer. "( Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
Atzori, F; Cortes, J; Geese, WJ; Gradishar, WJ; Rybicki, A; Somlo, G; Specht, JM; Strauss, LC; Sy, O; Vahdat, LT, 2013)		3.28
"Dasatinib is a novel tyrosine kinase inhibitor with activity against the Src family kinases. "( Dasatinib : a novel therapy for breast cancer?
Scher, KS; Somlo, G, 2013)		3.28
"Dasatinib is an effective and safe therapy option and can be used as first-line therapy for newly diagnosed CML-CP patients."( [Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia].
Hu, JD; Huang, XJ; Shen, ZX; Wang, JX; Zhou, L, 2013)		2.09
"Dasatinib is a potent BCR-ABL inhibitor with proven efficacy in adults with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) and in imatinib-resistant/intolerant disease. "( Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM, 2013)		3.28
"Dasatinib is a second-generation BCR-ABL inhibitor approved for the treatment of patients with chronic myeloid leukemia, both in the frontline and in the imatinib-resistant/intolerant settings. "( Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments.
Fermeglia, M; Gibbons, DL; Laurini, E; Posocco, P; Pricl, S; Quintás-Cardama, A, 2013)		2.09
"Dasatinib (BMS-354825) is a FDA-approved multitargeted kinase inhibitor of BCR/ABL and Src kinases. "( MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.
Fang, Y; He, Q; Jing, H; Lin, M; Luo, P; Yang, B; Ying, M; Zhong, L; Zhou, X, 2013)		2.09
"Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. "( The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
Hochhaus, A; Kantarjian, H, 2013)		2.16
"Dasatinib is an effective treatment option for patients with CML."( The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
Hochhaus, A; Kantarjian, H, 2013)		2.16
"Dasatinib is an oral multitarget tyrosine kinase inhibitor that targets BCR-ABL, c-Src, c-KIT, platelet-derived growth factor receptor β, and EphA2. "( Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.
Bergman, M; Bokar, J; Brell, J; Chee, CE; Dowlati, A; Fu, P; Gibbons, J; Gudena, V; Krishnamurthi, S; Meropol, NJ; Nock, CJ; O'Brien, T; Reese, A; Saltzman, J; Teston, L; Wright, JJ, 2013)		2.17
"Dasatinib is a novel second-generation inhibitor of multiple tyrosine kinases, indicated for the treatment for Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML), acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. "( Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.
Giannouli, A; Hatzitolios, AI; Kaiafa, G; Kakaletsis, N; Papadopoulos, N; Perifanis, V; Savopoulos, C; Zisekas, S, 2014)		2.07
"Dasatinib is a second generation tyrosine kinase inhibitor approved for clinical use in first line and imatinib-resistant chronic myeloid leukemia and Philadelphia positive (Ph+) acute lymphoblastic leukemia. "( Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Paydas, S, 2014)		3.29
"Dasatinib is a second generation tyrosine kinase inhibitor (TKI) approved for clinical use in patients with imatinib-resistant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL). "( Large granular lymphocytosis during dasatinib therapy.
Li, JY; Qiu, ZY; Xu, W, 2014)		2.12
"Dasatinib is a highly potent BCR-ABL kinase inhibitor with established efficacy and safety in imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. "( Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Akiyama, H; Fujisawa, S; Ishida, Y; Ishizawa, K; Matsue, K; Nakamae, H; Ogura, M; Onishi, S; Takamatsu, Y; Tanimoto, M; Taniwaki, M; Usuki, K; Utsunomiya, A, 2014)		2.16
"Dasatinib is a Bcr-bl and Src kinase inhibitor that has potential against HNSCC."( Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
Chen, CC; Huang, LY; Huang, WC; Lin, YC; Lin, YT; Wei, TT; Wu, MH, 2014)		1.39
"Dasatinib is a multikinase inhibitor that targets EphA2 and other kinases."( Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.
Bottsford-Miller, J; Broaddus, R; Coleman, RL; Dalton, HJ; Deavers, MT; Fellman, B; Han, HD; Hu, W; Huang, J; Huang, L; Jennings, NB; Kang, Y; Liu, T; Lu, C; Pecot, CV; Pradeep, S; Roh, JW; Rupaimoole, R; Sood, AK; Thanapprapasr, D; Urbauer, D; Zand, B, 2014)		1.35
"Dasatinib is an orally available short-acting dual ABL/SRC tyrosine kinase inhibitor (TKI). "( Dasatinib.
Hochhaus, A; Lindauer, M, 2014)		3.29
"Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph-positive ALL.We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia(ALL) (n519) or lymphoid blast phase of chronic myelogenous leukemia (CML-LB) (n515) with the combination of dasatinib and the hyper CVAD regimen. "( Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
Benjamini, O; Burger, J; Champlin, R; Cortes, J; Dumlao, TL; Faderl, S; Garcia-Manero, G; Garris, R; Jabbour, E; Jorgensen, J; Kantarjian, H; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, D, 2014)		2.13
"Dasatinib is a potent second generation TKI, and it is widely used in patients with CML, both in the up-front setting and failure after imatinib. "( Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Ar, MC; Aydin, Y; Baslar, Z; Elverdi, T; Eskazan, AE; Eyice, D; Ferhanoglu, B; Kurt, EA; Ongoren Aydin, S; Ozbek, U; Salihoglu, A; Soysal, T; Tuzuner, N; Yalniz, FF, 2014)		2.07
"Dasatinib is a compound developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor against wild-type BCR-ABL and SRC family kinases. "( Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.
Heo, SK; Jo, JC; Kim, H; Noh, EK; Park, JH; Yoon, DJ, 2014)		3.29
"Dasatinib, which is an inhibitor of BCR-ABL and SRC family tyrosine kinases, is used for the treatment of patients with Philadelphia chromosome (Ph) positive leukemia, especially for those who develop resistance or who are intolerant to imatinib. "( Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.
Al-Rabi, KH; Mustafa Ali, MK; Sabha, MM, 2015)		2.06
"Dasatinib is a BCR-ABL kinase inhibitor with improved potency compared with imatinib, for which efficacy and safety in imatinib-resistant and imatinib-intolerant patients with chronic myelogenous leukemia (CML) have been established. "( Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic p
Fujisawa, S; Hatta, Y; Inokuchi, K; Iwase, O; Kozai, Y; Kumagai, T; Matsuki, E; Oba, K; Ohashi, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Shinagawa, A; Shirasugi, Y; Takeuchi, J; Wakita, H; Yano, S; Yoshida, C, 2014)		2.08
"Dasatinib is a dual Src/Abl kinase inhibitor associated with higher affinity for BCR/ABL kinase than imatinib, and is used in the treatment of chronic myelocytic leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL)."( Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
Çengel, A; Özkurt, ZN; Taçoy, G; Türkoğlu, S, 2015)		2.58
"Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) for chronic, blastic, or accelerated phase chronic myeloid leukemia (CML) patients who are resistant or intolerant to previous treatment. "( The role of dasatinib in the management of chronic myeloid leukemia.
Chen, B; Chen, R, 2015)		2.24
"Dasatinib is a small-molecule inhibitor of the tyrosine kinases SRC and ABL that has been approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia."( Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.
Ando, T; Eguchi, Y; Honda, T; Ishigami, M; Isoda, H; Kimura, S; Kojima, K, 2015)		1.36
"Dasatinib is a tyrosine kinase inhibitor used for the treatment of CML by inhibiting ABL, and while it also inhibits ARG, there is currently no structure of ARG in complex with dasatinib."( Structure of the ABL2/ARG kinase in complex with dasatinib.
Boggon, TJ; Ha, BH; Koleske, AJ; Simpson, MA, 2015)		1.39
"Dasatinib is a tyrosine kinase inhibitor that targets SFK activity, and is used for the treatment of B cell and Abelson lymphomas."( Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Hou, T; Huang, Y; Li, J; Xiao, J; Xu, M; Yang, C, 2015)		2.58
"Dasatinib (Sprycel) is a selective protein tyrosine kinase inhibitor with immunomodulatory properties that abrogates multiple signal transduction pathways in immune cells."( Therapeutic effects of dasatinib in mouse model of multiple sclerosis.
Afraei, S; Azizi, G; Goudarzvand, M; Mirshafiey, A; Sedaghat, R, 2015)		1.45
"Dasatinib is a novel, oral, multi-targeted kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL) and Src family kinases. "( Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.
Hirose, T; Ishida, Y; Ito, S; Kato, Y; Kishino, S; Kondo, T; Kubo, K; Miyagishima, T; Mochizuki, N; Murai, K; Nagashima, T; Ogawa, K; Ohno, K; Oyake, T; Saitou, S; Sato, S; Shindo, M; Watanabe, R; Yamaguchi, K; Yamamoto, S; Yonezumi, M, 2016)		2.14
"Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families including cKIT."( Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Argiris, A; Cohen, EE; Cullen, KJ; Gilbert, J; Hayes, DN; Karrison, T; Kies, MS; Lenz, HJ; Lim, D; Razak, AR; Roberts, JD; Saba, NF; Takebe, N; Tanvetyanon, T; Vokes, EE; Wong, SJ; Worden, FP, 2016)		1.49
"Dasatinib is a tyrosine kinase inhibitor of the Src-family kinases (SFK) and in preclinical studies shown to have substantial activity in EOC."( A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.
Godwin, AK; Golemis, EA; Hirst, J; Pathak, HB; Schilder, RJ; Sethi, G; Zhou, Y, 2015)		1.36
"Dasatinib is a multikinase inhibitor in clinical trials for glioma, and thus far has failed to demonstrate significant efficacy. "( ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.
Becher, OJ; Chung, AH; Crabtree, D; Elmquist, WF; Halvorson, KG; Hu, G; Mittapalli, RK; Parrish, KE, 2016)		2.15
"Dasatinib is an orally available broad-spectrum tyrosine kinase inhibitor that is widely used to treat chronic myeloid leukemia. "( Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice.
Dagger, SA; Duyvestyn, JM; Langdon, WY; Taylor, SJ, 2016)		3.32
"Dasatinib is an important drug against chronic myeloid leukemia (CML). "( 2-Aminoxazole and 2-Aminothiazole Dasatinib Derivatives as Potent Inhibitors of Chronic Myeloid Leukemia K562 Cells.
Cai, ZP; Chai, XX; Fu, YJ; Xiong, YZ; Yang, MT; Zhou, Y, 2016)		2.16
"Dasatinib is a potent second-generation tyrosine kinase inhibitor designed to inhibit ABL and SRC kinases while also interfering with the c-Kit, platelet-derived growth factor receptor, and STAT5 pathways."( Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.
Bueso-Ramos, CE; Cortes, JE; Hidalgo, JE; Hoehn, D; Jabbour, EJ; Kanagal-Shamanna, R; Medeiros, LJ, 2016)		1.41
"Dasatinib (Sprycel) is a tyrosine kinase inhibitor approved for treatment of chronic myeloid leukemia. "( The Cancer Drug Dasatinib Increases PGC-1α in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice.
Lokurkar, IA; Long, JZ; Richter, EA; Spiegelman, BM; Sylow, L; Zeng, X, 2016)		2.22
"Dasatinib is a potent inhibitor of the altered tyrosine kinase activity in disease states associated with BCR/ABL1. "( Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature.
Fenton, B; Quick, DP; Shakespeare, A; Shanshal, M; Thirumala, S, 2016)		3.32
"Dasatinib is a novel oral prescription drug proposed for treating adult patients with chronic myeloid leukemia. "( Determination of dasatinib in the tablet dosage form by ultra high performance liquid chromatography, capillary zone electrophoresis, and sequential injection analysis.
Coufal, P; Gonzalez, AG; Hraníček, J; Kozlík, P; Taraba, L, 2017)		2.24
"Dasatinib is a competitive inhibitor of Src kinase, which is overexpressed in PDAC tumors."( Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
Bazin, IS; Bodoky, G; Deplanque, G; Elekes, A; Evans, TRJ; Harrison, M; Lin, C; Melichar, B; Moore, MJ; O'Dwyer, PJ; Pezet, D; Rock, E; Rosemurgy, A; Strauss, L; Van Cutsem, E, 2017)		1.43
"Dasatinib is a new small-molecule inhibitor of c-src phosphorylation."( Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
Fu, L; Gu, F; Guo, XJ; Lang, RG; Li, PZ; Li, WD; Liu, FF; Qian, XL; Sun, H; Zhang, J, 2017)		2.62
"Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against unmutated BCR-ABL in vitro. "( Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Bleickardt, E; Charbonnier, A; Collins, RH; Deininger, M; Dorlhiac-Llacer, PE; Francis, S; Hochhaus, A; Hughes, T; Kantarjian, HM; Khoroshko, N; Khoury, HJ; Kim, DW; Milone, JH; Otero, I; Paquette, RL; Réa, D; Shah, NP; Silver, RT; Strauss, L; Vela-Ojeda, J, 2008)		2.06
"Dasatinib is a substrate of both efflux proteins, ABCB1 and ABCG2."( Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Dang, P; Eadie, L; Frede, A; Hewett, D; Hiwase, DK; Hughes, TP; Kumar, S; Melo, J; Saunders, V; To, LB; White, DL; Zrim, S, 2008)		2.51
"Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). "( Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Brümmendorf, TH; Corm, S; Cortes, J; Coutre, S; Ernst, T; Gambacorti-Passerini, C; Hamerschlak, N; Hochhaus, A; Khoury, HJ; Kim, DW; Martinelli, G; Michallet, M; Radich, JP; Raffoux, E; Rege-Cambrin, G; Ritchie, E; Roy, L; Talpaz, M; Tang, JL; Van Tornout, JM; Zhu, C, 2008)		2.1
"Dasatinib, which is a multi-targeted kinase inhibitor mainly developed for Bcr-Abl and Src family kinases, has recently been shown to have significant activity against EphA2."( Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
Chang, Q; Hedley, DW; Jorgensen, C; Pawson, T, 2008)		1.46
"Dasatinib (Sprycel) is a new-targeted therapy used since 2005 in the treatment of chronic myelogenous leukemia and de novo Philadelphia positive acute lymphoblastic leukaemia patients, intolerant or resistant to imatinib. "( [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Bergeron, A; Cony-Makhoul, P; Corm, S; Dubruille, V; Nicolini, FE; Rea, D; Rigal-Huguet, F, 2008)		2.07
"Dasatinib (BMS-354825) is a dual Src/Abl kinase inhibitor with potent antiproliferative activity against hematologic malignancies harboring activated BCR-ABL."( Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner, R; Jove, R; Lee, F; Mesa, T; Vultur, A, 2008)		1.34
"Dasatinib is a tyrosine kinase inhibitor with activity against BCR-ABL, platelet-derived growth factor receptors (PDGFRs), c- KIT, fibroblast growth factor receptors (FGFRs), SRC family kinases (SFKs), and EPHA receptors, all of which have been implicated in the pathogenesis of Ph- leukemias and myeloid disorders."( Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.
Verstovsek, S, 2009)		1.34
"Dasatinib (BMS-354825) is a potent dual Abl/Src kinase inhibitor approved for clinical use in CML patients."( Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Bhatia, R; Chu, S; Copland, M; Holyoake, TL; Jove, R; Konig, H, 2008)		1.46
"Dasatinib (BMS-354825) is a small molecule Src/Abl tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. "( Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
Blake, SJ; Brown, MP; Diener, KR; Fraser, CK; Hayball, JD; Hughes, TP; Lyons, AB, 2009)		3.24
"Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. "( Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
Cortes, JE; Guilhot, F; Hughes, TP; Khoury, HJ; Kim, DW, 2009)		3.24
"Dasatinib is a tyrosine kinase inhibitor that has 325-fold greater in vitro activity against native BCR-ABL (breakpoint cluster region-Abelson leukemia virus) compared with imatinib and can overcome primary (intrinsic) and secondary (acquired) imatinib resistance."( New dosing schedules of dasatinib for CML and adverse event management.
Wong, SF, 2009)		1.38
"Dasatinib is a tyrosine kinase inhibitor (including BCR-ABL and the SRC family) that is effective in patients with chronic myeloid leukemia. "( Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
Agrawal, S; Bertz, R; Blackwood-Chirchir, A; Eley, T; Li, T; Luo, FR; Manning, J; Sanil, A, 2009)		2.02
"Dasatinib is a 325-fold more potent inhibitor of Bcr-Abl than imatinib and has been associated with high rates of durable responses in patients with CML in chronic phase (CP) after imatinib failure."( Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Bleickardt, E; Borthakur, G; Chen, TT; Cortes, JE; Kantarjian, HM; Liu, D; O'Brien, S; Quintás-Cardama, A; Ravandi, F, 2009)		2.52
"Dasatinib is a new SRC-ABL-kinase inhibitor that has been developed for treating chronic myelogenous leukemia patients, across all phases of disease, who are resistant or intolerant to imatinib."( Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Scuffham, PA; Taylor, MJ, 2009)		1.37
"Dasatinib is an oral potent adenosine triphosphate (ATP)-competitive inhibitor of BCR-ABL, cKIT, platelet-derived growth factor receptor, and SRC family kinases (SFKs), which has demonstrated high efficiency in patients with imatinib-resistant chronic myelogenous leukemia. "( The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.
Allart, S; Garcia, C; Gratacap, MP; Martin, V; Payrastre, B; Recher, C; Sié, P; Valéra, MC, 2009)		2.04
"Dasatinib is a small molecule kinase inhibitor that has recently been shown to inhibit Src family kinases (SFK) and also has activity against CaP. "( Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Brown, LG; Corey, E; Koreckij, T; Nguyen, H; Vessella, RL; Yu, EY, 2009)		3.24
"Dasatinib is a highly potent BCR-ABL inhibitor that has shown durable efficacy in patients with chronic phase (CP) chronic myeloid leukemia (CML) after resistance, suboptimal response, or intolerance to prior imatinib. "( Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Bleickardt, E; Branford, S; Hanfstein, B; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Lambert, A; Lipton, JH; Müller, MC; Radich, J; Rousselot, P, 2009)		3.24
"Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. "( Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Branford, S; Cortes, JE; Druker, BJ; Erben, P; Hochhaus, A; Hughes, TP; Kim, DW; Mukhopadhyay, J; Müller, MC; Pasquini, R; Ploughman, L; Radich, JP, 2009)		3.24
"Dasatinib is an effective agent for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR."( Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
Borthakur, G; Cortes, JE; Jabbour, E; Jones, D; Kantarjian, H; Koller, C; O'Brien, S; Ravandi, F; Shan, J; Walker, B; Zhao, W, 2010)		2.19
"Dasatinib is a dual Abl/Src kinase TKI that is structurally unrelated to imatinib and is approved for therapy of all phases of CML in patients who are resistant or intolerant to imatinib."( Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.
Ravandi, F; Santos, FP, 2009)		1.07
"Dasatinib is a dual BCR-ABL/Src-family kinase (SFK) inhibitor approved for patients with imatinib-resistant and -intolerant CML in any phase and Ph+ ALL."( Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Attar, EC; DeAngelo, DJ, 2010)		1.54
"Dasatinib is a potent inhibitor of SRC as well as other tyrosine kinases."( A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
Hodgson, L; Kelley, MJ; Kratzke, RA; Miller, AA; Otterson, GA; Pang, H; Ramnath, N; Vokes, EE, 2010)		1.41
"Dasatinib is a potent dual Abl/Src inhibitor approved for treatment of Philadelphia chromosome-positive (Ph-positive) leukemias. "( Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Fei, F; Groffen, J; Heisterkamp, N; Kim, YM; Müschen, M; Stoddart, S, 2010)		2.09
"Dasatinib is an oral, potent adenosine triphosphate-competitive inhibitor of multiple tyrosine kinases including BCR-ABL, c-KIT, platelet-derived growth factor receptor, and Src family kinases (SFKs). "( Dasatinib in solid tumors.
Haura, EB; Kim, LC; Rix, U, 2010)		3.25
"Dasatinib is a second-generation tyrosine kinase inhibitor that is approved for the treatment of imatinib-resistant or imatinib-intolerant chronic myeloid leukemia. "( Acute renal failure under dasatinib therapy.
Acikalin, MF; Ozkurt, S; Soydan, M; Temiz, G, 2010)		2.1
"Dasatinib is a dual Src/Abl inhibitor recently approved for Bcr-Abl+ leukemias with resistance or intolerance to prior therapy. "( Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.
Arceci, R; Blanchard, EG; Cayre, YE; Corey, SJ; Futami, M; Guerrouahen, BS; Kanerva, J; Kornblau, SM; Lee, FY; Nwawka, K; Robinson, LJ; Vaklavas, C; Whichard, ZL; Wieder, E, 2010)		3.25
"Dasatinib is a potent tyrosine kinase inhibitor that is used to treat chronic myeloid leukemia in patients resistant or intolerant to imatinib mesylate. "( The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.
Dewar, AL; Diamond, P; Fitter, S; Schultz, CG; Sims, NA; Vandyke, K; Zannettino, AC, 2010)		2.09
"Dasatinib is a novel tyrosine-kinase inhibitor approved for treatment of BCR-ABL positive chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) after imatinib failure. "( Pleural effusions due to dasatinib.
Brixey, AG; Light, RW, 2010)		2.11
"Dasatinib is a promising agent for the treatment of refractory chronic myeloid leukemia and acute lymphoblastic leukemia. "( Pleural effusions due to dasatinib.
Brixey, AG; Light, RW, 2010)		2.11
"Dasatinib is an orally administered multitargeted kinase inhibitor that targets Src family tyrosine kinases, Abl, c-Kit, and PDGFR. "( Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
Jian, W; Lerner, SP; Levitt, JM; Sonpavde, G; Yamashita, H, 2010)		3.25
"Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML). "( Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Bazarbachi, A; Mahfouz, RA; Otrock, ZK; Oweini, H, 2011)		2.05
"Dasatinib is a new dual Src/Bcr-Abl tyrosine kinase inhibitor initially developed for the treatment of chronic myeloid leukemia."( The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
Body, JJ; Ghanem, G; Id Boufker, H; Journé, F; Lagneaux, L; Najar, M; Piccart, M, 2010)		1.42
"Dasatinib is an oral kinase inhibitor of BCR-ABL that has been developed for treating CML patients across all phases of disease who are resistant or intolerant to imatinib."( Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar, O; Hjalte, F; Taylor, M, 2010)		1.4
"Dasatinib is a second-generation tyrosine kinase inhibitor that has been shown to be efficacious in treatment of patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to frontline imatinib."( Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Shayani, S, 2010)		2.52
"Dasatinib is a novel, potent, ATP-competitive inhibitor of Bcr-Abl, cKIT, and Src family kinases that exhibits efficacy in patients with imatinib-resistant chronic myelogenous leukemia. "( Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
Ghevaert, C; Massberg, S; Mazharian, A; Watson, SP; Zhang, L, 2011)		3.25
"Dasatinib is a kinase inhibitor that inhibits BCR-ABL, Src family kinases, c-Kit, and platelet-derived growth factor receptor kinase. "( The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Amrein, PC, 2011)		2.15
"Dasatinib is an oral dual tyrosine kinase inhibitor active against ABL1 and SRC family kinases. "( Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.
Alimena, G; Breccia, M, 2011)		2.12
"Dasatinib is a small molecule tyrosine kinase inhibitor that targets a wide variety of tyrosine kinases implicated in the pathophysiology of several neoplasias. "( Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero, JC; Ocaña, A; Pandiella, A; Seoane, S, 2011)		2.05
"Dasatinib is a potent oral inhibitor of tyrosine kinases including the SRC family kinases, which are activated in tumors, and implicated in invasion and bone metastasis. "( Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
Hatake, K; Ito, Y; Miyazaki, M; Nakagawa, K; Okamoto, I; Seriu, T; Takahashi, S; Ueda, K, 2011)		2.15
"Dasatinib is a potent second-generation tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia after imatinib failure. "( Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
Cho, BS; Goh, HG; Kim, D; Kim, DW; Kim, SH, 2011)		2.03
"Dasatinib (Sprycel®) is an orally administered small molecule inhibitor of multiple tyrosine kinases, including BCR-ABL and SRC family kinases, which is indicated for the treatment of adults with newly diagnosed chronic-phase chronic myeloid leukaemia (CML), CML (chronic-, accelerated- or blast-phase) with resistance or intolerance to prior therapy, including imatinib, or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy. "( Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Keam, SJ; McCormack, PL, 2011)		3.25
"Dasatinib is a potent BCR-ABL inhibitor effective in chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia (ALL) resistant/intolerant to imatinib. "( Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Baccarani, M; Candoni, A; Castagnola, C; Cimino, G; De Propris, MS; Elia, L; Fazi, P; Ferrara, F; Foà, R; Fozza, C; Guarini, A; Iacobucci, I; Leoni, P; Luppi, M; Mandelli, F; Martinelli, G; Meloni, G; Nobile, F; Paoloni, F; Sica, S; Soverini, S; Vignetti, M; Vitale, A; Zuffa, E, 2011)		3.25
"Dasatinib (Sprycel) is a potent antitumor agent prescribed for patients with chronic myeloid leukemia (CML). "( A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
Agrawal, S; Furlong, MT; Hawthorne, D; Krueger, L; Lago, M; Stouffer, B; Unger, S, 2012)		2.04
"Dasatinib is a potent, oral SRC-family kinase inhibitor with preclinical antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-negative, or basal-like, breast cancer cell lines. "( Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
Bengala, C; Fairchild, J; Finn, RS; Goldstein, LJ; Ibrahim, N; Roché, H; Sparano, J; Strauss, LC; Sy, O, 2011)		3.25
"Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). "( Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Agarwal, MB; Baccarani, M; Bradley-Garelik, MB; Cortes, JE; Hochhaus, A; Ipiña, JJ; Junghanss, C; Kantarjian, HM; Kim, DW; Milone, JH; Nicolini, FE; Ogura, M; Pavlovsky, C; Robak, T; Shah, NP; Undurraga, MS; Van Droogenbroeck, J; Vellenga, E; Wang, J; Zhu, C, 2012)		3.26
"Dasatinib is an oral tyrosine kinase inhibitor (TKI) of BCR-ABL and SRC family and ixabepilone is an epothilone B analog. "( Phase I trial of dasatinib and ixabepilone in patients with solid tumors.
Herbolsheimer, P; Jelinek, J; Kapoor, R; Perry, D; Smith, KL; Swain, SM; Verma, N; Veytsman, I, 2013)		2.17
"Dasatinib is a tyrosine kinase inhibitor used to treat imatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. "( Dasatinib inhibits proinflammatory functions of mature human neutrophils.
Futosi, K; Mócsai, A; Németh, T; Pick, R; Vántus, T; Walzog, B, 2012)		3.26
"Dasatinib is a multikinase inhibitor active against several tyrosine kinases including ABL, KIT, Lyn and Btk. "( Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release.
Blatt, K; Ghanim, V; Herrmann, H; Kneidinger, M; Marth, K; Valent, P; Valenta, R, 2012)		2.08
"Dasatinib is an FDA-approved drug for treating chronic myeloid leukemia cancer with a reported ability to cross the blood-brain barrier."( Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease.
Combs, CK; Dhawan, G, 2012)		1.1
"Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI), which was developed to treat patients with chronic myelogenous leukemia (CML), who had failed or were intolerant to therapy with imatinib."( Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Cortes, J; Santos, FP, 2012)		3.26
"Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. "( Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study.
Khagga, M; Thappali, SR; Vakkalanka, SK; Varanasi, KV; Veeraraghavan, S, 2012)		2.08
"Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)."( Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Akin, C; Donker, M; Jiang, Y; Lee, FY; Luo, R; Shah, NP, 2006)		2.5
"Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired resistance/intolerance. "( Dasatinib: BMS 354825.
, 2006)		3.22
"Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets oncogenic pathways and is a more potent inhibitor than imatinib against wild-type BCR-ABL."( The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
Borzillerri, R; Chang, CY; Cheng, JD; Kiefer, SE; Kish, K; Klei, HE; Lee, FY; Lombardo, LJ; Newitt, JA; Tokarski, JS; Wittekind, M; Xie, D; Zhang, Y, 2006)		1.39
"Dasatinib (BMS-354825) is a novel, orally active, multi-targeted kinase inhibitor that targets Src family kinases and is currently under clinical evaluation for the treatment of solid tumors."( Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Ashton, GH; Brunton, VG; Clark, EA; Evans, TR; Frame, MC; Lee, FY; Macpherson, IR; Sansom, OJ; Serrels, A, 2006)		1.26
"Dasatinib is a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases."( Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Agarwal, P; Apperley, J; Baccarani, M; Branford, S; Cortes, J; Coutre, S; Erben, P; Gollerkeri, A; Guilhot, F; Hamerschlak, N; Hochhaus, A; Kim, DW; Ottmann, O; Ritchie, E; Rousselot, P; Saglio, G; Shah, N, 2007)		2.5
"Dasatinib is an ATP-competitive, multi-targeted SRC and ABL kinase inhibitor that can bind BCR-ABL in both the active and inactive conformations. "( Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors.
Akahane, D; Nunoda, K; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Sashida, G; Takaku, T; Tauchi, T, 2007)		1.78
"Dasatinib is a novel, potent, oral, multitargeted kinase inhibitor of BCR-ABL and SRC-family kinases that showed marked efficacy in a phase 1 trial of patients with imatinib-resistant CML."( Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Agarwal, P; Amadori, S; Apperley, J; Baccarani, M; Branford, S; Bullorsky, EO; de Souza, CA; Gollerkeri, A; Guilhot, F; Heim, D; Hochhaus, A; Kim, DW; Larson, RA; Lipton, JH; Muller, MC; Roboz, GJ; Talpaz, M, 2007)		2.5
"Dasatinib is an orally active small molecule kinase inhibitor of both the src and abl proteins. "( Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Dering, J; Finn, RS; Ginther, C; Glaspy, P; Slamon, DJ; Tchekmedyian, N; Wilson, CA, 2007)		3.23
"Dasatinib is an orally bioavailable potent inhibitor of multiple tyrosine kinases, including ABL and SRC. "( Dasatinib.
Shah, NP, 2007)		3.23
"Dasatinib is a multitargeted kinase inhibitor that was recently approved for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. "( Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.
Clark, E; Fairchild, C; Han, X; Huang, F; Lee, F; Platero, S; Reeves, K; Shaw, P; Wong, TW, 2007)		2
"Dasatinib is a multi-targeted tyrosine kinase inhibitor active in vitro against most cell lines containing BCR-ABL mutations that confer resistance to imatinib."( A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Scheinfeld, N, 2007)		1.33
"Dasatinib (BMS-354825) is a novel, oral, potent, multi-targeted kinase inhibitor of Bcr-Abl and Src family kinases (SFK) and is a promising cancer therapeutic agent. "( Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Bhalla, K; Jove, R; Lee, FY; List, A; Nam, S; Smith, D; Vultur, A; Williams, A, 2007)		3.23
"Dasatinib is a novel, potent, multi-targeted oral kinase inhibitor."( Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Cortes, J; Jabbour, E; Kantarjian, H, 2007)		2.5
"Dasatinib is a multitargeted kinase inhibitor of BCR-ABL, SRC, C-KIT, PDGFRs, and ephrin A receptor kinases."( Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Martinelli, G; Paolini, S; Piccaluga, PP, 2007)		1.06
"Dasatinib is an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56(Lck) (Lck). "( Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
Jankowska, AM; Maciejewski, JP; Schade, AE; Schieven, GL; Susulic, V; Szpurka, H; Townsend, R; Zhang, R, 2008)		3.23
"dasatinib is a next-generation kinase inhibitor that binds to both SrC and to multiple conformations of BCR-ABL."( New strategies in controlling drug resistance.
Frame, D, 2007)		1.06
"Dasatinib is a novel, potent, multi-targeted kinase inhibitor that is approved in Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia following imatinib failure. "( Management of Bcr-Abl-positive leukemias with dasatinib.
Hochhaus, A, 2007)		2.04
"Dasatinib is a potent, multi-targeted kinase inhibitor that was recently approved for treatment of chronic myelogenous leukemia resistant to imatinib. "( Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.
Clark, E; Huang, F; Lee, F; Luo, FR; Reeves, K; Wang, XD; Xu, LA, 2007)		2.01
"Dasatinib is a multitargeted drug that blocks several tyrosine kinases. "( The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils.
Baumgartner, C; Bennett, KL; Ellmeier, W; Gleixner, KV; Herrmann, H; Kneidinger, M; Lee, FY; Lupinek, C; Rix, U; Schebesta, A; Schmidt, U; Superti-Furga, G; Thomas, WR; Valent, P; Valenta, R; Vales, A; Vrtala, S; Weghofer, M, 2008)		2.14
"Dasatinib is a small-molecule inhibitor of multiple tyrosine kinases, including BCR-ABL, SRC, c-KIT, ephrin A receptor and platelet-derived growth factor-beta receptor kinases, at nanomolar concentrations. "( Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam, SJ, 2008)		3.23
"Dasatinib (BMS-354825) is a potent, oral multi-targeted kinase inhibitor. "( Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Barrett, YC; Blackwood-Chirchir, A; Camuso, A; Fager, K; Galbraith, S; Lee, FY; Luo, FR; McGlinchey, K; Palme, H; Smykla, R; Wen, ML; Wild, R; Yang, Z, 2008)		2.01
"Dasatinib (BMS-354825) is a Src/ABL tyrosine kinase inhibitor currently approved for the treatment of chronic myeloid leukemia. "( The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
Blake, S; Hughes, TP; Lyons, AB; Mayrhofer, G, 2008)		2.08

Effects

Dasatinib has an acceptable tolerability profile; it is associated with myelosuppression. Dasatinib 100 mg QD has a favorable safety profile and maintains a similar degree of activity as the previously reported twice-daily dosing schedules.

Dasatinib monotherapy has demonstrated modest clinical activity in chronic myeloid leukemia in lymphoid blastic phase (CML-LBP) Dasatinib has superior preclinical activity in comparison with other tyrosine kinase inhibitors against cells with most common KIT mutation, exon 11.

ExcerptReferenceRelevance
"Dasatinib has a broader effect than other TKIs; the major known difference between dasatinib and other TKIs is the additional inhibition of Src family kinases."( Dasatinib-induced pulmonary arterial hypertension.
Eşkazan, AE; Özgür Yurttaş, N, 2018)		2.64
"Dasatinib has an acceptable tolerability profile; it is associated with myelosuppression, with fluid retention being the most common nonhematologic adverse event."( Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.
Keam, SJ; Keating, GM; Lyseng-Williamson, KA; McCormack, PL, 2013)		2.55
"Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible."( The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
Hochhaus, A; Kantarjian, H, 2013)		1.44
"Dasatinib has a manageable safety profile."( New dosing schedules of dasatinib for CML and adverse event management.
Wong, SF, 2009)		1.38
"Dasatinib 100 mg QD has a favorable safety profile and maintains a similar degree of activity as the previously reported twice-daily dosing schedules. "( Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Carducci, MA; Culine, S; Fizazi, K; Gross, ME; Hudes, G; Massard, C; Paliwal, P; Posadas, EM; Sternberg, CN; Trudel, GC; Wilding, G; Yu, EY, 2011)		2.2
"Dasatinib has a half-maximal inhibitory concentration 325 times lower than imatinib for BCR-ABL substrate phosphorylation in vitro and is less susceptible to most known molecular mechanisms of BCR-ABL imatinib resistance."( Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott, BL, 2012)		2.54
"Dasatinib has a wider spectrum of activity against a broader range of BCR-ABL forms than existing TK inhibitors. "( Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg, M, 2007)		3.23
"Dasatinib and quercetin have been discovered, and their combination has shown various anti-ageing effects."( Dasatinib plus quercetin attenuates some frailty characteristics in SAMP10 mice.
Kodama, A; Ota, H, 2022)		2.89
"Dasatinib has been associated with nephrotoxicity. "( Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity.
Abramson, MH; Adegbite, BO; Azeloglu, EU; Berman, EM; Campbell, KN; Chan, L; Chauhan, K; Coca, SG; El Ghaity-Beckley, S; Gutgarts, V; Jaimes, EA; Kremyanskaya, M; Marcellino, B; Mascarenhas, JO; Meliambro, KA; Musteata, FM; Muwonge, AN; Salvatore, SP, 2023)		2.62
"Dasatinib has modest antitumor activity with tolerable toxicities in patients with metastatic GISTs who have failed imatinib and sunitinib therapy."( A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Li, J; Li, Y; Liu, X; Shen, L; Wu, X; Zhang, B; Zhang, X; Zhou, Y, 2020)		2.23
"Dasatinib monotherapy has demonstrated modest clinical activity in chronic myeloid leukemia in lymphoid blastic phase (CML-LBP). "( Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
Cortes, JE; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, HM; Konopleva, M; Montalban Bravo, G; Morita, K; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K, 2021)		2.26
"Dasatinib has superior preclinical activity in comparison with other tyrosine kinase inhibitors against cells with the most common KIT mutation, exon 11"( A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
Borger, DR; Cohen, GI; Iafrarte, AJ; Jaslowski, AJ; Kalinsky, K; Kirkwood, JM; Koon, HB; Kuzel, TM; Lao, CD; Lawrence, DP; Lee, S; Leitao, MM; Margolin, KA; Pecora, AL; Rubin, KM; Tarhini, AA, 2017)		1.5
"Dasatinib has been associated with pleural/pericardial effusions and pulmonary hypertension, whereas nilotinib and ponatinib have been linked to the development of vascular occlusive events."( Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
Barber, MC; Mauro, MJ; Moslehi, J, 2017)		1.18
"Dasatinib has a broader effect than other TKIs; the major known difference between dasatinib and other TKIs is the additional inhibition of Src family kinases."( Dasatinib-induced pulmonary arterial hypertension.
Eşkazan, AE; Özgür Yurttaş, N, 2018)		2.64
"Dasatinib has increasingly been used to treat chronic myeloid leukemia (CML), although interstitial pneumonitis has been found as a complication in large clinical trials. "( Interstitial pneumonitis associated with dasatinib: two case reports and literature review.
Itani, H; Ito, Y; Iwamoto, K; Kondo, S; Nigi, A; Tamaki, S; Tanigawa, M; Tokui, T; Usui, E, 2019)		2.22
"Dasatinib has been shown to have preclinical activity against human prostate, breast, pancreatic, lung, and head and neck cancer."( Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro.
Bai, WL; Ji, WY; Song, Y; Sun, X, 2013)		1.43
"Dasatinib has an acceptable tolerability profile; it is associated with myelosuppression, with fluid retention being the most common nonhematologic adverse event."( Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.
Keam, SJ; Keating, GM; Lyseng-Williamson, KA; McCormack, PL, 2013)		2.55
"Dasatinib has no current role in the treatment of breast cancer, and its future is uncertain."( Dasatinib : a novel therapy for breast cancer?
Scher, KS; Somlo, G, 2013)		2.55
"Dasatinib has definite but limited activity in advanced mCRPC, and was poorly tolerated."( A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
Beumer, JH; Chatta, GS; Chen, CS; Christner, SM; Kraft, AS; Lilly, MB; Mitsuhashi, M; Twardowski, PW; Ye, W, 2013)		1.43
"Dasatinib has demonstrated efficacy in patients with chronic-phase chronic myeloid leukemia (CML) who had resistance or intolerance to imatinib. "( Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.
Costa, FF; De Souza, CA; Fachel, AA; Moreira, YB; Pagnano, KB; Silveira, RA; Verjovski-Almeida, S, 2014)		2.07
"Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible."( The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
Hochhaus, A; Kantarjian, H, 2013)		1.44
"Dasatinib has limited single-agent activity in unselected patients with metastatic breast cancer. "( Gene signature-guided dasatinib therapy in metastatic breast cancer.
Altan, M; Avritscher, R; Esteva, FJ; Hatzis, C; Hortobagyi, GN; Kwiatkowski, D; Moulder, S; Pusztai, L; Qi, Y; Strauss, L; Symmans, WF; Ueno, NT; Valero, V, 2014)		2.16
"Dasatinib has been associated with an increased risk of bleeding, with the most prominent risk noted in patients with advanced-stage chronic myeloid leukemia and thrombocytopenia. "( Subdural Hematoma Associated with Dasatinib and Intrathecal Methotrexate Treatment in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Nishioka, A; Sano, H; Shindo, T; Ureshino, H, )		1.85
"Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). "( Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.
Abruzzese, E; Alimena, G; Annunziata, M; Antolino, A; Bocchia, M; Bonifacio, M; Breccia, M; Capodanno, I; Castagnetti, F; Crugnola, M; Fava, C; Feo, C; Galimberti, S; Gozzini, A; Guarini, A; Iurlo, A; Latagliata, R; Leonetti Crescenzi, S; Luciano, L; Mauro, E; Porrini, R; Pregno, P; Rizzo, M; Rosti, G; Russo Rossi, A; Sgherza, N; Sorà, F; Stagno, F; Tiribelli, M; Trawinska, M; Vigneri, P, 2016)		2.28
"Dasatinib has Src-inhibitor activity."( Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Barry, WT; Crawford, J; Gu, L; Herndon, JE; Jha, G; Kelley, MJ; Ready, N; Shoemaker, D, 2017)		1.51
"Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. "( Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes, JE; Geyer, A; Jimenez, CA; Mauro, MJ; Pinilla-Ibarz, J; Smith, BD, 2017)		2.22
"Dasatinib has both anti-proliferative and anti-invasive effects in melanoma cells and combined with chemotherapy may have clinical benefit in the treatment of malignant melanoma."( Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N, 2008)		2.09
"Dasatinib has been reported to potently inhibit juxtamembrane domain mutant KIT(D816V) autophosphorylation and KIT-dependent activation of down stream signaling important for cell growth and survival of neoplastic cells. "( Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
Bhalla, K; Corless, CL; Fiskus, W; Heinrich, MC; Jillella, A; Kepten, I; Lewis, G; Manaloor, E; Ramalingam, P; Savage, N; Ustun, C, 2009)		2.14
"Dasatinib has a manageable safety profile."( New dosing schedules of dasatinib for CML and adverse event management.
Wong, SF, 2009)		1.38
"Dasatinib has demonstrated activity in all phases of CML and Ph+ acute lymphocytic leukemia and is approved for the treatment of adults in this setting."( Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Cortés, JE; Jabbour, E; Kantarjian, H, 2008)		1.07
"Dasatinib has pH-dependent solubility and is bioavailable as an oral formulation."( Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
Agrawal, S; Bertz, R; Blackwood-Chirchir, A; Eley, T; Li, T; Luo, FR; Manning, J; Sanil, A, 2009)		1.3
"Dasatinib has additive or synergistic activity in combination with a number of other agents, including cytotoxic agents and targeted therapies, providing a rationale for combination treatment in a clinical setting."( Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
Araujo, J; Logothetis, C, 2010)		2.52
"Dasatinib has significant clinical activity in patients with imatinib resistance."( First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Borthakur, G; Burger, J; Champlin, R; Cortes, J; Dara, S; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Garris, R; Jones, D; Jorgensen, J; Kantarjian, H; Kebriaei, P; O'Brien, S; Ravandi, F; Thomas, D; Wierda, W, 2010)		1.36
"Dasatinib has shown anti-proliferative and anti-invasive effects in vitro; however, not all melanoma cells tested were sensitive to dasatinib."( 2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.
Clynes, M; Crown, J; Doolan, P; Dowling, P; Eustace, AJ; Henry, M; Meleady, P; O'Donovan, N, 2011)		1.34
"Dasatinib 100 mg QD has a favorable safety profile and maintains a similar degree of activity as the previously reported twice-daily dosing schedules. "( Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Carducci, MA; Culine, S; Fizazi, K; Gross, ME; Hudes, G; Massard, C; Paliwal, P; Posadas, EM; Sternberg, CN; Trudel, GC; Wilding, G; Yu, EY, 2011)		2.2
"Dasatinib has no activity in patients with EGFR-mutant lung adenocarcinoma with acquired resistance to erlotinib and gefitinib."( Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Miller, VA; Pao, W; Riely, GJ; Rizvi, NA; Sima, CS, 2011)		2.15
"Dasatinib has transformed the treatment of chronic myelogenous leukemia, resulting in durable remissions and prolonged survival. "( Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications.
Ahmed, SI; Al-akhrass, F; Rallapalli, V; Rodriguez, GH; Safdar, A, 2012)		2.04
"Dasatinib has a half-maximal inhibitory concentration 325 times lower than imatinib for BCR-ABL substrate phosphorylation in vitro and is less susceptible to most known molecular mechanisms of BCR-ABL imatinib resistance."( Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott, BL, 2012)		2.54
"Dasatinib has minimal activity as a single-agent in patients with recurrent EOC/PPC."( Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Alpaugh, RK; Brady, WE; Fiorica, JV; Godwin, AK; Hu, W; Lankes, HA; Mannel, RS; Pathak, HB; Schilder, RJ; Shahin, MS; Sood, AK; Zhou, XC, 2012)		2.13
"Dasatinib has been shown in animal studies to cause fetal toxicities, but the effect of exposure during conception and pregnancy in humans is not known."( Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester.
Bayraktar, S; Escalón, MP; Morency, B, 2010)		1.31
"Dasatinib has considerable antineoplastic effects on Barrett's esophagus cell lines carrying genetic markers associated with dysplasia, which correlates with the reversal of p27 deregulation. "( Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Bremner, RM; Fowler, AJ; Inge, LJ; Paquette, KM; Richer, AL; Tran, N, 2013)		3.28
"Dasatinib has been shown preclinically to overcome resistance to gemcitabine. "( A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
Choe, JH; Choe, JM; Falchook, GS; Gallick, GE; George, GC; Hong, DS; Kurzrock, R; Moulder, SL; Naing, A; Piha-Paul, S; Strauss, LC; Wheler, JJ, 2013)		2.09
"Dasatinib has been shown to inhibit growth of Bcr-Abl-dependent chronic myeloid leukemia xenografts in nude mice."( Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Buettner, R; Cheng, JQ; Jove, R; Kim, D; Lee, FY; Lee, JH; Mirosevich, J; Nam, S; Zhang, S, 2005)		1.31
"Dasatinib has demonstrated high efficacy in Phase I and II studies in patients with CML following failure of imatinib therapy."( Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Cortes, J; Kantarjian, H; Quintás-Cardama, A, 2006)		1.29
"Dasatinib has high intrinsic permeability in Caco-2 cells, however, the efflux ratio was approximately two-fold indicating that it may be a substrate for an intestinal efflux transporter."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008)		1.31
"Dasatinib has activity against a number of Imatinib-resistant mutants providing an additional therapeutic option for these patients."( Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel, C, 2007)		1.06
"Dasatinib has shown in vitro and in vivo activity against BCR-ABL, including mutations that are resistant to other available TK inhibitors."( Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg, M, 2007)		2.5
"Dasatinib has a wider spectrum of activity against a broader range of BCR-ABL forms than existing TK inhibitors. "( Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg, M, 2007)		3.23
"Dasatinib has increased potency against ABL compared to the current therapy imatinib, and is effective in many cases where disease is resistant to imatinib."( The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
Blake, S; Hughes, TP; Lyons, AB; Mayrhofer, G, 2008)		1.36
"Dasatinib has been investigated in patients who were resistant or intolerant to imatinib."( Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Cortes, J; Kantarjian, H, 2008)		1.07
"Dasatinib has promising therapeutic potential in managing intracranial leukemic disease and substantial clinical activity in patients who experience CNS relapse while on imatinib therapy."( Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Arnan, M; Brethon, B; Brito-Babapulle, F; Dombret, H; Duarte, RF; Eccersley, L; Elonen, E; Gruber, F; Hjorth-Hansen, H; Höglund, M; Klamova, H; Knutsen, H; Koskenvesa, P; Lee, FY; Lundán, T; Luo, R; Mustjoki, S; Paquette, R; Parikh, S; Porkka, K; Raffoux, E; Rimpiläinen, J; Smykla, R; Wild, R; Zwaan, CM, 2008)		2.51

Actions

Dasatinib can enhance the efficacy of paclitaxel or gemcitabine by reducing the cell viability and inhibiting the cell proliferation. Dasatinib is known to cause adverse pulmonary events such as chylothorax.

ExcerptReferenceRelevance
"Dasatinib may increase Th1 and CD8"( Effects of dasatinib on CD8
Dai, J; He, L; Lin, M; Wang, X; Wei, X, 2020)		2.39
"Dasatinib is known to cause adverse pulmonary events such as chylothorax and has been described in the adult literature but not pediatric literature."( Dasatinib-induced Chylothorax in Chronic Myelogenous Leukemia in Pediatric Patient: Report of a Case and Review of Literature.
Adams, R; Diaz, E; Graham, R; Hickman, K; Ngwube, A, 2020)		2.72
"Dasatinib can enhance the efficacy of paclitaxel or gemcitabine by reducing the cell viability and inhibiting the cell proliferation."( Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells.
Lin, J; Ma, L; Su, GH; Wei, J, 2019)		2.68
"Dasatinib plays synergistic role with oxaliplatin in inhibiting gastric cancer cell growth both in vitro and in vivo, via inhibiting Src activity stimulated by oxaliplatin."( Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Ji, J; Liu, B; Lou, B; Shi, H; Shi, M; Yu, Y; Zhang, J; Zhou, C; Zhu, Z, 2013)		2.11
"Dasatinib may cause various adverse effects such as myelosuppression and pleural effusion. "( Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.
Chang, H; Chou, WC; Hung, YS, 2014)		2.09
"Dasatinib can cause partially reversible PAH. "( [Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review].
Jin, J; Wang, C; Xu, XM, 2016)		2.11
"Dasatinib may cause hemorrhagic colitis via immunological mechanisms in CML."( [Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase].
Ichikawa, K; Komatsu, N; Sato, E; Sunami, Y; Yasuda, H, 2011)		1.38
"Dasatinib did not cause any detectable toxicity of the retina."( Inhibition of PVR with a tyrosine kinase inhibitor, dasatinib, in the swine.
de Castro, JP; Kaplan, HJ; Liu, L; McDonald, K; Scott, PA; Tamiya, S; Umazume, K, 2013)		1.36

Treatment

Treatment with dasatinib caused a decrease in src-phosphorylation and inhibition of downstream pathways, including AKT and ERK1/2 in all cell lines tested. Only the MCF7-TAMR showed a concomitant decrease in markers of cell cycle progression.

ExcerptReferenceRelevance
"Dasatinib treatment that inhibited KRT17-mediated Src activation also resulted in OSCC drug sensitization."( MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
Chen, PM; Cho, CY; Chuang, SE; Huang, WC; Jang, TH; Lin, SC; Lo, GH; Tung, SL; Wang, LH; Yang, YY; Yen, TC, 2022)		1.44
"Dasatinib treatment was associated with a significant reduction in the levels of these biomarkers (P< 0.01)."( sVCAM-1, and TGFβ1 in chronic phase, chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Abdel Hammed, MR; Adam, EN; Ahmed, YA; Bakry, R; Elnaggar, MG, 2022)		1.44
"Dasatinib treatment was stopped for 26 patients who achieved deep molecular response (DMR) within 24 months and were able to maintain DMR for an additional 2 years."( Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group.
Fujita, A; Igarashi, T; Inokuchi, K; Kozai, Y; Kumagai, T; Oba, K; Ohashi, K; Ohyashiki, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Takezako, N; Wakita, H; Yamaguchi, H; Yamamoto, K; Yoshida, C, 2020)		1.54
"Dasatinib treatment may affect the final height of children with AML, and the use of dasatinib after the beginning of adolescence may lead to growth disorder, but dasatinib treatment has little effect on body height in the short-term treatment."( [Influence of dasatinib treatment on body height in children with acute myeloid leukemia].
Jia, YP; Lu, AD; Wu, J; Zhang, LP; Zheng, FY; Zuo, YX, 2020)		2.36
"Dasatinib treatment increased doxorubicin accumulation in myocytes and doxorubicin-induced myocyte damage, likely through its ability to bind to one or more ABC-type efflux transporters."( Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib.
Hasinoff, BB; Patel, D, 2020)		1.53
"Dasatinib treatment also led to a greater increase in bone density in tibiae without metastatic affection, which was accompanied by reduced recruitment of osteoclasts."( Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.
Borzikowsky, C; Damm, T; Gerle, M; Glüer, CC; Heilmann, T; Maass, N; Roscher, M; Rumpf, AL; Schem, C; Tietgen, M; Tiwari, S; Trauzold, A; Will, O, 2020)		2.72
"Dasatinib treatment markedly increases the number of large granular lymphocytes including natural killer (NK) cells in a proportion of Ph"( Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment.
Ishiyama, KI; Kadowaki, N; Kitawaki, T; Otsuka, Y; Takaori-Kondo, A, 2021)		2.27
"Dasatinib-treated NSML mice (0.1 mg/kg) were subjected to echocardiography and assessment of markers of HCM by qRT-PCR."( Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.
Bennett, AM; Giordano, FJ; Huang, Y; Mizuno, K; Perla, S; Vinks, AA; Yi, JS, 2022)		1.86
"Dasatinib treatment of between 0.05 and 0.5 mg/kg in NSML mice yielded an exposure-dependent inhibition of c-Src and PZR tyrosyl phosphorylation and inhibited AKT phosphorylation."( Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.
Bennett, AM; Giordano, FJ; Huang, Y; Mizuno, K; Perla, S; Vinks, AA; Yi, JS, 2022)		1.86
"Dasatinib TDM during treatment initiation was feasible and resulted in a significant reduction of the incidence of PlEff in the long run, without impairing molecular responses."( Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Bergeron, A; Bouchet, S; Busque, L; Cayssials, E; Cayuela, JM; Charbonnier, A; Coiteux, V; Cony-Makhoul, P; Dartigeas, C; Dubruille, V; Escoffre-Barbe, M; Etienne, G; Gardembas, M; Guerci, A; Guilhot, F; Guilhot, J; Huguet, F; Legros, L; Mahon, FX; Molimard, M; Mollica, L; Nicolini, FE; Réa, D; Rousselot, P; Roy, L, 2021)		2.79
"Dasatinib-treated YD-38 or HUVEC showed reduced HIF-1α expression and stability."( Anti-growth and pro-apoptotic effects of dasatinib on human oral cancer cells through multi-targeted mechanisms.
Bishop-Bailey, D; Choi, JS; Jang, BC; Park, JW; Park, NS; Park, YK; Shin, YM; Yadav, AK, 2021)		1.61
"Dasatinib-treated mice, particularly at 5 mg/kg, exhibited accelerated wound closure compared to DMSO-treated controls."( Dasatinib induces loss of vascular integrity and promotes cutaneous wound repair in mice.
Morales, NP; Supharattanasitthi, W; Svasti, S; Wichaiyo, S, 2021)		2.79
"Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18)."( Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
Cortes, J; Gooden, K; Kroog, G; le Coutre, P; Mahon, FX; Mayer, J; Rowlings, P; Saglio, G; Shah, NP; Subar, M, 2017)		1.16
"Dasatinib treatment may be beneficial to patients with PMF and resulted in significant improvements in splenomegaly, clinical symptoms, physical condition, and quality of life. "( Treatment of patients with primary myelofibrosis using dasatinib.
Li, WY; Li, ZD; Lu, XH; Pei, ZX; Song, QL; Xia, RX; Xu, QW; Xu, Y; Zhang, B, 2017)		2.15
"The dasatinib-treated OIR mice also showed a decrease in Src phosphorylation in the periretinal tufts."( Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Seo, S; Suh, W, 2017)		1.24
"dasatinib treatment cohorts and we analyze differences between the cohorts by fitting an established mathematical model of functional CML treatment to individual time courses."( Quantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparison.
Baldow, C; Glauche, I; Kuhn, M; Liebscher, H; Roeder, I; Rothe, T; Roy, A; Schulze, P; Wang, X, 2018)		1.41
"Dasatinib treatment of RANK-expressing MM cells re-sensitized them to anti-cancer drugs."( RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
Asano, R; Imano, M; Jinushi, M; Mashimo, K; Nishida, S; Sakaguchi, K; Satou, T; Takeda, T; Tsubaki, M, 2019)		1.46
"Dasatinib treatment inhibited the production of proinflammatory cytokines including IL-1β, TNF-α, and IL-6, and promoted the production of the anti-inflammatory cytokine IL-10."( Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis.
Bian, H; Bu, X; Cao, X; Guo, K; Yang, C; Zhang, D; Zhu, J; Zhu, Q, 2018)		1.44
"Dasatinib treatment of the mice with intrasplenic xenografts decreased tumor growth and increased survival times, compared with mice treated with vehicle only."( Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.
Corner, SM; Hix, JM; Kiupel, M; Smyth, LA; Takada, M; Yuzbasiyan-Gurkan, V, 2019)		1.43
"Dasatinib treated podocytes show significant changes in focal adhesions, actin cytoskeleton, and morphology that are not observed with other KIs."( Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity.
Au, VH; Azeloglu, EU; Bhattacharya, S; Calizo, RC; Campbell, KN; Cuttitta, CM; Ge, X; Jaimes, EA; Janssen, W; Jayaraman, G; Lee, JJ; Li, H; Liu, T; Murphy, B; Salem, F; van Hasselt, JGC; Wei, C; Wiener, RJ; Wong, JS; Wong, NJ, 2019)		1.49
"Dasatinib treatment inhibited the elevated phosphorylation of CBL-Y371H and CBL-C384R mutants."( CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
Barber, DL; Huang, K; Javadi, M; Richmond, TD, 2013)		1.11
"Dasatinib treatment of athymic nude mice resulted in impaired growth of PC3 cell tumor xenograft."( Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.
Al-Husein, B; DeRemer, DL; Goc, A; Katsanevas, K; Lou, U; Sabbineni, H; Somanath, PR; Steinbach, A, 2014)		1.12
"Dasatinib treatment caused tumor regression in vivo."( Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.
Cho, YJ; Liu, J; MacDonald, TJ; Petersen, W; Schneiderjan, M; Yuan, L; Zhang, H, 2014)		2.57
"Dasatinib treatment demonstrated anti‑ovarian cancer properties, by downregulating p‑Src expression and by inducing cancer cell apoptosis."( Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Hou, T; Huang, Y; Li, J; Xiao, J; Xu, M; Yang, C, 2015)		2.58
"Dasatinib treatment partly restored PF-00477736 sensitivity in resistant cells suggesting that the pharmacological interference of pro-survival pathways can overcome the resistance to Chk1 inhibitors."( Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Bertoni, F; Carrassa, L; Chilà, R; Damia, G; Kwee, I; Lupi, M; Restelli, V; Rinaldi, A, 2015)		1.14
"Dasatinib treatment primarily suppressed PDGF but not insulin-stimulated signaling (Erk versus Akt activation) in both CFb and cardiomyocytes."( Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model.
Balasubramanian, S; Bradshaw, AD; Kasiganesan, H; Kuppuswamy, D; O'Connor, R; Pleasant, DL; Quinones, L; Roche, S; Sundararaj, KP; Zhang, Y, 2015)		2.58
"Dasatinib treatment significantly decreased tumor size in the mouse bearing BTZ-resistant MCL cells, but not in the mouse bearing BTZ-sensitive MCL cells."( Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kang, HJ; Kim, A; Lee, SS; Park, S; Seong, KM, 2015)		1.14
"Dasatinib- or nilotinib-treated patients with baseline renal dysfunction had a greater incidence of transient reversible acute kidney injury (P = .011 and P < .001), and nilotinib-treated patients with renal dysfunction had a greater incidence of bleeding (P < .001)."( Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
Borthakur, G; Cortes, J; Daver, N; Ferrajoli, A; Jabbour, E; Jain, P; Kadia, T; Kantarjian, H; Lahoti, A; O'Brien, S; Pemmaraju, N; Pierce, S; Sasaki, K, 2016)		1.42
"Dasatinib treatment nearly doubles the survival of brainstem glioma-bearing ABC KO mice (44 vs."( ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.
Becher, OJ; Chung, AH; Crabtree, D; Elmquist, WF; Halvorson, KG; Hu, G; Mittapalli, RK; Parrish, KE, 2016)		1.43
"Dasatinib-treated patients in all stages of CML who developed lymphocytosis were more likely to achieve a complete cytogenetic response, and patients who had CML-CP with lymphocytosis were more likely to achieve major and deep molecular responses."( Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Cortes, JE; Hochhaus, A; le Coutre, P; Mohamed, H; Mustjoki, S; Porkka, K; Saglio, G; Schiffer, CA; Shah, NP, 2016)		1.43
"Dasatinib treatment markedly increases the number of large granular lymphocytes (LGLs) in a proportion of Ph"( Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph
Amakawa, R; Anzai, N; Arima, N; Hatanaka, K; Ishikawa, T; Ishiyama, K; Kadowaki, N; Kitawaki, T; Matsui, M; Moriguchi, T; Nakabo, Y; Nohgawa, M; Oka, S; Okada, M; Onaka, T; Sozu, T; Sugimoto, N; Tabata, S; Takaori-Kondo, A, 2017)		1.9
"Dasatinib treatment impaired cells migration, and both sequential and co-administration with PEM significantly increased apoptosis."( Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Bracco, E; Busso, S; Di Blasio, L; Lo Iacono, M; Monica, V; Papotti, M; Peracino, B; Primo, L; Scagliotti, G, 2016)		2.6
"Upon dasatinib treatment migration, invasion and adhesion could be inhibited in-vitro and in-vivo whereas proliferation was unchanged."( Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.
Bootz, F; Brägelmann, J; Brossart, P; Duensing, S; Kirfel, J; Konantz, M; Kristiansen, G; Lengerke, C; Perner, S; Queisser, A; Sanders, C; Schröck, A; Vogel, W; von Mässenhausen, A, 2016)		1.13
"Dasatinib treatment mediated endothelial cell dysfunction via increased production of ROS that was independent of Src family kinases."( Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Bouchet, S; Chaumais, MC; Guignabert, C; Huertas, A; Humbert, M; Jutant, EM; Le Hiress, M; Manéglier, B; Molimard, M; Montani, D; Phan, C; Rousselot, P; Sattler, C; Seferian, A; Simonneau, G; Sitbon, O; Tamura, Y; Thuillet, R; Tu, L, 2016)		2.6
"Dasatinib-treated mice were administered intraperitoneally with lipopolysaccharide (LPS) and serum cytokine (tumor necrosis factor-alpha [TNF-alpha], interleukin [IL]-10, and IL-6) levels and neutrophil accumulation in the lungs were analyzed. "( Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo.
Diener, KR; Fraser, CK; Hayball, JD; Hughes, TP; Kumar, R; Lousberg, EL, 2009)		3.24
"Dasatinib-treated mice had reduced serum levels of TNF-alpha in response to LPS administration; however, other inflammatory hallmarks of systemic LPS administration, such as secretion of IL-6 and accumulation of neutrophils in the lung, were unaffected. "( Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo.
Diener, KR; Fraser, CK; Hayball, JD; Hughes, TP; Kumar, R; Lousberg, EL, 2009)		3.24
"Dasatinib treatment reduced MMP-9 levels in the tumor microenvironment through the simultaneous inhibition of recruitment of MMP9+ myeloid cells and MMP-9 gene expression in tumor-infiltrating myeloid cells."( Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment.
Herrmann, A; Jove, R; Kujawski, M; Lee, F; Liang, W; Loera, S; Lu, J; Wen, W; Wu, J; Yen, Y; Yu, H, 2010)		1.08
"Dasatinib treatment also inhibits in vivo pancreatic tumor growth."( Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Merchant, NB; Nagaraj, NS; Revetta, F; Smith, JJ; Washington, MK, 2010)		1.08
"Dasatinib treatment caused loss of pSRC in all cell lines, with 50% growth inhibition for IGROV1 at 70 nM, OVCAR3 at 34 nM, A2780 at 4.1 μM and SKOV3 at 530 nM."( Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Adams, DJ; Ayeni, TA; Barry, WT; Berchuck, A; Grace, L; Murphy, SK; Rubatt, JM; Secord, AA; Starr, MD; Teoh, D, 2011)		2.53
"Dasatinib treatment of WM-266-4 cells resulted in phosphoprotein alterations to four unique protein species."( 2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.
Clynes, M; Crown, J; Doolan, P; Dowling, P; Eustace, AJ; Henry, M; Meleady, P; O'Donovan, N, 2011)		1.34
"Dasatinib treatment is associated with mild thrombocytopenia and an increased risk of bleeding, but its biological effect on megakaryocytopoiesis and platelet production is unknown."( Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
Ghevaert, C; Massberg, S; Mazharian, A; Watson, SP; Zhang, L, 2011)		2.53
"Dasatinib treatment impaired the metastatic phenotypes of the human prostate cancer cell lines, PC-3, DU-145, and LNCaP, by significantly reducing migration and invasion in modified Boyden chambers."( Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Lepler, S; Pampo, C; Rice, L; Siemann, DW, 2012)		1.39
"Dasatinib treatment inhibited Src signaling, decreased growth, and induced cell-cycle arrest and apoptosis in a subset of thyroid cancer cells. "( Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Chan, CM; Haugen, BR; Jing, X; Lim, DJ; Lund, GS; Pike, LA; Sams, SB; Schweppe, RE; Sharma, V; Zhou, Q, 2012)		2.09
"Dasatinib pre-treatment inhibited Akt and ERK phosphorylation in CLL cells upon stimulation with CXCL12."( Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12.
Cosimo, E; Leach, MT; McCaig, AM; Michie, AM, 2012)		2.54
"Treatment with dasatinib down-regulated miRNA-17 expression, leading to the restoration of WiF-1 and smad-7 which cause the inhibition of both Wnt/β-catenin and TGF-β/smads signalling."( Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt/β-catenin and TGF-β/smads pathways.
Abdelhamid, AM; Zaafan, MA, 2022)		2.5
"Treatment with dasatinib may offer a novel treatment strategy for IDH1-mutant AML."( Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML).
Baldus, CD; Bastian, L; Beder, T; Bultmann, M; Fransecky, L; Hänzelmann, S; Hartmann, A; Hübner, E; Lenk, L; Lipinski, S; Neumann, M; Richter, K; Röllig, C; Schewe, DM; Schultz, K; Silva, P; Spielmann, M; Steinhäuser, S; Vogiatzi, F; Xia, S; Yumiceba, V, 2023)		1.25
"Treatment with dasatinib for chronic myeloid leukemia (CML) has been associated with development of pleural effusion; however, data regarding its optimal management are limited. "( An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
Brokars, J; Chang, E; LeBlanc, TW; McBride, A; Reddy, SR; Tarbox, MH, 2023)		1.62
"Treatment with dasatinib and quercetin effectively attenuated spinal neuroinflammation and mitigated the hypersensitivities of the rats subjected to sciatic nerve CCI."( Astrocyte senescence-like response related to peripheral nerve injury-induced neuropathic pain.
Cheng, N; Deng, Y; Du, J; Hei, Z; Li, X; Liang, J; Xiang, P; Zhang, Z, 2023)		1.25
"Treatment with dasatinib increased significantly the number of apoptotic PE-MSC compared to NP-MSC (0.011 vs."( Targeting senescence improves angiogenic potential of adipose-derived mesenchymal stem cells in patients with preeclampsia.
Butler Tobah, YS; Chebib, FT; Cubro, H; Garovic, VD; Grande, JP; Jordan, KL; Kirkland, JL; Lerman, LO; Milic, NM; Suvakov, S; Tchkonia, T; Weissgerber, TL; White, WM; Woollard, JR; Xu, M; Zhu, XY, 2019)		0.85
"Treatment with dasatinib significantly increased the melanin content and tyrosinase activity through the up-regulation of MITF and tyrosinase expressions."( Dasatinib, a second-generation tyrosine kinase inhibitor, induces melanogenesis via ERK-CREB-MITF-tyrosinase signaling in normal human melanocytes.
Kang, B; Kang, HY; Kim, Y; Park, TJ, 2020)		2.34
"Treatment with dasatinib, a second-generation Bcr-Abl tyrosine kinase inhibitor, was initiated, and complete cytogenetic remission was achieved."( A case of long-term dasatinib-induced proteinuria and glomerular injury.
Hamatani, H; Hiromura, K; IIzuka, A; Ikeuchi, H; Ishizaki, T; Kaneko, Y; Koinuma, K; Nakasatomi, M; Sakairi, T; Watanabe, M; Watanabe, Y, 2020)		1.22
"Pretreatment with dasatinib may accentuate combination therapy toxicity."( Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
Bischoff, F; Bodurka, D; Coleman, RL; Fellman, BM; Garcia, ME; Hu, W; Meyer, LA; Nick, A; Palancia, J; Ram, P; Ramirez, PT; Schmeler, K; Soliman, P; Sood, AK; Westin, SN; Yuan, Y; Zhu, Z, 2021)		2.39
"Treatment with dasatinib, a tyrosine kinase inhibitor, is associated with edema, pleural effusion, and pulmonary edema. "( Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK pathway.
Dasgupta, SK; Le, A; Thiagarajan, P; Vijayan, KV, 2017)		2.25
"By treatment with dasatinib, he achieved complete hematological remission, but his difficulty in walking was not improved."( A first case of adrenomyeloneuropathy with mutation Y174S of the adrenoleukodystrophy gene.
Enya, M; Horikawa, Y; Kitagawa, J; Shimozawa, N; Takashima, S; Takeda, J; Yoshikura, N, 2017)		0.78
"Treatment with dasatinib is expected to produce 3.65, 0.59, and 0.15 more quality-adjusted life years (QALYs) in comparison with high-dose imatinib (600 and 800 mg) and nilotinib, respectively. "( An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.
Li, T; Lin, H; Liu, M; Wu, B; Zhong, H, 2017)		1.07
"Upon treatment with dasatinib, we observed a switch in activity at the invasive borders, correlating with impaired metastatic capacity in vivo."( Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer.
Anderson, KI; Brunton, VG; Campbell, AD; Carragher, NO; Edward, M; Evans, TR; Frame, MC; Karim, SA; McGarry, LC; McGhee, EJ; Morton, JP; Nobis, M; Quinn, J; Sansom, OJ; Schwarz, JP; Timpson, P; Wang, Y, 2013)		0.98
"Pretreatment with dasatinib, a broad spectrum tyrosine kinase inhibitor, blocked phosphorylation of PKCδ at both Tyr-64 and Tyr-155."( Inhibiting tyrosine phosphorylation of protein kinase Cδ (PKCδ) protects the salivary gland from radiation damage.
Adwan, TS; Anderson, SM; DeGregori, J; Reyland, ME; Wie, SM, 2014)		0.73
"Treatment with dasatinib or nilotinib is likely to be more cost-effective than treatment with high-dose imatinib in CP-CML patients who do not respond positively to standard-dose imatinib in the Thai context. "( Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
Chansung, K; Jootar, S; Kulpeng, W; Sompitak, S; Teerawattananon, Y, 2014)		1.06
"Treatment with dasatinib was then started and after 34-month follow-up the patient is still in major molecular response, thus suggesting that eradication of the T315I mutation could be achieved without third-generation tyrosine kinase inhibitors."( Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report.
Beaufils, N; Ciccolini, J; Colle, J; Costello, R; Fanciullino, R; Gabert, J; Hadjaj, D; Ivanov, V; Mercier, C; Sebahoun, G; Suchon, P; Venton, G, 2015)		0.76
"Treatment with dasatinib caused a decrease in src-phosphorylation and inhibition of downstream pathways, including AKT and ERK1/2 in all cell lines tested, but only the MCF7-TAMR showed a concomitant decrease in markers of cell cycle progression."( Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Dowsett, M; Guest, SK; Johnston, SR; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Ribas, R; Simigdala, N, 2016)		0.77
"Treatment with dasatinib or the heat shock protein 90 inhibitor IPI-504 may provide a therapeutic alternative for GIST patients whose tumors carry the imatinib-resistant PDGFRA(D842V) mutant isoform."( Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
Cools, J; Debiec-Rychter, M; Dewaele, B; Marynen, P; Prenen, H; Schöffski, P; Sciot, R; Vandenberghe, P; Wasag, B; Wozniak, A, 2008)		1.08
"Treatment with dasatinib decreased EphA2 phosphorylation in BxPC-3 xenografts, suggesting that dasatinib might have activity in pancreatic cancer due to EphA2 inhibition, besides its effects on Src."( Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
Chang, Q; Hedley, DW; Jorgensen, C; Pawson, T, 2008)		1.08
"Treatment with dasatinib alone significantly lowered sacrifice serum prostate-specific antigen levels compared to control, 2.3+/-0.4 vs 9.2+/-2.1 (P=0.004). "( Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Brown, LG; Corey, E; Koreckij, T; Nguyen, H; Vessella, RL; Yu, EY, 2009)		2.15
"Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. "( Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Ayala, M; Baccarani, M; Bleickardt, E; Boqué, C; Bradley-Garelik, MB; Chuah, C; Cortes, J; Hochhaus, A; Huguet, F; Kantarjian, H; Mayer, J; Moiraghi, B; Nakamae, H; Pasquini, R; Shah, NP; Shah, S; Shapiro, D; Shen, Z; Szatrowski, T; Zhu, C, 2010)		2.16
"Treatment with dasatinib blocked PTC tumor growth in an orthotopic model by more than 90% (P = 0.0014)."( Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Chan, CM; Haugen, BR; Jing, X; Lim, DJ; Lund, GS; Pike, LA; Sams, SB; Schweppe, RE; Sharma, V; Zhou, Q, 2012)		0.99
"Treatment with dasatinib attenuated the levels of autophosphorylated Bcr-Abl, p-CrkL, phospho-signal transducer and activator of transcription 5 (p-STAT5), p-c-Src, and p-Lyn; inhibited the activity of Lyn and c-Src; and induced apoptosis of the cultured CML cells. "( Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Balasis, M; Bali, P; Bhalla, K; Estrella, V; Fiskus, W; Herger, B; Kumaraswamy, S; Lee, F; Pranpat, M; Rao, R; Richon, V; Rocha, K, 2006)		0.91

Toxicity

Ponatinib and dasatinib seemed to be both safe for the clinical application of Ph-positive CNSL. Pleural effusion is a frequent side effect in patients during d asatinib treatment. Liver dysfunction is a common side effect associated with the treatment of dasasinib.

ExcerptReferenceRelevance
" This article speculates that cyclosporine eye drops would also be useful for any disease causing ectropion or eclabion of the eye as well as toxic epidermal necrolysis-related eye pathology (in particular corneal scarring)."( A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Scheinfeld, N, 2007)		0.61
" Recently, dasatinib dose optimisation in chronic-phase has reduced the incidence of such adverse events without modification of the efficacy, however, their optimal overall management can efficiently reduce their severity and minimize their impact on disease response."( [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Bergeron, A; Cony-Makhoul, P; Corm, S; Dubruille, V; Nicolini, FE; Rea, D; Rigal-Huguet, F, 2008)		1.01
" Here, we review the clinical profile of dasatinib in imatinib-resistant and -intolerant patients and share clinical approaches for managing adverse events (AEs) to ensure maximum patient benefit."( New dosing schedules of dasatinib for CML and adverse event management.
Wong, SF, 2009)		0.93
" Although these agents are normally safe and effective, they can cause side effects that lead to intolerance and necessitate switching to an alternative treatment."( Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Deininger, M; Hochhaus, A; Jabbour, E, 2011)		0.37
" In clinical trials of dasatinib, the adverse events that arise during therapy are mostly mild to moderate in severity and are usually reversible and manageable with appropriate intervention."( Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Shayani, S, 2010)		2.11
" Dasatinib was well-tolerated, with only 6 patients (13%) with drug-related grade 3-4 adverse events and 3 (6%) with grade 3 adverse events."( Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Carducci, MA; Culine, S; Fizazi, K; Gross, ME; Hudes, G; Massard, C; Paliwal, P; Posadas, EM; Sternberg, CN; Trudel, GC; Wilding, G; Yu, EY, 2011)		1.67
" Dasatinib, at the recommended dose of 100mg/day, is effective and safe also in unselected elderly subjects."( Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Abruzzese, E; Alimena, G; Annunziata, M; Binotto, G; Breccia, M; Castagnetti, F; Cavazzini, F; Crisà, E; Fava, C; Feo, C; Gozzini, A; Latagliata, R; Luciano, L; Montefusco, E; Musto, P; Occhini, U; Pregno, P; Rossi, AR; Rosti, G; Santini, V; Sorà, F; Stagno, F; Tiribelli, M; Ulisciani, S; Vigneri, P, 2011)		2.72
" Workup demonstrated pleuropericardial effusion that turned out to be a side effect of this new investigational drug."( New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report.
Baurain, JF; Humblet, Y; Machiels, JP; Mano, M; Mazzeo, F; Seront, E; Sterckx, M, )		0.13
" The hematologic/cytogenetic response, progression-free-survival (PFS), overall survival (OS) and adverse effects (AE) of the pts were assessed."( [Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
Hu, JD; Huang, XJ; Jin, J; Li, JY; Liu, T; Meng, FY; Shen, ZX; Wang, JM; Wang, JX; Wu, DP, 2012)		0.66
" Most common adverse events (AE) were any grade nausea (58%), hand-foot syndrome (44%), diarrhea (33%), fatigue (33%), vomiting (31%), and asthenia (31%)."( Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
Atzori, F; Cortes, J; Geese, WJ; Gradishar, WJ; Rybicki, A; Somlo, G; Specht, JM; Strauss, LC; Sy, O; Vahdat, LT, 2013)		1.83
" This review discusses the potential impact of treatment-, patient-, and disease-related characteristics on the emergence of adverse events during TKI therapy, with a focus on the underlying mechanisms believed to be responsible for a number of important adverse events associated with these agents and what implications they may have for treatment choice, particularly in the setting of first-line treatment."( Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine, E; Williams, C, 2013)		0.39
" (2) The drug-related adverse events were mostly grade 1/2 and were well-tolerated."( [Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia].
Hu, JD; Huang, XJ; Shen, ZX; Wang, JX; Zhou, L, 2013)		0.64
"Dasatinib is an effective and safe therapy option and can be used as first-line therapy for newly diagnosed CML-CP patients."( [Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia].
Hu, JD; Huang, XJ; Shen, ZX; Wang, JX; Zhou, L, 2013)		2.09
" In particular, muco-cutaneous side effects represent the most frequent non-hematological adverse events."( Tyrosine kinase inhibitors: muco-cutaneous side effects at the microscope.
Brazzelli, V; Croci, G; Grasso, V; Vassallo, C, 2014)		0.4
" In a cell-based model, sunitinib reduced CDK5 phosphorylation (pCDK5), calpain-dependent p35/p25 conversion and protected neuronal cells from the toxic effects of gp120."( Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W, 2014)		0.4
"Rare but serious cardiovascular and pulmonary adverse events (AEs) have been reported in patients with chronic myeloid leukemia treated with BCR-ABL inhibitors."( Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Cortes, J; Malhotra, R; Mauro, M; Saglio, G; Steegmann, JL; Ukropec, JA; Wallis, NT, 2015)		0.42
"Liver dysfunction is a common side effect associated with the treatment of dasatinib and its mechanism is poorly understood."( Autophagy protects against dasatinib-induced hepatotoxicity via p38 signaling.
Chen, C; Dai, J; He, Q; Luo, P; Ma, J; Ma, S; Shao, J; Wang, J; Yang, B; Yang, X, 2015)		0.94
" Although all TKIs are associated with nonhematologic adverse events (AEs), experience with imatinib suggested that toxicities are typically manageable and apparent early during drug development."( Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
Deininger, M; Moslehi, JJ, 2015)		0.42
"We analyzed the adverse event rates, response rates, and survival rates of 215 patients with CML-CP with or without renal and/or liver dysfunction who had been treated with front-line nilotinib (n = 108) or dasatinib (n = 107)."( Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
Borthakur, G; Cortes, J; Daver, N; Ferrajoli, A; Jabbour, E; Jain, P; Kadia, T; Kantarjian, H; Lahoti, A; O'Brien, S; Pemmaraju, N; Pierce, S; Sasaki, K, 2016)		0.88
" In conclusion, the combination treatment appeared safe with very promising efficacy."( Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.
Bjerrum, OW; Dreimane, A; Eriksson, KM; Gedde-Dahl, T; Gjertsen, BT; Gruber, FX; Hjorth-Hansen, H; Höglund, M; Koskenvesa, P; Lübking, A; Markevärn, B; Mustjoki, S; Olsson-Strömberg, U; Persson, I; Porkka, K; Richter, J; Stenke, L; Stentoft, J; Udby, L; Vestergaard, H, 2016)		0.67
" However, dasatinib treatment had adverse effect on glucose tolerance in diet-induced obese and Ob/Ob mice."( The Cancer Drug Dasatinib Increases PGC-1α in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice.
Lokurkar, IA; Long, JZ; Richter, EA; Spiegelman, BM; Sylow, L; Zeng, X, 2016)		1.18
"BCR-ABL1 tyrosine kinase inhibitors (TKIs) are established treatments for chronic myelogenous leukemia (CML); however, they are associated with infrequent, but clinically serious adverse events (AEs)."( Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Bilmes, R; Lin, J; Lingohr-Smith, M; Makenbaeva, D, 2017)		0.46
"We analyzed adverse events (AEs) in 201 chronic phase CML patients treated with nilotinib (n = 120) or dasatinib (n = 81) as first- or second-line therapy."( Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Bang, SM; Kim, I; Koh, Y; Lee, JO; Lee, JY; Park, S; Shin, DY; Suh, KJ; Yoon, SS, 2017)		0.93
"Some patients receiving a tyrosine kinase inhibitor (TKI) for the first-line treatment of chronic phase chronic myeloid leukemia (CML-CP) experience intolerable adverse events."( Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Anderson, L; Branford, S; D'Rozario, J; Gervasio, O; Hiwase, D; Hughes, T; Irving, I; Levetan, C; Powell, A; Roberts, W; Solterbeck, A; Tan, P; Taper, J; Traficante, R; Wright, M; Yeung, DT, 2018)		0.48
" Of the non-hematological adverse events associated with intolerance to prior imatinib or dasatinib, 74% resolved within 12 weeks of switching to nilotinib 300 mg bid."( Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Anderson, L; Branford, S; D'Rozario, J; Gervasio, O; Hiwase, D; Hughes, T; Irving, I; Levetan, C; Powell, A; Roberts, W; Solterbeck, A; Tan, P; Taper, J; Traficante, R; Wright, M; Yeung, DT, 2018)		0.7
"Chronic, low-grade adverse events are common in patients with chronic myeloid leukemia who are treated with imatinib."( Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
Abruzzese, E; Kim, DW; Mohamed, H; Pinilla-Ibarz, J; Rong, Y; Saussele, S; Williams, LA; Zyczynski, T, 2018)		0.78
"This multicenter cooperative study aimed to analyze the adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs) used as initial treatment for chronic-phase chronic myeloid leukemia (CML-CP) and their impact on outcome."( Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Fukuhara, T; Haseyama, Y; Hirayama, Y; Ikeda, H; Imamura, M; Ishihara, T; Ito, S; Kakinoki, Y; Kobayashi, H; Kobayashi, R; Kohda, K; Kondo, T; Kuroda, H; Kurosawa, M; Matsukawa, T; Mori, A; Nishio, M; Ota, S; Sakai, H; Sarashina, T; Sato, K; Shindo, M; Takahashi, T; Yamamoto, M; Yamamoto, S; Yoshida, M, 2018)		0.48
" The adverse event (AE) profile of dasatinib at 4 years was similar to that at 6 and 18 months."( Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
Hu, J; Huang, X; Jiang, Q; Jin, J; Li, J; Liu, T; Meng, F; Shen, Z; Wang, J; Wu, D, 2019)		1
" The present study aimed to examine the efficacy and safety of Yinishu as a second-line treatment for CML by comparing the baseline clinical characteristics, rates of adverse events and efficacy between Yinishu and SPRYCEL groups."( Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China.
Bao, Y; Chen, LF; Li, DJ; Li, WM; Meng, L; Ren, HB; Yuan, GL; Zhong, ZD; Zou, P, 2018)		0.77
" Only 6 patients discontinued due to adverse events."( Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Antolín, S; Atienza, M; Benito, S; Caballero, R; Carrasco, E; Escudero, MJ; Falcón, A; Gil-Martin, M; Montaño, Á; Montero, JC; Ocana, A; Orlando, J; Pandiella, A; Pernas, S; Ribelles, N; Rojo, F; Ruiz-Borrego, M; Urruticoechea, A, 2019)		0.82
"Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs)."( Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Ahaneku, H; Boddu, PC; Borthakur, G; Cortes, JE; Estrov, Z; Garcia-Manero, G; Jabbour, E; Jain, P; Kadia, TM; Kantarjian, H; Nogueras-González, GM; O'Brien, S; Ravandi, F; Sam, P; Sasaki, K; Verstovsek, S, 2019)		0.51
"There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice."( Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
Abruzzese, E; Annunziata, M; Baratè, C; Binotto, G; Bonifacio, M; Breccia, M; Caocci, G; Cattaneo, D; De Gregorio, F; Elena, C; Foà, R; Fozza, C; Galimberti, S; Iurlo, A; La Nasa, G; Luciano, L; Martino, B; Molica, M; Mulas, O; Orlandi, EM; Russo Rossi, A; Sgherza, N; Trawinska, MM, 2019)		0.51
"Nephrotoxicity is a critical adverse event that leads to discontinuation of kinase inhibitor (KI) treatment."( Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity.
Au, VH; Azeloglu, EU; Bhattacharya, S; Calizo, RC; Campbell, KN; Cuttitta, CM; Ge, X; Jaimes, EA; Janssen, W; Jayaraman, G; Lee, JJ; Li, H; Liu, T; Murphy, B; Salem, F; van Hasselt, JGC; Wei, C; Wiener, RJ; Wong, JS; Wong, NJ, 2019)		0.76
"Tyrosine kinase inhibitors are known to clinically induce various types of cardiovascular adverse events; however, it is still difficult to predict them at preclinical stage."( Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors.
Ando, K; Chiba, K; Fujiyoshi, M; Goto, A; Hagiwara-Nagasawa, M; Ishii, I; Izumi-Nakaseko, H; Kambayashi, R; Kanda, Y; Naito, AT; Sugiyama, A, 2020)		2
" Pleural effusion is a frequent side effect in patients during dasatinib treatment."( Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Bakanay, SM; Dilek, I; Kucuksahin, O; Maral, S, 2020)		1.01
" PPIs and H2RAs reduce the incidence of dasatinib discontinuation due to adverse events and increase the efficacy of dasatinib chemotherapy for patients."( Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients.
Eto, T; Fukazawa, M; Hayashi, T; Koutake, Y; Nagaishi, H; Nakashima, K; Taniguchi, J; Yasumori, N, 2020)		1.04
" The existing side effect prediction methods mainly focus on the chemical and biological properties of drugs."( Prediction of Side Effects Using Comprehensive Similarity Measures.
Kim, MH; Lee, T; Seo, S; Yoon, Y, 2020)		0.56
" Adverse cardiovascular events were recorded in both groups."( Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
Accurso, V; Badalamenti, G; Bronte, E; Di Lisi, D; Macaione, F; Novo, G; Novo, S; Rinaldi, G; Russo, A; Siragusa, S, 2020)		0.56
"Our study confirms that imatinib is a relatively safe drug, while it reveals that the latest-generation TKIs may cause a burden of cardiovascular complications."( Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
Accurso, V; Badalamenti, G; Bronte, E; Di Lisi, D; Macaione, F; Novo, G; Novo, S; Rinaldi, G; Russo, A; Siragusa, S, 2020)		0.56
" Renal adverse effects may range from asymptomatic proteinuria to renal failure, and their prompt identification and timely treatment is essential for optimal and safe care of the patient."( Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.
Bonomini, M; Di Liberato, L; Morroni, M; Piscitani, L; Sirolli, V, 2020)		0.79
" The most common adverse events were anemia, proteinuria, fatigue, neutropenia, and diarrhea."( A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Li, J; Li, Y; Liu, X; Shen, L; Wu, X; Zhang, B; Zhang, X; Zhou, Y, 2020)		0.79
" Moreover, prolonged treatment produces various adverse effects, such as serious vascular adverse events including stroke, myocardial infarction, and peripheral arterial occlusive disease."( [Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Takaku, T, 2020)		0.56
"Taken together, both blank and dasatinib loaded micelles appear to be safe and their applications in drug delivery for eye diseases should be explored."( Safety assessment of polymeric micelles as an ophthalmic drug delivery system for intravitreal administration of dasatinib.
Gao, Q; Lai, KL; Lee, WYT; Li, HY; Li, Q; Qian, X, 2021)		1.12
" Typical cardiovascular adverse events include pulmonary hypertension caused by dasatinib and arterial occlusive diseases caused by nilotinib and ponatinib."( [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
Miyazaki, S, 2021)		0.85
" However, some patients may require dose reductions to manage the occurrences of adverse events (AEs)."( Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
An, F; Brümmendorf, TH; Cortes, JE; Crescenzo, RJ; Ferdinand, R; Gambacorti-Passerini, C; Kim, DW; Kota, V; Leip, E; Lipton, JH, 2021)		0.62
" Measurements included medications, follow-ups, adverse events, allogeneic stem cell transplantation and quality-adjusted life years (QALYs)."( Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.
Guo, JJ; Hincapie, AL; Li, Y; Yue, X, 2022)		0.72
" Ponatinib, a third generation TKI, has shown a relatively high incidence of serious adverse effects including thrombotic vascular occlusion and heart failure, particularly in patients with a prior history of cardiovascular impairment."( Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
Al Nahedh, M; Aljurf, M; Baqal, OJ; Binzaid, AA; Samarkandi, HH; Soheib, M, 2021)		0.62
" However, other proteins are also inhibited, so they can cause a wide range of adverse effects (AEs)."( [Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center].
Belfrak, F; Beloufa, S; Benlazar, M; Benmehimda, NC; Mahi, E; Matmour, D; Merad, Y; Si-Ali, N; Toumi, H, 2022)		0.72
" No grade 4 adverse events were observed."( Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
Du, X; Jin, J; Liu, P; Lou, J; Meng, L; Wang, W; Yu, W, 2022)		1.01
" (3) Ponatinib and dasatinib seemed to be both safe for the clinical application of Ph-positive CNSL."( Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study.
Jia, T; Mao, J; Miao, L; Wang, Y; Xue, L; Zhu, Y, )		0.71
"This study aimed to conduct a thorough analysis of fluid retention-associated adverse events (AEs) associated with BCR::ABL inhibitors."( Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Cai, J; Huang, J; Jiang, Q; Lin, H; Wu, L; Ye, Q, 2023)		0.91
"Food and Drug Administration Adverse Event Reporting System (FAERS) database for BCR::ABL inhibitors was searched from 1 January 2004 to 30 September 2021."( Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Cai, J; Huang, J; Jiang, Q; Lin, H; Wu, L; Ye, Q, 2023)		0.91
"Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) often experience cutaneous adverse events, such as rashes and pruritus."( Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
Cha, SH; Kim, K; Song, YK, 2023)		0.91
" Two independent reviewers screened the results and selected articles on cutaneous adverse events."( Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
Cha, SH; Kim, K; Song, YK, 2023)		0.91

Pharmacokinetics

Dasatinib is a second-generation tyrosine kinase inhibitor of BCR-ABL 1. It is used for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML)

ExcerptReferenceRelevance
" To support the clinical development of dasatinib, we identified a pharmacodynamic biomarker to assess in vivo SRC kinase inhibition, with subsequent evaluation in cancer patients."( Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Barrett, YC; Blackwood-Chirchir, A; Camuso, A; Fager, K; Galbraith, S; Lee, FY; Luo, FR; McGlinchey, K; Palme, H; Smykla, R; Wen, ML; Wild, R; Yang, Z, 2008)		0.83
" Post marketing study commitments have been made upon (accelerated) approval such as additional pharmacokinetic studies in patients with renal- or hepatic impairment, in children, additional interactions studies and studies on the relative or absolute bioavailability."( Clinical pharmacokinetics of tyrosine kinase inhibitors.
Gelderblom, H; Guchelaar, HJ; van Erp, NP, 2009)		0.35
" Pharmacokinetic data indicated rapid absorption, dose proportionality, and lack of drug accumulation."( Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Agrawal, S; Brunton, VG; Demetri, GD; Evans, TR; Lo Russo, P; MacPherson, IR; Morgan, JA; Paliwal, P; Voi, M; Wang, D, 2009)		0.6
" The pharmacokinetic and cardiac studies indicated that coadministration of dasatinib with potent CYP3A4 inhibitors or agents that prolong the QTc interval should be avoided if possible."( Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
Agrawal, S; Blackwood-Chirchir, A; Burris, H; Chiappori, AA; Dhillon, N; Hong, D; Johnson, FM; Kaul, S; Luo, FR; Rosen, L; Sy, O, 2010)		0.84
" Pharmacokinetic studies were performed with the initial dose."( Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.
Adamson, PC; Agrawal, S; Aplenc, R; Balis, FM; Blaney, SM; Ingle, AM; Shusterman, S; Strauss, LC; Sun, J; Wright, JJ, 2011)		0.62
" Pharmacokinetic and pharmacodynamic studies of dasatinib were performed prior to starting cetuximab and following 14 days of treatment."( Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
Agrawal, S; Appleman, LJ; Argiris, A; Egloff, AM; Feinstein, TM; Grandis, JR; Stoller, RG; Wang, L; Yang, T, 2012)		0.91
" The validated method was successfully applied to the quantification of dasatinib and two active metabolites in a human pharmacokinetic study."( A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
Agrawal, S; Furlong, MT; Hawthorne, D; Krueger, L; Lago, M; Stouffer, B; Unger, S, 2012)		0.83
"Eighteen patients treated with dasatinib and H2RA, PPI or no acid suppressant from whom were obtained a total of 34 pharmacokinetic profiles were enrolled in the study."( Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Miura, M; Niioka, T; Sawada, K; Takahashi, N, 2012)		0.9
"The quantitation method was successfully applied for simultaneous estimation of methotrexate, dasatinib and N- deshydroxyethyl dasatinib in a pharmacokinetic study in Wistar rats."( Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study.
Khagga, M; Thappali, SR; Vakkalanka, SK; Varanasi, KV; Veeraraghavan, S, 2012)		0.86
" Recently developed pharmacokinetic models could explain this phenomenon."( Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Beijnen, JH; de Vries, N; Schinkel, AH; Sparidans, RW; Tang, SC; Wagenaar, E, 2013)		0.59
" The assay has been applied successfully in a pharmacokinetic study."( High-performance liquid chromatographic method for the determination of dasatinib in rabbit plasma using fluorescence detection and its application to a pharmacokinetic study.
Ezzeldin, E; Kassem, MG; Korashy, HM; Mostafa, GA, 2013)		0.62
" In this paper, the pharmacokinetic characteristics (absorption, distribution, metabolism and excretion) and drug-drug interactions of the approved TKIs are reviewed."( [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Ding, JF; Zhong, DF, 2013)		0.39
"This study examined whether oral administration of dasatinib to the rats with imatinib led to any pharmacokinetic interactions."( Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLC-MS/MS.
Ding, T; Geng, P; Ma, J; Wang, S; Wu, M; Zhang, Q; Zhou, Y, 2015)		0.91
" The study investigated pharmacokinetic (PK) and pharmacodynamic (PD) analyses of dasatinib in 51 newly diagnosed, chronic phase, chronic myeloid leukemia patients."( Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.
Hirose, T; Ishida, Y; Ito, S; Kato, Y; Kishino, S; Kondo, T; Kubo, K; Miyagishima, T; Mochizuki, N; Murai, K; Nagashima, T; Ogawa, K; Ohno, K; Oyake, T; Saitou, S; Sato, S; Shindo, M; Watanabe, R; Yamaguchi, K; Yamamoto, S; Yonezumi, M, 2016)		0.93
" PK parameters were obtained from the population pharmacokinetic analysis of dasatinib concentrations in plasma on day 28 after administration."( Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.
Hirose, T; Ishida, Y; Ito, S; Kato, Y; Kishino, S; Kondo, T; Kubo, K; Miyagishima, T; Mochizuki, N; Murai, K; Nagashima, T; Ogawa, K; Ohno, K; Oyake, T; Saitou, S; Sato, S; Shindo, M; Watanabe, R; Yamaguchi, K; Yamamoto, S; Yonezumi, M, 2016)		0.93
" Therefore, the key pharmacokinetic properties are summarized in this report."( Pharmacokinetics of Dasatinib.
Hořínková, J; Šíma, M; Slanař, O, 2019)		0.84
" Dasatinib is eliminated through cytochrome P450 (CYP) 3A4-mediated metabolism, with a terminal half-life of 3-4 h."( Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib.
Becker, G; Bilger, K; Levêque, D; Natarajan-Amé, S, 2020)		1.72
" Four months after starting dasatinib, we performed a pharmacokinetic study."( Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease.
Ishizuka, H; Kimura, S; Miura, M; Mori, J; Oshima, K; Takahashi, N; Tanimoto, T, 2020)		1.18
" The method was successfully applied for pharmacokinetic interaction between dasatinib and posaconazole."( Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats.
Lin, G; Wang, C; Wang, Y; Wen, C; Yang, S; Zhang, X; Zhou, Z, 2021)		1.07
" To this end, we investigated experimentally and assessed computationally the in vitro pharmacodynamic drug-drug interactions of the various dual and triple combinations to assess their subsequent combinatorial effects (synergistic/additive/antagonistic) in a HER2-therapy resistant BC cell line, JIMT-1."( Experimental and computational assessment of the synergistic pharmacodynamic drug-drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells.
Ait-Oudhia, S; Vaidya, TR, 2022)		0.72
" We developed a physiologically based pharmacokinetic (PBPK) model to assess drug-drug interaction (DDI) potential between dasatinib and known substrates for these transporters in a virtual population."( Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.
Bathena, S; Chang, M; Christopher, LJ; Roy, A; Shen, H, 2022)		1.16
"Dasatinib, a second-generation tyrosine kinase inhibitor of BCR-ABL 1, used for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML), exhibits high pharmacokinetic (PK) variability."( Population Pharmacokinetics and Pharmacogenetics Analyses of Dasatinib in Chinese Patients with Chronic Myeloid Leukemia.
Bian, J; Guo, N; He, H; He, S; Hu, L; Huang, L; Jiang, Q; Li, Y; Liu, B; Shao, Q; Zhao, J; Zhao, Y, 2023)		2.59

Compound-Compound Interactions

Cyclosporine had an additive or synergistic effect on T-cell proliferation when combined with dasatinib and imatinib. In xenografts derived from these two cell lines, d asatinib did not improve the efficacy of cetuximab combined with radiotherapy.

ExcerptReferenceRelevance
" Dasatinib in combination with temozolomide more effectively increased the therapeutic efficacy of temozolomide than when dasatinib was combined with carboplatin or irinotecan."( Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
de Groot, J; LaFortune, T; Milano, V; Piao, Y, 2009)		2.71
" Therefore, they are regularly co-administered along with treatments at risk of drug-drug interactions."( Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
Buclin, T; Decosterd, LA; Duchosal, MA; Haouala, A; Montemurro, M; Widmer, N, 2011)		0.61
" Drug-drug interactions and a maximum tolerated dose were not identified."( Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
Agrawal, S; Araujo, JC; Armstrong, AJ; Braud, EL; Gallick, GE; Logothetis, CJ; Lonberg, M; Mathew, P; Paliwal, P; Posadas, E; Trudel, GC, 2012)		1.82
" Cyclosporine had an additive or synergistic effect on T-cell proliferation when combined with dasatinib and imatinib for 3 of the 4 methods of stimulating T-cell proliferation."( Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.
Blake, SJ; Hughes, TP; Lyons, AB, 2012)		0.82
" KX-01 was evaluated as a single-agent and in combination with paclitaxel in MDA-MB-231, MDA-MB-157, and MDA-MB-468 human ER/PR/HER2-negative breast cancer cells."( Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Ali, A; Anbalagan, M; Bu, Y; Carrier, L; Hangauer, D; Jones, RK; Marsden, CG; Rowan, BG; Sheng, M, 2012)		0.38
"We conducted a phase I study of dasatinib, an oral SRC-family tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin in the treatment of advanced and recurrent epithelial ovarian cancer."( A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Barry, WT; Berchuck, A; Broadwater, G; Havrilesky, LJ; Lancaster, J; Lee, PS; Secord, AA; Teoh, DK; Wenham, RM; Yu, M, 2012)		0.99
"Due to the high incidence of myelosuppression with subsequent cycles, the recommended phase II dose of dasatinib is 150 mg daily in combination with paclitaxel and carboplatin."( A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Barry, WT; Berchuck, A; Broadwater, G; Havrilesky, LJ; Lancaster, J; Lee, PS; Secord, AA; Teoh, DK; Wenham, RM; Yu, M, 2012)		0.92
"The RP2D of dasatinib is 70 mg daily in combination with CapeOx/bevacizumab."( Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Arrowood, C; Blobe, GC; Brady, JC; Cohn, A; Haley, S; Hsu, SD; Hurwitz, HI; McCall, S; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Rushing, C; Starodub, A; Strickler, JH; Uronis, HE; Zafar, SY, 2014)		1.12
"Cetuximab is often combined with radiotherapy in advanced SCCHN."( Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.
Balart, J; Baro, M; de Llobet, LI; Figueras, A; Mesia, R; Skvortsova, I, 2014)		1.85
"In xenografts derived from these two cell lines, dasatinib did not improve the efficacy of cetuximab combined with radiotherapy."( Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.
Balart, J; Baro, M; de Llobet, LI; Figueras, A; Mesia, R; Skvortsova, I, 2014)		2.1
" The effect of the combination with the c-Met inhibitor cabozantinib was studied on cellular growth and invasion analyzed by the Chou-Talaly method."( Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
Andreiuolo, F; Cornilleau, G; Geoerger, B; Grill, J; Guerrini-Rousseau, L; Lacroix, L; Le Dret, L; Östman, A; Paulsson, J; Philippe, C; Puget, S; Richon, C; Truffaux, N; Vassal, G, 2015)		0.72
"Dasatinib exhibits antitumor effects in vitro that could be increased by the combination with another RTK inhibitor targeting c-Met."( Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
Andreiuolo, F; Cornilleau, G; Geoerger, B; Grill, J; Guerrini-Rousseau, L; Lacroix, L; Le Dret, L; Östman, A; Paulsson, J; Philippe, C; Puget, S; Richon, C; Truffaux, N; Vassal, G, 2015)		2.16
" The removal of AZD4547 from the optimized drug combination resulted in 80% of cell viability inhibition, while still maintaining the synergistic interaction."( A streamlined search technology for identification of synergistic drug combinations.
Berndsen, RH; Ding, X; Dyson, PJ; Griffioen, AW; Ho, CM; Nowak-Sliwinska, P; van den Bergh, H; Weiss, A, 2015)		0.42
"The use of imatinib combined with chemotherapy has demonstrated improved outcome in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL)."( Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ahn, JS; Choi, CW; Choi, SY; Eom, HS; Kim, DW; Kim, JS; Kim, SH; Kim, SJ; Kwak, JY; Lee, JJ; Lee, S; Park, SJ; Park, SK; Yang, DH; Yhim, HY; Yoon, JH, 2016)		0.67
" This trial determined the recommended phase II dose (RP2D) and clinical efficacy of the src kinase inhibitor dasatinib combined with zoledronic acid in bone predominant, HER2-negative breast cancer metastases."( TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Blackwell, K; Brewster, AM; Costelloe, CM; Hood, I; Hortobagyi, GN; Ibrahim, NK; Koenig, KB; Mitri, Z; Moulder-Thompson, S; Nanda, R; Rimawi, MF; Van Poznak, C; Wei, C, 2016)		0.93
" Despite a clear potential in inhibiting these proteins in ovarian cancer, as a single agent or in combination with a carboplatin treatment, we need to target kinases in tandem because of their capacity to trigger compensatory pathways that synergize to promote drug resistance."( Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Jean-Claude, B; Thibault, B, 2017)		1.9
"Here we target EGFR, c-Src and Met individually or in combination with carboplatin, using Gefitinib, Dasatinib and Crizotinib respectively, in a panel of carboplatin-sensitive (OVCAR-3, IGROV-1 and A2780) and carboplatin-resistant cells (SKOV-3 and EFO-21)."( Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Jean-Claude, B; Thibault, B, 2017)		2.11
"Crizotinib, Dasatinib and Gefitinib, alone or in combination with carboplatin, showed a cell-specific cytotoxic synergy in ovarian cancer cells."( Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Jean-Claude, B; Thibault, B, 2017)		2.28
" Here, we investigated the sensitivity of a panel of breast cancer cell lines to treatment with various types of HER-family inhibitors alone or in combination with other tyrosine kinase inhibitors or chemotherapeutic agents."( Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
Ashrafi, GH; Modjtahedi, H; Seddon, AM; Stanley, A, 2017)		0.46
" We previously identified Src family kinases as cooncogenic drivers along with T790M and found that the Src inhibitor dasatinib combined with an irreversible or a preclinical T790M-selective EGFR-TKI enhanced antitumor activity in T790M-positive cells."( T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.
Hayashi, H; Kawakami, H; Nakagawa, K; Takeda, M; Takegawa, N; Tanizaki, J; Tsurutani, J; Watanabe, S; Yonesaka, K; Yoshida, T, 2017)		0.93
"Polytherapy (or drug combination cancer therapy (DCCT)), targeting multiple mechanisms associated with tumor proliferation, can efficiently maximize therapeutic efficacy, decrease drug dosage, and reduce drug resistance."( Molecular Engineering-Based Aptamer-Drug Conjugates with Accurate Tunability of Drug Ratios for Drug Combination Targeted Cancer Therapy.
Fang, X; Fu, T; He, N; Huang, Q; Peng, Y; Sun, W; Tan, W; Wang, P; Zhang, P; Zhao, Z; Zhou, F, 2019)		0.51
" In this report, we describe the safe and effective use of trametinib combined with dasatinib in a patient with acute lymphoblastic leukemia (ALL)."( Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report.
Hu, BF; Shen, SH; Wang, GL; Wang, J, 2021)		1.13
"The patient was treated with dasatinib combined with an intermediate risk-oriented chemotherapy."( Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report.
Hu, BF; Shen, SH; Wang, GL; Wang, J, 2021)		1.19
" To this end, we investigated experimentally and assessed computationally the in vitro pharmacodynamic drug-drug interactions of the various dual and triple combinations to assess their subsequent combinatorial effects (synergistic/additive/antagonistic) in a HER2-therapy resistant BC cell line, JIMT-1."( Experimental and computational assessment of the synergistic pharmacodynamic drug-drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells.
Ait-Oudhia, S; Vaidya, TR, 2022)		0.72
" We developed a physiologically based pharmacokinetic (PBPK) model to assess drug-drug interaction (DDI) potential between dasatinib and known substrates for these transporters in a virtual population."( Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.
Bathena, S; Chang, M; Christopher, LJ; Roy, A; Shen, H, 2022)		1.16
" Herein, we demonstrated that dasatinib in combination with BMS-754807 inhibited lung cancer cell growth, while induced autophagy as well as cell cycle arrest at the G1 phase."( Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.
Dong, X; Gong, T; Li, G; Li, X; Liu, C; Niu, Y; Wang, Z; Xu, J; Yu, B; Zhang, C; Zhang, D; Zhang, L; Zhao, H; Zhao, X, 2023)		2.64
"Tyrosine kinase inhibitors combined with conventional chemotherapy (CC) in treating Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) has achieved promising efficacy and safety outcomes."( Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China.
Chen, M; Lin, Y; Liu, L; Lu, X; Ni, J; Yang, H; Zhang, L, 2023)		1.17
"A Markov model was established to simulate a hypothetical cohort of pediatric Ph-positive ALL patients receiving imatinib or dasatinib, combined with CC."( Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China.
Chen, M; Lin, Y; Liu, L; Lu, X; Ni, J; Yang, H; Zhang, L, 2023)		1.37
" The probabilistic sensitivity analysis indicated that treatment with dasatinib combined with CC achieved a 96."( Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China.
Chen, M; Lin, Y; Liu, L; Lu, X; Ni, J; Yang, H; Zhang, L, 2023)		1.4
"Dasatinib combined with CC is likely to be a cost-effective strategy compared to imatinib combination therapy for pediatric Ph-positive ALL in China at a WTP threshold of $37,765/QALY."( Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China.
Chen, M; Lin, Y; Liu, L; Lu, X; Ni, J; Yang, H; Zhang, L, 2023)		2.61
" The new XS004 ASD formulation of dasatinib provided, in contrast to original crystalline dasatinib, superior pH independence with stable bioavailability, thereby minimizing drug-drug interactions."( Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions.
Andersson, P; Brisander, M; Jesson, G; Larfors, G; Lennernäs, H; Liljebris, C; Stenke, L, 2023)		1.43

Bioavailability

Dasatinib is an orally bioavailable potent inhibitor of multiple tyrosine kinases, including ABL and SRC. It is indicated for the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.

ExcerptReferenceRelevance
" BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants."( Overriding imatinib resistance with a novel ABL kinase inhibitor.
Chen, P; Lee, FY; Norris, D; Sawyers, CL; Shah, NP; Tran, C, 2004)		0.32
" Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)."( Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Akin, C; Donker, M; Jiang, Y; Lee, FY; Luo, R; Shah, NP, 2006)		2.69
" BMS-354825 is an orally bioavailable dual Src/Bcr-Abl tyrosine kinase inhibitor currently undergoing clinical trials in cancer patients."( Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib).
Bhalla, KN; Chen, Z; Lee, FY; Wu, J, 2006)		0.54
" Based on the importance of EGFR signaling in lung cancer, the known cooperation between EGFR and Src proteins, and evidence of elevated Src activity in human lung cancers, we evaluated the effectiveness of a novel orally bioavailable Src inhibitor dasatinib (BMS-324825) in lung cancer cell lines with defined EGFR status."( Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Bagui, T; Haura, EB; Jove, R; Lee, FY; Morris, M; Song, L, 2006)		1.96
"Dasatinib is an orally bioavailable potent inhibitor of multiple tyrosine kinases, including ABL and SRC."( Dasatinib.
Shah, NP, 2007)		3.23
" Possible mechanisms contributing to the incomplete oral bioavailability of dasatinib in animals were investigated."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008)		0.82
" Absorption and first-pass metabolism were evaluated as possible reasons for the incomplete oral bioavailability using various in vitro and in vivo models like Caco-2 cells, P-glycoprotein (P-gp) knockout mice, and intra-portal dosing in rats."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008)		0.59
" Oral bioavailability of dasatinib ranged from 14% in the mouse to 34% in the dog."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008)		0.9
" The incomplete oral bioavailability may be due to both incomplete absorption and high first-pass metabolism."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008)		0.59
" The main aims of this model-based analysis were (1) to characterize the IOV and IIV of dasatinib, a novel, orally administered, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases that is indicated for the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia and (2) to demonstrate using simulated data that it is possible to estimate IIV and IOV in relative bioavailability (F(R)) of an orally administered drug, given an adequate sampling scheme."( Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
Blackwood-Chirchir, A; Dai, G; Pfister, M; Roy, A, 2008)		0.79
" We then utilized dasatinib (BMS-354825), a potent, orally bioavailable inhibitor of several tyrosine kinases, including the Src family kinases, to determine if SFKs blockade could abrogate cetuximab- and radiation-induced nuclear EGFR translocation."( Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
Dunn, EF; Iida, M; Li, C; Wheeler, DL, 2010)		2.14
" This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib (BMS-354825, Sprycel), a potent, orally bioavailable inhibitor of several tyrosine kinases, including the Src family kinases (SFKs)."( Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Armstrong, EA; Campbell, DA; Dunn, EF; Hintz, KA; Iida, M; Li, C; Myers, RA; Wheeler, DL, 2011)		2.03
" Herein, we report GZD824 (10a) as a novel orally bioavailable inhibitor against a broad spectrum of Bcr-Abl mutants including T315I."( Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
Bai, Y; Ding, K; Feng, Y; Lang, X; Leng, F; Li, Y; Liu, J; Long, H; Lu, X; Luo, J; Pan, J; Pan, X; Ren, X; She, M; Tu, Z; Wang, D; Wen, D; Zhang, F; Zhang, Z; Zhuang, X, 2013)		0.39
" Friend Leukemia Virus Strain B (FVB) mice were used to determine the bioavailability of elacridar after a 10 mg/kg dose of elacridar in the microemulsion, intraperitoneally (i."( Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Elmquist, WF; Mittapalli, RK; Sane, R, 2013)		0.39
" We have discovered a series of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl) ethynyl)benzamides that are selective and orally bioavailable DDR1 inhibitors."( Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
Ding, K; Duan, L; Gao, M; Lu, X; Luo, J; Ren, X; Tu, Z; Xu, Y; Zhang, L; Zhang, Y; Zhang, Z, 2013)		0.39
" The low bioavailability of Dasatinib may be due to both incomplete oral absorption and first-pass metabolism."( Synthesis and biopharmaceutical studies of JLTN as potential dasatinib prodrug.
Jiang, J; Lang, LW; Liu, F; Lu, HJ; Wang, JM; Wang, SC, 2013)		0.93
" We have examined the biological effects of a highly selective, orally bioavailable JAK2 inhibitor, BMS-911543, in combination with TKIs on CD34+ treatment-naïve IM-nonresponder cells."( Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Chen, M; Jiang, X; Lin, H; Lorenzi, MV; Rothe, K; Woolfson, A, 2014)		0.4
" Further optimization led to low nanomolar, orally bioavailable inhibitors that were selective for DDR1 and DDR2."( Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
Berdini, V; Buck, IM; Carr, ME; Cleasby, A; Coyle, JE; Curry, JE; Day, JE; Day, PJ; Hearn, K; Iqbal, A; Lee, LY; Martins, V; Mortenson, PN; Munck, JM; Murray, CW; Page, LW; Patel, S; Roomans, S; Saxty, G; Smith, K; Tamanini, E, 2015)		0.42
" It also displays good pharmacokinetics properties with an oral bioavailability of 35."( Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.
Ding, K; Lu, X; Luo, J; Pan, X; Ren, X; Wang, D; Yu, R; Zhang, Z; Zhuang, X, 2015)		0.42
" A pharmacokinetic study revealed that 18a had over 4 h of half-life and 24% bioavailability in rats."( Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
Chen, C; Hu, Z; Liang, X; Liu, J; Liu, Q; Liu, X; Lv, F; Qi, S; Qi, Z; Wang, A; Wang, B; Wang, L; Wang, W; Zhang, S; Zhao, Z; Zou, F, 2016)		0.43
" While senolytic treatment significantly improved vasomotor function (isolated organ chamber baths) in both groups of mice, this was due to increases in nitric oxide bioavailability in aged mice and increases in sensitivity to NO donors in hypercholesterolemic mice."( Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice.
Casaclang-Verzosa, G; Hagler, M; Jurk, D; Kirkland, JL; Miller, JD; Ogrodnik, MB; Palmer, AK; Pirtskhalava, T; Roos, CM; Schafer, MJ; Smith, LA; Tchkonia, T; Thalji, NM; Zhang, B; Zhu, Y, 2016)		0.43
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017)		0.46
" Dasatinib's bioavailability is highly dependent on gastric pH."( Pepsi® or Coke®? Influence of acid on dasatinib absorption.
Knoebel, RW; Larson, RA, 2018)		1.66
" curcumin, olive oil, and cocoa extract) could alter the function of ABC transporters and /or CYP450 enzymes, DAS bioavailability could potentially be affected following their co-administration."( Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats.
Abanmy, NO; Alzoman, NZ; Maher, HM; Shehata, SM, 2018)		0.73
" DSB-GNPs exhibited significantly more percentage growth inhibition and enhanced systemic bioavailability compared with pure DSB."( Gold nanoparticles for sustained antileukemia drug release: development, optimization and evaluation by quality-by-design approach.
Adena, SKR; Mishra, B; Upadhyay, M; Vardhan, H, 2019)		0.51
"The in vitro and in vivo evaluation exhibited that the DSB-GNPs have a potential cytotoxic effect, systemic bioavailability and sustained release making them a promising system of DSB delivery in the treatment of chronic myeloid leukemia."( Gold nanoparticles for sustained antileukemia drug release: development, optimization and evaluation by quality-by-design approach.
Adena, SKR; Mishra, B; Upadhyay, M; Vardhan, H, 2019)		0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
" The absolute bioavailability of dasatinib in humans is unknown due to the lack of an intravenous formulation preventing calculation of the reference exposure."( Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib.
Becker, G; Bilger, K; Levêque, D; Natarajan-Amé, S, 2020)		1.09
"Orally administered dasatinib 100 mg once daily was well absorbed by the patient but penetrated poorly into the CSF."( A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Gong, B; Gong, X; Li, L; Li, Y; Lin, D; Liu, B; Liu, K; Mi, Y; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhou, C, 2021)		1.28
"The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption."( Vitamin C Improves Dasatinib Concentrations Under Hypochlorhydric Conditions of the Simulated Stomach Duodenum Model.
Aburub, A; Fadda, HM; Moghrabi, FS, 2022)		1.05
" In a bioavailability study comparing formulations containing 110."( Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans.
Bartůněk, A; Beránek, J; Hauser, T; Hofmann, J; Ryšánek, P; Sedmak, G; Šíma, M; Slanař, O, 2023)		2.35

Dosage Studied

Intermittent dosing of dasatinib with a once daily regimen has been shown to reduce side effects while preserving clinical efficacy in early and advanced phase chronic myeloid leukemia (CML)

ExcerptRelevanceReference
" The oral efficacy of this class of inhibitors was demonstrated with 12m in inhibiting the proinflammatory cytokine IL-2 ex vivo in mice (ED50 approximately 5 mg/kg) and in reducing TNF levels in an acute murine model of inflammation (90% inhibition in LPS-induced TNFalpha production when dosed orally at 60 mg/kg, 2 h prior to LPS administration)."( 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
Barrish, JC; Behnia, K; Chen, P; Cook, LS; Das, J; de Fex, HF; Doweyko, AM; Fang, Q; Gillooly, KM; Lin, J; McIntyre, KW; Moquin, RV; Norris, D; Padmanabha, R; Pang, S; Pitt, S; Schieven, GL; Shen, DR; Shen, Z; Shuster, DJ; Wityak, J, 2006)		0.33
" Absorption and first-pass metabolism were evaluated as possible reasons for the incomplete oral bioavailability using various in vitro and in vivo models like Caco-2 cells, P-glycoprotein (P-gp) knockout mice, and intra-portal dosing in rats."( Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath, AV; Lee, FY; Marathe, PH; Wang, J, 2008)		0.59
" Subtherapeutic dosing is highly likely to result in the selection of a resistant clone; thus, it is of paramount importance to ensure the imatinib dose is sufficient."( New strategies in controlling drug resistance.
Frame, D, 2007)		0.34
"New clinical data are beginning to supply us with effective dosing and monitoring parameters for imatinib and dasatinib treatment of CML."( New strategies in controlling drug resistance.
Frame, D, 2007)		0.55
" The efficacy and tolerability of oral dasatinib has been established in the START phase II trials in adults with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) who were intolerant or resistant to imatinib, and optimal dasatinib dosage regimens were identified in phase III randomized trials."( Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam, SJ, 2008)		2.06
" Here, we review the clinical profile of dasatinib and discuss dosing strategies to manage these adverse events."( Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Wong, SF, 2009)		2.06
" A Phase III dose optimization study showed that the safety profile of dasatinib is improved and efficacy maintained when administered on a 100 mg once-daily dosing schedule compared with the 70 mg twice-daily schedule in patients with chronic phase (CP) CML."( Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Wong, SF, 2009)		2.03
" A dose of 70 mg twice daily remains the recommended dosage for use in patients with advanced phase CML or Ph+ ALL."( Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Wong, SF, 2009)		1.8
"The BCR-ABL inhibitor dasatinib achieves clinical remissions in chronic myeloid leukemia (CML) patients using a dosing schedule that achieves potent but transient BCR-ABL inhibition."( Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Balbas, M; Bleickardt, E; Kasap, C; Nicaise, C; Nicoll, JM; Sawyers, CL; Shah, NP; Weier, C, 2008)		0.66
" Recent clinical trial developments raise questions regarding the proper dosage and schedule of these newer agents as well as the timing of their use in the treatment of patients with CML."( Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.
Bixby, DL; Talpaz, M, 2008)		0.35
"Dasatinib, a tyrosine kinase inhibitor of BCR-ABL, was originally approved for the second-line treatment of any-phase chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia at a dosage of 70 mg twice daily."( New approved dasatinib regimen available for clinical use.
Snyder, DS, 2009)		2.16
"To discuss the new dasatinib dosing regimen for the treatment of chronic phase chronic myelogenous leukemia (CP CML) in patients who failed or were intolerant to imatinib therapy."( Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Tyler, T, 2009)		1.07
" Dasatinib was approved for the treatment of imatinib-resistant/intolerant patients with CML or Philadelphia chromosome-positive acute lymphoblastic leukemia at the dosage of 70 mg twice daily."( Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Tyler, T, 2009)		1.65
" As more clinical data become available and additional novel agents are developed, specific therapy and dosing strategies for individuals with CML will depend on the status of their disease, the anticipated side effects, and concurrent drug therapy."( Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors.
McFarland, KL; Wetzstein, GA, 2009)		0.35
" That dosing regimen, combined with appropriate management of dasatinib-related adverse events, may help patients adhere to their prescribed treatment and achieve maximum therapeutic benefit."( A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
Bryant, G, 2009)		0.96
" Discordant responses could be related to drug dosage variations and unknown BCR-ABL independent mechanisms."( BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Chan, YY; Kwan, TK; Lie, AK; Liu, HS; Ma, ES; Sim, JP; Wan, TS; Yeung, YM; Yip, SF, 2009)		0.35
"Pleural effusion is minimized with dasatinib 100 mg QD dosing and its occurrence does not affect short- or long-term efficacy."( Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.
Cortes, JE; Khoury, HJ; Matloub, Y; Paquette, RL; Porkka, K; Sinha, R, 2010)		2.08
" Segment 2 was designed to evaluate the safety of dasatinib as dosing was increased."( Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
Agrawal, S; Blackwood-Chirchir, A; Burris, H; Chiappori, AA; Dhillon, N; Hong, D; Johnson, FM; Kaul, S; Luo, FR; Rosen, L; Sy, O, 2010)		0.86
"The clinical efficacy of dasatinib in a wide variety of solid tumors and important Phase I/II studies utilizing dasatinib and the optimal dosage used in solid tumors."( Dasatinib in solid tumors.
Haura, EB; Kim, LC; Rix, U, 2010)		2.11
" In patients with chronic-phase chronic myelogenous leukemia, once-daily dosing has similar efficacy with improved safety, compared with twice-daily dosing."( Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Brigid Bradley-Garelik, M; Bullorsky, E; Charbonnier, A; Dombret, H; Ehninger, G; Larson, RA; Lilly, MB; Martinelli, G; Müller, MC; Ottmann, OG; Reiffers, JJ; Shah, NP; Zhu, C, 2010)		1.8
" In light of the potential role of NK cells in the immunesurveillance of residual leukemia and for future combinatory immunotherapeutic approaches, our data indicate that choice and dosing of the most suitable BCR/ABL-inhibitor for a given patient require careful consideration."( The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Grünebach, F; Hilpert, J; Krusch, M; Placke, T; Salih, HR; Salih, J; Steinle, A, 2010)		0.62
" A twice-daily dosing regimen was found to significantly correlate with development of effusions, and therefore once-daily dosing is now approved for treatment of chronic myeloid leukemia and acute lymphoblastic leukemia."( Pleural effusions due to dasatinib.
Brixey, AG; Light, RW, 2010)		0.66
" Imatinib is remarkably effective as treatment for CML in the chronic phase (at a dosage of 400 mg/d) and the accelerated phase (at 600 mg/d)."( Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Schiffer, CA; Zonder, JA, 2006)		0.33
" Although laboratory and clinical studies had led to the prevailing view that continual inhibition of the BCR-ABL kinase was required for optimal efficacy, recent data on dasatinib have upended this notion and have led to a change in the recommended dosing schedule."( How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Deininger, MW; Traer, E, 2010)		0.55
" The different dosing requirements of dasatinib (once daily with or without food) and nilotinib (twice daily with fasting) may be an additional factor in selecting frontline agents."( First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Liu, D; Rafiyath, S; Wei, G, 2010)		0.88
" Dose-response curves were constructed, and drug interaction was assessed by the Combination Index (CI) method."( Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Adams, DJ; Ayeni, TA; Barry, WT; Berchuck, A; Grace, L; Murphy, SK; Rubatt, JM; Secord, AA; Starr, MD; Teoh, D, 2011)		1.81
" Due to toxicity, the starting dosage was decreased to 70 mg twice daily."( A phase 2 trial of dasatinib in advanced melanoma.
Dudek, AZ; Jilaveanu, LB; Kluger, HM; McCann, C; Molinaro, A; Ritacco, J; Southard, N; Sznol, M, 2011)		0.7
" Four-year follow-up of a phase III dose-optimization trial confirmed that better progression-free survival (66%) and overall survival (82%) were obtained with a dose of 100 mg once daily (od) than with the standard 70 mg twice daily dosing (65% and 75%, respectively)."( Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.
Alimena, G; Breccia, M, 2011)		0.68
" Dasatinib, an oral Src family kinase inhibitor, has demonstrated both preclinical and clinical activity with twice-daily dosing in patients with metastatic CRPC."( Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Carducci, MA; Culine, S; Fizazi, K; Gross, ME; Hudes, G; Massard, C; Paliwal, P; Posadas, EM; Sternberg, CN; Trudel, GC; Wilding, G; Yu, EY, 2011)		1.67
"Dasatinib 100 mg QD has a favorable safety profile and maintains a similar degree of activity as the previously reported twice-daily dosing schedules."( Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Carducci, MA; Culine, S; Fizazi, K; Gross, ME; Hudes, G; Massard, C; Paliwal, P; Posadas, EM; Sternberg, CN; Trudel, GC; Wilding, G; Yu, EY, 2011)		2.2
" Twice-daily administration of dasatinib resulted in significantly more patients developing pleural effusions compared with the once-daily dosing schedule, particularly in advanced disease."( Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
Cho, BS; Goh, HG; Kim, D; Kim, DW; Kim, SH, 2011)		0.88
" Because continuous and adequate dosing is important to achieve this outcome, it is important to understand treatment adherence as part of managing long-term CML therapy."( Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Cziraky, M; Davis, C; Hamdan, M; Hirji, I; Oliveria, SA; Yood, MU, 2012)		0.63
" We demonstrate that dasatinib plus erlotinib can be safely co-administered on a continuous, daily dosing schedule with erlotinib, and established the recommended dose level of this combination."( Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; McLendon, RE; McSherry, F; Peters, KB; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Threatt, S; Vredenburgh, JJ; Zhang, S, 2012)		1.04
" Our findings argue for a careful timing and dosing of dasatinib application during leukemia/lymphoma treatment to enhance NK cell immunotherapeutic efforts."( Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
Einsele, H; Hassold, N; Kempf, K; Seggewiss-Bernhardt, R; Seystahl, K; Urlaub, D; Watzl, C; Wischhusen, J; Zekl, M, 2012)		0.84
" This work reports the study of metabolite profiling of dasatinib dosed to Wistar Han rats using automated DBS collection."( Metabolite profiling of dasatinib dosed to Wistar Han rats using automated dried blood spot collection.
Kang, P; Rahavendran, SV; Shen, Z, )		0.68
" Moreover, daily doses calculated based on refill records may not reflect accurate dosing regimens."( A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Chen, L; Griffin, JD; Guérin, A; Ponce de Leon, D; Wu, EQ, 2012)		0.58
" Other toxicities in all cycles included neutropenia (95% grade 3-4; 91% in the 150 mg dosing cohort), thrombocytopenia (35% grade 3-4), and fatigue (10% grade 3)."( A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Barry, WT; Berchuck, A; Broadwater, G; Havrilesky, LJ; Lancaster, J; Lee, PS; Secord, AA; Teoh, DK; Wenham, RM; Yu, M, 2012)		0.71
"Sorafenib or dasatinib displayed sigmoidal or saturation-type dose-response relationships for apoptosis induction, which were uniform or highly divergent, respectively, among individual CLL samples and therefore might complement each other in their clinical potential for CLL."( Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.
Claasen, J; Frenzel, LP; Gehrke, I; Hallek, M; Krause, G; Kuckertz, M; Patz, M; Veldurthy, A; Wendtner, CM, 2012)		0.99
" However, achieving maximum benefit with these drugs may require optimal dosing and adherence to therapy."( Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
Kralj, E; Kristl, A; Pajič, T; Trontelj, J, 2012)		0.63
" Glioma-bearing mice were orally dosed with dasatinib, a kinase inhibitor and dual BCRP/PgP substrate that is being currently tested in clinical trials."( Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
Agarwal, S; Decker, SA; Donelson, R; Elmquist, WF; Gallardo, JL; Mittapalli, RK; Ohlfest, JR; Pokorny, JL; Santacruz, KS; Sarkaria, JN; Seiler, C; Zellmer, DM, 2012)		0.98
" However, the newer targeted anticancer therapies have different pharmacokinetic (PK) and dosing characteristics compared with traditional cytotoxic drugs, making it possible to estimate the steady-state drug exposure with a single trough-level measurement."( Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S, 2012)		0.38
" The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily)."( EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.
Allgeier, A; Brandes, AA; Franceschi, E; Gorlia, T; Hegi, M; Lacombe, D; Laigle Donadey, F; Lhermitte, B; Strauss, LC; Stupp, R; van den Bent, MJ; van Herpen, C, 2012)		0.84
" Using (18)F-SKI249380-containing micelles as radiotracers to estimate therapeutic dosing requirements, we calculated intratumoral drug concentrations (24-60 nM) that were comparable to in vitro 50% inhibitory concentration values."( Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.
Benezra, M; Bradbury, MS; Hambardzumyan, D; Holland, EC; Larson, SM; Longo, V; Ozawa, T; Penate-Medina, O; Phillips, E; Pillarsetty, N; Smith-Jones, P; Veach, DR; Zanzonico, PB, 2012)		0.72
"Intermittent dosing of dasatinib with a once daily regimen has been shown to reduce side effects while preserving clinical efficacy in early and advanced phase chronic myeloid leukemia (CML)."( Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib.
Erben, P; Hochhaus, A; Klag, T; La Rosée, P; Leitner, A; Martiat, P; Müller, MC; Saussele, S; Schenk, T, 2013)		0.93
"Dasatinib 60 mg/m(2) and 80 mg/m(2) once-daily dosing were selected for phase II studies in children with Ph-positive leukemias."( Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM, 2013)		3.28
" With similar levels of efficacy, the choice of second-generation agents should be guided by the characteristics of the individual patient and the most suitable dosing regimen."( Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML).
Abruzzese, E; Breccia, M; Latagliata, R, 2014)		0.4
" We used Hill's equation for in vitro response of Ba/F3 cells transduced with various BCR-ABL mutants to determine IC(50) and the slope of the dose-response curve."( Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.
Druker, BJ; Eide, CA; O'Hare, T; Shukron, O; Vainstein, V, 2013)		0.39
" However, clinically relevant dosing of these adenosine triphosphate-mimetic agents in humans leads to inhibition of numerous tyrosine kinases beyond those touted by drug manufacturers and studied in landmark clinical trials."( Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Fancher, KM; Green, MR; Newton, MD, 2016)		0.43
" Dose-response curves were constructed, and the combination index (CI) for drug interaction was calculated."( Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.
Adams, DJ; Grace, L; Jia, J; Murphy, SK; Nixon, AB; Secord, AA; Teoh, D, 2014)		1.85
"A 23-year-old female with chronic myelogenous leukemia was treated with dasatinib at a dosage of 140 mg/d after failure of imatinib treatment and achieved complete cytogenetic response."( [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].
Liu, B; Mi, Y; Wang, J; Wang, Y, 2014)		0.88
" In TKI therapy for CML patients, therapeutic drug monitoring is a new strategy for dosage optimization to obtain a faster and more effective clinical response."( Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
Miura, M, 2015)		0.66
"The dasatinib concentration required to inhibit 50 % of the CrkL (CT10 regulator of kinase like) phosphorylation in bone marrow CD34+ cells (half maximal (50 %) inhibitory concentration (IC50)CD34+cells) was calculated from each patient's dose-response curve using flow cytometry."( Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.
Hirose, T; Ishida, Y; Ito, S; Kato, Y; Kishino, S; Kondo, T; Kubo, K; Miyagishima, T; Mochizuki, N; Murai, K; Nagashima, T; Ogawa, K; Ohno, K; Oyake, T; Saitou, S; Sato, S; Shindo, M; Watanabe, R; Yamaguchi, K; Yamamoto, S; Yonezumi, M, 2016)		1.26
" A 50 mg/kg/day dosage treatment could almost completely suppress tumor progression in the K562 cells inoculated xenograft mouse model."( Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
Chen, C; Hu, Z; Liang, X; Liu, J; Liu, Q; Liu, X; Lv, F; Qi, S; Qi, Z; Wang, A; Wang, B; Wang, L; Wang, W; Zhang, S; Zhao, Z; Zou, F, 2016)		0.43
"A 55-year-old male with chronic myelogenous leukemia was treated with dasatinib at a dosage of 100 mg/d."( [Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review].
Jin, J; Wang, C; Xu, XM, 2016)		0.9
" Here, we study wild-type mice dosed with dasatinib and find that it causes the transient induction of proliferation of quiescent hematopoietic stem cells (HSCs)."( Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice.
Dagger, SA; Duyvestyn, JM; Langdon, WY; Taylor, SJ, 2016)		2.14
" This clinical trial aimed to determine whether treatment with either of 2 dose schedules of dasatinib results in a progression-free survival (PFS) >50 % at 24 weeks in bone metastasis predominant MBC, to evaluate the toxicity of the 2 dosing regimens, and explore whether treatment results in decreased serum bone turnover markers and patient-reported "worst pain."( Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.
Barlow, WE; Dy, PA; Hayes, DF; Hortobagyi, GN; Keller, ET; Keller, JM; Lew, DL; Moinpour, CM; Schott, AF; Van Poznak, CH, 2016)		0.91
" Three analytical methods, namely ultra high performance liquid chromatography, capillary zone electrophoresis, and sequential injection analysis, were developed, validated, and compared for determination of the drug in the tablet dosage form."( Determination of dasatinib in the tablet dosage form by ultra high performance liquid chromatography, capillary zone electrophoresis, and sequential injection analysis.
Coufal, P; Gonzalez, AG; Hraníček, J; Kozlík, P; Taraba, L, 2017)		0.79
"For patients who experienced adverse drug events, the dose was reduced to 70 or 50 mg/d, whereas for those who tolerated the drug well, the dosage was increased to 140 mg/d (70 mg twice a day)."( Treatment of patients with primary myelofibrosis using dasatinib.
Li, WY; Li, ZD; Lu, XH; Pei, ZX; Song, QL; Xia, RX; Xu, QW; Xu, Y; Zhang, B, 2017)		0.7
" Interestingly, among patients whose DAS dosage was reduced, 59."( Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
Abruzzese, E; Annunziata, M; Baccarani, M; Binotto, G; Bocchia, M; Bonifacio, M; Breccia, M; Bucelli, C; Castagnetti, F; Cattaneo, D; Cortelezzi, A; Fava, C; Ferrero, D; Galimberti, S; Gozzini, A; Gugliotta, G; Iurlo, A; Latagliata, R; Luciano, L; Martino, B; Orlandi, EM; Pane, F; Pregno, P; Pungolino, E; Rege-Cambrin, G; Rosti, G; Saglio, G; Sica, S; Sorà, F; Specchia, G; Stagno, F; Tiribelli, M, 2018)		0.74
" Once-daily dosing regimens for dasatinib in the first and later lines of treatment were established through long-term (5-year and 7-year) trials."( Dasatinib dose management for the treatment of chronic myeloid leukemia.
Atallah, E; Rousselot, P; Saglio, G; Talpaz, M, 2018)		2.21
" A phase I study determined suitable dosing for children with Philadelphia chromosome-positive (Ph+) leukemias."( Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Bertrand, Y; Cardos, RC; Chung, NG; de Martino, ML; De Souza, CA; Fagioli, F; Gore, L; Hijiya, N; Kearns, PR; Lancaster, D; Landman-Parker, J; Place, AE; Rabin, KR; Sacchi, M; Saikia, T; Seo, JJ; Stork, LC; Swanink, R; Zwaan, CM, 2018)		1.92
" The initial dosage of dasatinib for CML-CP and CML-AP patients were 100 mg once daily and 70 mg twice daily (total = 140 mg/ day), respectively."( Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
Hu, J; Huang, X; Jiang, Q; Jin, J; Li, J; Liu, T; Meng, F; Shen, Z; Wang, J; Wu, D, 2019)		1.04
"Dasatinib was dosed at 100 or 200 mg PO BID at 32 and 8 h preoperatively."( A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
Beumer, JH; Christner, SM; Duska, LR; Faust, W; Fracasso, PM; Lothamer, H; Mills, AM; Parsons, SJ; Petroni, GR, 2019)		2.22
" Dasatinib tissue concentrations at 8 h after dosing were associated with modulation of pTyr419Src, total Src protein, and pTyr419Src/Src ratio."( A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
Beumer, JH; Christner, SM; Duska, LR; Faust, W; Fracasso, PM; Lothamer, H; Mills, AM; Parsons, SJ; Petroni, GR, 2019)		1.69
"3 mg/kg was intravenously administered to the halothane-anesthetized dogs for 10 min with an interval of 20 min between the dosing (n = 4)."( Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors.
Ando, K; Chiba, K; Fujiyoshi, M; Goto, A; Hagiwara-Nagasawa, M; Ishii, I; Izumi-Nakaseko, H; Kambayashi, R; Kanda, Y; Naito, AT; Sugiyama, A, 2020)		2
" Dasatinib is a novel tyrosine-kinase inhibitor approved for CML with Philadelphia (Ph) chromosome and the most common adverse effects of dasatinib are peripheral edema and pleural effusion, which sometimes impose the interruption or reduction of dosage of dasatinib treatment, accompanied by diuretic and steroid use."( The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama, R; Harada, K; Ishikawa, J, 2020)		1.74
"5 years old, and the mean dosage of dasatinib and tolvaptan were 58."( The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama, R; Harada, K; Ishikawa, J, 2020)		1.1
"To determine whether dasatinib given at a daily dosage of 80 mg/m2 is more effective than imatinib mesylate at a daily dosage of 300 mg/m2 to improve event-free survival of children with Philadelphia chromosome-positive ALL in the context of intensive chemotherapy without prophylactic cranial irradiation."( Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Cai, J; Chen, X; Cheng, C; Fang, Y; Gao, J; Hu, Q; Hu, S; Jeha, S; Jiang, H; Jin, R; Ju, X; Li, C; Li, CK; Liang, C; Pan, K; Pei, D; Pui, CH; Shen, S; Sun, L; Tang, J; Tian, X; Wang, N; Wu, X; Yang, JJ; Yang, M; Yu, J; Zhai, X; Zhang, H; Zhu, X; Zhu, Y, 2020)		1.28
"Intensive chemotherapy including dasatinib at a dosage of 80 mg/m2 per day yielded superior results in the treatment of Philadelphia chromosome-positive ALL compared with imatinib mesylate at a dosage of 300 mg/m2 per day and provided excellent control of central nervous system leukemia without the use of prophylactic cranial irradiation."( Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Cai, J; Chen, X; Cheng, C; Fang, Y; Gao, J; Hu, Q; Hu, S; Jeha, S; Jiang, H; Jin, R; Ju, X; Li, C; Li, CK; Liang, C; Pan, K; Pei, D; Pui, CH; Shen, S; Sun, L; Tang, J; Tian, X; Wang, N; Wu, X; Yang, JJ; Yang, M; Yu, J; Zhai, X; Zhang, H; Zhu, X; Zhu, Y, 2020)		1.24
" Escalating dose-response experiments on primary VS cells grown from 15 human tumors show that combination therapy with AZD2014 and dasatinib is more effective at reducing metabolic activity than either drug alone and exhibits a therapeutic effect at a physiologically reasonable concentration (~0."( Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.
Beauchamp, RL; DeSouza, P; Ramesh, V; Sagers, JE; Seist, R; Stankovic, KM; Vasilijic, S; Wu, L; Xu, L; Zhang, Y; Zhou, W, 2020)		1.01
"Dasatinib is administered at a fixed starting dosage of 100 mg once daily regardless of patient-specific factors."( Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia.
Do, YR; Ha, JE; Kim, DW; Kim, SH; Lee, JI; Lee, WS; Shin, H; Zang, DY, 2021)		2.36
"The starting dosage of dasatinib may need to be reduced (eg, 80 mg once daily or lower) for Asian patients with CP-CML, especially with lighter BW, to alleviate the risk of DLT occurrence without compromising the achievement of MR."( Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia.
Do, YR; Ha, JE; Kim, DW; Kim, SH; Lee, JI; Lee, WS; Shin, H; Zang, DY, 2021)		1.22
" However, limited clinical data are available regarding the dosage and CNS penetration of dasatinib."( A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Gong, B; Gong, X; Li, L; Li, Y; Lin, D; Liu, B; Liu, K; Mi, Y; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhou, C, 2021)		1.18
" The use of a higher drug dosage (140 mg/d) may increase systemic drug exposure and enhance the penetration of dasatinib into the CSF."( A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Gong, B; Gong, X; Li, L; Li, Y; Lin, D; Liu, B; Liu, K; Mi, Y; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhou, C, 2021)		1.17
"Based on this study, the use of a higher dosage of dasatinib (140 mg/d) is recommended in patients at high risk of CNS relapse or patients who need treatment for CNS leukemia."( A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Gong, B; Gong, X; Li, L; Li, Y; Lin, D; Liu, B; Liu, K; Mi, Y; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhou, C, 2021)		1.21
" This method was successfully applied to pure form, tablet dosage form, spiked human (urine and plasma)."( Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids.
Abdelhameed, AS; Alanazi, AM; AlRabiah, H; Alruqi, OS; Attia, MI; Attwa, MW, 2022)		0.94
" The challenge of understanding the cardiac safety data of ponatinib and the unique dosing schedule based on individual response will be discussed."( How I treat chronic-phase chronic myelogenous leukemia.
Berman, E, 2022)		0.72
" These data suggest that RWPs require more precise dosing to achieve CML clinical milestones and to mitigate AEs, but findings should be validated prospectively."( Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia.
Ahmad, M; Bucci, T; Cass, AS; Crona, DJ; Deal, A; Foster, MC; Kemper, R; Muluneh, B; Sketch, MR; Szeto, AH; Zeidner, JF; Zhu, A, 2022)		0.72
" Intermittent dosing of the senolytics, dasatinib plus quercetin, has shown an acceptable safety profile in clinical studies for other senescence-associated conditions."( Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial.
Craft, S; Garbarino, VR; Gonzales, MM; Kirkland, JL; Marques Zilli, E; Musi, N; Orr, ME; Petersen, RC; Seshadri, S; Tchkonia, T, 2022)		0.99
" Second, the binding of asciminib decreases the binding free energies of nilotinib by ∼3 and ∼7 kcal/mol for the wildtype and T315I-mutated protein, respectively, suggesting the possibility of reducing nilotinib dosage and lowering risk of developing resistance in the treatment of CML."( Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
Amiri, W; Friedman, R; Lindahl, E; Oruganti, B; Rahimullah, R; Yang, J, 2022)		0.72
" These results are to some extent in line with ours, although our analyses of dose-response matrices from combinations of asciminib with imatinib, nilotinib or dasatinib, show neither synergy nor antagonism, but suggest additive antiproliferative effects on BCR-ABL-dependent KCL22 cells."( Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase".
Cowan Jacob, SW; Grzesiek, S; Habazettl, JM; Jahnke, W; Loo, A; Manley, PW; Paladini, J; Wiget, A, 2022)		0.92
" Dosage of the substances was based on the large number of published data of recent years."( Differential in vitro effects of targeted therapeutics in primary human liver cancer: importance for combined liver cancer.
Fey, D; Malik, IA; Rajput, M; Salehzadeh, N; von Arnim, CAF; Werner, R; Wilting, J, 2022)		0.72
" TKI switches (49 times) and dosing changes (165 times) due to intolerance or insufficient response were frequent."( A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia.
Balabanov, S; Cantoni, N; Kahn, S; Kulenkampff, E; Lambert, JF; Schmidt, A; Seitz, P; Sommavilla, R; Zenhaeusern, R, 2022)		0.72
"All participants completed the scheduled drug dosing regimen (108/108 doses) and planned assessments (60/60)."( Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability.
Gelfond, J; Goros, M; Hashmi, S; Justice, J; Kellogg, D; Kirkland, J; Kritchevsky, S; LeBrasseur, N; Limper, A; Masternak, M; Musi, N; Nambiar, A; Pascual, R; Prata, L; Tchkonia, T, 2023)		1.3
" The TKI dosing is more flexible than has been described in the registration trials, and dose adjustments can be considered both in the frontline and later-line settings (e."( Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Issa, GC; Jabbour, E; Kantarjian, HM; Lipton, JH; Radich, JP; Sasaki, K; Senapati, J, 2023)		0.91
" From 4-13 months of age, C57BL/6 male and female mice received monthly oral dosing of either 100 mg/kg Fisetin or a 5 mg/kg Dasatinib (D) plus 50 mg/kg Quercetin (Q) cocktail."( Sexual dimorphic metabolic and cognitive responses of C57BL/6 mice to Fisetin or Dasatinib and quercetin cocktail oral treatment.
Bartke, A; Fang, Y; Hascup, ER; Hascup, KN; McFadden, S; Medina, D; Peck, MR; Quinn, K; Stockwell, R, 2023)		1.34
" The results of this study have broad applicability and help direct effective therapeutic drug usage and dosing regimens and may be useful for clinicians to select the most efficacious therapy at the most beneficial time."( The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism.
Eadie, LN; Hughes, TP; Kok, CH; Leow, BCS; White, DL; Yeung, DT, 2023)		0.91
"This study's findings suggested that low-dose dasatinib would be better suited for Chinese patients, and the dosage can be appropriately reduced according to the increase of age, especially for the elderly."( Population Pharmacokinetics and Pharmacogenetics Analyses of Dasatinib in Chinese Patients with Chronic Myeloid Leukemia.
Bian, J; Guo, N; He, H; He, S; Hu, L; Huang, L; Jiang, Q; Li, Y; Liu, B; Shao, Q; Zhao, J; Zhao, Y, 2023)		1.41
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
tyrosine kinase inhibitorAny protein kinase inhibitor that interferes with the action of tyrosine kinase.
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (8)

ClassDescription
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
1,3-thiazoles
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
N-arylpiperazine
N-(2-hydroxyethyl)piperazine
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Dasatinib Inhibition of BCR-ABL191
Acute myeloid leukemia09

Protein Targets (570)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency7.24740.002541.796015,848.9004AID1347395; AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency1.00080.006038.004119,952.5996AID1159521; AID1159523
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
GLS proteinHomo sapiens (human)Potency15.84890.35487.935539.8107AID624170
PPM1D proteinHomo sapiens (human)Potency0.05870.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency2.82120.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.11530.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency14.29040.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063
Smad3Homo sapiens (human)Potency1.25890.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency23.71010.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency10.43750.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency13.33320.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency15.48710.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency15.99010.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency9.53220.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency8.63890.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency2.68320.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency3.96650.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency16.78420.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency0.59250.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency13.19090.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743079; AID743080; AID743091
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency8.28520.00018.4406100.0000AID720579; AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.47300.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency14.95890.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency12.41870.023723.228263.5986AID743222; AID743223; AID743241
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
aryl hydrocarbon receptorHomo sapiens (human)Potency1.18830.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency1.33330.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency26.60320.001628.015177.1139AID1259385; AID1259395
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency15.84890.10009.191631.6228AID1346983
Histone H2A.xCricetulus griseus (Chinese hamster)Potency42.24970.039147.5451146.8240AID1224845; AID1224896
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency17.18950.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency4.33100.00378.618923.2809AID651784; AID651789; AID651793
tyrosine-protein kinase YesHomo sapiens (human)Potency0.00240.00005.018279.2586AID686947
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency25.11310.000627.21521,122.0200AID743219
gemininHomo sapiens (human)Potency17.81320.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency6.05960.005612.367736.1254AID624032; AID624044
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency10.59090.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency0.07350.00339.158239.8107AID1347407; AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency0.09440.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency10.59090.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency17.80950.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency18.83360.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)IC50 (µMol)30.00000.00010.33717.3000AID507074
Inhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)IC50 (µMol)10.00000.00090.97819.8200AID282242
Aurora kinase AHomo sapiens (human)IC50 (µMol)2.63300.00000.46208.6000AID627131
Inhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)IC50 (µMol)10.00000.03901.40367.4000AID282242
Mitogen-activated protein kinase 13Homo sapiens (human)IC50 (µMol)0.10000.00070.45956.3000AID1504524; AID271954; AID282235
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)27.30000.20005.677410.0000AID1473741
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)IC50 (µMol)0.10900.00104.6143100.0000AID507696
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)Ki0.01000.01000.01000.0100AID1515659
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)81.10000.00032.63119.0000AID1207734
Bile salt export pumpHomo sapiens (human)IC50 (µMol)11.55000.11007.190310.0000AID1449628; AID1473738
Tyrosine-protein kinase ABL1Homo sapiens (human)GI500.70010.00020.61369.6450AID1286550; AID1286558; AID1286560; AID1286561; AID1286562; AID1286563; AID1386050; AID1386051; AID1386084; AID1386085; AID1386086; AID1386087; AID1386088; AID1386089; AID1386090; AID1386091; AID1573067; AID1573068
Tyrosine-protein kinase ABL1Homo sapiens (human)IC50 (µMol)112.79550.00010.712810.0000AID1240468; AID1240469; AID1256160; AID1256161; AID1310125; AID1315391; AID1331473; AID1331474; AID1373713; AID1612818; AID1724048; AID1749148; AID1749203; AID1749204; AID1749205; AID1749206; AID1749207; AID1749208; AID1749209; AID1749210; AID1799577; AID1802640; AID1854085; AID1876062; AID1876260; AID1886530; AID1886531; AID1915579; AID271951; AID282229; AID303305; AID329185; AID463630; AID463631; AID463632; AID507079; AID507680; AID724974; AID724975; AID724976; AID724977; AID724978; AID724979; AID724980; AID724981
Tyrosine-protein kinase ABL1Homo sapiens (human)Ki0.00050.00021.399610.0000AID1515650
Tyrosine-protein kinase ABL1Mus musculus (house mouse)GI500.00100.00100.04300.0850AID1573066
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)IC50 (µMol)0.19220.00040.91515.1000AID1799177; AID1799403; AID375138; AID375139
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)0.71440.00000.536910.0000AID271971; AID282236; AID415072; AID507084; AID507689
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)IC50 (µMol)0.16400.00100.33498.9000AID507688
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)IC50 (µMol)0.71000.00010.545310.0000AID271972; AID282237
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)50.00000.00011.774010.0000AID1749220
Insulin receptorHomo sapiens (human)IC50 (µMol)50.00000.00170.847910.0000AID282246; AID507423
Tyrosine-protein kinase LckHomo sapiens (human)GI500.00100.00100.45700.8700AID1286554
Tyrosine-protein kinase LckHomo sapiens (human)IC50 (µMol)0.00150.00021.317310.0000AID1612823; AID1749181; AID1797004; AID1876284; AID271946; AID282231; AID463629; AID621337; AID627338
Tyrosine-protein kinase LckHomo sapiens (human)Ki0.01000.00060.32222.8000AID1515656
Proto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)IC50 (µMol)0.00040.00040.62452.5000AID1797004
Proto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)Ki0.00010.00010.00010.0001AID271945
Tyrosine-protein kinase FynHomo sapiens (human)IC50 (µMol)0.00120.00021.67898.6800AID1310126; AID1612822; AID1899933; AID271967
Tyrosine-protein kinase FynHomo sapiens (human)Ki0.01000.01003.75507.5000AID1515655
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)IC50 (µMol)0.00780.00060.56765.5450AID1823809; AID1823816; AID458664; AID767460
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)Ki0.01000.00320.00660.0100AID1515653
Tyrosine-protein kinase YesHomo sapiens (human)IC50 (µMol)0.00060.00040.57408.9000AID1310132; AID271968; AID282232; AID761477; AID761478
Tyrosine-protein kinase LynHomo sapiens (human)IC50 (µMol)0.00120.00020.55945.2000AID1612824
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)IC50 (µMol)1.26650.00010.34843.5970AID1310130; AID507422
Insulin-like growth factor 1 receptorHomo sapiens (human)IC50 (µMol)50.00000.00030.43088.0000AID282245
Tyrosine-protein kinase HCKHomo sapiens (human)GI500.03900.03904.61309.7000AID1286556
Tyrosine-protein kinase HCKHomo sapiens (human)IC50 (µMol)0.00100.00011.22267.7000AID507080
Platelet-derived growth factor receptor betaHomo sapiens (human)IC50 (µMol)0.02800.00060.80078.5000AID282234
Platelet-derived growth factor receptor betaHomo sapiens (human)Ki0.01000.00800.00900.0100AID1515658
Quinolone resistance protein NorAStaphylococcus aureusIC50 (µMol)11.50007.00008.50009.7000AID1460599
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)50.00000.00002.015110.0000AID1749225
Mast/stem cell growth factor receptor KitHomo sapiens (human)IC50 (µMol)0.02760.00070.470810.0000AID1310127; AID1724050; AID1749180; AID282233; AID360769; AID507683; AID507684; AID507685; AID507686; AID507687; AID732855
Breakpoint cluster region proteinHomo sapiens (human)GI500.70010.00020.62899.6450AID1286550; AID1286558; AID1286560; AID1286561; AID1286562; AID1286563; AID1386050; AID1386051; AID1386084; AID1386085; AID1386086; AID1386087; AID1386088; AID1386089; AID1386090; AID1386091; AID1573067; AID1573068
Breakpoint cluster region proteinHomo sapiens (human)IC50 (µMol)0.49690.00030.620010.0000AID1240468; AID1240469; AID1256160; AID1256161; AID1315391; AID1373713; AID1854085; AID1915579; AID271951; AID282229; AID463630
Fibroblast growth factor receptor 1Homo sapiens (human)IC50 (µMol)0.88000.00020.942010.0000AID271973; AID282238
Cytochrome P450 2A6Homo sapiens (human)IC50 (µMol)35.00000.00443.889510.0000AID1749221
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1749223
Angiotensin-converting enzyme Homo sapiens (human)Ki715.00000.00000.82557.5000AID1053270
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)GI500.00030.00030.64762.1000AID1286551
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)IC50 (µMol)0.00150.00020.533510.0000AID1206214; AID1310131; AID1612825; AID1724049; AID1749149; AID1854086; AID1876282; AID271950; AID282230; AID303306; AID415071; AID463628; AID498727; AID507081; AID592838; AID627293
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)Ki0.00020.00000.18970.8200AID1515651; AID1893830
Potassium voltage-gated channel subfamily E member 1Homo sapiens (human)IC50 (µMol)251.18900.12004.048010.0000AID1207363
Platelet-derived growth factor receptor alphaHomo sapiens (human)IC50 (µMol)0.03650.00010.491210.0000AID1310129; AID507695
Platelet-derived growth factor receptor alphaHomo sapiens (human)Ki0.01000.00080.00540.0100AID1515657
Tyrosine-protein kinase BlkMus musculus (house mouse)IC50 (µMol)0.00800.00730.00770.0080AID507682
Protein kinase C alpha typeHomo sapiens (human)IC50 (µMol)50.00000.00010.972010.0000AID282248
Cytochrome P450 2B6Homo sapiens (human)IC50 (µMol)50.00000.00113.418610.0000AID1749222
Cyclin-dependent kinase 2Homo sapiens (human)IC50 (µMol)5.00000.00041.044410.0000AID271970; AID282241
Ephrin type-A receptor 2Homo sapiens (human)IC50 (µMol)0.06890.00080.04360.2626AID1802324; AID360770
Ephrin type-B receptor 2Homo sapiens (human)IC50 (µMol)0.00440.00251.58758.5000AID507691
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)IC50 (µMol)50.00000.00020.738710.0000AID282243
RAC-beta serine/threonine-protein kinaseHomo sapiens (human)IC50 (µMol)50.00000.00050.50137.6000AID282243
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)50.00000.00002.398310.0000AID1749224
Vascular endothelial growth factor receptor 2Homo sapiens (human)IC50 (µMol)18.12000.00000.48308.8000AID282240; AID415074; AID507083
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)IC50 (µMol)1.70000.00020.46539.7000AID282239
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)IC50 (µMol)25.70000.00010.32759.5480AID1749178
Tyrosine-protein kinase CSKHomo sapiens (human)IC50 (µMol)0.00130.00131.33525.1800AID1612821
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)IC50 (µMol)38.00000.00000.734010.0000AID507072
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)IC50 (µMol)50.00000.00020.595310.0000AID507073
Serine/threonine-protein kinase mTORHomo sapiens (human)IC50 (µMol)22.50000.00000.857510.0000AID1310128; AID507076
Tyrosine-protein kinase TecHomo sapiens (human)IC50 (µMol)0.29700.00050.06310.4720AID329186
Tyrosine-protein kinase TXKHomo sapiens (human)IC50 (µMol)0.00030.00030.08210.4720AID507700
Tyrosine-protein kinase SYKHomo sapiens (human)IC50 (µMol)4.82000.00010.826010.0000AID1749179
Casein kinase I isoform alphaHomo sapiens (human)IC50 (µMol)0.00100.00102.249910.0000AID507421
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)IC50 (µMol)50.00000.00030.660710.0000AID507075
MAP kinase-activated protein kinase 2Homo sapiens (human)IC50 (µMol)50.00000.00201.16206.0000AID282247
Tyrosine-protein kinase BlkHomo sapiens (human)GI500.00500.00501.80174.1000AID1286555
Potassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)IC50 (µMol)251.18900.12004.048010.0000AID1207363
Ribosomal protein S6 kinase alpha-3Homo sapiens (human)IC50 (µMol)20.00000.00010.53729.9900AID627290
LIM domain kinase 1Homo sapiens (human)IC50 (µMol)0.60970.00240.32451.7783AID1857470; AID1857472; AID1857474; AID1857476; AID507694
LIM domain kinase 2Homo sapiens (human)IC50 (µMol)0.51860.00801.25137.9433AID1857471; AID1857473; AID1857475; AID1857476
Mitogen-activated protein kinase 12Homo sapiens (human)IC50 (µMol)0.10000.00070.47286.3000AID1504524; AID271954; AID282235
Ephrin type-B receptor 4Homo sapiens (human)IC50 (µMol)0.00100.00021.07365.1000AID507085
Serine/threonine-protein kinase SIK1Homo sapiens (human)IC50 (µMol)0.00100.00050.17710.9200AID1749150
Serine/threonine-protein kinase SIK1Homo sapiens (human)Ki0.01000.01000.01000.0100AID1515660
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)IC50 (µMol)50.00000.00051.350010.0000AID507077
Myelin transcription factor 1Homo sapiens (human)IC50 (µMol)0.06300.00720.03510.0630AID729550
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)81.10000.00032.59559.0000AID1207734
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)IC50 (µMol)1.70000.00020.68139.7000AID282239
Focal adhesion kinase 1Homo sapiens (human)IC50 (µMol)50.00000.00020.54168.3000AID282244
Protein kinase C zeta typeHomo sapiens (human)IC50 (µMol)50.00000.00012.445310.0000AID282251
Protein kinase C delta typeHomo sapiens (human)IC50 (µMol)50.00000.00010.844810.0000AID282249
Tyrosine-protein kinase BTKHomo sapiens (human)IC50 (µMol)0.02290.00010.25577.6000AID1612820; AID329184; AID329189; AID329190; AID671741
Tyrosine-protein kinase BTKHomo sapiens (human)Ki0.01000.00320.07030.4250AID1515652
Activated CDC42 kinase 1Homo sapiens (human)Ki0.01000.01000.01350.0170AID1515661
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)GI503.00001.10002.36673.0000AID1286552
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)IC50 (µMol)0.01430.00050.26572.8900AID1202712; AID1802639; AID732858
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)Ki0.01000.01000.01000.0100AID1515654
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)IC50 (µMol)0.22800.00100.30905.6500AID329195
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)32.59660.00091.901410.0000AID1207457; AID1207489; AID1207517; AID1749230
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)81.10000.00032.63119.0000AID1207734
Protein-tyrosine kinase 6Homo sapiens (human)IC50 (µMol)0.00710.00530.57702.3000AID1612819; AID621334
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)243.46530.00032.25459.6000AID1207275; AID1207551; AID1207734
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)249.05350.00033.64849.2000AID1207303; AID1207335
Ribosomal protein S6 kinase alpha-1Homo sapiens (human)IC50 (µMol)20.00000.00010.18611.2600AID627289
Mitogen-activated protein kinase 11Homo sapiens (human)IC50 (µMol)0.10000.00070.47546.3000AID1504524; AID271954; AID282235
Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)0.10000.00010.72667.8000AID1504524; AID271954; AID282235
Discoidin domain-containing receptor 2Homo sapiens (human)GI503.00001.40004.03337.7000AID1286553
Discoidin domain-containing receptor 2Homo sapiens (human)IC50 (µMol)0.11270.00040.39389.0000AID1141136; AID1141137; AID1202713; AID1242616; AID1612903; AID1802639; AID732857
Breakpoint cluster region proteinMus musculus (house mouse)GI500.00100.00100.04300.0850AID1573066
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Aurora kinase BHomo sapiens (human)IC50 (µMol)6.48500.00030.96349.8000AID621336
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)IC50 (µMol)0.10400.00601.062710.0000AID1396666; AID1396667
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)Ki0.03670.00050.47945.2000AID1396666; AID1396667
Serine/threonine-protein kinase SIK2Homo sapiens (human)IC50 (µMol)0.00300.00031.24656.6000AID1749151
Potassium voltage-gated channel subfamily D member 3Homo sapiens (human)IC50 (µMol)316.22801.40005.35009.3000AID1207423
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)2.00000.00401.966610.0000AID1873218
RAC-gamma serine/threonine-protein kinaseHomo sapiens (human)IC50 (µMol)50.00000.00060.47434.0000AID282243
Serine/threonine-protein kinase SIK3Homo sapiens (human)IC50 (µMol)0.00500.00102.01349.6000AID1749152
NF-kappa-B essential modulatorHomo sapiens (human)IC50 (µMol)10.00000.07000.41171.0000AID282242
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene C4 synthaseCavia porcellus (domestic guinea pig)Kd10.00000.93002.54785.7000AID625128
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)0.03250.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)0.03250.00304.57559.8200AID1804127
Bone morphogenetic protein receptor type-1BHomo sapiens (human)Kd15.02650.00091.14133.7000AID1424922; AID624825
Membrane-associated progesterone receptor component 1Homo sapiens (human)Kd30.00000.20400.20400.2040AID1425109
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)Kd10.00000.00331.51757.6000AID624974
Serine/threonine-protein kinase PLK4Homo sapiens (human)Kd16.66670.00081.51449.0000AID1425121; AID436044; AID625076
Serine/threonine-protein kinase 25Homo sapiens (human)Kd6.70000.01202.57349.2000AID435329; AID625059
ATP-dependent RNA helicase DDX3XHomo sapiens (human)Kd30.00000.43500.43500.4350AID1424975
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)Kd10.00000.00051.01525.2000AID624877
Pyridoxal kinaseHomo sapiens (human)Kd30.00000.28605.076516.4040AID1425106
Citron Rho-interacting kinaseHomo sapiens (human)Kd16.66670.03303.064648.8760AID1424954; AID435523; AID625065
Serine/threonine-protein kinase RIO3Homo sapiens (human)Kd10.00000.00771.40999.7000AID435191; AID624926
Dual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)Kd10.00000.02701.44715.3000AID624722
Serine/threonine-protein kinase Chk1Homo sapiens (human)Kd16.66670.00281.47448.7000AID1424953; AID435396; AID624831
Inhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)Kd10.00000.01201.58276.3000AID624836
Peripheral plasma membrane protein CASKHomo sapiens (human)Kd10.00000.01900.93302.8000AID624749
Aurora kinase AHomo sapiens (human)Kd16.43330.00010.73429.3000AID1424917; AID435518; AID624919
Cyclin-G-associated kinaseHomo sapiens (human)Kd0.03410.00030.908628.6510AID1205944; AID1425009; AID1876266; AID435821; AID625012
Serine/threonine-protein kinase DCLK1Homo sapiens (human)Kd10.00000.00491.83608.1000AID435284; AID624966
Inhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)Kd10.00000.00581.50585.9000AID624832
Muscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)Kd10.00000.00310.61284.1000AID435678; AID625022
Ephrin type-B receptor 6Homo sapiens (human)Kd0.01700.00001.07689.0000AID1424995; AID624957
Peroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)Kd30.00000.02601.31402.6020AID1424896
Mitogen-activated protein kinase 13Homo sapiens (human)Kd10.00000.00011.46676.6000AID624892
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)0.03250.00304.51689.8200AID1804127
3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)Kd10.00000.00171.34323.5000AID435189; AID624876
Mitogen-activated protein kinase kinase kinase 13Homo sapiens (human)Kd5.30000.01600.93165.3000AID624965
Death-associated protein kinase 3Homo sapiens (human)Kd10.00000.00101.82419.9000AID435155; AID435398; AID624834
Mitogen-activated protein kinase kinase kinase 7Homo sapiens (human)Kd3.70000.00151.66608.5000AID624724
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)Kd0.02730.00201.621211.4330AID1425155; AID435935; AID624925
Mitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)Kd30.00000.09401.39103.5070AID1424926
NUAK family SNF1-like kinase 1Homo sapiens (human)Kd10.00000.00370.52145.9000AID435150; AID625088
Dynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)Kd30.00000.01700.36100.7050AID1425097
Phosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)Kd10.00000.01802.48906.7000AID624751
Tyrosine-protein kinase JAK2Homo sapiens (human)Kd1.00000.00000.88517.0000AID435658; AID624973
Eukaryotic translation initiation factor 5BHomo sapiens (human)Kd30.00000.23200.23200.2320AID1424986
Rho-associated protein kinase 2Homo sapiens (human)Kd20.00000.00022.710556.0660AID1425158; AID624969
Serine/threonine-protein kinase ULK1Homo sapiens (human)Kd20.00000.00081.841023.2730AID1425208; AID624916
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)Kd20.00000.00572.009512.2010AID1424997; AID624835
Ribosomal protein S6 kinase alpha-5Homo sapiens (human)Kd14.00000.01701.973729.9570AID1425162; AID435831; AID436051; AID624736; AID624967
U5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)Kd30.00001.38201.38201.3820AID1425174
Ribosomal protein S6 kinase alpha-4Homo sapiens (human)Kd14.00000.01201.63967.2000AID1425161; AID435325; AID435441; AID624806; AID624927
Serine/threonine-protein kinase 16Homo sapiens (human)Kd20.00000.00171.24839.9690AID1425179; AID435692; AID624775
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)Kd10.00000.00321.00247.5000AID624958
Serine/threonine-protein kinase PAK 3Homo sapiens (human)Kd10.00000.00051.44835.7000AID435823; AID624873
Cyclin-dependent kinase-like 5Homo sapiens (human)Kd20.00000.00171.47887.3000AID1424951; AID624905
Serine/threonine-protein kinase 17BHomo sapiens (human)Kd10.00000.00482.19829.4000AID435401; AID624942
Serine/threonine-protein kinase 10Homo sapiens (human)Kd1.74270.00002.923457.4530AID1425177; AID435677; AID625030
Serine/threonine-protein kinase D3Homo sapiens (human)Kd16.66670.00892.273823.3410AID1425137; AID435554; AID625024
Cyclin-dependent kinase 14Homo sapiens (human)Kd10.00000.01600.99203.6000AID435689; AID625070
Structural maintenance of chromosomes protein 2Homo sapiens (human)Kd30.00000.20900.65751.1060AID1425173
Mitogen-activated protein kinase kinase kinase 6Homo sapiens (human)Kd20.00000.17001.57818.0000AID1425050; AID624962
Serine/threonine-protein kinase OSR1Homo sapiens (human)Kd10.00000.04802.34988.0000AID624977
Mitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)Kd3.35700.00822.364562.7720AID1425054; AID435910; AID624756
Serine/threonine-protein kinase LATS1Homo sapiens (human)Kd16.66670.01401.839310.7330AID1425033; AID435529; AID624963
Serine/threonine-protein kinase PAK 4Homo sapiens (human)Kd6.91530.00272.569430.3710AID1425100; AID435929; AID624811
Serine/threonine-protein kinase Chk2Homo sapiens (human)Kd10.00000.00711.27297.7000AID624803
Tyrosine-protein kinase ABL1Homo sapiens (human)EC50 (µMol)3.66670.00000.03450.1400AID1301834; AID1301835; AID1659072
Tyrosine-protein kinase ABL1Homo sapiens (human)Kd0.33130.00001.041113.4530AID1424890; AID1797044; AID1801731; AID435146; AID435514; AID435515; AID435644; AID435775; AID435776; AID435897; AID624978; AID624979; AID624980; AID624981; AID624982; AID624983; AID624984; AID624985; AID624986; AID624987; AID624988; AID624989; AID624990; AID624991; AID624992
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)Kd0.00370.00000.03150.2960AID1801731; AID375142
Epidermal growth factor receptorHomo sapiens (human)Kd0.42080.00011.351420.8270AID1424983; AID435156; AID435157; AID435402; AID435525; AID435652; AID435653; AID435791; AID435792; AID435906; AID435907; AID624996; AID624997; AID624998; AID624999; AID625000; AID625001; AID625002; AID625003; AID625004; AID625005; AID625006; AID625007
TransthyretinHomo sapiens (human)Kd3.10000.00301.348210.0000AID1774077
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)Kd0.57000.00661.14674.4000AID435556; AID624897
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)Kd1.40000.00081.29315.1000AID435796; AID624804
High affinity nerve growth factor receptorHomo sapiens (human)Kd10.00000.00201.34849.2000AID435201; AID624808
Guanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)Kd30.00000.18400.18400.1840AID1425011
ADP/ATP translocase 2Homo sapiens (human)Kd30.00000.45100.45100.4510AID1425169
Protein kinase C beta typeHomo sapiens (human)Kd30.00000.00132.708126.3240AID1425130
Insulin receptorHomo sapiens (human)Kd16.66670.00171.08237.9060AID1425026; AID435408; AID624784
Tyrosine-protein kinase LckHomo sapiens (human)Kd0.00250.00021.117424.2210AID1425034; AID435676; AID625013
Tyrosine-protein kinase FynHomo sapiens (human)Kd0.00160.00081.42388.4000AID1425008; AID1876283; AID435800; AID624727
Cyclin-dependent kinase 1Homo sapiens (human)Kd30.00000.28801.49523.0490AID1424937
Glycogen phosphorylase, liver formHomo sapiens (human)Kd30.00002.12102.12102.1210AID1425146
Tyrosine-protein kinase Fes/FpsHomo sapiens (human)Kd16.66670.00481.09867.4000AID1425003; AID435161; AID624852
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)Kd0.00060.00060.69938.1000AID1739051; AID435280; AID624995
Procathepsin LHomo sapiens (human)EC50 (µMol)0.03250.00304.48749.8200AID1804127
Adenine phosphoribosyltransferaseHomo sapiens (human)Kd30.00000.02900.02900.0290AID1424914
Tyrosine-protein kinase YesHomo sapiens (human)Kd0.00150.00031.370817.1520AID1425212; AID435328; AID625018
Tyrosine-protein kinase LynHomo sapiens (human)Kd0.00300.00061.04855.7000AID1425037; AID435804; AID624862
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)Kd2.34210.00070.864227.5420AID1425154; AID435323; AID435434; AID625121; AID625122; AID625123; AID625124
Insulin-like growth factor 1 receptorHomo sapiens (human)Kd16.66670.00101.921119.2170AID1425022; AID435164; AID624800
Signal recognition particle receptor subunit alphaHomo sapiens (human)Kd30.00000.00800.00800.0080AID1425176
Cytochrome c1, heme protein, mitochondrialHomo sapiens (human)Kd30.00000.20200.20200.2020AID1424969
Hepatocyte growth factor receptorHomo sapiens (human)Kd14.00000.00021.62978.5000AID1425076; AID435312; AID624794; AID624795; AID624796
Tyrosine-protein kinase HCKHomo sapiens (human)Kd0.00990.00032.034315.9930AID1425017; AID435311; AID624857
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)Kd10.00000.00051.17415.8000AID435192; AID624899
Platelet-derived growth factor receptor betaHomo sapiens (human)Kd0.09780.00011.005011.1070AID1425104; AID435926; AID624875
Tyrosine-protein kinase FgrHomo sapiens (human)Kd0.00200.00051.07217.8000AID1425005; AID435798; AID625011
Wee1-like protein kinase 2Homo sapiens (human)Kd0.34050.00392.18749.4000AID1450946; AID624746
Uncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)Kd10.00000.02501.47395.8000AID624747
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.03250.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)0.03250.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.03250.00304.45549.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)0.03250.00304.11059.8200AID1804127
Serine/threonine-protein kinase A-RafHomo sapiens (human)Kd30.00000.04709.683233.6550AID1424915
Mast/stem cell growth factor receptor KitHomo sapiens (human)Kd1.09740.00020.81599.8000AID1425032; AID1797044; AID435167; AID435410; AID435411; AID435675; AID435802; AID599957; AID599959; AID624786; AID624787; AID624788; AID624789; AID624790; AID624791; AID624792; AID624793
Glycogen phosphorylase, brain formHomo sapiens (human)Kd30.00003.56903.56903.5690AID1425145
Breakpoint cluster region proteinHomo sapiens (human)EC50 (µMol)3.66670.00000.03930.1400AID1301834; AID1301835; AID1659072
Breakpoint cluster region proteinHomo sapiens (human)Kd0.00500.00301.219617.3640AID1424919
Serine/threonine-protein kinase pim-1Homo sapiens (human)Kd16.66670.00101.139319.3160AID1425111; AID435931; AID624878
Fibroblast growth factor receptor 1Homo sapiens (human)Kd12.46670.00031.55816.2000AID1425004; AID435526; AID625132
Myosin light chain kinase, smooth muscleGallus gallus (chicken)Kd10.00000.00200.32031.7000AID435413
Cyclin-dependent kinase 4Homo sapiens (human)Kd20.00000.00331.60508.6000AID1424946; AID624780; AID624781
ADP/ATP translocase 3Homo sapiens (human)Kd30.00000.00600.25050.4950AID1425170
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)Kd0.00290.00021.50779.6000AID1286626; AID1425175; AID435195; AID498728; AID625016
cAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)Kd30.00000.05201.75353.4550AID1425128
Insulin receptor-related proteinHomo sapiens (human)Kd10.00000.00621.38144.6000AID435430; AID625075
Serine/threonine-protein kinase B-rafHomo sapiens (human)Kd1.07420.00021.625826.0180AID1424924; AID435901; AID435902; AID624946; AID624947
Phosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)Kd16.66670.00012.05699.5000AID1425110; AID435930; AID624797
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)Kd30.00000.00406.755688.9030AID1425093
Platelet-derived growth factor receptor alphaHomo sapiens (human)Kd0.00050.00040.70908.8000AID435827; AID625034
Tyrosine-protein kinase FerHomo sapiens (human)Kd16.66670.00141.36048.8000AID1425002; AID435160; AID625010
Protein kinase C alpha typeHomo sapiens (human)Kd30.00000.00031.792221.3520AID1425129
cAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)Kd16.66670.00392.947923.2450AID1425123; AID435932; AID624881
Vascular endothelial growth factor receptor 1 Homo sapiens (human)Kd5.00000.00070.95859.9000AID435429; AID624853
General transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)Kd30.00000.00201.690612.0220AID1424996
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)Kd10.00000.12002.32387.4000AID435555; AID624896
Casein kinase II subunit alpha'Homo sapiens (human)Kd16.66670.00102.530928.8720AID1424968; AID435789; AID624849
Ras-related protein Rab-6AHomo sapiens (human)Kd30.00000.03300.03300.0330AID1425150
Serine/threonine-protein kinase MAKHomo sapiens (human)Kd10.00000.02801.34612.6000AID625025
Cyclin-dependent kinase 11BHomo sapiens (human)Kd10.00000.00840.86792.1000AID435395; AID624708
Ephrin type-A receptor 1Homo sapiens (human)Kd0.00770.00411.80009.8000AID1424987; AID435793; AID625008
Fibroblast growth factor receptor 2Homo sapiens (human)Kd1.40000.03101.15795.5000AID435290; AID625131
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)Kd0.01800.00082.25459.2000AID624851
Multifunctional protein ADE2Homo sapiens (human)Kd30.00005.48105.48105.4810AID1425098
Fibroblast growth factor receptor 4Homo sapiens (human)Kd10.00000.11002.67737.2000AID435656; AID625130
Fibroblast growth factor receptor 3Homo sapiens (human)Kd8.47500.02301.26526.9000AID435291; AID435527; AID624782; AID624783
cAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)Kd30.00000.00208.557749.2780AID1425125
cAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)Kd7.07170.01300.74084.1000AID1425124; AID435182; AID624882
Ferrochelatase, mitochondrialHomo sapiens (human)Kd30.00000.24306.434367.9140AID1425001
Ribosomal protein S6 kinase beta-1Homo sapiens (human)Kd20.00000.00131.18054.8000AID1425164; AID624906
Tyrosine-protein kinase JAK1Homo sapiens (human)Kd15.00000.00161.21667.8000AID1425030; AID435165; AID624858; AID624859
Protein kinase C eta typeHomo sapiens (human)Kd10.00000.00040.28811.8000AID436034; AID625049
Cyclin-dependent kinase 2Homo sapiens (human)Kd16.66670.00701.517910.4870AID1424944; AID435785; AID624844
Beta-adrenergic receptor kinase 1Homo sapiens (human)Kd30.00000.17005.579122.4940AID1424908
Probable ATP-dependent RNA helicase DDX6Homo sapiens (human)Kd30.00004.10304.10304.1030AID1424977
Activin receptor type-2AHomo sapiens (human)Kd0.21000.01002.07898.9000AID436004; AID624838
Mitogen-activated protein kinase 3 Homo sapiens (human)Kd20.00000.43005.27439.8000AID1425061; AID436016; AID624885
MAP/microtubule affinity-regulating kinase 3Homo sapiens (human)Kd16.66670.00303.968958.2400AID1425069; AID435659; AID624863
Deoxycytidine kinaseHomo sapiens (human)Kd30.00000.01201.08752.1630AID1424970
Mitogen-activated protein kinase 1Homo sapiens (human)Kd20.00000.00012.74417.3000AID1425056; AID435654; AID624713
Ephrin type-A receptor 2Homo sapiens (human)Kd0.00260.00091.07528.1980AID1424988; AID1802323; AID435908; AID624951
Ephrin type-A receptor 3Homo sapiens (human)Kd0.00010.00012.15218.6000AID435794; AID625009
Ephrin type-A receptor 8Homo sapiens (human)Kd0.00020.00021.28757.7000AID435287; AID625120
Ephrin type-B receptor 2Homo sapiens (human)Kd0.00160.00043.153653.1980AID1424992; AID435288; AID625105
Leukocyte tyrosine kinase receptorHomo sapiens (human)Kd10.00000.00102.06317.5000AID435168; AID624743
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)Kd3.32770.00091.55758.7000AID1425207; AID435444; AID624912; AID624913
UMP-CMP kinase Homo sapiens (human)Kd30.00000.00300.00450.0060AID1424959
Phosphatidylethanolamine-binding protein 1Homo sapiens (human)Kd30.00000.00300.00300.0030AID1425107
Wee1-like protein kinaseHomo sapiens (human)Kd6.07770.00143.538965.1580AID1425210; AID1450945; AID435204; AID624914
Heme oxygenase 2Homo sapiens (human)Kd30.00000.11900.11900.1190AID1425018
Tyrosine-protein kinase receptor UFOHomo sapiens (human)Kd10.00000.00011.28916.3000AID436007; AID624840
Mitogen-activated protein kinase 4Homo sapiens (human)Kd10.00001.10003.05565.4000AID436017; AID624886
DnaJ homolog subfamily A member 1Homo sapiens (human)Kd30.00000.96200.96200.9620AID1424980
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)Kd16.66670.00061.06214.4000AID1424910; AID435899; AID624994
RAC-beta serine/threonine-protein kinaseHomo sapiens (human)Kd16.66670.00211.61968.7000AID1424911; AID435517; AID624839
G protein-coupled receptor kinase 4Homo sapiens (human)Kd10.00000.01201.68527.3000AID624739
Dual specificity protein kinase TTKHomo sapiens (human)Kd10.00000.00651.62698.5000AID435203; AID624910
DNA replication licensing factor MCM4Homo sapiens (human)Kd30.00000.62900.62900.6290AID1425072
Prostaglandin G/H synthase 2Homo sapiens (human)Kd10.00000.00901.87258.4000AID625141
Tyrosine-protein kinase receptor Tie-1Homo sapiens (human)Kd10.00000.00031.06455.7000AID435198; AID625017
Vascular endothelial growth factor receptor 3Homo sapiens (human)Kd10.00000.00150.94507.2000AID436018; AID624854
Vascular endothelial growth factor receptor 2Homo sapiens (human)Kd6.45000.00020.80635.7000AID435327; AID624860
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)Kd2.05670.00391.64299.6000AID1425039; AID435169; AID625137
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)Kd9.68460.00020.95599.9000AID1425006; AID435162; AID435310; AID435406; AID435407; AID435799; AID624934; AID624935; AID624936; AID624937; AID624938; AID624939; AID624940
Bone morphogenetic protein receptor type-1AHomo sapiens (human)Kd15.66670.06001.50107.0000AID1424921; AID435276; AID624945
Activin receptor type-1BHomo sapiens (human)Kd0.60630.00401.511015.2580AID1424901; AID435898; AID624943
TGF-beta receptor type-1Homo sapiens (human)Kd0.72770.00502.27859.6000AID1425196; AID435938; AID624961
Serine/threonine-protein kinase receptor R3Homo sapiens (human)Kd0.46000.00291.99369.5000AID435645; AID624778
TGF-beta receptor type-2Homo sapiens (human)Kd2.97370.08001.83516.9000AID1425197; AID435693; AID624909
Electron transfer flavoprotein subunit betaHomo sapiens (human)Kd30.00000.01200.01200.0120AID1424999
Tyrosine-protein kinase CSKHomo sapiens (human)Kd0.00800.00103.457839.5530AID1424960; AID435904; AID624948
Glycine--tRNA ligaseHomo sapiens (human)Kd30.00000.04000.04000.0400AID1425010
Protein kinase C iota typeHomo sapiens (human)Kd20.00000.02609.331651.0180AID1425133; AID624883
Exosome RNA helicase MTR4Homo sapiens (human)Kd30.00002.60702.60702.6070AID1425168
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)Kd10.00000.00060.84627.4000AID435552; AID436033; AID625036; AID625037; AID625038; AID625039; AID625040; AID625041; AID625042; AID625043; AID625044; AID625045
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)Kd10.00000.00170.83166.7000AID625046
Serine/threonine-protein kinase mTORHomo sapiens (human)Kd10.00000.00010.59939.2000AID624972
Megakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)Kd10.00000.26003.07007.7000AID624864
Tyrosine-protein kinase TecHomo sapiens (human)Kd0.02300.00101.00958.7000AID1425193; AID435197; AID624908
Tyrosine-protein kinase TXKHomo sapiens (human)Kd0.00210.00061.91966.0000AID435443; AID624911
Tyrosine-protein kinase ABL2Homo sapiens (human)Kd0.00140.00021.124914.9240AID1424891; AID435777; AID624993
Tyrosine-protein kinase FRKHomo sapiens (human)Kd0.00150.00031.242410.8370AID1425007; AID1619515; AID436019; AID624855
G protein-coupled receptor kinase 6Homo sapiens (human)Kd30.00001.18901.40201.6150AID1425012
Tyrosine-protein kinase ZAP-70Homo sapiens (human)Kd10.00000.01601.68444.2000AID435445; AID624744
Tyrosine-protein kinase SYKHomo sapiens (human)Kd2.75170.00702.00529.2260AID1425188; AID435442; AID624907
26S proteasome regulatory subunit 6BHomo sapiens (human)Kd30.00000.00500.00500.0050AID1425141
Mitogen-activated protein kinase 8Homo sapiens (human)Kd16.66670.01102.096526.0590AID1425063; AID435166; AID624889
Mitogen-activated protein kinase 9Homo sapiens (human)Kd16.66670.00201.45968.1000AID1425064; AID435409; AID624717
Dual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)Kd10.00000.00381.62649.9000AID435822; AID624902
Dual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)Kd16.66670.00502.04626.6000AID1425040; AID436022; AID624894
Casein kinase I isoform alphaHomo sapiens (human)Kd20.00000.00102.575619.3520AID1424961; AID624846
Casein kinase I isoform deltaHomo sapiens (human)Kd16.66670.01502.227018.3960AID1424962; AID435524; AID624716
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)Kd10.00000.00261.46028.4000AID624879
MAP kinase-activated protein kinase 2Homo sapiens (human)Kd6.84600.00032.027414.7420AID1425065; AID435180; AID624703
Cyclin-dependent kinase 8Homo sapiens (human)Kd10.00000.00141.29088.0000AID435903; AID624829
Elongation factor Tu, mitochondrialHomo sapiens (human)Kd30.00000.46400.46400.4640AID1425206
Choline-phosphate cytidylyltransferase AHomo sapiens (human)Kd30.00000.04100.04100.0410AID1425103
Cysteine--tRNA ligase, cytoplasmicHomo sapiens (human)Kd30.00000.01200.33200.6520AID1424932
Casein kinase I isoform epsilonHomo sapiens (human)Kd1.83200.01301.408612.4090AID1424963; AID435650; AID624847
Very long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)Kd30.00001.68901.68901.6890AID1424894
Dual specificity protein kinase CLK1Homo sapiens (human)Kd16.66670.00201.879129.8810AID1424955; AID435786; AID624764
Dual specificity protein kinase CLK2Homo sapiens (human)Kd10.00000.00701.13846.5000AID435787; AID624932
Dual specificity protein kinase CLK3Homo sapiens (human)Kd10.00000.01002.44999.0000AID436011; AID624931
Glycogen synthase kinase-3 alphaHomo sapiens (human)Kd16.66670.00602.475422.5430AID1425013; AID435801; AID625114
Glycogen synthase kinase-3 betaHomo sapiens (human)Kd16.66670.00701.00576.1680AID1425014; AID435163; AID624856
Cyclin-dependent kinase 7Homo sapiens (human)Kd16.66670.00251.67837.7000AID1424949; AID435278; AID624845
Cyclin-dependent kinase 9Homo sapiens (human)Kd16.66670.00101.61669.9010AID1424950; AID435279; AID624830
Ras-related protein Rab-27AHomo sapiens (human)Kd30.00004.49304.49304.4930AID1425149
Tyrosine-protein kinase BlkHomo sapiens (human)Kd0.00020.00020.82287.9000AID435646; AID624841
Interleukin-1 receptor-associated kinase 1Homo sapiens (human)Kd20.00000.00611.52528.5000AID1425027; AID624837
Ribosomal protein S6 kinase alpha-3Homo sapiens (human)Kd16.66670.01702.889637.6050AID1425160; AID435558; AID624960
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)Kd0.00140.00141.54897.4000AID435781; AID624842
cAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)Kd10.00000.00721.30665.8000AID436047; AID624976
Serine/threonine-protein kinase Nek2Homo sapiens (human)Kd15.50000.11001.56496.5000AID1425086; AID435665; AID624869
Serine/threonine-protein kinase Nek3Homo sapiens (human)Kd20.00000.17005.936838.0880AID1425087; AID624870
Serine/threonine-protein kinase Nek4Homo sapiens (human)Kd10.00000.46001.53202.7000AID624904
Tyrosine-protein kinase JAK3Homo sapiens (human)Kd5.32000.00021.06888.7000AID435674; AID624785
Dual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)Kd16.66670.00342.39436.5000AID1425043; AID435911; AID624895
Serine/threonine-protein kinase PLK1Homo sapiens (human)Kd16.66670.00010.57115.0000AID1425120; AID435934; AID624975
Death-associated protein kinase 1Homo sapiens (human)Kd10.00000.00141.25424.7000AID435283; AID624971
LIM domain kinase 1Homo sapiens (human)Kd0.75770.02601.784021.0890AID1425035; AID435803; AID624861
LIM domain kinase 2Homo sapiens (human)Kd0.37900.05704.971752.0560AID1425036; AID435294; AID625021
Mitogen-activated protein kinase 12Homo sapiens (human)Kd10.00000.00012.21389.9000AID435438; AID624766
Mitogen-activated protein kinase 10Homo sapiens (human)Kd16.66670.00101.63545.9000AID1425057; AID435293; AID624891
Tyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)Kd30.00003.31603.31603.3160AID1425211
5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)Kd30.00000.00601.468110.2120AID1425126
5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)Kd10.00000.01200.77985.0000AID435149; AID625047
Ephrin type-B receptor 3Homo sapiens (human)Kd0.01430.00692.17136.4100AID1424993; AID435159; AID624955
Ephrin type-A receptor 5Homo sapiens (human)Kd0.00150.00021.21005.9000AID1424990; AID435158; AID624737
Ephrin type-B receptor 4Homo sapiens (human)Kd0.00160.00032.167826.3990AID1424994; AID435404; AID624956
Ephrin type-B receptor 1Homo sapiens (human)Kd0.00040.00041.72167.3000AID435403; AID624954
Ephrin type-A receptor 4Homo sapiens (human)Kd0.00310.00123.152543.9420AID1424989; AID435795; AID624952
Adenylate kinase 2, mitochondrialHomo sapiens (human)Kd30.00001.03601.03601.0360AID1424909
Adenosine kinaseHomo sapiens (human)Kd30.00000.01301.83683.4930AID1424907
Hormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)Kd10.00000.00372.51399.8000AID625084
Serine/threonine-protein kinase SIK1Homo sapiens (human)Kd0.00390.00221.15303.2000AID435560; AID624733
Receptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)Kd10.00000.01301.55069.8000AID624763
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.03250.00304.57559.8200AID1804127
Ras-related protein Rab-10Homo sapiens (human)Kd30.00001.34801.34801.3480AID1425148
Cell division control protein 2 homologPlasmodium falciparum 3D7Kd10.00000.80003.23335.6000AID624760
Actin-related protein 3Homo sapiens (human)Kd30.00000.03602.77355.5110AID1424899
Actin-related protein 2Homo sapiens (human)Kd30.00000.00400.00400.0040AID1424898
Calcium-dependent protein kinase 1Plasmodium falciparum 3D7Kd0.64000.00030.85383.3000AID624759
GTP-binding nuclear protein RanHomo sapiens (human)Kd30.00000.75900.75900.7590AID1425153
Tubulin alpha-1A chainRattus norvegicus (Norway rat)Kd0.05500.02100.89824.9000AID435797
Casein kinase II subunit alphaHomo sapiens (human)Kd10.00000.00061.76357.5000AID436012; AID624848
Phosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)Kd10.00000.01700.86557.8000AID435828; AID624915
SRSF protein kinase 2Homo sapiens (human)Kd10.00000.01500.28031.1000AID435196; AID624768
Casein kinase I isoform gamma-2Homo sapiens (human)Kd16.66670.04601.45066.6000AID1424965; AID435282; AID624833
Mitogen-activated protein kinase kinase kinase 9Homo sapiens (human)Kd10.00000.00352.20939.9000AID435297; AID624706
Serine/threonine-protein kinase PknBMycobacterium tuberculosis H37RvKd10.00000.00321.27245.5000AID624753
Cyclin-dependent kinase 3Homo sapiens (human)Kd16.66670.00803.060263.6140AID1424945; AID435277; AID624828
Cyclin-dependent kinase-like 1Homo sapiens (human)Kd10.00000.01300.73322.1000AID624941
Cyclin-dependent kinase 6Homo sapiens (human)Kd30.00000.03201.20073.3560AID1424948
Cyclin-dependent-like kinase 5 Homo sapiens (human)Kd16.66670.04301.37578.3000AID1424947; AID436010; AID624970
Cyclin-dependent kinase 16Homo sapiens (human)Kd16.66670.00111.585510.0000AID1424941; AID435925; AID625033
Cyclin-dependent kinase 17Homo sapiens (human)Kd16.66670.00100.82335.6000AID1424942; AID435688; AID624776
ATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)Kd30.00000.98300.98300.9830AID1425108
Protein kinase C epsilon typeHomo sapiens (human)Kd10.00000.00020.58498.1000AID435320; AID625014
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)Kd10.66670.00021.13868.7730AID1425038; AID435808; AID624893
Angiopoietin-1 receptorHomo sapiens (human)Kd10.00000.00311.34646.7000AID435939; AID624799
Mitogen-activated protein kinase kinase kinase 10Homo sapiens (human)Kd10.00000.00382.10746.9000AID435432; AID624867
DNA topoisomerase 2-betaHomo sapiens (human)Kd30.00000.14801.22702.5970AID1425203
Protein kinase C theta typeHomo sapiens (human)Kd6.90370.00071.61407.2000AID1425134; AID435321; AID625051
Activin receptor type-1Homo sapiens (human)Kd10.41330.00401.485316.1210AID1424900; AID435274; AID624819
Macrophage-stimulating protein receptorHomo sapiens (human)Kd20.00000.00302.07188.4000AID1425078; AID624868
Focal adhesion kinase 1Homo sapiens (human)Kd16.66670.00051.225513.0390AID1425142; AID435184; AID624729
Protein kinase C delta typeHomo sapiens (human)Kd16.66670.00021.12619.2060AID1425131; AID435553; AID625048
Tyrosine-protein kinase BTKHomo sapiens (human)Kd0.00260.00061.529910.1530AID1424925; AID436008; AID624779
Tyrosine-protein kinase receptor TYRO3Homo sapiens (human)Kd10.00000.00202.20669.3000AID435326; AID625057
Cyclin-dependent kinase 18Homo sapiens (human)Kd16.66670.01401.49418.4000AID1424943; AID435826; AID624874
Activated CDC42 kinase 1Homo sapiens (human)Kd0.01110.00201.71389.6000AID1205061; AID1425201; AID435694; AID624807
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)Kd0.01480.00021.631471.4840AID1424972; AID435400; AID624850
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)Kd10.00000.01300.86005.6000AID435292; AID625020
Myotonin-protein kinaseHomo sapiens (human)Kd1.30000.00352.05287.0000AID435285; AID624950
Mitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)Kd1.51450.00311.468114.0430AID1425052; AID624959
Mitogen-activated protein kinase kinase kinase 12Homo sapiens (human)Kd10.00000.02201.05546.3000AID624762
Tyrosine-protein kinase MerHomo sapiens (human)Kd16.66670.00031.70556.8000AID1425075; AID436023; AID624767
Serine/threonine-protein kinase 4Homo sapiens (human)Kd14.60000.00021.712025.9020AID1425185; AID435433; AID625055
5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)Kd16.66670.00371.891315.3890AID1425122; AID435148; AID624773
Serine/threonine-protein kinase PAK 1Homo sapiens (human)Kd10.00000.00061.62064.4000AID435318; AID624871
Dual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)Kd0.71770.00022.659065.6770AID1425042; AID624721
Mitogen-activated protein kinase 7Homo sapiens (human)Kd16.66670.04202.00739.9000AID1425062; AID435655; AID624888
Serine/threonine-protein kinase PAK 2Homo sapiens (human)Kd16.66670.00312.30456.0000AID1425099; AID435439; AID624872
Serine/threonine-protein kinase 3Homo sapiens (human)Kd16.66670.00021.860217.5260AID1425182; AID435662; AID625054
Mitogen-activated protein kinase kinase kinase 1Homo sapiens (human)Kd5.63150.09702.599512.4730AID1425044; AID625026
cGMP-dependent protein kinase 2Homo sapiens (human)Kd10.00000.00310.83103.6000AID435322; AID625053
Integrin-linked protein kinaseHomo sapiens (human)Kd30.00000.02000.46031.3290AID1425024
Rho-associated protein kinase 1Homo sapiens (human)Kd20.00000.00031.755513.4620AID1425157; AID625015
Non-receptor tyrosine-protein kinase TNK1Homo sapiens (human)Kd6.89270.00181.006411.2690AID1425200; AID435833; AID624930
Serine/threonine-protein kinase PRP4 homologHomo sapiens (human)Kd10.00000.00841.18997.6000AID624750
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)Kd10.00000.02001.14875.4000AID435557; AID624924
Calcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)Kd10.00000.00131.72216.8000AID435394; AID624827
Calcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)Kd16.66670.00051.02097.8000AID1424929; AID435784; AID624731
Calcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)Kd16.66670.00031.504420.3010AID1424928; AID435647; AID624770
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)Kd20.00000.00012.101640.2910AID1424981; AID624712
Activin receptor type-2BHomo sapiens (human)Kd1.20830.00762.73289.9000AID1424902; AID435147; AID624820
Bone morphogenetic protein receptor type-2Homo sapiens (human)Kd16.66670.01902.591714.3770AID1424923; AID435780; AID624826
Protein-tyrosine kinase 6Homo sapiens (human)Kd0.02490.00431.74309.0000AID1425144; AID436049; AID625029
cGMP-dependent protein kinase 1 Homo sapiens (human)Kd16.66670.00160.70723.8000AID1425138; AID435546; AID625052
Cyclin-dependent kinase 13Homo sapiens (human)Kd20.00000.00091.25714.5180AID1424940; AID624761
Calcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)Kd10.00000.02702.29257.0000AID436009; AID624922
Inhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)Kd16.66670.00511.10938.3000AID1425023; AID435657; AID625074
Protein-tyrosine kinase 2-betaHomo sapiens (human)Kd16.66670.00111.945030.4140AID1425143; AID436048; AID624732
Maternal embryonic leucine zipper kinaseHomo sapiens (human)Kd16.66670.00492.283529.9330AID1425074; AID435660; AID625087
Structural maintenance of chromosomes protein 1AHomo sapiens (human)Kd30.00000.36500.36500.3650AID1425172
Chromodomain-helicase-DNA-binding protein 4Homo sapiens (human)Kd30.00000.00300.00300.0030AID1424952
Peroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)Kd30.00000.01400.14250.2710AID1424895
Serine/threonine-protein kinase D1Homo sapiens (human)Kd10.00000.01401.41168.4000AID436045; AID624884
Serine/threonine-protein kinase 38Homo sapiens (human)Kd10.00000.05601.56519.4000AID625067
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)Kd0.05500.00091.25487.0000AID624815
Ribosomal protein S6 kinase alpha-2Homo sapiens (human)Kd10.00000.00892.04219.6000AID435830; AID436050; AID624805; AID625127
Ephrin type-A receptor 7Homo sapiens (human)Kd16.66670.00251.44456.5000AID1424991; AID435286; AID624953
Delta(24)-sterol reductaseHomo sapiens (human)Kd30.00000.43200.43200.4320AID1424978
Ribosomal protein S6 kinase alpha-1Homo sapiens (human)Kd14.00000.02802.528622.7260AID1425159; AID435690; AID435829; AID624900; AID624901
Dual specificity testis-specific protein kinase 1Homo sapiens (human)Kd0.04370.03301.75685.6000AID1425194; AID435937; AID625056
Myosin light chain kinase, smooth muscleHomo sapiens (human)Kd6.69070.00301.20887.9000AID1425081; AID435664; AID624709
Mitogen-activated protein kinase 11Homo sapiens (human)Kd10.27330.00010.46103.7430AID1425058; AID435551; AID624890
Serine/threonine-protein kinase STK11Homo sapiens (human)Kd16.66670.00300.99495.9000AID1425178; AID435909; AID624798
Rhodopsin kinase GRK1Homo sapiens (human)Kd10.00000.00100.68642.2000AID624898
NT-3 growth factor receptorHomo sapiens (human)Kd10.00000.00341.20208.6000AID435202; AID624765
Serine/threonine-protein kinase N1Homo sapiens (human)Kd6.78630.00133.172949.8130AID1425117; AID435319; AID624745
Serine/threonine-protein kinase N2Homo sapiens (human)Kd16.66670.00181.75279.9000AID1425118; AID435933; AID625050
Mitogen-activated protein kinase 14Homo sapiens (human)EC50 (µMol)0.47000.00521.51415.9000AID1516991
Mitogen-activated protein kinase 14Homo sapiens (human)Kd0.35870.00000.50368.5000AID1286625; AID1425059; AID1799404; AID375143; AID435181; AID498730; AID624714
Calcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)Kd16.66670.03001.92155.4600AID1424930; AID435152; AID624843
Mitogen-activated protein kinase kinase kinase 11Homo sapiens (human)Kd16.66670.01101.563917.9840AID1425045; AID435414; AID624866
BDNF/NT-3 growth factors receptorHomo sapiens (human)Kd10.00000.00380.78757.2000AID435564; AID625032
Mitogen-activated protein kinase 6Homo sapiens (human)Kd10.00000.17001.91675.5000AID435289; AID624887
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)Kd10.00000.00041.55897.1000AID436042; AID625035
Discoidin domain-containing receptor 2Homo sapiens (human)Kd0.01950.00301.988842.2800AID1141134; AID1141140; AID1424973; AID435154; AID624777
AP2-associated protein kinase 1Homo sapiens (human)Kd13.25000.00121.370713.7110AID1424889; AID1876267; AID435896; AID625089
Myosin light chain kinase 3Homo sapiens (human)Kd20.00000.00201.618410.4240AID1425082; AID624738
Uncharacterized aarF domain-containing protein kinase 5Homo sapiens (human)Kd30.00000.20200.49900.7960AID1424906
Serine/threonine-protein kinase SBK1Homo sapiens (human)Kd1.20000.00320.90484.8000AID624812
Mitogen-activated protein kinase kinase kinase 19Homo sapiens (human)Kd0.07900.00050.84206.4000AID625136
Putative heat shock protein HSP 90-beta 2Homo sapiens (human)Kd30.00002.56602.56602.5660AID1425019
Serine/threonine-protein kinase TNNI3KHomo sapiens (human)Kd0.01100.01101.73457.2000AID435200; AID625097
Leucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)Kd10.00000.00041.20429.7000AID624740; AID624741
Serine/threonine-protein kinase MRCK alphaHomo sapiens (human)Kd11.33330.05704.554714.0200AID1424933; AID436024; AID624920
Serine/threonine-protein kinase MRCK gammaHomo sapiens (human)Kd1.20000.03701.96259.5000AID436013; AID625107
Acyl-CoA dehydrogenase family member 10Homo sapiens (human)Kd30.00000.07801.69973.9570AID1424892
Serine/threonine-protein kinase Nek5Homo sapiens (human)Kd10.00000.01302.41147.3000AID435534; AID624742
Serine/threonine-protein kinase N3Homo sapiens (human)Kd30.00000.09900.73651.3740AID1425119
Serine/threonine-protein kinase ULK3Homo sapiens (human)Kd17.30000.00121.33509.9000AID1425209; AID624818
Dual serine/threonine and tyrosine protein kinaseHomo sapiens (human)Kd10.00000.00531.73376.4000AID624758
Mitogen-activated protein kinase kinase kinase 15Homo sapiens (human)Kd10.00000.00250.99092.8000AID624801
Uncharacterized protein FLJ45252Homo sapiens (human)Kd30.00000.00301.22929.3110AID1425147
Acyl-CoA dehydrogenase family member 11Homo sapiens (human)Kd30.00001.91603.07304.1470AID1424893
Serine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)Kd30.00000.11600.76041.5000AID1424998
Serine/threonine-protein kinase MARK2Homo sapiens (human)Kd16.66670.00011.842511.1030AID1425068; AID435296; AID625106
Serine/threonine-protein kinase TAO1Homo sapiens (human)Kd20.00000.00042.161218.7570AID1425189; AID625126
STE20-related kinase adapter protein alphaHomo sapiens (human)Kd30.00000.31601.72083.6720AID1425186
AarF domain-containing protein kinase 1Homo sapiens (human)Kd30.00000.02303.113722.7470AID1424904
Serine/threonine-protein kinase tousled-like 2Homo sapiens (human)Kd10.00000.01600.90122.6000AID436054; AID624771
Serine/threonine-protein kinase 32CHomo sapiens (human)Kd10.00000.05502.16888.0000AID435834; AID624734
Serine/threonine-protein kinase pim-3Homo sapiens (human)Kd10.00000.00051.34285.8000AID435679; AID624802
Serine/threonine-protein kinase VRK2Homo sapiens (human)Kd3.20000.06301.99334.0000AID625058
Myosin light chain kinase family member 4Homo sapiens (human)Kd10.00000.01500.66593.4000AID435691; AID624809
Homeodomain-interacting protein kinase 1Homo sapiens (human)Kd10.00000.05501.66266.8000AID624726
Calcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)Kd10.00000.00111.85475.9000AID435393; AID625118
Mitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)Kd1.13300.00511.641315.4350AID1425053; AID435295; AID624921
Cyclin-dependent kinase-like 3Homo sapiens (human)Kd10.00000.00391.45495.1000AID624822
MAP kinase-activated protein kinase 5Homo sapiens (human)Kd16.66670.00801.12413.1180AID1425067; AID435806; AID624923
Serine/threonine-protein kinase BRSK2Homo sapiens (human)Kd10.00000.00351.98638.9000AID435783; AID624929
Serine/threonine-protein kinase NIM1Homo sapiens (human)Kd10.00000.14002.61888.7000AID624728
Eukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)Kd30.00000.00300.00300.0030AID1425015
Serine/threonine-protein kinase ULK2Homo sapiens (human)Kd10.00000.00081.08849.9000AID625085
Misshapen-like kinase 1Homo sapiens (human)Kd0.31950.00101.14258.9000AID1425077; AID624813
Serine/threonine-protein kinase DCLK2Homo sapiens (human)Kd10.00000.01601.69074.5000AID435651; AID624814
Calcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)Kd10.00000.00001.14115.1000AID435521; AID625143
Casein kinase I isoform alpha-likeHomo sapiens (human)Kd10.00000.25002.20567.1000AID435281; AID624723
Homeodomain-interacting protein kinase 4Homo sapiens (human)Kd10.00000.00051.33398.1000AID624720
Myosin-IIIaHomo sapiens (human)Kd10.00000.04101.66266.3000AID435170; AID625104
Ankyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)Kd10.00000.03201.65349.4000AID436005; AID624735
Serine/threonine-protein kinase Nek11Homo sapiens (human)Kd0.47000.17001.23503.1000AID624725
Atypical kinase COQ8A, mitochondrialHomo sapiens (human)Kd10.12670.09405.167365.3020AID1424905; AID435516; AID625116
Phosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)Kd20.00000.00302.75228.8000AID1425115; AID625134
Mitogen-activated protein kinase 15Homo sapiens (human)Kd16.66670.00490.68804.5000AID1425060; AID435405; AID624715
Serine/threonine-protein kinase Nek9Homo sapiens (human)Kd16.66670.01602.742819.6170AID1425089; AID435171; AID624704
Serine/threonine-protein kinase BRSK1Homo sapiens (human)Kd10.00000.01402.39248.4000AID435782; AID624702
Serine/threonine-protein kinase 35Homo sapiens (human)Kd0.77000.00200.97065.4000AID624711
Serine/threonine-protein kinase Nek7Homo sapiens (human)Kd16.66670.00303.67198.7000AID1425088; AID435666; AID624754
Rhodopsin kinase GRK7Homo sapiens (human)Kd10.00000.00091.27937.5000AID624719
Serine/threonine-protein kinase 32AHomo sapiens (human)Kd10.00000.01302.20435.5000AID624821
Myosin-IIIbHomo sapiens (human)Kd10.00000.08102.41557.1000AID436032; AID624817
ATP-dependent RNA helicase DDX1Homo sapiens (human)Kd30.00000.08600.08600.0860AID1424974
Dual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)Kd10.00000.02202.36937.6000AID624918
Cyclin-dependent kinase-like 2Homo sapiens (human)Kd10.00000.00051.35195.9000AID624928
Mitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)Kd1.36070.00100.93785.5000AID1425051; AID435431; AID624816
Serine/threonine-protein kinase Sgk3Homo sapiens (human)Kd10.00000.00341.35617.2000AID625073
Atypical kinase COQ8B, mitochondrialHomo sapiens (human)Kd10.00000.02702.32136.1000AID435778; AID625135
Aurora kinase BHomo sapiens (human)Kd16.66670.00201.061422.8520AID1424918; AID435519; AID624772
MAP/microtubule affinity-regulating kinase 4Homo sapiens (human)Kd16.66670.00541.10294.9000AID1425070; AID435924; AID625140
Calcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)Kd10.00000.00101.91486.8000AID435151; AID625119
Serine/threonine-protein kinase Nek1Homo sapiens (human)Kd16.66670.17002.42948.3000AID1425085; AID435533; AID625068
Cyclin-dependent kinase 15Homo sapiens (human)Kd10.00000.03201.88868.6000AID624718
PAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)Kd30.00001.06701.06701.0670AID1425102
Calcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)Kd16.66670.00003.233152.8470AID1424931; AID435648; AID625060
EKC/KEOPS complex subunit TP53RKHomo sapiens (human)Kd30.00000.31101.95193.8400AID1425204
Dual specificity testis-specific protein kinase 2Homo sapiens (human)Kd30.00000.00200.00200.0020AID1425195
SRSF protein kinase 1Homo sapiens (human)Kd10.00000.00551.08915.2000AID435936; AID624903
Protein cereblonHomo sapiens (human)EC50 (µMol)10.00000.00900.03650.0870AID1659072
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)Kd0.40920.04400.92852.9000AID1425116; AID1450947; AID436043; AID624757
Mitogen-activated protein kinase kinase kinase 5Homo sapiens (human)Kd16.66670.07006.564750.5360AID1425049; AID435412; AID625028
Phosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)Kd10.00000.03601.83819.7000AID435190; AID624824
Mitogen-activated protein kinase kinase kinase 3Homo sapiens (human)Kd15.14000.00601.53319.9000AID1425047; AID624865
Eukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)Kd23.33330.05801.92244.8360AID1424984; AID625080
Serine/threonine-protein kinase RIO1Homo sapiens (human)Kd10.00000.00901.31958.4000AID435324; AID625141
MAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)Kd10.00000.02601.97347.3000AID435661; AID624823
Serine/threonine-protein kinase RIO2Homo sapiens (human)Kd10.00000.04901.76679.1000AID625111
Cyclin-dependent kinase 19Homo sapiens (human)Kd10.00000.00151.92047.2000AID435522; AID625094
Transient receptor potential cation channel subfamily M member 6Homo sapiens (human)Kd10.00000.00790.00790.0079AID625110
Testis-specific serine/threonine-protein kinase 1Homo sapiens (human)Kd10.00000.02402.85776.3000AID435940; AID625142
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)0.03250.00304.57559.8200AID1804127
Serine/threonine-protein kinase 33Homo sapiens (human)Kd10.00000.00181.35424.9000AID436053; AID625138
Nucleolar GTP-binding protein 1Homo sapiens (human)Kd30.00000.00904.10358.1980AID1425016
Serine/threonine-protein kinase D2Homo sapiens (human)Kd16.66670.00812.372325.0190AID1425136; AID436046; AID625102
Serine/threonine-protein kinase DCLK3Homo sapiens (human)Kd10.00000.00451.40116.5000AID435399; AID624707
NUAK family SNF1-like kinase 2Homo sapiens (human)Kd16.66670.00010.67744.6000AID1425095; AID435559; AID625139
RNA cytidine acetyltransferaseHomo sapiens (human)Kd30.00001.24001.24001.2400AID1425083
Serine/threonine-protein kinase SIK2Homo sapiens (human)Kd0.01260.00111.816541.7950AID1425166; AID436052; AID625095
Myosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)Kd6.75000.04301.13125.4000AID435415; AID624705
STE20-like serine/threonine-protein kinase Homo sapiens (human)Kd1.20970.00003.857399.2320AID1425171; AID435832; AID625086
Serine/threonine-protein kinase TAO3Homo sapiens (human)Kd16.15000.00022.713114.1960AID1425191; AID625101
Homeodomain-interacting protein kinase 2Homo sapiens (human)Kd10.00000.00731.37395.0000AID625129
Tyrosine-protein kinase SrmsHomo sapiens (human)Kd0.01300.01302.60079.8000AID435561; AID624710
Homeodomain-interacting protein kinase 3Homo sapiens (human)Kd10.00000.00401.70469.7000AID625023
Serine/threonine-protein kinase PLK3Homo sapiens (human)Kd10.00000.00402.90568.5000AID435183; AID624933
dCTP pyrophosphatase 1Homo sapiens (human)Kd30.00000.57301.74033.0540AID1424971
Dual specificity protein kinase CLK4Homo sapiens (human)Kd10.00000.00201.41228.3000AID435788; AID625125
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)Kd10.00000.00141.41315.7000AID435531; AID625108
Serine/threonine-protein kinase Nek6Homo sapiens (human)Kd10.00000.00631.33854.4000AID435545; AID625079
Casein kinase I isoform gamma-1Homo sapiens (human)Kd16.66670.05302.06225.7000AID1424964; AID435397; AID625128
Serine/threonine-protein kinase PAK 6Homo sapiens (human)Kd16.66670.00041.91949.7000AID1425101; AID435188; AID625115
SNF-related serine/threonine-protein kinaseHomo sapiens (human)Kd10.00000.09000.55201.5000AID624752
Serine/threonine-protein kinase LATS2Homo sapiens (human)Kd10.00000.00101.68798.0000AID436021; AID625083
Serine/threonine-protein kinase 36Homo sapiens (human)Kd0.21000.18002.76518.3000AID435562; AID625096
Phenylalanine--tRNA ligase beta subunitHomo sapiens (human)Kd30.00000.00300.00450.0060AID1425000
Isoleucine--tRNA ligase, mitochondrialHomo sapiens (human)Kd30.00000.01100.01100.0110AID1425020
BMP-2-inducible protein kinaseHomo sapiens (human)Kd16.66670.00222.409756.0320AID1424920; AID435275; AID625109
Obg-like ATPase 1Homo sapiens (human)Kd30.00000.00300.00500.0070AID1425096
Interleukin-1 receptor-associated kinase 4Homo sapiens (human)Kd20.00000.00173.471934.1450AID1425029; AID625098
Serine/threonine-protein kinase 32BHomo sapiens (human)Kd10.00000.02402.70406.4000AID436055; AID625112
Mitogen-activated protein kinase kinase kinase 20Homo sapiens (human)Kd0.10230.00231.703413.6380AID1425213; AID435941; AID624755
Cyclin-dependent kinase 12Homo sapiens (human)Kd30.00000.03201.80325.6350AID1424939
Serine/threonine-protein kinase PLK2Homo sapiens (human)Kd10.00000.00081.80838.3000AID625063
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)Kd30.00003.92003.92003.9200AID1425084
Serine/threonine-protein kinase MARK1Homo sapiens (human)Kd10.00000.00401.26154.9000AID435807; AID625113
Serine/threonine-protein kinase pim-2Homo sapiens (human)Kd16.66670.00190.84155.0000AID1425112; AID435440; AID625064
Serine/threonine-protein kinase PAK 5Homo sapiens (human)Kd10.00000.00120.88013.3000AID435687; AID625117
Serine/threonine-protein kinase 26Homo sapiens (human)Kd11.26670.00741.73808.3000AID1425181; AID435663; AID625103
eIF-2-alpha kinase GCN2Homo sapiens (human)Kd1.60000.00331.18284.4000AID436020; AID624810
Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)Kd30.00000.00700.00700.0070AID1425187
Serine/threonine-protein kinase NLKHomo sapiens (human)Kd0.25930.00601.02264.4000AID1425090; AID435667; AID625100
Phosphatidylinositol 4-kinase betaHomo sapiens (human)Kd10.00000.03901.19823.5000AID624880
Serine/threonine-protein kinase 17AHomo sapiens (human)Kd10.00000.00101.72189.0000AID435790; AID624968
STE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)Kd10.00000.13000.98793.7000AID625071
Ephrin type-A receptor 6Homo sapiens (human)Kd6.05000.00111.02559.1000AID436015; AID624748
5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)Kd30.00000.00501.15819.1280AID1425127
Serine/threonine-protein kinase TBK1Homo sapiens (human)Kd20.00000.00091.767449.6010AID1425192; AID625072
Septin-9Homo sapiens (human)Kd30.00000.01000.24300.6350AID1425165
Death-associated protein kinase 2Homo sapiens (human)Kd10.00000.00161.12619.1000AID435153; AID625077
Ribosomal protein S6 kinase alpha-6Homo sapiens (human)Kd14.00000.00402.415323.7620AID1425163; AID435193; AID435194; AID625081; AID625082
TRAF2 and NCK-interacting protein kinaseHomo sapiens (human)Kd1.75400.00471.393510.0000AID1425199; AID435563; AID625093
Serine/threonine-protein kinase tousled-like 1Homo sapiens (human)Kd10.00000.02701.05134.0000AID435199; AID625069
Serine/threonine-protein kinase TAO2Homo sapiens (human)Kd17.70000.01002.017612.9420AID1425190; AID625099
Long-chain-fatty-acid--CoA ligase 5Homo sapiens (human)Kd30.00000.00800.63531.6900AID1424897
ALK tyrosine kinase receptorHomo sapiens (human)Kd10.00000.00051.35077.7000AID435779; AID624944
SRSF protein kinase 3Homo sapiens (human)Kd10.00000.01202.11549.3000AID625078
Serine/threonine-protein kinase ICKHomo sapiens (human)Kd23.33330.00071.47179.3000AID1425021; AID625090
Cyclin-dependent kinase 11AHomo sapiens (human)Kd10.00000.00520.66171.3000AID435649; AID625133
Aurora kinase CHomo sapiens (human)Kd10.00000.00131.08488.7000AID436006; AID624769
Calcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)Kd10.00000.00011.69969.6000AID435520; AID624730
RAC-gamma serine/threonine-protein kinaseHomo sapiens (human)Kd16.66670.00251.76466.2000AID1424912; AID435900; AID625019
Serine/threonine-protein kinase 38-likeHomo sapiens (human)Kd10.00000.02801.46926.9000AID436025; AID625092
Microtubule-associated serine/threonine-protein kinase 1Homo sapiens (human)Kd10.00000.01901.54206.2000AID625091
Serine/threonine-protein kinase SIK3Homo sapiens (human)Kd0.08750.00051.508610.3180AID1425167; AID624774
Mitogen-activated protein kinase kinase kinase 2Homo sapiens (human)Kd1.12000.00241.32986.9000AID1425046; AID625062
Thyroid hormone receptor-associated protein 3Homo sapiens (human)Kd30.00002.74602.74602.7460AID1425198
Dual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)Kd10.00000.02801.81299.5000AID436014; AID624964
Mitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)Kd0.34830.00051.949450.2140AID1425055; AID435805; AID625061
Receptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)Kd30.00000.01101.47976.7000AID1425156
Serine/threonine-protein kinase MRCK betaHomo sapiens (human)Kd11.40000.03403.625250.0050AID1424934; AID435912; AID625031
Interleukin-1 receptor-associated kinase 3Homo sapiens (human)Kd20.00000.00701.713725.5810AID1425028; AID435528; AID625066
Serine/threonine-protein kinase 24Homo sapiens (human)Kd10.00000.00650.89204.0840AID435532; AID624917
Casein kinase I isoform gamma-3Homo sapiens (human)Kd20.00000.09702.39788.7000AID1424966; AID435905; AID624949
Mitogen-activated protein kinase kinase kinase 4Homo sapiens (human)Kd10.20670.03902.39708.4000AID1425048; AID435530; AID625027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal proto-oncogene tyrosine-protein kinase Src Mus musculus (house mouse)Activity0.09100.09100.09100.0910AID1749280
Protein cereblonHomo sapiens (human)DC5010.00000.00800.48352.1000AID1772713
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3283)

Processvia Protein(s)Taxonomy
positive regulation of gene expressionBone morphogenetic protein receptor type-1BHomo sapiens (human)
cartilage condensationBone morphogenetic protein receptor type-1BHomo sapiens (human)
ovarian cumulus expansionBone morphogenetic protein receptor type-1BHomo sapiens (human)
osteoblast differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
eye developmentBone morphogenetic protein receptor type-1BHomo sapiens (human)
chondrocyte developmentBone morphogenetic protein receptor type-1BHomo sapiens (human)
inflammatory responseBone morphogenetic protein receptor type-1BHomo sapiens (human)
central nervous system neuron differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
proteoglycan biosynthetic processBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of bone mineralizationBone morphogenetic protein receptor type-1BHomo sapiens (human)
BMP signaling pathwayBone morphogenetic protein receptor type-1BHomo sapiens (human)
retinal ganglion cell axon guidanceBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of chondrocyte differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
ovulation cycleBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of osteoblast differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBone morphogenetic protein receptor type-1BHomo sapiens (human)
retina development in camera-type eyeBone morphogenetic protein receptor type-1BHomo sapiens (human)
endochondral bone morphogenesisBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of cartilage developmentBone morphogenetic protein receptor type-1BHomo sapiens (human)
cellular response to BMP stimulusBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptorsBone morphogenetic protein receptor type-1BHomo sapiens (human)
negative regulation of chondrocyte proliferationBone morphogenetic protein receptor type-1BHomo sapiens (human)
dorsal/ventral pattern formationBone morphogenetic protein receptor type-1BHomo sapiens (human)
protein phosphorylationBone morphogenetic protein receptor type-1BHomo sapiens (human)
cellular response to growth factor stimulusBone morphogenetic protein receptor type-1BHomo sapiens (human)
heme biosynthetic processMembrane-associated progesterone receptor component 1Homo sapiens (human)
positive regulation of lipoprotein transportMembrane-associated progesterone receptor component 1Homo sapiens (human)
positive regulation of protein localization to plasma membraneMembrane-associated progesterone receptor component 1Homo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
natural killer cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of cytokine productionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of endothelial cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
adaptive immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
mast cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
respiratory burst involved in defense responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
protein phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
inflammatory responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of gene expressionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
natural killer cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
neutrophil chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of neutrophil apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
natural killer cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
vascular endothelial growth factor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
mast cell degranulationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
innate immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
mast cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
neutrophil extravasationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of epithelial tube formationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK4Homo sapiens (human)
centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
positive regulation of centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
cilium assemblySerine/threonine-protein kinase PLK4Homo sapiens (human)
trophoblast giant cell differentiationSerine/threonine-protein kinase PLK4Homo sapiens (human)
de novo centriole assembly involved in multi-ciliated epithelial cell differentiationSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 25Homo sapiens (human)
response to oxidative stressSerine/threonine-protein kinase 25Homo sapiens (human)
establishment or maintenance of cell polaritySerine/threonine-protein kinase 25Homo sapiens (human)
signal transductionSerine/threonine-protein kinase 25Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase 25Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase 25Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase 25Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hydrogen peroxideSerine/threonine-protein kinase 25Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 25Homo sapiens (human)
positive regulation of axonogenesisSerine/threonine-protein kinase 25Homo sapiens (human)
Golgi localizationSerine/threonine-protein kinase 25Homo sapiens (human)
establishment of Golgi localizationSerine/threonine-protein kinase 25Homo sapiens (human)
Golgi reassemblySerine/threonine-protein kinase 25Homo sapiens (human)
translational initiationATP-dependent RNA helicase DDX3XHomo sapiens (human)
chromosome segregationATP-dependent RNA helicase DDX3XHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsATP-dependent RNA helicase DDX3XHomo sapiens (human)
response to virusATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA secondary structure unwindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of gene expressionATP-dependent RNA helicase DDX3XHomo sapiens (human)
Wnt signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of translationATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of cell growthATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of cell growthATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of protein-containing complex assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein autophosphorylationATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of type I interferon productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
DNA duplex unwindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of interferon-alpha productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of interferon-beta productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
stress granule assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of toll-like receptor 7 signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of toll-like receptor 8 signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
intracellular signal transductionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of translation in response to endoplasmic reticulum stressATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytosolic ribosome assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of viral genome replicationATP-dependent RNA helicase DDX3XHomo sapiens (human)
innate immune responseATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of translationATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of translational initiationATP-dependent RNA helicase DDX3XHomo sapiens (human)
lipid homeostasisATP-dependent RNA helicase DDX3XHomo sapiens (human)
cellular response to arsenic-containing substanceATP-dependent RNA helicase DDX3XHomo sapiens (human)
cellular response to osmotic stressATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of chemokine (C-C motif) ligand 5 productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
intrinsic apoptotic signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
cellular response to virusATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein acetylationATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein K63-linked ubiquitinationATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein localization to cytoplasmic stress granuleATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of gene expressionATP-dependent RNA helicase DDX3XHomo sapiens (human)
gamete generationATP-dependent RNA helicase DDX3XHomo sapiens (human)
cell differentiationATP-dependent RNA helicase DDX3XHomo sapiens (human)
biological_processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cellular response to starvationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
autophagosome organizationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cell migrationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
pyridoxal 5'-phosphate salvagePyridoxal kinaseHomo sapiens (human)
pyridoxal metabolic processPyridoxal kinaseHomo sapiens (human)
pyridoxamine metabolic processPyridoxal kinaseHomo sapiens (human)
mitotic cell cycleCitron Rho-interacting kinaseHomo sapiens (human)
mitotic cytokinesisCitron Rho-interacting kinaseHomo sapiens (human)
positive regulation of cytokinesisCitron Rho-interacting kinaseHomo sapiens (human)
negative regulation of hippo signalingCitron Rho-interacting kinaseHomo sapiens (human)
generation of neuronsCitron Rho-interacting kinaseHomo sapiens (human)
neuron apoptotic processCitron Rho-interacting kinaseHomo sapiens (human)
chromosome segregationSerine/threonine-protein kinase RIO3Homo sapiens (human)
maturation of SSU-rRNASerine/threonine-protein kinase RIO3Homo sapiens (human)
negative regulation of protein-containing complex assemblySerine/threonine-protein kinase RIO3Homo sapiens (human)
positive regulation of interferon-beta productionSerine/threonine-protein kinase RIO3Homo sapiens (human)
negative regulation of MDA-5 signaling pathwaySerine/threonine-protein kinase RIO3Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase RIO3Homo sapiens (human)
innate immune responseSerine/threonine-protein kinase RIO3Homo sapiens (human)
positive regulation of innate immune responseSerine/threonine-protein kinase RIO3Homo sapiens (human)
defense response to virusSerine/threonine-protein kinase RIO3Homo sapiens (human)
cellular response to dsRNASerine/threonine-protein kinase RIO3Homo sapiens (human)
cellular response to virusSerine/threonine-protein kinase RIO3Homo sapiens (human)
cellular response to dsDNASerine/threonine-protein kinase RIO3Homo sapiens (human)
apoptotic processDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to osmotic stressDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
JNK cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to heatDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to UVDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to woundingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to tumor necrosis factorDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
Fc-epsilon receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of JUN kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of JNK cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of telomerase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cellular response to lipopolysaccharideDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cellular response to interleukin-1Dual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of telomere cappingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
regulation of motor neuron apoptotic processDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase Chk1Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase Chk1Homo sapiens (human)
inner cell mass cell proliferationSerine/threonine-protein kinase Chk1Homo sapiens (human)
DNA replicationSerine/threonine-protein kinase Chk1Homo sapiens (human)
DNA repairSerine/threonine-protein kinase Chk1Homo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase Chk1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Chk1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase Chk1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleus organizationSerine/threonine-protein kinase Chk1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of double-strand break repair via homologous recombinationSerine/threonine-protein kinase Chk1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of cell population proliferationSerine/threonine-protein kinase Chk1Homo sapiens (human)
signal transduction in response to DNA damageSerine/threonine-protein kinase Chk1Homo sapiens (human)
mitotic G2/M transition checkpointSerine/threonine-protein kinase Chk1Homo sapiens (human)
positive regulation of cell cycleSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of gene expression, epigeneticSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of mitotic nuclear divisionSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of mitotic centrosome separationSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of G0 to G1 transitionSerine/threonine-protein kinase Chk1Homo sapiens (human)
cellular response to mechanical stimulusSerine/threonine-protein kinase Chk1Homo sapiens (human)
cellular response to caffeineSerine/threonine-protein kinase Chk1Homo sapiens (human)
replicative senescenceSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase Chk1Homo sapiens (human)
apoptotic process involved in developmentSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of DNA biosynthetic processSerine/threonine-protein kinase Chk1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cortical actin cytoskeleton organizationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
toll-like receptor 3 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
TRIF-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
Fc-epsilon receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
T cell receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stress-activated MAPK cascadeInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein maturationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
interleukin-1-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein localization to plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of establishment of endothelial barrierInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of bicellular tight junction assemblyInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of cell-matrix adhesionPeripheral plasma membrane protein CASKHomo sapiens (human)
cell adhesionPeripheral plasma membrane protein CASKHomo sapiens (human)
negative regulation of keratinocyte proliferationPeripheral plasma membrane protein CASKHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeripheral plasma membrane protein CASKHomo sapiens (human)
GMP metabolic processPeripheral plasma membrane protein CASKHomo sapiens (human)
GDP metabolic processPeripheral plasma membrane protein CASKHomo sapiens (human)
establishment of localization in cellPeripheral plasma membrane protein CASKHomo sapiens (human)
negative regulation of wound healingPeripheral plasma membrane protein CASKHomo sapiens (human)
calcium ion importPeripheral plasma membrane protein CASKHomo sapiens (human)
positive regulation of calcium ion importPeripheral plasma membrane protein CASKHomo sapiens (human)
negative regulation of cellular response to growth factor stimulusPeripheral plasma membrane protein CASKHomo sapiens (human)
regulation of synaptic vesicle exocytosisPeripheral plasma membrane protein CASKHomo sapiens (human)
protein localizationPeripheral plasma membrane protein CASKHomo sapiens (human)
regulation of neurotransmitter secretionPeripheral plasma membrane protein CASKHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
response to woundingAurora kinase AHomo sapiens (human)
liver regenerationAurora kinase AHomo sapiens (human)
G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
mitotic cell cycleAurora kinase AHomo sapiens (human)
chromatin remodelingAurora kinase AHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
apoptotic processAurora kinase AHomo sapiens (human)
spindle organizationAurora kinase AHomo sapiens (human)
spindle assembly involved in female meiosis IAurora kinase AHomo sapiens (human)
mitotic centrosome separationAurora kinase AHomo sapiens (human)
anterior/posterior axis specificationAurora kinase AHomo sapiens (human)
regulation of G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
negative regulation of gene expressionAurora kinase AHomo sapiens (human)
peptidyl-serine phosphorylationAurora kinase AHomo sapiens (human)
regulation of protein stabilityAurora kinase AHomo sapiens (human)
negative regulation of protein bindingAurora kinase AHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
negative regulation of apoptotic processAurora kinase AHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
positive regulation of mitotic nuclear divisionAurora kinase AHomo sapiens (human)
positive regulation of mitotic cell cycleAurora kinase AHomo sapiens (human)
regulation of centrosome cycleAurora kinase AHomo sapiens (human)
protein autophosphorylationAurora kinase AHomo sapiens (human)
cell divisionAurora kinase AHomo sapiens (human)
centrosome localizationAurora kinase AHomo sapiens (human)
cilium disassemblyAurora kinase AHomo sapiens (human)
protein localization to centrosomeAurora kinase AHomo sapiens (human)
positive regulation of mitochondrial fissionAurora kinase AHomo sapiens (human)
positive regulation of oocyte maturationAurora kinase AHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase AHomo sapiens (human)
neuron projection extensionAurora kinase AHomo sapiens (human)
mitotic spindle organizationAurora kinase AHomo sapiens (human)
regulation of cytokinesisAurora kinase AHomo sapiens (human)
receptor-mediated endocytosisCyclin-G-associated kinaseHomo sapiens (human)
endoplasmic reticulum organizationCyclin-G-associated kinaseHomo sapiens (human)
Golgi organizationCyclin-G-associated kinaseHomo sapiens (human)
negative regulation of neuron projection developmentCyclin-G-associated kinaseHomo sapiens (human)
synaptic vesicle uncoatingCyclin-G-associated kinaseHomo sapiens (human)
protein localization to Golgi apparatusCyclin-G-associated kinaseHomo sapiens (human)
intracellular transportCyclin-G-associated kinaseHomo sapiens (human)
clathrin coat assemblyCyclin-G-associated kinaseHomo sapiens (human)
chaperone cofactor-dependent protein refoldingCyclin-G-associated kinaseHomo sapiens (human)
clathrin coat disassemblyCyclin-G-associated kinaseHomo sapiens (human)
clathrin-dependent endocytosisCyclin-G-associated kinaseHomo sapiens (human)
protein localization to plasma membraneCyclin-G-associated kinaseHomo sapiens (human)
Golgi to lysosome transportCyclin-G-associated kinaseHomo sapiens (human)
regulation of clathrin coat assemblyCyclin-G-associated kinaseHomo sapiens (human)
neuron migrationSerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase DCLK1Homo sapiens (human)
nervous system developmentSerine/threonine-protein kinase DCLK1Homo sapiens (human)
central nervous system developmentSerine/threonine-protein kinase DCLK1Homo sapiens (human)
response to virusSerine/threonine-protein kinase DCLK1Homo sapiens (human)
endosomal transportSerine/threonine-protein kinase DCLK1Homo sapiens (human)
central nervous system projection neuron axonogenesisSerine/threonine-protein kinase DCLK1Homo sapiens (human)
forebrain developmentSerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein localization to nucleusSerine/threonine-protein kinase DCLK1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase DCLK1Homo sapiens (human)
axon extensionSerine/threonine-protein kinase DCLK1Homo sapiens (human)
dendrite morphogenesisSerine/threonine-protein kinase DCLK1Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase DCLK1Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase DCLK1Homo sapiens (human)
skeletal muscle contractionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
immune responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
I-kappaB phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
Rho protein signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to xenobiotic stimulusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to toxic substanceInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
anatomical structure morphogenesisInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to acetateInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
negative regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to lipopolysaccharideInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of interferon-alpha productionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to hydroperoxideInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
toll-like receptor 4 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to reactive oxygen speciesInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
non-canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to amino acidInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
striated muscle cell differentiationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to cholecystokininInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to cadmium ionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to virusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of protein phosphorylationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
neuromuscular junction developmentMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
memoryMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
regulation of synaptic assembly at neuromuscular junctionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of gene expressionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
cell differentiationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
protein autophosphorylationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
skeletal muscle acetylcholine-gated channel clusteringMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of protein geranylgeranylationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
multicellular organism developmentMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of kinase activityMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of neuron projection developmentMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
protein phosphorylationEphrin type-B receptor 6Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 6Homo sapiens (human)
axon guidanceEphrin type-B receptor 6Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA oxidasePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
lipid homeostasisPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
response to osmotic stressMitogen-activated protein kinase 13Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 13Homo sapiens (human)
positive regulation of interleukin-6 productionMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to UVMitogen-activated protein kinase 13Homo sapiens (human)
positive regulation of inflammatory responseMitogen-activated protein kinase 13Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to hydrogen peroxideMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to interleukin-1Mitogen-activated protein kinase 13Homo sapiens (human)
cellular response to sorbitolMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to anisomycinMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to sodium arseniteMitogen-activated protein kinase 13Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 13Homo sapiens (human)
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
type B pancreatic cell development3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
hyperosmotic response3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
epidermal growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phospholipase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
calcium-mediated signaling3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
actin cytoskeleton organization3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
T cell costimulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
activation of protein kinase B activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to insulin stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of toll-like receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of mast cell degranulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein autophosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to epidermal growth factor stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of protein localization to plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of sprouting angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of endothelial cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of neuron maturationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of axon extensionMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of neuron projection arborizationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of branching morphogenesis of a nerveMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
chromatin organizationDeath-associated protein kinase 3Homo sapiens (human)
regulation of DNA-templated transcriptionDeath-associated protein kinase 3Homo sapiens (human)
protein phosphorylationDeath-associated protein kinase 3Homo sapiens (human)
apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
regulation of smooth muscle contractionDeath-associated protein kinase 3Homo sapiens (human)
regulation of mitotic nuclear divisionDeath-associated protein kinase 3Homo sapiens (human)
regulation of mitotic cell cycleDeath-associated protein kinase 3Homo sapiens (human)
regulation of cell shapeDeath-associated protein kinase 3Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 3Homo sapiens (human)
negative regulation of translationDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of cell migrationDeath-associated protein kinase 3Homo sapiens (human)
regulation of actin cytoskeleton organizationDeath-associated protein kinase 3Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 3Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
regulation of myosin II filament organizationDeath-associated protein kinase 3Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 3Homo sapiens (human)
regulation of focal adhesion assemblyDeath-associated protein kinase 3Homo sapiens (human)
cellular response to type II interferonDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayDeath-associated protein kinase 3Homo sapiens (human)
apoptotic signaling pathwayDeath-associated protein kinase 3Homo sapiens (human)
regulation of cell motilityDeath-associated protein kinase 3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of T cell cytokine productionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
chromatin remodelingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
inflammatory responseMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
I-kappaB phosphorylationMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
negative regulation of gene expressionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of macroautophagyMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of interleukin-2 productionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
toll-like receptor 3 signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
toll-like receptor 4 signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
TRIF-dependent toll-like receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
interleukin-33-mediated signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
interleukin-17A-mediated signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
defense response to bacteriumMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
anoikisMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of cell cycleMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of cell sizeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
T cell receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
interleukin-1-mediated signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cellular response to hypoxiaMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cellular response to angiotensinMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
immune responseMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
toll-like receptor 2 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of cytokine-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
adaptive immune responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of T-helper 1 type immune responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
apoptotic processReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
inflammatory responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
JNK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytokine-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein ubiquitinationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of chemokine productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interferon-alpha productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interferon-beta productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of type II interferon productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-1 beta productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-12 productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-2 productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-6 productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
immature T cell proliferation in thymusReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of immature T cell proliferation in thymusReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
toll-like receptor 4 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
CD4-positive, alpha-beta T cell proliferationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
defense response to bacteriumReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to exogenous dsRNAReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
innate immune responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of T-helper 1 cell differentiationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of JNK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
defense response to Gram-positive bacteriumReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
T cell receptor signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein homooligomerizationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
stress-activated MAPK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of macrophage cytokine productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ERK1 and ERK2 cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 1 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to interleukin-1Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to interleukin-12Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to interleukin-18Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to lipoteichoic acidReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to peptidoglycanReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to muramyl dipeptideReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
activation of cysteine-type endopeptidase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
xenophagyReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of xenophagyReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
chromatin remodelingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
apoptotic processMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
chromosome segregationMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
regulation of sister chromatid cohesionMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
mitotic spindle assembly checkpoint signalingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
cell divisionMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
regulation of chromosome segregationMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
positive regulation of maintenance of mitotic sister chromatid cohesion, centromericMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
meiotic sister chromatid cohesion, centromericMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein phosphorylationNUAK family SNF1-like kinase 1Homo sapiens (human)
DNA damage responseNUAK family SNF1-like kinase 1Homo sapiens (human)
cell adhesionNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cell adhesionNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of myosin-light-chain-phosphatase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cell population proliferationNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of signal transduction by p53 class mediatorNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cellular senescenceNUAK family SNF1-like kinase 1Homo sapiens (human)
mitochondrion organizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial genome maintenanceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial fissionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
neural tube closureDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
apoptotic processDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrion organizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
inner mitochondrial membrane organizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
visual perceptionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial fusionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
axonal transport of mitochondrionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-17 productionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cristae formationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic processDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTP metabolic processDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
protein complex oligomerizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membrane fusionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cellular senescenceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membrane tubulationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane fusionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
phagocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
synaptic vesicle exocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
actin cytoskeleton organizationPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
neutrophil chemotaxisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
adherens junction assemblyPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
synaptic vesicle endocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
membrane organizationPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
clathrin-dependent endocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
cell-cell adhesionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
positive regulation of platelet aggregationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of platelet activationTyrosine-protein kinase JAK2Homo sapiens (human)
response to antibioticTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of SMAD protein signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
microglial cell activationTyrosine-protein kinase JAK2Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK2Homo sapiens (human)
chromatin remodelingTyrosine-protein kinase JAK2Homo sapiens (human)
transcription by RNA polymerase IITyrosine-protein kinase JAK2Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK2Homo sapiens (human)
apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
immune responseTyrosine-protein kinase JAK2Homo sapiens (human)
signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
G protein-coupled receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase JAK2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK2Homo sapiens (human)
mesoderm developmentTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cell-substrate adhesionTyrosine-protein kinase JAK2Homo sapiens (human)
response to amineTyrosine-protein kinase JAK2Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK2Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of cell-cell adhesionTyrosine-protein kinase JAK2Homo sapiens (human)
actin filament polymerizationTyrosine-protein kinase JAK2Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK2Homo sapiens (human)
erythrocyte differentiationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase JAK2Homo sapiens (human)
axon regenerationTyrosine-protein kinase JAK2Homo sapiens (human)
intracellular mineralocorticoid receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of insulin secretionTyrosine-protein kinase JAK2Homo sapiens (human)
response to lipopolysaccharideTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of interleukin-1 beta productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of interleukin-17 productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of natural killer cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
response to hydroperoxideTyrosine-protein kinase JAK2Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
symbiont-induced defense-related programmed cell deathTyrosine-protein kinase JAK2Homo sapiens (human)
response to tumor necrosis factorTyrosine-protein kinase JAK2Homo sapiens (human)
post-embryonic hemopoiesisTyrosine-protein kinase JAK2Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-12-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to interleukin-3Tyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-5-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
collagen-activated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-3-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
granulocyte-macrophage colony-stimulating factor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of T cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of protein import into nucleusTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK2Homo sapiens (human)
activation of Janus kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of DNA bindingTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of MAPK cascadeTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of neuron apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
post-translational protein modificationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of MHC class II biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of nitric oxide biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cell differentiationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase JAK2Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase JAK2Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of inflammatory responseTyrosine-protein kinase JAK2Homo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of NK T cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
type II interferon-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
growth hormone receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of growth hormone receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
mammary gland epithelium developmentTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-6-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of leukocyte proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
response to interleukin-12Tyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-35-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to dexamethasone stimulusTyrosine-protein kinase JAK2Homo sapiens (human)
extrinsic apoptotic signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to virusTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cold-induced thermogenesisTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of growth factor dependent skeletal muscle satellite cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of epithelial cell apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of postsynapse to nucleus signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of signaling receptor activityTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of T-helper 17 type immune responseTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of apoptotic signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
regulation of translational initiationEukaryotic translation initiation factor 5BHomo sapiens (human)
ribosome assemblyEukaryotic translation initiation factor 5BHomo sapiens (human)
translational initiationEukaryotic translation initiation factor 5BHomo sapiens (human)
epithelial to mesenchymal transitionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationRho-associated protein kinase 2Homo sapiens (human)
response to ischemiaRho-associated protein kinase 2Homo sapiens (human)
aortic valve morphogenesisRho-associated protein kinase 2Homo sapiens (human)
protein phosphorylationRho-associated protein kinase 2Homo sapiens (human)
smooth muscle contractionRho-associated protein kinase 2Homo sapiens (human)
canonical NF-kappaB signal transductionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of endothelial cell migrationRho-associated protein kinase 2Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyRho-associated protein kinase 2Homo sapiens (human)
positive regulation of gene expressionRho-associated protein kinase 2Homo sapiens (human)
negative regulation of gene expressionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of centrosome duplicationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of angiogenesisRho-associated protein kinase 2Homo sapiens (human)
actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
regulation of cell adhesionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of cell migrationRho-associated protein kinase 2Homo sapiens (human)
cortical actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
regulation of nervous system processRho-associated protein kinase 2Homo sapiens (human)
positive regulation of connective tissue growth factor productionRho-associated protein kinase 2Homo sapiens (human)
regulation of actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityRho-associated protein kinase 2Homo sapiens (human)
regulation of circadian rhythmRho-associated protein kinase 2Homo sapiens (human)
positive regulation of MAPK cascadeRho-associated protein kinase 2Homo sapiens (human)
modulation by host of viral processRho-associated protein kinase 2Homo sapiens (human)
negative regulation of nitric oxide biosynthetic processRho-associated protein kinase 2Homo sapiens (human)
regulation of keratinocyte differentiationRho-associated protein kinase 2Homo sapiens (human)
rhythmic processRho-associated protein kinase 2Homo sapiens (human)
centrosome duplicationRho-associated protein kinase 2Homo sapiens (human)
regulation of stress fiber assemblyRho-associated protein kinase 2Homo sapiens (human)
positive regulation of stress fiber assemblyRho-associated protein kinase 2Homo sapiens (human)
regulation of focal adhesion assemblyRho-associated protein kinase 2Homo sapiens (human)
mRNA destabilizationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of biomineral tissue developmentRho-associated protein kinase 2Homo sapiens (human)
cellular response to testosterone stimulusRho-associated protein kinase 2Homo sapiens (human)
response to transforming growth factor betaRho-associated protein kinase 2Homo sapiens (human)
protein localization to plasma membraneRho-associated protein kinase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionRho-associated protein kinase 2Homo sapiens (human)
blood vessel diameter maintenanceRho-associated protein kinase 2Homo sapiens (human)
regulation of angiotensin-activated signaling pathwayRho-associated protein kinase 2Homo sapiens (human)
negative regulation of protein localization to lysosomeRho-associated protein kinase 2Homo sapiens (human)
regulation of cellular response to hypoxiaRho-associated protein kinase 2Homo sapiens (human)
positive regulation of amyloid-beta formationRho-associated protein kinase 2Homo sapiens (human)
positive regulation of protein localization to early endosomeRho-associated protein kinase 2Homo sapiens (human)
positive regulation of amyloid precursor protein catabolic processRho-associated protein kinase 2Homo sapiens (human)
regulation of establishment of endothelial barrierRho-associated protein kinase 2Homo sapiens (human)
negative regulation of bicellular tight junction assemblyRho-associated protein kinase 2Homo sapiens (human)
cellular response to acetylcholineRho-associated protein kinase 2Homo sapiens (human)
positive regulation of connective tissue replacementRho-associated protein kinase 2Homo sapiens (human)
response to angiotensinRho-associated protein kinase 2Homo sapiens (human)
regulation of establishment of cell polarityRho-associated protein kinase 2Homo sapiens (human)
regulation of cell motilityRho-associated protein kinase 2Homo sapiens (human)
actomyosin structure organizationRho-associated protein kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationRho-associated protein kinase 2Homo sapiens (human)
mitotic cytokinesisRho-associated protein kinase 2Homo sapiens (human)
embryonic morphogenesisRho-associated protein kinase 2Homo sapiens (human)
regulation of cell junction assemblyRho-associated protein kinase 2Homo sapiens (human)
Rho protein signal transductionRho-associated protein kinase 2Homo sapiens (human)
autophagosome assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein localizationSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase ULK1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwaySerine/threonine-protein kinase ULK1Homo sapiens (human)
macroautophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
neuron projection regenerationSerine/threonine-protein kinase ULK1Homo sapiens (human)
neuron projection developmentSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of protein-containing complex assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
cellular response to nutrient levelsSerine/threonine-protein kinase ULK1Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of protein lipidationSerine/threonine-protein kinase ULK1Homo sapiens (human)
positive regulation of autophagosome assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
axon extensionSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK1Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of collateral sproutingSerine/threonine-protein kinase ULK1Homo sapiens (human)
endothelial cell proliferationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mRNA catabolic processSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of RNA splicingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to unfolded proteinSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
peptidyl-serine autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-mediated unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mRNA splicing, via endonucleolytic cleavage and ligationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to hydrogen peroxideSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to glucose stimulusSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
insulin metabolic processSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
peptidyl-serine trans-autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
negative regulation of cytokine productionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
chromatin remodelingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
inflammatory responseRibosomal protein S6 kinase alpha-5Homo sapiens (human)
axon guidanceRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of CREB transcription factor activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
post-translational protein modificationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
negative regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
interleukin-1-mediated signaling pathwayRibosomal protein S6 kinase alpha-5Homo sapiens (human)
regulation of postsynapse organizationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cis assembly of pre-catalytic spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
spliceosome conformational change to release U4 (or U4atac) and U1 (or U11)U5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
mRNA splicing, via spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
osteoblast differentiationU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
negative regulation of cytokine productionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
chromatin remodelingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
inflammatory responseRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of CREB transcription factor activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
post-translational protein modificationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
interleukin-1-mediated signaling pathwayRibosomal protein S6 kinase alpha-4Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase 16Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 16Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase 16Homo sapiens (human)
chemotaxisPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
modulation by host of viral processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
cell migrationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase PAK 3Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 3Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase PAK 3Homo sapiens (human)
dendrite developmentSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of actin filament polymerizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
ephrin receptor signaling pathwaySerine/threonine-protein kinase PAK 3Homo sapiens (human)
synapse organizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
dendritic spine morphogenesisSerine/threonine-protein kinase PAK 3Homo sapiens (human)
cellular response to organic cyclic compoundSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of postsynapse organizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
neuron migrationCyclin-dependent kinase-like 5Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of GTPase activityCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of axon extensionCyclin-dependent kinase-like 5Homo sapiens (human)
protein autophosphorylationCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of dendrite developmentCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of dendrite morphogenesisCyclin-dependent kinase-like 5Homo sapiens (human)
modulation of chemical synaptic transmissionCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of dendritic spine developmentCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of postsynapse organizationCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of cilium assemblyCyclin-dependent kinase-like 5Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 17BHomo sapiens (human)
apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 17BHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 17BHomo sapiens (human)
positive regulation of fibroblast apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 10Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 10Homo sapiens (human)
lymphocyte aggregationSerine/threonine-protein kinase 10Homo sapiens (human)
regulation of lymphocyte migrationSerine/threonine-protein kinase 10Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase D3Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D3Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D3Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D3Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 14Homo sapiens (human)
Wnt signaling pathwayCyclin-dependent kinase 14Homo sapiens (human)
cell divisionCyclin-dependent kinase 14Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 14Homo sapiens (human)
regulation of canonical Wnt signaling pathwayCyclin-dependent kinase 14Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 14Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
mitotic chromosome condensationStructural maintenance of chromosomes protein 2Homo sapiens (human)
meiotic chromosome condensationStructural maintenance of chromosomes protein 2Homo sapiens (human)
meiotic chromosome segregationStructural maintenance of chromosomes protein 2Homo sapiens (human)
cell divisionStructural maintenance of chromosomes protein 2Homo sapiens (human)
kinetochore organizationStructural maintenance of chromosomes protein 2Homo sapiens (human)
positive regulation of chromosome segregationStructural maintenance of chromosomes protein 2Homo sapiens (human)
positive regulation of chromosome separationStructural maintenance of chromosomes protein 2Homo sapiens (human)
positive regulation of chromosome condensationStructural maintenance of chromosomes protein 2Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
signal transductionMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
cellular response to stressMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase OSR1Homo sapiens (human)
cell volume homeostasisSerine/threonine-protein kinase OSR1Homo sapiens (human)
response to oxidative stressSerine/threonine-protein kinase OSR1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase OSR1Homo sapiens (human)
osmosensory signaling pathwaySerine/threonine-protein kinase OSR1Homo sapiens (human)
response to xenobiotic stimulusSerine/threonine-protein kinase OSR1Homo sapiens (human)
positive regulation of T cell chemotaxisSerine/threonine-protein kinase OSR1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase OSR1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase OSR1Homo sapiens (human)
chemokine (C-C motif) ligand 21 signaling pathwaySerine/threonine-protein kinase OSR1Homo sapiens (human)
chemokine (C-X-C motif) ligand 12 signaling pathwaySerine/threonine-protein kinase OSR1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase OSR1Homo sapiens (human)
renal sodium ion absorptionSerine/threonine-protein kinase OSR1Homo sapiens (human)
cellular hyperosmotic responseSerine/threonine-protein kinase OSR1Homo sapiens (human)
cellular hypotonic responseSerine/threonine-protein kinase OSR1Homo sapiens (human)
negative regulation of potassium ion transmembrane transportSerine/threonine-protein kinase OSR1Homo sapiens (human)
cellular response to chemokineSerine/threonine-protein kinase OSR1Homo sapiens (human)
negative regulation of potassium ion transmembrane transporter activitySerine/threonine-protein kinase OSR1Homo sapiens (human)
microvillus assemblyMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
negative regulation of cell-matrix adhesionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of cell migrationMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of ARF protein signal transductionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of hippo signalingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of GTPase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
regulation of JNK cascadeMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of keratinocyte migrationMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of focal adhesion assemblyMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of focal adhesion disassemblyMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
regulation of MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
neuron projection morphogenesisMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase LATS1Homo sapiens (human)
sister chromatid segregationSerine/threonine-protein kinase LATS1Homo sapiens (human)
inner cell mass cell fate commitmentSerine/threonine-protein kinase LATS1Homo sapiens (human)
inner cell mass cellular morphogenesisSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase LATS1Homo sapiens (human)
hormone-mediated signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
keratinocyte differentiationSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of actin filament polymerizationSerine/threonine-protein kinase LATS1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of intracellular estrogen receptor signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of protein-containing complex assemblySerine/threonine-protein kinase LATS1Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activitySerine/threonine-protein kinase LATS1Homo sapiens (human)
cytoplasmic sequestering of proteinSerine/threonine-protein kinase LATS1Homo sapiens (human)
cell divisionSerine/threonine-protein kinase LATS1Homo sapiens (human)
mammary gland epithelial cell differentiationSerine/threonine-protein kinase LATS1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase LATS1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase LATS1Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase LATS1Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of organ growthSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase PAK 4Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase PAK 4Homo sapiens (human)
signal transductionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cell migrationSerine/threonine-protein kinase PAK 4Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase PAK 4Homo sapiens (human)
dendritic spine developmentSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cellular response to organic cyclic compoundSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cell-cell adhesionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
negative regulation of endothelial cell apoptotic processSerine/threonine-protein kinase PAK 4Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 4Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Chk2Homo sapiens (human)
signal transduction in response to DNA damageSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase Chk2Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase Chk2Homo sapiens (human)
double-strand break repairSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorSerine/threonine-protein kinase Chk2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein catabolic processSerine/threonine-protein kinase Chk2Homo sapiens (human)
mitotic intra-S DNA damage checkpoint signalingSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of protein catabolic processSerine/threonine-protein kinase Chk2Homo sapiens (human)
signal transduction in response to DNA damageSerine/threonine-protein kinase Chk2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorSerine/threonine-protein kinase Chk2Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase Chk2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Chk2Homo sapiens (human)
thymocyte apoptotic processSerine/threonine-protein kinase Chk2Homo sapiens (human)
cellular response to gamma radiationSerine/threonine-protein kinase Chk2Homo sapiens (human)
mitotic spindle assemblySerine/threonine-protein kinase Chk2Homo sapiens (human)
replicative senescenceSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of autophagosome assemblySerine/threonine-protein kinase Chk2Homo sapiens (human)
mitotic DNA damage checkpoint signalingSerine/threonine-protein kinase Chk2Homo sapiens (human)
response to oxidative stressTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of phospholipase C activityTyrosine-protein kinase ABL1Homo sapiens (human)
mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
neural tube closureTyrosine-protein kinase ABL1Homo sapiens (human)
B-1 B cell homeostasisTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of protein phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
B cell proliferation involved in immune responseTyrosine-protein kinase ABL1Homo sapiens (human)
transitional one stage B cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
mismatch repairTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of DNA-templated transcriptionTyrosine-protein kinase ABL1Homo sapiens (human)
autophagyTyrosine-protein kinase ABL1Homo sapiens (human)
DNA damage responseTyrosine-protein kinase ABL1Homo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
canonical NF-kappaB signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
associative learningTyrosine-protein kinase ABL1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageTyrosine-protein kinase ABL1Homo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase ABL1Homo sapiens (human)
post-embryonic developmentTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of autophagyTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of endothelial cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
cerebellum morphogenesisTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of cell-cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
microspike assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein kinase ABL1Homo sapiens (human)
actin filament polymerizationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of endocytosisTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
neuron differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
BMP signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of BMP signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of axon extensionTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of microtubule polymerizationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of Cdc42 protein signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of interleukin-2 productionTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of osteoblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to oxidative stressTyrosine-protein kinase ABL1Homo sapiens (human)
response to endoplasmic reticulum stressTyrosine-protein kinase ABL1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
protein modification processTyrosine-protein kinase ABL1Homo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase ABL1Homo sapiens (human)
neuropilin signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
signal transduction in response to DNA damageTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of neuron apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
endothelial cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of T cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of vasoconstrictionTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase ABL1Homo sapiens (human)
alpha-beta T cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of fibroblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
spleen developmentTyrosine-protein kinase ABL1Homo sapiens (human)
thymus developmentTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
activated T cell proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
neuromuscular process controlling balanceTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of oxidoreductase activityTyrosine-protein kinase ABL1Homo sapiens (human)
neuron apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
myoblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of stress fiber assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
establishment of localization in cellTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
mitochondrial depolarizationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of focal adhesion assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
Bergmann glial cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
cardiac muscle cell proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
neuroepithelial cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase ABL1Homo sapiens (human)
ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
DNA conformation changeTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase ABL1Homo sapiens (human)
response to epinephrineTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of protein serine/threonine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisTyrosine-protein kinase ABL1Homo sapiens (human)
cellular senescenceTyrosine-protein kinase ABL1Homo sapiens (human)
cell-cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of dendrite developmentTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of long-term synaptic potentiationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of hematopoietic stem cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of extracellular matrix organizationTyrosine-protein kinase ABL1Homo sapiens (human)
podocyte apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to dopamineTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of establishment of T cell polarityTyrosine-protein kinase ABL1Homo sapiens (human)
DN4 thymocyte differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
protein localization to cytoplasmic microtubule plus-endTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of microtubule bindingTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of actin filament bindingTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of modification of synaptic structureTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of blood vessel branchingTyrosine-protein kinase ABL1Homo sapiens (human)
activation of protein kinase C activityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of Wnt signaling pathway, planar cell polarity pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell motilityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of endothelial cell apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of T cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of cellular senescenceTyrosine-protein kinase ABL1Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell cycleProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
negative regulation of extrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein phosphorylationProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
epidermal growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell differentiationProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell adhesionProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
negative regulation of intrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
progesterone receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
innate immune responseProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
activation of adenylate cyclase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cell population proliferationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
Schwann cell developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
thyroid gland developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein-containing complex assemblyRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
somatic stem cell population maintenanceRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of Rho protein signal transductionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
response to muscle stretchRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
ERBB2-ERBB3 signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
wound healingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
myelinationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of MAPK cascadeRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
type B pancreatic cell proliferationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
intermediate filament cytoskeleton organizationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell differentiationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
thymus developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
face developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
type II interferon-mediated signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
death-inducing signaling complex assemblyRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell motilityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
MAPK cascadeRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cell surface receptor signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junction developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
motor neuron axon guidanceReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell growthReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of microtubule-based processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of Rho protein signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
intracellular signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-EGFR signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAP kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of translationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of angiogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell adhesionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
oligodendrocyte differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of epithelial cell proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
semaphorin-plexin signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein targeting to membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAPK cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuron differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to amyloid-betaHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
protein phosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
axon guidanceHigh affinity nerve growth factor receptorHomo sapiens (human)
learning or memoryHigh affinity nerve growth factor receptorHomo sapiens (human)
circadian rhythmHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of cell population proliferationHigh affinity nerve growth factor receptorHomo sapiens (human)
response to xenobiotic stimulusHigh affinity nerve growth factor receptorHomo sapiens (human)
programmed cell death involved in cell developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of neuron projection developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
olfactory nerve developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
B cell differentiationHigh affinity nerve growth factor receptorHomo sapiens (human)
response to nutrient levelsHigh affinity nerve growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
nerve growth factor signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
mechanoreceptor differentiationHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of programmed cell deathHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of neuron apoptotic processHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of GTPase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of Ras protein signal transductionHigh affinity nerve growth factor receptorHomo sapiens (human)
protein autophosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
ephrin receptor signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
sympathetic nervous system developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
response to axon injuryHigh affinity nerve growth factor receptorHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painHigh affinity nerve growth factor receptorHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
neuron apoptotic processHigh affinity nerve growth factor receptorHomo sapiens (human)
response to hydrostatic pressureHigh affinity nerve growth factor receptorHomo sapiens (human)
response to electrical stimulusHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of synapse assemblyHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHigh affinity nerve growth factor receptorHomo sapiens (human)
Sertoli cell developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
axonogenesis involved in innervationHigh affinity nerve growth factor receptorHomo sapiens (human)
behavioral response to formalin induced painHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh affinity nerve growth factor receptorHomo sapiens (human)
cellular response to nicotineHigh affinity nerve growth factor receptorHomo sapiens (human)
cellular response to nerve growth factor stimulusHigh affinity nerve growth factor receptorHomo sapiens (human)
multicellular organism developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of kinase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
signal transductionGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of adenylate cyclase activityGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
response to nutrientGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cell population proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of cell population proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of cell migrationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of superoxide anion generationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of urine volumeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosisGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of synaptic transmissionGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cell divisionGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
regulation of calcium ion transportGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart processGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of neural precursor cell proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
chromosome segregationADP/ATP translocase 2Homo sapiens (human)
positive regulation of cell population proliferationADP/ATP translocase 2Homo sapiens (human)
adenine transportADP/ATP translocase 2Homo sapiens (human)
B cell differentiationADP/ATP translocase 2Homo sapiens (human)
erythrocyte differentiationADP/ATP translocase 2Homo sapiens (human)
regulation of mitochondrial membrane permeabilityADP/ATP translocase 2Homo sapiens (human)
adenine nucleotide transportADP/ATP translocase 2Homo sapiens (human)
mitochondrial ADP transmembrane transportADP/ATP translocase 2Homo sapiens (human)
negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayADP/ATP translocase 2Homo sapiens (human)
positive regulation of mitophagyADP/ATP translocase 2Homo sapiens (human)
proton transmembrane transportADP/ATP translocase 2Homo sapiens (human)
mitochondrial ATP transmembrane transportADP/ATP translocase 2Homo sapiens (human)
cellular response to leukemia inhibitory factorADP/ATP translocase 2Homo sapiens (human)
adaptive thermogenesisADP/ATP translocase 2Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
adaptive immune responseProtein kinase C beta typeHomo sapiens (human)
chromatin remodelingProtein kinase C beta typeHomo sapiens (human)
regulation of transcription by RNA polymerase IIProtein kinase C beta typeHomo sapiens (human)
protein phosphorylationProtein kinase C beta typeHomo sapiens (human)
calcium ion transportProtein kinase C beta typeHomo sapiens (human)
intracellular calcium ion homeostasisProtein kinase C beta typeHomo sapiens (human)
apoptotic processProtein kinase C beta typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C beta typeHomo sapiens (human)
signal transductionProtein kinase C beta typeHomo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
response to xenobiotic stimulusProtein kinase C beta typeHomo sapiens (human)
response to glucoseProtein kinase C beta typeHomo sapiens (human)
regulation of glucose transmembrane transportProtein kinase C beta typeHomo sapiens (human)
negative regulation of glucose transmembrane transportProtein kinase C beta typeHomo sapiens (human)
regulation of dopamine secretionProtein kinase C beta typeHomo sapiens (human)
dibenzo-p-dioxin metabolic processProtein kinase C beta typeHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C beta typeHomo sapiens (human)
response to vitamin DProtein kinase C beta typeHomo sapiens (human)
regulation of growthProtein kinase C beta typeHomo sapiens (human)
B cell activationProtein kinase C beta typeHomo sapiens (human)
positive regulation of odontogenesis of dentin-containing toothProtein kinase C beta typeHomo sapiens (human)
lipoprotein transportProtein kinase C beta typeHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein kinase C beta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C beta typeHomo sapiens (human)
response to ethanolProtein kinase C beta typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C beta typeHomo sapiens (human)
positive regulation of DNA-templated transcriptionProtein kinase C beta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
B cell receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
positive regulation of B cell receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
cellular response to carbohydrate stimulusProtein kinase C beta typeHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionProtein kinase C beta typeHomo sapiens (human)
regulation of synaptic vesicle exocytosisProtein kinase C beta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C beta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C beta typeHomo sapiens (human)
positive regulation of MAP kinase activityInsulin receptorHomo sapiens (human)
positive regulation of protein phosphorylationInsulin receptorHomo sapiens (human)
positive regulation of receptor internalizationInsulin receptorHomo sapiens (human)
heart morphogenesisInsulin receptorHomo sapiens (human)
regulation of DNA-templated transcriptionInsulin receptorHomo sapiens (human)
protein phosphorylationInsulin receptorHomo sapiens (human)
receptor-mediated endocytosisInsulin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayInsulin receptorHomo sapiens (human)
learningInsulin receptorHomo sapiens (human)
memoryInsulin receptorHomo sapiens (human)
positive regulation of cell population proliferationInsulin receptorHomo sapiens (human)
insulin receptor signaling pathwayInsulin receptorHomo sapiens (human)
epidermis developmentInsulin receptorHomo sapiens (human)
male gonad developmentInsulin receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationInsulin receptorHomo sapiens (human)
male sex determinationInsulin receptorHomo sapiens (human)
adrenal gland developmentInsulin receptorHomo sapiens (human)
positive regulation of cell migrationInsulin receptorHomo sapiens (human)
exocrine pancreas developmentInsulin receptorHomo sapiens (human)
receptor internalizationInsulin receptorHomo sapiens (human)
activation of protein kinase activityInsulin receptorHomo sapiens (human)
activation of protein kinase B activityInsulin receptorHomo sapiens (human)
cellular response to insulin stimulusInsulin receptorHomo sapiens (human)
glucose homeostasisInsulin receptorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyInsulin receptorHomo sapiens (human)
positive regulation of MAPK cascadeInsulin receptorHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processInsulin receptorHomo sapiens (human)
positive regulation of glycogen biosynthetic processInsulin receptorHomo sapiens (human)
positive regulation of glycolytic processInsulin receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionInsulin receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionInsulin receptorHomo sapiens (human)
regulation of embryonic developmentInsulin receptorHomo sapiens (human)
positive regulation of glucose importInsulin receptorHomo sapiens (human)
symbiont entry into host cellInsulin receptorHomo sapiens (human)
protein autophosphorylationInsulin receptorHomo sapiens (human)
positive regulation of developmental growthInsulin receptorHomo sapiens (human)
positive regulation of meiotic cell cycleInsulin receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin receptorHomo sapiens (human)
positive regulation of respiratory burstInsulin receptorHomo sapiens (human)
cellular response to growth factor stimulusInsulin receptorHomo sapiens (human)
dendritic spine maintenanceInsulin receptorHomo sapiens (human)
amyloid-beta clearanceInsulin receptorHomo sapiens (human)
transport across blood-brain barrierInsulin receptorHomo sapiens (human)
neuron projection maintenanceInsulin receptorHomo sapiens (human)
regulation of female gonad developmentInsulin receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayInsulin receptorHomo sapiens (human)
multicellular organism developmentInsulin receptorHomo sapiens (human)
positive regulation of kinase activityInsulin receptorHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
intracellular zinc ion homeostasisTyrosine-protein kinase LckHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase LckHomo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
hemopoiesisTyrosine-protein kinase LckHomo sapiens (human)
platelet activationTyrosine-protein kinase LckHomo sapiens (human)
T cell differentiationTyrosine-protein kinase LckHomo sapiens (human)
T cell costimulationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase LckHomo sapiens (human)
Fc-gamma receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell activationTyrosine-protein kinase LckHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase LckHomo sapiens (human)
release of sequestered calcium ion into cytosolTyrosine-protein kinase LckHomo sapiens (human)
regulation of lymphocyte activationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of leukocyte cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
innate immune responseTyrosine-protein kinase LckHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
response to singlet oxygenTyrosine-protein kinase FynHomo sapiens (human)
neuron migrationTyrosine-protein kinase FynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FynHomo sapiens (human)
heart processTyrosine-protein kinase FynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
calcium ion transportTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
axon guidanceTyrosine-protein kinase FynHomo sapiens (human)
learningTyrosine-protein kinase FynHomo sapiens (human)
feeding behaviorTyrosine-protein kinase FynHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FynHomo sapiens (human)
gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase FynHomo sapiens (human)
protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
forebrain developmentTyrosine-protein kinase FynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FynHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase FynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FynHomo sapiens (human)
response to ethanolTyrosine-protein kinase FynHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
dendrite morphogenesisTyrosine-protein kinase FynHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
activated T cell proliferationTyrosine-protein kinase FynHomo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase FynHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase FynHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTyrosine-protein kinase FynHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase FynHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein targeting to membraneTyrosine-protein kinase FynHomo sapiens (human)
dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase FynHomo sapiens (human)
regulation of glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to L-glutamateTyrosine-protein kinase FynHomo sapiens (human)
cellular response to glycineTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to membraneTyrosine-protein kinase FynHomo sapiens (human)
regulation of calcium ion import across plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityTyrosine-protein kinase FynHomo sapiens (human)
innate immune responseTyrosine-protein kinase FynHomo sapiens (human)
cell differentiationTyrosine-protein kinase FynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent kinase 1Homo sapiens (human)
DNA replicationCyclin-dependent kinase 1Homo sapiens (human)
DNA repairCyclin-dependent kinase 1Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IICyclin-dependent kinase 1Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
apoptotic processCyclin-dependent kinase 1Homo sapiens (human)
DNA damage responseCyclin-dependent kinase 1Homo sapiens (human)
mitotic nuclear membrane disassemblyCyclin-dependent kinase 1Homo sapiens (human)
centrosome cycleCyclin-dependent kinase 1Homo sapiens (human)
pronuclear fusionCyclin-dependent kinase 1Homo sapiens (human)
response to xenobiotic stimulusCyclin-dependent kinase 1Homo sapiens (human)
response to toxic substanceCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of gene expressionCyclin-dependent kinase 1Homo sapiens (human)
negative regulation of gene expressionCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
regulation of Schwann cell differentiationCyclin-dependent kinase 1Homo sapiens (human)
response to amineCyclin-dependent kinase 1Homo sapiens (human)
response to activityCyclin-dependent kinase 1Homo sapiens (human)
cell migrationCyclin-dependent kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
chromosome condensationCyclin-dependent kinase 1Homo sapiens (human)
epithelial cell differentiationCyclin-dependent kinase 1Homo sapiens (human)
animal organ regenerationCyclin-dependent kinase 1Homo sapiens (human)
protein localization to kinetochoreCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of protein import into nucleusCyclin-dependent kinase 1Homo sapiens (human)
regulation of circadian rhythmCyclin-dependent kinase 1Homo sapiens (human)
negative regulation of apoptotic processCyclin-dependent kinase 1Homo sapiens (human)
response to ethanolCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 1Homo sapiens (human)
regulation of embryonic developmentCyclin-dependent kinase 1Homo sapiens (human)
response to cadmium ionCyclin-dependent kinase 1Homo sapiens (human)
response to copper ionCyclin-dependent kinase 1Homo sapiens (human)
symbiont entry into host cellCyclin-dependent kinase 1Homo sapiens (human)
fibroblast proliferationCyclin-dependent kinase 1Homo sapiens (human)
rhythmic processCyclin-dependent kinase 1Homo sapiens (human)
response to axon injuryCyclin-dependent kinase 1Homo sapiens (human)
cell divisionCyclin-dependent kinase 1Homo sapiens (human)
ventricular cardiac muscle cell developmentCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of mitotic sister chromatid segregationCyclin-dependent kinase 1Homo sapiens (human)
protein-containing complex assemblyCyclin-dependent kinase 1Homo sapiens (human)
cellular response to hydrogen peroxideCyclin-dependent kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeCyclin-dependent kinase 1Homo sapiens (human)
cellular response to organic cyclic compoundCyclin-dependent kinase 1Homo sapiens (human)
Golgi disassemblyCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of protein localization to nucleusCyclin-dependent kinase 1Homo sapiens (human)
regulation of attachment of mitotic spindle microtubules to kinetochoreCyclin-dependent kinase 1Homo sapiens (human)
microtubule cytoskeleton organization involved in mitosisCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of mitochondrial ATP synthesis coupled electron transportCyclin-dependent kinase 1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingCyclin-dependent kinase 1Homo sapiens (human)
protein deubiquitinationCyclin-dependent kinase 1Homo sapiens (human)
glycogen metabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
5-phosphoribose 1-diphosphate biosynthetic processGlycogen phosphorylase, liver formHomo sapiens (human)
response to bacteriumGlycogen phosphorylase, liver formHomo sapiens (human)
glucose homeostasisGlycogen phosphorylase, liver formHomo sapiens (human)
necroptotic processGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
microtubule bundle formationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
centrosome cycleTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase Fes/FpsHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of microtubule polymerizationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell population proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of mast cell degranulationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of myeloid cell differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of monocyte differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
myoblast proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cardiac muscle cell proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of vesicle-mediated transportTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cellular response to vitamin DTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell motilityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
chemotaxisTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cell adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of macrophage chemotaxisMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of macrophage proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of protein phosphorylationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
response to ischemiaMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
inflammatory responseMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
signal transductionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
axon guidanceMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell population proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
negative regulation of cell population proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of cell shapeMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cytokine-mediated signaling pathwayMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
olfactory bulb developmentMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
forebrain neuron differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
hemopoiesisMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
monocyte differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
macrophage differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
osteoclast differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
ruffle organizationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of chemokine productionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of actin cytoskeleton organizationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulusMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
macrophage colony-stimulating factor signaling pathwayMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
negative regulation of apoptotic processMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation by host of viral processMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
innate immune responseMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of bone resorptionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell-cell junction maintenanceMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein autophosphorylationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
mammary gland duct morphogenesisMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of protein tyrosine kinase activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
microglial cell proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cellular response to cytokine stimulusMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of macrophage migrationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of cell motilityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of cell migrationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of MAPK cascadeMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of kinase activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
multicellular organism developmentMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
purine ribonucleoside salvageAdenine phosphoribosyltransferaseHomo sapiens (human)
grooming behaviorAdenine phosphoribosyltransferaseHomo sapiens (human)
GMP salvageAdenine phosphoribosyltransferaseHomo sapiens (human)
IMP salvageAdenine phosphoribosyltransferaseHomo sapiens (human)
AMP salvageAdenine phosphoribosyltransferaseHomo sapiens (human)
adenine salvageAdenine phosphoribosyltransferaseHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase YesHomo sapiens (human)
regulation of glucose transmembrane transportTyrosine-protein kinase YesHomo sapiens (human)
T cell costimulationTyrosine-protein kinase YesHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase YesHomo sapiens (human)
protein modification processTyrosine-protein kinase YesHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase YesHomo sapiens (human)
regulation of vascular permeabilityTyrosine-protein kinase YesHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase YesHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase YesHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase YesHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase YesHomo sapiens (human)
cellular response to retinoic acidTyrosine-protein kinase YesHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase YesHomo sapiens (human)
innate immune responseTyrosine-protein kinase YesHomo sapiens (human)
cell differentiationTyrosine-protein kinase YesHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase YesHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase YesHomo sapiens (human)
DNA damage checkpoint signalingTyrosine-protein kinase LynHomo sapiens (human)
B cell homeostasisTyrosine-protein kinase LynHomo sapiens (human)
regulation of cytokine productionTyrosine-protein kinase LynHomo sapiens (human)
regulation of protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
hematopoietic progenitor cell differentiationTyrosine-protein kinase LynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase LynHomo sapiens (human)
Fc receptor mediated stimulatory signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
tolerance induction to self antigenTyrosine-protein kinase LynHomo sapiens (human)
histamine secretion by mast cellTyrosine-protein kinase LynHomo sapiens (human)
platelet degranulationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of myeloid leukocyte differentiationTyrosine-protein kinase LynHomo sapiens (human)
immune response-regulating cell surface receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
Fc receptor mediated inhibitory signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase LynHomo sapiens (human)
regulation of B cell apoptotic processTyrosine-protein kinase LynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
DNA damage responseTyrosine-protein kinase LynHomo sapiens (human)
response to sterol depletionTyrosine-protein kinase LynHomo sapiens (human)
signal transductionTyrosine-protein kinase LynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein kinase LynHomo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase LynHomo sapiens (human)
response to toxic substanceTyrosine-protein kinase LynHomo sapiens (human)
response to hormoneTyrosine-protein kinase LynHomo sapiens (human)
response to carbohydrateTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase LynHomo sapiens (human)
oligodendrocyte developmentTyrosine-protein kinase LynHomo sapiens (human)
response to organic cyclic compoundTyrosine-protein kinase LynHomo sapiens (human)
fatty acid transportTyrosine-protein kinase LynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
erythrocyte differentiationTyrosine-protein kinase LynHomo sapiens (human)
eosinophil differentiationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of B cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase LynHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
response to insulinTyrosine-protein kinase LynHomo sapiens (human)
regulation of mast cell activationTyrosine-protein kinase LynHomo sapiens (human)
regulation of cell adhesion mediated by integrinTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of toll-like receptor 2 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
toll-like receptor 4 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of toll-like receptor 4 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
cellular response to heatTyrosine-protein kinase LynHomo sapiens (human)
interleukin-5-mediated signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase LynHomo sapiens (human)
C-X-C chemokine receptor CXCR4 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase LynHomo sapiens (human)
response to amino acidTyrosine-protein kinase LynHomo sapiens (human)
regulation of mast cell degranulationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of MAPK cascadeTyrosine-protein kinase LynHomo sapiens (human)
regulation of erythrocyte differentiationTyrosine-protein kinase LynHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase LynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
response to axon injuryTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of immune responseTyrosine-protein kinase LynHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
regulation of B cell receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase LynHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of glial cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of Fc receptor mediated stimulatory signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase LynHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of oligodendrocyte progenitor proliferationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of mast cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of mast cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
cellular response to retinoic acidTyrosine-protein kinase LynHomo sapiens (human)
regulation of monocyte chemotaxisTyrosine-protein kinase LynHomo sapiens (human)
regulation of platelet aggregationTyrosine-protein kinase LynHomo sapiens (human)
dendritic cell differentiationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of intracellular signal transductionTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic processTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of dendritic cell apoptotic processTyrosine-protein kinase LynHomo sapiens (human)
neuron projection developmentTyrosine-protein kinase LynHomo sapiens (human)
innate immune responseTyrosine-protein kinase LynHomo sapiens (human)
MAPK cascadeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
ureteric bud developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neural crest cell migrationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
embryonic epithelial tube formationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion moleculesProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neuron cell-cell adhesionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
signal transductionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
axon guidanceProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
posterior midgut developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of gene expressionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of neuron projection developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of neuron maturationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
regulation of cell adhesionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of cell migrationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
membrane protein proteolysisProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of cell adhesion mediated by integrinProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
ureter maturationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
glial cell-derived neurotrophic factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neuron maturationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of MAPK cascadeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of cell sizeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of DNA-templated transcriptionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
response to painProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
enteric nervous system developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
regulation of axonogenesisProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
retina development in camera-type eyeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
innervationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
Peyer's patch morphogenesisProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
cellular response to retinoic acidProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of metanephric glomerulus developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
lymphocyte migration into lymphoid organsProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
GDF15-GFRAL signaling pathwayProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway in absence of ligandProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of kinase activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
multicellular organism developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
peptidyl-tyrosine autophosphorylationInsulin-like growth factor 1 receptorHomo sapiens (human)
cardiac atrium developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
immune responseInsulin-like growth factor 1 receptorHomo sapiens (human)
signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
axonogenesisInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cell population proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor signaling pathwayInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of muscle cell apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cerebellum developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
hippocampus developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
establishment of cell polarityInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cell migrationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cytokinesisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to vitamin EInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of osteoblast proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to zinc ion starvationInsulin-like growth factor 1 receptorHomo sapiens (human)
response to nicotineInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyInsulin-like growth factor 1 receptorHomo sapiens (human)
response to alkaloidInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of MAPK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
estrous cycleInsulin-like growth factor 1 receptorHomo sapiens (human)
transcytosisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to ethanolInsulin-like growth factor 1 receptorHomo sapiens (human)
regulation of JNK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
protein autophosphorylationInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of axon regenerationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of DNA metabolic processInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to mechanical stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to estradiol stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to progesterone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to testosterone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to dexamethasone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of steroid hormone biosynthetic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular senescenceInsulin-like growth factor 1 receptorHomo sapiens (human)
dendritic spine maintenanceInsulin-like growth factor 1 receptorHomo sapiens (human)
amyloid-beta clearanceInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to L-glutamateInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of hepatocyte apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to aldosteroneInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of cholangiocyte apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to angiotensinInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to amyloid-betaInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to insulin-like growth factor stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
multicellular organism developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of kinase activityInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to glucose stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of MAPK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
cotranslational protein targeting to membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
SRP-dependent cotranslational protein targeting to membrane, signal sequence recognitionSignal recognition particle receptor subunit alphaHomo sapiens (human)
intracellular protein transportSignal recognition particle receptor subunit alphaHomo sapiens (human)
protein targeting to ERSignal recognition particle receptor subunit alphaHomo sapiens (human)
mitochondrial electron transport, ubiquinol to cytochrome cCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
response to glucagonCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
cellular respirationCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
proton transmembrane transportCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
endothelial cell morphogenesisHepatocyte growth factor receptorHomo sapiens (human)
signal transductionHepatocyte growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of autophagyHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of microtubule polymerizationHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of Rho protein signal transductionHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHepatocyte growth factor receptorHomo sapiens (human)
hepatocyte growth factor receptor signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
branching morphogenesis of an epithelial tubeHepatocyte growth factor receptorHomo sapiens (human)
positive chemotaxisHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of stress fiber assemblyHepatocyte growth factor receptorHomo sapiens (human)
excitatory postsynaptic potentialHepatocyte growth factor receptorHomo sapiens (human)
establishment of skin barrierHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
semaphorin-plexin signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of hydrogen peroxide-mediated programmed cell deathHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of guanyl-nucleotide exchange factor activityHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of endothelial cell chemotaxisHepatocyte growth factor receptorHomo sapiens (human)
liver developmentHepatocyte growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
phagocytosisHepatocyte growth factor receptorHomo sapiens (human)
multicellular organism developmentHepatocyte growth factor receptorHomo sapiens (human)
neuron differentiationHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of kinase activityHepatocyte growth factor receptorHomo sapiens (human)
cell migrationHepatocyte growth factor receptorHomo sapiens (human)
pancreas developmentHepatocyte growth factor receptorHomo sapiens (human)
nervous system developmentHepatocyte growth factor receptorHomo sapiens (human)
leukocyte migration involved in immune responseTyrosine-protein kinase HCKHomo sapiens (human)
innate immune response-activating signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase HCKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase HCKHomo sapiens (human)
inflammatory responseTyrosine-protein kinase HCKHomo sapiens (human)
cell adhesionTyrosine-protein kinase HCKHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
mesoderm developmentTyrosine-protein kinase HCKHomo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein kinase HCKHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase HCKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase HCKHomo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
positive regulation of actin filament polymerizationTyrosine-protein kinase HCKHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase HCKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase HCKHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase HCKHomo sapiens (human)
negative regulation of apoptotic processTyrosine-protein kinase HCKHomo sapiens (human)
leukocyte degranulationTyrosine-protein kinase HCKHomo sapiens (human)
respiratory burst after phagocytosisTyrosine-protein kinase HCKHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase HCKHomo sapiens (human)
regulation of inflammatory responseTyrosine-protein kinase HCKHomo sapiens (human)
regulation of phagocytosisTyrosine-protein kinase HCKHomo sapiens (human)
regulation of DNA-binding transcription factor activityTyrosine-protein kinase HCKHomo sapiens (human)
type II interferon-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
regulation of podosome assemblyTyrosine-protein kinase HCKHomo sapiens (human)
cell differentiationTyrosine-protein kinase HCKHomo sapiens (human)
innate immune responseTyrosine-protein kinase HCKHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
regulation of cell growthProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
columnar/cuboidal epithelial cell developmentProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
regulation of TOR signalingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
positive regulation of kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
multicellular organism developmentProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
signal transductionPlatelet-derived growth factor receptor betaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell population proliferationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phospholipase C activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of smooth muscle cell migrationPlatelet-derived growth factor receptor betaHomo sapiens (human)
peptidyl-tyrosine phosphorylationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell migrationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
regulation of actin cytoskeleton organizationPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell migration involved in vasculogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
aorta morphogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of MAP kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of mitotic nuclear divisionPlatelet-derived growth factor receptor betaHomo sapiens (human)
phosphatidylinositol metabolic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein autophosphorylationPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of calcium-mediated signalingPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPlatelet-derived growth factor receptor betaHomo sapiens (human)
cardiac myofibril assemblyPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell migration involved in coronary angiogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
retina vasculature development in camera-type eyePlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePlatelet-derived growth factor receptor betaHomo sapiens (human)
smooth muscle cell chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
metanephric glomerular mesangial cell proliferation involved in metanephros developmentPlatelet-derived growth factor receptor betaHomo sapiens (human)
metanephric glomerular capillary formationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of calcium ion importPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of DNA biosynthetic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
angiogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
multicellular organism developmentPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase FgrHomo sapiens (human)
immune response-regulating cell surface receptor signaling pathwayTyrosine-protein kinase FgrHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FgrHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FgrHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase FgrHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FgrHomo sapiens (human)
response to virusTyrosine-protein kinase FgrHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FgrHomo sapiens (human)
bone mineralizationTyrosine-protein kinase FgrHomo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase FgrHomo sapiens (human)
negative regulation of natural killer cell activationTyrosine-protein kinase FgrHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FgrHomo sapiens (human)
positive regulation of mast cell degranulationTyrosine-protein kinase FgrHomo sapiens (human)
regulation of innate immune responseTyrosine-protein kinase FgrHomo sapiens (human)
regulation of protein kinase activityTyrosine-protein kinase FgrHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase FgrHomo sapiens (human)
skeletal system morphogenesisTyrosine-protein kinase FgrHomo sapiens (human)
regulation of phagocytosisTyrosine-protein kinase FgrHomo sapiens (human)
defense response to Gram-positive bacteriumTyrosine-protein kinase FgrHomo sapiens (human)
myoblast proliferationTyrosine-protein kinase FgrHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase FgrHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FgrHomo sapiens (human)
cell differentiationTyrosine-protein kinase FgrHomo sapiens (human)
innate immune responseTyrosine-protein kinase FgrHomo sapiens (human)
mitotic cell cycleWee1-like protein kinase 2Homo sapiens (human)
female meiotic nuclear divisionWee1-like protein kinase 2Homo sapiens (human)
female pronucleus assemblyWee1-like protein kinase 2Homo sapiens (human)
positive regulation of phosphorylationWee1-like protein kinase 2Homo sapiens (human)
regulation of meiosis IWee1-like protein kinase 2Homo sapiens (human)
regulation of fertilizationWee1-like protein kinase 2Homo sapiens (human)
negative regulation of oocyte maturationWee1-like protein kinase 2Homo sapiens (human)
protein phosphorylationWee1-like protein kinase 2Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
regulation of TOR signalingSerine/threonine-protein kinase A-RafHomo sapiens (human)
regulation of proteasomal ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase A-RafHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase A-RafHomo sapiens (human)
protein modification processSerine/threonine-protein kinase A-RafHomo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase A-RafHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase A-RafHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
ovarian follicle developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
myeloid progenitor cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
lymphoid progenitor cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
immature B cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell chemotaxisMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of dendritic cell cytokine productionMast/stem cell growth factor receptor KitHomo sapiens (human)
glycosphingolipid metabolic processMast/stem cell growth factor receptor KitHomo sapiens (human)
inflammatory responseMast/stem cell growth factor receptor KitHomo sapiens (human)
signal transductionMast/stem cell growth factor receptor KitHomo sapiens (human)
spermatogenesisMast/stem cell growth factor receptor KitHomo sapiens (human)
spermatid developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
germ cell migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
regulation of cell shapeMast/stem cell growth factor receptor KitHomo sapiens (human)
visual learningMast/stem cell growth factor receptor KitHomo sapiens (human)
male gonad developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of phospholipase C activityMast/stem cell growth factor receptor KitHomo sapiens (human)
cytokine-mediated signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
stem cell population maintenanceMast/stem cell growth factor receptor KitHomo sapiens (human)
lamellipodium assemblyMast/stem cell growth factor receptor KitHomo sapiens (human)
actin cytoskeleton organizationMast/stem cell growth factor receptor KitHomo sapiens (human)
hemopoiesisMast/stem cell growth factor receptor KitHomo sapiens (human)
T cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
erythrocyte differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
melanocyte differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of pseudopodium assemblyMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of mast cell cytokine productionMast/stem cell growth factor receptor KitHomo sapiens (human)
somatic stem cell population maintenanceMast/stem cell growth factor receptor KitHomo sapiens (human)
embryonic hemopoiesisMast/stem cell growth factor receptor KitHomo sapiens (human)
ectopic germ cell programmed cell deathMast/stem cell growth factor receptor KitHomo sapiens (human)
intracellular signal transductionMast/stem cell growth factor receptor KitHomo sapiens (human)
hematopoietic stem cell migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
megakaryocyte developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
Fc receptor signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
Kit signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
erythropoietin-mediated signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
regulation of cell population proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinMast/stem cell growth factor receptor KitHomo sapiens (human)
negative regulation of programmed cell deathMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell degranulationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of MAPK cascadeMast/stem cell growth factor receptor KitHomo sapiens (human)
pigmentationMast/stem cell growth factor receptor KitHomo sapiens (human)
tongue developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of Notch signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATMast/stem cell growth factor receptor KitHomo sapiens (human)
response to cadmium ionMast/stem cell growth factor receptor KitHomo sapiens (human)
protein autophosphorylationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of long-term neuronal synaptic plasticityMast/stem cell growth factor receptor KitHomo sapiens (human)
digestive tract developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
stem cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
epithelial cell proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityMast/stem cell growth factor receptor KitHomo sapiens (human)
negative regulation of developmental processMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMast/stem cell growth factor receptor KitHomo sapiens (human)
cell chemotaxisMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of mast cell proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
melanocyte migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
melanocyte adhesionMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of pyloric antrum smooth muscle contractionMast/stem cell growth factor receptor KitHomo sapiens (human)
regulation of bile acid metabolic processMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of colon smooth muscle contractionMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of small intestine smooth muscle contractionMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
negative regulation of reproductive processMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of cell migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of MAP kinase activityMast/stem cell growth factor receptor KitHomo sapiens (human)
multicellular organism developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
B cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
hematopoietic progenitor cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, brain formHomo sapiens (human)
negative regulation of cellular extravasationBreakpoint cluster region proteinHomo sapiens (human)
renal system processBreakpoint cluster region proteinHomo sapiens (human)
protein phosphorylationBreakpoint cluster region proteinHomo sapiens (human)
phagocytosisBreakpoint cluster region proteinHomo sapiens (human)
signal transductionBreakpoint cluster region proteinHomo sapiens (human)
small GTPase-mediated signal transductionBreakpoint cluster region proteinHomo sapiens (human)
brain developmentBreakpoint cluster region proteinHomo sapiens (human)
actin cytoskeleton organizationBreakpoint cluster region proteinHomo sapiens (human)
keratinocyte differentiationBreakpoint cluster region proteinHomo sapiens (human)
regulation of Rho protein signal transductionBreakpoint cluster region proteinHomo sapiens (human)
inner ear morphogenesisBreakpoint cluster region proteinHomo sapiens (human)
regulation of vascular permeabilityBreakpoint cluster region proteinHomo sapiens (human)
neutrophil degranulationBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of neutrophil degranulationBreakpoint cluster region proteinHomo sapiens (human)
focal adhesion assemblyBreakpoint cluster region proteinHomo sapiens (human)
homeostasis of number of cellsBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of inflammatory responseBreakpoint cluster region proteinHomo sapiens (human)
positive regulation of phagocytosisBreakpoint cluster region proteinHomo sapiens (human)
modulation of chemical synaptic transmissionBreakpoint cluster region proteinHomo sapiens (human)
neuromuscular process controlling balanceBreakpoint cluster region proteinHomo sapiens (human)
regulation of small GTPase mediated signal transductionBreakpoint cluster region proteinHomo sapiens (human)
regulation of cell cycleBreakpoint cluster region proteinHomo sapiens (human)
definitive hemopoiesisBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of respiratory burstBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of blood vessel remodelingBreakpoint cluster region proteinHomo sapiens (human)
intracellular protein transmembrane transportBreakpoint cluster region proteinHomo sapiens (human)
cellular response to lipopolysaccharideBreakpoint cluster region proteinHomo sapiens (human)
activation of GTPase activityBreakpoint cluster region proteinHomo sapiens (human)
macrophage migrationBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of macrophage migrationBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processBreakpoint cluster region proteinHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of transmembrane transporter activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of innate immune responseSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
vitamin D receptor signaling pathwaySerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular response to type II interferonSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of brown fat cell differentiationSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of hematopoietic stem cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardioblast proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular detoxificationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 1Homo sapiens (human)
MAPK cascadeFibroblast growth factor receptor 1Homo sapiens (human)
skeletal system developmentFibroblast growth factor receptor 1Homo sapiens (human)
angiogenesisFibroblast growth factor receptor 1Homo sapiens (human)
ureteric bud developmentFibroblast growth factor receptor 1Homo sapiens (human)
in utero embryonic developmentFibroblast growth factor receptor 1Homo sapiens (human)
organ inductionFibroblast growth factor receptor 1Homo sapiens (human)
neuron migrationFibroblast growth factor receptor 1Homo sapiens (human)
epithelial to mesenchymal transitionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of mesenchymal cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
chondrocyte differentiationFibroblast growth factor receptor 1Homo sapiens (human)
protein phosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
sensory perception of soundFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
mesenchymal cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
gene expressionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phospholipase C activityFibroblast growth factor receptor 1Homo sapiens (human)
regulation of phosphate transportFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentFibroblast growth factor receptor 1Homo sapiens (human)
cell migrationFibroblast growth factor receptor 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
ventricular zone neuroblast divisionFibroblast growth factor receptor 1Homo sapiens (human)
cell projection assemblyFibroblast growth factor receptor 1Homo sapiens (human)
embryonic limb morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
midbrain developmentFibroblast growth factor receptor 1Homo sapiens (human)
neuron projection developmentFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentFibroblast growth factor receptor 1Homo sapiens (human)
inner ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
outer ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
middle ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
chordate embryonic developmentFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAP kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationFibroblast growth factor receptor 1Homo sapiens (human)
cellular response to fibroblast growth factor stimulusFibroblast growth factor receptor 1Homo sapiens (human)
regulation of cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of neuron differentiationFibroblast growth factor receptor 1Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
phosphatidylinositol-mediated signalingFibroblast growth factor receptor 1Homo sapiens (human)
paraxial mesoderm developmentFibroblast growth factor receptor 1Homo sapiens (human)
regulation of lateral mesodermal cell fate specificationFibroblast growth factor receptor 1Homo sapiens (human)
cell maturationFibroblast growth factor receptor 1Homo sapiens (human)
skeletal system morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
stem cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFibroblast growth factor receptor 1Homo sapiens (human)
calcium ion homeostasisFibroblast growth factor receptor 1Homo sapiens (human)
cardiac muscle cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
auditory receptor cell developmentFibroblast growth factor receptor 1Homo sapiens (human)
branching involved in salivary gland morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
lung-associated mesenchyme developmentFibroblast growth factor receptor 1Homo sapiens (human)
regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signalingFibroblast growth factor receptor 1Homo sapiens (human)
vitamin D3 metabolic processFibroblast growth factor receptor 1Homo sapiens (human)
diphosphate metabolic processFibroblast growth factor receptor 1Homo sapiens (human)
cementum mineralizationFibroblast growth factor receptor 1Homo sapiens (human)
stem cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
negative regulation of fibroblast growth factor productionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of mitotic cell cycle DNA replicationFibroblast growth factor receptor 1Homo sapiens (human)
response to sodium phosphateFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of stem cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of parathyroid hormone secretionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of endothelial cell chemotaxisFibroblast growth factor receptor 1Homo sapiens (human)
regulation of extrinsic apoptotic signaling pathway in absence of ligandFibroblast growth factor receptor 1Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
muscle structure developmentMyosin light chain kinase, smooth muscleGallus gallus (chicken)
tonic smooth muscle contractionMyosin light chain kinase, smooth muscleGallus gallus (chicken)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 4Homo sapiens (human)
response to xenobiotic stimulusCyclin-dependent kinase 4Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of fibroblast proliferationCyclin-dependent kinase 4Homo sapiens (human)
cell divisionCyclin-dependent kinase 4Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 4Homo sapiens (human)
regulation of transcription initiation by RNA polymerase IICyclin-dependent kinase 4Homo sapiens (human)
regulation of type B pancreatic cell proliferationCyclin-dependent kinase 4Homo sapiens (human)
cellular response to lipopolysaccharideCyclin-dependent kinase 4Homo sapiens (human)
cellular response to interleukin-4Cyclin-dependent kinase 4Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateCyclin-dependent kinase 4Homo sapiens (human)
cellular response to ionomycinCyclin-dependent kinase 4Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 4Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
signal transductionCyclin-dependent kinase 4Homo sapiens (human)
apoptotic processADP/ATP translocase 3Homo sapiens (human)
mitochondrial ADP transmembrane transportADP/ATP translocase 3Homo sapiens (human)
mitochondrial ATP transmembrane transportADP/ATP translocase 3Homo sapiens (human)
negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayADP/ATP translocase 3Homo sapiens (human)
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
circadian rhythmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
lymphocyte proliferationInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cellular response to interleukin-4Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
'de novo' XMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
primary ovarian follicle growthProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of cytokine productionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
learning or memoryProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mechanical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to acidic pHProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of gene expressionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of glucose metabolic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein processingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
skeletal muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of smooth muscle cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
macroautophagyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
forebrain developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
T cell costimulationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of protein-containing complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein destabilizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to nutrient levelsProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomere maintenance via telomeraseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to insulin stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of intracellular estrogen receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of integrin activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of toll-like receptor 3 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
adherens junction organizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
substrate adhesion-dependent cell spreadingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of dephosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of hippo signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intracellular signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
entry of bacterium into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
osteoclast developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ERBB2 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
angiotensin-activated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
odontogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of vascular permeabilityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stress fiber assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transcytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Notch signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Ras protein signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein autophosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
oogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
progesterone receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
leukocyte migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of small GTPase mediated signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mineralocorticoidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
myoblast proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to electrical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of mitochondrial depolarizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomerase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
uterus developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
branching involved in mammary gland duct morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell projection assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intestinal epithelial cell developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
interleukin-6-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hydrogen peroxideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to interleukin-1Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to lipopolysaccharideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to peptide hormone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to progesterone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fatty acidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hypoxiaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fluid shear stressProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of podosome assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
DNA biosynthetic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of heart rate by cardiac conductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein localization to nucleusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of TORC1 signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to prolactinProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of male germ cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ovarian follicle developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of lamellipodium morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor-beta signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of early endosome to late endosome transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of anoikisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of caveolin-mediated endocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
innate immune responseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
symbiont entry into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of protein phosphorylationcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
intracellular signal transductioncAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
negative regulation of cAMP/PKA signal transductioncAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
negative regulation of cAMP-dependent protein kinase activitycAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayInsulin receptor-related proteinHomo sapiens (human)
insulin receptor signaling pathwayInsulin receptor-related proteinHomo sapiens (human)
actin cytoskeleton organizationInsulin receptor-related proteinHomo sapiens (human)
male sex determinationInsulin receptor-related proteinHomo sapiens (human)
protein autophosphorylationInsulin receptor-related proteinHomo sapiens (human)
cellular response to alkaline pHInsulin receptor-related proteinHomo sapiens (human)
positive regulation of kinase activityInsulin receptor-related proteinHomo sapiens (human)
multicellular organism developmentInsulin receptor-related proteinHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase B-rafHomo sapiens (human)
myeloid progenitor cell differentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase B-rafHomo sapiens (human)
epidermal growth factor receptor signaling pathwaySerine/threonine-protein kinase B-rafHomo sapiens (human)
visual learningSerine/threonine-protein kinase B-rafHomo sapiens (human)
animal organ morphogenesisSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of fibroblast migrationSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of glucose transmembrane transportSerine/threonine-protein kinase B-rafHomo sapiens (human)
synaptic vesicle exocytosisSerine/threonine-protein kinase B-rafHomo sapiens (human)
thyroid gland developmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
T cell differentiation in thymusSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase B-rafHomo sapiens (human)
substrate adhesion-dependent cell spreadingSerine/threonine-protein kinase B-rafHomo sapiens (human)
somatic stem cell population maintenanceSerine/threonine-protein kinase B-rafHomo sapiens (human)
regulation of cell population proliferationSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
stress fiber assemblySerine/threonine-protein kinase B-rafHomo sapiens (human)
CD4-positive, alpha-beta T cell differentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
CD4-positive or CD8-positive, alpha-beta T cell lineage commitmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
response to peptide hormoneSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of neuron apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
regulation of T cell differentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
thymus developmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of axon regenerationSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of axonogenesisSerine/threonine-protein kinase B-rafHomo sapiens (human)
T cell receptor signaling pathwaySerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of stress fiber assemblySerine/threonine-protein kinase B-rafHomo sapiens (human)
response to cAMPSerine/threonine-protein kinase B-rafHomo sapiens (human)
long-term synaptic potentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
head morphogenesisSerine/threonine-protein kinase B-rafHomo sapiens (human)
face developmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
ERK1 and ERK2 cascadeSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeSerine/threonine-protein kinase B-rafHomo sapiens (human)
cellular response to calcium ionSerine/threonine-protein kinase B-rafHomo sapiens (human)
cellular response to xenobiotic stimulusSerine/threonine-protein kinase B-rafHomo sapiens (human)
endothelial cell apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
establishment of protein localization to membraneSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingSerine/threonine-protein kinase B-rafHomo sapiens (human)
cellular response to nerve growth factor stimulusSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of synaptic vesicle exocytosisSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of endothelial cell apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
epithelial cell maturationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
male gonad developmentPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
vestibular nucleus developmentPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
secretory granule organizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to cAMPPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to acidic pHPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to light stimulusPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cardiac muscle cell action potential involved in contractionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cardiac muscle cell contractionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
negative regulation of protein targeting to membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
negative regulation of delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
glycogen metabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
glycogen biosynthetic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
glycogen catabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
generation of precursor metabolites and energyPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
protein phosphorylationPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
positive regulation of glycogen catabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
quinone catabolic processRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cellular response to reactive oxygen speciesPlatelet-derived growth factor receptor alphaHomo sapiens (human)
luteinizationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
in utero embryonic developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell activationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
hematopoietic progenitor cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
estrogen metabolic processPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of cell population proliferationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
negative regulation of platelet activationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of phospholipase C activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
peptidyl-tyrosine phosphorylationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
signal transduction involved in regulation of gene expressionPlatelet-derived growth factor receptor alphaHomo sapiens (human)
extracellular matrix organizationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
lung developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
adrenal gland developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of cell migrationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
male genitalia developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
regulation of actin cytoskeleton organizationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
Leydig cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor receptor-alpha signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
wound healingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
odontogenesis of dentin-containing toothPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein autophosphorylationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of fibroblast proliferationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
embryonic digestive tract morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
embryonic cranial skeleton morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
embryonic skeletal system morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of calcium-mediated signalingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
white fat cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of chemotaxisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cardiac myofibril assemblyPlatelet-derived growth factor receptor alphaHomo sapiens (human)
roof of mouth developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
face morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell chemotaxisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
retina vasculature development in camera-type eyePlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet aggregationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cellular response to amino acid stimulusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
metanephric glomerular capillary formationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
regulation of mesenchymal stem cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of kinase activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
multicellular organism developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
microtubule cytoskeleton organizationTyrosine-protein kinase FerHomo sapiens (human)
regulation of protein phosphorylationTyrosine-protein kinase FerHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FerHomo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FerHomo sapiens (human)
germ cell developmentTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein kinase FerHomo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
regulation of lamellipodium assemblyTyrosine-protein kinase FerHomo sapiens (human)
regulation of fibroblast migrationTyrosine-protein kinase FerHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FerHomo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
actin cytoskeleton organizationTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of actin filament polymerizationTyrosine-protein kinase FerHomo sapiens (human)
response to lipopolysaccharideTyrosine-protein kinase FerHomo sapiens (human)
negative regulation of mast cell activation involved in immune responseTyrosine-protein kinase FerHomo sapiens (human)
adherens junction assemblyTyrosine-protein kinase FerHomo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase FerHomo sapiens (human)
cellular response to reactive oxygen speciesTyrosine-protein kinase FerHomo sapiens (human)
extracellular matrix-cell signalingTyrosine-protein kinase FerHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FerHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulusTyrosine-protein kinase FerHomo sapiens (human)
response to platelet-derived growth factorTyrosine-protein kinase FerHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
Kit signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
cell-cell adhesion mediated by cadherinTyrosine-protein kinase FerHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase FerHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
diapedesisTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase FerHomo sapiens (human)
Sertoli cell developmentTyrosine-protein kinase FerHomo sapiens (human)
interleukin-6-mediated signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
seminiferous tubule developmentTyrosine-protein kinase FerHomo sapiens (human)
adherens junction disassemblyTyrosine-protein kinase FerHomo sapiens (human)
cell adhesionTyrosine-protein kinase FerHomo sapiens (human)
chemotaxisTyrosine-protein kinase FerHomo sapiens (human)
angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell proliferationProtein kinase C alpha typeHomo sapiens (human)
desmosome assemblyProtein kinase C alpha typeHomo sapiens (human)
chromatin remodelingProtein kinase C alpha typeHomo sapiens (human)
protein phosphorylationProtein kinase C alpha typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C alpha typeHomo sapiens (human)
cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyProtein kinase C alpha typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C alpha typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C alpha typeHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
post-translational protein modificationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of macrophage differentiationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of bone resorptionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of mitotic cell cycleProtein kinase C alpha typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C alpha typeHomo sapiens (human)
response to interleukin-1Protein kinase C alpha typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C alpha typeHomo sapiens (human)
apoptotic signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiotensin-activated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of dense core granule biogenesisProtein kinase C alpha typeHomo sapiens (human)
intracellular signal transductionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C alpha typeHomo sapiens (human)
mesoderm formationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
neural tube closurecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of heart ratecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
renal water homeostasiscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
mRNA processingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein phosphorylationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein export from nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of macroautophagycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytokine-mediated signaling pathwaycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of insulin secretioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of interleukin-2 productioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
high-density lipoprotein particle assemblycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to heatcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
mitochondrial protein catabolic processcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of osteoblast differentiationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of gluconeogenesiscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of smoothened signaling pathwaycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of protein export from nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
sperm capacitationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of calcium-mediated signalingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cell cyclecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cardiac muscle contractioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of proteasomal protein catabolic processcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to coldcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of protein processingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to glucose stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to parathyroid hormone stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to glucagon stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cardiac conductioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of TORC1 signalingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of glycolytic process through fructose-6-phosphatecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein localization to lipid dropletcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of bicellular tight junction assemblycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
monocyte chemotaxisVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phospholipase C activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell differentiationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor-1 signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAP kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
embryonic morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 1 Homo sapiens (human)
negative regulation of vascular endothelial cell proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
hyaloid vascular plexus regressionVascular endothelial growth factor receptor 1 Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)General transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
response to hypoxiaGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
in utero embryonic developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription-coupled nucleotide-excision repairGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
nucleotide-excision repairGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
regulation of transcription by RNA polymerase IIGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription elongation by RNA polymerase IGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription by RNA polymerase IIGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription initiation at RNA polymerase II promoterGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
apoptotic processGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
response to oxidative stressGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
chromosome segregationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
determination of adult lifespanGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
UV protectionGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
post-embryonic developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
spinal cord developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
extracellular matrix organizationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
bone mineralizationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
central nervous system myelin formationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
DNA duplex unwindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
multicellular organism growthGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hair cell differentiationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
embryonic cleavageGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
erythrocyte maturationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
embryonic organ developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hair follicle maturationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hematopoietic stem cell differentiationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hematopoietic stem cell proliferationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
regulation of mitotic cell cycle phase transitionGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
positive regulation of mitotic recombinationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
positive regulation of cytokine productionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
translationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein phosphorylationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of cell population proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
response to virusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of translationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of chemokine productionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of stress-activated MAPK cascadeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of osteoblast proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cellular response to amino acid starvationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
response to interferon-alphaInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of apoptotic processInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of MAPK cascadeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of viral genome replicationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein autophosphorylationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
defense response to virusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
antiviral innate immune responseInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of NLRP3 inflammasome complex assemblyInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic progenitor cell differentiationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic stem cell proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic stem cell differentiationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
eiF2alpha phosphorylation in response to endoplasmic reticulum stressInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
double-strand break repairCasein kinase II subunit alpha'Homo sapiens (human)
apoptotic processCasein kinase II subunit alpha'Homo sapiens (human)
spermatogenesisCasein kinase II subunit alpha'Homo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
cerebral cortex developmentCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alpha'Homo sapiens (human)
liver regenerationCasein kinase II subunit alpha'Homo sapiens (human)
regulation of mitophagyCasein kinase II subunit alpha'Homo sapiens (human)
positive regulation of protein targeting to mitochondrionCasein kinase II subunit alpha'Homo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-cysteine methylationRas-related protein Rab-6AHomo sapiens (human)
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulumRas-related protein Rab-6AHomo sapiens (human)
antigen processing and presentationRas-related protein Rab-6AHomo sapiens (human)
neuron projection developmentRas-related protein Rab-6AHomo sapiens (human)
protein localization to Golgi apparatusRas-related protein Rab-6AHomo sapiens (human)
early endosome to Golgi transportRas-related protein Rab-6AHomo sapiens (human)
minus-end-directed organelle transport along microtubuleRas-related protein Rab-6AHomo sapiens (human)
protein localization to Golgi membraneRas-related protein Rab-6AHomo sapiens (human)
intracellular protein transportRas-related protein Rab-6AHomo sapiens (human)
intra-Golgi vesicle-mediated transportRas-related protein Rab-6AHomo sapiens (human)
retrograde transport, endosome to GolgiRas-related protein Rab-6AHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MAKHomo sapiens (human)
spermatogenesisSerine/threonine-protein kinase MAKHomo sapiens (human)
cell differentiationSerine/threonine-protein kinase MAKHomo sapiens (human)
photoreceptor cell maintenanceSerine/threonine-protein kinase MAKHomo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase MAKHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase MAKHomo sapiens (human)
negative regulation of non-motile cilium assemblySerine/threonine-protein kinase MAKHomo sapiens (human)
non-motile cilium assemblySerine/threonine-protein kinase MAKHomo sapiens (human)
intraciliary transportSerine/threonine-protein kinase MAKHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase MAKHomo sapiens (human)
cilium assemblySerine/threonine-protein kinase MAKHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2B6Homo sapiens (human)
steroid metabolic processCytochrome P450 2B6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2B6Homo sapiens (human)
cellular ketone metabolic processCytochrome P450 2B6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2B6Homo sapiens (human)
mitotic cell cycleCyclin-dependent kinase 11BHomo sapiens (human)
regulation of cell growthCyclin-dependent kinase 11BHomo sapiens (human)
regulation of DNA-templated transcriptionCyclin-dependent kinase 11BHomo sapiens (human)
protein phosphorylationCyclin-dependent kinase 11BHomo sapiens (human)
apoptotic processCyclin-dependent kinase 11BHomo sapiens (human)
regulation of mRNA processingCyclin-dependent kinase 11BHomo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 11BHomo sapiens (human)
positive regulation of cell-matrix adhesionEphrin type-A receptor 1Homo sapiens (human)
negative regulation of protein kinase activityEphrin type-A receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayEphrin type-A receptor 1Homo sapiens (human)
positive regulation of cell population proliferationEphrin type-A receptor 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-A receptor 1Homo sapiens (human)
positive regulation of cell migrationEphrin type-A receptor 1Homo sapiens (human)
negative regulation of cell migrationEphrin type-A receptor 1Homo sapiens (human)
substrate adhesion-dependent cell spreadingEphrin type-A receptor 1Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 1Homo sapiens (human)
positive regulation of angiogenesisEphrin type-A receptor 1Homo sapiens (human)
protein autophosphorylationEphrin type-A receptor 1Homo sapiens (human)
positive regulation of stress fiber assemblyEphrin type-A receptor 1Homo sapiens (human)
activation of GTPase activityEphrin type-A receptor 1Homo sapiens (human)
positive regulation of kinase activityEphrin type-A receptor 1Homo sapiens (human)
multicellular organism developmentEphrin type-A receptor 1Homo sapiens (human)
angiogenesisEphrin type-A receptor 1Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 2Homo sapiens (human)
angiogenesisFibroblast growth factor receptor 2Homo sapiens (human)
ureteric bud developmentFibroblast growth factor receptor 2Homo sapiens (human)
in utero embryonic developmentFibroblast growth factor receptor 2Homo sapiens (human)
epithelial to mesenchymal transitionFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
outflow tract septum morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
membranous septum morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
endochondral bone growthFibroblast growth factor receptor 2Homo sapiens (human)
apoptotic processFibroblast growth factor receptor 2Homo sapiens (human)
cell-cell signalingFibroblast growth factor receptor 2Homo sapiens (human)
axonogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
regulation of smoothened signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
post-embryonic developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic pattern specificationFibroblast growth factor receptor 2Homo sapiens (human)
animal organ morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 2Homo sapiens (human)
negative regulation of keratinocyte proliferationFibroblast growth factor receptor 2Homo sapiens (human)
morphogenesis of embryonic epitheliumFibroblast growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 2Homo sapiens (human)
orbitofrontal cortex developmentFibroblast growth factor receptor 2Homo sapiens (human)
ventricular zone neuroblast divisionFibroblast growth factor receptor 2Homo sapiens (human)
pyramidal neuron developmentFibroblast growth factor receptor 2Homo sapiens (human)
gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of Wnt signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
bone mineralizationFibroblast growth factor receptor 2Homo sapiens (human)
lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
epithelial cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
midbrain developmentFibroblast growth factor receptor 2Homo sapiens (human)
otic vesicle formationFibroblast growth factor receptor 2Homo sapiens (human)
hair follicle morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
response to lipopolysaccharideFibroblast growth factor receptor 2Homo sapiens (human)
lacrimal gland developmentFibroblast growth factor receptor 2Homo sapiens (human)
regulation of osteoblast proliferationFibroblast growth factor receptor 2Homo sapiens (human)
organ growthFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cellFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in hemopoiesisFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrowFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentFibroblast growth factor receptor 2Homo sapiens (human)
inner ear morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
odontogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 2Homo sapiens (human)
cell fate commitmentFibroblast growth factor receptor 2Homo sapiens (human)
response to ethanolFibroblast growth factor receptor 2Homo sapiens (human)
regulation of osteoblast differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell cycleFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 2Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 2Homo sapiens (human)
lung alveolus developmentFibroblast growth factor receptor 2Homo sapiens (human)
mesodermal cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
embryonic digestive tract morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
embryonic organ morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
digestive tract developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic organ developmentFibroblast growth factor receptor 2Homo sapiens (human)
reproductive structure developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic cranial skeleton morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
skeletal system morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
epidermis morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching morphogenesis of a nerveFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of epithelial cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
regulation of smooth muscle cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell divisionFibroblast growth factor receptor 2Homo sapiens (human)
ventricular cardiac muscle tissue morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
limb bud formationFibroblast growth factor receptor 2Homo sapiens (human)
bone developmentFibroblast growth factor receptor 2Homo sapiens (human)
bone morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in prostate gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
bud elongation involved in lung branchingFibroblast growth factor receptor 2Homo sapiens (human)
lung lobe morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
lung-associated mesenchyme developmentFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in lung morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
prostate gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
prostate epithelial cord elongationFibroblast growth factor receptor 2Homo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
squamous basal epithelial stem cell differentiation involved in prostate gland acinus developmentFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in mammary gland specificationFibroblast growth factor receptor 2Homo sapiens (human)
lateral sprouting from an epitheliumFibroblast growth factor receptor 2Homo sapiens (human)
mammary gland bud formationFibroblast growth factor receptor 2Homo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branch elongation involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in labyrinthine layer morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
regulation of morphogenesis of a branching structureFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell differentiation involved in lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell proliferation involved in lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to retinoic acidFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to hypoxiaFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 2Homo sapiens (human)
endocardial cushion developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of cell adhesionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
peripheral nervous system developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of gene expressionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
Schwann cell differentiationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cranial nerve developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of secretionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of cardiac muscle tissue developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
motor neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of motor neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
GMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
'de novo' IMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
purine nucleobase biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
'de novo' AMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
'de novo' XMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
response to bile acidFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of gene expressionFibroblast growth factor receptor 4Homo sapiens (human)
regulation of extracellular matrix disassemblyFibroblast growth factor receptor 4Homo sapiens (human)
cell migrationFibroblast growth factor receptor 4Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 4Homo sapiens (human)
regulation of lipid metabolic processFibroblast growth factor receptor 4Homo sapiens (human)
glucose homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
cholesterol homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of catalytic activityFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of proteolysisFibroblast growth factor receptor 4Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 4Homo sapiens (human)
phosphate ion homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 4Homo sapiens (human)
regulation of bile acid biosynthetic processFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of DNA biosynthetic processFibroblast growth factor receptor 4Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
MAPK cascadeFibroblast growth factor receptor 3Homo sapiens (human)
skeletal system developmentFibroblast growth factor receptor 3Homo sapiens (human)
endochondral ossificationFibroblast growth factor receptor 3Homo sapiens (human)
chondrocyte differentiationFibroblast growth factor receptor 3Homo sapiens (human)
endochondral bone growthFibroblast growth factor receptor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATFibroblast growth factor receptor 3Homo sapiens (human)
cell-cell signalingFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 3Homo sapiens (human)
bone mineralizationFibroblast growth factor receptor 3Homo sapiens (human)
chondrocyte proliferationFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 3Homo sapiens (human)
negative regulation of developmental growthFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFibroblast growth factor receptor 3Homo sapiens (human)
bone morphogenesisFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 3Homo sapiens (human)
bone maturationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor apoptotic signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 3Homo sapiens (human)
renal water homeostasiscAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
spermatogenesiscAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
male gonad developmentcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
high-density lipoprotein particle assemblycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
neural tube closurecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
renal water homeostasiscAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein phosphorylationcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
signal transductioncAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwaycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
high-density lipoprotein particle assemblycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
negative regulation of smoothened signaling pathwaycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
regulation of protein processingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
negative regulation of TORC1 signalingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
generation of precursor metabolites and energyFerrochelatase, mitochondrialHomo sapiens (human)
heme biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
heme A biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
heme B biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
cholesterol metabolic processFerrochelatase, mitochondrialHomo sapiens (human)
response to xenobiotic stimulusFerrochelatase, mitochondrialHomo sapiens (human)
response to light stimulusFerrochelatase, mitochondrialHomo sapiens (human)
detection of UVFerrochelatase, mitochondrialHomo sapiens (human)
response to lead ionFerrochelatase, mitochondrialHomo sapiens (human)
regulation of eIF2 alpha phosphorylation by hemeFerrochelatase, mitochondrialHomo sapiens (human)
response to insecticideFerrochelatase, mitochondrialHomo sapiens (human)
erythrocyte differentiationFerrochelatase, mitochondrialHomo sapiens (human)
very-low-density lipoprotein particle assemblyFerrochelatase, mitochondrialHomo sapiens (human)
response to ethanolFerrochelatase, mitochondrialHomo sapiens (human)
protoporphyrinogen IX metabolic processFerrochelatase, mitochondrialHomo sapiens (human)
response to arsenic-containing substanceFerrochelatase, mitochondrialHomo sapiens (human)
regulation of hemoglobin biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
heme O biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
response to methylmercuryFerrochelatase, mitochondrialHomo sapiens (human)
multicellular organismal-level iron ion homeostasisFerrochelatase, mitochondrialHomo sapiens (human)
response to platinum ionFerrochelatase, mitochondrialHomo sapiens (human)
cellular response to dexamethasone stimulusFerrochelatase, mitochondrialHomo sapiens (human)
G1/S transition of mitotic cell cycleRibosomal protein S6 kinase beta-1Homo sapiens (human)
behavioral fear responseRibosomal protein S6 kinase beta-1Homo sapiens (human)
skeletal muscle contractionRibosomal protein S6 kinase beta-1Homo sapiens (human)
apoptotic processRibosomal protein S6 kinase beta-1Homo sapiens (human)
signal transductionRibosomal protein S6 kinase beta-1Homo sapiens (human)
germ cell developmentRibosomal protein S6 kinase beta-1Homo sapiens (human)
long-term memoryRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to xenobiotic stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to mechanical stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to toxic substanceRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to glucoseRibosomal protein S6 kinase beta-1Homo sapiens (human)
skeletal muscle atrophyRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to electrical stimulus involved in regulation of muscle adaptationRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of smooth muscle cell migrationRibosomal protein S6 kinase beta-1Homo sapiens (human)
cell migrationRibosomal protein S6 kinase beta-1Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to nutrient levelsRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to nutrientRibosomal protein S6 kinase beta-1Homo sapiens (human)
TOR signalingRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to lipopolysaccharideRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to testosteroneRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to glucagonRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to tumor necrosis factorRibosomal protein S6 kinase beta-1Homo sapiens (human)
negative regulation of apoptotic processRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to L-leucineRibosomal protein S6 kinase beta-1Homo sapiens (human)
long-chain fatty acid import into cellRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to ethanolRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of translationRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of mitotic cell cycleRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of translational initiationRibosomal protein S6 kinase beta-1Homo sapiens (human)
regulation of glucose importRibosomal protein S6 kinase beta-1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayRibosomal protein S6 kinase beta-1Homo sapiens (human)
phosphatidylinositol-mediated signalingRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of skeletal muscle tissue growthRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationRibosomal protein S6 kinase beta-1Homo sapiens (human)
modulation of chemical synaptic transmissionRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to type II interferonRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to growth factor stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to dexamethasone stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of TORC1 signalingRibosomal protein S6 kinase beta-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to insulin stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to antibioticTyrosine-protein kinase JAK1Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK1Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK1Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
positive regulation of homotypic cell-cell adhesionTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-11-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
type III interferon-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
type II interferon-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
type I interferon-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-6-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
T-helper 17 cell lineage commitmentTyrosine-protein kinase JAK1Homo sapiens (human)
cellular response to virusTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-10-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
protein localization to cell-cell junctionTyrosine-protein kinase JAK1Homo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase JAK1Homo sapiens (human)
positive regulation of sprouting angiogenesisTyrosine-protein kinase JAK1Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK1Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK1Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK1Homo sapiens (human)
protein phosphorylationProtein kinase C eta typeHomo sapiens (human)
signal transductionProtein kinase C eta typeHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationProtein kinase C eta typeHomo sapiens (human)
cell differentiationProtein kinase C eta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C eta typeHomo sapiens (human)
positive regulation of keratinocyte differentiationProtein kinase C eta typeHomo sapiens (human)
positive regulation of B cell receptor signaling pathwayProtein kinase C eta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C eta typeHomo sapiens (human)
positive regulation of glial cell proliferationProtein kinase C eta typeHomo sapiens (human)
protein kinase C signalingProtein kinase C eta typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C eta typeHomo sapiens (human)
regulation of bicellular tight junction assemblyProtein kinase C eta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C eta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C eta typeHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of the force of heart contraction by chemical signalBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
tachykinin receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
heart developmentBeta-adrenergic receptor kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationBeta-adrenergic receptor kinase 1Homo sapiens (human)
viral genome replicationBeta-adrenergic receptor kinase 1Homo sapiens (human)
receptor internalizationBeta-adrenergic receptor kinase 1Homo sapiens (human)
positive regulation of catecholamine secretionBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of striated muscle contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
symbiont entry into host cellBeta-adrenergic receptor kinase 1Homo sapiens (human)
cardiac muscle contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of relaxation of smooth muscleBeta-adrenergic receptor kinase 1Homo sapiens (human)
regulation of the force of heart contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein phosphorylationBeta-adrenergic receptor kinase 1Homo sapiens (human)
P-body assemblyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
miRNA-mediated gene silencing by inhibition of translationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
negative regulation of translationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
viral RNA genome packagingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
stem cell population maintenanceProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
neuron differentiationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
P-body assemblyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
negative regulation of neuron differentiationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
stress granule assemblyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
positive regulation of protein phosphorylationActivin receptor type-2AHomo sapiens (human)
BMP signaling pathwayActivin receptor type-2AHomo sapiens (human)
gastrulation with mouth forming secondActivin receptor type-2AHomo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayActivin receptor type-2AHomo sapiens (human)
spermatogenesisActivin receptor type-2AHomo sapiens (human)
determination of left/right symmetryActivin receptor type-2AHomo sapiens (human)
mesoderm developmentActivin receptor type-2AHomo sapiens (human)
anterior/posterior pattern specificationActivin receptor type-2AHomo sapiens (human)
positive regulation of bone mineralizationActivin receptor type-2AHomo sapiens (human)
BMP signaling pathwayActivin receptor type-2AHomo sapiens (human)
activin receptor signaling pathwayActivin receptor type-2AHomo sapiens (human)
positive regulation of activin receptor signaling pathwayActivin receptor type-2AHomo sapiens (human)
odontogenesis of dentin-containing toothActivin receptor type-2AHomo sapiens (human)
sperm ejaculationActivin receptor type-2AHomo sapiens (human)
penile erectionActivin receptor type-2AHomo sapiens (human)
regulation of nitric oxide biosynthetic processActivin receptor type-2AHomo sapiens (human)
positive regulation of erythrocyte differentiationActivin receptor type-2AHomo sapiens (human)
positive regulation of osteoblast differentiationActivin receptor type-2AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIActivin receptor type-2AHomo sapiens (human)
embryonic skeletal system developmentActivin receptor type-2AHomo sapiens (human)
Sertoli cell proliferationActivin receptor type-2AHomo sapiens (human)
positive regulation of SMAD protein signal transductionActivin receptor type-2AHomo sapiens (human)
cellular response to BMP stimulusActivin receptor type-2AHomo sapiens (human)
protein phosphorylationActivin receptor type-2AHomo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-2AHomo sapiens (human)
positive regulation of macrophage chemotaxisMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of macrophage proliferationMitogen-activated protein kinase 3 Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
DNA-templated transcriptionMitogen-activated protein kinase 3 Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 3 Homo sapiens (human)
insulin receptor signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
Schwann cell developmentMitogen-activated protein kinase 3 Homo sapiens (human)
phosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
sensory perception of painMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 3 Homo sapiens (human)
BMP signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of cellular pHMitogen-activated protein kinase 3 Homo sapiens (human)
thyroid gland developmentMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 3 Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of stress-activated MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 3 Homo sapiens (human)
peptidyl-tyrosine autophosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
outer ear morphogenesisMitogen-activated protein kinase 3 Homo sapiens (human)
myelinationMitogen-activated protein kinase 3 Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 3 Homo sapiens (human)
response to exogenous dsRNAMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 3 Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
thymus developmentMitogen-activated protein kinase 3 Homo sapiens (human)
modulation of chemical synaptic transmissionMitogen-activated protein kinase 3 Homo sapiens (human)
cartilage developmentMitogen-activated protein kinase 3 Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of cytoskeleton organizationMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 3 Homo sapiens (human)
Bergmann glial cell differentiationMitogen-activated protein kinase 3 Homo sapiens (human)
face developmentMitogen-activated protein kinase 3 Homo sapiens (human)
lung morphogenesisMitogen-activated protein kinase 3 Homo sapiens (human)
trachea formationMitogen-activated protein kinase 3 Homo sapiens (human)
cardiac neural crest cell development involved in heart developmentMitogen-activated protein kinase 3 Homo sapiens (human)
ERK1 and ERK2 cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
interleukin-1-mediated signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
response to epidermal growth factorMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 3 Homo sapiens (human)
caveolin-mediated endocytosisMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of Golgi inheritanceMitogen-activated protein kinase 3 Homo sapiens (human)
xenophagyMitogen-activated protein kinase 3 Homo sapiens (human)
negative regulation of TORC1 signalingMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of xenophagyMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of early endosome to late endosome transportMitogen-activated protein kinase 3 Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 3 Homo sapiens (human)
protein phosphorylationMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
peptidyl-serine phosphorylationMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
positive regulation of protein bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
negative regulation of hippo signalingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
peptidyl-serine autophosphorylationMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
negative regulation of protein localization to nucleusMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
intracellular signal transductionMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
pyrimidine nucleotide metabolic processDeoxycytidine kinaseHomo sapiens (human)
CMP biosynthetic processDeoxycytidine kinaseHomo sapiens (human)
dAMP salvageDeoxycytidine kinaseHomo sapiens (human)
nucleoside phosphate biosynthetic processDeoxycytidine kinaseHomo sapiens (human)
positive regulation of macrophage chemotaxisMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of macrophage proliferationMitogen-activated protein kinase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 1Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 1Homo sapiens (human)
DNA damage responseMitogen-activated protein kinase 1Homo sapiens (human)
signal transductionMitogen-activated protein kinase 1Homo sapiens (human)
chemical synaptic transmissionMitogen-activated protein kinase 1Homo sapiens (human)
learning or memoryMitogen-activated protein kinase 1Homo sapiens (human)
insulin receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
Schwann cell developmentMitogen-activated protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
cytosine metabolic processMitogen-activated protein kinase 1Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 1Homo sapiens (human)
androgen receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
regulation of cellular pHMitogen-activated protein kinase 1Homo sapiens (human)
thyroid gland developmentMitogen-activated protein kinase 1Homo sapiens (human)
regulation of protein stabilityMitogen-activated protein kinase 1Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 1Homo sapiens (human)
regulation of stress-activated MAPK cascadeMitogen-activated protein kinase 1Homo sapiens (human)
mammary gland epithelial cell proliferationMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 1Homo sapiens (human)
response to nicotineMitogen-activated protein kinase 1Homo sapiens (human)
ERBB signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
outer ear morphogenesisMitogen-activated protein kinase 1Homo sapiens (human)
myelinationMitogen-activated protein kinase 1Homo sapiens (human)
response to exogenous dsRNAMitogen-activated protein kinase 1Homo sapiens (human)
steroid hormone mediated signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
negative regulation of cell differentiationMitogen-activated protein kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
thymus developmentMitogen-activated protein kinase 1Homo sapiens (human)
progesterone receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
T cell receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
B cell receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 1Homo sapiens (human)
regulation of cytoskeleton organizationMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 1Homo sapiens (human)
Bergmann glial cell differentiationMitogen-activated protein kinase 1Homo sapiens (human)
long-term synaptic potentiationMitogen-activated protein kinase 1Homo sapiens (human)
face developmentMitogen-activated protein kinase 1Homo sapiens (human)
lung morphogenesisMitogen-activated protein kinase 1Homo sapiens (human)
trachea formationMitogen-activated protein kinase 1Homo sapiens (human)
labyrinthine layer blood vessel developmentMitogen-activated protein kinase 1Homo sapiens (human)
cardiac neural crest cell development involved in heart developmentMitogen-activated protein kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeMitogen-activated protein kinase 1Homo sapiens (human)
response to epidermal growth factorMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 1Homo sapiens (human)
caveolin-mediated endocytosisMitogen-activated protein kinase 1Homo sapiens (human)
regulation of Golgi inheritanceMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 1Homo sapiens (human)
regulation of early endosome to late endosome transportMitogen-activated protein kinase 1Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 1Homo sapiens (human)
skeletal system developmentEphrin type-A receptor 2Homo sapiens (human)
vasculogenesisEphrin type-A receptor 2Homo sapiens (human)
osteoblast differentiationEphrin type-A receptor 2Homo sapiens (human)
blood vessel endothelial cell proliferation involved in sprouting angiogenesisEphrin type-A receptor 2Homo sapiens (human)
inflammatory responseEphrin type-A receptor 2Homo sapiens (human)
cell adhesionEphrin type-A receptor 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageEphrin type-A receptor 2Homo sapiens (human)
regulation of lamellipodium assemblyEphrin type-A receptor 2Homo sapiens (human)
notochord formationEphrin type-A receptor 2Homo sapiens (human)
cell migrationEphrin type-A receptor 2Homo sapiens (human)
negative regulation of angiogenesisEphrin type-A receptor 2Homo sapiens (human)
neural tube developmentEphrin type-A receptor 2Homo sapiens (human)
neuron differentiationEphrin type-A receptor 2Homo sapiens (human)
keratinocyte differentiationEphrin type-A receptor 2Homo sapiens (human)
osteoclast differentiationEphrin type-A receptor 2Homo sapiens (human)
positive regulation of cell migrationEphrin type-A receptor 2Homo sapiens (human)
negative regulation of chemokine productionEphrin type-A receptor 2Homo sapiens (human)
mammary gland epithelial cell proliferationEphrin type-A receptor 2Homo sapiens (human)
regulation of cell adhesion mediated by integrinEphrin type-A receptor 2Homo sapiens (human)
post-anal tail morphogenesisEphrin type-A receptor 2Homo sapiens (human)
regulation of blood vessel endothelial cell migrationEphrin type-A receptor 2Homo sapiens (human)
regulation of angiogenesisEphrin type-A receptor 2Homo sapiens (human)
cAMP metabolic processEphrin type-A receptor 2Homo sapiens (human)
symbiont entry into host cellEphrin type-A receptor 2Homo sapiens (human)
bone remodelingEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 2Homo sapiens (human)
axial mesoderm formationEphrin type-A receptor 2Homo sapiens (human)
cell motilityEphrin type-A receptor 2Homo sapiens (human)
defense response to Gram-positive bacteriumEphrin type-A receptor 2Homo sapiens (human)
notochord cell developmentEphrin type-A receptor 2Homo sapiens (human)
cell chemotaxisEphrin type-A receptor 2Homo sapiens (human)
branching involved in mammary gland duct morphogenesisEphrin type-A receptor 2Homo sapiens (human)
lens fiber cell morphogenesisEphrin type-A receptor 2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeEphrin type-A receptor 2Homo sapiens (human)
response to growth factorEphrin type-A receptor 2Homo sapiens (human)
protein localization to plasma membraneEphrin type-A receptor 2Homo sapiens (human)
activation of GTPase activityEphrin type-A receptor 2Homo sapiens (human)
negative regulation of lymphangiogenesisEphrin type-A receptor 2Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-A receptor 2Homo sapiens (human)
positive regulation of bicellular tight junction assemblyEphrin type-A receptor 2Homo sapiens (human)
pericyte cell differentiationEphrin type-A receptor 2Homo sapiens (human)
positive regulation of kinase activityEphrin type-A receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEphrin type-A receptor 2Homo sapiens (human)
multicellular organism developmentEphrin type-A receptor 2Homo sapiens (human)
cell adhesionEphrin type-A receptor 3Homo sapiens (human)
regulation of epithelial to mesenchymal transitionEphrin type-A receptor 3Homo sapiens (human)
positive regulation of neuron projection developmentEphrin type-A receptor 3Homo sapiens (human)
cell migrationEphrin type-A receptor 3Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-A receptor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationEphrin type-A receptor 3Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 3Homo sapiens (human)
negative regulation of endocytosisEphrin type-A receptor 3Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 3Homo sapiens (human)
regulation of focal adhesion assemblyEphrin type-A receptor 3Homo sapiens (human)
regulation of microtubule cytoskeleton organizationEphrin type-A receptor 3Homo sapiens (human)
cellular response to retinoic acidEphrin type-A receptor 3Homo sapiens (human)
fasciculation of sensory neuron axonEphrin type-A receptor 3Homo sapiens (human)
fasciculation of motor neuron axonEphrin type-A receptor 3Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-A receptor 3Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 3Homo sapiens (human)
axon guidanceEphrin type-A receptor 3Homo sapiens (human)
substrate-dependent cell migrationEphrin type-A receptor 8Homo sapiens (human)
cell adhesionEphrin type-A receptor 8Homo sapiens (human)
axon guidanceEphrin type-A receptor 8Homo sapiens (human)
neuron remodelingEphrin type-A receptor 8Homo sapiens (human)
regulation of cell adhesionEphrin type-A receptor 8Homo sapiens (human)
neuron projection developmentEphrin type-A receptor 8Homo sapiens (human)
regulation of cell adhesion mediated by integrinEphrin type-A receptor 8Homo sapiens (human)
positive regulation of MAPK cascadeEphrin type-A receptor 8Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 8Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEphrin type-A receptor 8Homo sapiens (human)
cellular response to follicle-stimulating hormone stimulusEphrin type-A receptor 8Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 8Homo sapiens (human)
negative regulation of protein kinase activityEphrin type-B receptor 2Homo sapiens (human)
regulation of autophagosome assemblyEphrin type-B receptor 2Homo sapiens (human)
angiogenesisEphrin type-B receptor 2Homo sapiens (human)
urogenital system developmentEphrin type-B receptor 2Homo sapiens (human)
negative regulation of protein phosphorylationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of immunoglobulin productionEphrin type-B receptor 2Homo sapiens (human)
negative regulation of cell adhesionEphrin type-B receptor 2Homo sapiens (human)
nervous system developmentEphrin type-B receptor 2Homo sapiens (human)
axon guidanceEphrin type-B receptor 2Homo sapiens (human)
axonal fasciculationEphrin type-B receptor 2Homo sapiens (human)
learning or memoryEphrin type-B receptor 2Homo sapiens (human)
learningEphrin type-B receptor 2Homo sapiens (human)
positive regulation of gene expressionEphrin type-B receptor 2Homo sapiens (human)
phosphorylationEphrin type-B receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-B receptor 2Homo sapiens (human)
optic nerve morphogenesisEphrin type-B receptor 2Homo sapiens (human)
hindbrain tangential cell migrationEphrin type-B receptor 2Homo sapiens (human)
central nervous system projection neuron axonogenesisEphrin type-B receptor 2Homo sapiens (human)
corpus callosum developmentEphrin type-B receptor 2Homo sapiens (human)
regulation of blood coagulationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of cell migrationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of B cell proliferationEphrin type-B receptor 2Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-B receptor 2Homo sapiens (human)
positive regulation of synaptic plasticityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionEphrin type-B receptor 2Homo sapiens (human)
B cell activationEphrin type-B receptor 2Homo sapiens (human)
inner ear morphogenesisEphrin type-B receptor 2Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATEphrin type-B receptor 2Homo sapiens (human)
negative regulation of Ras protein signal transductionEphrin type-B receptor 2Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 2Homo sapiens (human)
regulation of neuronal synaptic plasticityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of long-term neuronal synaptic plasticityEphrin type-B receptor 2Homo sapiens (human)
camera-type eye morphogenesisEphrin type-B receptor 2Homo sapiens (human)
negative regulation of axonogenesisEphrin type-B receptor 2Homo sapiens (human)
regulation of body fluid levelsEphrin type-B receptor 2Homo sapiens (human)
regulation of filopodium assemblyEphrin type-B receptor 2Homo sapiens (human)
positive regulation of synapse assemblyEphrin type-B receptor 2Homo sapiens (human)
roof of mouth developmentEphrin type-B receptor 2Homo sapiens (human)
dendritic spine developmentEphrin type-B receptor 2Homo sapiens (human)
dendritic spine morphogenesisEphrin type-B receptor 2Homo sapiens (human)
positive regulation of dendritic spine morphogenesisEphrin type-B receptor 2Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeEphrin type-B receptor 2Homo sapiens (human)
cellular response to lipopolysaccharideEphrin type-B receptor 2Homo sapiens (human)
commissural neuron axon guidanceEphrin type-B receptor 2Homo sapiens (human)
postsynaptic membrane assemblyEphrin type-B receptor 2Homo sapiens (human)
trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmissionEphrin type-B receptor 2Homo sapiens (human)
neuron projection retractionEphrin type-B receptor 2Homo sapiens (human)
vesicle-mediated intercellular transportEphrin type-B receptor 2Homo sapiens (human)
tight junction assemblyEphrin type-B receptor 2Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseEphrin type-B receptor 2Homo sapiens (human)
positive regulation of long-term synaptic potentiationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-B receptor 2Homo sapiens (human)
cellular response to amyloid-betaEphrin type-B receptor 2Homo sapiens (human)
negative regulation of NMDA glutamate receptor activityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of NMDA glutamate receptor activityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of protein localization to cell surfaceEphrin type-B receptor 2Homo sapiens (human)
regulation of T-helper 17 type immune responseEphrin type-B receptor 2Homo sapiens (human)
regulation of behavioral fear responseEphrin type-B receptor 2Homo sapiens (human)
protein phosphorylationEphrin type-B receptor 2Homo sapiens (human)
protein phosphorylationLeukocyte tyrosine kinase receptorHomo sapiens (human)
signal transductionLeukocyte tyrosine kinase receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayLeukocyte tyrosine kinase receptorHomo sapiens (human)
cell population proliferationLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of neuron projection developmentLeukocyte tyrosine kinase receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationLeukocyte tyrosine kinase receptorHomo sapiens (human)
negative regulation of apoptotic processLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionLeukocyte tyrosine kinase receptorHomo sapiens (human)
cellular response to retinoic acidLeukocyte tyrosine kinase receptorHomo sapiens (human)
regulation of cell population proliferationLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
regulation of neuron differentiationLeukocyte tyrosine kinase receptorHomo sapiens (human)
multicellular organism developmentLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein phosphorylationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
immune responseNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytokine-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of type II interferon productionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of interleukin-17 productionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of natural killer cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-12-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type III interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of T cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of NK T cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type II interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type I interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cellular response to virusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-10-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of protein localization to nucleusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of T-helper 17 type immune responseNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
intracellular signal transductionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cell differentiationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processUMP-CMP kinase Homo sapiens (human)
UMP biosynthetic processUMP-CMP kinase Homo sapiens (human)
UDP biosynthetic processUMP-CMP kinase Homo sapiens (human)
pyrimidine ribonucleotide biosynthetic processUMP-CMP kinase Homo sapiens (human)
nucleobase-containing small molecule interconversionUMP-CMP kinase Homo sapiens (human)
nucleoside monophosphate phosphorylationUMP-CMP kinase Homo sapiens (human)
CDP biosynthetic processUMP-CMP kinase Homo sapiens (human)
negative regulation of MAPK cascadePhosphatidylethanolamine-binding protein 1Homo sapiens (human)
G2/M transition of mitotic cell cycleWee1-like protein kinaseHomo sapiens (human)
microtubule cytoskeleton organizationWee1-like protein kinaseHomo sapiens (human)
negative regulation of G2/M transition of mitotic cell cycleWee1-like protein kinaseHomo sapiens (human)
establishment of cell polarityWee1-like protein kinaseHomo sapiens (human)
positive regulation of DNA replicationWee1-like protein kinaseHomo sapiens (human)
neuron projection morphogenesisWee1-like protein kinaseHomo sapiens (human)
cell divisionWee1-like protein kinaseHomo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleWee1-like protein kinaseHomo sapiens (human)
protein phosphorylationWee1-like protein kinaseHomo sapiens (human)
response to hypoxiaHeme oxygenase 2Homo sapiens (human)
response to oxidative stressHeme oxygenase 2Homo sapiens (human)
heme catabolic processHeme oxygenase 2Homo sapiens (human)
heme oxidationHeme oxygenase 2Homo sapiens (human)
neuron migrationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of cytokine-mediated signaling pathwayTyrosine-protein kinase receptor UFOHomo sapiens (human)
blood vessel remodelingTyrosine-protein kinase receptor UFOHomo sapiens (human)
phagocytosisTyrosine-protein kinase receptor UFOHomo sapiens (human)
inflammatory responseTyrosine-protein kinase receptor UFOHomo sapiens (human)
signal transductionTyrosine-protein kinase receptor UFOHomo sapiens (human)
spermatogenesisTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of macrophage cytokine productionTyrosine-protein kinase receptor UFOHomo sapiens (human)
forebrain cell migrationTyrosine-protein kinase receptor UFOHomo sapiens (human)
animal organ regenerationTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of type II interferon productionTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of natural killer cell differentiationTyrosine-protein kinase receptor UFOHomo sapiens (human)
secretion by cellTyrosine-protein kinase receptor UFOHomo sapiens (human)
erythrocyte homeostasisTyrosine-protein kinase receptor UFOHomo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase receptor UFOHomo sapiens (human)
cellular response to interferon-alphaTyrosine-protein kinase receptor UFOHomo sapiens (human)
ovulation cycleTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of neuron apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
innate immune responseTyrosine-protein kinase receptor UFOHomo sapiens (human)
symbiont entry into host cellTyrosine-protein kinase receptor UFOHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell maturationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of pinocytosisTyrosine-protein kinase receptor UFOHomo sapiens (human)
response to axon injuryTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of lymphocyte activationTyrosine-protein kinase receptor UFOHomo sapiens (human)
neuron apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
establishment of localization in cellTyrosine-protein kinase receptor UFOHomo sapiens (human)
vagina developmentTyrosine-protein kinase receptor UFOHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase receptor UFOHomo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase receptor UFOHomo sapiens (human)
dendritic cell differentiationTyrosine-protein kinase receptor UFOHomo sapiens (human)
neutrophil clearanceTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of viral life cycleTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of dendritic cell apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
platelet activationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase receptor UFOHomo sapiens (human)
natural killer cell differentiationTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell migrationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
nervous system developmentTyrosine-protein kinase receptor UFOHomo sapiens (human)
multicellular organism developmentTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 4Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 4Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 4Homo sapiens (human)
S-adenosylmethionine biosynthetic processS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
one-carbon metabolic processS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein hexamerizationS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein heterooligomerizationS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
cellular response to methionineS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
positive regulation of TORC1 signalingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
cellular response to leukemia inhibitory factorS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein foldingDnaJ homolog subfamily A member 1Homo sapiens (human)
response to unfolded proteinDnaJ homolog subfamily A member 1Homo sapiens (human)
spermatogenesisDnaJ homolog subfamily A member 1Homo sapiens (human)
response to heatDnaJ homolog subfamily A member 1Homo sapiens (human)
flagellated sperm motilityDnaJ homolog subfamily A member 1Homo sapiens (human)
androgen receptor signaling pathwayDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of protein ubiquitinationDnaJ homolog subfamily A member 1Homo sapiens (human)
positive regulation of apoptotic processDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of apoptotic processDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of JUN kinase activityDnaJ homolog subfamily A member 1Homo sapiens (human)
regulation of protein transportDnaJ homolog subfamily A member 1Homo sapiens (human)
protein localization to mitochondrionDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of establishment of protein localization to mitochondrionDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathwayDnaJ homolog subfamily A member 1Homo sapiens (human)
protein refoldingDnaJ homolog subfamily A member 1Homo sapiens (human)
protein phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
activation-induced cell death of T cellsRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
osteoblast differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
maternal placenta developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endothelial cell proliferationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell migration involved in sprouting angiogenesisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glycogen biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of glycogen biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glucose metabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of translationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein import into nucleusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nitric oxide biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
inflammatory responseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to oxidative stressRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
epidermal growth factor receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
G protein-coupled receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
canonical NF-kappaB signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell population proliferationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
insulin receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
apoptotic mitochondrial changesRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to heatRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
gene expressionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of autophagyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endothelial cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of gene expressionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of gene expressionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of long-chain fatty acid import across plasma membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
fibroblast migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of fibroblast migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of sodium ion transportRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose metabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of endopeptidase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of neuron projection developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of macroautophagyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein ubiquitinationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-threonine phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
virus-mediated perturbation of host defense responseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cytokine-mediated signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
mammalian oogenesis stageRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell growthRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
T cell costimulationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein ubiquitinationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of myelinationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
TOR signalingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of fatty acid beta-oxidationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endodeoxyribonuclease activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to foodRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
peripheral nervous system myelin maintenanceRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to insulin stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to fluid shear stressRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to reactive oxygen speciesRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
interleukin-18-mediated signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to vascular endothelial growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to decreased oxygen levelsRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
non-canonical NF-kappaB signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glucose homeostasisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of apoptotic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of apoptotic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
anoikisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of mRNA stabilityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of fat cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glycogen biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of Notch signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of proteolysisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of DNA-templated transcriptionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose importRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of organ growthRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein autophosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of lipid biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
behavioral response to painRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
striated muscle cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein metabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
excitatory postsynaptic potentialRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to growth hormoneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
mammary gland epithelial cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
labyrinthine layer blood vessel developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to UV-ARAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to growth factorRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to cadmium ionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to tumor necrosis factorRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to epidermal growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to prostaglandin E stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein serine/threonine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
establishment of protein localization to mitochondrionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
maintenance of protein location in mitochondrionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
execution phase of apoptosisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of postsynapse organizationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of tRNA methylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to oxidised low-density lipoprotein particle stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein localization to lysosomeRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to nucleusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to peptideRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of signal transduction by p53 class mediatorRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cilium assemblyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to plasma membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of I-kappaB phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of TORC1 signalingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to endoplasmic reticulumRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to nerve growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to insulin-like growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to cell surfaceRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of type B pancreatic cell developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of lymphocyte migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glycogen biosynthetic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
glucose metabolic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
regulation of translationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
insulin receptor signaling pathwayRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of long-chain fatty acid import across plasma membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose metabolic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell migrationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell migrationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of fatty acid beta-oxidationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
peripheral nervous system myelin maintenanceRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cellular response to insulin stimulusRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein modification processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
fat cell differentiationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glycogen biosynthetic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose importRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell cycleRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
mammary gland epithelial cell differentiationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cellular response to high light intensityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
organic substance transportRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein localization to plasma membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein targeting to membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
retinal rod cell apoptotic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell motilityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
signal transductionG protein-coupled receptor kinase 4Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathwayG protein-coupled receptor kinase 4Homo sapiens (human)
regulation of opsin-mediated signaling pathwayG protein-coupled receptor kinase 4Homo sapiens (human)
receptor internalizationG protein-coupled receptor kinase 4Homo sapiens (human)
protein phosphorylationG protein-coupled receptor kinase 4Homo sapiens (human)
regulation of signal transductionG protein-coupled receptor kinase 4Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
spindle organizationDual specificity protein kinase TTKHomo sapiens (human)
mitotic spindle organizationDual specificity protein kinase TTKHomo sapiens (human)
positive regulation of cell population proliferationDual specificity protein kinase TTKHomo sapiens (human)
female meiosis chromosome segregationDual specificity protein kinase TTKHomo sapiens (human)
protein localization to meiotic spindle midzoneDual specificity protein kinase TTKHomo sapiens (human)
chromosome segregationDual specificity protein kinase TTKHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity protein kinase TTKHomo sapiens (human)
protein localization to kinetochoreDual specificity protein kinase TTKHomo sapiens (human)
mitotic spindle assembly checkpoint signalingDual specificity protein kinase TTKHomo sapiens (human)
meiotic spindle assembly checkpoint signalingDual specificity protein kinase TTKHomo sapiens (human)
DNA replicationDNA replication licensing factor MCM4Homo sapiens (human)
DNA unwinding involved in DNA replicationDNA replication licensing factor MCM4Homo sapiens (human)
regulation of DNA-templated DNA replication initiationDNA replication licensing factor MCM4Homo sapiens (human)
double-strand break repair via break-induced replicationDNA replication licensing factor MCM4Homo sapiens (human)
DNA strand elongation involved in DNA replicationDNA replication licensing factor MCM4Homo sapiens (human)
mitotic DNA replication initiationDNA replication licensing factor MCM4Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
regulation of extracellular matrix assemblyTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
regulation of endothelial cell proliferationTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
lymphatic endothelial cell differentiationTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
angiogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
vasculogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
in utero embryonic developmentTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
aortic valve morphogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
signal transductionTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
mesoderm developmentTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
negative regulation of angiogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
negative regulation of cell migrationTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
response to retinoic acidTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
plasma membrane fusionTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
tissue remodelingTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
branching involved in lymph vessel morphogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
positive regulation of angiogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
multicellular organism developmentTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 3Homo sapiens (human)
vasculature developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
lymphangiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
sprouting angiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
respiratory system processVascular endothelial growth factor receptor 3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 3Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
negative regulation of apoptotic processVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of JNK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
regulation of blood vessel remodelingVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of protein kinase C signalingVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 3Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
branching involved in blood vessel morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of macroautophagyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial depolarizationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial fissionVascular endothelial growth factor receptor 2Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
ovarian follicle developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell maturationVascular endothelial growth factor receptor 2Homo sapiens (human)
endocardium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of cell shapeVascular endothelial growth factor receptor 2Homo sapiens (human)
mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of gene expressionVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of BMP signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
embryonic hemopoiesisVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor-2 signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
surfactant homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of neuron apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
cell fate commitmentVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
post-embryonic camera-type eye morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of positive chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of focal adhesion assemblyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 2Homo sapiens (human)
calcium ion homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
blood vessel endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular wound healingVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
semaphorin-plexin signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of hematopoietic progenitor cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of bone developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to hydrogen sulfideVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of endothelial cell apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of gene expressionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
Schwann cell developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
thyroid gland developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
peptidyl-serine autophosphorylationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
myelinationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
thymus developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of axon regenerationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of axonogenesisDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
face developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
trachea formationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
epithelial cell proliferation involved in lung morphogenesisDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of Golgi inheritanceDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of cell motilityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of early endosome to late endosome transportDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
hemopoiesisReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
leukocyte homeostasisReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
myeloid progenitor cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
pro-B cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of cell population proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
response to organonitrogen compoundReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cytokine-mediated signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
B cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
animal organ regenerationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
common myeloid progenitor cell proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
vascular endothelial growth factor signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
regulation of apoptotic processReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of MAP kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of MAPK cascadeReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
lymphocyte proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein autophosphorylationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cellular response to cytokine stimulusReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cellular response to glucocorticoid stimulusReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
dendritic cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
multicellular organism developmentReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
regulation of cardiac muscle cell apoptotic processBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of neural crest cell differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of gene expressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of gene expressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of transforming growth factor beta2 productionBone morphogenetic protein receptor type-1AHomo sapiens (human)
angiogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
osteoblast differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
in utero embryonic developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
mesoderm formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
somitogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
Mullerian duct regressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of mesenchymal cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
chondrocyte differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
outflow tract septum morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
outflow tract morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cardiac conduction system developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
atrioventricular valve developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
mitral valve morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
tricuspid valve morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
endocardial cushion morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cardiac right ventricle morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular trabecula myocardium morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular compact myocardium morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
endocardial cushion formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
immune responseBone morphogenetic protein receptor type-1AHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayBone morphogenetic protein receptor type-1AHomo sapiens (human)
ectoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal/ventral axis specificationBone morphogenetic protein receptor type-1AHomo sapiens (human)
neural crest cell developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of smooth muscle cell migrationBone morphogenetic protein receptor type-1AHomo sapiens (human)
central nervous system neuron differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
pituitary gland developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
neural plate mediolateral regionalizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
lung developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of bone mineralizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP signaling pathwayBone morphogenetic protein receptor type-1AHomo sapiens (human)
somatic stem cell population maintenanceBone morphogenetic protein receptor type-1AHomo sapiens (human)
hindlimb morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal aorta morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
odontogenesis of dentin-containing toothBone morphogenetic protein receptor type-1AHomo sapiens (human)
embryonic digit morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of osteoblast differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBone morphogenetic protein receptor type-1AHomo sapiens (human)
paraxial mesoderm structural organizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
lateral mesoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of lateral mesodermal cell fate specificationBone morphogenetic protein receptor type-1AHomo sapiens (human)
mesendoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
embryonic organ developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
developmental growthBone morphogenetic protein receptor type-1AHomo sapiens (human)
epithelial cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of epithelial cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of neurogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of muscle cell differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
roof of mouth developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of cardiac muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of cardiac muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of SMAD protein signal transductionBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular septum morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
heart formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
atrioventricular node cell developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
pharyngeal arch artery morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cellular response to BMP stimulusBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of miRNA transcriptionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of cardiac ventricle developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
fibrous ring of heart morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of cellular senescenceBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein phosphorylationBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal/ventral pattern formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
cellular response to growth factor stimulusBone morphogenetic protein receptor type-1AHomo sapiens (human)
G1/S transition of mitotic cell cycleActivin receptor type-1BHomo sapiens (human)
in utero embryonic developmentActivin receptor type-1BHomo sapiens (human)
hair follicle developmentActivin receptor type-1BHomo sapiens (human)
regulation of DNA-templated transcriptionActivin receptor type-1BHomo sapiens (human)
signal transductionActivin receptor type-1BHomo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of gene expressionActivin receptor type-1BHomo sapiens (human)
negative regulation of gene expressionActivin receptor type-1BHomo sapiens (human)
peptidyl-threonine phosphorylationActivin receptor type-1BHomo sapiens (human)
negative regulation of cell growthActivin receptor type-1BHomo sapiens (human)
activin receptor signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of activin receptor signaling pathwayActivin receptor type-1BHomo sapiens (human)
nodal signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of erythrocyte differentiationActivin receptor type-1BHomo sapiens (human)
protein autophosphorylationActivin receptor type-1BHomo sapiens (human)
extrinsic apoptotic signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of trophoblast cell migrationActivin receptor type-1BHomo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-1BHomo sapiens (human)
protein phosphorylationActivin receptor type-1BHomo sapiens (human)
nervous system developmentActivin receptor type-1BHomo sapiens (human)
proepicardium developmentTGF-beta receptor type-1Homo sapiens (human)
negative regulation of cell migrationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of extracellular matrix assemblyTGF-beta receptor type-1Homo sapiens (human)
skeletal system developmentTGF-beta receptor type-1Homo sapiens (human)
in utero embryonic developmentTGF-beta receptor type-1Homo sapiens (human)
kidney developmentTGF-beta receptor type-1Homo sapiens (human)
blastocyst developmentTGF-beta receptor type-1Homo sapiens (human)
epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
negative regulation of endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
lens development in camera-type eyeTGF-beta receptor type-1Homo sapiens (human)
ventricular trabecula myocardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
ventricular compact myocardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
regulation of DNA-templated transcriptionTGF-beta receptor type-1Homo sapiens (human)
apoptotic processTGF-beta receptor type-1Homo sapiens (human)
signal transductionTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
heart developmentTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell population proliferationTGF-beta receptor type-1Homo sapiens (human)
germ cell migrationTGF-beta receptor type-1Homo sapiens (human)
male gonad developmentTGF-beta receptor type-1Homo sapiens (human)
post-embryonic developmentTGF-beta receptor type-1Homo sapiens (human)
anterior/posterior pattern specificationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of gene expressionTGF-beta receptor type-1Homo sapiens (human)
regulation of epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
peptidyl-serine phosphorylationTGF-beta receptor type-1Homo sapiens (human)
collagen fibril organizationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell growthTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell migrationTGF-beta receptor type-1Homo sapiens (human)
regulation of protein ubiquitinationTGF-beta receptor type-1Homo sapiens (human)
negative regulation of chondrocyte differentiationTGF-beta receptor type-1Homo sapiens (human)
activin receptor signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
intracellular signal transductionTGF-beta receptor type-1Homo sapiens (human)
myofibroblast differentiationTGF-beta receptor type-1Homo sapiens (human)
wound healingTGF-beta receptor type-1Homo sapiens (human)
endothelial cell activationTGF-beta receptor type-1Homo sapiens (human)
extracellular structure organizationTGF-beta receptor type-1Homo sapiens (human)
endothelial cell migrationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionTGF-beta receptor type-1Homo sapiens (human)
filopodium assemblyTGF-beta receptor type-1Homo sapiens (human)
thymus developmentTGF-beta receptor type-1Homo sapiens (human)
neuron fate commitmentTGF-beta receptor type-1Homo sapiens (human)
embryonic cranial skeleton morphogenesisTGF-beta receptor type-1Homo sapiens (human)
skeletal system morphogenesisTGF-beta receptor type-1Homo sapiens (human)
mesenchymal cell differentiationTGF-beta receptor type-1Homo sapiens (human)
artery morphogenesisTGF-beta receptor type-1Homo sapiens (human)
cell motilityTGF-beta receptor type-1Homo sapiens (human)
positive regulation of filopodium assemblyTGF-beta receptor type-1Homo sapiens (human)
positive regulation of stress fiber assemblyTGF-beta receptor type-1Homo sapiens (human)
regulation of cell cycleTGF-beta receptor type-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTGF-beta receptor type-1Homo sapiens (human)
parathyroid gland developmentTGF-beta receptor type-1Homo sapiens (human)
roof of mouth developmentTGF-beta receptor type-1Homo sapiens (human)
pharyngeal system developmentTGF-beta receptor type-1Homo sapiens (human)
regulation of cardiac muscle cell proliferationTGF-beta receptor type-1Homo sapiens (human)
cardiac epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
positive regulation of SMAD protein signal transductionTGF-beta receptor type-1Homo sapiens (human)
ventricular septum morphogenesisTGF-beta receptor type-1Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisTGF-beta receptor type-1Homo sapiens (human)
coronary artery morphogenesisTGF-beta receptor type-1Homo sapiens (human)
response to cholesterolTGF-beta receptor type-1Homo sapiens (human)
cellular response to transforming growth factor beta stimulusTGF-beta receptor type-1Homo sapiens (human)
positive regulation of mesenchymal stem cell proliferationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of vasculature developmentTGF-beta receptor type-1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of tight junction disassemblyTGF-beta receptor type-1Homo sapiens (human)
epicardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
positive regulation of apoptotic signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
protein phosphorylationTGF-beta receptor type-1Homo sapiens (human)
cellular response to growth factor stimulusTGF-beta receptor type-1Homo sapiens (human)
nervous system developmentTGF-beta receptor type-1Homo sapiens (human)
endocardial cushion to mesenchymal transitionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of epithelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of Notch signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
response to hypoxiaSerine/threonine-protein kinase receptor R3Homo sapiens (human)
in utero embryonic developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
lymphangiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel maturationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel remodelingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel endothelial cell proliferation involved in sprouting angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
endocardial cushion morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of DNA replicationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell adhesionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
signal transductionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood circulationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of blood pressureSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of gene expressionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell growthSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of BMP signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of chondrocyte differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin receptor signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
wound healing, spreading of epidermal cellsSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dorsal aorta morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of focal adhesion assemblySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of SMAD protein signal transductionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
lymphatic endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
artery developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
venous blood vessel developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
endothelial tube morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
retina vasculature development in camera-type eyeSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to BMP stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of bicellular tight junction assemblySerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dorsal/ventral pattern formationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
heart developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to growth factor stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cell proliferation involved in endocardial cushion morphogenesisTGF-beta receptor type-2Homo sapiens (human)
superior endocardial cushion morphogenesisTGF-beta receptor type-2Homo sapiens (human)
blood vessel developmentTGF-beta receptor type-2Homo sapiens (human)
branching involved in blood vessel morphogenesisTGF-beta receptor type-2Homo sapiens (human)
vasculogenesisTGF-beta receptor type-2Homo sapiens (human)
in utero embryonic developmentTGF-beta receptor type-2Homo sapiens (human)
epithelial to mesenchymal transitionTGF-beta receptor type-2Homo sapiens (human)
heart loopingTGF-beta receptor type-2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationTGF-beta receptor type-2Homo sapiens (human)
lens development in camera-type eyeTGF-beta receptor type-2Homo sapiens (human)
positive regulation of tolerance induction to self antigenTGF-beta receptor type-2Homo sapiens (human)
positive regulation of B cell tolerance inductionTGF-beta receptor type-2Homo sapiens (human)
positive regulation of T cell tolerance inductionTGF-beta receptor type-2Homo sapiens (human)
outflow tract septum morphogenesisTGF-beta receptor type-2Homo sapiens (human)
membranous septum morphogenesisTGF-beta receptor type-2Homo sapiens (human)
outflow tract morphogenesisTGF-beta receptor type-2Homo sapiens (human)
aortic valve morphogenesisTGF-beta receptor type-2Homo sapiens (human)
atrioventricular valve morphogenesisTGF-beta receptor type-2Homo sapiens (human)
tricuspid valve morphogenesisTGF-beta receptor type-2Homo sapiens (human)
cardiac left ventricle morphogenesisTGF-beta receptor type-2Homo sapiens (human)
endocardial cushion fusionTGF-beta receptor type-2Homo sapiens (human)
growth plate cartilage chondrocyte growthTGF-beta receptor type-2Homo sapiens (human)
apoptotic processTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
Notch signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
smoothened signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
gastrulationTGF-beta receptor type-2Homo sapiens (human)
brain developmentTGF-beta receptor type-2Homo sapiens (human)
heart developmentTGF-beta receptor type-2Homo sapiens (human)
positive regulation of cell population proliferationTGF-beta receptor type-2Homo sapiens (human)
response to xenobiotic stimulusTGF-beta receptor type-2Homo sapiens (human)
regulation of gene expressionTGF-beta receptor type-2Homo sapiens (human)
positive regulation of epithelial cell migrationTGF-beta receptor type-2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionTGF-beta receptor type-2Homo sapiens (human)
activation of protein kinase activityTGF-beta receptor type-2Homo sapiens (human)
activin receptor signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
embryonic hemopoiesisTGF-beta receptor type-2Homo sapiens (human)
aorta morphogenesisTGF-beta receptor type-2Homo sapiens (human)
regulation of cell population proliferationTGF-beta receptor type-2Homo sapiens (human)
myeloid dendritic cell differentiationTGF-beta receptor type-2Homo sapiens (human)
positive regulation of angiogenesisTGF-beta receptor type-2Homo sapiens (human)
embryonic cranial skeleton morphogenesisTGF-beta receptor type-2Homo sapiens (human)
artery morphogenesisTGF-beta receptor type-2Homo sapiens (human)
positive regulation of NK T cell differentiationTGF-beta receptor type-2Homo sapiens (human)
roof of mouth developmentTGF-beta receptor type-2Homo sapiens (human)
positive regulation of SMAD protein signal transductionTGF-beta receptor type-2Homo sapiens (human)
SMAD protein signal transductionTGF-beta receptor type-2Homo sapiens (human)
ventricular septum morphogenesisTGF-beta receptor type-2Homo sapiens (human)
bronchus morphogenesisTGF-beta receptor type-2Homo sapiens (human)
trachea formationTGF-beta receptor type-2Homo sapiens (human)
mammary gland morphogenesisTGF-beta receptor type-2Homo sapiens (human)
lung lobe morphogenesisTGF-beta receptor type-2Homo sapiens (human)
Langerhans cell differentiationTGF-beta receptor type-2Homo sapiens (human)
secondary palate developmentTGF-beta receptor type-2Homo sapiens (human)
response to cholesterolTGF-beta receptor type-2Homo sapiens (human)
regulation of stem cell proliferationTGF-beta receptor type-2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formationTGF-beta receptor type-2Homo sapiens (human)
inferior endocardial cushion morphogenesisTGF-beta receptor type-2Homo sapiens (human)
lens fiber cell apoptotic processTGF-beta receptor type-2Homo sapiens (human)
miRNA transportTGF-beta receptor type-2Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processTGF-beta receptor type-2Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationTGF-beta receptor type-2Homo sapiens (human)
regulation of stem cell differentiationTGF-beta receptor type-2Homo sapiens (human)
cellular response to growth factor stimulusTGF-beta receptor type-2Homo sapiens (human)
protein phosphorylationTGF-beta receptor type-2Homo sapiens (human)
amino acid catabolic processElectron transfer flavoprotein subunit betaHomo sapiens (human)
respiratory electron transport chainElectron transfer flavoprotein subunit betaHomo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseElectron transfer flavoprotein subunit betaHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase CSKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of low-density lipoprotein particle clearanceTyrosine-protein kinase CSKHomo sapiens (human)
T cell costimulationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of Golgi to plasma membrane protein transportTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of bone resorptionTyrosine-protein kinase CSKHomo sapiens (human)
oligodendrocyte differentiationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of phagocytosisTyrosine-protein kinase CSKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase CSKHomo sapiens (human)
cellular response to peptide hormone stimulusTyrosine-protein kinase CSKHomo sapiens (human)
regulation of Fc receptor mediated stimulatory signaling pathwayTyrosine-protein kinase CSKHomo sapiens (human)
adherens junction organizationTyrosine-protein kinase CSKHomo sapiens (human)
tRNA aminoacylation for protein translationGlycine--tRNA ligaseHomo sapiens (human)
diadenosine tetraphosphate biosynthetic processGlycine--tRNA ligaseHomo sapiens (human)
mitochondrial glycyl-tRNA aminoacylationGlycine--tRNA ligaseHomo sapiens (human)
protein phosphorylationProtein kinase C iota typeHomo sapiens (human)
protein targeting to membraneProtein kinase C iota typeHomo sapiens (human)
cytoskeleton organizationProtein kinase C iota typeHomo sapiens (human)
actin filament organizationProtein kinase C iota typeHomo sapiens (human)
positive regulation of neuron projection developmentProtein kinase C iota typeHomo sapiens (human)
vesicle-mediated transportProtein kinase C iota typeHomo sapiens (human)
cell migrationProtein kinase C iota typeHomo sapiens (human)
cellular response to insulin stimulusProtein kinase C iota typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C iota typeHomo sapiens (human)
establishment of apical/basal cell polarityProtein kinase C iota typeHomo sapiens (human)
eye photoreceptor cell developmentProtein kinase C iota typeHomo sapiens (human)
negative regulation of apoptotic processProtein kinase C iota typeHomo sapiens (human)
negative regulation of neuron apoptotic processProtein kinase C iota typeHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityProtein kinase C iota typeHomo sapiens (human)
cell-cell junction organizationProtein kinase C iota typeHomo sapiens (human)
positive regulation of Notch signaling pathwayProtein kinase C iota typeHomo sapiens (human)
positive regulation of glucose importProtein kinase C iota typeHomo sapiens (human)
secretionProtein kinase C iota typeHomo sapiens (human)
Golgi vesicle buddingProtein kinase C iota typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C iota typeHomo sapiens (human)
positive regulation of glial cell proliferationProtein kinase C iota typeHomo sapiens (human)
membrane organizationProtein kinase C iota typeHomo sapiens (human)
cellular response to chemical stressProtein kinase C iota typeHomo sapiens (human)
response to interleukin-1Protein kinase C iota typeHomo sapiens (human)
regulation of postsynaptic membrane neurotransmitter receptor levelsProtein kinase C iota typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C iota typeHomo sapiens (human)
positive regulation of endothelial cell apoptotic processProtein kinase C iota typeHomo sapiens (human)
intracellular signal transductionProtein kinase C iota typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C iota typeHomo sapiens (human)
mRNA splicing, via spliceosomeExosome RNA helicase MTR4Homo sapiens (human)
maturation of 5.8S rRNAExosome RNA helicase MTR4Homo sapiens (human)
rRNA processingExosome RNA helicase MTR4Homo sapiens (human)
RNA catabolic processExosome RNA helicase MTR4Homo sapiens (human)
DNA damage responseExosome RNA helicase MTR4Homo sapiens (human)
snRNA catabolic processExosome RNA helicase MTR4Homo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
liver developmentPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of protein phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
vasculature developmentPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
glucose metabolic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phagocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
epidermal growth factor receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
insulin receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of lamellipodium assemblyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of gene expressionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to muscle inactivityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of macroautophagyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
actin cytoskeleton organizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
platelet activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of actin filament depolymerizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
T cell costimulationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of TOR signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cellular response to insulin stimulusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to muscle stretchPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
vascular endothelial growth factor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of multicellular organism growthPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to L-leucinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
anoikisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of cellular respirationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of neuron apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
T cell receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
relaxation of cardiac musclePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cardiac muscle contractionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
adipose tissue developmentPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cellular response to glucose stimulusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cellular response to hydrostatic pressurePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to dexamethasonePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cardiac muscle cell contractionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
energy homeostasisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of actin filament organizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
autosome genomic imprintingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to butyratePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of protein localization to membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of fibroblast apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of anoikisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of cell-matrix adhesionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of gene expressionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
endothelial cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
response to ischemiaPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
intracellular calcium ion homeostasisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
endocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
autophagyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion moleculesPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
G protein-coupled receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of autophagyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
platelet activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of neutrophil apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of Rac protein signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
embryonic cleavagePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of MAPK cascadePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
angiogenesis involved in wound healingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
platelet aggregationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of hypoxia-induced intrinsic apoptotic signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of sprouting angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
regulation of clathrin-dependent endocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
protein destabilizationSerine/threonine-protein kinase mTORHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase mTORHomo sapiens (human)
T-helper 1 cell lineage commitmentSerine/threonine-protein kinase mTORHomo sapiens (human)
heart morphogenesisSerine/threonine-protein kinase mTORHomo sapiens (human)
heart valve morphogenesisSerine/threonine-protein kinase mTORHomo sapiens (human)
energy reserve metabolic processSerine/threonine-protein kinase mTORHomo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processSerine/threonine-protein kinase mTORHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
inflammatory responseSerine/threonine-protein kinase mTORHomo sapiens (human)
DNA damage responseSerine/threonine-protein kinase mTORHomo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
lysosome organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
germ cell developmentSerine/threonine-protein kinase mTORHomo sapiens (human)
response to nutrientSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of cell sizeSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to starvationSerine/threonine-protein kinase mTORHomo sapiens (human)
response to heatSerine/threonine-protein kinase mTORHomo sapiens (human)
post-embryonic developmentSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of autophagySerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of lamellipodium assemblySerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of myotube differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
neuronal action potentialSerine/threonine-protein kinase mTORHomo sapiens (human)
protein catabolic processSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of cell growthSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of actin filament polymerizationSerine/threonine-protein kinase mTORHomo sapiens (human)
T cell costimulationSerine/threonine-protein kinase mTORHomo sapiens (human)
ruffle organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of myelinationSerine/threonine-protein kinase mTORHomo sapiens (human)
response to nutrient levelsSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to nutrient levelsSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to nutrientSerine/threonine-protein kinase mTORHomo sapiens (human)
TOR signalingSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to insulin stimulusSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
calcineurin-NFAT signaling cascadeSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to amino acid starvationSerine/threonine-protein kinase mTORHomo sapiens (human)
multicellular organism growthSerine/threonine-protein kinase mTORHomo sapiens (human)
TORC1 signalingSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of circadian rhythmSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase mTORHomo sapiens (human)
response to amino acidSerine/threonine-protein kinase mTORHomo sapiens (human)
anoikisSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of osteoclast differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of translationSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of cell sizeSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of glycolytic processSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIISerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of translational initiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of lipid biosynthetic processSerine/threonine-protein kinase mTORHomo sapiens (human)
behavioral response to painSerine/threonine-protein kinase mTORHomo sapiens (human)
rhythmic processSerine/threonine-protein kinase mTORHomo sapiens (human)
oligodendrocyte differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of oligodendrocyte differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
voluntary musculoskeletal movementSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of stress fiber assemblySerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of keratinocyte migrationSerine/threonine-protein kinase mTORHomo sapiens (human)
nucleus localizationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase mTORHomo sapiens (human)
cardiac muscle cell developmentSerine/threonine-protein kinase mTORHomo sapiens (human)
cardiac muscle contractionSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to methionineSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to amino acid stimulusSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to L-leucineSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to hypoxiaSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to osmotic stressSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of membrane permeabilitySerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of cellular response to heatSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of transcription of nucleolar large rRNA by RNA polymerase ISerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of wound healing, spreading of epidermal cellsSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of locomotor rhythmSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of cytoplasmic translational initiationSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of lysosome organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of pentose-phosphate shuntSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to leucine starvationSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of autophagosome assemblySerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
protein phosphorylationMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
positive regulation of cell population proliferationMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase TecHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
regulation of platelet activationTyrosine-protein kinase TecHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase TecHomo sapiens (human)
tissue regenerationTyrosine-protein kinase TecHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase TecHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase TXKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase TXKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase TXKHomo sapiens (human)
activation of phospholipase C activityTyrosine-protein kinase TXKHomo sapiens (human)
regulation of gene expressionTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase TXKHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase TXKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of type II interferon-mediated signaling pathwayTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of phospholipase C activityTyrosine-protein kinase ABL2Homo sapiens (human)
negative regulation of Rho protein signal transductionTyrosine-protein kinase ABL2Homo sapiens (human)
exploration behaviorTyrosine-protein kinase ABL2Homo sapiens (human)
cell adhesionTyrosine-protein kinase ABL2Homo sapiens (human)
signal transductionTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of autophagyTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase ABL2Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of endocytosisTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase ABL2Homo sapiens (human)
protein modification processTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of oxidoreductase activityTyrosine-protein kinase ABL2Homo sapiens (human)
cellular response to retinoic acidTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of establishment of T cell polarityTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of cell motilityTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of T cell migrationTyrosine-protein kinase ABL2Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein kinase ABL2Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ABL2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITyrosine-protein kinase FRKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FRKHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FRKHomo sapiens (human)
cell differentiationTyrosine-protein kinase FRKHomo sapiens (human)
innate immune responseTyrosine-protein kinase FRKHomo sapiens (human)
G protein-coupled receptor signaling pathwayG protein-coupled receptor kinase 6Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathwayG protein-coupled receptor kinase 6Homo sapiens (human)
Wnt signaling pathwayG protein-coupled receptor kinase 6Homo sapiens (human)
regulation of signal transductionG protein-coupled receptor kinase 6Homo sapiens (human)
protein phosphorylationG protein-coupled receptor kinase 6Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive thymic T cell selectionTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of T cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ZAP-70Homo sapiens (human)
immune responseTyrosine-protein kinase ZAP-70Homo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell activationTyrosine-protein kinase ZAP-70Homo sapiens (human)
B cell activationTyrosine-protein kinase ZAP-70Homo sapiens (human)
beta selectionTyrosine-protein kinase ZAP-70Homo sapiens (human)
negative thymic T cell selectionTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of alpha-beta T cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of alpha-beta T cell proliferationTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of calcium-mediated signalingTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell aggregationTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell migrationTyrosine-protein kinase ZAP-70Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase ZAP-70Homo sapiens (human)
cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
innate immune responseTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein import into nucleusTyrosine-protein kinase SYKHomo sapiens (human)
regulation of DNA-binding transcription factor activityTyrosine-protein kinase SYKHomo sapiens (human)
angiogenesisTyrosine-protein kinase SYKHomo sapiens (human)
cell activationTyrosine-protein kinase SYKHomo sapiens (human)
lymph vessel developmentTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of receptor internalizationTyrosine-protein kinase SYKHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase SYKHomo sapiens (human)
macrophage activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
neutrophil activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
leukocyte activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
serotonin secretion by plateletTyrosine-protein kinase SYKHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase SYKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
leukocyte cell-cell adhesionTyrosine-protein kinase SYKHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
animal organ morphogenesisTyrosine-protein kinase SYKHomo sapiens (human)
regulation of platelet activationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
leukotriene biosynthetic processTyrosine-protein kinase SYKHomo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase SYKHomo sapiens (human)
platelet activationTyrosine-protein kinase SYKHomo sapiens (human)
B cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
neutrophil chemotaxisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of protein-containing complex assemblyTyrosine-protein kinase SYKHomo sapiens (human)
receptor internalizationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of type I interferon productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of granulocyte macrophage colony-stimulating factor productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-10 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-12 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-3 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-4 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-8 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of mast cell cytokine productionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of superoxide anion generationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of superoxide anion generationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cell adhesion mediated by integrinTyrosine-protein kinase SYKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase SYKHomo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase SYKHomo sapiens (human)
interleukin-3-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
gamma-delta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
defense response to bacteriumTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase SYKHomo sapiens (human)
mast cell degranulationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of mast cell degranulationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of neutrophil degranulationTyrosine-protein kinase SYKHomo sapiens (human)
beta selectionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of MAPK cascadeTyrosine-protein kinase SYKHomo sapiens (human)
innate immune responseTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of B cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of gamma-delta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of bone resorptionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of alpha-beta T cell proliferationTyrosine-protein kinase SYKHomo sapiens (human)
blood vessel morphogenesisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of phagocytosisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of calcium-mediated signalingTyrosine-protein kinase SYKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of killing of cells of another organismTyrosine-protein kinase SYKHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to molecule of fungal originTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to lipidTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of arachidonic acid secretionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of platelet aggregationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cold-induced thermogenesisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of TORC1 signalingTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to lectinTyrosine-protein kinase SYKHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
blastocyst development26S proteasome regulatory subunit 6BHomo sapiens (human)
proteolysis26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome regulatory subunit 6BHomo sapiens (human)
positive regulation of proteasomal protein catabolic process26S proteasome regulatory subunit 6BHomo sapiens (human)
JUN phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
response to UVMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
response to oxidative stressMitogen-activated protein kinase 8Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 8Homo sapiens (human)
JUN phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 8Homo sapiens (human)
regulation of macroautophagyMitogen-activated protein kinase 8Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of cell killingMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of protein bindingMitogen-activated protein kinase 8Homo sapiens (human)
regulation of protein localizationMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to oxidative stressMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 8Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 8Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of protein metabolic processMitogen-activated protein kinase 8Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 8Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 8Homo sapiens (human)
energy homeostasisMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyMitogen-activated protein kinase 8Homo sapiens (human)
response to mechanical stimulusMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of establishment of protein localization to mitochondrionMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 9Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiationMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of protein ubiquitinationMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processMitogen-activated protein kinase 9Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 9Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 9Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 9Homo sapiens (human)
modulation of chemical synaptic transmissionMitogen-activated protein kinase 9Homo sapiens (human)
protein localization to tricellular tight junctionMitogen-activated protein kinase 9Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of podosome assemblyMitogen-activated protein kinase 9Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 9Homo sapiens (human)
inflammatory response to woundingMitogen-activated protein kinase 9Homo sapiens (human)
apoptotic signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of apoptotic signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of protein phosphorylationDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
JNK cascadeDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
response to woundingDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
smooth muscle cell apoptotic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hydrogen peroxideDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
Fc-epsilon receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of neuron apoptotic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of DNA replicationDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of JNK cascadeDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cell growth involved in cardiac muscle cell developmentDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cellular response to mechanical stimulusDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
negative regulation of motor neuron apoptotic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
regulation of cytokine productionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
response to ischemiaDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
inflammatory responseDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
stress-activated protein kinase signaling cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
negative regulation of hippo signalingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
p38MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of protein kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cardiac muscle contractionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to lipopolysaccharideDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
Golgi organizationCasein kinase I isoform alphaHomo sapiens (human)
cell surface receptor signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
viral protein processingCasein kinase I isoform alphaHomo sapiens (human)
cellular response to nutrientCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of Rho protein signal transductionCasein kinase I isoform alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
intermediate filament cytoskeleton organizationCasein kinase I isoform alphaHomo sapiens (human)
cell divisionCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of TORC1 signalingCasein kinase I isoform alphaHomo sapiens (human)
signal transductionCasein kinase I isoform alphaHomo sapiens (human)
microtubule nucleationCasein kinase I isoform deltaHomo sapiens (human)
Golgi organizationCasein kinase I isoform deltaHomo sapiens (human)
protein localization to Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
protein localization to ciliumCasein kinase I isoform deltaHomo sapiens (human)
protein localization to centrosomeCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform deltaHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform deltaHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform deltaHomo sapiens (human)
COPII vesicle coatingCasein kinase I isoform deltaHomo sapiens (human)
spindle assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
midbrain dopaminergic neuron differentiationCasein kinase I isoform deltaHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
signal transductionCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
endocytosisCasein kinase I isoform deltaHomo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of cytokine productionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
adaptive immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
dendritic cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of acute inflammatory responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
respiratory burst involved in defense responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
endocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
inflammatory responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
G protein-coupled receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
T cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
negative regulation of triglyceride catabolic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
neutrophil chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
secretory granule localizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
regulation of cell adhesion mediated by integrinPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of Rac protein signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
natural killer cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
T cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
T cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
mast cell degranulationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of MAP kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
innate immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
regulation of angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
negative regulation of cardiac muscle contractionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
platelet aggregationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cellular response to cAMPPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
neutrophil extravasationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
hepatocyte apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
regulation of calcium ion transmembrane transportPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
negative regulation of fibroblast apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
MAPK cascadeMAP kinase-activated protein kinase 2Homo sapiens (human)
toll-like receptor signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
leukotriene metabolic processMAP kinase-activated protein kinase 2Homo sapiens (human)
inflammatory responseMAP kinase-activated protein kinase 2Homo sapiens (human)
DNA damage responseMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
response to lipopolysaccharideMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of interleukin-6 productionMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of tumor necrosis factor productionMAP kinase-activated protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionMAP kinase-activated protein kinase 2Homo sapiens (human)
response to cytokineMAP kinase-activated protein kinase 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMAP kinase-activated protein kinase 2Homo sapiens (human)
p38MAPK cascadeMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of mRNA stabilityMAP kinase-activated protein kinase 2Homo sapiens (human)
macropinocytosisMAP kinase-activated protein kinase 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
inner ear developmentMAP kinase-activated protein kinase 2Homo sapiens (human)
positive regulation of macrophage cytokine productionMAP kinase-activated protein kinase 2Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of cellular response to heatMAP kinase-activated protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-activated protein kinase 2Homo sapiens (human)
protein ubiquitinationCyclin-dependent kinase 8Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 8Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 8Homo sapiens (human)
negative regulation of triglyceride metabolic processCyclin-dependent kinase 8Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 8Homo sapiens (human)
translational elongationElongation factor Tu, mitochondrialHomo sapiens (human)
response to ethanolElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrial translational elongationElongation factor Tu, mitochondrialHomo sapiens (human)
phosphatidylcholine biosynthetic processCholine-phosphate cytidylyltransferase AHomo sapiens (human)
CDP-choline pathwayCholine-phosphate cytidylyltransferase AHomo sapiens (human)
cysteinyl-tRNA aminoacylationCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
DNA repairCasein kinase I isoform epsilonHomo sapiens (human)
protein phosphorylationCasein kinase I isoform epsilonHomo sapiens (human)
protein localizationCasein kinase I isoform epsilonHomo sapiens (human)
negative regulation of Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
negative regulation of protein bindingCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform epsilonHomo sapiens (human)
regulation of protein localizationCasein kinase I isoform epsilonHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform epsilonHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform epsilonHomo sapiens (human)
circadian behaviorCasein kinase I isoform epsilonHomo sapiens (human)
canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of amyloid-beta formationCasein kinase I isoform epsilonHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform epsilonHomo sapiens (human)
endocytosisCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
signal transductionCasein kinase I isoform epsilonHomo sapiens (human)
temperature homeostasisVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
response to coldVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
energy derivation by oxidation of organic compoundsVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
epithelial cell differentiationVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
negative regulation of fatty acid biosynthetic processVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
negative regulation of fatty acid oxidationVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
regulation of cholesterol metabolic processVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK1Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK1Homo sapiens (human)
protein phosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
response to ionizing radiationDual specificity protein kinase CLK2Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK2Homo sapiens (human)
negative regulation of gluconeogenesisDual specificity protein kinase CLK2Homo sapiens (human)
protein autophosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
protein phosphorylationDual specificity protein kinase CLK3Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK3Homo sapiens (human)
regulation of systemic arterial blood pressureGlycogen synthase kinase-3 alphaHomo sapiens (human)
cardiac left ventricle morphogenesisGlycogen synthase kinase-3 alphaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
nervous system developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of UDP-glucose catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell migrationGlycogen synthase kinase-3 alphaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to insulin stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of heart contractionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glucose importGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to lithium ionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to glucocorticoid stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
autosome genomic imprintingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of mitophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of amyloid-beta formationGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein targeting to mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen synthase activity, transferring glucose-1-phosphateGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
ER overload responseGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of apoptotic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
epithelial to mesenchymal transitionGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell-matrix adhesionGlycogen synthase kinase-3 betaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrion organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 betaHomo sapiens (human)
hippocampus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
establishment of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
maintenance of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of cell migrationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axon extensionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of phosphoprotein phosphatase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule-based processGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 betaHomo sapiens (human)
regulation of circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of GTPase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of osteoblast differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cilium assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein autophosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of dendrite morphogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axonogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeGlycogen synthase kinase-3 betaHomo sapiens (human)
superior temporal gyrus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to retinoic acidGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 betaHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule anchoring at centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of cellular response to heatGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein localization to nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of long-term synaptic potentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein acetylationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to ciliumGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of dopaminergic neuron differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to amyloid-betaGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complex disassemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of mesenchymal stem cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
DNA repairCyclin-dependent kinase 7Homo sapiens (human)
transcription by RNA polymerase IICyclin-dependent kinase 7Homo sapiens (human)
transcription initiation at RNA polymerase II promoterCyclin-dependent kinase 7Homo sapiens (human)
snRNA transcription by RNA polymerase IICyclin-dependent kinase 7Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 7Homo sapiens (human)
protein stabilizationCyclin-dependent kinase 7Homo sapiens (human)
cell divisionCyclin-dependent kinase 7Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 7Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycleCyclin-dependent kinase 7Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 7Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 9Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 9Homo sapiens (human)
DNA repairCyclin-dependent kinase 9Homo sapiens (human)
regulation of DNA repairCyclin-dependent kinase 9Homo sapiens (human)
transcription by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
transcription initiation at RNA polymerase II promoterCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
cell population proliferationCyclin-dependent kinase 9Homo sapiens (human)
replication fork processingCyclin-dependent kinase 9Homo sapiens (human)
regulation of mRNA 3'-end processingCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
positive regulation by host of viral transcriptionCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
regulation of muscle cell differentiationCyclin-dependent kinase 9Homo sapiens (human)
nucleus localizationCyclin-dependent kinase 9Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 9Homo sapiens (human)
cellular response to cytokine stimulusCyclin-dependent kinase 9Homo sapiens (human)
negative regulation of protein localization to chromatinCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of protein localization to chromatinCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation-coupled chromatin remodelingCyclin-dependent kinase 9Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 9Homo sapiens (human)
exocytosisRas-related protein Rab-27AHomo sapiens (human)
blood coagulationRas-related protein Rab-27AHomo sapiens (human)
protein secretionRas-related protein Rab-27AHomo sapiens (human)
positive regulation of gene expressionRas-related protein Rab-27AHomo sapiens (human)
antigen processing and presentationRas-related protein Rab-27AHomo sapiens (human)
melanocyte differentiationRas-related protein Rab-27AHomo sapiens (human)
melanosome localizationRas-related protein Rab-27AHomo sapiens (human)
melanosome transportRas-related protein Rab-27AHomo sapiens (human)
multivesicular body organizationRas-related protein Rab-27AHomo sapiens (human)
cytotoxic T cell degranulationRas-related protein Rab-27AHomo sapiens (human)
natural killer cell degranulationRas-related protein Rab-27AHomo sapiens (human)
positive regulation of exocytosisRas-related protein Rab-27AHomo sapiens (human)
synaptic vesicle transportRas-related protein Rab-27AHomo sapiens (human)
positive regulation of phagocytosisRas-related protein Rab-27AHomo sapiens (human)
multivesicular body sorting pathwayRas-related protein Rab-27AHomo sapiens (human)
complement-dependent cytotoxicityRas-related protein Rab-27AHomo sapiens (human)
positive regulation of regulated secretory pathwayRas-related protein Rab-27AHomo sapiens (human)
positive regulation of reactive oxygen species biosynthetic processRas-related protein Rab-27AHomo sapiens (human)
positive regulation of constitutive secretory pathwayRas-related protein Rab-27AHomo sapiens (human)
exosomal secretionRas-related protein Rab-27AHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of insulin secretionTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of protein bindingTyrosine-protein kinase BlkHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase BlkHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase BlkHomo sapiens (human)
innate immune responseTyrosine-protein kinase BlkHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase BlkHomo sapiens (human)
cell differentiationTyrosine-protein kinase BlkHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein autophosphorylationInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
regulation of cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
JNK cascadeInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of type I interferon productionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
response to lipopolysaccharideInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor 2 signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor 9 signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cellular response to heatInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
interleukin-33-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein autophosphorylationInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
type I interferon-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
interleukin-1-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
response to interleukin-1Interleukin-1 receptor-associated kinase 1Homo sapiens (human)
cellular response to hypoxiaInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor 4 signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of MAP kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
intracellular signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
Toll signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
innate immune responseInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
gastrin-induced gastric acid secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
glucose metabolic processPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
heart developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
rhythmic behaviorPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of blood pressurePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of heart ratePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
iodide transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
erythrocyte differentiationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
intracellular chloride ion homeostasisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
response to insulinPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
social behaviorPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
corticosterone secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
inner ear morphogenesisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
inner ear developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
intestinal absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
auditory receptor cell developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of cardiac muscle contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of gastric acid secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
stomach developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
renal absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
renal sodium ion absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to cAMPPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to epinephrine stimulusPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
adrenergic receptor signaling pathwayPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cardiac muscle cell contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cochlea developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
non-motile cilium assemblyPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
skeletal system developmentRibosomal protein S6 kinase alpha-3Homo sapiens (human)
toll-like receptor signaling pathwayRibosomal protein S6 kinase alpha-3Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-3Homo sapiens (human)
chemical synaptic transmissionRibosomal protein S6 kinase alpha-3Homo sapiens (human)
central nervous system developmentRibosomal protein S6 kinase alpha-3Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-3Homo sapiens (human)
positive regulation of cell growthRibosomal protein S6 kinase alpha-3Homo sapiens (human)
response to lipopolysaccharideRibosomal protein S6 kinase alpha-3Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-3Homo sapiens (human)
negative regulation of apoptotic processRibosomal protein S6 kinase alpha-3Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRibosomal protein S6 kinase alpha-3Homo sapiens (human)
regulation of translation in response to stressRibosomal protein S6 kinase alpha-3Homo sapiens (human)
positive regulation of cell differentiationRibosomal protein S6 kinase alpha-3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein phosphorylationCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
phosphatidylinositol biosynthetic processCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
apoptotic processCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cell adhesionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
signal transductionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
mesoderm developmentCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
intracellular signal transductionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
protein autophosphorylationCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
B cell receptor signaling pathwayCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
adaptive immune responseCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
angiogenesiscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
endothelial cell proliferationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
cell adhesioncAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
peptidyl-serine phosphorylationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
myeloid cell differentiationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
regulation of cell adhesioncAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
regulation of cell migrationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
cell-substrate adhesioncAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
endothelial cell migrationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein autophosphorylationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
epithelial tube morphogenesiscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
kidney morphogenesiscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
regulation of epithelial cell differentiation involved in kidney developmentcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek2Homo sapiens (human)
blastocyst developmentSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek2Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase Nek2Homo sapiens (human)
regulation of mitotic nuclear divisionSerine/threonine-protein kinase Nek2Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine/threonine-protein kinase Nek2Homo sapiens (human)
regulation of mitotic centrosome separationSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase Nek2Homo sapiens (human)
spindle assemblySerine/threonine-protein kinase Nek2Homo sapiens (human)
centrosome separationSerine/threonine-protein kinase Nek2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek2Homo sapiens (human)
meiotic cell cycleSerine/threonine-protein kinase Nek2Homo sapiens (human)
positive regulation of telomerase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
regulation of attachment of spindle microtubules to kinetochoreSerine/threonine-protein kinase Nek2Homo sapiens (human)
mitotic spindle assemblySerine/threonine-protein kinase Nek2Homo sapiens (human)
negative regulation of centriole-centriole cohesionSerine/threonine-protein kinase Nek2Homo sapiens (human)
positive regulation of telomere cappingSerine/threonine-protein kinase Nek2Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek3Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase Nek3Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase Nek3Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek3Homo sapiens (human)
regulation of tubulin deacetylationSerine/threonine-protein kinase Nek3Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek4Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Nek4Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase Nek4Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek4Homo sapiens (human)
regulation of cellular senescenceSerine/threonine-protein kinase Nek4Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of dendritic cell cytokine productionTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK3Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
B cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-12 productionTyrosine-protein kinase JAK3Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
T cell homeostasisTyrosine-protein kinase JAK3Homo sapiens (human)
innate immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of FasL productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T-helper 1 cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of T cell apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of thymocyte apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-2Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-4Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-15Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-9Tyrosine-protein kinase JAK3Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
osteoblast differentiationDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of protein phosphorylationDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
response to ischemiaDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
apoptotic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
response to xenobiotic stimulusDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
ovulation cycle processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
stress-activated protein kinase signaling cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of prostaglandin secretionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
p38MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
signal transduction in response to DNA damageDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of apoptotic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
regulation of cell cycleDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cardiac muscle contractionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
bone developmentDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
negative regulation of cold-induced thermogenesisDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
regulation of signal transduction by p53 class mediatorDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
establishment of protein localizationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic sister chromatid segregationSerine/threonine-protein kinase PLK1Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IISerine/threonine-protein kinase PLK1Homo sapiens (human)
establishment of mitotic spindle orientationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic cytokinesisSerine/threonine-protein kinase PLK1Homo sapiens (human)
microtubule bundle formationSerine/threonine-protein kinase PLK1Homo sapiens (human)
double-strand break repairSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase PLK1Homo sapiens (human)
sister chromatid cohesionSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic chromosome condensationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic nuclear membrane disassemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
metaphase/anaphase transition of mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic spindle assembly checkpoint signalingSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrosome cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationSerine/threonine-protein kinase PLK1Homo sapiens (human)
female meiosis chromosome segregationSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein ubiquitinationSerine/threonine-protein kinase PLK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein destabilizationSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of cytokinesisSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of protein bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
homologous chromosome segregationSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of proteolysisSerine/threonine-protein kinase PLK1Homo sapiens (human)
Golgi inheritanceSerine/threonine-protein kinase PLK1Homo sapiens (human)
nuclear membrane disassemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of ubiquitin-protein transferase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
synaptonemal complex disassemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein localization to chromatinSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein localization to nuclear envelopeSerine/threonine-protein kinase PLK1Homo sapiens (human)
double-strand break repair via alternative nonhomologous end joiningSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of protein localization to nucleusSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic spindle assemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic cell cycle phase transitionSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of ubiquitin protein ligase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of protein localization to cell cortexSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationSerine/threonine-protein kinase PLK1Homo sapiens (human)
apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
defense response to tumor cellDeath-associated protein kinase 1Homo sapiens (human)
regulation of response to tumor cellDeath-associated protein kinase 1Homo sapiens (human)
protein phosphorylationDeath-associated protein kinase 1Homo sapiens (human)
apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsDeath-associated protein kinase 1Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of autophagyDeath-associated protein kinase 1Homo sapiens (human)
negative regulation of translationDeath-associated protein kinase 1Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 1Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
negative regulation of apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 1Homo sapiens (human)
cellular response to type II interferonDeath-associated protein kinase 1Homo sapiens (human)
cellular response to hydroperoxideDeath-associated protein kinase 1Homo sapiens (human)
apoptotic signaling pathwayDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of autophagic cell deathDeath-associated protein kinase 1Homo sapiens (human)
regulation of NMDA receptor activityDeath-associated protein kinase 1Homo sapiens (human)
protein phosphorylationLIM domain kinase 1Homo sapiens (human)
signal transductionLIM domain kinase 1Homo sapiens (human)
Rho protein signal transductionLIM domain kinase 1Homo sapiens (human)
nervous system developmentLIM domain kinase 1Homo sapiens (human)
positive regulation of actin filament bundle assemblyLIM domain kinase 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisLIM domain kinase 1Homo sapiens (human)
stress fiber assemblyLIM domain kinase 1Homo sapiens (human)
positive regulation of axon extensionLIM domain kinase 1Homo sapiens (human)
axon extensionLIM domain kinase 1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityLIM domain kinase 1Homo sapiens (human)
positive regulation of stress fiber assemblyLIM domain kinase 1Homo sapiens (human)
actin cytoskeleton organizationLIM domain kinase 1Homo sapiens (human)
positive regulation of protein phosphorylationLIM domain kinase 2Homo sapiens (human)
protein phosphorylationLIM domain kinase 2Homo sapiens (human)
spermatogenesisLIM domain kinase 2Homo sapiens (human)
phosphorylationLIM domain kinase 2Homo sapiens (human)
astral microtubule organizationLIM domain kinase 2Homo sapiens (human)
establishment of vesicle localizationLIM domain kinase 2Homo sapiens (human)
head developmentLIM domain kinase 2Homo sapiens (human)
cornea development in camera-type eyeLIM domain kinase 2Homo sapiens (human)
positive regulation of protein localization to nucleusLIM domain kinase 2Homo sapiens (human)
negative regulation of cilium assemblyLIM domain kinase 2Homo sapiens (human)
actin cytoskeleton organizationLIM domain kinase 2Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 12Homo sapiens (human)
signal transductionMitogen-activated protein kinase 12Homo sapiens (human)
muscle organ developmentMitogen-activated protein kinase 12Homo sapiens (human)
positive regulation of peptidase activityMitogen-activated protein kinase 12Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 12Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 12Homo sapiens (human)
myoblast differentiationMitogen-activated protein kinase 12Homo sapiens (human)
negative regulation of cell cycleMitogen-activated protein kinase 12Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 12Homo sapiens (human)
regulation of cell cycleMitogen-activated protein kinase 12Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 12Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 10Homo sapiens (human)
response to light stimulusMitogen-activated protein kinase 10Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 10Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 10Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 10Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 10Homo sapiens (human)
tyrosyl-tRNA aminoacylationTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
apoptotic processTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
response to starvationTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
regulation of glycolytic process5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
spermatogenesis5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
positive regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
import into nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
regulation of catalytic activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
lipid droplet disassembly5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
chromatin remodeling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
autophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
lipid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of autophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
response to muscle activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
Wnt signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of macroautophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of macroautophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of TOR signaling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to oxidative stress5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to glucose starvation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
glucose homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of circadian rhythm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of glycolytic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
rhythmic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
fatty acid homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of stress granule assembly5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of microtubule cytoskeleton organization5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to calcium ion5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to glucose stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to prostaglandin E stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to xenobiotic stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
energy homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of protein localization5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of hepatocyte apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of TORC1 signaling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of tubulin deacetylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein localization to lipid droplet5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
angiogenesisEphrin type-B receptor 3Homo sapiens (human)
urogenital system developmentEphrin type-B receptor 3Homo sapiens (human)
axon guidanceEphrin type-B receptor 3Homo sapiens (human)
axonal fasciculationEphrin type-B receptor 3Homo sapiens (human)
cell migrationEphrin type-B receptor 3Homo sapiens (human)
central nervous system projection neuron axonogenesisEphrin type-B receptor 3Homo sapiens (human)
corpus callosum developmentEphrin type-B receptor 3Homo sapiens (human)
regulation of cell-cell adhesionEphrin type-B receptor 3Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-B receptor 3Homo sapiens (human)
substrate adhesion-dependent cell spreadingEphrin type-B receptor 3Homo sapiens (human)
regulation of GTPase activityEphrin type-B receptor 3Homo sapiens (human)
protein autophosphorylationEphrin type-B receptor 3Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 3Homo sapiens (human)
thymus developmentEphrin type-B receptor 3Homo sapiens (human)
digestive tract morphogenesisEphrin type-B receptor 3Homo sapiens (human)
regulation of axonogenesisEphrin type-B receptor 3Homo sapiens (human)
positive regulation of synapse assemblyEphrin type-B receptor 3Homo sapiens (human)
roof of mouth developmentEphrin type-B receptor 3Homo sapiens (human)
dendritic spine developmentEphrin type-B receptor 3Homo sapiens (human)
dendritic spine morphogenesisEphrin type-B receptor 3Homo sapiens (human)
protein phosphorylationEphrin type-B receptor 3Homo sapiens (human)
axon guidanceEphrin type-A receptor 5Homo sapiens (human)
cAMP-mediated signalingEphrin type-A receptor 5Homo sapiens (human)
hippocampus developmentEphrin type-A receptor 5Homo sapiens (human)
positive regulation of CREB transcription factor activityEphrin type-A receptor 5Homo sapiens (human)
regulation of actin cytoskeleton organizationEphrin type-A receptor 5Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 5Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 5Homo sapiens (human)
neuron developmentEphrin type-A receptor 5Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusEphrin type-A receptor 5Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 5Homo sapiens (human)
angiogenesisEphrin type-B receptor 4Homo sapiens (human)
cell migration involved in sprouting angiogenesisEphrin type-B receptor 4Homo sapiens (human)
heart morphogenesisEphrin type-B receptor 4Homo sapiens (human)
cell adhesionEphrin type-B receptor 4Homo sapiens (human)
protein autophosphorylationEphrin type-B receptor 4Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 4Homo sapiens (human)
multicellular organism developmentEphrin type-B receptor 4Homo sapiens (human)
positive regulation of kinase activityEphrin type-B receptor 4Homo sapiens (human)
angiogenesisEphrin type-B receptor 1Homo sapiens (human)
immunological synapse formationEphrin type-B receptor 1Homo sapiens (human)
axon guidanceEphrin type-B receptor 1Homo sapiens (human)
skeletal muscle satellite cell activationEphrin type-B receptor 1Homo sapiens (human)
optic nerve morphogenesisEphrin type-B receptor 1Homo sapiens (human)
hindbrain tangential cell migrationEphrin type-B receptor 1Homo sapiens (human)
central nervous system projection neuron axonogenesisEphrin type-B receptor 1Homo sapiens (human)
neurogenesisEphrin type-B receptor 1Homo sapiens (human)
establishment of cell polarityEphrin type-B receptor 1Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-B receptor 1Homo sapiens (human)
cell-substrate adhesionEphrin type-B receptor 1Homo sapiens (human)
regulation of JNK cascadeEphrin type-B receptor 1Homo sapiens (human)
protein autophosphorylationEphrin type-B receptor 1Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 1Homo sapiens (human)
camera-type eye morphogenesisEphrin type-B receptor 1Homo sapiens (human)
modulation of chemical synaptic transmissionEphrin type-B receptor 1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painEphrin type-B receptor 1Homo sapiens (human)
positive regulation of synapse assemblyEphrin type-B receptor 1Homo sapiens (human)
cell chemotaxisEphrin type-B receptor 1Homo sapiens (human)
dendritic spine developmentEphrin type-B receptor 1Homo sapiens (human)
dendritic spine morphogenesisEphrin type-B receptor 1Homo sapiens (human)
neural precursor cell proliferationEphrin type-B receptor 1Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeEphrin type-B receptor 1Homo sapiens (human)
negative regulation of skeletal muscle satellite cell proliferationEphrin type-B receptor 1Homo sapiens (human)
negative regulation of satellite cell differentiationEphrin type-B receptor 1Homo sapiens (human)
protein phosphorylationEphrin type-B receptor 1Homo sapiens (human)
negative regulation of cellular response to hypoxiaEphrin type-A receptor 4Homo sapiens (human)
cell adhesionEphrin type-A receptor 4Homo sapiens (human)
negative regulation of cell adhesionEphrin type-A receptor 4Homo sapiens (human)
adult walking behaviorEphrin type-A receptor 4Homo sapiens (human)
motor neuron axon guidanceEphrin type-A receptor 4Homo sapiens (human)
positive regulation of cell population proliferationEphrin type-A receptor 4Homo sapiens (human)
glial cell migrationEphrin type-A receptor 4Homo sapiens (human)
negative regulation of epithelial to mesenchymal transitionEphrin type-A receptor 4Homo sapiens (human)
negative regulation of neuron projection developmentEphrin type-A receptor 4Homo sapiens (human)
negative regulation of translationEphrin type-A receptor 4Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-A receptor 4Homo sapiens (human)
corticospinal tract morphogenesisEphrin type-A receptor 4Homo sapiens (human)
positive regulation of cell migrationEphrin type-A receptor 4Homo sapiens (human)
negative regulation of cell migrationEphrin type-A receptor 4Homo sapiens (human)
adherens junction organizationEphrin type-A receptor 4Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 4Homo sapiens (human)
positive regulation of cell adhesionEphrin type-A receptor 4Homo sapiens (human)
protein autophosphorylationEphrin type-A receptor 4Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 4Homo sapiens (human)
negative regulation of axon regenerationEphrin type-A receptor 4Homo sapiens (human)
regulation of astrocyte differentiationEphrin type-A receptor 4Homo sapiens (human)
regulation of axonogenesisEphrin type-A receptor 4Homo sapiens (human)
positive regulation of dendrite morphogenesisEphrin type-A receptor 4Homo sapiens (human)
protein stabilizationEphrin type-A receptor 4Homo sapiens (human)
regulation of dendritic spine morphogenesisEphrin type-A receptor 4Homo sapiens (human)
positive regulation of protein tyrosine kinase activityEphrin type-A receptor 4Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeEphrin type-A receptor 4Homo sapiens (human)
nephric duct morphogenesisEphrin type-A receptor 4Homo sapiens (human)
cochlea developmentEphrin type-A receptor 4Homo sapiens (human)
fasciculation of sensory neuron axonEphrin type-A receptor 4Homo sapiens (human)
fasciculation of motor neuron axonEphrin type-A receptor 4Homo sapiens (human)
neuron projection guidanceEphrin type-A receptor 4Homo sapiens (human)
synapse pruningEphrin type-A receptor 4Homo sapiens (human)
neuron projection fasciculationEphrin type-A receptor 4Homo sapiens (human)
negative regulation of long-term synaptic potentiationEphrin type-A receptor 4Homo sapiens (human)
positive regulation of amyloid-beta formationEphrin type-A receptor 4Homo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic processEphrin type-A receptor 4Homo sapiens (human)
negative regulation of proteolysis involved in protein catabolic processEphrin type-A receptor 4Homo sapiens (human)
cellular response to amyloid-betaEphrin type-A receptor 4Homo sapiens (human)
regulation of modification of synaptic structureEphrin type-A receptor 4Homo sapiens (human)
regulation of synapse pruningEphrin type-A receptor 4Homo sapiens (human)
positive regulation of Rho guanyl-nucleotide exchange factor activityEphrin type-A receptor 4Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 4Homo sapiens (human)
axon guidanceEphrin type-A receptor 4Homo sapiens (human)
ADP biosynthetic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleobase-containing small molecule interconversionAdenylate kinase 2, mitochondrialHomo sapiens (human)
AMP metabolic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
ATP metabolic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleoside monophosphate phosphorylationAdenylate kinase 2, mitochondrialHomo sapiens (human)
purine ribonucleoside salvageAdenosine kinaseHomo sapiens (human)
dATP biosynthetic processAdenosine kinaseHomo sapiens (human)
ribonucleoside monophosphate biosynthetic processAdenosine kinaseHomo sapiens (human)
GMP salvageAdenosine kinaseHomo sapiens (human)
AMP salvageAdenosine kinaseHomo sapiens (human)
dAMP salvageAdenosine kinaseHomo sapiens (human)
purine nucleobase metabolic processAdenosine kinaseHomo sapiens (human)
signal transductionHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
intracellular signal transductionHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
regulation of sodium ion transportSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase SIK1Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase SIK1Homo sapiens (human)
regulation of myotube differentiationSerine/threonine-protein kinase SIK1Homo sapiens (human)
negative regulation of triglyceride biosynthetic processSerine/threonine-protein kinase SIK1Homo sapiens (human)
negative regulation of CREB transcription factor activitySerine/threonine-protein kinase SIK1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase SIK1Homo sapiens (human)
entrainment of circadian clock by photoperiodSerine/threonine-protein kinase SIK1Homo sapiens (human)
anoikisSerine/threonine-protein kinase SIK1Homo sapiens (human)
regulation of cell differentiationSerine/threonine-protein kinase SIK1Homo sapiens (human)
negative regulation of gluconeogenesisSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase SIK1Homo sapiens (human)
rhythmic processSerine/threonine-protein kinase SIK1Homo sapiens (human)
cardiac muscle cell differentiationSerine/threonine-protein kinase SIK1Homo sapiens (human)
positive regulation of anoikisSerine/threonine-protein kinase SIK1Homo sapiens (human)
morphogenesis of an epitheliumReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
Golgi to plasma membrane transportRas-related protein Rab-10Homo sapiens (human)
axonogenesisRas-related protein Rab-10Homo sapiens (human)
vesicle-mediated transportRas-related protein Rab-10Homo sapiens (human)
endosomal transportRas-related protein Rab-10Homo sapiens (human)
antigen processing and presentationRas-related protein Rab-10Homo sapiens (human)
polarized epithelial cell differentiationRas-related protein Rab-10Homo sapiens (human)
cellular response to insulin stimulusRas-related protein Rab-10Homo sapiens (human)
Golgi to plasma membrane protein transportRas-related protein Rab-10Homo sapiens (human)
regulated exocytosisRas-related protein Rab-10Homo sapiens (human)
establishment of neuroblast polarityRas-related protein Rab-10Homo sapiens (human)
endoplasmic reticulum tubular network organizationRas-related protein Rab-10Homo sapiens (human)
protein localization to plasma membraneRas-related protein Rab-10Homo sapiens (human)
establishment of protein localization to membraneRas-related protein Rab-10Homo sapiens (human)
establishment of protein localization to endoplasmic reticulum membraneRas-related protein Rab-10Homo sapiens (human)
cell-cell adhesionRas-related protein Rab-10Homo sapiens (human)
protein localization to basolateral plasma membraneRas-related protein Rab-10Homo sapiens (human)
exocytosisRas-related protein Rab-10Homo sapiens (human)
protein secretionRas-related protein Rab-10Homo sapiens (human)
establishment or maintenance of cell polarityActin-related protein 3Homo sapiens (human)
asymmetric cell divisionActin-related protein 3Homo sapiens (human)
positive regulation of lamellipodium assemblyActin-related protein 3Homo sapiens (human)
meiotic chromosome movement towards spindle poleActin-related protein 3Homo sapiens (human)
meiotic cytokinesisActin-related protein 3Homo sapiens (human)
Arp2/3 complex-mediated actin nucleationActin-related protein 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIActin-related protein 3Homo sapiens (human)
spindle localizationActin-related protein 3Homo sapiens (human)
cilium assemblyActin-related protein 3Homo sapiens (human)
actin polymerization-dependent cell motilityActin-related protein 3Homo sapiens (human)
cellular response to type II interferonActin-related protein 3Homo sapiens (human)
regulation of double-strand break repair via nonhomologous end joiningActin-related protein 2Homo sapiens (human)
cilium assemblyActin-related protein 2Homo sapiens (human)
establishment or maintenance of cell polarityActin-related protein 2Homo sapiens (human)
asymmetric cell divisionActin-related protein 2Homo sapiens (human)
positive regulation of lamellipodium assemblyActin-related protein 2Homo sapiens (human)
meiotic chromosome movement towards spindle poleActin-related protein 2Homo sapiens (human)
cytosolic transportActin-related protein 2Homo sapiens (human)
meiotic cytokinesisActin-related protein 2Homo sapiens (human)
Arp2/3 complex-mediated actin nucleationActin-related protein 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIActin-related protein 2Homo sapiens (human)
spindle localizationActin-related protein 2Homo sapiens (human)
cellular response to type II interferonActin-related protein 2Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationActin-related protein 2Homo sapiens (human)
ribosomal large subunit export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
ribosomal small subunit export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
mitotic sister chromatid segregationGTP-binding nuclear protein RanHomo sapiens (human)
mitotic cell cycleGTP-binding nuclear protein RanHomo sapiens (human)
DNA metabolic processGTP-binding nuclear protein RanHomo sapiens (human)
protein import into nucleusGTP-binding nuclear protein RanHomo sapiens (human)
protein export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
mitotic spindle organizationGTP-binding nuclear protein RanHomo sapiens (human)
spermatid developmentGTP-binding nuclear protein RanHomo sapiens (human)
viral processGTP-binding nuclear protein RanHomo sapiens (human)
hippocampus developmentGTP-binding nuclear protein RanHomo sapiens (human)
actin cytoskeleton organizationGTP-binding nuclear protein RanHomo sapiens (human)
positive regulation of protein bindingGTP-binding nuclear protein RanHomo sapiens (human)
pre-miRNA export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
positive regulation of protein import into nucleusGTP-binding nuclear protein RanHomo sapiens (human)
GTP metabolic processGTP-binding nuclear protein RanHomo sapiens (human)
cell divisionGTP-binding nuclear protein RanHomo sapiens (human)
snRNA import into nucleusGTP-binding nuclear protein RanHomo sapiens (human)
cellular response to mineralocorticoid stimulusGTP-binding nuclear protein RanHomo sapiens (human)
protein localization to nucleolusGTP-binding nuclear protein RanHomo sapiens (human)
ribosomal subunit export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
double-strand break repairCasein kinase II subunit alphaHomo sapiens (human)
protein phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
DNA damage responseCasein kinase II subunit alphaHomo sapiens (human)
signal transductionCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of translationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
rhythmic processCasein kinase II subunit alphaHomo sapiens (human)
protein stabilizationCasein kinase II subunit alphaHomo sapiens (human)
chaperone-mediated protein foldingCasein kinase II subunit alphaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of aggrephagyCasein kinase II subunit alphaHomo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
regulation of cell cycleCasein kinase II subunit alphaHomo sapiens (human)
cell surface receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
regulation of autophagyPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
autophagosome-lysosome fusionPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
positive regulation of autophagosome assemblyPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 2Homo sapiens (human)
angiogenesisSRSF protein kinase 2Homo sapiens (human)
protein phosphorylationSRSF protein kinase 2Homo sapiens (human)
positive regulation of cell population proliferationSRSF protein kinase 2Homo sapiens (human)
RNA splicingSRSF protein kinase 2Homo sapiens (human)
positive regulation of gene expressionSRSF protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 2Homo sapiens (human)
cell differentiationSRSF protein kinase 2Homo sapiens (human)
nuclear speck organizationSRSF protein kinase 2Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 2Homo sapiens (human)
positive regulation of neuron apoptotic processSRSF protein kinase 2Homo sapiens (human)
positive regulation of viral genome replicationSRSF protein kinase 2Homo sapiens (human)
negative regulation of viral genome replicationSRSF protein kinase 2Homo sapiens (human)
innate immune responseSRSF protein kinase 2Homo sapiens (human)
positive regulation of cell cycleSRSF protein kinase 2Homo sapiens (human)
regulation of mRNA splicing, via spliceosomeSRSF protein kinase 2Homo sapiens (human)
R-loop processingSRSF protein kinase 2Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 2Homo sapiens (human)
protein phosphorylationCasein kinase I isoform gamma-2Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-2Homo sapiens (human)
sphingolipid biosynthetic processCasein kinase I isoform gamma-2Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-2Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-2Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-2Homo sapiens (human)
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
maturation of 5.8S rRNADNA-dependent protein kinase catalytic subunitHomo sapiens (human)
somitogenesisDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
activation of innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
B cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immature B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
pro-B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repairDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatin remodelingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA damage responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
brain developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
heart developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
response to gamma radiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere cappingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-threonine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
mitotic G1 DNA damage checkpoint signalingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein destabilizationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cellular response to insulin stimulusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell differentiation in thymusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell receptor V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processome assemblyDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ectopic germ cell programmed cell deathDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein modification processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of circadian rhythmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of lymphocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of erythrocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of translationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
rhythmic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of smooth muscle cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of epithelial cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via alternative nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of hematopoietic stem cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of platelet formationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immunoglobulin V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere maintenanceDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
apoptotic processMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
DNA damage responseCyclin-dependent kinase 3Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 3Homo sapiens (human)
cell population proliferationCyclin-dependent kinase 3Homo sapiens (human)
G0 to G1 transitionCyclin-dependent kinase 3Homo sapiens (human)
negative regulation of Notch signaling pathwayCyclin-dependent kinase 3Homo sapiens (human)
cell divisionCyclin-dependent kinase 3Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 3Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 3Homo sapiens (human)
signal transductionCyclin-dependent kinase 3Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 3Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 3Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 1Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 1Homo sapiens (human)
regulation of cilium assemblyCyclin-dependent kinase-like 1Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 6Homo sapiens (human)
positive regulation of cell-matrix adhesionCyclin-dependent kinase 6Homo sapiens (human)
type B pancreatic cell developmentCyclin-dependent kinase 6Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 6Homo sapiens (human)
Notch signaling pathwayCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell population proliferationCyclin-dependent kinase 6Homo sapiens (human)
response to virusCyclin-dependent kinase 6Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 6Homo sapiens (human)
positive regulation of gene expressionCyclin-dependent kinase 6Homo sapiens (human)
astrocyte developmentCyclin-dependent kinase 6Homo sapiens (human)
dentate gyrus developmentCyclin-dependent kinase 6Homo sapiens (human)
lateral ventricle developmentCyclin-dependent kinase 6Homo sapiens (human)
T cell differentiation in thymusCyclin-dependent kinase 6Homo sapiens (human)
gliogenesisCyclin-dependent kinase 6Homo sapiens (human)
cell dedifferentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of myeloid cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of erythrocyte differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of monocyte differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of osteoblast differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell cycleCyclin-dependent kinase 6Homo sapiens (human)
positive regulation of fibroblast proliferationCyclin-dependent kinase 6Homo sapiens (human)
generation of neuronsCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of epithelial cell proliferationCyclin-dependent kinase 6Homo sapiens (human)
cell divisionCyclin-dependent kinase 6Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 6Homo sapiens (human)
hematopoietic stem cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of hematopoietic stem cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of cell motilityCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cellular senescenceCyclin-dependent kinase 6Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 6Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 6Homo sapiens (human)
signal transductionCyclin-dependent kinase 6Homo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron migrationCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic transmission, dopaminergicCyclin-dependent-like kinase 5 Homo sapiens (human)
protein phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
intracellular protein transportCyclin-dependent-like kinase 5 Homo sapiens (human)
cell-matrix adhesionCyclin-dependent-like kinase 5 Homo sapiens (human)
chemical synaptic transmissionCyclin-dependent-like kinase 5 Homo sapiens (human)
synapse assemblyCyclin-dependent-like kinase 5 Homo sapiens (human)
skeletal muscle tissue developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
motor neuron axon guidanceCyclin-dependent-like kinase 5 Homo sapiens (human)
visual learningCyclin-dependent-like kinase 5 Homo sapiens (human)
Schwann cell developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle exocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of macroautophagyCyclin-dependent-like kinase 5 Homo sapiens (human)
phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
sensory perception of painCyclin-dependent-like kinase 5 Homo sapiens (human)
cerebellar cortex formationCyclin-dependent-like kinase 5 Homo sapiens (human)
hippocampus developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
layer formation in cerebral cortexCyclin-dependent-like kinase 5 Homo sapiens (human)
central nervous system neuron developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
corpus callosum developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron differentiationCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of cell migrationCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of axon extensionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron projection developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of protein ubiquitinationCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of synaptic plasticityCyclin-dependent-like kinase 5 Homo sapiens (human)
receptor catabolic processCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic transmission, glutamatergicCyclin-dependent-like kinase 5 Homo sapiens (human)
protein localization to synapseCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
receptor clusteringCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of neuron apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of cell cycleCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of proteolysisCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of DNA-templated transcriptionCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of calcium ion-dependent exocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of protein export from nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
behavioral response to cocaineCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic plasticityCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle endocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
rhythmic processCyclin-dependent-like kinase 5 Homo sapiens (human)
axon extensionCyclin-dependent-like kinase 5 Homo sapiens (human)
oligodendrocyte differentiationCyclin-dependent-like kinase 5 Homo sapiens (human)
dendrite morphogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
cell divisionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of cell cycleCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCyclin-dependent-like kinase 5 Homo sapiens (human)
excitatory postsynaptic potentialCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of dendritic spine morphogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
calcium ion importCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of protein targeting to membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of protein localization to plasma membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic vesicle recyclingCyclin-dependent-like kinase 5 Homo sapiens (human)
cellular response to amyloid-betaCyclin-dependent-like kinase 5 Homo sapiens (human)
axonogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle transportCyclin-dependent-like kinase 5 Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 16Homo sapiens (human)
exocytosisCyclin-dependent kinase 16Homo sapiens (human)
spermatogenesisCyclin-dependent kinase 16Homo sapiens (human)
positive regulation of autophagyCyclin-dependent kinase 16Homo sapiens (human)
growth hormone secretionCyclin-dependent kinase 16Homo sapiens (human)
neuron projection developmentCyclin-dependent kinase 16Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 16Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusCyclin-dependent kinase 16Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 17Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 17Homo sapiens (human)
regulation of DNA-templated transcriptionMyelin transcription factor 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIMyelin transcription factor 1Homo sapiens (human)
nervous system developmentMyelin transcription factor 1Homo sapiens (human)
cell differentiationMyelin transcription factor 1Homo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cellular response to leukemia inhibitory factorATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
canonical glycolysisATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
fructose 1,6-bisphosphate metabolic processATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
fructose 6-phosphate metabolic processATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
MAPK cascadeProtein kinase C epsilon typeHomo sapiens (human)
macrophage activation involved in immune responseProtein kinase C epsilon typeHomo sapiens (human)
protein phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
apoptotic processProtein kinase C epsilon typeHomo sapiens (human)
signal transductionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of epithelial cell migrationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of fibroblast migrationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cell-substrate adhesionProtein kinase C epsilon typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
insulin secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of actin filament polymerizationProtein kinase C epsilon typeHomo sapiens (human)
negative regulation of protein ubiquitinationProtein kinase C epsilon typeHomo sapiens (human)
cell-substrate adhesionProtein kinase C epsilon typeHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cytokinesisProtein kinase C epsilon typeHomo sapiens (human)
locomotory exploration behaviorProtein kinase C epsilon typeHomo sapiens (human)
TRAM-dependent toll-like receptor 4 signaling pathwayProtein kinase C epsilon typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein kinase C epsilon typeHomo sapiens (human)
response to morphineProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of MAPK cascadeProtein kinase C epsilon typeHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of lipid catabolic processProtein kinase C epsilon typeHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolProtein kinase C epsilon typeHomo sapiens (human)
cell divisionProtein kinase C epsilon typeHomo sapiens (human)
establishment of localization in cellProtein kinase C epsilon typeHomo sapiens (human)
synaptic transmission, GABAergicProtein kinase C epsilon typeHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusProtein kinase C epsilon typeHomo sapiens (human)
mucus secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of mucus secretionProtein kinase C epsilon typeHomo sapiens (human)
cellular response to ethanolProtein kinase C epsilon typeHomo sapiens (human)
cellular response to prostaglandin E stimulusProtein kinase C epsilon typeHomo sapiens (human)
cellular response to hypoxiaProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of wound healingProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C epsilon typeHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activityProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cellular glucuronidationProtein kinase C epsilon typeHomo sapiens (human)
intracellular signal transductionProtein kinase C epsilon typeHomo sapiens (human)
chemotaxisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
negative regulation of cell population proliferationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of gene expressionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Schwann cell developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cerebellar cortex formationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
keratinocyte differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
thyroid gland developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
endodermal cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
myelinationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
type B pancreatic cell proliferationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
thymus developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of axon regenerationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cell motilityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of axonogenesisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Bergmann glial cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
face developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
trachea formationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
epithelial cell proliferation involved in lung morphogenesisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
placenta blood vessel developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
labyrinthine layer developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of Golgi inheritanceDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of endodermal cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of early endosome to late endosome transportDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
neuron differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAngiopoietin-1 receptorHomo sapiens (human)
angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
response to hypoxiaAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of protein phosphorylationAngiopoietin-1 receptorHomo sapiens (human)
endothelial cell proliferationAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of endothelial cell proliferationAngiopoietin-1 receptorHomo sapiens (human)
endochondral ossificationAngiopoietin-1 receptorHomo sapiens (human)
sprouting angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayAngiopoietin-1 receptorHomo sapiens (human)
cell-cell signalingAngiopoietin-1 receptorHomo sapiens (human)
heart developmentAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of endothelial cell migrationAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
regulation of establishment or maintenance of cell polarityAngiopoietin-1 receptorHomo sapiens (human)
substrate adhesion-dependent cell spreadingAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of Rac protein signal transductionAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of Rho protein signal transductionAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of apoptotic processAngiopoietin-1 receptorHomo sapiens (human)
regulation of vascular permeabilityAngiopoietin-1 receptorHomo sapiens (human)
response to peptide hormoneAngiopoietin-1 receptorHomo sapiens (human)
response to estrogenAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
Tie signaling pathwayAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of inflammatory responseAngiopoietin-1 receptorHomo sapiens (human)
response to cAMPAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of focal adhesion assemblyAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAngiopoietin-1 receptorHomo sapiens (human)
definitive hemopoiesisAngiopoietin-1 receptorHomo sapiens (human)
heart trabecula formationAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAngiopoietin-1 receptorHomo sapiens (human)
glomerulus vasculature developmentAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionAngiopoietin-1 receptorHomo sapiens (human)
regulation of endothelial cell apoptotic processAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of endothelial cell apoptotic processAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of MAPK cascadeAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of kinase activityAngiopoietin-1 receptorHomo sapiens (human)
multicellular organism developmentAngiopoietin-1 receptorHomo sapiens (human)
apoptotic processMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
smoothened signaling pathwayMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
negative regulation of DNA-templated transcriptionMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
neuron migrationDNA topoisomerase 2-betaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-betaHomo sapiens (human)
axonogenesisDNA topoisomerase 2-betaHomo sapiens (human)
B cell differentiationDNA topoisomerase 2-betaHomo sapiens (human)
forebrain developmentDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to hydrogen peroxideDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to ATPDNA topoisomerase 2-betaHomo sapiens (human)
cellular senescenceDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA topoisomerase 2-betaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-betaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-betaHomo sapiens (human)
regulation of cell growthProtein kinase C theta typeHomo sapiens (human)
regulation of DNA-templated transcriptionProtein kinase C theta typeHomo sapiens (human)
protein phosphorylationProtein kinase C theta typeHomo sapiens (human)
membrane protein ectodomain proteolysisProtein kinase C theta typeHomo sapiens (human)
inflammatory responseProtein kinase C theta typeHomo sapiens (human)
axon guidanceProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-17 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-2 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-4 productionProtein kinase C theta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C theta typeHomo sapiens (human)
CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
Fc-epsilon receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
positive regulation of T cell activationProtein kinase C theta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomerase activityProtein kinase C theta typeHomo sapiens (human)
cell chemotaxisProtein kinase C theta typeHomo sapiens (human)
negative regulation of T cell apoptotic processProtein kinase C theta typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere cappingProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 17 type immune responseProtein kinase C theta typeHomo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 2 cell activationProtein kinase C theta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C theta typeHomo sapiens (human)
outflow tract septum morphogenesisActivin receptor type-1Homo sapiens (human)
branching involved in blood vessel morphogenesisActivin receptor type-1Homo sapiens (human)
in utero embryonic developmentActivin receptor type-1Homo sapiens (human)
gastrulation with mouth forming secondActivin receptor type-1Homo sapiens (human)
mesoderm formationActivin receptor type-1Homo sapiens (human)
neural crest cell migrationActivin receptor type-1Homo sapiens (human)
acute inflammatory responseActivin receptor type-1Homo sapiens (human)
embryonic heart tube morphogenesisActivin receptor type-1Homo sapiens (human)
atrioventricular valve morphogenesisActivin receptor type-1Homo sapiens (human)
mitral valve morphogenesisActivin receptor type-1Homo sapiens (human)
endocardial cushion formationActivin receptor type-1Homo sapiens (human)
endocardial cushion fusionActivin receptor type-1Homo sapiens (human)
atrial septum primum morphogenesisActivin receptor type-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
germ cell developmentActivin receptor type-1Homo sapiens (human)
determination of left/right symmetryActivin receptor type-1Homo sapiens (human)
negative regulation of signal transductionActivin receptor type-1Homo sapiens (human)
regulation of ossificationActivin receptor type-1Homo sapiens (human)
positive regulation of cell migrationActivin receptor type-1Homo sapiens (human)
positive regulation of bone mineralizationActivin receptor type-1Homo sapiens (human)
BMP signaling pathwayActivin receptor type-1Homo sapiens (human)
activin receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
negative regulation of activin receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
positive regulation of osteoblast differentiationActivin receptor type-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionActivin receptor type-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIActivin receptor type-1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationActivin receptor type-1Homo sapiens (human)
smooth muscle cell differentiationActivin receptor type-1Homo sapiens (human)
pharyngeal system developmentActivin receptor type-1Homo sapiens (human)
positive regulation of SMAD protein signal transductionActivin receptor type-1Homo sapiens (human)
ventricular septum morphogenesisActivin receptor type-1Homo sapiens (human)
cardiac muscle cell fate commitmentActivin receptor type-1Homo sapiens (human)
endocardial cushion cell fate commitmentActivin receptor type-1Homo sapiens (human)
positive regulation of cardiac epithelial to mesenchymal transitionActivin receptor type-1Homo sapiens (human)
cellular response to BMP stimulusActivin receptor type-1Homo sapiens (human)
positive regulation of determination of dorsal identityActivin receptor type-1Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleActivin receptor type-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayActivin receptor type-1Homo sapiens (human)
dorsal/ventral pattern formationActivin receptor type-1Homo sapiens (human)
heart developmentActivin receptor type-1Homo sapiens (human)
protein phosphorylationActivin receptor type-1Homo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-1Homo sapiens (human)
defense responseMacrophage-stimulating protein receptorHomo sapiens (human)
signal transductionMacrophage-stimulating protein receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayMacrophage-stimulating protein receptorHomo sapiens (human)
single fertilizationMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage-stimulating protein receptorHomo sapiens (human)
response to virusMacrophage-stimulating protein receptorHomo sapiens (human)
macrophage colony-stimulating factor signaling pathwayMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of MAP kinase activityMacrophage-stimulating protein receptorHomo sapiens (human)
innate immune responseMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMacrophage-stimulating protein receptorHomo sapiens (human)
nervous system developmentMacrophage-stimulating protein receptorHomo sapiens (human)
cell migrationMacrophage-stimulating protein receptorHomo sapiens (human)
phagocytosisMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of kinase activityMacrophage-stimulating protein receptorHomo sapiens (human)
multicellular organism developmentMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of macrophage chemotaxisFocal adhesion kinase 1Homo sapiens (human)
positive regulation of macrophage proliferationFocal adhesion kinase 1Homo sapiens (human)
angiogenesisFocal adhesion kinase 1Homo sapiens (human)
placenta developmentFocal adhesion kinase 1Homo sapiens (human)
regulation of protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
heart morphogenesisFocal adhesion kinase 1Homo sapiens (human)
signal complex assemblyFocal adhesion kinase 1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
integrin-mediated signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
axon guidanceFocal adhesion kinase 1Homo sapiens (human)
positive regulation of cell population proliferationFocal adhesion kinase 1Homo sapiens (human)
regulation of cell shapeFocal adhesion kinase 1Homo sapiens (human)
regulation of endothelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
regulation of epithelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of epithelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionFocal adhesion kinase 1Homo sapiens (human)
positive regulation of fibroblast migrationFocal adhesion kinase 1Homo sapiens (human)
cell migrationFocal adhesion kinase 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationFocal adhesion kinase 1Homo sapiens (human)
negative regulation of cell-cell adhesionFocal adhesion kinase 1Homo sapiens (human)
establishment of cell polarityFocal adhesion kinase 1Homo sapiens (human)
positive regulation of cell migrationFocal adhesion kinase 1Homo sapiens (human)
regulation of cell adhesion mediated by integrinFocal adhesion kinase 1Homo sapiens (human)
detection of muscle stretchFocal adhesion kinase 1Homo sapiens (human)
netrin-activated signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisFocal adhesion kinase 1Homo sapiens (human)
regulation of cell population proliferationFocal adhesion kinase 1Homo sapiens (human)
negative regulation of apoptotic processFocal adhesion kinase 1Homo sapiens (human)
regulation of GTPase activityFocal adhesion kinase 1Homo sapiens (human)
regulation of osteoblast differentiationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of protein kinase activityFocal adhesion kinase 1Homo sapiens (human)
protein autophosphorylationFocal adhesion kinase 1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
ephrin receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
cell motilityFocal adhesion kinase 1Homo sapiens (human)
regulation of cytoskeleton organizationFocal adhesion kinase 1Homo sapiens (human)
regulation of focal adhesion assemblyFocal adhesion kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFocal adhesion kinase 1Homo sapiens (human)
growth hormone receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
positive regulation of wound healingFocal adhesion kinase 1Homo sapiens (human)
regulation of substrate adhesion-dependent cell spreadingFocal adhesion kinase 1Homo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processFocal adhesion kinase 1Homo sapiens (human)
negative regulation of anoikisFocal adhesion kinase 1Homo sapiens (human)
protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
epidermal growth factor receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
regulation of cell adhesionFocal adhesion kinase 1Homo sapiens (human)
microtubule cytoskeleton organizationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of cell-matrix adhesionProtein kinase C zeta typeHomo sapiens (human)
protein phosphorylationProtein kinase C zeta typeHomo sapiens (human)
inflammatory responseProtein kinase C zeta typeHomo sapiens (human)
signal transductionProtein kinase C zeta typeHomo sapiens (human)
cell surface receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
long-term memoryProtein kinase C zeta typeHomo sapiens (human)
positive regulation of cell population proliferationProtein kinase C zeta typeHomo sapiens (human)
cell migrationProtein kinase C zeta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C zeta typeHomo sapiens (human)
establishment of cell polarityProtein kinase C zeta typeHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-10 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-13 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-4 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-5 productionProtein kinase C zeta typeHomo sapiens (human)
cellular response to insulin stimulusProtein kinase C zeta typeHomo sapiens (human)
negative regulation of apoptotic processProtein kinase C zeta typeHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityProtein kinase C zeta typeHomo sapiens (human)
positive regulation of T-helper 2 cell differentiationProtein kinase C zeta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
vesicle transport along microtubuleProtein kinase C zeta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C zeta typeHomo sapiens (human)
positive regulation of protein transportProtein kinase C zeta typeHomo sapiens (human)
membrane depolarizationProtein kinase C zeta typeHomo sapiens (human)
membrane hyperpolarizationProtein kinase C zeta typeHomo sapiens (human)
long-term synaptic potentiationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C zeta typeHomo sapiens (human)
protein kinase C signalingProtein kinase C zeta typeHomo sapiens (human)
protein localization to plasma membraneProtein kinase C zeta typeHomo sapiens (human)
regulation of neurotransmitter receptor localization to postsynaptic specialization membraneProtein kinase C zeta typeHomo sapiens (human)
neuron projection extensionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialProtein kinase C zeta typeHomo sapiens (human)
positive regulation of T-helper 2 cell cytokine productionProtein kinase C zeta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C zeta typeHomo sapiens (human)
protein phosphorylationProtein kinase C delta typeHomo sapiens (human)
apoptotic processProtein kinase C delta typeHomo sapiens (human)
DNA damage responseProtein kinase C delta typeHomo sapiens (human)
signal transductionProtein kinase C delta typeHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressProtein kinase C delta typeHomo sapiens (human)
regulation of signaling receptor activityProtein kinase C delta typeHomo sapiens (human)
immunoglobulin mediated immune responseProtein kinase C delta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C delta typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C delta typeHomo sapiens (human)
termination of signal transductionProtein kinase C delta typeHomo sapiens (human)
negative regulation of actin filament polymerizationProtein kinase C delta typeHomo sapiens (human)
positive regulation of endodeoxyribonuclease activityProtein kinase C delta typeHomo sapiens (human)
negative regulation of protein bindingProtein kinase C delta typeHomo sapiens (human)
activation of protein kinase activityProtein kinase C delta typeHomo sapiens (human)
positive regulation of superoxide anion generationProtein kinase C delta typeHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C delta typeHomo sapiens (human)
cellular response to UVProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein dephosphorylationProtein kinase C delta typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C delta typeHomo sapiens (human)
B cell proliferationProtein kinase C delta typeHomo sapiens (human)
neutrophil activationProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein import into nucleusProtein kinase C delta typeHomo sapiens (human)
defense response to bacteriumProtein kinase C delta typeHomo sapiens (human)
negative regulation of MAP kinase activityProtein kinase C delta typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C delta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C delta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C delta typeHomo sapiens (human)
negative regulation of inflammatory responseProtein kinase C delta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C delta typeHomo sapiens (human)
protein stabilizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of filopodium assemblyProtein kinase C delta typeHomo sapiens (human)
cell chemotaxisProtein kinase C delta typeHomo sapiens (human)
cellular response to hydrogen peroxideProtein kinase C delta typeHomo sapiens (human)
cellular response to hydroperoxideProtein kinase C delta typeHomo sapiens (human)
negative regulation of platelet aggregationProtein kinase C delta typeHomo sapiens (human)
cellular senescenceProtein kinase C delta typeHomo sapiens (human)
positive regulation of phospholipid scramblase activityProtein kinase C delta typeHomo sapiens (human)
cellular response to angiotensinProtein kinase C delta typeHomo sapiens (human)
regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of glucosylceramide catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of sphingomyelin catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProtein kinase C delta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C delta typeHomo sapiens (human)
neutrophil homeostasisTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of type III hypersensitivityTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of type I hypersensitivityTyrosine-protein kinase BTKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase BTKHomo sapiens (human)
B cell affinity maturationTyrosine-protein kinase BTKHomo sapiens (human)
histamine secretion by mast cellTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of immunoglobulin productionTyrosine-protein kinase BTKHomo sapiens (human)
regulation of B cell cytokine productionTyrosine-protein kinase BTKHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
regulation of B cell apoptotic processTyrosine-protein kinase BTKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase BTKHomo sapiens (human)
mesoderm developmentTyrosine-protein kinase BTKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase BTKHomo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase BTKHomo sapiens (human)
proteoglycan catabolic processTyrosine-protein kinase BTKHomo sapiens (human)
negative regulation of B cell proliferationTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of B cell proliferationTyrosine-protein kinase BTKHomo sapiens (human)
response to lipopolysaccharideTyrosine-protein kinase BTKHomo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to reactive oxygen speciesTyrosine-protein kinase BTKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase BTKHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
B cell activationTyrosine-protein kinase BTKHomo sapiens (human)
innate immune responseTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of B cell differentiationTyrosine-protein kinase BTKHomo sapiens (human)
cell maturationTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of phagocytosisTyrosine-protein kinase BTKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTyrosine-protein kinase BTKHomo sapiens (human)
monocyte proliferationTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to molecule of fungal originTyrosine-protein kinase BTKHomo sapiens (human)
apoptotic signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to interleukin-7Tyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of interleukin-17A productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of synoviocyte proliferationTyrosine-protein kinase BTKHomo sapiens (human)
eosinophil homeostasisTyrosine-protein kinase BTKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
neuron migrationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
natural killer cell differentiationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell adhesionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
signal transductionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
neuropeptide signaling pathwayTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
spermatogenesisTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
forebrain cell migrationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
platelet activationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
secretion by cellTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of toll-like receptor signaling pathwayTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
ovulation cycleTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
apoptotic cell clearanceTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of neuron apoptotic processTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of innate immune responseTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
symbiont entry into host cellTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of inflammatory responseTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of lymphocyte activationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
neuron apoptotic processTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
establishment of localization in cellTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
vagina developmentTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
neuron cellular homeostasisTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
platelet aggregationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of viral life cycleTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
nervous system developmentTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
phagocytosisTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
multicellular organism developmentTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell migrationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of myelinationCyclin-dependent kinase 18Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 18Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 18Homo sapiens (human)
endocytosisActivated CDC42 kinase 1Homo sapiens (human)
cell surface receptor signaling pathwayActivated CDC42 kinase 1Homo sapiens (human)
small GTPase-mediated signal transductionActivated CDC42 kinase 1Homo sapiens (human)
phosphorylationActivated CDC42 kinase 1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationActivated CDC42 kinase 1Homo sapiens (human)
regulation of clathrin-dependent endocytosisActivated CDC42 kinase 1Homo sapiens (human)
protein phosphorylationActivated CDC42 kinase 1Homo sapiens (human)
regulation of cell growthEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
regulation of cell-matrix adhesionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
cell adhesionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
embryo implantationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
lactationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
cell population proliferationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
negative regulation of cell population proliferationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
regulation of extracellular matrix disassemblyEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
smooth muscle cell migrationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
peptidyl-tyrosine autophosphorylationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
ear developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
wound healing, spreading of cellsEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
protein autophosphorylationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
branching involved in mammary gland duct morphogenesisEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
mammary gland alveolus developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
smooth muscle cell-matrix adhesionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
axon developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
neuron projection extensionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
multicellular organism developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of kinase activityEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cellular defense responseTyrosine-protein kinase ITK/TSKHomo sapiens (human)
signal transductionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
activation of phospholipase C activityTyrosine-protein kinase ITK/TSKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
T cell activationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
gamma-delta T cell activationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase ITK/TSKHomo sapiens (human)
NK T cell differentiationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
regulation of sodium ion transportMyotonin-protein kinaseHomo sapiens (human)
protein phosphorylationMyotonin-protein kinaseHomo sapiens (human)
intracellular calcium ion homeostasisMyotonin-protein kinaseHomo sapiens (human)
nuclear envelope organizationMyotonin-protein kinaseHomo sapiens (human)
regulation of heart contractionMyotonin-protein kinaseHomo sapiens (human)
muscle cell apoptotic processMyotonin-protein kinaseHomo sapiens (human)
regulation of myotube differentiationMyotonin-protein kinaseHomo sapiens (human)
regulation of excitatory postsynaptic membrane potential involved in skeletal muscle contractionMyotonin-protein kinaseHomo sapiens (human)
regulation of synapse structural plasticityMyotonin-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationMyotonin-protein kinaseHomo sapiens (human)
regulation of skeletal muscle contraction by calcium ion signalingMyotonin-protein kinaseHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
vesicle targetingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
immune responseMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
innate immune responseMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
post-translational protein modificationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of protein kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of DNA-templated transcriptionMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
negative regulation of motor neuron apoptotic processMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
natural killer cell differentiationTyrosine-protein kinase MerHomo sapiens (human)
negative regulation of cytokine productionTyrosine-protein kinase MerHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase MerHomo sapiens (human)
phagocytosisTyrosine-protein kinase MerHomo sapiens (human)
cell surface receptor signaling pathwayTyrosine-protein kinase MerHomo sapiens (human)
cell-cell signalingTyrosine-protein kinase MerHomo sapiens (human)
spermatogenesisTyrosine-protein kinase MerHomo sapiens (human)
platelet activationTyrosine-protein kinase MerHomo sapiens (human)
secretion by cellTyrosine-protein kinase MerHomo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase MerHomo sapiens (human)
positive regulation of phagocytosisTyrosine-protein kinase MerHomo sapiens (human)
negative regulation of lymphocyte activationTyrosine-protein kinase MerHomo sapiens (human)
establishment of localization in cellTyrosine-protein kinase MerHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase MerHomo sapiens (human)
retina development in camera-type eyeTyrosine-protein kinase MerHomo sapiens (human)
vagina developmentTyrosine-protein kinase MerHomo sapiens (human)
neutrophil clearanceTyrosine-protein kinase MerHomo sapiens (human)
negative regulation of leukocyte apoptotic processTyrosine-protein kinase MerHomo sapiens (human)
nervous system developmentTyrosine-protein kinase MerHomo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase MerHomo sapiens (human)
cell migrationTyrosine-protein kinase MerHomo sapiens (human)
multicellular organism developmentTyrosine-protein kinase MerHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase MerHomo sapiens (human)
cell morphogenesisSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase 4Homo sapiens (human)
branching involved in blood vessel morphogenesisSerine/threonine-protein kinase 4Homo sapiens (human)
neural tube formationSerine/threonine-protein kinase 4Homo sapiens (human)
endocardium developmentSerine/threonine-protein kinase 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein import into nucleusSerine/threonine-protein kinase 4Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
signal transductionSerine/threonine-protein kinase 4Homo sapiens (human)
central nervous system developmentSerine/threonine-protein kinase 4Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 4Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
keratinocyte differentiationSerine/threonine-protein kinase 4Homo sapiens (human)
organ growthSerine/threonine-protein kinase 4Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase 4Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of fat cell differentiationSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of organ growthSerine/threonine-protein kinase 4Homo sapiens (human)
epithelial cell proliferationSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of epithelial cell proliferationSerine/threonine-protein kinase 4Homo sapiens (human)
protein tetramerizationSerine/threonine-protein kinase 4Homo sapiens (human)
canonical Wnt signaling pathwaySerine/threonine-protein kinase 4Homo sapiens (human)
primitive hemopoiesisSerine/threonine-protein kinase 4Homo sapiens (human)
cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 4Homo sapiens (human)
regulation of cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase 4Homo sapiens (human)
hepatocyte apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of hepatocyte apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of substrate-dependent cell migration, cell attachment to substrateSerine/threonine-protein kinase 4Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase 4Homo sapiens (human)
lipid droplet disassembly5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to hypoxia5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
glucose metabolic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
chromatin remodeling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
autophagy5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of cell population proliferation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
lipid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to UV5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cold acclimation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to gamma radiation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of autophagy5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
bile acid and bile salt transport5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
Wnt signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid oxidation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to caffeine5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of TOR signaling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of peptidyl-serine phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to oxidative stress5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
bile acid signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to glucose starvation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
glucose homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of circadian rhythm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to estrogen5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of glycolytic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of DNA-templated transcription5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of glucosylceramide biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of insulin receptor signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
rhythmic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of skeletal muscle tissue development5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of lipid catabolic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of vesicle-mediated transport5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
motor behavior5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
CAMKK-AMPK signaling cascade5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of stress granule assembly5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
neuron cellular homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to hydrogen peroxide5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of microtubule cytoskeleton organization5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to calcium ion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to glucose stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to ethanol5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to prostaglandin E stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to organonitrogen compound5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to hypoxia5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to xenobiotic stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
energy homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of bile acid secretion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of mitochondrial transcription5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of protein localization5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of hepatocyte apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of protein targeting to mitochondrion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of adipose tissue development5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of TORC1 signaling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of tubulin deacetylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein localization to lipid droplet5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cell migrationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of protein phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
exocytosisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of cell population proliferationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of cell migrationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of microtubule polymerizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
wound healingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
hepatocyte growth factor receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
ephrin receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
branching morphogenesis of an epithelial tubeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of stress fiber assemblySerine/threonine-protein kinase PAK 1Homo sapiens (human)
negative regulation of cell proliferation involved in contact inhibitionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of microtubule nucleationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein localization to cytoplasmic stress granuleSerine/threonine-protein kinase PAK 1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of cell growthDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of interleukin-8 productionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of heterotypic cell-cell adhesionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of MAP kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of epithelial cell proliferationDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of protein metabolic processDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of response to cytokine stimulusDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
ERK5 cascadeDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
cellular response to growth factor stimulusDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
cellular response to laminar fluid shear stressDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of chemokine (C-X-C motif) ligand 2 productionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 7Homo sapiens (human)
signal transductionMitogen-activated protein kinase 7Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayMitogen-activated protein kinase 7Homo sapiens (human)
cell differentiationMitogen-activated protein kinase 7Homo sapiens (human)
calcineurin-NFAT signaling cascadeMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of heterotypic cell-cell adhesionMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processMitogen-activated protein kinase 7Homo sapiens (human)
regulation of angiogenesisMitogen-activated protein kinase 7Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of inflammatory responseMitogen-activated protein kinase 7Homo sapiens (human)
positive regulation of protein metabolic processMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of response to cytokine stimulusMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to hydrogen peroxideMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to growth factor stimulusMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to laminar fluid shear stressMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to transforming growth factor beta stimulusMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of endothelial cell apoptotic processMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandMitogen-activated protein kinase 7Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 7Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
cardiac muscle hypertrophySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of protein kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
adherens junction assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PAK 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of stress fiber assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
dendritic spine developmentSerine/threonine-protein kinase PAK 2Homo sapiens (human)
bicellular tight junction assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
cellular response to organic cyclic compoundSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein localization to cell-cell junctionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosisSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of protein bindingSerine/threonine-protein kinase 3Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase 3Homo sapiens (human)
neural tube formationSerine/threonine-protein kinase 3Homo sapiens (human)
endocardium developmentSerine/threonine-protein kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 3Homo sapiens (human)
protein import into nucleusSerine/threonine-protein kinase 3Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase 3Homo sapiens (human)
JNK cascadeSerine/threonine-protein kinase 3Homo sapiens (human)
central nervous system developmentSerine/threonine-protein kinase 3Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 3Homo sapiens (human)
organ growthSerine/threonine-protein kinase 3Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase 3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of fat cell differentiationSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase 3Homo sapiens (human)
negative regulation of organ growthSerine/threonine-protein kinase 3Homo sapiens (human)
epithelial cell proliferationSerine/threonine-protein kinase 3Homo sapiens (human)
negative regulation of epithelial cell proliferationSerine/threonine-protein kinase 3Homo sapiens (human)
protein tetramerizationSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase 3Homo sapiens (human)
canonical Wnt signaling pathwaySerine/threonine-protein kinase 3Homo sapiens (human)
primitive hemopoiesisSerine/threonine-protein kinase 3Homo sapiens (human)
cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 3Homo sapiens (human)
regulation of cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 3Homo sapiens (human)
protein localization to centrosomeSerine/threonine-protein kinase 3Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase 3Homo sapiens (human)
hepatocyte apoptotic processSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 3Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase 3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein phosphorylationcGMP-dependent protein kinase 2Homo sapiens (human)
signal transductioncGMP-dependent protein kinase 2Homo sapiens (human)
positive regulation of chondrocyte differentiationcGMP-dependent protein kinase 2Homo sapiens (human)
tetrahydrobiopterin metabolic processcGMP-dependent protein kinase 2Homo sapiens (human)
protein localization to plasma membranecGMP-dependent protein kinase 2Homo sapiens (human)
positive regulation of protein localizationcGMP-dependent protein kinase 2Homo sapiens (human)
negative regulation of chloride transportcGMP-dependent protein kinase 2Homo sapiens (human)
protein kinase A signalingcGMP-dependent protein kinase 2Homo sapiens (human)
cell morphogenesisIntegrin-linked protein kinaseHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
branching involved in ureteric bud morphogenesisIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of protein phosphorylationIntegrin-linked protein kinaseHomo sapiens (human)
outflow tract morphogenesisIntegrin-linked protein kinaseHomo sapiens (human)
protein phosphorylationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of cell population proliferationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of signal transductionIntegrin-linked protein kinaseHomo sapiens (human)
fibroblast migrationIntegrin-linked protein kinaseHomo sapiens (human)
nerve developmentIntegrin-linked protein kinaseHomo sapiens (human)
myelination in peripheral nervous systemIntegrin-linked protein kinaseHomo sapiens (human)
cell projection organizationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of BMP signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of phosphorylationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionIntegrin-linked protein kinaseHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionIntegrin-linked protein kinaseHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of osteoblast differentiationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of DNA-templated transcriptionIntegrin-linked protein kinaseHomo sapiens (human)
neural precursor cell proliferationIntegrin-linked protein kinaseHomo sapiens (human)
platelet aggregationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin-linked protein kinaseHomo sapiens (human)
negative regulation of neural precursor cell proliferationIntegrin-linked protein kinaseHomo sapiens (human)
cell-matrix adhesionIntegrin-linked protein kinaseHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
epithelial to mesenchymal transitionRho-associated protein kinase 1Homo sapiens (human)
aortic valve morphogenesisRho-associated protein kinase 1Homo sapiens (human)
apical constrictionRho-associated protein kinase 1Homo sapiens (human)
protein phosphorylationRho-associated protein kinase 1Homo sapiens (human)
smooth muscle contractionRho-associated protein kinase 1Homo sapiens (human)
leukocyte cell-cell adhesionRho-associated protein kinase 1Homo sapiens (human)
signal transductionRho-associated protein kinase 1Homo sapiens (human)
canonical NF-kappaB signal transductionRho-associated protein kinase 1Homo sapiens (human)
Rho protein signal transductionRho-associated protein kinase 1Homo sapiens (human)
positive regulation of autophagyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of gene expressionRho-associated protein kinase 1Homo sapiens (human)
positive regulation of phosphatase activityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of angiogenesisRho-associated protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationRho-associated protein kinase 1Homo sapiens (human)
membrane to membrane dockingRho-associated protein kinase 1Homo sapiens (human)
actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
regulation of cell adhesionRho-associated protein kinase 1Homo sapiens (human)
regulation of cell migrationRho-associated protein kinase 1Homo sapiens (human)
cortical actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
neuron projection developmentRho-associated protein kinase 1Homo sapiens (human)
bleb assemblyRho-associated protein kinase 1Homo sapiens (human)
negative regulation of protein bindingRho-associated protein kinase 1Homo sapiens (human)
regulation of actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of dephosphorylationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of phosphorylationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of MAPK cascadeRho-associated protein kinase 1Homo sapiens (human)
regulation of keratinocyte differentiationRho-associated protein kinase 1Homo sapiens (human)
regulation of neuron differentiationRho-associated protein kinase 1Homo sapiens (human)
leukocyte migrationRho-associated protein kinase 1Homo sapiens (human)
leukocyte tethering or rollingRho-associated protein kinase 1Homo sapiens (human)
negative regulation of membrane protein ectodomain proteolysisRho-associated protein kinase 1Homo sapiens (human)
myoblast migrationRho-associated protein kinase 1Homo sapiens (human)
regulation of stress fiber assemblyRho-associated protein kinase 1Homo sapiens (human)
regulation of focal adhesion assemblyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of focal adhesion assemblyRho-associated protein kinase 1Homo sapiens (human)
mRNA destabilizationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of biomineral tissue developmentRho-associated protein kinase 1Homo sapiens (human)
regulation of microtubule cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
response to transforming growth factor betaRho-associated protein kinase 1Homo sapiens (human)
protein localization to plasma membraneRho-associated protein kinase 1Homo sapiens (human)
regulation of synapse maturationRho-associated protein kinase 1Homo sapiens (human)
podocyte cell migrationRho-associated protein kinase 1Homo sapiens (human)
motor neuron apoptotic processRho-associated protein kinase 1Homo sapiens (human)
blood vessel diameter maintenanceRho-associated protein kinase 1Homo sapiens (human)
regulation of angiotensin-activated signaling pathwayRho-associated protein kinase 1Homo sapiens (human)
neuron projection arborizationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of amyloid-beta clearanceRho-associated protein kinase 1Homo sapiens (human)
regulation of synaptic vesicle endocytosisRho-associated protein kinase 1Homo sapiens (human)
negative regulation of amyloid-beta formationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of amyloid precursor protein catabolic processRho-associated protein kinase 1Homo sapiens (human)
regulation of establishment of endothelial barrierRho-associated protein kinase 1Homo sapiens (human)
negative regulation of bicellular tight junction assemblyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of connective tissue replacementRho-associated protein kinase 1Homo sapiens (human)
response to angiotensinRho-associated protein kinase 1Homo sapiens (human)
regulation of establishment of cell polarityRho-associated protein kinase 1Homo sapiens (human)
regulation of cell motilityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of motor neuron apoptotic processRho-associated protein kinase 1Homo sapiens (human)
regulation of cell junction assemblyRho-associated protein kinase 1Homo sapiens (human)
mitotic cytokinesisRho-associated protein kinase 1Homo sapiens (human)
embryonic morphogenesisRho-associated protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationRho-associated protein kinase 1Homo sapiens (human)
actomyosin structure organizationRho-associated protein kinase 1Homo sapiens (human)
protein phosphorylationNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
protein autophosphorylationNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
spliceosomal tri-snRNP complex assemblySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
spliceosomal snRNP assemblySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
mRNA splicing, via spliceosomeSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
positive regulation of hippo signalingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
mRNA cis splicing, via spliceosomeSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
positive regulation of protein export from nucleusSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
regulation of mitotic cell cycle spindle assembly checkpointSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
positive regulation of miRNA processingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
MAPK cascadeReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of protein phosphorylationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
inflammatory responseReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
response to oxidative stressReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of gene expressionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein catabolic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of interleukin-8 productionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of tumor necrosis factor productionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
response to tumor necrosis factorReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine autophosphorylationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of programmed cell deathReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of neuron apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of macrophage differentiationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of JNK cascadeReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein autophosphorylationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of inflammatory responseReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of programmed necrotic cell deathReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of interleukin-6-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
T cell apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cellular response to hydrogen peroxideReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
regulation of ATP:ADP antiporter activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cellular response to tumor necrosis factorReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cellular response to growth factor stimulusReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
programmed necrotic cell deathReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ripoptosome assemblyReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
necroptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of execution phase of apoptosisReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ripoptosome assembly involved in necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
amyloid fibril formationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
signal transductionCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of skeletal muscle adaptationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
cell differentiationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of synapse structural plasticityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of dendritic spine developmentCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
positive regulation of dendritic spine morphogenesisCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
positive regulation of synapse maturationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of neuron migrationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of skeletal muscle adaptationCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
insulin secretionCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
cell differentiationCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of cell growthCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of the force of heart contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of membrane depolarizationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of transcription by RNA polymerase IICalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of heart contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cell communication by electrical couplingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
peptidyl-threonine phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
endoplasmic reticulum calcium ion homeostasisCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
relaxation of cardiac muscleCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cellular localizationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cellular response to calcium ionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cardiac muscle cell contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of heart rate by cardiac conductionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cardiac muscle cell action potentialCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cardiac muscle cell action potential involved in regulation of contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of relaxation of cardiac muscleCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
negative regulation of sodium ion transmembrane transportCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
chromatin remodelingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IIDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nervous system developmentDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
circadian rhythmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of microtubule polymerizationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of RNA splicingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
amyloid-beta formationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-serine autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-tyrosine autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of mRNA splicing, via spliceosomeDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of DNA methylation-dependent heterochromatin formationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of protein deacetylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIActivin receptor type-2BHomo sapiens (human)
gastrulation with mouth forming secondActivin receptor type-2BHomo sapiens (human)
kidney developmentActivin receptor type-2BHomo sapiens (human)
lymphangiogenesisActivin receptor type-2BHomo sapiens (human)
blood vessel remodelingActivin receptor type-2BHomo sapiens (human)
regulation of DNA-templated transcriptionActivin receptor type-2BHomo sapiens (human)
signal transductionActivin receptor type-2BHomo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayActivin receptor type-2BHomo sapiens (human)
determination of left/right symmetryActivin receptor type-2BHomo sapiens (human)
mesoderm developmentActivin receptor type-2BHomo sapiens (human)
heart developmentActivin receptor type-2BHomo sapiens (human)
response to glucoseActivin receptor type-2BHomo sapiens (human)
post-embryonic developmentActivin receptor type-2BHomo sapiens (human)
anterior/posterior pattern specificationActivin receptor type-2BHomo sapiens (human)
insulin secretionActivin receptor type-2BHomo sapiens (human)
lung developmentActivin receptor type-2BHomo sapiens (human)
positive regulation of bone mineralizationActivin receptor type-2BHomo sapiens (human)
BMP signaling pathwayActivin receptor type-2BHomo sapiens (human)
pancreas developmentActivin receptor type-2BHomo sapiens (human)
activin receptor signaling pathwayActivin receptor type-2BHomo sapiens (human)
positive regulation of activin receptor signaling pathwayActivin receptor type-2BHomo sapiens (human)
organ growthActivin receptor type-2BHomo sapiens (human)
odontogenesis of dentin-containing toothActivin receptor type-2BHomo sapiens (human)
positive regulation of osteoblast differentiationActivin receptor type-2BHomo sapiens (human)
embryonic foregut morphogenesisActivin receptor type-2BHomo sapiens (human)
skeletal system morphogenesisActivin receptor type-2BHomo sapiens (human)
roof of mouth developmentActivin receptor type-2BHomo sapiens (human)
lymphatic endothelial cell differentiationActivin receptor type-2BHomo sapiens (human)
artery developmentActivin receptor type-2BHomo sapiens (human)
venous blood vessel developmentActivin receptor type-2BHomo sapiens (human)
retina vasculature development in camera-type eyeActivin receptor type-2BHomo sapiens (human)
negative regulation of cold-induced thermogenesisActivin receptor type-2BHomo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-2BHomo sapiens (human)
protein phosphorylationActivin receptor type-2BHomo sapiens (human)
outflow tract septum morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
atrioventricular valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
cardiac muscle tissue developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
pharyngeal arch artery morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of gene expressionBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of SMAD protein signal transductionBone morphogenetic protein receptor type-2Homo sapiens (human)
osteoblast differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
mesoderm formationBone morphogenetic protein receptor type-2Homo sapiens (human)
maternal placenta developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
endothelial cell proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
lymphangiogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
blood vessel remodelingBone morphogenetic protein receptor type-2Homo sapiens (human)
chondrocyte developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of systemic arterial blood pressureBone morphogenetic protein receptor type-2Homo sapiens (human)
outflow tract morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
aortic valve developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
pulmonary valve developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
mitral valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
tricuspid valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
endocardial cushion developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of cell proliferation involved in heart valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayBone morphogenetic protein receptor type-2Homo sapiens (human)
cellular response to starvationBone morphogenetic protein receptor type-2Homo sapiens (human)
anterior/posterior pattern specificationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of epithelial cell migrationBone morphogenetic protein receptor type-2Homo sapiens (human)
regulation of lung blood pressureBone morphogenetic protein receptor type-2Homo sapiens (human)
proteoglycan biosynthetic processBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of cell growthBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of bone mineralizationBone morphogenetic protein receptor type-2Homo sapiens (human)
BMP signaling pathwayBone morphogenetic protein receptor type-2Homo sapiens (human)
activin receptor signaling pathwayBone morphogenetic protein receptor type-2Homo sapiens (human)
regulation of cell population proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of osteoblast differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of ossificationBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of vasoconstrictionBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBone morphogenetic protein receptor type-2Homo sapiens (human)
lung alveolus developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of smooth muscle cell proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of axon extension involved in axon guidanceBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of muscle cell differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
limb developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
endochondral bone morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of SMAD protein signal transductionBone morphogenetic protein receptor type-2Homo sapiens (human)
ventricular septum morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
atrial septum morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
lung vasculature developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
lymphatic endothelial cell differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
artery developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
venous blood vessel developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of cartilage developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
retina vasculature development in camera-type eyeBone morphogenetic protein receptor type-2Homo sapiens (human)
cellular response to BMP stimulusBone morphogenetic protein receptor type-2Homo sapiens (human)
endothelial cell apoptotic processBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of chondrocyte proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
semi-lunar valve developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
cellular response to growth factor stimulusBone morphogenetic protein receptor type-2Homo sapiens (human)
blood vessel developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
protein phosphorylationBone morphogenetic protein receptor type-2Homo sapiens (human)
protein phosphorylationProtein-tyrosine kinase 6Homo sapiens (human)
tyrosine phosphorylation of STAT proteinProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of neuron projection developmentProtein-tyrosine kinase 6Homo sapiens (human)
cell migrationProtein-tyrosine kinase 6Homo sapiens (human)
ERBB2 signaling pathwayProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of DNA replicationProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of cell cycleProtein-tyrosine kinase 6Homo sapiens (human)
negative regulation of growthProtein-tyrosine kinase 6Homo sapiens (human)
protein autophosphorylationProtein-tyrosine kinase 6Homo sapiens (human)
intestinal epithelial cell differentiationProtein-tyrosine kinase 6Homo sapiens (human)
negative regulation of protein tyrosine kinase activityProtein-tyrosine kinase 6Homo sapiens (human)
cellular response to retinoic acidProtein-tyrosine kinase 6Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayProtein-tyrosine kinase 6Homo sapiens (human)
innate immune responseProtein-tyrosine kinase 6Homo sapiens (human)
cell differentiationProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProtein-tyrosine kinase 6Homo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein phosphorylationcGMP-dependent protein kinase 1 Homo sapiens (human)
neuron migrationcGMP-dependent protein kinase 1 Homo sapiens (human)
signal transductioncGMP-dependent protein kinase 1 Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationcGMP-dependent protein kinase 1 Homo sapiens (human)
spermatid developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of inositol phosphate biosynthetic processcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of glutamate secretioncGMP-dependent protein kinase 1 Homo sapiens (human)
dendrite developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
cGMP-mediated signalingcGMP-dependent protein kinase 1 Homo sapiens (human)
cerebellum developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
actin cytoskeleton organizationcGMP-dependent protein kinase 1 Homo sapiens (human)
forebrain developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
positive regulation of circadian rhythmcGMP-dependent protein kinase 1 Homo sapiens (human)
regulation of GTPase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
collateral sproutingcGMP-dependent protein kinase 1 Homo sapiens (human)
relaxation of vascular associated smooth musclecGMP-dependent protein kinase 1 Homo sapiens (human)
cell growth involved in cardiac muscle cell developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of platelet aggregationcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell migrationcGMP-dependent protein kinase 1 Homo sapiens (human)
regulation of testosterone biosynthetic processcGMP-dependent protein kinase 1 Homo sapiens (human)
protein kinase A signalingcGMP-dependent protein kinase 1 Homo sapiens (human)
alternative mRNA splicing, via spliceosomeCyclin-dependent kinase 13Homo sapiens (human)
regulation of signal transductionCyclin-dependent kinase 13Homo sapiens (human)
hemopoiesisCyclin-dependent kinase 13Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-dependent kinase 13Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 13Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 13Homo sapiens (human)
negative regulation of stem cell differentiationCyclin-dependent kinase 13Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 13Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
nucleocytoplasmic transportCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
signal transductionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
negative regulation of protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of protein localizationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
intracellular signal transductionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of protein export from nucleusCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of muscle cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of muscle cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of synapse structural plasticityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of dendritic spine developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
immune responseInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
gene expressionInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of lipid storageInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of type I interferon productionInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
response to interferon-betaInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
regulation of protein-containing complex assemblyInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
mRNA stabilizationInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
defense response to virusInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
type I interferon-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of type I interferon-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
interleukin-17-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
cellular response to virusInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProtein-tyrosine kinase 2-betaHomo sapiens (human)
MAPK cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
oocyte maturationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hypoxiaProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell-matrix adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
sprouting angiogenesisProtein-tyrosine kinase 2-betaHomo sapiens (human)
adaptive immune responseProtein-tyrosine kinase 2-betaHomo sapiens (human)
marginal zone B cell differentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to ischemiaProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein phosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular defense responseProtein-tyrosine kinase 2-betaHomo sapiens (human)
signal transductionProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell surface receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
signal complex assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
integrin-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell population proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of cell population proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of cell shapeProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to xenobiotic stimulusProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to mechanical stimulusProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hormoneProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to glucoseProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of endothelial cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of muscle cell apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of macrophage chemotaxisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of neuron projection developmentProtein-tyrosine kinase 2-betaHomo sapiens (human)
glial cell proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
peptidyl-tyrosine phosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of cell adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell growthProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of bone mineralizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of actin filament polymerizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
cortical cytoskeleton organizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
neuron projection developmentProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to immobilization stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
peptidyl-tyrosine autophosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cocaineProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hydrogen peroxideProtein-tyrosine kinase 2-betaHomo sapiens (human)
activation of Janus kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
stress fiber assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cation stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of potassium ion transportProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of neuron apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
blood vessel endothelial cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
bone resorptionProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to ethanolProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of myeloid cell differentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of translationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of angiogenesisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of protein kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of JNK cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein autophosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesion assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of synaptic plasticityProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cAMPProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to calcium ionProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProtein-tyrosine kinase 2-betaHomo sapiens (human)
long-term synaptic potentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
long-term synaptic depressionProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein-containing complex assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
chemokine-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular response to retinoic acidProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular response to fluid shear stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
endothelin receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of postsynaptic density assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of ubiquitin-dependent protein catabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of B cell chemotaxisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of DNA biosynthetic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
G2/M transition of mitotic cell cycleMaternal embryonic leucine zipper kinaseHomo sapiens (human)
apoptotic processMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cell population proliferationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressMaternal embryonic leucine zipper kinaseHomo sapiens (human)
hemopoiesisMaternal embryonic leucine zipper kinaseHomo sapiens (human)
positive regulation of apoptotic processMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein autophosphorylationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
neural precursor cell proliferationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein phosphorylationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
mitotic sister chromatid segregationStructural maintenance of chromosomes protein 1AHomo sapiens (human)
DNA repairStructural maintenance of chromosomes protein 1AHomo sapiens (human)
sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
response to radiationStructural maintenance of chromosomes protein 1AHomo sapiens (human)
establishment of mitotic sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
establishment of meiotic sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
somatic stem cell population maintenanceStructural maintenance of chromosomes protein 1AHomo sapiens (human)
cell divisionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
meiotic cell cycleStructural maintenance of chromosomes protein 1AHomo sapiens (human)
response to DNA damage checkpoint signalingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic spindle assemblyStructural maintenance of chromosomes protein 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
double-strand break repair via homologous recombinationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
chromatin remodelingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
negative regulation of gene expressionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
regulation of cell fate specificationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
negative regulation of DNA-templated transcriptionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
regulation of synapse assemblyChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
terminal button organizationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
regulation of stem cell differentiationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
very long-chain fatty acid metabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
generation of precursor metabolites and energyPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
lipid metabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
prostaglandin metabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
spermatogenesisPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid catabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid oxidationPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA oxidasePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
hydrogen peroxide biosynthetic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
very long-chain fatty acid beta-oxidationPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
lipid homeostasisPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase D1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase D1Homo sapiens (human)
inflammatory responseSerine/threonine-protein kinase D1Homo sapiens (human)
Golgi organizationSerine/threonine-protein kinase D1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
integrin-mediated signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
nervous system developmentSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell migrationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of keratinocyte proliferationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of neuron projection developmentSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of skeletal muscle contraction by modulation of calcium ion sensitivity of myofibrilSerine/threonine-protein kinase D1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D1Homo sapiens (human)
cell differentiationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to amino acid starvationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase D1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of protein import into nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase D1Homo sapiens (human)
innate immune responseSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of osteoblast differentiationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of cell sizeSerine/threonine-protein kinase D1Homo sapiens (human)
negative regulation of endocytosisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase D1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of protein export from nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
Golgi vesicle transportSerine/threonine-protein kinase D1Homo sapiens (human)
defense response to Gram-negative bacteriumSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySerine/threonine-protein kinase D1Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of sarcomere organizationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to hydroperoxideSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to norepinephrine stimulusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of peptide hormone secretionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblySerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to angiotensinSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to endothelinSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell chemotaxisSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of integrin-mediated signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase 38Homo sapiens (human)
chromatin organizationSerine/threonine-protein kinase 38Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase 38Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 38Homo sapiens (human)
protein modification processSerine/threonine-protein kinase 38Homo sapiens (human)
negative regulation of MAP kinase activitySerine/threonine-protein kinase 38Homo sapiens (human)
postsynapse organizationSerine/threonine-protein kinase 38Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 38Homo sapiens (human)
neural crest cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nervous system developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
synapse assemblyReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
lactationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
embryonic pattern specificationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
central nervous system morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
olfactory bulb interneuron differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
regulation of cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial fragmentation involved in apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell fate commitmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of DNA-templated transcriptionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein autophosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland epithelial cell differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland alveolus developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cardiac muscle tissue regenerationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
establishment of planar polarity involved in nephron morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein localization to cell surfaceReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
chemical synaptic transmissionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
negative regulation of cell population proliferationRibosomal protein S6 kinase alpha-2Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
positive regulation of apoptotic processRibosomal protein S6 kinase alpha-2Homo sapiens (human)
negative regulation of cell cycleRibosomal protein S6 kinase alpha-2Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-2Homo sapiens (human)
positive regulation of protein phosphorylationEphrin type-A receptor 7Homo sapiens (human)
brain developmentEphrin type-A receptor 7Homo sapiens (human)
phosphorylationEphrin type-A receptor 7Homo sapiens (human)
regulation of cell-cell adhesionEphrin type-A receptor 7Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-A receptor 7Homo sapiens (human)
regulation of protein autophosphorylationEphrin type-A receptor 7Homo sapiens (human)
regulation of cysteine-type endopeptidase activity involved in apoptotic processEphrin type-A receptor 7Homo sapiens (human)
positive regulation of neuron apoptotic processEphrin type-A receptor 7Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 7Homo sapiens (human)
negative regulation of collateral sproutingEphrin type-A receptor 7Homo sapiens (human)
branching morphogenesis of a nerveEphrin type-A receptor 7Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEphrin type-A receptor 7Homo sapiens (human)
modulation of chemical synaptic transmissionEphrin type-A receptor 7Homo sapiens (human)
negative chemotaxisEphrin type-A receptor 7Homo sapiens (human)
neuron apoptotic processEphrin type-A receptor 7Homo sapiens (human)
negative regulation of synapse assemblyEphrin type-A receptor 7Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeEphrin type-A receptor 7Homo sapiens (human)
nephric duct morphogenesisEphrin type-A receptor 7Homo sapiens (human)
regulation of postsynapse organizationEphrin type-A receptor 7Homo sapiens (human)
axon guidanceEphrin type-A receptor 7Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 7Homo sapiens (human)
cholesterol biosynthetic processDelta(24)-sterol reductaseHomo sapiens (human)
cholesterol biosynthetic processDelta(24)-sterol reductaseHomo sapiens (human)
Ras protein signal transductionDelta(24)-sterol reductaseHomo sapiens (human)
protein localizationDelta(24)-sterol reductaseHomo sapiens (human)
negative regulation of cell population proliferationDelta(24)-sterol reductaseHomo sapiens (human)
response to hormoneDelta(24)-sterol reductaseHomo sapiens (human)
tissue developmentDelta(24)-sterol reductaseHomo sapiens (human)
male genitalia developmentDelta(24)-sterol reductaseHomo sapiens (human)
plasminogen activationDelta(24)-sterol reductaseHomo sapiens (human)
cholesterol biosynthetic process via desmosterolDelta(24)-sterol reductaseHomo sapiens (human)
cholesterol biosynthetic process via lathosterolDelta(24)-sterol reductaseHomo sapiens (human)
amyloid precursor protein catabolic processDelta(24)-sterol reductaseHomo sapiens (human)
skin developmentDelta(24)-sterol reductaseHomo sapiens (human)
membrane organizationDelta(24)-sterol reductaseHomo sapiens (human)
steroid metabolic processDelta(24)-sterol reductaseHomo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
chemical synaptic transmissionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of cell growthRibosomal protein S6 kinase alpha-1Homo sapiens (human)
negative regulation of TOR signalingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
negative regulation of apoptotic processRibosomal protein S6 kinase alpha-1Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRibosomal protein S6 kinase alpha-1Homo sapiens (human)
regulation of translation in response to stressRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of cell differentiationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-1Homo sapiens (human)
hepatocyte proliferationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of hepatic stellate cell activationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of protein phosphorylationDual specificity testis-specific protein kinase 1Homo sapiens (human)
spermatogenesisDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of protein autophosphorylationDual specificity testis-specific protein kinase 1Homo sapiens (human)
regulation of protein localizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
regulation of actin cytoskeleton organizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of phosphorylationDual specificity testis-specific protein kinase 1Homo sapiens (human)
positive regulation of stress fiber assemblyDual specificity testis-specific protein kinase 1Homo sapiens (human)
establishment of vesicle localizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of protein serine/threonine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
podocyte cell migrationDual specificity testis-specific protein kinase 1Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingDual specificity testis-specific protein kinase 1Homo sapiens (human)
positive regulation of protein localization to nucleusDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of cilium assemblyDual specificity testis-specific protein kinase 1Homo sapiens (human)
actin cytoskeleton organizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein phosphorylationMyosin light chain kinase, smooth muscleHomo sapiens (human)
smooth muscle contractionMyosin light chain kinase, smooth muscleHomo sapiens (human)
tonic smooth muscle contractionMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of cell migrationMyosin light chain kinase, smooth muscleHomo sapiens (human)
bleb assemblyMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of calcium ion transportMyosin light chain kinase, smooth muscleHomo sapiens (human)
aorta smooth muscle tissue morphogenesisMyosin light chain kinase, smooth muscleHomo sapiens (human)
cellular hypotonic responseMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of wound healingMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 11Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 11Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 11Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 11Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 11Homo sapiens (human)
cardiac muscle cell proliferationMitogen-activated protein kinase 11Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 11Homo sapiens (human)
bone developmentMitogen-activated protein kinase 11Homo sapiens (human)
cellular response to interleukin-1Mitogen-activated protein kinase 11Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 11Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 11Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 11Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 11Homo sapiens (human)
G1 to G0 transitionSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase STK11Homo sapiens (human)
tissue homeostasisSerine/threonine-protein kinase STK11Homo sapiens (human)
vasculature developmentSerine/threonine-protein kinase STK11Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
protein dephosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
autophagySerine/threonine-protein kinase STK11Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase STK11Homo sapiens (human)
spermatogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase STK11Homo sapiens (human)
response to ionizing radiationSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase STK11Homo sapiens (human)
response to activitySerine/threonine-protein kinase STK11Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of cell growthSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
activation of protein kinase activitySerine/threonine-protein kinase STK11Homo sapiens (human)
response to glucagonSerine/threonine-protein kinase STK11Homo sapiens (human)
response to lipidSerine/threonine-protein kinase STK11Homo sapiens (human)
protein localization to nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
glucose homeostasisSerine/threonine-protein kinase STK11Homo sapiens (human)
anoikisSerine/threonine-protein kinase STK11Homo sapiens (human)
positive thymic T cell selectionSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of gluconeogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of dendrite morphogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of axonogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
T cell receptor signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
Golgi localizationSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of cell cycleSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase STK11Homo sapiens (human)
epithelial cell proliferation involved in prostate gland developmentSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of epithelial cell proliferation involved in prostate gland developmentSerine/threonine-protein kinase STK11Homo sapiens (human)
cellular response to UV-BSerine/threonine-protein kinase STK11Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
response to thyroid hormoneSerine/threonine-protein kinase STK11Homo sapiens (human)
dendrite extensionSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of cold-induced thermogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of protein localization to nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of vesicle transport along microtubuleSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of TORC1 signalingSerine/threonine-protein kinase STK11Homo sapiens (human)
signal transductionSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of Wnt signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
visual perceptionRhodopsin kinase GRK1Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathwayRhodopsin kinase GRK1Homo sapiens (human)
rhodopsin mediated signaling pathwayRhodopsin kinase GRK1Homo sapiens (human)
regulation of opsin-mediated signaling pathwayRhodopsin kinase GRK1Homo sapiens (human)
protein autophosphorylationRhodopsin kinase GRK1Homo sapiens (human)
protein phosphorylationRhodopsin kinase GRK1Homo sapiens (human)
regulation of signal transductionRhodopsin kinase GRK1Homo sapiens (human)
activation of protein kinase B activityNT-3 growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityNT-3 growth factor receptorHomo sapiens (human)
negative regulation of protein phosphorylationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationNT-3 growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayNT-3 growth factor receptorHomo sapiens (human)
nervous system developmentNT-3 growth factor receptorHomo sapiens (human)
heart developmentNT-3 growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of gene expressionNT-3 growth factor receptorHomo sapiens (human)
cell differentiationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of cell migrationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationNT-3 growth factor receptorHomo sapiens (human)
neurotrophin signaling pathwayNT-3 growth factor receptorHomo sapiens (human)
positive regulation of positive chemotaxisNT-3 growth factor receptorHomo sapiens (human)
activation of GTPase activityNT-3 growth factor receptorHomo sapiens (human)
positive regulation of neuron projection developmentNT-3 growth factor receptorHomo sapiens (human)
positive regulation of kinase activityNT-3 growth factor receptorHomo sapiens (human)
cellular response to nerve growth factor stimulusNT-3 growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNT-3 growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNT-3 growth factor receptorHomo sapiens (human)
multicellular organism developmentNT-3 growth factor receptorHomo sapiens (human)
B cell homeostasisSerine/threonine-protein kinase N1Homo sapiens (human)
B cell apoptotic processSerine/threonine-protein kinase N1Homo sapiens (human)
negative regulation of protein phosphorylationSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of germinal center formationSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of immunoglobulin productionSerine/threonine-protein kinase N1Homo sapiens (human)
renal system processSerine/threonine-protein kinase N1Homo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of transcription by RNA polymerase IISerine/threonine-protein kinase N1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase N1Homo sapiens (human)
hyperosmotic responseSerine/threonine-protein kinase N1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase N1Homo sapiens (human)
epithelial cell migrationSerine/threonine-protein kinase N1Homo sapiens (human)
negative regulation of B cell proliferationSerine/threonine-protein kinase N1Homo sapiens (human)
post-translational protein modificationSerine/threonine-protein kinase N1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase N1Homo sapiens (human)
spleen developmentSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of androgen receptor signaling pathwaySerine/threonine-protein kinase N1Homo sapiens (human)
regulation of cell motilitySerine/threonine-protein kinase N1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase N1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase N1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase N2Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase N2Homo sapiens (human)
cell adhesionSerine/threonine-protein kinase N2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase N2Homo sapiens (human)
epithelial cell migrationSerine/threonine-protein kinase N2Homo sapiens (human)
cell projection organizationSerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of cytokinesisSerine/threonine-protein kinase N2Homo sapiens (human)
apical junction assemblySerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of viral genome replicationSerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of mitotic cell cycleSerine/threonine-protein kinase N2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase N2Homo sapiens (human)
regulation of cell motilitySerine/threonine-protein kinase N2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase N2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myeloid dendritic cell cytokine productionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
adaptive immune responseCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
inflammatory responseCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
signal transductionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
long-term memoryCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
regulation of T cell differentiation in thymusCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
myeloid dendritic cell differentiationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
regulation of osteoclast differentiationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
positive regulation of DNA-templated transcriptionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
intracellular signal transductionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
microtubule-based processMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of neuron apoptotic processMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
cell cycle G1/S phase transitionMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
negative regulation of amyloid-beta formationBDNF/NT-3 growth factors receptorHomo sapiens (human)
vasculogenesisBDNF/NT-3 growth factors receptorHomo sapiens (human)
neuron migrationBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of protein phosphorylationBDNF/NT-3 growth factors receptorHomo sapiens (human)
learningBDNF/NT-3 growth factors receptorHomo sapiens (human)
circadian rhythmBDNF/NT-3 growth factors receptorHomo sapiens (human)
feeding behaviorBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of cell population proliferationBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of gene expressionBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of neuron projection developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
glutamate secretionBDNF/NT-3 growth factors receptorHomo sapiens (human)
neuronal action potential propagationBDNF/NT-3 growth factors receptorHomo sapiens (human)
central nervous system neuron developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
cerebral cortex developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
myelination in peripheral nervous systemBDNF/NT-3 growth factors receptorHomo sapiens (human)
neuron differentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
brain-derived neurotrophic factor receptor signaling pathwayBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationBDNF/NT-3 growth factors receptorHomo sapiens (human)
neurotrophin signaling pathwayBDNF/NT-3 growth factors receptorHomo sapiens (human)
mechanoreceptor differentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
regulation of GTPase activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of MAPK cascadeBDNF/NT-3 growth factors receptorHomo sapiens (human)
negative regulation of neuron apoptotic processBDNF/NT-3 growth factors receptorHomo sapiens (human)
retinal rod cell developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein autophosphorylationBDNF/NT-3 growth factors receptorHomo sapiens (human)
oligodendrocyte differentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
peripheral nervous system neuron developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of axonogenesisBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of synapse assemblyBDNF/NT-3 growth factors receptorHomo sapiens (human)
long-term synaptic potentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
cellular response to amino acid stimulusBDNF/NT-3 growth factors receptorHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionBDNF/NT-3 growth factors receptorHomo sapiens (human)
negative regulation of anoikisBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of kinase activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeBDNF/NT-3 growth factors receptorHomo sapiens (human)
multicellular organism developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulusBDNF/NT-3 growth factors receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayBDNF/NT-3 growth factors receptorHomo sapiens (human)
trans-synaptic signaling by neuropeptide, modulating synaptic transmissionBDNF/NT-3 growth factors receptorHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 6Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 6Homo sapiens (human)
signal transductionMitogen-activated protein kinase 6Homo sapiens (human)
positive regulation of dendritic spine developmentMitogen-activated protein kinase 6Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 6Homo sapiens (human)
carbohydrate metabolic processPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
glycogen biosynthetic processPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
ossificationDiscoidin domain-containing receptor 2Homo sapiens (human)
endochondral bone growthDiscoidin domain-containing receptor 2Homo sapiens (human)
cell adhesionDiscoidin domain-containing receptor 2Homo sapiens (human)
signal transductionDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of extracellular matrix disassemblyDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of fibroblast migrationDiscoidin domain-containing receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen fibril organizationDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of bone mineralizationDiscoidin domain-containing receptor 2Homo sapiens (human)
biomineral tissue developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of collagen biosynthetic processDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of tissue remodelingDiscoidin domain-containing receptor 2Homo sapiens (human)
chondrocyte proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
response to muscle stretchDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayDiscoidin domain-containing receptor 2Homo sapiens (human)
negative regulation of apoptotic processDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of osteoblast differentiationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of protein kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein autophosphorylationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of fibroblast proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to hypoxiaDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of extracellular matrix disassemblyDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of wound healingDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDiscoidin domain-containing receptor 2Homo sapiens (human)
negative regulation of hydrogen peroxide-mediated programmed cell deathDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to angiotensinDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of hepatic stellate cell proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of hepatic stellate cell activationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of neuron projection developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionDiscoidin domain-containing receptor 2Homo sapiens (human)
multicellular organism developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDiscoidin domain-containing receptor 2Homo sapiens (human)
protein phosphorylationAP2-associated protein kinase 1Homo sapiens (human)
regulation of protein localizationAP2-associated protein kinase 1Homo sapiens (human)
positive regulation of Notch signaling pathwayAP2-associated protein kinase 1Homo sapiens (human)
protein stabilizationAP2-associated protein kinase 1Homo sapiens (human)
membrane organizationAP2-associated protein kinase 1Homo sapiens (human)
presynaptic endocytosisAP2-associated protein kinase 1Homo sapiens (human)
regulation of clathrin-dependent endocytosisAP2-associated protein kinase 1Homo sapiens (human)
regulation of vascular permeability involved in acute inflammatory responseMyosin light chain kinase 3Homo sapiens (human)
protein phosphorylationMyosin light chain kinase 3Homo sapiens (human)
sarcomere organizationMyosin light chain kinase 3Homo sapiens (human)
sarcomerogenesisMyosin light chain kinase 3Homo sapiens (human)
cardiac myofibril assemblyMyosin light chain kinase 3Homo sapiens (human)
positive regulation of sarcomere organizationMyosin light chain kinase 3Homo sapiens (human)
cellular response to interleukin-1Myosin light chain kinase 3Homo sapiens (human)
biological_processPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
cellular response to heatPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein stabilizationPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein foldingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
regulation of heart rateSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
regulation of cardiac muscle contractionSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
bundle of His cell to Purkinje myocyte communicationSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
regulation of cardiac conductionSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
negative regulation of GTPase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
MAPK cascadeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein import into nucleusLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endocytosisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
autophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
response to oxidative stressLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrion organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulum organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Golgi organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
lysosome organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
JNK cascadeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Rho protein signal transductionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
spermatogenesisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuromuscular junction developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein localizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
determination of adult lifespanLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to starvationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of autophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of autophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of protein kinase A signalingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein processingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of neuron projection developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of neuron maturationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of macroautophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
calcium-mediated signalingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
striatum developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
olfactory bulb developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
tangential migration from the subventricular zone to the olfactory bulbLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein ubiquitinationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of protein stabilityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to oxidative stressLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to reactive oxygen speciesLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
intracellular signal transductionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of kidney sizeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
exploration behaviorLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
locomotory exploration behaviorLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of lysosomal lumen pHLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of locomotionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of membrane potentialLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of programmed cell deathLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of MAP kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTP metabolic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein autophosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
intracellular distribution of mitochondriaLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuron projection morphogenesisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrion localizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of mitochondrial depolarizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of synaptic transmission, glutamatergicLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
canonical Wnt signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
excitatory postsynaptic potentialLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of dopamine receptor signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of dopamine receptor signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of ER to Golgi vesicle-mediated transportLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of canonical Wnt signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of dendritic spine morphogenesisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein localization to mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein localization to endoplasmic reticulum exit siteLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to manganese ionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of mitochondrial fissionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of excitatory postsynaptic potentialLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuron projection arborizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of synaptic vesicle endocytosisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein autoubiquitinationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of neuroblast proliferationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of synaptic vesicle transportLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of late endosome to lysosome transportLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of autophagosome assemblyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of thioredoxin peroxidase activity by peptidyl-threonine phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein targeting to mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein processing involved in protein targeting to mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to dopamineLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of microglial cell activationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Wnt signalosome assemblyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of retrograde transport, endosome to GolgiLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of CAMKK-AMPK signaling cascadeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of branching morphogenesis of a nerveLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of synaptic vesicle exocytosisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of reactive oxygen species metabolic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
signal transductionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cell migrationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actomyosin structure organizationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
actomyosin structure organizationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
fatty acid beta-oxidationAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase N3Homo sapiens (human)
signal transductionSerine/threonine-protein kinase N3Homo sapiens (human)
epithelial cell migrationSerine/threonine-protein kinase N3Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase N3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase N3Homo sapiens (human)
autophagySerine/threonine-protein kinase ULK3Homo sapiens (human)
smoothened signaling pathwaySerine/threonine-protein kinase ULK3Homo sapiens (human)
negative regulation of smoothened signaling pathwaySerine/threonine-protein kinase ULK3Homo sapiens (human)
positive regulation of smoothened signaling pathwaySerine/threonine-protein kinase ULK3Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK3Homo sapiens (human)
fibroblast activationSerine/threonine-protein kinase ULK3Homo sapiens (human)
cellular senescenceSerine/threonine-protein kinase ULK3Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK3Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK3Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK3Homo sapiens (human)
autophagosome assemblySerine/threonine-protein kinase ULK3Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK3Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK3Homo sapiens (human)
regulation of autophagySerine/threonine-protein kinase ULK3Homo sapiens (human)
positive regulation of kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
negative regulation of apoptotic processDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
cellular response to fibroblast growth factor stimulusDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
positive regulation of fibroblast growth factor receptor signaling pathwayDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
cellular response to stressMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
fatty acid beta-oxidationAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mRNA processingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
rRNA catabolic processSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
apoptotic chromosome condensationSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
negative regulation of DNA-templated transcriptionSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
IRE1-mediated unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase MARK2Homo sapiens (human)
neuron migrationSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
positive regulation of neuron projection developmentSerine/threonine-protein kinase MARK2Homo sapiens (human)
Wnt signaling pathwaySerine/threonine-protein kinase MARK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase MARK2Homo sapiens (human)
activation of protein kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polaritySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
mitochondrion localizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
axon developmentSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment or maintenance of cell polarity regulating cell shapeSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of microtubule bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
DNA repairSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase TAO1Homo sapiens (human)
negative regulation of microtubule depolymerizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase TAO1Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
central nervous system neuron developmentSerine/threonine-protein kinase TAO1Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase TAO1Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
neuron cellular homeostasisSerine/threonine-protein kinase TAO1Homo sapiens (human)
regulation of microtubule cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
execution phase of apoptosisSerine/threonine-protein kinase TAO1Homo sapiens (human)
positive regulation of protein acetylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein phosphorylationSTE20-related kinase adapter protein alphaHomo sapiens (human)
G1 to G0 transitionSTE20-related kinase adapter protein alphaHomo sapiens (human)
protein export from nucleusSTE20-related kinase adapter protein alphaHomo sapiens (human)
activation of protein kinase activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
skeletal muscle contractionMyosin-14Homo sapiens (human)
mitochondrion organizationMyosin-14Homo sapiens (human)
skeletal muscle tissue developmentMyosin-14Homo sapiens (human)
sensory perception of soundMyosin-14Homo sapiens (human)
regulation of cell shapeMyosin-14Homo sapiens (human)
neuronal action potentialMyosin-14Homo sapiens (human)
actin filament-based movementMyosin-14Homo sapiens (human)
actomyosin structure organizationMyosin-14Homo sapiens (human)
vocalization behaviorMyosin-14Homo sapiens (human)
negative regulation of mitochondrial fusionAarF domain-containing protein kinase 1Homo sapiens (human)
positive regulation of cristae formationAarF domain-containing protein kinase 1Homo sapiens (human)
mitochondrion organizationAarF domain-containing protein kinase 1Homo sapiens (human)
lipid homeostasisAarF domain-containing protein kinase 1Homo sapiens (human)
chromatin organizationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
negative regulation of autophagySerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
nucleus localizationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
cellular response to gamma radiationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
regulation of chromatin organizationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 32CHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 32CHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-3Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase pim-3Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase pim-3Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-3Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusSerine/threonine-protein kinase pim-3Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-3Homo sapiens (human)
protein localizationATP-dependent RNA helicase DDX42Homo sapiens (human)
regulation of apoptotic processATP-dependent RNA helicase DDX42Homo sapiens (human)
U2-type prespliceosome assemblyATP-dependent RNA helicase DDX42Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase VRK2Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase VRK2Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase VRK2Homo sapiens (human)
regulation of interleukin-1-mediated signaling pathwaySerine/threonine-protein kinase VRK2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase VRK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase VRK2Homo sapiens (human)
eye developmentHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein phosphorylationHomeodomain-interacting protein kinase 1Homo sapiens (human)
cell population proliferationHomeodomain-interacting protein kinase 1Homo sapiens (human)
positive regulation of cell population proliferationHomeodomain-interacting protein kinase 1Homo sapiens (human)
anterior/posterior pattern specificationHomeodomain-interacting protein kinase 1Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayHomeodomain-interacting protein kinase 1Homo sapiens (human)
retina layer formationHomeodomain-interacting protein kinase 1Homo sapiens (human)
neuron differentiationHomeodomain-interacting protein kinase 1Homo sapiens (human)
adherens junction assemblyHomeodomain-interacting protein kinase 1Homo sapiens (human)
positive regulation of angiogenesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
embryonic camera-type eye morphogenesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
embryonic retina morphogenesis in camera-type eyeHomeodomain-interacting protein kinase 1Homo sapiens (human)
definitive hemopoiesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
lens induction in camera-type eyeHomeodomain-interacting protein kinase 1Homo sapiens (human)
iris morphogenesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
endothelial cell apoptotic processHomeodomain-interacting protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathwayHomeodomain-interacting protein kinase 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorHomeodomain-interacting protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 1Homo sapiens (human)
smoothened signaling pathwayHomeodomain-interacting protein kinase 1Homo sapiens (human)
inflammatory responseCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of CREB transcription factor activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of apoptotic processCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
negative regulation of apoptotic processCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of phagocytosisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
regulation of dendrite developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of respiratory burstCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
regulation of granulocyte chemotaxisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of neutrophil chemotaxisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
response to UVMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
response to tumor necrosis factorMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein modification processCyclin-dependent kinase-like 3Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 3Homo sapiens (human)
negative regulation of axon extensionCyclin-dependent kinase-like 3Homo sapiens (human)
positive regulation of dendrite morphogenesisCyclin-dependent kinase-like 3Homo sapiens (human)
dendrite extensionCyclin-dependent kinase-like 3Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 3Homo sapiens (human)
MAPK cascadeMAP kinase-activated protein kinase 5Homo sapiens (human)
regulation of translationMAP kinase-activated protein kinase 5Homo sapiens (human)
signal transductionMAP kinase-activated protein kinase 5Homo sapiens (human)
Ras protein signal transductionMAP kinase-activated protein kinase 5Homo sapiens (human)
negative regulation of TOR signalingMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMAP kinase-activated protein kinase 5Homo sapiens (human)
protein autophosphorylationMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomerase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of dendritic spine developmentMAP kinase-activated protein kinase 5Homo sapiens (human)
cellular senescenceMAP kinase-activated protein kinase 5Homo sapiens (human)
stress-induced premature senescenceMAP kinase-activated protein kinase 5Homo sapiens (human)
regulation of signal transduction by p53 class mediatorMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomere cappingMAP kinase-activated protein kinase 5Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-activated protein kinase 5Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
exocytosisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase BRSK2Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase BRSK2Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
neuron differentiationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ERAD pathwaySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of ATP-dependent activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusSerine/threonine-protein kinase BRSK2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase BRSK2Homo sapiens (human)
microtubule cytoskeleton organization involved in establishment of planar polaritySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of retrograde protein transport, ER to cytosolSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of synaptic vesicle clusteringSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase NIM1Homo sapiens (human)
nuclear-transcribed mRNA catabolic process, nonsense-mediated decayEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
translational terminationEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
translationEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
autophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase ULK2Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK2Homo sapiens (human)
collateral sproutingSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK2Homo sapiens (human)
axon extensionSerine/threonine-protein kinase ULK2Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK2Homo sapiens (human)
negative regulation of collateral sproutingSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagosome assemblySerine/threonine-protein kinase ULK2Homo sapiens (human)
microvillus assemblyMisshapen-like kinase 1Homo sapiens (human)
regulation of cell-matrix adhesionMisshapen-like kinase 1Homo sapiens (human)
protein phosphorylationMisshapen-like kinase 1Homo sapiens (human)
JNK cascadeMisshapen-like kinase 1Homo sapiens (human)
chemical synaptic transmissionMisshapen-like kinase 1Homo sapiens (human)
brain developmentMisshapen-like kinase 1Homo sapiens (human)
regulation of cell-cell adhesionMisshapen-like kinase 1Homo sapiens (human)
actin cytoskeleton organizationMisshapen-like kinase 1Homo sapiens (human)
regulation of cell migrationMisshapen-like kinase 1Homo sapiens (human)
positive regulation of JNK cascadeMisshapen-like kinase 1Homo sapiens (human)
protein autophosphorylationMisshapen-like kinase 1Homo sapiens (human)
dendrite morphogenesisMisshapen-like kinase 1Homo sapiens (human)
positive regulation of p38MAPK cascadeMisshapen-like kinase 1Homo sapiens (human)
regulation of AMPA receptor activityMisshapen-like kinase 1Homo sapiens (human)
MAPK cascadeMisshapen-like kinase 1Homo sapiens (human)
neuron projection morphogenesisMisshapen-like kinase 1Homo sapiens (human)
regulation of MAPK cascadeMisshapen-like kinase 1Homo sapiens (human)
hippocampus developmentSerine/threonine-protein kinase DCLK2Homo sapiens (human)
pyramidal neuron developmentSerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein localization to nucleusSerine/threonine-protein kinase DCLK2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase DCLK2Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase DCLK2Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase DCLK2Homo sapiens (human)
intracellular signal transductionCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform alpha-likeHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform alpha-likeHomo sapiens (human)
signal transductionCasein kinase I isoform alpha-likeHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayCasein kinase I isoform alpha-likeHomo sapiens (human)
chromatin remodelingHomeodomain-interacting protein kinase 4Homo sapiens (human)
regulation of signal transduction by p53 class mediatorHomeodomain-interacting protein kinase 4Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 4Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 4Homo sapiens (human)
visual perceptionMyosin-IIIaHomo sapiens (human)
sensory perception of soundMyosin-IIIaHomo sapiens (human)
protein autophosphorylationMyosin-IIIaHomo sapiens (human)
cochlea morphogenesisMyosin-IIIaHomo sapiens (human)
regulation of actin filament lengthMyosin-IIIaHomo sapiens (human)
positive regulation of filopodium assemblyMyosin-IIIaHomo sapiens (human)
peptidyl-serine phosphorylationMyosin-IIIaHomo sapiens (human)
regulation of cell cycle processAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
regulation of cell cycle processAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek11Homo sapiens (human)
mitotic intra-S DNA damage checkpoint signalingSerine/threonine-protein kinase Nek11Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase Nek11Homo sapiens (human)
regulation of mitotic cell cycle phase transitionSerine/threonine-protein kinase Nek11Homo sapiens (human)
protein phosphorylationAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
ubiquinone biosynthetic processAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
phosphorylationAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
regulation of autophagyPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
positive regulation of autophagosome assemblyPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 15Homo sapiens (human)
regulation of COPII vesicle coatingMitogen-activated protein kinase 15Homo sapiens (human)
DNA damage responseMitogen-activated protein kinase 15Homo sapiens (human)
endoplasmic reticulum organizationMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of cell population proliferationMitogen-activated protein kinase 15Homo sapiens (human)
regulation of autophagyMitogen-activated protein kinase 15Homo sapiens (human)
negative regulation of cell migrationMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 15Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 15Homo sapiens (human)
dopamine uptakeMitogen-activated protein kinase 15Homo sapiens (human)
regulation of cilium assemblyMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 15Homo sapiens (human)
protein localization to ciliary transition zoneMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of metaphase/anaphase transition of meiosis IMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of spindle assemblyMitogen-activated protein kinase 15Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 15Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek9Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase Nek9Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek9Homo sapiens (human)
response to ionizing radiationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase BRSK1Homo sapiens (human)
response to UVSerine/threonine-protein kinase BRSK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase BRSK1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
neurotransmitter secretionSerine/threonine-protein kinase BRSK1Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase BRSK1Homo sapiens (human)
associative learningSerine/threonine-protein kinase BRSK1Homo sapiens (human)
response to UVSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase BRSK1Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase BRSK1Homo sapiens (human)
neuron differentiationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of synaptic plasticitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase BRSK1Homo sapiens (human)
centrosome duplicationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
microtubule cytoskeleton organization involved in establishment of planar polaritySerine/threonine-protein kinase BRSK1Homo sapiens (human)
synaptic vesicle cycleSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of synaptic vesicle clusteringSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of translational initiation by eIF2 alpha phosphorylationSerine/threonine-protein kinase 35Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek7Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine/threonine-protein kinase Nek7Homo sapiens (human)
cellular response to potassium ionSerine/threonine-protein kinase Nek7Homo sapiens (human)
spindle assemblySerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of telomerase activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblySerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of telomere cappingSerine/threonine-protein kinase Nek7Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase Nek7Homo sapiens (human)
signal transductionRhodopsin kinase GRK7Homo sapiens (human)
visual perceptionRhodopsin kinase GRK7Homo sapiens (human)
regulation of opsin-mediated signaling pathwayRhodopsin kinase GRK7Homo sapiens (human)
protein autophosphorylationRhodopsin kinase GRK7Homo sapiens (human)
regulation of signal transductionRhodopsin kinase GRK7Homo sapiens (human)
protein phosphorylationRhodopsin kinase GRK7Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 32AHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 32AHomo sapiens (human)
visual perceptionMyosin-IIIbHomo sapiens (human)
sensory perception of soundMyosin-IIIbHomo sapiens (human)
cochlea morphogenesisMyosin-IIIbHomo sapiens (human)
regulation of actin filament lengthMyosin-IIIbHomo sapiens (human)
peptidyl-serine phosphorylationMyosin-IIIbHomo sapiens (human)
positive regulation of filopodium assemblyMyosin-IIIbHomo sapiens (human)
spliceosomal complex assemblyATP-dependent RNA helicase DDX1Homo sapiens (human)
positive regulation of myeloid dendritic cell cytokine productionATP-dependent RNA helicase DDX1Homo sapiens (human)
double-strand break repairATP-dependent RNA helicase DDX1Homo sapiens (human)
tRNA splicing, via endonucleolytic cleavage and ligationATP-dependent RNA helicase DDX1Homo sapiens (human)
regulation of translational initiationATP-dependent RNA helicase DDX1Homo sapiens (human)
DNA duplex unwindingATP-dependent RNA helicase DDX1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionATP-dependent RNA helicase DDX1Homo sapiens (human)
response to exogenous dsRNAATP-dependent RNA helicase DDX1Homo sapiens (human)
innate immune responseATP-dependent RNA helicase DDX1Homo sapiens (human)
defense response to virusATP-dependent RNA helicase DDX1Homo sapiens (human)
nucleic acid metabolic processATP-dependent RNA helicase DDX1Homo sapiens (human)
protein localization to cytoplasmic stress granuleATP-dependent RNA helicase DDX1Homo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
DNA damage responseDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
smoothened signaling pathwayDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
positive regulation of glycogen biosynthetic processDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase-like 2Homo sapiens (human)
sex differentiationCyclin-dependent kinase-like 2Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
cell population proliferationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
positive regulation of MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
regulation of cell migrationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
regulation of cell population proliferationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandSerine/threonine-protein kinase Sgk3Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein phosphorylationAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
ubiquinone biosynthetic processAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
cerebellar Purkinje cell layer morphogenesisAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
microtubule cytoskeleton organizationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of cell cycleMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule cytoskeleton organizationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule bundle formationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein phosphorylationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
nervous system developmentMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of programmed cell deathMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cilium organizationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of cilium assemblyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
regulation of centrosome cycleMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cell divisionMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of protein localization to centrosomeMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
intracellular signal transductionMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek1Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek1Homo sapiens (human)
cilium assemblySerine/threonine-protein kinase Nek1Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 15Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 15Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
protein phosphorylationPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
regulation of respiratory gaseous exchangePAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of glycogen biosynthetic processPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of translationPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
protein autophosphorylationPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
regulation of glucagon secretionPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
energy homeostasisPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
MAPK cascadeCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calcium-mediated signalingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
cellular response to reactive oxygen speciesCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
regulation of protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
CAMKK-AMPK signaling cascadeCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of autophagy of mitochondrionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein phosphorylationEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
tRNA processingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
regulation of signal transduction by p53 class mediatorEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
tRNA threonylcarbamoyladenosine metabolic processEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein phosphorylationDual specificity testis-specific protein kinase 2Homo sapiens (human)
spermatogenesisDual specificity testis-specific protein kinase 2Homo sapiens (human)
actin cytoskeleton organizationDual specificity testis-specific protein kinase 2Homo sapiens (human)
focal adhesion assemblyDual specificity testis-specific protein kinase 2Homo sapiens (human)
protein phosphorylationSRSF protein kinase 1Homo sapiens (human)
chromosome segregationSRSF protein kinase 1Homo sapiens (human)
RNA splicingSRSF protein kinase 1Homo sapiens (human)
sperm DNA condensationSRSF protein kinase 1Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 1Homo sapiens (human)
positive regulation of viral genome replicationSRSF protein kinase 1Homo sapiens (human)
negative regulation of viral genome replicationSRSF protein kinase 1Homo sapiens (human)
innate immune responseSRSF protein kinase 1Homo sapiens (human)
regulation of mRNA splicing, via spliceosomeSRSF protein kinase 1Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 1Homo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 1Homo sapiens (human)
protein ubiquitinationProtein cereblonHomo sapiens (human)
positive regulation of Wnt signaling pathwayProtein cereblonHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
positive regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
negative regulation of monoatomic ion transmembrane transportProtein cereblonHomo sapiens (human)
locomotory exploration behaviorProtein cereblonHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProtein cereblonHomo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
G2/M transition of mitotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
mitotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
regulation of mitotic nuclear divisionMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
negative regulation of G2/M transition of mitotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein phosphorylationMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
negative regulation of G2/MI transition of meiotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
meiotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
response to ischemiaMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
response to endoplasmic reticulum stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
neuron intrinsic apoptotic signaling pathway in response to oxidative stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
innate immune responseMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of protein kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of DNA-templated transcriptionMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
neuron apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to hydrogen peroxideMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
endothelial cell apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
apoptotic signaling pathwayMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
programmed necrotic cell deathMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of p38MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to reactive nitrogen speciesMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
glycerophospholipid metabolic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phagocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
signal transductionPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phospholipid biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
fibroblast migrationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cell migrationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
actin cytoskeleton organizationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
keratinocyte differentiationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
focal adhesion assemblyPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cell chemotaxisPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
protein localization to plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
activation of GTPase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
ruffle assemblyPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
blood vessel developmentMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of cell proliferation in bone marrowMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of p38MAPK cascadeMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
negative regulation of cellular senescenceMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
acute inflammatory responseEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
phagocytosisEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
negative regulation of cell population proliferationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
regulation of eIF2 alpha phosphorylation by hemeEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
macrophage differentiationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
negative regulation of translational initiation by ironEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protoporphyrinogen IX metabolic processEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein autophosphorylationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
negative regulation of hemoglobin biosynthetic processEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
establishment of localization in cellEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
multicellular organismal-level iron ion homeostasisEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
integrated stress response signalingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
HRI-mediated signalingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
positive regulation of mitophagyEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
response to iron ion starvationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
regulation of translational initiation by eIF2 alpha phosphorylationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
maturation of SSU-rRNASerine/threonine-protein kinase RIO1Homo sapiens (human)
ribosomal small subunit biogenesisSerine/threonine-protein kinase RIO1Homo sapiens (human)
positive regulation of rRNA processingSerine/threonine-protein kinase RIO1Homo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionSerine/threonine-protein kinase RIO2Homo sapiens (human)
maturation of SSU-rRNASerine/threonine-protein kinase RIO2Homo sapiens (human)
ribosomal small subunit biogenesisSerine/threonine-protein kinase RIO2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase RIO2Homo sapiens (human)
positive regulation of ribosomal small subunit export from nucleusSerine/threonine-protein kinase RIO2Homo sapiens (human)
positive regulation of rRNA processingSerine/threonine-protein kinase RIO2Homo sapiens (human)
positive regulation of apoptotic processCyclin-dependent kinase 19Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 19Homo sapiens (human)
cellular response to lipopolysaccharideCyclin-dependent kinase 19Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 19Homo sapiens (human)
response to toxic substanceTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein tetramerizationTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
metal ion transportTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
monoatomic cation transmembrane transportTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein phosphorylationTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
spermatid developmentTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 33Homo sapiens (human)
mitotic DNA damage checkpoint signalingSerine/threonine-protein kinase 33Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityNucleolar GTP-binding protein 1Homo sapiens (human)
maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)Nucleolar GTP-binding protein 1Homo sapiens (human)
osteoblast differentiationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of DNA replicationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of cell population proliferationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of cell-cell adhesionNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of cell migrationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of protein ubiquitinationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of collagen bindingNucleolar GTP-binding protein 1Homo sapiens (human)
ribosomal large subunit biogenesisNucleolar GTP-binding protein 1Homo sapiens (human)
protein stabilizationNucleolar GTP-binding protein 1Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase D2Homo sapiens (human)
adaptive immune responseSerine/threonine-protein kinase D2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
cell adhesionSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of endothelial cell migrationSerine/threonine-protein kinase D2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of interleukin-2 productionSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of interleukin-8 productionSerine/threonine-protein kinase D2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of fibroblast growth factor receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of cell adhesionSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase D2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
T cell receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of T cell receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySerine/threonine-protein kinase D2Homo sapiens (human)
endothelial tube morphogenesisSerine/threonine-protein kinase D2Homo sapiens (human)
regulation of T cell apoptotic processSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of DNA biosynthetic processSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of endothelial cell chemotaxisSerine/threonine-protein kinase D2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase DCLK3Homo sapiens (human)
protein phosphorylationNUAK family SNF1-like kinase 2Homo sapiens (human)
apoptotic processNUAK family SNF1-like kinase 2Homo sapiens (human)
actin cytoskeleton organizationNUAK family SNF1-like kinase 2Homo sapiens (human)
protein localization to nucleusNUAK family SNF1-like kinase 2Homo sapiens (human)
regulation of hippo signalingNUAK family SNF1-like kinase 2Homo sapiens (human)
cellular response to glucose starvationNUAK family SNF1-like kinase 2Homo sapiens (human)
negative regulation of apoptotic processNUAK family SNF1-like kinase 2Homo sapiens (human)
rRNA modificationRNA cytidine acetyltransferaseHomo sapiens (human)
regulation of translationRNA cytidine acetyltransferaseHomo sapiens (human)
protein acetylationRNA cytidine acetyltransferaseHomo sapiens (human)
regulation of centrosome duplicationRNA cytidine acetyltransferaseHomo sapiens (human)
negative regulation of telomere maintenance via telomeraseRNA cytidine acetyltransferaseHomo sapiens (human)
ribosomal small subunit biogenesisRNA cytidine acetyltransferaseHomo sapiens (human)
positive regulation of translationRNA cytidine acetyltransferaseHomo sapiens (human)
tRNA acetylationRNA cytidine acetyltransferaseHomo sapiens (human)
rRNA acetylation involved in maturation of SSU-rRNARNA cytidine acetyltransferaseHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase SIK2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase SIK2Homo sapiens (human)
regulation of insulin receptor signaling pathwaySerine/threonine-protein kinase SIK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase SIK2Homo sapiens (human)
striated muscle contractionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
neuromuscular synaptic transmissionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
positive regulation of gene expressionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
skeletal muscle satellite cell differentiationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
peptidyl-threonine phosphorylationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
regulation of muscle filament slidingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
skeletal muscle cell differentiationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
protein autophosphorylationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cardiac muscle tissue morphogenesisMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cardiac muscle contractionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
apoptotic processSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of cell migrationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytoplasmic microtubule organizationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of apoptotic processSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein autophosphorylationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of focal adhesion assemblySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein phosphorylationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
DNA repairSerine/threonine-protein kinase TAO3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TAO3Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase TAO3Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase TAO3Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
negative regulation of JNK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase TAO3Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase TAO3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHomeodomain-interacting protein kinase 2Homo sapiens (human)
eye developmentHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
respiratory system processHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
adult walking behaviorHomeodomain-interacting protein kinase 2Homo sapiens (human)
cell population proliferationHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of cell population proliferationHomeodomain-interacting protein kinase 2Homo sapiens (human)
anterior/posterior pattern specificationHomeodomain-interacting protein kinase 2Homo sapiens (human)
gene expressionHomeodomain-interacting protein kinase 2Homo sapiens (human)
retina layer formationHomeodomain-interacting protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
neuron differentiationHomeodomain-interacting protein kinase 2Homo sapiens (human)
erythrocyte differentiationHomeodomain-interacting protein kinase 2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of BMP signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
PML body organizationHomeodomain-interacting protein kinase 2Homo sapiens (human)
thyroid gland developmentHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of protein bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
epigenetic regulation of gene expressionHomeodomain-interacting protein kinase 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of neuron apoptotic processHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of angiogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of JNK cascadeHomeodomain-interacting protein kinase 2Homo sapiens (human)
embryonic camera-type eye morphogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
voluntary musculoskeletal movementHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
neuron apoptotic processHomeodomain-interacting protein kinase 2Homo sapiens (human)
regulation of cell cycleHomeodomain-interacting protein kinase 2Homo sapiens (human)
embryonic retina morphogenesis in camera-type eyeHomeodomain-interacting protein kinase 2Homo sapiens (human)
lens induction in camera-type eyeHomeodomain-interacting protein kinase 2Homo sapiens (human)
SMAD protein signal transductionHomeodomain-interacting protein kinase 2Homo sapiens (human)
lung morphogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
iris morphogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
cellular response to hypoxiaHomeodomain-interacting protein kinase 2Homo sapiens (human)
intrinsic apoptotic signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of ubiquitin-dependent protein catabolic processHomeodomain-interacting protein kinase 2Homo sapiens (human)
smoothened signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein kinase SrmsHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase SrmsHomo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase SrmsHomo sapiens (human)
positive regulation of TORC1 signalingTyrosine-protein kinase SrmsHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase SrmsHomo sapiens (human)
cell differentiationTyrosine-protein kinase SrmsHomo sapiens (human)
innate immune responseTyrosine-protein kinase SrmsHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase SrmsHomo sapiens (human)
protein phosphorylationHomeodomain-interacting protein kinase 3Homo sapiens (human)
apoptotic processHomeodomain-interacting protein kinase 3Homo sapiens (human)
mRNA transcriptionHomeodomain-interacting protein kinase 3Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 3Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 3Homo sapiens (human)
negative regulation of apoptotic processHomeodomain-interacting protein kinase 3Homo sapiens (human)
negative regulation of JUN kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase PLK3Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase PLK3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IISerine/threonine-protein kinase PLK3Homo sapiens (human)
response to reactive oxygen speciesSerine/threonine-protein kinase PLK3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK3Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PLK3Homo sapiens (human)
response to osmotic stressSerine/threonine-protein kinase PLK3Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase PLK3Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine/threonine-protein kinase PLK3Homo sapiens (human)
endomitotic cell cycleSerine/threonine-protein kinase PLK3Homo sapiens (human)
response to radiationSerine/threonine-protein kinase PLK3Homo sapiens (human)
cytoplasmic microtubule organizationSerine/threonine-protein kinase PLK3Homo sapiens (human)
regulation of cytokinesisSerine/threonine-protein kinase PLK3Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PLK3Homo sapiens (human)
mitotic G1/S transition checkpoint signalingSerine/threonine-protein kinase PLK3Homo sapiens (human)
regulation of cell divisionSerine/threonine-protein kinase PLK3Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase PLK3Homo sapiens (human)
Golgi disassemblySerine/threonine-protein kinase PLK3Homo sapiens (human)
positive regulation of intracellular protein transportSerine/threonine-protein kinase PLK3Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase PLK3Homo sapiens (human)
positive regulation of chaperone-mediated autophagySerine/threonine-protein kinase PLK3Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxiaSerine/threonine-protein kinase PLK3Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase PLK3Homo sapiens (human)
dTTP catabolic processdCTP pyrophosphatase 1Homo sapiens (human)
dCTP catabolic processdCTP pyrophosphatase 1Homo sapiens (human)
nucleoside triphosphate catabolic processdCTP pyrophosphatase 1Homo sapiens (human)
DNA protectiondCTP pyrophosphatase 1Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK4Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK4Homo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cell surface receptor signaling pathwayMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
hemopoiesisMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to arsenic-containing substanceMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek6Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase Nek6Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase Nek6Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase Nek6Homo sapiens (human)
mitotic nuclear membrane disassemblySerine/threonine-protein kinase Nek6Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase Nek6Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase Nek6Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionSerine/threonine-protein kinase Nek6Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase Nek6Homo sapiens (human)
spindle assemblySerine/threonine-protein kinase Nek6Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek6Homo sapiens (human)
regulation of cellular senescenceSerine/threonine-protein kinase Nek6Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-1Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-1Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-1Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-1Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-1Homo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase PAK 6Homo sapiens (human)
learningSerine/threonine-protein kinase PAK 6Homo sapiens (human)
memorySerine/threonine-protein kinase PAK 6Homo sapiens (human)
locomotory behaviorSerine/threonine-protein kinase PAK 6Homo sapiens (human)
neuron projection arborizationSerine/threonine-protein kinase PAK 6Homo sapiens (human)
neuron projection extensionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 6Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein phosphorylationSNF-related serine/threonine-protein kinaseHomo sapiens (human)
myeloid cell differentiationSNF-related serine/threonine-protein kinaseHomo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase LATS2Homo sapiens (human)
inner cell mass cell fate commitmentSerine/threonine-protein kinase LATS2Homo sapiens (human)
inner cell mass cellular morphogenesisSerine/threonine-protein kinase LATS2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase LATS2Homo sapiens (human)
protein localizationSerine/threonine-protein kinase LATS2Homo sapiens (human)
hormone-mediated signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
keratinocyte differentiationSerine/threonine-protein kinase LATS2Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase LATS2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase LATS2Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activitySerine/threonine-protein kinase LATS2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase LATS2Homo sapiens (human)
canonical Wnt signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase LATS2Homo sapiens (human)
regulation of organ growthSerine/threonine-protein kinase LATS2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase LATS2Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase LATS2Homo sapiens (human)
epithelial cilium movement involved in extracellular fluid movementSerine/threonine-protein kinase 36Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 36Homo sapiens (human)
smoothened signaling pathwaySerine/threonine-protein kinase 36Homo sapiens (human)
brain developmentSerine/threonine-protein kinase 36Homo sapiens (human)
post-embryonic developmentSerine/threonine-protein kinase 36Homo sapiens (human)
axoneme assemblySerine/threonine-protein kinase 36Homo sapiens (human)
positive regulation of smoothened signaling pathwaySerine/threonine-protein kinase 36Homo sapiens (human)
regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase 36Homo sapiens (human)
cilium assemblySerine/threonine-protein kinase 36Homo sapiens (human)
translationPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
phenylalanyl-tRNA aminoacylationPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
protein heterotetramerizationPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
tRNA aminoacylation for protein translationIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
aminoacyl-tRNA metabolism involved in translational fidelityIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
isoleucyl-tRNA aminoacylationIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
mitochondrial translationIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
positive regulation of Notch signaling pathwayBMP-2-inducible protein kinaseHomo sapiens (human)
regulation of clathrin-dependent endocytosisBMP-2-inducible protein kinaseHomo sapiens (human)
regulation of bone mineralizationBMP-2-inducible protein kinaseHomo sapiens (human)
ATP metabolic processObg-like ATPase 1Homo sapiens (human)
ribosomal large subunit assemblyMidasinHomo sapiens (human)
ribosomal large subunit export from nucleusMidasinHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
neutrophil mediated immunityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
JNK cascadeInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
toll-like receptor 4 signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
toll-like receptor 9 signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
interleukin-33-mediated signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
innate immune responseInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
positive regulation of smooth muscle cell proliferationInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
interleukin-1-mediated signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
neutrophil migrationInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
Toll signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
intracellular signal transductionInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 32BHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 32BHomo sapiens (human)
positive regulation of programmed cell deathMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
GCN2-mediated signalingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
pyroptosisMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
inflammatory responseMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytoskeleton organizationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cell deathMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cell differentiationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
embryonic digit morphogenesisMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
limb developmentMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cellular response to gamma radiationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
positive regulation of mitotic DNA damage checkpointMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
chromosome segregationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
transcription by RNA polymerase IICyclin-dependent kinase 12Homo sapiens (human)
mRNA processingCyclin-dependent kinase 12Homo sapiens (human)
RNA splicingCyclin-dependent kinase 12Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-dependent kinase 12Homo sapiens (human)
regulation of MAP kinase activityCyclin-dependent kinase 12Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 12Homo sapiens (human)
protein autophosphorylationCyclin-dependent kinase 12Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 12Homo sapiens (human)
negative regulation of stem cell differentiationCyclin-dependent kinase 12Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 12Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusSerine/threonine-protein kinase PLK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine/threonine-protein kinase PLK2Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase PLK2Homo sapiens (human)
Ras protein signal transductionSerine/threonine-protein kinase PLK2Homo sapiens (human)
memorySerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of angiogenesisSerine/threonine-protein kinase PLK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase PLK2Homo sapiens (human)
Rap protein signal transductionSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of protein catabolic processSerine/threonine-protein kinase PLK2Homo sapiens (human)
regulation of centriole replicationSerine/threonine-protein kinase PLK2Homo sapiens (human)
regulation of synaptic plasticitySerine/threonine-protein kinase PLK2Homo sapiens (human)
long-term synaptic potentiationSerine/threonine-protein kinase PLK2Homo sapiens (human)
long-term synaptic depressionSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of apoptotic process in bone marrow cellSerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of cellular senescenceSerine/threonine-protein kinase PLK2Homo sapiens (human)
aerobic respirationNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
negative regulation of cell growthNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial respiratory chain complex I assemblyNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cellular response to interferon-betaNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
proton motive force-driven mitochondrial ATP synthesisNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
protein insertion into mitochondrial inner membraneNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
positive regulation of protein catabolic processNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
negative regulation of DNA-templated transcriptionNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cellular response to retinoic acidNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
reactive oxygen species metabolic processNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
apoptotic signaling pathwayNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
extrinsic apoptotic signaling pathwayNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
positive regulation of execution phase of apoptosisNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase MARK1Homo sapiens (human)
negative regulation of gene expressionSerine/threonine-protein kinase MARK1Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK1Homo sapiens (human)
neuron migrationSerine/threonine-protein kinase MARK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase MARK1Homo sapiens (human)
negative regulation of epithelial to mesenchymal transitionSerine/threonine-protein kinase MARK1Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase MARK1Homo sapiens (human)
Wnt signaling pathwaySerine/threonine-protein kinase MARK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase MARK1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase MARK1Homo sapiens (human)
regulation of dendrite developmentSerine/threonine-protein kinase MARK1Homo sapiens (human)
establishment of mitochondrion localizationSerine/threonine-protein kinase MARK1Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-2Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase pim-2Homo sapiens (human)
apoptotic mitochondrial changesSerine/threonine-protein kinase pim-2Homo sapiens (human)
response to virusSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
macroautophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of macroautophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-2Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase pim-2Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase PAK 5Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
signal transductionSerine/threonine-protein kinase PAK 5Homo sapiens (human)
learningSerine/threonine-protein kinase PAK 5Homo sapiens (human)
memorySerine/threonine-protein kinase PAK 5Homo sapiens (human)
locomotory behaviorSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cell population proliferationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cell migrationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwaySerine/threonine-protein kinase PAK 5Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 5Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 26Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase 26Homo sapiens (human)
cellular response to starvationSerine/threonine-protein kinase 26Homo sapiens (human)
microvillus assemblySerine/threonine-protein kinase 26Homo sapiens (human)
negative regulation of cell migrationSerine/threonine-protein kinase 26Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase 26Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 26Homo sapiens (human)
regulation of apoptotic processSerine/threonine-protein kinase 26Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 26Homo sapiens (human)
DNA damage checkpoint signalingeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of defense response to virus by hosteIF-2-alpha kinase GCN2Homo sapiens (human)
adaptive immune responseeIF-2-alpha kinase GCN2Homo sapiens (human)
T cell activation involved in immune responseeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of adaptive immune responseeIF-2-alpha kinase GCN2Homo sapiens (human)
regulation of translational initiationeIF-2-alpha kinase GCN2Homo sapiens (human)
protein phosphorylationeIF-2-alpha kinase GCN2Homo sapiens (human)
learningeIF-2-alpha kinase GCN2Homo sapiens (human)
long-term memoryeIF-2-alpha kinase GCN2Homo sapiens (human)
regulation of translational initiation by eIF2 alpha phosphorylationeIF-2-alpha kinase GCN2Homo sapiens (human)
viral translationeIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of translational initiation in response to stresseIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of CREB transcription factor activityeIF-2-alpha kinase GCN2Homo sapiens (human)
cellular response to amino acid starvationeIF-2-alpha kinase GCN2Homo sapiens (human)
cellular response to UVeIF-2-alpha kinase GCN2Homo sapiens (human)
eiF2alpha phosphorylation in response to endoplasmic reticulum stresseIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation by host of viral genome replicationeIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of neuron differentiationeIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of translational initiationeIF-2-alpha kinase GCN2Homo sapiens (human)
protein autophosphorylationeIF-2-alpha kinase GCN2Homo sapiens (human)
defense response to viruseIF-2-alpha kinase GCN2Homo sapiens (human)
regulation of feeding behavioreIF-2-alpha kinase GCN2Homo sapiens (human)
cellular response to coldeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of translational initiation in response to starvationeIF-2-alpha kinase GCN2Homo sapiens (human)
GCN2-mediated signalingeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of long-term synaptic potentiationeIF-2-alpha kinase GCN2Homo sapiens (human)
neuron projection extensioneIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of cytoplasmic translational initiation in response to stresseIF-2-alpha kinase GCN2Homo sapiens (human)
tricarboxylic acid cycleSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinate metabolic processSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinyl-CoA pathwaySuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinyl-CoA catabolic processSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinyl-CoA metabolic processSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase NLKHomo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase NLKHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase NLKHomo sapiens (human)
transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase NLKHomo sapiens (human)
Wnt signaling pathway, calcium modulating pathwaySerine/threonine-protein kinase NLKHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase NLKHomo sapiens (human)
negative regulation of Wnt signaling pathwaySerine/threonine-protein kinase NLKHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase NLKHomo sapiens (human)
protein stabilizationSerine/threonine-protein kinase NLKHomo sapiens (human)
cellular response to osmotic stressSerine/threonine-protein kinase NLKHomo sapiens (human)
negative regulation of TORC1 signalingSerine/threonine-protein kinase NLKHomo sapiens (human)
positive regulation of receptor signaling pathway via STATSerine/threonine-protein kinase NLKHomo sapiens (human)
lysosome organizationPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase betaHomo sapiens (human)
receptor-mediated endocytosisPhosphatidylinositol 4-kinase betaHomo sapiens (human)
signal transductionPhosphatidylinositol 4-kinase betaHomo sapiens (human)
inner ear developmentPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 17AHomo sapiens (human)
apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 17AHomo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
positive regulation of fibroblast apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
regulation of reactive oxygen species metabolic processSerine/threonine-protein kinase 17AHomo sapiens (human)
response to dietary excessSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein phosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cell volume homeostasisSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
inflammatory responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
signal transductionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
regulation of blood pressureSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of T cell chemotaxisSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
peptidyl-threonine phosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
intracellular chloride ion homeostasisSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of ion transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
intracellular signal transductionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
sodium ion transmembrane transportSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular response to potassium ionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
maintenance of lens transparencySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
chemokine (C-X-C motif) ligand 12 signaling pathwaySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
macrophage activationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of potassium ion transportSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein autophosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
regulation of inflammatory responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
renal sodium ion absorptionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular hyperosmotic responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular hypotonic responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of pancreatic juice secretionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of p38MAPK cascadeSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of potassium ion transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of potassium ion transmembrane transportSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
response to aldosteroneSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of creatine transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular response to chemokineSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
biological_processEphrin type-A receptor 6Homo sapiens (human)
axon guidanceEphrin type-A receptor 6Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 6Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 6Homo sapiens (human)
glycogen metabolic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of glycolytic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
negative regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ATP biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
sterol biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of fatty acid metabolic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
intracellular signal transduction5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
positive regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of fatty acid oxidation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of glucose import5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of catalytic activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
activation of innate immune responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
inflammatory responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
canonical NF-kappaB signal transductionSerine/threonine-protein kinase TBK1Homo sapiens (human)
response to virusSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
negative regulation of gene expressionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of macroautophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
regulation of type I interferon productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of type I interferon productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of interferon-alpha productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of interferon-beta productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
toll-like receptor 4 signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase TBK1Homo sapiens (human)
dendritic cell proliferationSerine/threonine-protein kinase TBK1Homo sapiens (human)
innate immune responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase TBK1Homo sapiens (human)
defense response to Gram-positive bacteriumSerine/threonine-protein kinase TBK1Homo sapiens (human)
defense response to virusSerine/threonine-protein kinase TBK1Homo sapiens (human)
type I interferon-mediated signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of type I interferon-mediated signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
antiviral innate immune responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
cGAS/STING signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
negative regulation of TORC1 signalingSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of xenophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
macroautophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of non-motile cilium assemblySeptin-9Homo sapiens (human)
protein localizationSeptin-9Homo sapiens (human)
cytoskeleton-dependent cytokinesisSeptin-9Homo sapiens (human)
protein phosphorylationDeath-associated protein kinase 2Homo sapiens (human)
apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 2Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 2Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
anoikisDeath-associated protein kinase 2Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of neutrophil chemotaxisDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of eosinophil chemotaxisDeath-associated protein kinase 2Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathwayDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorRibosomal protein S6 kinase alpha-6Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-6Homo sapiens (human)
central nervous system developmentRibosomal protein S6 kinase alpha-6Homo sapiens (human)
negative regulation of embryonic developmentRibosomal protein S6 kinase alpha-6Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeRibosomal protein S6 kinase alpha-6Homo sapiens (human)
negative regulation of mesoderm developmentRibosomal protein S6 kinase alpha-6Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-6Homo sapiens (human)
positive regulation of protein phosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein phosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoskeleton organizationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
response to organonitrogen compoundTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
Wnt signaling pathwayTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
microvillus assemblyTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
actin cytoskeleton organizationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
intracellular signal transductionTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
positive regulation of JNK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein autophosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
regulation of dendrite morphogenesisTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein localization to plasma membraneTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
neuron projection morphogenesisTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
regulation of MAPK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
MAPK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
chromatin organizationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
intracellular protein transportSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
regulation of chromatin organizationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein targeting to membraneSerine/threonine-protein kinase TAO2Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase TAO2Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase TAO2Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase TAO2Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase TAO2Homo sapiens (human)
regulation of cell shapeSerine/threonine-protein kinase TAO2Homo sapiens (human)
cell migrationSerine/threonine-protein kinase TAO2Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of protein autophosphorylationSerine/threonine-protein kinase TAO2Homo sapiens (human)
activation of protein kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of MAPK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase TAO2Homo sapiens (human)
focal adhesion assemblySerine/threonine-protein kinase TAO2Homo sapiens (human)
stress-activated MAPK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
basal dendrite morphogenesisSerine/threonine-protein kinase TAO2Homo sapiens (human)
basal dendrite arborizationSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TAO2Homo sapiens (human)
long-chain fatty acid metabolic processLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
long-chain fatty-acyl-CoA biosynthetic processLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
positive regulation of long-chain fatty acid import across plasma membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
protein autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
signal transductionALK tyrosine kinase receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayALK tyrosine kinase receptorHomo sapiens (human)
phosphorylationALK tyrosine kinase receptorHomo sapiens (human)
hippocampus developmentALK tyrosine kinase receptorHomo sapiens (human)
adult behaviorALK tyrosine kinase receptorHomo sapiens (human)
swimming behaviorALK tyrosine kinase receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
regulation of apoptotic processALK tyrosine kinase receptorHomo sapiens (human)
protein autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
neuron developmentALK tyrosine kinase receptorHomo sapiens (human)
negative regulation of lipid catabolic processALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityALK tyrosine kinase receptorHomo sapiens (human)
regulation of dopamine receptor signaling pathwayALK tyrosine kinase receptorHomo sapiens (human)
response to environmental enrichmentALK tyrosine kinase receptorHomo sapiens (human)
energy homeostasisALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of dendrite developmentALK tyrosine kinase receptorHomo sapiens (human)
regulation of neuron differentiationALK tyrosine kinase receptorHomo sapiens (human)
regulation of cell population proliferationALK tyrosine kinase receptorHomo sapiens (human)
multicellular organism developmentALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of kinase activityALK tyrosine kinase receptorHomo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
skeletal muscle tissue developmentSRSF protein kinase 3Homo sapiens (human)
cell differentiationSRSF protein kinase 3Homo sapiens (human)
muscle tissue developmentSRSF protein kinase 3Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 3Homo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 3Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 3Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase ICKHomo sapiens (human)
signal transductionSerine/threonine-protein kinase ICKHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase ICKHomo sapiens (human)
intraciliary anterograde transportSerine/threonine-protein kinase ICKHomo sapiens (human)
intraciliary retrograde transportSerine/threonine-protein kinase ICKHomo sapiens (human)
intraciliary transportSerine/threonine-protein kinase ICKHomo sapiens (human)
cilium assemblySerine/threonine-protein kinase ICKHomo sapiens (human)
mitotic cell cycleCyclin-dependent kinase 11AHomo sapiens (human)
regulation of cell growthCyclin-dependent kinase 11AHomo sapiens (human)
regulation of DNA-templated transcriptionCyclin-dependent kinase 11AHomo sapiens (human)
protein phosphorylationCyclin-dependent kinase 11AHomo sapiens (human)
apoptotic processCyclin-dependent kinase 11AHomo sapiens (human)
regulation of mRNA processingCyclin-dependent kinase 11AHomo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 11AHomo sapiens (human)
protein phosphorylationAurora kinase CHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase CHomo sapiens (human)
positive regulation of cytokinesisAurora kinase CHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase CHomo sapiens (human)
cell divisionAurora kinase CHomo sapiens (human)
meiotic cell cycleAurora kinase CHomo sapiens (human)
regulation of cytokinesisAurora kinase CHomo sapiens (human)
mitotic spindle organizationAurora kinase CHomo sapiens (human)
G1/S transition of mitotic cell cycleCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
response to ischemiaCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cellular response to interferon-betaCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
angiotensin-activated signaling pathwayCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of neurotransmitter secretionCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of neuronal synaptic plasticityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
negative regulation of hydrolase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
dendritic spine developmentCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cellular response to type II interferonCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
peptidyl-threonine autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of endocannabinoid signaling pathwayCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of neuron migrationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
mitochondrial genome maintenanceRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endothelial cell proliferationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of TOR signalingRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of angiogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell sizeRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
brain morphogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
homeostasis of number of cells within a tissueRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of vascular endothelial cell proliferationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of artery morphogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cellular senescenceRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
negative regulation of autophagySerine/threonine-protein kinase 38-likeHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 38-likeHomo sapiens (human)
regulation of cellular component organizationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
postsynapse organizationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein phosphorylationMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
cytoskeleton organizationMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
brain developmentMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase SIK3Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase SIK3Homo sapiens (human)
positive regulation of TORC2 signalingSerine/threonine-protein kinase SIK3Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase SIK3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase SIK3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIThyroid hormone receptor-associated protein 3Homo sapiens (human)
regulation of alternative mRNA splicing, via spliceosomeThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear-transcribed mRNA catabolic processThyroid hormone receptor-associated protein 3Homo sapiens (human)
mRNA processingThyroid hormone receptor-associated protein 3Homo sapiens (human)
circadian rhythmThyroid hormone receptor-associated protein 3Homo sapiens (human)
RNA splicingThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of circadian rhythmThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of mRNA splicing, via spliceosomeThyroid hormone receptor-associated protein 3Homo sapiens (human)
mRNA stabilizationThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIThyroid hormone receptor-associated protein 3Homo sapiens (human)
DNA repairDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
myoblast fusionDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
adipose tissue developmentDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
regulation of T cell mediated cytotoxicityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of adaptive immune responseReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of phosphatase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
activation of protein kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of type II interferon productionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
T cell differentiation in thymusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein modification processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
non-canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
T cell homeostasisReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of activated T cell proliferationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein autophosphorylationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
lymph node developmentReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
spleen developmentReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
thymus developmentReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
defense response to virusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of necroptotic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of activation-induced cell death of T cellsReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
necroptotic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cellular response to hydrogen peroxideReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
reactive oxygen species metabolic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
programmed necrotic cell deathReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
necroptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
execution phase of necroptosisReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
amyloid fibril formationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of CD8-positive, alpha-beta cytotoxic T cell extravasationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
signal transductionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
establishment or maintenance of cell polaritySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
signal transductionSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cell migrationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actomyosin structure organizationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
positive regulation of cytokine productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein phosphorylationInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to virusInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
positive regulation of macrophage tolerance inductionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of macrophage cytokine productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to peptidoglycanInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to lipopolysaccharideInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of interleukin-12 productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of interleukin-6 productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of tumor necrosis factor productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of protein catabolic processInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of protein-containing complex disassemblyInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
regulation of protein-containing complex disassemblyInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to exogenous dsRNAInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of MAP kinase activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of innate immune responseInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
interleukin-1-mediated signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to interleukin-1Interleukin-1 receptor-associated kinase 3Homo sapiens (human)
Toll signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
intracellular signal transductionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 24Homo sapiens (human)
signal transductionSerine/threonine-protein kinase 24Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressSerine/threonine-protein kinase 24Homo sapiens (human)
cellular response to starvationSerine/threonine-protein kinase 24Homo sapiens (human)
negative regulation of cell migrationSerine/threonine-protein kinase 24Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase 24Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 24Homo sapiens (human)
regulation of axon regenerationSerine/threonine-protein kinase 24Homo sapiens (human)
positive regulation of axon regenerationSerine/threonine-protein kinase 24Homo sapiens (human)
execution phase of apoptosisSerine/threonine-protein kinase 24Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNF-kappa-B essential modulatorHomo sapiens (human)
apoptotic processNF-kappa-B essential modulatorHomo sapiens (human)
inflammatory responseNF-kappa-B essential modulatorHomo sapiens (human)
immune responseNF-kappa-B essential modulatorHomo sapiens (human)
DNA damage responseNF-kappa-B essential modulatorHomo sapiens (human)
canonical NF-kappaB signal transductionNF-kappa-B essential modulatorHomo sapiens (human)
response to virusNF-kappa-B essential modulatorHomo sapiens (human)
positive regulation of macroautophagyNF-kappa-B essential modulatorHomo sapiens (human)
defense response to bacteriumNF-kappa-B essential modulatorHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNF-kappa-B essential modulatorHomo sapiens (human)
anoikisNF-kappa-B essential modulatorHomo sapiens (human)
innate immune responseNF-kappa-B essential modulatorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINF-kappa-B essential modulatorHomo sapiens (human)
T cell receptor signaling pathwayNF-kappa-B essential modulatorHomo sapiens (human)
positive regulation of T cell receptor signaling pathwayNF-kappa-B essential modulatorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityNF-kappa-B essential modulatorHomo sapiens (human)
establishment of vesicle localizationNF-kappa-B essential modulatorHomo sapiens (human)
protein-containing complex assemblyNF-kappa-B essential modulatorHomo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processNF-kappa-B essential modulatorHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-3Homo sapiens (human)
protein modification processCasein kinase I isoform gamma-3Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-3Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-3Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-3Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
placenta developmentMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
response to UV-CMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
regulation of gene expressionMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
male germ-line sex determinationMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
chorionic trophoblast cell differentiationMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of p38MAPK cascadeMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (676)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
transmembrane signaling receptor activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
protein bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
ATP bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
BMP bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
SMAD bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
metal ion bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
BMP receptor activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
transforming growth factor beta receptor activity, type IBone morphogenetic protein receptor type-1BHomo sapiens (human)
amyloid-beta bindingMembrane-associated progesterone receptor component 1Homo sapiens (human)
steroid bindingMembrane-associated progesterone receptor component 1Homo sapiens (human)
protein bindingMembrane-associated progesterone receptor component 1Homo sapiens (human)
heme bindingMembrane-associated progesterone receptor component 1Homo sapiens (human)
protein homodimerization activityMembrane-associated progesterone receptor component 1Homo sapiens (human)
metal ion bindingMembrane-associated progesterone receptor component 1Homo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK4Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 25Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 25Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 25Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 25Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 25Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 25Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 25Homo sapiens (human)
DNA bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
DNA helicase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA helicase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
mRNA bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
GTPase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
ATP bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
transcription factor bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
poly(A) bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
eukaryotic initiation factor 4E bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
ATP hydrolysis activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
ribonucleoside triphosphate phosphatase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
translation initiation factor bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA strand annealing activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
signaling adaptor activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA stem-loop bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
gamma-tubulin bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
ribosomal small subunit bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
CTPase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein serine/threonine kinase activator activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
cadherin bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
mRNA 5'-UTR bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
magnesium ion bindingPyridoxal kinaseHomo sapiens (human)
ATP bindingPyridoxal kinaseHomo sapiens (human)
zinc ion bindingPyridoxal kinaseHomo sapiens (human)
pyridoxal kinase activityPyridoxal kinaseHomo sapiens (human)
pyridoxal phosphate bindingPyridoxal kinaseHomo sapiens (human)
potassium ion bindingPyridoxal kinaseHomo sapiens (human)
sodium ion bindingPyridoxal kinaseHomo sapiens (human)
lithium ion bindingPyridoxal kinaseHomo sapiens (human)
protein homodimerization activityPyridoxal kinaseHomo sapiens (human)
transcription coactivator bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein serine/threonine kinase activityCitron Rho-interacting kinaseHomo sapiens (human)
protein bindingCitron Rho-interacting kinaseHomo sapiens (human)
ATP bindingCitron Rho-interacting kinaseHomo sapiens (human)
SH3 domain bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein kinase bindingCitron Rho-interacting kinaseHomo sapiens (human)
PDZ domain bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein serine/threonine kinase inhibitor activityCitron Rho-interacting kinaseHomo sapiens (human)
metal ion bindingCitron Rho-interacting kinaseHomo sapiens (human)
scaffold protein bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein serine kinase activityCitron Rho-interacting kinaseHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase RIO3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
caspase bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase RIO3Homo sapiens (human)
magnesium ion bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
MAP kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
JUN kinase kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
enzyme bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein phosphatase bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
molecular function activator activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Chk1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Chk1Homo sapiens (human)
protein domain specific bindingSerine/threonine-protein kinase Chk1Homo sapiens (human)
histone H3T11 kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein kinase bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
identical protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
guanylate kinase activityPeripheral plasma membrane protein CASKHomo sapiens (human)
protein serine/threonine kinase activityPeripheral plasma membrane protein CASKHomo sapiens (human)
protein bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
calmodulin bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
ATP bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
neurexin family protein bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
protein serine kinase activityPeripheral plasma membrane protein CASKHomo sapiens (human)
signaling receptor bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
protein kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase AHomo sapiens (human)
protein bindingAurora kinase AHomo sapiens (human)
ATP bindingAurora kinase AHomo sapiens (human)
protein kinase bindingAurora kinase AHomo sapiens (human)
ubiquitin protein ligase bindingAurora kinase AHomo sapiens (human)
histone H3S10 kinase activityAurora kinase AHomo sapiens (human)
protein heterodimerization activityAurora kinase AHomo sapiens (human)
protein serine kinase activityAurora kinase AHomo sapiens (human)
molecular function activator activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityCyclin-G-associated kinaseHomo sapiens (human)
protein bindingCyclin-G-associated kinaseHomo sapiens (human)
ATP bindingCyclin-G-associated kinaseHomo sapiens (human)
cyclin bindingCyclin-G-associated kinaseHomo sapiens (human)
protein-folding chaperone bindingCyclin-G-associated kinaseHomo sapiens (human)
protein serine kinase activityCyclin-G-associated kinaseHomo sapiens (human)
clathrin bindingCyclin-G-associated kinaseHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase DCLK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein-containing complex bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein tyrosine kinase activityMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
protein bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
ATP bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
metal ion bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
Wnt-protein bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
ephrin receptor activityEphrin type-B receptor 6Homo sapiens (human)
protein bindingEphrin type-B receptor 6Homo sapiens (human)
ATP bindingEphrin type-B receptor 6Homo sapiens (human)
signaling receptor activityEphrin type-B receptor 6Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 6Homo sapiens (human)
FAD bindingPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
flavin adenine dinucleotide bindingPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
pristanoyl-CoA oxidase activityPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
fatty acid bindingPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
protein bindingMitogen-activated protein kinase 13Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 13Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein serine/threonine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
3-phosphoinositide-dependent protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
ATP binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase activator activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein serine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein serine/threonine kinase activator activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
IkappaB kinase complex bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 3Homo sapiens (human)
protein bindingDeath-associated protein kinase 3Homo sapiens (human)
ATP bindingDeath-associated protein kinase 3Homo sapiens (human)
cAMP response element binding protein bindingDeath-associated protein kinase 3Homo sapiens (human)
small GTPase bindingDeath-associated protein kinase 3Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 3Homo sapiens (human)
protein homodimerization activityDeath-associated protein kinase 3Homo sapiens (human)
leucine zipper domain bindingDeath-associated protein kinase 3Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 3Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
transcription coactivator bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
type II transforming growth factor beta receptor bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
receptor tyrosine kinase bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
ubiquitin protein ligase bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
histone kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
scaffold protein bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine/threonine kinase bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
DNA-binding transcription factor bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
linear polyubiquitin bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
signaling receptor bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
LIM domain bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
signaling adaptor activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
identical protein bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein homodimerization activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
CARD domain bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
caspase bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
JUN kinase kinase kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein serine/threonine kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein bindingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
ATP bindingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein serine kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
histone H2A kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
p53 bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
protein serine/threonine kinase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
protein bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
ATP bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
metal ion bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
protein serine kinase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
magnesium ion bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTPase activityDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
protein bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTP bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
phosphatidic acid bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTPase-dependent fusogenic activityDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membrane bending activityDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cardiolipin bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
microtubule bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
protein bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
phosphatidylinositol kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
protein kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
signaling receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-12 receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK2Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK2Homo sapiens (human)
protein kinase bindingTyrosine-protein kinase JAK2Homo sapiens (human)
heme bindingTyrosine-protein kinase JAK2Homo sapiens (human)
type 1 angiotensin receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
acetylcholine receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
histone H3Y41 kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
SH2 domain bindingTyrosine-protein kinase JAK2Homo sapiens (human)
histone bindingTyrosine-protein kinase JAK2Homo sapiens (human)
identical protein bindingTyrosine-protein kinase JAK2Homo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase JAK2Homo sapiens (human)
insulin receptor substrate bindingTyrosine-protein kinase JAK2Homo sapiens (human)
metal ion bindingTyrosine-protein kinase JAK2Homo sapiens (human)
peptide hormone receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
tRNA bindingEukaryotic translation initiation factor 5BHomo sapiens (human)
RNA bindingEukaryotic translation initiation factor 5BHomo sapiens (human)
translation initiation factor activityEukaryotic translation initiation factor 5BHomo sapiens (human)
GTPase activityEukaryotic translation initiation factor 5BHomo sapiens (human)
protein bindingEukaryotic translation initiation factor 5BHomo sapiens (human)
GTP bindingEukaryotic translation initiation factor 5BHomo sapiens (human)
metal ion bindingEukaryotic translation initiation factor 5BHomo sapiens (human)
protease bindingRho-associated protein kinase 2Homo sapiens (human)
RNA bindingRho-associated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityRho-associated protein kinase 2Homo sapiens (human)
structural molecule activityRho-associated protein kinase 2Homo sapiens (human)
protein bindingRho-associated protein kinase 2Homo sapiens (human)
ATP bindingRho-associated protein kinase 2Homo sapiens (human)
small GTPase bindingRho-associated protein kinase 2Homo sapiens (human)
metal ion bindingRho-associated protein kinase 2Homo sapiens (human)
tau protein bindingRho-associated protein kinase 2Homo sapiens (human)
tau-protein kinase activityRho-associated protein kinase 2Homo sapiens (human)
endopeptidase activator activityRho-associated protein kinase 2Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activityRho-associated protein kinase 2Homo sapiens (human)
protein serine kinase activityRho-associated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
GTPase bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
RNA endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
platelet-derived growth factor receptor bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
enzyme bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Hsp70 protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
ADP bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Hsp90 protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
unfolded protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein tyrosine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H3S10 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H3S28 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H2AS1 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
RNA bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
RNA helicase activityU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
helicase activityU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
protein bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
ATP bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
ATP hydrolysis activityU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
identical protein bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
histone H3S10 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
histone H3S28 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingSerine/threonine-protein kinase 16Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 16Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 16Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
MAP kinase kinase activitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
SH3 domain bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
protein bindingCyclin-dependent kinase-like 5Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 5Homo sapiens (human)
kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
small GTPase bindingCyclin-dependent kinase-like 5Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 10Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 10Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 10Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 10Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 10Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 10Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D3Homo sapiens (human)
kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 14Homo sapiens (human)
protein bindingCyclin-dependent kinase 14Homo sapiens (human)
ATP bindingCyclin-dependent kinase 14Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 14Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 14Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
single-stranded DNA bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
protein bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
ATP bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
ATP hydrolysis activityStructural maintenance of chromosomes protein 2Homo sapiens (human)
chromatin bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase OSR1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase OSR1Homo sapiens (human)
creatine kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
microtubule bindingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase LATS1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
nuclear estrogen receptor bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase LATS1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cadherin binding involved in cell-cell adhesionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Chk2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
ubiquitin protein ligase bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase Chk2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Chk2Homo sapiens (human)
supercoiled DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
magnesium ion bindingTyrosine-protein kinase ABL1Homo sapiens (human)
four-way junction DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
bubble DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ABL1Homo sapiens (human)
DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
transcription coactivator activityTyrosine-protein kinase ABL1Homo sapiens (human)
actin monomer bindingTyrosine-protein kinase ABL1Homo sapiens (human)
nicotinate-nucleotide adenylyltransferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein kinase C bindingTyrosine-protein kinase ABL1Homo sapiens (human)
protein bindingTyrosine-protein kinase ABL1Homo sapiens (human)
ATP bindingTyrosine-protein kinase ABL1Homo sapiens (human)
kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
SH3 domain bindingTyrosine-protein kinase ABL1Homo sapiens (human)
syntaxin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
manganese ion bindingTyrosine-protein kinase ABL1Homo sapiens (human)
neuropilin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
SH2 domain bindingTyrosine-protein kinase ABL1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase ABL1Homo sapiens (human)
actin filament bindingTyrosine-protein kinase ABL1Homo sapiens (human)
mitogen-activated protein kinase bindingTyrosine-protein kinase ABL1Homo sapiens (human)
proline-rich region bindingTyrosine-protein kinase ABL1Homo sapiens (human)
delta-catenin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
sequence-specific double-stranded DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
ATP bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein phosphatase bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
heme bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
connexin bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
signaling receptor bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
small GTPase bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
enzyme bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
identical protein bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
metal ion bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
MAP kinase kinase kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
RNA polymerase I core bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signaling receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
coreceptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor tyrosine kinase bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
GPI-linked ephrin receptor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin p75 receptor bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
protein bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
ATP bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
nerve growth factor receptor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
kinase bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
identical protein bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
protein homodimerization activityHigh affinity nerve growth factor receptorHomo sapiens (human)
nerve growth factor bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin receptor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
GTP bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
metal ion bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled receptor bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
GTPase activityGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
adenine nucleotide transmembrane transporter activityADP/ATP translocase 2Homo sapiens (human)
RNA bindingADP/ATP translocase 2Homo sapiens (human)
ATP:ADP antiporter activityADP/ATP translocase 2Homo sapiens (human)
protein bindingADP/ATP translocase 2Homo sapiens (human)
proton transmembrane transporter activityADP/ATP translocase 2Homo sapiens (human)
adenine transmembrane transporter activityADP/ATP translocase 2Homo sapiens (human)
oxidative phosphorylation uncoupler activityADP/ATP translocase 2Homo sapiens (human)
ubiquitin protein ligase bindingADP/ATP translocase 2Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
protein tyrosine kinase activityNeuronal proto-oncogene tyrosine-protein kinase Src Mus musculus (house mouse)
chromatin bindingProtein kinase C beta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C beta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C beta typeHomo sapiens (human)
protein kinase C bindingProtein kinase C beta typeHomo sapiens (human)
calcium channel regulator activityProtein kinase C beta typeHomo sapiens (human)
protein bindingProtein kinase C beta typeHomo sapiens (human)
ATP bindingProtein kinase C beta typeHomo sapiens (human)
zinc ion bindingProtein kinase C beta typeHomo sapiens (human)
nuclear receptor coactivator activityProtein kinase C beta typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C beta typeHomo sapiens (human)
histone bindingProtein kinase C beta typeHomo sapiens (human)
nuclear androgen receptor bindingProtein kinase C beta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C beta typeHomo sapiens (human)
amyloid-beta bindingInsulin receptorHomo sapiens (human)
protein tyrosine kinase activityInsulin receptorHomo sapiens (human)
insulin receptor activityInsulin receptorHomo sapiens (human)
insulin-like growth factor receptor bindingInsulin receptorHomo sapiens (human)
protein bindingInsulin receptorHomo sapiens (human)
ATP bindingInsulin receptorHomo sapiens (human)
GTP bindingInsulin receptorHomo sapiens (human)
protein domain specific bindingInsulin receptorHomo sapiens (human)
insulin-like growth factor I bindingInsulin receptorHomo sapiens (human)
insulin-like growth factor II bindingInsulin receptorHomo sapiens (human)
cargo receptor activityInsulin receptorHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin receptorHomo sapiens (human)
insulin bindingInsulin receptorHomo sapiens (human)
insulin receptor substrate bindingInsulin receptorHomo sapiens (human)
protein-containing complex bindingInsulin receptorHomo sapiens (human)
PTB domain bindingInsulin receptorHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
protein serine/threonine phosphatase activityTyrosine-protein kinase LckHomo sapiens (human)
protein bindingTyrosine-protein kinase LckHomo sapiens (human)
ATP bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase LckHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase LckHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD4 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD8 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
identical protein bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase LckHomo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
ATPase bindingTyrosine-protein kinase LckHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)
protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
protein bindingTyrosine-protein kinase FynHomo sapiens (human)
ATP bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase FynHomo sapiens (human)
enzyme bindingTyrosine-protein kinase FynHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
identical protein bindingTyrosine-protein kinase FynHomo sapiens (human)
alpha-tubulin bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase FynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase FynHomo sapiens (human)
metal ion bindingTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
tau protein bindingTyrosine-protein kinase FynHomo sapiens (human)
tau-protein kinase activityTyrosine-protein kinase FynHomo sapiens (human)
growth factor receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase FynHomo sapiens (human)
disordered domain specific bindingTyrosine-protein kinase FynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
virus receptor activityCyclin-dependent kinase 1Homo sapiens (human)
chromatin bindingCyclin-dependent kinase 1Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein bindingCyclin-dependent kinase 1Homo sapiens (human)
ATP bindingCyclin-dependent kinase 1Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 1Homo sapiens (human)
kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 1Homo sapiens (human)
Hsp70 protein bindingCyclin-dependent kinase 1Homo sapiens (human)
histone kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
purine nucleobase bindingGlycogen phosphorylase, liver formHomo sapiens (human)
protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
ATP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glucose bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
AMP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
vitamin bindingGlycogen phosphorylase, liver formHomo sapiens (human)
bile acid bindingGlycogen phosphorylase, liver formHomo sapiens (human)
identical protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, liver formHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
ATP bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
microtubule bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
immunoglobulin receptor bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
phosphatidylinositol bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein tyrosine kinase activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
macrophage colony-stimulating factor receptor activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
ATP bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein phosphatase bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cytokine bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein homodimerization activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
growth factor bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
adenine phosphoribosyltransferase activityAdenine phosphoribosyltransferaseHomo sapiens (human)
protein bindingAdenine phosphoribosyltransferaseHomo sapiens (human)
AMP bindingAdenine phosphoribosyltransferaseHomo sapiens (human)
adenine bindingAdenine phosphoribosyltransferaseHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase YesHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase YesHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase YesHomo sapiens (human)
protein bindingTyrosine-protein kinase YesHomo sapiens (human)
ATP bindingTyrosine-protein kinase YesHomo sapiens (human)
enzyme bindingTyrosine-protein kinase YesHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase YesHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase YesHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase LynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase LynHomo sapiens (human)
platelet-derived growth factor receptor bindingTyrosine-protein kinase LynHomo sapiens (human)
integrin bindingTyrosine-protein kinase LynHomo sapiens (human)
protein bindingTyrosine-protein kinase LynHomo sapiens (human)
ATP bindingTyrosine-protein kinase LynHomo sapiens (human)
kinase activityTyrosine-protein kinase LynHomo sapiens (human)
SH3 domain bindingTyrosine-protein kinase LynHomo sapiens (human)
ubiquitin protein ligase bindingTyrosine-protein kinase LynHomo sapiens (human)
gamma-tubulin bindingTyrosine-protein kinase LynHomo sapiens (human)
glycosphingolipid bindingTyrosine-protein kinase LynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase LynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase LynHomo sapiens (human)
phosphoprotein bindingTyrosine-protein kinase LynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase LynHomo sapiens (human)
phosphorylation-dependent protein bindingTyrosine-protein kinase LynHomo sapiens (human)
phosphatidylinositol 3-kinase activator activityTyrosine-protein kinase LynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase LynHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
calcium ion bindingProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
signaling receptor activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
G-protein alpha-subunit bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein tyrosine kinase activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor receptor activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
ATP bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor I bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
identical protein bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor substrate bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein-containing complex bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein transporter activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor activityInsulin-like growth factor 1 receptorHomo sapiens (human)
RNA bindingSignal recognition particle receptor subunit alphaHomo sapiens (human)
GTP bindingSignal recognition particle receptor subunit alphaHomo sapiens (human)
ATP hydrolysis activitySignal recognition particle receptor subunit alphaHomo sapiens (human)
signal recognition particle bindingSignal recognition particle receptor subunit alphaHomo sapiens (human)
GTPase activitySignal recognition particle receptor subunit alphaHomo sapiens (human)
protein bindingCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
ubiquinol-cytochrome-c reductase activityCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
heme bindingCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
metal ion bindingCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
protein tyrosine kinase activityHepatocyte growth factor receptorHomo sapiens (human)
protein bindingHepatocyte growth factor receptorHomo sapiens (human)
ATP bindingHepatocyte growth factor receptorHomo sapiens (human)
semaphorin receptor activityHepatocyte growth factor receptorHomo sapiens (human)
protein phosphatase bindingHepatocyte growth factor receptorHomo sapiens (human)
identical protein bindingHepatocyte growth factor receptorHomo sapiens (human)
molecular function activator activityHepatocyte growth factor receptorHomo sapiens (human)
hepatocyte growth factor receptor activityHepatocyte growth factor receptorHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase HCKHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase HCKHomo sapiens (human)
protein bindingTyrosine-protein kinase HCKHomo sapiens (human)
ATP bindingTyrosine-protein kinase HCKHomo sapiens (human)
lipid bindingTyrosine-protein kinase HCKHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase HCKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase HCKHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein phosphatase bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein tyrosine kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet activating factor receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor beta-receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
signaling receptor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
ATP bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
enzyme bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein kinase bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
vascular endothelial growth factor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase FgrHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FgrHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FgrHomo sapiens (human)
protein bindingTyrosine-protein kinase FgrHomo sapiens (human)
ATP bindingTyrosine-protein kinase FgrHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase FgrHomo sapiens (human)
immunoglobulin receptor bindingTyrosine-protein kinase FgrHomo sapiens (human)
Fc-gamma receptor I complex bindingTyrosine-protein kinase FgrHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FgrHomo sapiens (human)
magnesium ion bindingWee1-like protein kinase 2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityWee1-like protein kinase 2Homo sapiens (human)
ATP bindingWee1-like protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityWee1-like protein kinase 2Homo sapiens (human)
protein bindingUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
ATP bindingUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
protein serine kinase activityUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
protein serine/threonine kinase activityUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
protein bindingSerine/threonine-protein kinase A-RafHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase A-RafHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase A-RafHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
MAP kinase kinase kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
protease bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
protein tyrosine kinase activityMast/stem cell growth factor receptor KitHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityMast/stem cell growth factor receptor KitHomo sapiens (human)
stem cell factor receptor activityMast/stem cell growth factor receptor KitHomo sapiens (human)
protein bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
ATP bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
cytokine bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
SH2 domain bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
protein homodimerization activityMast/stem cell growth factor receptor KitHomo sapiens (human)
metal ion bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
growth factor bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
protein bindingGlycogen phosphorylase, brain formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, brain formHomo sapiens (human)
protein serine/threonine kinase activityBreakpoint cluster region proteinHomo sapiens (human)
protein tyrosine kinase activityBreakpoint cluster region proteinHomo sapiens (human)
guanyl-nucleotide exchange factor activityBreakpoint cluster region proteinHomo sapiens (human)
GTPase activator activityBreakpoint cluster region proteinHomo sapiens (human)
protein bindingBreakpoint cluster region proteinHomo sapiens (human)
ATP bindingBreakpoint cluster region proteinHomo sapiens (human)
protein serine kinase activityBreakpoint cluster region proteinHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
transcription factor bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
manganese ion bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ribosomal small subunit bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 1Homo sapiens (human)
protein bindingFibroblast growth factor receptor 1Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 1Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 1Homo sapiens (human)
SH2 domain bindingFibroblast growth factor receptor 1Homo sapiens (human)
identical protein bindingFibroblast growth factor receptor 1Homo sapiens (human)
protein homodimerization activityFibroblast growth factor receptor 1Homo sapiens (human)
receptor-receptor interactionFibroblast growth factor receptor 1Homo sapiens (human)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
calmodulin bindingMyosin light chain kinase, smooth muscleGallus gallus (chicken)
ATP bindingMyosin light chain kinase, smooth muscleGallus gallus (chicken)
metal ion bindingMyosin light chain kinase, smooth muscleGallus gallus (chicken)
myosin light chain kinase activityMyosin light chain kinase, smooth muscleGallus gallus (chicken)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 4Homo sapiens (human)
protein bindingCyclin-dependent kinase 4Homo sapiens (human)
ATP bindingCyclin-dependent kinase 4Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activityCyclin-dependent kinase 4Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 4Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 4Homo sapiens (human)
ATP:ADP antiporter activityADP/ATP translocase 3Homo sapiens (human)
protein bindingADP/ATP translocase 3Homo sapiens (human)
nucleotide bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
protein bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
protein kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein kinase C bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signaling receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
insulin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase activator activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
enzyme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
heme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nuclear estrogen receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
SH2 domain bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transmembrane transporter bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cadherin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATPase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phosphoprotein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
BMP receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
connexin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
scaffold protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cAMP-dependent protein kinase inhibitor activitycAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cAMP-dependent protein kinase regulator activitycAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein domain specific bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
ubiquitin protein ligase bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein kinase A catalytic subunit bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cAMP bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityInsulin receptor-related proteinHomo sapiens (human)
protein bindingInsulin receptor-related proteinHomo sapiens (human)
ATP bindingInsulin receptor-related proteinHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin receptor-related proteinHomo sapiens (human)
insulin receptor substrate bindingInsulin receptor-related proteinHomo sapiens (human)
insulin receptor activityInsulin receptor-related proteinHomo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
MAP kinase kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
calcium ion bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
mitogen-activated protein kinase kinase bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
identical protein bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
scaffold protein bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
MAP kinase kinase kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium channel regulator activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
telethonin bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein-containing complex bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein serine/threonine kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
phosphorylase kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
protein bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
calmodulin bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
ATP bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
enzyme bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
tau-protein kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
dihydronicotinamide riboside quinone reductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
zinc ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
electron transfer activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donorsRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
chloride ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein homodimerization activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
FAD bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
melatonin bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
resveratrol bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein kinase activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor alpha-receptor activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
vascular endothelial growth factor receptor activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor receptor bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
ATP bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
vascular endothelial growth factor bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein homodimerization activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein-containing complex bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase BlkMus musculus (house mouse)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FerHomo sapiens (human)
epidermal growth factor receptor bindingTyrosine-protein kinase FerHomo sapiens (human)
protein bindingTyrosine-protein kinase FerHomo sapiens (human)
ATP bindingTyrosine-protein kinase FerHomo sapiens (human)
protein phosphatase 1 bindingTyrosine-protein kinase FerHomo sapiens (human)
lipid bindingTyrosine-protein kinase FerHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FerHomo sapiens (human)
protein kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
integrin bindingProtein kinase C alpha typeHomo sapiens (human)
protein bindingProtein kinase C alpha typeHomo sapiens (human)
ATP bindingProtein kinase C alpha typeHomo sapiens (human)
zinc ion bindingProtein kinase C alpha typeHomo sapiens (human)
enzyme bindingProtein kinase C alpha typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol bindingProtein kinase C alpha typeHomo sapiens (human)
magnesium ion bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein serine/threonine kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
AMP-activated protein kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein serine/threonine/tyrosine kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein domain specific bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
manganese ion bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase A regulatory subunit bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
channel activator activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
placental growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
ATP bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
ATP hydrolysis activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
protein-macromolecule adaptor activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
5'-3' DNA helicase activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
metal ion bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
4 iron, 4 sulfur cluster bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
DNA helicase activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
damaged DNA bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
RNA bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
double-stranded RNA bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
ATP bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein phosphatase regulator activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
identical protein bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
protein bindingCasein kinase II subunit alpha'Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha'Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
GTPase activityRas-related protein Rab-6AHomo sapiens (human)
protein bindingRas-related protein Rab-6AHomo sapiens (human)
GTP bindingRas-related protein Rab-6AHomo sapiens (human)
protein domain specific bindingRas-related protein Rab-6AHomo sapiens (human)
myosin V bindingRas-related protein Rab-6AHomo sapiens (human)
transcription coactivator activitySerine/threonine-protein kinase MAKHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase MAKHomo sapiens (human)
protein bindingSerine/threonine-protein kinase MAKHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MAKHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase MAKHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MAKHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MAKHomo sapiens (human)
monooxygenase activityCytochrome P450 2B6Homo sapiens (human)
iron ion bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-alpha-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
heme bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-beta-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2B6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2B6Homo sapiens (human)
RNA bindingCyclin-dependent kinase 11BHomo sapiens (human)
protein kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
protein bindingCyclin-dependent kinase 11BHomo sapiens (human)
ATP bindingCyclin-dependent kinase 11BHomo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
fibronectin bindingEphrin type-A receptor 1Homo sapiens (human)
protein kinase activityEphrin type-A receptor 1Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 1Homo sapiens (human)
ATP bindingEphrin type-A receptor 1Homo sapiens (human)
protein kinase bindingEphrin type-A receptor 1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEphrin type-A receptor 1Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 2Homo sapiens (human)
protein bindingFibroblast growth factor receptor 2Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 2Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 2Homo sapiens (human)
protein homodimerization activityFibroblast growth factor receptor 2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein tyrosine kinase activator activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ubiquitin protein ligase bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuregulin bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuregulin receptor activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
phosphoribosylaminoimidazole carboxylase activityMultifunctional protein ADE2Homo sapiens (human)
phosphoribosylaminoimidazolesuccinocarboxamide synthase activityMultifunctional protein ADE2Homo sapiens (human)
protein bindingMultifunctional protein ADE2Homo sapiens (human)
ATP bindingMultifunctional protein ADE2Homo sapiens (human)
identical protein bindingMultifunctional protein ADE2Homo sapiens (human)
5-amino-4-imidazole carboxylate lyase activityMultifunctional protein ADE2Homo sapiens (human)
cadherin bindingMultifunctional protein ADE2Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 4Homo sapiens (human)
protein bindingFibroblast growth factor receptor 4Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 4Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 4Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 3Homo sapiens (human)
protein bindingFibroblast growth factor receptor 3Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 3Homo sapiens (human)
identical protein bindingFibroblast growth factor receptor 3Homo sapiens (human)
protein serine/threonine kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
AMP-activated protein kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein kinase A regulatory subunit bindingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
magnesium ion bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein serine/threonine kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
AMP-activated protein kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ubiquitin protein ligase bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ferrochelatase activityFerrochelatase, mitochondrialHomo sapiens (human)
protein bindingFerrochelatase, mitochondrialHomo sapiens (human)
ferrous iron bindingFerrochelatase, mitochondrialHomo sapiens (human)
heme bindingFerrochelatase, mitochondrialHomo sapiens (human)
iron-responsive element bindingFerrochelatase, mitochondrialHomo sapiens (human)
identical protein bindingFerrochelatase, mitochondrialHomo sapiens (human)
protein homodimerization activityFerrochelatase, mitochondrialHomo sapiens (human)
2 iron, 2 sulfur cluster bindingFerrochelatase, mitochondrialHomo sapiens (human)
protein kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
PDZ domain bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
peptide bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
identical protein bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein phosphatase 2A bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK1Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK1Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK1Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK1Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK1Homo sapiens (human)
ubiquitin protein ligase bindingTyrosine-protein kinase JAK1Homo sapiens (human)
CCR5 chemokine receptor bindingTyrosine-protein kinase JAK1Homo sapiens (human)
metal ion bindingTyrosine-protein kinase JAK1Homo sapiens (human)
protein kinase activityProtein kinase C eta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
protein bindingProtein kinase C eta typeHomo sapiens (human)
ATP bindingProtein kinase C eta typeHomo sapiens (human)
enzyme bindingProtein kinase C eta typeHomo sapiens (human)
small GTPase bindingProtein kinase C eta typeHomo sapiens (human)
metal ion bindingProtein kinase C eta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C eta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
ATP bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
Edg-2 lysophosphatidic acid receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
beta-adrenergic receptor kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
RNA bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
RNA helicase activityProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
helicase activityProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
protein bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
ATP bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
ATP hydrolysis activityProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
protein domain specific bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cadherin bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
mRNA bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
protein bindingActivin receptor type-2AHomo sapiens (human)
activin receptor activityActivin receptor type-2AHomo sapiens (human)
activin bindingActivin receptor type-2AHomo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-2AHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityActivin receptor type-2AHomo sapiens (human)
protein bindingActivin receptor type-2AHomo sapiens (human)
ATP bindingActivin receptor type-2AHomo sapiens (human)
coreceptor activityActivin receptor type-2AHomo sapiens (human)
activin receptor activityActivin receptor type-2AHomo sapiens (human)
growth factor bindingActivin receptor type-2AHomo sapiens (human)
PDZ domain bindingActivin receptor type-2AHomo sapiens (human)
inhibin bindingActivin receptor type-2AHomo sapiens (human)
metal ion bindingActivin receptor type-2AHomo sapiens (human)
BMP receptor activityActivin receptor type-2AHomo sapiens (human)
phosphotyrosine residue bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
protein bindingMitogen-activated protein kinase 3 Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 3 Homo sapiens (human)
phosphatase bindingMitogen-activated protein kinase 3 Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
DNA-binding transcription factor bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine/threonine kinase activityMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
protein bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
ATP bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
tau protein bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
tau-protein kinase activityMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
protein serine kinase activityMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
deoxyadenosine kinase activityDeoxycytidine kinaseHomo sapiens (human)
deoxycytidine kinase activityDeoxycytidine kinaseHomo sapiens (human)
deoxyguanosine kinase activityDeoxycytidine kinaseHomo sapiens (human)
ATP bindingDeoxycytidine kinaseHomo sapiens (human)
protein homodimerization activityDeoxycytidine kinaseHomo sapiens (human)
cytidine kinase activityDeoxycytidine kinaseHomo sapiens (human)
phosphotyrosine residue bindingMitogen-activated protein kinase 1Homo sapiens (human)
DNA bindingMitogen-activated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
protein bindingMitogen-activated protein kinase 1Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 1Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
phosphatase bindingMitogen-activated protein kinase 1Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase 1Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
virus receptor activityEphrin type-A receptor 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 2Homo sapiens (human)
protein bindingEphrin type-A receptor 2Homo sapiens (human)
ATP bindingEphrin type-A receptor 2Homo sapiens (human)
growth factor bindingEphrin type-A receptor 2Homo sapiens (human)
cadherin bindingEphrin type-A receptor 2Homo sapiens (human)
molecular function activator activityEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
protein bindingEphrin type-A receptor 3Homo sapiens (human)
ATP bindingEphrin type-A receptor 3Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 8Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 8Homo sapiens (human)
ATP bindingEphrin type-A receptor 8Homo sapiens (human)
growth factor bindingEphrin type-A receptor 8Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 8Homo sapiens (human)
amyloid-beta bindingEphrin type-B receptor 2Homo sapiens (human)
protein tyrosine kinase activityEphrin type-B receptor 2Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 2Homo sapiens (human)
signaling receptor bindingEphrin type-B receptor 2Homo sapiens (human)
protein bindingEphrin type-B receptor 2Homo sapiens (human)
ATP bindingEphrin type-B receptor 2Homo sapiens (human)
axon guidance receptor activityEphrin type-B receptor 2Homo sapiens (human)
identical protein bindingEphrin type-B receptor 2Homo sapiens (human)
protein-containing complex bindingEphrin type-B receptor 2Homo sapiens (human)
protein kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein tyrosine kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein bindingLeukocyte tyrosine kinase receptorHomo sapiens (human)
ATP bindingLeukocyte tyrosine kinase receptorHomo sapiens (human)
receptor signaling protein tyrosine kinase activator activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
growth hormone receptor bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
protein bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
ATP bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type 1 angiotensin receptor bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
nucleoside diphosphate kinase activityUMP-CMP kinase Homo sapiens (human)
uridine kinase activityUMP-CMP kinase Homo sapiens (human)
ATP bindingUMP-CMP kinase Homo sapiens (human)
UMP kinase activityUMP-CMP kinase Homo sapiens (human)
CMP kinase activityUMP-CMP kinase Homo sapiens (human)
dCMP kinase activityUMP-CMP kinase Homo sapiens (human)
nucleoside monophosphate kinase activityUMP-CMP kinase Homo sapiens (human)
cytidylate kinase activityUMP-CMP kinase Homo sapiens (human)
RNA bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
serine-type endopeptidase inhibitor activityPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
protein bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
ATP bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
phosphatidylethanolamine bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
enzyme bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
protein kinase bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
magnesium ion bindingWee1-like protein kinaseHomo sapiens (human)
protein tyrosine kinase activityWee1-like protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityWee1-like protein kinaseHomo sapiens (human)
protein bindingWee1-like protein kinaseHomo sapiens (human)
ATP bindingWee1-like protein kinaseHomo sapiens (human)
heme oxygenase (decyclizing) activityHeme oxygenase 2Homo sapiens (human)
protein bindingHeme oxygenase 2Homo sapiens (human)
metal ion bindingHeme oxygenase 2Homo sapiens (human)
heme bindingHeme oxygenase 2Homo sapiens (human)
virus receptor activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
phosphatidylserine bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
protein bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
ATP bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
myosin heavy chain bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 4Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 4Homo sapiens (human)
protein bindingMitogen-activated protein kinase 4Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 4Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase 4Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase 4Homo sapiens (human)
protein heterodimerization activityMitogen-activated protein kinase 4Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 4Homo sapiens (human)
methionine adenosyltransferase activityS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
ATP bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
small molecule bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
identical protein bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
metal ion bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
G protein-coupled receptor bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
ATPase activator activityDnaJ homolog subfamily A member 1Homo sapiens (human)
protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
ATP bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
Hsp70 protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
Tat protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
ubiquitin protein ligase bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
metal ion bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
low-density lipoprotein particle receptor bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
unfolded protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
protein-folding chaperone bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
C3HC4-type RING finger domain bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
protein kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
calmodulin bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
enzyme bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein kinase bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nitric-oxide synthase regulator activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase inhibitor activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
identical protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein homodimerization activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol-3,4-bisphosphate bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
14-3-3 protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
potassium channel activator activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
metal ion bindingRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
molecular function activator activityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingG protein-coupled receptor kinase 4Homo sapiens (human)
rhodopsin kinase activityG protein-coupled receptor kinase 4Homo sapiens (human)
protein kinase activityG protein-coupled receptor kinase 4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein bindingDual specificity protein kinase TTKHomo sapiens (human)
ATP bindingDual specificity protein kinase TTKHomo sapiens (human)
identical protein bindingDual specificity protein kinase TTKHomo sapiens (human)
kinetochore bindingDual specificity protein kinase TTKHomo sapiens (human)
protein serine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
DNA helicase activityDNA replication licensing factor MCM4Homo sapiens (human)
single-stranded DNA bindingDNA replication licensing factor MCM4Homo sapiens (human)
protein bindingDNA replication licensing factor MCM4Homo sapiens (human)
ATP bindingDNA replication licensing factor MCM4Homo sapiens (human)
ATP hydrolysis activityDNA replication licensing factor MCM4Homo sapiens (human)
single-stranded DNA helicase activityDNA replication licensing factor MCM4Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
ATP bindingTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 3Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
protein phosphatase bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
protein homodimerization activityVascular endothelial growth factor receptor 3Homo sapiens (human)
protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
integrin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
coreceptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
identical protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
cadherin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
Hsp90 protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
MAP-kinase scaffold activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
PDZ domain bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein serine/threonine kinase activator activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
metal ion bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
scaffold protein bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein tyrosine kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cytokine receptor activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
vascular endothelial growth factor receptor activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
ATP bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
nuclear glucocorticoid receptor bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein-containing complex bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
phosphatidylinositol 3-kinase activator activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
growth factor bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein serine/threonine kinase activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
transforming growth factor beta receptor activity, type IBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
ATP bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein homodimerization activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
SMAD bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
metal ion bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP receptor activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
activin receptor activityActivin receptor type-1BHomo sapiens (human)
growth factor bindingActivin receptor type-1BHomo sapiens (human)
activin bindingActivin receptor type-1BHomo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-1BHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityActivin receptor type-1BHomo sapiens (human)
protein bindingActivin receptor type-1BHomo sapiens (human)
ATP bindingActivin receptor type-1BHomo sapiens (human)
activin receptor activity, type IActivin receptor type-1BHomo sapiens (human)
activin receptor activityActivin receptor type-1BHomo sapiens (human)
ubiquitin protein ligase bindingActivin receptor type-1BHomo sapiens (human)
inhibin bindingActivin receptor type-1BHomo sapiens (human)
SMAD bindingActivin receptor type-1BHomo sapiens (human)
metal ion bindingActivin receptor type-1BHomo sapiens (human)
I-SMAD bindingActivin receptor type-1BHomo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-1Homo sapiens (human)
growth factor bindingTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-1Homo sapiens (human)
protein kinase activityTGF-beta receptor type-1Homo sapiens (human)
protein serine/threonine kinase activityTGF-beta receptor type-1Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activity, type ITGF-beta receptor type-1Homo sapiens (human)
type II transforming growth factor beta receptor bindingTGF-beta receptor type-1Homo sapiens (human)
protein bindingTGF-beta receptor type-1Homo sapiens (human)
ATP bindingTGF-beta receptor type-1Homo sapiens (human)
ubiquitin protein ligase bindingTGF-beta receptor type-1Homo sapiens (human)
SMAD bindingTGF-beta receptor type-1Homo sapiens (human)
metal ion bindingTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-1Homo sapiens (human)
I-SMAD bindingTGF-beta receptor type-1Homo sapiens (human)
activin receptor activity, type ITGF-beta receptor type-1Homo sapiens (human)
activin bindingTGF-beta receptor type-1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor activity, type ISerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin receptor activity, type ISerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
SMAD bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP receptor activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-2Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta receptor activity, type IITGF-beta receptor type-2Homo sapiens (human)
protein bindingTGF-beta receptor type-2Homo sapiens (human)
ATP bindingTGF-beta receptor type-2Homo sapiens (human)
glycosaminoglycan bindingTGF-beta receptor type-2Homo sapiens (human)
kinase activator activityTGF-beta receptor type-2Homo sapiens (human)
type I transforming growth factor beta receptor bindingTGF-beta receptor type-2Homo sapiens (human)
SMAD bindingTGF-beta receptor type-2Homo sapiens (human)
metal ion bindingTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-2Homo sapiens (human)
molecular adaptor activityTGF-beta receptor type-2Homo sapiens (human)
activin receptor activityTGF-beta receptor type-2Homo sapiens (human)
activin bindingTGF-beta receptor type-2Homo sapiens (human)
protein serine/threonine kinase activityTGF-beta receptor type-2Homo sapiens (human)
protein bindingElectron transfer flavoprotein subunit betaHomo sapiens (human)
electron transfer activityElectron transfer flavoprotein subunit betaHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase CSKHomo sapiens (human)
protein bindingTyrosine-protein kinase CSKHomo sapiens (human)
ATP bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein kinase A catalytic subunit bindingTyrosine-protein kinase CSKHomo sapiens (human)
identical protein bindingTyrosine-protein kinase CSKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase CSKHomo sapiens (human)
proline-rich region bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein tyrosine kinase bindingTyrosine-protein kinase CSKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase CSKHomo sapiens (human)
bis(5'-nucleosyl)-tetraphosphatase (asymmetrical) activityGlycine--tRNA ligaseHomo sapiens (human)
glycine-tRNA ligase activityGlycine--tRNA ligaseHomo sapiens (human)
protein bindingGlycine--tRNA ligaseHomo sapiens (human)
ATP bindingGlycine--tRNA ligaseHomo sapiens (human)
transferase activityGlycine--tRNA ligaseHomo sapiens (human)
identical protein bindingGlycine--tRNA ligaseHomo sapiens (human)
protein dimerization activityGlycine--tRNA ligaseHomo sapiens (human)
protein kinase activityProtein kinase C iota typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C iota typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C iota typeHomo sapiens (human)
protein bindingProtein kinase C iota typeHomo sapiens (human)
ATP bindingProtein kinase C iota typeHomo sapiens (human)
phospholipid bindingProtein kinase C iota typeHomo sapiens (human)
metal ion bindingProtein kinase C iota typeHomo sapiens (human)
protein serine kinase activityProtein kinase C iota typeHomo sapiens (human)
RNA bindingExosome RNA helicase MTR4Homo sapiens (human)
RNA helicase activityExosome RNA helicase MTR4Homo sapiens (human)
protein bindingExosome RNA helicase MTR4Homo sapiens (human)
ATP bindingExosome RNA helicase MTR4Homo sapiens (human)
ATP hydrolysis activityExosome RNA helicase MTR4Homo sapiens (human)
protein serine/threonine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein kinase activator activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
insulin receptor substrate bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein serine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
insulin receptor substrate bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
protein serine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
RNA polymerase III type 1 promoter sequence-specific DNA bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
RNA polymerase III type 2 promoter sequence-specific DNA bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
RNA polymerase III type 3 promoter sequence-specific DNA bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
TFIIIC-class transcription factor complex bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
protein bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
identical protein bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
ribosome bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
phosphoprotein bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
protein tyrosine kinase activityMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
protein bindingMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
ATP bindingMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase TecHomo sapiens (human)
protein bindingTyrosine-protein kinase TecHomo sapiens (human)
ATP bindingTyrosine-protein kinase TecHomo sapiens (human)
phospholipid bindingTyrosine-protein kinase TecHomo sapiens (human)
metal ion bindingTyrosine-protein kinase TecHomo sapiens (human)
protein bindingTyrosine-protein kinase TXKHomo sapiens (human)
ATP bindingTyrosine-protein kinase TXKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase TXKHomo sapiens (human)
magnesium ion bindingTyrosine-protein kinase ABL2Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ABL2Homo sapiens (human)
actin monomer bindingTyrosine-protein kinase ABL2Homo sapiens (human)
protein kinase activityTyrosine-protein kinase ABL2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ABL2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ABL2Homo sapiens (human)
protein bindingTyrosine-protein kinase ABL2Homo sapiens (human)
ATP bindingTyrosine-protein kinase ABL2Homo sapiens (human)
manganese ion bindingTyrosine-protein kinase ABL2Homo sapiens (human)
actin filament bindingTyrosine-protein kinase ABL2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FRKHomo sapiens (human)
protein bindingTyrosine-protein kinase FRKHomo sapiens (human)
ATP bindingTyrosine-protein kinase FRKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FRKHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FRKHomo sapiens (human)
protein bindingG protein-coupled receptor kinase 6Homo sapiens (human)
ATP bindingG protein-coupled receptor kinase 6Homo sapiens (human)
beta-adrenergic receptor kinase activityG protein-coupled receptor kinase 6Homo sapiens (human)
G protein-coupled receptor kinase activityG protein-coupled receptor kinase 6Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ZAP-70Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
ATP bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
signaling receptor bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein serine/threonine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
integrin bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein bindingTyrosine-protein kinase SYKHomo sapiens (human)
ATP bindingTyrosine-protein kinase SYKHomo sapiens (human)
interleukin-15 receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase SYKHomo sapiens (human)
phosphatase bindingTyrosine-protein kinase SYKHomo sapiens (human)
Toll-like receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase SYKHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase SYKHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein binding26S proteasome regulatory subunit 6BHomo sapiens (human)
ATP binding26S proteasome regulatory subunit 6BHomo sapiens (human)
ATP hydrolysis activity26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome-activating activity26S proteasome regulatory subunit 6BHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
protein bindingMitogen-activated protein kinase 8Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 8Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 8Homo sapiens (human)
histone deacetylase regulator activityMitogen-activated protein kinase 8Homo sapiens (human)
histone deacetylase bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
protein serine/threonine kinase bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein bindingMitogen-activated protein kinase 9Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 9Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
JUN kinase kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
molecular adaptor activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein bindingCasein kinase I isoform alphaHomo sapiens (human)
ATP bindingCasein kinase I isoform alphaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein bindingCasein kinase I isoform deltaHomo sapiens (human)
ATP bindingCasein kinase I isoform deltaHomo sapiens (human)
cadherin bindingCasein kinase I isoform deltaHomo sapiens (human)
tau-protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein serine/threonine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
identical protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
ephrin receptor bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein serine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
mitogen-activated protein kinase bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 8Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 8Homo sapiens (human)
protein bindingCyclin-dependent kinase 8Homo sapiens (human)
ATP bindingCyclin-dependent kinase 8Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 8Homo sapiens (human)
ubiquitin protein ligase activityCyclin-dependent kinase 8Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 8Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 8Homo sapiens (human)
RNA bindingElongation factor Tu, mitochondrialHomo sapiens (human)
translation elongation factor activityElongation factor Tu, mitochondrialHomo sapiens (human)
GTPase activityElongation factor Tu, mitochondrialHomo sapiens (human)
protein bindingElongation factor Tu, mitochondrialHomo sapiens (human)
GTP bindingElongation factor Tu, mitochondrialHomo sapiens (human)
choline-phosphate cytidylyltransferase activityCholine-phosphate cytidylyltransferase AHomo sapiens (human)
protein bindingCholine-phosphate cytidylyltransferase AHomo sapiens (human)
calmodulin bindingCholine-phosphate cytidylyltransferase AHomo sapiens (human)
identical protein bindingCholine-phosphate cytidylyltransferase AHomo sapiens (human)
protein homodimerization activityCholine-phosphate cytidylyltransferase AHomo sapiens (human)
molecular function inhibitor activityCholine-phosphate cytidylyltransferase AHomo sapiens (human)
phosphatidylcholine bindingCholine-phosphate cytidylyltransferase AHomo sapiens (human)
tRNA bindingCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
cysteine-tRNA ligase activityCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
protein bindingCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
ATP bindingCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
identical protein bindingCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
metal ion bindingCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
RNA bindingCasein kinase I isoform epsilonHomo sapiens (human)
protein kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein bindingCasein kinase I isoform epsilonHomo sapiens (human)
ATP bindingCasein kinase I isoform epsilonHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
acyl-CoA dehydrogenase activityVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
long-chain fatty acyl-CoA dehydrogenase activityVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
protein bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
very-long-chain fatty acyl-CoA dehydrogenase activityVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
identical protein bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
fatty-acyl-CoA bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein bindingDual specificity protein kinase CLK1Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK1Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein bindingDual specificity protein kinase CLK2Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK2Homo sapiens (human)
identical protein bindingDual specificity protein kinase CLK2Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
RNA bindingDual specificity protein kinase CLK3Homo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein bindingDual specificity protein kinase CLK3Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK3Homo sapiens (human)
identical protein bindingDual specificity protein kinase CLK3Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
signaling receptor bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protease bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
p53 bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ubiquitin protein ligase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
dynactin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
NF-kappaB bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityCyclin-dependent kinase 7Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 7Homo sapiens (human)
protein bindingCyclin-dependent kinase 7Homo sapiens (human)
ATP bindingCyclin-dependent kinase 7Homo sapiens (human)
ATP-dependent activity, acting on DNACyclin-dependent kinase 7Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 7Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 7Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 7Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCyclin-dependent kinase 9Homo sapiens (human)
transcription coactivator bindingCyclin-dependent kinase 9Homo sapiens (human)
DNA bindingCyclin-dependent kinase 9Homo sapiens (human)
chromatin bindingCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation factor activityCyclin-dependent kinase 9Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein bindingCyclin-dependent kinase 9Homo sapiens (human)
ATP bindingCyclin-dependent kinase 9Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 9Homo sapiens (human)
kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 9Homo sapiens (human)
7SK snRNA bindingCyclin-dependent kinase 9Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
GTPase activityRas-related protein Rab-27AHomo sapiens (human)
G protein activityRas-related protein Rab-27AHomo sapiens (human)
protein bindingRas-related protein Rab-27AHomo sapiens (human)
GTP bindingRas-related protein Rab-27AHomo sapiens (human)
GDP bindingRas-related protein Rab-27AHomo sapiens (human)
protein domain specific bindingRas-related protein Rab-27AHomo sapiens (human)
myosin V bindingRas-related protein Rab-27AHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase BlkHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase BlkHomo sapiens (human)
protein bindingTyrosine-protein kinase BlkHomo sapiens (human)
ATP bindingTyrosine-protein kinase BlkHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase BlkHomo sapiens (human)
protein kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein serine/threonine kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
ATP bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein kinase bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
heat shock protein bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
identical protein bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein homodimerization activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein heterodimerization activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein serine kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
calmodulin bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein phosphatase 1 bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
outward rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein kinase A catalytic subunit bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein kinase A regulatory subunit bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein kinase bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein tyrosine kinase activityCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
protein bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
ATP bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
metal ion bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein phosphatase bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek4Homo sapiens (human)
manganese ion bindingSerine/threonine-protein kinase Nek4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek4Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK3Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK3Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
microtubule bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
anaphase-promoting complex bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein kinase activityDeath-associated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityDeath-associated protein kinase 1Homo sapiens (human)
protein bindingDeath-associated protein kinase 1Homo sapiens (human)
calmodulin bindingDeath-associated protein kinase 1Homo sapiens (human)
ATP bindingDeath-associated protein kinase 1Homo sapiens (human)
GTP bindingDeath-associated protein kinase 1Homo sapiens (human)
syntaxin-1 bindingDeath-associated protein kinase 1Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 1Homo sapiens (human)
protein kinase activityLIM domain kinase 1Homo sapiens (human)
protein serine/threonine kinase activityLIM domain kinase 1Homo sapiens (human)
protein bindingLIM domain kinase 1Homo sapiens (human)
ATP bindingLIM domain kinase 1Homo sapiens (human)
heat shock protein bindingLIM domain kinase 1Homo sapiens (human)
metal ion bindingLIM domain kinase 1Homo sapiens (human)
protein serine kinase activityLIM domain kinase 1Homo sapiens (human)
protein serine/threonine kinase activityLIM domain kinase 2Homo sapiens (human)
protein bindingLIM domain kinase 2Homo sapiens (human)
ATP bindingLIM domain kinase 2Homo sapiens (human)
metal ion bindingLIM domain kinase 2Homo sapiens (human)
protein serine kinase activityLIM domain kinase 2Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase 12Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
protein bindingMitogen-activated protein kinase 12Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 12Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
tRNA bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
RNA bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
tyrosine-tRNA ligase activityTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
interleukin-8 receptor bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
protein bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
ATP bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
small molecule bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cAMP-dependent protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cAMP-dependent protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
AMP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
ADP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
chromatin binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine/threonine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
metal ion binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
histone H2BS36 kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
ephrin receptor activityEphrin type-B receptor 3Homo sapiens (human)
protein bindingEphrin type-B receptor 3Homo sapiens (human)
ATP bindingEphrin type-B receptor 3Homo sapiens (human)
axon guidance receptor activityEphrin type-B receptor 3Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 3Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 5Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 5Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 5Homo sapiens (human)
protein bindingEphrin type-A receptor 5Homo sapiens (human)
ATP bindingEphrin type-A receptor 5Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEphrin type-B receptor 4Homo sapiens (human)
ephrin receptor activityEphrin type-B receptor 4Homo sapiens (human)
protein bindingEphrin type-B receptor 4Homo sapiens (human)
ATP bindingEphrin type-B receptor 4Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 1Homo sapiens (human)
protein bindingEphrin type-B receptor 1Homo sapiens (human)
ATP bindingEphrin type-B receptor 1Homo sapiens (human)
axon guidance receptor activityEphrin type-B receptor 1Homo sapiens (human)
protein-containing complex bindingEphrin type-B receptor 1Homo sapiens (human)
amyloid-beta bindingEphrin type-A receptor 4Homo sapiens (human)
protein kinase activityEphrin type-A receptor 4Homo sapiens (human)
protein tyrosine kinase activityEphrin type-A receptor 4Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 4Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 4Homo sapiens (human)
protein bindingEphrin type-A receptor 4Homo sapiens (human)
ATP bindingEphrin type-A receptor 4Homo sapiens (human)
kinase activityEphrin type-A receptor 4Homo sapiens (human)
PH domain bindingEphrin type-A receptor 4Homo sapiens (human)
identical protein bindingEphrin type-A receptor 4Homo sapiens (human)
ephrin receptor bindingEphrin type-A receptor 4Homo sapiens (human)
DH domain bindingEphrin type-A receptor 4Homo sapiens (human)
protein tyrosine kinase bindingEphrin type-A receptor 4Homo sapiens (human)
adenylate kinase activityAdenylate kinase 2, mitochondrialHomo sapiens (human)
protein bindingAdenylate kinase 2, mitochondrialHomo sapiens (human)
ATP bindingAdenylate kinase 2, mitochondrialHomo sapiens (human)
RNA bindingAdenosine kinaseHomo sapiens (human)
deoxyadenosine kinase activityAdenosine kinaseHomo sapiens (human)
ATP bindingAdenosine kinaseHomo sapiens (human)
metal ion bindingAdenosine kinaseHomo sapiens (human)
adenosine kinase activityAdenosine kinaseHomo sapiens (human)
protein bindingHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
ATP bindingHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
protein serine kinase activityHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
protein serine/threonine kinase activityHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SIK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
cAMP response element binding protein bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
histone deacetylase bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
14-3-3 protein bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SIK1Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
G protein activityRas-related protein Rab-10Homo sapiens (human)
protein bindingRas-related protein Rab-10Homo sapiens (human)
GTP bindingRas-related protein Rab-10Homo sapiens (human)
GDP bindingRas-related protein Rab-10Homo sapiens (human)
myosin V bindingRas-related protein Rab-10Homo sapiens (human)
cadherin binding involved in cell-cell adhesionRas-related protein Rab-10Homo sapiens (human)
actin filament bindingActin-related protein 3Homo sapiens (human)
structural constituent of cytoskeletonActin-related protein 3Homo sapiens (human)
protein bindingActin-related protein 3Homo sapiens (human)
ATP bindingActin-related protein 3Homo sapiens (human)
actin filament bindingActin-related protein 2Homo sapiens (human)
structural constituent of cytoskeletonActin-related protein 2Homo sapiens (human)
protein bindingActin-related protein 2Homo sapiens (human)
ATP bindingActin-related protein 2Homo sapiens (human)
nuclear export signal receptor activityGTP-binding nuclear protein RanHomo sapiens (human)
pre-miRNA bindingGTP-binding nuclear protein RanHomo sapiens (human)
magnesium ion bindingGTP-binding nuclear protein RanHomo sapiens (human)
chromatin bindingGTP-binding nuclear protein RanHomo sapiens (human)
RNA bindingGTP-binding nuclear protein RanHomo sapiens (human)
GTPase activityGTP-binding nuclear protein RanHomo sapiens (human)
G protein activityGTP-binding nuclear protein RanHomo sapiens (human)
protein bindingGTP-binding nuclear protein RanHomo sapiens (human)
GTP bindingGTP-binding nuclear protein RanHomo sapiens (human)
GDP bindingGTP-binding nuclear protein RanHomo sapiens (human)
protein domain specific bindingGTP-binding nuclear protein RanHomo sapiens (human)
cadherin bindingGTP-binding nuclear protein RanHomo sapiens (human)
dynein intermediate chain bindingGTP-binding nuclear protein RanHomo sapiens (human)
protein heterodimerization activityGTP-binding nuclear protein RanHomo sapiens (human)
importin-alpha family protein bindingGTP-binding nuclear protein RanHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingCasein kinase II subunit alphaHomo sapiens (human)
ATP bindingCasein kinase II subunit alphaHomo sapiens (human)
kinase activityCasein kinase II subunit alphaHomo sapiens (human)
identical protein bindingCasein kinase II subunit alphaHomo sapiens (human)
Hsp90 protein bindingCasein kinase II subunit alphaHomo sapiens (human)
protein serine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
GTP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
protein homodimerization activityPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
magnesium ion bindingSRSF protein kinase 2Homo sapiens (human)
RNA bindingSRSF protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 2Homo sapiens (human)
protein bindingSRSF protein kinase 2Homo sapiens (human)
ATP bindingSRSF protein kinase 2Homo sapiens (human)
14-3-3 protein bindingSRSF protein kinase 2Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-2Homo sapiens (human)
protein bindingCasein kinase I isoform gamma-2Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-2Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-2Homo sapiens (human)
double-stranded DNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine/threonine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ATP bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
enzyme bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein domain specific bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
U3 snoRNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
histone H2AXS139 kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
molecular function activator activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein bindingCyclin-dependent kinase 3Homo sapiens (human)
ATP bindingCyclin-dependent kinase 3Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 3Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 1Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 1Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 6Homo sapiens (human)
protein bindingCyclin-dependent kinase 6Homo sapiens (human)
ATP bindingCyclin-dependent kinase 6Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 6Homo sapiens (human)
FBXO family protein bindingCyclin-dependent kinase 6Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 6Homo sapiens (human)
microtubule bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
p53 bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
ErbB-2 class receptor bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
ATP bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
acetylcholine receptor activator activityCyclin-dependent-like kinase 5 Homo sapiens (human)
ErbB-3 class receptor bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
tau protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
tau-protein kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
Hsp90 protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
protein bindingCyclin-dependent kinase 16Homo sapiens (human)
ATP bindingCyclin-dependent kinase 16Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 17Homo sapiens (human)
protein bindingCyclin-dependent kinase 17Homo sapiens (human)
ATP bindingCyclin-dependent kinase 17Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 17Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 17Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificMyelin transcription factor 1Homo sapiens (human)
DNA bindingMyelin transcription factor 1Homo sapiens (human)
DNA-binding transcription factor activityMyelin transcription factor 1Homo sapiens (human)
zinc ion bindingMyelin transcription factor 1Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
6-phosphofructokinase activityATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
protein bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
protein-containing complex bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
cadherin bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
metal ion bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
ATP bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
monosaccharide bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
AMP bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
identical protein bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
fructose-6-phosphate bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
actin monomer bindingProtein kinase C epsilon typeHomo sapiens (human)
protein kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein bindingProtein kinase C epsilon typeHomo sapiens (human)
ATP bindingProtein kinase C epsilon typeHomo sapiens (human)
enzyme activator activityProtein kinase C epsilon typeHomo sapiens (human)
enzyme bindingProtein kinase C epsilon typeHomo sapiens (human)
signaling receptor activator activityProtein kinase C epsilon typeHomo sapiens (human)
ethanol bindingProtein kinase C epsilon typeHomo sapiens (human)
metal ion bindingProtein kinase C epsilon typeHomo sapiens (human)
14-3-3 protein bindingProtein kinase C epsilon typeHomo sapiens (human)
protein serine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAP-kinase scaffold activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein kinase activator activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activator activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
scaffold protein bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein kinase activityAngiopoietin-1 receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityAngiopoietin-1 receptorHomo sapiens (human)
protein bindingAngiopoietin-1 receptorHomo sapiens (human)
ATP bindingAngiopoietin-1 receptorHomo sapiens (human)
growth factor bindingAngiopoietin-1 receptorHomo sapiens (human)
signaling receptor activityAngiopoietin-1 receptorHomo sapiens (human)
identical protein bindingAngiopoietin-1 receptorHomo sapiens (human)
transcription corepressor activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
bHLH transcription factor bindingMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
DNA bindingDNA topoisomerase 2-betaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-betaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-betaHomo sapiens (human)
protein bindingDNA topoisomerase 2-betaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complex bindingDNA topoisomerase 2-betaHomo sapiens (human)
metal ion bindingDNA topoisomerase 2-betaHomo sapiens (human)
protein kinase activityProtein kinase C theta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
protein bindingProtein kinase C theta typeHomo sapiens (human)
ATP bindingProtein kinase C theta typeHomo sapiens (human)
metal ion bindingProtein kinase C theta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C theta typeHomo sapiens (human)
activin receptor activity, type IActivin receptor type-1Homo sapiens (human)
protein kinase activityActivin receptor type-1Homo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-1Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityActivin receptor type-1Homo sapiens (human)
protein bindingActivin receptor type-1Homo sapiens (human)
ATP bindingActivin receptor type-1Homo sapiens (human)
peptide hormone bindingActivin receptor type-1Homo sapiens (human)
protein homodimerization activityActivin receptor type-1Homo sapiens (human)
cadherin bindingActivin receptor type-1Homo sapiens (human)
SMAD bindingActivin receptor type-1Homo sapiens (human)
metal ion bindingActivin receptor type-1Homo sapiens (human)
activin bindingActivin receptor type-1Homo sapiens (human)
transforming growth factor beta bindingActivin receptor type-1Homo sapiens (human)
BMP receptor activityActivin receptor type-1Homo sapiens (human)
protein tyrosine kinase bindingActivin receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activity, type IActivin receptor type-1Homo sapiens (human)
macrophage colony-stimulating factor receptor activityMacrophage-stimulating protein receptorHomo sapiens (human)
protein bindingMacrophage-stimulating protein receptorHomo sapiens (human)
ATP bindingMacrophage-stimulating protein receptorHomo sapiens (human)
enzyme bindingMacrophage-stimulating protein receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityMacrophage-stimulating protein receptorHomo sapiens (human)
actin bindingFocal adhesion kinase 1Homo sapiens (human)
protein tyrosine kinase activityFocal adhesion kinase 1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityFocal adhesion kinase 1Homo sapiens (human)
protein tyrosine phosphatase activityFocal adhesion kinase 1Homo sapiens (human)
integrin bindingFocal adhesion kinase 1Homo sapiens (human)
protein bindingFocal adhesion kinase 1Homo sapiens (human)
ATP bindingFocal adhesion kinase 1Homo sapiens (human)
JUN kinase bindingFocal adhesion kinase 1Homo sapiens (human)
protein kinase bindingFocal adhesion kinase 1Homo sapiens (human)
protein phosphatase bindingFocal adhesion kinase 1Homo sapiens (human)
SH2 domain bindingFocal adhesion kinase 1Homo sapiens (human)
molecular function activator activityFocal adhesion kinase 1Homo sapiens (human)
protein kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C zeta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein bindingProtein kinase C zeta typeHomo sapiens (human)
ATP bindingProtein kinase C zeta typeHomo sapiens (human)
potassium channel regulator activityProtein kinase C zeta typeHomo sapiens (human)
protein kinase bindingProtein kinase C zeta typeHomo sapiens (human)
phospholipase bindingProtein kinase C zeta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C zeta typeHomo sapiens (human)
protein-containing complex bindingProtein kinase C zeta typeHomo sapiens (human)
metal ion bindingProtein kinase C zeta typeHomo sapiens (human)
14-3-3 protein bindingProtein kinase C zeta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein kinase activityProtein kinase C delta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein bindingProtein kinase C delta typeHomo sapiens (human)
ATP bindingProtein kinase C delta typeHomo sapiens (human)
enzyme activator activityProtein kinase C delta typeHomo sapiens (human)
enzyme bindingProtein kinase C delta typeHomo sapiens (human)
protein kinase bindingProtein kinase C delta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C delta typeHomo sapiens (human)
metal ion bindingProtein kinase C delta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase BTKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase BTKHomo sapiens (human)
protein bindingTyrosine-protein kinase BTKHomo sapiens (human)
ATP bindingTyrosine-protein kinase BTKHomo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingTyrosine-protein kinase BTKHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase BTKHomo sapiens (human)
identical protein bindingTyrosine-protein kinase BTKHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase BTKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase BTKHomo sapiens (human)
virus receptor activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein bindingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
ATP bindingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein bindingCyclin-dependent kinase 18Homo sapiens (human)
ATP bindingCyclin-dependent kinase 18Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 18Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 18Homo sapiens (human)
protein serine/threonine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
protein tyrosine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
GTPase inhibitor activityActivated CDC42 kinase 1Homo sapiens (human)
epidermal growth factor receptor bindingActivated CDC42 kinase 1Homo sapiens (human)
protein bindingActivated CDC42 kinase 1Homo sapiens (human)
ATP bindingActivated CDC42 kinase 1Homo sapiens (human)
ubiquitin protein ligase bindingActivated CDC42 kinase 1Homo sapiens (human)
identical protein bindingActivated CDC42 kinase 1Homo sapiens (human)
metal ion bindingActivated CDC42 kinase 1Homo sapiens (human)
WW domain bindingActivated CDC42 kinase 1Homo sapiens (human)
protein serine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
protein bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
collagen bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
ATP bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
protein tyrosine kinase collagen receptor activityEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
metal ion bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
ATP bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein serine/threonine kinase activityMyotonin-protein kinaseHomo sapiens (human)
protein bindingMyotonin-protein kinaseHomo sapiens (human)
ATP bindingMyotonin-protein kinaseHomo sapiens (human)
myosin phosphatase regulator activityMyotonin-protein kinaseHomo sapiens (human)
metal ion bindingMyotonin-protein kinaseHomo sapiens (human)
protein serine kinase activityMyotonin-protein kinaseHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein serine/threonine kinase activator activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein bindingTyrosine-protein kinase MerHomo sapiens (human)
ATP bindingTyrosine-protein kinase MerHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase MerHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 4Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
chromatin binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein serine/threonine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cAMP-dependent protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
metal ion binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
tau protein binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
tau-protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein serine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
histone H2BS36 kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
collagen bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
gamma-tubulin bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
metal ion bindingDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 7Homo sapiens (human)
enzyme inhibitor activityMitogen-activated protein kinase 7Homo sapiens (human)
protein bindingMitogen-activated protein kinase 7Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 7Homo sapiens (human)
mitogen-activated protein kinase bindingMitogen-activated protein kinase 7Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 7Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 7Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein tyrosine kinase activator activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 3Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
zinc ion bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein kinase activitycGMP-dependent protein kinase 2Homo sapiens (human)
cGMP-dependent protein kinase activitycGMP-dependent protein kinase 2Homo sapiens (human)
ATP bindingcGMP-dependent protein kinase 2Homo sapiens (human)
cGMP bindingcGMP-dependent protein kinase 2Homo sapiens (human)
identical protein bindingcGMP-dependent protein kinase 2Homo sapiens (human)
mitogen-activated protein kinase bindingcGMP-dependent protein kinase 2Homo sapiens (human)
protein serine kinase activitycGMP-dependent protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityIntegrin-linked protein kinaseHomo sapiens (human)
protein bindingIntegrin-linked protein kinaseHomo sapiens (human)
ATP bindingIntegrin-linked protein kinaseHomo sapiens (human)
protein kinase bindingIntegrin-linked protein kinaseHomo sapiens (human)
protein serine kinase activityIntegrin-linked protein kinaseHomo sapiens (human)
protein kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein bindingRho-associated protein kinase 1Homo sapiens (human)
ATP bindingRho-associated protein kinase 1Homo sapiens (human)
small GTPase bindingRho-associated protein kinase 1Homo sapiens (human)
metal ion bindingRho-associated protein kinase 1Homo sapiens (human)
tau protein bindingRho-associated protein kinase 1Homo sapiens (human)
tau-protein kinase activityRho-associated protein kinase 1Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
protein bindingNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
ATP bindingNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
RNA bindingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein bindingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
death receptor bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ubiquitin protein ligase bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
signaling adaptor activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
identical protein bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein homodimerization activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein-containing complex bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
death domain bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
JUN kinase kinase kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
actin bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calcium-dependent protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calcium-dependent protein serine/threonine phosphatase activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
sodium channel inhibitor activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
titin bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
transmembrane transporter bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
identical protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
tau protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
tau-protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
histone H3T45 kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
transcription coactivator activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
activin receptor activity, type IIActivin receptor type-2BHomo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-2BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityActivin receptor type-2BHomo sapiens (human)
protein bindingActivin receptor type-2BHomo sapiens (human)
ATP bindingActivin receptor type-2BHomo sapiens (human)
activin receptor activity, type IIActivin receptor type-2BHomo sapiens (human)
kinase activator activityActivin receptor type-2BHomo sapiens (human)
growth factor bindingActivin receptor type-2BHomo sapiens (human)
metal ion bindingActivin receptor type-2BHomo sapiens (human)
activin bindingActivin receptor type-2BHomo sapiens (human)
activin receptor activityActivin receptor type-2BHomo sapiens (human)
protein bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
ATP bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
activin receptor activity, type IIBone morphogenetic protein receptor type-2Homo sapiens (human)
growth factor bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
BMP bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
cadherin bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
metal ion bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
BMP receptor activityBone morphogenetic protein receptor type-2Homo sapiens (human)
protein tyrosine kinase bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
transforming growth factor beta receptor activityBone morphogenetic protein receptor type-2Homo sapiens (human)
protein tyrosine kinase activityProtein-tyrosine kinase 6Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein-tyrosine kinase 6Homo sapiens (human)
protein bindingProtein-tyrosine kinase 6Homo sapiens (human)
ATP bindingProtein-tyrosine kinase 6Homo sapiens (human)
identical protein bindingProtein-tyrosine kinase 6Homo sapiens (human)
signaling receptor bindingProtein-tyrosine kinase 6Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein kinase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
cGMP-dependent protein kinase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
calcium channel regulator activitycGMP-dependent protein kinase 1 Homo sapiens (human)
protein bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
ATP bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
cGMP bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
identical protein bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
mitogen-activated protein kinase p38 bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
protein serine kinase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
RNA bindingCyclin-dependent kinase 13Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 13Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 13Homo sapiens (human)
protein bindingCyclin-dependent kinase 13Homo sapiens (human)
ATP bindingCyclin-dependent kinase 13Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 13Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 13Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 13Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 13Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
K63-linked polyubiquitin modification-dependent protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
protein phosphatase bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
ubiquitin protein ligase bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
K48-linked polyubiquitin modification-dependent protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
identical protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
calmodulin-dependent protein kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein tyrosine kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
ATP bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
ubiquitin protein ligase bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
glutamate receptor bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
3-phosphoinositide-dependent protein kinase bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein-containing complex bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
neurotransmitter receptor regulator activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein serine/threonine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
calcium ion bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
ATP bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
lipid bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein serine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
chromatin bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
RNA bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
protein bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
ATP bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
ATP hydrolysis activityStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mediator complex bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
protein heterodimerization activityStructural maintenance of chromosomes protein 1AHomo sapiens (human)
DNA bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleosomal DNA bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
transcription coregulator bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
transcription corepressor activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
helicase activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
protein bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
ATP bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
zinc ion bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
ATP hydrolysis activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
histone deacetylase bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
ATP-dependent chromatin remodeler activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
chromatin bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
DNA bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
histone bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
acyl-CoA oxidase activityPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
protein bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
PDZ domain bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
protein homodimerization activityPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
FAD bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
flavin adenine dinucleotide bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
palmitoyl-CoA oxidase activityPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
protein kinase C bindingSerine/threonine-protein kinase D1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D1Homo sapiens (human)
kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
heat shock protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
phosphatidylinositol 3-kinase activator activitySerine/threonine-protein kinase D1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 38Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 38Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 38Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 38Homo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingSerine/threonine-protein kinase 38Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase 38Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 38Homo sapiens (human)
histone reader activitySerine/threonine-protein kinase 38Homo sapiens (human)
UFM1-modified protein reader activitySerine/threonine-protein kinase 38Homo sapiens (human)
transcription cis-regulatory region bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuregulin receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein homodimerization activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein tyrosine kinase activityEphrin type-A receptor 7Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 7Homo sapiens (human)
protein bindingEphrin type-A receptor 7Homo sapiens (human)
ATP bindingEphrin type-A receptor 7Homo sapiens (human)
axon guidance receptor activityEphrin type-A receptor 7Homo sapiens (human)
growth factor bindingEphrin type-A receptor 7Homo sapiens (human)
chemorepellent activityEphrin type-A receptor 7Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 7Homo sapiens (human)
delta24(24-1) sterol reductase activityDelta(24)-sterol reductaseHomo sapiens (human)
protein bindingDelta(24)-sterol reductaseHomo sapiens (human)
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptorDelta(24)-sterol reductaseHomo sapiens (human)
enzyme bindingDelta(24)-sterol reductaseHomo sapiens (human)
peptide antigen bindingDelta(24)-sterol reductaseHomo sapiens (human)
delta24-sterol reductase activityDelta(24)-sterol reductaseHomo sapiens (human)
FAD bindingDelta(24)-sterol reductaseHomo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein tyrosine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
ATP bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein kinase bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
metal ion bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein serine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
actin bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase, smooth muscleHomo sapiens (human)
protein bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
calmodulin bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
ATP bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
metal ion bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
protein bindingMitogen-activated protein kinase 11Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 11Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
p53 bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase STK11Homo sapiens (human)
protein bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
LRR domain bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
protein kinase activator activitySerine/threonine-protein kinase STK11Homo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase STK11Homo sapiens (human)
protein kinase activityRhodopsin kinase GRK1Homo sapiens (human)
ATP bindingRhodopsin kinase GRK1Homo sapiens (human)
rhodopsin kinase activityRhodopsin kinase GRK1Homo sapiens (human)
p53 bindingNT-3 growth factor receptorHomo sapiens (human)
neurotrophin receptor activityNT-3 growth factor receptorHomo sapiens (human)
protein bindingNT-3 growth factor receptorHomo sapiens (human)
ATP bindingNT-3 growth factor receptorHomo sapiens (human)
neurotrophin bindingNT-3 growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityNT-3 growth factor receptorHomo sapiens (human)
chromatin bindingSerine/threonine-protein kinase N1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
protein kinase C bindingSerine/threonine-protein kinase N1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase N1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase N1Homo sapiens (human)
nuclear receptor coactivator activitySerine/threonine-protein kinase N1Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase N1Homo sapiens (human)
histone H3T11 kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
histone bindingSerine/threonine-protein kinase N1Homo sapiens (human)
histone deacetylase bindingSerine/threonine-protein kinase N1Homo sapiens (human)
nuclear androgen receptor bindingSerine/threonine-protein kinase N1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
RNA bindingSerine/threonine-protein kinase N2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase N2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase N2Homo sapiens (human)
kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase N2Homo sapiens (human)
histone deacetylase bindingSerine/threonine-protein kinase N2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase N2Homo sapiens (human)
RNA polymerase bindingSerine/threonine-protein kinase N2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
calcium-dependent protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
small GTPase bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
mitogen-activated protein kinase kinase bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protease bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
ATP bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein homodimerization activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
neurotrophin bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
brain-derived neurotrophic factor bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
brain-derived neurotrophic factor receptor activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 6Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 6Homo sapiens (human)
protein bindingMitogen-activated protein kinase 6Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 6Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase 6Homo sapiens (human)
protein heterodimerization activityMitogen-activated protein kinase 6Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 6Homo sapiens (human)
phosphorylase kinase activityPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
calmodulin bindingPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
ATP bindingPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
enzyme bindingPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
tau-protein kinase activityPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
protein serine kinase activityPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
ATP bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
protein tyrosine kinase collagen receptor activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein serine/threonine kinase activityAP2-associated protein kinase 1Homo sapiens (human)
Notch bindingAP2-associated protein kinase 1Homo sapiens (human)
protein bindingAP2-associated protein kinase 1Homo sapiens (human)
ATP bindingAP2-associated protein kinase 1Homo sapiens (human)
AP-2 adaptor complex bindingAP2-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityAP2-associated protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityMyosin light chain kinase 3Homo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase 3Homo sapiens (human)
protein bindingMyosin light chain kinase 3Homo sapiens (human)
ATP bindingMyosin light chain kinase 3Homo sapiens (human)
protein serine/threonine kinase activityUncharacterized aarF domain-containing protein kinase 5Homo sapiens (human)
protein bindingUncharacterized aarF domain-containing protein kinase 5Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SBK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SBK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SBK1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 19Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 19Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 19Homo sapiens (human)
molecular_functionPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
ATP hydrolysis activityPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
ATP-dependent protein folding chaperonePutative heat shock protein HSP 90-beta 2Homo sapiens (human)
disordered domain specific bindingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
ATP bindingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
unfolded protein bindingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein bindingSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TNNI3KHomo sapiens (human)
SNARE bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
magnesium ion bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
actin bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTPase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
JUN kinase kinase kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
MAP kinase kinase kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTPase activator activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTP bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
microtubule bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
tubulin bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
syntaxin-1 bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
signaling receptor complex adaptor activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
clathrin bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
small GTPase bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTP-dependent protein kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
peroxidase inhibitor activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
co-receptor bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
identical protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein homodimerization activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
transmembrane transporter bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein kinase A bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
beta-catenin destruction complex bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
identical protein bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
protein bindingSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
flavin adenine dinucleotide bindingAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek5Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek5Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek5Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek5Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Nek5Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase N3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase N3Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase N3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK3Homo sapiens (human)
protein serine/threonine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein tyrosine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein bindingDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
ATP bindingDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein serine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
long-chain fatty acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
protein bindingAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
very-long-chain fatty acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
flavin adenine dinucleotide bindingAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
medium-chain fatty acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
RNA endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
unfolded protein bindingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
RNA bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
lipid bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein kinase activator activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
transferase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
alpha-tubulin bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
beta-tubulin bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein kinase activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
protein bindingSTE20-related kinase adapter protein alphaHomo sapiens (human)
ATP bindingSTE20-related kinase adapter protein alphaHomo sapiens (human)
kinase bindingSTE20-related kinase adapter protein alphaHomo sapiens (human)
protein kinase activator activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
protein serine/threonine kinase activator activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
microfilament motor activityMyosin-14Homo sapiens (human)
actin filament bindingMyosin-14Homo sapiens (human)
calmodulin bindingMyosin-14Homo sapiens (human)
ATP bindingMyosin-14Homo sapiens (human)
protein serine/threonine kinase activityAarF domain-containing protein kinase 1Homo sapiens (human)
ATP bindingAarF domain-containing protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 32CHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 32CHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 32CHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 32CHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 32CHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-3Homo sapiens (human)
RNA bindingATP-dependent RNA helicase DDX42Homo sapiens (human)
RNA helicase activityATP-dependent RNA helicase DDX42Homo sapiens (human)
protein bindingATP-dependent RNA helicase DDX42Homo sapiens (human)
ATP bindingATP-dependent RNA helicase DDX42Homo sapiens (human)
ATP hydrolysis activityATP-dependent RNA helicase DDX42Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase VRK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein domain specific bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase VRK2Homo sapiens (human)
protein bindingMyosin light chain kinase family member 4Homo sapiens (human)
ATP bindingMyosin light chain kinase family member 4Homo sapiens (human)
protein serine kinase activityMyosin light chain kinase family member 4Homo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase family member 4Homo sapiens (human)
protein bindingHomeodomain-interacting protein kinase 1Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
protein bindingCyclin-dependent kinase-like 3Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 3Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
p53 bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
MAP kinase kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
protein bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
ATP bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
protein serine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
mitogen-activated protein kinase bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
calmodulin bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATPase bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATPase regulator activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase NIM1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase NIM1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase NIM1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase NIM1Homo sapiens (human)
RNA bindingEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
translation release factor activityEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
GTPase activityEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
protein bindingEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
GTP bindingEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK2Homo sapiens (human)
protein kinase activityMisshapen-like kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMisshapen-like kinase 1Homo sapiens (human)
protein bindingMisshapen-like kinase 1Homo sapiens (human)
ATP bindingMisshapen-like kinase 1Homo sapiens (human)
protein serine kinase activityMisshapen-like kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase DCLK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase DCLK2Homo sapiens (human)
microtubule bindingSerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
ATP bindingCasein kinase I isoform alpha-likeHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform alpha-likeHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform alpha-likeHomo sapiens (human)
protein bindingHomeodomain-interacting protein kinase 4Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 4Homo sapiens (human)
histone kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
microfilament motor activityMyosin-IIIaHomo sapiens (human)
actin bindingMyosin-IIIaHomo sapiens (human)
protein kinase activityMyosin-IIIaHomo sapiens (human)
protein bindingMyosin-IIIaHomo sapiens (human)
calmodulin bindingMyosin-IIIaHomo sapiens (human)
ATP bindingMyosin-IIIaHomo sapiens (human)
ADP bindingMyosin-IIIaHomo sapiens (human)
plus-end directed microfilament motor activityMyosin-IIIaHomo sapiens (human)
protein serine kinase activityMyosin-IIIaHomo sapiens (human)
protein serine/threonine kinase activityMyosin-IIIaHomo sapiens (human)
protein serine/threonine kinase activityAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein bindingAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
ATP bindingAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein serine kinase activityAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek11Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek11Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek11Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek11Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek11Homo sapiens (human)
protein kinase activityAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
protein bindingAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
ATP bindingAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
kinase activityAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
ADP bindingAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
ATP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
identical protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
chromatin bindingMitogen-activated protein kinase 15Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
protein bindingMitogen-activated protein kinase 15Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 15Homo sapiens (human)
kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
SH3 domain bindingMitogen-activated protein kinase 15Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek9Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
protein kinase activator activitySerine/threonine-protein kinase Nek9Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek9Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
gamma-tubulin bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 35Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 35Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 35Homo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activitySerine/threonine-protein kinase 35Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek7Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek7Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek7Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
molecular function activator activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
protein bindingRhodopsin kinase GRK7Homo sapiens (human)
ATP bindingRhodopsin kinase GRK7Homo sapiens (human)
rhodopsin kinase activityRhodopsin kinase GRK7Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 32AHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 32AHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 32AHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 32AHomo sapiens (human)
actin bindingMyosin-IIIbHomo sapiens (human)
protein bindingMyosin-IIIbHomo sapiens (human)
ATP bindingMyosin-IIIbHomo sapiens (human)
protein serine kinase activityMyosin-IIIbHomo sapiens (human)
protein serine/threonine kinase activityMyosin-IIIbHomo sapiens (human)
microfilament motor activityMyosin-IIIbHomo sapiens (human)
DNA bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
chromatin bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
transcription coregulator activityATP-dependent RNA helicase DDX1Homo sapiens (human)
RNA bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
RNA helicase activityATP-dependent RNA helicase DDX1Homo sapiens (human)
double-stranded RNA bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
nuclease activityATP-dependent RNA helicase DDX1Homo sapiens (human)
exonuclease activityATP-dependent RNA helicase DDX1Homo sapiens (human)
protein bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
ATP bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
poly(A) bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
ATP hydrolysis activityATP-dependent RNA helicase DDX1Homo sapiens (human)
DNA/RNA helicase activityATP-dependent RNA helicase DDX1Homo sapiens (human)
magnesium ion bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
manganese ion bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
calcium channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Sgk3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Sgk3Homo sapiens (human)
potassium channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
sodium channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
chloride channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
phosphatidylinositol bindingSerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein kinase activityAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
ATP bindingAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
lipid bindingAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
ATP hydrolysis activityAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
ATP bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytoskeletal anchor activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
gamma-tubulin bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
ubiquitin bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
tau protein bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
tau-protein kinase activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein serine kinase activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein tyrosine kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
14-3-3 protein bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 15Homo sapiens (human)
protein bindingCyclin-dependent kinase 15Homo sapiens (human)
ATP bindingCyclin-dependent kinase 15Homo sapiens (human)
metal ion bindingCyclin-dependent kinase 15Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 15Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 15Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 15Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
protein serine/threonine kinase activityPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
protein bindingPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol bindingPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein tyrosine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calcium ion bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
p53 bindingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein serine/threonine kinase activityEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein bindingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
ATP bindingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
hydrolase activityEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein serine kinase activityEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein kinase activityDual specificity testis-specific protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityDual specificity testis-specific protein kinase 2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity testis-specific protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityDual specificity testis-specific protein kinase 2Homo sapiens (human)
protein bindingDual specificity testis-specific protein kinase 2Homo sapiens (human)
ATP bindingDual specificity testis-specific protein kinase 2Homo sapiens (human)
metal ion bindingDual specificity testis-specific protein kinase 2Homo sapiens (human)
protein serine kinase activityDual specificity testis-specific protein kinase 2Homo sapiens (human)
magnesium ion bindingSRSF protein kinase 1Homo sapiens (human)
RNA bindingSRSF protein kinase 1Homo sapiens (human)
protein kinase activitySRSF protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 1Homo sapiens (human)
protein bindingSRSF protein kinase 1Homo sapiens (human)
ATP bindingSRSF protein kinase 1Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 1Homo sapiens (human)
protein bindingProtein cereblonHomo sapiens (human)
transmembrane transporter bindingProtein cereblonHomo sapiens (human)
metal ion bindingProtein cereblonHomo sapiens (human)
protein serine/threonine kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein bindingMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
ATP bindingMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
metal ion bindingMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein serine kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein domain specific bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
1-phosphatidylinositol-3-phosphate 5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
kinase bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phosphatidylinositol kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
1-phosphatidylinositol-5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein bindingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
ATP bindingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
heme bindingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein homodimerization activityEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein serine kinase activityEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase RIO1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase RIO1Homo sapiens (human)
hydrolase activitySerine/threonine-protein kinase RIO1Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase RIO1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase RIO1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase RIO1Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase RIO2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase RIO2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase RIO2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase RIO2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase RIO2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase RIO2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 19Homo sapiens (human)
ATP bindingCyclin-dependent kinase 19Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 19Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 19Homo sapiens (human)
protein serine/threonine kinase activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
ATP bindingTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
metal ion bindingTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein serine kinase activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
monoatomic cation channel activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
magnesium ion bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein-containing complex bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 33Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 33Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 33Homo sapiens (human)
RNA bindingNucleolar GTP-binding protein 1Homo sapiens (human)
GTPase activityNucleolar GTP-binding protein 1Homo sapiens (human)
protein bindingNucleolar GTP-binding protein 1Homo sapiens (human)
GTP bindingNucleolar GTP-binding protein 1Homo sapiens (human)
preribosome bindingNucleolar GTP-binding protein 1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
protein kinase C bindingSerine/threonine-protein kinase D2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase DCLK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase DCLK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase DCLK3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase DCLK3Homo sapiens (human)
magnesium ion bindingNUAK family SNF1-like kinase 2Homo sapiens (human)
protein serine/threonine kinase activityNUAK family SNF1-like kinase 2Homo sapiens (human)
protein bindingNUAK family SNF1-like kinase 2Homo sapiens (human)
ATP bindingNUAK family SNF1-like kinase 2Homo sapiens (human)
protein serine kinase activityNUAK family SNF1-like kinase 2Homo sapiens (human)
RNA bindingRNA cytidine acetyltransferaseHomo sapiens (human)
protein bindingRNA cytidine acetyltransferaseHomo sapiens (human)
ATP bindingRNA cytidine acetyltransferaseHomo sapiens (human)
N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
tRNA N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
DNA polymerase bindingRNA cytidine acetyltransferaseHomo sapiens (human)
mRNA N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
tRNA bindingRNA cytidine acetyltransferaseHomo sapiens (human)
rRNA cytidine N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase SIK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SIK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase SIK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SIK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SIK2Homo sapiens (human)
calmodulin-dependent protein kinase activityMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
protein bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
calmodulin bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
ATP bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
myosin light chain bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
protein serine/threonine kinase activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
ATP bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
identical protein bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein homodimerization activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
cadherin bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein serine kinase activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
protein kinase inhibitor activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TAO3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TAO3Homo sapiens (human)
transferase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
transcription coactivator activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
transcription corepressor activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
SMAD bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
virion bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase SrmsHomo sapiens (human)
protein bindingTyrosine-protein kinase SrmsHomo sapiens (human)
ATP bindingTyrosine-protein kinase SrmsHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase SrmsHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase SrmsHomo sapiens (human)
protein kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 3Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
p53 bindingSerine/threonine-protein kinase PLK3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK3Homo sapiens (human)
magnesium ion bindingdCTP pyrophosphatase 1Homo sapiens (human)
protein bindingdCTP pyrophosphatase 1Homo sapiens (human)
pyrimidine deoxyribonucleotide bindingdCTP pyrophosphatase 1Homo sapiens (human)
identical protein bindingdCTP pyrophosphatase 1Homo sapiens (human)
nucleoside triphosphate diphosphatase activitydCTP pyrophosphatase 1Homo sapiens (human)
dCTP diphosphatase activitydCTP pyrophosphatase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein bindingDual specificity protein kinase CLK4Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK4Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
transcription corepressor bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek6Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
kinesin bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
ubiquitin protein ligase bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek6Homo sapiens (human)
DNA-binding transcription factor bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-1Homo sapiens (human)
protein bindingCasein kinase I isoform gamma-1Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-1Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 6Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 6Homo sapiens (human)
magnesium ion bindingSNF-related serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activitySNF-related serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingSNF-related serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activitySNF-related serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase LATS2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase LATS2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase LATS2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase LATS2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase LATS2Homo sapiens (human)
transcription corepressor bindingSerine/threonine-protein kinase 36Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 36Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 36Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 36Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 36Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 36Homo sapiens (human)
magnesium ion bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
RNA bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
phenylalanine-tRNA ligase activityPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
protein bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
ATP bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
tRNA bindingIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
aminoacyl-tRNA editing activityIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
isoleucine-tRNA ligase activityIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
ATP bindingIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
protein bindingBMP-2-inducible protein kinaseHomo sapiens (human)
ATP bindingBMP-2-inducible protein kinaseHomo sapiens (human)
protein serine kinase activityBMP-2-inducible protein kinaseHomo sapiens (human)
phosphatase regulator activityBMP-2-inducible protein kinaseHomo sapiens (human)
AP-2 adaptor complex bindingBMP-2-inducible protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityBMP-2-inducible protein kinaseHomo sapiens (human)
protein bindingObg-like ATPase 1Homo sapiens (human)
ATP bindingObg-like ATPase 1Homo sapiens (human)
GTP bindingObg-like ATPase 1Homo sapiens (human)
ATP hydrolysis activityObg-like ATPase 1Homo sapiens (human)
ribosomal large subunit bindingObg-like ATPase 1Homo sapiens (human)
cadherin bindingObg-like ATPase 1Homo sapiens (human)
metal ion bindingObg-like ATPase 1Homo sapiens (human)
protein bindingMidasinHomo sapiens (human)
ATP bindingMidasinHomo sapiens (human)
ATP hydrolysis activityMidasinHomo sapiens (human)
magnesium ion bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein serine/threonine kinase activityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
interleukin-1 receptor bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
ATP bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
kinase activityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein kinase bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein serine kinase activityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 32BHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 32BHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 32BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 32BHomo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
RNA bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein kinase activator activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
ribosome bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
small ribosomal subunit rRNA bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 12Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 12Homo sapiens (human)
protein bindingCyclin-dependent kinase 12Homo sapiens (human)
ATP bindingCyclin-dependent kinase 12Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 12Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 12Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 12Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 12Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK2Homo sapiens (human)
ATP-dependent protein bindingSerine/threonine-protein kinase PLK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK2Homo sapiens (human)
protein bindingNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
ATP bindingNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
endopeptidase activator activityNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
phosphatidylserine bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MARK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase MARK1Homo sapiens (human)
phosphatidic acid bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MARK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 5Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 5Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 26Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 26Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 26Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 26Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 26Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 26Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 26Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 26Homo sapiens (human)
tRNA bindingeIF-2-alpha kinase GCN2Homo sapiens (human)
protein serine/threonine kinase activityeIF-2-alpha kinase GCN2Homo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityeIF-2-alpha kinase GCN2Homo sapiens (human)
ATP bindingeIF-2-alpha kinase GCN2Homo sapiens (human)
protein serine kinase activityeIF-2-alpha kinase GCN2Homo sapiens (human)
magnesium ion bindingSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinate-CoA ligase (ADP-forming) activitySuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
protein bindingSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
ATP bindingSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
MAP kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
protein bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
ubiquitin protein ligase bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
SH2 domain bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
DNA-binding transcription factor bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
14-3-3 protein bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 17AHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 17AHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 17AHomo sapiens (human)
protein serine/threonine kinase activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein bindingSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
ATP bindingSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
kinase activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein kinase bindingSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein serine kinase activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
molecular_functionEphrin type-A receptor 6Homo sapiens (human)
protein bindingEphrin type-A receptor 6Homo sapiens (human)
ATP bindingEphrin type-A receptor 6Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 6Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cAMP-dependent protein kinase inhibitor activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cAMP-dependent protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
phosphorylase kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase activator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ADP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
AMP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleic acid bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
protein phosphatase bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
phosphoprotein bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein bindingSeptin-9Homo sapiens (human)
GTP bindingSeptin-9Homo sapiens (human)
cadherin bindingSeptin-9Homo sapiens (human)
GTPase activitySeptin-9Homo sapiens (human)
molecular adaptor activitySeptin-9Homo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 2Homo sapiens (human)
protein bindingDeath-associated protein kinase 2Homo sapiens (human)
calmodulin bindingDeath-associated protein kinase 2Homo sapiens (human)
ATP bindingDeath-associated protein kinase 2Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 2Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 2Homo sapiens (human)
A-type (transient outward) potassium channel activityPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
metal ion bindingPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein kinase activityRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-6Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-6Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein bindingTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
ATP bindingTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
MAP kinase kinase kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
mitogen-activated protein kinase kinase bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
neuropilin bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
long-chain fatty acid-CoA ligase activityLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
protein bindingLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
ATP bindingLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
arachidonate-CoA ligase activityLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
oleoyl-CoA ligase activityLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
protein tyrosine kinase activityALK tyrosine kinase receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityALK tyrosine kinase receptorHomo sapiens (human)
protein bindingALK tyrosine kinase receptorHomo sapiens (human)
ATP bindingALK tyrosine kinase receptorHomo sapiens (human)
heparin bindingALK tyrosine kinase receptorHomo sapiens (human)
receptor signaling protein tyrosine kinase activator activityALK tyrosine kinase receptorHomo sapiens (human)
identical protein bindingALK tyrosine kinase receptorHomo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein bindingSRSF protein kinase 3Homo sapiens (human)
ATP bindingSRSF protein kinase 3Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 3Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase ICKHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase ICKHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ICKHomo sapiens (human)
protein bindingSerine/threonine-protein kinase ICKHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase ICKHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ICKHomo sapiens (human)
protein kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
ATP bindingCyclin-dependent kinase 11AHomo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
protein kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase CHomo sapiens (human)
protein bindingAurora kinase CHomo sapiens (human)
ATP bindingAurora kinase CHomo sapiens (human)
protein serine kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
glutamate receptor bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein kinase activityRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
actin bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 38-likeHomo sapiens (human)
magnesium ion bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
microtubule bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase SIK3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SIK3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase SIK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SIK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SIK3Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase SIK3Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
transcription coregulator activityThyroid hormone receptor-associated protein 3Homo sapiens (human)
transcription coactivator activityThyroid hormone receptor-associated protein 3Homo sapiens (human)
RNA bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
protein bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
ATP bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear receptor coactivator activityThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear vitamin D receptor bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear thyroid hormone receptor bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
phosphoprotein bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
DNA bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
transcription coactivator activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
transcription coactivator activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
identical protein bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein-containing complex bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
magnesium ion bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein serine/threonine kinase activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
ATP bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein kinase bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein homodimerization activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein heterodimerization activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 24Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 24Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 24Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 24Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase 24Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 24Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 24Homo sapiens (human)
protein bindingNF-kappa-B essential modulatorHomo sapiens (human)
protein domain specific bindingNF-kappa-B essential modulatorHomo sapiens (human)
polyubiquitin modification-dependent protein bindingNF-kappa-B essential modulatorHomo sapiens (human)
ubiquitin protein ligase bindingNF-kappa-B essential modulatorHomo sapiens (human)
signaling adaptor activityNF-kappa-B essential modulatorHomo sapiens (human)
identical protein bindingNF-kappa-B essential modulatorHomo sapiens (human)
protein homodimerization activityNF-kappa-B essential modulatorHomo sapiens (human)
metal ion bindingNF-kappa-B essential modulatorHomo sapiens (human)
protein heterodimerization activityNF-kappa-B essential modulatorHomo sapiens (human)
K63-linked polyubiquitin modification-dependent protein bindingNF-kappa-B essential modulatorHomo sapiens (human)
linear polyubiquitin bindingNF-kappa-B essential modulatorHomo sapiens (human)
transferrin receptor bindingNF-kappa-B essential modulatorHomo sapiens (human)
protein kinase activityCasein kinase I isoform gamma-3Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-3Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-3Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-3Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (489)

Processvia Protein(s)Taxonomy
plasma membraneBone morphogenetic protein receptor type-1BHomo sapiens (human)
dendriteBone morphogenetic protein receptor type-1BHomo sapiens (human)
neuronal cell bodyBone morphogenetic protein receptor type-1BHomo sapiens (human)
receptor complexBone morphogenetic protein receptor type-1BHomo sapiens (human)
HFE-transferrin receptor complexBone morphogenetic protein receptor type-1BHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1BHomo sapiens (human)
plasma membraneMembrane-associated progesterone receptor component 1Homo sapiens (human)
extracellular regionMembrane-associated progesterone receptor component 1Homo sapiens (human)
mitochondrial outer membraneMembrane-associated progesterone receptor component 1Homo sapiens (human)
endoplasmic reticulumMembrane-associated progesterone receptor component 1Homo sapiens (human)
plasma membraneMembrane-associated progesterone receptor component 1Homo sapiens (human)
membraneMembrane-associated progesterone receptor component 1Homo sapiens (human)
smooth endoplasmic reticulum membraneMembrane-associated progesterone receptor component 1Homo sapiens (human)
specific granule membraneMembrane-associated progesterone receptor component 1Homo sapiens (human)
neuron projectionMembrane-associated progesterone receptor component 1Homo sapiens (human)
neuronal cell bodyMembrane-associated progesterone receptor component 1Homo sapiens (human)
cell bodyMembrane-associated progesterone receptor component 1Homo sapiens (human)
synapseMembrane-associated progesterone receptor component 1Homo sapiens (human)
endoplasmic reticulumMembrane-associated progesterone receptor component 1Homo sapiens (human)
endomembrane systemMembrane-associated progesterone receptor component 1Homo sapiens (human)
membraneMembrane-associated progesterone receptor component 1Homo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
XY bodySerine/threonine-protein kinase PLK4Homo sapiens (human)
nucleolusSerine/threonine-protein kinase PLK4Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK4Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK4Homo sapiens (human)
cytosolSerine/threonine-protein kinase PLK4Homo sapiens (human)
cleavage furrowSerine/threonine-protein kinase PLK4Homo sapiens (human)
deuterosomeSerine/threonine-protein kinase PLK4Homo sapiens (human)
procentrioleSerine/threonine-protein kinase PLK4Homo sapiens (human)
procentriole replication complexSerine/threonine-protein kinase PLK4Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK4Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 25Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 25Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 25Homo sapiens (human)
FAR/SIN/STRIPAK complexSerine/threonine-protein kinase 25Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 25Homo sapiens (human)
eukaryotic translation initiation factor 3 complexATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytosolic small ribosomal subunitATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX3XHomo sapiens (human)
extracellular regionATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleusATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleoplasmATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX3XHomo sapiens (human)
centrosomeATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytosolATP-dependent RNA helicase DDX3XHomo sapiens (human)
plasma membraneATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytoplasmic stress granuleATP-dependent RNA helicase DDX3XHomo sapiens (human)
lamellipodiumATP-dependent RNA helicase DDX3XHomo sapiens (human)
cell leading edgeATP-dependent RNA helicase DDX3XHomo sapiens (human)
secretory granule lumenATP-dependent RNA helicase DDX3XHomo sapiens (human)
extracellular exosomeATP-dependent RNA helicase DDX3XHomo sapiens (human)
ficolin-1-rich granule lumenATP-dependent RNA helicase DDX3XHomo sapiens (human)
NLRP3 inflammasome complexATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleusATP-dependent RNA helicase DDX3XHomo sapiens (human)
P granuleATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
endoplasmic reticulumPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
endocytic vesiclePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
intracellular membrane-bounded organellePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
extracellular regionPyridoxal kinaseHomo sapiens (human)
nucleusPyridoxal kinaseHomo sapiens (human)
nucleoplasmPyridoxal kinaseHomo sapiens (human)
cytosolPyridoxal kinaseHomo sapiens (human)
secretory granule lumenPyridoxal kinaseHomo sapiens (human)
specific granule lumenPyridoxal kinaseHomo sapiens (human)
extracellular exosomePyridoxal kinaseHomo sapiens (human)
cytosolPyridoxal kinaseHomo sapiens (human)
cytosolCitron Rho-interacting kinaseHomo sapiens (human)
membraneCitron Rho-interacting kinaseHomo sapiens (human)
cytosolSerine/threonine-protein kinase RIO3Homo sapiens (human)
preribosome, small subunit precursorSerine/threonine-protein kinase RIO3Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO3Homo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein kinase Chk1Homo sapiens (human)
condensed nuclear chromosomeSerine/threonine-protein kinase Chk1Homo sapiens (human)
extracellular spaceSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleusSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Chk1Homo sapiens (human)
replication forkSerine/threonine-protein kinase Chk1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Chk1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Chk1Homo sapiens (human)
cytosolSerine/threonine-protein kinase Chk1Homo sapiens (human)
intracellular membrane-bounded organelleSerine/threonine-protein kinase Chk1Homo sapiens (human)
chromatinSerine/threonine-protein kinase Chk1Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleusSerine/threonine-protein kinase Chk1Homo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
nucleusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
membrane raftInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
basement membranePeripheral plasma membrane protein CASKHomo sapiens (human)
nuclear laminaPeripheral plasma membrane protein CASKHomo sapiens (human)
nucleolusPeripheral plasma membrane protein CASKHomo sapiens (human)
cytoplasmPeripheral plasma membrane protein CASKHomo sapiens (human)
cytosolPeripheral plasma membrane protein CASKHomo sapiens (human)
cell-cell junctionPeripheral plasma membrane protein CASKHomo sapiens (human)
focal adhesionPeripheral plasma membrane protein CASKHomo sapiens (human)
actin cytoskeletonPeripheral plasma membrane protein CASKHomo sapiens (human)
nuclear matrixPeripheral plasma membrane protein CASKHomo sapiens (human)
vesiclePeripheral plasma membrane protein CASKHomo sapiens (human)
presynaptic membranePeripheral plasma membrane protein CASKHomo sapiens (human)
ciliary membranePeripheral plasma membrane protein CASKHomo sapiens (human)
Schaffer collateral - CA1 synapsePeripheral plasma membrane protein CASKHomo sapiens (human)
basement membranePeripheral plasma membrane protein CASKHomo sapiens (human)
cell-cell junctionPeripheral plasma membrane protein CASKHomo sapiens (human)
basolateral plasma membranePeripheral plasma membrane protein CASKHomo sapiens (human)
plasma membranePeripheral plasma membrane protein CASKHomo sapiens (human)
spindle microtubuleAurora kinase AHomo sapiens (human)
nucleusAurora kinase AHomo sapiens (human)
nucleoplasmAurora kinase AHomo sapiens (human)
centrosomeAurora kinase AHomo sapiens (human)
centrioleAurora kinase AHomo sapiens (human)
spindleAurora kinase AHomo sapiens (human)
cytosolAurora kinase AHomo sapiens (human)
postsynaptic densityAurora kinase AHomo sapiens (human)
microtubule cytoskeletonAurora kinase AHomo sapiens (human)
basolateral plasma membraneAurora kinase AHomo sapiens (human)
midbodyAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
ciliary basal bodyAurora kinase AHomo sapiens (human)
germinal vesicleAurora kinase AHomo sapiens (human)
axon hillockAurora kinase AHomo sapiens (human)
pronucleusAurora kinase AHomo sapiens (human)
perinuclear region of cytoplasmAurora kinase AHomo sapiens (human)
mitotic spindleAurora kinase AHomo sapiens (human)
meiotic spindleAurora kinase AHomo sapiens (human)
mitotic spindle poleAurora kinase AHomo sapiens (human)
glutamatergic synapseAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
chromosome passenger complexAurora kinase AHomo sapiens (human)
spindle midzoneAurora kinase AHomo sapiens (human)
kinetochoreAurora kinase AHomo sapiens (human)
Golgi apparatusCyclin-G-associated kinaseHomo sapiens (human)
cytosolCyclin-G-associated kinaseHomo sapiens (human)
focal adhesionCyclin-G-associated kinaseHomo sapiens (human)
membraneCyclin-G-associated kinaseHomo sapiens (human)
clathrin-coated vesicleCyclin-G-associated kinaseHomo sapiens (human)
vesicleCyclin-G-associated kinaseHomo sapiens (human)
intracellular membrane-bounded organelleCyclin-G-associated kinaseHomo sapiens (human)
perinuclear region of cytoplasmCyclin-G-associated kinaseHomo sapiens (human)
presynapseCyclin-G-associated kinaseHomo sapiens (human)
vesicleCyclin-G-associated kinaseHomo sapiens (human)
cytoplasmCyclin-G-associated kinaseHomo sapiens (human)
intracellular membrane-bounded organelleCyclin-G-associated kinaseHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase DCLK1Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
nucleoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
plasma membraneMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
neuromuscular junctionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
postsynaptic membraneMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
receptor complexMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
plasma membraneMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
extracellular regionEphrin type-B receptor 6Homo sapiens (human)
cytosolEphrin type-B receptor 6Homo sapiens (human)
plasma membraneEphrin type-B receptor 6Homo sapiens (human)
plasma membraneEphrin type-B receptor 6Homo sapiens (human)
dendriteEphrin type-B receptor 6Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
peroxisomal matrixPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
cytosolPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
membranePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
cytosolMitogen-activated protein kinase 13Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 13Homo sapiens (human)
nucleusMitogen-activated protein kinase 13Homo sapiens (human)
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
nucleus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasm3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
focal adhesion3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
postsynaptic density3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasmic vesicle3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell projection3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
nucleusDeath-associated protein kinase 3Homo sapiens (human)
nucleoplasmDeath-associated protein kinase 3Homo sapiens (human)
cytosolDeath-associated protein kinase 3Homo sapiens (human)
PML bodyDeath-associated protein kinase 3Homo sapiens (human)
nucleusDeath-associated protein kinase 3Homo sapiens (human)
cytoplasmDeath-associated protein kinase 3Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
nucleusMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
plasma membraneMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
endosome membraneMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
ATAC complexMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
plasma membraneReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulumReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytosolReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoskeletonReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
vesicleReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein-containing complexReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
kinetochoreMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
nucleoplasmMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
cytosolMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
membraneMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
intracellular membrane-bounded organelleMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
outer kinetochoreMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
kinetochoreMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
nucleusMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
fibrillar centerNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleusNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleoplasmNUAK family SNF1-like kinase 1Homo sapiens (human)
cytoplasmNUAK family SNF1-like kinase 1Homo sapiens (human)
microtubule cytoskeletonNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleoplasmDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial outer membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial inner membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cytosolDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial cristaDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
dendriteDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
axon cytoplasmDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cytoplasmDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
microtubuleDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
phagocytic cupPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
uropodPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
adherens junctionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
focal adhesionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
endosome membranePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
ruffle membranePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
presynapsePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK2Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK2Homo sapiens (human)
nucleusTyrosine-protein kinase JAK2Homo sapiens (human)
nucleoplasmTyrosine-protein kinase JAK2Homo sapiens (human)
cytoplasmTyrosine-protein kinase JAK2Homo sapiens (human)
cytosolTyrosine-protein kinase JAK2Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK2Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK2Homo sapiens (human)
caveolaTyrosine-protein kinase JAK2Homo sapiens (human)
focal adhesionTyrosine-protein kinase JAK2Homo sapiens (human)
granulocyte macrophage colony-stimulating factor receptor complexTyrosine-protein kinase JAK2Homo sapiens (human)
endosome lumenTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-12 receptor complexTyrosine-protein kinase JAK2Homo sapiens (human)
membrane raftTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-23 receptor complexTyrosine-protein kinase JAK2Homo sapiens (human)
postsynapseTyrosine-protein kinase JAK2Homo sapiens (human)
glutamatergic synapseTyrosine-protein kinase JAK2Homo sapiens (human)
euchromatinTyrosine-protein kinase JAK2Homo sapiens (human)
cytosolTyrosine-protein kinase JAK2Homo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
nucleusEukaryotic translation initiation factor 5BHomo sapiens (human)
cytoplasmEukaryotic translation initiation factor 5BHomo sapiens (human)
cytosolEukaryotic translation initiation factor 5BHomo sapiens (human)
synapseEukaryotic translation initiation factor 5BHomo sapiens (human)
cytoplasmEukaryotic translation initiation factor 5BHomo sapiens (human)
nucleusRho-associated protein kinase 2Homo sapiens (human)
centrosomeRho-associated protein kinase 2Homo sapiens (human)
cytosolRho-associated protein kinase 2Homo sapiens (human)
plasma membraneRho-associated protein kinase 2Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleRho-associated protein kinase 2Homo sapiens (human)
centrosomeRho-associated protein kinase 2Homo sapiens (human)
cytoskeletonRho-associated protein kinase 2Homo sapiens (human)
cytoplasmRho-associated protein kinase 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosome membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK1Homo sapiens (human)
mitochondrial outer membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK1Homo sapiens (human)
axonSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
recycling endosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
omegasome membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
Atg1/ULK1 kinase complexSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
nuclear inner membraneSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Ire1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
AIP1-IRE1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-TRAF2-ASK1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-RACK1-PP2A complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleusU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
nucleoplasmU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
membraneU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U4/U6 x U5 tri-snRNP complexU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
spliceosomal complexU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U5 snRNPU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U2-type precatalytic spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U2-type catalytic step 1 spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
catalytic step 2 spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-4Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-4Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
Golgi-associated vesicleSerine/threonine-protein kinase 16Homo sapiens (human)
cytosolSerine/threonine-protein kinase 16Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase 16Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 16Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 3Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase PAK 3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 3Homo sapiens (human)
ruffle membraneCyclin-dependent kinase-like 5Homo sapiens (human)
glutamatergic synapseCyclin-dependent kinase-like 5Homo sapiens (human)
nucleusCyclin-dependent kinase-like 5Homo sapiens (human)
nucleoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
centrosomeCyclin-dependent kinase-like 5Homo sapiens (human)
dendrite cytoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
ciliary basal bodyCyclin-dependent kinase-like 5Homo sapiens (human)
dendritic growth coneCyclin-dependent kinase-like 5Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
ciliary tipCyclin-dependent kinase-like 5Homo sapiens (human)
postsynaptic density, intracellular componentCyclin-dependent kinase-like 5Homo sapiens (human)
nucleusCyclin-dependent kinase-like 5Homo sapiens (human)
dendrite cytoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
nucleusSerine/threonine-protein kinase 17BHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 17BHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentSerine/threonine-protein kinase 17BHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase 17BHomo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase 17BHomo sapiens (human)
Flemming bodySerine/threonine-protein kinase 17BHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17BHomo sapiens (human)
cytosolSerine/threonine-protein kinase 10Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase 10Homo sapiens (human)
specific granule membraneSerine/threonine-protein kinase 10Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 10Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 10Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase D3Homo sapiens (human)
cytosolSerine/threonine-protein kinase D3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D3Homo sapiens (human)
cytosolSerine/threonine-protein kinase D3Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 14Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 14Homo sapiens (human)
cytosolCyclin-dependent kinase 14Homo sapiens (human)
plasma membraneCyclin-dependent kinase 14Homo sapiens (human)
cytoplasmic cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 14Homo sapiens (human)
cytoplasmCyclin-dependent kinase 14Homo sapiens (human)
cytosolCyclin-dependent kinase 14Homo sapiens (human)
nucleusCyclin-dependent kinase 14Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensed chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensed nuclear chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensin complexStructural maintenance of chromosomes protein 2Homo sapiens (human)
nucleusStructural maintenance of chromosomes protein 2Homo sapiens (human)
nucleoplasmStructural maintenance of chromosomes protein 2Homo sapiens (human)
nucleolusStructural maintenance of chromosomes protein 2Homo sapiens (human)
cytoplasmStructural maintenance of chromosomes protein 2Homo sapiens (human)
cytosolStructural maintenance of chromosomes protein 2Homo sapiens (human)
extracellular exosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensed chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
chromatinStructural maintenance of chromosomes protein 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase OSR1Homo sapiens (human)
cytosolSerine/threonine-protein kinase OSR1Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase OSR1Homo sapiens (human)
cytosolSerine/threonine-protein kinase OSR1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
focal adhesionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase LATS1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS1Homo sapiens (human)
nucleusSerine/threonine-protein kinase LATS1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase LATS1Homo sapiens (human)
cytosolSerine/threonine-protein kinase LATS1Homo sapiens (human)
midbodySerine/threonine-protein kinase LATS1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS1Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 4Homo sapiens (human)
adherens junctionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
focal adhesionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 4Homo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein kinase Chk2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Chk2Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase Chk2Homo sapiens (human)
PML bodySerine/threonine-protein kinase Chk2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Chk2Homo sapiens (human)
nucleusSerine/threonine-protein kinase Chk2Homo sapiens (human)
ruffleTyrosine-protein kinase ABL1Homo sapiens (human)
nucleusTyrosine-protein kinase ABL1Homo sapiens (human)
nucleoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
nucleolusTyrosine-protein kinase ABL1Homo sapiens (human)
cytoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
mitochondrionTyrosine-protein kinase ABL1Homo sapiens (human)
cytosolTyrosine-protein kinase ABL1Homo sapiens (human)
actin cytoskeletonTyrosine-protein kinase ABL1Homo sapiens (human)
nuclear bodyTyrosine-protein kinase ABL1Homo sapiens (human)
dendriteTyrosine-protein kinase ABL1Homo sapiens (human)
growth coneTyrosine-protein kinase ABL1Homo sapiens (human)
nuclear membraneTyrosine-protein kinase ABL1Homo sapiens (human)
neuronal cell bodyTyrosine-protein kinase ABL1Homo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
postsynapseTyrosine-protein kinase ABL1Homo sapiens (human)
protein-containing complexTyrosine-protein kinase ABL1Homo sapiens (human)
plasma membraneTyrosine-protein kinase ABL1Homo sapiens (human)
cytosolTyrosine-protein kinase ABL1Mus musculus (house mouse)
cytosolProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
nucleusProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
mitochondrial inner membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cytoskeletonProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
plasma membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
focal adhesionProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
endosome membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell junctionProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
perinuclear region of cytoplasmProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein-containing complexProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
plasma membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
plasma membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
nucleusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
mitochondrial outer membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
Golgi apparatusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
plasma membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
pseudopodiumRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
mitochondrionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
semaphorin receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
endosome membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ruffle membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelin sheathReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
perinuclear region of cytoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeHigh affinity nerve growth factor receptorHomo sapiens (human)
late endosomeHigh affinity nerve growth factor receptorHomo sapiens (human)
plasma membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
cell surfaceHigh affinity nerve growth factor receptorHomo sapiens (human)
endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
dendriteHigh affinity nerve growth factor receptorHomo sapiens (human)
early endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
late endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
neuronal cell bodyHigh affinity nerve growth factor receptorHomo sapiens (human)
recycling endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
protein-containing complexHigh affinity nerve growth factor receptorHomo sapiens (human)
receptor complexHigh affinity nerve growth factor receptorHomo sapiens (human)
axonHigh affinity nerve growth factor receptorHomo sapiens (human)
plasma membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleoplasmGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cytoplasmGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
centrosomeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cytosolGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
membraneGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
dendriteGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
midbodyGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cell bodyGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
synapseGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
extracellular exosomeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
neuronal dense core vesicleGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
extracellular vesicleGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
heterotrimeric G-protein complexGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cytoplasmGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
nucleusADP/ATP translocase 2Homo sapiens (human)
mitochondrionADP/ATP translocase 2Homo sapiens (human)
mitochondrial inner membraneADP/ATP translocase 2Homo sapiens (human)
plasma membraneADP/ATP translocase 2Homo sapiens (human)
membraneADP/ATP translocase 2Homo sapiens (human)
mitochondrial nucleoidADP/ATP translocase 2Homo sapiens (human)
mitochondrial permeability transition pore complexADP/ATP translocase 2Homo sapiens (human)
MMXD complexADP/ATP translocase 2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
nucleoplasmNeuronal proto-oncogene tyrosine-protein kinase Src Mus musculus (house mouse)
cytosolNeuronal proto-oncogene tyrosine-protein kinase Src Mus musculus (house mouse)
plasma membraneNeuronal proto-oncogene tyrosine-protein kinase Src Mus musculus (house mouse)
nucleusProtein kinase C beta typeHomo sapiens (human)
nucleoplasmProtein kinase C beta typeHomo sapiens (human)
cytoplasmProtein kinase C beta typeHomo sapiens (human)
centrosomeProtein kinase C beta typeHomo sapiens (human)
cytosolProtein kinase C beta typeHomo sapiens (human)
plasma membraneProtein kinase C beta typeHomo sapiens (human)
brush border membraneProtein kinase C beta typeHomo sapiens (human)
calyx of HeldProtein kinase C beta typeHomo sapiens (human)
extracellular exosomeProtein kinase C beta typeHomo sapiens (human)
presynaptic cytosolProtein kinase C beta typeHomo sapiens (human)
spectrinProtein kinase C beta typeHomo sapiens (human)
nuclear envelopeInsulin receptorHomo sapiens (human)
nuclear lumenInsulin receptorHomo sapiens (human)
lysosomeInsulin receptorHomo sapiens (human)
late endosomeInsulin receptorHomo sapiens (human)
plasma membraneInsulin receptorHomo sapiens (human)
caveolaInsulin receptorHomo sapiens (human)
external side of plasma membraneInsulin receptorHomo sapiens (human)
endosome membraneInsulin receptorHomo sapiens (human)
membraneInsulin receptorHomo sapiens (human)
dendrite membraneInsulin receptorHomo sapiens (human)
neuronal cell body membraneInsulin receptorHomo sapiens (human)
extracellular exosomeInsulin receptorHomo sapiens (human)
insulin receptor complexInsulin receptorHomo sapiens (human)
receptor complexInsulin receptorHomo sapiens (human)
plasma membraneInsulin receptorHomo sapiens (human)
axonInsulin receptorHomo sapiens (human)
pericentriolar materialTyrosine-protein kinase LckHomo sapiens (human)
immunological synapseTyrosine-protein kinase LckHomo sapiens (human)
cytosolTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
membrane raftTyrosine-protein kinase LckHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
cytosolProto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
nucleusTyrosine-protein kinase FynHomo sapiens (human)
mitochondrionTyrosine-protein kinase FynHomo sapiens (human)
endosomeTyrosine-protein kinase FynHomo sapiens (human)
cytosolTyrosine-protein kinase FynHomo sapiens (human)
actin filamentTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
postsynaptic densityTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
perikaryonTyrosine-protein kinase FynHomo sapiens (human)
cell bodyTyrosine-protein kinase FynHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase FynHomo sapiens (human)
perinuclear endoplasmic reticulumTyrosine-protein kinase FynHomo sapiens (human)
glial cell projectionTyrosine-protein kinase FynHomo sapiens (human)
Schaffer collateral - CA1 synapseTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
mitochondrial matrixCyclin-dependent kinase 1Homo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 1Homo sapiens (human)
nucleusCyclin-dependent kinase 1Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 1Homo sapiens (human)
mitochondrionCyclin-dependent kinase 1Homo sapiens (human)
endoplasmic reticulum membraneCyclin-dependent kinase 1Homo sapiens (human)
centrosomeCyclin-dependent kinase 1Homo sapiens (human)
cytosolCyclin-dependent kinase 1Homo sapiens (human)
spindle microtubuleCyclin-dependent kinase 1Homo sapiens (human)
membraneCyclin-dependent kinase 1Homo sapiens (human)
midbodyCyclin-dependent kinase 1Homo sapiens (human)
extracellular exosomeCyclin-dependent kinase 1Homo sapiens (human)
mitotic spindleCyclin-dependent kinase 1Homo sapiens (human)
cyclin A1-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin A2-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin B1-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 1Homo sapiens (human)
nucleusCyclin-dependent kinase 1Homo sapiens (human)
extracellular regionGlycogen phosphorylase, liver formHomo sapiens (human)
cytosolGlycogen phosphorylase, liver formHomo sapiens (human)
secretory granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, liver formHomo sapiens (human)
ficolin-1-rich granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, liver formHomo sapiens (human)
cytoplasmic vesicleTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytoplasmTyrosine-protein kinase Fes/FpsHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytosolTyrosine-protein kinase Fes/FpsHomo sapiens (human)
focal adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase Fes/FpsHomo sapiens (human)
microtubule cytoskeletonTyrosine-protein kinase Fes/FpsHomo sapiens (human)
plasma membraneTyrosine-protein kinase Fes/FpsHomo sapiens (human)
nucleoplasmMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
plasma membraneMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell surfaceMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
intracellular membrane-bounded organelleMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
CSF1-CSF1R complexMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
receptor complexMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
plasma membraneMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
extracellular regionAdenine phosphoribosyltransferaseHomo sapiens (human)
nucleoplasmAdenine phosphoribosyltransferaseHomo sapiens (human)
cytoplasmAdenine phosphoribosyltransferaseHomo sapiens (human)
cytosolAdenine phosphoribosyltransferaseHomo sapiens (human)
secretory granule lumenAdenine phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeAdenine phosphoribosyltransferaseHomo sapiens (human)
cytoplasmAdenine phosphoribosyltransferaseHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase YesHomo sapiens (human)
centrosomeTyrosine-protein kinase YesHomo sapiens (human)
cytosolTyrosine-protein kinase YesHomo sapiens (human)
actin filamentTyrosine-protein kinase YesHomo sapiens (human)
plasma membraneTyrosine-protein kinase YesHomo sapiens (human)
focal adhesionTyrosine-protein kinase YesHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase YesHomo sapiens (human)
plasma membraneTyrosine-protein kinase YesHomo sapiens (human)
plasma membraneTyrosine-protein kinase LynHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase LynHomo sapiens (human)
nucleusTyrosine-protein kinase LynHomo sapiens (human)
cytoplasmTyrosine-protein kinase LynHomo sapiens (human)
lysosomal membraneTyrosine-protein kinase LynHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase LynHomo sapiens (human)
cytosolTyrosine-protein kinase LynHomo sapiens (human)
plasma membraneTyrosine-protein kinase LynHomo sapiens (human)
adherens junctionTyrosine-protein kinase LynHomo sapiens (human)
mitochondrial cristaTyrosine-protein kinase LynHomo sapiens (human)
endocytic vesicle membraneTyrosine-protein kinase LynHomo sapiens (human)
intracellular membrane-bounded organelleTyrosine-protein kinase LynHomo sapiens (human)
membrane raftTyrosine-protein kinase LynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase LynHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase LynHomo sapiens (human)
glutamatergic synapseTyrosine-protein kinase LynHomo sapiens (human)
postsynaptic specialization, intracellular componentTyrosine-protein kinase LynHomo sapiens (human)
integrin alpha2-beta1 complexTyrosine-protein kinase LynHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
early endosomeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
endosome membraneProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
dendriteProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neuronal cell bodyProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
receptor complexProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
plasma membrane protein complexProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
axonProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
plasma membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
caveolaInsulin-like growth factor 1 receptorHomo sapiens (human)
membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
T-tubuleInsulin-like growth factor 1 receptorHomo sapiens (human)
neuronal cell bodyInsulin-like growth factor 1 receptorHomo sapiens (human)
intracellular membrane-bounded organelleInsulin-like growth factor 1 receptorHomo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexInsulin-like growth factor 1 receptorHomo sapiens (human)
receptor complexInsulin-like growth factor 1 receptorHomo sapiens (human)
protein kinase complexInsulin-like growth factor 1 receptorHomo sapiens (human)
axonInsulin-like growth factor 1 receptorHomo sapiens (human)
plasma membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor complexInsulin-like growth factor 1 receptorHomo sapiens (human)
signal recognition particle receptor complexSignal recognition particle receptor subunit alphaHomo sapiens (human)
endoplasmic reticulum membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
extracellular exosomeSignal recognition particle receptor subunit alphaHomo sapiens (human)
endoplasmic reticulum membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
nucleusCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
mitochondrionCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
mitochondrial respiratory chain complex IIICytochrome c1, heme protein, mitochondrialHomo sapiens (human)
membraneCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
extracellular regionHepatocyte growth factor receptorHomo sapiens (human)
plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
basal plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
cell surfaceHepatocyte growth factor receptorHomo sapiens (human)
membraneHepatocyte growth factor receptorHomo sapiens (human)
postsynapseHepatocyte growth factor receptorHomo sapiens (human)
basal plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
receptor complexHepatocyte growth factor receptorHomo sapiens (human)
actin filamentTyrosine-protein kinase HCKHomo sapiens (human)
nucleusTyrosine-protein kinase HCKHomo sapiens (human)
lysosomeTyrosine-protein kinase HCKHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase HCKHomo sapiens (human)
cytosolTyrosine-protein kinase HCKHomo sapiens (human)
plasma membraneTyrosine-protein kinase HCKHomo sapiens (human)
caveolaTyrosine-protein kinase HCKHomo sapiens (human)
focal adhesionTyrosine-protein kinase HCKHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase HCKHomo sapiens (human)
transport vesicleTyrosine-protein kinase HCKHomo sapiens (human)
cell projectionTyrosine-protein kinase HCKHomo sapiens (human)
intracellular membrane-bounded organelleTyrosine-protein kinase HCKHomo sapiens (human)
plasma membraneTyrosine-protein kinase HCKHomo sapiens (human)
membraneProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
receptor complexProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
nucleusPlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoplasmPlatelet-derived growth factor receptor betaHomo sapiens (human)
Golgi apparatusPlatelet-derived growth factor receptor betaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
focal adhesionPlatelet-derived growth factor receptor betaHomo sapiens (human)
membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
apical plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoplasmic vesiclePlatelet-derived growth factor receptor betaHomo sapiens (human)
lysosomal lumenPlatelet-derived growth factor receptor betaHomo sapiens (human)
intracellular membrane-bounded organellePlatelet-derived growth factor receptor betaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
receptor complexPlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoskeletonTyrosine-protein kinase FgrHomo sapiens (human)
actin cytoskeletonTyrosine-protein kinase FgrHomo sapiens (human)
ruffle membraneTyrosine-protein kinase FgrHomo sapiens (human)
extracellular regionTyrosine-protein kinase FgrHomo sapiens (human)
mitochondrial inner membraneTyrosine-protein kinase FgrHomo sapiens (human)
mitochondrial intermembrane spaceTyrosine-protein kinase FgrHomo sapiens (human)
cytosolTyrosine-protein kinase FgrHomo sapiens (human)
plasma membraneTyrosine-protein kinase FgrHomo sapiens (human)
aggresomeTyrosine-protein kinase FgrHomo sapiens (human)
secretory granule lumenTyrosine-protein kinase FgrHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase FgrHomo sapiens (human)
plasma membraneTyrosine-protein kinase FgrHomo sapiens (human)
nucleoplasmWee1-like protein kinase 2Homo sapiens (human)
cytosolWee1-like protein kinase 2Homo sapiens (human)
plasma membraneWee1-like protein kinase 2Homo sapiens (human)
cytoplasmWee1-like protein kinase 2Homo sapiens (human)
nucleusWee1-like protein kinase 2Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cellular_componentSerine/threonine-protein kinase A-RafHomo sapiens (human)
cytosolSerine/threonine-protein kinase A-RafHomo sapiens (human)
cytosolSerine/threonine-protein kinase A-RafHomo sapiens (human)
mitochondrionSerine/threonine-protein kinase A-RafHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
fibrillar centerMast/stem cell growth factor receptor KitHomo sapiens (human)
acrosomal vesicleMast/stem cell growth factor receptor KitHomo sapiens (human)
extracellular spaceMast/stem cell growth factor receptor KitHomo sapiens (human)
plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
cell-cell junctionMast/stem cell growth factor receptor KitHomo sapiens (human)
external side of plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
cytoplasmic side of plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
receptor complexMast/stem cell growth factor receptor KitHomo sapiens (human)
extracellular regionGlycogen phosphorylase, brain formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, brain formHomo sapiens (human)
membraneGlycogen phosphorylase, brain formHomo sapiens (human)
azurophil granule lumenGlycogen phosphorylase, brain formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, brain formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, brain formHomo sapiens (human)
cytosolBreakpoint cluster region proteinHomo sapiens (human)
plasma membraneBreakpoint cluster region proteinHomo sapiens (human)
postsynaptic densityBreakpoint cluster region proteinHomo sapiens (human)
membraneBreakpoint cluster region proteinHomo sapiens (human)
axonBreakpoint cluster region proteinHomo sapiens (human)
dendritic spineBreakpoint cluster region proteinHomo sapiens (human)
extracellular exosomeBreakpoint cluster region proteinHomo sapiens (human)
protein-containing complexBreakpoint cluster region proteinHomo sapiens (human)
Schaffer collateral - CA1 synapseBreakpoint cluster region proteinHomo sapiens (human)
glutamatergic synapseBreakpoint cluster region proteinHomo sapiens (human)
membraneBreakpoint cluster region proteinHomo sapiens (human)
nucleusSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleolusSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytosolSerine/threonine-protein kinase pim-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 1Homo sapiens (human)
nucleusFibroblast growth factor receptor 1Homo sapiens (human)
cytosolFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 1Homo sapiens (human)
membraneFibroblast growth factor receptor 1Homo sapiens (human)
cytoplasmic vesicleFibroblast growth factor receptor 1Homo sapiens (human)
receptor complexFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytosolMyosin light chain kinase, smooth muscleGallus gallus (chicken)
stress fiberMyosin light chain kinase, smooth muscleGallus gallus (chicken)
cleavage furrowMyosin light chain kinase, smooth muscleGallus gallus (chicken)
lamellipodiumMyosin light chain kinase, smooth muscleGallus gallus (chicken)
cytoplasmMyosin light chain kinase, smooth muscleGallus gallus (chicken)
nucleusCyclin-dependent kinase 4Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 4Homo sapiens (human)
nucleolusCyclin-dependent kinase 4Homo sapiens (human)
cytosolCyclin-dependent kinase 4Homo sapiens (human)
bicellular tight junctionCyclin-dependent kinase 4Homo sapiens (human)
nuclear membraneCyclin-dependent kinase 4Homo sapiens (human)
cyclin D1-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin D2-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin D3-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 4Homo sapiens (human)
chromatinCyclin-dependent kinase 4Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 4Homo sapiens (human)
nucleusCyclin-dependent kinase 4Homo sapiens (human)
cytoplasmCyclin-dependent kinase 4Homo sapiens (human)
nucleusADP/ATP translocase 3Homo sapiens (human)
mitochondrionADP/ATP translocase 3Homo sapiens (human)
mitochondrial inner membraneADP/ATP translocase 3Homo sapiens (human)
membraneADP/ATP translocase 3Homo sapiens (human)
TIM23 mitochondrial import inner membrane translocase complexADP/ATP translocase 3Homo sapiens (human)
extracellular regionInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
peroxisomal membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular exosomeInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
podosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nucleoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrial inner membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
lysosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
late endosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytosolProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
actin filamentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
caveolaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell junctionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ruffle membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neuronal cell bodyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic growth coneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
membrane raftProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
perinuclear region of cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
extracellular exosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
synaptic membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
glutamatergic synapseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
postsynaptic specialization, intracellular componentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic filopodiumProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
axonemecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
centrosomecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cytosolcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
plasma membranecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
focal adhesioncAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
membranecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
plasma membrane raftcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
extracellular exosomecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
ciliary basecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
nucleotide-activated protein kinase complexcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein-containing complexcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cytosolcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
plasma membraneInsulin receptor-related proteinHomo sapiens (human)
receptor complexInsulin receptor-related proteinHomo sapiens (human)
insulin receptor complexInsulin receptor-related proteinHomo sapiens (human)
plasma membraneInsulin receptor-related proteinHomo sapiens (human)
axonInsulin receptor-related proteinHomo sapiens (human)
nucleusSerine/threonine-protein kinase B-rafHomo sapiens (human)
cytosolSerine/threonine-protein kinase B-rafHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase B-rafHomo sapiens (human)
neuron projectionSerine/threonine-protein kinase B-rafHomo sapiens (human)
intracellular membrane-bounded organelleSerine/threonine-protein kinase B-rafHomo sapiens (human)
cell bodySerine/threonine-protein kinase B-rafHomo sapiens (human)
presynapseSerine/threonine-protein kinase B-rafHomo sapiens (human)
cytosolSerine/threonine-protein kinase B-rafHomo sapiens (human)
mitochondrionSerine/threonine-protein kinase B-rafHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase B-rafHomo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
lysosomePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
Z discPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cytosolPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
phosphorylase kinase complexPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
nucleoplasmRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
extracellular exosomeRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
nucleusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
nucleoplasmPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cytoplasmPlatelet-derived growth factor receptor alphaHomo sapiens (human)
endoplasmic reticulum membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
Golgi apparatusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
microvillusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
ciliumPlatelet-derived growth factor receptor alphaHomo sapiens (human)
external side of plasma membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell junctionPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein-containing complexPlatelet-derived growth factor receptor alphaHomo sapiens (human)
receptor complexPlatelet-derived growth factor receptor alphaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
cytosolTyrosine-protein kinase BlkMus musculus (house mouse)
actin cytoskeletonTyrosine-protein kinase FerHomo sapiens (human)
microtubule cytoskeletonTyrosine-protein kinase FerHomo sapiens (human)
lamellipodiumTyrosine-protein kinase FerHomo sapiens (human)
cell junctionTyrosine-protein kinase FerHomo sapiens (human)
nucleusTyrosine-protein kinase FerHomo sapiens (human)
cytoplasmTyrosine-protein kinase FerHomo sapiens (human)
cytosolTyrosine-protein kinase FerHomo sapiens (human)
adherens junctionTyrosine-protein kinase FerHomo sapiens (human)
cell cortexTyrosine-protein kinase FerHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase FerHomo sapiens (human)
chromatinTyrosine-protein kinase FerHomo sapiens (human)
plasma membraneTyrosine-protein kinase FerHomo sapiens (human)
ciliary basal bodyProtein kinase C alpha typeHomo sapiens (human)
nucleoplasmProtein kinase C alpha typeHomo sapiens (human)
cytoplasmProtein kinase C alpha typeHomo sapiens (human)
mitochondrionProtein kinase C alpha typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C alpha typeHomo sapiens (human)
cytosolProtein kinase C alpha typeHomo sapiens (human)
plasma membraneProtein kinase C alpha typeHomo sapiens (human)
mitochondrial membraneProtein kinase C alpha typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C alpha typeHomo sapiens (human)
extracellular exosomeProtein kinase C alpha typeHomo sapiens (human)
alphav-beta3 integrin-PKCalpha complexProtein kinase C alpha typeHomo sapiens (human)
axonemecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
acrosomal vesiclecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
mitochondrial matrixcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
centrosomecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
plasma membranecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nuclear speckcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
neuromuscular junctioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
sperm flagellumcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
dendritic spinecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
plasma membrane raftcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
extracellular exosomecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
ciliary basecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
glutamatergic synapsecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
calcium channel complexcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
extracellular spaceVascular endothelial growth factor receptor 1 Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
focal adhesionVascular endothelial growth factor receptor 1 Homo sapiens (human)
actin cytoskeletonVascular endothelial growth factor receptor 1 Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
nucleusGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
nucleoplasmGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
cytoplasmGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
spindleGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
cytosolGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription factor TFIIH core complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription factor TFIID complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription factor TFIIH holo complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
CAK-ERCC2 complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
MMXD complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
nucleusGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
nucleoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cytosolInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
ribosomeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
membraneInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
perinuclear region of cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
nucleusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
PcG protein complexCasein kinase II subunit alpha'Homo sapiens (human)
acrosomal vesicleCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
nucleoplasmCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha'Homo sapiens (human)
chromatinCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
Golgi membraneRas-related protein Rab-6AHomo sapiens (human)
acrosomal membraneRas-related protein Rab-6AHomo sapiens (human)
endoplasmic reticulum membraneRas-related protein Rab-6AHomo sapiens (human)
Golgi apparatusRas-related protein Rab-6AHomo sapiens (human)
trans-Golgi networkRas-related protein Rab-6AHomo sapiens (human)
cytosolRas-related protein Rab-6AHomo sapiens (human)
plasma membraneRas-related protein Rab-6AHomo sapiens (human)
membraneRas-related protein Rab-6AHomo sapiens (human)
secretory granule membraneRas-related protein Rab-6AHomo sapiens (human)
cytoplasmic vesicleRas-related protein Rab-6AHomo sapiens (human)
trans-Golgi network membraneRas-related protein Rab-6AHomo sapiens (human)
extracellular exosomeRas-related protein Rab-6AHomo sapiens (human)
endosome to plasma membrane transport vesicleRas-related protein Rab-6AHomo sapiens (human)
Golgi apparatusRas-related protein Rab-6AHomo sapiens (human)
endomembrane systemRas-related protein Rab-6AHomo sapiens (human)
photoreceptor outer segmentSerine/threonine-protein kinase MAKHomo sapiens (human)
photoreceptor inner segmentSerine/threonine-protein kinase MAKHomo sapiens (human)
nucleusSerine/threonine-protein kinase MAKHomo sapiens (human)
centrosomeSerine/threonine-protein kinase MAKHomo sapiens (human)
axonemeSerine/threonine-protein kinase MAKHomo sapiens (human)
midbodySerine/threonine-protein kinase MAKHomo sapiens (human)
motile ciliumSerine/threonine-protein kinase MAKHomo sapiens (human)
photoreceptor connecting ciliumSerine/threonine-protein kinase MAKHomo sapiens (human)
mitotic spindleSerine/threonine-protein kinase MAKHomo sapiens (human)
ciliumSerine/threonine-protein kinase MAKHomo sapiens (human)
nucleusSerine/threonine-protein kinase MAKHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MAKHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2B6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2B6Homo sapiens (human)
cytoplasmCytochrome P450 2B6Homo sapiens (human)
nucleusCyclin-dependent kinase 11BHomo sapiens (human)
cytoplasmCyclin-dependent kinase 11BHomo sapiens (human)
nucleusCyclin-dependent kinase 11BHomo sapiens (human)
plasma membraneEphrin type-A receptor 1Homo sapiens (human)
receptor complexEphrin type-A receptor 1Homo sapiens (human)
plasma membraneEphrin type-A receptor 1Homo sapiens (human)
collagen-containing extracellular matrixFibroblast growth factor receptor 2Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 2Homo sapiens (human)
nucleusFibroblast growth factor receptor 2Homo sapiens (human)
cytoplasmFibroblast growth factor receptor 2Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 2Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 2Homo sapiens (human)
cell cortexFibroblast growth factor receptor 2Homo sapiens (human)
cell surfaceFibroblast growth factor receptor 2Homo sapiens (human)
membraneFibroblast growth factor receptor 2Homo sapiens (human)
cytoplasmic vesicleFibroblast growth factor receptor 2Homo sapiens (human)
excitatory synapseFibroblast growth factor receptor 2Homo sapiens (human)
receptor complexFibroblast growth factor receptor 2Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 2Homo sapiens (human)
extracellular spaceReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
lateral plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cytoplasmMultifunctional protein ADE2Homo sapiens (human)
cytosolMultifunctional protein ADE2Homo sapiens (human)
membraneMultifunctional protein ADE2Homo sapiens (human)
extracellular exosomeMultifunctional protein ADE2Homo sapiens (human)
cell-cell junctionFibroblast growth factor receptor 4Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 4Homo sapiens (human)
endosomeFibroblast growth factor receptor 4Homo sapiens (human)
endoplasmic reticulumFibroblast growth factor receptor 4Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 4Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 4Homo sapiens (human)
transport vesicleFibroblast growth factor receptor 4Homo sapiens (human)
receptor complexFibroblast growth factor receptor 4Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 4Homo sapiens (human)
focal adhesionFibroblast growth factor receptor 3Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 3Homo sapiens (human)
endoplasmic reticulumFibroblast growth factor receptor 3Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 3Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 3Homo sapiens (human)
cell surfaceFibroblast growth factor receptor 3Homo sapiens (human)
transport vesicleFibroblast growth factor receptor 3Homo sapiens (human)
receptor complexFibroblast growth factor receptor 3Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 3Homo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
ciliary basecAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
centrosomecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
plasma membranecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
extracellular exosomecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ciliary basecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
mitochondrial inner membraneFerrochelatase, mitochondrialHomo sapiens (human)
mitochondrial matrixFerrochelatase, mitochondrialHomo sapiens (human)
mitochondrionFerrochelatase, mitochondrialHomo sapiens (human)
nucleoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
mitochondrionRibosomal protein S6 kinase beta-1Homo sapiens (human)
mitochondrial outer membraneRibosomal protein S6 kinase beta-1Homo sapiens (human)
cytosolRibosomal protein S6 kinase beta-1Homo sapiens (human)
cell surfaceRibosomal protein S6 kinase beta-1Homo sapiens (human)
neuron projectionRibosomal protein S6 kinase beta-1Homo sapiens (human)
perinuclear region of cytoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
postsynapseRibosomal protein S6 kinase beta-1Homo sapiens (human)
glutamatergic synapseRibosomal protein S6 kinase beta-1Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
cytoplasmTyrosine-protein kinase JAK1Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK1Homo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase JAK1Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK1Homo sapiens (human)
nucleusTyrosine-protein kinase JAK1Homo sapiens (human)
cytoplasmTyrosine-protein kinase JAK1Homo sapiens (human)
endosomeTyrosine-protein kinase JAK1Homo sapiens (human)
cytosolTyrosine-protein kinase JAK1Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK1Homo sapiens (human)
focal adhesionTyrosine-protein kinase JAK1Homo sapiens (human)
cytosolTyrosine-protein kinase JAK1Homo sapiens (human)
cytoplasmProtein kinase C eta typeHomo sapiens (human)
cytosolProtein kinase C eta typeHomo sapiens (human)
plasma membraneProtein kinase C eta typeHomo sapiens (human)
cell-cell junctionProtein kinase C eta typeHomo sapiens (human)
extracellular exosomeProtein kinase C eta typeHomo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmBeta-adrenergic receptor kinase 1Homo sapiens (human)
cytosolBeta-adrenergic receptor kinase 1Homo sapiens (human)
plasma membraneBeta-adrenergic receptor kinase 1Homo sapiens (human)
ciliumBeta-adrenergic receptor kinase 1Homo sapiens (human)
membraneBeta-adrenergic receptor kinase 1Homo sapiens (human)
presynapseBeta-adrenergic receptor kinase 1Homo sapiens (human)
postsynapseBeta-adrenergic receptor kinase 1Homo sapiens (human)
P-bodyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
nucleusProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytosolProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmic stress granuleProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
membraneProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
RISC complexProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmic stress granuleProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
P-bodyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmActivin receptor type-2AHomo sapiens (human)
plasma membraneActivin receptor type-2AHomo sapiens (human)
cell surfaceActivin receptor type-2AHomo sapiens (human)
inhibin-betaglycan-ActRII complexActivin receptor type-2AHomo sapiens (human)
receptor complexActivin receptor type-2AHomo sapiens (human)
plasma membraneActivin receptor type-2AHomo sapiens (human)
activin receptor complexActivin receptor type-2AHomo sapiens (human)
nucleusMitogen-activated protein kinase 3 Homo sapiens (human)
nuclear envelopeMitogen-activated protein kinase 3 Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 3 Homo sapiens (human)
early endosomeMitogen-activated protein kinase 3 Homo sapiens (human)
late endosomeMitogen-activated protein kinase 3 Homo sapiens (human)
endoplasmic reticulum lumenMitogen-activated protein kinase 3 Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 3 Homo sapiens (human)
cytosolMitogen-activated protein kinase 3 Homo sapiens (human)
cytoskeletonMitogen-activated protein kinase 3 Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 3 Homo sapiens (human)
caveolaMitogen-activated protein kinase 3 Homo sapiens (human)
focal adhesionMitogen-activated protein kinase 3 Homo sapiens (human)
pseudopodiumMitogen-activated protein kinase 3 Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 3 Homo sapiens (human)
nucleusMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
cytosolMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
plasma membraneMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
dendriteMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
extracellular exosomeMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
plasma membraneMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
nucleoplasmDeoxycytidine kinaseHomo sapiens (human)
cytosolDeoxycytidine kinaseHomo sapiens (human)
mitochondrionDeoxycytidine kinaseHomo sapiens (human)
cytoplasmDeoxycytidine kinaseHomo sapiens (human)
extracellular regionMitogen-activated protein kinase 1Homo sapiens (human)
nucleusMitogen-activated protein kinase 1Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 1Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 1Homo sapiens (human)
early endosomeMitogen-activated protein kinase 1Homo sapiens (human)
late endosomeMitogen-activated protein kinase 1Homo sapiens (human)
endoplasmic reticulum lumenMitogen-activated protein kinase 1Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 1Homo sapiens (human)
centrosomeMitogen-activated protein kinase 1Homo sapiens (human)
cytosolMitogen-activated protein kinase 1Homo sapiens (human)
cytoskeletonMitogen-activated protein kinase 1Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 1Homo sapiens (human)
caveolaMitogen-activated protein kinase 1Homo sapiens (human)
focal adhesionMitogen-activated protein kinase 1Homo sapiens (human)
pseudopodiumMitogen-activated protein kinase 1Homo sapiens (human)
azurophil granule lumenMitogen-activated protein kinase 1Homo sapiens (human)
synapseMitogen-activated protein kinase 1Homo sapiens (human)
mitotic spindleMitogen-activated protein kinase 1Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 1Homo sapiens (human)
nucleusMitogen-activated protein kinase 1Homo sapiens (human)
plasma membraneEphrin type-A receptor 2Homo sapiens (human)
focal adhesionEphrin type-A receptor 2Homo sapiens (human)
cell surfaceEphrin type-A receptor 2Homo sapiens (human)
lamellipodiumEphrin type-A receptor 2Homo sapiens (human)
leading edge membraneEphrin type-A receptor 2Homo sapiens (human)
lamellipodium membraneEphrin type-A receptor 2Homo sapiens (human)
ruffle membraneEphrin type-A receptor 2Homo sapiens (human)
tight junctionEphrin type-A receptor 2Homo sapiens (human)
receptor complexEphrin type-A receptor 2Homo sapiens (human)
plasma membraneEphrin type-A receptor 2Homo sapiens (human)
extracellular regionEphrin type-A receptor 3Homo sapiens (human)
nucleoplasmEphrin type-A receptor 3Homo sapiens (human)
early endosomeEphrin type-A receptor 3Homo sapiens (human)
cytosolEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 3Homo sapiens (human)
actin cytoskeletonEphrin type-A receptor 3Homo sapiens (human)
nuclear membraneEphrin type-A receptor 3Homo sapiens (human)
dendriteEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 8Homo sapiens (human)
early endosome membraneEphrin type-A receptor 8Homo sapiens (human)
neuron projectionEphrin type-A receptor 8Homo sapiens (human)
dendriteEphrin type-A receptor 8Homo sapiens (human)
plasma membraneEphrin type-A receptor 8Homo sapiens (human)
extracellular regionEphrin type-B receptor 2Homo sapiens (human)
nucleoplasmEphrin type-B receptor 2Homo sapiens (human)
cytosolEphrin type-B receptor 2Homo sapiens (human)
plasma membraneEphrin type-B receptor 2Homo sapiens (human)
cell surfaceEphrin type-B receptor 2Homo sapiens (human)
axonEphrin type-B receptor 2Homo sapiens (human)
dendriteEphrin type-B receptor 2Homo sapiens (human)
presynaptic membraneEphrin type-B receptor 2Homo sapiens (human)
neuronal cell bodyEphrin type-B receptor 2Homo sapiens (human)
dendritic spineEphrin type-B receptor 2Homo sapiens (human)
postsynaptic membraneEphrin type-B receptor 2Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseEphrin type-B receptor 2Homo sapiens (human)
postsynapseEphrin type-B receptor 2Homo sapiens (human)
glutamatergic synapseEphrin type-B receptor 2Homo sapiens (human)
plasma membraneEphrin type-B receptor 2Homo sapiens (human)
dendriteEphrin type-B receptor 2Homo sapiens (human)
plasma membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
receptor complexLeukocyte tyrosine kinase receptorHomo sapiens (human)
plasma membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoplasmic side of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extrinsic component of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
nucleusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoplasmNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytosolNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoskeletonNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-12 receptor complexNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extracellular exosomeNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-23 receptor complexNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytosolNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
nucleoplasmUMP-CMP kinase Homo sapiens (human)
nucleolusUMP-CMP kinase Homo sapiens (human)
cytosolUMP-CMP kinase Homo sapiens (human)
extracellular exosomeUMP-CMP kinase Homo sapiens (human)
cytoplasmUMP-CMP kinase Homo sapiens (human)
nucleusUMP-CMP kinase Homo sapiens (human)
nucleusPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
cytosolPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
extracellular exosomePhosphatidylethanolamine-binding protein 1Homo sapiens (human)
nucleusWee1-like protein kinaseHomo sapiens (human)
nucleoplasmWee1-like protein kinaseHomo sapiens (human)
nucleolusWee1-like protein kinaseHomo sapiens (human)
cytoplasmWee1-like protein kinaseHomo sapiens (human)
endoplasmic reticulum membraneHeme oxygenase 2Homo sapiens (human)
plasma membraneHeme oxygenase 2Homo sapiens (human)
membraneHeme oxygenase 2Homo sapiens (human)
specific granule membraneHeme oxygenase 2Homo sapiens (human)
extracellular spaceTyrosine-protein kinase receptor UFOHomo sapiens (human)
plasma membraneTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell surfaceTyrosine-protein kinase receptor UFOHomo sapiens (human)
actin cytoskeletonTyrosine-protein kinase receptor UFOHomo sapiens (human)
intracellular membrane-bounded organelleTyrosine-protein kinase receptor UFOHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase receptor UFOHomo sapiens (human)
plasma membraneTyrosine-protein kinase receptor UFOHomo sapiens (human)
receptor complexTyrosine-protein kinase receptor UFOHomo sapiens (human)
nucleusMitogen-activated protein kinase 4Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 4Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 4Homo sapiens (human)
cytosolMitogen-activated protein kinase 4Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 4Homo sapiens (human)
nucleusMitogen-activated protein kinase 4Homo sapiens (human)
cytosolS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
methionine adenosyltransferase complexS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
cytosolS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
nucleusDnaJ homolog subfamily A member 1Homo sapiens (human)
mitochondrionDnaJ homolog subfamily A member 1Homo sapiens (human)
cytosolDnaJ homolog subfamily A member 1Homo sapiens (human)
microtubule cytoskeletonDnaJ homolog subfamily A member 1Homo sapiens (human)
membraneDnaJ homolog subfamily A member 1Homo sapiens (human)
perinuclear region of cytoplasmDnaJ homolog subfamily A member 1Homo sapiens (human)
extracellular exosomeDnaJ homolog subfamily A member 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneDnaJ homolog subfamily A member 1Homo sapiens (human)
cytoplasmDnaJ homolog subfamily A member 1Homo sapiens (human)
cytosolDnaJ homolog subfamily A member 1Homo sapiens (human)
cytoplasmRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
mitochondrial intermembrane spaceRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nucleusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
spindleRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
plasma membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell-cell junctionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell cortexRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
microtubule cytoskeletonRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
lamellipodiumRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
vesicleRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
ciliary basal bodyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
postsynapseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glutamatergic synapseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein-containing complexRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nucleusRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
early endosomeRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
plasma membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cell cortexRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
ruffle membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
intracellular membrane-bounded organelleRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cytosolG protein-coupled receptor kinase 4Homo sapiens (human)
plasma membraneG protein-coupled receptor kinase 4Homo sapiens (human)
cell cortexG protein-coupled receptor kinase 4Homo sapiens (human)
photoreceptor disc membraneG protein-coupled receptor kinase 4Homo sapiens (human)
cytoplasmG protein-coupled receptor kinase 4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
cytoplasmDual specificity protein kinase TTKHomo sapiens (human)
spindleDual specificity protein kinase TTKHomo sapiens (human)
membraneDual specificity protein kinase TTKHomo sapiens (human)
kinetochoreDual specificity protein kinase TTKHomo sapiens (human)
nucleusDual specificity protein kinase TTKHomo sapiens (human)
chromosome, telomeric regionDNA replication licensing factor MCM4Homo sapiens (human)
nucleusDNA replication licensing factor MCM4Homo sapiens (human)
nucleoplasmDNA replication licensing factor MCM4Homo sapiens (human)
membraneDNA replication licensing factor MCM4Homo sapiens (human)
MCM complexDNA replication licensing factor MCM4Homo sapiens (human)
CMG complexDNA replication licensing factor MCM4Homo sapiens (human)
nucleusDNA replication licensing factor MCM4Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
plasma membraneTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
receptor complexTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
extracellular regionVascular endothelial growth factor receptor 3Homo sapiens (human)
nucleoplasmVascular endothelial growth factor receptor 3Homo sapiens (human)
cytosolVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 3Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 3Homo sapiens (human)
extracellular regionVascular endothelial growth factor receptor 2Homo sapiens (human)
nucleusVascular endothelial growth factor receptor 2Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
early endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
endoplasmic reticulumVascular endothelial growth factor receptor 2Homo sapiens (human)
Golgi apparatusVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
external side of plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
cell junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
membrane raftVascular endothelial growth factor receptor 2Homo sapiens (human)
anchoring junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
sorting endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 2Homo sapiens (human)
extracellular regionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
mitochondrionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
early endosomeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
late endosomeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
peroxisomal membraneDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
endoplasmic reticulumDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
Golgi apparatusDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
microtubuleDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
cell-cell junctionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
focal adhesionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
cytoplasmic side of plasma membraneDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
perinuclear region of cytoplasmDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
endoplasmic reticulumReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
endoplasmic reticulum lumenReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
endosome membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
receptor complexReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
caveolaBone morphogenetic protein receptor type-1AHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
external side of plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
dendriteBone morphogenetic protein receptor type-1AHomo sapiens (human)
neuronal cell bodyBone morphogenetic protein receptor type-1AHomo sapiens (human)
HFE-transferrin receptor complexBone morphogenetic protein receptor type-1AHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
receptor complexBone morphogenetic protein receptor type-1AHomo sapiens (human)
cytosolActivin receptor type-1BHomo sapiens (human)
plasma membraneActivin receptor type-1BHomo sapiens (human)
cell surfaceActivin receptor type-1BHomo sapiens (human)
receptor complexActivin receptor type-1BHomo sapiens (human)
activin receptor complexActivin receptor type-1BHomo sapiens (human)
plasma membraneActivin receptor type-1BHomo sapiens (human)
nucleusTGF-beta receptor type-1Homo sapiens (human)
endosomeTGF-beta receptor type-1Homo sapiens (human)
plasma membraneTGF-beta receptor type-1Homo sapiens (human)
bicellular tight junctionTGF-beta receptor type-1Homo sapiens (human)
cell surfaceTGF-beta receptor type-1Homo sapiens (human)
membrane raftTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta ligand-receptor complexTGF-beta receptor type-1Homo sapiens (human)
receptor complexTGF-beta receptor type-1Homo sapiens (human)
plasma membraneTGF-beta receptor type-1Homo sapiens (human)
activin receptor complexTGF-beta receptor type-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cell surfaceSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dendriteSerine/threonine-protein kinase receptor R3Homo sapiens (human)
neuronal cell bodySerine/threonine-protein kinase receptor R3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP receptor complexSerine/threonine-protein kinase receptor R3Homo sapiens (human)
extracellular regionTGF-beta receptor type-2Homo sapiens (human)
cytosolTGF-beta receptor type-2Homo sapiens (human)
plasma membraneTGF-beta receptor type-2Homo sapiens (human)
caveolaTGF-beta receptor type-2Homo sapiens (human)
external side of plasma membraneTGF-beta receptor type-2Homo sapiens (human)
membraneTGF-beta receptor type-2Homo sapiens (human)
membrane raftTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta ligand-receptor complexTGF-beta receptor type-2Homo sapiens (human)
receptor complexTGF-beta receptor type-2Homo sapiens (human)
plasma membraneTGF-beta receptor type-2Homo sapiens (human)
mitochondrionElectron transfer flavoprotein subunit betaHomo sapiens (human)
mitochondrial matrixElectron transfer flavoprotein subunit betaHomo sapiens (human)
electron transfer flavoprotein complexElectron transfer flavoprotein subunit betaHomo sapiens (human)
mitochondrionElectron transfer flavoprotein subunit betaHomo sapiens (human)
cytoplasmTyrosine-protein kinase CSKHomo sapiens (human)
cytosolTyrosine-protein kinase CSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase CSKHomo sapiens (human)
cell-cell junctionTyrosine-protein kinase CSKHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase CSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase CSKHomo sapiens (human)
mitochondrial matrixGlycine--tRNA ligaseHomo sapiens (human)
cytosolGlycine--tRNA ligaseHomo sapiens (human)
secretory granuleGlycine--tRNA ligaseHomo sapiens (human)
axonGlycine--tRNA ligaseHomo sapiens (human)
extracellular exosomeGlycine--tRNA ligaseHomo sapiens (human)
cytoplasmGlycine--tRNA ligaseHomo sapiens (human)
mitochondrionGlycine--tRNA ligaseHomo sapiens (human)
Golgi membraneProtein kinase C iota typeHomo sapiens (human)
nucleusProtein kinase C iota typeHomo sapiens (human)
nucleoplasmProtein kinase C iota typeHomo sapiens (human)
endosomeProtein kinase C iota typeHomo sapiens (human)
cytosolProtein kinase C iota typeHomo sapiens (human)
plasma membraneProtein kinase C iota typeHomo sapiens (human)
brush borderProtein kinase C iota typeHomo sapiens (human)
bicellular tight junctionProtein kinase C iota typeHomo sapiens (human)
microtubule cytoskeletonProtein kinase C iota typeHomo sapiens (human)
apical plasma membraneProtein kinase C iota typeHomo sapiens (human)
cell leading edgeProtein kinase C iota typeHomo sapiens (human)
Schmidt-Lanterman incisureProtein kinase C iota typeHomo sapiens (human)
intercellular bridgeProtein kinase C iota typeHomo sapiens (human)
extracellular exosomeProtein kinase C iota typeHomo sapiens (human)
tight junctionProtein kinase C iota typeHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein kinase C iota typeHomo sapiens (human)
glutamatergic synapseProtein kinase C iota typeHomo sapiens (human)
PAR polarity complexProtein kinase C iota typeHomo sapiens (human)
nuclear exosome (RNase complex)Exosome RNA helicase MTR4Homo sapiens (human)
exosome (RNase complex)Exosome RNA helicase MTR4Homo sapiens (human)
nucleusExosome RNA helicase MTR4Homo sapiens (human)
nucleoplasmExosome RNA helicase MTR4Homo sapiens (human)
nucleolusExosome RNA helicase MTR4Homo sapiens (human)
nuclear speckExosome RNA helicase MTR4Homo sapiens (human)
TRAMP complexExosome RNA helicase MTR4Homo sapiens (human)
catalytic step 2 spliceosomeExosome RNA helicase MTR4Homo sapiens (human)
nucleusExosome RNA helicase MTR4Homo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
intercalated discPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
lamellipodiumPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
perinuclear region of cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IBPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
nucleusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
nucleolusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
midbodyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
intracellular membrane-bounded organellePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
PML bodySerine/threonine-protein kinase mTORHomo sapiens (human)
lysosomal membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
cytosolSerine/threonine-protein kinase mTORHomo sapiens (human)
Golgi membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase mTORHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase mTORHomo sapiens (human)
mitochondrial outer membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
lysosomeSerine/threonine-protein kinase mTORHomo sapiens (human)
lysosomal membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
cytosolSerine/threonine-protein kinase mTORHomo sapiens (human)
endomembrane systemSerine/threonine-protein kinase mTORHomo sapiens (human)
membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
dendriteSerine/threonine-protein kinase mTORHomo sapiens (human)
TORC1 complexSerine/threonine-protein kinase mTORHomo sapiens (human)
TORC2 complexSerine/threonine-protein kinase mTORHomo sapiens (human)
phagocytic vesicleSerine/threonine-protein kinase mTORHomo sapiens (human)
nuclear envelopeSerine/threonine-protein kinase mTORHomo sapiens (human)
nucleusSerine/threonine-protein kinase mTORHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase mTORHomo sapiens (human)
cytosolMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
plasma membraneMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
cytosolTyrosine-protein kinase TecHomo sapiens (human)
cytoskeletonTyrosine-protein kinase TecHomo sapiens (human)
plasma membraneTyrosine-protein kinase TecHomo sapiens (human)
plasma membraneTyrosine-protein kinase TecHomo sapiens (human)
nucleusTyrosine-protein kinase TXKHomo sapiens (human)
nucleoplasmTyrosine-protein kinase TXKHomo sapiens (human)
nucleolusTyrosine-protein kinase TXKHomo sapiens (human)
cytoplasmTyrosine-protein kinase TXKHomo sapiens (human)
cytosolTyrosine-protein kinase TXKHomo sapiens (human)
plasma membraneTyrosine-protein kinase TXKHomo sapiens (human)
plasma membraneTyrosine-protein kinase TXKHomo sapiens (human)
cytosolTyrosine-protein kinase ABL2Homo sapiens (human)
actin cytoskeletonTyrosine-protein kinase ABL2Homo sapiens (human)
plasma membraneTyrosine-protein kinase ABL2Homo sapiens (human)
extracellular regionTyrosine-protein kinase FRKHomo sapiens (human)
nucleusTyrosine-protein kinase FRKHomo sapiens (human)
nucleoplasmTyrosine-protein kinase FRKHomo sapiens (human)
cytosolTyrosine-protein kinase FRKHomo sapiens (human)
azurophil granule lumenTyrosine-protein kinase FRKHomo sapiens (human)
specific granule lumenTyrosine-protein kinase FRKHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase FRKHomo sapiens (human)
plasma membraneTyrosine-protein kinase FRKHomo sapiens (human)
plasma membraneG protein-coupled receptor kinase 6Homo sapiens (human)
membraneG protein-coupled receptor kinase 6Homo sapiens (human)
cytoplasmG protein-coupled receptor kinase 6Homo sapiens (human)
membrane raftTyrosine-protein kinase ZAP-70Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase ZAP-70Homo sapiens (human)
immunological synapseTyrosine-protein kinase ZAP-70Homo sapiens (human)
cytoplasmTyrosine-protein kinase ZAP-70Homo sapiens (human)
cytosolTyrosine-protein kinase ZAP-70Homo sapiens (human)
plasma membraneTyrosine-protein kinase ZAP-70Homo sapiens (human)
cell-cell junctionTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell receptor complexTyrosine-protein kinase ZAP-70Homo sapiens (human)
plasma membraneTyrosine-protein kinase ZAP-70Homo sapiens (human)
cytoplasmTyrosine-protein kinase SYKHomo sapiens (human)
nucleusTyrosine-protein kinase SYKHomo sapiens (human)
cytoplasmTyrosine-protein kinase SYKHomo sapiens (human)
cytosolTyrosine-protein kinase SYKHomo sapiens (human)
plasma membraneTyrosine-protein kinase SYKHomo sapiens (human)
early phagosomeTyrosine-protein kinase SYKHomo sapiens (human)
B cell receptor complexTyrosine-protein kinase SYKHomo sapiens (human)
protein-containing complexTyrosine-protein kinase SYKHomo sapiens (human)
T cell receptor complexTyrosine-protein kinase SYKHomo sapiens (human)
plasma membraneTyrosine-protein kinase SYKHomo sapiens (human)
proteasome complex26S proteasome regulatory subunit 6BHomo sapiens (human)
nucleus26S proteasome regulatory subunit 6BHomo sapiens (human)
nucleoplasm26S proteasome regulatory subunit 6BHomo sapiens (human)
cytosol26S proteasome regulatory subunit 6BHomo sapiens (human)
membrane26S proteasome regulatory subunit 6BHomo sapiens (human)
inclusion body26S proteasome regulatory subunit 6BHomo sapiens (human)
synapse26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome accessory complex26S proteasome regulatory subunit 6BHomo sapiens (human)
cytosolic proteasome complex26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome regulatory subunit 6BHomo sapiens (human)
cytoplasmMitogen-activated protein kinase 8Homo sapiens (human)
nucleusMitogen-activated protein kinase 8Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 8Homo sapiens (human)
cytosolMitogen-activated protein kinase 8Homo sapiens (human)
axonMitogen-activated protein kinase 8Homo sapiens (human)
synapseMitogen-activated protein kinase 8Homo sapiens (human)
basal dendriteMitogen-activated protein kinase 8Homo sapiens (human)
nucleusMitogen-activated protein kinase 8Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 9Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 9Homo sapiens (human)
cytosolMitogen-activated protein kinase 9Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 9Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 9Homo sapiens (human)
Schaffer collateral - CA1 synapseMitogen-activated protein kinase 9Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 9Homo sapiens (human)
nucleusMitogen-activated protein kinase 9Homo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
axonDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
dendrite cytoplasmDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
perikaryonDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
nucleoplasmDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
membraneDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
mRNA cleavage and polyadenylation specificity factor complexCasein kinase I isoform alphaHomo sapiens (human)
keratin filamentCasein kinase I isoform alphaHomo sapiens (human)
kinetochoreCasein kinase I isoform alphaHomo sapiens (human)
centrosomeCasein kinase I isoform alphaHomo sapiens (human)
spindleCasein kinase I isoform alphaHomo sapiens (human)
cytosolCasein kinase I isoform alphaHomo sapiens (human)
ciliumCasein kinase I isoform alphaHomo sapiens (human)
membraneCasein kinase I isoform alphaHomo sapiens (human)
nuclear speckCasein kinase I isoform alphaHomo sapiens (human)
beta-catenin destruction complexCasein kinase I isoform alphaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform alphaHomo sapiens (human)
cytoplasmCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
nucleoplasmCasein kinase I isoform deltaHomo sapiens (human)
Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
centrosomeCasein kinase I isoform deltaHomo sapiens (human)
spindleCasein kinase I isoform deltaHomo sapiens (human)
cytosolCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
plasma membraneCasein kinase I isoform deltaHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneCasein kinase I isoform deltaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform deltaHomo sapiens (human)
perinuclear region of cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IBPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 2Homo sapiens (human)
nucleoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
centrosomeMAP kinase-activated protein kinase 2Homo sapiens (human)
cytosolMAP kinase-activated protein kinase 2Homo sapiens (human)
extracellular exosomeMAP kinase-activated protein kinase 2Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 8Homo sapiens (human)
nucleusCyclin-dependent kinase 8Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 8Homo sapiens (human)
nucleolusCyclin-dependent kinase 8Homo sapiens (human)
CKM complexCyclin-dependent kinase 8Homo sapiens (human)
ubiquitin ligase complexCyclin-dependent kinase 8Homo sapiens (human)
mediator complexCyclin-dependent kinase 8Homo sapiens (human)
protein-containing complexCyclin-dependent kinase 8Homo sapiens (human)
nucleusCyclin-dependent kinase 8Homo sapiens (human)
mitochondrionElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrial outer membraneElongation factor Tu, mitochondrialHomo sapiens (human)
membraneElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrial nucleoidElongation factor Tu, mitochondrialHomo sapiens (human)
synapseElongation factor Tu, mitochondrialHomo sapiens (human)
extracellular exosomeElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrionElongation factor Tu, mitochondrialHomo sapiens (human)
nucleusCholine-phosphate cytidylyltransferase AHomo sapiens (human)
nuclear envelopeCholine-phosphate cytidylyltransferase AHomo sapiens (human)
endoplasmic reticulumCholine-phosphate cytidylyltransferase AHomo sapiens (human)
endoplasmic reticulum membraneCholine-phosphate cytidylyltransferase AHomo sapiens (human)
cytosolCholine-phosphate cytidylyltransferase AHomo sapiens (human)
glycogen granuleCholine-phosphate cytidylyltransferase AHomo sapiens (human)
endoplasmic reticulumCholine-phosphate cytidylyltransferase AHomo sapiens (human)
cytoplasmCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
cytosolCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
cytoplasmCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
nucleusCasein kinase I isoform epsilonHomo sapiens (human)
nucleoplasmCasein kinase I isoform epsilonHomo sapiens (human)
cytoplasmCasein kinase I isoform epsilonHomo sapiens (human)
cytosolCasein kinase I isoform epsilonHomo sapiens (human)
growth coneCasein kinase I isoform epsilonHomo sapiens (human)
neuronal cell bodyCasein kinase I isoform epsilonHomo sapiens (human)
ribonucleoprotein complexCasein kinase I isoform epsilonHomo sapiens (human)
cytoplasmCasein kinase I isoform epsilonHomo sapiens (human)
nucleusCasein kinase I isoform epsilonHomo sapiens (human)
nucleoplasmVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
nucleolusVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrionVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial inner membraneVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial matrixVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial membraneVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial nucleoidVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
nucleusDual specificity protein kinase CLK1Homo sapiens (human)
nucleusDual specificity protein kinase CLK2Homo sapiens (human)
nucleoplasmDual specificity protein kinase CLK2Homo sapiens (human)
nuclear bodyDual specificity protein kinase CLK2Homo sapiens (human)
nuclear speckDual specificity protein kinase CLK2Homo sapiens (human)
nucleusDual specificity protein kinase CLK2Homo sapiens (human)
acrosomal vesicleDual specificity protein kinase CLK3Homo sapiens (human)
nucleusDual specificity protein kinase CLK3Homo sapiens (human)
nucleoplasmDual specificity protein kinase CLK3Homo sapiens (human)
membraneDual specificity protein kinase CLK3Homo sapiens (human)
nuclear speckDual specificity protein kinase CLK3Homo sapiens (human)
intermediate filament cytoskeletonDual specificity protein kinase CLK3Homo sapiens (human)
mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 alphaHomo sapiens (human)
neuronal cell bodyGlycogen synthase kinase-3 alphaHomo sapiens (human)
apical dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 alphaHomo sapiens (human)
proximal dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 alphaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 alphaHomo sapiens (human)
axonGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
glutamatergic synapseGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrionGlycogen synthase kinase-3 betaHomo sapiens (human)
centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
plasma membraneGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
dendriteGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 betaHomo sapiens (human)
presynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
Wnt signalosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 7Homo sapiens (human)
fibrillar centerCyclin-dependent kinase 7Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 7Homo sapiens (human)
nucleusCyclin-dependent kinase 7Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 7Homo sapiens (human)
cytosolCyclin-dependent kinase 7Homo sapiens (human)
plasma membraneCyclin-dependent kinase 7Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase 7Homo sapiens (human)
transcription factor TFIIH core complexCyclin-dependent kinase 7Homo sapiens (human)
transcription factor TFIIH holo complexCyclin-dependent kinase 7Homo sapiens (human)
CAK-ERCC2 complexCyclin-dependent kinase 7Homo sapiens (human)
transcription factor TFIIK complexCyclin-dependent kinase 7Homo sapiens (human)
cytoplasmCyclin-dependent kinase 7Homo sapiens (human)
nucleusCyclin-dependent kinase 7Homo sapiens (human)
nucleusCyclin-dependent kinase 9Homo sapiens (human)
nucleusCyclin-dependent kinase 9Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 9Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-dependent kinase 9Homo sapiens (human)
membraneCyclin-dependent kinase 9Homo sapiens (human)
PML bodyCyclin-dependent kinase 9Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation factor complexCyclin-dependent kinase 9Homo sapiens (human)
P-TEFb complexCyclin-dependent kinase 9Homo sapiens (human)
photoreceptor outer segmentRas-related protein Rab-27AHomo sapiens (human)
extracellular regionRas-related protein Rab-27AHomo sapiens (human)
lysosomeRas-related protein Rab-27AHomo sapiens (human)
late endosomeRas-related protein Rab-27AHomo sapiens (human)
cytosolRas-related protein Rab-27AHomo sapiens (human)
dendriteRas-related protein Rab-27AHomo sapiens (human)
multivesicular body membraneRas-related protein Rab-27AHomo sapiens (human)
Weibel-Palade bodyRas-related protein Rab-27AHomo sapiens (human)
melanosome membraneRas-related protein Rab-27AHomo sapiens (human)
specific granule lumenRas-related protein Rab-27AHomo sapiens (human)
melanosomeRas-related protein Rab-27AHomo sapiens (human)
extracellular exosomeRas-related protein Rab-27AHomo sapiens (human)
exocytic vesicleRas-related protein Rab-27AHomo sapiens (human)
exocytic vesicleRas-related protein Rab-27AHomo sapiens (human)
apical plasma membraneRas-related protein Rab-27AHomo sapiens (human)
Golgi apparatusRas-related protein Rab-27AHomo sapiens (human)
secretory granuleRas-related protein Rab-27AHomo sapiens (human)
melanosomeRas-related protein Rab-27AHomo sapiens (human)
cytosolTyrosine-protein kinase BlkHomo sapiens (human)
plasma membraneTyrosine-protein kinase BlkHomo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cell surfaceInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
nucleoplasmInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
lipid dropletInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cytosolInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
endosome membraneInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein-containing complexInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
early endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
endoplasmic reticulumPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cytoplasmPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
lysosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
early endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
late endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
endoplasmic reticulumPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
basolateral plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transport vesiclePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cytoplasmic vesicle membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
neuron projectionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
ciliary basePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
lumenal side of membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
basolateral part of cellPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
monoatomic ion channel complexPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-3Homo sapiens (human)
nucleolusRibosomal protein S6 kinase alpha-3Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-3Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-3Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-3Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-3Homo sapiens (human)
nucleoplasmCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cytosolCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
plasma membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
ruffle membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
plasma membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
kinetochoreSerine/threonine-protein kinase Nek2Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase Nek2Homo sapiens (human)
condensed nuclear chromosomeSerine/threonine-protein kinase Nek2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleolusSerine/threonine-protein kinase Nek2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek2Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek2Homo sapiens (human)
microtubuleSerine/threonine-protein kinase Nek2Homo sapiens (human)
midbodySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase Nek2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek3Homo sapiens (human)
axonSerine/threonine-protein kinase Nek3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek4Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary rootletSerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary transition zoneSerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary basal bodySerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary plasmSerine/threonine-protein kinase Nek4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek4Homo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
endosomeTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK3Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
nucleoplasmDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytoskeletonDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
spindle microtubuleSerine/threonine-protein kinase PLK1Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK1Homo sapiens (human)
synaptonemal complexSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindleSerine/threonine-protein kinase PLK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase PLK1Homo sapiens (human)
microtubule cytoskeletonSerine/threonine-protein kinase PLK1Homo sapiens (human)
midbodySerine/threonine-protein kinase PLK1Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindle midzoneSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic spindle poleSerine/threonine-protein kinase PLK1Homo sapiens (human)
chromatinSerine/threonine-protein kinase PLK1Homo sapiens (human)
outer kinetochoreSerine/threonine-protein kinase PLK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK1Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK1Homo sapiens (human)
cytoplasmDeath-associated protein kinase 1Homo sapiens (human)
plasma membraneDeath-associated protein kinase 1Homo sapiens (human)
postsynaptic densityDeath-associated protein kinase 1Homo sapiens (human)
actin cytoskeletonDeath-associated protein kinase 1Homo sapiens (human)
glutamatergic synapseDeath-associated protein kinase 1Homo sapiens (human)
DAPK1-calmodulin complexDeath-associated protein kinase 1Homo sapiens (human)
cytoplasmDeath-associated protein kinase 1Homo sapiens (human)
nucleusDeath-associated protein kinase 1Homo sapiens (human)
postsynapseLIM domain kinase 1Homo sapiens (human)
glutamatergic synapseLIM domain kinase 1Homo sapiens (human)
male germ cell nucleusLIM domain kinase 1Homo sapiens (human)
cytoplasmLIM domain kinase 1Homo sapiens (human)
cytosolLIM domain kinase 1Homo sapiens (human)
cytoskeletonLIM domain kinase 1Homo sapiens (human)
focal adhesionLIM domain kinase 1Homo sapiens (human)
membraneLIM domain kinase 1Homo sapiens (human)
nuclear speckLIM domain kinase 1Homo sapiens (human)
lamellipodiumLIM domain kinase 1Homo sapiens (human)
neuron projectionLIM domain kinase 1Homo sapiens (human)
nucleusLIM domain kinase 1Homo sapiens (human)
neuron projectionLIM domain kinase 1Homo sapiens (human)
cytoplasmLIM domain kinase 1Homo sapiens (human)
nucleusLIM domain kinase 2Homo sapiens (human)
cytoplasmLIM domain kinase 2Homo sapiens (human)
cis-Golgi networkLIM domain kinase 2Homo sapiens (human)
centrosomeLIM domain kinase 2Homo sapiens (human)
perinuclear region of cytoplasmLIM domain kinase 2Homo sapiens (human)
mitotic spindleLIM domain kinase 2Homo sapiens (human)
nucleusLIM domain kinase 2Homo sapiens (human)
cytoplasmLIM domain kinase 2Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 12Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 12Homo sapiens (human)
cytosolMitogen-activated protein kinase 12Homo sapiens (human)
nucleusMitogen-activated protein kinase 12Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 12Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 10Homo sapiens (human)
cytosolMitogen-activated protein kinase 10Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 10Homo sapiens (human)
nucleusMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
nucleusTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
cytoplasmTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
cytosolTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
extracellular spaceTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
cytosolTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
nuclear bodyTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
membrane5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
Golgi apparatus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytosol5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytoplasmic stress granule5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nuclear speck5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
axon5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
dendrite5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
neuronal cell body5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
extracellular regionEphrin type-B receptor 3Homo sapiens (human)
cytosolEphrin type-B receptor 3Homo sapiens (human)
plasma membraneEphrin type-B receptor 3Homo sapiens (human)
dendriteEphrin type-B receptor 3Homo sapiens (human)
plasma membraneEphrin type-B receptor 3Homo sapiens (human)
rough endoplasmic reticulumEphrin type-A receptor 5Homo sapiens (human)
plasma membraneEphrin type-A receptor 5Homo sapiens (human)
external side of plasma membraneEphrin type-A receptor 5Homo sapiens (human)
axonEphrin type-A receptor 5Homo sapiens (human)
dendriteEphrin type-A receptor 5Homo sapiens (human)
neuronal cell bodyEphrin type-A receptor 5Homo sapiens (human)
perinuclear region of cytoplasmEphrin type-A receptor 5Homo sapiens (human)
plasma membraneEphrin type-A receptor 5Homo sapiens (human)
dendriteEphrin type-A receptor 5Homo sapiens (human)
extracellular regionEphrin type-B receptor 4Homo sapiens (human)
cytosolEphrin type-B receptor 4Homo sapiens (human)
plasma membraneEphrin type-B receptor 4Homo sapiens (human)
extracellular exosomeEphrin type-B receptor 4Homo sapiens (human)
receptor complexEphrin type-B receptor 4Homo sapiens (human)
plasma membraneEphrin type-B receptor 4Homo sapiens (human)
extracellular regionEphrin type-B receptor 1Homo sapiens (human)
endoplasmic reticulumEphrin type-B receptor 1Homo sapiens (human)
cytosolEphrin type-B receptor 1Homo sapiens (human)
plasma membraneEphrin type-B receptor 1Homo sapiens (human)
axonEphrin type-B receptor 1Homo sapiens (human)
early endosome membraneEphrin type-B receptor 1Homo sapiens (human)
filopodium tipEphrin type-B receptor 1Homo sapiens (human)
membrane raftEphrin type-B receptor 1Homo sapiens (human)
extracellular exosomeEphrin type-B receptor 1Homo sapiens (human)
glutamatergic synapseEphrin type-B receptor 1Homo sapiens (human)
plasma membraneEphrin type-B receptor 1Homo sapiens (human)
dendriteEphrin type-B receptor 1Homo sapiens (human)
cytoplasmEphrin type-A receptor 4Homo sapiens (human)
mitochondrial outer membraneEphrin type-A receptor 4Homo sapiens (human)
plasma membraneEphrin type-A receptor 4Homo sapiens (human)
adherens junctionEphrin type-A receptor 4Homo sapiens (human)
cell surfaceEphrin type-A receptor 4Homo sapiens (human)
filopodiumEphrin type-A receptor 4Homo sapiens (human)
axonEphrin type-A receptor 4Homo sapiens (human)
dendriteEphrin type-A receptor 4Homo sapiens (human)
neuromuscular junctionEphrin type-A receptor 4Homo sapiens (human)
early endosome membraneEphrin type-A receptor 4Homo sapiens (human)
presynaptic membraneEphrin type-A receptor 4Homo sapiens (human)
dendritic spineEphrin type-A receptor 4Homo sapiens (human)
dendritic shaftEphrin type-A receptor 4Homo sapiens (human)
perikaryonEphrin type-A receptor 4Homo sapiens (human)
axon terminusEphrin type-A receptor 4Homo sapiens (human)
axonal growth coneEphrin type-A receptor 4Homo sapiens (human)
Schaffer collateral - CA1 synapseEphrin type-A receptor 4Homo sapiens (human)
postsynaptic density membraneEphrin type-A receptor 4Homo sapiens (human)
glutamatergic synapseEphrin type-A receptor 4Homo sapiens (human)
plasma membraneEphrin type-A receptor 4Homo sapiens (human)
dendriteEphrin type-A receptor 4Homo sapiens (human)
mitochondrial intermembrane spaceAdenylate kinase 2, mitochondrialHomo sapiens (human)
extracellular exosomeAdenylate kinase 2, mitochondrialHomo sapiens (human)
sperm mitochondrial sheathAdenylate kinase 2, mitochondrialHomo sapiens (human)
cytoplasmAdenylate kinase 2, mitochondrialHomo sapiens (human)
mitochondrionAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleoplasmAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
plasma membraneAdenosine kinaseHomo sapiens (human)
nucleusAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
cytoplasmHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
nucleusSerine/threonine-protein kinase SIK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase SIK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK1Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
membraneReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
exocystRas-related protein Rab-10Homo sapiens (human)
plasma membraneRas-related protein Rab-10Homo sapiens (human)
Golgi membraneRas-related protein Rab-10Homo sapiens (human)
endosomeRas-related protein Rab-10Homo sapiens (human)
endoplasmic reticulum membraneRas-related protein Rab-10Homo sapiens (human)
Golgi apparatusRas-related protein Rab-10Homo sapiens (human)
trans-Golgi networkRas-related protein Rab-10Homo sapiens (human)
cytosolRas-related protein Rab-10Homo sapiens (human)
cytoskeletonRas-related protein Rab-10Homo sapiens (human)
plasma membraneRas-related protein Rab-10Homo sapiens (human)
adherens junctionRas-related protein Rab-10Homo sapiens (human)
focal adhesionRas-related protein Rab-10Homo sapiens (human)
ciliumRas-related protein Rab-10Homo sapiens (human)
endosome membraneRas-related protein Rab-10Homo sapiens (human)
cytoplasmic vesicle membraneRas-related protein Rab-10Homo sapiens (human)
secretory granule membraneRas-related protein Rab-10Homo sapiens (human)
phagocytic vesicle membraneRas-related protein Rab-10Homo sapiens (human)
insulin-responsive compartmentRas-related protein Rab-10Homo sapiens (human)
perinuclear region of cytoplasmRas-related protein Rab-10Homo sapiens (human)
recycling endosomeRas-related protein Rab-10Homo sapiens (human)
recycling endosome membraneRas-related protein Rab-10Homo sapiens (human)
extracellular exosomeRas-related protein Rab-10Homo sapiens (human)
exocytic vesicleRas-related protein Rab-10Homo sapiens (human)
endoplasmic reticulum tubular networkRas-related protein Rab-10Homo sapiens (human)
recycling endosomeRas-related protein Rab-10Homo sapiens (human)
secretory vesicleRas-related protein Rab-10Homo sapiens (human)
membraneRas-related protein Rab-10Homo sapiens (human)
Golgi apparatusRas-related protein Rab-10Homo sapiens (human)
nucleusActin-related protein 3Homo sapiens (human)
cytoplasmActin-related protein 3Homo sapiens (human)
cytosolActin-related protein 3Homo sapiens (human)
brush borderActin-related protein 3Homo sapiens (human)
cell-cell junctionActin-related protein 3Homo sapiens (human)
focal adhesionActin-related protein 3Homo sapiens (human)
actin cytoskeletonActin-related protein 3Homo sapiens (human)
membraneActin-related protein 3Homo sapiens (human)
lamellipodiumActin-related protein 3Homo sapiens (human)
site of double-strand breakActin-related protein 3Homo sapiens (human)
extracellular exosomeActin-related protein 3Homo sapiens (human)
Arp2/3 protein complexActin-related protein 3Homo sapiens (human)
extracellular regionActin-related protein 2Homo sapiens (human)
nucleusActin-related protein 2Homo sapiens (human)
cytoplasmActin-related protein 2Homo sapiens (human)
cytosolActin-related protein 2Homo sapiens (human)
focal adhesionActin-related protein 2Homo sapiens (human)
actin cytoskeletonActin-related protein 2Homo sapiens (human)
membraneActin-related protein 2Homo sapiens (human)
actin capActin-related protein 2Homo sapiens (human)
azurophil granule lumenActin-related protein 2Homo sapiens (human)
site of double-strand breakActin-related protein 2Homo sapiens (human)
cell projectionActin-related protein 2Homo sapiens (human)
extracellular exosomeActin-related protein 2Homo sapiens (human)
ficolin-1-rich granule lumenActin-related protein 2Homo sapiens (human)
Arp2/3 protein complexActin-related protein 2Homo sapiens (human)
cell cortexActin-related protein 2Homo sapiens (human)
Flemming bodyGTP-binding nuclear protein RanHomo sapiens (human)
male germ cell nucleusGTP-binding nuclear protein RanHomo sapiens (human)
manchetteGTP-binding nuclear protein RanHomo sapiens (human)
nucleusGTP-binding nuclear protein RanHomo sapiens (human)
nuclear envelopeGTP-binding nuclear protein RanHomo sapiens (human)
nucleoplasmGTP-binding nuclear protein RanHomo sapiens (human)
nucleolusGTP-binding nuclear protein RanHomo sapiens (human)
cytoplasmGTP-binding nuclear protein RanHomo sapiens (human)
centrioleGTP-binding nuclear protein RanHomo sapiens (human)
cytosolGTP-binding nuclear protein RanHomo sapiens (human)
membraneGTP-binding nuclear protein RanHomo sapiens (human)
midbodyGTP-binding nuclear protein RanHomo sapiens (human)
sperm flagellumGTP-binding nuclear protein RanHomo sapiens (human)
melanosomeGTP-binding nuclear protein RanHomo sapiens (human)
recycling endosomeGTP-binding nuclear protein RanHomo sapiens (human)
extracellular exosomeGTP-binding nuclear protein RanHomo sapiens (human)
chromatinGTP-binding nuclear protein RanHomo sapiens (human)
nuclear poreGTP-binding nuclear protein RanHomo sapiens (human)
protein-containing complexGTP-binding nuclear protein RanHomo sapiens (human)
RNA nuclear export complexGTP-binding nuclear protein RanHomo sapiens (human)
nucleusGTP-binding nuclear protein RanHomo sapiens (human)
cytoplasmGTP-binding nuclear protein RanHomo sapiens (human)
PcG protein complexCasein kinase II subunit alphaHomo sapiens (human)
PML bodyCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
plasma membraneCasein kinase II subunit alphaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alphaHomo sapiens (human)
Sin3-type complexCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleusPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
autophagosomePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
endoplasmic reticulum membranePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
cytosolPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
nucleusSRSF protein kinase 2Homo sapiens (human)
nucleoplasmSRSF protein kinase 2Homo sapiens (human)
nucleolusSRSF protein kinase 2Homo sapiens (human)
cytoplasmSRSF protein kinase 2Homo sapiens (human)
cytosolSRSF protein kinase 2Homo sapiens (human)
nuclear speckSRSF protein kinase 2Homo sapiens (human)
chromatinSRSF protein kinase 2Homo sapiens (human)
nucleusSRSF protein kinase 2Homo sapiens (human)
cytoplasmSRSF protein kinase 2Homo sapiens (human)
cytosolCasein kinase I isoform gamma-2Homo sapiens (human)
cell cortexCasein kinase I isoform gamma-2Homo sapiens (human)
membraneCasein kinase I isoform gamma-2Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-2Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-2Homo sapiens (human)
nucleusCasein kinase I isoform gamma-2Homo sapiens (human)
chromosome, telomeric regionDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleoplasmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleolusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cytosolDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
membraneDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatinDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
transcription regulator complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase-DNA ligase 4 complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processomeDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-containing complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-DNA complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nonhomologous end joining complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cellular_componentMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 3Homo sapiens (human)
nucleusCyclin-dependent kinase 3Homo sapiens (human)
cytoplasmCyclin-dependent kinase 3Homo sapiens (human)
nucleoplasmCyclin-dependent kinase-like 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase-like 1Homo sapiens (human)
ciliary transition zoneCyclin-dependent kinase-like 1Homo sapiens (human)
intracellular membrane-bounded organelleCyclin-dependent kinase-like 1Homo sapiens (human)
extracellular exosomeCyclin-dependent kinase-like 1Homo sapiens (human)
nucleusCyclin-dependent kinase-like 1Homo sapiens (human)
ruffleCyclin-dependent kinase 6Homo sapiens (human)
nucleusCyclin-dependent kinase 6Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 6Homo sapiens (human)
cytoplasmCyclin-dependent kinase 6Homo sapiens (human)
centrosomeCyclin-dependent kinase 6Homo sapiens (human)
cytosolCyclin-dependent kinase 6Homo sapiens (human)
cyclin D1-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin D3-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin D2-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cytoplasmCyclin-dependent kinase 6Homo sapiens (human)
nucleusCyclin-dependent kinase 6Homo sapiens (human)
microtubuleCyclin-dependent-like kinase 5 Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cytoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cytosolCyclin-dependent-like kinase 5 Homo sapiens (human)
plasma membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
postsynaptic densityCyclin-dependent-like kinase 5 Homo sapiens (human)
membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
protein kinase 5 complexCyclin-dependent-like kinase 5 Homo sapiens (human)
lamellipodiumCyclin-dependent-like kinase 5 Homo sapiens (human)
cell junctionCyclin-dependent-like kinase 5 Homo sapiens (human)
filopodiumCyclin-dependent-like kinase 5 Homo sapiens (human)
axonCyclin-dependent-like kinase 5 Homo sapiens (human)
dendriteCyclin-dependent-like kinase 5 Homo sapiens (human)
growth coneCyclin-dependent-like kinase 5 Homo sapiens (human)
neuromuscular junctionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron projectionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuronal cell bodyCyclin-dependent-like kinase 5 Homo sapiens (human)
perikaryonCyclin-dependent-like kinase 5 Homo sapiens (human)
presynapseCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
cytoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicleCyclin-dependent kinase 16Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 16Homo sapiens (human)
cytosolCyclin-dependent kinase 16Homo sapiens (human)
plasma membraneCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmic side of plasma membraneCyclin-dependent kinase 16Homo sapiens (human)
microtubule cytoskeletonCyclin-dependent kinase 16Homo sapiens (human)
neuron projectionCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 16Homo sapiens (human)
nucleusCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 17Homo sapiens (human)
nucleusCyclin-dependent kinase 17Homo sapiens (human)
nucleusMyelin transcription factor 1Homo sapiens (human)
nucleoplasmMyelin transcription factor 1Homo sapiens (human)
cytosolMyelin transcription factor 1Homo sapiens (human)
chromatinMyelin transcription factor 1Homo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
nucleusATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
cytoplasmATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
cytosolATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
membraneATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
extracellular exosomeATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
membraneATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
6-phosphofructokinase complexATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
Golgi apparatusProtein kinase C epsilon typeHomo sapiens (human)
nucleusProtein kinase C epsilon typeHomo sapiens (human)
cytoplasmProtein kinase C epsilon typeHomo sapiens (human)
mitochondrionProtein kinase C epsilon typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C epsilon typeHomo sapiens (human)
cytosolProtein kinase C epsilon typeHomo sapiens (human)
plasma membraneProtein kinase C epsilon typeHomo sapiens (human)
intracellular membrane-bounded organelleProtein kinase C epsilon typeHomo sapiens (human)
intermediate filament cytoskeletonProtein kinase C epsilon typeHomo sapiens (human)
synapseProtein kinase C epsilon typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C epsilon typeHomo sapiens (human)
cell peripheryProtein kinase C epsilon typeHomo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
mitochondrionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
early endosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
late endosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
endoplasmic reticulumDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Golgi apparatusDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
centrosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
plasma membraneDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
focal adhesionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
stress fiberAngiopoietin-1 receptorHomo sapiens (human)
actin filamentAngiopoietin-1 receptorHomo sapiens (human)
extracellular regionAngiopoietin-1 receptorHomo sapiens (human)
cytoplasmAngiopoietin-1 receptorHomo sapiens (human)
plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
microvillusAngiopoietin-1 receptorHomo sapiens (human)
cell-cell junctionAngiopoietin-1 receptorHomo sapiens (human)
focal adhesionAngiopoietin-1 receptorHomo sapiens (human)
basal plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
cell surfaceAngiopoietin-1 receptorHomo sapiens (human)
basolateral plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
apical plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
centriolar satelliteAngiopoietin-1 receptorHomo sapiens (human)
membrane raftAngiopoietin-1 receptorHomo sapiens (human)
plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
receptor complexAngiopoietin-1 receptorHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
heterochromatinDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-betaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
cytosolDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
immunological synapseProtein kinase C theta typeHomo sapiens (human)
cytosolProtein kinase C theta typeHomo sapiens (human)
plasma membraneProtein kinase C theta typeHomo sapiens (human)
aggresomeProtein kinase C theta typeHomo sapiens (human)
centriolar satelliteProtein kinase C theta typeHomo sapiens (human)
plasma membraneActivin receptor type-1Homo sapiens (human)
apical part of cellActivin receptor type-1Homo sapiens (human)
activin receptor complexActivin receptor type-1Homo sapiens (human)
BMP receptor complexActivin receptor type-1Homo sapiens (human)
plasma membraneActivin receptor type-1Homo sapiens (human)
stress fiberMacrophage-stimulating protein receptorHomo sapiens (human)
vacuoleMacrophage-stimulating protein receptorHomo sapiens (human)
plasma membraneMacrophage-stimulating protein receptorHomo sapiens (human)
cell surfaceMacrophage-stimulating protein receptorHomo sapiens (human)
receptor complexMacrophage-stimulating protein receptorHomo sapiens (human)
plasma membraneMacrophage-stimulating protein receptorHomo sapiens (human)
stress fiberFocal adhesion kinase 1Homo sapiens (human)
nucleusFocal adhesion kinase 1Homo sapiens (human)
cytoplasmFocal adhesion kinase 1Homo sapiens (human)
centrosomeFocal adhesion kinase 1Homo sapiens (human)
cytosolFocal adhesion kinase 1Homo sapiens (human)
cytoskeletonFocal adhesion kinase 1Homo sapiens (human)
plasma membraneFocal adhesion kinase 1Homo sapiens (human)
focal adhesionFocal adhesion kinase 1Homo sapiens (human)
cell cortexFocal adhesion kinase 1Homo sapiens (human)
ciliary basal bodyFocal adhesion kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleFocal adhesion kinase 1Homo sapiens (human)
perinuclear region of cytoplasmFocal adhesion kinase 1Homo sapiens (human)
plasma membraneFocal adhesion kinase 1Homo sapiens (human)
focal adhesionFocal adhesion kinase 1Homo sapiens (human)
dendritic spineFocal adhesion kinase 1Homo sapiens (human)
stress fiberProtein kinase C zeta typeHomo sapiens (human)
nuclear envelopeProtein kinase C zeta typeHomo sapiens (human)
cytoplasmProtein kinase C zeta typeHomo sapiens (human)
endosomeProtein kinase C zeta typeHomo sapiens (human)
microtubule organizing centerProtein kinase C zeta typeHomo sapiens (human)
cytosolProtein kinase C zeta typeHomo sapiens (human)
plasma membraneProtein kinase C zeta typeHomo sapiens (human)
cell-cell junctionProtein kinase C zeta typeHomo sapiens (human)
bicellular tight junctionProtein kinase C zeta typeHomo sapiens (human)
postsynaptic densityProtein kinase C zeta typeHomo sapiens (human)
membraneProtein kinase C zeta typeHomo sapiens (human)
apical plasma membraneProtein kinase C zeta typeHomo sapiens (human)
nuclear matrixProtein kinase C zeta typeHomo sapiens (human)
cell junctionProtein kinase C zeta typeHomo sapiens (human)
cell leading edgeProtein kinase C zeta typeHomo sapiens (human)
vesicleProtein kinase C zeta typeHomo sapiens (human)
myelin sheath abaxonal regionProtein kinase C zeta typeHomo sapiens (human)
axon hillockProtein kinase C zeta typeHomo sapiens (human)
apical cortexProtein kinase C zeta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C zeta typeHomo sapiens (human)
extracellular exosomeProtein kinase C zeta typeHomo sapiens (human)
tight junctionProtein kinase C zeta typeHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein kinase C zeta typeHomo sapiens (human)
glutamatergic synapseProtein kinase C zeta typeHomo sapiens (human)
PAR polarity complexProtein kinase C zeta typeHomo sapiens (human)
extracellular regionProtein kinase C delta typeHomo sapiens (human)
nucleusProtein kinase C delta typeHomo sapiens (human)
nucleoplasmProtein kinase C delta typeHomo sapiens (human)
cytoplasmProtein kinase C delta typeHomo sapiens (human)
mitochondrionProtein kinase C delta typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C delta typeHomo sapiens (human)
cytosolProtein kinase C delta typeHomo sapiens (human)
plasma membraneProtein kinase C delta typeHomo sapiens (human)
cell-cell junctionProtein kinase C delta typeHomo sapiens (human)
nuclear matrixProtein kinase C delta typeHomo sapiens (human)
azurophil granule lumenProtein kinase C delta typeHomo sapiens (human)
endolysosomeProtein kinase C delta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C delta typeHomo sapiens (human)
extracellular exosomeProtein kinase C delta typeHomo sapiens (human)
nucleusTyrosine-protein kinase BTKHomo sapiens (human)
cytoplasmTyrosine-protein kinase BTKHomo sapiens (human)
cytosolTyrosine-protein kinase BTKHomo sapiens (human)
plasma membraneTyrosine-protein kinase BTKHomo sapiens (human)
cytoplasmic vesicleTyrosine-protein kinase BTKHomo sapiens (human)
membrane raftTyrosine-protein kinase BTKHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase BTKHomo sapiens (human)
plasma membraneTyrosine-protein kinase BTKHomo sapiens (human)
nucleusTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
nuclear envelopeTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
endoplasmic reticulum membraneTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
plasma membraneTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell surfaceTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
plasma membraneTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
receptor complexTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cellular_componentCyclin-dependent kinase 18Homo sapiens (human)
nucleusCyclin-dependent kinase 18Homo sapiens (human)
cytoplasmCyclin-dependent kinase 18Homo sapiens (human)
nucleusActivated CDC42 kinase 1Homo sapiens (human)
cytoplasmActivated CDC42 kinase 1Homo sapiens (human)
endosomeActivated CDC42 kinase 1Homo sapiens (human)
cytosolActivated CDC42 kinase 1Homo sapiens (human)
plasma membraneActivated CDC42 kinase 1Homo sapiens (human)
clathrin-coated pitActivated CDC42 kinase 1Homo sapiens (human)
adherens junctionActivated CDC42 kinase 1Homo sapiens (human)
membraneActivated CDC42 kinase 1Homo sapiens (human)
clathrin-coated vesicleActivated CDC42 kinase 1Homo sapiens (human)
cytoplasmic vesicle membraneActivated CDC42 kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleActivated CDC42 kinase 1Homo sapiens (human)
perinuclear region of cytoplasmActivated CDC42 kinase 1Homo sapiens (human)
cytoophidiumActivated CDC42 kinase 1Homo sapiens (human)
Grb2-EGFR complexActivated CDC42 kinase 1Homo sapiens (human)
plasma membraneActivated CDC42 kinase 1Homo sapiens (human)
extracellular spaceEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
plasma membraneEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
extracellular exosomeEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
receptor complexEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
plasma membraneEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
nucleusTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cytosolTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cell-cell junctionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase ITK/TSKHomo sapiens (human)
nuclear outer membraneMyotonin-protein kinaseHomo sapiens (human)
mitochondrial outer membraneMyotonin-protein kinaseHomo sapiens (human)
endoplasmic reticulum membraneMyotonin-protein kinaseHomo sapiens (human)
cytosolMyotonin-protein kinaseHomo sapiens (human)
plasma membraneMyotonin-protein kinaseHomo sapiens (human)
nuclear membraneMyotonin-protein kinaseHomo sapiens (human)
sarcoplasmic reticulum membraneMyotonin-protein kinaseHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
Golgi membraneMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
basolateral plasma membraneMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
plasma membraneMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
growth coneMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
photoreceptor outer segmentTyrosine-protein kinase MerHomo sapiens (human)
extracellular spaceTyrosine-protein kinase MerHomo sapiens (human)
cytoplasmTyrosine-protein kinase MerHomo sapiens (human)
plasma membraneTyrosine-protein kinase MerHomo sapiens (human)
plasma membraneTyrosine-protein kinase MerHomo sapiens (human)
receptor complexTyrosine-protein kinase MerHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
nucleusSerine/threonine-protein kinase 4Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
cytosolSerine/threonine-protein kinase 4Homo sapiens (human)
nuclear bodySerine/threonine-protein kinase 4Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase 4Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
apical plasma membrane5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nuclear speck5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
axon5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
dendrite5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
neuronal cell body5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
chromatin5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
ruffleSerine/threonine-protein kinase PAK 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
chromosomeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin filamentSerine/threonine-protein kinase PAK 1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
focal adhesionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
intercalated discSerine/threonine-protein kinase PAK 1Homo sapiens (human)
Z discSerine/threonine-protein kinase PAK 1Homo sapiens (human)
lamellipodiumSerine/threonine-protein kinase PAK 1Homo sapiens (human)
axonSerine/threonine-protein kinase PAK 1Homo sapiens (human)
dendriteSerine/threonine-protein kinase PAK 1Homo sapiens (human)
nuclear membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
ruffle membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
spindleDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
nucleusMitogen-activated protein kinase 7Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 7Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 7Homo sapiens (human)
cytosolMitogen-activated protein kinase 7Homo sapiens (human)
PML bodyMitogen-activated protein kinase 7Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 7Homo sapiens (human)
nucleusMitogen-activated protein kinase 7Homo sapiens (human)
nucleusSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
secretory granuleSerine/threonine-protein kinase PAK 2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 3Homo sapiens (human)
centrosomeSerine/threonine-protein kinase 3Homo sapiens (human)
nucleusSerine/threonine-protein kinase 3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 3Homo sapiens (human)
cytosolSerine/threonine-protein kinase 3Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase 3Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
cytosolcGMP-dependent protein kinase 2Homo sapiens (human)
apical plasma membranecGMP-dependent protein kinase 2Homo sapiens (human)
nuclear membranecGMP-dependent protein kinase 2Homo sapiens (human)
cytosolIntegrin-linked protein kinaseHomo sapiens (human)
plasma membraneIntegrin-linked protein kinaseHomo sapiens (human)
focal adhesionIntegrin-linked protein kinaseHomo sapiens (human)
membraneIntegrin-linked protein kinaseHomo sapiens (human)
sarcomereIntegrin-linked protein kinaseHomo sapiens (human)
lamellipodiumIntegrin-linked protein kinaseHomo sapiens (human)
focal adhesionIntegrin-linked protein kinaseHomo sapiens (human)
stress fiberIntegrin-linked protein kinaseHomo sapiens (human)
Golgi membraneRho-associated protein kinase 1Homo sapiens (human)
ruffleRho-associated protein kinase 1Homo sapiens (human)
extracellular regionRho-associated protein kinase 1Homo sapiens (human)
centrioleRho-associated protein kinase 1Homo sapiens (human)
cytosolRho-associated protein kinase 1Homo sapiens (human)
cytoskeletonRho-associated protein kinase 1Homo sapiens (human)
plasma membraneRho-associated protein kinase 1Homo sapiens (human)
cytoplasmic stress granuleRho-associated protein kinase 1Homo sapiens (human)
lamellipodiumRho-associated protein kinase 1Homo sapiens (human)
blebRho-associated protein kinase 1Homo sapiens (human)
secretory granule lumenRho-associated protein kinase 1Homo sapiens (human)
Schaffer collateral - CA1 synapseRho-associated protein kinase 1Homo sapiens (human)
cytoskeletonRho-associated protein kinase 1Homo sapiens (human)
cytoplasmRho-associated protein kinase 1Homo sapiens (human)
cytoplasmic stress granuleRho-associated protein kinase 1Homo sapiens (human)
cytoplasmNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
membraneNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
kinetochoreSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
nucleusSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
nuclear speckSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
catalytic step 2 spliceosomeSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
mitochondrionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytosolReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
plasma membraneReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
endosome membraneReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
death-inducing signaling complexReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein-containing complexReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
receptor complexReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ripoptosomeReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
centrosomeCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
sarcoplasmic reticulum membraneCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
synapseCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
membraneCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
sarcoplasmic reticulum membraneCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
membraneCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
sarcoplasmic reticulum membraneCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
sarcolemmaCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytoskeletonDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nuclear speckDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
axonDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
dendriteDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
ribonucleoprotein complexDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmActivin receptor type-2BHomo sapiens (human)
plasma membraneActivin receptor type-2BHomo sapiens (human)
protein-containing complexActivin receptor type-2BHomo sapiens (human)
receptor complexActivin receptor type-2BHomo sapiens (human)
activin receptor complexActivin receptor type-2BHomo sapiens (human)
plasma membraneActivin receptor type-2BHomo sapiens (human)
caveolaBone morphogenetic protein receptor type-2Homo sapiens (human)
extracellular spaceBone morphogenetic protein receptor type-2Homo sapiens (human)
nucleoplasmBone morphogenetic protein receptor type-2Homo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
clathrin-coated pitBone morphogenetic protein receptor type-2Homo sapiens (human)
adherens junctionBone morphogenetic protein receptor type-2Homo sapiens (human)
basal plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
cell surfaceBone morphogenetic protein receptor type-2Homo sapiens (human)
postsynaptic densityBone morphogenetic protein receptor type-2Homo sapiens (human)
apical plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
axonBone morphogenetic protein receptor type-2Homo sapiens (human)
dendriteBone morphogenetic protein receptor type-2Homo sapiens (human)
neuronal cell bodyBone morphogenetic protein receptor type-2Homo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
receptor complexBone morphogenetic protein receptor type-2Homo sapiens (human)
ruffleProtein-tyrosine kinase 6Homo sapiens (human)
nucleusProtein-tyrosine kinase 6Homo sapiens (human)
nucleoplasmProtein-tyrosine kinase 6Homo sapiens (human)
cytoplasmProtein-tyrosine kinase 6Homo sapiens (human)
cytosolProtein-tyrosine kinase 6Homo sapiens (human)
plasma membraneProtein-tyrosine kinase 6Homo sapiens (human)
nuclear bodyProtein-tyrosine kinase 6Homo sapiens (human)
plasma membraneProtein-tyrosine kinase 6Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
acrosomal vesiclecGMP-dependent protein kinase 1 Homo sapiens (human)
nucleoplasmcGMP-dependent protein kinase 1 Homo sapiens (human)
cytoplasmcGMP-dependent protein kinase 1 Homo sapiens (human)
Golgi apparatuscGMP-dependent protein kinase 1 Homo sapiens (human)
cytosolcGMP-dependent protein kinase 1 Homo sapiens (human)
plasma membranecGMP-dependent protein kinase 1 Homo sapiens (human)
sarcolemmacGMP-dependent protein kinase 1 Homo sapiens (human)
cyclin K-CDK13 complexCyclin-dependent kinase 13Homo sapiens (human)
extracellular regionCyclin-dependent kinase 13Homo sapiens (human)
extracellular spaceCyclin-dependent kinase 13Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 13Homo sapiens (human)
Golgi apparatusCyclin-dependent kinase 13Homo sapiens (human)
cytosolCyclin-dependent kinase 13Homo sapiens (human)
nuclear speckCyclin-dependent kinase 13Homo sapiens (human)
ficolin-1-rich granule lumenCyclin-dependent kinase 13Homo sapiens (human)
nuclear cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 13Homo sapiens (human)
nucleusCyclin-dependent kinase 13Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-dependent kinase 13Homo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
nucleusInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
nucleoplasmInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
PML bodyInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
mitochondrial membraneInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
serine/threonine protein kinase complexInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
NMDA selective glutamate receptor complexProtein-tyrosine kinase 2-betaHomo sapiens (human)
nucleusProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytoplasmProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytosolProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytoskeletonProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell cortexProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic densityProtein-tyrosine kinase 2-betaHomo sapiens (human)
lamellipodiumProtein-tyrosine kinase 2-betaHomo sapiens (human)
dendriteProtein-tyrosine kinase 2-betaHomo sapiens (human)
growth coneProtein-tyrosine kinase 2-betaHomo sapiens (human)
neuronal cell bodyProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell bodyProtein-tyrosine kinase 2-betaHomo sapiens (human)
perinuclear region of cytoplasmProtein-tyrosine kinase 2-betaHomo sapiens (human)
apical dendriteProtein-tyrosine kinase 2-betaHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
presynapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
glutamatergic synapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic density, intracellular componentProtein-tyrosine kinase 2-betaHomo sapiens (human)
dendritic spineProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
plasma membraneProtein-tyrosine kinase 2-betaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cell cortexMaternal embryonic leucine zipper kinaseHomo sapiens (human)
membraneMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cytoplasmMaternal embryonic leucine zipper kinaseHomo sapiens (human)
chromosome, centromeric regionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
kinetochoreStructural maintenance of chromosomes protein 1AHomo sapiens (human)
condensed nuclear chromosomeStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleusStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleoplasmStructural maintenance of chromosomes protein 1AHomo sapiens (human)
chromosomeStructural maintenance of chromosomes protein 1AHomo sapiens (human)
cytosolStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nuclear matrixStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic cohesin complexStructural maintenance of chromosomes protein 1AHomo sapiens (human)
meiotic cohesin complexStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic spindle poleStructural maintenance of chromosomes protein 1AHomo sapiens (human)
cohesin complexStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleusStructural maintenance of chromosomes protein 1AHomo sapiens (human)
chromosome, telomeric regionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
nucleusChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
nucleoplasmChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
cytoplasmChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
centrosomeChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
membraneChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
NuRD complexChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
site of DNA damageChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
cerebellar granule cell to Purkinje cell synapseChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
chromatinChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
protein-containing complexChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
RNA polymerase II transcription regulator complexChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
nucleusChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peroxisomal membranePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peroxisomal matrixPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
cytosolPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
membranePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
autophagosome membraneSerine/threonine-protein kinase D1Homo sapiens (human)
nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
trans-Golgi networkSerine/threonine-protein kinase D1Homo sapiens (human)
cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D1Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase D1Homo sapiens (human)
cell cortexSerine/threonine-protein kinase D1Homo sapiens (human)
Z discSerine/threonine-protein kinase D1Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase D1Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase D1Homo sapiens (human)
cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
site of double-strand breakSerine/threonine-protein kinase 38Homo sapiens (human)
nucleusSerine/threonine-protein kinase 38Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38Homo sapiens (human)
cytosolSerine/threonine-protein kinase 38Homo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase 38Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
extracellular regionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial matrixReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic density membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
glutamatergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA-ergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-2Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-2Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
plasma membraneEphrin type-A receptor 7Homo sapiens (human)
glutamatergic synapseEphrin type-A receptor 7Homo sapiens (human)
plasma membraneEphrin type-A receptor 7Homo sapiens (human)
dendriteEphrin type-A receptor 7Homo sapiens (human)
Golgi membraneDelta(24)-sterol reductaseHomo sapiens (human)
nucleusDelta(24)-sterol reductaseHomo sapiens (human)
endoplasmic reticulumDelta(24)-sterol reductaseHomo sapiens (human)
endoplasmic reticulum membraneDelta(24)-sterol reductaseHomo sapiens (human)
membraneDelta(24)-sterol reductaseHomo sapiens (human)
cytoplasmDelta(24)-sterol reductaseHomo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-1Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-1Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cytoplasmic vesicleDual specificity testis-specific protein kinase 1Homo sapiens (human)
cytoplasmDual specificity testis-specific protein kinase 1Homo sapiens (human)
centrosomeDual specificity testis-specific protein kinase 1Homo sapiens (human)
cytosolDual specificity testis-specific protein kinase 1Homo sapiens (human)
lamellipodiumDual specificity testis-specific protein kinase 1Homo sapiens (human)
perinuclear region of cytoplasmDual specificity testis-specific protein kinase 1Homo sapiens (human)
cytoplasmDual specificity testis-specific protein kinase 1Homo sapiens (human)
nucleusDual specificity testis-specific protein kinase 1Homo sapiens (human)
stress fiberMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytosolMyosin light chain kinase, smooth muscleHomo sapiens (human)
plasma membraneMyosin light chain kinase, smooth muscleHomo sapiens (human)
actin cytoskeletonMyosin light chain kinase, smooth muscleHomo sapiens (human)
lamellipodiumMyosin light chain kinase, smooth muscleHomo sapiens (human)
cleavage furrowMyosin light chain kinase, smooth muscleHomo sapiens (human)
cleavage furrowMyosin light chain kinase, smooth muscleHomo sapiens (human)
stress fiberMyosin light chain kinase, smooth muscleHomo sapiens (human)
lamellipodiumMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase, smooth muscleHomo sapiens (human)
nucleoplasmMitogen-activated protein kinase 11Homo sapiens (human)
cytosolMitogen-activated protein kinase 11Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 11Homo sapiens (human)
nucleusMitogen-activated protein kinase 11Homo sapiens (human)
nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase STK11Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase STK11Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase STK11Homo sapiens (human)
cytosolSerine/threonine-protein kinase STK11Homo sapiens (human)
membraneSerine/threonine-protein kinase STK11Homo sapiens (human)
Z discSerine/threonine-protein kinase STK11Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase STK11Homo sapiens (human)
serine/threonine protein kinase complexSerine/threonine-protein kinase STK11Homo sapiens (human)
intracellular protein-containing complexSerine/threonine-protein kinase STK11Homo sapiens (human)
nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase STK11Homo sapiens (human)
photoreceptor disc membraneRhodopsin kinase GRK1Homo sapiens (human)
cytoplasmRhodopsin kinase GRK1Homo sapiens (human)
plasma membraneNT-3 growth factor receptorHomo sapiens (human)
receptor complexNT-3 growth factor receptorHomo sapiens (human)
plasma membraneNT-3 growth factor receptorHomo sapiens (human)
axonNT-3 growth factor receptorHomo sapiens (human)
nucleusSerine/threonine-protein kinase N1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase N1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase N1Homo sapiens (human)
endosomeSerine/threonine-protein kinase N1Homo sapiens (human)
cytosolSerine/threonine-protein kinase N1Homo sapiens (human)
midbodySerine/threonine-protein kinase N1Homo sapiens (human)
cleavage furrowSerine/threonine-protein kinase N1Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase N1Homo sapiens (human)
nucleusSerine/threonine-protein kinase N2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase N2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase N2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase N2Homo sapiens (human)
cytosolSerine/threonine-protein kinase N2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase N2Homo sapiens (human)
nuclear bodySerine/threonine-protein kinase N2Homo sapiens (human)
lamellipodiumSerine/threonine-protein kinase N2Homo sapiens (human)
midbodySerine/threonine-protein kinase N2Homo sapiens (human)
cleavage furrowSerine/threonine-protein kinase N2Homo sapiens (human)
apical junction complexSerine/threonine-protein kinase N2Homo sapiens (human)
intermediate filament cytoskeletonSerine/threonine-protein kinase N2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase N2Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase N2Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
fibrillar centerCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
extracellular exosomeCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
centrosomeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
microtubuleMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
centrosomeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
early endosomeBDNF/NT-3 growth factors receptorHomo sapiens (human)
cytosolBDNF/NT-3 growth factors receptorHomo sapiens (human)
plasma membraneBDNF/NT-3 growth factors receptorHomo sapiens (human)
postsynaptic densityBDNF/NT-3 growth factors receptorHomo sapiens (human)
axonBDNF/NT-3 growth factors receptorHomo sapiens (human)
dendriteBDNF/NT-3 growth factors receptorHomo sapiens (human)
early endosome membraneBDNF/NT-3 growth factors receptorHomo sapiens (human)
terminal boutonBDNF/NT-3 growth factors receptorHomo sapiens (human)
perinuclear region of cytoplasmBDNF/NT-3 growth factors receptorHomo sapiens (human)
receptor complexBDNF/NT-3 growth factors receptorHomo sapiens (human)
axon terminusBDNF/NT-3 growth factors receptorHomo sapiens (human)
plasma membraneBDNF/NT-3 growth factors receptorHomo sapiens (human)
postsynaptic densityBDNF/NT-3 growth factors receptorHomo sapiens (human)
axonBDNF/NT-3 growth factors receptorHomo sapiens (human)
dendritic spineBDNF/NT-3 growth factors receptorHomo sapiens (human)
nucleusMitogen-activated protein kinase 6Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 6Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 6Homo sapiens (human)
cytosolMitogen-activated protein kinase 6Homo sapiens (human)
septin cytoskeletonMitogen-activated protein kinase 6Homo sapiens (human)
protein-containing complexMitogen-activated protein kinase 6Homo sapiens (human)
nucleusMitogen-activated protein kinase 6Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 6Homo sapiens (human)
cytosolPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
phosphorylase kinase complexPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
focal adhesionDiscoidin domain-containing receptor 2Homo sapiens (human)
actin cytoskeletonDiscoidin domain-containing receptor 2Homo sapiens (human)
apical plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
receptor complexDiscoidin domain-containing receptor 2Homo sapiens (human)
plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
cytosolAP2-associated protein kinase 1Homo sapiens (human)
plasma membraneAP2-associated protein kinase 1Homo sapiens (human)
clathrin-coated pitAP2-associated protein kinase 1Homo sapiens (human)
clathrin-coated vesicleAP2-associated protein kinase 1Homo sapiens (human)
cell leading edgeAP2-associated protein kinase 1Homo sapiens (human)
terminal boutonAP2-associated protein kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleAP2-associated protein kinase 1Homo sapiens (human)
presynapseAP2-associated protein kinase 1Homo sapiens (human)
cytoplasmMyosin light chain kinase 3Homo sapiens (human)
cytosolMyosin light chain kinase 3Homo sapiens (human)
cytoplasmMyosin light chain kinase 3Homo sapiens (human)
actin cytoskeletonMyosin light chain kinase 3Homo sapiens (human)
membraneUncharacterized aarF domain-containing protein kinase 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SBK1Homo sapiens (human)
extracellular exosomePutative heat shock protein HSP 90-beta 2Homo sapiens (human)
perinuclear region of cytoplasmPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein-containing complexPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
plasma membranePutative heat shock protein HSP 90-beta 2Homo sapiens (human)
cytosolPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
nucleusSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
Golgi membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
extracellular spaceLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial outer membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial inner membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial matrixLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
lysosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulumLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulum membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Golgi apparatusLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Golgi-associated vesicleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
trans-Golgi networkLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytosolLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoskeletonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
plasma membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
microvillusLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
axonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
dendriteLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
growth coneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
synaptic vesicle membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmic vesicleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmic side of mitochondrial outer membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
dendrite cytoplasmLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuron projectionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuronal cell bodyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
terminal boutonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
perikaryonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
intracellular membrane-bounded organelleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
amphisomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
autolysosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
extracellular exosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulum exit siteLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
multivesicular body, internal vesicleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
postsynapseLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
glutamatergic synapseLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
caveola neckLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
presynaptic cytosolLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
ribonucleoprotein complexLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Wnt signalosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytosolSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
lamellipodiumSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cell leading edgeSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cytosolSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
cell leading edgeSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
mitochondrionAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
mitochondrial matrixAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
cytoplasmAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
nucleusSerine/threonine-protein kinase N3Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase N3Homo sapiens (human)
cytosolSerine/threonine-protein kinase N3Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase N3Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK3Homo sapiens (human)
ciliary tipSerine/threonine-protein kinase ULK3Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK3Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK3Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytoplasmDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
basolateral plasma membraneDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
apical plasma membraneDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
anchoring junctionDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
cytoplasmDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
nucleusAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mitochondrial inner membraneAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
peroxisomeAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mitochondrial membraneAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mitochondrionAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
cytoplasmAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
cytosolSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
endoplasmic reticulum quality control compartmentSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
IRE1-TRAF2-ASK1 complexSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase MARK2Homo sapiens (human)
actin filamentSerine/threonine-protein kinase MARK2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
lateral plasma membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
dendriteSerine/threonine-protein kinase MARK2Homo sapiens (human)
microtubule bundleSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytosolSerine/threonine-protein kinase TAO1Homo sapiens (human)
microtubule cytoskeletonSerine/threonine-protein kinase TAO1Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase TAO1Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase TAO1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TAO1Homo sapiens (human)
nucleusSTE20-related kinase adapter protein alphaHomo sapiens (human)
nucleoplasmSTE20-related kinase adapter protein alphaHomo sapiens (human)
cytoplasmSTE20-related kinase adapter protein alphaHomo sapiens (human)
cytosolSTE20-related kinase adapter protein alphaHomo sapiens (human)
serine/threonine protein kinase complexSTE20-related kinase adapter protein alphaHomo sapiens (human)
intracellular protein-containing complexSTE20-related kinase adapter protein alphaHomo sapiens (human)
stress fiberMyosin-14Homo sapiens (human)
cytosolMyosin-14Homo sapiens (human)
brush borderMyosin-14Homo sapiens (human)
membraneMyosin-14Homo sapiens (human)
growth coneMyosin-14Homo sapiens (human)
actomyosinMyosin-14Homo sapiens (human)
extracellular exosomeMyosin-14Homo sapiens (human)
myosin II filamentMyosin-14Homo sapiens (human)
myosin II complexMyosin-14Homo sapiens (human)
cytoplasmMyosin-14Homo sapiens (human)
myosin filamentMyosin-14Homo sapiens (human)
mitochondrionAarF domain-containing protein kinase 1Homo sapiens (human)
mitochondrial inner membraneAarF domain-containing protein kinase 1Homo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
intermediate filamentSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
cytosolSerine/threonine-protein kinase pim-3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-3Homo sapiens (human)
nucleusATP-dependent RNA helicase DDX42Homo sapiens (human)
nucleoplasmATP-dependent RNA helicase DDX42Homo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX42Homo sapiens (human)
cytosolATP-dependent RNA helicase DDX42Homo sapiens (human)
Cajal bodyATP-dependent RNA helicase DDX42Homo sapiens (human)
membraneATP-dependent RNA helicase DDX42Homo sapiens (human)
nuclear speckATP-dependent RNA helicase DDX42Homo sapiens (human)
U2-type prespliceosomeATP-dependent RNA helicase DDX42Homo sapiens (human)
nucleusATP-dependent RNA helicase DDX42Homo sapiens (human)
nucleusSerine/threonine-protein kinase VRK2Homo sapiens (human)
nuclear envelopeSerine/threonine-protein kinase VRK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase VRK2Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase VRK2Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase VRK2Homo sapiens (human)
mitochondrial membraneSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase VRK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase VRK2Homo sapiens (human)
nucleusSerine/threonine-protein kinase VRK2Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 1Homo sapiens (human)
nucleoplasmHomeodomain-interacting protein kinase 1Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 1Homo sapiens (human)
centrosomeHomeodomain-interacting protein kinase 1Homo sapiens (human)
cytosolHomeodomain-interacting protein kinase 1Homo sapiens (human)
nuclear speckHomeodomain-interacting protein kinase 1Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 1Homo sapiens (human)
PML bodyHomeodomain-interacting protein kinase 1Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 1Homo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
cytoplasmCyclin-dependent kinase-like 3Homo sapiens (human)
nucleusCyclin-dependent kinase-like 3Homo sapiens (human)
nucleoplasmMAP kinase-activated protein kinase 5Homo sapiens (human)
cytosolMAP kinase-activated protein kinase 5Homo sapiens (human)
septin cytoskeletonMAP kinase-activated protein kinase 5Homo sapiens (human)
protein-containing complexMAP kinase-activated protein kinase 5Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 5Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase BRSK2Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase BRSK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase BRSK2Homo sapiens (human)
distal axonSerine/threonine-protein kinase BRSK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK2Homo sapiens (human)
cytosolEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
translation release factor complexEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
cytoplasmic vesicle membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytoplasmMisshapen-like kinase 1Homo sapiens (human)
Golgi apparatusMisshapen-like kinase 1Homo sapiens (human)
cytosolMisshapen-like kinase 1Homo sapiens (human)
postsynaptic densityMisshapen-like kinase 1Homo sapiens (human)
axonMisshapen-like kinase 1Homo sapiens (human)
dendriteMisshapen-like kinase 1Homo sapiens (human)
extracellular exosomeMisshapen-like kinase 1Homo sapiens (human)
cytoplasmMisshapen-like kinase 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase DCLK2Homo sapiens (human)
cytoskeletonSerine/threonine-protein kinase DCLK2Homo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
cytosolCasein kinase I isoform alpha-likeHomo sapiens (human)
nucleusCasein kinase I isoform alpha-likeHomo sapiens (human)
cytoplasmCasein kinase I isoform alpha-likeHomo sapiens (human)
nucleusHomeodomain-interacting protein kinase 4Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 4Homo sapiens (human)
cytoplasmMyosin-IIIaHomo sapiens (human)
filopodiumMyosin-IIIaHomo sapiens (human)
stereocilium tipMyosin-IIIaHomo sapiens (human)
filopodium tipMyosin-IIIaHomo sapiens (human)
myosin complexMyosin-IIIaHomo sapiens (human)
filamentous actinMyosin-IIIaHomo sapiens (human)
photoreceptor inner segmentMyosin-IIIaHomo sapiens (human)
stereocilium tipMyosin-IIIaHomo sapiens (human)
filopodium tipMyosin-IIIaHomo sapiens (human)
nucleusAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
cell projectionAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
cytoplasmAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek11Homo sapiens (human)
nucleolusSerine/threonine-protein kinase Nek11Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek11Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek11Homo sapiens (human)
mitochondrionAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
membraneAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
nucleoplasmPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
autophagosomePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
endoplasmic reticulumPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
cytosolPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
intracellular organellePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
extracellular exosomePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
axonemeMitogen-activated protein kinase 15Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 15Homo sapiens (human)
nucleusMitogen-activated protein kinase 15Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 15Homo sapiens (human)
autophagosomeMitogen-activated protein kinase 15Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 15Homo sapiens (human)
centrioleMitogen-activated protein kinase 15Homo sapiens (human)
cell-cell junctionMitogen-activated protein kinase 15Homo sapiens (human)
bicellular tight junctionMitogen-activated protein kinase 15Homo sapiens (human)
cytoplasmic vesicleMitogen-activated protein kinase 15Homo sapiens (human)
ciliary basal bodyMitogen-activated protein kinase 15Homo sapiens (human)
meiotic spindleMitogen-activated protein kinase 15Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 15Homo sapiens (human)
nucleusMitogen-activated protein kinase 15Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek9Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek9Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek9Homo sapiens (human)
nucleusSerine/threonine-protein kinase BRSK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase BRSK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase BRSK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK1Homo sapiens (human)
synaptic vesicleSerine/threonine-protein kinase BRSK1Homo sapiens (human)
cell junctionSerine/threonine-protein kinase BRSK1Homo sapiens (human)
presynaptic active zoneSerine/threonine-protein kinase BRSK1Homo sapiens (human)
distal axonSerine/threonine-protein kinase BRSK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 35Homo sapiens (human)
nucleolusSerine/threonine-protein kinase 35Homo sapiens (human)
nuclear bodySerine/threonine-protein kinase 35Homo sapiens (human)
nucleusSerine/threonine-protein kinase 35Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 35Homo sapiens (human)
microtubule organizing centerSerine/threonine-protein kinase Nek7Homo sapiens (human)
spindle poleSerine/threonine-protein kinase Nek7Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek7Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek7Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek7Homo sapiens (human)
microtubuleSerine/threonine-protein kinase Nek7Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek7Homo sapiens (human)
photoreceptor disc membraneRhodopsin kinase GRK7Homo sapiens (human)
cytoplasmRhodopsin kinase GRK7Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase 32AHomo sapiens (human)
cytoplasmMyosin-IIIbHomo sapiens (human)
stereocilium tipMyosin-IIIbHomo sapiens (human)
myosin complexMyosin-IIIbHomo sapiens (human)
stereocilium tipMyosin-IIIbHomo sapiens (human)
filopodium tipMyosin-IIIbHomo sapiens (human)
photoreceptor inner segmentMyosin-IIIbHomo sapiens (human)
nucleusATP-dependent RNA helicase DDX1Homo sapiens (human)
nucleoplasmATP-dependent RNA helicase DDX1Homo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX1Homo sapiens (human)
mitochondrionATP-dependent RNA helicase DDX1Homo sapiens (human)
cytosolATP-dependent RNA helicase DDX1Homo sapiens (human)
cytoplasmic stress granuleATP-dependent RNA helicase DDX1Homo sapiens (human)
membraneATP-dependent RNA helicase DDX1Homo sapiens (human)
cleavage bodyATP-dependent RNA helicase DDX1Homo sapiens (human)
tRNA-splicing ligase complexATP-dependent RNA helicase DDX1Homo sapiens (human)
ribonucleoprotein complexATP-dependent RNA helicase DDX1Homo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytosolDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ubiquitin ligase complexDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ribonucleoprotein complexDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoskeletonDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase-like 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase-like 2Homo sapiens (human)
centrosomeCyclin-dependent kinase-like 2Homo sapiens (human)
nucleusCyclin-dependent kinase-like 2Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
early endosomeSerine/threonine-protein kinase Sgk3Homo sapiens (human)
cytosolSerine/threonine-protein kinase Sgk3Homo sapiens (human)
recycling endosomeSerine/threonine-protein kinase Sgk3Homo sapiens (human)
mitochondrionAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
cytosolAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
plasma membraneAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
mitochondrial membraneAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
microtubule organizing centerMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
centrosomeMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule organizing centerMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytosolMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule cytoskeletonMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
dendriteMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
midbodyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
neuron projectionMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
gamma-tubulin complexMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
ciliary basal bodyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
Golgi membraneCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
plasma membraneCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
pericentriolar materialSerine/threonine-protein kinase Nek1Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek1Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek1Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase Nek1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 15Homo sapiens (human)
nucleusCyclin-dependent kinase 15Homo sapiens (human)
cytosolCyclin-dependent kinase 15Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytosolPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytosolPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
nucleusPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
nucleusEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
nucleoplasmEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
cytoplasmEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
EKC/KEOPS complexEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
cytosolEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
nucleusEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
nucleusDual specificity testis-specific protein kinase 2Homo sapiens (human)
nucleoplasmDual specificity testis-specific protein kinase 2Homo sapiens (human)
nuclear bodyDual specificity testis-specific protein kinase 2Homo sapiens (human)
nucleusDual specificity testis-specific protein kinase 2Homo sapiens (human)
cytoplasmDual specificity testis-specific protein kinase 2Homo sapiens (human)
nucleusSRSF protein kinase 1Homo sapiens (human)
nucleoplasmSRSF protein kinase 1Homo sapiens (human)
cytoplasmSRSF protein kinase 1Homo sapiens (human)
endoplasmic reticulumSRSF protein kinase 1Homo sapiens (human)
cytosolSRSF protein kinase 1Homo sapiens (human)
plasma membraneSRSF protein kinase 1Homo sapiens (human)
nuclear matrixSRSF protein kinase 1Homo sapiens (human)
nuclear speckSRSF protein kinase 1Homo sapiens (human)
chromatinSRSF protein kinase 1Homo sapiens (human)
nucleusSRSF protein kinase 1Homo sapiens (human)
cytoplasmSRSF protein kinase 1Homo sapiens (human)
nucleusProtein cereblonHomo sapiens (human)
cytoplasmProtein cereblonHomo sapiens (human)
cytosolProtein cereblonHomo sapiens (human)
membraneProtein cereblonHomo sapiens (human)
perinuclear region of cytoplasmProtein cereblonHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexProtein cereblonHomo sapiens (human)
Golgi membraneMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
nucleoplasmMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
nucleolusMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
endoplasmic reticulumMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
endoplasmic reticulum membraneMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
Golgi apparatusMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
cytosolMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
membraneMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
cytoplasmMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
nucleusMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
external side of plasma membraneMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein-containing complexMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein kinase complexMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
IRE1-TRAF2-ASK1 complexMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
mRNA cleavage and polyadenylation specificity factor complexPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
nucleusPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
focal adhesionPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
nuclear speckPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
lamellipodiumPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
ruffle membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
cytosolEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
cytosolEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
nucleusEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
cytoplasmEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase RIO1Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO1Homo sapiens (human)
preribosome, small subunit precursorSerine/threonine-protein kinase RIO1Homo sapiens (human)
methyltransferase complexSerine/threonine-protein kinase RIO1Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO1Homo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytosolMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase RIO2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase RIO2Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO2Homo sapiens (human)
preribosome, small subunit precursorSerine/threonine-protein kinase RIO2Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO2Homo sapiens (human)
nucleusSerine/threonine-protein kinase RIO2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 19Homo sapiens (human)
cytosolCyclin-dependent kinase 19Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase 19Homo sapiens (human)
CKM complexCyclin-dependent kinase 19Homo sapiens (human)
nucleusCyclin-dependent kinase 19Homo sapiens (human)
cytosolCyclin-dependent kinase 19Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
brush border membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
apical plasma membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
acrosomal vesicleTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
motile ciliumTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase 33Homo sapiens (human)
nucleusSerine/threonine-protein kinase 33Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 33Homo sapiens (human)
nucleusNucleolar GTP-binding protein 1Homo sapiens (human)
nucleoplasmNucleolar GTP-binding protein 1Homo sapiens (human)
nucleolusNucleolar GTP-binding protein 1Homo sapiens (human)
cytoplasmNucleolar GTP-binding protein 1Homo sapiens (human)
cytosolNucleolar GTP-binding protein 1Homo sapiens (human)
membraneNucleolar GTP-binding protein 1Homo sapiens (human)
nuclear membraneNucleolar GTP-binding protein 1Homo sapiens (human)
perinuclear region of cytoplasmNucleolar GTP-binding protein 1Homo sapiens (human)
nucleolusNucleolar GTP-binding protein 1Homo sapiens (human)
nucleusSerine/threonine-protein kinase D2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase D2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase D2Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase D2Homo sapiens (human)
cytosolSerine/threonine-protein kinase D2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D2Homo sapiens (human)
cytosolSerine/threonine-protein kinase D2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase DCLK3Homo sapiens (human)
nucleusSerine/threonine-protein kinase DCLK3Homo sapiens (human)
chromosome, telomeric regionRNA cytidine acetyltransferaseHomo sapiens (human)
nucleusRNA cytidine acetyltransferaseHomo sapiens (human)
nucleoplasmRNA cytidine acetyltransferaseHomo sapiens (human)
nucleolusRNA cytidine acetyltransferaseHomo sapiens (human)
membraneRNA cytidine acetyltransferaseHomo sapiens (human)
midbodyRNA cytidine acetyltransferaseHomo sapiens (human)
telomerase holoenzyme complexRNA cytidine acetyltransferaseHomo sapiens (human)
small-subunit processomeRNA cytidine acetyltransferaseHomo sapiens (human)
nucleolusRNA cytidine acetyltransferaseHomo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase SIK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK2Homo sapiens (human)
nucleusSerine/threonine-protein kinase SIK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK2Homo sapiens (human)
nucleusMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
sarcomereMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
synapseMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytosolSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cell leading edgeSTE20-like serine/threonine-protein kinase Homo sapiens (human)
perinuclear region of cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
extracellular exosomeSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase TAO3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TAO3Homo sapiens (human)
PML bodyHomeodomain-interacting protein kinase 2Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 2Homo sapiens (human)
nucleoplasmHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmic stress granuleHomeodomain-interacting protein kinase 2Homo sapiens (human)
nuclear bodyHomeodomain-interacting protein kinase 2Homo sapiens (human)
RNA polymerase II transcription regulator complexHomeodomain-interacting protein kinase 2Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmTyrosine-protein kinase SrmsHomo sapiens (human)
cytosolTyrosine-protein kinase SrmsHomo sapiens (human)
plasma membraneTyrosine-protein kinase SrmsHomo sapiens (human)
cytosolHomeodomain-interacting protein kinase 3Homo sapiens (human)
plasma membraneHomeodomain-interacting protein kinase 3Homo sapiens (human)
nuclear bodyHomeodomain-interacting protein kinase 3Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 3Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 3Homo sapiens (human)
PML bodyHomeodomain-interacting protein kinase 3Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleolusSerine/threonine-protein kinase PLK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK3Homo sapiens (human)
Golgi stackSerine/threonine-protein kinase PLK3Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK3Homo sapiens (human)
dendriteSerine/threonine-protein kinase PLK3Homo sapiens (human)
neuronal cell bodySerine/threonine-protein kinase PLK3Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK3Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK3Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleusdCTP pyrophosphatase 1Homo sapiens (human)
nucleoplasmdCTP pyrophosphatase 1Homo sapiens (human)
mitochondriondCTP pyrophosphatase 1Homo sapiens (human)
cytosoldCTP pyrophosphatase 1Homo sapiens (human)
cytosoldCTP pyrophosphatase 1Homo sapiens (human)
nucleusDual specificity protein kinase CLK4Homo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nuclear bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
PML bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek6Homo sapiens (human)
spindle poleSerine/threonine-protein kinase Nek6Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek6Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek6Homo sapiens (human)
microtubuleSerine/threonine-protein kinase Nek6Homo sapiens (human)
nuclear speckSerine/threonine-protein kinase Nek6Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytosolCasein kinase I isoform gamma-1Homo sapiens (human)
nucleusCasein kinase I isoform gamma-1Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-1Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-1Homo sapiens (human)
fibrillar centerSerine/threonine-protein kinase PAK 6Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 6Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase PAK 6Homo sapiens (human)
cell junctionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 6Homo sapiens (human)
nucleusSNF-related serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase LATS2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS2Homo sapiens (human)
nucleusSerine/threonine-protein kinase LATS2Homo sapiens (human)
cytosolSerine/threonine-protein kinase LATS2Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase LATS2Homo sapiens (human)
nucleusSerine/threonine-protein kinase LATS2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS2Homo sapiens (human)
extracellular regionSerine/threonine-protein kinase 36Homo sapiens (human)
nucleusSerine/threonine-protein kinase 36Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 36Homo sapiens (human)
cytosolSerine/threonine-protein kinase 36Homo sapiens (human)
cytoskeletonSerine/threonine-protein kinase 36Homo sapiens (human)
cell projectionSerine/threonine-protein kinase 36Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 36Homo sapiens (human)
cytoplasmPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
cytosolPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
phenylalanine-tRNA ligase complexPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
membranePhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
mitochondrial matrixIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
mitochondrionIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
nuclear speckBMP-2-inducible protein kinaseHomo sapiens (human)
cytoplasmBMP-2-inducible protein kinaseHomo sapiens (human)
nucleusBMP-2-inducible protein kinaseHomo sapiens (human)
extracellular regionObg-like ATPase 1Homo sapiens (human)
nucleolusObg-like ATPase 1Homo sapiens (human)
cytoplasmObg-like ATPase 1Homo sapiens (human)
centrosomeObg-like ATPase 1Homo sapiens (human)
cytosolObg-like ATPase 1Homo sapiens (human)
membraneObg-like ATPase 1Homo sapiens (human)
platelet alpha granule lumenObg-like ATPase 1Homo sapiens (human)
extracellular exosomeObg-like ATPase 1Homo sapiens (human)
cytoplasmObg-like ATPase 1Homo sapiens (human)
nucleusMidasinHomo sapiens (human)
nucleoplasmMidasinHomo sapiens (human)
nucleolusMidasinHomo sapiens (human)
cytosolMidasinHomo sapiens (human)
membraneMidasinHomo sapiens (human)
intermediate filament cytoskeletonMidasinHomo sapiens (human)
nucleusMidasinHomo sapiens (human)
preribosome, large subunit precursorMidasinHomo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cell surfaceInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
extrinsic component of plasma membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
extracellular spaceInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cytosolInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
endosome membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
nucleusMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cyclin K-CDK12 complexCyclin-dependent kinase 12Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 12Homo sapiens (human)
nuclear speckCyclin-dependent kinase 12Homo sapiens (human)
nuclear cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 12Homo sapiens (human)
nucleusCyclin-dependent kinase 12Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-dependent kinase 12Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK2Homo sapiens (human)
cytosolSerine/threonine-protein kinase PLK2Homo sapiens (human)
dendriteSerine/threonine-protein kinase PLK2Homo sapiens (human)
chromatinSerine/threonine-protein kinase PLK2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK2Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK2Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK2Homo sapiens (human)
nucleoplasmNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cytoplasmNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrionNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial inner membraneNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial respirasomeNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial respiratory chain complex INADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial membraneNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MARK1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase MARK1Homo sapiens (human)
microtubule cytoskeletonSerine/threonine-protein kinase MARK1Homo sapiens (human)
dendriteSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PAK 5Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 5Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 5Homo sapiens (human)
nuclear membraneSerine/threonine-protein kinase PAK 5Homo sapiens (human)
synapseSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 26Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 26Homo sapiens (human)
Golgi-associated vesicleSerine/threonine-protein kinase 26Homo sapiens (human)
cytosolSerine/threonine-protein kinase 26Homo sapiens (human)
vesicle membraneSerine/threonine-protein kinase 26Homo sapiens (human)
membraneSerine/threonine-protein kinase 26Homo sapiens (human)
apical plasma membraneSerine/threonine-protein kinase 26Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase 26Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 26Homo sapiens (human)
cell peripherySerine/threonine-protein kinase 26Homo sapiens (human)
FAR/SIN/STRIPAK complexSerine/threonine-protein kinase 26Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 26Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 26Homo sapiens (human)
cytoplasmeIF-2-alpha kinase GCN2Homo sapiens (human)
cytosolic ribosomeeIF-2-alpha kinase GCN2Homo sapiens (human)
cytosoleIF-2-alpha kinase GCN2Homo sapiens (human)
cytoplasmeIF-2-alpha kinase GCN2Homo sapiens (human)
nucleuseIF-2-alpha kinase GCN2Homo sapiens (human)
mitochondrionSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
mitochondrial matrixSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinate-CoA ligase complex (ADP-forming)Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
extracellular exosomeSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
mitochondrionSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinate-CoA ligase complexSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
nucleusSerine/threonine-protein kinase NLKHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase NLKHomo sapiens (human)
cytosolSerine/threonine-protein kinase NLKHomo sapiens (human)
nucleusSerine/threonine-protein kinase NLKHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase NLKHomo sapiens (human)
Golgi membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
mitochondrial outer membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase betaHomo sapiens (human)
Golgi apparatusPhosphatidylinositol 4-kinase betaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase betaHomo sapiens (human)
rough endoplasmic reticulum membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
perinuclear region of cytoplasmPhosphatidylinositol 4-kinase betaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-kinase betaHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17AHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase 17AHomo sapiens (human)
nuclear speckSerine/threonine-protein kinase 17AHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17AHomo sapiens (human)
nucleoplasmSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cytosolSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cell cortexSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
basolateral plasma membraneSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
apical plasma membraneSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
intracellular membrane-bounded organelleSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cell bodySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cytoplasmSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cytosolSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
nucleoplasmEphrin type-A receptor 6Homo sapiens (human)
plasma membraneEphrin type-A receptor 6Homo sapiens (human)
dendriteEphrin type-A receptor 6Homo sapiens (human)
plasma membraneEphrin type-A receptor 6Homo sapiens (human)
extracellular space5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase TBK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase TBK1Homo sapiens (human)
intracellular membrane-bounded organelleSerine/threonine-protein kinase TBK1Homo sapiens (human)
serine/threonine protein kinase complexSerine/threonine-protein kinase TBK1Homo sapiens (human)
stress fiberSeptin-9Homo sapiens (human)
cytoplasmSeptin-9Homo sapiens (human)
microtubuleSeptin-9Homo sapiens (human)
axonemeSeptin-9Homo sapiens (human)
actin cytoskeletonSeptin-9Homo sapiens (human)
perinuclear region of cytoplasmSeptin-9Homo sapiens (human)
non-motile ciliumSeptin-9Homo sapiens (human)
septin complexSeptin-9Homo sapiens (human)
septin ringSeptin-9Homo sapiens (human)
microtubule cytoskeletonSeptin-9Homo sapiens (human)
cell division siteSeptin-9Homo sapiens (human)
cytoplasmDeath-associated protein kinase 2Homo sapiens (human)
Golgi apparatusDeath-associated protein kinase 2Homo sapiens (human)
cytoplasmic vesicleDeath-associated protein kinase 2Homo sapiens (human)
autophagosome lumenDeath-associated protein kinase 2Homo sapiens (human)
intracellular membrane-bounded organelleDeath-associated protein kinase 2Homo sapiens (human)
cytoplasmDeath-associated protein kinase 2Homo sapiens (human)
nucleusDeath-associated protein kinase 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
sarcolemmaPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
GABA-ergic synapsePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
postsynaptic specialization membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
dendritic spinePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
postsynaptic membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
fibrillar centerRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleolusRibosomal protein S6 kinase alpha-6Homo sapiens (human)
mitochondrionRibosomal protein S6 kinase alpha-6Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-6Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleusTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
nucleoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytosolTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoskeletonTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
apical plasma membraneTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
recycling endosomeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
extracellular exosomeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
presynapseTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
glutamatergic synapseTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
postsynaptic density, intracellular componentTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase TAO2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase TAO2Homo sapiens (human)
nucleolusSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytosolSerine/threonine-protein kinase TAO2Homo sapiens (human)
axonSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytoplasmic vesicle membraneSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytoplasmic vesicleSerine/threonine-protein kinase TAO2Homo sapiens (human)
neuron projectionSerine/threonine-protein kinase TAO2Homo sapiens (human)
dendritic growth coneSerine/threonine-protein kinase TAO2Homo sapiens (human)
axonal growth coneSerine/threonine-protein kinase TAO2Homo sapiens (human)
receptor complexSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TAO2Homo sapiens (human)
nucleoplasmLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
nucleolusLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
mitochondrionLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
mitochondrial outer membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
endoplasmic reticulumLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
endoplasmic reticulum membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
plasma membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
endoplasmic reticulumLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
mitochondrionLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
plasma membraneALK tyrosine kinase receptorHomo sapiens (human)
plasma membraneALK tyrosine kinase receptorHomo sapiens (human)
extracellular exosomeALK tyrosine kinase receptorHomo sapiens (human)
protein-containing complexALK tyrosine kinase receptorHomo sapiens (human)
receptor complexALK tyrosine kinase receptorHomo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular_componentSRSF protein kinase 3Homo sapiens (human)
nucleusSRSF protein kinase 3Homo sapiens (human)
cytoplasmSRSF protein kinase 3Homo sapiens (human)
fibrillar centerSerine/threonine-protein kinase ICKHomo sapiens (human)
nucleusSerine/threonine-protein kinase ICKHomo sapiens (human)
cytosolSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliumSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliary basal bodySerine/threonine-protein kinase ICKHomo sapiens (human)
ciliary tipSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliary baseSerine/threonine-protein kinase ICKHomo sapiens (human)
nucleusSerine/threonine-protein kinase ICKHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliumSerine/threonine-protein kinase ICKHomo sapiens (human)
nucleusCyclin-dependent kinase 11AHomo sapiens (human)
cytoplasmCyclin-dependent kinase 11AHomo sapiens (human)
nucleusCyclin-dependent kinase 11AHomo sapiens (human)
condensed chromosomeAurora kinase CHomo sapiens (human)
nucleusAurora kinase CHomo sapiens (human)
cytoplasmAurora kinase CHomo sapiens (human)
spindleAurora kinase CHomo sapiens (human)
midbodyAurora kinase CHomo sapiens (human)
spindle midzoneAurora kinase CHomo sapiens (human)
chromosome passenger complexAurora kinase CHomo sapiens (human)
kinetochoreAurora kinase CHomo sapiens (human)
spindle midzoneAurora kinase CHomo sapiens (human)
spindle pole centrosomeAurora kinase CHomo sapiens (human)
spindle microtubuleAurora kinase CHomo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
mitochondrionCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
postsynaptic densityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
dendritic spineCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
nucleusRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
membraneRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytosolSerine/threonine-protein kinase 38-likeHomo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase 38-likeHomo sapiens (human)
membraneSerine/threonine-protein kinase 38-likeHomo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytoplasmMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
cytoskeletonMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
plasma membraneMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
axonMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
dendriteMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
neuron projectionMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
neuronal cell bodyMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK3Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
exon-exon junction complexThyroid hormone receptor-associated protein 3Homo sapiens (human)
nucleusThyroid hormone receptor-associated protein 3Homo sapiens (human)
nucleoplasmThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear speckThyroid hormone receptor-associated protein 3Homo sapiens (human)
extracellular exosomeThyroid hormone receptor-associated protein 3Homo sapiens (human)
mediator complexThyroid hormone receptor-associated protein 3Homo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
chromosomeDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
nucleolusDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
plasma membraneMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
nucleusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
nucleusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cytosolReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein-containing complexReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cytosolSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
lamellipodiumSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cell leading edgeSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
Golgi membraneSerine/threonine-protein kinase 24Homo sapiens (human)
nucleusSerine/threonine-protein kinase 24Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 24Homo sapiens (human)
nucleolusSerine/threonine-protein kinase 24Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 24Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 24Homo sapiens (human)
cytosolSerine/threonine-protein kinase 24Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 24Homo sapiens (human)
FAR/SIN/STRIPAK complexSerine/threonine-protein kinase 24Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 24Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 24Homo sapiens (human)
cytosolNF-kappa-B essential modulatorHomo sapiens (human)
spindle poleNF-kappa-B essential modulatorHomo sapiens (human)
nucleusNF-kappa-B essential modulatorHomo sapiens (human)
nucleoplasmNF-kappa-B essential modulatorHomo sapiens (human)
cytoplasmNF-kappa-B essential modulatorHomo sapiens (human)
cytosolNF-kappa-B essential modulatorHomo sapiens (human)
IkappaB kinase complexNF-kappa-B essential modulatorHomo sapiens (human)
mitotic spindleNF-kappa-B essential modulatorHomo sapiens (human)
ubiquitin ligase complexNF-kappa-B essential modulatorHomo sapiens (human)
protein-containing complexNF-kappa-B essential modulatorHomo sapiens (human)
nucleusNF-kappa-B essential modulatorHomo sapiens (human)
cytoplasmNF-kappa-B essential modulatorHomo sapiens (human)
cytoplasmCasein kinase I isoform gamma-3Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-3Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-3Homo sapiens (human)
nucleusCasein kinase I isoform gamma-3Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
perinuclear region of cytoplasmMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1957)

Assay IDTitleYearJournalArticle
AID1345861Human SRC proto-oncogene, non-receptor tyrosine kinase (Src family)2005Cancer research, Jun-01, Volume: 65, Issue:11
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
AID1345848Human SIK family kinase 3 (QIK subfamily)2015The Biochemical journal, Jan-15, Volume: 465, Issue:2
The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
AID1345890Human salt inducible kinase 2 (QIK subfamily)2015The Biochemical journal, Jan-15, Volume: 465, Issue:2
The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
AID1345606Human ABL proto-oncogene 1, non-receptor tyrosine kinase (Abl family)2013Genes to cells : devoted to molecular & cellular mechanisms, Feb, Volume: 18, Issue:2
Activity-based kinase profiling of approved tyrosine kinase inhibitors.
AID1345829Human salt inducible kinase 1 (QIK subfamily)2015The Biochemical journal, Jan-15, Volume: 465, Issue:2
The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
AID1802639LanthaScreen Eu Kinase Activity Assay from Article 10.1111/cbdd.12863: \\Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.\\2017Chemical biology & drug design, 03, Volume: 89, Issue:3
Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
AID1797044Kinase Assay and Binding Constant Measurement from Article 10.1073/pnas.0504952102: \\Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.\\2005Proceedings of the National Academy of Sciences of the United States of America, Aug-02, Volume: 102, Issue:31
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
AID1799403Tyrosine Kinase Inhibition Assay from Article 10.1038/nchembio.162: \\A new screening assay for allosteric inhibitors of cSrc.\\2009Nature chemical biology, Jun, Volume: 5, Issue:6
A new screening assay for allosteric inhibitors of cSrc.
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID1799177Kinetics Assay for IC50 Determination from Article 10.1021/jm9002928: \\Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.\\2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID1799404Serine/Threonine Kinase Inhibition Assay from Article 10.1038/nchembio.162: \\A new screening assay for allosteric inhibitors of cSrc.\\2009Nature chemical biology, Jun, Volume: 5, Issue:6
A new screening assay for allosteric inhibitors of cSrc.
AID1802324HotSpot Kinase Activity Assay from Article 10.1021/acschembio.6b00709: \\Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.\\2016ACS chemical biology, 12-16, Volume: 11, Issue:12
Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.
AID1802323Kinobeads Competition Assay from Article 10.1021/acschembio.6b00709: \\Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.\\2016ACS chemical biology, 12-16, Volume: 11, Issue:12
Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.
AID1802640FRET-Based Z'-Lyte Assay from Article 10.1111/cbdd.12863: \\Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.\\2017Chemical biology & drug design, 03, Volume: 89, Issue:3
Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
AID1799577Kinase Assay from Article 10.1111/j.1747-0285.2007.00556.x: \\Crystal structure of the T315I mutant of AbI kinase.\\2007Chemical biology & drug design, Sep, Volume: 70, Issue:3
Crystal structure of the T315I mutant of AbI kinase.
AID1797004Lck Kinase Inhibition Assay from Article 10.1021/jm060727j: \\2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-met2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID1801731Kinome-Wide Inhibitor Profiling from Article 10.1021/acschembio.5b01018: \\Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.\\2016ACS chemical biology, 05-20, Volume: 11, Issue:5
Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID627338Inhibition of LCK using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1425182Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1424971Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1612815Inhibition of LCK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID435152Binding constant for CAMK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID507684Inhibition of cKIT D816V mutant2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID1817039Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay
AID329191Inhibition of TAP-tagged Btk T474I mutant2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID282233Inhibition of c-kit2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1424895Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID303305Inhibition of Abl kinase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID624908Binding constant for TEC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424922Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435831Binding constant for RPS6KA5(Kin.Dom.1 - C-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625121Binding constant for RET kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1439891Antiproliferative activity against human K562 cells2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
RITA Mimics: Synthesis and Mechanistic Evaluation of Asymmetric Linked Trithiazoles.
AID1425126Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID624743Binding constant for LTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID271973Inhibition of FGFR12006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID760497Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID435410Binding constant for KIT kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625097Binding constant for TNNI3K kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424953Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1764401Ratio of drug concentration in brain to plasma of P-gp knock out Sprague-Dawley rat2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID1734722Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID624971Binding constant for DAPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624967Binding constant for RPS6KA5(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID360782Inhibition of viral spread in Dengue virus-infected african green monkey Vero cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 6 days by immunofluorescence assay relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID507074Inhibition of recombinant PI3Kdelta by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID435281Binding constant for full-length CSNK1A1L2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID729551Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells at 10 uM by TR-FRET based binding assay2013European journal of medicinal chemistry, Mar, Volume: 61Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
AID624868Binding constant for MST1R kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624745Binding constant for PKN1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624981Binding constant for ABL1(F317L)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507680Inhibition of ABL T315I mutant2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID709933Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID435165Binding constant for JAK1(Kin.Dom.1/JH2 - pseudokinase) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425030Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435911Binding constant for MEK6 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID718818Inhibition of Abl at 100 uM2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
AID435407Binding constant for FLT3(D835Y) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1473869Ratio of drug concentration at steady state in patient with advanced phase CML and Ph+ ALL at 100 mg, po BID after 12 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID435279Binding constant for full-length CDK92008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID360790Antiviral activity against Dengue virus 2 infected in human Huh7 cells2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID1425208Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435545Binding constant for NEK6 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435563Binding constant for TNIK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID282238Inhibition of FGFR1 kinase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID625091Binding constant for MAST1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425164Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435694Binding constant for TNK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID735399Cytotoxicity against human LXFA 983L cells after 4 days by propidium iodide staining2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.
AID1206297Antiinvasive activity against human MDA-MB-231 cells at 0.1 uM after 24 hrs by transwell assay2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625114Binding constant for GSK3A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625103Binding constant for MST4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425177Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624912Binding constant for TYK2(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624767Binding constant for MERTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1473865Drug concentration at steady state in patient with advanced phase CML and Ph+ ALL at 100 mg, po BID after 12 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1616470Protac activity against VHL/BCR-ABL in human K562 cells assessed as induction of BCR-ABL degradation at 20 times IC50 incubated for 12 hrs followed by drug wash-out and incubation in drug-free medium up to 72 hrs by Western blot analysis2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
AID1224792Delta TM value showing the stabilisation of RIOK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435930Binding constant for PHKG2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424990Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID677647Antiangiogenic activity in HUVEC co-cultured with vascular smooth muscle cells assessed as inhibition of network formation at 1.8 to 15 uM after 72 hrs2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: from in silico screening to cyclodextrin formulation.
AID1764399Unbound plasma concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID625127Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435534Binding constant for NEK5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID724977Inhibition of human recombinant ABL1 G250E mutant expressed in insect cells after 30 mins by FRET assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1915580Cytotoxicity against human K562 cells2021European journal of medicinal chemistry, Jan-01, Volume: 209Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID625141Binding constant for RIOK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624995Binding constant for CSF1R kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625095Binding constant for SIK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624881Binding constant for PKAC-alpha kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1186126Antiproliferative activity against human GXF251L cells after 4 days by modified propidium iodide assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.
AID435934Binding constant for PLK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424901Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435646Binding constant for BLK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624844Binding constant for CDK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624737Binding constant for EPHA5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625008Binding constant for EPHA1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425062Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID458676Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells relative to control by Western blot2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
AID498533Antiproliferative activity against human CML cells2009Nature chemical biology, Mar, Volume: 5, Issue:3
A pulse at the heart of targeted therapy.
AID1224765Delta TM value showing the stabilisation of CK1G2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624726Binding constant for HIPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID282248Inhibition of PKCalpha2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID415074Inhibition of VEGFR22009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Structure-based virtual screening of Src kinase inhibitors.
AID1424995Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624920Binding constant for MRCKA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1205061Inhibition of ACK1 kinase (unknown origin)2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.
AID435779Binding constant for ALK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID282266Toxicity in nude mouse2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID627293Inhibition of c-Src using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID463628Inhibition of Src2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Selectively nonselective kinase inhibition: striking the right balance.
AID625118Binding constant for CAMK1D kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424949Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID640177Cytotoxicity against human K562 cells after 72 hrs by WST-8 reagent based MTT assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives.
AID1734864Inhibition of Fra1 phosphorylation in human MDA-MB-231 cells at 0.03 to 0.3 uM incubated for 20 hrs by Western blot analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID436021Binding constant for LATS2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224781Delta TM value showing the stabilisation of PAK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435402Binding constant for EGFR(G719S) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1242627Inhibition of c-Kit (unknown origin) using biotinylated HER2 peptide as substrate at 0.003 uM by time resolved fluorescence method2015ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
AID624963Binding constant for LATS1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425110Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID735396Cytotoxicity against human RXF 393NL cells after 4 days by propidium iodide staining2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.
AID1425102Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1886532Vasculo-toxicity in human HMVEC cells assessed as reduction in vascular structure integrity by measuring AUC measured after 6 hrs by calcein AM dye based fluorescence assay2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
AID1425212Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435198Binding constant for TIE1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424947Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425072Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID436053Binding constant for full-length STK332008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1207363Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells expressing hKvLQT1/hminK measured using IonWorks Quattro automated patch clamp platform
AID625026Binding constant for MAP3K1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1876318Antiviral activity against MERS-CoV infected in 1 hr pretreated african green monkey Vero E6 cells measured after 48 hrs by fluorescence based plate reader method2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
AID624754Binding constant for NEK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624916Binding constant for ULK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425168Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1873218Inhibition of ABCG2 (unknown origin) expressed in human K562 cells assessed as extrusion of Hoechst 33342 using Hoechst 33342 as substrate by flow cytometry2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID375158Antiproliferative activity against human DU145 cells assessed as reduction of cell count at 100 nM after 5 hrs2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID1424932Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID360778Antiviral activity against Modoc virus M544 infected in african green monkey Vero cells2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID624904Binding constant for NEK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625004Binding constant for EGFR(L858R,T790M) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624945Binding constant for BMPR1A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625038Binding constant for PIK3CA(E542K) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625018Binding constant for YES kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435785Binding constant for full-length CDK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624979Binding constant for ABL1(F317I)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624845Binding constant for CDK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID375156Antiproliferative activity against human PC3 cells assessed as reduction of cell count at 100 nM after 5 hrs2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID436033Binding constant for PIK3CA kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1246523Therapeutic index, ratio of CC50 for HEK293 cells to IC50 for human K562 cells2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1425074Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435280Binding constant for CSF1R kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1240469Inhibition of Bcr-Abl T315I mutant (unknown origin) using Tyr2 peptide substrate after 2 hrs by FRET-based Z'-lyte assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.
AID329198Inhibition of basal TNFalpha release in human U937 cells at 2 uM after 1 hr by ELISA2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID1424943Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1616418Protac activity against VHL/BCR-ABL in human K562 cells assessed as induction of BCR-ABL degradation at 100 nM by Western blot analysis2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
AID1425192Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID282222Antiproliferative activity against human PC3 cells after 72 hrs2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1424977Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624893Binding constant for MEK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625043Binding constant for PIK3CA(I800L) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424924Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435798Binding constant for FGR kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID671741Inhibition of human BTK by enzymatic assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
AID1425174Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1421413Inhibition of recombinant human Erbb4 at 1000 nM after 60 mins by ELISA relative to control2018European journal of medicinal chemistry, Oct-05, Volume: 158Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
AID1424896Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507073Inhibition of recombinant PI3Kbeta by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID624802Binding constant for PIM3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624836Binding constant for IKK-beta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1207457Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) K1 cells stably expressing hERG measured using IonWorks Quattro automated patch clamp platform
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1425146Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID638912Inhibition of c-Kit at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID271968Inhibition of Yes2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID732825Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID624873Binding constant for PAK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224748Delta TM value showing the stabilisation of AMPKA2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624976Binding constant for PRKX kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1460609Inhibition of NorA in Staphylococcus aureus SA1199B harboring GrlA A116E mutant assessed as potentiation of CPX-induced antibacterial activity by measuring fold reduction in CPX MIC at 6.25 to 12.5 ug/ml by checkerboard assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID435275Binding constant for BIKE kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1573074Antiproliferative activity against human HCT116 cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID624781Binding constant for CDK4-cyclinD3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435937Binding constant for TESK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID724665Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1224779Delta TM value showing the stabilisation of NEK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID329181Binding affinity to Btk from human K562 cells extract by LC-MSMS2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID624740Binding constant for LRRK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1734825Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 0.1 uM incubated for 24 hrs by annexin V-FITC and propidium iodide staining based flow cytometry analysis (Rvb = 2 %)2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID1373718Inhibition of colony formation in human MCF7 cells at 7.5 uM incubated for 10 days by crystal violet staining based plate cloning test2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells.
AID1310140Antimigratory activity in human MDA-MB-231 cells assessed as reduction in cell motility at 10 nM at 6 hrs by microscopy based scratch-wound cell migration assay2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID1396666Inhibition of human full length PKMYT1 expressed in HEK293 cells using EFS (247 to 259 residues) as substrate after 1 hr by fluorescence polarization immunoasay
AID767460Inhibition of CSF1R (unknown origin)2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Selectivity data: assessment, predictions, concordance, and implications.
AID624915Binding constant for PIP5K2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224749Delta TM value showing the stabilisation of CAMK1D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1425040Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID271971Inhibition of Her12006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID1876319Antiviral activity against SARS-CoV in 2 hrs pretreated african green monkey Vero E6 cells measured after 48 hrs by CellTireGlo luminescent cell viability assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
AID624770Binding constant for CAMK2D kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1857476Inhibition of LIMK1/LIMK2 in human SH-SY5Y cells assessed as effect on phospho cofilin serine 3 phosphorylation incubated for 2 hr by AlphaLISA SureFire assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity.
AID624769Binding constant for AURKC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1450952Selectivity ratio of Kd for recombinant human N-terminal His6-tagged Wee1 kinase domain (291 to 575 residues) to Kd for recombinant human N-terminal His6-tagged Wee2 kinase domain (202 to 492 residues)2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.
AID1573088Antiproliferative activity against human GL261 cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID1310129Inhibition of human PDGFRalpha using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID435149Binding constant for AMPK-alpha2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1450947Binding affinity to recombinant human N-terminal His6-tagged Myt1 kinase domain (75 to 361 residues) by isothermal titration calorimetry2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.
AID1772713PROTAC activity at CRBN/Bcr-Abl in human K562 cells assessed as degrading activity by Western blotting analysis2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
AID625140Binding constant for MARK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435654Binding constant for full-length ERK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1286541Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1424910Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435151Binding constant for CAMK1G kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424939Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1206292Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 0.3 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 94.4%)2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID1207489Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) cells stable expressing hERG measured using IonWorks Barracuda automated patch clamp platform
AID435900Binding constant for AKT3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424944Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624813Binding constant for MINK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625142Binding constant for TSSK1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425103Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435411Binding constant for KIT(D816V) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID329192Inhibition of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells after 1 hr2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID1206294Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G0/G1 phase at 0.3 uM after 24 to 48 hrs by flow cytometric analysis2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID625053Binding constant for PRKG2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435676Binding constant for LCK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1186996Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM after 24 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID624750Binding constant for PRP4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1724049Inhibition of Src (unknown origin)2020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
AID1310168Half life in nude mouse at 10 mg/kg, iv via oral gavage2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID1734720Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID435806Binding constant for MAPKAPK5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1286553Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID329189Inhibition of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells at >= 100 nM after 1 hr2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID624866Binding constant for MLK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1301837Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
AID1425116Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435559Binding constant for SNARK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1764402Unbound brain-to-plasma concentration ratio in P-gp knock out Sprague-Dawley rat2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID435293Binding constant for JNK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1612830Antiproliferative activity against human NHDF cells after 72 hrs by CellTiter 96 aqueous one solution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID1409089Inhibition of human ABL at 100 uM2018Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
AID624784Binding constant for INSR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625073Binding constant for SGK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424972Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID329202Inhibition of antigen-induced histamine release in wild-type BMMCs at 1 uM after 30 mins2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID435652Binding constant for EGFR(L747-E749del, A750P) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID282262Clearance in Sprague-Dawley rat at 10 mg/kg, iv2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1450955Binding affinity to recombinant human N-terminal His6-tagged Myt1 kinase domain (75 to 361 residues) assessed as change in melting temperature at 50 uM by differential scanning fluorimetry2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.
AID507704Inhibition of FES at 10 mM2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID592838Inhibition of c-SRC2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.
AID435278Binding constant for full-length CDK72008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625050Binding constant for PKN2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624882Binding constant for PKAC-beta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID718820Inhibition of EPHA2 at 100 uM2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
AID1425014Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625009Binding constant for EPHA3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435677Binding constant for LOK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1310134Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 5 days by PrestoBlue assay2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID360781Inhibition of viral spread in Dengue virus-infected african green monkey Vero cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 5 days by immunofluorescence assay relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID436017Binding constant for ERK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID282232Inhibition of yes kinase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID435394Binding constant for CAMK2B kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID463631Inhibition of Bcr-Abl Y253F mutant2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Selectively nonselective kinase inhibition: striking the right balance.
AID625096Binding constant for STK36 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID329193Inhibition of LPS-induced Btk T474I autophosphorylation on Tyr223 in human U937 cells after 1 hr2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID625012Binding constant for GAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1734721Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID435163Binding constant for full-length GSK3B2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424899Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID724650Inhibition of BCR-ABL T315I mutant in mouse BA/F3 cells after 4 hrs by Western blotting analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1515661Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID624911Binding constant for TXK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1331474Inhibition of recombinant human Abl T315I mutant using abtide as substrate by [gamma-32P]ATP based assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
AID640176Growth inhibition of human U937 cells at 10 uM after 72 hrs by WST-8 reagent based MTT assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives.
AID435326Binding constant for TYRO3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435780Binding constant for BMPR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624858Binding constant for JAK1(JH2domain-pseudokinase) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625046Binding constant for PIK3CB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1386050Inhibition of wild type BCR-ABL1 (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of cell proliferation after 48 hrs by BriteLight luciferase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
AID1425005Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435558Binding constant for RPS6KA3(Kin.Dom.1 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624951Binding constant for EPHA2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425017Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425130Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624988Binding constant for ABL1(T315I)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID638914Inhibition of PDGFRbeta at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID1425153Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1409088Inhibition of human c-Src at 100 uM2018Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
AID624827Binding constant for CAMK2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID282236Inhibition of Her1 kinase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1424986Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1315387Cytotoxicity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.
AID624733Binding constant for SIK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425027Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID436013Binding constant for DMPK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624931Binding constant for CLK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1315386Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 96 hrs by MTT assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.
AID435935Binding constant for RIPK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1240468Inhibition of wild type Bcr-Abl (unknown origin) using Tyr2 peptide substrate after 2 hrs by FRET-based Z'-lyte assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.
AID1612812Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID507422Inhibition of recombinant Ret by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID1886531Inhibition of ABL1 T315I mutant (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
AID1424992Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625109Binding constant for BIKE kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1817043Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID1425150Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1186994Cytotoxicity against human HepG2 cells assessed as cell viability at 1 uM after 24 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID435529Binding constant for LATS1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624994Binding constant for AKT1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624961Binding constant for TGFBR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224807Delta TM value showing the stabilisation of YSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID436012Binding constant for full-length CSNK2A12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224758Delta TM value showing the stabilisation of CDK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435822Binding constant for MEK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624792Binding constant for KIT(V559D,T670I) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224755Delta TM value showing the stabilisation of CAMK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435655Binding constant for ERK5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625115Binding constant for PAK6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625107Binding constant for DMPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1876247Antiviral activity against DENV infected in 180 mins pretreated african green monkey Vero cells incubated for 1 to 72 hrs2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID624830Binding constant for CDK9 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID735397Cytotoxicity against human PRXF DU145 cells after 4 days by propidium iodide staining2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.
AID624957Binding constant for EPHB6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224795Delta TM value showing the stabilisation of SLK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435532Binding constant for MST3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1386085Inhibition of BCR-ABL1 Q252H mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
AID624905Binding constant for CDKL5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425075Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424998Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1240405Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.
AID710011Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1425022Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425128Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224778Delta TM value showing the stabilisation of NEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624953Binding constant for EPHA7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625117Binding constant for PAK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624888Binding constant for ERK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624761Binding constant for CDC2L5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625080Binding constant for EIF2AK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624703Binding constant for MAPKAPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID638922Inhibition of RON at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID1616472Protac activity against VHL/BCR-ABL in human K562 cells assessed as reduction in BCR-ABL-mediated STAT5 phosphorylation at 20 times IC50 incubated for 12 hrs followed by drug wash-out and incubation in drug-free medium up to 72 hrs by Western blot analysi2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
AID507682Inhibition of mouse BLK2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID1425082Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624829Binding constant for CDK8 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1612826Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID1310175Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability at 0.03 to 300 uM after 5 days by PrestoBlue assay2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID1425189Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID375154Inhibition of human DU145 cell adhesion at 100 nM after 5 hrs by light microscopy2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID624820Binding constant for ACVR2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435167Binding constant for KIT(V559D) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224800Delta TM value showing the stabilisation of MST4 (2) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1246518Cytotoxicity against human K562 cells assessed as reduction in cell viability2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID435276Binding constant for BMPR1A kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625055Binding constant for MST1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424978Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625129Binding constant for HIPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424960Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1421417Inhibition of recombinant human ABL at 1000 nM after 60 mins by ELISA relative to control2018European journal of medicinal chemistry, Oct-05, Volume: 158Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
AID507683Inhibition of cKIT2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID1425196Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425118Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425034Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425169Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625143Binding constant for CAMKK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425186Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425009Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID303309Growth inhibition of human M07e cells after 48 hrs by [3H]thymidine uptake assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID435321Binding constant for PRKCQ kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224805Delta TM value showing the stabilisation of VRK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624930Binding constant for TNK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624985Binding constant for ABL1(M351T)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624885Binding constant for ERK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1573085Antiproliferative activity against human LN18 cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID724675Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1205872Angiostatic activity in human ECRF24 cells assessed as inhibition of cell migration after 7 hrs by laser scanner cytometry based wound closure assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.
AID1425176Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1612822Inhibition of Fyn A (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID1734827Antimigratory activity against human MDA-MB-231 cells assessed as inhibition of cell migration at 0.3 uM incubated for 20 hrs by wound healing assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID1450945Binding affinity to recombinant human N-terminal His6-tagged Wee1 kinase domain (291 to 575 residues) expressed in Escherichia coli BL21 (DE3) by isothermal titration calorimetry2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.
AID1425011Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624869Binding constant for NEK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424988Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID375152Inhibition of human PC3 cell adhesion at 100 nM after 5 hrs by light microscopy2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID282251Inhibition of PKCzeta2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID624753Binding constant for PKNB(M.tuberculosis) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425063Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1695245Growth inhibition of human Ri1 cells incubated for 72 hrs2020RSC medicinal chemistry, Jun-01, Volume: 11, Issue:6
Understanding the mechanism of action of pyrrolo[3,2-
AID435322Binding constant for PRKG2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624834Binding constant for DAPK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425201Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1053271Inhibition of ACE (unknown origin) assessed as 3-Hydroxybutyril-glycil-glycil-glycine conversion to 3-hydroxybutyric acid at 500 uM after 60 mins by WST assay relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID435162Binding constant for FLT3(N841I) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624839Binding constant for AKT2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID360775Antiviral activity against Dengue virus 1 Hawaii infected in african green monkey Vero cells2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID498532Cmax in chronic myeloid leukemia patient2009Nature chemical biology, Mar, Volume: 5, Issue:3
A pulse at the heart of targeted therapy.
AID625029Binding constant for BRK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625135Binding constant for ADCK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1515656Binding affinity to wild-type human partial length LCK (R207 to P509 residues) expressed in bacterial expression system by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID435931Binding constant for PIM1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID638920Inhibition of EPH-B2 at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID282265Antitumor activity against human K562 xenograft in nude mouse at 50 mg/kg, po for 10 days in 5 day on and 2 day off schedule2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1772722PROTAC activity at CRBN/Bcr-Abl in human K562 cells assessed as reduction in Bcr-Abl level after 16 hrs by Western blotting analysis2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
AID507075Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID435518Binding constant for AURKA kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435821Binding constant for GAK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1246519Cytotoxicity against imatinib resistant human IR-K562 cells assessed as reduction in cell viability2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1206281Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 0.3 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.58%)2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID1739051Binding affinity to human CSF1R2020European journal of medicinal chemistry, Aug-01, Volume: 199A multi-scale systems pharmacology approach uncovers the anti-cancer molecular mechanism of Ixabepilone.
AID760519Cytotoxicity against human HMEC after 72 hrs by WST1 assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1823816Inhibition of CSF1R (unknown origin) by enzymatic assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.
AID435329Binding constant for YSK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435433Binding constant for full-length MST12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1616414Protac activity against VHL/BCR-ABL in human K562 cells assessed as induction of BCR-ABL degradation at 10 uM by Western blot analysis2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
AID1286552Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1515646Ratio of drug concentration in unbound HEK293 cell to media2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID627290Inhibition of RSK2 using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1224799Delta TM value showing the stabilisation of NDR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435804Binding constant for LYN kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1893830Binding affinity to Src (unknown origin) assessed as inhibition constant2021European journal of medicinal chemistry, Jan-15, Volume: 2102-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents.
AID1286561Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1205868Cytotoxicity against human ECRF24 cells after 72 hrs by MTT assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.
AID435678Binding constant for MUSK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435801Binding constant for full-length GSK3A2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224777Delta TM value showing the stabilisation of MST4(1) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID507701Inhibition of TIE2 at 10 mM2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID435190Binding constant for full-length PIP5K1A2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625098Binding constant for IRAK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424907Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624751Binding constant for PIP5K1C kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1515660Binding affinity to wild-type human partial length SIK (M1 to Y304 residues) expressed in bacterial expression system by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID1424942Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625123Binding constant for RET(V804L) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625125Binding constant for CLK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425171Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1202518Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2015European journal of medicinal chemistry, , Volume: 96Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.
AID1310136Inhibition of FAK phosphorylation at tyrosine 861 in human MDA-MB-231 cells at 3 to 100 nM preincubated for 1.5 hrs followed by serum stimulation for 1 hr by Western blot analysis2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID1425101Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425198Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1734822Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 0.1 uM incubated for 24 hrs by annexin V-FITC and propidium iodide staining based flow cytometry analysis (Rvb = 0.2 %)2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID624996Binding constant for EGFR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724671Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID435560Binding constant for SNF1LK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1424905Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1504524Inhibition of MAPK p38 (unknown origin)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer.
AID1182700Antiproliferative activity against human HMC-1.2 cells carrying V560G, D816V mutant assessed as cell growth inhibition by MTT assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Development and biological evaluation of potent and selective c-KIT(D816V) inhibitors.
AID1425002Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624843Binding constant for CAMK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625010Binding constant for FER kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425206Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424962Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435561Binding constant for SRMS kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID282257Cmax in Sprague-Dawley rat at 10 mg/kg, po2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID624755Binding constant for ZAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435188Binding constant for PAK6 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID282252Cmax in Sprague-Dawley rat at 10 mg/kg, iv2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1857473Inhibition of PAK mediated recombinant LIMK2 phosphorylation (347 to 659 residues) (unknown origin) incubated for 45 mins followed by ATP addition measured after 180 mins by RapidFire Mass Spectrometry kinase assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID624759Binding constant for PFCDPK1(P.falciparum) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID760499Cytotoxicity against human KM12 cells after 48 hrs by SRB assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID624812Binding constant for SBK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424891Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1421415Inhibition of recombinant human c-SRC at 1000 nM after 60 mins by ELISA relative to control2018European journal of medicinal chemistry, Oct-05, Volume: 158Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
AID624842Binding constant for BMX kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1175325Inhibition of c-Src (unknown origin) at 100 uM2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID625116Binding constant for ADCK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435829Binding constant for RPS6KA1(Kin.Dom.2 - C-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1695243Growth inhibition of human MEC-1 cells incubated for 72 hrs2020RSC medicinal chemistry, Jun-01, Volume: 11, Issue:6
Understanding the mechanism of action of pyrrolo[3,2-
AID435169Binding constant for full-length MEK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1286588Inhibition of BCR/ABL in human KU812 cells assessed as downregulation of CrkL phosphorylation at T207 site at 0.1 uM after 1 hr by immunoblotting method2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1224787Delta TM value showing the stabilisation of PIM2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID724676Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID624710Binding constant for SRMS kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1734724Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 40 mg/kg, po qd for 21 days and measured every 3 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID435796Binding constant for ERBB2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624936Binding constant for FLT3(D835Y) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436049Binding constant for PTK6 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID507703Inhibition of EGFR T790M mutant at 10 mM2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID624791Binding constant for KIT(V559D) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID282255Mean residence time in Sprague-Dawley rat at 10 mg/kg, iv2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID435323Binding constant for RET(M918T) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425136Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224769Delta TM value showing the stabilisation of GSK3B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625047Binding constant for AMPK-alpha2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID443957Cytotoxicity against Philadelphia chromosome positive human ALL3 cells by Alamar Blue fluorescent assay2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors.
AID1424928Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435199Binding constant for TLK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1373722Toxicity in Kunming mouse assessed as survival rat at 200 mg/kg, po dosed once for 2 weeks2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells.
AID435201Binding constant for TRKA kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435319Binding constant for PKN1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID282244Inhibition of FAK2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1425086Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224763Delta TM value showing the stabilisation of CLK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID507077Inhibition of DNA-PK by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID625087Binding constant for MELK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435904Binding constant for full-length CSK2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224773Delta TM value showing the stabilisation of ASK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1573072Antiproliferative activity against human H460 cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID329200Inhibition of antigen-induced IL6 secretion in mouse mast cells at 1 uM after 24 hrs by ELISA2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID435800Binding constant for FYN kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID303306Inhibition of Src2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID625016Binding constant for SRC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624850Binding constant for DDR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624977Binding constant for OSR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID745320Inhibition of EGFR (unknown origin) at 10 uM relative to control2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID435408Binding constant for INSR kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624891Binding constant for JNK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1206304Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of colony formation at >0.01 uM after 12 days by crystal violet staining-based assay2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID1612821Inhibition of CSK (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID1425054Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624918Binding constant for DYRK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID498534Half life in chronic myeloid leukemia patient2009Nature chemical biology, Mar, Volume: 5, Issue:3
A pulse at the heart of targeted therapy.
AID1515651Binding affinity to wild-type human partial length SRC (L240 to L536 residues) expressed in bacterial expression system by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID624722Binding constant for MKK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435924Binding constant for MARK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1631451Antiviral activity against Dengue virus 2 NGC infected in human HuH7 cells assessed as reduction in viral titer after 24 hrs2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1875895Antiviral activity against pseudo typed HCV infected in human Huh-7.5.1 cells assessed as inhibition of viral infection2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1375356Antitumor activity against human K562 cells overexpressing GFP-fussed full length mouse eIF4E xenografted in SCID mouse assessed as tumor growth inhibition at 2.5 mg/kg, po qd administered via gavage for 5 days on 2 days off per cycle for 2 cycles relativ2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
AID435830Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625108Binding constant for MKNK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625082Binding constant for RSK4(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724664Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID271950Inhibition of Src in presence of ATP2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID435290Binding constant for FGFR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1612818Inhibition of ABL1 (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID360789Inhibition of Dengue virus 2 assembly in african green monkey Vero cells assessed as virus-induced membrane structures at 2.5 uM after 4 days postinfection by electron microscopy2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID1283286Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.
AID1186991Cytotoxicity against human HepG2 cells assessed as cell viability at 1 uM after 4 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID624975Binding constant for PLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1286626Binding affinity to SRC (unknown origin)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1424890Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1310135Inhibition of SRC phosphorylation at tyrosine 416 in human MDA-MB-231 cells at 3 to 100 nM preincubated for 1.5 hrs followed by serum stimulation for 1 hr by Western blot analysis2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID1425098Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID375148Inhibition of cSrc in human PC3 cells assessed as reduction of phosphorylated FAK Y576/Y577 level at 100 nM after 5 hrs by immunoblot2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID624914Binding constant for WEE1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624704Binding constant for NEK9 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435519Binding constant for AURKB kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID724649Inhibition of BCR-ABL T315I mutant-mediated CRK1 phosphorylation in mouse BA/F3 cells after 4 hrs by Western blotting analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID458665Inhibition of mouse GM-CSF-stimulated cell proliferation of growth factor dependent mouse FDC-P1 cells expressing human FMS after 48 hrs by resazurin dye reduction assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
AID1206283Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 0.3 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 95.5%)2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID624879Binding constant for PIK3CG kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425121Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1315389Cytotoxicity against human K562 cells assessed as reduction in cell viability after 96 hrs by MTT assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.
AID435556Binding constant for RAF1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624766Binding constant for p38-gamma kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1612819Inhibition of BRK (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID435193Binding constant for RPS6KA6(Kin.Dom.1 - C-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435286Binding constant for EPHA7 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425105Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624862Binding constant for LYN kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435409Binding constant for full-length JNK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425158Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624856Binding constant for GSK3B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID282237Inhibition of Her2 kinase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID745318Inhibition of human recombinant SRC at 10 uM relative to control2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1425127Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224754Delta TM value showing the stabilisation of CAMK2G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435940Binding constant for full-length TSSK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625077Binding constant for DAPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424994Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1473866Ratio of drug concentration at steady state in patient with chronic phase CML at 70 to 90 mg, po BID after 12 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID435805Binding constant for MAP4K5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1616413Growth inhibition of human K562 cells incubated for 2 days by CCK8 assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
AID624823Binding constant for MKNK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425144Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1515654Binding affinity to wild-type human partial length DDR1 (R565 to V876 residues) expressed in bacterial expression system by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID624786Binding constant for KIT kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624919Binding constant for AURKA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1875892Antiviral activity against MERS-CoV infected in 1 hr pretreated African green monkey Vero E6 cells ssessed as inhibition of cytopathic effect incubated for 48 hrs by plate reader method2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1886527Cytotoxicity against human iPSC-CM cells assessed as reduction in contractile alterations or amplitude in cell voltage by VF2.1.Cl dye based assay2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
AID1206216Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID435799Binding constant for FLT3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624727Binding constant for FYN kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424917Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1315388Cytotoxicity against human U937 cells assessed as reduction in cell viability after 96 hrs by MTT assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.
AID282246Inhibition of IR kinase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1425060Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624965Binding constant for LZK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID360776Antiviral activity against Dengue virus 3 H87 infected in african green monkey Vero cells2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID1310171Antimigratory activity in Tg(brn3c:mGFP) zebrafish neuromasts at 1 to 10 uM treated for 20 to 48 hrs post fertilization measured at 72 hrs post fertilization by fluorescent microscopy2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID1246527Resistance index, ratio of IC50 for imatinib resistant human IR-K562 cells to IC50 for human K562 cells2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID282249Inhibition of PKCdelta2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID282239Inhibition of MEK2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1612824Inhibition of Lyn B (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID624950Binding constant for DMPK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424999Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID436052Binding constant for full-length SNF1LK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425067Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1301849Hematotoxicity in human PHA/IL2-stimulated PBMC2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
AID1242619Inhibition of DDR1 (unknown origin) at 0.0015 uM after 1 hr by time resolved fluorescence method2015ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
AID625037Binding constant for PIK3CA(C420R) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1515659Binding affinity to wild-type human partial length RIPK2 (M1 to K310 residues) expressed in bacterial expression system by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID624729Binding constant for FAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID732826Antiproliferative activity against human T47D cells after 72 hrs by MTT assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID1875939Antiviral activity against DENV infected in human Huh-7 cells assessed as inhibition of viral replication2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID282240Inhibition of VEGFR2 kinase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1141140Binding affinity to wild type DDR2 (unknown origin) by FLiK assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Identification of type II and III DDR2 inhibitors.
AID732831Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID458666Selectivity index, ratio of IC50 for mouse GM-CSF-stimulated proliferation of mouse FDC-P1 cells expressing human FMS to IC50 for human FMS-mediated mouse FDC-P1 cells proliferation in presence of human CSF12010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
AID435936Binding constant for full-length SRPK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID732828Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID638917Inhibition of ErbB2 at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID435443Binding constant for TXK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1141136Inhibition of wild type DDR2 (unknown origin) preincubated for 30 mins before substrate addition by FRET assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Identification of type II and III DDR2 inhibitors.
AID435555Binding constant for PRKR kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425178Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424898Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID735398Cytotoxicity against human PAXF 1657L cells after 4 days by propidium iodide staining2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.
AID1654861Antiviral activity against HCV genotype 2a pseudoparticle infected in human Huh7.5 cells assessed as reduction in viral replication at 2 to 4 uM2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID1425042Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435896Binding constant for AAK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424965Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID724975Inhibition of human recombinant ABL1 M351T mutant expressed in insect cells after 30 mins by FRET assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1424967Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1286563Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID624709Binding constant for MYLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425084Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624721Binding constant for MEK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436022Binding constant for full-length MEK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424976Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1876266Binding affinity to GAK (unknown origin) assessed as dissociation constant2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID435662Binding constant for MST2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID360787Inhibition of viral spread in Dengue virus-infected asian tiger mosquito C6/36 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 5 days by immunofluorescence assay relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID1205944Binding affinity to human GAK fused to T7 bacteriophage expressed in Escherichia coli BL21 after 1 hr by qPCR analysis2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents.
AID435528Binding constant for IRAK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624889Binding constant for JNK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID709994Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1764400Unbound brain concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID1425122Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624764Binding constant for CLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1256162Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
AID436032Binding constant for MYO3B kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID360788Inhibition of viral spread in Dengue virus-infected asian tiger mosquito C6/36 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 6 days by immunofluorescence assay relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID435516Binding constant for ADCK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224786Delta TM value showing the stabilisation of PIM1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1875893Antiviral activity against SARS-CoV infected in 2 hrs pretreated African green monkey Vero E6 cells assessed as inhibition of cytopathic effect incubated for 48 hrs by celltitre-glo luminescent assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID435148Binding constant for AMPK-alpha1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424908Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435932Binding constant for PKAC-alpha kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625072Binding constant for TBK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID282234Inhibition of PDGFRbeta2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1450946Binding affinity to recombinant human N-terminal His6-tagged Wee2 kinase domain (202 to 492 residues) expressed in Escherichia coli BL21 (DE3) by isothermal titration calorimetry2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.
AID624990Binding constant for ABL1(Y253F)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1893833Oral bioavailability in rat relative to control2021European journal of medicinal chemistry, Jan-15, Volume: 2102-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents.
AID435328Binding constant for YES kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625112Binding constant for YANK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435933Binding constant for PKN2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424919Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1373713Inhibition of human BCR/ABL V299L mutant2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells.
AID1424951Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1573061Antiproliferative activity against human K562 cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID624706Binding constant for MLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID745322Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1301834Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
AID638921Inhibition of c-Met at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID1695244Growth inhibition of human PCL12 cells incubated for 72 hrs2020RSC medicinal chemistry, Jun-01, Volume: 11, Issue:6
Understanding the mechanism of action of pyrrolo[3,2-
AID1207551Inhibition of long-lasting type calcium current (hICa) in Chinese Hamster Ovary (CHO) cells expressing hCav1.2 measured using IonWorks Quattro automated patch clamp platform
AID624934Binding constant for FLT3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624960Binding constant for RSK2(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507424Inhibition of recombinant PDGFR by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID1425204Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1310146Cardiotoxicity in wild-type zebrafish embryos at >10 uM treated for 4 hrs measured after 48 hrs by fluorescent microscopy2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID625001Binding constant for EGFR(L747-S752del, P753S) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1141137Inhibition of DDR2 T654M mutant (unknown origin) preincubated for 30 mins before substrate addition by FRET assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Identification of type II and III DDR2 inhibitors.
AID282253AUC (total) in Sprague-Dawley rat at 10 mg/kg, iv2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1424904Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1286555Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID436048Binding constant for full-length PTK2B2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625054Binding constant for MST2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1246525Therapeutic index, ratio of CC50 for HEK293 cells to IC50 for human THP1 cells2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID435524Binding constant for full-length CSNK1D2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1772712Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
AID507079Inhibition of recombinant c-Abl by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID625056Binding constant for TESK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435514Binding constant for ABL1(M351T) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1876062Inhibition of c-Abl (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID745323Cytotoxicity against human K562 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID625011Binding constant for FGR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424959Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224768Delta TM value showing the stabilisation of DMPK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID375143Activity of human N-terminal His-tagged p38alpha expressed in Escherichia coli BL21 (DE3)2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID624884Binding constant for PRKD1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625015Binding constant for ROCK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435795Binding constant for EPHA4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1283290Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.
AID303308Growth inhibition of human M07ep210 cells after 48 hrs by [3H]thymidine uptake assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID625086Binding constant for SLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1286560Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID282241Inhibition of CDK22004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1189756Induction of apoptosis in human SH-SY5Y cells assessed as accumulation of hypodiploid cells at 0.1 uM after 24 hrs by propidium iodide staining-based cytofluorimetry2015Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1
Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
AID435659Binding constant for full-length MARK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1386087Inhibition of BCR-ABL1 E255K mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
AID435675Binding constant for KIT(V559D,T670I) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625000Binding constant for EGFR(L747-E749del, A750P) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425107Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625021Binding constant for LIMK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435192Binding constant for ROS1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425099Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1206301Inhibition of ERK phosphorylation in human MDA-MB-231 cells at 0.001 to 1 uM after 20 hrs by Western blot analysis2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID1425133Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1573086Antiproliferative activity against human SK-N-FI cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID1176842Inhibition of c-SRC (unknown origin) at 1 uM by ELISA method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
AID1224784Delta TM value showing the stabilisation of PCTK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID709934Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1186123Antiproliferative activity against human RXF 393NL cells after 4 days by modified propidium iodide assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.
AID724648Inhibition of BCR-ABL T315I mutant-mediated STAT5 phosphorylation in mouse BA/F3 cells after 4 hrs by Western blotting analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID760498Cytotoxicity against human U251 cells after 48 hrs by SRB assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID709935Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1425029Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424912Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624999Binding constant for EGFR(G719S) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID463630Inhibition of wild type Bcr-Abl2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Selectively nonselective kinase inhibition: striking the right balance.
AID624825Binding constant for BMPR1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624713Binding constant for ERK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID761478Inhibition of Yes1 (unknown origin) assessed as kinase-dependent enzymatic production of ADP from ATP using coupled luminescence-based reaction by ADP-Glo kinase assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1224761Delta TM value showing the stabilisation of CLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID282263Oral bioavailability in Sprague-Dawley rat at 10 mg/kg, po2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID724672Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID624874Binding constant for PCTK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625036Binding constant for PIK3CA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435289Binding constant for ERK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID507076Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID1425191Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625067Binding constant for NDR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1616471Protac activity against VHL/BCR-ABL in human K562 cells assessed as reduction in BCR-ABL phosphorylation at 20 times IC50 incubated for 12 hrs followed by drug wash-out and incubation in drug-free medium up to 72 hrs by Western blot analysis2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
AID435663Binding constant for full-length MST42008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625126Binding constant for TAOK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1286559Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID435166Binding constant for full-length JNK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625058Binding constant for VRK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435292Binding constant for ITK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1186128Antiproliferative activity against human PRXF DU145 cells after 4 days by modified propidium iodide assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.
AID732855Inhibition of c-KIT (unknown origin) using Ser/Thr 6 peptide as substrate incubated for 1 hr prior to substrate addition measured after 2 hrs by FRET assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID1425173Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625131Binding constant for FGFR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624896Binding constant for PRKR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1286554Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID624796Binding constant for MET(Y1235D) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624742Binding constant for NEK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1242637Antiproliferative activity against human NCI-H2286 cells expressing DDR2 mutant after 72 hrs by alamar blue assay2015ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
AID435910Binding constant for MAP4K4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID436015Binding constant for EPHA6 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1310130Inhibition of human RET using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID638919Inhibition of EPH-A2 at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID625119Binding constant for CAMK1G kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625041Binding constant for PIK3CA(H1047L) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1186993Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM after 4 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1224770Delta TM value showing the stabilisation of JAK1~B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1246521Cytotoxicity against human U937 cells assessed as reduction in cell viability2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID624758Binding constant for RIPK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID627131Inhibition of Aurora A using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1612811Inhibition of BRK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID435647Binding constant for CAMK2D kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425114Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425157Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435157Binding constant for EGFR(G719C) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1386086Inhibition of BCR-ABL1 Y253H mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
AID624991Binding constant for ABL1-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID638924Inhibition of FGFR1 at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID624831Binding constant for CHEK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425052Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID705593Time dependent inhibition of CYP3A4 in human liver microsomes2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1612903Inhibition of DDR2 (unknown origin) using poly (Glu, Tyr) 4:1 substrate after 60 mins by ELISA2019European journal of medicinal chemistry, Feb-01, Volume: 163Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.
AID435941Binding constant for ZAK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1310149Solubility of the compound in water at pH 2.62016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID360770Inhibition of EPHA22007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID599957Binding affinity to human KIT incubated for 1 hr by kinase binding assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
AID1875894Antiviral activity against pseudo typed HCV infected in human Huh-7.5.1 cells assessed as prevention of pseudo particle entry2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1425211Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1616469Induction of cell death in human K562 cells assessed as reduction in cell viability at 20 times IC50 incubated for 12 hrs followed by drug wash-out and incubation in drug-free medium up to 144 hrs by CCK8 assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
AID625022Binding constant for MUSK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624913Binding constant for TYK2(JH2domain-pseudokinase) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224783Delta TM value showing the stabilisation of PAK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1373714Growth inhibition of human K562 cells2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells.
AID1425213Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224798Delta TM value showing the stabilisation of DRAK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1425149Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID638915Inhibition of RET at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID625093Binding constant for TNIK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625059Binding constant for YSK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425141Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624822Binding constant for CDKL3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID732856Inhibition of BCR/ABL (unknown origin) using tyrosine 2 peptide as substrate incubated for 1 hr prior to substrate addition measured after 2 hrs by FRET assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID435690Binding constant for RPS6KA1(Kin.Dom.1 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625045Binding constant for PIK3CA(Q546K) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1186125Antiproliferative activity against human LXFA 983L cells after 4 days by modified propidium iodide assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.
AID498730Binding affinity to p38alpha2009Nature chemical biology, Jun, Volume: 5, Issue:6
A new screening assay for allosteric inhibitors of cSrc.
AID375142Activity of wild type chicken c N-terminal His-tagged Src expressed in Escherichia coli BL21 (DE3)2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID624941Binding constant for CDKL1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624747Binding constant for SgK110 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1771926Binding affinity to non-phosphorylated ABL1 (unknown origin) assessed as change in melting temperature by SYPRO orange dye based DSF assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Design and Development of a Chemical Probe for Pseudokinase Ca
AID435277Binding constant for full-length CDK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435776Binding constant for ABL1(Y253F) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435782Binding constant for BRSK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1310133Selectivity ratio of IC50 for human ABL to IC50 for C-terminal His-tagged full length human SRC expressed in insect cells2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID360780Inhibition of viral spread in Dengue virus-infected african green monkey Vero cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 4 days by immunofluorescence assay relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID435312Binding constant for MET kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224752Delta TM value showing the stabilisation of CAMK2B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435150Binding constant for ARK5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224774Delta TM value showing the stabilisation of p38beta produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625104Binding constant for MYO3A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425200Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1876249Antiviral activity against HIV-1 in U87/CD4/CCR5 cells expressing HIV-1-envelope-protein assessed as decreased cell-cell fusion at 300 nM2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID435688Binding constant for full-length PCTK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625136Binding constant for YSK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724666Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1310137Increase in total SRC in human MDA-MB-231 cells preincubated for 1.5 hrs followed by serum stimulation for 1 hr by Western blot analysis2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID621337Inhibition of LCK2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
AID624814Binding constant for DCAMKL2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1857470Inhibition of recombinant LIMK1 (330 to 637 residues) (unknown origin) incubated for 45 mins followed by ATP addition measured after 105 mins by RapidFire Mass Spectrometry kinase assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity.
AID507689Inhibition of EGFR2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID271946Inhibition of human Lck in presence of ATP2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID1224772Delta TM value showing the stabilisation of MAP2K6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435533Binding constant for NEK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435191Binding constant for full-length RIOK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1573073Antiproliferative activity against human NCI-H226 cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID435171Binding constant for NEK9 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624940Binding constant for FLT3(R834Q) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624795Binding constant for MET(M1250T) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1612814Inhibition of Fyn A (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID435645Binding constant for ACVRL1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1817045Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
AID624921Binding constant for MAP4K3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425037Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID360784Inhibition of viral spread in Dengue virus-infected human Huh7 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 5 days by immunofluorescence assay relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID435310Binding constant for FLT3(ITD) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435546Binding constant for PRKG1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425016Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507430Inhibition of AXL at 10 mM2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID621336Inhibition of AurB2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
AID1573075Antiproliferative activity against human SW620 cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID624962Binding constant for ASK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507702Inhibition of IRAK4 at 10 mM2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID1876230Antiviral activity against DENV infected in 180 mins pretreated human C6/36 cells incubated for 1 to 72 hrs2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID435181Binding constant for full-length p38-alpha2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425137Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625070Binding constant for PFTK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1695218Growth inhibition of human SU-DHL-2 cells incubated for 72 hrs2020RSC medicinal chemistry, Jun-01, Volume: 11, Issue:6
Understanding the mechanism of action of pyrrolo[3,2-
AID625019Binding constant for AKT3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724668Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID624735Binding constant for ANKK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1757412Inhibition of ABL (unknown origin) at 1 uM by ELISA2021European journal of medicinal chemistry, Apr-15, Volume: 216Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
AID624707Binding constant for DCAMKL3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425104Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435832Binding constant for SLK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435438Binding constant for full-length p38-gamma2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1207517Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay
AID624715Binding constant for ERK8 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624880Binding constant for PIK4CB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425070Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435808Binding constant for full-length MEK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625110Binding constant for TRPM6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1286625Binding affinity to P38-alpha (unknown origin)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1425115Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624857Binding constant for HCK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425083Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1612810Inhibition of ABL1 (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID435395Binding constant for CDC2L1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624974Binding constant for PIK3CD kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID739095Inhibition of Bcr-Abl T315I mutant (unknown origin) phosphorylation transfected in mouse Ba/F3 cells after 1 hr by Western blot analysis2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.
AID625030Binding constant for LOK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435440Binding constant for PIM2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID724981Inhibition of human recombinant wild type ABL1 expressed in insect cells after 30 mins by FRET assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID435826Binding constant for full-length PCTK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1310172Cardiotoxicity in wild-type zebrafish embryos assessed as heart enlargement at 1 to 10 uM treated for 4 hrs measured after 48 hrs by fluorescent microscopy2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID624804Binding constant for ERBB2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID638913Inhibition of PDGFRalpha at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID625052Binding constant for PRKG1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1202713Inhibition of DDR2 (unknown origin) assessed as reduction in collagen-induced DDR2 activation2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
AID625134Binding constant for PIP5K2C kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624901Binding constant for RSK1(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625078Binding constant for SRPK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435792Binding constant for EGFR(S752-I759del) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1876063Antiviral activity against MERS-CoV2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1425023Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID282261Mean residence time in Sprague-Dawley rat at 10 mg/kg, po2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID436044Binding constant for PLK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID458668Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 2.5 nM relative to control by Western blot2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
AID624935Binding constant for FLT3(D835H) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID282256Volume of distribution in Sprague-Dawley rat at 10 mg/kg, iv2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID624964Binding constant for DYRK1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625035Binding constant for PHKG1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID732857Inhibition of DDR2 (unknown origin) using fluorescein-labeled poly GAT as substrate incubated for 1 hr prior to substrate addition measured after 1 hr by TR-FRET assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID329199Inhibition of LPS-induced TNFalpha release in human U937 cells at 2 uM after 1 hr by ELISA2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID1224793Delta TM value showing the stabilisation of RSK2a produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID724678Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID435160Binding constant for FER kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625081Binding constant for RSK4(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435525Binding constant for EGFR(L858R) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1876284Inhibition of LCK (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1206299Inhibition of Src in human MDA-MB-231 cells assessed as reduction of FAK phosphorylation at >0.03 uM after 20 hrs by Western blot analysis2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID360777Antiviral activity against Dengue virus 4 H241 infected in african green monkey Vero cells2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID624723Binding constant for CSNK1A1L kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624933Binding constant for PLK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID745324Cytotoxicity against human HCT116 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1206215Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID435523Binding constant for CIT kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1757413Inhibition of EphA2 (unknown origin) at 1 uM by ELISA2021European journal of medicinal chemistry, Apr-15, Volume: 216Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
AID1286571Antiproliferative activity against human CHL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1424925Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435901Binding constant for BRAF kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID329186Inhibition of recombinant Tec kinase2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID1053270Inhibition of ACE (unknown origin) assessed as 3-Hydroxybutyril-glycil-glycil-glycine conversion to 3-hydroxybutyric acid after 60 mins by WST assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1425195Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1734835Inhibition of Src in human MDA-MB-231 cells assessed as inhibition of FAK phosphorylation at 0.03 to 0.3 uM incubated for 20 hrs by Western blot analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID624954Binding constant for EPHB1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1854085Inhibition of BCR-ABL phosphorylation in human K562 cells2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID435515Binding constant for ABL1(Q252H) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435551Binding constant for full-length p38-beta2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424948Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224801Delta TM value showing the stabilisation of MST1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1386091Inhibition of BCR-ABL1 E459K mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
AID624811Binding constant for PAK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625092Binding constant for NDR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435666Binding constant for full-length NEK72008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624860Binding constant for VEGFR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424985Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435400Binding constant for DDR1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID329194Inhibition of LPS-induced Btk autophosphorylation of tyrosine in human Namalwa cells2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID435794Binding constant for EPHA3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1734824Induction of apoptosis in human MDA-MB-231 cells assessed as live cells at 0.1 uM incubated for 24 hrs by annexin V-FITC and propidium iodide staining based flow cytometry analysis (Rvb = 96.95 %)2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID1424989Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435788Binding constant for CLK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624952Binding constant for EPHA4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624782Binding constant for FGFR3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID463629Inhibition of Lck2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Selectively nonselective kinase inhibition: striking the right balance.
AID436024Binding constant for MRCKA kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1473863AUC in patient with advanced phase CML and Ph+ ALL at 100 mg, po BID after 12 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID271972Inhibition of Her22006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID621334Inhibition of BRK pretreated for 30 mins by microplate reader2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
AID1515645Permeability of compound in 5% DMSO after 7 hrs by PAMPA2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID624997Binding constant for EGFR(E746-A750del) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435183Binding constant for PLK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624772Binding constant for AURKB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424952Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625033Binding constant for PCTK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625027Binding constant for MAP3K4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436051Binding constant for RPS6KA5(Kin.Dom.2 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625061Binding constant for MAP4K5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1207335Inhibition of fast sodium current (INa) in HEK293 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID1310150Solubility of the compound in water at pH 72016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID1573066Inhibition of wild type BCR/ABL (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell growth2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID435790Binding constant for DRAK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624871Binding constant for PAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224802Delta TM value showing the stabilisation of TNIK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1424991Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435786Binding constant for full-length CLK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624929Binding constant for BRSK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425111Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435834Binding constant for YANK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435441Binding constant for RPS6KA4(Kin.Dom.2 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424892Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424889Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1734863Inhibition of ERK phosphorylation in human MDA-MB-231 cells at 0.03 to 0.3 uM incubated for 20 hrs by Western blot analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID709938Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1516991Inhibition of recombinant Nanoluc-tagged p38alpha (unknown origin) expressed in HEK293 cells incubated for 2 to 3 mins by NanoBRET assay
AID625085Binding constant for ULK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1256160Inhibition of wild type Bcr-Abl (unknown origin) by ADP-Glo assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
AID1425024Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624854Binding constant for FLT4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1886524Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
AID435650Binding constant for full-length CSNK1E2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID282260Half life in Sprague-Dawley rat at 10 mg/kg, po2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID282221Antiproliferative activity against human K562 cells after 72 hrs2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID624841Binding constant for BLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625013Binding constant for LCK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625120Binding constant for EPHA8 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625076Binding constant for PLK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435777Binding constant for ABL2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID507688Inhibition of cRAF2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID1224794Delta TM value showing the stabilisation of RSK2b produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1734823Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 0.1 uM incubated for 24 hrs by annexin V-FITC and propidium iodide staining based flow cytometry analysis (Rvb = 0.85 %)2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID625122Binding constant for RET(M918T) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435182Binding constant for full-length PKAC-beta2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624734Binding constant for YANK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1857471Inhibition of recombinant LIMK2 (347 to 659 residues) (unknown origin) incubated for 45 mins followed by ATP addition measured after 180 mins by RapidFire Mass Spectrometry kinase assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity.
AID435158Binding constant for EPHA5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID436004Binding constant for ACVR2A kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435552Binding constant for PIK3CA(E545K) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID709991Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1424997Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID282254Half life in Sprague-Dawley rat at 10 mg/kg, iv2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1425097Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID724978Inhibition of human recombinant ABL1 Q252H mutant expressed in insect cells after 30 mins by FRET assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1224760Delta TM value showing the stabilisation of CHEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID724674Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID624903Binding constant for SRPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1893831Binding affinity to Abl (unknown origin) assessed as inhibition constant2021European journal of medicinal chemistry, Jan-15, Volume: 2102-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents.
AID638911Inhibition of KDR at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID435168Binding constant for LTK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424893Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624711Binding constant for STK35 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID329197Decrease in LPS-induced TNFalpha release in human U937 cells after 1 hr by ELISA2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID1424930Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1386090Inhibition of BCR-ABL1 F359V mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
AID1425109Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID760495Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1857472Inhibition of PAK mediated recombinant LIMK1 phosphorylation (330 to 637 residues) (unknown origin) incubated for 45 mins followed by ATP addition measured after 105 mins by RapidFire Mass Spectrometry kinase assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity.
AID1315391Inhibition of BRC/ABL1 (unknown origin) after 40 mins by ADP-Glo assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.
AID1310125Inhibition of human ABL using EAIYAAPFAKKK as substrate in presence of [gamma-33P]ATP2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID1460600Growth inhibition of Staphylococcus aureus SA1902 up to 100 ug/ml by broth microdilution assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1515652Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID1242638Antiproliferative activity against human HCC366 cells expressing DDR2 mutant after 72 hrs by alamar blue assay2015ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
AID436047Binding constant for full-length PRKX2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1421419Inhibition of recombinant human IGF1R at 1000 nM after 60 mins by ELISA relative to control2018European journal of medicinal chemistry, Oct-05, Volume: 158Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
AID624789Binding constant for KIT(D816V) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1315390Cytotoxicity against human L02 cells assessed as reduction in cell viability after 96 hrs by MTT assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.
AID1206291Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 0.3 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 4.25%)2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID435828Binding constant for full-length PIP5K2B2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1573084Antiproliferative activity against human SW1088 cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID282247Inhibition of MK22004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1425140Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1814382Inhibition of c-SRC (unknown origin) at 100 uM incubated for 60 mins by ELISA relative to control2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia.
AID435908Binding constant for EPHA2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425188Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1612820Inhibition of BTK (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID282258Tmax in in Sprague-Dawley rat at 10 mg/kg, po2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID360783Inhibition of viral spread in Dengue virus-infected human Huh7 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 4 days by immunofluorescence assay relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID1425051Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425073Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1310147Toxicity in wild-type zebrafish embryos assessed as mortality at >10 uM treated for 4 hrs measured after 48 hrs by fluorescent microscopy2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID624909Binding constant for TGFBR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436008Binding constant for full-length BTK2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624818Binding constant for ULK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435827Binding constant for PDGFRA kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625014Binding constant for PRKCE kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1460601Growth inhibition of Staphylococcus aureus SAK2378 up to 100 ug/ml by broth microdilution assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1734726Toxicity in SCID mouse xenografted with MDA-MB-231 cells assessed as change in body weight at 40 mg/kg, po qd for 21 days and measured every 3 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID1774077Binding affinity to TTR V3OM mutant (unknown origin) expressed in Escherichia coli incubated for 60 mins by tryptophan intrinsic fluorescence method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1425038Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID271945Inhibition of murine Lck in presence of ATP2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID1425019Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID761477Inhibition of Yes1 (unknown origin) by [gamma-33P]-ATP radiolabeled enzyme activity assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1425080Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1202712Inhibition of DDR1b (unknown origin) assessed as reduction in collagen-induced DDR1b activation2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
AID436054Binding constant for TLK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624956Binding constant for EPHB4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425006Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1246524Therapeutic index, ratio of CC50 for HEK293 cells to IC50 for imatinib resistant human IR-K562 cells2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1425081Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624790Binding constant for KIT(L576P) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224803Delta TM value showing the stabilisation of PBK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID282225AUC (0-4 hrs) in BALB/c mouse at 50 mg/kg, po after 4 hrs2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID435413Binding constant for MLCK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1450954Binding affinity to recombinant human N-terminal His6-tagged Wee2 kinase domain (202 to 492 residues) expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature at 50 uM by differential scanning fluorimetry2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.
AID435531Binding constant for MKNK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1301836Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
AID282264Antitumor activity against human K562 xenograft in nude mouse at 5 mg/kg, po for 10 days in 5 day on and 2 day off schedule2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID624895Binding constant for MEK6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425194Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425162Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425069Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624917Binding constant for MST3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724673Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1425181Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1409082Inhibition of human EPHA2 at 100 uM2018Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
AID1425000Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624776Binding constant for PCTK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1506674Binding affinity to SRC (unknown origin) assessed as on rate constant
AID1425007Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624902Binding constant for MEK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID375189Inhibition of cSrc in human PC3 cells assessed as effect on total FAK level at 100 nM after 5 hrs by immunoblot2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID435161Binding constant for FES kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424921Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1515657Binding affinity to PDGFRalpha V561D mutant (unknown origin) by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID435905Binding constant for full-length CSNK1G32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1310128Inhibition of human mTOR using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID625139Binding constant for SNARK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1286551Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1425145Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1695219Growth inhibition of human MAVER-1 cells incubated for 72 hrs2020RSC medicinal chemistry, Jun-01, Volume: 11, Issue:6
Understanding the mechanism of action of pyrrolo[3,2-
AID458669Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 0.25 nM relative to control by Western blot2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
AID724976Inhibition of human recombinant ABL1 H396P mutant expressed in insect cells after 30 mins by FRET assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID329196Decrease in basal TNFalpha release in human U937 cells after 1 hr by ELISA2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID303307Growth inhibition of human K562 cells after 48 hrs by [3H]thymidine uptake assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID624992Binding constant for ABL1-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1573062Antiproliferative activity against human K562R cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID1206214Inhibition of human Src2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID1473868Ratio of drug concentration at steady state patient with chronic phase CML at 70 to 90 mg, po BID after 12 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID624809Binding constant for MYLK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624849Binding constant for CSNK2A2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625007Binding constant for EGFR(T790M) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID760491Cytotoxicity against human SW620 cells after 48 hrs by SRB assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID435429Binding constant for FLT1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624756Binding constant for MAP4K4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224750Delta TM value showing the stabilisation of CAMK1G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1425156Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625133Binding constant for CDC2L2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID282243Inhibition of AKT2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID375138Inhibition of wild type chicken N-terminal His-tagged cSrc expressed in Escherichia coli BL21 (DE3)2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1425119Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID271951Inhibition of Bcr-Abl in presence of ATP2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID1224776Delta TM value showing the stabilisation of ERK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625066Binding constant for IRAK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507695Inhibition of PDGFRa2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID709996Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1460603Growth inhibition of Staphylococcus aureus SA1199B up to 100 ug/ml by broth microdilution assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID375191Inhibition of cSrc in human DU145 cells assessed as effect on total FAK level at 100 nM after 5 hrs by immunoblot2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID709993Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID507696Inhibition of RIPK22009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID624978Binding constant for ABL1(E255K)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435564Binding constant for TRKB kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435320Binding constant for PRKCE kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424940Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424923Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1659069Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
AID1224766Delta TM value showing the stabilisation of CK1G3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1425096Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625048Binding constant for PRKCD kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID732830Antiproliferative activity against human NCI-H23 cells after 72 hrs by MTT assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1734865Inhibition of Fra1 expression in human MDA-MB-231 cells at 0.03 to 0.3 uM incubated for 20 hrs by Western blot analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID625138Binding constant for STK33 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624865Binding constant for MAP3K3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID329203Inhibition of antigen-induced histamine release in Tec-deficient BMMC at 1 uM after 30 mins2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID1206302Effect on AKT phosphorylation in human MDA-MB-231 cells at 0.001 to 1 uM after 20 hrs by Western blot analysis2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID1424954Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435291Binding constant for FGFR3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624922Binding constant for CAMK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435146Binding constant for ABL1(H396P) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425185Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425068Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID463632Inhibition of Bcr-Abl T315I mutant2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Selectively nonselective kinase inhibition: striking the right balance.
AID625064Binding constant for PIM2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID360771Inhibition of p38 MAPK2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID1424894Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID458667Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 25 nM relative to control by Western blot2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID624906Binding constant for S6K1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507080Inhibition of recombinant HCK by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID507082Inhibition of recombinant c-Src T338I mutant by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID1425012Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1612817Inhibition of SRC (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID1424955Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624859Binding constant for JAK1(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1650167Inhibition of ABL1 in human HEK293T cells assessed as reduction in cell viability at 1 uM measured after 48 hrs relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
AID1424909Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1573068Inhibition of BCR/ABL T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell growth2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID624910Binding constant for TTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624835Binding constant for ERN1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624725Binding constant for NEK11 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435693Binding constant for TGFBR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1386088Inhibition of BCR-ABL1 E255V mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
AID1613018Antiproliferative activity against human NCI-H2286 cells harboring DDR2 mutation after 72 hrs by CCK8 assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.
AID624851Binding constant for ERBB3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435197Binding constant for TEC kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435691Binding constant for SgK085 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624775Binding constant for STK16 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624785Binding constant for JAK3(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624840Binding constant for AXL kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724979Inhibition of human recombinant ABL1 E255K mutant expressed in insect cells after 30 mins by FRET assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1425036Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224790Delta TM value showing the stabilisation of PLK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID498727Inhibition of wild type cSrc2009Nature chemical biology, Jun, Volume: 5, Issue:6
A new screening assay for allosteric inhibitors of cSrc.
AID625032Binding constant for TRKB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1205870Antiangiogenic activity in chicken embryo chorioallantoic membrane model assessed as inhibition of vasculature formation at 20 uM, iv dosed for 3 consecutive days by FITC-dextran fluorescence angiography2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.
AID1425095Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625024Binding constant for PRKD3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724667Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1425138Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1515662Antiproliferative activity against human K562 cells assessed as reduction in cell viability by measuring ATP level incubated for 3 days by Celltiter-Glo assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID624939Binding constant for FLT3(N841I) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435823Binding constant for full-length PAK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624968Binding constant for DRAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425049Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435200Binding constant for full-length TNNI3K2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1396667Inhibition of N-[3',6'-dihydroxy-3-oxo-3H-spiro(2-benzofuran-1,9'-xanthen)-5-yl]-N'-[2-(4-{4-[N-(2-chloro-6-methylphenyl)-5-carboxamido]-thiazol-2-yl})-amino-2-methyl-pyrimid-6-yl)piperazinyl]-ethyl]thiourea binding to human PKMYT1 kinase doamin expressed
AID1424918Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435396Binding constant for CHEK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624821Binding constant for YANK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435897Binding constant for ABL1(T315I) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1454437Displacement of CAT-1 from catalytic site of N-terminal His6-tagged ABL (83 to 534 residues) (unknown origin) expressed in Escherichia coli co-expressing Protein Tyrosine Phosphatase 1b at 25 uM by 19F NMR spectroscopy based dual-site competition assay2017ACS medicinal chemistry letters, Jun-08, Volume: 8, Issue:6
AID435287Binding constant for EPHA8 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1876260Inhibition of Abl (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID435658Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1260957Inhibition of recombinant EphA2 kinase domain (unknown origin) at 1 uM after 30 mins by ELISA2015European journal of medicinal chemistry, Oct-20, Volume: 103Δ(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system.
AID1425018Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID282224Antiproliferative activity against human WiDr cells after 72 hrs2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1424941Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID360774Antiviral activity against Dengue virus 2 infected in african green monkey Vero cells2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID507694Inhibition of LIMK12009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID624983Binding constant for ABL1(H396P)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425032Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507083Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID1857475Inhibition of recombinant LIMK2(unknown origin) expressed in HEK293 cells using NanoGlo substrate incubated for 2 hrs followed by substrate addition by NanoBRET assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity.
AID624937Binding constant for FLT3(ITD) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425120Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624800Binding constant for IGF1R kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424900Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435404Binding constant for EPHB4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624719Binding constant for GRK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1612813Inhibition of CSK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID624870Binding constant for NEK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624793Binding constant for KIT(V559D,V654A) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1286564Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1473862AUC in patient with chronic phase CML at 70 to 90 mg, po BID after 12 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1206290Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 0.3 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.05%)2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID1424920Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624947Binding constant for BRAF(V600E) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425045Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624798Binding constant for LKB1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435403Binding constant for EPHB1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID360779Antiviral activity against Poliovirus 1 infected in african green monkey Vero cells2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID1206296Antimigratory activity against human MDA-MB-231 cells at 0.03 to 0.3 uM after 20 hrs by wound healing assay2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID1425035Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1205873Angiostatic activity in human ECRF24 cells assessed as inhibition of cell migration at 50 uM after 7 hrs by laser scanner cytometry based wound closure assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.
AID435195Binding constant for SRC kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1301835Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
AID1424934Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1460608Inhibition of Staphylococcus aureus SAK2378 norA assessed as potentiation of CPX-induced antibacterial activity by measuring fold reduction in CPX MIC at 12.5 to 25 ug/ml by checkerboard assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID435553Binding constant for PRKCD kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID745319Cytotoxicity against human NCI-H661 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID282235Inhibition of p38 kinase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID282229Inhibition of Bcr-Abl kinase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1817044Cytotoxicity against human KU812 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
AID435401Binding constant for full-length DRAK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID360785Inhibition of viral spread in Dengue virus-infected human Huh7 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 6 days by immunofluorescence assay relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID724984Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID624987Binding constant for ABL1(Q252H)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625005Binding constant for EGFR(L861Q) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624867Binding constant for MLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID709995Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1301838Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
AID625040Binding constant for PIK3CA(E545K) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724677Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID624787Binding constant for KIT(A829P) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID745325Cytotoxicity against human DLD1 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID435899Binding constant for AKT1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID360786Inhibition of viral spread in Dengue virus-infected asian tiger mosquito C6/36 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 4 days by immunofluorescence assay relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID435445Binding constant for ZAP70 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224791Delta TM value showing the stabilisation of PRKACA produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1425148Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425187Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625094Binding constant for CDK11 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624705Binding constant for MYLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624883Binding constant for PRKCI kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID638910Inhibition of Flt-1 at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID435526Binding constant for FGFR1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425039Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1886523Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
AID1425003Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID329183Binding affinity to Itk from human K562 cells extract by LC-MSMS2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID507085Inhibition of recombinant EphB4R by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID435517Binding constant for AKT2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625044Binding constant for PIK3CA(M1043I) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1573083Antiproliferative activity against human SK-N-MC cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID329187Inhibition of recombinant Itk2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID1573082Antiproliferative activity against human DaOY cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID1612823Inhibition of LCK (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID282259AUC (total) in Sprague-Dawley rat at 10 mg/kg, po2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1186995Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM after 24 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1613039Inhibition of DDR2 I638F mutant phosphorylation in human NCI-H2286 cells at 100 nM after 2 hrs by Western blot analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.
AID435170Binding constant for MYO3A kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435789Binding constant for full-length CSNK2A22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID724974Inhibition of human recombinant ABL1 Y253F mutant expressed in insect cells after 30 mins by FRET assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID435398Binding constant for DAPK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625006Binding constant for EGFR(S752-I759del) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624808Binding constant for TRKA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1772723PROTAC activity at CRBN/Bcr-Abl in human K562 cells assessed as reduction in c-Abl level after 16 hrs by Western blotting analysis2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
AID624828Binding constant for CDK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1460602Growth inhibition of Staphylococcus aureus SA1199 up to 100 ug/ml by broth microdilution assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1301839Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
AID1515658Binding affinity to wild-type human partial length PDGFRB (V582 to Y1009 residues) expressed in bacterial expression system by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID624748Binding constant for EPHA6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435783Binding constant for full-length BRSK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1176843Inhibition of ABL (unknown origin) at 1 uM by ELISA method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
AID435285Binding constant for DMPK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID739091Inhibition of Bcr-Abl T315I mutant (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction of phosphorylated CrkL level after 1 hr by Western blot analysis2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.
AID625068Binding constant for NEK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1613037Antitumor activity against human NCI-H2286 cells xenografted in SCID mouse assessed as tumor growth inhibition at 50 mg/kg, po qd for 10 consecutive days relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.
AID624717Binding constant for JNK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424996Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624926Binding constant for RIOK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1814383Inhibition of ABL (unknown origin) at 100 uM incubated for 60 mins by ELISA relative to control2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia.
AID624925Binding constant for RIPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425170Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624894Binding constant for MEK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435442Binding constant for SYK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID732858Inhibition of DDR1 (unknown origin) using fluorescein-labeled poly GAT as substrate incubated for 1 hr prior to substrate addition measured after 1 hr by TR-FRET assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID624875Binding constant for PDGFRB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625003Binding constant for EGFR(L858R) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID458664Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
AID624946Binding constant for BRAF kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624774Binding constant for QSK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425147Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID709937Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1425008Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425043Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1286558Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID435196Binding constant for full-length SRPK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1616455Antitumor activity against luciferse expressing human K562 cells xenografted in NOD/SCID mouse assessed as attenuation of tumor progression at 5 mg/kg, ip QD for 12 days by serial volumetric analysis2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
AID435311Binding constant for HCK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424969Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435803Binding constant for full-length LIMK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435775Binding constant for ABL1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1876267Binding affinity to AAK1 (unknown origin) assessed as dissociation constant2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID735400Cytotoxicity against human GXF251L cells after 4 days by propidium iodide staining2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.
AID624898Binding constant for GRK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624779Binding constant for BTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435294Binding constant for full-length LIMK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625034Binding constant for PDGFRA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436046Binding constant for PRKD2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1186992Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM after 4 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID625051Binding constant for PRKCQ kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1310127Inhibition of human KIT using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID1386089Inhibition of BCR-ABL1 E355G mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
AID436005Binding constant for ANKK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435906Binding constant for EGFR(L747-T751del,Sins) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435205Selectivity for ABL1 as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 02008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624810Binding constant for GCN2(Kin.Dom.2,S808G) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425155Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435296Binding constant for MARK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435415Binding constant for MYLK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID732829Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID1425078Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435664Binding constant for MYLK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435282Binding constant for full-length CSNK1G22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435802Binding constant for KIT(V559D,V654A) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1817042Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay
AID1186124Antiproliferative activity against human CXF 1103L cells after 4 days by modified propidium iodide assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.
AID625042Binding constant for PIK3CA(H1047Y) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID329190Inhibition of TAP-tagged wild-type Btk2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID435147Binding constant for ACVR2B kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425210Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435689Binding constant for full-length PFTK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID729593Inhibition of EPHA2 (unknown origin) at 100 uM after 60 mins by ELISA relative to control2013European journal of medicinal chemistry, Mar, Volume: 61Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
AID624771Binding constant for TLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1734813Inhibition of colony formation in human MDA-MB-231 cells at 0.1 uM treated for 12 days by crystal violet staining based visual analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID1425055Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624886Binding constant for ERK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1373715Growth inhibition of human HL60 cells2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells.
AID435781Binding constant for full-length BMX2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1817046Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
AID624973Binding constant for JAK2(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224751Delta TM value showing the stabilisation of CAMK2A produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624797Binding constant for PHKG2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224797Delta TM value showing the stabilisation of MPSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1425058Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435154Binding constant for DDR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID735401Cytotoxicity against human CXF 1103L cells after 4 days by propidium iodide staining2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.
AID435651Binding constant for DCAMKL2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624716Binding constant for CSNK1D kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625023Binding constant for HIPK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID638916Inhibition of EGFR at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID435430Binding constant for INSRR kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624982Binding constant for ABL1(F317L)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425053Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1206308Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 40 mg/kg/day administered for 18 days measured every 3 days during compound dosing2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID435907Binding constant for EGFR(L861Q) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624794Binding constant for MET kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1421420Inhibition of recombinant human EPHA2 at 1000 nM after 60 mins by ELISA relative to control2018European journal of medicinal chemistry, Oct-05, Volume: 158Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
AID625071Binding constant for STK39 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425020Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425088Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507084Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID329182Binding affinity to Tec kinase from human K562 cells extract by LC-MSMS2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID435324Binding constant for full-length RIOK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424926Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624816Binding constant for HPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224764Delta TM value showing the stabilisation of CK1G1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624846Binding constant for CSNK1A1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435925Binding constant for PCTK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1246526Therapeutic index, ratio of CC50 for HEK293 cells to IC50 for human U937 cells2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1893832Clearance in rat relative to hepatic blood flow2021European journal of medicinal chemistry, Jan-15, Volume: 2102-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents.
AID625057Binding constant for TYRO3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID282250Inhibition of PKCtau2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID624724Binding constant for TAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1484897Inhibition of EPH-A2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA relative to control2017European journal of medicinal chemistry, Jul-28, Volume: 135The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
AID436014Binding constant for full-length DYRK1B2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624899Binding constant for ROS1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624806Binding constant for RPS6KA4(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1659072Protac activity at Cereblon/BCR/ABL T315I mutant (unknown origin) expressed in mouse BaF3 cells assessed as reduction in BCR-ABL T315I mutant driven cell viability incubated for 3 days by CCK8 assay2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
AID1425025Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625100Binding constant for NLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435444Binding constant for TYK2(Kin.Dom.2/JH1 - catalytic) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624837Binding constant for IRAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224806Delta TM value showing the stabilisation of VRK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1424915Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1876248Antiviral activity against DENV infected in 180 mins pretreated human Huh-7 cells incubated for 1 to 72 hrs2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1286565Antiproliferative activity against human KU812 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID624959Binding constant for MAP4K2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1612829Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID435203Binding constant for TTK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1310131Inhibition of C-terminal His-tagged full length human SRC expressed in insect cells preincubated for 20 mins using poly[Glu,Tyr]4:1 as substrate measured after 5 to 120 mins in presence of [gamma-33P]ATP by Kinome assay2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID507081Inhibition of recombinant c-Src by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID1425143Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507072Inhibition of recombinant PI3Kalpha by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID1854086Inhibition of SRC (unknown origin)2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID435557Binding constant for RIPK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1386084Inhibition of BCR-ABL1 G250H mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of BCR-ABL1-mediated cell proliferation after 48 hrs by BriteLight luciferase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
AID435903Binding constant for CDK8 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624993Binding constant for ABL2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1224762Delta TM value showing the stabilisation of CLK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID599959Binding affinity to human KIT D816V mutant incubated for 1 hr by kinase binding assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
AID624765Binding constant for TRKC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624838Binding constant for ACVR2A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624927Binding constant for RPS6KA4(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID729550Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells by TR-FRET based binding assay2013European journal of medicinal chemistry, Mar, Volume: 61Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
AID1424911Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435204Binding constant for WEE1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1206282Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 0.3 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 2.67%)2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID1425047Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1331472Inhibition of recombinant human Src using KVEKIGEGTYGVVYK as substrate by [gamma-32P]ATP based assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
AID1224804Delta TM value showing the stabilisation of VRK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID507691Inhibition of EPHB22009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID1286568Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1425076Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624805Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435938Binding constant for TGFBR1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435283Binding constant for DAPK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625069Binding constant for TLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624819Binding constant for ACVR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435189Binding constant for full-length PDPK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1168646Antiviral activity against Dengue virus assessed as inhibition of viral RNA replication2014European journal of medicinal chemistry, Nov-24, Volume: 87A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.
AID1246522Cytotoxicity against HEK293 cells assessed as reduction in cell viability2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID624887Binding constant for ERK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435909Binding constant for full-length LKB12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID627289Inhibition of RSK1 using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1286569Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID624969Binding constant for ROCK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224771Delta TM value showing the stabilisation of MEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID498728Binding affinity to wild type cSrc by fluorescence based binding assay2009Nature chemical biology, Jun, Volume: 5, Issue:6
A new screening assay for allosteric inhibitors of cSrc.
AID1224785Delta TM value showing the stabilisation of PDK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625017Binding constant for TIE1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435432Binding constant for MLK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425056Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1450953Binding affinity to recombinant human N-terminal His6-tagged Wee1 kinase domain (291 to 575 residues) expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature at 50 uM by differential scanning fluorimetry2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.
AID625063Binding constant for PLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507687Inhibition of cKIT V654A mutant2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID1424946Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1764398Substrate activity at P-gp (unknown origin) assessed as net efflux ratio2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID360769Inhibition of c-Kit2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID1202517Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2015European journal of medicinal chemistry, , Volume: 96Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.
AID282223Antiproliferative activity against human MDA-MB-231 cells after 72 hrs2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1207423Inhibition of transient outward potassium current (Ito) current in Chinese Hamster Ovary (CHO) K1 cells expressing human Kv4.3 measured using IonWorks Quattro automated patch clamp platform
AID1616432Induction of ternary complex formation between VHL and BCR-ABL (unknown origin) using recombinant ABL kinase domain and recombinant VHL/EloB/EloC by SEC-MALS analysis2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
AID435284Binding constant for DCAMKL1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624826Binding constant for BMPR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624730Binding constant for CAMK2A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624861Binding constant for LIMK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1612828Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter 96 aqueous one solution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID435554Binding constant for PRKD3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425059Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1460599Inhibition of NorA in Staphylococcus aureus SA1199B harboring GrlA A116E mutant assessed as inhibition of ethidium bromide efflux after 5 mins by fluorometric method2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID436055Binding constant for full-length YANK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID282230Inhibition of src kinase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID724669Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID435687Binding constant for PAK7/PAK5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID375150Inhibition of cSrc in human DU145 cells assessed as reduction of phosphorylated FAK Y576/Y577 level at 100 nM after 5 hrs by immunoblot2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID360767Antiviral activity against Dengue virus infected in african green monkey Vero cells administered after viral challenge after 3 days by viral plaque assay2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID1425028Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624773Binding constant for AMPK-alpha1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435898Binding constant for ACVR1B kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID729592Inhibition of ABL (unknown origin) at 100 uM after 60 mins by ELISA relative to control2013European journal of medicinal chemistry, Mar, Volume: 61Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
AID507421Inhibition of recombinant CK1 by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID435327Binding constant for VEGFR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID709997Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID435521Binding constant for CAMKK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424906Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507700Inhibition of TXK2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID1734836Increase in cleaved caspase-3 level in human MDA-MB-231 cells at 0.03 to 0.3 uM incubated for 20 hrs by Western blot analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID624932Binding constant for CLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1659071Antiproliferative activity against wild type mouse BA/F3 cells incubated for 3 days by CCK8 assay2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
AID435667Binding constant for full-length NLK2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424983Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435414Binding constant for MLK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1573063Antiproliferative activity against human MOLT4 cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID435797Binding constant for ERBB4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424966Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1286566Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1425165Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID436010Binding constant for full-length CDK52008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425061Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID436023Binding constant for MERTK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625025Binding constant for MAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1484899Inhibition of c-Src (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA relative to control2017European journal of medicinal chemistry, Jul-28, Volume: 135The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
AID709990Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID329184Inhibition of recombinant Btk2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID1425093Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624943Binding constant for ACVR1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625130Binding constant for FGFR4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435288Binding constant for EPHB2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424984Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID282242Inhibition of IKK2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID271947Inhibition of anti CD3/anti CD28-induced T cell proliferation2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID624944Binding constant for ALK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435318Binding constant for PAK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624872Binding constant for PAK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625060Binding constant for CAMKK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625137Binding constant for MEK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424937Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424970Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624958Binding constant for PIK3C2G kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624984Binding constant for ABL1(H396P)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425077Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID745321Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1425179Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1695242Growth inhibition of human Jeko-1 cells incubated for 72 hrs2020RSC medicinal chemistry, Jun-01, Volume: 11, Issue:6
Understanding the mechanism of action of pyrrolo[3,2-
AID625002Binding constant for EGFR(L747-T751del,Sins) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1286557Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID435661Binding constant for full-length MKNK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435295Binding constant for MAP4K3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625102Binding constant for PRKD2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425021Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435674Binding constant for JAK3(Kin.Dom.2/JH1 - catalytic) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624746Binding constant for WEE2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624852Binding constant for FES kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID282226Cmax in BALB/c mouse at 50 mg/kg, po after 4 hrs2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID436045Binding constant for PRKD1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1734841Antitumor activity against human MDA-MB-435 cells xenografted in SCID mouse assessed as tumor growth inhibition at 40 mg/kg, po QD for 21 days and measured every 3 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID435155Binding constant for full-length DLK2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1206303Inhibition of Src phosphorylation in human MDA-MB-231 cells at 0.001 to 1 uM after 20 hrs by Western blot analysis2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
AID1425106Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435399Binding constant for DCAMKL3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID677651Antiangiogenic activity in HUVEC co-cultured with vascular smooth muscle cells assessed as inhibition of network formation at 0.15 uM after 72 hrs2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: from in silico screening to cyclodextrin formulation.
AID624989Binding constant for ABL1(T315I)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1331469Inhibition of wild type recombinant human Abl assessed as residual activity at 100 uM using abtide as substrate by [gamma-32P]ATP based assay relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
AID1310132Inhibition of human YES using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P] ATP2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID1224788Delta TM value showing the stabilisation of PIM3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625106Binding constant for MARK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID435153Binding constant for full-length DAPK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID282227Plasma concentration in BALB/c mouse at 50 mg/kg, po after 4 hrs2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID624728Binding constant for NIM1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436042Binding constant for full-length PHKG12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624752Binding constant for SNRK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625099Binding constant for TAOK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1331475Cytotoxicity against human K562 cells assessed as decrease in cell viability by MTT assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
AID1424961Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID375146Inhibition of cSrc in human DU145 cells assessed as reduction of phosphorylated Src Y416 level at 100 nM after 5 hrs by immunoblot2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID375144Inhibition of cSrc in human PC3 cells assessed as reduction of phosphorylated Src Y416 level at 100 nM after 5 hrs by immunoblot2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID625105Binding constant for EPHB2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624708Binding constant for CDC2L1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435412Binding constant for MAP3K5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624949Binding constant for CSNK1G3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1876064Cytotoxicity against African green monkey Vero E6 cells2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1425001Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624876Binding constant for PDPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425209Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1654860Antiviral activity against HCV genotype 1b pseudoparticle infected in human Huh7.5 cells assessed as reduction in viral replication at 2 to 4 uM2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID507426Inhibition of TRKB at 10 mM2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID624972Binding constant for MTOR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435530Binding constant for MAP3K4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435397Binding constant for CSNK1G1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID415072Inhibition of EGFR2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Structure-based virtual screening of Src kinase inhibitors.
AID1425197Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID760493Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1224759Delta TM value showing the stabilisation of CDKL1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624900Binding constant for RSK1(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507685Inhibition of cKIT D816H mutant2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID1224757Delta TM value showing the stabilisation of CDK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624864Binding constant for CTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424980Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1460604Synergistic antibacterial activity against Staphylococcus aureus SAK1902 in presence of CPX by checkerboard assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID745317Inhibition of human recombinant ABL at 10 uM relative to control2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1425125Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435406Binding constant for FLT3(D835H) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1876282Inhibition of SRC (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID435297Binding constant for MLK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435660Binding constant for full-length MELK2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625065Binding constant for CIT kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1915579Inhibition of Bcr-Abl (unknown origin)2021European journal of medicinal chemistry, Jan-01, Volume: 209Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID624738Binding constant for MLCK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624832Binding constant for IKK-alpha kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID271954Inhibition of p38 kinase2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID1424933Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624980Binding constant for ABL1(F317I)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425050Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1141134Binding affinity to human acrylodan-labeled N-terminal His-tagged DDR2 (558 to 855 aa) by FLiK assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Identification of type II and III DDR2 inhibitors.
AID1734834Inhibition of Src in human MDA-MB-231 cells assessed as reduction in phosphorylation of SRC at 0.03 to 0.3 uM incubated for 20 hrs by Western blot analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID1573087Antiproliferative activity against human U87 cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID435657Binding constant for full-length IKK-epsilon2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1256161Inhibition of Bcr-Abl T315I mutant (unknown origin) by ADP-Glo assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
AID1425123Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625124Binding constant for RET(V804M) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1286570Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1425100Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435939Binding constant for TIE2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1331473Inhibition of wild type recombinant human Abl using abtide as substrate by [gamma-32P]ATP based assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
AID1473867Ratio of drug concentration at steady state in patient with advanced phase CML and Ph+ ALL at 100 mg, po BID after 12 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID624799Binding constant for TIE2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624777Binding constant for DDR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1205867Cytotoxicity against human A2780 cells after 72 hrs by MTT assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.
AID624924Binding constant for RIPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1473864Drug concentration at steady state in patient with chronic phase CML at 70 to 90 mg, po BID after 12 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID624712Binding constant for DYRK1A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224789Delta TM value showing the stabilisation of PLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435562Binding constant for STK36 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435194Binding constant for RPS6KA6(Kin.Dom.2 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID436007Binding constant for AXL kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624923Binding constant for MAPKAPK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID709992Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1424981Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425166Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425193Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624966Binding constant for DCAMKL1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435274Binding constant for ACVR1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435692Binding constant for STK16 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624928Binding constant for CDKL2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624801Binding constant for MAP3K15 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435648Binding constant for CAMKK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425124Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424964Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424973Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1460598Inhibition of NorA in Staphylococcus aureus SA1199B harboring GrlA A116E mutant assessed as inhibition of ethidium bromide efflux at 50 uM measured after 5 mins by fluorometric method relative to control2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID435912Binding constant for MRCKB kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624763Binding constant for RIPK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224753Delta TM value showing the stabilisation of CAMK2D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID436020Binding constant for GCN2(Kin.Dom.2,S808G) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624807Binding constant for TNK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624762Binding constant for DLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID760492Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID435434Binding constant for RET kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425131Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625111Binding constant for RIOK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625084Binding constant for HUNK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID732824Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID375139Inhibition of chicken N-terminal His-tagged cSrc T338M mutant expressed in Escherichia coli BL21 (DE3)2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
AID625074Binding constant for IKK-epsilon kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1301840Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
AID625132Binding constant for FGFR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435807Binding constant for MARK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435926Binding constant for PDGFRB kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425090Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID640178Cytotoxicity against human U937 cells after 72 hrs by WST-8 reagent based MTT assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives.
AID625020Binding constant for ITK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435325Binding constant for RPS6KA4(Kin.Dom.1 - C-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435653Binding constant for EGFR(L747-S752del, P753S) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625113Binding constant for MARK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1875917Antiviral activity against SARS-CoV2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID271970Inhibition of Cdk22006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID624783Binding constant for FGFR3(G697C) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435787Binding constant for CLK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425135Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435393Binding constant for CAMK1D kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625062Binding constant for MAP3K2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID329188Reduction of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells at 30 nM after 1 hr2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID638923Inhibition of IGF1R at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID1229717Antiviral activity against DENV by CPE-reduction assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases.
AID1425175Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1515650Binding affinity to ABL (unknown origin) by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID507425Inhibition of TRKA at 10 mM2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID1454442Displacement of CAT-1 from catalytic site of N-terminal His6-tagged ABL T315I mutant (unknown origin) at 25 uM by 19F NMR spectroscopy based dual-site competition assay2017ACS medicinal chemistry letters, Jun-08, Volume: 8, Issue:6
AID1425015Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1857474Inhibition of recombinant LIMK1(unknown origin) expressed in HEK293 cells using NanoGlo substrate incubated for 2 hrs followed by substrate addition by NanoBRET assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity.
AID1286556Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID624741Binding constant for LRRK2(G2019S) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID415071Inhibition of Src kinase2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Structure-based virtual screening of Src kinase inhibitors.
AID624955Binding constant for EPHB3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424968Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1176844Inhibition of EPHA2 (unknown origin) at 1 uM by ELISA method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
AID282245Inhibition of IGF1R kinase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID624815Binding constant for ERBB4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625090Binding constant for ICK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435431Binding constant for MAP4K1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1373716Growth inhibition of human KG1a cells2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells.
AID1425190Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435929Binding constant for PAK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624833Binding constant for CSNK1G2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1873492Inhibition of N-terminal 6His-tagged SARS-CoV2 nsp3 Mac1 (200 to 380 residues) expressed in Escherichia coli BL21 (DE3)2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Design, synthesis and evaluation of inhibitors of the SARS-CoV-2 nsp3 macrodomain.
AID1224780Delta TM value showing the stabilisation of OSR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID436019Binding constant for FRK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624848Binding constant for CSNK2A1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425085Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425112Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID732827Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
AID1224775Delta TM value showing the stabilisation of ERK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624780Binding constant for CDK4-cyclinD1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID329195Inhibition of Itk F435T mutant2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID624998Binding constant for EGFR(G719C) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1886530Inhibition of ABL1 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
AID1573067Inhibition of BCR/ABL E225K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell growth2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID435156Binding constant for EGFR kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624714Binding constant for p38-alpha kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436043Binding constant for PKMYT1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624948Binding constant for CSK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435793Binding constant for EPHA1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435902Binding constant for BRAF(V600E) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1573065Antiproliferative activity against human Jurkat cells2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
AID625039Binding constant for PIK3CA(E545A) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425048Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID360768Inhibition of PDGFR2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID624877Binding constant for PIK3C2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625088Binding constant for ARK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624938Binding constant for FLT3(K663Q) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425026Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID436034Binding constant for PRKCH kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624778Binding constant for ACVRL1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1283298Resistance index, ratio IC50 for mouse BA/F3 cells expressing BCR-ABL T315I mutant to IC50 for human K562 cells2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.
AID1242622Inhibition of c-Src (unknown origin) using biotinylated HER2 peptide as substrate at 0.003 uM by time resolved fluorescence method2015ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
AID436016Binding constant for full-length ERK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425057Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID329201Inhibition of antigen-induced histamine release in human basophils at 1 uM after 30 mins2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID435649Binding constant for CDC2L2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1186127Antiproliferative activity against human PAXF 1657L cells after 4 days by modified propidium iodide assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.
AID1386051Inhibition of BCR-ABL1 T315I mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of cell proliferation after 48 hrs by BriteLight luciferase assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
AID1424931Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624970Binding constant for CDK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724985Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID624890Binding constant for p38-beta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1240407Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.
AID1286567Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1424974Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425117Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID739092Inhibition of Bcr-Abl T315I mutant (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction of phosphorylated STAT5 level after 1 hr by Western blot analysis2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.
AID1425004Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624824Binding constant for PIP5K1A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424950Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1865204Binding affinity to P38alpha (unknown origin) measured at 0.51 to 10 uM after 360 secs by SPR analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia.
AID1886534Vasculo-toxicity in human HMVEC cells assessed as reduction in vascular structure integrity at 10 uM measured after 6 hrs by calcein AM dye based fluorescence assay2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
AID435833Binding constant for full-length TNK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624863Binding constant for MARK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425010Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425167Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424993Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624732Binding constant for PYK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435679Binding constant for PIM3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224782Delta TM value showing the stabilisation of PAK5 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1425142Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625083Binding constant for LATS2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425129Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1286550Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID435184Binding constant for PTK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1460605Synergistic antibacterial activity against Staphylococcus aureus SA1199 in presence of CPX by checkerboard assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1425071Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435405Binding constant for ERK8 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1373719Inhibition of cell migration of mouse B16-BL6 cells at 8.13 uM incubated for 24 to 48 hrs by cell wound scratch assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells.
AID1515653Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID435656Binding constant for FGFR4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1876283Binding affinity to Fyn (unknown origin) assessed as dissociation constant2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1724048Inhibition of ABL (unknown origin)2020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
AID436006Binding constant for full-length AURKC2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425159Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID760494Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1425134Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID282228Protein binding in human serum at 10 uM2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1425163Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425065Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624817Binding constant for MYO3B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625049Binding constant for PRKCH kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1515655Binding affinity to wild-type human partial length FYN (T243 to L534 residues) expressed in bacterial expression system by TR-FRET assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
Controlling cellular distribution of drugs with permeability modifying moieties.
AID1425089Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624855Binding constant for FRK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424929Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1207734Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID271967Inhibition of Fyn2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
AID507423Inhibition of recombinant INSR by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID624907Binding constant for SYK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425207Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624803Binding constant for CHEK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424902Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID329185Inhibition of recombinant Abl kinase2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
AID624892Binding constant for p38-delta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1207303Inhibition of fast sodium current (INa) in Chinese Hamster Ovary (CHO) K1 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID1207395Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells transfected with KCNQ1 / Kv1.7 / KvLQT1 and KCNE1/minK measured using IonWorks automated patch clamp platform
AID1424975Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1772740Antitumor activity against human K562 cells xenografted in NOD-SCID mouse assessed as tumor growth inhibition at 5 mg/kg, ip administered daily 10 days2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
AID624897Binding constant for RAF1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724980Inhibition of human recombinant ABL1 T315I mutant expressed in insect cells after 30 mins by FRET assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID1724050Inhibition of c-kit (unknown origin)2020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
AID760501Cytotoxicity against human NCI60 cells after 48 hrs by SRB assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1425044Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624853Binding constant for FLT1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435522Binding constant for CDK11 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435439Binding constant for PAK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435164Binding constant for IGF1R kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425087Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435520Binding constant for CAMK2A kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425033Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624878Binding constant for PIM1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID638918Inhibition of c-Src at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
AID709936Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1424914Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624720Binding constant for HIPK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424897Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425013Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID436050Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425199Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1242616Inhibition of DDR2 (unknown origin) after 1 hr by time resolved fluorescence method2015ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
AID1224796Delta TM value showing the stabilisation of LOK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1734838Inhibition of MEK phosphorylation in human MDA-MB-231 cells at 0.03 to 0.3 uM incubated for 20 hrs by Western blot analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
AID435159Binding constant for EPHB3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425046Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID360773Antiviral activity against Dengue virus 2 infected in asian tiger mosquito C6/36 cells2007Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
AID624749Binding constant for CASK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1823809Inhibition of NanoLuc-fused CSF1R (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.
AID1616468Growth inhibition of human K562 cells assessed as reduction in cell density at 20 times IC50 incubated for 12 hrs followed by drug wash-out and incubation in drug-free medium up to 144 hrs by CCK8 assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
AID1425064Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625031Binding constant for MRCKB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425203Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1899933Inhibition of from NanoLuc-fused Fyn (unknown origin) transfected in HEK293 cells using tracer K4 incubated for 1 hr by NanoBRET assay2022European journal of medicinal chemistry, Feb-05, Volume: 229ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.
AID1286562Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID625128Binding constant for CSNK1G1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425161Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424963Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435665Binding constant for NEK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624847Binding constant for CSNK1E kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID724670Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
AID625079Binding constant for NEK6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624736Binding constant for RPS6KA5(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1286589Inhibition of BCR/ABL in human MEG01 cells assessed as downregulation of CrkL phosphorylation at T207 site at 0.1 uM after 1 hr by immunoblotting method2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1286543Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID624942Binding constant for DRAK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224767Delta TM value showing the stabilisation of DAPK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1286587Inhibition of BCR/ABL in human K562 cells assessed as downregulation of CrkL phosphorylation at T207 site at 0.1 uM after 1 hr by immunoblotting method2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
AID1246520Cytotoxicity against human THP1 cells assessed as reduction in cell viability2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID435527Binding constant for FGFR3(G697C) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID677650Antiangiogenic activity in HUVEC co-cultured with vascular smooth muscle cells assessed as inhibition of cell growth at 0.15 uM after 72 hrs2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: from in silico screening to cyclodextrin formulation.
AID624718Binding constant for PFTAIRE2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1915581Cytotoxicity against human DU-145 cells2021European journal of medicinal chemistry, Jan-01, Volume: 209Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID624731Binding constant for CAMK2G kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID729552Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells at 5 uM by TR-FRET based binding assay2013European journal of medicinal chemistry, Mar, Volume: 61Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
AID625028Binding constant for ASK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625089Binding constant for AAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435784Binding constant for CAMK2G kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID282231Inhibition of lck inase2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
AID1310126Inhibition of human FYN using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
AID507686Inhibition of cKIT V560G mutant2009Leukemia, Mar, Volume: 23, Issue:3
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
AID436025Binding constant for NDR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435202Binding constant for TRKC kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1612825Inhibition of SRC (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID436011Binding constant for full-length CLK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1612816Inhibition of Lyn B (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
AID1425154Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1876259Antiviral activity against SARS-CoV infected in african green monkey Vero E6 cells measured after 50 hrs by cell-titre glo assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID624788Binding constant for KIT(D816H) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425108Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1205869Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.
AID436009Binding constant for full-length CAMK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624760Binding constant for PFPK5(P.falciparum) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1814378Inhibition of EPHA2 (unknown origin) at 100 uM incubated for 60 mins by ELISA relative to control2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia.
AID435778Binding constant for full-length ADCK42008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435180Binding constant for MAPKAPK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425172Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID436018Binding constant for FLT4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425160Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID760496Cytotoxicity against human DU145 cells after 48 hrs by SRB assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1424987Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435644Binding constant for ABL1(E255K) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1207275Inhibition of long-lasting type calcium current (ICaL) in HEK293 cells (alpha1C/beta2a/alpha2delta1) cells measured using IonWorks Barracuda automated patch clamp platform
AID625101Binding constant for TAOK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624768Binding constant for SRPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424945Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624739Binding constant for GRK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624744Binding constant for ZAP70 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624986Binding constant for ABL1(Q252H)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624702Binding constant for BRSK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624757Binding constant for PKMYT1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224756Delta TM value showing the stabilisation of CAMKK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625075Binding constant for INSRR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435791Binding constant for EGFR(E746-A750del) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID640175Growth inhibition of human K562 cells at 10 uM after 72 hrs by WST-8 reagent based MTT assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives.
AID710013Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID493040Navigating the Kinome2011Nature chemical biology, Apr, Volume: 7, Issue:4
Navigating the kinome.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,662)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's411 (15.44)29.6817
2010's1638 (61.53)24.3611
2020's613 (23.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 82.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index82.92 (24.57)
Research Supply Index7.98 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index150.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (82.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials216 (7.98%)5.53%
Reviews347 (12.82%)6.00%
Case Studies400 (14.78%)4.05%
Observational24 (0.89%)0.25%
Other1,720 (63.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (332)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Safety and Clinical Efficacy of Dasatinib Plus Human CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Subjects With Ph-positive Acute Lymphoblastic Leukemia [NCT05523661]Phase 115 participants (Anticipated)Interventional2021-03-01Recruiting
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma [NCT02559778]Phase 2500 participants (Anticipated)Interventional2015-09-30Recruiting
Dasatinib Combination for Chronic Lymphocytic Leukemia Patients With Chemo Refractory Disease [NCT01051115]Phase 235 participants (Anticipated)Interventional2008-10-31Recruiting
A Multicenter, Open-label, Phase Ii Study of Dasatinib in Combination With Melphalan and Prednisone (D-MP) in Advanced, Relapsed / Refractory Multiple Myeloma Patients [NCT01116128]Phase 28 participants (Actual)Interventional2008-02-29Terminated(stopped due to difficulty in enrolling patients)
Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer [NCT00371345]Phase 292 participants (Actual)Interventional2006-12-31Completed
Treatment With Second Generation TYROSINE KINASE INHIBITORS (2G TKI) Post Imatinib Failure: Factors Predicting Response and Predictive Value of Response [NCT01188278]173 participants (Actual)Observational2010-07-31Completed
Comparison of Biomarker Modulation by Inhibition of EGFR and/or Src Family Kinases Using Erlotinib and Dasatinib in Head and Neck Lung Cancers [NCT00779389]Phase 158 participants (Actual)Interventional2009-01-31Completed
Molecular Analysis for Therapy Choice (MATCH) [NCT02465060]Phase 26,452 participants (Anticipated)Interventional2015-08-17Active, not recruiting
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib [NCT02297139]Phase 217 participants (Actual)Interventional2015-07-31Completed
A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma [NCT01234935]Phase 28 participants (Actual)Interventional2011-01-13Completed
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations [NCT02954523]Phase 1/Phase 210 participants (Actual)Interventional2016-10-31Active, not recruiting
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia [NCT03216070]Phase 412 participants (Anticipated)Interventional2016-04-01Recruiting
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease [NCT04685590]Phase 248 participants (Anticipated)Interventional2021-12-22Recruiting
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer [NCT01471106]Phase 226 participants (Actual)Interventional2014-01-21Active, not recruiting
Effectiveness of Dasatinib(Sprycel®) in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study [NCT02389972]128 participants (Actual)Observational2013-04-11Completed
A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults With Acute Lymphoblastic Leukemia/Lymphoma [NCT03023046]Phase 254 participants (Actual)Interventional2017-02-23Completed
Persistence Of Major Molecular Remission In Chronic Myeloid Leukemia After A Second Stop Of Tki Treatment In Patients Who Failed An Initial Stop Attempt: A Multicenter Prospective Trial [NCT03573596]Phase 2134 participants (Anticipated)Interventional2018-02-01Recruiting
Dasatinib Combined With Multi-agents Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation [NCT03560908]Phase 10 participants (Actual)Interventional2018-07-01Withdrawn(stopped due to No enough eligable participants enrolled)
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease [NCT03516279]Phase 240 participants (Anticipated)Interventional2019-06-26Recruiting
Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) [NCT02819804]Phase 11 participants (Actual)Interventional2017-08-17Terminated(stopped due to Due to funding and accrual issues)
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib [NCT01342679]Phase 221 participants (Actual)Interventional2011-04-30Completed
Ancillary Observational Study of Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab [NCT03318770]60 participants (Anticipated)Observational2019-05-10Recruiting
Multicenter, Non-randomized Phase II Pilot Study to Assess the Efficacy and Safety of Dasatinib After Allogeneic Stem Cell Transplantation in Patients With de Novo Philadelphia Positive (Bcr-abl +) Acute Lymphoblastic Leukemia [NCT01310010]Phase 230 participants (Anticipated)Interventional2010-04-30Completed
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease [NCT03844360]Phase 41,500 participants (Anticipated)Interventional2016-01-31Recruiting
Effect of Omega-3 Fatty Acid, Eicosapentaenoic Acid, and Its Metabolites in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase [NCT04006847]Phase 1/Phase 21 participants (Actual)Interventional2020-09-14Terminated(stopped due to Product complaint)
A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma [NCT02043587]Phase 231 participants (Actual)Interventional2014-01-31Terminated(stopped due to Original investigator for the trial has left)
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic My [NCT00123474]Phase 3724 participants (Actual)Interventional2005-07-31Completed
Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone Metastasis Predominant Metastatic Breast Cancer [NCT00410813]Phase 285 participants (Actual)Interventional2007-03-31Completed
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular Remission [NCT04147533]Phase 2150 participants (Anticipated)Interventional2020-06-16Active, not recruiting
A Phase II Study of BMS-354825 in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate [NCT00101595]Phase 296 participants (Actual)Interventional2005-01-31Completed
A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma [NCT01660971]Phase 119 participants (Actual)Interventional2012-07-30Active, not recruiting
A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib [NCT00777036]Phase 2130 participants (Actual)Interventional2009-03-20Active, not recruiting
A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [NCT01460160]Phase 2106 participants (Actual)Interventional2012-04-13Completed
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) [NCT00792948]Phase 297 participants (Actual)Interventional2009-09-01Active, not recruiting
PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction [NCT04925648]Phase 222 participants (Anticipated)Interventional2021-10-18Recruiting
Extension Study of a Study to Evaluate Efficacy and Safety of Imatinib (Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase [NCT02421926]0 participants (Actual)Observational2014-10-31Withdrawn
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib [NCT01660906]Phase 439 participants (Actual)Interventional2012-12-31Completed
A Phase 2, Randomized, Open Label, Pivotal Study to Evaluate the Efficacy and Safety of HQP1351 in CML CP Patients Who Are Resistant and/or Intolerant to First- and Second-Generation Tyrosine Kinase Inhibitors [NCT04126681]Phase 2144 participants (Actual)Interventional2019-10-21Active, not recruiting
Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents [NCT02848131]Phase 230 participants (Anticipated)Interventional2016-07-31Enrolling by invitation
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG [NCT01256398]Phase 266 participants (Actual)Interventional2010-12-14Completed
Single Nuclei RNA-sequencing to Map Adipose Cellular Populations and Senescent Cells in Older Subjects [NCT05653258]Phase 2/Phase 3160 participants (Anticipated)Interventional2023-09-30Not yet recruiting
Phase II Trial of Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in Combination With Dasatinib and Quercetin, as a Novel Neoadjuvant Pre-Surgical Therapy for Head and Neck Squamous Cell Carcinoma [NCT05724329]Phase 224 participants (Anticipated)Interventional2023-02-05Recruiting
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) [NCT02081378]Phase 1326 participants (Actual)Interventional2014-04-24Completed
A Phase I/II Study of BMS-354825 in Subjects With Imatinib Resistant or Intolerant Philadelphia Chromosome Positive Chronic Myelogenous Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Treatment [NCT00337454]Phase 1/Phase 248 participants Interventional2005-07-31Completed
Explore the Synergy of Combination TKI Therapy - A Pilot Study to Evaluate the Effect of Imatinib on Dasatinib Pharmacokinetics in Healthy Volunteers [NCT02129166]Phase 10 participants (Actual)Interventional2014-09-30Withdrawn(stopped due to PI resigned)
A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients With Embryonal and Alveolar Rhabdomyosarcoma [NCT03041701]Phase 1/Phase 214 participants (Actual)Interventional2017-07-07Terminated(stopped due to The pharmaceutical company discontinued availability of the drug and we were forced to close the study before phase II was completed. Only one participant was enrolled on phase II.)
N-of-1 Trial of Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy [NCT02142036]Phase 250 participants (Actual)Interventional2014-05-31Completed
Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent Glioblastoma [NCT05432518]Early Phase 110 participants (Anticipated)Interventional2023-06-27Recruiting
Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response [NCT02326311]Phase 3502 participants (Anticipated)Interventional2015-06-10Recruiting
Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) [NCT00390793]Phase 2107 participants (Actual)Interventional2006-09-28Active, not recruiting
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase With Addition of Lower Dose Tyrosine Kinas Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve a Deep Molecular Remission [NCT05143840]Phase 28 participants (Anticipated)Interventional2022-04-22Recruiting
A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) [NCT02750514]Phase 2295 participants (Actual)Interventional2016-05-09Terminated(stopped due to The standard of care for the patient population changed and we were unable to accrue any longer.)
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME [NCT03878524]Phase 12 participants (Actual)Interventional2020-04-01Active, not recruiting
KISS Study: A Phase II Study of Dasatinib Followed by Imatinib in Newly Diagnosed, Previously Untreated Patients With Chronic Phase CML [NCT03193281]Phase 291 participants (Actual)Interventional2017-07-17Active, not recruiting
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) [NCT02013648]Phase 3203 participants (Anticipated)Interventional2014-07-31Active, not recruiting
Combination of Autophagy Selective Therapeutics (COAST) in Advanced Solid Tumors or Relapsed Prostate Cancer, A Phase I/II Trial [NCT05036226]Phase 1/Phase 276 participants (Anticipated)Interventional2022-03-03Recruiting
A Phase I Trial of Dasatinib (Src Inhibitor), Bevacizumab (Anti-VEGF Monoclonal Antibody) and Metronomic Paclitaxel + or - Methylnaltrexone in Patients With Advanced Malignancies [NCT01015222]Phase 1122 participants (Actual)Interventional2009-11-30Completed
Treatment-free Remission Accomplished With Dasatinib in Patients With CML [NCT02268370]Phase 2131 participants (Actual)Interventional2014-10-31Active, not recruiting
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme [NCT00423735]Phase 264 participants (Actual)Interventional2007-01-24Completed
An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Target Total Therapy for Adult Ph-like Acute Lymphoblastic Leukemia [NCT03564470]Phase 2/Phase 3120 participants (Anticipated)Interventional2016-02-14Recruiting
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease [NCT03654768]Phase 284 participants (Anticipated)Interventional2018-10-24Active, not recruiting
A Phase I Study of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT03515200]Phase 112 participants (Actual)Interventional2018-04-20Terminated(stopped due to Due to departure of PI from St. Jude)
A Pilot Study of Oral Dasatinib in Subjects With MDS and Excess Marrow Blasts [NCT00624585]18 participants (Actual)Interventional2008-02-29Completed
A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer [NCT00598091]Phase 130 participants (Actual)Interventional2007-04-30Terminated(stopped due to Low accrual, unable to meet endpoint in timely manner)
A Bioequivalence Study Between the Generic Dasatinib Tablet and Reference Product in Vivo [NCT05640804]Phase 156 participants (Actual)Interventional2018-09-09Completed
A Phase I/II Study of Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (BMS Protocol 180129) [NCT00550615]Phase 1/Phase 238 participants (Actual)Interventional2007-09-17Completed
Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI [NCT01218477]Phase 1/Phase 233 participants (Actual)Interventional2011-01-31Completed
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) [NCT02269267]Phase 2173 participants (Actual)Interventional2014-12-18Completed
SEN-SURVIVORS: An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer [NCT04733534]Phase 260 participants (Anticipated)Interventional2022-06-06Recruiting
Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma [NCT02596828]Phase 24 participants (Actual)Interventional2016-04-30Completed
A Phase I/II Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia [NCT00949988]Phase 1/Phase 23 participants (Actual)Interventional2009-05-31Terminated(stopped due to Three subjects were enrolled and all three subjects withdrew.)
Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Subjects Who Experienced Clinical Benefit on Protocol CA180-002 [NCT00978731]Phase 146 participants (Actual)Interventional2005-12-31Completed
BMS CA180157: A Phase I Combination Study of Dasatinib Plus Vorinostat in Accelerated Phase, Chronic Phase Refractory to Second Line Therapy or Blast Crisis Chronic Myelogenous Leukemia (CML), and in Philadelphia Chromosome Positive Acute Lymphoblastic Le [NCT00816283]Phase 15 participants (Actual)Interventional2008-09-30Completed
Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study [NCT02546791]101 participants (Actual)Observational2015-07-22Completed
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia [NCT04580121]Phase 159 participants (Actual)Interventional2020-11-04Completed
A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab [NCT04164069]Phase 19 participants (Anticipated)Interventional2020-09-02Active, not recruiting
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial [NCT03297606]Phase 2720 participants (Anticipated)Interventional2018-03-23Recruiting
Study of Dasatinib (BMS-354825) in Subjects With Chronic Myelogenous Leukemia With Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant to or Intolerant of Imatinib Mesylate [NCT00298987]Phase 2400 participants (Anticipated)Interventional2006-02-28Completed
A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder [NCT00706641]25 participants (Actual)Interventional2008-06-30Completed
[NCT00454753]0 participants Expanded AccessNo longer available
Phase I/II Study of Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis [NCT00566618]Phase 1/Phase 231 participants (Actual)Interventional2007-11-01Completed
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: A Phase 2, Single-Center, 20-week, Open-Label, Randomized Controlled Trial. [NCT04313634]Phase 2120 participants (Anticipated)Interventional2020-06-09Active, not recruiting
An Open-Label, Multicenter, Phase II Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia Refractory to Conventional Chemotherapy or in Molecular Relapse. Intergroupe Français Des leucémie aiguë myéloblastique [NCT02113319]Phase 227 participants (Actual)Interventional2007-04-30Completed
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment [NCT05780073]Phase 260 participants (Anticipated)Interventional2023-10-16Recruiting
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies [NCT01254864]Phase 2190 participants (Actual)Interventional2011-03-16Completed
Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging [NCT05422885]Phase 1/Phase 212 participants (Actual)Interventional2022-05-20Active, not recruiting
A Phase I Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [NCT00560352]Phase 116 participants (Actual)Interventional2008-02-29Terminated
Phase I Study of Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): ALL-6 Protocol [NCT00940524]Phase 17 participants (Actual)Interventional2009-07-31Completed
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone [NCT02143414]Phase 253 participants (Actual)Interventional2015-06-30Active, not recruiting
A Phase II Trial of Dasatinib in Advanced Sarcomas [NCT00464620]Phase 2366 participants (Actual)Interventional2007-05-31Completed
A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects With Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or Wit [NCT00123487]Phase 3638 participants (Actual)Interventional2005-06-30Completed
A Phase II Study of Dasatinib (NSC 732517) in Previously-Treated Patients With Metastatic Colorectal Cancer [NCT00504153]Phase 219 participants (Actual)Interventional2007-07-31Completed
Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer [NCT00439270]Phase 1/Phase 249 participants (Actual)Interventional2007-07-31Completed
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00549848]Phase 3600 participants (Actual)Interventional2007-10-29Completed
A Randomized, Multicenter, Open-label Phase II Study of Dasatinib (BMS-354825) Administered Orally at a Dose of 50mg Twice Daily or 100mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia Who Are Resistant [NCT00482703]Phase 1/Phase 223 participants (Actual)Interventional2007-05-31Completed
Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis [NCT00979160]Phase 230 participants (Anticipated)Interventional2009-11-30Not yet recruiting
A Phase 2 Trial of Dasatinib in Patients With Lung Adenocarcinoma With Acquired Resistance to Erlotinib or Gefitinib [NCT00570401]Phase 222 participants (Actual)Interventional2006-06-30Completed
Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer [NCT00371254]Phase 255 participants (Actual)Interventional2006-12-31Completed
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer [NCT00452673]Phase 152 participants (Actual)Interventional2007-06-30Completed
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer [NCT00918385]Phase 257 participants (Actual)Interventional2009-05-31Terminated(stopped due to Permanent closure of trial to further accrual based on IDE disapproval)
A Phase 2 Study of Dasatinib in Advanced Melanoma [NCT00436605]Phase 239 participants (Actual)Interventional2006-12-31Completed
A Phase I/II Trial of Dasatinib in Combination With Trastuzumab and Paclitaxel in the First Line Treatment of Her2-Positive Metastatic Breast Cancer (MBC) Patients [NCT01306942]Phase 1/Phase 237 participants (Actual)Interventional2011-07-31Completed
Randomized Phase II of Lomustine Versus Lomustine-Dasatinib in Patients With Recurrent Glioblastoma [NCT00948389]Phase 1/Phase 228 participants (Actual)Interventional2009-10-31Terminated(stopped due to Inability to meet protocol objectives)
A Prospective, Single-arm, Multi-center Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in RefrActory MetAstatic Gastrointestinal Stromal Tumor [NCT02776878]57 participants (Anticipated)Interventional2016-05-31Recruiting
Phase II Efficacy and Safety Study of Dasatinib in Patients With Chronic and Accelerated Phase Chronic Myeloid Leukemia Relapsing After Allogeneic Blood or Bone Marrow Transplantation [NCT00895297]Phase 250 participants (Anticipated)Interventional2010-02-28Terminated(stopped due to Slow recruitment. No safety concerns during this study.)
D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab [NCT02744768]Phase 260 participants (Anticipated)Interventional2017-05-31Recruiting
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy [NCT02638428]Phase 290 participants (Anticipated)Interventional2015-12-31Recruiting
A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity [NCT02779283]Phase 17 participants (Actual)Interventional2016-01-13Completed
Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia [NCT03625388]Phase 256 participants (Actual)Interventional2018-11-05Completed
Phase II Study of Dasatinib in Non Small Cell Lung Cancer [NCT00459342]Phase 235 participants (Actual)Interventional2007-03-31Completed
A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma [NCT00459108]Phase 225 participants (Actual)Interventional2007-04-30Terminated(stopped due to Halted early for futility.)
Pilot Study to Test the Safety and Efficacy of Metformin, Dasatinib, Rapamycin and Nutritional Supplements (Bio-quercetin; Bio-fisetin; Glucosamine; Nicotinamide Riboside; Trans-resveratrol) in Reducing Clinical Measures of Aging in Older Adults [NCT04994561]Phase 10 participants (Actual)Interventional2022-06-30Withdrawn(stopped due to Study was withdrawn)
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib. An Observational Multicentric Study. [NCT01761890]147 participants (Actual)Observational2014-01-28Active, not recruiting
A Phase 1 Study of ABL001 in Combination With Dasatinib, Prednisone, and Blinatumomab in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML) [NCT03595917]Phase 140 participants (Anticipated)Interventional2018-07-24Recruiting
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors [NCT00859937]Phase 255 participants (Actual)Interventional2009-03-16Completed
A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI) [NCT00767520]Phase 2155 participants (Actual)Interventional2009-02-28Completed
A Preoperative Biological Trial of Cetuximab, Dasatinib or the Combination in Colorectal Cancer Patients With Resectable Liver Metastases [NCT00835679]Early Phase 19 participants (Actual)Interventional2009-12-31Terminated
A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma [NCT00820170]Phase 1/Phase 255 participants (Actual)Interventional2009-01-31Completed
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma [NCT00671788]Phase 235 participants (Actual)Interventional2008-06-30Completed
A Prospective Study on Early Conversion of Dasatinib in CML-CP Patients Who Have Not Early Molecular Response on Imatinib [NCT04136015]200 participants (Anticipated)Observational2019-10-22Enrolling by invitation
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401) [NCT02680951]Phase 10 participants (Actual)Interventional2015-12-31Withdrawn(stopped due to Withdrawn due to lack of participants.)
SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial [NCT06018467]Phase 2120 participants (Anticipated)Interventional2023-09-06Recruiting
A Phase I Study of Ixabepilone Combined With Dasatinib in Patients With Solid Tumors [NCT00717704]Phase 119 participants (Actual)Interventional2008-07-31Completed
Open-label, Non-randomized, Two-treatment, Single-period, Single Dose, Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL® 100 mg Film-coated Tablets (Dasatinib) in Adult Human Subjects [NCT06145217]Phase 118 participants (Actual)Interventional2023-08-22Completed
A Phase I Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in Locally Advanced Squamous Cell Carcinoma of Head and Neck (HNSCC) [NCT00882583]Phase 122 participants (Actual)Interventional2009-07-31Terminated(stopped due to Low accrual)
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer. [NCT00920868]Phase 122 participants (Actual)Interventional2009-05-31Completed
A Phase I Trial of A SRC Kinase Inhibitor, Dasatinib,in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian, Peritoneal, and Tubal Cancer [NCT00672295]Phase 111 participants (Actual)Interventional2007-08-31Completed
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic [NCT00696072]Phase 2120 participants (Actual)Interventional2008-08-31Completed
Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma [NCT00895960]Phase 116 participants (Actual)Interventional2009-05-07Terminated(stopped due to Sponsor withdrew support; Study did not progress to Phase II.)
Phase II Study of Dasatinib in Advanced Non-small Cell Lung Cancer With Ex Vivo and In Vivo Assessment of Tumor Target Modulation [NCT00858403]Phase 27 participants (Actual)Interventional2009-03-31Terminated(stopped due to Slow Accrual)
Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction [NCT00608361]Phase 180 participants (Actual)Interventional2008-10-31Completed
A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia [NCT00829647]Phase 1/Phase 20 participants (Actual)Interventional2009-01-31Withdrawn(stopped due to Unable to enroll)
Phase I Study of Dasatinib Plus Erlotinib in Recurrent Malignant Glioma [NCT00609999]Phase 147 participants (Actual)Interventional2008-01-31Completed
Randomized, Open Label Study of Dasatinib (100mg qd) vs. High-Dose Imatinib (600mg) in Patients With Chronic Phase CML Who Have Had Suboptimal Response After 3-18 Months of Therapy With Imatinib (400mg) [NCT00854841]0 participants Expanded AccessAvailable
Phase II Study Assessing Safety and Clinical Activity of the Combination of ASTX727 With Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) [NCT05007873]Phase 270 participants (Anticipated)Interventional2021-10-21Recruiting
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection [NCT05527418]Phase 224 participants (Anticipated)Interventional2023-11-30Not yet recruiting
A Pre-Surgical Study to Evaluate Molecular Changes That Occur in Human Breast Cancer Tissue After Short Term Exposure to Dasatinib and To Correlate These Alterations With Pharmacokinetics Parameters [NCT01410708]Phase 20 participants (Actual)InterventionalWithdrawn
Preliminary Evaluation of TKI Exposure-response Relationships in Real World Patients (RWPs) With Chronic Myelogenous Leukemia (CML) [NCT03885830]45 participants (Actual)Observational2019-06-20Completed
Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) [NCT00850382]Phase 1/Phase 289 participants (Actual)Interventional2009-06-30Completed
Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children With Diffuse Intrinsic Pontine Glioma [NCT00996723]Phase 125 participants (Actual)Interventional2009-10-31Completed
A Phase 1, Open-label, Dose-escalation Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [NCT00892190]Phase 19 participants (Actual)Interventional2011-04-30Completed
A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma [NCT01092728]Phase 219 participants (Actual)Interventional2011-03-31Terminated(stopped due to Slow accrual.)
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer [NCT00860158]Phase 21 participants (Actual)Interventional2009-03-31Terminated(stopped due to Slow accrual; closed by funder)
A Phase 1 Study of Combining Ibrutinib, Dasatinib and Prednisone in Patients 60 Years or Older With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia [NCT02815059]Phase 10 participants (Actual)Interventional2016-09-28Withdrawn(stopped due to Termination of Investigator Initiated Studies using Ibrutinib)
The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients [NCT02690922]Phase 440 participants (Anticipated)Interventional2016-03-31Not yet recruiting
A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer [NCT00903006]Phase 1/Phase 211 participants (Actual)Interventional2009-11-30Terminated(stopped due to Low Accrual)
The Effect of Omeprazole on the Pharmacokinetics of Dasatinib (BMS-354825) in Healthy Subjects [NCT00655746]Phase 114 participants (Actual)Interventional2008-04-30Completed
A Phase I Single Arm Dose Escalation Study of the Combination of Dasatinib (Sprycel®) With Lenalidomide (Revlimid®) and Dexamethasone in Subjects With Relapsed and/ or Refractory Multiple Myeloma [NCT00560391]Phase 135 participants (Actual)Interventional2008-05-31Completed
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) [NCT00720109]Phase 2/Phase 363 participants (Actual)Interventional2008-07-14Completed
A Study to Document the Long-Term Safety and Efficacy of BMS-354825 in Subjects With Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Previou [NCT01030718]Phase 1/Phase 254 participants (Actual)Interventional2006-01-31Completed
Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor [NCT00754325]Phase 2100 participants (Actual)Interventional2008-09-30Completed
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer [NCT00744497]Phase 31,930 participants (Actual)Interventional2008-10-31Completed
A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression [NCT02059265]Phase 235 participants (Actual)Interventional2014-02-14Terminated(stopped due to Interim monitoring)
Phase I Study to Evaluate the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Patients With Chronic Myelogenous Leukemia [NCT02047149]Phase 12 participants (Actual)Interventional2014-01-31Terminated(stopped due to Low accrual)
A Phase II Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia [NCT00866736]Phase 265 participants (Actual)Interventional2009-03-31Completed
A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma [NCT00507767]Phase 215 participants (Actual)Interventional2007-07-31Completed
A Phase I Dose-Escalation Study of Erlotinib in Combination With Dasatinib in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638. [NCT00895128]Phase 165 participants (Actual)Interventional2009-04-30Completed
A Phase II Study to Determine the Activity of Dasatinib Administered Orally (PO) at a Dose of 100 mg Once Daily (QD) in Chronic Phase Chronic Myelogenous Leukemia (CML), at a Dose of 70 mg Twice Daily (BID) in Advanced Phase Chronic Myelogenous Leukemia ( [NCT00529763]Phase 2121 participants (Actual)Interventional2007-11-17Completed
Safety And Efficacy Of Tyrosine Kinase Inhibitor Cessation For Chronic Myeloid Leukemia Patients With Stable Molecular Response In A Real World Population [NCT04626024]Phase 2100 participants (Anticipated)Interventional2020-12-22Recruiting
A Phase I Study of BMS-354825 in Patients With Solid Tumors [NCT00339144]Phase 116 participants (Actual)Interventional2007-01-31Completed
An Open-label, Randomized Study of Dasatinib vs High-dose (800-mg) Imatinib in the Treatment of Subjects With Chronic Phase Chronic Myeloid Leukemia Who Have Had a Suboptimal Response After at Least 3 Months of Therapy With 400 mg Imatinib [NCT00320190]Phase 252 participants (Actual)Interventional2006-08-31Terminated(stopped due to Terminated due to slow participant accrual)
An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia [NCT00481247]Phase 3547 participants (Actual)Interventional2007-09-30Completed
PhaseⅡClinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS [NCT01887561]Phase 2100 participants (Anticipated)Interventional2012-11-30Recruiting
A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML). [NCT01916785]Phase 2289 participants (Actual)Interventional2009-05-31Completed
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825) [NCT00254423]Phase 2156 participants (Actual)Interventional2005-11-08Active, not recruiting
An Open Label, Non-Randomized, Two-Treatment, Single-Period, Single-Dose, Drug-Drug Interaction Study to Evaluate the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) 90 mg Film-Coated Tablets in Healthy Adult Subjects Under Fasting Cond [NCT05433896]Phase 117 participants (Actual)Interventional2020-11-01Completed
Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors. A Multi Center Phase II Trial [NCT00568750]Phase 247 participants (Actual)Interventional2008-01-22Completed
A Phase II Trial of Dasatinib in KIT-Positive Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas [NCT00700882]Phase 281 participants (Actual)Interventional2009-07-02Completed
The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy With Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients With Refractory Or Recurrent Brain Tumors [NCT02015728]20 participants (Anticipated)Interventional2013-12-31Active, not recruiting
Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors [NCT01751425]Phase 18 participants (Actual)Interventional2013-07-24Terminated(stopped due to Per PI Request. 2) No additional benefit was noted with the addition of Ruxolitinib.)
Clinical Trial for the Safety and Efficacy of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma [NCT04603872]Early Phase 1120 participants (Anticipated)Interventional2020-11-01Recruiting
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas [NCT00474812]Phase 251 participants (Actual)Interventional2007-05-31Completed
A Phase II Study of Dasatinib (NSC #732517) in Patients With Chemo-Sensitive Relapsed Small Cell Lung Cancer [NCT00470054]Phase 244 participants (Actual)Interventional2007-04-30Completed
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies. [NCT01643603]Phase 15 participants (Actual)Interventional2012-05-31Terminated(stopped due to Study terminated due to slow accrual.)
Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) [NCT01644773]Phase 136 participants (Actual)Interventional2012-11-27Completed
Phase II Trial of Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [NCT01173679]Phase 210 participants (Actual)Interventional2010-07-31Terminated(stopped due to Slow accrual)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (C [NCT01357655]Phase 270 participants (Actual)Interventional2011-09-30Terminated(stopped due to No participants enrolled in this trial could receive the SMO antagonist as a recommended phase 2 dose was not determined by a different, concurrently-run trial.)
Pilot Study to Investigate the Safety and Feasibility of Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD) [NCT04063124]Phase 1/Phase 25 participants (Actual)Interventional2020-02-14Completed
Phase 1 Trial of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia [NCT00872976]Phase 10 participants (Actual)Interventional2009-05-31Withdrawn(stopped due to Business Objectives Changed)
A Phase 2 Multicenter Study of First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT01004497]Phase 251 participants (Actual)Interventional2010-03-31Completed
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia [NCT05042531]30 participants (Anticipated)Interventional2021-11-13Recruiting
Phase I-II Study of Dasatinib and Erlotinib in Non-Small Cell Lung Cancer [NCT00826449]Phase 1/Phase 253 participants (Actual)Interventional2009-02-28Completed
Phase I Trial of the Combination of Dasatinib and Lapatinib [NCT00662636]Phase 127 participants (Actual)Interventional2008-08-31Completed
Assessment of Metabolic Outcomes Among Patients With Chronic Myelogenous Leukemia (CML) Initiating Therapy With a Tyrosine Kinase Inhibitor (TKI) [NCT02733445]2,650 participants (Actual)Observational2015-12-31Completed
An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Dasatinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lympho [NCT02888990]Phase 271 participants (Actual)Interventional2007-08-31Completed
Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM) [NCT00869401]Phase 1/Phase 2217 participants (Actual)Interventional2009-06-30Completed
A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple-Negative Breast Cancer Patients Developing Effective Therapies for Er-Negative Breast Cancer Using Genomics and Proteomics: Project 3 [NCT00817531]Phase 222 participants (Actual)Interventional2008-12-31Terminated(stopped due to terminated due to futility after interim analysis)
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma [NCT00892177]Phase 2144 participants (Actual)Interventional2009-10-31Completed
Multicenter, Open-label, Non-randomized Phase II Trial of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Who Meet Criteria for Late Suboptimal Response After Prior Imatinib Treatment [NCT01802450]Phase 218 participants (Actual)Interventional2013-03-31Active, not recruiting
Retrospective, Non-interventional Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database [NCT05286528]1,484 participants (Actual)Observational2020-11-18Completed
Effects of Gastric pH on the Pharmacokinetics of Dasatinib in Healthy Volunteers [NCT01398046]Phase 110 participants (Actual)Interventional2011-08-31Completed
Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia (ESCAPE1b) [NCT01426334]Phase 14 participants (Actual)Interventional2011-09-30Terminated
An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid [NCT00852566]Phase 246 participants (Actual)Interventional2009-03-31Completed
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT00787267]Phase 237 participants (Actual)Interventional2008-09-30Terminated(stopped due to Poor accrual)
Targeted Removal of Pro-Inflammatory Cells: An Open Label Human Pilot Study in Idiopathic Pulmonary Fibrosis [NCT02874989]Phase 126 participants (Actual)Interventional2016-12-16Completed
Prospective Non-randomized Stratified Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) in Adults With Ph+ Chronic Myeloid Leukemia With Stable Deep Molecular Response [NCT04578847]Phase 2100 participants (Anticipated)Interventional2020-01-15Active, not recruiting
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial [NCT01627132]Phase 250 participants (Anticipated)Interventional2012-02-29Recruiting
[NCT01872442]Phase 20 participants Interventional2013-10-15Completed
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders [NCT05838560]Phase 240 participants (Anticipated)Interventional2023-07-01Recruiting
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment [NCT04877522]Phase 4347 participants (Anticipated)Interventional2022-08-30Recruiting
Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer [NCT01395017]Phase 2202 participants (Actual)Interventional2011-06-30Completed
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC). [NCT00564876]Phase 22 participants (Actual)Interventional2007-11-30Terminated(stopped due to Lack of accrual, study closed.)
A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104 [NCT00538980]Phase 210 participants (Actual)Interventional2007-04-30Terminated(stopped due to This study was terminated due to lack of efficacy.)
Single-Dose Pharmacokinetics of Dasatinib in Subjects With Hepatic Impairment Compared to Healthy Adult Subjects [NCT00382668]40 participants (Anticipated)Observational2006-10-31Completed
A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid Leukemia [NCT01725204]Phase 240 participants (Actual)Interventional2012-09-30Completed
Phase I Trial Evaluating the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Recurrent Non-small Cell Lung Cancer (NSCLC) [NCT00444015]Phase 134 participants (Actual)Interventional2007-03-31Completed
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis [NCT00982488]Phase 2238 participants (Actual)Interventional2007-10-31Completed
A Phase I Dose Escalation of MK0457 in Combination With Dasatinib in Patients With Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT00500006]Phase 13 participants (Actual)Interventional2007-10-31Terminated
Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients With BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia ? A Multi-center Trial [NCT00036738]Phase 228 participants (Actual)Interventional2001-07-13Completed
A Phase Ib/IIa Single-arm, Open-label Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Philadelphia Chromosome Positive (Ph+) Chroni [NCT02923986]Phase 1/Phase 20 participants (Actual)Interventional2017-09-01Withdrawn(stopped due to No enrollment)
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia [NCT06124157]Phase 3680 participants (Anticipated)Interventional2024-01-22Not yet recruiting
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors [NCT01445509]Phase 150 participants (Actual)Interventional2008-12-29Completed
A Phase 0 Pharmacodynamic Study of Dasatinib in Women With Newly Diagnosed Endometrial Cancer [NCT01482728]Early Phase 112 participants (Actual)Interventional2012-01-31Completed
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML) [NCT04835584]Phase 1/Phase 2109 participants (Anticipated)Interventional2021-05-07Recruiting
A Phase I Dose-Escalation Study of BMS-354825 in Patients With Refractory Solid Tumors [NCT00099606]Phase 160 participants Interventional2004-07-31Completed
Phase I Study of BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia [NCT00103701]Phase 10 participants Interventional2003-11-30Completed
A Dose-Finding Phase Ib Study of the Oral BCL-2 Inhibitor Venetoclax (ABT-199) in Combination With Standard Induction Therapy, Dasatinib, Prednisone, (and Rituximab in CD20+ Patients) in Adult Patients With Newly Diagnosed and Relapsed Philadelphia Chromo [NCT04872790]Phase 120 participants (Anticipated)Interventional2022-09-02Recruiting
A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR Alterations [NCT03352427]Phase 23 participants (Actual)Interventional2017-12-06Terminated(stopped due to Low accrual)
Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Subjects Who Experienced Clinical Benefit on Protocol CA 180-002 [NCT00345826]Phase 119 participants (Actual)Interventional2005-11-30Completed
A Randomized Multi-Center Open Label Study of BMS-354825 vs Imatinib Mesylate (Gleevec®) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Iamtinib at a Dose of 400-600 [NCT00112775]Phase 20 participants Interventional2005-03-31Active, not recruiting
A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 60 [NCT00103844]Phase 2150 participants (Actual)Interventional2005-02-28Completed
A Phase II Clinical Trial of Dasatinib in Patients With Metastatic Pancreatic Cancer [NCT00544908]Phase 27 participants (Actual)Interventional2007-09-30Terminated(stopped due to Toxicity)
Phase II Trial of Dasatinib in Advanced (Stage IIIB/IV) Squamous Cell Lung Cancer [NCT01491633]Phase 25 participants (Actual)Interventional2011-09-30Terminated(stopped due to Safety issues/concerns per DF/HCC PI)
A Phase I Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus, and Cyclophosphamide in Patients With Advanced Solid Tumors [NCT02389309]Phase 114 participants (Actual)Interventional2015-10-05Active, not recruiting
Phase II Trial of Cetuximab and Dasatinib in Patients With Cetuximab-resistant, Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck and Low Serum IL-6 [NCT01488318]Phase 221 participants (Actual)Interventional2011-09-30Terminated(stopped due to PI leaving the institution)
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase [NCT04971226]Phase 3405 participants (Actual)Interventional2021-10-06Active, not recruiting
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL) [NCT02420717]Phase 211 participants (Actual)Interventional2015-07-15Terminated(stopped due to Study was closed early due to low accrual and lack of response.)
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults [NCT04530565]Phase 3348 participants (Anticipated)Interventional2021-01-25Recruiting
A Phase II, Single-Institution, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of a Single Agent Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [NCT00918463]Phase 22 participants (Actual)Interventional2009-06-30Terminated(stopped due to The study was terminated early due to lack of accrual.)
PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC [NCT04284202]Phase 230 participants (Anticipated)Interventional2020-03-01Not yet recruiting
Phase I Open-Labeled Trial of Gemcitabine and Dasatinib in Advanced Solid Tumors [NCT00429234]Phase 154 participants (Actual)Interventional2007-01-31Completed
A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor [NCT00495872]Phase 1204 participants (Actual)Interventional2007-06-30Completed
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined With FOLFOX Chemotherapy in Metastatic Colorectal Cancer (CA180048) [NCT00501410]Phase 186 participants (Actual)Interventional2007-04-23Completed
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in Patients With Chronic Myeloid Leukemia in Chronic Phase: an Randomized Controlled Trial. [NCT04933526]Phase 4118 participants (Anticipated)Interventional2021-07-01Recruiting
Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast Cancer [NCT05198843]Phase 1/Phase 218 participants (Anticipated)Interventional2022-11-08Recruiting
Phase I Study of Cetuximab Plus Dasatinib (BMS-354825) in Advanced Solid Malignancies [NCT00388427]Phase 131 participants (Actual)Interventional2007-06-30Completed
Cytochrome P450 Inhibition With Ketoconazole to Decrease Dosage and Costs of Dasatinib for Chronic Myelogenous Leukemia [NCT05638763]Phase 215 participants (Anticipated)Interventional2024-11-30Recruiting
A Phase I Dose-Escalation Study To Determine The Safety, Pharmacokinetics, And Pharmacodynamics Of BMS-354825 In The Treatment Of Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Hematologic Resistance To Imatinib Mesylate (Gleevec [NCT00064233]Phase 142 participants (Actual)Interventional2003-11-30Completed
Phase I Study to Evaluate the Effect of Ketoconazole on the Pharmacokinetics of Dasatinib and the Effect of Dasatinib on Pharmacodynamic Markers in Patients With Advanced Solid Tumors [NCT00162214]Phase 160 participants Interventional2005-08-31Terminated
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma [NCT00429949]Phase 221 participants (Actual)Interventional2007-01-31Completed
A Phase II Study of Dasatinib (NSC #732517) in Patients With Previously Treated Malignant Mesothelioma [NCT00509041]Phase 246 participants (Actual)Interventional2007-08-31Completed
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib and Venetoclax: A Phase II Study [NCT02689440]Phase 2155 participants (Actual)Interventional2016-02-19Active, not recruiting
A Randomized Controlled Study of Dasatinib Combined With Reduced Intensive Consolidation Chemotherapy in Newly Diagosed Philadelphia Chromesome Positive Adult Lymphoblastic Leukemia [NCT05026229]60 participants (Anticipated)Interventional2021-09-06Recruiting
Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase [NCT03079505]Phase 310 participants (Actual)Interventional2017-08-03Terminated(stopped due to Protocol Deviation)
The Efficiency of CAMS-2016 Trial for the Newly Diagnosed Pediatric Acute Myeloid Leukemia: A Prospective Single Centre Trial From China [NCT03173612]132 participants (Anticipated)Interventional2016-08-31Recruiting
An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis [NCT00764309]Phase 1/Phase 247 participants (Actual)Interventional2009-01-31Completed
A Phase II Proof-of-Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive In Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies [NCT01620216]Phase 212 participants (Actual)Interventional2012-05-11Terminated(stopped due to Unable to recruit enough eligible subjects)
Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib (FOLFOX-D) in First-line Metastatic Pancreatic Adenocarcinoma [NCT01652976]Phase 244 participants (Actual)Interventional2012-07-31Completed
A Phase II Study Using a BFM Regimen Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT04845035]Phase 223 participants (Anticipated)Interventional2024-01-31Recruiting
Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy as Consolidation and Maintenance Therapy for Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction [NCT04329325]Phase 217 participants (Actual)Interventional2020-03-30Active, not recruiting
A Randomized Phase 2 Pilot Study of Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Dasatinib in Patients With Metastatic Melanoma [NCT01876212]Phase 215 participants (Actual)Interventional2014-05-16Completed
Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer [NCT05725200]Phase 240 participants (Anticipated)Interventional2022-09-27Recruiting
Phase I Study of Dasatinib in Combination With Ipilimumab for Patients With Advanced Gastrointestinal Stromal Tumor and Other Sarcomas [NCT01643278]Phase 129 participants (Actual)Interventional2012-07-31Completed
A Randomized Phase II Trial of Dasatinib Plus Abiraterone Compared to Abiraterone Alone for Metastatic, Castration-Resistant Prostate Cancer Prior to Chemotherapy [NCT01685125]Phase 296 participants (Anticipated)Interventional2012-09-30Active, not recruiting
Phase I Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies. [NCT01609816]Phase 18 participants (Actual)Interventional2015-02-12Terminated(stopped due to Low accrual. No Analyses were performed)
An Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer [NCT01990196]Phase 245 participants (Actual)Interventional2014-09-23Active, not recruiting
A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (BMS Trial CA180038) [NCT00316953]Phase 148 participants (Actual)Interventional2006-03-31Completed
Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study) [NCT02652052]10 participants (Anticipated)Interventional2016-03-01Recruiting
Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. [NCT01636908]43 participants (Actual)Interventional2011-08-31Completed
A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies [NCT01744652]Phase 162 participants (Actual)Interventional2013-03-31Completed
Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE [NCT01850004]Phase 284 participants (Actual)Interventional2014-01-22Completed
A Phase II Trial of Dasatinib to Treat Women With Stage IV or Inoperable Stage III Advanced Breast Cancer [NCT00546104]Phase 231 participants (Actual)Interventional2007-10-31Completed
Dasatinib in Patients With Waldenström Macroglobulinemia (WM) Progressing on Ibrutinib [NCT04115059]Phase 16 participants (Anticipated)Interventional2019-11-04Recruiting
Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples. [NCT01703910]Phase 229 participants (Actual)Interventional2012-11-30Completed
A Phase II Randomized Double-Blind Trial of Dasatinib Modulation of Hyperinflammation in Moderate and Severe Patients With COVID-19 [NCT04830735]Phase 20 participants (Actual)Interventional2022-08-05Withdrawn(stopped due to PI decided not to pursue study)
Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation [NCT01514864]Phase 219 participants (Actual)Interventional2012-05-31Terminated(stopped due to Lack of efficacy and slow accrual)
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) [NCT00364286]Phase 217 participants (Actual)Interventional2006-08-31Completed
A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer. [NCT01771458]Phase 2742 participants (Actual)Interventional2012-10-31Active, not recruiting
A Trial of De-escalation and Stopping Treatment in Chronic Myeloid Leukaemia Patients With Excellent Responses to Tyrosine Kinase Inhibitor Therapy [NCT01804985]Phase 2168 participants (Anticipated)Interventional2013-12-31Active, not recruiting
Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC) [NCT01999985]Phase 125 participants (Actual)Interventional2013-12-31Completed
Evaluation of DASATINIB Monotherapy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE [NCT06055621]Phase 235 participants (Anticipated)Interventional2023-12-31Not yet recruiting
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-protocol B Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric P [NCT05751044]Phase 1/Phase 226 participants (Anticipated)Interventional2023-10-01Not yet recruiting
Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer [NCT01440998]Phase 118 participants (Actual)Interventional2011-09-20Completed
RAVEN: A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax [NCT05192889]Phase 1/Phase 290 participants (Anticipated)Interventional2022-08-25Recruiting
Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older. [NCT02494882]Phase 112 participants (Actual)Interventional2015-06-29Active, not recruiting
A Phase III, Prospective Randomised Comparison of Imatinib (STI571, Glivec/Gleevec) 400mg Daily Versus Dasatinib 100mg in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia [NCT01460693]Phase 3814 participants (Actual)Interventional2008-08-31Completed
Prospective, Open Label, Randomized Phase II Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-risk Neuroblastoma [NCT01467986]Phase 2130 participants (Actual)Interventional2013-08-31Completed
A Phase II Multicenter Study on the Treatment of Adult de Novo Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) With the Protein Tyrosine Kinase Inhibitor BMS-354825. EudraCT Number 2005-005107-42. [NCT00391989]Phase 253 participants (Actual)Interventional2006-09-30Completed
Dasatinib and Quercetin, a Combination of Senolytics to Treat Fibrotic Non-alcoholic Fatty Liver Disease - the TRUTH Study [NCT05506488]Phase 1/Phase 230 participants (Anticipated)Interventional2023-03-01Recruiting
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma [NCT02428855]Phase 28 participants (Actual)Interventional2015-04-30Completed
A Umbrella Study in Relapsed/Refractory Peripheral T-cell Lymphoma Guided by Molecular Subtypes [NCT05559008]Phase 1/Phase 2116 participants (Anticipated)Interventional2022-09-30Recruiting
MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients With Tumors With DDR2 Mutations [NCT04439305]Phase 20 participants (Actual)Interventional2016-02-25Withdrawn(stopped due to zero accrual)
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib [NCT01593254]Phase 2262 participants (Actual)Interventional2012-09-12Completed
A Phase II Study to Determine the Activity of BMS-354825 in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who Are Intolerant of Imatinib [NCT00101660]Phase 2387 participants (Actual)Interventional2005-02-28Completed
A Phase II Study of BMS-354825 in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate [NCT00101816]Phase 2124 participants (Actual)Interventional2004-12-31Completed
A Phase II Study of a Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia (ALL) Incorporating Inotuzumab Ozogamicin (InO) [NCT04747912]Phase 225 participants (Anticipated)Interventional2021-03-02Recruiting
Treatment Optimization for Patients With Chronic Myeloid Leukemia (CML) With Treatment naïve Disease (1st Line) and Patients With Resistance or Intolerance Against Alternative Abl-Kinase Inhibitors (≥2nd Line) [NCT02890784]Phase 3291 participants (Actual)Interventional2016-08-31Completed
A Phase II Study of BMS-354825 in Subjects With Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate [NCT00101647]Phase 2197 participants (Actual)Interventional2004-12-31Completed
The Safety and Effectivness of Quercetin and Dasatinib on the Epigenetic Aging Rates in Healthy Individuals [NCT04946383]Phase 225 participants (Anticipated)Interventional2020-12-16Active, not recruiting
Open Label Phase II Study to Evaluate the Safety of Standard Induction and Consolidation Therapy in Combination With Dasatinib in Newly Diagnosed Adult Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) [NCT01724879]Phase 219 participants (Actual)Interventional2011-11-30Completed
Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial [NCT00788125]Phase 1/Phase 27 participants (Actual)Interventional2008-09-03Terminated(stopped due to Terminated early due a shift in resources after lackluster performance of the drug.)
ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease [NCT04785300]Phase 1/Phase 220 participants (Anticipated)Interventional2022-07-06Enrolling by invitation
Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia [NCT05993949]Phase 120 participants (Anticipated)Interventional2023-10-02Recruiting
An Open-Label Randomized Phase III Study of Dasatinib vs. High-Dose (600 mg) Imatinib Mesylate in the Treatment of Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Are Imatinib Failures or Who Have Had a Suboptimal [NCT00362466]Phase 33 participants (Actual)Interventional2007-04-30Terminated(stopped due to Insufficient Enrollment)
An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Four-Period, Full Replicate, Crossover, Single Dose, Oral Comparative Bioavailability Study of XS004 (Dasatinib) 100 mg Film-Coated Tablets, Formulation G of Xspray Pharma AB, Sweden, and S [NCT05439408]Phase 1110 participants (Actual)Interventional2021-06-07Completed
A Phase II Study of Dasatinib (BMS-354825) in Subjects With Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib [NCT00349518]Phase 2/Phase 30 participants (Actual)Interventional2006-12-31Withdrawn
A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase [NCT00324077]Phase 10 participants (Actual)Interventional2006-08-31Withdrawn(stopped due to Insufficient Enrollment)
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer [NCT01260688]Phase 222 participants (Actual)Interventional2010-10-31Completed
A Phase II Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity [NCT01441882]Phase 219 participants (Actual)Interventional2011-10-31Completed
Phase I Trial of Induction Dasatinib Therapy in Patients With Resectable Malignant Pleural Mesothelioma [NCT00652574]Phase 156 participants (Actual)Interventional2008-03-12Completed
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced Gastrointestinal Stromal Tumors: a Randomized, Open, Controlled, Single-center Clinical Study [NCT05751733]258 participants (Anticipated)Interventional2023-02-01Recruiting
A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leu [NCT01238211]Phase 261 participants (Actual)Interventional2010-12-14Completed
Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis [NCT00255346]Phase 268 participants (Actual)Interventional2005-11-15Completed
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) [NCT01498445]Phase 1/Phase 232 participants (Actual)Interventional2012-06-12Terminated(stopped due to The study was terminated early during the phase II portion of the study due to slow enrollment.)
A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer [NCT01826838]Phase 10 participants (Actual)Interventional2013-01-31Withdrawn(stopped due to Lack of patients)
Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia [NCT03331211]100 participants (Anticipated)Observational [Patient Registry]2017-11-01Recruiting
Efficacy and Safety of Dasatinib 70 mg as First-Line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) [NCT04155411]Phase 465 participants (Anticipated)Interventional2019-12-01Recruiting
First-Line Dasatinib or Nilotinib Followed by Response Guided Switch to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia [NCT02709083]Phase 27 participants (Actual)Interventional2016-10-31Terminated(stopped due to Original principal investigator left institution)
A Phase 1A Dose Escalation and Phase 1B Expansion Study to Evaluate the Safety and Tolerability of ETC-1907206 in Combination With Dasatinib in Advanced Haematologic Malignancies [NCT03414450]Phase 10 participants (Actual)Interventional2018-04-25Withdrawn(stopped due to Withdrawal requested by D3)
A Randomized Controlled Study of Tyrosine Kinase Inhibitor Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed Philadelphia Chromesome Positive Adult Acute Lymphoblastic Leukemia [NCT05024357]80 participants (Anticipated)Interventional2021-09-06Recruiting
Open-label, Randomized, 3-period, 3-treatment Crossover, Bioequivalence Study Comparing Dasatinib (BMS-354825) Liquid Formulation and the Dispersed Tablet Formulation Relative to the Reference Tablet Formulation in Health Subjects [NCT01392703]Phase 1141 participants (Actual)Interventional2011-07-31Completed
Frontline Asciminib Combination in Chronic Phase CML [NCT03906292]Phase 2125 participants (Actual)Interventional2019-08-19Active, not recruiting
Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia [NCT02523976]Phase 230 participants (Actual)Interventional2015-08-01Completed
Phase I Study of SRC/ABL Tyrosine Kinase Inhibitor Dasatinib [BMS-354825] in Children and Adolescents With Relapsed or Refractory Leukemia, Protocol ITCC 005 [NCT00306202]Phase 163 participants (Actual)Interventional2006-03-31Completed
A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia [NCT00563290]Phase 27 participants (Actual)Interventional2007-11-30Completed
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma [NCT03117751]Phase 2/Phase 3790 participants (Actual)Interventional2017-03-29Active, not recruiting
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations [NCT02883049]Phase 35,937 participants (Actual)Interventional2012-02-29Active, not recruiting
BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy [NCT00570700]Phase 238 participants (Actual)Interventional2007-07-31Completed
Personalized Treatment Selection for Metastatic Breast Cancer [NCT00780676]Phase 297 participants (Actual)Interventional2009-06-30Terminated(stopped due to Closed early for futility.)
A Phase I Study of Dasatinib With Concurrent Chemoradiation for Stage III NSCLC Principal Investigator: Howard Safran, MD. [NCT00787852]Phase 111 participants (Actual)Interventional2009-03-31Terminated(stopped due to for efficacy and safety reasons)
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer [NCT00924352]Phase 1/Phase 256 participants (Actual)Interventional2009-06-30Completed
Efficacy and Safety of Dasatinib in the First-line Treatment of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) [NCT04925141]Phase 462 participants (Actual)Interventional2016-05-10Completed
Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epidermal Growth Factor Receptor (nEGFR) [NCT02720185]Phase 25 participants (Actual)Interventional2017-05-03Terminated(stopped due to Study terminated early due to COVID-19 related slow enrollment and funding)
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer [NCT00385580]Phase 294 participants (Actual)Interventional2007-01-31Completed
Phase II Study of Dasatinib (BMS-354825) in Relapsed Chronic Lymphocytic Leukemia [NCT00438854]Phase 215 participants (Actual)Interventional2006-12-31Completed
A Phase I/II Study of Dasatinib and Dacarbazine in Patients With Metastatic Melanoma [NCT00597038]Phase 1/Phase 250 participants (Actual)Interventional2007-11-30Completed
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication [NCT02233049]Phase 2250 participants (Anticipated)Interventional2014-10-31Recruiting
Bioequivalence Studies of Dasatinib 100 mg Tablets in Healthy Colombian Subjects in Postprandial Condition [NCT05944783]Phase 446 participants (Anticipated)Interventional2023-11-01Not yet recruiting
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents [NCT03020030]Phase 3560 participants (Actual)Interventional2017-03-03Active, not recruiting
A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase [NCT00070499]Phase 2406 participants (Actual)Interventional2004-08-15Active, not recruiting
A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination Dasatinib (BMS-354825) Plus Nivolumab (BMS-936558) in Patients Chronic Myeloid Leukemia (CML) [NCT02011945]Phase 135 participants (Actual)Interventional2014-02-07Completed
Phase I/II Study of the Combination of Dasatinib With Chemotherapy for High Risk Acute Myeloid Leukemia (AML) Patients [NCT01876953]Phase 1/Phase 220 participants (Actual)Interventional2013-09-13Terminated(stopped due to Due to the budget issues, the study discontinued at Phase II.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00036738 (5) [back to overview]Overall Survival
NCT00036738 (5) [back to overview]Relapse Free Survival
NCT00036738 (5) [back to overview]Leukemia-free Survival
NCT00036738 (5) [back to overview]Transplant-related Mortality
NCT00036738 (5) [back to overview]Transplant-related Mortality
NCT00070499 (5) [back to overview]2-year Overall Survival (OS)
NCT00070499 (5) [back to overview]Two Year Relapse-free Survival
NCT00070499 (5) [back to overview]Hematologic Response
NCT00070499 (5) [back to overview]Molecular Response Rate at 12 Months
NCT00070499 (5) [back to overview]Toxicity
NCT00101647 (16) [back to overview]Major and Overall Hematologic Response (MaHR and OHR)
NCT00101647 (16) [back to overview]Minimal Clinically Significant Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G)
NCT00101647 (16) [back to overview]Number of Participants Who Achieved a Major Molecular Response (MMR) During Treatment Period
NCT00101647 (16) [back to overview]Percentage of Participants Who Achieved OHR and Did Not Progress at 12 Months and 24 Months
NCT00101647 (16) [back to overview]Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point Within the Dosing Interval of 12 Hours (AUC[0-T])
NCT00101647 (16) [back to overview]Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Maximum Observed Plasma Concentration (Cmax)
NCT00101647 (16) [back to overview]Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Plasma Half-life (T-HALF)
NCT00101647 (16) [back to overview]MaHR and MCyR Among Participants With Baseline BCR-ABL Point Mutations
NCT00101647 (16) [back to overview]Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Time to Maximum Observed Plasma Concentration (Tmax)
NCT00101647 (16) [back to overview]Best Cytogenetic Response
NCT00101647 (16) [back to overview]Best Confirmed Hematologic Response
NCT00101647 (16) [back to overview]Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, Hematologic Toxicities, and Toxicities Leading to Discontinuation
NCT00101647 (16) [back to overview]Time to OHR
NCT00101647 (16) [back to overview]Percentage of Participants Who Achieved MaHR and Did Not Progress at 24 Months in the Imatinib-Resistant Group (Based on the Kaplan-Meier Estimate of the Duration of Response)
NCT00101647 (16) [back to overview]Percentage of Participants Who Achieved MaHR and Did Not Progress at 12 Months (Based on the Kaplan-Meier Estimate of the Duration of Response)
NCT00101647 (16) [back to overview]Median Time in Days From First Dosing Date to Date of MaHR
NCT00101660 (11) [back to overview]Minimal Clinically Significant Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire Scores
NCT00101660 (11) [back to overview]Median Time From First Dosing Until CHR
NCT00101660 (11) [back to overview]Median Time From First Dosing Date to Date of MCyR
NCT00101660 (11) [back to overview]Number of Imatinib-intolerant Participants With MCyR
NCT00101660 (11) [back to overview]Percentage of Participants Who Achieved MCyR and Did Not Progress at 12 and 24 Months
NCT00101660 (11) [back to overview]Number of Imatinib-resistant Participants With Major Cytogenetic Response (MCyR)
NCT00101660 (11) [back to overview]Number of Imitanib-intolerant Participants With Drug-related Adverse Events (AEs), Death Within 30 Days of Last Dose, Death, and AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Grade 3-4 Thrombocytopenia, Grade 4-4 Neutropenia, and Any AE
NCT00101660 (11) [back to overview]Number of Imitanib-resistant Participants With Drug-related AEs, Death Within 30 Days of Last Dose, Death, AEs Leading to Discontinuation, SAEs, Grade 3-4 Thrombocytopenia, Grade 3-4 Neutropenia, and Any AE
NCT00101660 (11) [back to overview]Number of Participants With Complete Hematologic Response (CHR)
NCT00101660 (11) [back to overview]Number of Participants With Major Molecular Response (MMR)
NCT00101660 (11) [back to overview]Percentage of Participants Who Acheived CHR and Did Not Progress at 12 Months and 24 Months
NCT00101816 (18) [back to overview]Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), AEs Leading to Discontinuation, Drug-Related AEs
NCT00101816 (18) [back to overview]Time to MaHR and OHR
NCT00101816 (18) [back to overview]Median Duration of Major Hematologic Response (MaHR)
NCT00101816 (18) [back to overview]Pharmacokinetics (PK) of Dasatinib's Metabolite BMS-582691 - Time to Maximum Observed Plasma Concentration (Tmax)
NCT00101816 (18) [back to overview]Pharmacokinetics (PK) of Dasatinib's Metabolite BMS-582691 - Maximum Observed Plasma Concentration (Cmax)
NCT00101816 (18) [back to overview]Pharmacokinetics (PK) of Dasatinib's Metabolite BMS-582691 - Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point Within the Dosing Interval of 12 h (AUC[0-T])
NCT00101816 (18) [back to overview]Pharmacokinetics (PK) of Dasatinib - Maximum Observed Plasma Concentration (Cmax)
NCT00101816 (18) [back to overview]Pharmacokinetics (PK) of Dasatinib - Time to Maximum Observed Plasma Concentration (Tmax)
NCT00101816 (18) [back to overview]Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Plasma Half-life (T-HALF)
NCT00101816 (18) [back to overview]Pharmacokinetics (PK) of Dasatinib - Plasma Half-life (T-HALF)
NCT00101816 (18) [back to overview]Pharmacokinetics (PK) of Dasatinib - Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point Within the Dosing Interval of 12 h or 24 h(AUC[0-T])
NCT00101816 (18) [back to overview]Median Duration of Overall Hematologic Response (OHR)
NCT00101816 (18) [back to overview]Major and Overall Hematologic Response (MaHR and OHR)
NCT00101816 (18) [back to overview]MaHR and Major Cytogenetic Response (MCyR) Among Participants With Baseline BCR-ABL Point Mutations
NCT00101816 (18) [back to overview]Minimally Significant Changes From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G)
NCT00101816 (18) [back to overview]Number of Participants Achieving Major Molecular Response (MMR)
NCT00101816 (18) [back to overview]Number of Participants With CHR or NEL, MiHR, or no Hematologic Response
NCT00101816 (18) [back to overview]Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response
NCT00103844 (13) [back to overview]Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Hematologic Toxicities Prior to Crossover
NCT00103844 (13) [back to overview]Time to MCyR Prior to Crossover
NCT00103844 (13) [back to overview]Major Molecular Response (MMR)
NCT00103844 (13) [back to overview]Duration of MCyR at 24 Months
NCT00103844 (13) [back to overview]Complete Hematologic Response (CHR) at Any Time Prior to Crossover
NCT00103844 (13) [back to overview]CHR After Crossover
NCT00103844 (13) [back to overview]Blood Sample Collection for Pharmacokinetic (PK) Analysis of Dasatinib
NCT00103844 (13) [back to overview]Time to CHR Prior to Crossover
NCT00103844 (13) [back to overview]Number of Participants With Major Cytogenetic Response (MCyR) at Week 12
NCT00103844 (13) [back to overview]MCyR at Any Time Prior to Crossover
NCT00103844 (13) [back to overview]Duration of MCyR at 12 Months and 18 Months
NCT00103844 (13) [back to overview]Duration of Complete Hematologic Response (CHR)
NCT00103844 (13) [back to overview]Cytogenetic Response After Crossover
NCT00123474 (22) [back to overview]Percent of Participants Overall Survival at 24, 36, 48, 60, 72, and 84 Months Follow-Up - All Randomized Participants
NCT00123474 (22) [back to overview]Percent of Imatinib-Resistant Participants With Overall Survival (OS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up
NCT00123474 (22) [back to overview]Percent of Participants Intolerant to Imatinib With MCyR at 6 Months and at 24 Months Follow-Up, by QD and BID Schedules and by Total Daily Dose
NCT00123474 (22) [back to overview]Percent of Participants Intolerant to Imatinib With CHR at 6 Months and at 24 Months Follow-Up
NCT00123474 (22) [back to overview]Percent of Imatinib Intolerant Participants With Overall Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-up
NCT00123474 (22) [back to overview]Percent of Imatinib Intolerant Participants With Progression Free Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-Up
NCT00123474 (22) [back to overview]Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up
NCT00123474 (22) [back to overview]Number of Participants With MCyR Whose Disease Progressed by 24 Months
NCT00123474 (22) [back to overview]Number of Participants With CHR Whose Disease Progressed by 24 Months
NCT00123474 (22) [back to overview]Percent of Imatinib-Resistant Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up
NCT00123474 (22) [back to overview]Time to MCyR in Participants With MCyR at 24 Months Follow-Up
NCT00123474 (22) [back to overview]Percent of Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up by Dose Schedule and Total Daily Dose - All Randomized Participants
NCT00123474 (22) [back to overview]Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up
NCT00123474 (22) [back to overview]Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 24 Months Follow-Up
NCT00123474 (22) [back to overview]Number of Participants With MCyR and Baseline BCR-ABL Gene Mutation - All Treated Participants
NCT00123474 (22) [back to overview]Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 6 Months Follow-Up
NCT00123474 (22) [back to overview]Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) That Led to Treatment Discontinuation at 24 Months of Follow-up
NCT00123474 (22) [back to overview]Time to MCyR in Participants With MCyR at 6 Months Follow-Up
NCT00123474 (22) [back to overview]Time to CHR in Participants With CHR at 6 Months Follow-Up
NCT00123474 (22) [back to overview]Time to CHR in Participants With CHR At 24 Months Follow-Up
NCT00123474 (22) [back to overview]Percent of Participants With MCyR At or Prior to 24 Months Follow-Up
NCT00123474 (22) [back to overview]Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) That Led toTreatment Discontinuation After 7 Year Follow-up
NCT00123487 (18) [back to overview]Number of Participants With Grade 4 Myelosuppression Determined From Hematology Evaluations
NCT00123487 (18) [back to overview]Number of Participants With Maximal QTcF Intervals up to Year 2 in Treated Participants
NCT00123487 (18) [back to overview]Number of Participants With Normal Baseline Versus Worst Grade 3/4 Biochemistry Laboratory Abnormalities up to Year 2 in Treated Participants
NCT00123487 (18) [back to overview]Number of Participants With Normal Baseline Versus Worst Grade 3/4 Hematology Laboratory Abnormalities up to Year 2 in Treated Participants
NCT00123487 (18) [back to overview]Percent of Participants With Major Cytogenetic Response (MCyR) - Randomized Population
NCT00123487 (18) [back to overview]Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population
NCT00123487 (18) [back to overview]Percent of Participants With Overall Hematologic Response - Randomized Population
NCT00123487 (18) [back to overview]Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population
NCT00123487 (18) [back to overview]Progression Free Survival (PFS) and Overall Survival (OS) at 24, 36, 48, and 60 Months - Randomized Population
NCT00123487 (18) [back to overview]Percent of Participants With Major Hematological Response (MaHR) With 2 Years of Follow-up From Date of Last Enrollment - Randomized Population
NCT00123487 (18) [back to overview]Median Time to Major Hematologic Response (MaHR) - Randomized Population
NCT00123487 (18) [back to overview]Number of Participants With Best Confirmed Hematologic Response, Major Hematologic Response (MaHR) and Overall Hematologic Response - Randomized Population
NCT00123487 (18) [back to overview]Number of Participants With Best Cytogenic Response (CyR) - Randomized Population
NCT00123487 (18) [back to overview]Number of Participants With Changes From Baseline in QT Interval Corrected With Fridericia Formula (QTcF) up to Year 2 in Treated Participants
NCT00123487 (18) [back to overview]Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation and Drug-related Fluid Retention AEs, up to Year 7 in Treated Participants
NCT00123487 (18) [back to overview]Median Duration of a Major Hematologic Response (MaHR) in Those Participants Who Achieved a MaHR During the Study
NCT00123487 (18) [back to overview]Median Overall Survival (OS) - Randomized Population
NCT00123487 (18) [back to overview]Median Progression Free Survival (PFS) - Randomized Population
NCT00255346 (2) [back to overview]Duration of Response (Survival)
NCT00255346 (2) [back to overview]Participant Response Rate
NCT00306202 (49) [back to overview]Number of Participants With FLT3 and KIT Mutations in Stratum4 Ph- ALL/AML at Baseline
NCT00306202 (49) [back to overview]Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0.
NCT00306202 (49) [back to overview]Duration of Major Cytogenetic Response (MCyR) in Responders (Stratum 1 [Ph+ CP-CML] and Stratum 2/3 [Ph+ ALL or AP/BP-CML])
NCT00306202 (49) [back to overview]Duration of Complete Hematologic Response (CHR): Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ALL or AP/BP-CML)
NCT00306202 (49) [back to overview]Duration of Complete Cytogenetic Response (CCyR) in Responders: Stratum 1 [Ph+ CP-CML] and Stratum 2/3 [Ph+ ALL or AP/BP-CML]
NCT00306202 (49) [back to overview]Number of Participants With Molecular Responses in Stratum 1 (Ph+ CP-CML)
NCT00306202 (49) [back to overview]Number of Participants With Major Hematologic Response (MaHR) in Stratum 2/3 (Ph+ ALL or AP/BP-CML) Within First 6 and 24 Weeks
NCT00306202 (49) [back to overview]Number of Participants With Major Cytogenetic Response (MCyR) in Stratum 1 (Ph+ CP-CML) Within First 12 and 24 Weeks
NCT00306202 (49) [back to overview]Number of Participants With Hematology Abnormalities by NCI CTCAE Version 3.0
NCT00306202 (49) [back to overview]Number of Participants With Hematologic Toxicity at Baseline by NCI CTCAE Version 3.0
NCT00306202 (49) [back to overview]Number of Participants With FLT3 and KIT Mutations in Stratum4 Ph- ALL/AML at End-Of-Treatment
NCT00306202 (49) [back to overview]Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic Parameter: Observed Maximum Plasma Concentration (Cmax) by Dose Level and Age Group
NCT00306202 (49) [back to overview]Number of Participants With BCR-ABL Mutations at Baseline: Stratum1 Ph+ CP-CML and Stratum 2/3 Ph+ALL or AP/BP-CML
NCT00306202 (49) [back to overview]Dasatinib Plasma Pharmacokinetic Parameter: Terminal Half-life (T 1/2) by Dose Level and Age Group
NCT00306202 (49) [back to overview]Dasatinib Plasma Pharmacokinetic Parameter: Terminal Half-life (T 1/2) by Age Group
NCT00306202 (49) [back to overview]Dasatinib Plasma Pharmacokinetic Parameter: Observed Maximum Plasma Concentration (Cmax) by Dose Level and Age Group
NCT00306202 (49) [back to overview]Dasatinib Plasma Pharmacokinetic Parameter: Dose Normalized Observed Maximum Plasma Concentration (Cmax) by Age Group
NCT00306202 (49) [back to overview]Dasatinib Plasma Pharmacokinetic Parameter: Dose Normalized Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) by Age Group
NCT00306202 (49) [back to overview]Dasatinib Plasma Pharmacokinetic Parameter: Dose Normalized Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Age Group
NCT00306202 (49) [back to overview]Dasatinib Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) by Dose Level and Age Group
NCT00306202 (49) [back to overview]Dasatinib Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Dose Level and Age Group
NCT00306202 (49) [back to overview]Dasatinib Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) by Age Group
NCT00306202 (49) [back to overview]Dasatinib Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) By Dose Level and Age Group
NCT00306202 (49) [back to overview]Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Dose Level and Age Group
NCT00306202 (49) [back to overview]Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) By Dose Level and Age Group
NCT00306202 (49) [back to overview]Concentration of Dasatinib in Cerebrospinal Fluid (CSF) by Dose Level and Age Group
NCT00306202 (49) [back to overview]Best Hematologic Response (HR) At Any Time: Stratum 4 (Ph- ALL/AML)
NCT00306202 (49) [back to overview]Best Hematologic Response (HR) At Any Time: Stratum 2/3 (Ph+ ALL or AP/BP-CML)
NCT00306202 (49) [back to overview]Best Hematologic Response (HR) At Any Time: Stratum 1 (Ph+ CP-CML)
NCT00306202 (49) [back to overview]Best Cytogenetic Response (CyR) in Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML)
NCT00306202 (49) [back to overview]Time to Major Hematologic Response (MaHR): Stratum 2/3 (PH+ ALL or AP/BP-CML)
NCT00306202 (49) [back to overview]Time to Major Cytogenetic Response (MCyR) in Responders: Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML)
NCT00306202 (49) [back to overview]Time to Complete Hematologic Response (CHR): Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ALL or AP/BP-CML)
NCT00306202 (49) [back to overview]Recommended Phase II Dose of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
NCT00306202 (49) [back to overview]Progression Free Survival (PFS)
NCT00306202 (49) [back to overview]Percentage of Participants With Confirmed Hematologic Response (HR) at Recommended Phase II Dose: Stratum 1 (Ph+ CP-CML)
NCT00306202 (49) [back to overview]Overall Survival (OS)
NCT00306202 (49) [back to overview]Number of Participants With Major Molecular Response (MMR) in Stratum 2/3 (Ph+ ALL or AP/BP-CML)
NCT00306202 (49) [back to overview]Number of Participants With Major Hematologic Response (MaHR) at Any Time in Stratum 2/3 (Ph+ ALL or AP/BP-CML) and Stratum 4 (Ph- ALL/AML)
NCT00306202 (49) [back to overview]Number of Participants With Major Cytogenetic Response (MCyR) at Any Time in Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML)
NCT00306202 (49) [back to overview]Number of Participants With Dose-limiting Toxicity (DLT)
NCT00306202 (49) [back to overview]Duration of Major Hematologic Response (MaHR): Stratum 2/3 (Ph+ALL or AP/BP-CML)
NCT00306202 (49) [back to overview]Percentage of Participants With Confirmed Hematologic Response (HR) at Recommended Phase II Dose: Stratum 2/3 (Ph+ALL or AP/BP-CML)
NCT00306202 (49) [back to overview]Percentage of Participants With Complete Cytogenetic Response (CCyR) or Major Cytogenetic Response (MCyR) at Recommended Phase II Dose
NCT00306202 (49) [back to overview]Number of Participants With BCR-ABL Mutations at End-of-Treatment: Stratum1 Ph+ CP-CML and Stratum2/3 Ph+ ALL or AP/BP-CML
NCT00306202 (49) [back to overview]Number of Participants With Serum Chemistry Abnormalities (Liver and Renal Function) by NCI CTCAE Version 3.0
NCT00306202 (49) [back to overview]Number of Participants With Serum Chemistry Abnormalities (Liver and Renal Function) at Baseline by NCI CTCAE Version 3.0
NCT00306202 (49) [back to overview]Number of Participants With Serum Chemistry Abnormalities (Calcium, Magnesium, and Phosphate) by NCI CTCAE Version 3.0
NCT00306202 (49) [back to overview]Number of Participants With Serum Chemistry Abnormalities (Calcium, Magnesium, and Phosphate) at Baseline by NCI CTCAE Version 3.0
NCT00320190 (2) [back to overview]Percentage of Participants With On-study AEs of Special Interest
NCT00320190 (2) [back to overview]Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation
NCT00339144 (25) [back to overview]Number of Participants With Clinically Significant Change in QT Interval Corrected for Heart Rate (QTcF)
NCT00339144 (25) [back to overview]Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
NCT00339144 (25) [back to overview]Accumulation Index (AI) of Dasatinib
NCT00339144 (25) [back to overview]AUC (0-t) of Metabolite BMS-582691
NCT00339144 (25) [back to overview]AUC[TAU] of Dasatinib
NCT00339144 (25) [back to overview]Cmax of Metabolite BMS-582691
NCT00339144 (25) [back to overview]Maximum Plasma Concentration (Cmax) of Dasatinib
NCT00339144 (25) [back to overview]Mean Apparent Oral Clearance (CLo) of Dasatinib
NCT00339144 (25) [back to overview]Mean Apparent Volume of Distribution (Vz/F) of Dasatinib
NCT00339144 (25) [back to overview]Mean Serum Concentration of Bone Alkaline Phosphatase (BAP) Biological Marker
NCT00339144 (25) [back to overview]Mean Serum Concentration of Tartrate-resistant Acid Phosphatase Isoform 5b (TRACP-5b) Biological Marker
NCT00339144 (25) [back to overview]Mean Urine Concentration of Deoxypyridinoline (Dpyr) Biological Marker
NCT00339144 (25) [back to overview]Mean Urine Concentration of Urinary N-telopeptide Type 1 Collagen (NTx) Biological Marker
NCT00339144 (25) [back to overview]Number of Participants Who Died, Experienced Adverse Events (AEs), Serious AEs (SAEs), Drug Related AEs and Discontinued Due to AEs
NCT00339144 (25) [back to overview]Number of Participants With Grade 3 or 4 Hematology Abnormalities
NCT00339144 (25) [back to overview]Number of Participants With Grade 3-4 Serum Chemistry Abnormalities
NCT00339144 (25) [back to overview]Area Under the Plasma-concentration-time Curve [AUC (INF)] of Dasatinib on Day 1
NCT00339144 (25) [back to overview]Tmax of the Metabolite BMS-582691
NCT00339144 (25) [back to overview]Time to Reach Maximum Observed Plasma Concentration of Dasatinib (Tmax)
NCT00339144 (25) [back to overview]Terminal Elimination Half-life (T-half) of Dasatinib
NCT00339144 (25) [back to overview]Maximum Tolerated Dose (MTD) and Maximum Acceptable Dose (MAD) of Dasatinib as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to Dasatinib Treatment
NCT00339144 (25) [back to overview]Most Frequent Grade 3-4 Hematology Abnormalities Occurring in >=10% Participants: Low Lymphocyte Count
NCT00339144 (25) [back to overview]Number of Participants With Complete Response (CR) or Partial Response (PR)
NCT00339144 (25) [back to overview]Most Frequent Serum Chemistry Laboratory Abnormalities Occurring in >=10% Participants: High Magnesium
NCT00339144 (25) [back to overview]Number of Participants With Clinically Meaningful Vital Signs
NCT00362466 (1) [back to overview]Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs
NCT00364286 (1) [back to overview]Participants With Objective Response
NCT00371254 (21) [back to overview]Number of Participants With Abnormalities (Grade 1 or 2) in Partial Thromboplastin Time (PTT)
NCT00371254 (21) [back to overview]Number of Participants With Abnormal Vital Signs Measurements
NCT00371254 (21) [back to overview]Mean Number of Weeks of Complete Response (CR) or Partial Response (PR)
NCT00371254 (21) [back to overview]Proportion of Participants With Progression-Free Survival (PFS) at Weeks 9, 17, and 25
NCT00371254 (21) [back to overview]Number of Participants With Grade 3 or 4 Serum Chemistry Abnormalities in Creatinine, Bicarbonate, Inorganic Phosphorous and Bilirubin (Total).
NCT00371254 (21) [back to overview]Number of Participants With Grade 3 or 4 Serum Chemistry Abnormalities in Calcium, Potassium, Magnesium and Sodium
NCT00371254 (21) [back to overview]Number of Participants With Grade 3 or 4 Serum Chemistry Abnormalities in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase
NCT00371254 (21) [back to overview]Number of Participants With Grade 3 or 4 Abnormalities in Hematology Measurements
NCT00371254 (21) [back to overview]Number of Participants With Abnormalities (Grade 1 or 2) in Prothrombin Time (PT)
NCT00371254 (21) [back to overview]Number of Participants Who Experienced Drug-related SAEs, Drug-related AEs, Drug-related Grade 3 AEs and Discontinuations Due to Drug-related AEs
NCT00371254 (21) [back to overview]Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs) or Adverse Events (AEs)
NCT00371254 (21) [back to overview]Most Frequent Drug-related Adverse Events (AEs)
NCT00371254 (21) [back to overview]Mean Plasma Concentration at Week 7
NCT00371254 (21) [back to overview]Mean Change in Concentration of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) From Baseline
NCT00371254 (21) [back to overview]Mean Change in Concentration of Collagen Type IV From Baseline
NCT00371254 (21) [back to overview]Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) at or After 16 Weeks on Study
NCT00371254 (21) [back to overview]Percentage of Participants With Complete Response (CR) or Partial Response (PR)
NCT00371254 (21) [back to overview]Number of Participants With Identified Electrocardiogram (ECG) Abnormalities
NCT00371254 (21) [back to overview]Mean Plasma Concentration at Week 3
NCT00371254 (21) [back to overview]Number of Participants With Complete Response (CR) or Partial Response (PR)
NCT00371254 (21) [back to overview]Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) at or After 16 Weeks on Study
NCT00371345 (19) [back to overview]Median Progression Free Survival (PFS)
NCT00371345 (19) [back to overview]Number of Participants Who Progressed
NCT00371345 (19) [back to overview]Number of Participants With Objective Response
NCT00371345 (19) [back to overview]Percentage of Participants With Objective Response
NCT00371345 (19) [back to overview]Percentage of Response-evaluable Participants With Disease Control (DCR)
NCT00371345 (19) [back to overview]Best Overall Response
NCT00371345 (19) [back to overview]Number of Participants With Death, Adverse Events (AEs), and AEs Leading to Discontinuation
NCT00371345 (19) [back to overview]Number Of Participants With Notable Drug-related AEs
NCT00371345 (19) [back to overview]Number of Participants With On-study CTCAE Version 3.0 Grade 3-4 Laboratory Abnormalities
NCT00371345 (19) [back to overview]Number of Participants With Serious AEs (SAEs), Drug-related AEs, Drug-related SAEs, and Drug-Related Grade 3 AEs
NCT00371345 (19) [back to overview]Number of Response-evaluable Participants With Disease Control (DCR)
NCT00371345 (19) [back to overview]Percentage of Participants With Progression-free Survival (PFS) at Weeks 9, 17, and 25
NCT00371345 (19) [back to overview]Pharmacodynamics: Percent Change From Baseline In Plasma Level of Collagen Type IV at Week 3 in Participants With and Without DCR
NCT00371345 (19) [back to overview]Pharmacodynamics: Percent Change From Baseline In Plasma Level of Collagen Type IV at Week 5 in Participants With and Without DCR
NCT00371345 (19) [back to overview]Pharmacodynamics: Percent Change From Baseline In Plasma Level of VEGFR2 at Week 3 in Participants With and Without DCR
NCT00371345 (19) [back to overview]Pharmacodynamics: Percent Change From Baseline In Plasma Level of VEGFR2 at Week 5 in Participants With and Without DCR
NCT00371345 (19) [back to overview]Pharmacokinetics (PK): Plasma Concentration of Dasatinib at Week 3
NCT00371345 (19) [back to overview]PK: Plasma Concentration of Dasatinib at Week 7 or Week 9
NCT00371345 (19) [back to overview]Duration Of Objective Response
NCT00385580 (39) [back to overview]Number of Participants With QTc Prolongation
NCT00385580 (39) [back to overview]Number of Participants Who Experienced Drug-related SAEs, Drug-related AEs, Drug-related Grade 3/4 AEs and Discontinuations Due to Drug-related AEs.
NCT00385580 (39) [back to overview]Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AEs
NCT00385580 (39) [back to overview]Median Change From Baseline in Total FAPSI-8 Scores at Weeks 12, 24 and 36
NCT00385580 (39) [back to overview]Median Change From Baseline in Individual FAPSI Scores at Week 24
NCT00385580 (39) [back to overview]Median Change From Baseline in Individual FAPSI Scores at Week 12
NCT00385580 (39) [back to overview]Mean Plasma Concentration at Dose 50 mg (Week 6)
NCT00385580 (39) [back to overview]Mean Plasma Concentration at 70 mg Dasatinib Dose (Week 6)
NCT00385580 (39) [back to overview]Mean Plasma Concentration at 70 mg Dasatinib Dose (Week 2)
NCT00385580 (39) [back to overview]Median Number of Months to Disease Progression
NCT00385580 (39) [back to overview]Median Number of Months of uNTx Response
NCT00385580 (39) [back to overview]Median Number of Months of BAP Response
NCT00385580 (39) [back to overview]Number of Participants With Positive Urinalysis
NCT00385580 (39) [back to overview]Number of Participants With Grade 3-4 Serum Chemistry Abnormalities in Creatinine, Potassium, Sodium and Phosphorous
NCT00385580 (39) [back to overview]Number of Participants With Grade 3-4 Serum Chemistry Abnormalities in Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Bilirubin and Calcium
NCT00385580 (39) [back to overview]Number of Participants With Grade 3-4 Hematology Abnormalities
NCT00385580 (39) [back to overview]Number of Participants With a Baseline uNTx Value >ULN, With a Decrease, Increase or no Change in uNTx
NCT00385580 (39) [back to overview]Number of Participants With a Baseline uNTx Value <=ULN, With a Decrease, Increase or no Change in uNTx
NCT00385580 (39) [back to overview]Number of Participants With a Response
NCT00385580 (39) [back to overview]Number of Participants With a Baseline BAP Value > ULN, With a Decrease, Increase or no Change in BAP
NCT00385580 (39) [back to overview]Mean Plasma Concentration at 50 mg Dasatinib Dose (Week 2)
NCT00385580 (39) [back to overview]Mean Plasma Concentration at 100 mg Dasatinib Dose (Week 6)
NCT00385580 (39) [back to overview]Mean Plasma Concentration at 100 mg Dasatinib Dose (Week 2)
NCT00385580 (39) [back to overview]Percentage of Participants With Confirmed Improved Bone Scan
NCT00385580 (39) [back to overview]Percentage of Participants With a Response
NCT00385580 (39) [back to overview]Percentage of Participants With a Decrease in PSA by at Least 50% From Baseline
NCT00385580 (39) [back to overview]Number of Participants With a Baseline BAP Value <= ULN, With a Decrease, Increase or no Change in BAP
NCT00385580 (39) [back to overview]Number of Participants With Increase in PSA Doubling Time
NCT00385580 (39) [back to overview]Number of Participants With Disease Progression
NCT00385580 (39) [back to overview]Number of Participants With Decrease in PSA Velocity
NCT00385580 (39) [back to overview]Number of Participants With Decrease in PSA Log Slope
NCT00385580 (39) [back to overview]Number of Participants With CR, PR or SD
NCT00385580 (39) [back to overview]Number of Participants With CR or PR
NCT00385580 (39) [back to overview]Number of Participants With BAP Response
NCT00385580 (39) [back to overview]Number of Participants With Abnormal Lactate Dehydrogenase (LD)
NCT00385580 (39) [back to overview]Number of Participants With a uNTx Response
NCT00385580 (39) [back to overview]Number of Participants With a Decrease in PSA by at Least 50% From Baseline
NCT00385580 (39) [back to overview]Number of Participants With a Confirmed Improved Bone Scan
NCT00385580 (39) [back to overview]Number of Months of Decrease in PSA by at Least 50% From Baseline
NCT00391989 (1) [back to overview]Rate of Hematological Complete Remission (HCR) Obtained During the BMS Induction Treatment Within Day +85 From the Start of BMS (i.e., Whenever Achieved From the Start of the Experimental Drug).
NCT00410813 (11) [back to overview]Change in Serum Bone Turnover Markers Over Time -- BAP
NCT00410813 (11) [back to overview]Change in Serum Bone Turnover Markers Over Time -- NTx
NCT00410813 (11) [back to overview]Change in Serum Bone Turnover Markers Over Time -- OC
NCT00410813 (11) [back to overview]Change in Serum Bone Turnover Markers Over Time -- OPG
NCT00410813 (11) [back to overview]Change in Serum Bone Turnover Markers Over Time -- TRAP
NCT00410813 (11) [back to overview]Circulating Tumor Cells (CTC) Response Rate
NCT00410813 (11) [back to overview]Mean Patient-reported Pain
NCT00410813 (11) [back to overview]Progression-free Survival
NCT00410813 (11) [back to overview]Change in Serum Bone Turnover Markers Over Time
NCT00410813 (11) [back to overview]Response Rate (Complete and Partial, Confirmed and Unconfirmed)
NCT00410813 (11) [back to overview]Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
NCT00423735 (7) [back to overview]Overall Survival
NCT00423735 (7) [back to overview]Treatment Response Rates at Six Months
NCT00423735 (7) [back to overview]Rate of Adverse Events
NCT00423735 (7) [back to overview]Correlation of Molecular Markers and Tumor Response
NCT00423735 (7) [back to overview]Progression-free Survival
NCT00423735 (7) [back to overview]Number of Patients Achieving Objective Response (Partial or Complete Response) OR 6-month Progression-free Survival (6mPFS)
NCT00423735 (7) [back to overview]Number of Patients Achieving 6-month Progression-free Survival (6mPFS)
NCT00429949 (6) [back to overview]Duration of Response
NCT00429949 (6) [back to overview]Event-free Survival (EFS) for Participants With Plateau Phase Disease
NCT00429949 (6) [back to overview]Event-free Survival (EFS) for Participants With Relapsed Disease
NCT00429949 (6) [back to overview]Time to Response
NCT00429949 (6) [back to overview]Response Rate [Complete Response (CR) and Partial Response (PR)]
NCT00429949 (6) [back to overview]Safety and Tolerability of Dasatinib (Grade III-IV Toxicities)
NCT00436605 (2) [back to overview]Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria
NCT00436605 (2) [back to overview]Progression-free Survival
NCT00438854 (4) [back to overview]Median Time to Disease Progression
NCT00438854 (4) [back to overview]Median Overall Survival
NCT00438854 (4) [back to overview]Complete Response Rate
NCT00438854 (4) [back to overview]Overall Objective Response
NCT00439270 (16) [back to overview]Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity (AUC[Inf]) of Docetaxel
NCT00439270 (16) [back to overview]Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs), Drug-related AEs Leading to Discontinuation, and Drug-related Grade 3 or 4 AEs in the Overall Population
NCT00439270 (16) [back to overview]Number of Months of Progression-free Survival (PFS)
NCT00439270 (16) [back to overview]Duration of Prostate Specific Antigen (PSA) Response
NCT00439270 (16) [back to overview]Maximum Tolerated Dose (MTD) of Dasatinib Administered With Docetaxel
NCT00439270 (16) [back to overview]Percentage of Participants With a Prostate Specific Antigen (PSA) Response
NCT00439270 (16) [back to overview]Percentage of Participants With an Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00439270 (16) [back to overview]Percentage of Participants With Improvement on Bone Scan
NCT00439270 (16) [back to overview]Recommended Phase 2 Dose of Dasatinib Administered With Docetaxel, 75 mg/m^2
NCT00439270 (16) [back to overview]Area Under the Concentration-time Curve (AUC) From 0 to 10 Hours Postdose (AUC [0-10])and AUC in 1 Dosing Interval, From Time 0 to 24 Hours (AUC[Tau])of Dasatinib Coadministered With Docetaxel
NCT00439270 (16) [back to overview]Baseline Scores and Changes in Pain Intensity From Baseline on the Brief Pain Inventory Short Form (BPI-sf) Scores Through Cycle 6
NCT00439270 (16) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Dasatinib and of Docetaxel
NCT00439270 (16) [back to overview]Number of Participants by Best On-study Bone Scan Assessment From Baseline
NCT00439270 (16) [back to overview]Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00439270 (16) [back to overview]Number of Participants Meeting the Criteria for On-study Abnormal Results Grade 3-4 of Clinical Laboratory Tests
NCT00439270 (16) [back to overview]Number of Participants With Death as Outcome, Drug-related Serious Adverse Events (SAEs), Drug-related Adverse Events (AEs), Drug-related AEs Leading to Discontinuation, and Drug-related Grade 3 or 4 AEs in the Phase 2 Cohort
NCT00452673 (6) [back to overview]Objective Response Rate (ORR) and Disease Control Rate - Efficacy Evaluable Population
NCT00452673 (6) [back to overview]Number of Participants On-Study With Grade 3 - 4 Hematology Laboratory Test Values in Those Participants With a Baseline Laboratory Value of Grade 0 - Safety Population
NCT00452673 (6) [back to overview]Number of Participants With Overall Response to Tumor - Efficacy Evaluable Population
NCT00452673 (6) [back to overview]Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population
NCT00452673 (6) [back to overview]Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population
NCT00452673 (6) [back to overview]Number of Participants On-study With Grade 3 - 4 Chemistry Laboratory Values in Those Participants With a Baseline Laboratory Value of Grade 0 - Safety Population
NCT00459108 (5) [back to overview]Overall Survival
NCT00459108 (5) [back to overview]Response Rate (Complete and Partial Response)
NCT00459108 (5) [back to overview]Median Progression-free Survival
NCT00459108 (5) [back to overview]Four Month Progression-free Survival (PFS)
NCT00459108 (5) [back to overview]Safety and Tolerability
NCT00459342 (6) [back to overview]Phospho-Src (pSrc) Expression
NCT00459342 (6) [back to overview]Epidermal Growth Factor Receptor (EGFR) Copy Number
NCT00459342 (6) [back to overview]Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR))
NCT00459342 (6) [back to overview]Epidermal Growth Factor Receptor (EGFR) Mutational Status
NCT00459342 (6) [back to overview]Time to Progression (TTP)
NCT00459342 (6) [back to overview]Progression-free Survival (PFS)
NCT00464620 (11) [back to overview]Number of Participants With Tumors With Kinase Expression
NCT00464620 (11) [back to overview]"Median Time-to-progression of Subjects With Indolent Sarcomas Treated With Dasatinib."
NCT00464620 (11) [back to overview]Number of Participants With Tumors With Mutations in Kinases
NCT00464620 (11) [back to overview]Response Rate: Number of Participants With Objective Tumor Response
NCT00464620 (11) [back to overview]Median Time-to-progression of Subjects Enrolled in the Aggressive Subtype.
NCT00464620 (11) [back to overview]6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST)
NCT00464620 (11) [back to overview]"6 Month Progression-free Survival Rate of Indolent Sarcomas Treated With Dasatinib"
NCT00464620 (11) [back to overview]Median Time-to-progression of Subjects With GIST Treated With Dasatinib.
NCT00464620 (11) [back to overview]6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype.
NCT00464620 (11) [back to overview]Overall Survival Rates at 2 and 5 Years From Registration of Subjects Enrolled in the Aggressive Subtype Treated With Dasatinib.
NCT00464620 (11) [back to overview]Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib.
NCT00470054 (5) [back to overview]Overall Survival
NCT00470054 (5) [back to overview]Number of Participants With Grade 3 or Higher Adverse Events
NCT00470054 (5) [back to overview]Progression Free Survival (PFS)
NCT00470054 (5) [back to overview]6 Week Progression Free Survival
NCT00470054 (5) [back to overview]Response to Therapy
NCT00474812 (5) [back to overview]Gait Speed
NCT00474812 (5) [back to overview]Objective Response Rate (Complete Response, Partial Response, or Stable Disease), Evaluated Using the New International Criteria Proposed by the RECIST Committee
NCT00474812 (5) [back to overview]Median Progression Free Survival (PFS)
NCT00474812 (5) [back to overview]Gait Speed
NCT00474812 (5) [back to overview]Median Overall Survival
NCT00481247 (9) [back to overview]Percentage of Participants With Overall Survival (OS)
NCT00481247 (9) [back to overview]Percentage of Participants With Progression-free Survival (PFS)
NCT00481247 (9) [back to overview]Time to Confirmed Complete Cytogenic Response (cCCyR) Overall
NCT00481247 (9) [back to overview]Time to Major Molecular Response (MMR) Overall
NCT00481247 (9) [back to overview]Number of Participants With Adverse Events (AEs), Drug-related AEs, Drug-related Serious Adverse Events (SAEs), Drug-related AEs Leading to Discontinuation, and All Deaths
NCT00481247 (9) [back to overview]Number of Participants With Grade 3/4 Abnormalities in On-study Laboratory Test Results
NCT00481247 (9) [back to overview]Percentage of Participants Remaining in Confirmed Complete Cytogenetic Response (cCCyR)
NCT00481247 (9) [back to overview]Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months
NCT00481247 (9) [back to overview]Percentage of Participants With Major Molecular Response (MMR) at Any Time
NCT00482703 (12) [back to overview]Time to Major Cytogenetic Response (MCyR)
NCT00482703 (12) [back to overview]Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment
NCT00482703 (12) [back to overview]Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at End of Study
NCT00482703 (12) [back to overview]Time to CHR
NCT00482703 (12) [back to overview]Number of Participants With Major Cytogenetic Response at Months 0 - 24 (Duration of MCyR Life Table)
NCT00482703 (12) [back to overview]Expression of BCR-ABL Gene Mutations of RNA (mRNA)
NCT00482703 (12) [back to overview]Mutational Spectrum of BCR-ABL
NCT00482703 (12) [back to overview]Number of Participants With CHR at Months 0 - 24 (Duration of MCyR Life Table)
NCT00482703 (12) [back to overview]Complete Hematologic Response (CHR) in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24
NCT00482703 (12) [back to overview]Number of Participants With Progression-Free Survival (PFS) at Months 0 - 24 (PFS Life Table)
NCT00482703 (12) [back to overview]Hematologic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at End of Study
NCT00482703 (12) [back to overview]Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24
NCT00504153 (2) [back to overview]Progression-free Survival Rate
NCT00504153 (2) [back to overview]Response Rate (RR) (Complete or Partial Responders)
NCT00507767 (1) [back to overview]Number of Participants With Progression-free Survival at 12-weeks
NCT00509041 (4) [back to overview]Number of Participants With Overall Tumor Response
NCT00509041 (4) [back to overview]Progression Free Survival
NCT00509041 (4) [back to overview]Overall Survival
NCT00509041 (4) [back to overview]24 Week Progression Free Survival
NCT00529763 (17) [back to overview]Mean Oral Clearance (CLo) of Dasatinib Following 70 mg BID and 100 QD Dose Administration
NCT00529763 (17) [back to overview]Duration of Major Cytogenetic Response (MCyR) in Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants
NCT00529763 (17) [back to overview]Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), and Drug-related Fluid Retention AEs of Special Interest
NCT00529763 (17) [back to overview]Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Major Cytogenetic Response (MCyR)
NCT00529763 (17) [back to overview]Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Complete Hematologic Response (CHR)
NCT00529763 (17) [back to overview]Mean Dasatinib Plasma Concentrations
NCT00529763 (17) [back to overview]Percentage of Participants With Complete, Major, and Overall Hematologic Response (CHR, MaHR, & OHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Blast Phase CML/Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
NCT00529763 (17) [back to overview]Time to Complete and Major Hematologic Response (CHR and MaHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Participants (Ph+ ALL)
NCT00529763 (17) [back to overview]Progression-free Survival Among CP CML Participants
NCT00529763 (17) [back to overview]Time to Major Cytogenetic Response (MCyR) in Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants
NCT00529763 (17) [back to overview]Progression-free Survival Among AD CML and Ph+ ALL Participants
NCT00529763 (17) [back to overview]Duration of CHR Among AD CML and Ph+ ALL Participants
NCT00529763 (17) [back to overview]Duration of MaHR Among AD CML and Ph+ ALL Participants
NCT00529763 (17) [back to overview]Mean Maximum Concentration (Cmax) of Dasatinib Following 70 mg BID and 100 QD Dose Administration
NCT00529763 (17) [back to overview]Mean Apparent Volume of Distribution (Vz/F) of Dasatinib Following 70 mg BID and 100 QD Dose Administration
NCT00529763 (17) [back to overview]Mean (Tmax) and (T-Half) of Dasatinib Following 70 mg BID and 100 QD Dose Administration
NCT00529763 (17) [back to overview]Mean (AUC[0-T]), (AUC[INF]), and (AUC[TAU])of Dasatinib Following 70 mg BID and 100 QD Dose Administration
NCT00544908 (2) [back to overview]Progression-free Survival (PFS) Rate at 4 Months
NCT00544908 (2) [back to overview]Response Rate
NCT00546104 (5) [back to overview]To Measure Response to Protocol Therapy Per RECIST Criteria
NCT00546104 (5) [back to overview]Characterization and Comparison of SRC (A Protein Tyrosine Kinase)Dysregulation at Baseline (All Patients), After 4 Weeks of Dasatinib Treatment (All Patients), and at Progression (Only Patients Who Progress After Documented Response)
NCT00546104 (5) [back to overview]Estimation of the Proportion of Progression-free Patients at 16 Wks.
NCT00546104 (5) [back to overview]To Explore the Association Between Each Patient's SRC Signature and Their Time to Progression.
NCT00546104 (5) [back to overview]Correlate SRC Dysregulation Results With Response to Dasatinib Therapy
NCT00549848 (6) [back to overview]Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5%
NCT00549848 (6) [back to overview]Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase.
NCT00549848 (6) [back to overview]Probability of CNS Relapse
NCT00549848 (6) [back to overview]Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01%
NCT00549848 (6) [back to overview]Probability of Overall Survival
NCT00549848 (6) [back to overview]Probability of Event-free Survival
NCT00550615 (2) [back to overview]Number of Participants With Clinical Response Rates
NCT00550615 (2) [back to overview]Maximum Tolerated Dose
NCT00560352 (6) [back to overview]Progression-free Survival
NCT00560352 (6) [back to overview]Duration of Response
NCT00560352 (6) [back to overview]Maximum Tolerated Dose (MTD) and Recommended MTD of Dasatinib in Combination With Bortezomib and Dexamethasone
NCT00560352 (6) [back to overview]MTD and Recommended MTD of Bortezomib in Combination With Dasatinib and Dexamethasone
NCT00560352 (6) [back to overview]Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs) Leading to Discontinuation, AEs Leading to Discontinuation, AEs, and Drug-related AEs by Grade
NCT00560352 (6) [back to overview]Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry
NCT00560391 (10) [back to overview]Recommended Phase II Dose (RP2D) of the Combination (Dasatinib + Lenalidomide + Dexamethasone)
NCT00560391 (10) [back to overview]Number of Participants With Serum Chemistry Abnormalities (Worst On-study Grade vs Baseline): High Calcium, Low Calcium, Low Magnesium, and Low Phosphorus
NCT00560391 (10) [back to overview]Number of Participants With Hematology Abnormalities (Worst On-study Grade vs Baseline): Leukopenia, Neutropenia, Thrombocytopenia, and Anemia
NCT00560391 (10) [back to overview]Number of Participants With Complete Response and Very Good Partial Response
NCT00560391 (10) [back to overview]Number of Participants Who Died, Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation
NCT00560391 (10) [back to overview]Number of Participants With Minimal Response
NCT00560391 (10) [back to overview]Number of Participants With Partial Response
NCT00560391 (10) [back to overview]Number of Participants With Dose-limiting Toxicity (DLT)
NCT00560391 (10) [back to overview]Number of Participants in the Dose Escalation Phase Who Reached Maximum Tolerated Dose (MTD) of Dasatinib With Lenalidomide and Dexamethasone
NCT00560391 (10) [back to overview]Number of Participants With Serum Chemistry Abnormalities (Worst On-study Grade vs Baseline): Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Total Bilirubin (TB), and Serum Creatinine (SC)
NCT00563290 (2) [back to overview]Progression-free Survival
NCT00563290 (2) [back to overview]Objective Response Rate (Complete Response and Partial Response)
NCT00566618 (2) [back to overview]Phase I - Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) for Dasatinib in Combination With Zoledronic Acid
NCT00566618 (2) [back to overview]Objective Response in Bone From Time of Initiation of Therapy to > 6 Months
NCT00570401 (1) [back to overview]Determine the Overall Objective Response
NCT00570700 (2) [back to overview]Number of Subjects With Dasatinib Toxicity Using Common Terminology Criteria (CTC) (v. 3.0)
NCT00570700 (2) [back to overview]Number of Subjects With Disease Control (DC) (Based on PSA, Bone Scan, FACT-P, RECIST)
NCT00597038 (4) [back to overview]Recommended Phase II Dose
NCT00597038 (4) [back to overview]Number of Participants With 12 Month Overall Survival (OS)
NCT00597038 (4) [back to overview]Number of Participants With Progression Free Survival (PFS) at 6 Months
NCT00597038 (4) [back to overview]Phase II - Number of Participants With Overall Response (OR)
NCT00624585 (4) [back to overview]Number of Participants With Stable Disease (SD)
NCT00624585 (4) [back to overview]Number of Participants With Hematologic Improvement
NCT00624585 (4) [back to overview]Number of Participants With Marrow Complete Remission (CR)
NCT00624585 (4) [back to overview]Number of Participants With Partial Remission (PR)
NCT00655746 (6) [back to overview]Dasatinib PK Parameter: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-T])
NCT00655746 (6) [back to overview]Dasatinib PK Parameter: Plasma Half-Life (T-HALF)
NCT00655746 (6) [back to overview]Dasatinib PK Parameters: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF])
NCT00655746 (6) [back to overview]Dasatinib PK Parameter Time of Maximum Observed Plasma Concentration(Tmax)
NCT00655746 (6) [back to overview]Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations
NCT00655746 (6) [back to overview]Dasatinib Pharmacokinetic (PK) Parameter: Maximum Observed Plasma Concentration (Cmax)
NCT00671788 (4) [back to overview]Overall Survival
NCT00671788 (4) [back to overview]Progression-free Survival
NCT00671788 (4) [back to overview]Progression-free Survival at 6 Months
NCT00671788 (4) [back to overview]Tumor Response
NCT00696072 (7) [back to overview]Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population
NCT00696072 (7) [back to overview]Number of Participants With Adverse Events (AEs) Leading to Discontinuation, Serious Adverse Events (SAEs), and Deaths
NCT00696072 (7) [back to overview]Percentage of Participants With PFS At 6 Months and At 12 Months - ITT Population
NCT00696072 (7) [back to overview]Median Progression Free Survival (PFS) - Intent to Treat (ITT) Population
NCT00696072 (7) [back to overview]Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression
NCT00696072 (7) [back to overview]Percentage of Participants Best Overall Response After Change From Letrozole to Letrozole Plus Dasatinib
NCT00696072 (7) [back to overview]Median Time to Treatment Failure (TTF) - ITT Population
NCT00700882 (3) [back to overview]Progression-free Survival
NCT00700882 (3) [back to overview]Objective Response Rate Among KIT-positive Patients
NCT00700882 (3) [back to overview]Duration of Response for Dasatinib Monotherapy in This Patient Population
NCT00706641 (7) [back to overview]Reduced Ki-67 Expression
NCT00706641 (7) [back to overview]Pathologic Complete Response (pCR) Rate
NCT00706641 (7) [back to overview]Increase in Cas3 Expression
NCT00706641 (7) [back to overview]Feasibility
NCT00706641 (7) [back to overview]Grade 3/4 Toxicities
NCT00706641 (7) [back to overview]Post-Cystectomy Pathologic Stage
NCT00706641 (7) [back to overview]Reduced pSFK Expression
NCT00720109 (5) [back to overview]Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
NCT00720109 (5) [back to overview]Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
NCT00720109 (5) [back to overview]Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
NCT00720109 (5) [back to overview]Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
NCT00720109 (5) [back to overview]Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
NCT00744497 (15) [back to overview]Overall Survival: Time From Randomization to Date of Death
NCT00744497 (15) [back to overview]Number of Participants With Serious Adverse Event (SAEs), Drug-related SAEs, Drug-related AEs, Drug-related AEs Leading to Discontinuation, and All Deaths
NCT00744497 (15) [back to overview]Number of Participants With Drug-Related Adverse Events (AEs) of Special Interest
NCT00744497 (15) [back to overview]Number of Participants With Changes From Baseline in Fridericia-corrected QTc Interval
NCT00744497 (15) [back to overview]Number of Participants With and Without Pericardial Effusion at Baseline and On-study and With Left Ventricular Ejection Fraction (LVEF) <40% and >=40% On-study
NCT00744497 (15) [back to overview]Number of Participants With Abnormalities in Results of Clinical Laboratory Tests in Hematology
NCT00744497 (15) [back to overview]Number of Participants With Abnormalities in Results of Clinical Laboratory Tests Assessing Liver Function, Renal Function, and Electrolytes
NCT00744497 (15) [back to overview]Percentage of Participants With a Reduction in Pain Intensity From Baseline
NCT00744497 (15) [back to overview]Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00744497 (15) [back to overview]Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline
NCT00744497 (15) [back to overview]Progression-free Survival (PFS)
NCT00744497 (15) [back to overview]Time to First Skeletal-related Event (SRE)
NCT00744497 (15) [back to overview]Time to Prostate Specific Antigen (PSA) Progression
NCT00744497 (15) [back to overview]Number of Participants by Maximal On-study Fridericia-corrected QTc Interval
NCT00744497 (15) [back to overview]Number of Participants With Abnormal Results in Urinalysis
NCT00754325 (7) [back to overview]Median Time of Progression-free Survival (PFS)
NCT00754325 (7) [back to overview]Percentage of Participants With Clinical Benefit for At Least 6 Months
NCT00754325 (7) [back to overview]Number of Participants With Disease Progression (PD) or Death
NCT00754325 (7) [back to overview]Number of Participants With Best Overall Response
NCT00754325 (7) [back to overview]Number of Participants With Serious Adverse Events, Death, and Discontinuation Due to Adverse Events
NCT00754325 (7) [back to overview]Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD)
NCT00754325 (7) [back to overview]Percentage of Participants With Progression Free Survival (PFS) at 6 Months
NCT00764309 (4) [back to overview]Reasons for Discontinuation of Study Treatment
NCT00764309 (4) [back to overview]Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), or Adverse Events (AEs)
NCT00764309 (4) [back to overview]Laboratory Test Results Summary of Toxicity: Hematology
NCT00764309 (4) [back to overview]Laboratory Test Results Summary of Toxicity: Blood Chemistry Per (NCI-CTCAE) Version 3.0 Grade (GR)
NCT00767520 (9) [back to overview]Participants With Disease Progression or Death for Exemestane Plus Dasatinib vs Exemestane Plus Placebo
NCT00767520 (9) [back to overview]Percentage of Participants With Clinical Benefit (CB) for Exemestane Plus Dasatinib Arm vs Exemestane Plus Placebo Arm at 6 Months
NCT00767520 (9) [back to overview]Number of Participants With Grade 1-4 Serum Chemistry Abnormalities in Potassium, Magnesium, Sodium, Phosphorous, Uric Acid, and Bicarbonate (as Per the NCI CTCAE, Version 3.0)
NCT00767520 (9) [back to overview]Percentage of Participants With Response in Exemestane Plus Dasatinib Arm and Exemestane Plus Placebo Arms
NCT00767520 (9) [back to overview]Progression Free Survival (PFS) Distribution for Exemestane Plus Dasatinib vs Exemestane Plus Placebo
NCT00767520 (9) [back to overview]Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AEs (as Per National Cancer Institute [NCI] Common Toxicity Criteria for Adverse Events [CTCAE], Version 3.0)
NCT00767520 (9) [back to overview]Number of Participants With Grade 1-4 Hematology Abnormalities (as Per the NCI CTCAE, Version 3.0)
NCT00767520 (9) [back to overview]Number of Participants With Best Overall Response
NCT00767520 (9) [back to overview]Number of Participants With Grade 1-4 Serum Chemistry Abnormalities in Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Bilirubin, Calcium, Creatinine, and Albumin (as Per the NCI CTCAE, Version 3.0)
NCT00777036 (21) [back to overview]Complete Hematologic Response (CHR) Rate in Cohorts 1 and 3
NCT00777036 (21) [back to overview]Complete Hematologic Response (CHR) Rate
NCT00777036 (21) [back to overview]Complete Cytogenetic Response (CCyR) Rate
NCT00777036 (21) [back to overview]Rate of Best Cytogenetic Response
NCT00777036 (21) [back to overview]Major Molecular Response (MMR) Rate up to 2 Years
NCT00777036 (21) [back to overview]Major Cytogenetic Response (MCyR) Rate up to 2 Years
NCT00777036 (21) [back to overview]Complete Molecular Response (CMR) Rate up to 2 Years
NCT00777036 (21) [back to overview]Complete Cytogenetic Response (CCyR) Rate up to 2 Years
NCT00777036 (21) [back to overview]Time to Major Cytogenetic Response (MCyR)
NCT00777036 (21) [back to overview]Time to Complete Hematologic Response (CHR)
NCT00777036 (21) [back to overview]Time to Complete Cytogenetic Response (CCyR)
NCT00777036 (21) [back to overview]Progression-Free Survival (PFS) Rate at 2 Years
NCT00777036 (21) [back to overview]Overall Survival (OS) Rate at 2 Years
NCT00777036 (21) [back to overview]Major Molecular Response (MMR) Rate
NCT00777036 (21) [back to overview]Major Cytogenetic Response (MCyR) Rate in Cohort 2
NCT00777036 (21) [back to overview]Major Cytogenetic Response (MCyR) Rate
NCT00777036 (21) [back to overview]Duration of Major Cytogenetic Response (MCyR)
NCT00777036 (21) [back to overview]Duration of Complete Hemotologic Response (CHR)
NCT00777036 (21) [back to overview]Duration of Complete Cytogenetic Response (CCyR)
NCT00777036 (21) [back to overview]Disease-Free Survival Rate at 2 Years
NCT00777036 (21) [back to overview]Complete Molecular Response (CMR) Rate
NCT00780676 (1) [back to overview]Clinical Benefit (CB) Rate (CB = Participants With Objective Tumor Response or Stable Disease > 6 Months)
NCT00787267 (3) [back to overview]Overall Survival
NCT00787267 (3) [back to overview]Tumor Response
NCT00787267 (3) [back to overview]Grade 3-5 Toxicity Associated With Dasatinib Treatment
NCT00787852 (1) [back to overview]Number of Patients Who Came Off Study for Toxicity Using CTC Version 3.0
NCT00788125 (1) [back to overview]Maximum Administered Dose of Dasatinib (Phase I)
NCT00792948 (3) [back to overview]Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation
NCT00792948 (3) [back to overview]Overall Survival (OS)
NCT00792948 (3) [back to overview]Continuous Complete Remission (CCR) Rate
NCT00817531 (1) [back to overview]Clinical Efficacy
NCT00820170 (5) [back to overview]Median Overall Survival for Phase II Participants
NCT00820170 (5) [back to overview]Median Progression Free Survival for Phase II Participants
NCT00820170 (5) [back to overview]Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel.
NCT00820170 (5) [back to overview]Participant Adverse Events to Measure Safety and Tolerability of Dasatinib When Administered in Combination With Weekly Paclitaxel.
NCT00820170 (5) [back to overview]Median Time To Progression for Phase II Participants
NCT00826449 (3) [back to overview]Phase I: Maximum Tolerable Dose (MTD) of Dasatinib Given With Erlotinib Hydrochloride
NCT00826449 (3) [back to overview]Phase II: Progression-Free Survival (PFS) Rate
NCT00826449 (3) [back to overview]Phase II: Number of Participant With Response According to Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00858403 (2) [back to overview]Number of Participants With Serious Adverse Events (SAEs)
NCT00858403 (2) [back to overview]Number of Participants With Progression Free Survival (PFS) at 6 Months
NCT00859937 (3) [back to overview]Overall Survival
NCT00859937 (3) [back to overview]Progression-free Survival
NCT00859937 (3) [back to overview]Response Rate
NCT00869401 (4) [back to overview]The Number of Dose Limiting Toxicities(DLT) in Order to Determine Maximum Tolerable Dose(MTD) of Dasatinib Combined With Radiation and Temozolomide in This Patient Population.
NCT00869401 (4) [back to overview]Overall Survival
NCT00869401 (4) [back to overview]Progression-free Survival
NCT00869401 (4) [back to overview]Objective Response
NCT00882583 (1) [back to overview]MTD of Daily Oral Dasatinib in Combination With Cetuximab/RT in Cohort A and Daily Oral Dasatinib in Combination With Cetuximab/Cis or Carboplatin/RT in Cohort B 2. MTD of Daily Oral Dasatinib in Combination With Cisplatin/Cetuximab/RT in Cohort B
NCT00892177 (7) [back to overview]Objective Response (Phase II)
NCT00892177 (7) [back to overview]Time-to-disease Progression (Phase II)
NCT00892177 (7) [back to overview]Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I)
NCT00892177 (7) [back to overview]Overall Survival (Phase II)
NCT00892177 (7) [back to overview]Number of Participants With Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 (Phase II)
NCT00892177 (7) [back to overview]Progression-free Survival at 6 Months (PFS6) (Phase II)
NCT00892177 (7) [back to overview]Patient-reported QOL, as Measure by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) (Phase II)
NCT00918385 (3) [back to overview]Overall Response Rate of Men With High AR Activity
NCT00918385 (3) [back to overview]Overall Response Rate of Men With Low AR Activity
NCT00918385 (3) [back to overview]Progression Free Survival (PFS)
NCT00924352 (8) [back to overview]Incidence of Grade 4 Adverse Events (AEs) With the Combination of Dasatinib and Ixabepilone (Phase II)
NCT00924352 (8) [back to overview]Incidence of Grade 3 Adverse Events (AEs) With the Combination of Dasatinib and Ixabepilone (Phase II)
NCT00924352 (8) [back to overview]Best Overall Response of the Combination of Dasatinib and Ixabepilone (Phase II)
NCT00924352 (8) [back to overview]Determination of the Dose Limiting Toxicities (DLTs) of the Combination of Dasatinib and Ixabepilone (Phase I)
NCT00924352 (8) [back to overview]Clinical Benefit Rate of the Combination of Dasatinib and Ixabepilone (Phase II)
NCT00924352 (8) [back to overview]Determination of the Maximum Tolerated Dose (MTD) of Dasatinib When Given in Combination With Ixabepilone (Phase I)
NCT00924352 (8) [back to overview]Determination of the Maximum Tolerated Dose (MTD) of Ixabepilone When Given in Combination With Dasatinib (Phase I)
NCT00924352 (8) [back to overview]Evaluation of Progression-free Survival (PFS) of the Combination of Dasatinib and Ixabepilone (Phase II)
NCT00948389 (6) [back to overview]Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs
NCT00948389 (6) [back to overview]Number of Participants With Dose-limiting Toxicities (DLTs)
NCT00948389 (6) [back to overview]Deaths Within 30 Days of Protocol Treatment Discontinuation
NCT00948389 (6) [back to overview]Number of Participants With Worst Grade of Biochemistry Abnormality Per NCI CTCAE Version 3.0 Criteria
NCT00948389 (6) [back to overview]Number of Participants With Worst Grade of Hematological Toxicity Per NCI CTCAE Version 3.0 Criteria
NCT00948389 (6) [back to overview]Number of Participants With Disease Progression at 12 Months
NCT00978731 (12) [back to overview]Number of Participants With Grade 3-4 Hematology Abnormalities
NCT00978731 (12) [back to overview]Number of Participants With Dose Interruptions and Dose Reductions
NCT00978731 (12) [back to overview]Number of Participants With Best Cytogenetic Response
NCT00978731 (12) [back to overview]Number of Participants With Major Cytogenetic Response (MCyR)
NCT00978731 (12) [back to overview]Median Number of Months of Progression-free Survival (PFS) (Kaplan Meier Method)
NCT00978731 (12) [back to overview]Number of Participants With Grade 3-4 Serum Chemistry Abnormalities
NCT00978731 (12) [back to overview]Median Number of Months of CHR (Kaplan Meier Method)
NCT00978731 (12) [back to overview]Median Number of Months of Overall Survival (OS) (Kaplan Meier Method)
NCT00978731 (12) [back to overview]Number of Participants With Complete Hematologic Response (CHR)
NCT00978731 (12) [back to overview]Median Number of Months of Major Cytogenetic Response (MCyR)
NCT00978731 (12) [back to overview]Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation.
NCT00978731 (12) [back to overview]Number of Participants Who Experienced Drug-related AEs and Drug-related SAEs.
NCT00982488 (1) [back to overview]Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related AEs of Special Interest
NCT01030718 (21) [back to overview]Participants With Detectable Mutations of RNA (mRNA) of BCR-ABL at Baseline and at Best Achievement
NCT01030718 (21) [back to overview]Participants With CML-AP/BP: Percentage of Participants With Hematologic Response
NCT01030718 (21) [back to overview]Participants With CML-Accelerated or Blast Phase (AP/BP): Percentage of Participants With Cytogenetic Response
NCT01030718 (21) [back to overview]Participants With Chronic Phase CML (CML-CP): Percentage of Participants With Cytogenetic Response
NCT01030718 (21) [back to overview]Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation
NCT01030718 (21) [back to overview]Participants With CML-AP/BP and Ph+ALL: Duration of Complete Cytogenetic Response (CCyR)
NCT01030718 (21) [back to overview]Duration of Complete Hematologic Response (CHR) in Chronic Phase CML, Accelerated or Blast Phase CML, and Ph+ALL
NCT01030718 (21) [back to overview]Duration of Major Hematologic Response (MaHR) in Accelerated or Blast Phase CML, and Ph+ALL
NCT01030718 (21) [back to overview]Duration of Overall Hematologic Response (OHR) in Accelerated or Blast Phase CML, and Ph+ALL
NCT01030718 (21) [back to overview]Time to Complete Hematologic Response (CHR) in Chronic Phase CML, Accelerated or Blast Phase CML, and Ph+ALL
NCT01030718 (21) [back to overview]Time to Overall Hematologic Response (OHR) in Accelerated or Blast Phase CML, and Ph+ALL
NCT01030718 (21) [back to overview]Status of Point Mutations of BCR-ABL at Baseline (BL) and End of Study (EOS)
NCT01030718 (21) [back to overview]Participants With CML-CP: Time to Complete Cytogenetic Response (CCyR)
NCT01030718 (21) [back to overview]Time to Major Hematologic Response (MaHR) in Accelerated or Blast Phase CML, and Ph+ALL
NCT01030718 (21) [back to overview]Participants With CML-CP: Percentage of Participants With Complete Hematologic Response (CHR)
NCT01030718 (21) [back to overview]Participants With CML-AP/BP and Ph+ALL: Time to Major Cytogenetic Response (MCyR)
NCT01030718 (21) [back to overview]Participants With CML-AP/BP and Ph+ ALL: Time to Complete Cytogenetic Response (CCyR)
NCT01030718 (21) [back to overview]Participants With CML-AP/BP and Ph+ ALL: Duration of Major Cytogenetic Response (MCyR)
NCT01030718 (21) [back to overview]Participants With Ph+ ALL: Percentage of Participants With Hematologic Response
NCT01030718 (21) [back to overview]Participants With Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL): Percentage of Participants With Cytogenetic Response
NCT01030718 (21) [back to overview]Participants With CML-CP: Time to Major Cytogenetic Response (MCyR)
NCT01092728 (2) [back to overview]Progression-Free Survival
NCT01092728 (2) [back to overview]Biologic Response Evaluation of Tumors With and Without Resectable Tumors
NCT01173679 (2) [back to overview]Progression-Free and Overall Survival
NCT01173679 (2) [back to overview]Toxicities
NCT01218477 (5) [back to overview]Percentage of Participants With a Major Hematologic Response (MHR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP)
NCT01218477 (5) [back to overview]Recommended Phase 2 Dose (RP2D) of BMS-833923 Plus Dasatinib in Chronic Myeloid Leukemia-Chronic Phase
NCT01218477 (5) [back to overview]Percentage of Participants With a Major Cytogenetic Response (MCyR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP)
NCT01218477 (5) [back to overview]Number of Participants With Grade 3-4 Abnormalities on Laboratory Test Results
NCT01218477 (5) [back to overview]Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities
NCT01238211 (7) [back to overview]30 Day Survival Rate
NCT01238211 (7) [back to overview]Complete Response Rate
NCT01238211 (7) [back to overview]Cumulative Incidence of Death
NCT01238211 (7) [back to overview]Disease-free Survival
NCT01238211 (7) [back to overview]Event-free Survival
NCT01238211 (7) [back to overview]Overall Survival
NCT01238211 (7) [back to overview]Cumulative Incidence of Relapse
NCT01256398 (6) [back to overview]Response
NCT01256398 (6) [back to overview]Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.
NCT01256398 (6) [back to overview]Overall Survival (OS)
NCT01256398 (6) [back to overview]Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)
NCT01256398 (6) [back to overview]Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause
NCT01256398 (6) [back to overview]Disease Free Survival (DFS)
NCT01260688 (15) [back to overview]Dose Reductions
NCT01260688 (15) [back to overview]Overall Response Rate
NCT01260688 (15) [back to overview]Dose Interruption Due to AEs
NCT01260688 (15) [back to overview]12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2)
NCT01260688 (15) [back to overview]Number Who Experienced Study Medication Dose Intensity
NCT01260688 (15) [back to overview]Number of Participants With Toxicities
NCT01260688 (15) [back to overview]Number of Participants With Increased Alkaline Phosphatase BAP
NCT01260688 (15) [back to overview]Qualtiy of Life Assessment Number of Participants With a Score ≥2 on the Present Pain Intensity (PPI) Scale
NCT01260688 (15) [back to overview]Quality of Life Assessment Using Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire
NCT01260688 (15) [back to overview]Overall Response Rate
NCT01260688 (15) [back to overview]Non-AE Related Treatment Discontinuation
NCT01260688 (15) [back to overview]Treatment Related Deaths
NCT01260688 (15) [back to overview]Treatment Discontinuation Due to Adverse Events (AEs)
NCT01260688 (15) [back to overview]Treatment Discontinuation
NCT01260688 (15) [back to overview]Participants for Which Bone Biomarkers for Beta-C Telopeptide Was Reduced
NCT01306942 (20) [back to overview]Phosphorylation Status of Phosphorylated SRC (p-SRC) in Skin After Treatment (Phase II)
NCT01306942 (20) [back to overview]Phosphorylation Status of Phosphorylated SRC (p-SRC) in Skin After Treatment (Phase I)
NCT01306942 (20) [back to overview]Phosphorylation Status of Phosphorylated ERK (p-ERK) in Skin After Treatment (Phase II)
NCT01306942 (20) [back to overview]Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Trastuzumab and Paclitaxel (Phase I)
NCT01306942 (20) [back to overview]Number of Participants With Correlation Between Lymphocytosis and Efficacy.
NCT01306942 (20) [back to overview]Number of Participants With Dose Limiting Toxicity (DLT) Within the First Cycle of Dasatinib in Combination With Trastuzumab and Paclitaxel (Phase I)
NCT01306942 (20) [back to overview]Objective Response Rate (ORR)
NCT01306942 (20) [back to overview]Phosphorylated AKT (p-AKT) Protein Expression Change in Peripheral Blood Mononuclear Cells After 8 Hours of Treatment (Phase II)
NCT01306942 (20) [back to overview]Phosphorylation Status of Phosphorylated ERK (p-ERK) in Skin After Treatment (Phase I)
NCT01306942 (20) [back to overview]Phosphorylation Status of Phosphorylated AKT (p-AKT) in Skin After Treatment (Phase II)
NCT01306942 (20) [back to overview]Phosphorylation Status of Phosphorylated AKT (p-AKT) in Skin After Treatment (Phase I)
NCT01306942 (20) [back to overview]Dasatinib Maximun Plasma Concentration (Cmax) Value (Pharmacokinetics (PK) Phase I)
NCT01306942 (20) [back to overview]Dasatinib Area Under the Plasma Concentration-time Curve (AUC) Value (Pharmacokinetics (PK) Phase I)
NCT01306942 (20) [back to overview]Phosphorylated SRC (p-SRC) Protein Expression Change in Peripheral Blood Mononuclear Cells After 8 Hours of Treatment (Phase II)
NCT01306942 (20) [back to overview]To Evaluate the Clinical Benefit Rate (CBR)
NCT01306942 (20) [back to overview]The Number of Participants Who Experienced Adverse Events (AE)
NCT01306942 (20) [back to overview]Response Duration (RD)
NCT01306942 (20) [back to overview]Progression Free Survival (PFS)
NCT01306942 (20) [back to overview]Recommended Phase II Dose (RP2D) of Dasatinib in Combination With Trastuzumab and Paclitaxel (Phase I).
NCT01306942 (20) [back to overview]Time to Progression (TTP)
NCT01357655 (2) [back to overview]Number of Participants With Major Molecular Response
NCT01357655 (2) [back to overview]Number of Participants Experiencing Serious Adverse Events (SAE), Drug-Related Adverse Event (AE), AE Leading to Discontinuation, and Death
NCT01392703 (8) [back to overview]Time of Maximum Observed Plasma Concentration (Tmax) of Dasatinib
NCT01392703 (8) [back to overview]Number of Participants With at Least 1 Adverse Event (AE), With at Least 1 Treatment-related AE, Who Discontinued Due to AEs, and With at Least 1 Serious Adverse Event (SAE)
NCT01392703 (8) [back to overview]Maximum Observed Concentration (Cmax) of Dasatinib
NCT01392703 (8) [back to overview]Half-life of Dasatinib
NCT01392703 (8) [back to overview]Area Under the Plasma Concentration-time Curve From Zero to the Last Time of the Last Quantifiable Concentration (AUC[0-T])of Dasatinib
NCT01392703 (8) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-INF]) of Dasatinib
NCT01392703 (8) [back to overview]Number of Participants With Clinically Significant Changes in Vital Signs or Electrocardiogram (ECG) Findings
NCT01392703 (8) [back to overview]Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests
NCT01395017 (2) [back to overview]Overall Survival
NCT01395017 (2) [back to overview]Progression Free Survival (PFS)
NCT01441882 (1) [back to overview]Incidence of Adverse Events (Number of Participants Affected)
NCT01460160 (6) [back to overview]3-year Event-free Survival (EFS) Rate
NCT01460160 (6) [back to overview]Complete Remission Rate
NCT01460160 (6) [back to overview]Event-Free Survival (EFS) Rate (Kaplan-Meier Estimates)
NCT01460160 (6) [back to overview]Number of Participants Experiencing Adverse Events
NCT01460160 (6) [back to overview]Percentage of Participants Negative for Minimal Residual Disease (MRD)
NCT01460160 (6) [back to overview]Percentage of Participants With BCR-ABL Mutations at Baseline and at Time of Disease Progression or Relapse
NCT01488318 (4) [back to overview]Response to Treatment
NCT01488318 (4) [back to overview]Overall Response Rate (ORR)
NCT01488318 (4) [back to overview]Progression-free Survival (PFS)
NCT01488318 (4) [back to overview]Overall Survival (OS)
NCT01491633 (5) [back to overview]Types and Frequency of DDR2 Mutations
NCT01491633 (5) [back to overview]Response Rate
NCT01491633 (5) [back to overview]Survival
NCT01491633 (5) [back to overview]Time on Study
NCT01491633 (5) [back to overview]Toxicities
NCT01498445 (4) [back to overview]Duration of Response
NCT01498445 (4) [back to overview]Number of Participants With Hematologic Responses During First 3 Months of Treatment
NCT01498445 (4) [back to overview]Overall Survival
NCT01498445 (4) [back to overview]Ph I Study: Maximum Tolerated Dose (MTD) Dasatinib
NCT01514864 (5) [back to overview]Number of Participants With Laboratory Testing Results That Meet the Criteria for Grade 3 or 4 Abnormality
NCT01514864 (5) [back to overview]Progression-free Survival (PFS) Distribution
NCT01514864 (5) [back to overview]Progression-free Survival (PFS)
NCT01514864 (5) [back to overview]Overall Survival
NCT01514864 (5) [back to overview]Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation
NCT01593254 (5) [back to overview]Overall Survival (OS)
NCT01593254 (5) [back to overview]Percentage of Patients Achieving Major Molecular Response (MMR) After 12 Months of CML Treatment
NCT01593254 (5) [back to overview]Progression Free Survival (PFS)
NCT01593254 (5) [back to overview]Median Time to Major Molecular Response (MMR)
NCT01593254 (5) [back to overview]Time to Molecular Response (MR)^4.5
NCT01620216 (5) [back to overview]Clinical Activity
NCT01620216 (5) [back to overview]Overall Survival
NCT01620216 (5) [back to overview]Presence of Active/Aberrant Kinase Pathways
NCT01620216 (5) [back to overview]Clinical Activity
NCT01620216 (5) [back to overview]Progression-free Survival
NCT01652976 (11) [back to overview]Drug Compliance
NCT01652976 (11) [back to overview]Freedom From Metastasis
NCT01652976 (11) [back to overview]Median Overall Survival
NCT01652976 (11) [back to overview]Median Time To Progression
NCT01652976 (11) [back to overview]Progression Free Survival (PFS)
NCT01652976 (11) [back to overview]Response Rate
NCT01652976 (11) [back to overview]Site of Failure
NCT01652976 (11) [back to overview]Clinical Benefit Rate
NCT01652976 (11) [back to overview]Safety and Tolerability
NCT01652976 (11) [back to overview]Quality of Life, as Measured by the Functional Assessment of Chronic Illness Therapy; Hepatobiliary Cancer (FACT-Hep) Questionnaire (Version 4.0)
NCT01652976 (11) [back to overview]Quality of Life, as Measured by the Cancer Therapy Satisfaction Questionnaire (CTSQ), 2007
NCT01660906 (6) [back to overview]Number of Participants With a Major Molecular Response (MMR) and MR 4.5 After Switching to Dasatinib
NCT01660906 (6) [back to overview]Number of Participants With at Least 1 AE, Discontinuations Due to AE, Treatment-related AE, Serious Adverse Event (SAE), Treatment-related SAE, or Death as Outcome
NCT01660906 (6) [back to overview]The Number of Imatinib-related Adverse Events (AEs) That Were Resolved, Improved, Remained Unchanged, or Worsened After 3 Months of Dasatinib Treatment
NCT01660906 (6) [back to overview]Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib
NCT01660906 (6) [back to overview]The Percentage of Participants With at Least 1 Imatinib-related Grade 1 or Grade 2 Chronic Adverse Events (AEs) That Improved Without Worsening Within 3 Months of Switching to Dasatinib
NCT01660906 (6) [back to overview]Mean Change From Baseline in Patient Reported Quality of Life Measurements by The European Organization for Research and Treatment of Cancer - Quality of Life (QoL) Questionnaire (EORTC QLQ) Score After Switching to Dasatinib
NCT01850004 (9) [back to overview]Number of Participants Who Did Not Experience Loss of Complete Molecular Response (CMR) (MR4.5) and Major Molecular Response (MMR)
NCT01850004 (9) [back to overview]Number of Participants Who Experience Intermittent Loss of Complete Molecular Response (CMR) (MR4.5) But no Loss of Major Molecular Response (MMR)
NCT01850004 (9) [back to overview]Overall Survival (OS)
NCT01850004 (9) [back to overview]Major Molecular Response (MMR) Rate
NCT01850004 (9) [back to overview]Relapse-Free Survival (RFS) Rate
NCT01850004 (9) [back to overview]Progression Free Survival (PFS) Rate
NCT01850004 (9) [back to overview]Event-Free Survival (EFS) Rate
NCT01850004 (9) [back to overview]Time to Transformation to Accelerated Phase/Blast Crisis (AP/BC)
NCT01850004 (9) [back to overview]Progression Free Survival
NCT01876212 (15) [back to overview]T Cell-recruiting Chemokine CXCL10/IP-10
NCT01876212 (15) [back to overview]Treg CD4FoxP3 Suppressor Cells
NCT01876212 (15) [back to overview]Treg CD4FoxP3 Suppressor Cells
NCT01876212 (15) [back to overview]Treg CD4FoxP3 Suppressor Cells
NCT01876212 (15) [back to overview]T Cell-recruiting Chemokine CXCL10/IP-10
NCT01876212 (15) [back to overview]Immune Response Rate
NCT01876212 (15) [back to overview]Monocytic Myeloid Derived Suppressor Cells (M-MDSC)
NCT01876212 (15) [back to overview]Monocytic Myeloid Derived Suppressor Cells (M-MDSC)
NCT01876212 (15) [back to overview]Monocytic Myeloid Derived Suppressor Cells (M-MDSC)
NCT01876212 (15) [back to overview]Objective Response Rate (ORR)
NCT01876212 (15) [back to overview]Overall Survival (OS)
NCT01876212 (15) [back to overview]Polymorphonucler Myeloid-derived Suppressor Cells (PMN-MDSC)
NCT01876212 (15) [back to overview]Polymorphonucler Myeloid-derived Suppressor Cells (PMN-MDSC)
NCT01876212 (15) [back to overview]Polymorphonucler Myeloid-derived Suppressor Cells (PMN-MDSC)
NCT01876212 (15) [back to overview]Progression-free Survival (PFS)
NCT01876953 (1) [back to overview]Maximum Tolerated Dose of Dasatinib (Phase I)
NCT01999985 (3) [back to overview]Median Progression Free Survival
NCT01999985 (3) [back to overview]Number of Participants With Objective Response
NCT01999985 (3) [back to overview]Maximum Tolerated Dose (MTD) of Afatinib (BIBW 2992) in Combination With Dasatinib
NCT02011945 (24) [back to overview]Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Advanced Phase (CML-AP) Participants
NCT02011945 (24) [back to overview]Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), No Prior Dasatinib Participants
NCT02011945 (24) [back to overview]Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Advanced Phase (CML-AP) Participants
NCT02011945 (24) [back to overview]Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), Prior Dasatinib Participants
NCT02011945 (24) [back to overview]Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), No Prior Dasatinib Participants
NCT02011945 (24) [back to overview]Incidence of Adverse Events (AEs)
NCT02011945 (24) [back to overview]Incidence of Serious Adverse Events (SAEs)
NCT02011945 (24) [back to overview]Incidence of Serious Adverse Events (SAEs)
NCT02011945 (24) [back to overview]Incidence of Laboratory Abnormalities in Specific Thyroid Tests
NCT02011945 (24) [back to overview]Incidence of Change From Baseline in Clinical Laboratory Tests: Hematology
NCT02011945 (24) [back to overview]Incidence of Adverse Events (AEs)
NCT02011945 (24) [back to overview]Incidence of Abnormalities in Clinical Laboratory Tests: Liver Tests
NCT02011945 (24) [back to overview]Time to Molecular Response 4.5(MR4.5) - CML-CP Prior Dasatinib Participants
NCT02011945 (24) [back to overview]Time to Molecular Response 4.5(MR4.5) - CML-CP No Prior Dasatinib Participants
NCT02011945 (24) [back to overview]Time to Molecular Response 4.5(MR4.5) - CML-AP Participants
NCT02011945 (24) [back to overview]Time to Major Molecular Response (MMR) - CML-CP Prior Dasatinib Participants
NCT02011945 (24) [back to overview]Time to Major Molecular Response (MMR) - CML-CP No Prior Dasatinib Participants
NCT02011945 (24) [back to overview]Time to Major Molecular Response (MMR) - CML-AP Participants
NCT02011945 (24) [back to overview]Incidence of Dose Limiting Toxicities (DLT)
NCT02011945 (24) [back to overview]Duration of Molecular Response 4.5 (MR4.5) - CML-CP No Prior Dasatinib Participants
NCT02011945 (24) [back to overview]Duration of Major Molecular Response (MMR) - CML-CP Prior Dasatinib Participants
NCT02011945 (24) [back to overview]Duration of Major Molecular Response (MMR) - CML-CP No Prior Dasatinib Participants
NCT02011945 (24) [back to overview]Duration of Major Molecular Response (MMR) - CML-AP Participants
NCT02011945 (24) [back to overview]Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), Prior Dasatinib Participants
NCT02059265 (5) [back to overview]Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1
NCT02059265 (5) [back to overview]Duration of Overall Survival (OS)
NCT02059265 (5) [back to overview]Duration of Progression-free Survival (PFS)
NCT02059265 (5) [back to overview]ARID1A Mutation Status in Formalin-fixed, Paraffin Embedded Tissue Using Next-generation Exon-capture Sequencing
NCT02059265 (5) [back to overview]Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0
NCT02143414 (6) [back to overview]Minimal Residual Disease Negativity
NCT02143414 (6) [back to overview]Overall Survival Rate (Cohort I)
NCT02143414 (6) [back to overview]Incidence of Dose-limiting Toxicity (Cohort II)
NCT02143414 (6) [back to overview]Disease-free Survival (Cohort II)
NCT02143414 (6) [back to overview]Complete Response Rate (Cohort I)
NCT02143414 (6) [back to overview]Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT02269267 (7) [back to overview]Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs.
NCT02269267 (7) [back to overview]Patient-reported Health Status Related to Sleep Status of Patients at Baseline (Before Stopping Tyrosine Kinase Inhibitors (TKIs)
NCT02269267 (7) [back to overview]Patient-reported Health Status Related to Sleep Status of Patients at 6 Months (After Stopping Tyrosine Kinase Inhibitors (TKIs)
NCT02269267 (7) [back to overview]Patient-reported Health Status Related to Fatigue of Patients at Baseline (Before Stopping Tyrosine Kinase Inhibitors (TKIs)
NCT02269267 (7) [back to overview]Patient-reported Health Status Related to Fatigue of Patients at 6 Months (After Stopping Tyrosine Kinase Inhibitors (TKIs)
NCT02269267 (7) [back to overview]Patient-reported Health Status Related to Diarrhea of Patients at Baseline (Before Stopping Tyrosine Kinase Inhibitors (TKIs)
NCT02269267 (7) [back to overview]Patient-reported Health Status Related to Diarrhea of Patients at 6 Months (After Stopping Tyrosine Kinase Inhibitors (TKIs)
NCT02297139 (4) [back to overview]Duration of Treatment
NCT02297139 (4) [back to overview]Number of Participants Who Received Dasatinib Treatment
NCT02297139 (4) [back to overview]Number of Participants With Adverse Events
NCT02297139 (4) [back to overview]Number of Participants With Serious Adverse Events
NCT02420717 (4) [back to overview]Progression-free Survival
NCT02420717 (4) [back to overview]Overall Survival
NCT02420717 (4) [back to overview]Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)
NCT02420717 (4) [back to overview]Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)
NCT02428855 (4) [back to overview]Median Progression Free Survival (PFS)
NCT02428855 (4) [back to overview]Overall Survival
NCT02428855 (4) [back to overview]Objective Response Rate (ORR)
NCT02428855 (4) [back to overview]Number of Participants With Adverse Events
NCT02720185 (3) [back to overview]Plasma Membrane Epidermal Growth Factor Receptor (EGFR) Expression, Measured by VECTRA Imaging
NCT02720185 (3) [back to overview]Number of Participants With Pathologic Complete Response (pCR)
NCT02720185 (3) [back to overview]Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks
NCT02750514 (18) [back to overview]Progression Free Survival Rate (PFSR) at 24 Weeks
NCT02750514 (18) [back to overview]Objective Response Rate (ORR)
NCT02750514 (18) [back to overview]Number of Participants Experiencing Laboratory Abnormalities in Thyroid Tests
NCT02750514 (18) [back to overview]Progression Free Survival Rate (PFSR) at 24 Weeks
NCT02750514 (18) [back to overview]Progression Free Survival Rate (PFSR) at 24 Weeks
NCT02750514 (18) [back to overview]Percentage of Participants Experiencing Adverse Events (AEs)
NCT02750514 (18) [back to overview]Duration of Response (DOR)
NCT02750514 (18) [back to overview]Objective Response Rate (ORR)
NCT02750514 (18) [back to overview]Progression Free Survival Rate (PFSR) at 24 Weeks
NCT02750514 (18) [back to overview]Objective Response Rate (ORR)
NCT02750514 (18) [back to overview]Number of Participants Experiencing Laboratory Abnormalities in Hepatic Tests
NCT02750514 (18) [back to overview]Duration of Response (DOR)
NCT02750514 (18) [back to overview]Objective Response Rate (ORR)
NCT02750514 (18) [back to overview]Duration of Response (DOR)
NCT02750514 (18) [back to overview]Duration of Response (DOR)
NCT02750514 (18) [back to overview]Percentage of Participants Experiencing Serious Adverse Events (SAEs)
NCT02750514 (18) [back to overview]Percentage of Participants Experiencing Death
NCT02750514 (18) [back to overview]Percentage of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
NCT03023046 (5) [back to overview]Event-free Survival
NCT03023046 (5) [back to overview]Number of Participants With Complete Measurable Residual Disease (MRD) Response Rate
NCT03023046 (5) [back to overview]Overall Survival
NCT03023046 (5) [back to overview]Number of Participants With Morphological Complete Response Rate
NCT03023046 (5) [back to overview]Number of Participants With Adverse Events
NCT03041701 (9) [back to overview]Phase II: Progression Free Survival (PFS) in Participants Receiving Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib
NCT03041701 (9) [back to overview]Phase II: Number of Participants With Grade ≥3 Adverse Events Related to Treatment With Ganitumab and Dasatinib
NCT03041701 (9) [back to overview]Phase II: Number of Participants Who Experience an Objective Clinical Response (CR or PR) When Treated With Ganitumab Plus Dasatinib
NCT03041701 (9) [back to overview]Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT03041701 (9) [back to overview]Phase I: Number of Participants With Grade ≥3 Adverse Events Related to Treatment With Ganitumab and Dasatinib
NCT03041701 (9) [back to overview]Phase II: Number of Participants With Stable Disease >= 6 Months as Defined by the Response Evaluation Criteria in Solid Tumors (RECIST) in Participants Receiving Ganitumab With Dasatinib
NCT03041701 (9) [back to overview]Phase II: Number of Participants That is Without Progression at 4 Months
NCT03041701 (9) [back to overview]Phase I: Safe Dose of Dasatinib When Given With Ganitumab in Participants With Relapsed or Refractory Embryonal or Alveolar Rhabdomyosarcoma (RMS)
NCT03041701 (9) [back to overview]Phase I: Number of Participants With a Dose-Limiting Toxicity (DLT)
NCT03352427 (5) [back to overview]Overall Survival
NCT03352427 (5) [back to overview]Overall Response Rate (OR) (Partial Response or Better) in Participants With Refractory or Recurrent Glioma
NCT03352427 (5) [back to overview]Overall Survival
NCT03352427 (5) [back to overview]Progression-free Survival in Participants With Newly Diagnosed High-grade Glioma (HGG)
NCT03352427 (5) [back to overview]Progression-free Survival in Participants With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
NCT04063124 (6) [back to overview]Senescence Marker IL-6 in CSF
NCT04063124 (6) [back to overview]Montreal Cognitive Assessment (MoCA)
NCT04063124 (6) [back to overview]Alzheimer's Disease Marker - CSF Amyloid Beta
NCT04063124 (6) [back to overview]Alzheimer's Disease Marker - CSF Tau
NCT04063124 (6) [back to overview]Brain Penetrance of Dasatinib (D)
NCT04063124 (6) [back to overview]Brain Penetrance of Quercetin (Q)
NCT05286528 (3) [back to overview]Overall Survival Rate: All Participants
NCT05286528 (3) [back to overview]Overall Survival Rate: Type of First Line TKI
NCT05286528 (3) [back to overview]Overall Survival Rate: Type of Second Line TKI

Overall Survival

Number of patients surviving up to five years post-transplant. (NCT00036738)
Timeframe: Assessed up to 5 years

InterventionParticipants (Count of Participants)
6 Months1 Year2 Years3 Years4 Years5 Years
Treatment (Allogeneic Nonmyeloablative HSCT)262419171613

[back to top]

Relapse Free Survival

Number of patients with relapsed disease within 1 Year post-transplant. Relapse is defined as the detection of > 5% blasts after a documented complete remission. (NCT00036738)
Timeframe: Assessed up to 1 year

InterventionParticipants (Count of Participants)
Treatment (Allogeneic Nonmyeloablative HSCT)3

[back to top]

Leukemia-free Survival

Number of patients surviving in CR up to five years post-transplant. (NCT00036738)
Timeframe: Assessed up to 5 years

InterventionParticipants (Count of Participants)
6 Months1 Year2 Years3 Years4 Years5 Years
Treatment (Allogeneic Nonmyeloablative HSCT)191713111110

[back to top] [back to top] [back to top]

2-year Overall Survival (OS)

Overall survival was measured from the date of registration to study until death from any cause with observations censored at the date of last contact for patients last known to be alive. (NCT00070499)
Timeframe: Every three months for the first year, every six months in years 2 and 3, and annually for years 4 and 5

InterventionPercent of population (Number)
Standard Dose Imatinib A89
High Dose Imatinib95
Dasatinib97
Standard Dose Imatinib B98

[back to top]

Two Year Relapse-free Survival

Relapse-free survival is measured from the date of documented (possibly unconfirmed) hematologic complete remission until loss of hematologic complete remission or death from any cause. Observations are censored at the date of last contact for patients last known to be alive with report of loss of hematologic complete remission. (NCT00070499)
Timeframe: every 3 months for the first year, every six months for years 2 and 3, annually for years 4 and 5

InterventionPercent of population (Number)
Standard Dose Imatinib A83
High Dose Imatinib97
Dasatinib96
Standard Dose Imatinib B95

[back to top]

Hematologic Response

Hematologic response assesses whether patients' blood counts return to normal (NCT00070499)
Timeframe: 1 month after starting treatment

Interventionparticipants (Number)
Standard Dose Imatinib A63
High Dose Imatinib66
Dasatinib107
Standard Dose Imatinib B112

[back to top]

Molecular Response Rate at 12 Months

Median value of baseline bcr-abl/bcr ratio from pretreatment was used as the baseline value for assessing each patient's molecular response. Molecular response criteria were: 1) not failed treatment on or before 12-month evaluation; 2) met criteria for hemalotogic response; 3) bcr-abl/bcr ration at 12-months must be 10,000 times smaller than the pretreatment ratio. (NCT00070499)
Timeframe: pretreatment and after 12 months of treatment

Interventionparticipants (Number)
Standard Dose Imatinib A5
High Dose Imatinib14
Dasatinib27
Standard Dose Imatinib B18

[back to top]

Toxicity

Number of patients with Grade 3-5 adverse events that are related to study drug by given type of adverse event (NCT00070499)
Timeframe: Patients were assessed for adverse events monthly every 4 weeks for the first year, every 6 months for years 2 and 3, and annually for years 4 and 5.

,,,
InterventionParticipants with a given type of AE (Number)
ALT, SGPT (serum glutamic pyruvic transaminase)AST, SGOT (serum glutamic oxaloacetic trans.)Bilirubin (hyperbilirubinemia)Bronchospasm, wheezingCNS cerebrovascular ischemiaCPK (creatine phosphokinase)Cardiac-ischemia/infarctionColitisConduction abnor/Atrioventricular heart blockConstipationDehydrationDiarrheaDistention/bloating, abdominalDizzinessDyspnea (shortness of breath)Edema: head and neckEdema: limbEdema: trunk/genitalEdema: visceraFatigue (asthenia, lethargy, malaise)Febrile neutropeniaGGT (gamma-glutamyl transpeptidase)Glucose, serum-high (hyperglycemia)HematomaHemoglobinHepatobiliary/Pancreas-Other (Specify)Hot flashes/flushesHypertensionHypoxiaInfection with Grade 3 or 4 neutrophils - BloodInfection with Grade 3/4 neut - Lung (pneumonInfec with norm ANC or Grade 1 or 2 neut - ColonInf with no ANC or Grade 1/2 netLung (pneumonia)Infec with norm ANC or Grade 1 or 2 neut - ScrotumInfect with norm ANC or Grade 1 or 2 neut - SinusInf with no ANC or Grade 1/2 neut - Ur tract NOSInfection with unknown ANC - SinusLeft ventricular diastolic dysfunctionLeukocytes (total WBC)LymphopeniaMetabolic/Laboratory-Other (Specify)Mood alteration - depressionMucositis/stomatitis (clinical exam) - Oral cavityMuscle weak, not due to neurop. Whole body/generalNauseaNeuropathy: motorNeuropathy: sensoryNeutrophils/granulocytes (ANC/AGC)Pain - Abdomen NOSPain - BackPain - BonePain - Chest/thorax NOSPain - Extremity-limbPain - Head/headachePain - JointPain - MusclePain-Other (Specify)Pericardial effusion (non-malignant)Phosphate, serum-low (hypophosphatemia)PlateletsPleural effusion (non-malignant)Potassium, serum-high (hyperkalemia)Potassium, serum-low (hypokalemia)Prolonged QTc intervalProteinuriaPruritus/itchingPulmonary/Upper Respiratory-Other (Specify)Rash/desquamationRash: acne/acneiformRestrictive cardiomyopathyRetinal detachmentSodium, serum-high (hypernatremia)Syncope (fainting)Vaginal mucositisVision-blurred visionVomitingWatery eye (epiphora, tearing)Weight gain
Dasatinib110011231116007010013031120110120211011331000011183021031003122411110101001111113
High Dose Imatinib310000000006102021011110081001001100000210001200124131111300014000001040100001001
Standard Dose Imatinib A111003000001010200101000500000000001001101002008101001010006000000010000001100
Standard Dose Imatinib B32010000000201221001000050000000000000310020100151101032110111102002020010000000

[back to top]

Major and Overall Hematologic Response (MaHR and OHR)

MaHR=best confirmed response of complete hematologic response (CHR) or No Evidence of Leukemia (NEL). OHR=best confirmed response of MaHR or minor hematologic response (MiHR). Confirmed hematologic response=response confirmed ≥4 weeks after first documented event with no concomitant use of anagrelide or hydroxyurea. Maintaining a response=no 2 consecutive records of nonresponse at assessment. Criteria for CHR and NEL specified in Outcome Measure 2 and criteria for MiHR in Outcome Measure 4. (NCT00101647)
Timeframe: Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during treatment; at end of treatment

,,
Interventionparticipants (Number)
MaHROHR
Imatinib-intolerant912
Imatinib-resistant103127
Total112139

[back to top]

Minimal Clinically Significant Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G)

Number of subjects with minimally significant changes from baseline in the health-related quality of life questionnaire FACT-G. FACT-G=27 questions in 4 domains: physical, social/family, emotional, and functional well-being (PWB, SWB, EWB, FWB). Total score=0 to 108; higher score=better health-related quality of life. Total Score change of 7 or more=minimal clinical important change; PWB, EWB, and FWB score change of 3 or more, and SWB score change of 2 or more=minimal clinically important change. (NCT00101647)
Timeframe: Baseline, every 2 weeks for the first 3 cycles, following every 4-week cycle, and once at follow-up.(treatment continued until discontinuation due to toxicity, disease progression, or other protocol-specified criteria).

,,
InterventionParticipants (Number)
Total FACT-GPhysical Well-BeingSocial/Family Well-BeingEmotional Well-BeingFunctional Well-Being
Imatinib-intolerant54674
Imatinib-resistant7685507763
Total8189568467

[back to top]

Number of Participants Who Achieved a Major Molecular Response (MMR) During Treatment Period

Number of participants who achieved an MMR at any time during the treatment period. MMR was calculated by measuring BCR-ABL transcripts in blood during treatment using quantitative reverse transcription-polymerase chain reaction (RT-PCR). BCR-ABL=the fused gene found in subjects with this type of Chronic Myeloid Leukemia (CML). (NCT00101647)
Timeframe: Baseline, every 12 weeks throughout study (treatment continued until discontinuation due to toxicity, disease progression, or other protocol-specified criteria).

,,
Interventionparticipants (Number)
MMR in Assessed Participants w/CCyR(n=2;n=39;n=41)MMR in Assessed Subjects w/o CCyR(n=2;n=51;n=53)
Imatinib-intolerant20
Imatinib-resistant1711
Total191

[back to top]

Percentage of Participants Who Achieved OHR and Did Not Progress at 12 Months and 24 Months

Percentage of participants who achieved OHR and did not progress at specified timepoints, based on the Kaplan-Meier estimate of the duration of response. OHR=best confirmed response of MaHR or MiHR. MaHR criteria in Outcome Measure 2. MiHR= <15% blasts in bone marrow and <15% blasts in peripheral blood (PB); <30% blasts+promyelocytes in bone marrow and <30% blasts+promyelocytes in PB; <20% basophils in PB; no extramedullary disease other than spleen and liver. Confirmed hematologic response= confirmed ≥4 weeks after 1st documented event with no concomitant use of anagrelide or hydroxyurea. (NCT00101647)
Timeframe: 12 months, 24 months

,,
InterventionPercentage of responders (Number)
OHR at 12 monthsOHR at 24 months
Imatinib-intolerant69.834.9
Imatinib-resistant69.751.2
Total69.850.0

[back to top]

Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point Within the Dosing Interval of 12 Hours (AUC[0-T])

The AUC(0-T) was calculated using the mixed log-linear trapezoidal algorithm in Kinetica™. In the calculation of AUC(0-T), predose concentrations that were less than the lower limit of quantitation (LLQ) were assigned a value of zero. (NCT00101647)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

,
Interventionng∙h/mL (Mean)
Dasatinib (n=29; n=27)BMS-582691 (n=24; n=24)
Day 1207.769.51
Day 8265.0218.67

[back to top]

Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Maximum Observed Plasma Concentration (Cmax)

The Cmax was obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the concentration-time curve was identified by least-square linear regression of at least 3 data points that yielded a maximum G-criteria,which is also referred to as adjusted R-squared. (NCT00101647)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

,
Interventionng/mL (Mean)
Dasatinib (n=29; n=27)BMS-582691 (n=24; n=24)
Study Day 169.312.81
Study Day 889.184.52

[back to top]

Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Plasma Half-life (T-HALF)

The T-HALF was calculated as Ln2/Lz,where Lz was the absolute value of the slope of the terminal log-linear phase. (NCT00101647)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

,
Interventionhours (Mean)
Dasatinib (n=28; n=26)BMS-582691 (n=22; n=20)
Day 13.153.30
Day 85.185.70

[back to top]

MaHR and MCyR Among Participants With Baseline BCR-ABL Point Mutations

Major hematologic and cytogenetic responses (MaHR and MCyR) to dasatinib in subjects with mutations at baseline, including imatinib-resistant mutations (IRM) and specific BCR-ABL mutations (SBAM). BCR-ABL=the fused gene found in subjects with this type of CML. Criteria for MaHR are specified in Outcome Measure 2. MCyR=combined complete cytogenetic and partial cytogenetic response rate. Complete Cytogenetic Response= 0% Ph+ Cells in Metaphase in Bone Marrow, Partial Cytogenetic Response > 0% to 35% Ph+ Cells in Metaphase in Bone Marrow. (NCT00101647)
Timeframe: Baseline, at time of disease progression. (treatment continued until discontinuation due to toxicity, disease progression, or other protocol-specified criteria).

,
InterventionPercentage of participants (Number)
Participants with IRM (n=90)with ≥1 IRM in P-loop (n=35)with ≥1 IRM in activation loop (n=15)with ≥1 IRM in P-loop & activation loop (n=3)with ≥1 IRM in other location only (n=43)w/ ≥1 IRM w/2-4-fold increase in IR (n=15)w/ ≥1 IMR w/≥5-fold increase in IR (n=60)SBAM [M244V] at baseline (n=7)SBAM [L248V] at baseline (n=3)SBAM [G250E] at baseline (n=10)SBAM [Y253F/H] at baseline (n=11)SBAM [E255K/V] at baseline (n=11)SBAM [T315I] at baseline (n=9)SBAM [F317L] at baseline (n=4)SBAM [M351T/V] at baseline (n=13)SBAM [E355G] at baseline (n=4)SBAM [F359C/I/V] at baseline (n=12)SBAM [V379I] at baseline (n=6)SBAM [H396R] at baseline (n=6)SBAM [S417Y] at baseline (n=3)SBAM [E459K] at baseline (n=3)
Participants Achieving MaHR7369733374876786100608264010085508367673333
Participants Achieving MCyR4031536744333571672045180038504267330100

[back to top]

Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Time to Maximum Observed Plasma Concentration (Tmax)

The Tmax was obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the concentration-time curve was identified by least-square linear regression of at least 3 data points that yielded a maximum G-criteria,which is also referred to as adjusted R-squared. (NCT00101647)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

,
Interventionhours (Mean)
Dasatinib (n=29; n=27)BMS-582691 (n=24; n=24)
Day 11.261.86
Day 81.131.75

[back to top]

Best Cytogenetic Response

Number of participants with complete, partial, minor, minimal, or no cytogenetic response. Determination of cytogenetic response based on the prevalence (percentage) of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase in a bone marrow sample (aspirates/biopsies). (NCT00101647)
Timeframe: Baseline (within 4 weeks of therapy start); Every month for Cycles 1-3; Every 12 weeks for Cycles 4+; end of treatment

,,
InterventionParticipants (Number)
Complete (0% Ph+ metaphases)Partial (>0% to 35% Ph+ metaphases)Minor (>35% to 65% Ph+ metaphases)Minimal (>65% to 95% Ph+ metaphases)No Response (>95% to 100% Ph+ metaphases)Unable to determine
Imatinib-intolerant500341
Imatinib-resistant53128373714
Total58128404115

[back to top]

Best Confirmed Hematologic Response

Number of participants with confirmed complete hematologic response (CHR) or No Evidence of Leukemia (NEL), minor hematologic response (MiHR), or no hematologic response. Confirmed hematologic response=response that is confirmed after at least 4 weeks with no concomitant use of anagrelide or hydroxyurea use during this interval. Criteria for CHR and NEL are specified in Outcome Measure 2; criteria for MiHR are specified in Outcome Measure 4. (NCT00101647)
Timeframe: Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during treatment; at end of treatment

,,
InterventionParticipants (Number)
Complete HR (CHR)No Evidence of Leukemia (NEL)Minor HR (MiHR)No Response
Imatinib-intolerant7231
Imatinib-resistant80232434
Total87252735

[back to top]

Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, Hematologic Toxicities, and Toxicities Leading to Discontinuation

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition regardless of causal relationship with treatment. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death) (NCT00101647)
Timeframe: Continuous from pretreatment through each 4-week cycle and at follow-up. (treatment continued until discontinuation due to toxicity, disease progression, or other protocol-specified criteria).

,
InterventionParticipants (Number)
Any AEGrade 3/4 AEsDrug-Related AEsDrug-Related Grade 3-4 AEsDeath within 30 days of last doseSAEsFluid-Retention AEs -OverallFluid-Retention AEs - Superficial EdemaFluid-Retention AEs -Pleural EffusionFluid-Retention AEs - OtherGrade 3/4 Hematologic Toxicity - AnemiaGrade 3/4 Hematologic Toxicity - ThrombocytopeniaGrade 3/4 Hematologic Toxicity - NeutropeniaGrade 3/4 Hematologic Toxicity - LeukopeniaDiscontinuations due to Study Drug Toxicity
Imatinib-intolerant1312131121210844111013112
Imatinib-resistant16011615595151131047360431111321209119

[back to top]

Time to OHR

Median time (in months) from first dosing date to date of OHR. OHR=best confirmed response of MaHR or MiHR. Criteria for MaHR specified in Outcome Measure 2. MiHR= <15% blasts in bone marrow and <15% blasts in peripheral blood (PB); <30% blasts+promyelocytes in bone marrow and <30% blasts+promyelocytes in PB; <20% basophils in PB; no extramedullary disease other than spleen and liver. Confirmed hematologic response = response confirmed ≥4 weeks after 1st documented event with no concomitant use of anagrelide or hydroxyurea. (NCT00101647)
Timeframe: Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during treatment; at end of treatment

Interventiondays (Median)
Imatinib-intolerant34
Imatinib-resistant30
Total30

[back to top]

Percentage of Participants Who Achieved MaHR and Did Not Progress at 24 Months in the Imatinib-Resistant Group (Based on the Kaplan-Meier Estimate of the Duration of Response)

Percentage of participants in the Imatinib-Resistant Group who achieved MaHR and did not progress at Month 24, based on the Kaplan-Meier estimate of the duration of response. MaHR=best confirmed response of complete hematologic response (CHR) or No Evidence of Leukemia (NEL). Criteria for MaHR and NEL are specified in Outcome Measure 2. (NCT00101647)
Timeframe: 24 months

Interventionpercentage of responders (Number)
Imatinib-resistant60.9
Total59.6

[back to top]

Percentage of Participants Who Achieved MaHR and Did Not Progress at 12 Months (Based on the Kaplan-Meier Estimate of the Duration of Response)

MaHR=best response of CHR or NEL. CHR=white blood cells ≤institutional upper limit of normal (iULN); absolute neutrophil count (ANC) ≥1000/mm3; platelets ≥100,000/mm3; no blasts/promyelocytes in peripheral blood (PB); bone marrow blasts ≤5%; <5% myelocytes+metamyelocytes in PB; PB basophils ≤ iULN; no extramedullary involvement. NEL=WBC ≤iULN; no blasts/promyelocytes in PB; bone marrow blasts ≤5%; <5% myelocytes+metamyelocytes in PB; PB basophils ≤iULN; no extramedullary involvement; at least 1 of: ANC ≥500/mm3 & <1000/mm3; platelets ≥20,000/mm3 & <100,000/mm3. (NCT00101647)
Timeframe: 12 months

Interventionpercentage of responders (Number)
Imatinib-intolerant85.7
Imatinib-resistant78.3
Total79.0

[back to top]

Median Time in Days From First Dosing Date to Date of MaHR

MaHR=best response of CHR or NEL. CHR=white blood cells ≤institutional upper limit of normal (iULN); absolute neutrophil count (ANC) ≥1000/mm3; platelets ≥100,000/mm3; no blasts/promyelocytes in peripheral blood (PB); bone marrow blasts ≤5%; <5% myelocytes+metamyelocytes in PB; PB basophils ≤ iULN; no extramedullary involvement. NEL=WBC ≤iULN; no blasts/promyelocytes in PB; bone marrow blasts ≤5%; <5% myelocytes+metamyelocytes in PB; PB basophils ≤iULN; no extramedullary involvement; at least 1 of: ANC ≥500/mm3 & <1000/mm3; platelets ≥20,000/mm3 & <100,000/mm3. (NCT00101647)
Timeframe: Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during treatment; at end of treatment

InterventionDays (Median)
Imatinib-intolerant84
Imatinib-resistant63
Total65

[back to top]

Minimal Clinically Significant Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire Scores

Health-related quality of life as measured by FACT-G, which comprises 27 questions in 4 domains: PWB, SWB, EWB, FWB. Total FACT-G score=summation of the 4 subscale scores and ranges from 0 to 108. Higher scores=better health-related quality of life. Total Score change of 7 or more=minimal clinical important change; PWB, EWB, & FWB score change of 3 or more, and SWB score change of 2 or more=minimal clinical important change. Baseline FACT-G measurements can be found in Baseline Characteristics. (NCT00101660)
Timeframe: Baseline, Day 29, every 4 weeks for the first 24 weeks, then every 12 weeks for the remainder of treatment, after end of treatment. Treatment continued until disease progression or development of toxicity or until other protocol-defined criteria.

InterventionParticipants (Number)
Imatinib-intolerant: Total FACT-G (n=80)Imatinib-intolerant: PWB (n=80)Imatinib-intolerant: SWB (n=80)Imatinib-intolerant: EWB (n=80)Imatinib-intolerant: FWB (n=80)Imatinib-resistant: Total FACT-G (n=241)Imatinib-resistant: PWB (n=241)Imatinib-resistant: SWB (n=241)Imatinib-resistant: EWB (n=241)Imatinib-resistant: FWB (n=241)
Dasatinib,70 mg BID34363340321071039410789

[back to top]

Median Time From First Dosing Until CHR

CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets <450,000/mm^3; no blasts or promyelocytes in peripheral blood; <5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤20%; no extramedullary involvement. Response, as defined, must be maintained for at least 4 weeks after first documented. A CHR could begin only 14 days after dosing start date. (NCT00101660)
Timeframe: Baseline (within 72 hours of start of therapy), weekly until Week 12, every 3 months until off-study

InterventionMonths (Median)
Imatinib-intolerant (n=93)Imatinib-resistant (n=259)
Dasatinib, 70 mg BID0.490.53

[back to top]

Median Time From First Dosing Date to Date of MCyR

MCyR is the combination of CCyR-0% Ph+ metaphases and PCyR - 1% to 35% Ph+ metaphases. (NCT00101660)
Timeframe: Baseline (within 4 weeks of Day 1) and every 12 weeks

InterventionMonths (Median)
Imatinib-intolerantImatinib-resistant
Dasatinib, 70 mg BID2.792.92

[back to top]

Number of Imatinib-intolerant Participants With MCyR

Determination of cytogenetic response was based on the prevalence of Ph+ metaphases among cells with metaphases in a bone marrow sample. MCyR is the combination of CCyR-0% Ph+ metaphases and PCyR - 1% to 35% Ph+ metaphases. (NCT00101660)
Timeframe: Baseline to 2 years

InterventionParticipants (Number)
Dastinib, 70 mg, BID81

[back to top]

Percentage of Participants Who Achieved MCyR and Did Not Progress at 12 and 24 Months

Based on the Kaplan-Meier estimate of the duration of response. Determination of cytogenetic response was based on the prevalence of Ph+ metaphases among cells with metaphases in a bone marrow sample. MCyR is the combination of Complete Cytogenetic Response (CCyR)-0% Ph+ metaphases and Partial Cytogenetic Response (PCyR) - 1% to 35% Ph+ metaphases. (NCT00101660)
Timeframe: 12 and 24 Months

InterventionPercentage of participants (Number)
Imatinib-intolerant group: 12 months (n=81)Imatinib-intolerant group: 24 months (n=81)Imatinib-resistant group: 12 months (n=159)Imatinib-resistant group: 24 months (n=159)
Dasatanib, 70 mg BID98.596.793.783.6

[back to top]

Number of Imatinib-resistant Participants With Major Cytogenetic Response (MCyR)

Cytogenetic response was based on the prevalence of Ph+ metaphases among cells with metaphases in a bone marrow sample. MCyR is the combination of Complete Cytogenetic Response (CCyR)-0% Ph+ metaphases plus Partial Cytogenetic Response (PCyR)-1% to 35% Ph+ metaphases. (NCT00101660)
Timeframe: 2 years

InterventionParticipants (Number)
Dasatinib, 70 mg, Twice Daily (BID)159

[back to top] [back to top] [back to top]

Number of Participants With Complete Hematologic Response (CHR)

CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets <450,000/mm^3; no blasts or promyelocytes in peripheral blood; <5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤20%; no extramedullary involvement. Response, as defined, must be maintained for at least 4 weeks after first documented. A CHR could begin only 14 days after dosing start date. (NCT00101660)
Timeframe: Baseline (within 72 hours of start of therapy), weekly until Week 12, every 3 months until off-study

InterventionParticipants (Number)
Imatinib-intolerant (n=99)Imatinib-resistant (n=288)
Dasatinib, 70 mg BID93259

[back to top]

Number of Participants With Major Molecular Response (MMR)

MMR is defined as ≤3 log reduction in BCR-ABL levels from the standardized baseline value of BCR-ABL:Control Gene ratio. The international ratio is obtained by multiplying BCR-ABL:Control gene ratio by the lab-specific conversion factor. (NCT00101660)
Timeframe: Baseline to 2 years

InterventionParticipants (Number)
Imatinib-intolerant (n=99)Imatinib-resistant (n=288)
Dasatinib, 70 mg BID73102

[back to top]

Percentage of Participants Who Acheived CHR and Did Not Progress at 12 Months and 24 Months

Based on the Kaplan-Meier estimate of the duration of response. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm^3; no blasts or promyelocytes in peripheral blood; <5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤20%; no extramedullary involvement. Response, as defined, must be maintained for at least 4 weeks after first documented. A CHR could begin only 14 days after dosing start date. (NCT00101660)
Timeframe: 12 and 24 months

InterventionPercentage of participants (Number)
Imatinib-intolerant: 12 months (n=93)Imatinib-intolerant: 24 months (n=93)Imatinib-resistant: 12 months (n=259)Imatinib-resistant: 24 months (n=259)
Dasatinib,70 mg BID97.793.590.478.8

[back to top] [back to top]

Time to MaHR and OHR

Median time from first dosing to date of OHR and/or MaHR in subjects who achieved OHR and MaHR. MaHR=best confirmed response of complete hematologic response (CHR) or No Evidence of Leukemia (NEL). OHR=best confirmed response of MaHR or minor hematologic response (MiHR). Criteria for MaHR are specified in Outcome Measure 2. Criteria for MiHR are specified in Outcome Measure 1. (NCT00101816)
Timeframe: Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during Cycle 1 and 2; After every 2nd cycle during Cycles 3+; at end of treatment

Interventiondays (Median)
Participants Acheiving MaHR63.5
Participants Acheiving OHR30.0

[back to top]

Median Duration of Major Hematologic Response (MaHR)

MaHR=best confirmed response of CHR or NEL. CHR=white blood cells ≤ institutional upper limit of normal (iULN); absolute neutrophil count (ANC) ≥1000/mm3; platelets ≥100,000/mm3; no blasts/promyelocytes in peripheral blood (PB); bone marrow blasts ≤5%; <5% myelocytes+metamyelocytes in PB; PB basophils ≤ iULN; no extramedullary involvement. NEL=WBC ≤ iULN; no blasts/promyelocytes in PB; bone marrow blasts ≤5%; <5% myelocytes+metamyelocytes in PB; PB basophils ≤ iULN; no extramedullary involvement; at least 1 of the following: ANC ≥500/mm3 & <1000/mm3; platelets ≥20,000/mm3 & <100,000/mm3. (NCT00101816)
Timeframe: Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during Cycle 1 and 2; After every 2nd cycle during Cycles 3+; at end of treatment

Interventionmonths (Median)
Participants Acheiving MaHR22.4

[back to top]

Pharmacokinetics (PK) of Dasatinib's Metabolite BMS-582691 - Time to Maximum Observed Plasma Concentration (Tmax)

The Tmax was obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the concentration-time curve was identified by least-square linear regression of at least 3 data points that yielded a maximum G-criteria,which is also referred to as adjusted R-squared. (NCT00101816)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

Interventionhours (Mean)
Imatinib-intolerant1.71
Imatinib-resistant1.90

[back to top]

Pharmacokinetics (PK) of Dasatinib's Metabolite BMS-582691 - Maximum Observed Plasma Concentration (Cmax)

The Cmax was obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the concentration-time curve was identified by least-square linear regression of at least 3 data points that yielded a maximum G-criteria,which is also referred to as adjusted R-squared. (NCT00101816)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

Interventionng/mL (Mean)
Study Day 12.44
Study Day 83.87

[back to top]

Pharmacokinetics (PK) of Dasatinib's Metabolite BMS-582691 - Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point Within the Dosing Interval of 12 h (AUC[0-T])

The AUC(0-T) was calculated using the mixed log-linear trapezoidal algorithm in Kinetica™. In the calculation of AUC(0-T), predose concentrations that were less than the lower limit of quantitation (LLQ) were assigned a value of zero. (NCT00101816)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

Interventionng∙h/mL (Mean)
Imatinib-intolerant7.08
Imatinib-resistant13.81

[back to top]

Pharmacokinetics (PK) of Dasatinib - Maximum Observed Plasma Concentration (Cmax)

The Cmax was obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the concentration-time curve was identified by least-square linear regression of at least 3 data points that yielded a maximum G-criteria,which is also referred to as adjusted R-squared. (NCT00101816)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

Interventionng/mL (Mean)
Study Day 160.34
Study Day 8110.42

[back to top]

Pharmacokinetics (PK) of Dasatinib - Time to Maximum Observed Plasma Concentration (Tmax)

The Tmax was obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the concentration-time curve was identified by least-square linear regression of at least 3 data points that yielded a maximum G-criteria,which is also referred to as adjusted R-squared. (NCT00101816)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

Interventionhours (Mean)
Study Day 11.79
Study Day 81.22

[back to top]

Pharmacokinetics (PK) of Dasatinib and Its Metabolite BMS-582691 - Plasma Half-life (T-HALF)

The T-HALF was calculated as Ln2/Lz,where Lz was the absolute value of the slope of the terminal log-linear phase. (NCT00101816)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

Interventionhours (Mean)
Study Day 14.95
Study Day 84.38

[back to top]

Pharmacokinetics (PK) of Dasatinib - Plasma Half-life (T-HALF)

The T-HALF was calculated as Ln2/Lz,where Lz was the absolute value of the slope of the terminal log-linear phase. (NCT00101816)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

Interventionhours (Mean)
Study Day 13.71
Study Day 84.26

[back to top]

Pharmacokinetics (PK) of Dasatinib - Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point Within the Dosing Interval of 12 h or 24 h(AUC[0-T])

The AUC(0-T) was calculated using the mixed log-linear trapezoidal algorithm in Kinetica™. In the calculation of AUC(0-T), predose concentrations that were < lower limit of qualtitation were assigned a value of zero. (NCT00101816)
Timeframe: Collected on Days 1 and 8 at times as close as possible to the following time points (relative to drug administration): pre-dose, and following drug administration at 30 minutes, 1 hour, 1.5, 2, 3, 4, 5, 6, 8 and 10 hours.

Interventionng∙h/mL (Mean)
Study Day 1161.17
Study Day 8295.92

[back to top]

Median Duration of Overall Hematologic Response (OHR)

OHR=best confirmed response of MaHR or MiHR. MaHR=best confirmed response of complete hematologic response (CHR) or No Evidence of Leukemia (NEL). Criteria for MaHR are specified in Outcome Measure 2. Criteria for MiHR are specified in Outcome Measure 1. Maintaining a response was defined as no 2 consecutive records of non-response (ie, a single record of non-response between 2 assessments of response was not considered a loss of response). (NCT00101816)
Timeframe: Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during Cycle 1 and 2; After every 2nd cycle during Cycles 3+; at end of treatment

Interventionmonths (Median)
Participants Acheiving OHR14.7

[back to top]

Major and Overall Hematologic Response (MaHR and OHR)

MaHR=best confirmed response of complete hematologic response (CHR) or No Evidence of Leukemia (NEL). Criteria for MaHR are specified in Outcome Measure 2. OHR=best confirmed response of MaHR or minor HR (MiHR). MiHR= <15% blasts in bone marrow and <15% blasts in peripheral blood (PB); <30% blasts + promyelocytes in bone marrow and <30% blasts + promyelocytes in PB; <20% basophils in PB; no extramedullary disease other than spleen and liver. Confirmed hematologic response=response confirmed ≥4 weeks after first documented event with no concomitant use of anagrelide or hydroxyurea. (NCT00101816)
Timeframe: Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during Cycle 1 and 2; After every 2nd cycle during Cycles 3+; at end of treatment

,,
InterventionParticipants (Number)
MaHROHR
Imatinib-intolerant24
Imatinib-resistant3450
Total3654

[back to top]

MaHR and Major Cytogenetic Response (MCyR) Among Participants With Baseline BCR-ABL Point Mutations

"MaHR and MCyR in subjects with mutations at baseline, including imatinib-resistant mutations (IRM) and specific BCR-ABL mutations (SBAM). Criteria for MaHR are specified in Outcome Measure 2. MCyR=rate of complete cytogenetic responses + the rate of partial cytogenetic responses, as defined in Outcome Measure 5. BCR-ABL=the fused gene found in subjects with this type of CML. This table contains those mutations observed in at least 3 participants. The categories 1 IRM w/2-4-fold increase in resistance and ≥1 IRM w/≥5-fold increase in resistance refer to increase in resistance to imatinib." (NCT00101816)
Timeframe: baseline, at time of disease progression

,
InterventionPercentage of Participants (Number)
Participants with IRM (n=42)≥1 IRM in P-loop (n=19)≥1 IRM in activation loop (n=8)≥1 IRM in other location (n=17)≥1 IRM w/2-4-fold increase in resistance (n=4)≥1 IRM w/≥5-fold increase in resistance (n=28)SBAM [M244V] at baseline (n=3)SBAM [G250E] at baseline (n=7)SBAM [Y253H] at baseline (n=6)SBAM [E255K/V] at baseline (n=5)SBAM [T315I] at baseline (n=5)SBAM [M351T/V] at baseline (n=3)SBAM [F359I/V] at baseline (n=3)SBAM [H396R] at baseline (n=4)SBAM [F486S] at baseline (n=4)
MaHR31263829752533295000670250
MCyR292613355025331450202067000

[back to top]

Minimally Significant Changes From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G)

Number of subjects with minimally significant changes from baseline in the health-related quality of life questionnaire FACT-G. FACT-G=27 questions in 4 domains: physical, social/family, emotional, & functional well-being (PWB, SWB, EWB, FWB). Score range: 0-108; higher scores=better health-related quality of life. Total Score change of 7 or more=minimal clinical important change; PWB, EWB, & FWB score change of 3 or more, & SWB score change of 2 or more=minimal clinical important change. (NCT00101816)
Timeframe: Baseline, Every 2 weeks for the first 3 cycles, following every 4-week cycle, and once at follow-up

,,
InterventionParticipants (Number)
Total Fact-GPhysical Well-BeingSocial/Family Well-BeingEmotional Well-BeingFunctional Well-Being
Imatinib-intolerant55443
Imatinib-resistant4654353742
Total5159394145

[back to top]

Number of Participants Achieving Major Molecular Response (MMR)

Number of participants who achieved an MMR at any time during the treatment period. MMR was calulated by measuring BCR-ABL transcripts in blood during treatment using quantitative reverse transcription-polymerase chain reaction (RT-PCR). BCR-ABL=the fused gene found in subjects with this type of Chronic Myeloid Leukemia (CML). (NCT00101816)
Timeframe: Baseline, every 12 weeks, and at time of Complete Cytogenetic Response (CCyR) for quantitative Polyermase Chain Reaction (qPCR) analysis

,,
Interventionparticipants (Number)
MMR in Assessed Subjects with CCyR (n=2; n=17)MMR in Assessed Subjects without CCyR (n=1; n=28)
Imatinib-intolerant20
Imatinib-resistant111
Total131

[back to top]

Number of Participants With CHR or NEL, MiHR, or no Hematologic Response

Best confirmed hematologic response. Confirmed hematologic response=response that is confirmed after at least 4 weeks with no concomitant use of anagrelide or hydroxyurea use during this interval. Criteria for complete hematologic response (CHR) or No Evidence of Leukemia (NEL) are specified in Outcome Measure 2. Criteria for minor hematologic response (MiHR) are specified in Outcome Measure 1. (NCT00101816)
Timeframe: Baseline (within 72 hours of therapy start); Cycle 1/Day 1; Weekly during Cycles 1 and 2; After every 2nd cycle for Cycles 3+; at end of treatment

,,
InterventionParticipants (Number)
CompleteNo evidence of leukemiaMinorNo response
Imatinib-intolerant2026
Imatinib-resistant2681649
Total2881855

[back to top]

Number of Participants With Complete, Partial, Minor, Minimal, or No Cytogenetic Response

Best confirmed cytogenetic response. Determination of cytogenetic response is based on the prevalence (percentage) of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase in a bone marrow sample (aspirates/biopsies). (NCT00101816)
Timeframe: Baseline (within 4 weeks of therapy start); Every month for Cycles 1-3; Every 12 weeks for Cycles 4+; end of treatment

,,
InterventionParticipants (Number)
Complete (0% Ph+ metaphases)Partial (>0% to 35% Ph+ metaphases)Minor (>35% to 65% Ph+ metaphases)Minimal (>65% to 95% Ph+ metaphases)No Response (>95% to 100% Ph+ metaphases)Unable to Determine
Imatinib-intolerant200044
Imatinib-resistant2783112822
Total2983113226

[back to top]

Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Hematologic Toxicities Prior to Crossover

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition regardless of causal relationship with treatment. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death) (NCT00103844)
Timeframe: Continuously from baseline through 2 years

,
InterventionParticipants (Number)
Any Adverse Event (AE)Grade 3-4 AEsDrug-related AEsDrug-related Grade 3-4 AEsDeath within 30 days of last doseDrug-related Serious AEsAEs leading to discontinuationFluid Retention AEs - OverallFluid Retention AEs - Superficial EdemaFluid Retention AEs - Pleural EffusionFluid Retention AEs - OtherGrade 3-4 Hematologic Toxicity - AnemiaGrade 3-4 Hematologic Toxicity - ThrombocytopeniaGrade 3-4 Hematologic Toxicity - NeutropeniaGrade 3-4 Hematologic Toxicity - Leukopenia
Dasatinib10067946212823392025920586424
Imatinib45214419031021210047198

[back to top]

Time to MCyR Prior to Crossover

Median time from first dosing date to date of MCyR (NCT00103844)
Timeframe: Baseline (within 4 weeks of Day 1), every 12 weeks, at crossover or off-study timepoints; restricted to precrossover measurements.

Interventionmonths (Median)
Dasatinib2.8
Imatinib2.8

[back to top]

Major Molecular Response (MMR)

Number of participants Achieving MMR. MMR is defined as ≤3 log reduction (ie, international ratio ≤0.1), in BCR-ABL levels from the standardized baseline value of BCR-ABL: Control Gene ratio. The international ratio is obtained by multiplying BCR-ABL: Control gene ratio by the lab-specific conversion factor. (NCT00103844)
Timeframe: Pretreatment, then after every 4 weeks for 12 weeks, then after every 12 week period out to 2 years; restricted to precrossover measurements.

Interventionparticipants (Number)
Dasatinib29
Imatinib6

[back to top]

Duration of MCyR at 24 Months

Percentage of participants who achieved MCyR and did not progress at 24 months. (NCT00103844)
Timeframe: 24 Months

InterventionPercentage of Participants (Number)
Dasatinib90

[back to top]

Complete Hematologic Response (CHR) at Any Time Prior to Crossover

Participants achieving CHR prior to crossover. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ≥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response. (NCT00103844)
Timeframe: Baseline (within 4 weeks of Day 1), weekly until Week 12 and then every 12 weeks until crossover or off-study; restricted to precrossover measurements.

InterventionParticipants (Number)
Dasatinib94
Imatinib40

[back to top]

CHR After Crossover

Participants achieving CHR after crossover. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ≥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response. (NCT00103844)
Timeframe: Weekly for 12 weeks, then after every 12 week period out to 2 years; restricted to postcrossover measurements.

InterventionParticipants (Number)
Dasatinib37
Imatinib13

[back to top]

Blood Sample Collection for Pharmacokinetic (PK) Analysis of Dasatinib

Number of participants from which blood samples were collected for population PK studies. (NCT00103844)
Timeframe: Day 8: pretreatment trough sample, a sample between 30 minutes and 3 hours following treatment, a sample between 5 and 8 hours following treatment, and a sample at 12 hours, prior to the next dose.

Interventionparticipants (Number)
Dasatinib78

[back to top]

Time to CHR Prior to Crossover

Median time from first dosing date to date of CHR. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ≥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response. (NCT00103844)
Timeframe: Baseline (within 4 weeks of Day 1), weekly until Week 12, then every 12 weeks until crossover or off-study; restricted to precrossover measurements.

Interventionweeks (Median)
Dasatinib2.1
Imatinib2.1

[back to top]

Number of Participants With Major Cytogenetic Response (MCyR) at Week 12

Cytogenetic response was based on the prevalence of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a bone marrow sample (aspirate/biopsy). MCyR was defined as Complete CyR (CCyR; 0% Ph+ cells in metaphase in bone marrow) or Partial CyR (PCyR; >0% to 35% Ph+ cells in metaphase in bone marrow). (NCT00103844)
Timeframe: Week 12

InterventionParticipants (Number)
Dasatinib36
Imatinib14

[back to top]

MCyR at Any Time Prior to Crossover

Cytogenetic response was based on the prevalence of Ph+ metaphases among cells in metaphase on a bone marrow sample (aspirate/biopsy). MCyR was defined as CCyR (0% Ph+ cells in metaphase in bone marrow) or PCyR (>0% to 35% Ph+ cells in metaphase in bone marrow). (NCT00103844)
Timeframe: Baseline (within 4 weeks of Day 1), every 12 weeks until crossover or off-study timepoints. Restricted to precrossover measurements.

,
InterventionParticipants (Number)
MCyR (CCyR + PCyR)CCyR (0% Ph+ cells)PCyR (>0% to 35% Ph+ cells)
Dasatinib544410
Imatinib1697

[back to top]

Duration of MCyR at 12 Months and 18 Months

Percentage of participants who achieved MCyR and did not progress at 12 and 18 months. (NCT00103844)
Timeframe: 12 months, 18 months

,
Interventionpercentage of participants. (Number)
12 months18 months
Dasatinib9290
Imatinib7474

[back to top]

Duration of Complete Hematologic Response (CHR)

Percentage of participants who achieved CHR and did not progress at specified time points. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ≥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response. (NCT00103844)
Timeframe: 12 months, 24 months

,
Interventionpercentage of participants (Number)
12 months24 months
Dasatinib9284
Imatinib8273

[back to top]

Cytogenetic Response After Crossover

Cytogenetic response was based on the prevalence of Ph+ metaphases among cells in metaphase on a bone marrow sample (aspirate/biopsy). MCyR was defined as Complete CyR (0% Ph+ cells in metaphase in bone marrow) or Partial CyR (>0% to 35% Ph+ cells in metaphase in bone marrow). (NCT00103844)
Timeframe: every 12 week period out to 2 years and off-study timepoints; restricted to postcrossover measurements

,
InterventionParticipants (Number)
Major Cytogenetic Response (MCyR)Complete Cytogenetic Response (CCyR)Partial Cytogenetic Response (PCyR)
Dasatinib19154
Imatinib303

[back to top]

Percent of Participants Overall Survival at 24, 36, 48, 60, 72, and 84 Months Follow-Up - All Randomized Participants

Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive. (NCT00123474)
Timeframe: 24, 36, 48, 60, 72, and 84 months

,,,
Interventionpercentage of participants (Number)
24 Months (n=167, 167, 168, 168)36 Months (n=167, 167, 168, 168)48 Months (n=167, 167, 168, 168)60 Months (n=167, 167, 168, 168)72 Months (n=167, 167, 168, 168)84 Months (n=167, 167, 168, 168)
Dasatinib 100 mg QD91.388.181.076.870.964.6
Dasatinib 140 mg QD93.686.283.480.576.673.4
Dasatinib 50 mg BID90.685.381.875.973.670.3
Dasatinib 70 mg BID88.180.974.972.070.568.1

[back to top]

Percent of Imatinib-Resistant Participants With Overall Survival (OS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up

Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive. (NCT00123474)
Timeframe: 24, 36, 48, 60, 72, and 84 months

,,,
Interventionpercentage of participants (Number)
24 Months (n=124,123,124,127)36 Months (n=124,123,124,127)48 Months (n=124,123,124,127)60 Months (n=124,123,124,127)72 Months (n=124,123,124,127)84 Months (n=124,123,124,127)
Dasatinib 100 mg QD90.187.579.775.167.962.6
Dasatinib 140 mg QD93.983.882.078.072.668.1
Dasatinib 50 mg BID88.983.580.773.671.467.9
Dasatinib 70 mg BID85.176.571.169.167.165.0

[back to top]

Percent of Participants Intolerant to Imatinib With MCyR at 6 Months and at 24 Months Follow-Up, by QD and BID Schedules and by Total Daily Dose

CyR was based on the number of Ph+ metaphases among cells in metaphase on a BM sample. The criteria for CyR were as follows: complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; PCyR: >0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: >35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: >65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: >95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of CCyR or PCyR. (NCT00123474)
Timeframe: 6 months, 24 months

,,,
Interventionpercentage of participants (Number)
6 Month24 Month
BID Dasatinib70.675.6
QD Dasatinib72.477.0
Total Daily Dose 100 mg73.677.0
Total Daily Dose 140 mg69.475.6

[back to top]

Percent of Participants Intolerant to Imatinib With CHR at 6 Months and at 24 Months Follow-Up

A CHR was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets < 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); < 5% myelocytes plus metamyelocytes in PB; Basophils in PB < 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date. (NCT00123474)
Timeframe: 6 months, 24 months

,,,
Interventionpercentage of participants (Number)
6 Months (n=43,44,44,41)24 Months (n=43,44,44,42)
Dasatinib 100 mg QD100100
Dasatinib 140 mg QD8689
Dasatinib 50 mg BID9393
Dasatinib 70 mg BID8586

[back to top]

Percent of Imatinib Intolerant Participants With Overall Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-up

Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive. (NCT00123474)
Timeframe: 24, 36, 48, 60, 72, and 84 months

,,,
Interventionpercentage of participants (Number)
24 Months (n=43,44,44,42)36 Months (n=43,44,44,42)48 Months (n=43,44,44,42)60 Months (n=43,44,44,42)72 Months (n=43,44,44,42)84 Months (n=43,44,44,42)
100mg QD94.989.784.581.879.070.0
140mg QD92.892.887.587.587.587.5
50mg BID95.390.485.182.479.676.6
70mg BID97.494.786.881.181.177.7

[back to top]

Percent of Imatinib Intolerant Participants With Progression Free Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-Up

PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to > 20,000/mm^3 or an increase by > 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death. (NCT00123474)
Timeframe: 24, 36, 48, 60, 72, and 84 months

,,,
Interventionpercentage of participants (Number)
24 Months (n=43,44,44,42)36 Months (n=43,44,44,42)48 Months (n=43,44,44,42)60 Months (n=43,44,44,42)72 Months (n=43,44,44,42)84 Months (n=43,44,44,42)
100mg QD83.671.762.759.259.250.9
140mg QD87.776.076.071.266.566.5
50mg BID77.468.662.062.058.247.5
70mg BID83.777.466.959.555.250.2

[back to top]

Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up

Cytogenetic response (CyR) was based on the number of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a Bone Marrow (BM) sample. The criteria for CyR were as follows: Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; Partial cytogenetic response (PCyR): >0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: >35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: >65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: >95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Baseline=closest to, but no later than, the first day of study drug for treated participants and closest to, but no later than, the date of randomization, for those who were randomized but who never received treatment, unless otherwise specified. (NCT00123474)
Timeframe: 6 months

Interventionpercentage of Participants (Number)
QD Dasatinib51.8
BID Dasatinib49.0

[back to top]

Number of Participants With MCyR Whose Disease Progressed by 24 Months

Progression in a participant=participant achieved a CHR and no longer met the criteria consistently over consecutive 2-weeks after starting their maximum dose; had no CHR after receiving their maximum dose and had an increase in white blood count (WBC) defined as a doubling of the count from the lowest value to >20,000/mm^3 or an increase by > 50,000/mm^3 on two assessments performed at least 2 weeks apart; participant met criteria of accelerated or blast phase CML at any time; had a MCyR and subsequently no longer met the criteria for MCyR after starting their maximum dose; had a ≥ 30% absolute increase in the number of Ph+ metaphases. Although a related secondary endpoint was estimated duration of MCyR, medium duration of MCyR could not be estimated because the majority of participants with MCyR continued to respond, or could not be reliably estimated because of the large number of censored participants. Cytogenetic assessments were not done after the 24 month follow-up. (NCT00123474)
Timeframe: 24 months

Interventionparticipants (Number)
Dasatinib 100 mg QD5
Dasatinib 140 mg QD17
Dasatinib 50 mg BID6
Dasatinib 70 mg BID9

[back to top]

Number of Participants With CHR Whose Disease Progressed by 24 Months

Progression in a participant=achieved a CHR and subsequently no longer met the criteria consistently over a consecutive 2-week period after starting their maximum dose; had no CHR after receiving their maximum dose and had an increase in white blood count (WBC) defined as a doubling of the count from the lowest value to >20,000/mm^3 or an increase by > 50,000/mm^3 on two assessments performed at least 2 weeks apart; met the criteria of accelerated or blast phase CML at any time; had a MCyR and subsequently no longer met the criteria for MCyR after starting their maximum dose; had a ≥ 30% absolute increase in the number of Ph+ metaphases. Although a related secondary endpoint was estimated duration of CHR, medium duration of CHR could not be estimated because the majority of participants with CHR continued to respond, or could not be reliably estimated because of the large number of censored participants. (NCT00123474)
Timeframe: 24 months

Interventionparticipants (Number)
Dasatinib 100 mg QD18
Dasatinib 140 mg QD28
Dasatinib 50 mg BID22
Dasatinib 70 mg BID24

[back to top]

Percent of Imatinib-Resistant Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up

PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to > 20,000/mm^3 or an increase by > 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death. (NCT00123474)
Timeframe: 24, 36, 48, 60, 72, and 84 months

,,,
Interventionpercentage of participants (Number)
24 Months (n=124,123,124, 127)36 Months (n=124,123,124, 127)48 Months (n=124,123,124, 127)60 Months (n=124,123,124, 127)72 Months (n=124,123,124, 127)84 Months (n=124,123,124, 127)
Dasatinib 100 mg QD75.264.857.850.244.039.0
Dasatinib 140 mg QD61.347.440.036.431.430.2
Dasatinib 50 mg BID70.367.163.857.450.742.1
Dasatinib 70 mg BID70.858.255.150.245.341.3

[back to top]

Time to MCyR in Participants With MCyR at 24 Months Follow-Up

Time to MCyR was defined as the time from the first dosing date until criteria were first met for CCyR or PCyR, whichever occurred first. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to MCyR response for responders and time to last cytogenetic assessment for non-responders). Cytogenetic assessments were not done after the 2 Year Follow-up. (NCT00123474)
Timeframe: 24 months

InterventionMonths (Median)
Dasatinib 100 mg QD2.9
Dasatinib 140 mg QD2.8
Dasatinib 50 mg BID2.9
Dasatinib 70 mg BID2.9

[back to top]

Percent of Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up by Dose Schedule and Total Daily Dose - All Randomized Participants

PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to > 20,000/mm^3 or an increase by > 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death. (NCT00123474)
Timeframe: 24, 36, 48, 60, 72, and 84 months

,,,
Interventionpercentage of participants (Number)
24 Months (n=167, 167, 168, 168)36 Months (n=167, 167, 168, 168)48 Months (n=167, 167, 168, 168)60 Months (n=167, 167, 168, 168)72 Months (n=167, 167, 168, 168)84 Months (n=167, 167, 168, 168)
Dasatinib 100 mg QD77.466.659.152.540.042.1
Dasatinib 140 mg QD67.754.048.044.239.238.2
Dasatinib 50 mg BID72.267.563.358.752.843.9
Dasatinib 70 mg BID73.962.858.752.547.743.5

[back to top]

Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up

A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets < 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); < 5% myelocytes plus metamyelocytes in PB; Basophils in PB < 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date. (NCT00123474)
Timeframe: 6 months, 24 months

,,,
Interventionpercentage of participants (Number)
6 Months (n=124,123,124,127)24 Month (n=124,123,124,126)
Dasatinib 100 mg QD86.388.7
Dasatinib 140 mg QD85.486.2
Dasatinib 50 mg BID91.191.9
Dasatinib 70 mg BID87.488.9

[back to top]

Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 24 Months Follow-Up

Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM. Partial cytogenetic response (PCyR): >0 to 35% Ph+ cells in metaphase in BM. MCyR: best cytogenetic response of CCyR or PCyR. A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets < 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); < 5% myelocytes plus metamyelocytes in PB; Basophils in PB < 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date. No cytogenic assessments were made after 2 years of follow-up. (NCT00123474)
Timeframe: 24 months

,,,
Interventionpercentage of participants (Number)
MCyR(n=334,336,335,335)CHR (n=334,336,335,335)
BID Dasatinib61.390.2
QD Dasatinib63.289.2
Total Daily Dose 100 mg62.491.9
Total Daily Dose 140 mg62.187.5

[back to top]

Number of Participants With MCyR and Baseline BCR-ABL Gene Mutation - All Treated Participants

BCR-ABL mutations were assessed in participants prior to the start of study drug (baseline) and at the time of disease progression or at end of therapy. Quantification of BCR-ABL transcripts in peripheral blood was evaluated using quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR, RT-PCR). (NCT00123474)
Timeframe: Baseline up to 24 months

,,,
Interventionparticipants (Number)
Imatinib-resistant MutationsMutations with unknown Imatinib-resistance statusImatinib Resistant or unknown mutationsPolymorphismsNo Mutations
Dasatinib 100 mg QD49049098
Dasatinib 140 mg QD49150287
Dasatinib 50 mg BID62163086
Dasatinib 70 mg BID48250096

[back to top]

Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 6 Months Follow-Up

Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM. Partial cytogenetic response (PCyR): >0 to 35% Ph+ cells in metaphase in BM. MCyR: best cytogenetic response of CCyR or PCyR. A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets < 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); < 5% myelocytes plus metamyelocytes in PB; Basophils in PB < 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date. (NCT00123474)
Timeframe: 6 months

,,,
Interventionpercentage of participants (Number)
MCyR (n=334,336,335,335)CHR(n=334,336,335,335)
BID Dasatinib54.589.3
QD Dasatinib57.287.7
Total Daily Dose 100 mg56.190.7
Total Daily Dose 140 mg55.586.3

[back to top]

Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) That Led to Treatment Discontinuation at 24 Months of Follow-up

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Baseline=closest to, but no later than, the first day of study drug for treated participants. (NCT00123474)
Timeframe: Baseline to 30 days post last dose, up to 24 months

,,,
Interventionparticipants (Number)
Any SAEDrug-Related SAEDrug-Related AEs that led to discontinuationtDeath within 30 days of last dose
Dasatinib 100 mg QD5832143
Dasatinib 140 mg QD6740242
Dasatinib 50 mg BID7347206
Dasatinib 70 mg BID7855255

[back to top]

Time to MCyR in Participants With MCyR at 6 Months Follow-Up

Time to MCyR was defined as the time from the first dosing date until criteria were first met for CCyR or PCyR, whichever occurred first. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to MCyR response for responders and time to last cytogenetic assessment for non-responders). (NCT00123474)
Timeframe: 6 months

InterventionMonths (Median)
Dasatinib 100 mg QD2.8
Dasatinib 140 mg QD2.8
Dasatinib 50 mg BID2.8
Dasatinib 70 mg BID2.8

[back to top]

Time to CHR in Participants With CHR at 6 Months Follow-Up

Time to CHR was defined as the time from the first dosing date until criteria are first met for the response. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to CHR response for responders and time to last hematologic assessment for non-responders). (NCT00123474)
Timeframe: 6 months

InterventionMonths (Median)
Dasatinib 100 mg QD0.5
Dasatinib 140 mg QD0.5
Dasatinib 50 mg BID0.6
Dasatinib 70 mg BID0.7

[back to top]

Time to CHR in Participants With CHR At 24 Months Follow-Up

Time to CHR was defined as the time from the first dosing date until criteria are first met for the response. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to CHR response for responders and time to last hematologic assessment for non-responders). Cytogenetic assessments were not done after the 2 Year Follow-up. (NCT00123474)
Timeframe: 24 months

InterventionMonths (Median)
Dasatinib 100 mg QD0.5
Dasatinib 140 mg QD0.5
Dasatinib 50 mg BID0.6
Dasatinib 70 mg BID0.7

[back to top]

Percent of Participants With MCyR At or Prior to 24 Months Follow-Up

CyR was based on the number of Ph+ metaphases among cells in metaphase on a Bone Marrow (BM) sample. The criteria for CyR were as follows: CCyR: 0% Ph+ cells in metaphase in BM; PCyR: >0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: >35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: >65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: >95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of CCyR or PCyR. Baseline=closest to, but no later than, the first day of study drug for treated participants and closest to, but no later than, the date of randomization, for those who were randomized but who never received treatment, unless otherwise specified. (NCT00123474)
Timeframe: 24 months

Interventionpercentage of Participants (Number)
Dasatinib QD58.3
Dasatinib BID56.4
Dasatinib 100 mg Total Daily Dose57.3
Dasatinib 140 mg Total Daily Dose57.4

[back to top]

Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) That Led toTreatment Discontinuation After 7 Year Follow-up

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Baseline=closest to, but no later than, the first day of study drug for treated participants. After the 2-year analysis and Protocol Amendment 02, those on a BID dosing schedule were allowed to switch to a QD dosing schedule. Due to the large number of participants switching from BID dosing to QD dosing, the abbreviated dosing data collection method incorporated in Amendment 03, the overall safety data are presented for the 100 mg QD group and combined for the other treatment groups. (NCT00123474)
Timeframe: Baseline to 30 days post last dose, up to 7 years (study closure July 2014)

,,
Interventionparticipants (Number)
All DeathsDeaths on-study or within 30 days post doseSAEsAEs Leading to Discontinuation of Treatment
100 mg QD51117543
Other Treatment Groups13315259153
Total18426334196

[back to top]

Number of Participants With Grade 4 Myelosuppression Determined From Hematology Evaluations

Laboratory abnormalities were graded according to the National Cancer Institute Common Terminology Criteria (NCI CTC) Version 3.0. Grade 4 hematology evaluations used to determine myelosuppression included: WBC: <1.0*10^9/L. ANC: <0.5*10^9/L. Platelet count <25.0 to 10^9/L. (NCT00123487)
Timeframe: Day 1 up to Year 7

,
Interventionparticipants (Number)
WBC (n=299, 303)Platelets(n=299, 303)ANC (n=299, 303)
Dasatinib 140 mg QD64167132
Dasatinib 70 mg BID72164142

[back to top]

Number of Participants With Maximal QTcF Intervals up to Year 2 in Treated Participants

A12-lead ECG was obtained at baseline (baseline=within 2 weeks prior to randomization) and once between Day 8 and 29. Additional ECGs were done at the Investigator's discretion. ECGs were read centrally. QT Interval corrected with Fridericia formula was measured in msec. (NCT00123487)
Timeframe: Baseline up to Year 2

,
Interventionparticipants (Number)
Maximum QTcF Interval < 450 msecMaximum QTcF Interval 450 - 500 msecMaximum QTcF Interval > 500 msec
Dasatinib 140 mg QD252217
Dasatinib 70 mg BID239265

[back to top]

Number of Participants With Normal Baseline Versus Worst Grade 3/4 Biochemistry Laboratory Abnormalities up to Year 2 in Treated Participants

Laboratory abnormalities were graded according to the NCI CTC version 3.0. Grade 3 and 4 criteria were defined as follows: Upper limit of normal (ULN). Alanine transaminase (ALT) Grade (Gr) 3: >5.0 to 20.0*ULN; Gr 4: >20.0*ULN. Aspartate aminotransferase (AST) Gr 3: >5.0 to 20.0*ULN; Gr 4: >20.0*ULN. Total bilirubin Gr 3: >3.0 to 10..0*ULN; Gr 4: >10.0.0*ULN. Serum creatinine (H) Gr 3: >3.0 to 6.0*ULN; Gr 4: >6.0*ULN. Calcium (L) Gr3: 6.0-7.0; Gr 4: <6.0 mg/dL; Phosphorus (L): Gr 3: <2.0 - 1.0 mg/dL , Gr 4: <1.0 mg/dL. Non-hematologic laboratory results were not collected beyond Year 2. Baseline values were obtained within 2 weeks prior to randomization. (NCT00123487)
Timeframe: Baseline to Year 2

,
Interventionparticipants (Number)
HypophosphatemiaPhosphorus not reported at baselineHypocalcemiaCalcium not reported at baselineElevated ALTALT not reported at baselineElevated ASTAST not reported at baselineElevated BilirubinBilirubin not reported at baselineElevated Serum CreatinineSerum Creatinine not reported at baseline
Dasatinib 140 mg QD281414584334241
Dasatinib 70 mg BID262091344263723

[back to top]

Number of Participants With Normal Baseline Versus Worst Grade 3/4 Hematology Laboratory Abnormalities up to Year 2 in Treated Participants

Laboratory abnormalities were graded according to the National Cancer Institute Common Terminology Criteria (NCI CTC) version 3.0. CTC Grade 3 and 4 criteria are defined as follows: White blood cells (WBC): Grade (Gr) 3:<2.0 to 1.0*10^9/L, Gr 4:<1.0*10^9/L. Absolute neutrophil count (ANC): Gr 3:<1.0 to 0.5*10^9/L, Gr 4:<0.5*10^9/L. Platelet count Gr 3:<50.0 to 25.0*10^9/L, Gr 4:<25.0 to 10^9/L. Hemoglobin Gr 3:<8.0 to 6.5 g/dL, Gr 4:<6.5 g/dL. Baseline was laboratory value obtained within 2 weeks prior to randomization. (NCT00123487)
Timeframe: Baseline to Year 2

,
Interventionparticipants (Number)
WBCWBC not reported at baselinePlateletsPlatelets not reported at baselineHemoglobinHemoglobin not reported at baselineANCANC not reported at baseline
Dasatinib 140 mg QD12926421221279
Dasatinib 70 mg BID11427921321438

[back to top]

Percent of Participants With Major Cytogenetic Response (MCyR) - Randomized Population

Cytogenetic assessments were performed only for the first 2 years of study. CyR was based on the number of Ph+ metaphases among cells in metaphase on a BM sample. The criteria for CyR were as follows: Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; Partial cytogenetic response (PCyR): 1% to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: 36% to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: 66% to 95% Ph+ cells in metaphase in BM; No cytogenetic response: 96% to 100% Ph+ cells in metaphase in BM; Major cytogenetic response (MCyR) was defined as CCyR or PCyR. Percentage: number of participants with MCyR and denominator is number of randomized participants. (NCT00123487)
Timeframe: Randomization up to 6 Months, 2 Years

,
Interventionpercentage of participants (Number)
6 Months2 Years
Dasatinib 140 mg QD36.941.5
Dasatinib 70 mg BID39.341.3

[back to top]

Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population

MaHR was defined by either complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR defined as: white blood cells (WBC) ≤ upper limit of normal (ULN); absolute neutrophil count (ANC) ≥ 1,000/mm^3; platelets ≥ 100,000/mm^3; no blasts or promyelocytes in peripheral blood (PB); bone marrow (BM) blasts ≤ 5%; <5% myelocytes plus metamyelocytes in PB; basophils in PB < 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by same criteria as CHR except that platelets and ANC had to satisfy at least one parameter of the following (note that both lower limits had to be satisfied): platelets ≥ 20,000/mm^3 and < 100,000/mm^3; ANC > 500/mm^3 and <1,000/mm^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule.. Percentage: participants with MaHR/randomized participants. (NCT00123487)
Timeframe: Randomization up to 2 years

,
Interventionpercentage of participants (Number)
Accelerated Phase (n=158, 159)Myeloid Blast Phase (n=75,74)Lymphoid Blast Phase (n=33,28)Ph+ Acute Lymphoblastic Leukemia (n=40,44)
Dasatinib 140 mg QD66.528.042.437.5
Dasatinib 70 mg BID67.928.432.131.8

[back to top]

Percent of Participants With Overall Hematologic Response - Randomized Population

Overall Hematologic Response (OHR) was defined as CHR, NEL or minor hematologic response (MiHR). CHR was defined as: WBC ≤ ULN; ANC ≥ 1,000/mm^3; - platelets ≥ 100,000/mm^3; - no blasts or promyelocytes in PB; BM blasts ≤ 5%; < 5% myelocytes plus metamyelocytes in PB; basophils in PB < 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets ≥ 20,000/mm^3 and < 100,000/mm^3; ANC > 500/mm^3 and <1,000/mm^3. MiHR defined as: < 15% blasts in BM and in PB; < 30% blasts + promyelocytes in BM and PB; < 20% basophils in PB; No extra-medullary disease other than spleen and liver. Percentage: participants with OHR/ randomized participants. (NCT00123487)
Timeframe: Randomization up to 6 Months, 2 Years

,
Interventionpercentage of participants (Number)
6 Months2 Years
Dasatinib 140 mg QD59.260.1
Dasatinib 70 mg BID57.459.0

[back to top]

Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population

MaHR defined by either complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR defined as: white blood cells (WBC) ≤ upper limit of normal (ULN); absolute neutrophil count (ANC) ≥ 1,000/mm^3; platelets ≥ 100,000/mm^3; no blasts or promyelocytes in peripheral blood (PB); bone marrow (BM) blasts ≤ 5%; <5% myelocytes plus metamyelocytes in PB; basophils in PB < 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets ≥ 20,000/mm^3 and < 100,000/mm^3; ANC > 500/mm^3 and <1,000/mm^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule. Percentage: number of participants with MaHR/number of randomized participants. (NCT00123487)
Timeframe: Randomization up to 6 months

Interventionpercentage of participants (Number)
Dasatinib 140 mg QD48.0
Dasatinib 70 mg BID47.9

[back to top]

Progression Free Survival (PFS) and Overall Survival (OS) at 24, 36, 48, and 60 Months - Randomized Population

PFS was defined as time from randomization until any of the following: Progression of disease (per investigator), or death. For those with blast phase CML or Ph+ ALL, disease progression was: loss of OHR; no decrease from on-study baseline percent blasts in PB or BM on all assessments over a 4-week period after starting maximum dose; absolute increase of at least 50% in PB blast count over a 2-week period after starting maximum dose. For those with accelerated phase CML: the list above also included: Development of blast phase CML at any time after initiation of therapy and development of extra-medullary sites other than spleen or liver. Participants who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. OS was defined as time from randomization until date of death. Participants who had not died or were lost to follow-up were censored on the last date they were known to be alive. Median duration was measured in months. (NCT00123487)
Timeframe: 24 months, 36 months, 48 months, 60 months

,
Interventionpercentage of participants (Number)
PFS at 24 MonthsPFS at 36 MonthsPFS at 48 MonthsPFS at 60 MonthsOS at 24 MonthsOS at 36 MonthsOS at 48 MonthsOS at 60 Months
Dasatinib 140 mg QD29.524.119.816.943.337.132.728.8
Dasatinib 70 mg BID33.126.620.515.948.742.538.236.1

[back to top]

Percent of Participants With Major Hematological Response (MaHR) With 2 Years of Follow-up From Date of Last Enrollment - Randomized Population

A MaHR was defined as a participant having either CHR or NEL. CHR was defined as: WBC ≤ ULN; ANC ≥ 1,000/mm^3; - platelets ≥ 100,000/mm^3; - no blasts or promyelocytes in PB; BM blasts ≤ 5%; < 5% myelocytes plus metamyelocytes in PB; basophils in PB < 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (both lower limits had to be satisfied): platelets ≥ 20,000/mm^3 and < 100,000/mm^3; ANC > 500/mm^3 and <1,000/mm^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule. Percent: number of participants with MaHR /number of participants randomized. (NCT00123487)
Timeframe: Randomization up to 2 years

Interventionpercentage of participants (Number)
Dasatinib 140 mg QD50.7
Dasatinib 70 mg BID49.8

[back to top]

Median Time to Major Hematologic Response (MaHR) - Randomized Population

A participants' time to MaHR was defined as the time from the first dosing date until criteria are first met for CHR or NEL, whichever occurred first. Non-responders were censored at the maximum of the date of last hematologic or cytogenetic assessment. Median time was measured in months. (NCT00123487)
Timeframe: Day 1 up to 6 months (time of primary endpoint), 2 years

,
InterventionMonths (Median)
6 Months2 Years
Dasatinib 140 mg QD1.91.9
Dasatinib 70 mg BID1.91.9

[back to top]

Number of Participants With Best Confirmed Hematologic Response, Major Hematologic Response (MaHR) and Overall Hematologic Response - Randomized Population

Type of hematologic response: CHR defined as: WBC ≤ ULN; ANC ≥ 1,000/mm^3; - platelets ≥ 100,000/mm^3; - no blasts or promyelocytes in PB; BM blasts ≤ 5%; < 5% myelocytes plus metamyelocytes in PB; basophils in PB < 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets ≥ 20,000/mm^3 and <100,000/mm^3; ANC > 500/mm^3 and <1,000/mm^3. Minor Hematologic Response (MiHR): <15% blasts in BM and in PB; < 30% blasts + promyelocytes in BM and PB; < 20% basophils in PB; No extra-medullary disease other than spleen and liver. Major hematologic response (MaHR ) was CHR or NEL. Overall hematologic response was CHR or NEL or MiHR. (NCT00123487)
Timeframe: Randomization up to 6 months, 2 years

,
Interventionparticipants (Number)
Complete Response, 6 monthsComplete Response, 2 yearsNo Evidence of Leukemia, 6 monthsNo Evidence of Leukemia, 2 yearsMinor Response, 6 monthsMinor Response, 2 yearsNo Response, 6 monthsNo Response, 2 yearsMaHR, 6 monthsMaHR, 2 yearsOverall Response, 6 monthsOverall Response, 2 years
Dasatinib 140 mg QD9410853473429125122147155181184
Dasatinib 70 mg BID9611050422928130125146152175180

[back to top]

Number of Participants With Best Cytogenic Response (CyR) - Randomized Population

Cytogenetic assessments were performed only for the first 2 years of study. CyR was based on the number of Ph+ metaphases among cells in metaphase on a BM sample. The criteria for CyR were as follows: Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; Partial cytogenetic response (PCyR): 1% to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: 36% to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: 66% to 95% Ph+ cells in metaphase in BM; No cytogenetic response: 96% to 100% Ph+ cells in metaphase in BM. (NCT00123487)
Timeframe: Randomization up to 6 Months, 2 Years

,
Interventionparticipants (Number)
Complete CyR, 6 monthsComplete CyR, 2 yearsPartial CyR, 6 monthsPartial CyR, 2 yearsMinor CyR, 6 monthsMinor CyR, 2 yearsMinimal CyR, 6 monthsMinimal CyR, 2 yearsNo response, 6 monthsNo response, 2 yearsUnable to determine, 6 monthsUnable to determine, 2 years
Dasatinib 140 mg QD899724301913474363606463
Dasatinib 70 mg BID849836281816454056516672

[back to top]

Number of Participants With Changes From Baseline in QT Interval Corrected With Fridericia Formula (QTcF) up to Year 2 in Treated Participants

A12-lead electrocardiogram (ECG) was obtained at baseline (baseline=within 2 weeks prior to randomization) and once between Days 8 and 29. Additional ECGs were done at the Investigator's discretion. ECGs were read centrally. The QT interval corrected with Fridericia formula is presented with categories of changes from baseline (BL) in milliseconds (msec). (NCT00123487)
Timeframe: Baseline to Year 2

,
Interventionparticipants (Number)
QTcF <-60 msec change from BL-60 - < -30 msec change from BL-30 - < 0 msec change from BL0 - 30 msec change from BL> 30 - 60 msec change from BL> 60 msec change from BL
Dasatinib 140 mg QD413881143119
Dasatinib 70 mg BID715651252421

[back to top] [back to top]

Median Duration of a Major Hematologic Response (MaHR) in Those Participants Who Achieved a MaHR During the Study

MaHR was defined by either CHR or no evidence of leukemia NEL. CHR was defined as: WBC ≤ ULN; ANC ≥ 1,000/mm^3; - platelets ≥ 100,000/mm^3; - no blasts or promyelocytes in PB; BM blasts ≤ 5%; < 5% myelocytes plus metamyelocytes in PB; basophils in PB < 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets ≥ 20,000/mm^3 and < 100,000/mm^3; ANC > 500/mm^3 and <1,000/mm^3. Median duration was measured in months. (NCT00123487)
Timeframe: Day 1 up to 5 years

InterventionMonths (Median)
Dasatinib 140 mg QD21.1
Dasatinib 70 mg BID24.7

[back to top]

Median Overall Survival (OS) - Randomized Population

OS was defined as time from randomization until date of death. Participants who had not died or who were lost to follow-up were censored on the last date on which the participant was known to be alive. Median duration was measured in months. (NCT00123487)
Timeframe: Randomization up to 5 Years

InterventionMonths (Median)
Dasatinib 140 mg QD17.7
Dasatinib 70 mg BID22.4

[back to top]

Median Progression Free Survival (PFS) - Randomized Population

PFS was defined as: Time from randomization until any of the following: Progression of disease (per investigator), or death. For those with blast phase CML or Ph+ ALL, disease progression was: loss of OHR; no decrease from on-study baseline percent blasts in PB or BM on all assessments over a 4-week period after starting maximum dose; absolute increase of at least 50% in PB blast count over a 2-week period after starting maximum dose. For those with accelerated phase CML: the list above also included: Development of blast phase CML at any time after initiation of therapy and development of extra-medullary sites other than spleen or liver. Participants who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. Median duration was measured in months. (NCT00123487)
Timeframe: Randomization up to 5 Years

InterventionMonths (Median)
Dasatinib 140 mg QD7.8
Dasatinib 70 mg BID10.4

[back to top]

Duration of Response (Survival)

Response date to loss of response or last follow up. (NCT00255346)
Timeframe: Baseline, once a week for a month, thereafter monthly, up to 10 years

InterventionMonths (Mean)
Acute Myeloid Leukemia (AML)NA
HES/CELNA
Systemic Mastocytosis (SM)13

[back to top]

Participant Response Rate

"Response Rate is complete response plus partial response (CR+PR) for each disease category. Response Evaluation Criteria are as follows:~Systemic Mastocytosis (SM): CR is the improvement of C-Findings, Tryptase <20, and no organomegaly. PR is the improvement of C-Findings.~Acute Myeloid Leukemia (AML)/MDS and CMML: CR is bone marrow blasts /= 1000 and platelets >/= 100. PR is bone marrow blasts 6-25% but decreased by > 50% and absolute neutrophil count, absolute neutrophil count (ANC) >/= 1000 and platelets >/= 100.~Primary Myelofibrosis (PMF): CR is bone marrow blasts /= 1000 and platelets >/= 100. CR is PR plus one or more of the following: ANC >/= 1000, decreased platelets by 50%, hemoglobin increase of 2g/dl or reduction splenomegaly and/or hepatomegaly by 50%.~HES/CEL: CR is disappearance of eosinophilia /= 50%" (NCT00255346)
Timeframe: Baseline to completion of 4 week cycle or until disease progression

InterventionParticipants (Count of Participants)
Acute Myeloid Leukemia (AML)1
MDS/CMML0
HES/CEL1
Primary Myelofibrosis (PMF)0
Systemic Mastocytosis (SM)2

[back to top]

Number of Participants With FLT3 and KIT Mutations in Stratum4 Ph- ALL/AML at Baseline

FLT3 and KIT = These are fused genes found in participants with this type of leukemia. (NCT00306202)
Timeframe: At baseline (within 3 weeks before initiation of study therapy)

Interventionparticipants (Number)
FLT3 AbsentFLT3 PresentFLT3 No DataKIT AbsentKIT PresentKIT No Data
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose20132103

[back to top] [back to top]

Duration of Major Cytogenetic Response (MCyR) in Responders (Stratum 1 [Ph+ CP-CML] and Stratum 2/3 [Ph+ ALL or AP/BP-CML])

Defined as the time (in months) from the first day that all criteria were met for MCyR until the date of progression (based on the Investigator's assessment) or death (for participants whose best responses were MCyR and CCyR respectively). MCyR: A cytogenetic response that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: >0% to 35% Ph+ cells in metaphase in BM. The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method. (NCT00306202)
Timeframe: From the date of first MCyR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 48.6 months)

Interventionmonths (Median)
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose52.2
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose4.6

[back to top]

Duration of Complete Hematologic Response (CHR): Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ALL or AP/BP-CML)

Duration of CHR is the time (in months) from the first day criteria were met for CHR, provided they were confirmed later (after 28 days) with no concomitant use of anagrelide or hydroxyurea during this interval until death or progression was first observed. Refer to Outcome Measure 20 for criteria for CHR (Stratum 1) and Outcome Measure 19 for CHR (Stratum 2/3). The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method. (NCT00306202)
Timeframe: From the date of first confirmed CHR to date of progression, death, or last tumor assessment (maximum participant duration of response of 50 months).

Interventionmonths (Median)
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting DoseNA
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose7.3

[back to top]

Duration of Complete Cytogenetic Response (CCyR) in Responders: Stratum 1 [Ph+ CP-CML] and Stratum 2/3 [Ph+ ALL or AP/BP-CML]

Defined as time (in months) from the first day that all criteria were met for CCyR until the date of progression (based on the Investigator's assessment) or death (for participants whose best response was CCyR). CCyR = 0% Ph+ metaphases of ≥ 20 analyzed metaphases in BM aspiration. The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method. (NCT00306202)
Timeframe: From the date of first CCyR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 45.1 months)

Interventionmonths (Median)
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose48.1
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose4.6

[back to top]

Number of Participants With Molecular Responses in Stratum 1 (Ph+ CP-CML)

Molecular response was calculated by measuring p210 variant of BCR-ABL transcripts in blood during treatment using quantitative polymerase chain reaction (qPCR) assay. Major molecular response (MMR): Ratio of the BCR-ABL to ABL <10^-3 or 0.1% on the international scale. Complete molecular response (CMR): Complete absence of BCR-ABL or the ratio is <10^-4.5 or 0.00316% on the international scale. Confirmed MMR or CMR = Criteria met again >6 weeks. BCR-ABL=the fused gene found in participants with this type of CML. (NCT00306202)
Timeframe: At baseline (within 3 weeks before initiation of study therapy), After hematologic response, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63])

,
Interventionparticipants (Number)
MMR (Overall)CMR (Unconfirmed)CMR (Confirmed)
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)631
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)210

[back to top]

Number of Participants With Major Hematologic Response (MaHR) in Stratum 2/3 (Ph+ ALL or AP/BP-CML) Within First 6 and 24 Weeks

Defined as participants having as best response a CHR or CHRp. Criteria: CHR-WBC in PB:≤ULN; Immature cells in PB:No blasts, promyelocytes, myelocytes, metamyelocytes; Platelet count (untransfused):≥100,000/mm^3 and ≤450,000/mm^3; ANC:≥ 1000/mm^3; Blasts in BM:<5%; Extra medullary disease:No extramedullary leukemia, including no hepato or splenomegaly (regardless of CNS involvement). CHRp-CHR except platelet count (untransfused) and ANC:20,000/mm^3 ≤platelet <100,000/mm^3 and /or 500/mm^3 ≤ANC ≤1000/mm^3. (NCT00306202)
Timeframe: After completion of Week 6 and 24 (measured at weeks 7 and 25)

,
Interventionparticipants (Number)
MaHR within first 6 weeksMaHR within first 24 weeks
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)22
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)56

[back to top]

Number of Participants With Major Cytogenetic Response (MCyR) in Stratum 1 (Ph+ CP-CML) Within First 12 and 24 Weeks

Cytogenetic responses were based on the karyotype analysis of the percentage of Ph+ metaphases among cells in metaphase on a BM sample. At least 20 metaphase cells from a BM sample were evaluated. MCyR: A cytogenetic response that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: >0% to 35% Ph+ cells in metaphase in BM. (NCT00306202)
Timeframe: After completion of Week 12 and 24 (measured at Weeks 13 and 25)

,
Interventionparticipants (Number)
MCyR within first 12 weeksMCyR within first 24 weeks
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)69
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)25

[back to top]

Number of Participants With Hematology Abnormalities by NCI CTCAE Version 3.0

GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. WBC: GR1=NCT00306202)
Timeframe: Days 8, 15, 22, 29, 36, 43, then every 3 weeks, then every 3 months after 1 Year, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])

,,,,,,,
Interventionparticipants (Number)
WBC GR1WBC GR2WBC GR3WBC GR4ANC GR1ANC GR2ANC GR3ANC GR4Platelet GR1Platelet GR2Platelet GR3Platelet GR4Hemoglobin GR1Hemoglobin GR2Hemoglobin GR3Hemoglobin GR4
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)6000341040203400
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)4100302141004100
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)2301122300441511
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)1313120422130340
Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2)0113000600150330
Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2)0101002300150320
Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2)1002010401040230
Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2)1122002400150312

[back to top]

Number of Participants With Hematologic Toxicity at Baseline by NCI CTCAE Version 3.0

GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. White Blood Cell (WBC):GR1=NCT00306202)
Timeframe: At baseline (within 1 week before initiation of study therapy)

,,
Interventionparticipants (Number)
WBC GR1WBC GR2WBC GR3WBC GR4ANC GR1ANC GR2ANC GR3ANC GR4Platelet GR1Platelet GR2Platelet GR3Platelet GR4Hemoglobin GR1Hemoglobin GR2Hemoglobin GR3Hemoglobin GR4
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose1000110010007100
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose2201212252327710
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose32643031353867730

[back to top]

Number of Participants With FLT3 and KIT Mutations in Stratum4 Ph- ALL/AML at End-Of-Treatment

FLT3 and KIT = These are fused genes found in participants with this type of leukemia. (NCT00306202)
Timeframe: At EOT (Median duration of therapy in months: Stratum 4=1.14 [Range: 0.03-3.38])

Interventionparticipants (Number)
FLT3 AbsentFLT3 PresentFLT3 No DataKIT AbsentKIT PresentKIT No Data
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose60186018

[back to top]

Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic Parameter: Observed Maximum Plasma Concentration (Cmax) by Dose Level and Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

,,,
Interventionng/mL (Geometric Mean)
Infants and Toddlers (age<2yr; n=0; n=0; n=0; n=1)Children (age>=2 & <12yr; n=10; n=16; n=7; n=7)Adolescents (age>=12 & <18yr; n=8; n=8; n=9; n=2)Above 18 years (n=0; n=1; n=0; n=0)Total
Dasatinib 100 mg/m^2NA6.06.9NA6.5
Dasatinib 120 mg/m^21.24.84.3NA4.1
Dasatinib 60 mg/m^2NA3.63.1NA3.4
Dasatinib 80 mg/m^2NA3.43.62.23.4

[back to top]

Number of Participants With BCR-ABL Mutations at Baseline: Stratum1 Ph+ CP-CML and Stratum 2/3 Ph+ALL or AP/BP-CML

BCR-ABL, also referred to as the Philadelphia chromosome, is formed from the fusion of the BCR gene on chromosome 22 with the ABL gene on chromosome 9. (NCT00306202)
Timeframe: At baseline (within 3 weeks before initiation of study therapy)

,
Interventionparticipants (Number)
L384MG250ET315IY253HY253FNo MutationNo Data
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose11000150
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose00111113

[back to top]

Dasatinib Plasma Pharmacokinetic Parameter: Terminal Half-life (T 1/2) by Dose Level and Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

,,,
Interventionhour (Mean)
Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1)Children (age>=2 & <12yr; n=10; n=14; n=7; n=5)Adolescents (age>=12 & <18yr; n=8; n=5; n=7; n=2)Above 18 years (n=0; n=1; n=0; n=0)Total
Dasatinib 100 mg/m^22.54.64.5NA4.4
Dasatinib 120 mg/m^21.83.23.5NA3.1
Dasatinib 60 mg/m^2NA2.43.7NA3.0
Dasatinib 80 mg/m^2NA3.95.17.34.4

[back to top]

Dasatinib Plasma Pharmacokinetic Parameter: Terminal Half-life (T 1/2) by Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

Interventionhours (Geometric Mean)
Infants and Toddlers (age<2 years old; n=2)Children (age>=2 and <12 years old; n=36)Adolescents (age>=12 and <18 years old; n=22)Above 18 years (n=1)Total (n=61)
Dasatinib 60 mg/m^2 QD Starting Dose2.13.03.87.33.3

[back to top]

Dasatinib Plasma Pharmacokinetic Parameter: Observed Maximum Plasma Concentration (Cmax) by Dose Level and Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

,,,
Interventionng/mL (Geometric Mean)
Infants and Toddlers (age>2yr; n=0; n=0; n=1; n=1)Children (age>=2 & <12yr; n=11; n=16; n=9; n=7)Adolescents (age>=12; n=9; n=8; n=9; n=2)Above 18 years (n=0; n=1; n=0; n=0)Total
Dasatinib 100 mg/m^230.6111.2235.1NA148.1
Dasatinib 120 mg/m^253.8208.4123.3NA163.9
Dasatinib 60 mg/m^2NA110.692.6NA102.1
Dasatinib 80 mg/m^2NA142.5116.5143.2133.6

[back to top]

Dasatinib Plasma Pharmacokinetic Parameter: Dose Normalized Observed Maximum Plasma Concentration (Cmax) by Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Dose Normalized Cmax is the maximum observed concentration of drug substance in plasma normalized for different dasatinib dose levels. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

Interventionng/mL/mg/m^2 (Geometric Mean)
Infants and Toddlers (age<2 years old; n=2)Children (age>=2 and <12 years old; n=43)Adolescents (age>=12 and <18 years old; n=28)Above 18 Years (n=1)Total (n=74)
Dasatinib 60 mg/m^2 QD Starting Dose1.01.91.00.91.5

[back to top]

Dasatinib Plasma Pharmacokinetic Parameter: Dose Normalized Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) by Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time, normalized by dasatinib dose level. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

Interventionng.h/mL/mg/m^2 (Geometric Mean)
Infants and Toddlers (age<2 years old; n=2)Children (age>=2 and <12 years old; n=36)Adolescents (age>=12 and <18 years old; n=22)Above 18 Years (n=1)Total (n=61)
Dasatinib 60 mg/m^2 QD Starting Dose3.26.74.22.45.4

[back to top]

Dasatinib Plasma Pharmacokinetic Parameter: Dose Normalized Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-T] is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration, normalized by dasatinib dose level. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

Interventionng.h/mL/mg/m^2 (Geometric Mean)
Infants and Toddlers (age<2 years old; n=2)Children (age>=2 and <12 years old; n=40)Adolescents (age>=12 and <18 years old; n=28)Above 18 Years (n=1)Total (n=71)
Dasatinib 60 mg/m^2 QD Starting Dose2.86.13.82.24.9

[back to top]

Dasatinib Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) by Dose Level and Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(INF) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

,,,
Interventionng.h/mL (Geometric Mean)
Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1)Children (age>=2 & <12yr; n=10; n=14; n=7; n=5)Adolescents (age>=12 & <18yr; n=8; n=5; n=7; n=2)Above 18 years (n=0; n=1; n=0; n=0)Total
Dasatinib 100 mg/m^2127.7429.11008.90589.8
Dasatinib 120 mg/m^2142.1817.6547.80594.4
Dasatinib 60 mg/m^20313.9305.80310.3
Dasatinib 80 mg/m^20513.6605.1390.0527.8

[back to top]

Dasatinib Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Dose Level and Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-T) is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

,,,
Interventionng.h/mL (Geometric Mean)
Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1)Children (age>=2 & <12yr; n=10; n=16; n=8; n=6)Adolescents (age>=12 & <18yr; n=9; n=8; n=9; n=2)Above 18 years (n=0; n=1; n=0; n=0)Total
Dasatinib 100 mg/m^2100.8373.5787.0NA504.1
Dasatinib 120 mg/m^2134.9676.7526.1NA534.9
Dasatinib 60 mg/m^2NA295.0320.8NA307.0
Dasatinib 80 mg/m^2NA490.8488.1367.2484.3

[back to top]

Dasatinib Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) by Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

Interventionhours (Median)
Infants and Toddlers (age<2 years old; n=2)Children (age>=2 and <12 years old; n=43)Adolescents (age>=12 and <18 years old; n=28)Above 18 Years (n=1)Total (n=74)
Dasatinib 60 mg/m^2 QD Starting Dose0.51.11.00.91.0

[back to top]

Dasatinib Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) By Dose Level and Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

,,,
Interventionhour (Median)
Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1)Children (age>=2 & <12yr; n=11; n=16; n=9; n=7)Adolescents (age>=12 & <12yr; n=9; n=8; n=9; n=2)Above 18 years (n=0; n=1; n=0; n=0)Total
Dasatinib 100 mg/m^20.51.11.0NA1.0
Dasatinib 120 mg/m^20.51.01.6NA1.0
Dasatinib 60 mg/m^2NA1.11.0NA1.0
Dasatinib 80 mg/m^2NA1.51.10.91.1

[back to top]

Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Dose Level and Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-T) is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

,,,
Interventionng.h/mL (Geometric Mean)
Infants and Toddlers (age<2yr; n=0; n=0; n=0; n=1)Children (age>=2 & <12yr; n=7; n=12; n=5; n=6)Adolescents (age>=12 & <12yr; n=6; n=8; n=9; n=2)Above 18 years (n=0; n=1; n=0; n=0)Total
Dasatinib 100 mg/m^2NA25.420.0NA21.8
Dasatinib 120 mg/m^21.923.615.8NA16.3
Dasatinib 60 mg/m^2NA8.812.3NA10.3
Dasatinib 80 mg/m^2NA16.613.56.614.7

[back to top]

Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) By Dose Level and Age Group

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration. (NCT00306202)
Timeframe: During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).

,,,
Interventionhour (Median)
Infants and Toddlers (age<2yr; n=0; n=0; n=0; n=1)Children (age>=2 & <12yr; n=10; n=16; n=7; n=7)Adolescents (age>=12 & <18yr ; n=8; n=8; n=9; n=2)Above 18 years (n=0; n=1; n=0; n=0)Total
Dasatinib 100 mg/m^2NA2.12.0NA2.0
Dasatinib 120 mg/m^20.92.02.1NA2.0
Dasatinib 60 mg/m^2NA2.02.0NA2.0
Dasatinib 80 mg/m^2NA2.02.00.92.0

[back to top]

Concentration of Dasatinib in Cerebrospinal Fluid (CSF) by Dose Level and Age Group

Concentration of dasatinib in CSF was assessed only in participants who had lumbar puncture during the treatment. y=years (NCT00306202)
Timeframe: 4 hours after oral dose

,,,
Interventionng/mL (Mean)
Children (age>=2 & <12 y; n=3, n=9, n=3, n=1)Adolescents (age>=12 & <18 y; n=1; n=1; n=3; n=0)Total (Children + Adolescents;n=4; n=10; n=6; n=1)
Dasatinib 100 mg/m^21.72.62.1
Dasatinib 120 mg/m^23.8NA3.8
Dasatinib 60 mg/m^21.11.11.1
Dasatinib 80 mg/m^21.51.01.4

[back to top]

Best Hematologic Response (HR) At Any Time: Stratum 4 (Ph- ALL/AML)

HR was determined by CBC, differential, and platelet count. Unable to determine = Participants without any valid hematologic assessments. (NCT00306202)
Timeframe: Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 10, 13, 19, 25, 31, 37; then every 12 weeks upto 24 months; then once/year; EOT (Median duration of therapy in months: Stratum 4=1.14 [Range: 0.03-3.38])

,,,
Interventionparticipants (Number)
Best Confirmed HR-No ResponseBest Confirmed HR-Unable to DetermineBest Unconfirmed HR-No ResponseBest Unconfirmed HR-Unable to Determine
Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2)6060
Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2)6060
Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2)5151
Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2)6060

[back to top]

Best Hematologic Response (HR) At Any Time: Stratum 2/3 (Ph+ ALL or AP/BP-CML)

HR was determined by CBC, differential, and platelet count. Refer to outcome measure 15 for criteria for CHR and CHRp. Criteria for minor hematologic response (MiHR): CHRp except blasts in BM-≥5% and ≤15% blasts in BM. Unconfirmed HR = All criteria met. periph=peripheral. Confirmed HR = Criteria for HR fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval. (NCT00306202)
Timeframe: Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 13, 19, 25, 31, 37; then every 12 weeks up to 24 months; then once/year; EOT (Median duration of therapy in months: Stratum 2/3=3.02 [Range: 0.53-37.72])

,
Interventionparticipants (Number)
Best Confirmed HR-CompleteBest Confirmed HR-Complete except periph. recoveryBest Confirmed HR-No ResponseBest Unconfirmed HR-CompleteBest Unconfirmed HR-MinorBest Unconfirmed HR-No Response
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)116305
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)513711

[back to top]

Best Hematologic Response (HR) At Any Time: Stratum 1 (Ph+ CP-CML)

HR: Determined by complete blood count (CBC), differential, and platelet count (PLT). Criteria for complete hematologic response (CHR): WBC in PB: <10,000/mm^3; Immature cells in PB: No blasts or promyelocytes (myelocytes + metamyelocytes) <5%; Basophils in PB: <5%; Platelet count (untransfused): <450,000/mm^3; Extra medullary disease: No extramedullary leukemia, including no splenomegaly. Unconfirmed HR = All criteria met. Confirmed HR = Criteria for HR fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval. (NCT00306202)
Timeframe: Days 8, 15, 22, 29, 36, 43; Weeks 7, 13, 25, 37; then every 12 weeks upto 24 months; then once/year; EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63])

,
Interventionparticipants (Number)
Best Confirmed HR-CompleteBest Confirmed HR-No ResponseBest Unconfirmed Hematologic Response-CompleteBest Unconfirmed Hematologic Response-No Response
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)101101
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)6060

[back to top]

Best Cytogenetic Response (CyR) in Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML)

Best CyR was assessed based on the percentages of Ph+ metaphases of ≥20 analyzed metaphases in BM sample. Participants with complete, partial, minor, minimal, or no CyR. Refer to Outcome Measure 7 for definitions of CCyR and PCyR. Minor CyR:>35%-65% Ph+ cells in metaphase in BM. Minimal CyR:>65%-95% Ph+ cells in metaphase in BM. No CyR:>95%-100% Ph+ cells in metaphase in BM. Unable to determine:Participants without valid cytogenetic assessment (i.e., at least 1 metaphase observed and number of Ph+ metaphases smaller than total number of metaphases [%Ph+ <100%]). (NCT00306202)
Timeframe: Strata 1 and 2/3: At Weeks 7, 13, then every 12 weeks, and EOT; Stratum 2/3: Additionally at Weeks 4, 19, 25, 31 (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72])

,,,
Interventionparticipants (Number)
No Response (>95% - 100%)Minimal (>65% - 95%)Minor (>35% - 65%)Partial (>0% - 35%)Complete (0%)Unable to determine
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)101180
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)000060
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)000044
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)100080

[back to top]

Time to Major Hematologic Response (MaHR): Stratum 2/3 (PH+ ALL or AP/BP-CML)

Defined as time (in days) from first dose of dasatinib until the first day MaHR criteria were met, provided they were confirmed later (after 28 days) with no concomitant use of anagrelide or hydroxyurea during this interval. MaHR: Defined as participants having as best response a CHR or CHRp. Refer to Outcome Measure 15 for criteria for CHR and CHRp. Estimated by the Kaplan-Meier method and a 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method. (NCT00306202)
Timeframe: Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 13, 19, 25, 31, 37; then every 12 weeks upto 24 months; then once/year; until confirmed MaHR (maximum participant time to first MaHR of 44 days).

Interventiondays (Median)
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose36.0

[back to top]

Time to Major Cytogenetic Response (MCyR) in Responders: Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML)

Defined as time (in days) from the first dose of dasatinib until criteria were first met for MCyR. MCyR: A CyR that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: >0% to 35% Ph+ cells in metaphase in BM. The Kaplan-Meier plot was used. A 2-sided, 95% confidence interval (CI) for the median was computed using the Brookmeyer and Crowley method. (NCT00306202)
Timeframe: Strata 1 and 2/3: At Weeks 7, 13, 25, 37, then every 12 weeks; Stratum 2/3: Additionally at Weeks 4, 19, 31; until first MCyR (maximum participant time to first MCyR of 92 days).

Interventiondays (Median)
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose75.0
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose33.5

[back to top]

Time to Complete Hematologic Response (CHR): Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ALL or AP/BP-CML)

Time to CHR is the time (in days) from first dose of dasatinib until the first day CHR criteria were met, provided they were confirmed later after 28 days with no concomitant use of anagrelide or hydroxyurea during this interval. Refer to Outcome Measure 16 for criteria to CHR in Stratum 1 and to Outcome Measure 15 for criteria for CHR in Stratum 2/3. Estimated by the Kaplan-Meier method and a 2-sided 95% CI for median was computed using the Brookmeyer and Crowley method. (NCT00306202)
Timeframe: Days 8, 15, 22, 29, 36, 43; Weeks 7, 13, 25, 37; at Week 4, 19, 31 (only stratum 2/3); then every 12 weeks upto 24 months; then once/year; until criteria was first met for CHR (maximum participant time to first CHR of 65 days).

Interventiondays (Median)
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose21.5
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose39.5

[back to top] [back to top]

Progression Free Survival (PFS)

Time in months from 1st first dose until progression (resistance or refractory disease) or death was first documented by investigator. Progressive disease: Resistant disease for which investigator may electively stop treatment or refractory disease requiring cessation of study treatment. The PFS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median PFS time was computed using the method of Brookmeyer and Crowley. (NCT00306202)
Timeframe: From the date of randomization to date of progression, death, last tumor assessment, or 5 years after EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])

Interventionmonths (Median)
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose53.6
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose4.9
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose1.4

[back to top] [back to top]

Overall Survival (OS)

Defined as time in months from start of study therapy to death. The OS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median OS time was computed using the Brookmeyer and Crowley method. (NCT00306202)
Timeframe: From start of study therapy until death or 5 years after EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])

Interventionmonths (Median)
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting DoseNA
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose8.6
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose3.0

[back to top]

Number of Participants With Major Molecular Response (MMR) in Stratum 2/3 (Ph+ ALL or AP/BP-CML)

Molecular response was calculated by measuring BCR-ABL transcripts in blood during treatment using qPCR assay. MMR: Ratio of the BCR-ABL to ABL <10^-3 or a ≥3 log reduction from baseline in participants with p190 variant; ratio of the BCR-ABL to ABL <10^-3 on the international scale in participants with p210 variant. BCR-ABL=the fused gene found in participants with this type of CML. (NCT00306202)
Timeframe: At baseline (within 3 weeks before initiation of study therapy), After hematologic response, EOT (Median duration of therapy in months: Stratum 2/3=3.02 [Range: 0.53-37.72])

Interventionparticipants (Number)
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)2
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)6

[back to top]

Number of Participants With Major Hematologic Response (MaHR) at Any Time in Stratum 2/3 (Ph+ ALL or AP/BP-CML) and Stratum 4 (Ph- ALL/AML)

Defined as participants having as best response complete hematologic response (CHR) or CHR with incomplete platelet recovery (CHRp). Criteria: CHR-WBC in Peripheral Blood (PB):≤ULN; Immature cells in PB:No blasts, promyelocytes, myelocytes, metamyelocytes; Platelet count (untransfused):≥100,000/mm^3 and ≤450,000/mm^3; ANC:≥ 1000/mm^3; Blasts in BM:<5%; Extra medullary disease:No extramedullary leukemia, including no hepato or splenomegaly (regardless of CNS involvement). CHRp-CHR except platelet count (untransfused) & ANC:20,000/mm^3 ≤platelet <100,000/mm^3 & /or 500/mm^3 ≤ANC ≤1000/mm^3. (NCT00306202)
Timeframe: Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 13, 19, 25, 31, 37; at Week 10 (only stratum 4); then every 12 weeks upto 24 months; then once/year; EOT(Median duration of therapy in months: Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])

Interventionparticipants (Number)
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)2
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)6
Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2)0
Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2)0
Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2)0
Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2)0

[back to top]

Number of Participants With Major Cytogenetic Response (MCyR) at Any Time in Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ ALL or AP/BP-CML)

Cytogenetic responses were based on the karyotype analysis of the percentage of Ph+ metaphases among cells in metaphase on a BM sample. At least 20 metaphase cells from a BM sample were evaluated. MCyR: A cytogenetic response that is either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR: 0% Ph+ cells in metaphase in BM. PCyR: >0% to 35% Ph+ cells in metaphase in BM. (NCT00306202)
Timeframe: Strata 1 and 2/3: At Week 7, 13, then every 12 weeks, and EOT; Stratum 2/3: Additionally at Week 4, 19, 31 (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72])

Interventionparticipants (Number)
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)9
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)6
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)4
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)7

[back to top]

Number of Participants With Dose-limiting Toxicity (DLT)

DLTs: AEs which were at least possibly drug-related occurring within first 3 weeks of dasatinib therapy (toxicities occurring after 21 days were also considered) and are:- --Any nonhematologic clinically-apparent toxicity of Grade(GR)≥3 occurring despite appropriate medical management and GR4 laboratory abnormality/GR3 lasting ≥7 days --GR4 neutropenia or thrombocytopenia lasting ≥7 days and not explained by the presence of leukemia after hematopoietic reconstitution --Any clinically important toxicity of GR≥2 requiring treatment discontinuation or interruption ≥7 days. (NCT00306202)
Timeframe: From the date of first dose until at least 30 days after the last dose of study drug (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])

Interventionparticipants (Number)
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)0
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)0
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)0
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)0
Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2)1
Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2)0
Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2)0
Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2)1

[back to top]

Duration of Major Hematologic Response (MaHR): Stratum 2/3 (Ph+ALL or AP/BP-CML)

Duration of MaHR is the time (in months) from the first day criteria were met for MaHR, provided they were confirmed later at least after 28 days with no concomitant use of anagrelide or hydroxyurea during this interval, until death or progression was first observed. MaHR: Defined as participants having as best response a CHR or CHRp. Refer to outcome measure 20 for criteria for CHR or CHRp. The Kaplan-Meier plot was used. A 2-sided, 95% CI for the median was computed using the Brookmeyer and Crowley method. (NCT00306202)
Timeframe: From the date of first confirmed MaHR to date of progression, death, or last tumor assessment (maximum participant duration of response of 37 months).

Interventionmonths (Median)
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose4.4

[back to top] [back to top] [back to top]

Number of Participants With BCR-ABL Mutations at End-of-Treatment: Stratum1 Ph+ CP-CML and Stratum2/3 Ph+ ALL or AP/BP-CML

BCR-ABL = These are fused genes found in participants with this type of leukemia. (NCT00306202)
Timeframe: At EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72])

,
Interventionparticipants (Number)
T315INo MutationNo Data
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose089
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose494

[back to top]

Number of Participants With Serum Chemistry Abnormalities (Liver and Renal Function) by NCI CTCAE Version 3.0

GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. AST and ALT: GR1=>ULN-2.5*ULN; GR2=>2.5-5.0*ULN; GR3=>5.0-20.0*ULN; GR4:>20.0*ULN. Total bilirubin:GR1=>ULN-1.5*ULN, GR2=>1.5-3.0*ULN, GR3=>3-10*ULN, GR4=>10*ULN. Creatinine: GR1=>ULN-1.5*ULN, GR2=>1.5-3.0*ULN, GR3=>3.0-6.0*ULN, GR4=>6.0*ULN. (NCT00306202)
Timeframe: Days 22 and 43, then every 12 weeks, then every 24 weeks after 24 months of treatment, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])

,,,,,,,
Interventionparticipants (Number)
AST GR1AST GR2AST GR3AST GR4High ALT GR1High ALT GR2High ALT GR3High ALT GR4Total Bilirubin GR1Total Bilirubin GR2Total Bilirubin GR3Total Bilirubin GR4High Serum Creatinine GR1High Serum Creatinine GR2High Serum Creatinine GR3High Serum Creatinine GR4
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)1000400020101000
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)3000400001001000
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)5210421010001100
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)3120210210001000
Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2)2100310021000100
Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2)2100201001000000
Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2)1110011001001000
Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2)4110222012000000

[back to top]

Number of Participants With Serum Chemistry Abnormalities (Liver and Renal Function) at Baseline by NCI CTCAE Version 3.0

GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. Aspartate aminotransferase (AST) and alanine aminotransferase(ALT): GR1=>ULN-2.5*ULN; GR2=>2.5-5.0*ULN; GR3=>5.0-20.0*ULN; GR4=>20.0*ULN. Total bilirubin:GR1=>ULN-1.5*ULN, GR2=>1.5-3.0*ULN, GR3=>3-10*ULN, GR4=>10*ULN. Creatinine: GR1=>ULN-1.5*ULN, GR2=>1.5-3.0*ULN, GR3=>3.0-6.0*ULN, GR4=>6.0*ULN. ULN=upper limit of normal. (NCT00306202)
Timeframe: At baseline (within 1 week before initiation of study therapy)

,,
Interventionparticipants (Number)
AST GR1AST GR2AST GR3AST GR4AST GR Not ReportedHigh ALT GR1High ALT GR2High ALT GR3High ALT GR4High ALT GR Not ReportedHigh Total Bilirubin GR1High Total Bilirubin GR2High Total Bilirubin GR3High Total Bilirubin G4High Total Bilirubin GR Not ReportedHigh Serum Creatinine GR1High Serum Creatinine GR2High Serum Creatinine GR3High Serum Creatinine GR4High Serum Creatinine GR Not Reported
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose10001200003000020000
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose32103620000100001000
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose81002650001000140001

[back to top]

Number of Participants With Serum Chemistry Abnormalities (Calcium, Magnesium, and Phosphate) by NCI CTCAE Version 3.0

GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. Low calcium: GR1=NCT00306202)
Timeframe: Days 22 and 43, then every 12 weeks, then every 24 weeks after 24 months of treatment, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])

,,,,,,,
Interventionparticipants (Number)
Low Calcium GR1Low Calcium GR2Low Calcium GR3Low Calcium GR4Low magnesium GR1Low Magnesium GR2Low Magnesium GR3Low Magnesium GR4Low Phosphate GR1Low Phosphate GR2Low Phosphate GR3Low Phosphate GR4
Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)300010002100
Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)000010001000
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)210050002000
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)210000002100
Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2)121040002110
Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2)010010001110
Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2)200010000010
Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2)020000002200

[back to top]

Number of Participants With Serum Chemistry Abnormalities (Calcium, Magnesium, and Phosphate) at Baseline by NCI CTCAE Version 3.0

GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. Low calcium: GR1=NCT00306202)
Timeframe: At baseline (within 1 week before initiation of study therapy)

,,
Interventionparticipants (Number)
Low Calcium GR1Low Calcium GR2Low Calcium GR3Low Calcium GR4Low Calcium GR Not ReportedLow Magnesium GR1Low Magnesium GR2Low Magnesium GR3Low Magnesium GR4Low Magnesium GR Not ReportedLow Phosphate GR1Low Phosphate GR2Low Phosphate GR3Low Phosphate GR4Low Phosphate GR Not Reported
Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose000000000000002
Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose000006000010100
Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose100020000200002

[back to top]

Percentage of Participants With On-study AEs of Special Interest

GI=gastrointestinal. AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with treatment. Grade 1=mild; Grade 2=moderate; Grade 3=severe and undesirable; Grade 4=life-threatening or disabling; Grade 5=death. Percentages based on the number of participants with a specific grade at baseline. Participants without on-study test values for a particular laboratory analyte are not included in the reporting of that analyte. (NCT00320190)
Timeframe: Months 1 to 12, continuously, and Months 12 to 24, continuously

,
InterventionPercentage of Participants (Number)
Fluid retention (Any grade)Fluid retention (Grades 3-5)Fluid retention: Superficial edema (Any grade)Fluid retention: Superficial edema (Grades 3-5)Fluid retention: Generalized edema (Any grade)Fluid retention: Generalized edema (Grades 3-5)Hemorrhage (Any grade)Hemorrhage (Grades 3-5)Hemorrhage: GI bleeding (Any grade)Hemorrhage: GI bleeding (Grades 3-5)Hemorrhage: Other bleeding (Any grade)Hemorrhage: Other bleeding (Grades 3-5)Diarrhea (Any grade)Diarrhea (Grades 3-5)Skin rash (Any grade)Skin rash (Grades 3-5)
Dasatinib, 100 mg5.30005.3000000026.3042.10
Imatinib, 800 mg38.57.730.807.77.715.407.707.7030.8015.40

[back to top] [back to top]

Number of Participants With Clinically Significant Change in QT Interval Corrected for Heart Rate (QTcF)

QT interval corrected for heart rate (QTcF) was assessed using triplicate 12-lead serial ECGs. (NCT00339144)
Timeframe: Baseline, Day 1, Day 14 and Day 28

Interventionparticipants (Number)
Dasatinib 100 mg0
Dasatinib 150 mg0
Dasatinib 200 mg0

[back to top]

Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings

Standard 12-lead ECG was used to record selected ECG parameters like RR interval (the time between the two R waves in ECG), PR interval (interval measured from the beginning of the P wave to the beginning of the QRS complex; QRS complex is the name for some of the deflections seen on a typical ECG)), QRS duration, QT interval (time between onset of ventricular depolarization and end of ventricular repolarization), QT interval corrected for heart rate using Bazett's (QTcB) and Fridericia's (QTcF) formulas. (NCT00339144)
Timeframe: From screening Day -1, and at pre-dose, 1 and 4 hours (post-dose) on Days 1, 14 and 28 in first treatment course, at pre-dose, 1 and 4 hours (post-dose) during the second and fourth week in subsequent courses and at the end of study

Interventionparticipants (Number)
Dasatinib 100 mg0
Dasatinib 150 mg0
Dasatinib 200 mg0

[back to top]

Accumulation Index (AI) of Dasatinib

AI of Dasatinib was calculated as ratio of geometric mean of AUC(TAU) (area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration) on Day 14 or Day 28 on Day 1. (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28

,,
Interventionratio (Geometric Mean)
Day 14 (n = 5, 4, 2)Day 28 (n= 3, 2, 2)
Dasatinib 100 mg0.811.12
Dasatinib 150 mg1.780.48
Dasatinib 200 mg2.301.72

[back to top]

AUC (0-t) of Metabolite BMS-582691

AUC (0-t) was calculated using plasma concentration values of metabolite at time 0 to the time of the last measurable concentration (t). (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28

,,
Interventionng*hr/mL (Geometric Mean)
Day 1 (n = 8, 3, 3)Day 14 (n = 5, 4, 2)Day 28 (n= 3, 1, 2)
Dasatinib 100 mg21.2415.2427.20
Dasatinib 150 mg5.9926.0513.03
Dasatinib 200 mg36.9637.654.67

[back to top]

AUC[TAU] of Dasatinib

Area under the plasma concentration-time curve within the dosing interval was determined. AUC(TAU), from time 0 to the time of the last measurable concentration (24 hours) was calculated for Day 1, 14, 28 respectively. (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28

,,
Interventionng*hours/ml (Geometric Mean)
Day 1 (n = 9, 3, 4)Day 14 (n = 5, 4, 2)Day 28 (n= 3, 2, 2)
Dasatinib 100 mg524.55499.69738.76
Dasatinib 150 mg530.81694.90273.10
Dasatinib 200 mg528.65716.27534.33

[back to top]

Cmax of Metabolite BMS-582691

Maximum plasma concentration was obtained from plasma concentration versus time data of metabolite (BMS-582691). (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28

,,
Interventionng/ml (Geometric Mean)
Day 1 (n = 8, 3, 3)Day 14 (n = 5, 4, 2)Day 28 (n= 3, 1, 2)
Dasatinib 100 mg5.184.636.68
Dasatinib 150 mg2.894.614.66
Dasatinib 200 mg7.905.993.04

[back to top]

Maximum Plasma Concentration (Cmax) of Dasatinib

Cmax was obtained from the plasma concentration versus time data after oral administration of dasatinib. (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28

,,
Interventionnanograms (ng)/ml (Geometric Mean)
Day 1 (n = 9, 3, 4)Day 14 (n = 5, 4, 2)Day 28 (n= 3, 2, 2)
Dasatinib 100 mg139.83137.03253.77
Dasatinib 150 mg127.1166.43103.32
Dasatinib 200 mg124.48102.6180.92

[back to top]

Mean Apparent Oral Clearance (CLo) of Dasatinib

Apparent oral clearance was obtained from the plasma concentration versus time data. (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 14 and 28

,,
InterventionL/hour (Geometric Mean)
Day 14 (n = 5, 4, 2)Day 28 (n= 3, 2, 2)
Dasatinib 100 mg200.12135.36
Dasatinib 150 mg215.86549.26
Dasatinib 200 mg279.22374.30

[back to top]

Mean Apparent Volume of Distribution (Vz/F) of Dasatinib

Apparent volume of distribution after oral dosing was obtained from plasma concentration versus time data. (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 14 and 28

,,
InterventionL (Geometric Mean)
Day 14 (n = 5, 4, 2)Day 28 (n= 3, 2, 2)
Dasatinib 100 mg1156.57566.93
Dasatinib 150 mg1285.053443.56
Dasatinib 200 mg2903.183362.08

[back to top]

Mean Serum Concentration of Bone Alkaline Phosphatase (BAP) Biological Marker

BAP is a measure of bone metabolism. A decrease in BAP relative to the baseline indicates decrease in bone metabolism. Serum BAP was quantified with ELISA. (NCT00339144)
Timeframe: Serum samples were assessed on baseline (Day -1), and pre-dose on Days 14, 28

InterventionU/L (Mean)
Day -1 (n = 16)Day 14 (n= 13)Day 28 (n= 7)
Dasatinib (Total)29.1132.3428.20

[back to top]

Mean Serum Concentration of Tartrate-resistant Acid Phosphatase Isoform 5b (TRACP-5b) Biological Marker

TRACP-5b is a measure of bone metabolism. A decrease in TRACP-5b relative to the baseline indicates decrease in bone metabolism. Serum TRACP-5b was quantified with enzyme-linked-immunosorbent serologic assay (ELISA). (NCT00339144)
Timeframe: Serum samples were assessed at baseline (Day -1) and on Days 14 and 28

InterventionU/L (Mean)
Day -1 (n = 16)Day 14 (n= 12)Day 28 (n= 7)
Dasatinib (Total)5.134.133.40

[back to top]

Mean Urine Concentration of Deoxypyridinoline (Dpyr) Biological Marker

Urine levels of DPyr is a measure of bone resorption. A decrease in Dpyr relative to the baseline indicates decrease in bone metabolism. Mean urine concentration of Dpyr biological marker was determined using ELISA. (NCT00339144)
Timeframe: Urine samples were collected at baseline (Day -1) and 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6 12 and 24 hours post dose on Days 14 and 28

,,
Interventionnanomol (nmol)/mL (Mean)
Day -1 (n = 9, 3, 4)Day 14 (n= 6, 3, 4)Day 28 (n= 3, 2, 2)
Dasatinib 100 mg37.7927.0815.77
Dasatinib 150 mg50.3725.3740.55
Dasatinib 200 mg116.8546.7314.80

[back to top]

Mean Urine Concentration of Urinary N-telopeptide Type 1 Collagen (NTx) Biological Marker

Urine NTx is a measure of bone metabolism. A decrease in the marker relative to baseline indicates a decrease in bone metabolism. Mean urine concentration of NTx biological marker was determined using enzyme linked immuno-sorbent assay (ELISA). (NCT00339144)
Timeframe: Urine samples were collected at baseline (Day -1) and 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 14 and 28.

,,
Interventionnmol*bone collagen equivalent (BCE)/mmol (Mean)
Day -1 ( n= 9, 3, 4)Day 14 (n= 6, 3, 4)Day 28 (n= 3, 2, 2)
Dasatinib 100 mg51.7151.5525.33
Dasatinib 150 mg62.5736.4740.10
Dasatinib 200 mg103.9051.3336.15

[back to top] [back to top]

Number of Participants With Grade 3 or 4 Hematology Abnormalities

Hematology abnormalities were graded per the National Cancer Institute (NCI) Common. Terminology Criteria (CTC) version 3.0 criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Grade 3 and 4 criteria are as follows: Absolute Neutrophil Count (ANC): Grade 3: 0.5 - <1.0*10^9/L, Grade 4: <0.5*10^9/L; lymphocytes: Grade 3: 0.2 - <0.5*10^9/L, Grade 4: <0.2*10^9/L. (NCT00339144)
Timeframe: From start of study drug therapy up to 30 days after the last dose.

,,
Interventionparticipants (Number)
Low neutrophils countLow lymphocyte count
Dasatinib 100 mg10
Dasatinib 150 mg01
Dasatinib 200 mg02

[back to top]

Number of Participants With Grade 3-4 Serum Chemistry Abnormalities

Abnormalities were graded according to the NCI CTC, version 3.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Grade 3 and 4 criteria are as follows: phosphorous: Grade 3: 1.0-<2.0 mg/dL, Grade 4: <1.0 mg/dL; calcium: Grade 3: 6.0-<7.0 or >12.5-13.5 mg/dL, Grade 4: <0.6->13.5 mg/dL; magnesium: Grade 3: >3.0 - 8.0 mg/dL or >1.23 - 3.30 mmol/L, Grade 4: >8.0 mg/dL or >3.30 mmol/L; albumin: Grade 3: <2 g/dL or <20 g/L. (NCT00339144)
Timeframe: From start of study drug therapy up to 30 days after the last dose.

,,
Interventionparticipants (Number)
Low phosphorusLow calciumHigh magnesiumLow albumin
Dasatinib 100 mg0010
Dasatinib 150 mg0000
Dasatinib 200 mg1111

[back to top]

Area Under the Plasma-concentration-time Curve [AUC (INF)] of Dasatinib on Day 1

AUC(INF), area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration within the dosing interval was calculated for Day 1. (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Day 1

Interventionng*hours/ml (Geometric Mean)
Dasatinib 100 mg537.98
Dasatinib 150 mg544.36
Dasatinib 200 mg595.62

[back to top]

Tmax of the Metabolite BMS-582691

Tmax of the metabolite was obtained using plasma concentration versus time data of metabolite BMS-582691. (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28

,,
Interventionhours (Median)
Day 1 (n = 8, 3, 3)Day 14 (n = 5, 4, 2)Day 28 (n= 3, 1, 2)
Dasatinib 100 mg1.51.01.5
Dasatinib 150 mg1.51.81.0
Dasatinib 200 mg2.03.01.8

[back to top]

Time to Reach Maximum Observed Plasma Concentration of Dasatinib (Tmax)

Tmax, time to reach maximum observed plasma concentration of dasatinib was obtained directly from the plasma concentration versus time data. (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28

,,
Interventionhours (Median)
Day 1 (n = 9, 3, 4)Day 14 (n = 5, 4, 2)Day 28 (n= 3, 2, 2)
Dasatinib 100 mg1.01.00.5
Dasatinib 150 mg1.01.00.5
Dasatinib 200 mg1.32.33.3

[back to top]

Terminal Elimination Half-life (T-half) of Dasatinib

T-half of dasatinib was calculated using plasma concentration versus time data. (NCT00339144)
Timeframe: Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28

,,
Interventionhours (Mean)
Day 1 (n = 9, 3, 4)Day 14 (n = 5, 4, 2)Day 28 (n= 3, 2, 2)
Dasatinib 100 mg4.775.754.36
Dasatinib 150 mg4.685.048.33
Dasatinib 200 mg7.627.957.66

[back to top] [back to top]

Most Frequent Grade 3-4 Hematology Abnormalities Occurring in >=10% Participants: Low Lymphocyte Count

Abnormalities were graded according to the NCI CTC, version 3.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Most frequent hematology Grade 3 and 4 abnormalities occurring in >=10% participants were recorded. Grade 3 and 4 criteria are as follows: lymphocyte count: Grade 3: 0.2 - <0.5*10^9/L, Grade 4: <0.2*10^9/L. (NCT00339144)
Timeframe: From start of study drug therapy up to 30 days after the last dose.

Interventionparticipants (Number)
Dasatinib 100 mg0
Dasatinib 150 mg1
Dasatinib 200 mg2

[back to top]

Number of Participants With Complete Response (CR) or Partial Response (PR)

Tumor response was defined as the number of participants whose best response was CR or PR as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR: disappearance of all target/non-target lesions; PR: >= 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. (NCT00339144)
Timeframe: Within 4 weeks of first study drug administration, thereafter recorded every 4 or 8 weeks.

,,
Interventionparticipants (Number)
CRPR
Dasatinib 100 mg00
Dasatinib 150 mg00
Dasatinib 200 mg00

[back to top]

Most Frequent Serum Chemistry Laboratory Abnormalities Occurring in >=10% Participants: High Magnesium

Abnormalities were graded according to the NCI-CTC, version 3.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Most frequent (>=10%) serum laboratory abnormalities were recorded. The following definitions specify the NCI-CTC AE criteria for serum laboratory abnormalities in the data presented: magnesium: Grade 3: >3.0 - 8.0 mg/dL or >1.23 - 3.30 mmol/L, Grade 4: >8.0 mg/dL or >3.30 mmol/L. (NCT00339144)
Timeframe: From start of study drug therapy up to 30 days after the last dose.

Interventionparticipants (Number)
Dasatinib 100 mg1
Dasatinib 150 mg0
Dasatinib 200 mg1

[back to top]

Number of Participants With Clinically Meaningful Vital Signs

Vital signs measurements (including blood pressure, body temperature and pulse rate) were recorded. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs were clinically significant. (NCT00339144)
Timeframe: From screening, Day 1 , 8, 15 and 22 in the 1st treatment course, Day 8 and 22 in the second and subsequent courses and at the end of study

Interventionparticipants (Number)
Dasatinib 100 mg0
Dasatinib 150 mg0
Dasatinib 200 mg0

[back to top]

Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs

An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. (NCT00362466)
Timeframe: From 2 weeks prior to randomization through Month 36. At least every 4 weeks until all study-related toxicities resolve to baseline, stabilize, or are deemed irreversible.

,
Interventionevents (Number)
AEsSAEsAEs leading to DiscontinuationDeaths
Dasatinib3000
Imatinib1000

[back to top]

Participants With Objective Response

Number of participants with an Objective Response defined as Complete Response (CR) or Partial Response (PR). Responses evaluated every 3 months +/- 1 week by each component and overall by National Cancer Institute Working Group (NCIWG) criteria where Response judged, Nodes for CR: None; PR: > 50% decrease; Liver/Spleen CR: Not palpable; PR: > 50% decrease; Symptoms for CR: None; PR: Not applicable (N/A); polymorphonuclear leukocyte (PMN) for CR: >1,500/μl, PR: > 1,500/μl or >50% improvement from baseline; Platelets for CR: >100,000/μl, PR: >100,000/μl or > 50% improvement from baseline; Hemoglobin (untransfused) for CR: >11,0 g/dl; PR: >11.0 g/dl or >50% improvement from baseline; Lymphocytes for CR: <4,000/μl and PR: >50% decrease; Bone Marrow aspirate for CR: <30% lymphocytes, N/A for PR; Bone Biopsy for CR: No lymphocyte infiltrate; PR: < 30% lymphocytes with residual disease on biopsy for nodular PR. (NCT00364286)
Timeframe: up to 3 months

InterventionParticipants (Number)
Complete Response (CR)Partial Response (PR)No Objective Response
Dasatinib0113

[back to top]

Number of Participants With Abnormalities (Grade 1 or 2) in Partial Thromboplastin Time (PTT)

PTT is a measure of the clotting ability of the blood. Abnormalities were graded according to the NCI CTC, version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and 5=death. (NCT00371254)
Timeframe: Throughout study, from start of study drug therapy up to 30 days after the last dose.

InterventionParticipants (Number)
Dasatinib 100 mg BID0
Dasatinib 70 mg BID0

[back to top]

Number of Participants With Abnormal Vital Signs Measurements

Vital signs included systolic and diastolic blood pressure and heart rate. The investigator used his or her judgement to decide whether or not the values were abnormal. (NCT00371254)
Timeframe: At each study visit (Week 3, 5, 7, 9, 13, 17 and 25) and end of treatment (up to 17 weeks)

Interventionparticipants (Number)
Dasatinib 100 mg BID0
Dasatinib 70 mg BID0

[back to top]

Mean Number of Weeks of Complete Response (CR) or Partial Response (PR)

Mean number of weeks of CR/PR (time from first date of CR/PR until first date PD observed. Tumor response defined per RECIST: CR: disappearance of all target/non-target lesions; PR: >=30% decrease in sum of LDs of target lesions relative to baseline sum LD; PD: appearance of new lesion or >=20% increase in sum of LD of target lesions relative to smallest sum LD or unequivocal progression of existing non-target lesions. Participants who died without reported PD were considered to have PD on date of death. For participants who neither progressed nor died, date of last tumor assessment used. (NCT00371254)
Timeframe: Baseline to end of study drug therapy (up to 53.86 weeks)

Interventionweeks (Mean)
Dasatinib 100 mg BID31

[back to top]

Proportion of Participants With Progression-Free Survival (PFS) at Weeks 9, 17, and 25

PFS:time from first dose until the date that progressive disease (PD) or clinical PD (cPD) observed,per RECIST criteria.PD:appearance of new lesion/s,or >=20% increase in the sum of the LD of target lesions,relative to smallest sum LD recorded since treatment start,or unequivocal progression of existing non-target lesions;cPD:deterioration related to disease requiring treatment discontinuation,but without radiographic PD.Participants who died without PD were considered to have PD on the date of death.For participants who neither progressed nor died,date of the last tumor assessment was used. (NCT00371254)
Timeframe: Weeks 9, 17, and 25

,
InterventionProportion of Participants (Number)
Week 9Week 17Week 25
Dasatinib 100 mg BID0.400.320.21
Dasatinib 70 mg BID0.350.140.00

[back to top]

Number of Participants With Grade 3 or 4 Serum Chemistry Abnormalities in Creatinine, Bicarbonate, Inorganic Phosphorous and Bilirubin (Total).

Abnormalities were graded according to the NCI CTC, version 3.0: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening. Grade 3 and 4 criteria are defined as follows: Creatinine: Grade 3-4 : > 3.0 -6.0 ULN (upper limit of normal),Bicarbonate: Grade 3-4: <16 -<22 mEq/L, Phosphorous: Grade 3-4 : <1.0 - <2.0 mg/dL, Bilirubin, total: Grade 3-4: >3.0 - >10.0 ULN. (NCT00371254)
Timeframe: Throughout study, from start of study drug therapy up to 30 days after the last dose.

,
Interventionparticipants (Number)
CreatinineBicarbonateInorganic PhosphorusBilirubin, Total
Dasatinib 100 mg BID0010
Dasatinib 70 mg BID0020

[back to top]

Number of Participants With Grade 3 or 4 Serum Chemistry Abnormalities in Calcium, Potassium, Magnesium and Sodium

Abnormalities were graded according to the NCI CTC, version 3.0: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening. Grade 3 and 4 criteria are defined as follows: Calcium: Grade 3-4 : <6.0 - <7.0 or >12.5 - >13.5 mg/dL, Potassium: Grade 3-4 : <2.5 - <3.0 or >6.0 - >7.0 mEq/L, Magnesium: Grade 3-4 : <0.6 - <0.8 or >2.46 - >6.6 mEq/L, Sodium:< 120- 130 or >155 - >160 mEq/L. (NCT00371254)
Timeframe: Throughout study, from start of study drug therapy up to 30 days after the last dose.

,
Interventionparticipants (Number)
High calciumLow calciumHigh potassiumLow potassiumHigh magnesiumLow magnesiumHigh sodiumLow sodium
Dasatinib 100 mg BID00010000
Dasatinib 70 mg BID01000000

[back to top]

Number of Participants With Grade 3 or 4 Serum Chemistry Abnormalities in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase

Abnormalities were graded according to the NCI CTC, version 3.0: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening. Grade 3 and 4 criteria are defined as follows: ALT, AST and alkaline phosphatase: Grade 3: >5-20 x upper limit of normal (ULN), Grade 4: >20 x ULN. (NCT00371254)
Timeframe: Throughout study, from start of study drug therapy up to 30 days after the last dose.

,
Interventionparticipants (Number)
Alkaline phosphataseAlanine aminotransferaseAspartate aminotransferase
Dasatinib 100 mg BID110
Dasatinib 70 mg BID133

[back to top]

Number of Participants With Grade 3 or 4 Abnormalities in Hematology Measurements

Abnormalities were graded according to the NCI CTC, version 3.0: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening. Grades 3 and 4 criteria are defined as follows: Granulocytes: Grade 3 <1.0 - 0.5 x 10^9/L; Grade 4, <0.5 x 10^9/L. Hemoglobin: Grade 3, <8.0 - 6.5 g/dL; Grade 4, <6.5 g/dL. Platelets: Grade 3, <50.0 - 25.0 x 10^9/L; Grade 4, <25.0 x 10^9/L. Leukocytes: Grade 3, <2.0 - 1.0 x 10^9/L; Grade 4, <1.0 x 10^9/L. (NCT00371254)
Timeframe: Throughout study, from start of study drug therapy up to 30 days after the last dose.

,
Interventionparticipants (Number)
GranulocytesHemoglobinPlatelet CountLeukocytes
Dasatinib 100 mg BID3000
Dasatinib 70 mg BID0000

[back to top]

Number of Participants With Abnormalities (Grade 1 or 2) in Prothrombin Time (PT)

PT is a measure of the clotting ability of the blood. Abnormalities were graded according to the NCI CTC, version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and 5=death. (NCT00371254)
Timeframe: Throughout study, from start of study drug therapy up to 30 days after the last dose.

,
Interventionparticipants (Number)
Grade 1Grade 2
Dasatinib 100 mg BID30
Dasatinib 70 mg BID00

[back to top] [back to top]

Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs) or Adverse Events (AEs)

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). An SAE was defined as an AE that resulted in death, was life-threatening, required hospitalization (or prolongation of existing hospitalization), or was an important medical event. (NCT00371254)
Timeframe: From start of study drug therapy up to 30 days after the last dose.

,
Interventionparticipants (Number)
DeathSerious adverse events (SAEs)All adverse events (AEs)
Dasatinib 100 mg BID11123
Dasatinib 70 mg BID0321

[back to top] [back to top]

Mean Plasma Concentration at Week 7

Mean plasma concentration was obtained directly from the concentration-time data. (NCT00371254)
Timeframe: At pre-dose and 1, 3, 6 and 12 hours after each dose administration

,
Interventionnanograms (ng)/mL (Mean)
0 hour (n = 2, 6)1 hour (n = 2, 6)3 hour (n = 3, 6)6 hour (n = 2, 6)12 hour (n = 1, 5)
Dasatinib 100 mg BID8.87120.9237.0415.758.39
Dasatinib 70 mg BID4.8984.3644.8014.2518.87

[back to top]

Mean Change in Concentration of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) From Baseline

VEGFR2 is a measure of anti-angiogenic activity. Plasma samples for assessment of change in concentration of VEGFR2 were obtained and analyzed by enzyme-linked immunosorbent assay. (NCT00371254)
Timeframe: Baseline, Week 3 and Week 5

,
Interventionpercentage of baseline (Geometric Mean)
Week 3 (n = 17, 12)Week 5 (n = 8, 11)
Dasatinib 100 mg BID25.0733.56
Dasatinib 70 mg BID18.5925.12

[back to top]

Mean Change in Concentration of Collagen Type IV From Baseline

Collagen Type IV is a measure of anti-angiogenic activity. Plasma samples for assessment of change in concentration of Collagen Type IV were obtained and analyzed by enzyme-linked immunosorbent assay. (NCT00371254)
Timeframe: Baseline, Week 3 and Week 5

,
Interventionpercentage of baseline (Geometric Mean)
Week 3 (n = 17, 12)Week 5 (n = 8, 11)
Dasatinib 100 mg BID39.5134.31
Dasatinib 70 mg BID26.9235.18

[back to top]

Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) at or After 16 Weeks on Study

The percentage of participants whose best response was CR, PR or SD (per the RECIST) at or after 16 weeks on study: CR: disappearance of all target/non-target lesions; PR: >=30% decrease in the sum of the LDs of target lesions relative to baseline sum LD; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; PD: appearance of new lesion/s, or >=20% increase in the sum of the LD of target lesions, relative to the smallest sum LD recorded since treatment start, or unequivocal progression of existing non-target lesions. (NCT00371254)
Timeframe: Baseline to 16 weeks

Interventionpercentage of participants (Number)
Dasatinib 100 mg BID13.04
Dasatinib 70 mg BID5.0

[back to top]

Percentage of Participants With Complete Response (CR) or Partial Response (PR)

The percentage of participants whose best response was CR or PR, per the RECIST: CR: disappearance of all target/non-target lesions; PR: >= 30% decrease in the sum of the LDs of target lesions relative to the baseline sum LD. (NCT00371254)
Timeframe: Baseline to end of study drug therapy (up to 65 weeks).

Interventionpercentage of participants (Number)
Dasatinib 100 mg BID8.7
Dasatinib 70 mg BID0.0

[back to top]

Number of Participants With Identified Electrocardiogram (ECG) Abnormalities

ECGs were performed and all recordings were evaluated by the investigator. Abnormalities, if present at any study time point, were listed. The following ECG variables were collected: heart rate, PR interval, QRS width, and QT interval. Abnormalities in ECGs were defined by reference to institutional reports. (NCT00371254)
Timeframe: Baseline, Weeks 3, 9, 17 and 25, then every 8 weeks until the end of study treatment (up to 17 weeks).

Interventionparticipants (Number)
Dasatinib 100 mg BID4
Dasatinib 70 mg BID3

[back to top]

Mean Plasma Concentration at Week 3

Mean plasma concentration was obtained directly from the concentration-time data. (NCT00371254)
Timeframe: At pre-dose and 1, 3, 6 and 12 hours after each dose administration

,,
Interventionnanograms (ng)/mL (Mean)
0 hour (n = 10, 10, 1)1 hour (n = 10, 10, 1)3 hour (n = 10, 10, 1)6 hour (n = 10, 10, 1)12 hour (n = 7, 6, 1)
Dasatinib 100 mg BID9.02103.3550.9819.029.11
Dasatinib 50 mg BID2.8835.0532.5810.353.60
Dasatinib 70 mg BID7.1466.4135.4714.2815.43

[back to top]

Number of Participants With Complete Response (CR) or Partial Response (PR)

Tumor response was defined as the number of participants whose best response was CR or PR, per the Response Evaluation Criteria in Solid Tumor (RECIST): CR: disappearance of all target/non-target lesions; PR: >= 30% decrease in the sum of the LDs of target lesions relative to the baseline sum LD. (NCT00371254)
Timeframe: Baseline to end of study drug therapy (up to 65 weeks).

Interventionparticipants (Number)
Dasatinib 100 mg BID2
Dasatinib 70 mg BID0

[back to top]

Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) at or After 16 Weeks on Study

The number of participants whose best response was CR, PR or SD (per the RECIST) at or after 16 weeks on study: CR: disappearance of all target/non-target lesions; PR: >=30% decrease in the sum of the LDs of target lesions relative to baseline sum LD; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; PD: appearance of new lesion/s, or >=20% increase in the sum of the LD of target lesions, relative to the smallest sum LD recorded since treatment start, or unequivocal progression of existing non-target lesions. (NCT00371254)
Timeframe: Baseline to 16 weeks.

InterventionParticipants (Number)
Dasatinib 100 mg BID3
Dasatinib 70 mg BID1

[back to top]

Median Progression Free Survival (PFS)

PFS was defined as time from first dosing date until the first date that PD was observed. The distribution of PFS was estimated using the Kaplan-Meier product limit method. A two-sided 95% confidence interval (Brookmeyer and Crowley method) for the median PFS was computed. (NCT00371345)
Timeframe: From Baseline (Week 0) to time of PD or discontinuation of last participant from study treatment (Week 45)

Interventionweeks (Median)
Her2/Neu-amplified Tumor8.1
ER and/or PgR Positive Tumor8.1

[back to top]

Number of Participants Who Progressed

PFS was defined as time from first dosing date until the first date that Progressive Disease (PD) was observed. (NCT00371345)
Timeframe: From Baseline (Week 0) to time of PD or discontinuation of last participant from study treatment (Week 45)

Interventionparticipants (Number)
Her2/Neu-amplified Tumor22
ER and/or PgR Positive Tumor39
All Participants61

[back to top]

Number of Participants With Objective Response

Tumor response was assessed according RECIST criteria: PR=at least 30% reduction in the sum of the LD of all target lesions in reference to the baseline sum LD, CR=Disappearance of all non-target lesions. Objective tumor response was defined as a PR or CR. (NCT00371345)
Timeframe: From day of first treatment through Week 25 or at time of discontinuation from study treatment.

Interventionparticipants (Number)
Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib0
Her2/Neu-amplified Tumor, 100 mg BID1
ER and/or PgR Positive Tumor, 70 mg BID Dasatinib1
ER and/or PgR Positive Tumor, 100 mg BID Dasatinib1

[back to top]

Percentage of Participants With Objective Response

Tumor response was assessed according RECIST criteria: PR=at least 30% reduction in the sum of the LD of all target lesions in reference to the baseline sum LD, CR=Disappearance of all non-target lesions. Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. (NCT00371345)
Timeframe: From day of first treatment through Week 25 or at time of discontinuation from study treatment

Interventionpercentage of participants (Number)
Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib0
Her2/Neu-amplified Tumor, 100 mg BID Dasatinib11.11
ER and/or PgR Positive Tumor, 70 mg BID Dasatinib3.23
ER and/or PgR Positive Tumor, 100 mg BID Dasatinib7.14
All Response-evaluable Participants4.35

[back to top]

Percentage of Response-evaluable Participants With Disease Control (DCR)

Disease control was defined in response-evaluable participants as having a best response of objective response (CR or PR) or SD at/after 16 Weeks. (NCT00371345)
Timeframe: From day of first treatment through Week 25 or at time of discontinuation from study treatment.

Interventionpercentage of participants (Mean)
Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib6.67
Her2/Neu-amplified Tumor, 100 mg BID Dasatinib11.11
ER and/or PgR Positive Tumor, 70 mg BID Dasatinib16.13
ER and/or PgR Positive Tumor, 100 mg BID Dasatinib14.29

[back to top]

Best Overall Response

Response assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target and non-target lesions; Partial Response (PR)=≥30% decrease in sum of longest diameter (LD) of target lesions; SD=small changes not meeting above criteria; Progressive Disease (PD)=appearance of new lesion(s), ≥ 20% increase in the sum of the LD of target lesions, or progression of existing non-target lesions; Clinical Progression (cPD)=deterioration related to disease requiring treatment without radiographic PD. (NCT00371345)
Timeframe: From day of first treatment through Week 25 or at time of discontinuation from study treatment

,,,
Interventionparticipants (Number)
Complete Response (CR)Unconfirmed partial responsePartial Response (PR)Stable Disease (SD)Progressive Disease (PD)Clinical Progression (cPD)Discontinuation Due To Drug Toxicity (Tox)No Reassessment -Reasons Other Than Tox/PD
ER and/or PgR Positive Tumor, 100 mg BID Dasatinib00137120
ER and/or PgR Positive Tumor, 70 mg BID Dasatinib011515351
Her2/Neu-amplified Tumor, 100 mg BID00124110
Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib000212010

[back to top]

Number of Participants With Death, Adverse Events (AEs), and AEs Leading to Discontinuation

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. (NCT00371345)
Timeframe: Continuous assessment beginning at initiation of study drug until 30 days after the last dose of study drug

,
Interventionparticipants (Number)
All DeathsAll AEsAEs Leading to Discontinuation
Dasatinib 100 mg64711
Dasatinib 70 mg6235

[back to top] [back to top]

Number of Participants With On-study CTCAE Version 3.0 Grade 3-4 Laboratory Abnormalities

Normal ranges for laboratory abnormalities: granulocytes=1.5x10^3-8x10^3 mm^3 (range may have varied by institution); hemoglobin=12-16 g/dL; platelets=150-440x10^9c/L; partial thromboplastin time=27-37.1 seconds; alkaline phosphatase=38-126 U/L; alanine aminotransferase=15-48 U/L; aspartate aminotransferase=14-38 U/L; creatine=0.7-1.1 mg/dL; hypokalemia (potassium [K])=3.5-5mEq/L; hyponatremia (sodium [Na])=135-145 mEq/L; phosphorous=2.4-4.5 mg/dL; bilirubin=0-1.2. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening/disabling, Gr 5=Death. (NCT00371345)
Timeframe: Continuous assessment beginning at initiation of study drug until 30 days after the last dose of study drug

,
Interventionparticipants (Number)
GranulocytesHemoglobinPlatelet CountPartial Thromboplastin TimeAlkaline PhosphataseAlanine AminotransferaseAspartate AminotransferaseCreatinineHypokalemiaHyponatremiaPhosphorousBilirubin
Dasatinib 100 mg111011300111
Dasatinib 70 mg100100111020

[back to top] [back to top]

Number of Response-evaluable Participants With Disease Control (DCR)

Disease control was defined in response-evaluable participants as having a best response of CR or PR (or uPR), or SD at/after 16 Weeks. (NCT00371345)
Timeframe: From day of first treatment through Week 25 or at time of discontinuation from study treatment.

,,,
Interventionparticipants (Number)
Participants with CRParticipants with unconfirmed PR (uCR)Participants with PRParticipants with SD ≥16 weeksTotal Participants with DCR
ER and/or PgR Positive Tumor, 100 mg BID Dasatinib00112
ER and/or PgR Positive Tumor, 70 mg BID Dasatinib01135
Her2/Neu-amplified Tumor, 100 mg BID Dasatinib00101
Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib00011

[back to top]

Percentage of Participants With Progression-free Survival (PFS) at Weeks 9, 17, and 25

PFS was defined as time from first dosing date until the first date that progressive disease (PD) was observed. (NCT00371345)
Timeframe: At Weeks 9, 17, and 25

,,,
Interventionpercentage of participants (Number)
Week 9Week 17Week 25
ER and/or PgR Positive Tumor, 100 mg BID Dasatinib332517
ER and/or PgR Positive Tumor, 70 mg BID Dasatinib32187
Her2/Neu-amplified Tumor, 100 mg BID Dasatinib502513
Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib2170

[back to top]

Pharmacodynamics: Percent Change From Baseline In Plasma Level of Collagen Type IV at Week 3 in Participants With and Without DCR

Collagen Type IV is a circulating marker related to the modulation of the vascular endothelial growth factor (VEGF)-pathway. An assay of Collagen Type IV in plasma was performed by ELISA. (NCT00371345)
Timeframe: At Baseline and Week 3 of treatment (Day 15 ±4 days)

,
Interventionpercent change (Mean)
Participants with no DCR (n=27, n=16)Participants with DCR (n=2, n=3)All Participants (n=29, n=19)
Dasatinib 100 mg35.9240.7436.67
Dasatinib 70 mg32.0722.0131.35

[back to top]

Pharmacodynamics: Percent Change From Baseline In Plasma Level of Collagen Type IV at Week 5 in Participants With and Without DCR

Collagen Type IV is a circulating marker related to the modulation of the vascular endothelial growth factor (VEGF)-pathway. An assay of Collagen Type IV in plasma was performed by ELISA. (NCT00371345)
Timeframe: Week 5

,
Interventionpercent change (Mean)
Participants with no DCR (n=20, n=12)Participants with DCR (n=3, n=3)All Participants (n=23, n=15)
Dasatinib 100 mg28.4564.5134.97
Dasatinib 70 mg45.3717.1341.33

[back to top]

Pharmacodynamics: Percent Change From Baseline In Plasma Level of VEGFR2 at Week 3 in Participants With and Without DCR

VEGF-stimulated disruption of the cadherin-catenin complex leads to tumor cell invasion and metastasis. VEGFR2 plasma levels were assayed by ELISA as a marker of VEGF pathway modulation. (NCT00371345)
Timeframe: At Baseline and Week 3 of treatment (Day 15 ±4 days)

,
Interventionpercent change (Mean)
Participants with no DCR (n=27, n=16)Participants with DCR (n=2, n=3)All Participants (n=29, n=19)
Dasatinib 100 mg23.61-5.0318.57
Dasatinib 70 mg21.8814.7721.37

[back to top]

Pharmacodynamics: Percent Change From Baseline In Plasma Level of VEGFR2 at Week 5 in Participants With and Without DCR

VEGF-stimulated disruption of the cadherin-catenin complex leads to tumor cell invasion and metastasis. VEGFR2 plasma levels were assayed by ELISA as a marker of VEGF pathway modulation. (NCT00371345)
Timeframe: At Baseline and Week 5 of treatment

,
Interventionpercent change (Mean)
Participants with no DCR (n=20, n=12)Participants with DCR (n=3, n=3)All Participants (n=23, n=15)
Dasatinib 100 mg26.3637.2528.47
Dasatinib 70 mg27.2316.4625.77

[back to top]

Pharmacokinetics (PK): Plasma Concentration of Dasatinib at Week 3

Blood samples (3 mL) were used for measurement of dasatinib plasma concentration and metabolites. (NCT00371345)
Timeframe: PK assessment was performed at Week 3 visit (Day 15 ±4 days). Blood samples were obtained at Time = 0 hours, and at 1, 3 and 6 hours after each dose, and a trough sample was obtained immediately prior to any dose (~12 hours).

,
Interventionng/ml (Mean)
Time 0 hours (100 mg, n=16; 70 mg, n=13)Time 1 hour (100 mg, n=16; 70 mg, n=14)Time 3 hours (100 mg, n=17; 70 mg, n=14)Time 6 hours (100 mg, n=17; 70 mg, n=13)Time 12 hours (100 mg, n=16; 70 mg, n=9)
Dasatinib 100 mg6.9677.2130.2112.647.41
Dasatinib 70 mg10.82107.0958.0123.1911.88

[back to top]

PK: Plasma Concentration of Dasatinib at Week 7 or Week 9

Blood samples (3 mL) were used for measurement of dasatinib plasma concentration and metabolites. (NCT00371345)
Timeframe: PK assessment was performed at Week 7 or 9 visit. Blood samples were obtained at Time = 0 hours, and at 1, 3 and 6 hours after each dose, and a trough sample was obtained immediately prior to any dose (~12 hours).

,,
Interventionng/ml (Mean)
Time 0 hours (100 mg, n=5; 70 mg, n=7; 50 mg, n=1)Time 1 hour (100 mg, n=5; 70 mg, n=8; 50 mg, n=1)Time 3 hours (100 mg, n=5; 70 mg, n=9; 50 mg, n=1)Time 6 hours (100 mg, n=5; 70 mg, n=8; 50 mg, n=1)Time 12 hours (100 mg, n=4; 70 mg, n=6; 50 mg, n=1
Dasatinib 100 mg9.49131.0955.2623.5810.52
Dasatinib 50 mg6.064.7535.7435.919.02
Dasatinib 70 mg6.6249.2842.2713.035.00

[back to top]

Duration Of Objective Response

Duration of objective response was defined as the time (in weeks) between the first date that criteria for CR or PR were met and the first date that progressive disease (PD) or clinical progressive disease (cPD) was observed. Date of death was used as PD date for participants who died before reporting PD. Participants who neither progressed nor died were censored at the date of their last tumor assessment. (NCT00371345)
Timeframe: the time (in weeks) between the first date that criteria for PR were met and the first date that PD or cPD was observed

Interventionweeks (Number)
Participant CA180088-18-88009, HER-2 Group31.14
Participant CA180088-16-88002, ER and/or PgR Group18.14
Participant CA180088-29-88085, ER and/or PgR Group8.29

[back to top]

Number of Participants With QTc Prolongation

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. QTc is the QT interval corrected for heart rate. A prolonged QT interval is a risk factor for ventricular tachyarrhythmias and sudden death. (NCT00385580)
Timeframe: From start of study drug therapy up to 30 days after the last dose.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)3
Dasatinib 100 mg or 70 mg Twice Daily (BID)10

[back to top] [back to top]

Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AEs

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. (NCT00385580)
Timeframe: From start of study drug therapy up to 30 days after the last dose.

,
Interventionparticipants (Number)
DeathsAEsSAEsAll AEs Leading to Discontinuation
Dasatinib 100 mg Once Daily (QD)2481013
Dasatinib 100 mg or 70 mg Twice Daily (BID)247118

[back to top]

Median Change From Baseline in Total FAPSI-8 Scores at Weeks 12, 24 and 36

The FAPSI-8 is a symptom index comprised of the most important clinician-rated symptoms or concerns to monitor when assessing the value of treatment for advanced prostate cancer. It includes 8 items developed to measure symptoms/concerns specific to prostate cancer such as fatigue, pain (3-items), weight loss, difficulty with urination (2-items) and concerns about the condition becoming worse. Participants respond to each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 12, every 12 weeks thereafter and at the end of the treatment.

,
InterventionUnits on a scale (Median)
Week 12 (n=26, 29)Week 24 (n=14, 6)Week 36 (n=4, 5)
Dasatinib 100 mg Once Daily (QD)0.00-2.50NA
Dasatinib 100 mg or 70 mg Twice Daily (BID)-2.00-2.00NA

[back to top]

Median Change From Baseline in Individual FAPSI Scores at Week 24

FAPSI-8:symptom index of important clinician-rated symptoms/concerns to monitor when assessing value of treatment for advanced prostate cancer. Participants respond to each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). GP1:I have lack of energy, GP4:I have pain, GE6:I worry that my condition will get worse, C2: I am losing weight, P2:I have certain areas in my body where I experience significant pain,P3:My pain keeps me from doing things I want to do, P7:I have difficulty urinating, P8:My problems with urinating limit my activities. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 12, every 12 weeks thereafter and at the end of the treatment.

,
InterventionUnits on a scale (Median)
GP1GP4GE6C2P2P3P7P8
Dasatinib 100 mg Once Daily (QD)0.00-0.50-0.500.000.000.000.000.00
Dasatinib 100 mg or 70 mg Twice Daily (BID)0.00-0.50-0.50-0.500.000.000.000.00

[back to top]

Median Change From Baseline in Individual FAPSI Scores at Week 12

FAPSI-8:symptom index of important clinician-rated symptoms/concerns to monitor when assessing value of treatment for advanced prostate cancer. Participants respond to each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). GP1:I have lack of energy, GP4:I have pain, GE6:I worry that my condition will get worse, C2: I am losing weight, P2:I have certain areas in my body where I experience significant pain,P3:My pain keeps me from doing things I want to do, P7:I have difficulty urinating, P8:My problems with urinating limit my activities. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 12, every 12 weeks thereafter and at the end of the treatment.

,
InterventionUnits on a scale (Median)
GP1GP4GE6C2P2P3P7P8
Dasatinib 100 mg Once Daily (QD)0.000.000.000.000.000.000.000.00
Dasatinib 100 mg or 70 mg Twice Daily (BID)-1.000.000.000.000.000.000.000.00

[back to top]

Mean Plasma Concentration at Dose 50 mg (Week 6)

Mean plasma concentration was obtained directly from the concentration-time data. (NCT00385580)
Timeframe: At pre-dose, 1 hour, 3 hours, 6 hours and at 12 hours after any dose for BID and QD group.

,,
Interventionng/mL (Mean)
0 hour (n=1,1,3)1hour (n=1,1,4)3 hour (n=1,1,4)6 hour (n=1,1,3)12 hour (n=1,1,3)
Dasatinib 100 mg Once Daily (QD)3.54134.8927.3513.202.16
Dasatinib 100 mg Twice Daily (BID)7.4362.6220.6510.298.33
Dasatinib 70 mg BID3.6831.9913.287.503.12

[back to top]

Mean Plasma Concentration at 70 mg Dasatinib Dose (Week 6)

Mean plasma concentration was obtained directly from the concentration-time data. (NCT00385580)
Timeframe: At pre-dose, 1 hour, 3 hours, 6 hours and at 12 hours after any dose for BID group.

,
Interventionng/mL (Mean)
0 hour (n=9,12)1hour (n=10,11)3 hour (n=10,12)6 hour (n=8,11)12 hour (n=5,11)
Dasatinib 100 mg Twice Daily (BID)7.2954.6730.9816.137.72
Dasatinib 70 mg BID6.0577.8324.1711.8116.29

[back to top]

Mean Plasma Concentration at 70 mg Dasatinib Dose (Week 2)

Mean plasma concentration was obtained directly from the concentration-time data. (NCT00385580)
Timeframe: At pre-dose, 1 hour, 3 hours, 6 hours and at 12 hours after any dose for BID and QD group.

,,
Interventionng/mL (Mean)
0 hour (n=1,1,17)1hour (n=1,1,20)3 hour (n=1,1,20)6 hour (n=1,1,19)12 hour (n=1,1,18)
Dasatinib 100 mg Once Daily (QD)2.16140.1543.5017.0924.52
Dasatinib 100 mg Twice Daily (BID)11.6910.3744.9052.7712.54
Dasatinib 70 mg BID7.0866.4727.6014.0111.91

[back to top]

Median Number of Months to Disease Progression

Measured from date of first dose to date of first 3 consecutive measurements that confirm PSA progression, date of disease progression,or death date.Disease progression:progression of target lesions or unequivocal progression of non-measurable lesions/disease as evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI),loss of PSA response or Investigator-defined clinical progression based on physical examination,history,symptoms,and ECOG-PS.For participants who did not progress or die,date of last PSA measurement or tumor assessment was used, whichever occurred first. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 12 and every 12 weeks thereafter and at the end of the treatment.

Interventionmonths (Median)
Dasatinib 100 mg Once Daily (QD)4.7
Dasatinib 100 mg or 70 mg Twice Daily (BID)2.8

[back to top]

Median Number of Months of uNTx Response

uNTx is a measure of bone metabolism.The median number of months of uNTx response was calculated for participants with baseline uNTx =< ULN and uNTx progression during treatment, from first dose of dasatinib to uNTx progression.For participant with baseline uNTx above ULN, it was time from uNTx response to uNTx progression.For participants with baseline uNTx equal to or below ULN or uNTx response and no uNTx progression, the date of last uNTx assessment was used. Duration of uNTx response was not defined for participants with baseline value greater than ULN who never achieved uNTx responses. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

Interventionmonths (Median)
Dasatinib 100 mg Once Daily (QD)NA
Dasatinib 100 mg or 70 mg Twice Daily (BID)NA

[back to top]

Median Number of Months of BAP Response

The median number of months of the BAP response was calculated for participants with baseline BAP <= ULN, from first dose of dasatinib to the first time BAP is above ULN. For participants with baseline BAP > ULN, it was the time from BAP response to the first time BAP was above ULN. For participants with baseline BAP =< ULN or BAP, and no BAP above ULN, last BAP assessment date was used. The median number of months of response was not defined for participants with baseline value > ULN, that never achieved BAP response. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

Interventionmonths (Median)
Dasatinib 100 mg Once Daily (QD)NA
Dasatinib 100 mg or 70 mg Twice Daily (BID)NA

[back to top]

Number of Participants With Positive Urinalysis

"Participants' urine samples were tested for the presence of blood, glucose and protein. If these substances were present in a participant's urine, the results were given as positive." (NCT00385580)
Timeframe: Data was collected prior treatment with the study drug, Week 2, Week 4, Week 8, Week 12 , every 4 weeks thereafter and at the end of the treatment.

,
Interventionparticipants (Number)
BloodGlucoseProtein
Dasatinib 100 mg Once Daily (QD)20221
Dasatinib 100 mg or 70 mg Twice Daily (BID)21126

[back to top]

Number of Participants With Grade 3-4 Serum Chemistry Abnormalities in Creatinine, Potassium, Sodium and Phosphorous

Abnormalities were graded per the NCI CTC, version 3.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Grade 3 and 4 criteria are as follows: phosphorous: Grade 3: 1.0-<2.0 mg/dL, Grade 4: <1.0 mg/dL; sodium: Grade 3: 120-<130 or >155-160mEq/L, Grade 4: <120 or >160 mEq/L; creatinine: Grade 3: >3.0-6.0 * ULN, Grade 4: >6.0 * ULN; potassium: Grade 3: 2.5 -<3.0 or >6.0 -7.0 mEq/L, Grade 4: < 2.5 or >7.0 mEq/L. (NCT00385580)
Timeframe: Data was collected prior treatment with the study drug, Week 2, Week 4, Week 8, Week 12 , every 4 weeks thereafter and at the end of the treatment.

,
Interventionparticipants (Number)
CreatinineHyperkalemiaHypokalemiaHypernatremiaHyponatremiaPhosphorus, Inorganic
Dasatinib 100 mg Once Daily (QD)002012
Dasatinib 100 mg or 70 mg Twice Daily (BID)001012

[back to top]

Number of Participants With Grade 3-4 Serum Chemistry Abnormalities in Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Bilirubin and Calcium

Abnormalities were graded according to the NCI CTC, version 3.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Grade 3 and 4 criteria are as follows: alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase: Grade 3: 5.0-20.0 * ULN (upper limit of normal), Grade 4: >20.0 * ULN; calcium: Grade 3: 6.0-<7.0 or >12.5-13.5 mg/dL, Grade 4: <0.6->13.5 mg/dL; bilirubin: Grade 3: >3-10 * ULN, Grade 4: >10 * ULN. (NCT00385580)
Timeframe: Data was collected prior treatment with the study drug, Week 2, Week 4, Week 8, Week 12 , every 4 weeks thereafter and at the end of the treatment.

,
Interventionparticipants (Number)
Alanine AminotransferaseAspartate AminotransferaseAlkaline PhosphataseBilirubinHypercalcemiaHypocalcemia
Dasatinib 100 mg Once Daily (QD)006001
Dasatinib 100 mg or 70 mg Twice Daily (BID)000000

[back to top]

Number of Participants With Grade 3-4 Hematology Abnormalities

Abnormalities were graded per the NCI CTC, version 3.0 criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Grade 3 and 4 criteria are as follows: Hemoglobin: Grade 3:6.5 - <8.0g/dL, Grade 4: <6.5g/dL. Platelets: Grade 3: 25.0 - <50.0*10^9/L, Grade 4: <25.0*10. Absolute Neutrophil Count (ANC): Grade 3: 0.5 - <1.0*10^9/L, Grade 4: <0.5*10^9/L. Leukocytes: Grade 3: 1.0 - <2.0*10^9/L, Grade 4: <1.0*10^9/L. (NCT00385580)
Timeframe: Data was collected prior treatment with the study drug, Week 2, Week 4, Week 8, Week 12 , every 4 weeks thereafter and at the end of the treatment.

,
Interventionparticipants (Number)
Absolute Neutrophil Count (ANC)HemoglobinPlatelet CountLeukocytes
Dasatinib 100 mg Once Daily (QD)0000
Dasatinib 100 mg or 70 mg Twice Daily (BID)1110

[back to top]

Number of Participants With a Baseline uNTx Value >ULN, With a Decrease, Increase or no Change in uNTx

uNTx is a measure of bone metabolism. A decrease in the marker relative to baseline indicates a decrease in bone metabolism. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

,
Interventionparticipants (Number)
0-35 percent decrease>35-70 percent decrease>70 percent decreaseNo change or increase
Dasatinib 100 mg Once Daily (QD)6344
Dasatinib 100 mg or 70 mg Twice Daily (BID)4911

[back to top]

Number of Participants With a Baseline uNTx Value <=ULN, With a Decrease, Increase or no Change in uNTx

uNTx is a measure of bone metabolism. A decrease in the marker relative to baseline indicates a decrease in bone metabolism. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

,
Interventionparticipants (Number)
0-35 percent decrease>35-70 percent decrease>70 percent decreaseNo change or increase
Dasatinib 100 mg Once Daily (QD)21356
Dasatinib 100 mg or 70 mg Twice Daily (BID)61217

[back to top]

Number of Participants With a Response

Response = confirmed prostate specific antigen (PSA) response (decrease in PSA =>50% from baseline), confirmed improved bone scan (disappearance of => 1 lesion, no new lesions, new pain not developing), confirmed complete response (CR: disappearance of all lesions) or confirmed partial response (PR: =>30% in sum of longest diameter [LD] of all lesions compared to baseline sum LD), stable disease (SD: neither sufficient increase for progressive disease [PD: =>20% increase in sum of LD of all target lesions] nor sufficient shrinkage for PR), based on Response Criteria in Solid Tumors [RECIST]. (NCT00385580)
Timeframe: Within 2 weeks of first study drug administration, thereafter recorded every 4 weeks.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)12
Dasatinib 100 mg or 70 mg Twice Daily (BID)13

[back to top]

Number of Participants With a Baseline BAP Value > ULN, With a Decrease, Increase or no Change in BAP

BAP is a measure of bone metabolism. A decrease in BAP relative to baseline indicates a decrease in bone metabolism. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

,
Interventionparticipants (Number)
0-35 percent decrease>35-70 percent decrease>70 percent decreaseNo change or increase
Dasatinib 100 mg Once Daily (QD)6118
Dasatinib 100 mg or 70 mg Twice Daily (BID)6308

[back to top]

Mean Plasma Concentration at 50 mg Dasatinib Dose (Week 2)

Mean plasma concentration was obtained directly from the concentration-time data. (NCT00385580)
Timeframe: At pre-dose, 1 hour, 3 hours, 6 hours and at 12 hours after any dose for BID and QD group.

,,
Interventionng/mL (Mean)
0 hour (n=2,2,1)1hour (n=2,2,1)3 hour (n=2,2,1)6 hour (n=2,2,1)12 hour (n=2,2,1)
Dasatinib 100 mg Once Daily (QD)2.2860.3528.3812.9647.97
Dasatinib 100 mg Twice Daily (BID)7.3942.1523.186.0912.90
Dasatinib 70 mg BID14.21117.7157.0823.6315.92

[back to top]

Mean Plasma Concentration at 100 mg Dasatinib Dose (Week 6)

Mean plasma concentration was obtained directly from the concentration-time data. (NCT00385580)
Timeframe: At pre-dose, 1 hour, 3 hours, 6 hours and at 12 hours after any dose for BID and QD group.

,,
Interventionng/mL (Mean)
0 hour (n=31,8,1)1hour (n=36,9,1)3 hour (n=36,9,1)6 hour (n=36,9,1)12 hour (n=26,8,1)
Dasatinib 100 mg Once Daily (QD)15.4689.5540.1015.1517.27
Dasatinib 100 mg Twice Daily (BID)10.6159.7533.2616.2715.92
Dasatinib 70 mg BID8.6878.7829.8513.6813.93

[back to top]

Mean Plasma Concentration at 100 mg Dasatinib Dose (Week 2)

Mean plasma concentration was obtained directly from the concentration-time data. (NCT00385580)
Timeframe: At pre-dose, 1 hour, 3 hours, 6 hours and at 12 hours after any dose for BID and QD group.

,,
Interventionng/mL (Mean)
0 hour (n=39,18,1)1hour (n=41,19,1)3 hour (n=41,19,1)6 hour (n=41,18,1)12 hour (n=30,12,1)
Dasatinib 100 mg Once Daily (QD)3.17102.9845.2819.3716.86
Dasatinib 100 mg Twice Daily (BID)8.1573.0537.5815.0210.51
Dasatinib 70 mg BID5.4683.2423.738.889.89

[back to top]

Percentage of Participants With Confirmed Improved Bone Scan

An improved bone scan was defined as 1 or more of the following: disappearance of at least 1 lesion, no new lesions appearing since the most recent prior assessment, or new pain not developing in an area that was previously visualized. A response is considered confirmed if it is noted on 2 examinations at least 4 weeks apart. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 12, every 12 weeks thereafter and at the end of the treatment.

InterventionPercentage of Participants (Number)
Dasatinib 100 mg Once Daily (QD)0.0
Dasatinib 100 mg or 70 mg Twice Daily (BID)2.6

[back to top]

Percentage of Participants With a Response

Response = confirmed PSA response (decrease in PSA =>50% from baseline), confirmed improved bone scan (disappearance of => 1 lesion, no new lesions, new pain not developing), confirmed CR (disappearance of all lesions) or confirmed PR (=>30% in sum of LD of all lesions compared to baseline sum LD), SD (neither sufficient increase for PD [=>20% increase in sum of LD of all target lesions] nor sufficient shrinkage for PR), based on RECIST. (NCT00385580)
Timeframe: Within 2 weeks of first study drug administration, thereafter recorded every 4 weeks.

InterventionPercentage of Participants (Number)
Dasatinib 100 mg Once Daily (QD)25.00
Dasatinib 100 mg or 70 mg Twice Daily (BID)27.70

[back to top]

Percentage of Participants With a Decrease in PSA by at Least 50% From Baseline

PSA is a marker of prostate cancer and a PSA response is defined as a decrease in the PSA value by at least 50% from baseline for 2 successive evaluations, each at least 2 weeks apart, for a total of 3 measurements. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

InterventionPercentage of Participants (Number)
Dasatinib 100 mg Once Daily (QD)2.3
Dasatinib 100 mg or 70 mg Twice Daily (BID)2.3

[back to top]

Number of Participants With a Baseline BAP Value <= ULN, With a Decrease, Increase or no Change in BAP

BAP is a measure of bone metabolism. A decrease in BAP relative to the baseline indicates decrease in bone metabolism. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

,
Interventionparticipants (Number)
0-35 percent decrease>35-70 percent decrease>70 percent decreaseNo change or increase
Dasatinib 100 mg Once Daily (QD)125110
Dasatinib 100 mg or 70 mg Twice Daily (BID)14207

[back to top]

Number of Participants With Increase in PSA Doubling Time

PSA is a marker of prostate cancer. PSA doubling time is defined as log 2 divided by the slope of the log PSA line. An increase in PSA doubling time indicates improvement in anti-tumor activity. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)34
Dasatinib 100 mg or 70 mg Twice Daily (BID)32

[back to top]

Number of Participants With Disease Progression

Disease progression: progression of target lesions or unequivocal progression of non-measurable lesions/disease as evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI), not as evaluated by bone scan (non-measurable lesions included visceral and bone lesions), loss of PSA response (only for participants who achieved a PSA response) or Investigator-defined clinical progression based on physical examination, history, symptoms, and ECOG-PS. For participants who did not progress or die, date of last PSA measurement or tumor assessment was used, whichever occurred first. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 12 and every 12 weeks thereafter and at the end of the treatment.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)30
Dasatinib 100 mg or 70 mg Twice Daily (BID)34

[back to top]

Number of Participants With Decrease in PSA Velocity

PSA is a marker of prostate cancer. PSA velocity measures the rate of change of PSA values. A decrease in PSA values and hence PSA velocity is an early indicator of potential anti-tumor activity. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)25
Dasatinib 100 mg or 70 mg Twice Daily (BID)16

[back to top]

Number of Participants With Decrease in PSA Log Slope

PSA is a marker of prostate cancer. A decrease in PSA value is an early indicator of potential anti-tumor activity. Log (PSA) is assumed to have a linear relationship with time. The PSA log slope is defined as the slope of the log PSA line. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)38
Dasatinib 100 mg or 70 mg Twice Daily (BID)34

[back to top]

Number of Participants With CR, PR or SD

Disease control rate is defined as the number of participants whose best response was CR, PR or SD, per RECIST: CR: disappearance of all target/non-target lesions; PR: >= 30% decrease in the sum of the LDs of target lesions relative to the baseline sum LD; SD: neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR; PD: defined as appearance of new lesion/s, or >=20% increase in the sum of the LD of target lesions, relative to the smallest sum LD recorded since treatment start, or unequivocal progression of existing non-target lesions. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 12, every 12 weeks thereafter and at the end of the treatment.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)11
Dasatinib 100 mg or 70 mg Twice Daily (BID)12

[back to top]

Number of Participants With CR or PR

Tumor response was defined as the number of participants whose best response was CR or PR, per RECIST: CR: disappearance of all target/non-target lesions; PR: >= 30% decrease in the sum of the LDs of target lesions relative to the baseline sum LD (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 12, every 12 weeks thereafter and at the end of the treatment.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)1
Dasatinib 100 mg or 70 mg Twice Daily (BID)0

[back to top]

Number of Participants With BAP Response

BAP is a measure of bone metabolism. A BAP response is calculated for participants with a baseline BAP value > ULN. It is defined as on-study BAP values within normal limits. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)4
Dasatinib 100 mg or 70 mg Twice Daily (BID)5

[back to top]

Number of Participants With Abnormal Lactate Dehydrogenase (LD)

LDH is a laboratory safety parameter. Normal ranges for LD vary with both age and disease status, and another reason for variation in upper limit of normal (ULN) and lower limit of normal (LLN) is that LD was measured via a local (versus a standardized) laboratory. It is therefore not possible to provide one ULN and LLN for the population. (NCT00385580)
Timeframe: Data was collected prior treatment with the study drug, Week 2, Week 4, Week 8, Week 12, every 4 weeks thereafter and at the end of the treatment.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)33
Dasatinib 100 mg or 70 mg Twice Daily (BID)41

[back to top]

Number of Participants With a uNTx Response

uNTx is a measure of bone metabolism. uNTx response is defined for participants with baseline uNTx above ULN. It is defined as either on-study uNTx values decreasing to within normal limits or 35% or more decrease in uNTx from baseline, whichever happens first. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)10
Dasatinib 100 mg or 70 mg Twice Daily (BID)10

[back to top]

Number of Participants With a Decrease in PSA by at Least 50% From Baseline

PSA is a marker of prostate cancer and a PSA response is defined as a decrease in the PSA value by at least 50% from baseline, for 2 successive evaluations, each at least 2 weeks apart, for a total of 3 measurements. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)1
Dasatinib 100 mg or 70 mg Twice Daily (BID)1

[back to top]

Number of Participants With a Confirmed Improved Bone Scan

An improved bone scan was defined as 1 or more of the following: disappearance of at least 1 lesion, no new lesions appearing since the most recent prior assessment, or new pain not developing in an area that was previously visualized. A response is considered confirmed if it is noted on 2 examinations at least 4 weeks apart. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 12, every 12 weeks thereafter and at the end of the treatment.

Interventionparticipants (Number)
Dasatinib 100 mg Once Daily (QD)0
Dasatinib 100 mg or 70 mg Twice Daily (BID)1

[back to top]

Number of Months of Decrease in PSA by at Least 50% From Baseline

PSA is a marker of prostate cancer. The duration of PSA response is measured from the time that the first of the 2 consecutive measurements met the criteria for confirmed PSA response, until the date of the first of the 3 consecutive measurements that confirm PSA progression, or the date of disease progression, or the date of death. (NCT00385580)
Timeframe: Prior to treatment with the study drug, Week 4, Week 8, Week 12 and every 4 weeks thereafter.

Interventionmonths (Number)
Dasatinib 100 mg Once Daily (QD)0.82
Dasatinib 100 mg or 70 mg Twice Daily (BID)11.17

[back to top]

Rate of Hematological Complete Remission (HCR) Obtained During the BMS Induction Treatment Within Day +85 From the Start of BMS (i.e., Whenever Achieved From the Start of the Experimental Drug).

(NCT00391989)
Timeframe: End of the study, up to day 85

InterventionPatients (Number)
Study Group53

[back to top]

Change in Serum Bone Turnover Markers Over Time -- BAP

Analysis included mean values of the serum biomarker BAP at baseline, 4, and 8 weeks. (NCT00410813)
Timeframe: at baseline, 4, and 8 weeks

Interventionug/L (Mean)
BAP at Baseline24.07
BAP at 4 Weeks24.35
BAP at 8 Weeks25.61

[back to top]

Change in Serum Bone Turnover Markers Over Time -- NTx

Analysis included mean values of the serum biomarker NTx at baseline, 4, and 8 weeks. (NCT00410813)
Timeframe: at baseline, 4, and 8 weeks

InterventionnM BCE (Mean)
NTx at Baseline21.84
NTx at 4 Weeks19.23
NTx at 8 Weeks12.88

[back to top]

Change in Serum Bone Turnover Markers Over Time -- OC

Analysis included mean values of the serum biomarker OC at baseline, 4, and 8 weeks. (NCT00410813)
Timeframe: at baseline, 4, and 8 weeks

Interventionng/mL (Mean)
OC at Baseline11.08
OC at 4 Weeks13.10
OC at 8 Weeks13.54

[back to top]

Change in Serum Bone Turnover Markers Over Time -- OPG

Analysis included mean values of the serum biomarker OPG at baseline, 4, and 8 weeks. (NCT00410813)
Timeframe: at baseline, 4, and 8 weeks

Interventionpmol/L (Mean)
OPG at Baseline4.56
OPG at 4 Weeks6.53
OPG at 8 Weeks6.71

[back to top]

Change in Serum Bone Turnover Markers Over Time -- TRAP

Analysis included mean values of the serum biomarker TRAP at baseline, 4, and 8 weeks. (NCT00410813)
Timeframe: at baseline, 4, and 8 weeks

InterventionU/L (Mean)
TRAP at Baseline6.83
TRAP at 4 Weeks5.41
TRAP at 8 Weeks5.59

[back to top]

Circulating Tumor Cells (CTC) Response Rate

CTC response at 4 weeks is defined as the number of patients with initially elevated CTCs (>= 5 cells/7.5 ml), whose CTC level drops to < 5. (NCT00410813)
Timeframe: Up to 4 weeks

Interventionparticipants (Number)
Dasatinib4

[back to top]

Mean Patient-reported Pain

"Patient's rating of worst pain experienced between prestudy and week 24. Changes of >=2 points on the Brief Pain Inventory (BPI) are of interest. Pain is self-reported on the Brief Pain Inventory Short Form, on a 0-10 response scale, with higher scores reflecting more pain and more interference with functioning." (NCT00410813)
Timeframe: Baseline, 8, 16, and 24 weeks

Interventionunits on a scale (Mean)
Dasatinib - Baseline3.37
Dasatinib - Week 83.82
Dasatinib - Week 163.06
Dasatinib - Week 243.73

[back to top]

Progression-free Survival

RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed, unequivocal progression of non-measurable disease, the appearance of any new lesion/site, death due to disease without prior documentation of progression and without symptomatic deterioration, development of one or more new bone lesions from baseline, or symptomatic deterioration related to disease progression. Time from date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free are censored at last date of contact. (NCT00410813)
Timeframe: Up to 2 years

Interventionweeks (Median)
Dasatinib, 100 mg, Daily10.3
Dasatinib, 70 mg, Twice Daily15.3

[back to top]

Change in Serum Bone Turnover Markers Over Time

Analysis included mean values of the serum biomarkers sRANKL, IL-6, DKK, VEGF at baseline, 4, and 8 weeks. (NCT00410813)
Timeframe: at baseline, 4, and 8 weeks

,,
Interventionpg/mL (Mean)
DKKIL-6VEGFsRANKL
Serum Biomarker at 4 Weeks1470.5019.03424.21531173
Serum Biomarker at 8 Weeks1575.0532.03412.33553459
Serum Biomarker at Baseline1157.64250.17459.01772172

[back to top]

Response Rate (Complete and Partial, Confirmed and Unconfirmed)

Complete Response (CR) is complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms, normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. Progression is 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed, unequivocal progression of non-measurable disease, appearance of any new lesion/site, death due to disease without prior documentation of progression and without symptomatic deterioration. Symptomatic deterioration is global deterioration of health status requiring discontinuation of treatment without objective evidence of progression. (NCT00410813)
Timeframe: Up to 2 years

,
Interventionparticipants (Number)
Partial ResponseStable/No ResponseIncreasing DiseaseAssessment Inadequate
Dasatinib, 100 mg, Daily114206
Dasatinib, 70 mg, Twice Daily0181010

[back to top] [back to top]

Overall Survival

Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. The study is not designed for a comparison of the treatment arms to each other. (NCT00423735)
Timeframe: Analysis occurs after all patients have been on study for at least 6 months. (Patients are followed from registration to death or study termination whichever occurs first.)

Interventionmonths (Median)
Stage 1: Dasatinib 200mg/Day6.5
Stage 1B: Dasatinib up to 400mg/Day8.9

[back to top]

Treatment Response Rates at Six Months

Best response is assessed using standard criteria for patients with malignant gliomas (Macdonald 1990) as reported by the site. Complete response (CR): Complete disappearance of all enhancing tumor on consecutive CT or MRI scans at least 1 month apart; off corticosteroids; neurologically stable/improved. Partial response (PR): ≥ 50% decrease in size of enhancing tumor on consecutive CT or MRI scans at least 1 month apart; corticosteroids stable/reduced; neurologically stable/improved. Stable disease (SD): Does not qualify for CR, PR, or PD. Progressive disease (PD): ≥ 25% increase in the size of enhancing tumor or any new tumor; neurologically worse; steroids stable/increased. The best tumor response is defined as the best radiographic response for patients evaluable for radiographic response prior to progression, up to six months. The study is not designed for a comparison of the treatment arms to each other. (NCT00423735)
Timeframe: From registration to 6 months

,
Interventionpercentage of participants (Number)
CR or PRStableProgressionNo scan done and no clinical progression reported
Stage 1: Dasatinib 200mg/Day0.019.076.24.8
Stage 1B: Dasatinib up to 400mg/Day0.027.669.03.4

[back to top]

Rate of Adverse Events

The rate of patients' worst overall grade of adverse event is reported. Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. The study is not designed for a comparison of the treatment arms to each other. (NCT00423735)
Timeframe: Analysis occurs after all patients have been on study for at least 6 months. (Patients are followed from registration to death or study termination whichever occurs first.)

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3Grade 4Grade 5
Stage 1: Dasatinib 200mg/Day0.014.357.114.314.3
Stage 1B: Dasatinib up to 400mg/Day10.317.244.83.417.2

[back to top]

Correlation of Molecular Markers and Tumor Response

The following markers were examined: p-SRC, PDGFR, EPHA2, c-KIT. Patients were categorized based on the number of positive molecular markers they had: 2 vs. 3 and 4. Correlation of marker category and best tumor response was tested using Fisher's exact test. The best tumor response is defined as the best radiographic response for patients evaluable for radiographic response prior to progression up to six months. Patients are combined from the two treatment arms. (NCT00423735)
Timeframe: From registration to 6 months

,
InterventionParticipants (Count of Participants)
2 postivie molecular markers3 or 4 positive molecular markers
Progressive Disease1323
Stable Disease48

[back to top]

Progression-free Survival

Progression-free survival time is measured from randomization to the date of first progression or death, else the last follow-up date on which the patient was reported alive, and is estimated by the Kaplan-Meier method. Progression is defined as ≥ 25% increase in the size of enhancing tumor or any new tumor, neurologically worse, or steroids stable/increased. The study is not designed for a comparison of the treatment arms to each other. (NCT00423735)
Timeframe: Analysis occurs after all patients have been on study for at least 6 months. (Patients are followed from registration to death or study termination whichever occurs first.)

Interventionmonths (Mean)
Stage 1: Dasatinib 200mg/Day1.7
Stage 1B: Dasatinib up to 400mg/Day1.8

[back to top]

Number of Patients Achieving Objective Response (Partial or Complete Response) OR 6-month Progression-free Survival (6mPFS)

Study design and efficacy determination uses the hybrid endpoint of 6mPFS or complete/partial response of any duration prior to or at 6 months. Null hypothesis = 11%; alternative hypothesis = 25%. Simon's minmax 2-stage design was used with type I and type II error both set at 10%. Stage 1 and 1B: If 2 or fewer patients were alive and progression-free at 6 months or achieved complete/partial response, then there would be no further accrual and the alternative hypothesis would be rejected. Otherwise accrual would continue to a total of 50 analyzable patients to address the primary endpoint. Complete Response: Complete disappearance of all enhancing tumor on consecutive CT or MRI scans at least 1 month apart; off corticosteroids; neurologically stable/improved. Partial Response: ≥ 50% decrease in size of enhancing tumor on consecutive CT or MRI scans at least 1 month apart; corticosteroids stable/reduced; neurologically stable/improved. (NCT00423735)
Timeframe: Registration to 6 months

Interventionparticipants (Number)
Stage 1: Dasatinib 200mg/Day1
Stage 1B: Dasatinib up to 400mg/Day2

[back to top]

Number of Patients Achieving 6-month Progression-free Survival (6mPFS)

This study utilized a two-stage phase II design (Stage 1B and 2). The primary endpoint of 6-month progression-free survival (6mPFS) would be assessed based on the patients combined from 1B and 2 if the study continued to Stage 2. Null hypothesis = 11%; alternative hypothesis = 25%. Simon's minmax 2-stage design was used with type I and type II error both set at 10%. If the first stage met its criteria (see secondary outcome measure), then accrual would continue, otherwise there would be no further accrual and the alternative hypothesis would be rejected. Following Stage 2 accrual completion and 6 months of follow-up, if 9 or more patients were alive without progression by 6 months, the null hypothesis would be rejected in favor of the alternative. (NCT00423735)
Timeframe: Registration to 6 months

Interventionparticipants (Number)
Stage 1: Dasatinib 200mg/Day1
Stage 1B: Dasatinib up to 400mg/Day2

[back to top]

Duration of Response

Duration of response is measured from the first date that criteria are met for complete response or partial response until the first date that criteria for relapse or progressive disease are met. (NCT00429949)
Timeframe: Completion of treatment (median duration of therapy was 51 days)

Interventioncycles (Number)
Dasatinib3

[back to top]

Event-free Survival (EFS) for Participants With Plateau Phase Disease

EFS is defined as time from the start of the treatment until the first date that criteria for progressive disease are met, therapy was discontinued for toxicity, or death, whichever occurs first. Those patients alive will be censored at the date of last clinical contact. If progression is based upon serum or urine paraprotein measurements, which must be repeated for confirmation, event-free progression is still measured from the start of treatment until the first date that progression is detected. (NCT00429949)
Timeframe: Completion of treatment (median duration of therapy was 51 days)

Interventiondays (Median)
Dasatinib138

[back to top]

Event-free Survival (EFS) for Participants With Relapsed Disease

EFS is defined as time from the start of the treatment until the first date that criteria for progressive disease are met, therapy was discontinued for toxicity, or death, whichever occurs first. Those patients alive will be censored at the date of last clinical contact. If progression is based upon serum or urine paraprotein measurements, which must be repeated for confirmation, event-free progression is still measured from the start of treatment until the first date that progression is detected. (NCT00429949)
Timeframe: Completion of treatment (median duration of therapy was 51 days)

Interventiondays (Median)
Dasatinib31

[back to top]

Time to Response

Time to response is measured from the start of treatment until the first date that criteria are met for complete response or partial response. (NCT00429949)
Timeframe: Completion of treatment (median duration of therapy was 51 days)

Interventioncycles (Number)
Dasatinib5

[back to top]

Response Rate [Complete Response (CR) and Partial Response (PR)]

"CR requires all of the following:~Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 weeks. The presence of oligoclonal bands consistent with oligoclonal immune response reconstitution does not exclude CR.~< 5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if biopsy is performed. If absence of monoclonal protein is sustained for 6 weeks it is not necessary to repeat the bone marrow.~No increase in the size or number of lytic bone lesions (development of a compression fracture does not exclude response).~Disappearance of soft tissue plasmacytoma~PR requires all of the following:~50% reduction in the level of the serum monoclonal paraprotein maintained for a minimum of 6 weeks.~-Reduction in 24 hr urinary light chain excretion by either > 90% or to < 200 mg, maintained for a minimum of 6 weeks.~50% reduction in the size of soft tissue plas" (NCT00429949)
Timeframe: Completion of treatment (median duration of therapy was 51 days)

,
Interventionparticipants (Number)
Complete responsePartial response
Dasatinib 100 mg BID01
Dasatinib 70 mg BID00

[back to top]

Safety and Tolerability of Dasatinib (Grade III-IV Toxicities)

Toxicities were graded using the NCI Common Toxicity Criteria v3.0. (NCT00429949)
Timeframe: Up to 30 days following end of treatment (median duration of therapy was 51 days)

Interventionparticipants (Number)
Grade III anemiaGrade III neutropeniaGrade III thrombocytopeniaGrade IV thrombocytopeniaGrade III epistaxisGrade III gastrointestinal bleedGrade III acute renal failureGrade III headacheGrade III aphasia due to laryngeal plasmacytomaGrade III neuropathyGrade III fatigueGrade III hypertensionGrade III diarrheaGrade III leg/hip painGrade III generalized painGrade III hypercalcemiaGrade IV hypoglycemiaGrade IV hyperglycemiaGrade III pneumoniaGrade III pulmonary edemaGrade III pneumonitis/pulmonary infiltratesGrade III pulmonary hypertensionGrade III hypoxiaGrade III dyspneaGrade IV dyspnea
Dasatinib5223212111111131113121111

[back to top]

Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria

Only those patients who have measurable disease present at baseline, have received at least one course of therapy, and have had their disease re-evaluated will be considered evaluable for response. A Simon's optimum two-stage design will be used. (NCT00436605)
Timeframe: After every 8 weeks (or 2 courses), assessed up to 4 weeks after completion of treatment

Interventionparticipants (Number)
Treatment (Kinase Inhibitor Therapy)2

[back to top]

Progression-free Survival

Progression will be evaluated in this study using the new international criteria proposed by the RECIST Committee. A Simon's optimum two-stage design will be used (NCT00436605)
Timeframe: Time from start treatment to time of progression, assessed up to 6 months

Interventionweeks (Mean)
Treatment (Kinase Inhibitor Therapy)8

[back to top]

Median Time to Disease Progression

The median time to disease progression, measured from the start of treatment. (NCT00438854)
Timeframe: 1 year

InterventionMonths (Median)
Dasatinib Treatment7.5

[back to top]

Median Overall Survival

The median survival time, as measured from the start of treatment until death from any cause. (NCT00438854)
Timeframe: 3 years

InterventionMonths (Median)
Dasatinib Treatment27

[back to top]

Complete Response Rate

The number of participants with a 100% reduction in nodal mass. (NCT00438854)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Dasatinib Treatment0

[back to top]

Overall Objective Response

"Overall objective response rate in terms of complete response, nodular partial response, and partial response to treatment. Objective response is when a biopsy shows. In general response is defined as the following (not complete criteria):~Complete response (CR) requires all of the following for a period of at least 2 months:~Absence of lymphadenopathy~No hepatomegaly or splenomegaly~Absence of constitutional symptoms~Normal complete blood count~Nodular partial response (nPR): Met the criteria for CR, but had residual bone marrow biopsy nodules as the only evidence of disease~Partial response (PR): requires at least the following:~50% decrease in peripheral blood lymphocyte count~50% reduction in lymphadenopathy~50% reduction in the size of the liver and/or spleen" (NCT00438854)
Timeframe: 2 years

Interventionparticipants who responded (Number)
Dasatinib Treatment3

[back to top]

Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity (AUC[Inf]) of Docetaxel

(NCT00439270)
Timeframe: Cycle 1, Day 1 at 0, 0.5, 1, 1.25, 1.5, 2, 3, 4, 7, 10, 24, and 48 hours postdose

Interventionng.h/mL (Geometric Mean)
Dasatinib, 50 mg + Docetaxel, 60 mg/m^23085.59
Dasatinib, 50 mg + Docetaxel, 75 mg/m^22064.49
Dasatinib, 70 mg + Docetaxel, 75 mg/m^22113.37
Dasatinib, 100 mg + Docetaxel, 75 mg/m^22663.83
Dasatinib, 120 mg + Docetaxel, 75 mg/m^23283.27

[back to top] [back to top]

Number of Months of Progression-free Survival (PFS)

"PFS defined as time in months from the first dosing date to the date of disease progression or the date of death. Patients who neither progressed nor died were censored on the date of their last on-study prostate specific antigen (PSA) measurement, tumor assessment, or radionuclide bone scan assessment (whichever occurred last). Disease progression defined as either of the following: progression on radionuclide bone scan, death, or at least 2 of the following:~tumor progression, as defined by modified Response Evaluation Criteria in Solid Tumors; PSA progression; or investigator-defined clinical progression based on physical examination, history, symptoms, and performance status." (NCT00439270)
Timeframe: Patients with an event: time from first dose to disease progression or death, whichever occurs first. Patients without an event: time to last on-study PSA measurement, tumor assessment, or radionuclide bone scan assessment, whichever occurs last

InterventionMonths (Median)
Dasatinib, 100 mg + Docetaxel, 75 mg/m^211.5

[back to top]

Duration of Prostate Specific Antigen (PSA) Response

Duration of response is computed for participants with confirmed PSA response. It is measured in months from the time of the first of 2 consecutive measurements meeting the criteria for confirmed PSA response to the date of the first of 3 consecutive measurements that confirm PSA progression, the date of disease progression, or the date of death. Participants who neither progressed (PSA or disease) nor died were censored on the date of their last PSA assessment. PSA response is defined as a decrease of >=50% in PSA levels from baseline, sustained for at least 6 weeks and confirmed by at least 2 measurements. PSA progression is defined as 3 consecutive increases in PSA from baseline or nadir, each measurement at least 1 week apart. The final confirming PSA measurement had to be ≥5ng/mL higher than baseline or nadir and also represent at least a 50% increase from baseline or nadir (ie, the value is ≥1.5*baseline or nadir PSA). (NCT00439270)
Timeframe: At pretreatment visit, and on Day 1 of Cycles 2 through 12, then every other cycle, where investigator deems appropriate, and at end of treatment

InterventionMonths (Median)
Dasatinib, 100 mg + Docetaxel, 75 mg/m^29.5

[back to top]

Maximum Tolerated Dose (MTD) of Dasatinib Administered With Docetaxel

MTD was defined by dose-limiting toxicity (DLT) criteria. DLT was defined as grade 4 neutropenia causing treatment interruption for >14 days, febrile neutropenia, grade 4 thrombocytopenia, grade 3 thrombocytopenia with a bleeding episode requiring platelet transfusion, nausea and/or vomiting despite medical intervention/prophylaxis causing treatment interruption for >14 days, grade 3-4 asthenia/fatigue, any other grade >=3 nonhematologic toxicity except alopecia or transient arthralgia/myalgia (unless unresponsive to intervention), or interruption of study drug for >14 days due to toxicity. When defined, the MTD would serve as recommended Phase 2 dose of each drug in the combination of oral dasatinib and intravenous docetaxel. (NCT00439270)
Timeframe: From Day 3 of first 21-day cycle to Cycle 2 , Day 21 (or Study Day 42)

Interventionmg (Number)
All Treated (Phase 1)NA

[back to top]

Percentage of Participants With a Prostate Specific Antigen (PSA) Response

PSA response rate is defined as a decrease of >=50% in PSA levels from baseline, sustained for at least 6 weeks and confirmed by at least 2 measurements (NCT00439270)
Timeframe: At pretreatment visit, and on Day 1 of Cycles 2 through 12, then every other cycle, where investigator deems appropriate, and at end of treatment (up to 51.6 months)

InterventionPercentage of participants (Number)
Dasatinib, 100 mg + Docetaxel, 75 mg/m^264.7

[back to top]

Percentage of Participants With an Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)

Objective response rate is defined as the percentage of participants who have achieved best responses of confirmed Complete Response (CR) or Partial Response (PR) where confirmed requires repeat evaluations for a minimum of 4 weeks after the criteria for response are first met. RECIST: CR=disappearance of clinical and radiologic evidence of target lesions; PR=a 30% or greater decrease in the sum of the longest diameter (LD) of all lesions in reference to the baseline sum LD. (NCT00439270)
Timeframe: Pretreatment visit then every 6 weeks thereafter (up to 51.6 months)

InterventionPercentage of participants (Number)
Dasatinib, 100 mg + Docetaxel, 75 mg/m^244.1

[back to top]

Percentage of Participants With Improvement on Bone Scan

Improvement=disappearance of at least 1 lesion, no new lesions appearing since the most recent prior assessment, and new pain not developing in an area that was previously visualized (NCT00439270)
Timeframe: From Day 1 of therapy to last bone scan assessment (up to 51.6 months)

InterventionPercentage of participants (Number)
Dasatinib, 100 mg + Docetaxel, 75 mg/m^223.5

[back to top] [back to top]

Area Under the Concentration-time Curve (AUC) From 0 to 10 Hours Postdose (AUC [0-10])and AUC in 1 Dosing Interval, From Time 0 to 24 Hours (AUC[Tau])of Dasatinib Coadministered With Docetaxel

(NCT00439270)
Timeframe: Cycle 1, Day 14 at 0, 0.5 , 1, 2, 3, 4, 7, 10, and 24 hours postdose

,,,,
Interventionng.h/mL (Geometric Mean)
AUC(0-10) (n=3, 1, 3, 28, 3)AUC(tau) (n=3, 1, 3, 21, 3)
Dasatinib, 100 mg + Docetaxel, 75 mg/m^2277.07389.66
Dasatinib, 120 mg + Docetaxel, 75 mg/m^2461.82556.47
Dasatinib, 50 mg + Docetaxel, 60 mg/m^2173.13205.43
Dasatinib, 50 mg + Docetaxel, 75 mg/m^271.7582.20
Dasatinib, 70 mg + Docetaxel, 75 mg/m^2149.79200.63

[back to top]

Baseline Scores and Changes in Pain Intensity From Baseline on the Brief Pain Inventory Short Form (BPI-sf) Scores Through Cycle 6

The BPI-sf assessed intensity of pain in the last 24 hours as well as impact of pain on daily functions. Patients rated the severity of their pain at its worst, least, and average in the last 24 hours using an 11-point rating scale with endpoints of no pain (0 points) and pain as bad as you can imagine (11 points). They were asked to rate their present pain and pain at the time they completed the BPI-sf. Using an 11-point rating scale with endpoints of does not interfere (0 points) and completely interferes (11 points), the BPI-sf similarly assessed to what extent pain interfered with mood, walking, general activity, work, relations with others, sleep, and enjoyment of life. The BPI-sf also asked patients to mark the location of their pain on a body drawing and included other questions about pain treatment and the extent of pain relief. The BPI-sf was collected in the Phase 2 portion of the study only. For on-treatment visits, the BPI-sf was completed prior to the docetaxel infusion. (NCT00439270)
Timeframe: At pretreatment visit and on Day 1 of Cycles 2 through 6, then Day 1 of every other cycle, at end of treatment, and at follow-up visit

InterventionUnits on a scale (Median)
Baseline: Average of pain (n=18)Baseline: Average of pain interference (n=18)Cycle 2: Average of pain (n=11)Cycle 2: Average of pain interference (n=11)Cycle 3: Average of pain (n=7)Cycle 3: Average of pain interference (n=7)Cycle 4: Average of pain (n=10)Cycle 4: Average of pain interference (n=10)Cycle 5: Average of pain (n=5)Cycle 5: Average of pain interference (n=5)Cycle 6: Average of pain (n=9)Cycle 6: Average of pain interference (n=9)
Dasatinib, 100 mg + Docetaxel, 75 mg/m^2 (Phase 2 )1.01.0-0.80.0-0.5-0.0-1.0-0.1-0.80.0-0.80.0

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Dasatinib and of Docetaxel

(NCT00439270)
Timeframe: Docetaxel: Cycle 1, Day 1 at 0, 0.5, 1, 1.25, 1.5, 2, 3, 4, 7, 10, 24, and 48 hours postdose; dasatanib: Cycle 1, Day 14 at 0, .5, 1, 2, 3, 4, 7, 10, and 24 hours postdose

,,,,
Interventionng/mL (Geometric Mean)
Dasatinib (n=3, 1, 3, 29, 3)Docetaxel (n=3, 3, 3, 34, 3)
Dasatinib, 100 mg + Docetaxel, 75 mg/m^283.912125.49
Dasatinib, 120 mg + Docetaxel, 75 mg/m^2164.992412.41
Dasatinib, 50 mg + Docetaxel, 60 mg/m^242.702226.25
Dasatinib, 50 mg + Docetaxel, 75 mg/m^221.991763.34
Dasatinib, 70 mg + Docetaxel, 75 mg/m^230.001748.43

[back to top]

Number of Participants by Best On-study Bone Scan Assessment From Baseline

Stable=no new lesions appeared at any 6-week assessment or new pain was not developed in an area that was previously visualized for a minimum of 18 weeks; no change=stable disease prior to 18 weeks and then discontinued treatment; progression=2 or more new areas of focal uptake or new adverse clinical symptoms in an area previously visualized; improved=disappearance of at least 1 lesion, no new lesions appearing since the most recent prior assessment, and new pain not developing in an area that was previously visualized. (NCT00439270)
Timeframe: From Day 1 of therapy to last bone scan assessment (up to 51.6 months)

InterventionParticipants (Number)
ImprovedStableNo changeProgressionNot evaluable
Dasatinib, 100 mg + Docetaxel, 75 mg/m^2817711

[back to top]

Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)

"RECIST for target lesions: Complete Response (CR)=disappearance of clinical and radiologic evidence of target lesions. Partial Response (PR)=a 30% or greater decrease in the sum of the longest diameter (LD) of all lesions in reference to the baseline sum LD. Stable disease (SD)=neither sufficient increase to qualify for Progressive Disease (PD) nor sufficient shrinkage to qualify for PR.~PD=a 20% or greater increase in the sum of LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline; unequivocal progression of nonmeasurable disease/lesions as evaluated by CT scan or MRI (not as evaluated by radionuclide bone scan) and/or new lesions are present.~To qualify as SD, patients had to exhibit SD for a minimum of 18 weeks. Those with evaluations noted as SD prior to 18 weeks and discontinued were reported as no change." (NCT00439270)
Timeframe: Pretreatment visit then every 6 weeks thereafter (up to 51.6 months)

InterventionParticipants (Number)
Complete responsePartial responseStable diseaseNo changeProgressive diseaseNot evaluable
Dasatinib, 100 mg + Docetaxel, 75 mg/m^201513213

[back to top]

Number of Participants Meeting the Criteria for On-study Abnormal Results Grade 3-4 of Clinical Laboratory Tests

ULN=upper limit of normal. Graded by Common Toxicity Criteria: 1 (least severe) to 4 (life threatening ). Absolute neutrophil count (*10^9/L), Grade 3, <1.0-0.5; Grade 4, <0.5. Hemoglobin (mmol/L), Grade 3, <4.9-4.0; Grade 4, <4.0. Platelets (*10^9/L), Grade 3, <50.0-25.0; Grade 4, <25.0. Leukocytes (*10^9/L) Grade 3, <2.0-1.0; Grade 4, <1.0. ALP, ALT, and AST (*ULN), Grade 3, >5.0-20.0; Grade 4, >20.0. Total bilirubin (*ULN), Grade 3, >3.0-10.0; Grade 4, >10.0. Creatinine (*ULN), Grade 3, >3.0-6.0; Grade 4, >6.0. Hypercalcemia (mmol/L), Grade 3, >3.1-3.4; Grade 4, >3.4. Hypocalcemia mmol/L), Grade 3, <1.75-1.5; Grade 4, <1.5. Hyperkalemia (mmol/L), Grade 3, >6.0-7.0; Grade 4, >7.0. Hypokalemia (mmol/L), Grade 3, <3.0-2.5; Grade 4, <2.5. Hypernatremia (mmol/L), Grade 3, >155-160; Grade 4, >160. Hyponatremia (mmol/L), Grade 3, <130-120; Grade 4, <120. Phosphorus (mmol/L), Grade 3, <0.6-0.3; Grade 4, <0.3. Prothrombin time (seconds), Grade 3, >2.0; Grade 4, not defined. (NCT00439270)
Timeframe: From Day 2 of Cycle 1 to up to 30 days after last dose of study drug (up to approximately 49 months)

,,,,
InterventionParticipants (Number)
Absolute neutrophil countHemoglobinPlatelet countLeukocytesAlanine aminotransferase (ALT)Aspartate aminotransferase (AST)Alkaline phosphatase (ALP)Total bilirubinHypercalcemiaHypocalcemiaCreatinineHyperkalemiaHypokalemiaHypernatremiaHyponatremiaPhosphorus, inorganicProthrombin time
Dasatinib, 100 mg + Docetaxel, 75 mg/m^210000010010100210
Dasatinib, 120 mg + Docetaxel, 75 mg/m^200000000000010000
Dasatinib, 50 mg + Docetaxel, 60 mg/m^200000010000000000
Dasatinib, 50 mg + Docetaxel, 75 mg/m^200000010000000010
Dasatinib, 70 mg + Docetaxel, 75 mg/m^200000000000000000

[back to top] [back to top]

Objective Response Rate (ORR) and Disease Control Rate - Efficacy Evaluable Population

Objective response rate was the percentage of participants, (n/N; number with objective response per Number evaluated) whose best response is either a Complete Response (CR) or a Partial Response (PR). Disease control rate was defined as percentage (n/N) of participants with stable disease greater than (>) 6 months, PR, or CR. Efficacy Evaluable Population: All participants with at least one measurable lesion at baseline, who received at least one dose of combination study drug and have at least one on-study tumor assessment or stopped study treatment prior to first assessment, were evaluated. Those who stop treatment prior to tumor assessment for reasons unrelated to disease or drug were excluded. (NCT00452673)
Timeframe: Day 1 up to 30 days post last dose

,,,
Interventionpercentage of participants (Number)
Objective Response RateDisease control rate
100 mg Dasatinib + 1000 mg/m^2Capecitabine24.056.00
50 mg Dasatinib + 825 mg/m^2Capecitabine50.075.0
70 mg Dasatinib + 1000 mg/m^2Capecitabine040.0
70 mg Dasatinib + 825 mg/m^2Capecitabine16.6733.33

[back to top]

Number of Participants On-Study With Grade 3 - 4 Hematology Laboratory Test Values in Those Participants With a Baseline Laboratory Value of Grade 0 - Safety Population

National Cancer Institute Common terminology criteria (CTC), Version 3 used to assess parameters. Lower limit of normal (LLN). CTC criteria: Absolute neutrophil count (ANC). Leukocytes (White blood cells) Grade (Gr) 1:NCT00452673)
Timeframe: Day 1 up to 30 days post last dose

,,,
Interventionparticipants (Number)
Leukocytes ( N=7, 9, 5, 29)ANC (N=6, 9, 6, 30)Platelet Count (N=7, 9, 6, 30)Hemoglobin (N=7, 6, 4, 18)
100 mg Dasatinib + 1000 mg/m^2Capecitabine1313
50 mg Dasatinib + 825 mg/m^2Capecitabine0000
70 mg Dasatinib + 1000 mg/m^2Capecitabine0000
70 mg Dasatinib + 825 mg/m^2Capecitabine0000

[back to top]

Number of Participants With Overall Response to Tumor - Efficacy Evaluable Population

Complete Response (CR): disappearance of all target and non-target lesions, with confirmation at >=4 weeks interval; Partial Response (PR): >= 30% decrease in sum of longest diameter (LDs) of target lesions, taking as reference the baseline sum LD, with confirmation at >= 4 weeks interval. Progressive Disease (PD): Appearance of new lesion(s), or >=20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since treatment start, or unequivocal progression of existing non-target lesions. Stable disease was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, without unequivocal progression of non-target lesions, after >=6 weeks on study. Radiological tumor assessment by computed tomography (CT) or magnetic resonance imaging (MRI) occurred every 6 weeks. For those patients who were on treatment > 24 weeks, the tumor assessment occurred every 9 weeks. (NCT00452673)
Timeframe: Day 1 to 30 days post last dose

,,,
Interventionparticipants (Number)
Complete ResponseUnconfirmed partial responsePartial ResponseStable DiseaseProgressive DiseaseClinical ProgressionDiscontinuation due to study drug toxicity
100 mg Dasatinib + 1000 mg/m^2Capecitabine03611311
50 mg Dasatinib + 825 mg/m^2Capecitabine0120100
70 mg Dasatinib + 1000 mg/m^2Capecitabine0102200
70 mg Dasatinib + 825 mg/m^2Capecitabine0111210

[back to top]

Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population

Adverse events (AEs) were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious AE (SAE)=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. (NCT00452673)
Timeframe: Day 1 up to 30 days post last dose

,,,
Interventionparticipants (Number)
Deaths within 30 days of last doseDeaths reported beyond 30 days post last doseParticipants with SAEsParticipants with Grade 3 - 4 SAEsParticipants with AEsAEs leading to discontinuation of therapyParticipants with study drug-related AEs
100 mg Dasatinib + 1000 mg/m^2Capecitabine04131130428
50 mg Dasatinib + 825 mg/m^2Capecitabine0022727
70 mg Dasatinib + 1000 mg/m^2Capecitabine0044646
70 mg Dasatinib + 825 mg/m^2Capecitabine0021939

[back to top]

Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population

Safety was assessed from first dose of study drug through at least 30 days after the last dose, until resolution of drug-related toxicity or when toxicity was deemed irreversible, whichever was longer. An adverse event (AE) was considered a dose limiting toxicity (DLT) if it occurred in the first 21 days and was at least possibly related to study drugs and were: Clinically-evident toxicity of Grade >= 3, or of Grade 2 which required interruption of treatment for >= 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory value of Grade >= 3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which in the judgment of the investigator required a dose reduction or removal from further study therapy. (NCT00452673)
Timeframe: Day 1 to 30 days post last dose

Interventionparticipants (Number)
50 mg Dasatinib + 825 mg/m^2Capecitabine1
70 mg Dasatinib + 825 mg/m^2Capecitabine1
70 mg Dasatinib + 1000 mg/m^2Capecitabine1
100 mg Dasatinib + 1000 mg/m^2Capecitabine2

[back to top]

Number of Participants On-study With Grade 3 - 4 Chemistry Laboratory Values in Those Participants With a Baseline Laboratory Value of Grade 0 - Safety Population

CTC, Version 3 used to assess parameters. (ULN)=upper limit of normal: (ALT)= alanine transaminase; (AST)=aspartate aminotransferase; (ALP)=alkaline phosphatase. ALT Grade (Gr)1:>ULN to 2.5*ULN; Gr 2: >2.5 to 5.0*ULN; Gr 3: >5.0 to 20.0*ULN; Gr 4: >20.0*ULN. AST Gr 1: >ULN to 2.5*ULN; Gr 2: >2.5 to 5.0*ULN; Gr 3: >5.0 to 20.0*ULN; Gr 4: >20.0*ULN. Total bilirubin Gr 1: >ULN to 1.5*ULN; Gr 2: >1.5 to 3.0*ULN; Gr 3: >3.0 to 10.0*ULN; Gr 4: >10.0*ULN. ALP (U/L) Gr1:>ULN to 2.5*ULN, Gr2:>2.5 to 5.0*ULN, Gr3:>5.0 to 20.0*ULN, Gr4:>20.0*ULN. Albumin (low) Gr 1:NCT00452673)
Timeframe: Day 1 to 30 days post last dose

,,,
Interventionparticipants (Number)
Alkaline Phosphatase (N=4, 6, 5, 21)Alanine Aminotransferase (N=6, 9, 6, 25)Aspartate Aminotransferase (N=4, 8, 6, 25)Total Bilirubin (N=6, 9, 6, 29)
100 mg Dasatinib + 1000 mg/m^2Capecitabine0210
50 mg Dasatinib + 825 mg/m^2Capecitabine0000
70 mg Dasatinib + 1000 mg/m^2Capecitabine0000
70 mg Dasatinib + 825 mg/m^2Capecitabine0000

[back to top]

Overall Survival

Estimated using the product-limit method of Kaplan and Meier. (NCT00459108)
Timeframe: Up to 4 years

InterventionMonths (Median)
Oral Dasatinib7.5

[back to top]

Response Rate (Complete and Partial Response)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Response = CR + PR (NCT00459108)
Timeframe: 4 months

Interventionpercentage of responding patients (Number)
Oral Dasatinib0

[back to top]

Median Progression-free Survival

Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00459108)
Timeframe: Until disease progression or death, up to 4 years

InterventionMonths (Median)
Oral Dasatinib3.7

[back to top]

Four Month Progression-free Survival (PFS)

Progression-free survival calculated using the method of Kaplan-Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00459108)
Timeframe: 4 months

Interventionpercentage of participants (Number)
Oral Dasatinib40

[back to top]

Safety and Tolerability

Summarize observed grade 3 and higher toxicities related to dasatanib. The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 were used for reporting. (NCT00459108)
Timeframe: Up to 4 years

Interventionparticipants (Number)
Grade 3 : AST, SGOTGrade 3 : AnorexiaGrade 3 : Sudden deathGrade 3 : DehydrationGrade 3 : DiarrheaGrade 3 : DizzinessGrade 3 : Edema:head and neckGrade 3 : Fatigue (asthenia, lethargy, malaise)Grade 3 : Glucose, serum-high (hyperglycemia)Grade 3 : HemoglobinGrade 3 : Hemorrhage, GI - ColonGrade 3 : Hemorrhage, GI - StomachGrade 3 : Infection with normal ANCGrade 3 : Leukocytes (total WBC)Grade 3 : LymphopeniaGrade 3 : NauseaGrade 3 : Pain - Head/headacheGrade 3 : Pain - Middle earGrade 3 : Phosphate, serum-low (hypophosphatemia)Grade 3 : PlateletsGrade 3 : Pneumonitis/pulmonary infiltratesGrade 3 : Potassium, serum-low (hypokalemia)Grade 3 : ProteinuriaGrade 3 : Sodium, serum-low (hyponatremia)Grade 3 : Thrombotic microangiopathyGrade 3 : Urinary retentionGrade 3 : VomitingGrade 4 : AST, SGOTGrade 4 : AnorexiaGrade 4 : Sudden deathGrade 4 : DehydrationGrade 4 : DiarrheaGrade 4 : DizzinessGrade 4 : Edema:head and neckGrade 4 : Fatigue (asthenia, lethargy, malaise)Grade 4 : Glucose, serum-high (hyperglycemia)Grade 4 : HemoglobinGrade 4 : Hemorrhage, GI - ColonGrade 4 : Hemorrhage, GI - StomachGrade 4 : Infection with normal ANCGrade 4 : Leukocytes (total WBC)Grade 4 : LymphopeniaGrade 4 : NauseaGrade 4 : Pain - Head/headacheGrade 4 : Pain - Middle earGrade 4 : Phosphate, serum-low (hypophosphatemia)Grade 4 : PlateletsGrade 4 : Pneumonitis/pulmonary infiltratesGrade 4 : Potassium, serum-low (hypokalemia)Grade 4 : ProteinuriaGrade 4 : Sodium, serum-low (hyponatremia)Grade 4 : Thrombotic microangiopathyGrade 4 : Urinary retentionGrade 4 : VomitingGrade 5 : AST, SGOTGrade 5 : AnorexiaGrade 5 : Sudden deathGrade 5 : DehydrationGrade 5 : DiarrheaGrade 5 : DizzinessGrade 5 : Edema:head and neckGrade 5 : Fatigue (asthenia, lethargy, malaise)Grade 5 : Glucose, serum-high (hyperglycemia)Grade 5 : HemoglobinGrade 5 : Hemorrhage, GI - ColonGrade 5 : Hemorrhage, GI - StomachGrade 5 : Infection with normal ANCGrade 5 : Leukocytes (total WBC)Grade 5 : LymphopeniaGrade 5 : NauseaGrade 5 : Pain - Head/headacheGrade 5 : Pain - Middle earGrade 5 : Phosphate, serum-low (hypophosphatemia)Grade 5 : PlateletsGrade 5 : Pneumonitis/pulmonary infiltratesGrade 5 : Potassium, serum-low (hypokalemia)Grade 5 : ProteinuriaGrade 5 : Sodium, serum-low (hyponatremia)Grade 5 : Thrombotic microangiopathyGrade 5 : Urinary retentionGrade 5 : Vomiting
Oral Dasatinib220210181211112321311113113000001010100000000000000000001000000000000000000000000

[back to top]

Phospho-Src (pSrc) Expression

(NCT00459342)
Timeframe: Baseline

Interventionparticipants (Number)
pSrc positivepSrc negativepSrc unknown
Dasatinib101113

[back to top]

Epidermal Growth Factor Receptor (EGFR) Copy Number

(NCT00459342)
Timeframe: Baseline

Interventionparticipants (Number)
EGFR amplfiedEGFR not amplifiedEGFR copy number unknown
Dasatinib31714

[back to top]

Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR))

Objective response defined as participants with Complete Response (CR) or Partial Response (PR) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. RECIST definitions are Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Response measured by tumor size on computed tomography scans and by metabolic activity on positron emission tomography scans. (NCT00459342)
Timeframe: 12 weeks

Interventionparticipants (Number)
Partial RemissionStable DiseaseProgressive Disease
Dasatinib11217

[back to top]

Epidermal Growth Factor Receptor (EGFR) Mutational Status

(NCT00459342)
Timeframe: Baseline

Interventionparticipants (Number)
EGFR mutantEGFR wild typeEGFR not tested
Dasatinib9223

[back to top]

Time to Progression (TTP)

(NCT00459342)
Timeframe: Time from start of treatment to time of progression or death, assessed radiographically every 6 weeks

Interventiondays (Mean)
Dasatinib92

[back to top]

Progression-free Survival (PFS)

Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death. (NCT00459342)
Timeframe: Time from start of treatment to time of progression or death, assessed at 2 months

Interventionmonths (Median)
Dasatinib1.36

[back to top]

Number of Participants With Tumors With Kinase Expression

Obtain tumor tissue for creation of tissue microarrays to examine the frequency of kinase expression such as SRC and/or FAK in leiomyosarcoma, liposarcoma, osteosarcoma, MFH, rhabdomyosarcoma, MPNST, chondrosarcoma, Ewing's, Alveolar soft part sarcoma (ASPS), chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma, and GIST if activity of the drug in a subtype warrants further study. The outcome measure demonstrates the number of participants who had tissue that was able to generate tissue microarray for kinase expression. (NCT00464620)
Timeframe: Up to 37 weeks

InterventionParticipants (Count of Participants)
Osteosarcoma11
Leiomyosarcoma24
MFH/Undifferentiated Pleomorphic Sarcoma16

[back to top]

"Median Time-to-progression of Subjects With Indolent Sarcomas Treated With Dasatinib."

"To estimate the median time-to-progression of subjects with indolent sarcomas treated with dasatinib." (NCT00464620)
Timeframe: Up to 24 months

Interventionmonths (Median)
Indolent Subtype: Dasatinib, 70 mg, Twice Daily5.8

[back to top]

Number of Participants With Tumors With Mutations in Kinases

Obtain tumor tissue to examine the frequency of mutations in kinases such as PDGFR in leiomyosarcoma, liposarcoma, osteosarcoma, MFH, rhabdomyosarcoma, MPNST, chondrosarcoma, Ewing's, ASPS, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma and GIST if activity of the drug in a subtype warrants further study. The outcome measure demonstrates the tissue that was able to generate tissue microarray for PDGFR analysis. (NCT00464620)
Timeframe: Up to 37 weeks

InterventionParticipants (Count of Participants)
Osteosarcoma11
Leiomyosarcoma24
MFH/Undifferentiated Pleomorphic Sarcoma16

[back to top]

Response Rate: Number of Participants With Objective Tumor Response

Assessment of objective tumor response for response rate with MRI or CT using Choi criteria: Complete Remission (CR) Complete disappearance of all measurable and evaluable disease for at least 4 weeks; Partial Remission (PR) A 10% or greater decrease from the baseline in the sum of the largest diameters of all measurable target lesions. (NCT00464620)
Timeframe: Up to 24 months

InterventionParticipants (Count of Participants)
GIST: Dasatinib, 70 mg, Twice Daily12
Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily14
Indolent Subtype: Dasatinib, 70 mg, Twice Daily20

[back to top]

Median Time-to-progression of Subjects Enrolled in the Aggressive Subtype.

To estimate the median time-to-progression of subjects with leiomyosarcoma, liposarcoma, osteosarcoma including high-grade chondrosarcomas, Ewing's sarcoma, MFH, rhabdomyosarcoma and MPNST treated with dasatinib. (NCT00464620)
Timeframe: Up to 37 weeks

Interventionmonths (Median)
Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily1.9

[back to top]

6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST)

To estimate the 6 month progression-free survival rate of gastrointestinal stromal tumors (GIST). Progression is defined using Choi criteria, as a 10% or greater increase in the sum of all measurable target lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or unequivocal reappearance of any lesion which had disappeared, or appearance of any new lesions of greater than double slice thickness in size, or any new or enlarging solid nodule in a previously hypodense treated mass. (NCT00464620)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
GIST: Dasatinib, 70 mg, Twice Daily14

[back to top]

"6 Month Progression-free Survival Rate of Indolent Sarcomas Treated With Dasatinib"

"Estimate the 6 month progression-free survival rate of indolent sarcomas treated with dasatinib. Progression is defined using Choi criteria, as a 10% or greater increase in the sum of all measurable target lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or unequivocal reappearance of any lesion which had disappeared, or appearance of any new lesions of greater than double slice thickness in size, or any new or enlarging solid nodule in a previously hypodense treated mass." (NCT00464620)
Timeframe: At 6 months

InterventionParticipants (Count of Participants)
Indolent Subtypes: Dasatinib, 70 mg, Twice Daily52

[back to top]

Median Time-to-progression of Subjects With GIST Treated With Dasatinib.

To estimate the median time-to-progression of subjects with GIST treated with dasatinib. (NCT00464620)
Timeframe: Up to 30 months

Interventionmonths (Median)
GIST: Dasatinib, 70 mg, Twice Daily2.9

[back to top]

6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype.

To estimate the 6 month progression-free survival rate of subjects with leiomyosarcoma, liposarcoma, osteosarcoma including high-grade chondrosarcomas, Ewing's sarcoma, Malignant fibrous histiocytoma (MFH), rhabdomyosarcoma and MPNST treated with dasatinib. (NCT00464620)
Timeframe: At 6 months

InterventionParticipants (Count of Participants)
UPSLeiomyosarcomaOsteosarcomaRhabdomyosarcomaEwing's SarcomaLiposarcomaMPNST
Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily6550100

[back to top]

Overall Survival Rates at 2 and 5 Years From Registration of Subjects Enrolled in the Aggressive Subtype Treated With Dasatinib.

To estimate the overall survival rates at 2 and 5 years from registration of subjects enrolled in the aggressive subtype treated with dasatinib. (NCT00464620)
Timeframe: At 2 and 5 years

Interventionparticipants (Number)
Ewing's Sarcoma : 2 year overall survival rateEwing's Sarcoma : 5 year overall survival rateLeiomyosarcoma : 2 year overall survival rateLeiomyosarcoma : 5 year overall survival rateLiposarcoma : 2 year overall survival rateLiposarcoma : 5 year overall survival rateMPNST : 2 year overall survival rateMPNST : 5 year overall survival rateOsteosarcoma : 2 year overall survival rateOsteosarcoma : 5 year overall survival rateRhabdomyosarcoma : 2 year overall survival rateRhabdomyosarcoma : 5 year overall survival rateUPS : 2 year overall survival rateUPS : 5 year overall survival rate
Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily70212000015087266

[back to top]

Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib.

To estimate the overall survival rates at 2 and 5 years from registration of subjects treated with dasatinib. (NCT00464620)
Timeframe: At 2 and 5 years

,
InterventionParticipants (Count of Participants)
2 years overall survival5 years overall survival
GIST: Dasatinib, 70 mg, Twice Daily218
Indolent Subtype: Dasatinib, 70 mg, Twice Daily4814

[back to top]

Overall Survival

Overall survival (OS) was defined as the time from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00470054)
Timeframe: Time from registration to death (up to 3 years)

Interventionweeks (Median)
Dasatinib17

[back to top]

Number of Participants With Grade 3 or Higher Adverse Events

"The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 was used to evaluate toxicity.~Grade 1: mild; Grade 2: moderate; Grade 3: Severe; Grade 4: Life Threatening; Grade 5: Death." (NCT00470054)
Timeframe: Assessed during treatment

Interventionparticipants (Number)
Dasatinib12

[back to top]

Progression Free Survival (PFS)

"PFS was defined as the time from registration until disease progression or death, whichever occurs first. The median PFS with 95% CI was estimated using the Kaplan-Meier method.~Progression is defined as in the primary outcome measure." (NCT00470054)
Timeframe: Time from registration to progression (up to 3 years)

Interventionweeks (Median)
Dasatinib5.9

[back to top]

6 Week Progression Free Survival

"Percentage of patients who were alive and progression free at 6-weeks. The 6-week progression free survival was estimated using the Kaplan Meier method.~Progressive Disease was defined by the Response Evaluation Criteria In Solid Tumors (RECIST) criteria as 20% increase in sum of longest diameter of target lesions." (NCT00470054)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Dasatinib43

[back to top]

Response to Therapy

"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:~Complete Response (CR): disappearance of all target lesions;~Partial Response (PR) 30% decrease in sum of longest diameter of target lesions;~Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions;~Stable Disease (SD): small changes that do not meet above criteria." (NCT00470054)
Timeframe: Assessed every 2 cycles (up to 3 years)

Interventionparticipants (Number)
Complete ResponsePartial ResponseStable DiseaseProgressionInadequately assessed
Dasatinib007288

[back to top]

Gait Speed

Gait speed, determined by a 4 meter walk along a properly measured stretch of hallway while being timed with a stopwatch. (NCT00474812)
Timeframe: at 8 weeks

Interventionmeters per second (Mean)
Dasatinib Treatment4.6

[back to top]

Objective Response Rate (Complete Response, Partial Response, or Stable Disease), Evaluated Using the New International Criteria Proposed by the RECIST Committee

Response is defined as CR (Complete Response), PR (Partial Response) or SD (Stable Disease) per Response Evaluation Criteria in Solid Tumor (RECIST criteria). Possible evaluations include: CR: Disappearance of all target lesions. PR: At least a 30% decrease in the size of target lesions. SD: neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as progressive disease (PD). Progressive disease (PD) is defined as: at least a 20% increase in the sum of the LD of target lesions. (NCT00474812)
Timeframe: Up to 5 years

Interventionparticipants (Number)
Progressive diseaseStable Disease
Dasatinib Treatment2410

[back to top]

Median Progression Free Survival (PFS)

Number of months patients were free of disease progression, defined as < 20% increase in the sum of the LD of target lesions nor the appearance of one or more new lesions. (NCT00474812)
Timeframe: Up to 5 years

Interventionmonths (Median)
Dasatinib Treatment2.1

[back to top]

Gait Speed

Gait speed, determined by a 4 meter walk along a properly measured stretch of hallway while being timed with a stopwatch. (NCT00474812)
Timeframe: baseline

Interventionmeters per second (Mean)
Dasatinib Treatment4.1

[back to top]

Median Overall Survival

From the date of onset of treatment to the date of death and to the date of last follow-up for those still alive, assessed up to 24 months (NCT00474812)
Timeframe: assessed up to 24 months

Interventionmonths (Median)
Dasatinib Treatment4.7

[back to top]

Percentage of Participants With Overall Survival (OS)

OS was defined as the time from randomization to the date of death. If the participant had not died, survival was censored on last date the participant was known to be alive. (NCT00481247)
Timeframe: Participants were followed-up for at least 5 years

InterventionPercentage of participants (Number)
Dasatinib90.9
Imatinib89.6

[back to top]

Percentage of Participants With Progression-free Survival (PFS)

PFS was defined as the time from randomization until progression (any progression/death within 30 days of last dosing date, or between 30-60 days of last dosing prior to start of secondary therapy). Those who did not progress/die or who progressed/died after 60 days of last dose were censored at last on-study hematologic/cytogenetic assessment; those with progression/death 30-60 days of last dosing date and after start date of secondary therapy censored at last on-study hematologic/cytogenetic assessment prior to start of secondary therapy; those who had not received study treatment censored on date randomized. (NCT00481247)
Timeframe: Participants were followed-up for at least 5 years

InterventionPercentage of participants (Number)
Dasatinib88.9
Imatinib89.2

[back to top]

Time to Confirmed Complete Cytogenic Response (cCCyR) Overall

"The time to cCCyR for all randomized participants is defined as the time from the randomization date until criteria are first met for complete cytogenic response (provided it is confirmed later). The time to cCCyR analysis censors nonresponders who do not progress at their last cytogenetic assessments and nonresponders who progress at the maximum time of all randomized participants.~." (NCT00481247)
Timeframe: Day 1 to 5 years

InterventionMonths (Median)
Dasatinib3.1
Imatinib5.8

[back to top]

Time to Major Molecular Response (MMR) Overall

The time to MMR for all randomized participants is defined as the time from randomization date until measurement criteria are first met for MMR. The time to MMR analysis censors nonresponders who do not progress at their last molecular assessments and nonresponders who progress at the maximum time of all randomized participants. (NCT00481247)
Timeframe: Day 1 to 5 years

InterventionMonths (Median)
Dasatinib9.3
Imatinib15.0

[back to top] [back to top]

Number of Participants With Grade 3/4 Abnormalities in On-study Laboratory Test Results

ULN=upper limit of normal. Grade 3=Severe AE; Grade 4=Life-threatening or disabling AE. Absolute neutrophil count: Grade 3 <1000-500/mm^3; Grade 4 <500/mm^3. Hemoglobin: Grade 3 <8.0-6.5 g/dL; Grade 4 <6.5 g/dL. Platelets: Grade 3 <50,000-25,000/mm^3; Grade 4 <25,000/mm^3. ALT/AST: Grade 3 >5.0-20*ULN; Grade 4 >20*ULN. Total bilirubin: Grade 3 >3-10*ULN; Grade 4 >10*ULN. Sample normal ranges (may vary by institution): ALT, Female: 7-30 U/L, Male: 10-55 U/L; AST, Female: 9-25 U/L, Male10-40 U/L; Total bilirubin: 0.0-1.0 mg/dL. Creatinine: Grade 3 >3.0-6.0*ULN; Grade 4 >6.0*ULN. Phosphate: Grade 3 <2.0-1.0 mg/dL; Grade 4 <1.0 mg/dL. Calcium: Grade 3 <7.0-6.0 mg/dL; Grade 4 <6.0 mg/dL. Potassium: Grade 3 <3.0-2.5 mmol/L; Grade 4 <2.5 mmol/L. (NCT00481247)
Timeframe: From date of last person, first visit to date of last person, last visit (approximately 8 years)

,
InterventionParticipants (Number)
Grade 3/4 Absolute neutrophil countGrade 3/4 HemoglobinGrade 3/4 PlateletsGrade 3/4 Alanine aminotransferase (ALT)Grade 3/4 Aspartate aminotransferase (AST)Grade 3/4 Total bilirubinGrade 3/4 CreatinineGrade 3/4 PhosphateGrade 3/4 CalciumGrade 3/4 Potassium
Dasatinib74355622331990
Imatinib61233743027978

[back to top]

Percentage of Participants Remaining in Confirmed Complete Cytogenetic Response (cCCyR)

"Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from bone marrow (BM) sample. (Ideally, 25 metaphases but at least 20 metaphases from a BM sample were evaluated). Complete Cytogenetic Response (CCyR)=0% Ph+ cells in metaphase in BM. A cCCyR=those in which all measurements up to at least 28 days after the initial response show an equivalent or better CCyR.~Percentage of participants in cCCyR at years 2, 3, 4 and 5 was computed for all randomized participants who achieved cCCyR as measured from the time of first confirmation until the date of progression or death. Participants with cCCyR who neither progress nor die are censored on the date of their last cytogenetic assessment. Participants without cCCyR are considered to have progressed on Day 1." (NCT00481247)
Timeframe: Years 2, 3, 4 and 5

,
Interventionpercentage of participants (Number)
At Year 2At Year 3At Year 4At Year 5
Dasatinib98.096.995.693.1
Imatinib96.995.795.791.0

[back to top]

Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months

Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from bone marrow (BM) sample. (Ideally, 25 metaphases but at least 20 metaphases from a BM sample were evaluated). Complete Cytogenetic Response (CCyR)=0% Ph+ cells in metaphase in BM. A cCCyR=those in which all measurements up to at least 28 days after the initial response show an equivalent or better CCyR. (NCT00481247)
Timeframe: Pretreatment, every 3 months up to 12 months

InterventionParticipants (Number)
Dasatinib204
Imatinib177

[back to top]

Percentage of Participants With Major Molecular Response (MMR) at Any Time

Molecular response was assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value). (NCT00481247)
Timeframe: Planned total follow-up duration of 5 years

InterventionPercentage of participants (Number)
Dasatinib76.4
Imatinib64.2

[back to top]

Time to Major Cytogenetic Response (MCyR)

Time to MCyR is defined as the time from first dose of Dasatinib (BMS-354825) until the first day criteria for CCyR or PCyR, whichever occurs first, are first met. MCyR = a complete and a partial cytogenetic response (CyR), based on the percentage of Ph+ metaphases among at least 20 metaphase cells in each bone marrow sample. Percentage of Ph+ Cells in Metaphase in bone marrow: Complete Cytogenetic Response (CCyR) = 0; Partial Cytogenetic Response (PCyR) 1 - 35 (NCT00482703)
Timeframe: time from first dose of Dasatinib (BMS-354825) until the first day criteria for CCyR or PCyR, whichever occurs first, are first met

Interventionmonths (Median)
Dasatinib 100 mg QD Starting Dose Cohort5.5
Dasatinib 50 mg BID Starting Dose Cohort4.2

[back to top]

Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations, and Deaths During Treatment

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. (NCT00482703)
Timeframe: Throughout study period to last observation. Dosing period=6 months; if beneficial, medication may continue in the extension period (ending in January 2009). Last observation=30 days past last dosing day or the discontinuation day.

,
Interventionparticipants (Number)
AEs (symptoms/signs and laboratory abnormalities)SAEs (symptoms/signs and laboratory abnormalities)DeathsAEs that led to discontinuation
Dasatinib 100 mg QD Starting Dose Cohort11400
Dasatinib 50 mg BID Starting Dose Cohort12600

[back to top]

Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at End of Study

Cytogenetic response (CyR) as reflected in the major cytogenetic response was determined by bone marrow (BM) aspirates and are based on the percentage of Ph+ metaphases among at least 20 metaphase cells in each BM sample. Major Cytogenetic Response (MCyR) = Complete Cytogenetic Response (CCyR; 0 Ph+ Cells in Metaphase in BM), or Partial Cytogenetic Response (PCyR; 1 - 35 Ph+ Cells in Metaphase in BM). (NCT00482703)
Timeframe: Baseline and at the end of long term extension period (The enrollment period was followed by an extension period until the launch of dasatinib in Japan, January 2009.)

,
Interventionpercentage of participants (Number)
MCyRCCyR
Dasatinib 100 mg QD Starting Dose Cohort5536
Dasatinib 50 mg BID Starting Dose Cohort9267

[back to top]

Time to CHR

Time to CHR = time from first dose of Dasatinib until the first day CHR criteria are met (provided subjects achieved a cCHR). CHR=all of the following criteria: white blood cell count ≤ upper limit of normal; platelets <450,000/mm³; no blasts or promyelocytes in peripheral blood; <5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils <20%; no extramedullary involvement. A confirmed CHR (cCHR) is obtained when all above criteria are maintained for at least 28 days after they are first met. All hematologic responses can begin only 14 days after the dosing start date. (NCT00482703)
Timeframe: time from first dose of Dasatinib (BMS-354825) until the first day CHR criteria are met

Interventionmonths (Median)
Dasatinib 100 mg QD Starting Dose Cohort1.0
Dasatinib 50 mg BID Starting Dose Cohort0.6

[back to top]

Number of Participants With Major Cytogenetic Response at Months 0 - 24 (Duration of MCyR Life Table)

MCyR = a complete and a partial cytogenetic response (CyR), based on the percentage of Ph+ metaphases among at least 20 metaphase cells in each bone marrow sample. Percentage of Ph+ Cells in Metaphase in BM: Complete Cytogenetic Response (CCyR) = 0; Partial Cytogenetic Response (PCyR) 1 - 35 (NCT00482703)
Timeframe: Months 0, 4, 8, 12, 16, 20, 24

,
Interventionparticipants (Number)
Month 0Month 4Month 8Month 12Month 16Month 20Month 24
Dasatinib 100 mg QD Starting Dose Cohort6664300
Dasatinib 50 mg BID Starting Dose Cohort11998310

[back to top]

Expression of BCR-ABL Gene Mutations of RNA (mRNA)

Number of participants with positive (>= 2.0 log copies/mg) and negative (<2.0 log copies/mg) expression of mRNA at Baseline and at end of study. (NCT00482703)
Timeframe: Baseline and at the end of long term extension period (The enrollment period was followed by an extension period until the launch of dasatinib in Japan, January 2009.)

,
Interventionparticipants (Number)
Positive at BaselineNegative at BaselinePositive at End-of-StudyNegative at End-of-Study
Dasatinib 100 mg QD Starting Dose Cohort11083
Dasatinib 50 mg BID Starting Dose Cohort11139

[back to top]

Mutational Spectrum of BCR-ABL

Number of participants with a particular BCR-ABL mutation at Baseline and End-of-Study. (NCT00482703)
Timeframe: Baseline and at the end of long term extension period (The enrollment period was followed by an extension period until the launch of dasatinib in Japan, January 2009.)

,
Interventionparticipants (Number)
G250E mutation at BaselineG250E mutation at End-of-StudyF317L mutation at BaselineF317L mutation at End-of-StudyT315I mutation at BaselineT315I mutation at End-of-Study
Dasatinib 100 mg QD Starting Dose Cohort110100
Dasatinib 50 mg BID Starting Dose Cohort300011

[back to top]

Number of Participants With CHR at Months 0 - 24 (Duration of MCyR Life Table)

CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils < 20%; no extramedullary involvement. A confirmed CHR (cCHR) is obtained when all above criteria are maintained for at least 28 days after they are first met. All hematologic responses can begin only 14 days after the dosing start date. (NCT00482703)
Timeframe: Months 0, 4, 8, 12, 16, 20, 24

,
Interventionparticipants (Number)
Month 0Month 4Month 8Month 12Month 16Month 20Month 24
Dasatinib 100 mg QD Starting Dose Cohort10999840
Dasatinib 50 mg BID Starting Dose Cohort101088740

[back to top]

Complete Hematologic Response (CHR) in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24

CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils < 20%; no extramedullary involvement. A confirmed CHR (cCHR) is obtained when all above criteria are maintained for at least 28 days after they are first met. All hematologic responses can begin only 14 days after the dosing start date. (NCT00482703)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Dasatinib 100 mg QD Starting Dose Cohort91
Dasatinib 100 mg QD Starting Dose - Imatinib-resistant86
Dasatinib 100 mg QD Starting Dose - Imatinib-intolerant100
Dasatinib 50 mg BID Starting Dose Cohort83
Dasatinib 50 mg BID Starting Dose - Imatinib-resistant86
Dasatinib 50 mg BID Starting Dose - Imatinib-intolerant80

[back to top]

Number of Participants With Progression-Free Survival (PFS) at Months 0 - 24 (PFS Life Table)

Progressed disease=achieving a CHR and subsequently no longer meeting criteria consistently over a consecutive 2-week period after starting maximum dose; no CHR after receiving maximum dose and an increase in white blood cell count (doubling of the count from lowest value to >20,000/mm3 or an increase by >50,000/mm3 on 2 assessments done at least 2 weeks apart); meeting the criteria of accelerated or blastic phase CML at any time; having an MCyR and subsequently no longer meeting the criteria for MCyR after starting maximum dose; or having a >=30% absolute increase in number of Ph+ metaphases. (NCT00482703)
Timeframe: Months 0, 4, 8, 12, 16, 20, 24

,
Interventionparticipants (Number)
Month 0Month 4Month 8Month 12Month 16Month 20Month 24
Dasatinib 100 mg QD Starting Dose Cohort111199970
Dasatinib 50 mg BID Starting Dose Cohort121210101070

[back to top]

Hematologic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at End of Study

CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils < 20%; no extramedullary involvement. A confirmed CHR (cCHR) is obtained when all above criteria are maintained for at least 28 days after they are first met. All hematologic responses can begin only 14 days after the dosing start date. (NCT00482703)
Timeframe: Baseline and at the end of long term extension period (The enrollment period was followed by an extension period until the launch of dasatinib in Japan, January 2009.)

Interventionpercentage of participants (Number)
Dasatinib 100 mg QD Starting Dose Cohort91
Dasatinib 50 mg BID Starting Dose Cohort83

[back to top]

Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24

Cytogenetic responses (CyR) are based on the percentage of Philadelphia-positive (Ph+) metaphases among at least 20 metaphase cells in each bone marrow (BM) sample. The criteria for cytogenetic responses are as follows. Best CyR is defined as the best response obtained at any time during the study. Major Cytogenetic Response (MCyR) = Complete Cytogenetic Response (CCyR; 0 Ph+ Cells in Metaphase in BM), and Partial Cytogenetic Response (PCyR; 1 - 35 Ph+ Cells in Metaphase in BM). (NCT00482703)
Timeframe: Week 24

,,,,,
Interventionpercentage of participants (Number)
MCyRCCyR
Dasatinib 100 mg QD Starting Dose - Imatinib-intolerant7550
Dasatinib 100 mg QD Starting Dose - Imatinib-resistant2914
Dasatinib 100 mg QD Starting Dose Cohort4527
Dasatinib 50 mg BID Starting Dose - Imatinib-intolerant10080
Dasatinib 50 mg BID Starting Dose - Imatinib-resistant8643
Dasatinib 50 mg BID Starting Dose Cohort9258

[back to top]

Progression-free Survival Rate

Progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Patients who are still alive and have not progressed will be censored at the date of the last negative examination. A Simon (1989), optimal, two-stage design will be employed. The progression-free survival count will be the proportion of subjects who are alive and progression-free at 4 months. (NCT00504153)
Timeframe: From the start of treatment to the time of disease progression or death from any cause, assessed at 4 months after completion of treatment (i.e., up to 12 months.)

Interventionpercentage of participants (Number)
Dasatinib (Tyrosine Kinase Inhibitor)5.3

[back to top]

Response Rate (RR) (Complete or Partial Responders)

Response will be evaluated in this study using the new international criteria proposed by the RECIST Committee. The response rate is the proportion of subjects who experienced a complete or partial response. (NCT00504153)
Timeframe: Every 2 courses, assessed up to 8 weeks after completion of study treatment (i.e., up to 10 months)

Interventionpercentage of participants (Number)
Dasatinib (Tyrosine Kinase Inhibitor)0

[back to top]

Number of Participants With Progression-free Survival at 12-weeks

Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease. (NCT00507767)
Timeframe: At 12-weeks

Interventionparticipants (Number)
Dasatinib1

[back to top]

Number of Participants With Overall Tumor Response

"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:~Complete Response (CR): disappearance of all target lesions;~Partial Response (PR) 30% decrease in sum of longest diameter of target lesions;~Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions;~Stable Disease (SD): small changes that do not meet above criteria.~Overall tumor response is the total number of CR and PRs." (NCT00509041)
Timeframe: Duration of study until progression (up to 3 years)

Interventionparticipants (Number)
Complete ResponsePartial Response
Dasatinib02

[back to top]

Progression Free Survival

Progression free survival (PFS) was defined as the time from registration to progression or death of any cause. Progression free and alive patients were censored at the date of last follow-up. The median PFS with 95% CI was estimated using the Kaplan Meier method. (NCT00509041)
Timeframe: Time from registration to progression or death (up to 3 years)

Interventionweeks (Median)
Dasatinib9.1

[back to top]

Overall Survival

Overall survival (OS) was defined as the time from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00509041)
Timeframe: Time from registration to death (up to 3 years)

Interventionweeks (Median)
Dasatinib26.1

[back to top]

24 Week Progression Free Survival

Percentage of participants who were alive and progression free at 24 weeks. The 24 week progression free survival, with 95% confidence interval, was estimated using the Kaplan Meier method. (NCT00509041)
Timeframe: 24 weeks

Interventionpercentage of participants (Number)
Dasatinib23

[back to top]

Mean Oral Clearance (CLo) of Dasatinib Following 70 mg BID and 100 QD Dose Administration

(NCT00529763)
Timeframe: Day 1 (0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 hours postdose), Day 8 (0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 hours postdose)

,
InterventionmL/h (Mean)
Day 1Day 8
100 mg QD221.84211.09
70 mg BID564.97441.08

[back to top]

Duration of Major Cytogenetic Response (MCyR) in Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants

"The duration of time from when the first day all criteria are met for CCyR or PCyR until the date of progression or death. Participants who neither progress nor die will be censored on the date of their last cytogenetic assessment. The duration of MCyR will be estimated via the Kaplan-Meier product-limit method.~Major Cytogenetic Response (MCyR) = Complete Cytogenetic Response (CCyR: 0% Ph-chromosome-positive cells in metaphase in BM) or Partial Cytogenetic Response (PCyR: 1-35% Ph-chromosome-positive cells in metaphase in BM)." (NCT00529763)
Timeframe: From first dose until the date of progression or death. (Up to approximately 12 months of follow up after dasatinib treatment [data cut-off date: 18-Jun-2010])

InterventionMonths (Number)
Chronic Phase (CP) CMLNA

[back to top] [back to top]

Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Major Cytogenetic Response (MCyR)

"Major Cytogenetic Response (MCyR) is defined as Complete Cytogenetic Response (CCyR) or Partial Cytogenetic Response (PCyR).~CCyR: 0% Ph-chromosome-positive cells in metaphase in bone marrow [BM] PCyR: 1-35% Ph-chromosome-positive cells in metaphase in [BM]." (NCT00529763)
Timeframe: From first dose up to approximately 12 months of follow up after dasatinib treatment (data cut-off date: 18-Jun-2010)

InterventionPercentage of participants (Number)
Chronic Phase (CP) CML50.8

[back to top]

Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Complete Hematologic Response (CHR)

Complete Hematologic Response (CHR) is obtained when all the following criteria are met: WBC ≤ institutional ULN; platelets ≤ 450,000/mm3; ≤20% basophils in peripheral blood; no blasts or promyelocytes in PB cells; < 5% myelocytes plus metamyelocytes in PB cells; no extra-medullary involvement including no hepatomegaly or splenomegaly. (NCT00529763)
Timeframe: From first dose up to approximately 12 months of follow up after dasatinib treatment (data cut-off date: 18-Jun-2010)

InterventionPercentage of participants (Number)
Chronic Phase (CP) CML91.5

[back to top]

Mean Dasatinib Plasma Concentrations

Mean dasatinib plasma concentrations following 70 mg BID dose in AD CML or Ph+ ALL participants and following 100 mg QD dose in CP CML participants (NCT00529763)
Timeframe: Day 1 (0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 hours postdose), Days 6 and 7 (0 hours postdose), Day 8 (0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 hours postdose),

,
Interventionng/mL (Mean)
Day 1: 0.5 hours postdoseDay 1 : 1 hour postdoseDay 1 : 2 hours postdoseDay 1 : 3 hours postdoseDay 1 : 4 hours postdoseDay 1 : 5 hours postdoseDay 1 : 6 hours postdoseDay 1 : 8 hours postdoseDay 1 : 12 hours postdoseDay 1 : 24 hours postdoseDay 6: 0 hours postdoseDay 7: 0 hours postdoseDay 8: 0 hours postdoseDay 8: 0.5 hours postdoseDay 8: 1 hours postdoseDay 8: 2 hours postdoseDay 8: 3 hours postdoseDay 8: 4 hours postdoseDay 8: 5 hours postdoseDay 8: 6 hours postdoseDay 8: 8 hours postdoseDay 8: 12 hours postdose
100 mg QD133.18130.86100.6964.9038.1826.3320.7114.006.572.593.153.022.75102.69168.51102.0571.2345.1731.1623.6215.417.55
70 mg BID56.7454.5729.5016.6512.028.537.374.482.421.078.938.778.2248.7452.5544.3231.6418.3313.7410.917.233.96

[back to top]

Percentage of Participants With Complete, Major, and Overall Hematologic Response (CHR, MaHR, & OHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Blast Phase CML/Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

"Major hematologic response: (MaHR) = complete hematologic response (CHR) + no evidence of leukemia (NEL).~CHR=white blood cells (WBC) ≤upper limit of normal (ULN); absolute neutrophil count (ANC) ≥1,000/mm3; platelets ≥100,000/mm3; no blasts/promyelocytes, <20% basophils & <5% myelocytes+metamyelocytes in peripheral blood (PB); BM blasts ≤5%; no extra-medullary involvement/hepatomegaly/splenomegaly.~NEL=CHR except platelets ≥20,000/mm3 & <100,000/mm3; ANC >500/mm3 & <1,000/mm3.~Overall hematologic response (OHR)=CHR+NEL+ return to chronic phase (RTC=<15% blasts in BM and PB; <30% blasts+promyelocytes in BM & PB; <20% basophils in PB; no extra-medullar disease other than spleen & liver)" (NCT00529763)
Timeframe: From first dose up to approximately 12 months of follow up after dasatinib treatment (data cut-off date: 18-Jun-2010)

,
InterventionPercentage of participants (Number)
CHRMaHROHR
Advanced Disease CML - Accelerated Phase (AP)52.084.092.0
Advanced Disease CML - Blast Phase/PH+ ALL16.229.735.1

[back to top]

Time to Complete and Major Hematologic Response (CHR and MaHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Participants (Ph+ ALL)

"The time from first dose of Dasatinib until the first day CHR or MaHR criteria are met (for all confirmed responses). Time to CHR is computed only for participants whose best response is CHR. Major HR (MaHR) includes CHR or no evidence of leukemia (NEL).~Major hematologic response: (MaHR) = complete hematologic response (CHR) + no evidence of leukemia (NEL).~CHR=white blood cells (WBC) ≤upper limit of normal (ULN); absolute neutrophil count (ANC) ≥1,000/mm3; platelets ≥100,000/mm3; no blasts/promyelocytes, <20% basophils & <5% myelocytes+metamyelocytes in peripheral blood (PB); BM blasts ≤5%; no extra-medullary involvement/hepatomegaly/splenomegaly.~NEL=CHR except platelets ≥20,000/mm3 & <100,000/mm3; ANC >500/mm3 & <1,000/mm3." (NCT00529763)
Timeframe: From first dose of Dasatinib until the first day CHR criteria are met (for all confirmed responses). (Up to approximately 12 months of follow up after dasatinib treatment [data cut-off date: 18-Jun-2010])

,,
InterventionWeeks (Median)
CHRMaHR
Advanced Disease CML - Accelerated Phase (AP)16.012.1
Advanced Disease CML - Blast Phase/PH+ ALL12.112.1
Total12.112.1

[back to top]

Progression-free Survival Among CP CML Participants

"Progression-free survival is defined as the time from first dosing date until the time progressive disease (PD) is first documented. Participants who die without a reported prior progression will be considered to have progressed on the date of their death. Participants who do not progress nor die will be censored on the date of their last hematologic or cytogenetic assessment, whichever comes last. PFS will be analyzed via the Kaplan-Meier product-limit method.~Participants were considered as having PD if they: achieved a hematologic response but subsequently no longer meet the criteria consistently on all assessment over a consecutive 2-week period after starting maximum dose; had no decrease from their baseline percent blasts in PB or BM on all assessments over a 4-week period, or had an increase by at least 50% in PB blast count (absolute) over a 2-week period after starting their maximum (individually-tolerated) dose." (NCT00529763)
Timeframe: From first dosing date until the time progressive disease (PD) is first documented. (Up to approximately 12 months of follow up after dasatinib treatment [data cut-off date: 18-Jun-2010])

InterventionMonths (Number)
Chronic Phase (CP) CMLNA

[back to top]

Time to Major Cytogenetic Response (MCyR) in Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants

"Time to MCyR is defined as the time from the first dosing date until day criteria were first met for CCyR or PCyR, whichever occurred first.~Major Cytogenetic Response (MCyR) is defined as Complete Cytogenetic Response (CCyR: 0% Ph-chromosome-positive cells in metaphase in BM) or Partial Cytogenetic Response (PCyR: 1-35% Ph-chromosome-positive cells in metaphase in BM)." (NCT00529763)
Timeframe: From first dose up to the day criteria were first met for CCyR or PCyR, whichever occurred first. (Up to approximately 12 months of follow up after dasatinib treatment [data cut-off date: 18-Jun-2010])

InterventionWeeks (Median)
Chronic Phase (CP) CML12.1

[back to top]

Progression-free Survival Among AD CML and Ph+ ALL Participants

"Progression-free survival is defined as the time from first dosing date until the time progressive disease (PD) is first documented. Participants who die without a reported prior progression will be considered to have progressed on the date of their death. Participants who do not progress nor die will be censored on the date of their last hematologic or cytogenetic assessment whichever comes last. PFS will be analyzed via the Kaplan-Meier product-limit method.~Progressive disease (PD) = Hematologic response achieved but subsequently no longer meet the criteria consistently on all assessment over a 2-week period;, and no decrease from their baseline percent blasts in PB or BM on all assessments over a 4-week period or have an increase by at least 50% in PB blast count (absolute) over a 2-week period." (NCT00529763)
Timeframe: From first dose until the time progressive disease (PD) is first documented. (Up to approximately 12 months of follow up after dasatinib treatment [data cut-off date: 18-Jun-2010])

InterventionMonths (Number)
Advanced Disease CML - Accelerated Phase (AP)25.7
Advanced Disease CML - Blast Phase/PH+ ALL4.3

[back to top]

Duration of CHR Among AD CML and Ph+ ALL Participants

"Time from the first day all criteria are met for CHR until the date treatment is discontinued due to progressive disease (PD) or death. Participants who neither progress nor die will be censored on the date of their last assessment.~CHR=white blood cells (WBC) ≤ upper limit of normal (ULN); absolute neutrophil count (ANC) ≥1,000/mm3; platelets ≥100,000/mm3; no blasts/promyelocytes, <20% basophils and <5% myelocytes+metamyelocytes in peripheral blood (PB); BM blasts ≤5%; no extra-medullary involvement/hepatomegaly/splenomegaly.~PD = Hematologic response achieved but subsequently no longer meet the criteria consistently on all assessment over a 2-week period;, and no decrease from their baseline percent blasts in PB or BM on all assessments over a 4-week period or have an increase by at least 50% in PB blast count (absolute) over a 2-week period." (NCT00529763)
Timeframe: From first dose until the date of disease progression (PD) or death. (Up to approximately 12 months of follow up after dasatinib treatment [data cut-off date: 18-Jun-2010])

InterventionMonths (Number)
Advanced Disease CML - Accelerated Phase (AP)NA
Advanced Disease CML - Blast Phase/PH+ ALLNA

[back to top]

Duration of MaHR Among AD CML and Ph+ ALL Participants

"Time from the first day all criteria are met for CHR or NEL or MaHR until the date of progression or death. Participants who neither progress nor die will be censored on the date of their last assessment.~MAHR = CHR or no evidence of leukemia (NEL). CHR=white blood cells (WBC) ≤ upper limit of normal (ULN); absolute neutrophil count (ANC) ≥1,000/mm3; platelets ≥100,000/mm3; no blasts/promyelocytes, <20% basophils and <5% myelocytes+metamyelocytes in peripheral blood (PB); BM blasts ≤5%; no extra-medullary involvement/hepatomegaly/splenomegaly.~NEL=CHR except platelets ≥20,000/mm3 and <100,000/mm3; ANC >500/mm3 and <1,000/mm3.~Progressive disease (PD) = Hematologic response achieved but subsequently no longer meet the criteria consistently on all assessment over a 2-week period;, and no decrease from their baseline percent blasts in PB or BM on all assessments over a 4-week period or have an increase by at least 50% in PB blast count (absolute) over a 2-week period." (NCT00529763)
Timeframe: From first dose until the date of disease progression (PD) or death. (Up to approximately 12 months of follow up after dasatinib treatment [data cut-off date: 18-Jun-2010])

InterventionMonths (Number)
Advanced Disease CML - Accelerated Phase (AP)NA
Advanced Disease CML - Blast Phase/PH+ ALL11.2

[back to top]

Mean Maximum Concentration (Cmax) of Dasatinib Following 70 mg BID and 100 QD Dose Administration

Cmax=maximum observed plasma concentration of dasatinib (NCT00529763)
Timeframe: Day 1 (0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 hours postdose), Day 8 (0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 hours postdose)

,
Interventionng/mL (Mean)
Day 1Day 8
100 mg QD170.53181.79
70 mg BID71.0171.54

[back to top]

Mean Apparent Volume of Distribution (Vz/F) of Dasatinib Following 70 mg BID and 100 QD Dose Administration

(NCT00529763)
Timeframe: Day 1 (0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 hours postdose), Day 8 (0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 hours postdose)

,
InterventionmL/h (Mean)
Day 1Day 8
100 mg QD1454.711719.14
70 mg BID3785.783446.74

[back to top]

Mean (Tmax) and (T-Half) of Dasatinib Following 70 mg BID and 100 QD Dose Administration

Tmax=time of maximum observed plasma concentration. T-Half=plasma half-life. (NCT00529763)
Timeframe: Day 1 (0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 hours postdose), Day 8 (0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 hours postdose)

,
Interventionhours (Mean)
Tmax: Day 1Tmax: Day 8T-Half: Day 1T-Half: Day 8
100 mg QD1.501.234.785.71
70 mg BID1.171.624.354.80

[back to top]

Mean (AUC[0-T]), (AUC[INF]), and (AUC[TAU])of Dasatinib Following 70 mg BID and 100 QD Dose Administration

Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration AUC(0-T)for dasatinib. AUC(INF)=area under the plasma concentration-time curve from time zero extrapolated to infinite time. AUC(TAU)=area under the plasma concentration-time curve for a dosing interval (NCT00529763)
Timeframe: Day 1 (0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 hours postdose), Day 8 (0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 hours postdose)

,
Interventionng*h/mL (Mean)
AUC(0-T): Day 1AUC(0-T): Day 8AUC(INF): Day 1AUC(INF): Day 8AUC(TAU): Day 1AUC(TAU): Day 8
100 mg QD505.73567.30526.33588.52511.07568.85
70 mg BID161.30214.60174.26247.10163.56218.05

[back to top]

Progression-free Survival (PFS) Rate at 4 Months

Progressive disease - appearance of one or more new lesions. Unequivocal progression of existing non-target lesions. Although a clear progression of non-target lesions only is exceptional, in such circumstances, the opinion of the treating physician should prevail and the progression status should be confirmed later on by a review panel (or study chair/primary investigator). (NCT00544908)
Timeframe: Four months.

Interventionpercentage of participants (Number)
Dasatinib0

[back to top]

Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT00544908)
Timeframe: After every two cycles, up to 5 years

Interventionpercentage of participants (Number)
Dasatinib0

[back to top]

To Measure Response to Protocol Therapy Per RECIST Criteria

"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Progression At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as a reference the smallest sum longest diameter recorded since treatment started, or the appearance of one or more new lesions.~RECIST 1.0 Overall response:~Complete Response (CR) Partial Response (PR) Stable Disease (SD) Progressive Disease (PD)~CR= CR+CR and No new lesions PR= CR+SD; PR+SD and no new lesions SD= SD+SD and no new lesions PD= PD+any new lesions" (NCT00546104)
Timeframe: 16 weeks

Interventionpercentage of participants (Number)
Dasatinib16.7

[back to top]

Characterization and Comparison of SRC (A Protein Tyrosine Kinase)Dysregulation at Baseline (All Patients), After 4 Weeks of Dasatinib Treatment (All Patients), and at Progression (Only Patients Who Progress After Documented Response)

For the 20 patients with evaluable biopsies at baseline and week 4, the median relative change from baseline in tissue biomarker levels of phospho-Src (p-Src) (NCT00546104)
Timeframe: 4 weeks

Interventionpercentage of change in p-SRC (Median)
Dasatinib-0.125

[back to top]

Estimation of the Proportion of Progression-free Patients at 16 Wks.

"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as appropriate.~Proportion progression-free at 16 weeks.From first day of study related treatment with Dasatinib until the date of first documented progression or date of death from any cause, whichever came first." (NCT00546104)
Timeframe: 16 weeks

Interventionpercentage of participants (Number)
Dasatinib0

[back to top]

To Explore the Association Between Each Patient's SRC Signature and Their Time to Progression.

Spearman's correlation between the change in SRC signature from baseline to 4 weeks and time to progression (NCT00546104)
Timeframe: Baseline Src measure to first progression

Interventioncorrelation coefficient (Number)
Dasatinib0.27

[back to top]

Correlate SRC Dysregulation Results With Response to Dasatinib Therapy

Since all patients progressed there is no comparison to between responders and non-responders. (NCT00546104)
Timeframe: 16 weeks

Interventionpercentage change in p-SRC (Mean)
Dasatinib-.10

[back to top]

Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5%

To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol. (NCT00549848)
Timeframe: Middle of remission induction, Day 15 in Total XVI and Day 19 in Total XV

InterventionParticipants (Count of Participants)
TOTXVI PEG 350022
TOTXVI PEG 250026
TOTXVI Not Randomized31
All Eligible Patients in TOTXV55

[back to top]

Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase.

"The primary objective of this study is to compare the distributions of continuous complete remission of patients randomized on the first day of the continuation phase to receive a higher dose of PEG-asparaginase or to receive the conventional dose (2,500 units/m2).~The randomization will occur on the starting day of the continuation phase, at which time all information necessary for performing the randomization should be available. In the rare case that immunophenotype and/or Day-15 MRD is not available, we will make the following assumptions: If immunophenotype is unknown at the time the randomization is to be executed, then it will be assumed B-lineage. If Day-15 MRD is unknown at the time of randomization, then it will be assumed negative (<0.01%). Past experience indicate that few patients will fall into these unknown categories." (NCT00549848)
Timeframe: 3.5 years after the last enrollment up to 12.5 years

InterventionPercentage of participants (Number)
PEG 3500 Units/m^291.6
PEG 2500 Units/m^290.7

[back to top]

Probability of CNS Relapse

To assess whether intensification of CNS-directed intrathecal and systemic chemotherapy will improve outcome in patients at high-risk of CNS relapse. (NCT00549848)
Timeframe: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years

InterventionPercentage of participants (Number)
TOTXVI PEG 35000.8
TOTXVI PEG 25001.8
TOTXVI Not Randomized2.7
All Eligible Patients in TOTXV5.7

[back to top]

Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01%

To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol. (NCT00549848)
Timeframe: End of remission induction; day 42 in Total XVI and day 46 in Total XV

InterventionParticipants (Count of Participants)
TOTXVI PEG 35007
TOTXVI PEG 250012
TOTXVI Not Randomized20
All Eligible Patients in TOTXV44

[back to top]

Probability of Overall Survival

To estimate the overall survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV. (NCT00549848)
Timeframe: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years

InterventionPercentage of participants (Number)
TOTXVI PEG 350097.5
TOTXVI PEG 250095.6
TOTVI Not Randomized90.8
All Eligible Patients in TOTXV93.5

[back to top]

Probability of Event-free Survival

"To estimate the event-free survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV (NCT00137111).~EFS will be measured from the date of complete response to the date of initial failure for patients who fail. Failure includes the traditional endpoints of failure to achieve a complete remission, relapse in any site, secondary malignancy, and death during induction or remission. EFS time will be measured to the date of last contact for patients who are failure free at the time of analysis. The EFS time is defined to be zero (0) for patients who die during induction therapy or fail to achieve a complete remission." (NCT00549848)
Timeframe: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years

InterventionPercentage of participants (Number)
TOTXVI PEG 350092.4
TOTXVI PEG 250091.1
TOTXVI Not Randomized86.3
All Eligible Patients in TOTXV87.1

[back to top]

Number of Participants With Clinical Response Rates

"The Objective response rate (CR+PR) and the Clinical Benefit Rate (CR+PR+SD) were calculated according to revised response criteria for malignant lymphoma (Cheson) CR - Complete response is defined as: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy.~PR - Partial response is defined as: ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses.~SD - Stable Disease is define as: Failing to attain the criteria needed for a PR, but not fulfilling those for progressive disease." (NCT00550615)
Timeframe: after 2-28 day cycles of therapy

InterventionParticipants (Count of Participants)
Objective response rateClinical Benefit Rate
Evauable Participants From Both Phases of the Trial717

[back to top]

Maximum Tolerated Dose

(NCT00550615)
Timeframe: after 1-28 day cycle of therapy

Interventionmilligrams PO daily (Number)
All Phase I Participants200

[back to top]

Progression-free Survival

Progression-free survival was defined as the time from start of treatment until progression or death, whichever occurred first. Participants were to be followed-up for 12 months following the last dose of dasatinib for progression and survival. PFS was analyzed for the all-treated population. (NCT00560352)
Timeframe: Day 1 to disease progression or death, whichever came first (maximum reached: 14 months)

InterventionMonths (Median)
All Treated6.3

[back to top]

Duration of Response

Duration of response calculated for those with best response=CR (M-protein [MP] undetectable by immunofixation [IF], ≤5% plasma cells in bone marrow, no soft tissue plasmacytomas); VGPR (MP detectable by IF, or ≥90% drop in serum [S] MP and urine [U] MP<100 mg/24h); PR(≥50% drop in S MP and ≥90% drop in U MP or U protein <200 mg/24h, ≥50% drop in BL ST PC size); or MR (≥25% to <50% drop in S MP and ≥50% to <90% drop in U MP and ≥25% to <50% drop in BL ST PC). Duration of response calculated from day criteria for CR, VGPR, PR, and MR were met until progression or death, whichever came first. (NCT00560352)
Timeframe: First occurrence of response to disease progression or death, whichever occurred first (maximum reached: 12.2 months)

,
InterventionMonths (Number)
Partial response (PR)Minimal response (MR)
Dasatinib, 140 mg QD012.2
Dasatinib, 50 mg BID5.4NA

[back to top] [back to top] [back to top] [back to top]

Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry

S=serum; U=urine; MP=M-protein; ST=soft tissue, PC=plasmacytomas; IF=immunofixation; BL=baseline. RR calculated on best response any time. CR=MP undetectable by IF, ≤5% plasma cells in bone marrow, and no ST PC. VGPR=MP detectable by IF, or ≥90% drop in S MP and U MP<100 mg/24h. PR= ≥50% drop in S MP and ≥90% drop in U MP or U protein <200 mg/24h, ≥50% drop in BL ST PC size. MR= ≥25% to <50% drop in S MP and ≥50% to <90% drop in U MP and ≥25% to <50% drop in BL ST PC. SD=Not CR, VGPR, PR, or MR. PD= ≥25% rise in S or U M-component; new/increased size of bone lesions, ST PC, or hypercalcemia. (NCT00560352)
Timeframe: Day 1 until last tumor assessment (maximum reached: 9 months)

,,
InterventionPercentage of participants (Number)
Complete response (CR)Very good partial response (VGPR)Partial response (PR)Minimal response (MR)Stable disease (SD)Progressive disease (PD)Unable to determineNot reported
Dasatinib, 100 mg QD0000033.333.333.3
Dasatinib, 140 mg QD00025002550
Dasatinib, 50 mg BID0014.3057.114.3014.3

[back to top] [back to top]

Number of Participants With Serum Chemistry Abnormalities (Worst On-study Grade vs Baseline): High Calcium, Low Calcium, Low Magnesium, and Low Phosphorus

Grading as per NCI CTCAE Version 3.0 criteria. GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Calcium (low): GR1: ULN - 11.5 mg/dL, GR2: >11.5 - 12.5 mg/dL, GR3: >12.5 - 13.5 mg/dL, GR4: >13.5 mg/dL. Magnesium (Low): GR1: NCT00560391)
Timeframe: Baseline (pretreatment); Cycles 1 and 2 (within 24 hours of Days 1, 4, 8, 11, 15, 18, 21, and 25); beyond Cycle 2 (within 24 hours of Days 1 and 15,off treatment visit ) (median duration of dasatinib treatment=5.2 mo [range 0 to 33 mo])

,,,,
Interventionparticipants (Number)
High Calcium; GR 0 at BL, GR 0PBLHigh Calcium; GR 0 at BL, GR 1 to 2 PBLHigh Calcium; GR 0 at BL, GR 3 to 4 PBLHigh Calcium; GR 1 to 2 at BL, GR 0 PBLHigh Calcium; GR 1 to 2 at BL, GR 1 to 2 PBLHigh Calcium; GR 1 to 2 at BL, GR 3 to 4 PBLLow Calcium; GR 0 at BL, GR 0 PBLLow Calcium; GR 0 at BL, GR 1 to 2 PBLLow Calcium; GR 0 at BL, GR 3 to 4 PBLLow Calcium; GR 1 to 2 at BL, GR 0 PBLLow Calcium; GR 1 to 2 at BL, GR 1 to 2 PBLLow Calcium; GR 1 to 2 at BL, GR 3 to 4 PBLLow Magnesium; GR 0 at BL, GR 0 PBLLow Magnesium; GR 0 at BL, GR 1 to 2 PBLLow Magnesium; GR 0 at BL, GR 3 to 4 PBLLow Magnesium; GR 1 to 2 at BL, GR 0 PBLLow Magnesium; GR 1 to 2 at BL, GR 1 to 2 PBLLow Magnesium; GR 1 to 2 at BL, GR 3 to 4 PBLLow Magnesium; GR Not reported at BLLow Phosphorus; GR 0 at BL, GR 0 PBLLow Phosphorus; GR 0 at BL, GR 1 to 2 PBLLow Phosphorus; GR 0 at BL, GR 3 to 4 PBLLow Phosphorus; GR 1 to 2 at BL, GR 0 PBLLow Phosphorus; GR 1 to 2 at BL, GR 1 to 2 PBLLow Phosphorus; GR 1 to 2 at BL, GR 3 to 4 PBLLow Phosphorus; GR 3 to 4 at BL, GR 0 PBLLow Phosphorus; GR 3 to 4 at BL, GR 1 to 2 PBLLow Phosphorus; GR 3 to 4 at BL, GR 3 to 4 PBL
Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg3000001200003000000200000001
Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg4000202400002300100321000000
Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg151001011220117610300826001000
Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg4100012300102300100131000000
Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg2000100200101200000030000000

[back to top]

Number of Participants With Hematology Abnormalities (Worst On-study Grade vs Baseline): Leukopenia, Neutropenia, Thrombocytopenia, and Anemia

As per NCI CTCAE Version 3.0 criteria. Grade (GR)1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. White blood cell (WBC):GR1=NCT00560391)
Timeframe: Baseline (pretreatment); Cycles 1 and 2 (within 24 hours of Days 1, 4, 8, 11, 15, 18, 21, and 25); beyond Cycle 2 (within 24 hours of Days 1 and 15,off treatment visit ) (median duration of dasatinib treatment=5.2 mo [range 0 to 33 mo])

,,,,
Interventionparticipants (Number)
Leukopenia; GR 0 at BL, GR 0 PBLLeukopenia; GR 0 at BL, GR 1 to 2 PBLLeukopenia; GR 0 at BL, GR 3 to 4 PBLLeukopenia; GR 1 to 2 at BL, GR 0 PBLLeukopenia; GR 1 to 2 at BL, GR 1 to 2 PBLLeukopenia; GR 1 to 2 at BL, GR 3 to 4 PBLNeutropenia; GR 0 at BL, GR 0 PBLNeutropenia; GR 0 at BL, GR 1 to 2 PBLNeutropenia; GR 0 at BL, GR 3 to 4 PBLNeutropenia; GR 1 to 2 at BL, GR 0Neutropenia; GR 1 to 2 at BL, GR 1 to 2 PBLNeutropenia; GR 1 to 2 at BL, GR 3 to 4 PBLThrombocytopenia; GR 0 at BL, GR 0 PBLThrombocytopenia; GR 0 at BL, GR 1 to 2 PBLThrombocytopenia; GR 0 at BL, GR 3 to 4 PBLThrombocytopenia; GR 1 to 2 at BL, GR 0 PBLThrombocytopenia; GR 1 to 2 at BL, GR 1 to 2 PBLThrombocytopenia; GR 1 to 2 at BL, GR 3 to 4 PBLAnemia; GR 0 at BL, GR 0 PBLAnemia; GR 0 at BL, GR 1 to 2 PBLAnemia; GR 0 at BL, GR 3 to 4 PBLAnemia; GR 1 to 2 at BL, GR 0 PBLAnemia; GR 1 to 2 at BL, GR 1 to 2 PBLAnemia; GR 1 to 2 at BL, GR 3 to 4 PBLAnemia; GR 3 to 4 at BL, GR 0 PBLAnemia; GR 3 to 4 at BL, GR 1 to 2 PBLAnemia; GR 3 to 4 at BL, GR 3 to 4 PBLAnemia; GR Not reported at BL
Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg0300000210000200100100110000
Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg1200030300031300110300110001
Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg2630151380142520350610550000
Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg0120030230010300120000410010
Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg2100001110001100010100110000

[back to top]

Number of Participants With Complete Response and Very Good Partial Response

Response criteria were based on The International Uniform Response Criteria for Multiple Myeloma (with a slight modification). Complete response was achieved when there was negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow. Very good partial response was achieved when serum and urine M-component was detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-component plus urine M-component < 100 mg per 24 hour. (NCT00560391)
Timeframe: Baseline, At the end of the treatment period (median duration of dasatinib treatment=5.2 months [range 0 to 33 months]).

,,,,
Interventionparticipants (Number)
Complete responseVery good partial responseNo responseNot reportedResponse Undetermined
Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg00100
Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg01100
Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg031100
Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg00410
Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg00200

[back to top]

Number of Participants Who Died, Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation

AE: New untoward medical occurrence or worsening of a preexisting medical condition that does not have causal relationship with this treatment. SAE: Untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency/abuse; life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization/prolongs existing hospitalization. Grade 1= Mild; Grade 2= Moderate; Grade 3= Severe; Grade 4 = Life-threatening or disabling. (NCT00560391)
Timeframe: Baseline (pretreatment), from the date of first dose until at least 30 days after the last dose of study drug (median duration of dasatinib treatment=5.2 months [range 0 to 33 months]).

,,,,
Interventionparticipants (Number)
All deathsDeaths within 30 days of last doseAll SAEsDrug-related SAEsAEs leading to discontinuationDrug-related AEs leading to discontinuationAll AEsDrug-related AEs
Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg00211033
Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg10511066
Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg3294871717
Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg31312266
Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg21211033

[back to top]

Number of Participants With Minimal Response

Response criteria was based on The International Uniform Response Criteria for Multiple Myeloma (with a slight modification). Minimal Response was achieved when there was 25% to 49% reduction of serum M-Protein, 50% to 89% reduction in 24 hour urinary M-protein which still exceeded 200 mg/24 hour. If the serum and urine M-protein were unmeasurable, 25% to 49% reduction in plasma cells was required. In addition, if present at baseline, a 25% to 49% reduction in the size of soft tissue plasmacytomas was also required. (NCT00560391)
Timeframe: Baseline, at the end of the treatment period (median duration of dasatinib treatment=5.2 months [range 0 to 33 months]).

Interventionparticipants (Number)
Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg0
Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg0
Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg0
Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg0
Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg0

[back to top]

Number of Participants With Partial Response

Partial response was achieved when there was ≥50% reduction of serum M-protein (Mpr)and reduction in 24 hour urinary Mpr by ≥90% or to <200 mg/24 hr. If the serum and urine Mpr were unmeasurable, a ≥50% decrease in the difference between involved and uninvolved free light chain (FLC) levels was required in place of the Mpr criteria. If serum, urine Mpr, and serum FLC assay were unmeasurable, ≥50% reduction in plasma cells was required in place of Mpr, provided baseline bone marrow plasma cell percentage was ≥30%; a ≥50% reduction in the size of soft tissue plasmacytomas was also required. (NCT00560391)
Timeframe: Baseline, at the end of the treatment period (median duration of dasatinib treatment=5.2 months [range 0 to 33 months]).

Interventionparticipants (Number)
Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg1
Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg1
Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg2
Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg4
Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg3

[back to top]

Number of Participants With Dose-limiting Toxicity (DLT)

DLTs: At least possibly drug-related AEs occurring during the first cycle of treatment and are:GR4 neutropenia >5 days/neutropenic fever;platelet count <10000mm^3 on >1 occasion;GR4 fatigue,or 2-point decline in ECOG performance status;>=GR3 nausea,diarrhea,and vomiting despite medical intervention;Any other clinically significant non-hematologic toxicity of >=GR3 considered not related to underlying MM;Any GR3/4 laboratory abnormality requiring hospitalization;dose interruption of either dasatinib and/or lenalidomide for >15 days due to any toxicity related to treatment with the combination. (NCT00560391)
Timeframe: From the date of first dose until at least 30 days after the last dose of study drug (median duration of dasatinib treatment=5.2 months [range 0 to 33 months]).

Interventionparticipants (Number)
Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg1
Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg0
Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg0
Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg1
Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg0

[back to top]

Number of Participants in the Dose Escalation Phase Who Reached Maximum Tolerated Dose (MTD) of Dasatinib With Lenalidomide and Dexamethasone

The MTD is considered the last dose level combination tested just below the maximum administered dose (MAD) level combination and for which DLTs were observed in less than 33% of participants during the escalation and expansion phase. Please refer to outcome 2 for the complete definition of DLT. If the MTD was not reached at the highest dose administered as defined by protocol, the highest dose (dasatinib 140 mg QD + lenalidomide 25 mg QD) administered was selected for the dose expansion phase of the study. (NCT00560391)
Timeframe: From the date of first dose to end of treatment (median duration of dasatinib treatment=5.2 months [range 0 to 33 months]).

Interventionparticipants (Number)
Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg0
Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg0
Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg0
Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg0
Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg0

[back to top]

Number of Participants With Serum Chemistry Abnormalities (Worst On-study Grade vs Baseline): Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Total Bilirubin (TB), and Serum Creatinine (SC)

Grading as per NCI CTCAE Version 3.0 criteria. GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Aspartate aminotransferase (AST) and alanine aminotransferase(ALT): GR1=>ULN-2.5*ULN (upper limit of normal); GR2=>2.5-5.0*ULN; GR3=>5.0-20.0*ULN; GR4:>20.0*ULN; TB:GR1=>ULN-1.5*ULN, GR2=>1.5-3.0*ULN, GR3=>3-10*ULN, GR4=>10*ULN; SC: GR1=>ULN-1.5*ULN, GR2=>1.5-3.0*ULN, GR3=>3.0-6.0*ULN, GR4=>6.0*ULN. BL=Baseline; PBL=post baseline. (NCT00560391)
Timeframe: Baseline (pretreatment); Cycles 1 and 2 (within 24 hours of Days 1, 4, 8, 11, 15, 18, 21, and 25); beyond Cycle 2 (within 24 hours of Days 1 and 15,off treatment visit ) (median duration of dasatinib treatment=5.2 mo [range 0 to 33 mo])

,,,,
Interventionparticipants (Number)
AST; GR 0 at BL, GR 0 PBLAST; GR 0 at BL, GR 1 to 2 PBLAST; GR 0 at BL, GR 3 to 4 PBLAST; GR 1 to 2 at BL, GR 0 PBLAST; GR 1 to 2 at BL, GR 1 to 2 PBLAST; GR 1 to 2 at BL, GR 3 to 4 PBLHigh ALT; GR 0 at BL, GR 0 PBLALT; GR 0 at BL, GR 1 to 2 PBLALT; GR 0 at BL, GR 3 to 4 PBLALT; GR 1 to 2 at BL, GR 0 PBLALT; GR 1 to 2 at BL, GR 1 to 2 PBLALT; GR 1 to 2 at BL, GR 3 to 4 PBLTotal Bilirubin; GR 0 at BL, GR 0 PBLTotal Bilirubin; GR 0 at BL, GR 1 to 2 PBLTotal Bilirubin; GR 0 at BL, GR 3 to 4 PBLSC; GR 0 at BL, GR 0 PBLSC; GR 0 at BL, GR 1 to 2 PBLSC; GR 0 at BL, GR 3 to 4 PBLSC; GR 1 to 2 at BL, GR 0 PBLSC; GR 1 to 2 at BL, GR 1 to 2 PBLSC; GR 1 to 2 at BL, GR 3 to 4 PBL
Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg200010101010210120000
Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg500010230010420600000
Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg58003159002113401231001
Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg420000240000510420000
Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg020010101010110110010

[back to top]

Progression-free Survival

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT00563290)
Timeframe: Time from start of treatment to time of progression, assessed up to 12 weeks

Interventionweeks (Median)
Arm I and Arm II4

[back to top]

Objective Response Rate (Complete Response and Partial Response)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00563290)
Timeframe: Every 2 courses during treatment, assessed up to 12 weeks after completion of treatment

Interventionpercentage of patients (Number)
Arm I: Dasatinib0
Arm II: Dasatinib0

[back to top]

Phase I - Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) for Dasatinib in Combination With Zoledronic Acid

To determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for dasatinib in combination with zoledronic acid. (NCT00566618)
Timeframe: day 1 (+/- 48 hours) prior to therapy during cycle 2 and all subsequent cycles

Interventionmg (Number)
Dasatinibzoledronic acid
Phase I1004

[back to top]

Objective Response in Bone From Time of Initiation of Therapy to > 6 Months

Objective response rate is defined as the clinical benefit rate (complete and partial response) + stable disease > 6 months in bone. (NCT00566618)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Central ReviewSite Review
Phase I/Phase II87

[back to top]

Determine the Overall Objective Response

To determine the overall response rate in patients with acquired erlotinib hydrochloride- or gefitinibresistant advanced adenocarcinoma of the lung treated with dasatinib using the RECIST criteria. Response and progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.22 Changes in only the largest diameter (uni-dimensional measurement) of the tumor lesions are used in the RECIST. (NCT00570401)
Timeframe: 2 years

Interventionparticipants (Number)
Stable Disease (SD)Progression of Disease (POD)
Dasatinib613

[back to top]

Number of Subjects With Dasatinib Toxicity Using Common Terminology Criteria (CTC) (v. 3.0)

Due to relatively poor drug tolerance and relatively rapid PSA increases in most patients it was not feasible to continue patients on treatment until there was radiographic evidence of disease progression. (NCT00570700)
Timeframe: From initial date of treatment through study completion, up to 2 years

InterventionParticipants (Count of Participants)
Dasatinib12

[back to top]

Number of Subjects With Disease Control (DC) (Based on PSA, Bone Scan, FACT-P, RECIST)

"A positive effect will be defined as a complete response, partial response, or stable disease. Lack of positive effect will be defined as progressive disease. Subjects with a mixed response should be continued on therapy until they either fulfill the criteria for positive effect or lack of positive effect, with evaluation every 56 days.~The disease control (DC) rate was evaluated as a composite endpoint of the treatment effect on four parameters: 1) Prostate-specific antigen (PSA), 2) measurable disease (if present) by RECIST criteria, 3) bone scan, and 4) quality-of-life as measured by the FACT-P questionnaire." (NCT00570700)
Timeframe: From day 56 (8 weeks) and every 8 weeks thereafter until the date of first documented progression or date of death from any cause, whichever came first, assessed until death, the patient withdraws consent, or the study ends, up to 2 years

InterventionParticipants (Count of Participants)
Dasatinib5

[back to top] [back to top]

Number of Participants With 12 Month Overall Survival (OS)

Phase II - To determine Overall Survival of patients treated with the combination of dasatinib and DTIC at 12 months. (NCT00597038)
Timeframe: 12 Months

Interventionparticipants (Number)
Phase I Dose Escalation9
Phase II Dose Treatment8

[back to top]

Number of Participants With Progression Free Survival (PFS) at 6 Months

Phase II - PFS Rate in patients receiving dasatinib 70 mg orally (PO) twice a day (BID). Tumor assessments were made at baseline and at the end of every second cycle (i.e. every 6 weeks). Partial and complete responses were defined by the best treatment response achieved. Stable disease was defined as maintenance of the sum of lesions diameters between a 30% reduction and a 20% increase of overall tumour size over 12 weeks or longer. (NCT00597038)
Timeframe: 6 Months

Interventionparticipants (Number)
Phase II Dose Treatment6

[back to top]

Phase II - Number of Participants With Overall Response (OR)

Phase II - To determine the overall response rate (ORR) of the combination of dasatinib and DTIC by the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). Tumor assessments were made at baseline and at the end of every second cycle (i.e. every 6 weeks). Partial and complete responses were defined by the best treatment response achieved. (NCT00597038)
Timeframe: 1 Year 6 Months

Interventionparticipants (Number)
Phase II Dose Treatment4

[back to top]

Number of Participants With Stable Disease (SD)

(NCT00624585)
Timeframe: 1 Year 4 Months

Interventionparticipants (Number)
Dasatinib Dose Escalation10

[back to top]

Number of Participants With Hematologic Improvement

Hematologic improvement in platelets, red blood cell (RBC), neutrophils according to modified IWG Criteria; Cytogenetic response (modified IWG); Change in percentage of blasts in bone marrow and peripheral blood; Src-Tyr416 phosphorylation in medullary myeloblasts. Hematologic improvements must last ≥ 8 weeks. (NCT00624585)
Timeframe: 1 Year 4 Months

Interventionparticipants (Number)
Dasatinib Dose Escalation0

[back to top]

Number of Participants With Marrow Complete Remission (CR)

"Complete remission (modified IWG); IWG = International MDS Working Group.~Bone Marrow Response must last ≥4 weeks. Bone marrow evaluation: Bone marrow showing ≤5% myeloblasts with normal maturation of all cell lines." (NCT00624585)
Timeframe: 1 Year 4 Months

Interventionparticipants (Number)
Dasatinib Dose Escalation3

[back to top]

Number of Participants With Partial Remission (PR)

Partial remission (PR) (modified IWG); IWG = International MDS Working Group. All of the CR criteria (if abnormal prior to treatment), except: Bone marrow evaluation: Blasts decreased by ≥ 50% over pretreatment but still >5%. Cellularity and morphology are not relevant. (NCT00624585)
Timeframe: 1 Year 4 Months

Interventionparticipants (Number)
Dasatinib Dose Escalation0

[back to top]

Dasatinib PK Parameter: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-T])

area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])for dasatinib (NCT00655746)
Timeframe: Day 1 and Day 6 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose

Interventionng∙h/mL (Geometric Mean)
Dasatinib (Day 1)249.46
Dasatinib + Omeprazole (Day 6)137.49

[back to top]

Dasatinib PK Parameter: Plasma Half-Life (T-HALF)

Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. T-Half=plasma half-life (NCT00655746)
Timeframe: Day 1 and Day 6 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose

Interventionhours (Mean)
Dasatinib (Day 1)4.00
Dasatinib + Omeprazole (Day 6)4.29

[back to top]

Dasatinib PK Parameters: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF])

Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. AUC(INF)=area under the plasma concentration-time curve from time zero extrapolated to infinite time (NCT00655746)
Timeframe: Day 1 and Day 6 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose

Interventionng∙h/mL (Geometric Mean)
Dasatinib (Day 1)265.40
Dasatinib + Omeprazole (Day 6)152.84

[back to top]

Dasatinib PK Parameter Time of Maximum Observed Plasma Concentration(Tmax)

Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Tmax=time of maximum observed plasma concentration (NCT00655746)
Timeframe: Day 1 and Day 6 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose

Interventionhours (Median)
Dasatinib (Day 1)0.75
Dasatinib + Omeprazole (Day 6)1.00

[back to top]

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations

An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. (NCT00655746)
Timeframe: At Informed Consent (within 21 days of Day 1) through Study Discharge (Day 7)

,,,
InterventionParticipants (Number)
Number of Participants with ≥1 AEDeathSAEDiscontinuation due to AEs
All Participants4000
Dasatinib (Day 1)3000
Dasatinib + Omeprazole (Day 6)2000
Omeprazole (Days 2-5)2000

[back to top]

Dasatinib Pharmacokinetic (PK) Parameter: Maximum Observed Plasma Concentration (Cmax)

Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmax=maximum observed plasma concentration of dasatinib (NCT00655746)
Timeframe: Day 1 and Day 6 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose

Interventionng/mL (Geometric Mean)
Dasatinib (Day 1)65.58
Dasatinib + Omeprazole (Day 6)38.64

[back to top]

Overall Survival

(NCT00671788)
Timeframe: Every other cycle up to 5 years

Interventionmonths (Median)
Dasatinib18.4

[back to top]

Progression-free Survival

"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since study entry, or unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.~CT scan or MRI is used to follow lesion for measurable disease every other cycle for the first 6 months; every three months thereafter; and at any time if clinically indicated based on symptoms or physical signs suggestive of progressive disease or rising serum tumor marker levels. Responses must be confirmed by repeat imaging 4 weeks following documentation of response." (NCT00671788)
Timeframe: Every other cycle for the first 6 months; every three months thereafter; and any time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.

Interventionmonths (Median)
Dasatinib2.1

[back to top]

Progression-free Survival at 6 Months

"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since study entry, or unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.~CT scan or MRI is used to follow lesion for measurable disease every other cycle for the first 6 months; every three months thereafter; and at any time if clinically indicated based on symptoms or physical signs suggestive of progressive disease or rising serum tumor marker levels. Responses must be confirmed by repeat imaging 4 weeks following documentation of response." (NCT00671788)
Timeframe: Scans to assess progression were done every other cycle for the first 6 months; every three months thereafter; and any time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.

Interventionpercentage of participants (Number)
Dasatinib20.6

[back to top]

Tumor Response

"Complete and Partial Tumor Response by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Per RECIST v1.0 for target lesions and assessed by MRIor CT scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD.~CT scan or MRI is used to follow lesion for measurable disease every other cycle for the first 6 months; every three months thereafter; and at any time if clinically indicated based on symptoms or physical signs suggestive of progressive disease or rising serum tumor marker levels. Responses must be confirmed by repeat imaging 4 weeks following documentation of response." (NCT00671788)
Timeframe: Every other cycle for the first 6 months; every three months thereafter; and any time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.

Interventionpercentage of participants (Number)
Dasatinib0

[back to top]

Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population

CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than, equal to 6 months. CR= Disappearance of all target lesions. No new lesions. PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started. Physical examination,radiological assessment, and bone scans (if applicable) were used to assess outcome. (NCT00696072)
Timeframe: First dose of study drug to last dose plus 7 days, up to study completion (approximately 6 years)

,
Interventionparticipants (Number)
CBR (CR+PR+SD)CBR, DFI <= 2 YearsCBR, DFI > 2 Years
Dasatinib Plus Letrozole402020
Letrozole402020

[back to top]

Number of Participants With Adverse Events (AEs) Leading to Discontinuation, Serious Adverse Events (SAEs), and Deaths

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00696072)
Timeframe: First dose of study drug to last dose plus 30 days, up to study completion (approximately 6 years)

,
Interventionparticipants (Number)
DeathsSAEsAEs Leading to Discontinuation
Dasatinib Plus Letrozole111410
Letrozole1626

[back to top]

Percentage of Participants With PFS At 6 Months and At 12 Months - ITT Population

Progression=At least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. ITT population: from time of first enrollment to first PD for all ITT participants. (NCT00696072)
Timeframe: At 6 months and at 12 months

,
Interventionpercentage of participants (Number)
6 Month (n=39, 39)12 Month (n=29, 20)
Dasatinib Plus Letrozole77.264.6
Letrozole66.242.9

[back to top]

Median Progression Free Survival (PFS) - Intent to Treat (ITT) Population

PFS was measured in months. Progression=At least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Study initiated 2008 and completed 2014. (NCT00696072)
Timeframe: Day 1 to Study Completion (approximately 6 years)

Interventionmonths (Median)
Dasatinib Plus Letrozole20.1
Letrozole9.9

[back to top]

Number of Participants With Complete Response, Partial Response, Stable Disease, and Disease Progression

CR= Disappearance of all target lesions. No new lesions. PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started. Progression (PD): At least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00696072)
Timeframe: First dose of study drug to last dose plus 7 days, up to study completion (approximately 6 years)

,
Interventionparticipants (Number)
CRPRSDSD >=6 monthsPDNot Evaluable
Dasatinib Plus Letrozole112322774
Letrozole0153025160

[back to top]

Percentage of Participants Best Overall Response After Change From Letrozole to Letrozole Plus Dasatinib

Participants in single-agent letrozole treatment arm who developed progressive disease, could continue letrozole, and add dasatinib to their treatment regimen. CBR=participants with CR + participants with partial response (PR) + participants with SD for a length of time ≥6 months divided by the total number of participants (%). CR= Disappearance of all target lesions. No new lesions. PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started. PD=At least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00696072)
Timeframe: First dose of study drug to last dose plus 7 days, up to study completion (approximately 6 years)

Interventionpercentage of participants (Number)
Best Response of SDBest Response of SD ≥6 monthsBest Response of CBRBest Response of PDBest Response Not AvailableBest Response Not EvaluableBest Response Pending
Crossed Over From Letrozole to Letrozole + Dasatinib34.322.922.920.02.92.940.0

[back to top]

Median Time to Treatment Failure (TTF) - ITT Population

Time to TTF was measured in months. The number of participants with events (PD or off treatment due to any reason) was evaluated. The first PD was defined as the event for cross over participants in the single- agent letrozole treatment arm to add dasatinib to their regimen. (NCT00696072)
Timeframe: First dose of study drug to last dose plus 7 days, up to study completion (approximately 6 years)

InterventionMonths (Median)
Dasatinib Plus Letrozole10.2
Letrozole9.2

[back to top]

Progression-free Survival

Progression-free survival is defined as the time from registration to development of progressive disease. Patients without documented progressive disease are censored at the date of last disease assessment. Progressive disease is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s). (NCT00700882)
Timeframe: Every 6 weeks; up to 5 years

Interventionmonths (Median)
Dasatinib2.1

[back to top]

Objective Response Rate Among KIT-positive Patients

Objective response is defined as complete response (CR) or partial response (PR) per Solid Tumor Response Criteria (RECIST). Complete response is defined as disappearance of all target and non-target lesions. Partial response is defined as at least 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter. (NCT00700882)
Timeframe: Every 6 weeks; up to 5 years

Interventionproportion of participants (Number)
Dasatinib0.182

[back to top]

Duration of Response for Dasatinib Monotherapy in This Patient Population

Duration of response is defined as the period measured from the time that measurement criteria are met for complete or partial response (whichever status is recorded first) until the first date that progressive disease is objectively documented, taking as reference the smallest measurements recorded since treatment started. Progressive disease is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s). (NCT00700882)
Timeframe: Every 6 weeks; up to 5 years

Interventionmonths (Median)
Dasatinib4.2

[back to top]

Reduced Ki-67 Expression

Ki-67 levels were analyzed pre and post treatment (NCT00706641)
Timeframe: Baseline to post dasatinib therapy

Interventionparticipants (Number)
Experimental: Neoadjuvant Dasatinib + Radical Cystectomy4

[back to top]

Pathologic Complete Response (pCR) Rate

Pathologic complete response (pCR) rate is defined as no residual evidence of muscle-invasive disease at cystectomy (< pT0). (NCT00706641)
Timeframe: 24 months

Interventionparticipants (Number)
Experimental: Neoadjuvant Dasatinib + Radical Cystectomy0

[back to top]

Increase in Cas3 Expression

Cas3 levels were analyzed pre and post treatment (NCT00706641)
Timeframe: Baseline to post dasatinib therapy

Interventionparticipants (Number)
Experimental: Neoadjuvant Dasatinib + Radical Cystectomy3

[back to top]

Feasibility

Feasibility for this trial is defined as at least 60% (>=14 of 23) of patients completing study therapy in the absence of Dose Limiting Toxicity (DLT) (NCT00706641)
Timeframe: From enrollment to completion of radical cystectomy

Interventionparticipants (Number)
DLTAbsence of DLT
Experimental: Neoadjuvant Dasatinib + Radical Cystectomy815

[back to top]

Grade 3/4 Toxicities

Report grade 3/4 toxicities during treatment with dasatinib prior to radical cystectomy in patients with muscle invasive transitional cell carcinoma of the bladder. (NCT00706641)
Timeframe: Time of consent through 30 days after treatment discontinuation

Interventionpercentage of particpants (Number)
AnemiaFatigueDiarrheaNauseaAnorexiaAbdominal PainDyspneaHematuriaSuperventricular and Nodal ArrythmiaEnteric FistulaDeep Vein Thrombosis Pulmonary Embolism
Experimental: Neoadjuvant Dasatinib + Radical Cystectomy48444484488

[back to top]

Post-Cystectomy Pathologic Stage

Tumor Node Metastasis (TNM) Staging. This system classifies tumors by size and extent of the primary tumor (T), involvement of regional lymph nodes (N), and the presence or absence of distant metastases (M) T0=No evidence of primary tumor, Tis=Carcinoma in situ, and T1, T2, T3, T4=Increasing size and/or local extension of the primary tumor, TX=Not assessed N0=No Regional lymph node metastases, N1, N2, N3=Increasing number or extent of regional lymph node involvement, NX=not assessed M0=No distant metastases, M1=Distant metastases present (NCT00706641)
Timeframe: Staged Post-Cystectomy and dasatinib treatment

Interventionpercentage of particpants (Number)
T1TisT2T3T4Unresectable
Experimental: Neoadjuvant Dasatinib + Radical Cystectomy23274195

[back to top]

Reduced pSFK Expression

pSFK levels were analyzed pre and post treatment (NCT00706641)
Timeframe: Baseline to post dasatinib therapy

Interventionparticipants (Number)
Experimental: Neoadjuvant Dasatinib + Radical Cystectomy16

[back to top]

Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy

Percent of patients MRD Positive (MRD > 0.01%) at End of Induction. (NCT00720109)
Timeframe: At the end of induction therapy (at 5 weeks)

InterventionPercentage of participants (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)40.7
Standard-risk29.2
High-risk100.0

[back to top]

Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy

Event-Free Survival (EFS) curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed. (NCT00720109)
Timeframe: At 3 years

InterventionPercent probability (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)79.8
Standard-risk83.2
High-risk66.7

[back to top]

Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation

A 1-sample Z-test of proportions (alpha=5%, 1-sided test) will be used. (NCT00720109)
Timeframe: At end of consolidation (at 11 weeks)

InterventionPercentage of participants (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)10.5
Standard-risk0
High-risk66.7

[back to top]

Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)

An event is defined as: Induction failure, relapse at any site, secondary malignancy, or death. (NCT00720109)
Timeframe: From the time entry on study to first event or date of last follow-up, assessed up to 7 years

Interventionpercentage of patients (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)79.8
Standard-risk83.2
High-risk66.7

[back to top]

Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events

Number of patients in safety cohort with dose limiting toxicity (DLT)(including treatment delay) (NCT00720109)
Timeframe: Weeks 3 through 23 of treatment (From week 3 Induction through Intensification Block 1)

InterventionPts with DLTs (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)1

[back to top]

Overall Survival: Time From Randomization to Date of Death

Overall survival is defined as time in months from the randomization date to the date of death due to any cause (in the randomized population). If the patient did not die, survival was censored on the last date he or she was known to be alive. (NCT00744497)
Timeframe: From randomization to death or date of last contact (maximum reached: 45 months)

InterventionMonths (Median)
Placebo21.2
Dasatinib21.5

[back to top] [back to top] [back to top]

Number of Participants With Changes From Baseline in Fridericia-corrected QTc Interval

QTc interval measured by electrocardiogram (ECG). Although a participant may have had several ECGs, only the longest QTc interval was included. (NCT00744497)
Timeframe: At baseline, approximately 12 weeks after starting treatment, and then whenever clinically indicated up to within 30 days of end of dosing

,
InterventionParticipants (Number)
0 to 30 msecs increase (n=591, 540)>30 to 60 msecs increase (n=591, 540)>60 msecs increase (n=591, 540)Decrease (n=591, 540)
Dasatinib1994726268
Placebo2035232304

[back to top]

Number of Participants With and Without Pericardial Effusion at Baseline and On-study and With Left Ventricular Ejection Fraction (LVEF) <40% and >=40% On-study

BL=baseline; OS=on-study (NCT00744497)
Timeframe: At baseline, approximately 12 weeks after start of treatment, and thereafter whenever clinically indicated

,
InterventionParticipants (Number)
Pericardial effusion at BL/absent OSPericardial effusion at BL/present OSPericardial effusion at BL/not reported OSPericardial effusion absent at BL/ absent OSPericardial effusion absent at BL/present OSPericardial effusion absent at BL/not reported OSPericardial not reported at BLLVEF OS <40%LVEF OS >=40%LVEF not reported OS
Dasatinib1105452618452566194
Placebo30158424132162607151

[back to top]

Number of Participants With Abnormalities in Results of Clinical Laboratory Tests in Hematology

Abnormalities were graded according to the Common Toxicity Criteria (CTC), version 3.0, of the National Cancer Institute. CTC are graded from 1 (least severe) to 4 (life threatening ). Grade 3 and 4 criteria are defined as follows: Absolute neutrophil count, Grade 3, neutrophils <1.0-0.5*10^9/L; Grade 4, <0.5*10^9/L. Hemoglobin, Grade 3, <4.9-4.0 mmol/L; Grade 4, <4.0 mmol/L. Platelets, Grade 3, <50.0-25.0*10^9/L; Grade 4, <25.0*10^9/L. Leukocytes, Grade 3, <2.0-1.0*10^9/L; Grade 4, <1.0*10^9/L. (NCT00744497)
Timeframe: At baseline, within 3 days prior to each infusion of docetaxel (each cycle) and at end of treatment. If docetaxel is discontinued, every other cycle.

,
InterventionParticipants (Number)
Absolute neutrophil count (All grades)Absolute neutrophil count (Grades 3 and 4)Hemoglobin (All grades)Hemoglobin (Grades 3 and 4)Platelets (All grades)Platelets (Grades 3 and 4)Leukocytes (All grades)Leukocytes (Grades 3 and 4)
Dasatinib1614672059100314930
Placebo844171244108612832

[back to top]

Number of Participants With Abnormalities in Results of Clinical Laboratory Tests Assessing Liver Function, Renal Function, and Electrolytes

ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal. Abnormalities were graded according to the Common Toxicity Criteria (CTC), version 3.0, of the National Cancer Institute. CTC are graded from 1 (least severe) to 4 (life threatening). ALP, ALT, and AST, Grade 3, >5.0-20.0*ULN; Grade 4, >20.0*ULN. Total bilirubin, Grade 3, >3.0-10.0*ULN; Grade 4, >10.0*ULN. Creatinine, Grade 3, >3.0-6.0*ULN; Grade 4, >6.0*ULN. Hypercalcemia(serum calcium, mmol/L), Grade 3, >3.1-3.4; Grade 4, >3.4. Hypocalcemia (serum calcium, mmol/L), Grade 3, <1.75-1.5; Grade 4, <1.5. Hyperkalemia(serum calcium, mmol/L), Grade 3, >6.0-7.0; Grade 4, >7.0. Hypokalemia(serum calcium, mmol/L), Grade 3, <3.0-2.5; Grade 4, <2.5. Hypernatremia (serum calcium, mmol/L), Grade 3, >155-160; Grade 4, >160. Hyponatremia (serum sodium, mmol/L), Grade 3, <130-120; Grade 4, <120. Phosphorus (serum sodium, mmol/L), Grade 3, <0.6-0.3; Grade 4, <0.3. (NCT00744497)
Timeframe: At baseline, within 3 days prior to each infusion of docetaxel (each cycle), to end of treatment. If docetaxel is discontinued, every other cycle.

,
InterventionParticipants (Number)
ALP (All grades)ALP (Grades 3 and 4)ALT (All grades)ALT (Grades 3 and 4)AST (All grades)AST (Grades 3 and 4)Total bilirubin (All grades)Total bilirubin (Grades 3 and 4)Creatinine (All grades)Creatinine (Grades 3 and 4)Hypercalcemia (All grades)Hypercalcemia (Grades 3 and 4)Hypocalcemia (All grades)Hypocalcemia (Grades 3 and 4)Hyperkalemia (All grades)Hyperkalemia (Grades 3 and 4)Hypokalemia (All grades)Hypokalemia (Grades 3 and 4)Hypernatremia (All grades)Hypernatremia (Grades 3 and 4)Hyponatremia (All grades)Hyponatremia (Grades 3 and 4)Phosporus (All grades)Phosphorus (Grades 3 and 4)
Dasatinib3756825662665413184534137725152141521610102414325793
Placebo44791186521244911533561308231641110769302303618943

[back to top]

Percentage of Participants With a Reduction in Pain Intensity From Baseline

The percentage of participants with a reduction in pain intensity from baseline was defined as the number of participants who achieved a 30% or more decrease in pain intensity from baseline for at least 2 consecutive pain assessments (at least 14 days apart) within 14 days of end of dosing divided by the number of randomized participants who had a baseline pain intensity of at least 2. Pain intensity was assessed based on question 3 of the brief pain inventory questionnaire. (NCT00744497)
Timeframe: At baseline, prior to each docetaxel infusion (every 3 weeks), at end of treatment, and at follow-up (within 14 days of end of dosing)

InterventionPercentage of participants (Number)
Placebo71.52
Dasatinib66.59

[back to top]

Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST)

Objective tumor response rate=the percentage of randomized participants with a best tumor response of partial (PR) or complete response (CR), within 42 days of end of dosing, divided by total number of patients who were evaluable (with at least 1 target lesion at baseline). By RECIST: CR=disappearance of clinical and radiologic evidence of target and nontarget lesions confirmed by another evaluation at least 6 weeks later. PR=a >30% or greater decrease in the sum of longest diameter (LD) of target lesions in reference to the baseline sum LD confirmed by another evaluation at least 6 weeks later. Stable disease=neither sufficient increase to qualify for PD nor shrinkage to qualify for PR, and at least 8 weeks since start of study therapy. Progressive disease=a 20% or greater increase in sum of LD of all target lesions, taking as reference the smallest sum of LD at or following baseline, or unequivocal progression on existing nontarget lesions, or new lesions are present. (NCT00744497)
Timeframe: At baseline and every 12 weeks thereafter to end of treatment, at end of treatment, and at follow-up (within 42 days of end of dosing)

InterventionPercentage of participants (Number)
Placebo31.85
Dasatinib30.45

[back to top]

Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline

The percentage of participants who had an on-study uNTx value confirmed (at least 3 weeks later) within normal limits (or ≥3 and <60 nmol/mmol creatinine, if normal limits were missing) or an on-study uNTx level reduction from baseline of ≥35%, even when on-study uNTx value remained abnormal. (NCT00744497)
Timeframe: At baseline, prior to each docetaxel infusion (every 3 weeks) to end of treatment, at end of treatment, and at follow-up (within 14 days of end of dosing)

InterventionPercentage of participants (Number)
Placebo60.60
Dasatinib66.04

[back to top]

Progression-free Survival (PFS)

PFS is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Those who progressed or died while on subsequent cancer therapy and those who did not die or progress were censored at their last radiologic bone scan/imaging, skeletal related-event, or tumor assessment or at measurement of prostate specific antigen levels, whichever occurred last prior to start of subsequent cancer therapy ,if any. Participants with no assessments were censored on the day of randomization. (NCT00744497)
Timeframe: From day of randomization to disease progression or death (or to last clinical assessment, if subsequent cancer therapy started or no progression or death) (maximum reached: approximately 43 months)

InterventionMonths (Median)
Placebo11.1
Dasatinib11.8

[back to top] [back to top]

Time to Prostate Specific Antigen (PSA) Progression

PSA progression is defined as the time from randomization to the date of the first PSA level measurement that led to confirmed PSA progression, for participants who had not started subsequent cancer therapy. For participants who did not progress or who progressed on cancer therapy, PSA progression is defined as the time from randomization to the date of the last PSA level measurement before the start of cancer therapy, if any. Participants who had no on-study PSA level measurements were censored on the day they were randomized. (NCT00744497)
Timeframe: From randomization to date of first PSA measurement leading to confirmed PSA progression (or to last bone scan assessment, if no progression or if cancer therapy started) (maximum reached: 30 months)

InterventionMonths (Median)
Placebo6.9
Dasatinib7.2

[back to top]

Number of Participants by Maximal On-study Fridericia-corrected QTc Interval

QTc interval measured by electrocardiogram (ECG). Although a participant may have had several ECGs, only the longest QTc interval was included. (NCT00744497)
Timeframe: At baseline, approximately 12 weeks after starting treatment, and then whenever clinically indicated up to within 30 days of end of dosing

,
InterventionParticipants (Number)
<450 msecs (n=600, 548)450-500 msecs (n=600, 548)>500 msecs (n=600, 548)
Dasatinib497483
Placebo550437

[back to top]

Number of Participants With Abnormal Results in Urinalysis

Abnormal=positive, defined as the presence of >=30 mg/dL of protein; a small, moderate, or large amount of blood; or >0 g/dL glucose in urine. BL=baseline; neg=negative (NCT00744497)
Timeframe: At baseline, within 3 days prior to each infusion of docetaxel (each cycle), to end of treatment. If docetaxel is discontinued, every other cycle.

,
InterventionParticipants (Number)
Protein, urine: postiveBlood, urine: positiveGlucose, urine: positive
Dasatinib336307154
Placebo246289179

[back to top]

Median Time of Progression-free Survival (PFS)

Progression free survival (PFS) was defined as the time in months from randomization to either the date the subject was first recorded as having PD (even if the subject went off treatment because of toxicity), or the date of death if the subject died due to any causes before progression. Progression=At least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00754325)
Timeframe: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years)

Interventionmonths (Median)
Fulvestrant and Dasatinib5.6
Fulvestrant5.3

[back to top]

Percentage of Participants With Clinical Benefit for At Least 6 Months

Clinical benefit rate (CBR) was defined as the percentage of participants that had Stable Disease (SD), complete response (CR), or partial response (PR) for greater than or equal to 6 months if there was no evidence of progression at or before assessment performed on or after Study Day 161. CR= Disappearance of all target lesions. No new lesions. PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started. Physical examination, radiological assessment, and bone scans (if applicable) were used to assess outcome. (NCT00754325)
Timeframe: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years)

Interventionpercentage of participants (Number)
Fulvestrant and Dasatinib38.0
Fulvestrant42.9

[back to top]

Number of Participants With Disease Progression (PD) or Death

This endpoint evaluated the progression free survival (PFS) of participants amongst the total evaluable population. Progression free survival (PFS) was defined as the time from randomization to either the date the subject was first recorded as having PD (even if the subject went off treatment because of toxicity), or the date of death if the subject died due to any causes before progression. Participants with no recorded post-baseline tumor assessment had PFS censored at the day of randomization. Participants lost to follow-up were censored at the last date of contact. Participants that had not progressed or died had PFS censored at the date of last follow-up. (NCT00754325)
Timeframe: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years)

Interventionparticipants (Number)
Fulvestrant and Dasatinib35
Fulvestrant40

[back to top]

Number of Participants With Best Overall Response

Best overall response rate (ORR) = number of participants with measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) having a best response of complete response (CR) or partial response (PR) divided by number of randomized participants. RECIST 1.1 response criteria applies. To be recorded as best response, CR or PR had to be confirmed at ≥ 4 weeks interval. An unconfirmed CR was recorded as PR. (NCT00754325)
Timeframe: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years)

Interventionparticipants (Number)
Fulvestrant and Dasatinib1
Fulvestrant2

[back to top]

Number of Participants With Serious Adverse Events, Death, and Discontinuation Due to Adverse Events

Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00754325)
Timeframe: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years)

,
Interventionparticipants (Number)
Serious Adverse EventsDeathsDiscontinued due to AEs
Fulvestrant11166
Fulvestrant and Dasatinib14157

[back to top]

Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD)

Table represents the best response achieved over this time frame. CR = Disappearance of all target lesions. No new lesions. PR = At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started. Progression (PD): At least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00754325)
Timeframe: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years)

,
Interventionparticipants (Number)
Complete Response, CRPartial Response, PRStable Disease, SDDisease Progression, PDNot Evaluable
Fulvestrant0328162
Fulvestrant and Dasatinib0134114

[back to top]

Percentage of Participants With Progression Free Survival (PFS) at 6 Months

PFS rate was defined as the percentage of participants experiencing no disease progression or death from any cause at 6 months after randomization. Progression free survival (PFS) was defined as the time from randomization to either the date the subject was first recorded as having PD (even if the subject went off treatment because of toxicity), or the date of death if the subject died due to any causes before progression. Progression=At least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Kaplan Meier assessments were used to estimate the percentages. (NCT00754325)
Timeframe: at 6 months

Interventionpercentage of participants (Number)
Fulvestrant and Dasatinib48.1
Fulvestrant44.6

[back to top]

Reasons for Discontinuation of Study Treatment

"Participants who discontinued the study due to any AEs were recorded.~Significant drug-related discontinuations were those SAEs recorded on the SAE case report forms with relationship to study drug of related or missing and action taken regarding study drug of discontinued or missing." (NCT00764309)
Timeframe: From start of study drug therapy up to 30 days after the last dose. The duration of dasatinib dosing in this study was up to 2 years

InterventionParticipants (Number)
AEsSAEsDrug-Related AEsDrug-Related SAEsSignificant Drug-Related Pericardial EffusionSignificant Drug-Related Pleural EffusionSignificant Drug-Related Bone Marrow SuppressionSignificant Worsening of Underlying SclerodermaUnforeseen toxicity of dasatinibSignificant Drug-Related Peripheral Edema
100 mg Dasatinib, Oral Administration13483020000

[back to top]

Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), or Adverse Events (AEs)

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. (NCT00764309)
Timeframe: From start of study drug therapy up to 30 days after the last dose. The duration of dasatinib dosing in this study was up to 2 years

InterventionParticipants (Number)
DeathsAEsSAEsDrug-Related DeathDrug-Related AEsDrug-Related SAEs
100 mg Dasatinib, Oral Administration03170245

[back to top]

Laboratory Test Results Summary of Toxicity: Hematology

Toxicity was graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0. (Grade (GR)0=normal, GR1=mild, GR2=moderate, GR3=severe, GR4=life threatening). Granulocyte count (x 10^9 /L), GR1: ≥1.0 - <1.5, GR2: ≥0.5 - <1.0; Hemoglobin (g/dL), GR0: 13-17, GR1: <13 - 10.0 , GR2: 8.0 - <10.0, GR3: 6.5 - <8.0; Platelet count (x 10^9 /L) GR0: 150-400, GR2: ≥50.0 - <75.0; Leukocyte count (x 10^9 /L ), GR0: 3.5-11.1, GR2: 2.0 - <3.0. (NCT00764309)
Timeframe: From start of study drug therapy up to 30 days after the last dose. The duration of dasatinib dosing in this study was up to 2 years

Interventionparticipants (Number)
Granulocyte count, GR0Granulocyte count, GR1Granulocyte count, GR2Granulocyte count, GR not reportedHemoglobin, GR0Hemoglobin, GR1Hemoglobin, GR2Hemoglobin, GR3Hemoglobin, GR not reportedPlatelet count, GR0Platelet count, GR2Platelet count, GR not reportedLeukocyte count, GR0Leukocyte count, GR2Leukocyte count, GR not reported
100 mg Dasatinib, Oral Administration2811141781129112911

[back to top]

Laboratory Test Results Summary of Toxicity: Blood Chemistry Per (NCI-CTCAE) Version 3.0 Grade (GR)

GR0=normal,1=mild,2=moderate,3=severe,4=life-threatening. ALP(U/L) GR0:40-135,GR1:>135-337; ALT(U/L) GR0:0-47,GR1:>47-117; AST(U/L) GR0:0-37,GR1:>37-93; High(↑) Calcium(mg/dL) GR0:8.4-10.2,GR1:>10.2-11.5; Low(↓) Calcium(mg/dL) GR0:8.4-10.2,GR1:<8.4-8.0,GR2:7.0-<8.0; CK(U/L) GR0:24-195,GR1:>195-488, GR2:>488-975; Creatinine(mg/dL) GR0:0.6-1.4,GR1:>1.4-2.1,GR2:>2.1-4.2; ↑Potassium(mEq/L) GR0:3.6-5.2,GR1:>5.2-5.5,GR2:>5.5-6.0; ↑Sodium(mEq/L) GR0:134-146; ↓Sodium(mEq/L) GR0:134-146,GR1:<134-130; Inorganic Phosphorus(mg/dL) GR0:2.4-4.9,GR2:≥2.0-<2.5; Total Bilirubin(mg/dL) GR0:0-1.1,GR1:>1.1-2.75. (NCT00764309)
Timeframe: From start of study drug therapy up to 30 days after the last dose. The duration of dasatinib dosing in this study was up to 2 years

Interventionparticipants (Number)
Alkaline Phosphatase (ALP), GR0ALP, GR1Alanine Aminotransferase (ALT), GR0ALT, GR1Aspartate Aminotransferase (AST), GR0AST, GR1High Calcium, GR0High Calcium, GR1Low Calcium, GR0Low Calcium, GR1Low Calcium, GR2Creatine Kinase (CK), GR0CK, GR1CK, GR2CK, GR not reportedCreatinine, GR 0Creatinine, GR1Creatinine, GR2High Potassium, GR0High Potassium, GR1High Potassium, GR2Low Potassium, GR 0Low Potassium, GR 1High Sodium, GR0Low Sodium, GR0Low Sodium, GR1Inorganic Phosphorus, GR 0Inorganic Phosphorus, GR 2Total Bilirubin, GR0Total Bilirubin, GR1
100 mg Dasatinib, Oral Administration301247211023828211611222632282127431283301301

[back to top]

Participants With Disease Progression or Death for Exemestane Plus Dasatinib vs Exemestane Plus Placebo

PD is an increase (≥ 20%) in sum of longest diameters from smallest value during study (including baseline). (NCT00767520)
Timeframe: Prior to study therapy, at 8 week intervals until progression occurs. Maximum participant PFS of ____ months)

,
Interventionparticipants (Number)
Disease ProgressionDeathCensored
Exemestane + Dasatinib56419
Exemestane + Placebo59019

[back to top]

Percentage of Participants With Clinical Benefit (CB) for Exemestane Plus Dasatinib Arm vs Exemestane Plus Placebo Arm at 6 Months

CB = participants whose best response is CR, PR, or stable disease(SD). CR = Disappearance of all measurable and non-measurable lesions, and no new lesions; PR = Decrease ≥30% from baseline in sum of longest diameters of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions. SD = Disease re-assessment not qualifying as CR, PR or PD(≥20% increase in sum of longest diameters from smallest value). Confidence interval computed by Clopper-Pearson method. (NCT00767520)
Timeframe: at 6 months

Interventionpercentage of participants (Number)
Exemestane + Dasatinib30.61
Exemestane + Placebo12.24

[back to top]

Number of Participants With Grade 1-4 Serum Chemistry Abnormalities in Potassium, Magnesium, Sodium, Phosphorous, Uric Acid, and Bicarbonate (as Per the NCI CTCAE, Version 3.0)

Grade (GR)1= mild, GR2= moderate, GR3= severe, GR4= life threatening. Ranges are provided by the local laboratory and may vary according to sex and age. Phosphorous, GR1:ULN 3.0 mg/dL,GR 3:<0.3 0.8mg/dL; Uric acid, GR1:>ULN 10 mg/dL, GR4:>10 mg/dL; Low potassium, GR1:ULN-5.5 mmol/L, GR2:>5.5-6.0 mmol/L; Bicarbonate, GR1:ULN-150 mmol/L,GR2:>150-155 mmol/L. (NCT00767520)
Timeframe: Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.

,
Interventionparticipants (Number)
Low Sodium; Grade 1Low Sodium; Grade 3Low Sodium; Grade Not reportedInorganic Phosphorus; Grade 1Inorganic Phosphorus; Grade 2Inorganic Phosphorus; Grade 3Inorganic Phosphorus; Grade Not reportedLow Magnesium; Grade 1Low Magnesium; Grade 3Low Magnesium; Grade 4Low Magnesium; Grade Not reportedUric acid; Grade 1Uric acid; Grade 4Uric acid; Grade Not reportedLow Potassium; Grade 1Low Potassium; Grade 3Low Potassium; Grade Not reportedHigh Potassium; Grade 1High Potassium; Grade 2High Potassium; Grade Not reportedBicarbonate; Grade 1Bicarbonate; Grade 2Bicarbonate; Grade Not reportedHigh Magnesium; Grade 1High Magnesium; Grade 2High Magnesium; Grade 3High Magnesium; Grade Not reportedHigh Sodium; Grade 1High Sodium; Grade 2High Sodium; Grade Not reported
Exemestane + Dasatinib161327534107162211135231101910227213
Exemestane + Placebo100018146112180040060081145212100

[back to top]

Percentage of Participants With Response in Exemestane Plus Dasatinib Arm and Exemestane Plus Placebo Arms

Response= Proportion of response-evaluable participants whose best response is CR or PR. Confidence intervals was computed using the Clopper-Pearson method. CR = Disappearance of all measurable and non-measurable lesions, and no new lesions; PR = Decrease ≥30% from baseline in sum of longest diameters of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions. (NCT00767520)
Timeframe: Prior to study therapy, at 8 week intervals until progression occurs (maximum participant response was 39 weeks)

Interventionpercentage of participants (Number)
Exemestane + Dasatinib6.12
Exemestane + Placebo0

[back to top]

Progression Free Survival (PFS) Distribution for Exemestane Plus Dasatinib vs Exemestane Plus Placebo

PFS= The time (weeks) from date of randomization to date of progressive disease(PD). PFS for each randomization arm was estimated using the Kaplan-Meier product-limit method. A point estimate and a 95% confidence interval (CI) for the median PFS was computed for each randomization arm using the Brookmeyer & Crowley method. PD=Increase (≥ 20%) in sum of longest diameters from smallest value during study (including baseline). (NCT00767520)
Timeframe: Prior to study therapy, at 8 week intervals until progression occurs (maximum participant PFS of 71 weeks)

Interventionweeks (Median)
Exemestane + Dasatinib18.1
Exemestane + Placebo16.1

[back to top]

Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AEs (as Per National Cancer Institute [NCI] Common Toxicity Criteria for Adverse Events [CTCAE], Version 3.0)

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Grade (GR)1 = mild, GR 2 = moderate, GR 3=severe, GR 4=life threatening, GR 5=death. (NCT00767520)
Timeframe: From start of study drug therapy up to 30 days after the last dose. Median duration of therapy (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.

,
Interventionparticipants (Number)
All DeathsAll SAEsDrug-related SAEsAEs leading to discontinuationAll AEsDrug-related AEsDrug-related Grade 3/4 AEsDrug-related Grade 5 AEs
Exemestane + Dasatinib102210207770260
Exemestane + Placebo21346674881

[back to top]

Number of Participants With Grade 1-4 Hematology Abnormalities (as Per the NCI CTCAE, Version 3.0)

Abnormalities were graded per NCI-CTC, Version 3.0 criteria. Grade (GR)1 = mild, GR 2 = moderate, GR 3 = severe, GR 4 = life threatening. Normal ranges are provided by the Local Laboratory and may vary according to sex and age. Granulocytes, GR 1;NCT00767520)
Timeframe: Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.

,
Interventionparticipants (Number)
Granulocytes; Grade 1Granulocytes; Grade 2Granulocytes; Grade 3Granulocytes; Grade 4Granulocytes; Grade Not reportedHemoglobin; Grade 1Hemoglobin; Grade 2Hemoglobin; Grade 3Hemoglobin; Grade 4Hemoglobin; Grade Not reportedPlatelet Count; Grade 1Platelet Count; Grade 2Platelet Count; Grade 3Platelet Count; Grade Not reportedLeukocytes; Grade 1Leukocytes; Grade 2Leukocytes; Grade 4Leukocytes; Grade Not reported
Exemestane + Dasatinib181020242111121020223702
Exemestane + Placebo91020216220211012210

[back to top]

Number of Participants With Best Overall Response

Complete response (CR) = Disappearance of all measurable and non-measurable lesions, and no new lesions; Partial response (PR) = Decrease ≥30% from baseline in sum of longest diameters (LD) of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions. SD = Disease re-assessment not qualifying as CR, PR or PD(≥20% increase in sum of longest diameters from smallest value). (NCT00767520)
Timeframe: at 6 months

,
Interventionparticipants (Number)
Complete response (CR)Partial response (PR)Stable Disease (SD)Disease ProgressionUnable to assessNot reported
Exemestane + Dasatinib03211528
Exemestane + Placebo001423111

[back to top]

Number of Participants With Grade 1-4 Serum Chemistry Abnormalities in Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Bilirubin, Calcium, Creatinine, and Albumin (as Per the NCI CTCAE, Version 3.0)

Grade (GR) 1 = mild, GR 2 = moderate, GR 3 = severe, GR 4 = life threatening). Normal ranges are provided by the Local Laboratory and may vary according to sex and age. Alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, GR 1: >ULN-2.5 x ULN (upper limit of normal), GR 2: >2.5-5.0 x ULN, GR 3: 5.0-20.0 x ULN; Low calcium, GR 1: ULN - 11.5 mg/dL; bilirubin, GR 1: >ULN-1.5 x ULN,GR 3: >3-10 x ULN; Creatinine, GR1:>ULN-1.5 x ULN, GR2: >1.5-3.0 x ULN; Albumin, GR1:NCT00767520)
Timeframe: Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.

,
Interventionparticipants (Number)
Alkaline Phosphatase; Grade 1Alkaline Phosphatase; Grade 2Alkaline Phosphatase; Grade 3Alkaline Phosphatase; Grade Not reportedAlanine Aminotransferase; Grade 1Alanine Aminotransferase; Grade 2Alanine Aminotransferase; Grade 3Alanine Aminotransferase; Grade Not reportedAspartate Aminotransferase; Grade 1Aspartate Aminotransferase; Grade 2Aspartate Aminotransferase; Grade 3Aspartate Aminotransferase; Grade Not reportedLow Calcium ; Grade 1Low Calcium ; Grade 2Low Calcium ; Grade 4Low Calcium ; Grade Not reportedHigh Calcium ; Grade 1High Calcium ; Grade Not reportedCreatinine; Grade 1Creatinine; Grade 2Creatinine; Grade Not reportedBilirubin; Grade 1Bilirubin; Grade 3Bilirubin; Grade Not reportedAlbumin; Grade 1Albumin; Grade 2Albumin; Grade Not reported
Exemestane + Dasatinib20322384023473216212821332203962
Exemestane + Placebo151000163301871061201201310610630

[back to top]

Complete Hematologic Response (CHR) Rate in Cohorts 1 and 3

Complete Hematologic Response (CHR) rate defined as the proportion of all treated participants who achieve a confirmed CHR while on-study. CHR is defined as including no more than 5% blasts in bone marrow and normal white blood cell count without blasts in peripheral blood. The percentage of treated participants in each arm with CHR is reported. (NCT00777036)
Timeframe: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)

Interventionpercentage of participants (Number)
Cohort 193.1
Cohort 396.4

[back to top]

Complete Hematologic Response (CHR) Rate

Complete Hematologic Response (CHR) rate is defined as the proportion of all treated participants who achieve a confirmed CHR while on-study, expressed as percentage. CHR is defined as including no more than 5% blasts in bone marrow and normal white blood cell count without blasts in peripheral blood, expressed as percentage. The denominator of the CHR response rate consists of all treated participants in Cohort 2, and the numerator is all participants in Cohort 2 achieving CHR. 95% confidence interval was calculated by Clopper-Pearson exact method. (NCT00777036)
Timeframe: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)

Interventionpercentage of participants (Number)
Cohort 229.4

[back to top]

Complete Cytogenetic Response (CCyR) Rate

Complete Cytogenetic Response (CCyR) rate is defined as the proportion of all treated participants who achieve a CCyR while on-study, expressed as a percentage. CCyR rate is defined as 0% Ph+ metaphases in at least 20 metaphases in bone marrow. The denominator of the CCyR response rate consists of all treated participants in Cohort 3, and the numerator is all participants in Cohort 3 achieving CCyR. 95% confidence interval was calculated by Clopper-Pearson exact method. (NCT00777036)
Timeframe: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)

Interventionpercentage of participants (Number)
Cohort 394.0

[back to top]

Rate of Best Cytogenetic Response

The number of participants achieving their best on-study cytogenetic response was reported as a percentage of all treated participants in that arm. (Based on >=20 Metaphases) (NCT00777036)
Timeframe: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)

,,,,
Interventionpercentage of participants (Number)
Complete (0%)Partial (>0% - 35%)Minor (>35% - 65%)Minimal (>65% - 95%)No Response (>95% - 100%)Unable to Determine
Cohort 182.86.93.43.403.4
Cohort 229.423.5005.941.2
Cohort 394.02.401.202.4
Cohort 3a96.12.002.000
Cohort 3b90.93.00006.1

[back to top]

Major Molecular Response (MMR) Rate up to 2 Years

Molecular response will be assessed using BCR-ABL transcript levels measurement by real-time qPCR. MMR for participants with the p210 BCR-ABL transcript variant is defined according to the recommendations of Hughes et al. as a ratio BCR-ABL/ABL <= 10-3 or 0.1% on the international scale proposed by the authors. The standardized baseline, as established in the IRIS trial, is taken to represent 100% on the international scale and a 3-log reduction in ratio (BCR-ABL transcripts/ABL or BCR) from the standardized baseline (MMR) is fixed at 0.1%. In this study, ABL or other housekeeping gene, will be used as the control-gene. For a participant with the p190 BCR-ABL transcript variant, on-study assessments will be compared to the participant's individual baseline BCR-ABL/ABL ratio and a reduction to < 0.1% or a 3-log reduction from baseline will be considered an MMR. The percentage of treated participants with MMR is reported by arm. (NCT00777036)
Timeframe: 24 months

,,,,
Interventionpercentage of participants (Number)
12 months24 months
Cohort 141.455.2
Cohort 223.529.4
Cohort 352.470.2
Cohort 3a56.974.5
Cohort 3b45.563.6

[back to top]

Major Cytogenetic Response (MCyR) Rate up to 2 Years

Major Cytogenetic Response (MCyR) rate is defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response. The percentage of treated participants with MCyR is reported by arm. (NCT00777036)
Timeframe: 24 months

,,,,
Interventionpercentage of participants (Number)
12 months24 months
Cohort 189.789.7
Cohort 258.858.8
Cohort 396.496.4
Cohort 3a98.098.0
Cohort 3b93.993.9

[back to top]

Complete Molecular Response (CMR) Rate up to 2 Years

Molecular response will be assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR). (CMR) is defined as absence of BCR-ABL rearrangements by real-time qPCR analysis. The percentage of treated participants with CMR is reported by arm. (NCT00777036)
Timeframe: 24 months

,,,,
Interventionpercentage (Number)
12 months24 months
Cohort 16.917.2
Cohort 211.811.8
Cohort 38.321.4
Cohort 3a9.829.4
Cohort 3b6.19.1

[back to top]

Complete Cytogenetic Response (CCyR) Rate up to 2 Years

Complete Cytogenetic Response (CCyR) rate is defined as the proportion of all treated participants who achieve a CCyR while on-study. CCyR rate is defined as 0% Ph+ metaphases in at least 20 metaphases in bone marrow. The percentage of treated participants with CCyR is reported by arm. (NCT00777036)
Timeframe: 24 months

,,,,
Interventionpercentage of participants (Number)
12 months24 months
Cohort 175.982.8
Cohort 241.241.2
Cohort 392.994.0
Cohort 3a96.196.1
Cohort 3b87.990.9

[back to top]

Time to Major Cytogenetic Response (MCyR)

Time to MCyR is defined as the time from first dose of dasatinib until the first day MCyR criteria are met, computed only for participants whose best response is MCyR. (Based on >=20 Metaphases) (NCT00777036)
Timeframe: From first dose until MCyR criteria are met (assessed up to September 2016, approximately 90 months)

Interventionmonths (Median)
Cohort 13.1
Cohort 21.6
Cohort 33.0
Cohort 3a3.3
Cohort 3b3.0

[back to top]

Time to Complete Hematologic Response (CHR)

Time to CHR is defined as the time from first dose of dasatinib until the first day CHR criteria are met, provided they are confirmed 4 weeks later, computed only for participants whose best response is CHR. (NCT00777036)
Timeframe: From first dose until CHR criteria are met, assessed up to September 2016 (approximately 90 months)

Interventionmonths (Median)
Cohort 10.7
Cohort 22.5
Cohort 31.2
Cohort 3a1.2
Cohort 3b1.0

[back to top]

Time to Complete Cytogenetic Response (CCyR)

Time to CCyR is defined as the time from first dose of dasatinib until the first day CCyR criteria are met, computed only for participants whose best response is CCyR. (Based on >=20 Metaphases) (NCT00777036)
Timeframe: From first dose until CCyR criteria are met, assessed up to September 2016 (approximately 90 months)

Interventionmonths (Median)
Cohort 13.9
Cohort 21.6
Cohort 35.6
Cohort 3a5.7
Cohort 3b5.6

[back to top]

Progression-Free Survival (PFS) Rate at 2 Years

PFS is defined as time from the first dosing date until the time PD is first documented by the investigator or death. Participants who die without a reported date of progression will be considered to have progressed on the date of death. Participants who neither progress nor die will be censored on the date of their last cytogenetic or hematologic assessment. The percentages of progression-free participants at 2 years are based on Kaplan-Meier estimation. Disease Progression was defined as any of the following criteria: -For CP-CML, progression to AP-CML or BP-CML while at highest tolerated dose -Increasing WBC -Loss of CHR (defined as any of the following: WBC count rises to >20.0x10^9/L; Platelet count rises to >600x10^9/L; appearance of extramedullary disease; appearance of >5% myelocytes+metamyelocytes in blood; appearance of blasts/promyelocytes in peripheral blood) -Loss of MCyR or increase in Ph+ bone marrow cells by >=30% from nadir -Death from any case during treatment (NCT00777036)
Timeframe: 2 years

Interventionpercentage (Number)
Cohort 181.7
Cohort 220.5
Cohort 395.1
Cohort 3a94.0
Cohort 3b96.8

[back to top]

Overall Survival (OS) Rate at 2 Years

OS is defined as time from the first dosing date until the time of death. All participants will be followed yearly for survival for up to 5 years after treatment discontinuation. Participants who have not died or who are lost to follow-up will be censored on the last date the participant is known to be alive. The percentages of surviving participants at 2 years are based on Kaplan-Meier estimation. (NCT00777036)
Timeframe: 2 years

Interventionpercentage (Number)
Cohort 196.4
Cohort 232.2
Cohort 3100
Cohort 3a100
Cohort 3b100

[back to top]

Major Molecular Response (MMR) Rate

Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR). MMR for participants with the p210 BCR-ABL transcript variant was defined as a ratio BCR-ABL/ABL <= 10-3 or 0.1% on the international scale. In this study, ABL was used as the control-gene. For a participant with the p190 BCR-ABL transcript variant (occurring in Cohort 2 only), on-study assessments were compared to the participant's individual baseline BCR-ABL/ABL ratio and a reduction to < 0.1% or a 3-log reduction from baseline was considered an MMR. (NCT00777036)
Timeframe: From date of first treatment to date of MMR (assessed up to September 2016, approximately 90 months)

Interventionpercentage of participants (Number)
Cohort 162.1
Cohort 229.4
Cohort 379.8
Cohort 3a88.2
Cohort 3b66.7

[back to top]

Major Cytogenetic Response (MCyR) Rate in Cohort 2

Major Cytogenetic Response (MCyR) rate was defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response. The percentage of treated participants in each arm with MCyR is reported. (NCT00777036)
Timeframe: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)

Interventionpercent of participants (Number)
Cohort 252.9

[back to top]

Major Cytogenetic Response (MCyR) Rate

Major Cytogenetic Response (MCyR) rate is defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response, expressed as percentage. The denominator of the MCyR response rate consists of all treated participants in Cohort 1, and the numerator is all participants in Cohort 1 achieving MCyR. 95% confidence interval was calculated by Clopper-Pearson exact method. (NCT00777036)
Timeframe: From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)

Interventionpercentage of participants (Number)
Cohort 189.7

[back to top]

Duration of Major Cytogenetic Response (MCyR)

Duration of MCyR will be computed from the first day criteria are met for MCyR until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death. Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic or cytogenetic assessment, whichever comes last. (Based on >=20 Metaphases) (NCT00777036)
Timeframe: From first day criteria are met for MCyR until the date PD is reported or death (assessed up to September 2016, approximately 90 months)

Interventionmonths (Median)
Cohort 1NA
Cohort 211.2
Cohort 3NA
Cohort 3aNA
Cohort 3bNA

[back to top]

Duration of Complete Hemotologic Response (CHR)

Duration of CHR will be computed from the first day all criteria are met for CHR, provided they are confirmed 4 weeks later, until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death. Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic assessment. (NCT00777036)
Timeframe: From first day criteria are met for CHR until date of disease progression or death (assessed up to September 2016, approximately 90 months)

Interventionmonths (Median)
Cohort 1NA
Cohort 2NA
Cohort 3NA
Cohort 3aNA
Cohort 3bNA

[back to top]

Duration of Complete Cytogenetic Response (CCyR)

Duration of CCyR will be computed from the first day criteria are met for CCyR until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death. Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic or cytogenetic assessment, whichever comes last. (Based on >=20 Metaphases) (NCT00777036)
Timeframe: From first day criteria are met for CCyR until the date of progressive disease or death (assessed up to September 2016, approximately 90 months)

Interventionmonths (Median)
Cohort 1NA
Cohort 2NA
Cohort 3NA
Cohort 3aNA
Cohort 3bNA

[back to top]

Disease-Free Survival Rate at 2 Years

Disease free survival is defined as time from CCyR for participants with newly diagnosed chronic phase CML and for participants with chronic phase CML who are resistant or intolerant to imatinib (cohort 3 and cohort 1), and as time from CHR for participants with advanced phase CML and PH + ALL (cohort 2) until the time progression is first documented by the investigator or death from any cause. The percentages of disease-free participants at 2 years are based on Kaplan-Meier estimation. (CML: Chronic Myeloid Leukemia) (NCT00777036)
Timeframe: 2 years

Interventionpercentage (Number)
Cohort 186.9
Cohort 260.0
Cohort 398.7
Cohort 3a97.9
Cohort 3b100

[back to top]

Complete Molecular Response (CMR) Rate

Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR). (CMR) is defined as absence of BCR-ABL rearrangements by real-time qPCR analysis. The percentage of treated participants with CMR is reported by arm. (NCT00777036)
Timeframe: From date of first treatment to date of CMR (assessed up to September 2016, approximately 90 months)

Interventionpercentage (Number)
Cohort 124.1
Cohort 217.6
Cohort 329.8
Cohort 3a43.1
Cohort 3b9.1

[back to top]

Clinical Benefit (CB) Rate (CB = Participants With Objective Tumor Response or Stable Disease > 6 Months)

Rate of participants with response complete, partial response or stable disease categorized by Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Radiological response assessments must be repeated every 8 weeks during therapy. (NCT00780676)
Timeframe: Tumor status assessed every 8 weeks during therapy, up to 6 months

InterventionPercentage of Participants (Number)
Dasatinib Sensitivity Signature0
SRC Pathway Activity Signature0
Dasatinib Target Index7.7

[back to top]

Overall Survival

Overall survival (OS) is the duration from date of consent to date of death from any cause. (NCT00787267)
Timeframe: Progression and survival every 6 months

Interventionmonths (Median)
Dasatinib3.7

[back to top]

Tumor Response

"Tumor response rate was defined by RECIST criteria:~CR (complete response) = disappearance of all target lesions taking as reference the baseline sum of the longest diameter (LD); PR (partial response) = at least a 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = at least a 20% increase in the sum of the longest diameter of target lesions as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD (stable disease) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since the treatment started" (NCT00787267)
Timeframe: 2 years

Interventionparticipants (Number)
Complete ResponsePartial ResponseStable DiseaseProgression of Disease
Dasatinib00511

[back to top]

Grade 3-5 Toxicity Associated With Dasatinib Treatment

Number of subjects with Grade 3-5 toxicity as assessed using NCI CTCAE criteria with the attribution of possibly, probably, or definitely related to protocol treatment. (NCT00787267)
Timeframe: Duration of dasatinib treatment plus 30 days

Interventionparticipants (Number)
Dasatinib12

[back to top]

Number of Patients Who Came Off Study for Toxicity Using CTC Version 3.0

6 patients came off study for toxicity (NCT00787852)
Timeframe: within 28 days after the last radiation treatment

Interventionparticipants (Number)
Group 16

[back to top]

Maximum Administered Dose of Dasatinib (Phase I)

This field captured the maximum dose of dasatinib administered. (NCT00788125)
Timeframe: 28 days after start of course 1

Interventionmg/m2 dose BID (Number)
Period 1: 35 mg/m^2/Dose BID PO Dasatinib x 17 Days35

[back to top]

Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation

Will be estimated using the method of Kaplan-Meier. (NCT00792948)
Timeframe: 12 months

InterventionProbability of 12-month RFS (Number)
Treatment0.83

[back to top]

Overall Survival (OS)

OS will be estimated using the method of Kaplan-Meier. (NCT00792948)
Timeframe: From the date of initial registration on the study until death from any cause, assessed up to 5 years

InterventionProbability of surviving 12 months (Number)
Treatment0.88

[back to top]

Continuous Complete Remission (CCR) Rate

Will be testing using an exact binomial test (NCT00792948)
Timeframe: 18 months

Interventionpercentage of participants (Number)
Treatment57

[back to top]

Clinical Efficacy

The clinical response was assessed using RECIST and based on the changes in the longest diameter of the target lesion measured. Complete Response (CR), Disappearance of the target lesion; Partial Response (PR), >=30% decrease in the diameter of target lesion compared to baseline; Progressive disease (PD), >= 20% increase in the diameter of target lession, taking as reference the smallest diameter recorded since the baseline measurement or the appearance of new lesion; Stable disease (SD), neither sufficient shrinkage as PR or sufficient increase as PD. (NCT00817531)
Timeframe: Assessment at pre-surgery or 3 to 4 weeks of treatment.

Interventionparticipants (Number)
Partial Response (PR)Stable Disease (SD)Progression Disease (PD)
Dasatinib2155

[back to top]

Median Overall Survival for Phase II Participants

Overall Survival for Phase II Participants (NCT00820170)
Timeframe: Through study completion, up to 2 years

Interventionmonths (Median)
Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg20.6

[back to top]

Median Progression Free Survival for Phase II Participants

Per RECIST criteria, Progression (PD) is defined at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00820170)
Timeframe: Through study completion, up to 2 years

Interventionmonths (Median)
Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg5.2

[back to top]

Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel.

(NCT00820170)
Timeframe: Through completion of Phase I, up to 1 year

Interventionmg of dasatinib (Number)
Dasatinib and Paclitaxel120

[back to top]

Participant Adverse Events to Measure Safety and Tolerability of Dasatinib When Administered in Combination With Weekly Paclitaxel.

Evaluate adverse events using CTCAE v3 (NCT00820170)
Timeframe: Through study completion, up to 2 years

InterventionParticipants (Count of Participants)
Arm 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg3
Arm 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg40
Arm 3: Paclitaxel 80 mg/m2 + Dasatinib 150 mg5
Paclitaxel 80 mg/m2 + Dasatinib 70 mg3
No Arm Selected4

[back to top]

Median Time To Progression for Phase II Participants

(NCT00820170)
Timeframe: Through study completion, up to 2 years

Interventionmonths (Median)
Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg5.84

[back to top]

Phase I: Maximum Tolerable Dose (MTD) of Dasatinib Given With Erlotinib Hydrochloride

MTD defined as the highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Dose-limiting toxicity (DLT) defined using NCI Common Terminology Common Terminology Criteria for Adverse Events (CTCAE) version 3 as: grade 3 or higher non-hematologic toxicity (excluding initial nausea and vomiting), grade 4 neutropenia, febrile neutropenia, or grade 4 thrombocytopenia. Grade 3-4 nausea and vomiting that cannot be controlled within 2 weeks with anti-emetics considered a DLT. (NCT00826449)
Timeframe: Baseline and at Day 21

Interventionmg/day (Number)
Dasatinib + Erlotinib70

[back to top]

Phase II: Progression-Free Survival (PFS) Rate

A modified Thall, Simon, and Estey (1995) design used in the phase II study to monitor the proportion of patients with NSCLC who are alive and progression free (PFS) at twelve weeks after commencing treatment with dasatinib and erlotinib. (NCT00826449)
Timeframe: 12 Weeks

InterventionPercentage of Participants (Number)
Dasatinib + Erlotinib53

[back to top]

Phase II: Number of Participant With Response According to Response Evaluation Criteria in Solid Tumors (RECIST)

Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. Patients who have a partial or complete response or stable disease are defined as progression free. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): At least 20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase. (NCT00826449)
Timeframe: 12 Weeks

Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Progressive Disease (PD)Stable Disease (SD)
Dasatinib + Erlotinib051315

[back to top]

Number of Participants With Serious Adverse Events (SAEs)

We evaluated toxicity of dasatinib in this patient population. (NCT00858403)
Timeframe: 1 year, 4 months

InterventionParticipants (Number)
Treatment With Dasatinib3

[back to top]

Number of Participants With Progression Free Survival (PFS) at 6 Months

We planned to estimate the 6 month progression free survival rate of dasatinib in this patient population. (NCT00858403)
Timeframe: 1 year, 4 months

InterventionParticipants (Number)
Treatment With Dasatinib1

[back to top]

Overall Survival

Kaplan-Meier curves will be generated and 90% confidence intervals will be derived. (NCT00859937)
Timeframe: Up to 5 years

Interventionmonths (Median)
Adenoid Cystic Carcinoma14.5
Non Adenoid Cystic Carcinoma4.8

[back to top]

Progression-free Survival

Progression-free survival from start of treatment to the time of disease progression or death from any cause was estimated using the Kaplan-Meier method. (NCT00859937)
Timeframe: up to 5 years

Interventionmonths (Median)
Adenoid Cystic Carcinoma4.8
Non Adenoid Cystic Carcinoma2.7

[back to top]

Response Rate

Response rate is percentage of the best overall response which recoded from the start of the treatment until diseases progression/recurrence. Response criteria are defined using the international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee: Complete Response, Disappearance of all target lesions; Partial Response, >=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions. (NCT00859937)
Timeframe: Up to 2 months

,
Interventionparticipants (Number)
Complete responsePartial responseStable diseaseProgressive diseaseOther
Adenoid Cystic Carcinoma0120127
Non Adenoid Cystic Carcinoma00743

[back to top]

The Number of Dose Limiting Toxicities(DLT) in Order to Determine Maximum Tolerable Dose(MTD) of Dasatinib Combined With Radiation and Temozolomide in This Patient Population.

Doselimiting toxicity will be defined as: Adverse event at least possibly related to the study medication. All by CTCAE v3.0 criteria: Greater than or equal to grade 3: diarrhea or skin rash or desquamation or (other) clinically relevant non-hematological adverse event or non-hematologic adverse event at least possibly due to drug therapy. Or greater than or equal to grade 4: neutropenia or leukopenia or thrombocytopenia or radiation dermatitis or hematologic adverse event OR failure to administer greater than 75% of dasatinib TMZ or interruption of RT for more than 5 days due to adverse events.OR severe acute central nervous system deterioration attributable to TMZ, RT and or dasatinib which cannot be controlled with corticosteroid administration. The MTD for this study will be defined as the highest safely tolerated dose level where at most 1 out of 6 patients experience DLT with the next higher dose having at least 2 patients out of a maximum of 6 patients experience DLT. (NCT00869401)
Timeframe: Every cycle from first dose to end of rest period prior cycle 3

Interventionparticipants with Dose Limiting Toxicits (Number)
Dose Level 0 Phase I1
Dose Level 0-A Phase I0
Dose Level 1 Phase I1

[back to top]

Overall Survival

Overall survival (OS) is the primary endpoint and is defined as the time from study registration to time of death due to any cause. All patients who meet the eligibility criteria, have signed a consent form, and have received at least one dose of the regimens will be considered evaluable. Patients who are lost to follow-up will be censored at the date of their last follow-up. Patients still alive at the time of analysis will be censored. Only Phase II was evaluated for survival (NCT00869401)
Timeframe: Up to 5 years post treatment

InterventionMonths (Median)
Group 1 (Phase II) Dasatinib + Radiation + Temozolomide15.6
Group 2 (Phase II) Placebo + Radiation + Temozolomide19.3

[back to top]

Progression-free Survival

Progression-free survival (PFS) is defined as the time from study registration to the date of first observation of disease progression or death due to any cause (whichever comes first). If a patient has not progressed or died, progression-free survival is censored at the time of last follow-up. Only Phase II patients were evaluated for Progression-free survival (NCT00869401)
Timeframe: Up to 5 years post treatment

InterventionMonths (Median)
Group 1 (Phase II) Dasatinib + Radiation + Temozolomide6.2
Group 2 (Phase II) Placebo + Radiation + Temozolomide7.8

[back to top]

Objective Response

Objective response to treatment will be determined by a combination of the results of neurological exam and the MRI and/or CT measurement of the tumor at each evaluation as is used for all NCCTG neuro-oncology trials. The proportion of patients in each response category will be summarized. Only phase II patients were evaluated for response. (NCT00869401)
Timeframe: Up to 5 years post treatment

,
InterventionProportion of participants (Number)
ProgressionStableREGRPartial ResponseComplete Response
Group 1 (Phase II) Dasatinib + Radiation + Temozolomide.31.59.08.020
Group 2 (Phase II) Placebo + Radiation + Temozolomide.19.73.02.060

[back to top]

MTD of Daily Oral Dasatinib in Combination With Cetuximab/RT in Cohort A and Daily Oral Dasatinib in Combination With Cetuximab/Cis or Carboplatin/RT in Cohort B 2. MTD of Daily Oral Dasatinib in Combination With Cisplatin/Cetuximab/RT in Cohort B

The Maximum Tolerated Dose (MTD) for Dasatinib was defined as a) the dose producing DLT ( Dose limiting toxicity) in 0-1 out of 6 patients, or b) the dose level below the dose which produced DLT in <2 out of 6 patients, or c) the dose of 150mg PO QD with less than 33% rate of DLT. (NCT00882583)
Timeframe: Last day of Radiation

,
InterventionParticipants (Count of Participants)
Dose 70 mgDose 100mgDose 150mg
Cohort A430
Cohort B732

[back to top]

Objective Response (Phase II)

Objective response to treatment will be determined by the results of neurological exam and the MRI and/or CT measurement of the tumor at each evaluation as is used for all NCCTG neuro-oncology trials. The percentage of patients in each response category will be summarized, 95% confidence intervals calculated, and rates between the 2 arms will be compared using a Fisher's Exact test. For bi-dimensionally measurable disease, CR: total disappearance of all tumor and that patients be on no corticosteroids or on only adrenal replacement maintenance; PR: ≥ 50% reduction in product of perpendicular diameters of contrast enhancement or mass with no new lesions, and stable or decreasing steroid dosing; PD: >25% increase in product of perpendicular diameters of contrast enhancement or mass or appearance of new lesions; REGR: unequivocal reduction in extent of contrast-enhancement, or a decrease in mass effect, no new lesions (for evaluable disease); SD: failure to qualify for CR, PR,REGR or PD. (NCT00892177)
Timeframe: Up to 3 years

,
Interventionpercentage of participants (Number)
CRPRREGRSDPDMissing/Unknown
Phase II: Arm A (Bevacizumab + Dasatinib)2.42.410.857.812.014.5
Phase II: Arm B (Bevacizumab + Placebo)2.65.318.457.95.310.5

[back to top]

Time-to-disease Progression (Phase II)

Time-to-disease progression is defined as the time from start of study therapy to documentation of disease progression. Patients who die without documentation of progression will be considered to have had tumor progression at the time of death unless there is documented evidence that no progression occurred before death. Patients who fail to return for evaluation after beginning therapy will be censored for progression on the last day of therapy or date last known to be alive, whichever is later. Patients who are still alive and have not progressed will be censored for progression at the time of the last tumor assessment. Patients who experience major treatment violations will be censored for progression on the date the treatment violation occurred. The time-to-progression distribution will be estimated using the Kaplan-Meier method. (NCT00892177)
Timeframe: Up to 3 years

Interventionmonths (Median)
Phase II: Arm A (Bevacizumab + Dasatinib)3.3
Phase II: Arm B (Bevacizumab + Placebo)3.5

[back to top]

Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I)

The Maximum Tolerated Dose (MTD) will be based on the assessment of dose-limiting toxicities (DLT) during the first 4 weeks of treatment only (i.e., following the first 2 treatment cycles), and will be defined as the dose at which fewer than one-third of patients experience a DLT to study treatment. The MTD is the dose level at which 0/6 or 1/6 patients experience DLT with the next higher dose having at least 2 out of 3 or 2 out of 6 patients encountering DLT.> Three patients will be treated at each dose level, and can be enrolled simultaneously. If one DLT is encountered, an additional 3 patients will be added to that dose level. If at any point two DLTs are encountered within a given dose level, then the MTD has been exceeded and if only three patients have been treated at the next lower dose three more patients are treated at the next lower dose. The number of patients who developed DLTs are reported here by dose level, with the MTD reported in the statistical analysis section. (NCT00892177)
Timeframe: 14 days

Interventionparticipants who developed DLTs (Number)
Phase I : Dose Level 00
Phase I : Dose Level 10
Phase I : Dose Level 20
Phase I : Dose Level 3 Cohort 10
Phase I: Dose Level 3 Cohort 21

[back to top]

Overall Survival (Phase II)

Survival time is defined to be the length of time from start of study therapy to death due to any cause. All patients meeting the eligibility criteria that have signed a consent form and begun treatment will be considered evaluable for estimation of the survival distribution. The distribution of overall survival for both arms of the study will be estimated using the Kaplan-Meier method, and be compared using log-rank tests. (NCT00892177)
Timeframe: Up to 3 years

Interventionmonths (Median)
Phase II: Arm A (Bevacizumab + Dasatinib)7.3
Phase II: Arm B (Bevacizumab + Placebo)7.9

[back to top]

Number of Participants With Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 (Phase II)

"Adverse events were collected systematically at the end of each cycle and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0. Events are scored as: 1=Mild symptoms, 2= Moderate, 3=Severe, 4=Life-threatening, and 5=Death. The number of patients reporting a grade 3 or higher event regardless of attribution are summarized here. A complete list of all adverse events reported during treatment can be found in the Adverse Events Section." (NCT00892177)
Timeframe: Up to 3 years

,
Interventionparticipants (Number)
Grade 3 Adverse EventGrade 4 Adverse EventGrade 5 Adverse Event
Phase II: Arm A (Bevacizumab + Dasatinib)4285
Phase II: Arm B (Bevacizumab + Placebo)2323

[back to top]

Progression-free Survival at 6 Months (PFS6) (Phase II)

The primary endpoint is the proportion of patients alive and progression-free 6 months after study treatment initiation (PFS6). All eligible consented patients that received treatment will be considered evaluable. Those who die will be considered to have had disease progression unless documented evidence clearly indicates no progression has occurred. PFS6 is defined as the time from start of study therapy to the date of first observation of disease progression or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS6 will be estimated as the number of evaluable patients progression free and still alive at 6 months divided by the total number of evaluable patients. The confidence interval will be calculated according to the Clopper-Pearson Method. (NCT00892177)
Timeframe: 6 months

Interventionproportion of participants (Number)
Phase II: Arm A (Bevacizumab + Dasatinib)0.29
Phase II: Arm B (Bevacizumab + Placebo)0.18

[back to top]

Patient-reported QOL, as Measure by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) (Phase II)

"FACT-Br questionnaires were used to assess QOL at every other cycle of treatment (prior to cycles 3, 5, 7, etc.). FACT-Br includes 50 questions used to assess patients' self-assessment in 4 broad categories: Physical, Social/Family, Emotional, and Function Well-being. Scores range from 0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very Much. Higher scores can be interpreted as having higher quality of life. The scores for all 50 questions were summed to give a total score per patient per cycle. Therefore the possible range is from 0 to 200. Below is the reported mean and standard deviation for patients at baseline and during cycles 2, 4, 6, 8, and 10." (NCT00892177)
Timeframe: Baseline to cycle 10 (20 weeks).

,
Interventionunits on a scale (Mean)
Cycle 0Cycle 2Cycle 4Cycle 6Cycle 8Cycle10
Phase II: Arm A (Bevacizumab + Dasatinib)139.5131.2137.6140.1142.3142.1
Phase II: Arm B (Bevacizumab + Placebo)138.3133.5137.4137.7142.8149.3

[back to top]

Overall Response Rate of Men With High AR Activity

Tumor response was based on Response Criteria in Solid Tumors (RECIST). Complete response (CR) is defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. (NCT00918385)
Timeframe: During monotherapy (at least 12 weeks)

Interventionpercentage of patients with CR,PR (Number)
Arm 1=High AR Nilutamide0

[back to top]

Overall Response Rate of Men With Low AR Activity

Tumor response is based on Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. (NCT00918385)
Timeframe: During dasatinib monotherapy ( at least 12 weeks)

Interventionpercentage of patients with CR,PR (Number)
Arm 2= Low AR Dasatinib0

[back to top]

Progression Free Survival (PFS)

PFS is the interval from start of monotherapy until first disease progression or death, whichever occurred first. (NCT00918385)
Timeframe: During monotherapy ( at least 12 weeks)

Interventionmonths (Median)
Arm 1=High AR Nilutamide2.8
Arm 2= Low AR Dasatinib2.6

[back to top]

Incidence of Grade 4 Adverse Events (AEs) With the Combination of Dasatinib and Ixabepilone (Phase II)

All treatment emergent adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (NCT00924352)
Timeframe: Adverse events were collected beginning on day 1 of treatment until one month after the end of study treatment.

Interventionparticipants (Number)
Ixabepilone + Dasatinib5

[back to top]

Incidence of Grade 3 Adverse Events (AEs) With the Combination of Dasatinib and Ixabepilone (Phase II)

All treatment emergent adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (NCT00924352)
Timeframe: Adverse events were collected beginning on day 1 of treatment until one month after the end of study treatment.

Interventionparticipants (Number)
Ixabepilone + Dasatinib31

[back to top]

Best Overall Response of the Combination of Dasatinib and Ixabepilone (Phase II)

Best overall response is defined as the best response across all time points. Response was evaluated via changes from baseline in radiological tumor measurements performed after every two treatment cycles and at the end of treatment or time of progression. Response was evaluated using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00924352)
Timeframe: Response to treatment was assessed after about every 8 weeks of treatment, for up to 27.2 months.

Interventionparticipants (Number)
Complete ResponsePartial ResponseStable DiseaseProgressive DiseaseNot Evaluable
Ixabepilone + Dasatinib04112312

[back to top]

Determination of the Dose Limiting Toxicities (DLTs) of the Combination of Dasatinib and Ixabepilone (Phase I)

DLTs were assessed using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Dose limiting toxicity was defined as any grade 4 hematologic event or any grade 3 or 4 non-hematologic event occurring during cycle 1 that is attributable to dasatinib, ixabepilone, or the combination. The following events were excluded from this definition: grade 4 neutropenia lasting for 3 days or less; grade 3 nausea responsive to antiemetics; grade 3 infection with normal ANC or grade 1 or 2 neutrophils; grade 3 diarrhea responsive to optimal use of antidiarrheal therapy. (NCT00924352)
Timeframe: DLTs were assessed during the first cycle of combination therapy (days 1-28).

,,
Interventionparticipants (Number)
DLT: Grade 4 ThrombocytopeniaDLT: Grade 4 Leukopenia
Ixabepilone + Dasatinib (Dose Level 0)00
Ixabepilone + Dasatinib (Dose Level 1)00
Ixabepilone + Dasatinib (Dose Level 2)11

[back to top]

Clinical Benefit Rate of the Combination of Dasatinib and Ixabepilone (Phase II)

Clinical benefit rate was defined as the percentage of participants experiencing stable disease (SD) of at least 24 weeks (from the start of treatment) plus complete response (CR) and partial response (PR). Response was evaluated via changes from baseline in radiological tumor measurements performed after every two treatment cycles and at the end of treatment or time of progression. Response was evaluated using RECIST version 1.0 guidelines, where CR is the disappearance of all target lesions; PR is >=30% decrease in the sum of the longest diameter(LD) of target lesions; SD is neither sufficient shrinkage in sum of longest diameter of target lesions to be PR nor increase of >=20%. (NCT00924352)
Timeframe: Response to treatment was assessed after about every 8 weeks of treatment, for up to 27.2 months.

Interventionpercentage of participants (Number)
Ixabepilone + Dasatinib26.0

[back to top]

Determination of the Maximum Tolerated Dose (MTD) of Dasatinib When Given in Combination With Ixabepilone (Phase I)

The MTD of dasatinib (taken daily, continuously) when given in combination with ixabepilone (administered on Days 1, 8, and 15 of a 28-day cycle) was determined using a standard 3 + 3 dose escalation cohort design. The total sample and the number of patients who receive each dose in this design depends on the frequency of dose limiting toxicities (DLT) at each dosage. The MTD was defined as the dose at which ≤ 1 of 6 patients experienced DLT, and above which ≥ 2 of 6 patients experienced DLT. (NCT00924352)
Timeframe: MTD was assessed during the first cycle of combination therapy (days 1-28).

Interventionmg daily (Number)
Ixabepilone + Dasatinib100

[back to top]

Determination of the Maximum Tolerated Dose (MTD) of Ixabepilone When Given in Combination With Dasatinib (Phase I)

The MTD of ixabepilone (administered on Days 1, 8, and 15 of a 28-day cycle) when given in combination with dasatinib (taken daily, continuously) was determined using a standard 3 + 3 dose escalation cohort design. The total sample and the number of patients who receive each dose in this design depends on the frequency of dose limiting toxicities (DLT) at each dosage. The MTD was defined as the dose at which ≤ 1 of 6 patients experienced DLT, and above which ≥ 2 of 6 patients experienced DLT. (NCT00924352)
Timeframe: MTD was assessed during the first cycle of combination therapy (days 1-28).

Interventionmg/m2 (Number)
Ixabepilone + Dasatinib20

[back to top]

Evaluation of Progression-free Survival (PFS) of the Combination of Dasatinib and Ixabepilone (Phase II)

Disease progression was determined through radiology imaging measurements and by clinical or symptomatic progression during or after treatment. Progression is defined per RECIST v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion, progression of existing non-target lesions, or the appearance of 1 or more new lesions. (NCT00924352)
Timeframe: PFS was measured from day 1 of treatment until time of progression (assessed about every 8 weeks) or death, whichever came first, for up to 27.2 months.

Interventionmonths (Median)
Ixabepilone + Dasatinib6.01

[back to top]

Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs

SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires inpatient hospitalization or prolongation. AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Treatment-related(Tx-R)=certainly, probably, possibly related and unknown relationship to study drug. AE grades(Gr) 1=Mild; 2=Moderate; 3=Severe; 4=Life-threatening. (NCT00948389)
Timeframe: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after cycle 6. Median number of cycles = 1.0 (range: 1.0 - 7.0).

,,,,
Interventionparticipants (Number)
Deaths within 30 days of Tx DiscontinuationTx-R Deaths within 30 days of Tx DiscontinuationAt Least 1 SAEAt Least 1 Tx-R SAEDiscontinuations Due to AEsAt Least 1 AEAt Least 1 Gr 3/4 AEAt Least 1 Tx-R AEAt Least 1 Tx-R Gr 3/4 AE
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2104107450
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2105436250
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2001003220
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2000001010
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2004119470

[back to top]

Number of Participants With Dose-limiting Toxicities (DLTs)

Grades (gr) according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0. DLTs were defined as adverse drug reactions as follows: absolute neutrophil counts <0.5x10^9/L (gr4) lasting for 7 consecutive days; febrile neutropenia (neutrophil count <1x10^9/L and fever of >=38.5°C); thrombocytopenia (gr4); any gr3/4 nonhematological toxicity except nausea, vomiting and fever which could be rapidly controlled with appropriate measures; any toxicity which did not allow administering at least 70% of the intended dose intensity for both agents. (NCT00948389)
Timeframe: The duration for observation of DLT was 2 6-week cycles in participants with escalated dose (QD to BID) and 1 6 -week cycle for participants starting with BID regime. For participants receiving dasatinib at 150 mg, DLTs were only documented over cycle 1.

Interventionparticipants (Number)
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^23
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^23
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^24

[back to top]

Deaths Within 30 Days of Protocol Treatment Discontinuation

(NCT00948389)
Timeframe: From time of randomization through within 30 days after protocol treatment discontinuation. Median (full range) number of 6-week treatment cycles was 1.0 (1.0-7.0).

Interventionparticipants (Number)
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^21
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^20
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^21
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^20
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^20

[back to top]

Number of Participants With Worst Grade of Biochemistry Abnormality Per NCI CTCAE Version 3.0 Criteria

Grades (gr) 1=mild; gr2=moderate; gr3=severe; gr4=life-threatening. For details of NCI CTCAE laboratory values for each grade, please refer to http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30. Low Potassium=Hypokalemia, High Potassium=Hyperkalemia, Low Sodium=Hyponatremia, Low Calcium=Hypocalcemia, High Bilirubin=Hyperbilirubinemia, low phosphatase=Hypophosphatemia, Low Potassium=Hypokalemia. (NCT00948389)
Timeframe: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after 6 cycles. Median number of cycles = 1.0 (range: 1.0 - 7.0).

,,,,
Interventionparticipants (Number)
At least 1 Gr 1-4 HypokalemiaAt least 1 Gr 1-4 HyperkalemiaAt least 1 Gr 1-4 HyponatremiaAt least 1 Gr 1-4 HypernatremiaAt least 1 Gr 1-4 CreatinineAt least 1 Gr 1-4 HypocalcemiaAt least 1 Gr1-4 HyperbilirubinemiaAt least 1 Gr 1-4 Aspartate Aminotransferase / ASTAt least 1 Gr 1-4 HypophosphatemiaAt least 1 Gr 3-4 Hypokalemia
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^21000030410
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^21011030210
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^20101210010
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^20000001000
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^23005020631

[back to top]

Number of Participants With Worst Grade of Hematological Toxicity Per NCI CTCAE Version 3.0 Criteria

Neutrophils (neutropenia): Grade (gr)1 NCT00948389)
Timeframe: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after cycle 6. Median number of cycles = 1.0 (range: 1.0 - 7.0).

,,,,
Interventionparticipants (Number)
At least 1 Grade 1-4 NeutropeniaAt least 1 Grade 1-4 LeukopeniaAt least 1 Grade 1-4 LymphocytopeniaAt least 1 Grade 1-4 ThrombocytopeniaAt least 1 Grade 1-4 AnemiaAt least 1 Grade 3-4 NeutropeniaAt least 1 Grade 3-4 LeukopeniaAt least 1 Grade 3-4 LymphocytopeniaAt least 1 Grade 3-4 ThrombocytopeniaAt least 1 Grade 3-4 Anemia
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^22446600121
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^23556621440
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^22323111000
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^20001000000
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^25699944550

[back to top]

Number of Participants With Disease Progression at 12 Months

As measured by brain magnetic resonance imaging. (NCT00948389)
Timeframe: 12 months

Interventionparticipants (Number)
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^26
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^23
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^27
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^29
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^21

[back to top]

Number of Participants With Grade 3-4 Hematology Abnormalities

Abnormalities were graded per the National Cancer Institute(NCI)Common Toxicity Criteria (CTC), v3.0(Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Grade 3 and 4 criteria are as follows: Hemoglobin: Grade 3:6.5 - <8.0g/dL, Grade 4: <6.5g/dL. Platelets: Grade 3: 25.0 - <50.0*10^9/L, Grade 4: <25.0*10. Absolute Neutrophil Count (ANC): Grade 3: 0.5 - <1.0*10^9/L, Grade 4: <0.5*10^9/L.White Blood Cells (WBC) : Grade 3: 1.0 - <2.0*10^9/L, Grade 4: <1.0*10^9/L. (NCT00978731)
Timeframe: From start of study until up to 30 days after end of study participation. Median duration of exposure (on-study time) was 23.4 months.

,,,
Interventionparticipants (Number)
WBCANCPlatelet CountHemoglobin
Accelerated Phase CML: BID Dosing at Study Entry0001
Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry2330
CML: BID Dosing at Study Entry1111
Myeloid Blast Phase CML: BID Dosing at Study Entry0211

[back to top]

Number of Participants With Dose Interruptions and Dose Reductions

Dose interruptions and reductions were allowed, in order to optimize individual participant's hematologic, cytogenetic, and molecular response while maintaining and evaluating safety and tolerability of long-term exposure to dasatinib. A dose reduction is defined as the administration of a dose at a lower level compared to previous dose and such that reduced dose, or a lower dose, is given at least 4 consecutive times. In determining the reductions, dose level would be compared to the previous non-null dose. Dose interruption is defined as a complete omission of dosing for 4 consecutive times. (NCT00978731)
Timeframe: From start of study to final assessment (up to 32.2 months).

,,,
Interventionparticipants (Number)
Dose interruptionsDose reductions
Accelerated Phase CML: BID Dosing at Study Entry22
Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry78
CML: BID Dosing at Study Entry94
Myeloid Blast Phase CML: BID Dosing at Study Entry21

[back to top]

Number of Participants With Best Cytogenetic Response

Cytogenetic responses are based on the prevalence of Ph+ metaphases among cells in metaphase on a bone marrow sample. CCyR: 0% Ph+ cells in metaphase in bone marrow, PCyR: >0% to 35% Ph+ cells in metaphase in bone marrow, Minor CyR: >35% to 65% Ph+ cells in metaphase in bone marrow, Minimal CyR: >65% to 95% Ph+ cells in metaphase in bone marrow and No CyR: >95% to 100% Ph+ cells in metaphase in bone marrow. (NCT00978731)
Timeframe: Pre-treatment to study discontinuation. Median duration of exposure (on-study time) was 23.4 months.

,
Interventionparticipants (Number)
Complete (0%)Partial (1-35%)Minor (36-65%)Minimal (66-95%)No responseUnable to determine
Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry1030342
Participants With CML: BID Dosing at Study Entry721131

[back to top]

Number of Participants With Major Cytogenetic Response (MCyR)

Cytogenetic responses are based on the prevalence of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a bone marrow sample. MCyR is defined as number of participants with Complete Cytogenetic Response (CCyR): 0% Ph+ cells in metaphase in bone marrow or Partial Cytogenetic Response (PCyR): >0% to 35% Ph+ cells in metaphase in bone marrow. (NCT00978731)
Timeframe: Pre-treatment to study discontinuation. Median duration of exposure (on-study time) was 23.4 months.

Interventionparticipants (Number)
Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry13
Participants With CML: BID Dosing at Study Entry9

[back to top]

Median Number of Months of Progression-free Survival (PFS) (Kaplan Meier Method)

Interval between randomization date & earliest date of disease progression/death due to any cause, assessed by the Independent Radiology Review Committee (IRRC) using modified World Health Organization (WHO) criteria to define progressive disease (PD): >=25% increase in sum of products of diameters (SOPD) of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion. If no progression/death, date of last tumor assessment used. For participants who had no on-study tumor assessments & were still alive, date of randomization used. (NCT00978731)
Timeframe: Baseline to study discontinuation. Median duration of exposure (on-study time) was 23.4 months.

Interventionmonths (Median)
All Participants32.0

[back to top]

Number of Participants With Grade 3-4 Serum Chemistry Abnormalities

Abnormalities were graded per the NCI (CTC), v3.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Grade 3 and 4 criteria are as follows: Alanine aminotransferase (ALT): Grade 3: 5.0-20.0 * ULN (upper limit of normal), Grade 4: >20.0 * ULN; Calcium: Grade 3: 6.0-<7.0 or >12.5-13.5 mg/dL, Grade 4: <0.6->13.5 mg/dL; Bilirubin: Grade 3: >3-10 * ULN, Grade 4: >10 * ULN; Creatinine: Grade 3: >3.0-6.0 * ULN, Grade 4: >6.0 * ULN; Albumin: Grade 3: <2g/dL (Grade 4 not defined in NCI CTC); Magnesium: Grade 3: 0.6-<0.8 or >2.46-6.6mEq/L, Grade 4: <0.6 or >6.6mEq/L. (NCT00978731)
Timeframe: From start of study until up to 30 days after end of study participation. Median duration of exposure (on-study time) was 23.4 months.

,,,
Interventionparticipants (Number)
Low AlbuminHigh ALTHigh Total BilirubinLow CalciumLow MagnesiumHigh Serum Creatinine
Accelerated Phase CML: BID Dosing at Study Entry000000
Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry110000
CML: BID Dosing at Study Entry010000
Myeloid Blast Phase CML: BID Dosing at Study Entry000000

[back to top]

Median Number of Months of CHR (Kaplan Meier Method)

CHR: WBC<=ULN (range: 9.29-12.5*10^3 cuL); ANC >=1000/mm^3;Platelets <450000/mm^3,no blasts/promyelocytes in peripheral blood; <5% myelocytes+metamyelocytes in peripheral blood; basophils in peripheral blood <20% & no extramedullary involvement. Duration computed for chronic phase participants, measured in months from first day CHR criteria met, provided they are confirmed 4 weeks later, until progression of disease, treatment discontinuation due to progressive disease or death. Participants who neither discontinue due to progression, nor progress nor die censored on date of last assessment. (NCT00978731)
Timeframe: Pre-treatment to study discontinuation. Median duration of exposure (on-study time) was 23.4 months.

Interventionmonths (Median)
Participants With Chronic Myelogenous Leukemia (CML)52.0

[back to top]

Median Number of Months of Overall Survival (OS) (Kaplan Meier Method)

Overall survival was defined as the median number of months from baseline to death from any cause. (NCT00978731)
Timeframe: Baseline to study discontinuation. Median duration of exposure (on-study time) was 23.4 months.

Interventionmonths (Median)
All ParticipantsNA

[back to top]

Number of Participants With Complete Hematologic Response (CHR)

CHR should meet all of the following criteria: WBC <= Institutional ULN; ANC >= 1000/mm^3 ; Platelets < 450 000/mm^3 , no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; basophils in peripheral blood < 20% and no extramedullary involvement (including no hepatomegaly or splenomegaly). CHR can begin only 14 days after the start of treatment. (NCT00978731)
Timeframe: Pre-treatment to study discontinuation. Median duration of exposure (on-study time) was 23.4 months.

Interventionparticipants (Number)
Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry16
CML: BID Dosing at Study Entry13

[back to top]

Median Number of Months of Major Cytogenetic Response (MCyR)

MCyR: 0% Ph+ cells in metaphase in bone marrow or Partial Cytogenetic Response (PCyR): >0% to 35% Ph+ cells in metaphase in bone marrow.The duration of MCyR was computed for chronic phase participants whose best response is either CCyR or PCyR. It was measured in months from the time measurement criteria are first met for CCyR or PCyR (whichever status is recorded first) until the date of progression or death. Participants who neither progress nor die are censored on the date of their last cytogenetic assessment. (NCT00978731)
Timeframe: Pre-treatment to study discontinuation. Median duration of exposure (on-study time) was 23.4 months.

Interventionmonths (Median)
Participants With Chronic Myelogenous Leukemia (CML)50.1

[back to top]

Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation.

AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to AEs were recorded. These data differ from that in the Participant Flow section. This is because the data were collected on 2 different pages of the Case Report Form and were not reconciled. (NCT00978731)
Timeframe: From start of study until up to 30 days after end of study participation. Median duration of exposure (on-study time) was 23.4 months.

,,,
Interventionparticipants (Number)
DeathsSAEsAEsDiscontinuation due to AEs
Accelerated Phase CML: BID Dosing at Study Entry1351
Chronic Myelogenous Leukemia (CML): QD Dosing at Study Entry310224
CML: BID Dosing at Study Entry29153
Myeloid Blast Phase CML: BID Dosing at Study Entry1340

[back to top] [back to top] [back to top]

Participants With Detectable Mutations of RNA (mRNA) of BCR-ABL at Baseline and at Best Achievement

Detectable BCR-ABL transcripts (b3a2, b2a2 or minor) >=2.0 log copy/micrograms RNA, as measured by real-time quantitative PCR (RQ-PCR) at baseline and best achievement post-dose. (NCT01030718)
Timeframe: At baseline, every 12 weeks up to 2 years on study (including study CA180031/NCT00337454), every 24 weeks thereafter, and at discontinuation

,,
Interventionparticipants (Number)
BaselineBest Achievement
CML - Accelerated Phase and Blast Phase (CML-AP/BP)117
CML - Chronic Phase (CML-CP)2812
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)106

[back to top]

Participants With CML-AP/BP: Percentage of Participants With Hematologic Response

Major Hematologic Response=Complete Hematologic Response (CHR) or No Evidence of Leukemia (NEL). CHR=WBC 1,000/mm3; platelets >100,000/mm3; no blasts or promyelocytes in peripheral blood; BM blasts ≤5%; <5% myelocytes + metamyelocytes in peripheral blood; <20% basophils in peripheral blood; no extramedullary involvement. NEL=(see Outcome Measure 15, below). Overall hematologic response (OHR)=best response of CHR, NEL or return to chronic phase (RTC). (NCT01030718)
Timeframe: baseline; every 4 weeks < 6 months on study (including study CA180031/NCT00337454); every 12 weeks >=6 months and <=2 years; every 24 weeks >2 years; at discontinuation

,,
InterventionPercentage of Participants (Number)
Overall hematologic response (OHR)Major hematologic response (MaHR)Complete hematologic response (CHR)
CML-AP/BP - Imatinib Intolerant67670
CML-AP/BP - Imatinib Resistant757575
CML-AP/BP - Total Cohort737355

[back to top]

Participants With CML-Accelerated or Blast Phase (AP/BP): Percentage of Participants With Cytogenetic Response

Cytogenetic responses (CyR) are based on the percentage of Ph+ metaphases among at least 20 metaphase cells in each bone marrow (BM) sample. The criteria for cytogenetic responses are as follows. Best CyR is defined as the best response obtained at any time during the study. Major Cytogenetic Response (MCyR) = Complete Cytogenetic Response (CCyR; 0 Ph+ Cells in Metaphase in BM), plus Partial Cytogenetic Response (PCyR; 1 - 35 Ph+ Cells in Metaphase in BM). (NCT01030718)
Timeframe: At baseline, every 12 weeks up to 2 years on study (including study CA180031/NCT00337454), every 24 weeks thereafter

,,
InterventionPercentage of Participants (Number)
Major cytogenetic response (MCyR)Complete cytogenetic response (CCyR)
CML-AP/BP - Imatinib Intolerant00
CML-AP/BP - Imatinib Resistant3825
CML-AP/BP - Total Cohort2718

[back to top]

Participants With Chronic Phase CML (CML-CP): Percentage of Participants With Cytogenetic Response

Cytogenetic responses (CyR) are based on the percentage of Ph+ metaphases among at least 20 metaphase cells in each bone marrow (BM) sample. The criteria for cytogenetic responses are as follows. Best CyR is defined as the best response obtained at any time during the study. Major Cytogenetic Response (MCyR) = Complete Cytogenetic Response (CCyR; 0 Ph+ Cells in Metaphase in BM), plus Partial Cytogenetic Response (PCyR; 1 - 35 Philadelphia positive [Ph+] Cells in Metaphase in BM). (NCT01030718)
Timeframe: At baseline, every 24 weeks thereafter (including study CA180031/NCT00337454)

,,
InterventionPercentage of Participants (Number)
Major cytogenetic response (MCyR)Complete cytogenetic response (CCyR)
CML - Chronic Phase (CML-CP) - Imatinib Intolerant10092
CML - Chronic Phase (CML-CP) - Imatinib Resistant6144
CML - Chronic Phase (CML-CP) Total7763

[back to top]

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. (NCT01030718)
Timeframe: baseline; every 4 weeks (if on study < 6 months, including CA180-031(NCT00337454); every 12 weeks (if on study >=6 months and <=2 years); every 24 weeks (if on study >2 years); at discontinuation

,,
Interventionparticipants (Number)
AEs (symptoms/signs and laboratory abnormalities)SAEs (symptoms/signs and laboratory abnormalities)DeathsAEs that led to discontinuation
CML - Accelerated Phase and Blast Phase (CML-AP/BP)11927
CML - Chronic Phase (CML-CP)301314
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)131134

[back to top]

Participants With CML-AP/BP and Ph+ALL: Duration of Complete Cytogenetic Response (CCyR)

Cytogenetic responses (CyR) are based on the percentage of Ph+ metaphases among at least 20 metaphase cells in each bone marrow (BM) sample. Complete Cytogenetic Response (CCyR) = 0 Ph+ Cells in Metaphase in BM. Duration of CCyR was measured from the time measurement criteria are first met for CCyR until the first date of PD or death. Subjects who neither relapsed nor died will be censored on the date of their last assessment. (NCT01030718)
Timeframe: At baseline, every 12 weeks up to 2 years on study (including study CA180031/NCT00337454), every 24 weeks thereafter

InterventionDays (Median)
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)96.5

[back to top]

Duration of Complete Hematologic Response (CHR) in Chronic Phase CML, Accelerated or Blast Phase CML, and Ph+ALL

Duration of CHR was computed only for chronic phase CML subjects whose best response is CHR. It was measured from the first day complete hematologic response criteria are met provided they are confirmed 28 days later until the date treatment is discontinued due to PD or death. Subjects who neither progressed nor died were censored on the date of their last hematologic assessment. (NCT01030718)
Timeframe: baseline; every 4 weeks < 6 months on study (including study CA180031/NCT00337454); every 12 weeks >=6 months and <=2 years; every 24 weeks >2 years; at discontinuation

InterventionDays (Median)
CML - Chronic Phase (CML-CP)1160
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)373

[back to top]

Duration of Major Hematologic Response (MaHR) in Accelerated or Blast Phase CML, and Ph+ALL

Major Hematologic Response (MaHR)=Complete Hematologic Response (CHR) or No Evidence of Leukemia (NEL; see Outcome Measures 14 and 15 for full definitions). Subjects who neither progressed nor died were censored on the date of their last hematologic assessment. (NCT01030718)
Timeframe: baseline; every 4 weeks < 6 months on study (including study CA180031/NCT00337454); every 12 weeks >=6 months and <=2 years; every 24 weeks >2 years; at discontinuation

InterventionDays (Median)
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)102.5

[back to top]

Duration of Overall Hematologic Response (OHR) in Accelerated or Blast Phase CML, and Ph+ALL

The overall hematologic response (OHR) rate is defined as the proportion of all treated subjects with a best response of major or minor hematologic response. Subjects who neither progressed nor died were censored on the date of last hematologic assessment. (NCT01030718)
Timeframe: baseline; every 4 weeks < 6 months on study (including study CA180031/NCT00337454); every 12 weeks >=6 months and <=2 years; every 24 weeks >2 years; at discontinuation

InterventionDays (Median)
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)104

[back to top]

Time to Complete Hematologic Response (CHR) in Chronic Phase CML, Accelerated or Blast Phase CML, and Ph+ALL

CHR=all of the following criteria: WBC ≤institutional upper limit of normal(ULN); platelets <450,000/mm³; no blasts or promyelocytes in peripheral blood; <5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils <20%; no extramedullary involvement. Time to CHR=time from first dose of dasatinib until the first day criteria for CHR are met provided they are confirmed 28 days later and was computed only for chronic phase CML subjects whose best response is CHR. Subjects who neither progressed nor died were censored at date of last hematologic assessment. (NCT01030718)
Timeframe: baseline; every 4 weeks < 6 months on study (including study CA180031/NCT00337454); every 12 weeks >=6 months and <=2 years; every 24 weeks >2 years; at discontinuation

InterventionDays (Median)
CML - Chronic Phase (CML-CP)12.5
CML - Accelerated Phase and Blast Phase (CML-AP/BP)89
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)98.5

[back to top]

Time to Overall Hematologic Response (OHR) in Accelerated or Blast Phase CML, and Ph+ALL

The overall hematologic response (OHR) rate is defined as the proportion of all treated subjects with a best response of major or minor hematologic response. Time to OHR = time from first dose of dasatinib until the first day measurement criteria are first met for hematologic response provided they were confirmed 28 days later. Subjects who neither progressed nor died were censored on the date of last hematologic assessment. (NCT01030718)
Timeframe: baseline; every 4 weeks < 6 months on study (including study CA180031/NCT00337454); every 12 weeks >=6 months and <=2 years; every 24 weeks >2 years; at discontinuation

InterventionDays (Median)
CML - Accelerated Phase and Blast Phase (CML-AP/BP)38.5
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)13

[back to top]

Status of Point Mutations of BCR-ABL at Baseline (BL) and End of Study (EOS)

Point mutations of BCR-ABL detected or undetected in the Quantitative real-time PCR polymerase chain reaction (RQ-PCR) products (NCT01030718)
Timeframe: At baseline and discontinuation--the study period was extended until the launch of dasatinib in Japan, January 2009.

,,
Interventionparticipants (Number)
Undetectable at BL → Detectable at EOSDetectable at BL → Detectable at EOSDetectable at BL → Undetectable at EOSDetectable at BL → Not Analyzed at EOS
CML - Accelerated Phase and Blast Phase (CML-AP/BP)1101
CML - Chronic Phase (CML-CP)1221
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)7301

[back to top]

Participants With CML-CP: Time to Complete Cytogenetic Response (CCyR)

Cytogenetic responses (CyR) are based on the percentage of Ph+ metaphases among at least 20 metaphase cells in each bone marrow (BM) sample. Complete Cytogenetic Response (CCyR) = 0 Ph+ Cells in Metaphase in BM. Time to complete CCyR is defined as the time from first dose of dasatinib until measurement criteria are first met for CCyR, and is computed only for subjects whose best response is CCyR. (NCT01030718)
Timeframe: At baseline, every 24 weeks thereafter (including study CA180031/NCT00337454),

InterventionDays (Median)
CML - Chronic Phase (CML-CP)169

[back to top]

Time to Major Hematologic Response (MaHR) in Accelerated or Blast Phase CML, and Ph+ALL

Major Hematologic Response=Complete Hematologic Response (CHR) or No Evidence of Leukemia (NEL; see Outcome Measures 14 and 15 for full definitions). Time to major hematologic response (MaHR)=time from first dose of dasatinib until the first day the measurement criteria for MaHR and is computed only for advanced diseases subjects whose best response is a major hematologic response. Subjects who neither progressed nor died were censored on the date of their last hematologic assessment. (NCT01030718)
Timeframe: baseline; every 4 weeks < 6 months on study (including study CA180031/NCT00337454); every 12 weeks >=6 months and <=2 years; every 24 weeks >2 years; at discontinuation

InterventionDays (Median)
CML - Accelerated Phase and Blast Phase (CML-AP/BP)45.5
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)59

[back to top]

Participants With CML-CP: Percentage of Participants With Complete Hematologic Response (CHR)

CHR=all of the following criteria: white blood cell count (WBC) ≤institutional upper limit of normal(ULN); platelets <450,000/mm³; no blasts or promyelocytes in peripheral blood; <5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils <20%; no extramedullary involvement. (NCT01030718)
Timeframe: baseline; every 4 weeks < 6 months on study (including study CA180031/NCT00337454), every 12 weeks >=6 months and <=2 years; every 24 weeks >2 years; at discontinuation

InterventionPercentage of Participants (Number)
CML - Chronic Phase (CML-CP) Total93
CML - Chronic Phase (CML-CP) - Imatinib Resistant89
CML - Chronic Phase (CML-CP) - Imatinib Intolerant100

[back to top]

Participants With CML-AP/BP and Ph+ALL: Time to Major Cytogenetic Response (MCyR)

Major Cytogenetic Response (MCyR) = Complete Cytogenetic Response (CCyR; 0 Ph+ Cells in Metaphase in BM), plus Partial Cytogenetic Response (PCyR; 1 - 35 Ph+ Cells in Metaphase in BM). Time to MCyR was defined as the time from first dose of dasatinib until measurement criteria were first met for CCyR or PCyR (whichever status is recorded first). (NCT01030718)
Timeframe: At baseline, every 12 weeks up to 2 years on study (including study CA180031/NCT00337454), every 24 weeks thereafter

InterventionDays (Median)
CML - Accelerated Phase and Blast Phase (CML-AP/BP)85
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)85

[back to top]

Participants With CML-AP/BP and Ph+ ALL: Time to Complete Cytogenetic Response (CCyR)

Cytogenetic responses (CyR) are based on the percentage of Ph+ metaphases among at least 20 metaphase cells in each bone marrow (BM) sample. Complete Cytogenetic Response (CCyR) = 0 Ph+ Cells in Metaphase in BM. Time to complete CCyR is defined as the time from first dose of dasatinib until measurement criteria are first met for CCyR, and is computed only for subjects whose best response is CCyR. (NCT01030718)
Timeframe: At baseline, every 12 weeks up to 2 years on study (including study CA180031/NCT00337454), every 24 weeks thereafter

InterventionDays (Median)
CML - Accelerated Phase and Blast Phase (CML-AP/BP)215
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)82

[back to top]

Participants With CML-AP/BP and Ph+ ALL: Duration of Major Cytogenetic Response (MCyR)

Major Cytogenetic Response (MCyR) = Complete Cytogenetic Response (CCyR; 0 Ph+ Cells in Metaphase in BM), plus Partial Cytogenetic Response (PCyR; 1 - 35 Ph+ Cells in Metaphase in BM). Duration of MCyR was measured from the time measurement criteria are first met for CCyR or PCyR (whichever status is recorded first) until the first date of progressive disease (PD) or death. Subjects who neither relapsed nor died were censored on the date of their last assessment. (NCT01030718)
Timeframe: At baseline, every 12 weeks up to 2 years on study (including study CA180031/NCT00337454), every 24 weeks thereafter

InterventionDays (Median)
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)85

[back to top]

Participants With Ph+ ALL: Percentage of Participants With Hematologic Response

Major Hematologic Response=Complete Hematologic Response (CHR) or No Evidence of Leukemia (NEL). CHR=(see Outcome Measure 14, above). NEL=WBC ≤ULN; BM blasts ≤5%; no blasts or promyelocytes in peripheral blood; <5% myelocytes plus metamyelocytes in peripheral blood; <20% peripheral blood basophils; no extramedullary involvement; and at least 1 of the following: ANC ≥500/mm3 and <2000/mm3 or platelets ≥20,000/mm3 and <100,000/mm3. Overall hematologic response (OHR)=best response of CHR, NEL or return to chronic phase (RTC). (NCT01030718)
Timeframe: baseline; every 4 weeks < 6 months on study (including study CA180031/NCT00337454); every 12 weeks >=6 months and <=2 years; every 24 weeks >2 years; at discontinuation

,,
InterventionPercentage of Participants (Number)
Overall hematologic response (OHR)Major hematologic response (MaHR)Complete hematologic response (CHR)
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) - Intolerant10075.550
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) - Resistant56330
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) - Total Cohort694615

[back to top]

Participants With Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL): Percentage of Participants With Cytogenetic Response

Cytogenetic responses (CyR) are based on the percentage of Ph+ metaphases among at least 20 metaphase cells in each bone marrow (BM) sample. The criteria for cytogenetic responses are as follows. Best CyR is defined as the best response obtained at any time during the study. Major Cytogenetic Response (MCyR) = Complete Cytogenetic Response (CCyR; 0 Ph+ Cells in Metaphase in BM), plus Partial Cytogenetic Response (PCyR; 1 - 35 Ph+ Cells in Metaphase in BM). (NCT01030718)
Timeframe: At baseline, every 12 weeks up to 2 years on study (including study CA180031/NCT00337454), every 24 weeks thereafter

,,
InterventionPercentage of Participants (Number)
Major cytogenetic response (MCyR)Complete cytogenetic response (CCyR)
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) - Intolerant100100
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) - Resistant3322
Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) - Total Cohort5446

[back to top]

Participants With CML-CP: Time to Major Cytogenetic Response (MCyR)

Major Cytogenetic Response (MCyR) = Complete Cytogenetic Response (CCyR; 0 Ph+ Cells in Metaphase in BM), plus Partial Cytogenetic Response (PCyR; 1 - 35 Ph+ Cells in Metaphase in BM). Time to MCyR was defined as the time from first dose of dasatinib until measurement criteria were first met for CCyR or PCyR (whichever status is recorded first). (NCT01030718)
Timeframe: At baseline, every 24 weeks thereafter (including study CA180031/NCT00337454)

InterventionDays (Median)
CML - Chronic Phase (CML-CP)169

[back to top]

Progression-Free Survival

Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to date of first evidence of progression or the date of last follow-up for patients who do not progress. (NCT01092728)
Timeframe: Evaluated every 2 cycles (8 weeks) until disease progression or last follow-up, up to two years

InterventionWeeks (Median)
Dasatinib + Unresectable8.00

[back to top]

Biologic Response Evaluation of Tumors With and Without Resectable Tumors

"Biologic response defined as either (complete or partial) metabolic tumor response after 7 days dasatinib treatment by positron emission tomography (PET) scan, >/= 25% decrease in Fluorodeoxyglucose (FDG) activity on PET without >15% increase in tumoral Ki-67 expression or >/=25% decrease in tumoral Ki-67 expression without >15% increase in FDG activity on PET scan. Complete Metabolic Response (CMR): FDG-avidity all lesions reduced to background FDG-avidity level. Partial Metabolic Response (PMR): >/=25% decrease in FDG-avidity as represented by change in mean Standardized Uptake Values (SUV) max. SUVmax measured by drawing region of interest slightly outside each lesion corresponding to those on CT image & adjusted for body weight. Measureable disease by PET scan defined as lesions that can be determined to have FDG-avidity of SUVmax of 3 and 2 x background.~PR or CR confirmatory disease assessment performed >4 weeks (28 days) after criteria for response first met." (NCT01092728)
Timeframe: Assessment at 7 Days with confirmatory disease assessment performed no less than 4 weeks (28 days) afterwards

Interventionparticipants (Number)
Complete Metabolic ResponsePartial Metabolic Response
Dasatinib + Unresectable01

[back to top]

Progression-Free and Overall Survival

To describe the progression-free and overall surivial (NCT01173679)
Timeframe: 2 years

Interventionmonths (Median)
Progression-free survivalOverall survival
Dasatinib, Rituximab, Fludarabine8.7524

[back to top]

Toxicities

Dasatinib may enhance the myelosuppression expected from fludarabine. This toxicity will be monitored with frequent CBC's. If after Day 21 of a cycle there is a grade 4 cytopenia, a dose reduction will occur in the next cycle of treatment, and that cycle cannot start until the ANC > 1,000 and the platelets > 25,000. There is also a risk for pleural effusions with dasatinib, but the risk will be low, since there is a break from dasatinib dosing on days 15-28 of each cycle. Nevertheless, if a grade 2 pleural effusion occurs, there will be a dose reduction in the next cycle of treatment. (NCT01173679)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Platelets72308625Neutropenia72308625Fatigue72308625Dyspnea72308625Pleural effusion72308625Bleeding72308625Fever alone72308625Infection72308625
345Did not have any
Dasatinib, Rituximab, Fludarabine4
Dasatinib, Rituximab, Fludarabine3
Dasatinib, Rituximab, Fludarabine1
Dasatinib, Rituximab, Fludarabine0
Dasatinib, Rituximab, Fludarabine9

[back to top]

Percentage of Participants With a Major Hematologic Response (MHR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP)

MHR was defined as complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR for CML-Adv criteria: white blood cell count (WBC) ≤upper limit normal; absolute neutrophil count (ANC) ≥1,000/mm^3; platelets ≥100,000/mm^3; no blasts or promyelocytes in peripheral blood (PB); basophils <5% in PB; myelocytes + metamyelocytes < 5% in PB; no extramedullary involvement; blasts must be <5%, if bone marrow assessment (BMA) performed. NEL had same criteria, but with lower thresholds for reconstitution of PB counts, as follows: Platelets ≥ 20,000/mm^3 or ANC >500/mm^3. Confirmed MHR obtained if these criteria met and maintained for ≥28 days. CHR for CML-CP criteria WBC ≤10,000/mm^3; platelets <450,000/mm^3; basophils <5% in PB; no blasts or promyelocytes in PB; myelocytes + metamyelocytes <5% in PB; no extramedullary involvement; blasts must be <5% if BMA performed. Confirmed CHR obtained if these criteria met and maintained for ≥28 days. Nilo=nilotinib; SOR=suboptimal response. (NCT01218477)
Timeframe: Day 1 to Week 80

InterventionPercentage of participants (Number)
CML-CP with imatinib or nilo resistance/SOR (n=2)CML-CP with dasatinib resistance/SOR (n=5)CML-CP with imatinib or nilo resistance/SOR (n=1)
Dasatinib, 100/140 mg QD, Plus BMS-833923, 50-200 BID/QD5060100

[back to top] [back to top]

Percentage of Participants With a Major Cytogenetic Response (MCyR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP)

Cytogenetic response (CyR) was based on the proportion of Philadelphia chromosome-positive (Ph+) cells in metaphase analysis of bone marrow. Complete cytogenetic response (CCyR)=0 Ph+ cells; Partial CyR (PCyR)=1 to 35 Ph+ cells; Minor CyCR= 36-65 Ph+ cells; Minimal CyCR= 66-95 Ph+ cells; No response= >96 Ph+ cells. MCyR=CCyR + PCyR. Nilo=nilotinib; SOR=suboptimal response. (NCT01218477)
Timeframe: Day 1 to Week 80

InterventionPercentage of participants (Number)
CML-CP with imatinib or nilo resistance/SOR (n=6)CML-CP with dasatinib resistance/SOR (n=10)CML-Adv with imatinib or nilo resistance/SOR (n=3)
Dasatinib, 100/140 mg QD, Plus BMS-833923, 50-200 BID/QD66.72066.7

[back to top]

Number of Participants With Grade 3-4 Abnormalities on Laboratory Test Results

ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal. Abnormalities were graded according to the Common Toxicity Criteria of the National Cancer Institute from 1 (least severe) to 4 (life threatening). ANC (*10^9): Grade 3, <1.0- 0.5; Grade 4, <0.5. Hemoglobin (mmol/L): Grade 3, <4.9-4.0; Grade 4, <4.0. Platelet count (*10^9/L): Grade 3, <50.0-25.0; Grade 4, <25. WBCs (*10^9): Grade 3, <2.0-1.0; Grade 4, <1.0. Hypocalcemia (mmol/L): Grade 3, <1.75-1.5; Grade 4, <1.5. Hyperkalemia (mmol/L): Grade 3, >6.0-7.0; Grade 4, >7.0. Hypokalemia (mmol/L): Grade 3, <3.0-2.5; Grade 4, <2.5. Hyponatremia (mmol/L), Grade 3, <130-120; Grade 4, <120. Hypermagnesemia (mg/dL): Grade 3, >1.23-3.30; Grade 4, >3.30. Phosphorus (mmol/L): Grade 3, <0.6-0.3; Grade 4, <0.3. Lipase (*ULN): Grade 3, >2.0-5.0; Grade 4, >5.0. (NCT01218477)
Timeframe: Day 1 to Week 80

,,,
InterventionParticipants (Number)
Absolute neutrophil count (ANC)HemoglobinPlatelet count (n=1, 8, 14, 2)White blood cell count (WBC)HypocalcemiaHyperkalemiaHypokalemiaHyponatremiaHypermagnesemiaPhosphorus, inorganic (n=3, 8, 12, 2)Lipase, total (n=3, 3,14, 2)
Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QD00000000000
Dasatinib, 100/140 mg QD00100000000
Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID53331020130
Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QD00000101002

[back to top] [back to top]

30 Day Survival Rate

Percentage of participants who were alive 30 days after starting induction treatment. (NCT01238211)
Timeframe: 30 days

Interventionpercentage of participants (Number)
Treatment (Daunorubicin Hydrochloride, Cytarabine, Dasatinib)97

[back to top]

Complete Response Rate

Percentage of participants who achieve a CR. Complete remission (CR) is defined as: disappearance of all clinical and/or radiologic evidence of disease. Neutrophil count > 1.0 x 10^9/L and platelet count > 100 x 10^9/L, and normal bone marrow differential (< 5% blasts). (NCT01238211)
Timeframe: 60 months

Interventionpercentage of patients (Number)
Treatment (Daunorubicin Hydrochloride, Cytarabine, Dasatinib)90

[back to top]

Cumulative Incidence of Death

(NCT01238211)
Timeframe: 36 months

InterventionParticipants (Count of Participants)
Treatment (Daunorubicin Hydrochloride, Cytarabine, Dasatinib)15

[back to top]

Disease-free Survival

Disease free survival (DFS) is defined as the time from achievement of CR to relapse or death, whichever comes first. The 3 year DFS rate with 95% CI was estimated using the Kaplan-Meier method. (NCT01238211)
Timeframe: 3 years

Interventionpercentage of patients (Number)
Treatment (Daunorubicin Hydrochloride, Cytarabine, Dasatinib)75

[back to top]

Event-free Survival

"Event free survival (EFS) is defined as the time from registration to failure to achieve complete remission (CR), relapse after CR is attained or death, whichever comes first. The 1 year EFS rate with 95% CI was estimated using the Kaplan-Meier method,~Complete remission (CR) is defined as: disappearance of all clinical and/or radiologic evidence of disease. Neutrophil count > 1.0 x 10^9/L and platelet count > 100 x 10^9/L, and normal bone marrow differential (< 5% blasts)." (NCT01238211)
Timeframe: 1 year

Interventionpercentage of patients (Number)
Treatment (Daunorubicin Hydrochloride, Cytarabine, Dasatinib)83

[back to top]

Overall Survival

Overall survival (OS) is defined as time from registration to death. The 3 year OS rate with 95% CI was estimated using the Kaplan-Meier method. (NCT01238211)
Timeframe: 3 years

Interventionpercentage of patients (Number)
Treatment (Daunorubicin Hydrochloride, Cytarabine, Dasatinib)77

[back to top]

Cumulative Incidence of Relapse

(NCT01238211)
Timeframe: 60 months

InterventionParticipants (Count of Participants)
Treatment (Daunorubicin Hydrochloride, Cytarabine, Dasatinib)10

[back to top]

Response

Proportion of patients reaching a CR. A CR requires the following: an absolute neutrophil count (segs and bands) >1000/μL, no circulating blasts, platelets >100,000/μL; adequate bone marrow cellularity with trilineage hematopoiesis, and <5% marrow leukemia blast cells. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement). (NCT01256398)
Timeframe: 10 years

Interventionproportion of participants (Number)
Treatment (Chemotherapy, Transplant).9846

[back to top]

Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.

Proportions will be estimated based on the combined and individual cohorts. (NCT01256398)
Timeframe: 10 years

InterventionParticipants (Count of Participants)
Treatment (Chemotherapy, Transplant)5

[back to top]

Overall Survival (OS)

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: 10 years

InterventionMonths (Median)
Treatment (Chemotherapy, Transplant)55.9

[back to top]

Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)

Proportions will be estimated based on the combined and individual cohorts. (NCT01256398)
Timeframe: 10 years

Interventionproportion of participants (Number)
Treatment (Chemotherapy, Transplant)0.667

[back to top]

Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: At 3 years after CR

Interventionpercentage of patients (Number)
Treatment (Chemotherapy, Transplant)52.6

[back to top]

Disease Free Survival (DFS)

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: 10 years

InterventionMonths (Median)
Treatment (Chemotherapy, Transplant)29.7

[back to top]

Dose Reductions

The number of participants with dose reductions in each arm (NCT01260688)
Timeframe: Duration of Study (median duration on study = 4 cycles)

InterventionParticipants (Count of Participants)
Arm I - Cediranib Plus Dasatinib5
Arm II - Cediranib Alone4

[back to top]

Overall Response Rate

Best overall response rate of each evaluable patient (NCT01260688)
Timeframe: Duration of Study (median duration on study = 4 cycles)

Interventionmonths (Median)
Arm I - Cediranib Plus Dasatinib2.6
Arm II - Cediranib Alone6.4

[back to top]

Dose Interruption Due to AEs

The number of participants with dose-interruptions in each arm due to adverse events (NCT01260688)
Timeframe: Through study completion (median duration on study = 4 cycles)

InterventionParticipants (Count of Participants)
Arm I - Cediranib Plus Dasatinib8
Arm II - Cediranib Alone6

[back to top]

12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2)

Progression is defined using the Prostate Cancer Clinical Trials Working Group (PCWG2) criteria, which includes a compilation of prostate-specific antigen (PSA), bone scan, and CT-scan assessments (Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01260688)
Timeframe: 3 months

Interventionparticipants (Number)
Arm I - Cediranib Plus Dasatinib2
Arm II - Cediranib Alone8

[back to top]

Number Who Experienced Study Medication Dose Intensity

Number of patients who experienced study medication dose of over 80% during Cycle 1 was assessed. (NCT01260688)
Timeframe: Cycle 1 (an average of 28 days)

Interventionparticipant (Number)
Arm I - Cediranib Plus Dasatinib6
Arm II - Cediranib Alone9

[back to top]

Number of Participants With Toxicities

Incidence of toxicities graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) v4.0 (NCT01260688)
Timeframe: Up to 30 days after last dose of study drugs

Interventionparticipants (Number)
Arm I - Cediranib Plus Dasatinib11
Arm II - Cediranib Alone11

[back to top]

Number of Participants With Increased Alkaline Phosphatase BAP

Number of participants with increased alkaline phosphatase BAP (NCT01260688)
Timeframe: Through study completion (median duration on study = 4 cycles)

Interventionparticipants (Number)
Arm I - Cediranib Plus Dasatinib5
Arm II - Cediranib Alone10

[back to top]

Qualtiy of Life Assessment Number of Participants With a Score ≥2 on the Present Pain Intensity (PPI) Scale

Present Pain Intensity (PPI) scale. Scale is measured 0-5, where 0=no pain, 1=mild pain, 2=discomforting pain, 3=distressing pain, 4=horrible pain and 5=excruciating pain Participants who were up to completing the assessment (did not decline) and who reported a score >=2 at the end of any cycle are reported. (NCT01260688)
Timeframe: After every cycle (median duration on study = 4 cycles)

InterventionParticipants (Count of Participants)
Arm I - Cediranib Plus Dasatinib4
Arm II - Cediranib Alone8

[back to top]

Quality of Life Assessment Using Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire

Scale is measured on a range from 0 (worst quality of life) to 156 (best quality of life). (NCT01260688)
Timeframe: Up to 16 weeks

,
Interventionunits on a scale (Median)
BaselineCycle 2 (8 weeks)Cycle 3 (12 weeks)Cycle 4 (16 weeks)
Arm I - Cediranib Plus Dasatinib117.5120.6109.1114.5
Arm II - Cediranib Alone108.5107105.893.8

[back to top]

Overall Response Rate

Response Rate of Stable Disease and Progressive Disease (NCT01260688)
Timeframe: Duration of Study (median duration on study = 4 cycles)

,
Interventionpercentage of participants (Number)
Stable DiseaseProgressive Disease
Arm I - Cediranib Plus Dasatinib2245
Arm II - Cediranib Alone7718

[back to top] [back to top] [back to top]

Treatment Discontinuation Due to Adverse Events (AEs)

Treatment discontinuation due to Adverse Events (NCT01260688)
Timeframe: Through study completion (median duration on study = 4 cycles)

Interventionparticipants (Number)
Arm I - Cediranib Plus Dasatinib2
Arm II - Cediranib Alone1

[back to top]

Treatment Discontinuation

Discontinuation of treatment in cycle 1 (average of 28 days) (NCT01260688)
Timeframe: Cycle 1 (average of 28 days)

InterventionParticipants (Count of Participants)
Arm I - Cediranib Plus Dasatinib7
Arm II - Cediranib Alone6

[back to top]

Participants for Which Bone Biomarkers for Beta-C Telopeptide Was Reduced

Participants for which beta-C telopeptide was reduced (NCT01260688)
Timeframe: Through study completion (median duration on study = 4 cycles)

InterventionParticipants (Count of Participants)
Arm I - Cediranib Plus Dasatinib7
Arm II - Cediranib Alone6

[back to top]

Phosphorylation Status of Phosphorylated SRC (p-SRC) in Skin After Treatment (Phase II)

"p-SRC was analyzed in the skin biopsies taken at cycle 1 day 1 at 0 hours and 8 hours, only in patients accepting to participate.~A semi-quantitative H-score (or histo score) determined by the estimation of the percentage of tumour cells positively stained with low, medium, or high staining intensity. The final score is determined after applying a weighting factor to each estimate. The formula used is H-score = (low %) × 1 + (medium %) × 2 + (high %) × 3, and the results ranged from minimum 0 to maximum 300.~Aim: to confirm the mechanism of action identified in preclinical models where the combination of dasatinib and trastuzumab show a statistically significant reduction in the phosphorylated levels of SRC." (NCT01306942)
Timeframe: Cycle 1 day 1 at 0 hours and at 8 hours

Interventionscore on a scale (Mean)
H-score 0 hoursH-score 8 hours
Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m210527

[back to top]

Phosphorylation Status of Phosphorylated SRC (p-SRC) in Skin After Treatment (Phase I)

"p-SRC was analyzed in the skin biopsies taken at cycle 1 day 1 at 0 hours and 8 hours, cycle 1 day 4 and cycle 2 day 1, only in patients accepting to participate.~A semi-quantitative H-score (or histo score) determined by the estimation of the percentage of tumour cells positively stained with low, medium, or high staining intensity. The final score is determined after applying a weighting factor to each estimate. The formula used is H-score = (low %) × 1 + (medium %) × 2 + (high %) × 3, and the results ranged from minimum 0 to maximum 300.~Aim: to confirm the mechanism of action identified in preclinical models where the combination of dasatinib and trastuzumab show a statistically significant reduction in the phosphorylated levels of SRC." (NCT01306942)
Timeframe: Cycle 1 day 1 at 0 hours and at 8 hours, cycle 1 day 4 and cycle 2 day 1

Interventionscore on a scale (Mean)
H-score Cycle 1, day 1, 0 hoursH-score Cycle 1, day 1, 8 hoursH-score Cycle 1, day 4H-score Cycle 2, day 1
Phase I: Dasatinib + Trastuzumab + Paclitaxel103281420

[back to top]

Phosphorylation Status of Phosphorylated ERK (p-ERK) in Skin After Treatment (Phase II)

"Phosphorylated extracellular signal-regulated kinases (p-ERK) 1 and 2 expression were analyzed in the skin biopsies taken at the cycle 1 day 1 at 0 hours and 8 hours, only in patients accepting to participate.~A semi-quantitative H-score (or histo score) determined by the estimation of the percentage of tumour cells positively stained with low, medium, or high staining intensity. The final score is determined after applying a weighting factor to each estimate. The formula used is H-score = (low %) × 1 + (medium %) × 2 + (high %) × 3, and the results ranged from minimum 0 to maximum 300.~Aim: to confirm the mechanism of action identified in preclinical models where the combination of dasatinib and trastuzumab show a statistically significant reduction in the phosphorylated levels of ERK" (NCT01306942)
Timeframe: Cycle 1 day 1 at 0 hours and at 8 hours

Interventionscore on a scale (Mean)
H-score 0 hoursH-score 8 hours
Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m26016

[back to top]

Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Trastuzumab and Paclitaxel (Phase I)

MTD is determined by testing increasing doses of dasatinib on dose escalation cohorts 3 to 6 patients per dose level. MTD reflects the highest dose tested in which a DLT is experienced by 0 out of 3 or 1 out of 6 patients among the dose levels (NCT01306942)
Timeframe: Up to cycle 1

Interventionmg (Number)
Phase I: Dasatinib + Trastuzumab + Paclitaxel100

[back to top]

Number of Participants With Correlation Between Lymphocytosis and Efficacy.

Efficacy (ORR, CBR, TTP, RD and PFS) was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria, and were correlated Lymphocytes, that were measured in the weekly hematology analyses performed within the first cycle. (NCT01306942)
Timeframe: Cycle 1

InterventionParticipants (Count of Participants)
Dasatinib 100mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m20
Dasatinib 140mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m20
PhaseII Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m20

[back to top]

Number of Participants With Dose Limiting Toxicity (DLT) Within the First Cycle of Dasatinib in Combination With Trastuzumab and Paclitaxel (Phase I)

DLT was defined as the occurrence of any of the following adverse events or abnormal laboratory value (graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03), assessed as possibly, probably or definitively related to study drugs, occurring within the first cycle of study treatment: Need of any dose modification within the first cycle due to toxicity, grade 3 or 4 neutropenia complicated with fever ≥38.5° C or infection, grade 4 neutropenia (absolute neutrophil count (ANC)<0.5x1000000000/L) of at least 7 days duration, grade 3 thrombocytopenia complicated by hemorrhage, grade 4 thrombocytopenia, any grade 4 non-hematologic toxicity, grade 3 non-hematologic toxicities except nausea, vomiting, or diarrhea that can be controlled by appropriate medical intervention or prophylaxis, inability to resume dosing for cycle 2 at the current dose level within 14 days due to treatment related toxicity. (NCT01306942)
Timeframe: Up to cycle 1

InterventionParticipants (Count of Participants)
Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m21
Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m22

[back to top]

Objective Response Rate (ORR)

Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. ORR is defined as the percentage of patients with a Complete Response (CR) or Partial Response (PR) out of the patients who had measurable disease at baseline. Per RECIST, Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as an >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01306942)
Timeframe: Through study treatment, an average of 24 months

InterventionParticipants (Count of Participants)
Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m223

[back to top]

Phosphorylated AKT (p-AKT) Protein Expression Change in Peripheral Blood Mononuclear Cells After 8 Hours of Treatment (Phase II)

Sequential peripheral blood mononuclear cells (PBMCs) on Cycle 1 Day 1 before treatment and 8 hours (h) after treatment (0h and 8h) were assessed to explore changes in the expression of p-AKT proteins measured by enzyme-linked immunosorbent assay (ELISA). For ELISA analyses, a duplicate of 100 µg of the extract was used to detect p-AKT (Ser473). ELISA is a plate-based assay technique designed for detecting and quantifying proteins. The instrumentation used for protein signal-detection is an absorbance spectrophotometer (AS), which measures Absorbance (A). A is the quantity of light absorbed by a sample. As different compounds absorb light at different wavelengths, an AS can be used to distinguish compounds by analyzing the pattern of wavelengths absorbed by a given sample. Additionally, the amount of light absorbed is directly proportional to the concentration of absorbing compounds in that sample, so an AS can also be used to determine concentrations of compounds in the sample. (NCT01306942)
Timeframe: Cycle 1 day 1 at 0 hours and at 8 hours

InterventionAbsorbance 450 nm (Mean)
Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m20.04

[back to top]

Phosphorylation Status of Phosphorylated ERK (p-ERK) in Skin After Treatment (Phase I)

"p-ERK was analyzed in the skin biopsies taken at cycle 1 day 1 at 0 hours and 8 hours, cycle 1 day 4 at 8 hours, and cycle 2 day 1 at 8 hours, only in patients accepting to participate.~A semi-quantitative H-score (or histo score) determined by the estimation of the percentage of tumour cells positively stained with low, medium, or high staining intensity. The final score is determined after applying a weighting factor to each estimate. The formula used is H-score = (low %) × 1 + (medium %) × 2 + (high %) × 3, and the results ranged from minimum 0 to maximum 300.~Aim: to confirm the mechanism of action identified in preclinical models where the combination of dasatinib and trastuzumab show a statistically significant reduction in the phosphorylated levels of ERK" (NCT01306942)
Timeframe: Cycle 1 day 1 at 0 hours and at 8 hours, cycle 1 day 4 at 8 hours and cycle 2 day 1 at 8 hours

Interventionscore on a scale (Mean)
H-score Cycle 1, day 1, 0 hoursH-score Cycle 1, day 1, 8 hoursH-score Cycle 1, day 4, 8 hoursH-score Cycle 2, day 1, 8 hours
Phase I: Dasatinib + Trastuzumab + Paclitaxel63201411

[back to top]

Phosphorylation Status of Phosphorylated AKT (p-AKT) in Skin After Treatment (Phase II)

"p-AKT was analyzed in the skin biopsies taken at cycle 1, day 1 at 0 hours and 8 hours, only in patients accepting to participate.~A semi-quantitative H-score (or histo score) determined by the estimation of the percentage of tumour cells positively stained with low, medium, or high staining intensity. The final score is determined after applying a weighting factor to each estimate. The formula used is H-score = (low %) × 1 + (medium %) × 2 + (high %) × 3, and the results ranged from minimum 0 to maximum 300.~Aim: to confirm the mechanism of action identified in preclinical models where the combination of dasatinib and trastuzumab show a statistically significant reduction in the phosphorylated levels of AKT" (NCT01306942)
Timeframe: Cycle 1 day 1 at 0 hours and at 8 hours

Interventionscore on a scale (Mean)
H-score 0 hoursH-score 8 hours
Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m27020

[back to top]

Phosphorylation Status of Phosphorylated AKT (p-AKT) in Skin After Treatment (Phase I)

"p-AKT was analyzed in the skin biopsies taken at cycle 1, day 1 at 0 hours and 8 hours, and cycle 2 day 1, only in patients accepting to participate.~A semi-quantitative H-score (or histo score) determined by the estimation of the percentage of tumour cells positively stained with low, medium, or high staining intensity. The final score is determined after applying a weighting factor to each estimate. The formula used is H-score = (low %) × 1 + (medium %) × 2 + (high %) × 3, and the results ranged from minimum 0 to maximum 300.~Aim: to confirm the mechanism of action identified in preclinical models where the combination of dasatinib and trastuzumab show a statistically significant reduction in the phosphorylated levels of AKT" (NCT01306942)
Timeframe: Cycle 1 day 1 at 0 hours and at 8 hours and cycle 2 day 1

Interventionscore on a scale (Mean)
H-score Cycle 1, day 1, 0 hoursH-score Cycle 1, day 1, 8 hoursH-score Cycle 1, day 4, 8 hoursH-score Cycle 2, day 1, 8 hours
Phase I: Dasatinib + Trastuzumab + Paclitaxel65201013

[back to top]

Dasatinib Maximun Plasma Concentration (Cmax) Value (Pharmacokinetics (PK) Phase I)

"To assess the influence of the concomitant administration of paclitaxel and trastuzumab on dasatinib PKs, we compared dasatinib exposures alone (first PK occasion: day 2 of cycle 1) or combined (second PK occasion: day 18 on cycle 1).~The mean profiles of dasatinib plasma concentrations were determined by dose and PK occasion." (NCT01306942)
Timeframe: Cycle 1 day 2 and day 18

,
Interventionng/mL (Mean)
Day 2 Dasatinib aloneDay 18 Dasatinib in combination P and T
Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2191.078.4
Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2422.3314.4

[back to top]

Dasatinib Area Under the Plasma Concentration-time Curve (AUC) Value (Pharmacokinetics (PK) Phase I)

"To assess the influence of the concomitant administration of paclitaxel and trastuzumab on dasatinib PKs, we compared dasatinib exposures alone (first PK occasion: day 2 of cycle 1) or combined (second PK occasion: day 18 on cycle 1).~The area under the plasma concentration-time curve from time zero to 8 hours post dose (AUC0-8) were calculated in all treated patients, as the dasatinib plasmatic half-life is very short and concentrations at 24 hours post dose could only be quantified in some patients." (NCT01306942)
Timeframe: Cycle 1 day 2 and day 18

,
Interventionng·h/mL (Mean)
Day 2 Dasatinib aloneDay 18 Dasatinib in combination P and T
Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2530.6248.1
Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m21159.21047.3

[back to top]

Phosphorylated SRC (p-SRC) Protein Expression Change in Peripheral Blood Mononuclear Cells After 8 Hours of Treatment (Phase II)

Sequential peripheral blood mononuclear cells (PBMCs) on Cycle 1 Day 1 before treatment and 8 hours (h) after treatment (0h and 8h) were assessed to explore changes in the expression of p-SRC proteins measured by enzyme-linked immunosorbent assay (ELISA). For ELISA analyses, a duplicate of 100 µg of the extract was used to detect p-SRC (Tyr416). ELISA is a plate-based assay technique designed for detecting and quantifying proteins. The instrumentation used for protein signal-detection is an absorbance spectrophotometer (AS), which measures Absorbance (A). A is the quantity of light absorbed by a sample. As different compounds absorb light at different wavelengths, an AS can be used to distinguish compounds by analyzing the pattern of wavelengths absorbed by a given sample. Additionally, the amount of light absorbed is directly proportional to the concentration of absorbing compounds in that sample, so an AS can also be used to determine concentrations of compounds in the sample. (NCT01306942)
Timeframe: Cycle 1 day 1 at 0 hours and at 8 hours

InterventionAbsorbance 450 nm (Mean)
Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m20.36

[back to top]

To Evaluate the Clinical Benefit Rate (CBR)

Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. CBR is defined as the percentage of patients with a Complete Response (CR) or Partial Response (PR) plus stable disease lasting at least 6 months out of the efficacy population. Per RECIST, CR is defined as the disappearance of all target lesions; PR is defined as an >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01306942)
Timeframe: Through study treatment, an average of 24 months

InterventionParticipants (Count of Participants)
Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m224

[back to top]

The Number of Participants Who Experienced Adverse Events (AE)

Safety was assessed by standard clinical (blood pressure, pulse and body temperature, electrocardiogram (ECG), left ventricular ejection fraction (LVEF)) and laboratory tests (hematology: hemoglobin, platelet count, red blood cells (RBC), white blood cells (WBC) with differential (neutrophils) and absolute lymphocyte count, and serum chemistry: alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, creatinine, sodium, potassium, magnesium, phosphate and calcium). Adverse events grade were defined by the NCI CTCAE v 4.03. (NCT01306942)
Timeframe: Through study treatment, an average of 24 months

InterventionParticipants (Count of Participants)
Dasatinib 100mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m26
Dasatinib 140mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m24
PhaseII Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m229

[back to top]

Response Duration (RD)

Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. RD is defined as the time from the date when the measurement criteria are met for complete response (CR) or partial response (PR) (whichever status is recorded first) until the date of first observation of disease progression or death occurred. Per RECIST, CR is defined as the disappearance of all target lesions; PR is defined as an >=30% decrease in the sum of the longest diameter of target lesions. For responding patients not known to have died as of the data cut-off date and who do not have progression, RD will be censored at the date of last visit with adequate assessment. For responding patients who receive subsequent anticancer therapy (after discontinuation from the study treatment) prior to progression, RD will be censored at the date of last visit with adequate assessment prior to the initiation of post-discontinuation anticancer therapy. (NCT01306942)
Timeframe: Through study treatment, an average of 24 months

Interventionmonths (Median)
Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m218.4

[back to top]

Progression Free Survival (PFS)

PFS is defined as the time from the date of the first dose to the first date of objectively determined progressive disease or death from any cause. For patients not known to have died as of the data cut-off date and who do not have objectively-determined progressive disease, PFS will be censored at the date of the last objective progression-free assessment. For patients who receive subsequent systemic anticancer therapy (after discontinuation from the study treatment) prior to objective disease progression or death, PFS will be censored at the date of last objective progression-free assessment prior to the initiation of post-discontinuation systemic anticancer therapy. (NCT01306942)
Timeframe: Through study treatment, an average of 24 months

Interventionmonths (Median)
Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m223.9

[back to top] [back to top]

Time to Progression (TTP)

TTP is defined as the time from the date of the first dose to the first date of objectively determined progressive disease. For patients not known to have objectively-determined progressive disease, TTP will be censored at the date of the last objective progression-free assessment. For patients who receive subsequent systemic anticancer therapy (after discontinuation from the study treatment) prior to objective disease progression, TTP will be censored at the date of last objective progression-free assessment prior to the initiation of post-discontinuation systemic anticancer therapy. (NCT01306942)
Timeframe: Through study treatment, an average of 24 months

Interventionmonths (Median)
Phase II:Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m223.9

[back to top]

Number of Participants With Major Molecular Response

Major molecular response (MMR) was assessed using BCR-ABL transcript levels measured by real-time quantitative polymerase chain reaction (qPCR). MMR was defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value). Number of participants with MMR by timepoint are cumulative. (NCT01357655)
Timeframe: Baseline up to 12 months

,
InterventionParticipants (Count of Participants)
Baseline3 Months6 Months12 Months
Dasatinib193034
Dasatinib + SMO Antagonist (BMS-833923)0000

[back to top] [back to top]

Time of Maximum Observed Plasma Concentration (Tmax) of Dasatinib

Single-dose pharmacokinetic parameters, such as Tmax, were derived using noncompartmental methods from plasma dasatinib concentration-time data. (NCT01392703)
Timeframe: Days 1-2, Days 5-6, and Days 9-10

InterventionHours (Median)
Dasatinib, 100 mg as Tablets + Water1.00
Dasatinib, 100 mg as Liquid + Water0.53
Dasatinib, 100 mg as Tablets in Orange Juice + Water0.50

[back to top] [back to top]

Maximum Observed Concentration (Cmax) of Dasatinib

Single-dose pharmacokinetic parameters, including Cmax, were derived using noncompartmental methods from plasma dasatinib concentration-time data. (NCT01392703)
Timeframe: Days 1-2, Days 5-6, and Days 9-10

Interventionng/mL (Geometric Mean)
Dasatinib, 100 mg as Tablets + Water114
Dasatinib, 100 mg as Liquid + Water106
Dasatinib, 100 mg as Tablets in Orange Juice + Water110

[back to top]

Half-life of Dasatinib

(NCT01392703)
Timeframe: Days 1-2, Days 5-6, and Days 9-10

InterventionHours (Mean)
Dasatinib, 100 mg as Tablets + Water4.96
Dasatinib, 100 mg as Liquid + Water4.82
Dasatinib, 100 mg as Tablets in Orange Juice + Water4.91

[back to top]

Area Under the Plasma Concentration-time Curve From Zero to the Last Time of the Last Quantifiable Concentration (AUC[0-T])of Dasatinib

Single-dose pharmacokinetic, such as AUC(0-T),parameters were derived using noncompartmental methods from plasma dasatinib concentration-time data. (NCT01392703)
Timeframe: Days 1-2, Days 5-6, and Days 9-10

Interventionng*h/mL (Geometric Mean)
Dasatinib, 100 mg as Tablets + Water374
Dasatinib, 100 mg as Liquid + Water327
Dasatinib, 100 mg as Tablets in Orange Juice + Water342

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-INF]) of Dasatinib

Single-dose pharmacokinetic parameters, such as AUC(0-INF) were derived using noncompartmental methods from plasma dasatinib concentration-time data. (NCT01392703)
Timeframe: Days 1-2, Days 5-6, and Days 9-10

Interventionng*h/mL (Geometric Mean)
Dasatinib, 100 mg as Tablets + Water429
Dasatinib, 100 mg as Liquid + Water338
Dasatinib, 100 mg as Tablets in Orange Juice + Water353

[back to top]

Number of Participants With Clinically Significant Changes in Vital Signs or Electrocardiogram (ECG) Findings

Blood pressure and heart rate were measured after the participant had been seated quietly for at least 5 minutes. ECG findings were recorded after the participant had been supine for at least 5 minutes. Clinically significant as reported by principal investigator. (NCT01392703)
Timeframe: Day -1, Screening, and Days 1, 5, 9 and 10 (at study discharge)

InterventionParticipants (Number)
Respiratory rateTemperatureSystolic blood pressureDiastolic blood pressureHeart rateQT and QTc IntervalsQRS and PR intervals
All Treated0000000

[back to top]

Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests

Criteria for normal: bilirubin (0.2 to 1.3 mg/dL); lactate dehydrogenase (101 to 227 U/L); eosinophils (0.06 to 0.87*103 c/μL); erythrocytes (4.2 to 5.8*10^6 c/μL). Participants were required to fast for a minimum of 4 hours prior to the collection of specimens for clinical laboratory tests at screening and for at least 8 hours prior to collection on Day -1. Marked abnormalities were reported for the treatment regiment that participants received just prior to clinical laboratory testing. (NCT01392703)
Timeframe: Day -1, Screening, and Day 9 of current treatment regimen

,,
InterventionParticipants (Number)
Elevated bilirubinElevated lactate dehydrogenaseBlood in urine (2+)Elevated eosinophilsLow erythrocytes
Dasatinib, 100 mg as Liquid + Water01000
Dasatinib, 100 mg as Tablets + Water00101
Dasatinib, 100 mg as Tablets in Orange Juice + Water10010

[back to top]

Overall Survival

Overall survival (OS) is the time from randomization until time of death from any cause by 02 December 2013. (NCT01395017)
Timeframe: From randomization until date of death from any cause by 02 December 2013

InterventionDays (Median)
Dasatinib + GEM375
Placebo + GEM393

[back to top]

Progression Free Survival (PFS)

PFS - time from randomization to unequivocal local or distant disease progression, death or discontinuation from trial for any reason by 02 December 2013. Progression events were determined according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 every 8 weeks. (NCT01395017)
Timeframe: Time from randomization to earliest PFS event by 02 December 2013

InterventionDays (Median)
Dasatinib + GEM167
Placebo + GEM166

[back to top]

Incidence of Adverse Events (Number of Participants Affected)

Assessed According to the NCI Common Terminology Criteria for Adverse Events Version 4.0. Adverse events will be tabulated and summarized according to key reporting criteria (i.e., grade or seriousness, unanticipated, treatment attribution). Refer to the Adverse Event tables below for specific details. (NCT01441882)
Timeframe: Up to 4 years

InterventionParticipants (Count of Participants)
Treatment (Dasatinib)8

[back to top]

3-year Event-free Survival (EFS) Rate

"3-year EFS rate is defined as the percentage of participants without event after 3 years since the start of study treatment.~Events for EFS are defined as ANY first one of the following:~Lack of complete response in bone marrow~Relapse at any site~Development of second malignant neoplasm~Death from any cause" (NCT01460160)
Timeframe: From first dose to 3 years following first dose

InterventionPercentage of Participants (Number)
Dasatinib Cohort66.0

[back to top]

Complete Remission Rate

Complete Remission rate is defined as the percentage of participants achieving a complete remission, i.e. < 5% lymphoblasts in bone marrow and in CSF, with no evidence of other extramedullary disease. Complete remission will be assessed at the end of Induction IA, end of induction IB and end of the consolidation period for all treated participants. (NCT01460160)
Timeframe: From first dose to End of Induction Period Ia (up to 5 weeks) or Ib (up to 9 weeks) or End of Consolidation Period (up to 22 weeks)

InterventionPercentage of Partcipants (Number)
End of Induction period IaEnd of Induction period IbEnd of Consolidation period
Dasatinib Cohort65.188.793.4

[back to top]

Event-Free Survival (EFS) Rate (Kaplan-Meier Estimates)

Overall estimation of the EFS of dasatinib plus chemotherapy was performed utilizing the Kaplan-Meier (KM) Product Limit method. The 3-year and 5-year EFS rates were computed with the corresponding 95% CI's using Greenwood's formula. Analyses of EFS included KM plots with number of patients at risk. Participants who neither relapse nor die or who are lost to follow-up were censored on the date of their last bone marrow, CSF assessment or physical exam, whichever occurred last. (NCT01460160)
Timeframe: From first dose to 3 years or 5 years following first dose

InterventionPercentage of Participants (Number)
3-year EFS Estimate5-year EFS Estimate
Dasatinib Cohort65.553.1

[back to top]

Number of Participants Experiencing Adverse Events

Number of participants experiencing different types of all causality all grade adverse events (NCT01460160)
Timeframe: From first dose to 100 days following last dose (up to approximately 23 months)

InterventionParticipants (Count of Participants)
Adverse Events (AEs)Drug-related AEsAEs leading to discontinuationSerious Adverse Events (SAEs)Deaths
Dasatinib Cohort10688710115

[back to top]

Percentage of Participants Negative for Minimal Residual Disease (MRD)

MRD was by real-time qPCR for clone-specific immunoglobulin and T-cell receptor gene rearrangements (IG/TCR). Participants were declared as MRD negative if the MRD level is undetectable providing the assay lower limit of quantification is at least 0.1% (NCT01460160)
Timeframe: From first dose to End of Induction Period Ia (up to 5 weeks) or Ib (up to 9 weeks) or End of Consolidation Period (up to 22 weeks)

InterventionPercentage of Participants (Number)
End of Induction period IaEnd of Induction period IbEnd of Consolidation period
Dasatinib Cohort28.352.871.7

[back to top]

Percentage of Participants With BCR-ABL Mutations at Baseline and at Time of Disease Progression or Relapse

A BCR-ABL mutation is defined as the presence of a detectable amino acid substitution in the ABL kinase domain, assessed by Real-time quantitative PCR. (NCT01460160)
Timeframe: At baseline (prior to start of study treatment) and at disease progression or relapse (up to approximately 3 years)

InterventionPercentage of participants (Number)
At BaselineAt Disease Progression or Relapse
Dasatinib Cohort1.36.5

[back to top]

Response to Treatment

Response of evaluable patients to treatment, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. (NCT01488318)
Timeframe: Up to 36 months

Interventionparticipants (Number)
Patients experiencing Stable Disease (SD)Patients experiencing Progressive Disease (PD)
CETUXIMAB + DASATINIB58

[back to top]

Overall Response Rate (ORR)

Number of patients experiencing a Complete Response (CR) + Partial Response (PR) to study treatment / Total number of evaluable patients, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. (NCT01488318)
Timeframe: Up to 36 months

Interventionpercentage of participants (Number)
CETUXIMAB + DASATINIB0

[back to top]

Progression-free Survival (PFS)

(NCT01488318)
Timeframe: Up to 36 months

Interventionmonths (Median)
CETUXIMAB + DASATINIB1.7

[back to top]

Overall Survival (OS)

From date of entry into the study until the date of death from any cause, assessed up to 60 months. (NCT01488318)
Timeframe: Up to 60 months

Interventionmonths (Median)
CETUXIMAB + DASATINIB5.1

[back to top]

Types and Frequency of DDR2 Mutations

Determine frequency of DDR2 mutations in study patients (NCT01491633)
Timeframe: 2 years

Interventionparticipants (Number)
Dasatinib0

[back to top]

Response Rate

Determine the overall response rate of patients with squamous cell carcinoma of the lung treated with dasatinib (NCT01491633)
Timeframe: 2 years

Interventionpercent (Number)
DasatinibNA

[back to top]

Survival

Establish the overall survival of patients with SCC treated with dasatinib (NCT01491633)
Timeframe: 2 years

Interventiondays (Mean)
Dasatinib112

[back to top]

Time on Study

Number of days participant remained on study (NCT01491633)
Timeframe: 2 years

Interventiondays (Mean)
Dasatinib22

[back to top]

Toxicities

Define the toxicities of dasatinib when administered to the patient population. NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 will be utilized for adverse event reporting. (NCT01491633)
Timeframe: 2 years

Interventiongrade 3 toxicities (Number)
Dasatinib3

[back to top]

Duration of Response

Duration of Response will be measured from the date the given response is achieved to the date the response is first known to be lost (NCT01498445)
Timeframe: up to seven years

InterventionMonths (Median)
Phase I - Dasatinib 100 mg + Decitabine 10 mg/m236.8
Phase I - Dasatinib 100 mg + Decitabine 20 mg/m282
Phase I - Dasatinib 140 mg + Decitabine 10 mg/m257.8
Phase I - Dasatinib 140 mg + Decitabine 20 mg/m258
Phase II - Dasatinib 140 mg + Decitabine 10 mg/m261
Phase II - Dasatinib 140 mg + Decitabine 20 mg/m237

[back to top]

Number of Participants With Hematologic Responses During First 3 Months of Treatment

Number of participants with hematologic response (HR) to therapy during first 3 months of combination dasatinib and decitabine therapy, where HR defined as any hematologic response observed during the first 3 months of treatment. Overall Hematologic Response (OHR) is defined as complete hematologic response (CHR), no evidence of leukemia (NEL) or minor hematologic response (MiHR) (NCT01498445)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Phase I - Dasatinib 100 mg + Decitabine 10 mg/m23
Phase I - Dasatinib 100 mg + Decitabine 20 mg/m21
Phase I - Dasatinib 140 mg + Decitabine 10 mg/m25
Phase I - Dasatinib 140 mg + Decitabine 20 mg/m24
Phase II - Dasatinib 140 mg + Decitabine 10 mg/m23
Phase II - Dasatinib 140 mg + Decitabine 20 mg/m23

[back to top]

Overall Survival

Overall Survival will be measured from the date treatment is started to the date of death or last follow-up. (NCT01498445)
Timeframe: Up to seven years

InterventionMonths (Median)
Phase I - Dasatinib 100 mg + Decitabine 10 mg/m212.0
Phase I - Dasatinib 100 mg + Decitabine 20 mg/m27.0
Phase I - Dasatinib 140 mg + Decitabine 10 mg/m257.8
Phase I - Dasatinib 140 mg + Decitabine 20 mg/m258.2
Phase II - Dasatinib 140 mg + Decitabine 10 mg/m262.0
Phase II - Dasatinib 140 mg + Decitabine 20 mg/m237.5

[back to top]

Ph I Study: Maximum Tolerated Dose (MTD) Dasatinib

Maximum tolerated dose (MTD) defined as highest dose at which 0 of 3 or NCT01498445)
Timeframe: End of first 28-day cycle

InterventionMilligrams (Number)
Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2NA
Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2NA
Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2140
Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2140

[back to top]

Number of Participants With Laboratory Testing Results That Meet the Criteria for Grade 3 or 4 Abnormality

Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to adverse event. Laboratory values graded by Common Terminology Criteria for Adverse Events, volume 3. Hemoglobin, Grade 3: <8.0 - 6.5 g/dL, <4.9-4.0 mmol/L, <80-65 g/L. Alkaline phosphatase, Grade 3: >5.0-20.0*upper limit of normal (ULN). Total bilirubin, Grade 3: >3.0-10.0*ULN. Calcium, low, Grade 3: <7.0-6.0 mg/dL, <1.75-1.5 mmol/L. (NCT01514864)
Timeframe: From enrollment of last patient to 24 months or until all patients have died, whichever occurs first

InterventionParticipants (Number)
Hemoglobin, Grade 3Alkaline phosphatase, Grade 3Total bilirubin, Grade 3Calcium, low, Grade 3
Dasatinib, 140 mg2111

[back to top]

Progression-free Survival (PFS) Distribution

PFS distribution is defined as the percentage of patients with no documentation of disease progression at a specified time point. Confidence interval computed using the Brookmeyer and Crowley method (NCT01514864)
Timeframe: From Day 1 of study treatment to Week 12

InterventionPercentage of participants (Median)
Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation)1.41
Dasatinib, 140 mg (NSCLC With DDR2 Mutation)1.38

[back to top]

Progression-free Survival (PFS)

PFS is defined as the time from treatment start date to the earliest evidence of disease progression or death. Patients who die or whose disease does not progress will be censored on the date of their last tumor assessment. (NCT01514864)
Timeframe: From Day 1 of study treatment to Week 12

InterventionMonths (Median)
Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation)1.41
Dasatinib, 140 mg (NSCLC With DDR2 Mutation)1.38

[back to top]

Overall Survival

Overall survival is defined as the time from treatment start date to the date of death. If a patient does not die, survival will be censored on the last date the patient was known to be alive. (NCT01514864)
Timeframe: From enrollment of last patient to 24 months or until all patients have died, whichever occurs first

InterventionMonths (Median)
Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation)3.06
Dasatinib, 140 mg (NSCLC With DDR2 Mutation)4.21

[back to top] [back to top]

Overall Survival (OS)

OS is the time from randomization date to death date. Participants who have not died will be censored on the last date they are known to be alive. (NCT01593254)
Timeframe: From randomization to study completion. Approximately 115 months

InterventionMonths (Median)
Arm 1: Imatinib (≥400 mg)NA
Arm 2: Dasatinib (100 mg)NA

[back to top]

Percentage of Patients Achieving Major Molecular Response (MMR) After 12 Months of CML Treatment

"Major Molecular Response, is defined as a 3-log reduction in BCR-ABL transcripts from the standardized baseline, which represents 100% on the international scale, so a 3-log reduction is fixed at 0.1% for MMR; N/A = not applicable. 95% CI is Clopper-Pearson(Exact) two-sided 95% confidence intervals.~P-value is based on Cochran-Mantel-Haenszel (CMH) test stratified by Sokal score(high, intermediate, low, and unknown) and time between 3 month molecular analysis and randomization (<=4 weeks vs >4 weeks)." (NCT01593254)
Timeframe: At 12 months after Day 1 initiation of 1st line treatment with imatinib or imatinib at any dose, after less than optimal response to first-line imatinib.

InterventionPercentage of Patients (Number)
Arm 1: Imatinib (≥400 mg)12.8
Arm 2: Dasatinib (100 mg)28.7

[back to top]

Progression Free Survival (PFS)

"PFS is the time from randomization date to progression date or death date, whichever occurs first. Participants who neither progress nor die will be censored.~Progression is defined as the following, meeting the criteria for accelerated or blast crisis CML are met at any time or death from any cause during treatment.~Accelerated phase of CML:~The presence of ≥15%, but < 30% blasts in the blood or bone marrow~At least 30% blasts plus promyelocytes in the blood or bone marrow~At least 20% peripheral basophils~Thrombocytopenia (fewer than 100,000 platelets/mm3) unrelated to treatment.~Blast phase of CML~At least 30% blasts in the blood or bone marrow~Extramedullary involvement (e.g., chloromas), but not hepatosplenomegaly" (NCT01593254)
Timeframe: From randomization to study completion. Approximately 115 months

InterventionMonths (Median)
Arm 1: Imatinib (≥400 mg)NA
Arm 2: Dasatinib (100 mg)NA

[back to top]

Median Time to Major Molecular Response (MMR)

"Median Time to Major Molecular Response (MMR) is the time between randomization date and first date that MMR (or MR4.5) criteria are satisfied. Participants who do not achieve MMR (or MR4.5) will be censored.~Major Molecular Response, is defined as a 3-log reduction in BCR-ABL transcripts from the standardized baseline, which represents 100% on the international scale, so a 3-log reduction is fixed at 0.1% for MMR." (NCT01593254)
Timeframe: From randomization to study completion. Approximately 115 months

InterventionMonths (Median)
Arm 1: Imatinib (≥400 mg)19.7
Arm 2: Dasatinib (100 mg)13.9

[back to top]

Time to Molecular Response (MR)^4.5

"Time to Molecular Response (MR)^4.5 is the time between randomization date and first date that MMR (or MR4.5) criteria are satisfied. Participants who do not achieve MMR (or MR4.5) will be censored.~MR4.5 is defined as a 4.5-log reduction in BCR-ABL transcript from the standardized baseline (0.0032% IS, either detectable disease <= 0.0032% BCR-ABL (IS) or undetectable disease in cDNA (in same volume used for BCR-ABL) with >= 32,000 ABL transcripts." (NCT01593254)
Timeframe: From randomization to study completion. Approximately 115 months

InterventionMonths (Median)
Arm 1: Imatinib (≥400 mg)67.7
Arm 2: Dasatinib (100 mg)74.5

[back to top]

Clinical Activity

Will be defined as defined as a decrease of at least 25% in bone marrow blast counts or peripheral blood blast. The proportion of patients achieving the endpoint along with its 95% exact binomial confidence interval will be presented. (NCT01620216)
Timeframe: Up to 28 days

InterventionParticipants (Count of Participants)
Group I (Dasatinib)1
Group II (Sutinib Malate)0
Group III (Sorafenib Tosylate)4

[back to top]

Overall Survival

Kaplan-Meier method will be used to estimate the survival curve. (NCT01620216)
Timeframe: From the date of subject registration to death, regardless of causes of death, assessed up to 3 years

InterventionDays (Mean)
Group I (Dasatinib)57
Group II (Sutinib Malate)75
Group III (Sorafenib Tosylate)130

[back to top]

Presence of Active/Aberrant Kinase Pathways

Presence of active/aberrant kinase pathways will be determined using a small molecule kinase inhibitor screen, to rapidly identify therapeutic tyrosine kinase targets in leukemia patients while simultaneously providing individualized therapeutic options. Will be correlated with treatment response, mutational analysis using next generation sequencing, and characterization of aberrant gene expression in primary leukemia samples. (NCT01620216)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Group I (Dasatinib)4
Group II (Sutinib Malate)2
Group III (Sorafenib Tosylate)6
Group IV (Ponatinib Hydrochloride)0
Group V (Pacritinib)0
Group VI (Ruxolitinib)0
Group VII (Idelalisib)0

[back to top]

Clinical Activity

Will be defined as a decrease of at least 25% in bone marrow blast counts or in peripheral blood blasts in subjects who have failed the initial inhibitor but are then treated with another inhibitor identified on repeat pre-clinical activity testing. The proportion of patients achieving the endpoint along with its 95% exact binomial confidence interval will be presented. (NCT01620216)
Timeframe: Up to 28 days

InterventionParticipants (Count of Participants)
Group I (Dasatinib)0
Group II (Sutinib Malate)0
Group III (Sorafenib Tosylate)0

[back to top]

Progression-free Survival

Kaplan-Meier method will be used to estimate the survival curve. (NCT01620216)
Timeframe: From the start of study drug treatment to death, regardless of cause of death, or date of disease progression defined as a >= 50% increase in leukemic bone marrow blasts, whichever occurs first, assessed up to 3 years

InterventionParticipants (Count of Participants)
Group I (Dasatinib)1
Group II (Sutinib Malate)1
Group III (Sorafenib Tosylate)0
Group IV (Ponatinib Hydrochloride)0
Group V (Pacritinib)0
Group VI (Ruxolitinib)0
Group VII (Idelalisib)0

[back to top]

Drug Compliance

To determine patient compliance with oral therapy. For this outcome measure, compliance with oral therapy is defined as the percentage of subjects that took dasatinib for at least one cycle. Compliance with oral therapy was documented with a medication diary that subjects were asked to complete to document whether each dose of dasatinib was taken. (NCT01652976)
Timeframe: 3 years

Interventionpercentage of subjects (Number)
Dasatinib and mFOLFOX693.2

[back to top]

Freedom From Metastasis

To determine the rate of freedom from metastasis (FFM), which is defined as the percentage of subjects with documented progressive disease (by RECIST 1.1 criteria) who had no new lesions. RECIST 1.1 criteria defines progressive disease as the appearance of one or more new lesions and/or the increase of the sum of the largest diameter of the target lesions by at least 20% from the smallest sum collected (the sum must also have increased by at least 5 mm). (NCT01652976)
Timeframe: 3 years

Interventionpercentage of subjects (Number)
Dasatinib and mFOLFOX665.5

[back to top]

Median Overall Survival

To determine median overall survival (OS) in months (NCT01652976)
Timeframe: 4 years

Interventionmonths (Median)
Dasatinib and mFOLFOX610.6

[back to top]

Median Time To Progression

To determine the median time to progression (TTP). TTP is defined as the time (in months) from when a subject achieves either a complete or partial response by RECIST 1.1 criteria until progressive disease (by RECIST 1.1 criteria) or death occurs. (NCT01652976)
Timeframe: 3 years

Interventionmonths (Median)
Dasatinib and mFOLFOX69.8

[back to top]

Progression Free Survival (PFS)

Determine activity of 5-Fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus dasatinib on progression free survival (PFS) in patients with metastatic pancreatic adenocarcinoma (NCT01652976)
Timeframe: 3 years

Interventionmonths (Median)
Dasatinib and mFOLFOX64

[back to top]

Response Rate

To determine the response rate (RR) by RECIST 1.1 criteria. The response rate is the number of subjects who had either a complete or partial response by RECIST 1.1 criteria. RECIST 1.1 criteria defines a partial response as a decrease of the sum of the largest diameter each target lesion by at least 30%. A complete response is defined as the disappearance of all target lesions (except lymph nodes, whose short axis must measure 10 mm or less). The imaging modality used for all RECIST assessments in this study was CT. (NCT01652976)
Timeframe: 3 years

Interventionpercentage of subjects (Number)
Dasatinib and mFOLFOX625

[back to top]

Site of Failure

To determine the site of failure of this regimen in this population. The site of failure is the anatomical site(s) where disease progression by RECIST 1.1 criteria was noted on imaging. (NCT01652976)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Left pleural effusionLiverLungsPancreas/liverPeritoneal carcinomatosisperitoneal carcinomatosis/liverSpleen/liver
Dasatinib and mFOLFOX611234111

[back to top]

Clinical Benefit Rate

To determine the clinical benefit rate (CBR). The CBR is defined as the percentage of subjects who achieved either a complete or partial response or stable disease by RECIST 1.1 criteria. RECIST 1.1 criteria defines a partial response as a decrease of the sum of the largest diameter each target lesion by at least 30%. A complete response is defined as the disappearance of all target lesions (except lymph nodes, whose short axis must measure 10 mm or less). By RECIST 1.1 criteria, a subject is considered to have stable disease when the sum of the largest diameter of the target lesions has neither decreased enough to qualify as a partial response not increased enough to qualify as progressive disease. (NCT01652976)
Timeframe: 3 years

Interventionpercentage of subjects (Number)
Dasatinib and mFOLFOX656.82

[back to top]

Safety and Tolerability

To determine the safety profile and tolerability of this regimen in this population by evaluating acute treatment related toxicities using CTCAE v4.0 criteria. Using the CTCAE v4.0, the severity of each adverse event reported was graded on a scale of 1 (mild severity) to 5 (fatal). For this outcome measure the percentage of subjects experiencing any adverse event of each CTCAE grade was tabulated. (NCT01652976)
Timeframe: 3 years

Interventionpercentage of subjects (Number)
Percent of subjects experiencing a Grade 1 eventPercent of subjects experiencing a grade 2 eventPercent of subjects experiencing a Grade 3 eventPercent of subjects experiencing a Grade 4 eventPercent of subjects experiencing a grade 5 event
Dasatinib and mFOLFOX688.690.986.422.79.1

[back to top]

Quality of Life, as Measured by the Functional Assessment of Chronic Illness Therapy; Hepatobiliary Cancer (FACT-Hep) Questionnaire (Version 4.0)

The FACT-Hep consists of 45 questions where subjects respond with a score on a scale of 0 (worst)-4 (best). The responses to the questions are summed to calculate 5 subscores: Physical Well-Being (PWB), Social Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), and Hepatobiliary Cancer Subscale (HCS). The mean difference in each of the 5 subscores from baseline, as well as the total score of the 5 subscores (the FACT-Hep Total Score) for the entire study population is reported here. The mean difference in the FACT-G Total Score (calculated by summing the PWB, SWB, EWB, and FWB subscores) is also reported here. A negative mean difference indicates a decrease from baseline in QOL. Score ranges- PWB subscore: 0-28, SWB subscore: 0-28, EWB subscore: 0-24, FWB subscore: 0-28, HCS subscore: 0-72, FACT-G Total Score: 0-108, and FACT-Hep Total Score: 0-180. A higher value for each subscore or total score indicates better QOL. (NCT01652976)
Timeframe: 3 years

Interventionscore on a scale (Mean)
Subscore difference for PWBSubscore difference for SWBSubscore difference for EWBSubscore difference for FWBSubscore difference for HCSDifference in FACT-G Total ScoreDifference in FACT-Hep Total Score
Dasatinib and mFOLFOX6-4.4-0.90.6-2.8-6.3-7.4-13.7

[back to top]

Quality of Life, as Measured by the Cancer Therapy Satisfaction Questionnaire (CTSQ), 2007

To determine the quality of life (QOL) of patients receiving this therapy using the CTSQ questionnaire. The CTSQ consists of 16 questions where subjects respond with a score on a scale of 0 (worst)-4 (best). The responses to the questions are used to calculate 3 subscores: Expectations of Therapy (ET), Feelings about Side Effects (FSE), and Satisfaction with Therapy (SWT). Each subscore is calculated by multiplying the mean response value for the questions used to calculate that subscore by 25. The maximum value is 100 and the minimum value is 0 for all 3 subscores. A higher subscore indicates better QOL in that area. The mean difference in each of the 3 subscores from baseline and 95% confidence interval for the entire study population is reported here. A negative mean difference indicates a decrease from baseline in QOL for that area. (NCT01652976)
Timeframe: 3 years

Interventionscore on a scale (Mean)
Subscore difference for ETSubscore difference for FSESubscore difference for SWT
Dasatinib and mFOLFOX6-8.42.1-0.5

[back to top]

Number of Participants With a Major Molecular Response (MMR) and MR 4.5 After Switching to Dasatinib

Molecular responses were assessed at 6 and 12 months after switching to dasatinib to determine if these baseline responses could be maintained. MR4.5, the number of treated participants with BCR-ABL transcripts ≤ 0.0032% (IS) at 6 and 12 months from the date of dasatinib initiation; MMR, Major Molecular Response = 3-log reduction in BCR-ABL gene transcripts from a standardized baseline. (NCT01660906)
Timeframe: 6 and 12 months

InterventionParticipants (Count of Participants)
MMR, Month 6MMR, Month 12MR4.5, Month 6MR4.5, Month 12
Dasatinib (100 mg)13131822

[back to top] [back to top] [back to top]

Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib

The MD Anderson Symptom Inventory Chronic Myeloid Leukemia (MDASI-CML) is a validated questionnaire completed by study participants to assess symptom severity and symptom interference on daily function. These categories are divided into 5 domain summary scores: Core Symptom Severity Score, Interference Score, Symptom Severity Score, CML-Specific Symptom Severity Score, and 5 Most Severe Symptom Score. Scores were evaluated at baseline and after switching to Dasatinib on a range from 1 to 10; 1=not present/did not interfere, 10=as bad as you can imagine/interfered completely. (NCT01660906)
Timeframe: Baseline to 3, 6, 12 months

Interventionunits on a scale (Mean)
Core Symptom Severity Score, Month 3; n=37Core Symptom Severity Score, Month 6; n=36Core Symptom Severity Score, Month 12; n=37Interference Score, Month 3; n=37Interference Score, Month 6; n=35Interference Score, Month 12; n=36Symptom Severity Score, Month 3; n=37Symptom Severity Score, Month 6; n=36Symptom Severity Score, Month 12; n=37CML-specific Symptom Severity Score, Month 3; n=37CML-specific Symptom Severity Score, Month 6; n=36CML-specific Symptom Severity Score,Month 12; n=365 Most Severe Symptom Score, Month 3; n=375 Most Severe Symptom Score, Month 6; n=365 Most Severe Symptom Score, Month 12; n=37
Dasatinib (100 mg)-1.35-1.44-1.06-1.24-1.28-1.30-1.73-1.80-1.46-2.52-2.60-2.24-1.61-1.69-1.43

[back to top] [back to top]

Mean Change From Baseline in Patient Reported Quality of Life Measurements by The European Organization for Research and Treatment of Cancer - Quality of Life (QoL) Questionnaire (EORTC QLQ) Score After Switching to Dasatinib

The EORTC QLQ-C30 questionnaire is completed by study participants to assess quality of life through nine multi-item scales: five functional scales (physical, role, cognitive, emotional and social functioning); three symptom scales (fatigue, pain and nausea/vomiting); and a global health status/QoL scale. Six single-item scales are also included (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures were evaluated at baseline and after switching to Dasatinib as an average raw score that was standardized by transformation, so that final scores were on a range in score from 0 to 100. A high score for a functional scale represents a healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale and single-item measures represents a high level of problematic symptomatology. (NCT01660906)
Timeframe: Baseline to 6, 12 months

Interventionunits on a scale (Mean)
Global Health Status/QOL, Month 6; n=36Global Health Status/QOL, Month 12; n=35Cognitive Functioning, Month 6; n=35Cognitive Functioning, Month 12; n=35Emotional Functioning, Month 6; n=35Emotional Functioning, Month 12; n=35Physical Functioning, Month 6; n=36Physical Functioning, Month 12; n=36Role Functioning, Month 6; n=36Role Functioning, Month 12; n=36Social Functioning, Month 6; n=35Social Functioning, Month 12; n=35Fatigue, Month 6; n=36Fatigue, Month 12; n=36Nausea and Vomiting, Month 6; n=36Nausea and Vomiting, Month 12; n=36Pain, Month 6; n=36Pain, Month 12; n=36Appetite Loss, Month 6; n=35Appetite Loss, Month 12; n=36Constipation, Month 6; n=36Constipation, Month 12; n=35Diarrhoea, Month 6; n=36Diarrhoea, Month 12; n=35Dyspnoea, Month 6; n=36Dyspnoea, Month 12; n=36Financial Difficulties, Month 6; n=35Financial Difficulties, Month 12; n=35Insomnia, Month 6; n=36Insomnia, Month 12; n=36
Dasatinib (100 mg)0.462.861.901.4311.1912.62-1.670.74-4.172.7813.8114.76-6.79-8.33-9.72-4.63-2.78-8.801.901.85-0.938.570.00-2.865.569.26-10.48-13.330.93-1.85

[back to top]

Number of Participants Who Did Not Experience Loss of Complete Molecular Response (CMR) (MR4.5) and Major Molecular Response (MMR)

Assessment of BCR-ABL kinetics in patients who are in CMR (MR4.5) or less when transcript levels are still measurable. CMR (MR4.5) defined as ≤ 0.0032% (IS) or ≥ 4.5 log reduction of BCR-ABL transcript levels molecular response. (NCT01850004)
Timeframe: From 12 months after Dasatinib treatment discontinuation to 5 years after the first visit of the last enrolled participant (up to approximately 82 months)

InterventionParticipants (Count of Participants)
Total12

[back to top]

Number of Participants Who Experience Intermittent Loss of Complete Molecular Response (CMR) (MR4.5) But no Loss of Major Molecular Response (MMR)

The number of participants who did not lose major molecular response (MMR) 60 months after discontinuing study treatment who were in MR4.5 at the time of discontinuation and lost MR4.5. Molecular response will be assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (Q-PCR). MMR is defined as BCR-ABL transcripts < 0.1% Internal Standard (IS). CMR (MR4.5) defined as ≤ 0.0032% (IS) or ≥ 4.5 log reduction of BCR-ABL transcript levels molecular response. (NCT01850004)
Timeframe: 60 months after last dose

InterventionParticipants (Count of Participants)
Total19

[back to top]

Overall Survival (OS)

Overall survival (OS) is defined as the time from dasatinib treatment discontinuation to the date of death (due to any cause) or last known alive date. Participants who do not die will be censored on their last known alive date. (NCT01850004)
Timeframe: From 12 months after Dasatinib treatment discontinuation to the date of death or last known alive date (up to approximately 82 months)

InterventionMonths (Median)
TotalNA

[back to top]

Major Molecular Response (MMR) Rate

Major Molecular Response (MMR) rate at 12 months is the percentage of participants who maintain MMR (BCR-ABL transcripts < 0.1% on the International Scale [IS]) at 12 months after Dasatinib discontinuation without restarting Dasatinib (NCT01850004)
Timeframe: At 12 months after Dasatinib discontinuation (assessed up to approximately June 4, 2018)

InterventionPercentage of Participants (Number)
Total47.6

[back to top]

Relapse-Free Survival (RFS) Rate

"RFS is the percentage of participants who did not relapse at the specified timepoints. Participants who did not relapse were censored on the date of their last molecular assessment. Relapse is defined as any of the following events while on study: the loss of Major Molecular Response (MMR), loss of Complete Cytogenetic Response (CCyR), loss of Complete Hematologic Response (CHR) or progression to advanced/blastic phase.~MMR is defined as BCR-ABL transcripts < 0.1% IS. Cytogenetic response (CyR) is based on the prevalence of Ph+ cells in metaphase from bone marrow (BM) sample based on evaluation of at least 20 metaphases. CCyR is defined as 0% Ph+ cells in metaphase in BM. CHR is obtained when all the following criteria are met in peripheral blood (PB) sampling: white blood cell ≤10,000/mm3; Platelets < 450,000/mm3; PB basophils <5%; No blasts or promyelocytes in PB; <5% myelocytes plus metamyelocytes in PB; No extramedullary involvement (including no hepatomegaly or splenomegaly)." (NCT01850004)
Timeframe: From 12 months after Dasatinib treatment discontinuation to every 6 months thereafter (up to approximately 60 months)

InterventionPercentage of Participants (Number)
At 6 MonthsAt 12 MonthsAt 18 MonthsAt 24 monthsAt 30 monthsAt 36 monthsAt 42 monthsAt 48 monthsAt 54 monthsAt 60 months
Total61.948.747.546.346.345.043.843.843.843.8

[back to top]

Progression Free Survival (PFS) Rate

Progression free survival (PFS) is defined as the percentage of participants who experienced death (due to any cause) or accelerated phase, or blast crisis. Participants who neither progress nor die will be censored on the date of their last molecular assessment. Progression is defined as Transformation to Accelerated Phase or Blast Crisis (AP/BC) Accelerated Phase (AP) Blasts in PB or BM 15-29%; Blast + promyelocytes >= 30% with blasts < 30% or ACA in Ph+ cells (clonal progression), or basophils in blood >= 20%,or platelets < 100 x 109 /L unrelated to therapy Blastic Phase or Crisis (BP/BC) Blasts in PB or BM >= 30%, or extramedullary blast cell involvement (with the exception of spleen and liver) (NCT01850004)
Timeframe: From 12 months after Dasatinib treatment discontinuation to every 6 months thereafter (up to approximately 60 months)

InterventionPercentage of participants (Number)
At 6 monthsAt 12 monthsAt 18 monthsAt 24 monthsAt 30 monthsAt 36 monthsAt 42 monthsAt 48 monthsAt 54 monthsAt 60 months
Total100.0100.0100.098.798.798.798.798.798.798.7

[back to top]

Event-Free Survival (EFS) Rate

"Event-free survival (EFS) rate is defined as the percentage of surviving participants with no loss of Major Molecular Response (MMR) at the specified timepoints after dasatinib discontinuation. MMR is defined as BCR-ABL transcripts < 0.1% IS. Loss of MMR is defined per the European LeukemiaNet (ELN) definition of progression. Progression is defined as Transformation to Accelerated Phase or Blast Crisis (AP/BC):~Accelerated Phase (AP) Blasts in PB or BM 15-29%; Blast + promyelocytes ≥ 30% with blasts < 30% or ACA in Ph+ cells (clonal progression), or basophils in blood ≥ 20%,or platelets < 100 x 10^9 /L unrelated to therapy~Blastic Phase or Crisis (BP/BC) Blasts in PB or BM ≥ 30%, or extramedullary blast cell involvement (with exception of spleen and liver)~The date of progression is defined as the date any of the above criteria is first met. Participants who have not progressed will be censored on the date of last examination." (NCT01850004)
Timeframe: From 12 months after Dasatinib treatment discontinuation to every 12 months thereafter (up to approximately 60 months)

InterventionPercentage of participants (Number)
At 12 monthsAt 24 monthsAt 36 monthsAt 48 monthsAt 60 months
Total48.746.345.043.843.8

[back to top]

Time to Transformation to Accelerated Phase/Blast Crisis (AP/BC)

Time to Transformation to AP/BC is defined as the rate at which participants experienced transformation to accelerated phase/blast crisis (AP/BC) since discontinuation. Participants who did not develop to AP, late phase, or BC phase were censored on their last molecular measurement date. (NCT01850004)
Timeframe: From 12 months after Dasatinib treatment discontinuation to 5 years after the first visit of the last enrolled participant (up to approximately 82 months)

InterventionMonths (Median)
TotalNA

[back to top]

Progression Free Survival

Progression-free survival (PFS) is defined as the time from treatment discontinuation to the date of progression or death (due to any cause), whichever occurs first. Participants who neither progress nor die will be censored on the date of their last molecular assessment. (NCT01850004)
Timeframe: From treatment discontinuation to the date of progression or death due to any cause, whichever occurs first (up to 82 months)

InterventionMonths (Median)
TotalNA

[back to top]

T Cell-recruiting Chemokine CXCL10/IP-10

Circulating serum concentration (levels) of T cell-recruiting chemokine CXCL10/IP-10 analyzed via ELISA assay. Higher levels of T cell-recruiting chemokine CXCL10/IP-1 correlate with patients exhibiting objective clinical response immunotherapy. (NCT01876212)
Timeframe: At between 5 and 7 weeks, post treatment

Interventionpg/mL (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)501.43
Vaccine + Dasatinib (Cycle 1, D1)194.96

[back to top]

Treg CD4FoxP3 Suppressor Cells

Percentage of Treg CD4FoxP3 suppressor cells in patients' peripheral blood. The accumulation of Treg CD4FoxP3 suppressor cell populations correlates with tumor progression (disease progression) and negative prognosis. (NCT01876212)
Timeframe: At baseline (prior to treatment)

Interventionpercentage of cells (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)6.67
Vaccine + Dasatinib (Cycle 1, D1)8.04

[back to top]

Treg CD4FoxP3 Suppressor Cells

Percentage of Treg CD4FoxP3 suppressor cells in patients' peripheral blood. The accumulation of Treg CD4FoxP3 suppressor cell populations correlates with tumor progression (disease progression) and negative prognosis. (NCT01876212)
Timeframe: At between 4 and 6 weeks, post treatment

Interventionpercentage of cells (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)8.06
Vaccine + Dasatinib (Cycle 1, D1)6.27

[back to top]

Treg CD4FoxP3 Suppressor Cells

Percentage of Treg CD4FoxP3 suppressor cells in patients' peripheral blood. The accumulation of Treg CD4FoxP3 suppressor cell populations correlates with tumor progression (disease progression) and negative prognosis. (NCT01876212)
Timeframe: At between 7 and 10 weeks, post treatment

Interventionpercentage of cells (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)7.38
Vaccine + Dasatinib (Cycle 1, D1)6.6

[back to top]

T Cell-recruiting Chemokine CXCL10/IP-10

Circulating serum concentration (levels) of T cell-recruiting chemokine CXCL10/IP-10 analyzed via ELISA assay. Higher levels of T cell-recruiting chemokine CXCL10/IP-1 correlate with patients exhibiting objective clinical response immunotherapy. (NCT01876212)
Timeframe: At baseline (prior to treatment)

Interventionpg/mL (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)296.68
Vaccine + Dasatinib (Cycle 1, D1)268.06

[back to top]

Immune Response Rate

"Immune Response is defined as improved peripheral blood CD8+ T cell responses against 3 or more peptide epitopes after active vaccination with Type I-polarized autologous dendritic cell (αDC1) vaccine incorporating 6 tumor blood vessel-associated antigen (TBVA)-derived peptides.~The measure of Immune Response for this study is expressed as a proportion of responders: The number of HLA-A2+ melanoma patients with improved peripheral blood CD8+ T cell responses (responders) divided by the total number of evaluable patients." (NCT01876212)
Timeframe: Up to 13 months

Interventionproportion of participants (Number)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)0.29
Vaccine + Dasatinib (Cycle 1, D1)0.67

[back to top]

Monocytic Myeloid Derived Suppressor Cells (M-MDSC)

Percentage of Monocytic Myeloid Derived Suppressor Cells (M-MDSC) present in patients' peripheral blood. The accumulation of M-MDSC populations correlates with tumor progression (disease progression) and negative prognosis. (NCT01876212)
Timeframe: At baseline (prior to treatment)

Interventionpercentage of cells (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)6.23
Vaccine + Dasatinib (Cycle 1, D1)11.65

[back to top]

Monocytic Myeloid Derived Suppressor Cells (M-MDSC)

Percentage of Monocytic Myeloid Derived Suppressor Cells (M-MDSC) present in patients' peripheral blood. The accumulation of M-MDSC populations correlates with tumor progression (disease progression) and negative prognosis. (NCT01876212)
Timeframe: At between 4 and 6 weeks, post treatment

Interventionpercentage of cells (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)8.7
Vaccine + Dasatinib (Cycle 1, D1)8.78

[back to top]

Monocytic Myeloid Derived Suppressor Cells (M-MDSC)

Percentage of Monocytic Myeloid Derived Suppressor Cells (M-MDSC) present in patients' peripheral blood. The accumulation of M-MDSC populations correlates with tumor progression (disease progression) and negative prognosis. (NCT01876212)
Timeframe: At between 7 and 10 weeks, post treatment

Interventionpercentage of cells (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)9.32
Vaccine + Dasatinib (Cycle 1, D1)8.32

[back to top]

Objective Response Rate (ORR)

"The proportion of evaluable patients that achieved either partial or complete responses. Calculation: The number of patients who experienced a Partial Response (PR) + the number of patients who experienced a Complete Response (CR) / total number of response-evaluable patients.~Per RECIST v1.1, Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters." (NCT01876212)
Timeframe: Up to 13 months

Interventionproportion of participants (Number)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)0
Vaccine + Dasatinib (Cycle 1, D1)0.6667

[back to top]

Overall Survival (OS)

The length of time from the start of study treatment, that patients remain alive. (NCT01876212)
Timeframe: Up to 30 months

Interventionmonths (Median)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)3.667
Vaccine + Dasatinib (Cycle 1, D1)17.83

[back to top]

Polymorphonucler Myeloid-derived Suppressor Cells (PMN-MDSC)

Percentage of Polymorphonucler myeloid-derived suppressor cells (PMN-MDSC) present in patients' peripheral blood. The accumulation/increase of M-MDSC populations correlates with tumor progression (disease progression) and negative prognosis. (NCT01876212)
Timeframe: At baseline (prior to treatment)

Interventionpercentage of cells (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)12.36
Vaccine + Dasatinib (Cycle 1, D1)11.59

[back to top]

Polymorphonucler Myeloid-derived Suppressor Cells (PMN-MDSC)

Percentage of Polymorphonucler myeloid-derived suppressor cells (PMN-MDSC) present in patients' peripheral blood. The accumulation/increase of M-MDSC populations correlates with tumor progression (disease progression) and negative prognosis. (NCT01876212)
Timeframe: At between 4 and 6 weeks, post treatment

Interventionpercentage of cells (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)10.14
Vaccine + Dasatinib (Cycle 1, D1)14.61

[back to top]

Polymorphonucler Myeloid-derived Suppressor Cells (PMN-MDSC)

Percentage of Polymorphonucler myeloid-derived suppressor cells (PMN-MDSC) present in patients' peripheral blood. The accumulation/increase of M-MDSC populations correlates with tumor progression (disease progression) and negative prognosis. (NCT01876212)
Timeframe: At between 7 and 10 weeks, post treatment

Interventionpercentage of cells (Mean)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)9.41
Vaccine + Dasatinib (Cycle 1, D1)12.45

[back to top]

Progression-free Survival (PFS)

The length of time after study treatment that a patient lives with disease but the disease does not progress. Patients were followed for 1 year after removal from study treatment or until death, whichever occurs first. Per RECIST 1.1, Progressive Disease is defined as a ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression. (NCT01876212)
Timeframe: Up to 15 months

Interventionmonths (Median)
Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1)1.967
Vaccine + Dasatinib (Cycle 1, D1)7.867

[back to top]

Maximum Tolerated Dose of Dasatinib (Phase I)

Maximum tolerated dose of dasatinib, determined according to incidence of dose limiting toxicity (DLT), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I) (NCT01876953)
Timeframe: From the first dose of Dasatinib through the DLT observation period (Day +28)

Interventionmg/m2 (Number)
Dasatinib 100mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day100

[back to top]

Median Progression Free Survival

Estimate the 6-month progression free survival (PFS) rate in participants with acquired EGFR resistance. Response Criteria for Phase 1B will follow RECIST v.1.1: Progressive Disease (PD) is defined as at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT01999985)
Timeframe: Up to 6 Months

Interventionmonths (Median)
Dose Escalation and Expansion5.5

[back to top]

Number of Participants With Objective Response

Estimates objective response rate (complete response [CR] and partial response [PR]) in participants with acquired EGFR resistance (NCT01999985)
Timeframe: Up to 6 Months

Interventionparticipants (Number)
Dose Escalation and Expansion0

[back to top]

Maximum Tolerated Dose (MTD) of Afatinib (BIBW 2992) in Combination With Dasatinib

"The MTD for this combined treatment will be defined as either:~The highest dosage cohort in which six patients had been treated and there were less than two dose limiting toxicities (DLTs) or,~Afatinib at the highest tolerated dose investigated (40 mg by mouth [PO] daily) plus dasatinib at the highest tolerated dose investigated (cohort 3, 140 mg PO daily)." (NCT01999985)
Timeframe: Up to 6 Months

Interventionmg (Number)
AfatinibDasatinib daily
Dose Escalation and Expansion30100

[back to top]

Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Advanced Phase (CML-AP) Participants

"Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (RQ-PCR).~MMR is defined as ≥ 3-log reduction in BCR-ABL transcripts or a ratio of ≤ 0.1% on the International Scale (IS)." (NCT02011945)
Timeframe: upto 36 Months

,
InterventionPercentage (Number)
MMR Rate by 6 MonthsMMR Rate by 12 MonthsMMR Rate by 24 MonthsMMR Rate by 36 Months
Dose Level 10000
Dose Level 233.366.766.766.7

[back to top]

Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), No Prior Dasatinib Participants

"Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (RQ-PCR).~A molecular response 4.5 (MR4.5) was defined as ≥ 4.5-log reduction in BCR-ABL transcripts or a ratio of ≤ 0.00316% on the International Scale (IS)." (NCT02011945)
Timeframe: upto 36 Months

,
InterventionPercentage (Number)
MR4.5 Rate by 6 MonthsMR4.5 Rate by 12 MonthsMR4.5 Rate by 24 MonthsMR4.5 Rate by 36 Months
Dose Level 10.00.00.0100
Dose Level 20.00.00.00.0

[back to top]

Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Advanced Phase (CML-AP) Participants

"Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (RQ-PCR).~A molecular response 4.5 (MR4.5) was defined as ≥ 4.5-log reduction in BCR-ABL transcripts or a ratio of ≤ 0.00316% on the International Scale (IS)." (NCT02011945)
Timeframe: upto 36 Months

,
InterventionPercentage (Number)
MR4.5 Rate by 6 MonthsMR4.5 Rate by 12 MonthsMR4.5 Rate by 24 MonthsMR4.5 Rate by 36 Months
Dose Level 10.00.00.00.0
Dose Level 20.00.00.00.0

[back to top]

Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), Prior Dasatinib Participants

"Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (RQ-PCR).~MMR is defined as ≥ 3-log reduction in BCR-ABL transcripts or a ratio of ≤ 0.1% on the International Scale (IS)." (NCT02011945)
Timeframe: upto 36 Months

,,
InterventionPercentage (Number)
MMR Rate by 6 MonthsMMR Rate by 12 MonthsMMR Rate by 24 MonthsMMR Rate by 36 Months
Dasatinib Only0000
Dose Level 125252525.0
Dose Level 218.227.336.445.5

[back to top]

Rate of Major Molecular Response (MMR) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), No Prior Dasatinib Participants

"Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (RQ-PCR).~MMR is defined as ≥ 3-log reduction in BCR-ABL transcripts or a ratio of ≤ 0.1% on the International Scale (IS)." (NCT02011945)
Timeframe: upto 36 Months

,
InterventionPercentage of Participants (Number)
MMR Rate by 6 MonthsMMR Rate by 12 MonthsMMR Rate by 24 MonthsMMR Rate by 36 Months
Dose Level 1100100100100
Dose Level 20000

[back to top]

Incidence of Adverse Events (AEs)

Any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. (NCT02011945)
Timeframe: Initiation of study drug to discontinuation of nivolumab stop date + 100 days or discontinuation of dasatinib + 30 days

InterventionNumber of Adverse Events (Number)
CML-CP, Prior dasatinib treatment
Dasatinib Only1

[back to top]

Incidence of Serious Adverse Events (SAEs)

Any untoward medical occurrence that at any dose: results in death, is life threatening, requires in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is a important medical event.Requires inpatient hospitalization or causes prolongation of existing hospitalization, results. (NCT02011945)
Timeframe: Initiation of study drug to within 100 days of discontinuation of nivolumab dosing and 30 days of dasatinib dosing

,
InterventionNumber of Adverse Events (Number)
CML-CP, No Prior dasatinib treatmentCML-CP, Prior dasatinib treatmentCML-AP participants
Dose Level 1034
Dose Level 2242

[back to top]

Incidence of Serious Adverse Events (SAEs)

Any untoward medical occurrence that at any dose: results in death, is life threatening, requires in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is a important medical event.Requires inpatient hospitalization or causes prolongation of existing hospitalization, results. (NCT02011945)
Timeframe: Initiation of study drug to within 100 days of discontinuation of nivolumab dosing and 30 days of dasatinib dosing

InterventionNumber of Adverse Events (Number)
CML-CP, Prior dasatinib treatment
Dasatinib Only0

[back to top]

Incidence of Laboratory Abnormalities in Specific Thyroid Tests

Free T3 (FT3) Free T4 (FT4) Lower Limit of Normal (LLN) (NCT02011945)
Timeframe: Up to 40 Months

,,
InterventionNumber of Incidences (Number)
TSH > ULNTSH > ULN: WITH TSH ≤ ULN AT BASELINETSH > ULN: WITH AT LEAST ONE FT3/FT4 TEST < LLNTSH > ULN: WITH ALL OTHER FT3/FT4 TEST ≥ LLNTSH > ULN: WITH FT3/FT4 TEST MISSINGTSH > 2*ULNTSH > 2*ULN: WITH TSH <= ULN AT BASELINETSH > 2*ULN: WITH AT LEAST ONE FT3/FT4 TEST < LLNTSH > 2*ULN: WITH ALL OTHER FT3/FT4 TEST ≥ LLNTSH > 2*ULN: WITH FT3/FT4 TEST MISSINGTSH < LLNTSH < LLN: WITH TSH >= LLN AT BASELINETSH < LLN: WITH AT LEAST ONE FT3/FT4 TEST > ULNTSH < LLN: WITH ALL OTHER FT3/FT4 TEST ≤ ULNTSH < LLN: WITH FT3/FT4 TEST MISSING
Dasatinib Only000000000000000
Dose Level 1432112120033012
Dose Level 2431121010011100

[back to top]

Incidence of Change From Baseline in Clinical Laboratory Tests: Hematology

The number of participants with a shift in laboratory test results from baseline to Grade 3-4 in hematology (NCT02011945)
Timeframe: Up to 40 Months

,,
InterventionParticipants (Number)
HemoglobinPlateletsAbsolute Neutrophil Count (ANC)White Blood Cell (WBC)
Dasatinib Only0000
Dose Level 12551
Dose Level 24433

[back to top]

Incidence of Adverse Events (AEs)

Any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. (NCT02011945)
Timeframe: Initiation of study drug to discontinuation of nivolumab stop date + 100 days or discontinuation of dasatinib + 30 days

,
InterventionNumber of Adverse Events (Number)
CML-CP, No Prior dasatinib treatmentCML-CP, Prior dasatinib treatmentCML-AP participants
Dose Level 1184
Dose Level 22113

[back to top]

Incidence of Abnormalities in Clinical Laboratory Tests: Liver Tests

"The number of participants with an abnormal Liver function test.~Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN)" (NCT02011945)
Timeframe: Up to 40 Months

,,
InterventionParticipants (Number)
ALT or AST > 3xULNALT or AST > 5xULNALT or AST > 10xULNALT or AST > 20xULNTotal Bilirubin (Tbili) > 2xULNALT or AST > 3xULN w/ Tbili > 2xULN within 1 dayALT or AST > 3xULN w/ Tbili > 2xULN within 30 days
Dasatinib Only0000000
Dose Level 11000111
Dose Level 21000100

[back to top]

Time to Molecular Response 4.5(MR4.5) - CML-CP Prior Dasatinib Participants

measured from the date of first dosing until measurement criteria are first met for MR4.5. The participants who do not respond will be censored on the date of their last molecular assessment. It is defined for all treated participants. (NCT02011945)
Timeframe: Up to 36 Months

InterventionMonths (Median)
Dasatinib OnlyNA
Dose Level 1NA
Dose Level 2NA

[back to top]

Time to Molecular Response 4.5(MR4.5) - CML-CP No Prior Dasatinib Participants

measured from the date of first dosing until measurement criteria are first met for MR4.5. The participants who do not respond will be censored on the date of their last molecular assessment. It is defined for all treated participants. (NCT02011945)
Timeframe: Up to 36 Months

InterventionMonths (Median)
Dose Level 135.25
Dose Level 2NA

[back to top]

Time to Molecular Response 4.5(MR4.5) - CML-AP Participants

measured from the date of first dosing until measurement criteria are first met for MR4.5. The participants who do not respond will be censored on the date of their last molecular assessment. It is defined for all treated participants. (NCT02011945)
Timeframe: Up to 36 Months

InterventionMonths (Median)
Dose Level 1NA
Dose Level 2NA

[back to top]

Time to Major Molecular Response (MMR) - CML-CP Prior Dasatinib Participants

measured from the date of first dosing until measurement criteria are first met for MMR. The participants who do not respond will be censored on the date of their last molecular assessment. It is defined for all treated participants. (NCT02011945)
Timeframe: Up to 36 Months

InterventionMonths (Median)
Dasatinib OnlyNA
Dose Level 1NA
Dose Level 235.45

[back to top]

Time to Major Molecular Response (MMR) - CML-CP No Prior Dasatinib Participants

measured from the date of first dosing until measurement criteria are first met for MMR. The participants who do not respond will be censored on the date of their last molecular assessment. It is defined for all treated participants. (NCT02011945)
Timeframe: Up to 36 Months

InterventionMonths (Median)
Dose Level 10.53
Dose Level 2NA

[back to top]

Time to Major Molecular Response (MMR) - CML-AP Participants

measured from the date of first dosing until measurement criteria are first met for MMR. The participants who do not respond will be censored on the date of their last molecular assessment. It is defined for all treated participants. (NCT02011945)
Timeframe: Up to 36 Months

InterventionMonths (Median)
Dose Level 1NA
Dose Level 25.54

[back to top]

Incidence of Dose Limiting Toxicities (DLT)

"DLT will be determined based on the incidence and intensity of drug related adverse events (AEs). The following drug-related AEs (whether related to one or both agents) occurring during the first 6 weeks of combined treatment with both dasatinib plus nivolumab (ie, Weeks 3 to 8, inclusive) would be considered DLTs:~Grade 4 hematologic AE lasting > 7 days despite appropriate medical intervention, except as noted below;~Grade 3 or Grade 4 nonhematologic AE irrespective of duration;~Grade 2 nonhematologic AE lasting > 7 days despite appropriate medical intervention (exception: asymptomatic laboratory values of Grade 2 which do not require medical intervention);~Any toxicity managed by discontinuation of nivolumab;~Grade ≥ 2 AE not controlled by medical intervention and requiring dasatinib treatment interruption for > 28 consecutive days;~Grade ≥ 2 AE not controlled by medical intervention and requiring missing 2 consecutive doses of nivolumab." (NCT02011945)
Timeframe: Week 3 to week 6

InterventionNumber of Incidence (Number)
Dasatinib Only0
Dose Level 10
Dose Level 20

[back to top]

Duration of Molecular Response 4.5 (MR4.5) - CML-CP No Prior Dasatinib Participants

will be computed for participants who have achieved MR4.5. It will be defined as the time from the first assessment in which MR4.5, is documented until the first assessment at which disease progression (or confirmed loss of MR4.5 documented. Participants who neither progress nor die will be censored on the date of their last molecular assessment (NCT02011945)
Timeframe: Up to 36 Months

InterventionMonths (Median)
Dose Level 1NA

[back to top]

Duration of Major Molecular Response (MMR) - CML-CP Prior Dasatinib Participants

will be computed for participants who have achieved MMR. It will be defined as the time from the first assessment in which MMR, is documented until the first assessment at which disease progression (or confirmed loss of MMR) is documented. Participants who neither progress nor die will be censored on the date of their last molecular assessment (NCT02011945)
Timeframe: Up to 36 Months

InterventionMonths (Median)
Dose Level 1NA
Dose Level 2NA

[back to top]

Duration of Major Molecular Response (MMR) - CML-CP No Prior Dasatinib Participants

will be computed for participants who have achieved MMR. It will be defined as the time from the first assessment in which MMR, is documented until the first assessment at which disease progression (or confirmed loss of MMR) is documented. Participants who neither progress nor die will be censored on the date of their last molecular assessment (NCT02011945)
Timeframe: Up to 36 Months

InterventionMonths (Median)
Dose Level 1NA

[back to top]

Duration of Major Molecular Response (MMR) - CML-AP Participants

will be computed for participants who have achieved MMR. It will be defined as the time from the first assessment in which MMR, is documented until the first assessment at which disease progression (or confirmed loss of MMR) is documented. Participants who neither progress nor die will be censored on the date of their last molecular assessment (NCT02011945)
Timeframe: Up to 36 Months

InterventionMonths (Median)
Dose Level 2NA

[back to top]

Rate of Molecular Response 4.5 (MR4.5) : Chronic Myelogenous Leukemia - Chronic Phase (CML-CP), Prior Dasatinib Participants

"Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (RQ-PCR).~A molecular response 4.5 (MR4.5) was defined as ≥ 4.5-log reduction in BCR-ABL transcripts or a ratio of ≤ 0.00316% on the International Scale (IS)." (NCT02011945)
Timeframe: upto 36 Months

,,
InterventionPercentage (Number)
MR4.5 Rate by 6 MonthsMR4.5 Rate by 12 MonthsMR4.5 Rate by 24 MonthsMR4.5 Rate by 36 Months
Dasatinib Only0000
Dose Level 10.00.00.00.0
Dose Level 20.00.00.00.0

[back to top]

Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1

Complete and Partial Tumor Response by RECIST 1.1. RECIST 1.1 defines complete response as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and the disappearance of all non-target lesions and normalization of tumor marker level. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Only those patients who have measurable disease present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response. These patients will have their response classified according to the definitions stated above. Complete and partial responses are included in the objective tumor response rate. (NCT02059265)
Timeframe: CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; then every 3 months x 2; then every 6 months thereafter until disease progression for up to 5 years.

InterventionParticipants (Count of Participants)
Treatment (Dasatinib)1

[back to top]

Duration of Overall Survival (OS)

Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. (NCT02059265)
Timeframe: Every cycle during treatment, then every 3 months for the first 2 years, then every six months for the next three years and then annually for the next 5 years.

InterventionMonths (Median)
Treatment (Dasatinib)16.92

[back to top]

Duration of Progression-free Survival (PFS)

PFS will be characterized with Kaplan-Meier plots and estimates of the median time until death or progression. (NCT02059265)
Timeframe: Duration of time from start of treatment to time of progression or death, whichever occurs first, assessed up to 5 years

InterventionMonths (Median)
Treatment (Dasatinib)2.14

[back to top]

ARID1A Mutation Status in Formalin-fixed, Paraffin Embedded Tissue Using Next-generation Exon-capture Sequencing

ARID1A mutation status will be tabulated to determine the correlation between BAF250a IHC and ARID1A mutations. (NCT02059265)
Timeframe: Up to 5 years

InterventionSpearman Correlation Coefficient (Number)
Treatment (Dasatinib)0.82

[back to top]

Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0

The frequency and severity of all toxicities are tabulated. (NCT02059265)
Timeframe: Up to 5 years

InterventionCount of Participants with >= grade 3 AE (Number)
Treatment (Dasatinib)20

[back to top]

Minimal Residual Disease Negativity

To estimate in each cohort the rate of minimal residual disease (MRD) negativity. (NCT02143414)
Timeframe: Participants are assessed after induction treatment and again after re-induction treatment, if re-induction treatment is received (i.e. up to 85 days after registration)

,
InterventionParticipants (Count of Participants)
MRD-MRD+
Cohort I (Ph-)121
Cohort II (Ph+/Ph-like)79

[back to top]

Overall Survival Rate (Cohort I)

To evaluate the 3-year overall survival rate in elderly participants with newly diagnosed Ph-negative ALL treated with blinatumomab followed by POMP maintenance. Overall (NCT02143414)
Timeframe: From the day of registration on study until death from any cause, assessed at 3 years

Interventionpercentage of participants (Number)
Cohort I (Ph-)34

[back to top]

Incidence of Dose-limiting Toxicity (Cohort II)

Defined as any grade 4 or higher treatment-related, non-hematologic toxicity in the first cycle of post-remission therapy (blinatumomab/dasatinib) graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Only participants with Ph-positive ALL or Ph-like DSMKF ALL were evaluated. (NCT02143414)
Timeframe: Up to day 42 of post-remission therapy

InterventionParticipants (Count of Participants)
Cohort II (Ph+/Ph-like)0

[back to top]

Disease-free Survival (Cohort II)

An estimate of disease free survival in Ph-positive ALL and Ph-like DSMKF ALL (Cohort II). Disease free survival is measured by the number of years between the date the patient first achieves complete remission (CR) or complete remission with incomplete platelet recovery (CRi) until relapse from CR/CRi or death from any cause. CR is defined as having <5% marrow aspirate blasts, ANC >1,000/mcL, platelets > 100,000/mcL, no blasts in peripheral blood, and C1 extramedullary disease status. CRi is the same as CR but platelet count may be <= 100,000/mcL and/or ANC <=1,000/mcL. (NCT02143414)
Timeframe: Duration of treatment and follow up until death or date of primary analysis (about 7.5 years)

Interventionyears (Median)
Cohort II (Ph+/Ph-like)5.3

[back to top]

Complete Response Rate (Cohort I)

Complete response rate is measured by the number of participants achieving complete remission (CR) or complete remission with incomplete platelet recovery (CRi) rate. CR is defined as having <5% marrow aspirate blasts, ANC >1,000/mcL, platelets > 100,000/mcL, no blasts in peripheral blood, and C1 extramedullary disease status. CRi is the same as CR but platelet count may be <= 100,000/mcL and/or ANC <=1,000/mcL. (NCT02143414)
Timeframe: Participants are assessed after induction treatment and again after re-induction treatment, if re-induction treatment is received (i.e. up to 85 days after registration)

InterventionParticipants (Count of Participants)
CR or CRiNo CR or CRi
Cohort I (Ph-)1910

[back to top] [back to top]

Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs.

The number of patients who develop molecular recurrence after discontinuing TKIs. This will be reported as the number of new occurrences from the end of the prior time frame. (NCT02269267)
Timeframe: 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 27, 30, 33, 36 months

InterventionParticipants (Count of Participants)
Less or equal to one monthOne month to two monthsTwo months to three monthsThree months to four monthsFour months to five monthsFive months to six monthsSix months to eight monthsEight months to 10 monthsTen months to 12 months12 months to 14 months14 months to 16 months16 months to 18 months18 months to 20 months20 months to 22 months22 months to 24 months24 months to 27 months27 months to 30 months30 months to 33 months33 months to 36 months36 months
Discontinuation of TKI Medication0412117523422100112002

[back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top]

Duration of Treatment

Duration of treatment for participants who received dasatinib treatment for prostate cancer and chronic phase chronic myeloid leukemia who had also participated on prior protocols CA180-227, CA180-363 and CA180-056 investigating dasatinib. Dasatinib tablet administered once a day by mouth. (NCT02297139)
Timeframe: From first dose on this study (CA180-597) to last dose on this study (up to approximately 76 months)

InterventionMonths (Median)
Prostate Cancer25.3
Chronic Phase - Chronic Myeloid Leukemia (CP-CML)55.9

[back to top]

Number of Participants Who Received Dasatinib Treatment

Number of participants who received dasatinib treatment for prostate cancer and chronic phase chronic myeloid leukemia who had also participated on prior protocols CA180-227, CA180-363 and CA180-056 investigating dasatinib. Dasatinib tablet administered once a day by mouth. (NCT02297139)
Timeframe: From first dose on this study (CA180-597) to last dose on this study (up to approximately 76 months)

InterventionParticipants (Count of Participants)
Prostate Cancer1
Chronic Phase - Chronic Myeloid Leukemia (CP-CML)16

[back to top]

Number of Participants With Adverse Events

Number of Participants with Adverse Events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. (NCT02297139)
Timeframe: From first dose on this study (CA180-597) to 30 days after last dose of study therapy (up to approximately 77 months)

InterventionParticipants (Count of Participants)
Prostate Cancer1
Chronic Phase - Chronic Myeloid Leukemia (CP-CML)15

[back to top]

Number of Participants With Serious Adverse Events

Number of participants with serious adverse events (SAEs). SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. (NCT02297139)
Timeframe: From first dose on this study (CA180-597) to 30 days after last dose of study therapy (up to approximately 77 months)

InterventionParticipants (Count of Participants)
Prostate Cancer0
Chronic Phase - Chronic Myeloid Leukemia (CP-CML)8

[back to top]

Progression-free Survival

Time from date of treatment start until the date of first objective documentation of disease-relapse. (NCT02420717)
Timeframe: Up to 4 years 7 months

InterventionMonths (Median)
Phase I Ruxolitinib 15mg2.3
Phase I Ruxolitinib 20mg1.8
Phase I Ruxolitinib 25mg1.9

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT02420717)
Timeframe: Up to 4 years 7 months

InterventionMonths (Median)
Phase I Ruxolitinib 15mg4.8
Phase I Ruxolitinib 20mg5.4
Phase I Ruxolitinib 25mg38.5

[back to top]

Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)

Complete Response (CR) is disappearance of all clinical and/or radiologic evidence of disease, Neutrophil count ≥ 1.0 x 10^9/L, Platelet count ≥ 100 x 10^9/L, Normal bone marrow differential (≤ 5% blasts), No extra-medullary leukemia. Complete Remission with Incomplete Blood Count Recovery (CRi) is CR except for ANC < 1.0 x 10^9/L and/or platelets < 100 x 10^9/L. (NCT02420717)
Timeframe: 42 days

InterventionParticipants (Count of Participants)
Phase I Ruxolitinib 15mg0
Phase I Ruxolitinib 20mg1
Phase I Ruxolitinib 25mg0

[back to top]

Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)

The method of Thall, Simon and Estey will be used for toxicity monitoring for this study. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 whenever possible. Safety data will be summarized by category, severity and frequency. (NCT02420717)
Timeframe: 42 days

InterventionMilligrams (mg) (Number)
Phase I Ruxolitinib 15mg25

[back to top]

Median Progression Free Survival (PFS)

"The median amount of time from registration until disease progression or death, whichever occurs first. Disease progression was assessed via RECIST 1.1 criteria:~> Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)." (NCT02428855)
Timeframe: From registration until disease progression or death, median duration of 8.7 weeks

InterventionWeeks (Median)
Dasatinib8.7

[back to top]

Overall Survival

The median amount of time from registration until death. Participants are censored at the date last known alive. (NCT02428855)
Timeframe: From the time of registration until death, median duration of 37.9 weeks

InterventionWeeks (Median)
Dasatinib37.9

[back to top]

Objective Response Rate (ORR)

"The number of participants that achieved either a complete or partial response, as assessed by Response Criteria in Solid Tumors (RECIST 1.1)~Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters." (NCT02428855)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Complete Response (CR)Partial Response (CR)
Dasatinib00

[back to top]

Number of Participants With Adverse Events

The number of participants that experienced an adverse event as assessed by Common Toxicology Criteria for Adverse Events (CTCAE 4.0) (NCT02428855)
Timeframe: From the start of treatment until 30 days after the end of treatment, median duration of 3 months

InterventionParticipants (Count of Participants)
Dasatinib8

[back to top]

Plasma Membrane Epidermal Growth Factor Receptor (EGFR) Expression, Measured by VECTRA Imaging

An increase of at least 25% from baseline to post-dasatinib treatment will be considered significant. VECTRA is an automated pathology imaging system used to detect biomarkers in samples. (NCT02720185)
Timeframe: 7-10 days

Interventionpercentage plasma EGFR (Mean)
BaselineAfter Treatment
Dasatinib 100mg0.540.40

[back to top]

Number of Participants With Pathologic Complete Response (pCR)

Examine pCR rates to standard neoadjuvant chemotherapy in nuclear Epidermal Growth Factor Receptor (nEGFR) + TNBC. pCR will be defined as ypT0 ypNO (absence of cancer in breast tissue and lymph nodes) an assessed by the investigator. (NCT02720185)
Timeframe: Up to 4 weeks

InterventionParticipants (Count of Participants)
Dasatinib 100mg1

[back to top]

Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks

Safety and tolerability of dasatinib in participants with operable Triple negative breast cancer (TNBC) will be based on NCI Adverse Events (AE) Version 4.0 and will be assessed by frequency tables. AEs were collected on day 1 of treatment and a minimum of 14 days after the last dose. AEs reported here were ranked as either possibly related, probably related, or definitely related to the study intervention. All AEs (including not related and unlikely related) are summarized in the AE section. (NCT02720185)
Timeframe: Up to 4 weeks

Interventionadverse events (Number)
FatigueAnemiaCreatinine IncreaseLow E-GFRNauseaInsomniaBody AchesConstipationHeadacheDyspepsia
Dasatinib 100mg4211111111

[back to top]

Progression Free Survival Rate (PFSR) at 24 Weeks

"The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive (>=1%) Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative (<1%) Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 24 weeks after first dose

,
InterventionProportion of Participants (Number)
Study Track 1Study Track 2Study Track 3Study Track 4
Nivolumab + DasatinibNANA0.191NA
Nivolumab + IpilimumabNA0.455NA0.391

[back to top]

Objective Response Rate (ORR)

"ORR is defined as the percentage of participants whose confirmed best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR was assessed by investigator per RECIST1.1.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 2 years following last dose (up to 30 months)

InterventionPercent of Participants (Number)
Study Track 2Study Track 3
Nivolumab + BMS98601600

[back to top]

Number of Participants Experiencing Laboratory Abnormalities in Thyroid Tests

"The following measurements will be considered laboratory abnormalities for thyroid tests:~TSH value > ULN and~With baseline TSH value ≤ ULN~At least one T3/T4 test value < LLN~Low TSH < LLN and~With baseline TSH value ≥ LLN~At least one T3/T4 test value > ULN TSH = thyroid stimulating hormone ULN=Upper Limit of Normal LLN=Lower Limit of Normal T3=Triiodothyronine T4=Thyroxine" (NCT02750514)
Timeframe: From first dose to 100 days following last dose (approximately 9 months)

,,,,
InterventionParticipants (Number)
TSH > ULNTSH > ULN WITH TSH <= ULN AT BASELINETSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLNTSH < LLNTSH < LLN WITH TSH >= LLN AT BASELINETSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN
Nivolumab964553
Nivolumab + BMS986016311000
Nivolumab + BMS986205966440
Nivolumab + Dasatinib1693311
Nivolumab + Ipilimumab2417820165

[back to top]

Progression Free Survival Rate (PFSR) at 24 Weeks

"The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive (>=1%) Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative (<1%) Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 24 weeks after first dose

InterventionProportion of Participants (Number)
Study Track 5
Nivolumab + BMS9862050.111

[back to top]

Progression Free Survival Rate (PFSR) at 24 Weeks

"The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive (>=1%) Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative (<1%) Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 24 weeks after first dose

InterventionProportion of Participants (Number)
Study Track 1Study Track 2
Nivolumab0.302NA

[back to top]

Percentage of Participants Experiencing Adverse Events (AEs)

This outcome measure describes the percentage of participants who experienced any grade, all causality AEs during the specified time frame (NCT02750514)
Timeframe: From first dose to 100 days following last dose

InterventionPercent of Participants (Number)
Nivolumab100.0
Nivolumab + Dasatinib100.0
Nivolumab + BMS986016100.0
Nivolumab + Ipilimumab98.9
Nivolumab + BMS986205100.0

[back to top]

Duration of Response (DOR)

"DOR, computed for all treated participants with a confirmed BOR of CR or PR, is defined as the time between the date of first response and the date of first documented disease progression (as determined by RECIST 1.1) or death due to any cause.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 2 years following last dose (up to 30 months)

InterventionMonths (Median)
Study Track 1Study Track 3Study Track 4
Nivolumab + Dasatinib8.57NANA

[back to top]

Objective Response Rate (ORR)

"ORR is defined as the percentage of participants whose confirmed best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR was assessed by investigator per RECIST1.1.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 2 years following last dose (up to 30 months)

InterventionPercent of Participants (Number)
Study Track 1Study Track 2
Nivolumab17.50

[back to top]

Progression Free Survival Rate (PFSR) at 24 Weeks

"The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive (>=1%) Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative (<1%) Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 24 weeks after first dose

InterventionProportion of Participants (Number)
Study Track 2Study Track 3
Nivolumab + BMS986016NANA

[back to top]

Objective Response Rate (ORR)

"ORR is defined as the percentage of participants whose confirmed best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR was assessed by investigator per RECIST1.1.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 2 years following last dose (up to 30 months)

,
InterventionPercent of Participants (Number)
Study Track 1Study Track 2Study Track 3Study Track 4
Nivolumab + Dasatinib25.002.41.9
Nivolumab + Ipilimumab025.05.620.0

[back to top]

Number of Participants Experiencing Laboratory Abnormalities in Hepatic Tests

"The following measurements will be considered laboratory abnormalities for hepatic tests:~ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN~Total bilirubin > 2 x ULN~Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN~Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN ALT=Alanine aminotransferase AST=Aspartate aminotransferase ULN=Upper Limit of Normal" (NCT02750514)
Timeframe: From first dose to 100 days following last dose (approximately 9 months)

,,,,
InterventionParticipants (Number)
ALT OR AST > 3XULNALT OR AST > 5XULNALT OR AST > 10XULNALT OR AST > 20XULNTOTAL BILIRUBIN > 2XULNConcurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULNConcurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN
Nivolumab4220100
Nivolumab + BMS9860161000000
Nivolumab + BMS9862053221322
Nivolumab + Dasatinib3000000
Nivolumab + Ipilimumab5311222

[back to top]

Duration of Response (DOR)

"DOR, computed for all treated participants with a confirmed BOR of CR or PR, is defined as the time between the date of first response and the date of first documented disease progression (as determined by RECIST 1.1) or death due to any cause.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 2 years following last dose (up to 30 months)

InterventionMonths (Median)
Study Track 2Study Track 3Study Track 4
Nivolumab + IpilimumabNANA12.65

[back to top]

Objective Response Rate (ORR)

"ORR is defined as the percentage of participants whose confirmed best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR was assessed by investigator per RECIST1.1.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 2 years following last dose (up to 30 months)

InterventionPercent of Participants (Number)
Study Track 5
Nivolumab + BMS9862052.3

[back to top]

Duration of Response (DOR)

"DOR, computed for all treated participants with a confirmed BOR of CR or PR, is defined as the time between the date of first response and the date of first documented disease progression (as determined by RECIST 1.1) or death due to any cause.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 2 years following last dose (up to 30 months)

InterventionMonths (Median)
Study Track 5
Nivolumab + BMS9862053.75

[back to top]

Duration of Response (DOR)

"DOR, computed for all treated participants with a confirmed BOR of CR or PR, is defined as the time between the date of first response and the date of first documented disease progression (as determined by RECIST 1.1) or death due to any cause.~Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3).~Results for each study track are presented only for treatment groups who received a treatment in that specific track." (NCT02750514)
Timeframe: From first dose to 2 years following last dose (up to 30 months)

InterventionMonths (Median)
Study Track 1
Nivolumab12.81

[back to top]

Percentage of Participants Experiencing Serious Adverse Events (SAEs)

This outcome measure describes the percentage of participants who experienced any grade, all causality SAEs during the specified time frame (NCT02750514)
Timeframe: From first dose to 100 days following last dose

InterventionPercent of Participants (Number)
Nivolumab57.1
Nivolumab + Dasatinib53.8
Nivolumab + BMS98601661.1
Nivolumab + Ipilimumab58.1
Nivolumab + BMS98620560.5

[back to top]

Percentage of Participants Experiencing Death

This outcome measure describes the percentage of participants who died (due to any cause) during the specified time frame (NCT02750514)
Timeframe: From first dose to up to 45 months following first dose

InterventionPercent of Participants (Number)
Nivolumab57.1
Nivolumab + Dasatinib55.7
Nivolumab + BMS98601666.7
Nivolumab + Ipilimumab46.2
Nivolumab + BMS98620562.8

[back to top]

Percentage of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

This outcome measure describes the percentage of participants who experienced all causality AEs leading to discontinuation of study therapy during the specified time frame (NCT02750514)
Timeframe: From first dose to 100 days following last dose

InterventionPercent of Participants (Number)
Nivolumab14.3
Nivolumab + Dasatinib23.6
Nivolumab + BMS9860165.6
Nivolumab + Ipilimumab11.8
Nivolumab + BMS98620514.0

[back to top]

Event-free Survival

Events were defined as any of the following: (1) unable to achieve either morphologic complete remission (CR) or MRD- by MFC, (2) relapse after CR, (3) MRD recurrence after achieving MRD-, or (4) death from any cause. (NCT03023046)
Timeframe: Up to 2 years

InterventionPercentage of Participants (Number)
Treatment (Chemotherapy)32

[back to top]

Number of Participants With Complete Measurable Residual Disease (MRD) Response Rate

"Response was determined by having no detectable disease by multiparameter flow cytometry (MFC-). For Ph+ subjects, complete molecular response (CMR) by BCR-ABL RT-PCR was assigned when MFC was undetectable.~When no measurable residual disease was detected by MFC (MFC-) per EuroFlow criteria, high-throughput sequencing-based MRD testing (HTS; ClonoSEQ) was performed." (NCT03023046)
Timeframe: Within 4 cycles of study therapy

InterventionParticipants (Count of Participants)Participants (Count of Participants)
MFC-72545885MFC-72545886CMR72545885HTS-72545885HTS-72545886
Achieve within 4 cyclesNot achieved within 4 cycles
Ph+ Subjects20
Ph- Subjects9
Ph+ Subjects11
Ph+ Subjects17
Ph+ Subjects8
Ph- Subjects6
Ph+ Subjects16
Ph- Subjects16

[back to top]

Overall Survival

Alive at 2 years after enrollment (NCT03023046)
Timeframe: Up to 2 years

InterventionPercentage of Participants (Number)
Treatment (Chemotherapy)70

[back to top]

Number of Participants With Morphological Complete Response Rate

Morphological complete remission (CR) was determined by bone marrow aspirate morphology and defined as <5% blasts by morphology, absolute neutrophil count >1000/uL, and platelet count >100,000/uL. (NCT03023046)
Timeframe: Within 4 cycles of study therapy

InterventionParticipants (Count of Participants)
Ph+ Subjects27
Ph- Subjects20

[back to top]

Number of Participants With Adverse Events

Grade 1 or higher non-hematologic adverse events will be assessed by Common Terminology Criteria for Adverse Events version 5.0. (NCT03023046)
Timeframe: Within 28 days of the last dose of the study drugs

InterventionParticipants (Count of Participants)
Treatment (Chemotherapy)44

[back to top]

Phase II: Progression Free Survival (PFS) in Participants Receiving Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib

PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Progressive disease is at least a 20% increase in the sum of the diameters of target lesions) taking as reference the smallest sum of diameters while on study. (NCT03041701)
Timeframe: Participants were followed for the duration of their treatment which ranged from 0-6 cycles (each cycle is 28 days) and averaged approximately 2 months.

InterventionMonths (Median)
Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg1.93
Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg0.88

[back to top] [back to top]

Phase II: Number of Participants Who Experience an Objective Clinical Response (CR or PR) When Treated With Ganitumab Plus Dasatinib

Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. (NCT03041701)
Timeframe: Participants were followed for the duration of their treatment which ranged from 0-6 cycles (each cycle is 28 days) and averaged approximately 2 months.

,
InterventionParticipants (Count of Participants)
Complete ResponsePartial Response
Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg00
Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg00

[back to top]

Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT03041701)
Timeframe: Date treatment consent signed to date off study, approximately 14 months and 18 days for phase 1 dose level 1, 27 months and 2 days for phase 1 dose level 2, and 1 month and 24 days for phase 2 dose level 1.

InterventionParticipants (Count of Participants)
Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg7
Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg6
Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg1

[back to top] [back to top]

Phase II: Number of Participants With Stable Disease >= 6 Months as Defined by the Response Evaluation Criteria in Solid Tumors (RECIST) in Participants Receiving Ganitumab With Dasatinib

Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Stable disease is neither sufficient shrinkage to qualify for partial response (i.e., at least a 30% decrease in the sum of the diameters of target lesions) nor sufficient increase to qualify for progressive disease (i.e., at least a 20% increase in the sum of the diameters of target lesions) taking as reference the smallest sum of diameters while on study. (NCT03041701)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg1
Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg0

[back to top]

Phase II: Number of Participants That is Without Progression at 4 Months

Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Progressive disease is least a 20% increase in the sum of the diameters of target lesions) taking as reference the smallest sum of diameters while on study. (NCT03041701)
Timeframe: At 4 months

InterventionParticipants (Count of Participants)
Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg1
Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg0

[back to top]

Phase I: Safe Dose of Dasatinib When Given With Ganitumab in Participants With Relapsed or Refractory Embryonal or Alveolar Rhabdomyosarcoma (RMS)

The safe dose or maximum tolerated dose (MTD) is defined as the dose level at which no more than 1 of up to 3-6 participants experience a dose-limiting toxicity (DLT) during the first cycle of treatment, and the dose below that at which at least 2 (of ≤6) participants have DLT as a result of the drug. A DLT is any toxicity of grade 3 or higher, with the specific exception of grade 3 nausea and vomiting of < 5 days duration, grade 3 fever or infection < 5 days duration, and grade 3 neutropenia or thrombocytopenia, for example. (NCT03041701)
Timeframe: First 35 days of treatment

Interventionmg/m^2 (Number)
All Participants60

[back to top]

Phase I: Number of Participants With a Dose-Limiting Toxicity (DLT)

A DLT is any toxicity of grade 3 or higher, with the specific exception of grade 3 nausea and vomiting of < 5 days duration, grade 3 fever or infection < 5 days duration, and grade 3 neutropenia or thrombocytopenia, for example. (NCT03041701)
Timeframe: First 35 days of treatment

InterventionParticipants (Count of Participants)
Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg1
Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg2

[back to top]

Overall Survival

Percentage of participants alive at 2 years. (NCT03352427)
Timeframe: up to 17 months

Interventionpercentage of participants (Number)
Dasatinib+Everolimus0

[back to top]

Overall Response Rate (OR) (Partial Response or Better) in Participants With Refractory or Recurrent Glioma

The overall response assessment will take into account response in both target and non-target lesions, as well as the appearance of new lesions. Partial Response (PR) will be defined as ≥50% decrease in size of tumor in comparison to baseline measurements. Complete Response (CR) will be defined as the disappearance of all abnormal signal. This includes return to normal size of the brain stem for brain stem lesions. Reported as percentage of participants with partial or better response at 56 days. (NCT03352427)
Timeframe: 56 Days

Interventionpercentage of participants (Number)
Dasatinib+Everolimus0

[back to top]

Overall Survival

Percentage of patients alive at one year. (NCT03352427)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Dasatinib+Everolimus0

[back to top]

Progression-free Survival in Participants With Newly Diagnosed High-grade Glioma (HGG)

Percentage of participants without progression, defined as 25% increase in the size of the tumor or appearance of new lesions. (NCT03352427)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Dasatinib+Everolimus0

[back to top]

Progression-free Survival in Participants With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

Percentage of participants without progression, defined as 25% increase in the size of the tumor or appearance of new lesions. (NCT03352427)
Timeframe: 8 months

Interventionpercentage of participants (Number)
Dasatinib+Everolimus0

[back to top]

Senescence Marker IL-6 in CSF

Laboratory measure of level of IL-6 found in CSF collected pre and post treatment (NCT04063124)
Timeframe: Change from 0 to 12 weeks

Interventionpg/ml (Mean)
Intermittent D+Q0.37

[back to top]

Montreal Cognitive Assessment (MoCA)

A test which scores the participant with score ranges between 0 and 30. A score of 26 or over is considered normal. Individuals with mild cognitive impairment score lower and individuals with Alzheimer's disease score even lower. (NCT04063124)
Timeframe: Change from 0 to 12 weeks

Interventionpoints (Mean)
Intermittent D+Q-0.20

[back to top]

Alzheimer's Disease Marker - CSF Amyloid Beta

Cerebrospinal Fluid collected by lumbar puncture analyzed for level of amyloid beta proteins present in CSF (NCT04063124)
Timeframe: Change from 0 to 12 weeks

Interventionpg/ml (Mean)
Intermittent D+Q78

[back to top]

Alzheimer's Disease Marker - CSF Tau

Cerebrospinal Fluid collected by lumbar puncture analyzed for level of tau proteins present in CSF (NCT04063124)
Timeframe: Change from 0 to 12 weeks

Interventionpg/ml (Mean)
Intermittent D+Q-21

[back to top]

Brain Penetrance of Dasatinib (D)

Cerebrospinal Fluid (CSF) collected by lumbar puncture before and after 12 weeks of treatment to determine levels of drug that reach the central nervous system will be measured by high performance liquid chromatography/mass spectrometry (HPLC/MS) (NCT04063124)
Timeframe: Change from 0 to 12 weeks

Interventionng/ml (Mean)
Intermittent D+Q0.27

[back to top]

Brain Penetrance of Quercetin (Q)

CSF collected by lumbar puncture before and after 12 weeks of treatment to determine levels of drug that reach the central nervous system using HPLC/MS (NCT04063124)
Timeframe: Change from 0 to 12 weeks

Interventionng/ml (Mean)
Intermittent D+Q0

[back to top]

Overall Survival Rate: All Participants

Overall survival rate in this study was defined as percentage of participants alive during analysis period of 01-January-2011 till 30-June-2020. 5 years overall survival rate was demonstrated with Kaplan-Meier curve. (NCT05286528)
Timeframe: 5 years, during analysis period from 01-January-2011 till 30-June-2020 (retrieved data assessed in this observational study for approximately 1.2 years)

InterventionPercentage of participants (Number)
Participants With CML77.1

[back to top]

Overall Survival Rate: Type of First Line TKI

Overall survival rate in this study was defined as percentage of participants alive during analysis period of 01-January-2011 till 30-June-2020. 5 years overall survival rate was demonstrated with Kaplan-Meier curve. (NCT05286528)
Timeframe: 5 years, during analysis period from 01-January-2011 till 30-June-2020 (retrieved data assessed in this observational study for approximately 1.2 years)

InterventionPercentage of participants (Number)
Participants With CML77.1

[back to top]

Overall Survival Rate: Type of Second Line TKI

Overall survival rate in this study was defined as percentage of participants alive during analysis period of 01-January-2011 till 30-June-2020. 5 years overall survival rate was demonstrated with Kaplan-Meier curve. (NCT05286528)
Timeframe: 5 years, during analysis period from 01-January-2011 till 30-June-2020 (retrieved data assessed in this observational study for approximately 1.2 years)

InterventionPercentage of participants (Number)
Participants With CML71.5

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aminolevulinic acid
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.		2.6104-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
adenine
[no description available]		6.011206-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
quinacrine
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.		2.0710acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
betaine
glycine betaine : The amino acid betaine derived from glycine.		5.4941amino-acid betaine;
glycine derivative		fundamental metabolite
carbamates
[no description available]		2.1110amino-acid anion
carnitine
[no description available]		2.0710amino-acid betainehuman metabolite;
mouse metabolite
methane
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed). methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).		2.5220alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
coumarin
2H-chromen-2-one: coumarin derivative		2.830coumarinsfluorescent dye;
human metabolite;
plant metabolite
salicylic acid
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).		3.0240monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
bupropion
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.		3.620aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
guaiacol
Guaiacol: An agent thought to have disinfectant properties and used as an expectorant. (From Martindale, The Extra Pharmacopoeia, 30th ed, p747). methylcatechol : Any member of the class of catechols carrying one or more methyl substituents.. guaiacol : A monomethoxybenzene that consists of phenol with a methoxy substituent at the ortho position.		2.0710guaiacolsdisinfectant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
expectorant;
plant metabolite
aminocaproic acid
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.		3.2310amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
creatine
[no description available]		2.1310glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
alanine
[no description available]		2.0510alpha-amino acid;
amino acid zwitterion		fundamental metabolite
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		3.02402-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		2.5720sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
glycine
[no description available]		3.8620alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glycerol
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.		2.0810alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
histamine
[no description available]		2.0710aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
thioctic acid
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.		2.610dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
melatonin
[no description available]		2.0810acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
acetanilide
acetanilide: a phenylacetamide; use ACETANILIDES for the plural group meaning of the singular term. N-phenylacetamide : A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is substituted by a phenyl group.		2.0710acetamides;
anilide		analgesic
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		8.99370pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
niacin
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.		3.2310pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
phosphorylcholine
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.		3.0340phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
picolinic acid
picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206. picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.		2.610pyridinemonocarboxylic acidhuman metabolite;
MALDI matrix material
pteridines
[no description available]		2.0810azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
pteridines
pyrazinamide
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.		3.930monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
pyridoxine
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).		3.620hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thiamine
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.		3.7320primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		2.0510pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		340isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
bremazocine
[no description available]		2.0510
b 844-39
[no description available]		3.7320diarylmethane
perillic acid
perillic acid: d-limonene metabolite; structure given in first source		2.1110alpha,beta-unsaturated monocarboxylic acid;
cyclohexenecarboxylic acid		antineoplastic agent;
human metabolite;
mouse metabolite
pk 11195
PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine		3.0740aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes		antineoplastic agent
1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.		2.0810monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
pd 173074
[no description available]		3.3260aromatic amine;
biaryl;
dimethoxybenzene;
pyridopyrimidine;
tertiary amino compound;
ureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
3-aminobenzamide
[no description available]		2.610benzamides;
substituted aniline		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
enprofylline
enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.		2.0710oxopurineanti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug
pleconaril
WIN 63843: structure given in first source		2.7620
4,5,6,7-tetrabromo-2-azabenzimidazole
4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor		4.0840
4-(2-aminoethyl)benzenesulfonylfluoride
[no description available]		2.610
jtv519
[no description available]		2.8930
phenytoin
[no description available]		4.1340imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
oxyquinoline
Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.		2.0710monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
tacrine
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.		2.4820acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
N-(2-aminoethyl)-5-chloro-1-naphthalenesulfonamide
[no description available]		2.0310naphthalenes;
sulfonic acid derivative
abt 702
[no description available]		2.0810bipyridines
acebutolol
Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.		6.1731aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		3.8830acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
acetarsol
[no description available]		2.0710acetamides;
anilide
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		3.9530monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohydroxamic acid
acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.		3.2310acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
ethacridine
Ethacridine: A topically applied anti-infective agent.		2.0710acridines
4-(acetylamino)benzeneacetic acid
[no description available]		2.0710acetamides;
anilide
adiphenine
adiphenine: was heading 1963-94; use DIPHENYLACETIC ACIDS to search ADIPHENINE 1966-94		2.0710diarylmethane
ag 1295
[no description available]		2.0310quinoxaline derivativegeroprotector
rtki cpd
[no description available]		3.6620aromatic ether;
monochlorobenzenes;
quinazolines		antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector
tyrphostin a23
tyrphostin A23: inhibits EGF-stimulated thymidine incorporation as well as EGF-stimulated receptor autophosphorylation & tyrosine phosphorylation & cell proliferation; structure given in first source		2.0310catechols
aklomide
aklomide: structure		2.0710carbonyl compound;
organohalogen compound
alaproclate
alaproclate: specific 5-hydroxytryptamine uptake inhibitors; RN given refers to (DL)-isomer		3.2310alpha-amino acid ester
albendazole
[no description available]		3.6120aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
albuterol
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).		4.1340phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
alendronate
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.		3.23101,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alfuzosin
alfuzosin: structure given in first source		3.2310monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
alosetron
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.		3.2310imidazoles;
pyridoindole		antiemetic;
gastrointestinal drug;
serotonergic antagonist
alprazolam
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.		4.1940organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
alprenolol
Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.		3.0440secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
altretamine
Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.		3.620triamino-1,3,5-triazine
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		3.7320adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
ambenonium
ambenonium : A symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens.		3.2310quaternary ammonium ionEC 3.1.1.8 (cholinesterase) inhibitor
diatrizoic acid
Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.		3.6120acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
amifostine anhydrous
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.		3.2310diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
aminoglutethimide
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.		2.4820dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid
p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.		3.620N-acylglycineDaphnia magna metabolite
theophylline
[no description available]		3.8730dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
2-aminothiazole
2-aminothiazole: RN given refers to parent cpd; structure. 1,3-thiazol-2-amine : A primary amino compound that is 1,3-thiazole substituted by an amino group at position 2.		2.6101,3-thiazoles;
primary amino compound
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		4.1401-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
dan 2163
[no description available]		3.0740aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
amitriptyline
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.		3.6120carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amlexanox
amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.		3.2750monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
amlodipine
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.		3.8830dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
amodiaquine
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.		4.740aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
amoxapine
Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.		3.8830dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
amprolium
Amprolium: A veterinary coccidiostat that interferes with THIAMINE metabolism.. amprolium : An organic chloride salt having 1-[(4-amino-2-propylpyrimidin-5-yl)methyl]-2-methylpyridin-1-ium as the counterion. Used for prevention of coccidiosis in poultry and cattle.. amprolium(1+) : A pyridinium ion that is the cationic portion of amprolium, a veterinary drug which is used for prevention of coccidiosis in poultry and cattle.		2.0710pyridinium ioncoccidiostat
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		2.0810acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole
[no description available]		3.6120nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
antazoline
Antazoline: An antagonist of histamine H1 receptors.. antazoline : A member of the class of imidazolines that is 2-aminomethyl-2-imidazoline in which the exocyclic amino hydrogens are replaced by benzyl and phenyl groups. Antazoline is only found in individuals that have taken the drug.		2.0710aromatic amine;
imidazolines;
tertiary amino compound		cholinergic antagonist;
H1-receptor antagonist;
xenobiotic
anthralin
Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.		2.0810anthracenesantipsoriatic
antipyrine
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.		2.7630pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
[no description available]		2.0710aporphine alkaloid
arecoline
Arecoline: An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.. arecoline : A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine.		2.0710enoate ester;
methyl ester;
pyridine alkaloid;
tetrahydropyridine		metabolite;
muscarinic agonist
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		4.4660benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
astemizole
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.		4.7580benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
atenolol
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.		4.1240ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
azathioprine
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.		4.1340aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
baclofen
[no description available]		3.9530amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
bendazac
bendazac : A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.		3.2310indazoles;
monocarboxylic acid		non-steroidal anti-inflammatory drug;
radical scavenger
bendroflumethiazide
Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810). bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.		3.620benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
benserazide
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.. benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.		2.0710carbohydrazide;
catechols;
primary alcohol;
primary amino compound		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
benzamide
benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.		2.610benzamides
benzbromarone
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.		5.03601-benzofurans;
aromatic ketone		uricosuric drug
benzocaine
Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.		2.4820benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
benzothiazide
benzothiazide: structure. benzthiazide : 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema.		2.0710benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
benzyl benzoate
benzyl benzoate: structure; acarosan, a moist powder composed of wetted cellulose and benzyl benzoate, is used on carpets as an acaricide. benzyl benzoate : A benzoate ester obtained by the formal condensation of benzoic acid with benzyl alcohol. It has been isolated from the plant species of the genus Polyalthia.		2.0810benzoate ester;
benzyl ester		acaricide;
plant metabolite;
scabicide
bepridil
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.		2.4820pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
betaxolol
[no description available]		3.620propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bethanechol
Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.. bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.		3.620carbamate ester;
quaternary ammonium ion		muscarinic agonist
bicalutamide
bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.		3.8930(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
bay h 4502
bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1.		2.0810biphenyls;
imidazoles
biperiden
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.		3.2310piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide
[no description available]		2.0610hydroxycinnamic acid
bisacodyl
Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)		3.8830diarylmethane
bisindolylmaleimide i
bisindolylmaleimide I: a bis(indolyl)maleimide		3.2150
bisindolylmaleimide iv
[no description available]		2.5120indoles;
maleimides
bisoprolol
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.		3.2310secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bithionol
Bithionol: Halogenated anti-infective agent that is used against trematode and cestode infestations.. bithionol : An aryl sulfide that is diphenyl sulfide in which each phenyl group is substituted at position 2 by hydroxy and at positions 3 and 5 by chlorine. A fungicide and anthelmintic, it was used in various topical drug products for the treatment of liver flukes, but withdrawn after being shown to be a potent photosensitizer with the potential to cause serious skin disorders.		2.3110aryl sulfide;
bridged diphenyl antifungal drug;
bridged diphenyl fungicide;
dichlorobenzene;
organochlorine pesticide;
polyphenol		antifungal agrochemical;
antiplatyhelmintic drug
bohemine
bohemine : Purine substituted on C-2, C-6 and N-9 with (3-hydroxypropyl)amino, benzylamino and isopropyl groups respectively; a synthetic, cell-permeable, cyclin-dependent kinase (CDK) inhibitor that is structurally similar to olomoucine and roscovitine.		2.0310purinesEC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bretylium
bretylium: RN given refers to parent cpd. bretylium : A quaternary ammonium cation having 2-bromobenzyl, ethyl and two methyl groups attached to the nitrogen. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.		2.0710quaternary ammonium ionadrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent
bromhexine
Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).		2.5420organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
bromopride
bromopride: RN given refers to parent cpd; structure		2.0810benzamides
seratrodast
[no description available]		2.0710organic molecular entity
bronopol
[no description available]		2.0810nitro compound
bufexamac
Bufexamac: A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally.. bufexamac : A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties.		2.8930aromatic ether;
hydroxamic acid		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
buflomedil
buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure		2.3110aromatic ketone
bumetanide
[no description available]		3.8830amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
buspirone
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.		4.3930azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
busulfan
[no description available]		9.7950methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
secbutabarbital
secbutabarbital: Butabarbital (a synonym for Secbutabarbital) should be distinguished from Butobarbital		3.2310barbiturates
butacaine
butacaine: was MH 1965-92; BUTAPROBENZ & BUTOCAIN were see BUTACAINE 1978-92; use 4-AMINOBENZOIC ACID to search BUTACAINE 1966-92		2.0710benzoate ester
butamben
butamben: structure. butamben : An amino acid ester resulting from the formal condensation of the carboxy group of 4-aminobenzoic acid with the hydroxy group of butan-1-ol. Its local anaesthetic properties have been used for surface anaesthesia of the skin and mucous membranes, and for relief of pain and itching associated with some anorectal disorders.		2.0710amino acid ester;
benzoate ester;
primary amino compound;
substituted aniline		local anaesthetic
cadralazine
cadralazine: structure given in first source		2.8930organic molecular entity
caffeine
[no description available]		4.8150purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		9.890aromatic ether;
nitrile;
polyether;
tertiary amino compound
beta-glycerophosphoric acid
beta-glycerophosphoric acid: plays role in mineralization of bone in vitro. glycerol 2-phosphate : A glycerol monophosphate having the phosphate group at the 2-position.		2.0510glycerol monophosphateEscherichia coli metabolite;
plant metabolite
camostat
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.		3.9220benzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide		anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor
camphor, (+-)-isomer
[no description available]		2.610bornane monoterpenoid;
cyclic monoterpene ketone		plant metabolite
candesartan cilexetil
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects		3.5110biphenyls
candesartan
candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.		3.7320benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
carbamylcholine
[no description available]		2.0710
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		3.8830dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carbinoxamine
carbinoxamine: Note: tradenames that start with Histex refer to more than one drug. carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.		3.9330monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
carisoprodol
Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.		3.2310carbamate estermuscle relaxant
carmofur
[no description available]		3.4110organohalogen compound;
pyrimidines
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		2.7930N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
carprofen
carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.		2.0810carbazoles;
organochlorine compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent
carteolol
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.		2.0710quinolone;
secondary alcohol		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
carvedilol
[no description available]		4.1640carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
celecoxib
[no description available]		9.4760organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
cetirizine
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.		3.9830ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
cetraxate
[no description available]		2.3110benzenes;
monocarboxylic acid
cetylpyridinium
Cetylpyridinium: Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges.		2.610pyridinium ion
chelerythrine
chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.		2.4620benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		8.8730aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlorcyclizine
chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness		4.1940diarylmethane
chlordiazepoxide
Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.		3.6120benzodiazepine
chlormezanone
Chlormezanone: A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.. chlormezanone : A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.		3.23101,3-thiazine;
lactam;
monochlorobenzenes;
sulfone		antipsychotic agent;
anxiolytic drug;
muscle relaxant
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		6.2260aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chlorothiazide
Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.		3.5820benzothiadiazineantihypertensive agent;
diuretic
chloroxylenol
chloroxylenol: topical antiseptic; RN given refers to parent cpd; structure. 4-chloro-3,5-dimethylphenol : A member of the class of phenols that is 3,5-xylenol which is substituted at position 4 by chlorine. It is bactericidal against most Gram-positive bacteria but less effective against Staphylococci and Gram-negative bacteria, and often inactive against Pseudomonas species. It is ineffective against bacterial spores.		2.5720monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
chlorphenesin carbamate
[no description available]		2.0810carbamate ester;
monochlorobenzenes;
secondary alcohol		muscle relaxant
chlorpheniramine
Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.		3.6120monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		5.1170organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpropamide
Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.		3.8830monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorthalidone
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.		3.6120isoindoles;
monochlorobenzenes;
sulfonamide
chlorzoxazone
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.		3.61201,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
ci 994
tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.		2.8930acetamides;
benzamides;
substituted aniline		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
cifenline
[no description available]		2.0810diarylmethane
ciclopirox
[no description available]		2.0810cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone		antibacterial agent;
antiseborrheic
ciglitazone
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.		2.0810aromatic ether;
thiazolidinone		antineoplastic agent;
insulin-sensitizing drug
cilostazol
[no description available]		3.8930lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		4.0940aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
aricine
[no description available]		2.0710cinchona alkaloid
ciprofibrate
[no description available]		2.5820cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		3.8830aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
cisapride
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed). cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.		2.0810benzamides
citalopram
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.		3.61202-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
clioquinol
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.		2.0810monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
clobazam
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.. clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.		2.08101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator
clofazimine
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.		3.6620monochlorobenzenes;
phenazines		dye;
leprostatic drug;
non-steroidal anti-inflammatory drug
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		3.6120aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clofoctol
[no description available]		2.3110diarylmethane
clomiphene
[no description available]		3.8830tertiary amineestrogen antagonist;
estrogen receptor modulator
clomipramine
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.		560dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clonazepam
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.		3.23101,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		3.930clonidine;
imidazoline
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide
[no description available]		2.0810sulfonamide
chlorazepate
clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.		3.23101,4-benzodiazepinoneanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug
clotrimazole
[no description available]		3.620conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
cloxyquin
cloxyquin: has antitubercular activity; structure in first source		2.0710organochlorine compound;
quinolines
cromolyn
cromoglycic acid : A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.		2.5420chromones;
dicarboxylic acid		anti-asthmatic drug;
calcium channel blocker
cyclandelate
Cyclandelate: A direct-acting SMOOTH MUSCLE relaxant used to dilate BLOOD VESSELS.. cyclandelate : The ester obtained by formal condensation of mandelic acid and 3,3,5-tricyclohexanol. It is a direct-acting smooth muscle relaxant used to dilate blood vessels.		2.0710carboxylic ester;
secondary alcohol		vasodilator agent
cyclobenzaprine
cyclobenzaprine: RN given refers to parent cpd; Lisseril is synonymous for HCl; structure. cyclobenzaprine : 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.		3.8830carbotricyclic compoundantidepressant;
muscle relaxant;
tranquilizing drug
cyclofenil
Cyclofenil: A gonadal stimulant and inducer of ovulation. It is used in the treatment of infertility and amenorrhea, but is thought to be less effective than CLOMIPHENE.		3.2310organic molecular entity
cyclosporine
cyclosporin A : A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.		2.5920
cyproheptadine
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.		4.1120piperidines;
tertiary amine		anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
damnacanthal
damnacanthal: structure given in first source; isolated from the stem bark and roots of Morinda lucida; a selective inhibitor of p56(lck) tyrosine kinase activity		2.0310aldehyde;
monohydroxyanthraquinone
danthron
danthron: structure. chrysazin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8.		2.610dihydroxyanthraquinoneapoptosis inducer;
plant metabolite
dapi
DAPI: RN given refers to parent cpd.		2.0710indolesfluorochrome
dapsone
[no description available]		3.8830substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
debrisoquin
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.		2.0710carboxamidine;
isoquinolines		adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent
deferiprone
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.		2.6104-pyridonesiron chelator;
protective agent
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		3.2310acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
desipramine
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.		4.0940dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		3.2310primary amine
r 59022
R 59022: diacylglycerol kinase inhibitor; structure given in first source; platelet activator factor antagonist		2.0310diarylmethane
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		4.1401,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazoxide
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.		3.8830benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
dibenzothiophene
dibenzothiophene : A mancude organic heterotricyclic parent that consists of a thiophene ring flanked by two benzene rings ortho-fused across the 2,3- and 4,5-positions.		2.0710dibenzothiophenes;
mancude organic heterotricyclic parent		keratolytic drug
dibucaine
Dibucaine: A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006). cinchocaine : A monocarboxylic acid amide that is the 2-(diethylamino)ethyl amide of 2-butoxyquinoline-4-carboxylic acid. One of the most potent and toxic of the long-acting local anesthetics, its parenteral use was restricted to spinal anesthesia. It is now generally only used (usually as the hydrochloride) in creams and ointments and in suppositories for temporary relief of pain and itching associated with skin and anorectal conditions.		2.0710aromatic ether;
monocarboxylic acid amide;
tertiary amino compound		topical anaesthetic
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		3.8730amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
dichlorophen
Dichlorophen: Nontoxic laxative vermicide effective for taenia infestation. It tends to produce colic and nausea. It is also used as a veterinary fungicide, anthelmintic, and antiprotozoan. (From Merck, 11th ed.)		2.3110bridged diphenyl fungicide;
diarylmethane
dichlorphenamide
Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.		3.620dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
dicyclomine
Dicyclomine: A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.. dicyclomine : The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.		3.620carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
pentetic acid
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.		3.2310pentacarboxylic acidcopper chelator
diflunisal
Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.		3.6920monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
dilacor xr
5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate : A lactam that is 2,3-dihydro-1,5-benzothiazepin-4(5H)-one in which positions 2 and 3 are substituted by 4-methoxyphenyl and acetoxy, respectively, while the hydrogen attached to the nitrogen is substituted by a 2-(dimethylamino)ethyl group.		2.0710acetate ester;
aromatic ether;
benzothiazepine;
lactam;
tertiary amino compound
dimercaprol
Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.		3.2310dithiol;
primary alcohol		chelator
dimethadione
Dimethadione: An anticonvulsant that is the active metabolite of TRIMETHADIONE.		2.0710oxazolidinone
diphenhydramine
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.		3.2310ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
diphenylpyraline
diphenylpyraline: RN given refers to parent cpd; structure. allergen : A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.. diphenylpyraline : A member of the class of piperidines that is the benzhydryl ether derivative of 1-methyl-4-hydroxypiperidine. A sedating antihistamine, it is used as the hydrochloride for the symptomatic relief of allergic conditions including rhinitis and hay fever, and in pruritic skin disorders. It is also used as the teoclate salt (piprinhydrinate) as an ingredient in compound preparations for the symptomatic relief of coughs and the common cold.		2.0710piperidines;
tertiary amine		cholinergic antagonist;
H1-receptor antagonist
dipyridamole
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.		4.7240piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
disopyramide
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.		4.1440monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
disulfiram
[no description available]		5.0360organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		9.1540branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
n(6),n(6)-dimethyladenine
N(6),N(6)-dimethyladenine : A tertiary amine that is adenine substituted at N-6 by geminal methyl groups.		2.4520tertiary amine
domperidone
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.		2.5520benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
donepezil
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.		4.140aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
doxapram
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.		3.2310morpholines;
pyrrolidin-2-ones		central nervous system stimulant
doxazosin
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.		3.9530aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
doxepin
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.		3.6120dibenzooxepine;
tertiary amino compound		antidepressant
doxylamine
Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.		3.620pyridines;
tertiary amine		anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative
droperidol
Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.		3.8830aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
dyclonine
[no description available]		2.0710aromatic ketone;
piperidines		topical anaesthetic
dyphylline
Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.		3.620oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
ebastine
[no description available]		2.0810organic molecular entity
ebselen
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.		3.9930benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
econazole
Econazole: An imidazole derivative that is commonly used as a topical antifungal agent.. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.. 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group.		2.0710dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes
edrophonium
Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.. edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.		3.2310phenols;
quaternary ammonium ion		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
ellipticine
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.		2.0310indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
emodin
Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.		3.4110trihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
enoxacin
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.		2.08101,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
epinastine
epinastine: RN given refers parent cpd. epinastine : A benzazepine that is 6,11-dihydro-5H-dibenzo[b,e]azepine in which the azepine ring is fused to the e side of 4,5-dihydro-1H-imidazol-2-amine.		2.0810benzazepine;
guanidines		anti-allergic agent;
H1-receptor antagonist;
histamine antagonist;
ophthalmology drug
estazolam
Estazolam: A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than DIAZEPAM or NITRAZEPAM.. estazolam : A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia.		3.2310triazoles;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA modulator
ethacrynic acid
Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.		3.6120aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
profenamine
profenamine: was heading 1972-94 (see under PHENOTHIAZINES 1972-90); use PHENOTHIAZINES to search ETHOPROPAZINE 1972-94. profenamine : A member of the class of phenothiazines that is phenothiazine in which the hydrogen attached to the nitrogen is substituted by a 2-(diethylamino)propyl group. An antimuscarinic, it is used as the hydrochloride for the symptomatic treatment of Parkinson's disease.		2.0710phenothiazines;
tertiary amino compound		adrenergic antagonist;
antidyskinesia agent;
antiparkinson drug;
histamine antagonist;
muscarinic antagonist
ethosuximide
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.		3.8830dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
ethotoin
ethotoin: was heading 1966-94 (see under HYDANTOINS 1966-90); use HYDANTOINS to search ETHOTOIN 1966-94. ethotoin : An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.		3.620imidazolidine-2,4-dioneanticonvulsant
etidronate
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.		3.94301,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
etodolac
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.		3.6120monocarboxylic acid;
organic heterotricyclic compound		antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
2-hexyloxybenzamide
2-hexyloxybenzamide: structure		2.610aromatic ether;
benzamides		antifungal agent
brl 42810
[no description available]		3.95302-aminopurines;
acetate ester		antiviral drug;
prodrug
famotidine
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.		4.37411,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
felbamate
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.		3.620carbamate esteranticonvulsant;
neuroprotective agent
4-biphenylylacetic acid
biphenyl-4-ylacetic acid : A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis.		2.0810biphenyls;
monocarboxylic acid		non-steroidal anti-inflammatory drug
felodipine
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.		3.8730dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
fenbendazole
Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.. fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.		2.8930aryl sulfide;
benzimidazoles;
carbamate ester		antinematodal drug
fenfluramine
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.. fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.		2.0810(trifluoromethyl)benzenes;
secondary amino compound		appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
fenofibrate
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE		4.4530aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
fenoldopam
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.		3.620benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
fenoprofen
Fenoprofen: A propionic acid derivative that is used as a non-steroidal anti-inflammatory agent.. fenoprofen : A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.		3.2310monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
berotek
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.		2.5120resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
fexofenadine
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.		3.2310piperidines;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
fipexide
fipexide: regulates dopaminergic systems at macromolecular level		3.2310benzodioxoles
flavoxate
Flavoxate: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.. flavoxate : A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.		3.2310carboxylic ester;
flavones;
piperidines;
tertiary amino compound		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
flecainide
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).		3.8830aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
fleroxacin
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.		2.4720difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		3.6120conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flucytosine
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.		3.6120aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
fluphenazine
[no description available]		4.740N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
flumazenil
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.		3.8830ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
fluorescite
fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.		3.6120benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye		fluorescent dye;
radioopaque medium
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		8.66152nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
fluoxetine
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.		3.8830(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
flurazepam
Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.		3.23101,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
flurbiprofen
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.		3.620fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluspirilene
Fluspirilene: A long-acting injectable antipsychotic agent used for chronic schizophrenia.		3.4110diarylmethane
flutamide
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.		4.140(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
fomepizole
Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL.. fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.		3.2310pyrazolesantidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		3.2310carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		5.280chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		3.620gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
gabexate
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.		2.610benzoate ester
gemfibrozil
[no description available]		4.6440aromatic etherantilipemic drug
glafenine
Glafenine: An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.. glafenine : A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.		3.620aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound		inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gliclazide
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.		2.4820N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
glimepiride
glimepiride: structure given in first source		3.8830sulfonamide
glipizide
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.		3.6120aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
glutaral
Glutaral: One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.. glutaraldehyde : A dialdehyde comprised of pentane with aldehyde functions at C-1 and C-5.		2.610dialdehydecross-linking reagent;
disinfectant;
fixative
glyburide
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.		4.6540monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester
[no description available]		3.2310benzenes
go 6976
[no description available]		3.2150indolocarbazole;
organic heterohexacyclic compound		EC 2.7.11.13 (protein kinase C) inhibitor
gossypol
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.		2.0810
granisetron
[no description available]		3.2310aromatic amide;
indazoles
guaifenesin
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.		3.620methoxybenzenes
guanethidine
Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.		3.620azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
guanfacine
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.		3.6120acetamides
guanidine
Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.		3.2310carboxamidine;
guanidines;
one-carbon compound
gw8510
GW8510: 3' substituted indolone as a scaffold for the development of neuroprotective drug; structure in first source		2.0610
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
[no description available]		2.0610bromobenzenes;
isoquinolines;
olefinic compound;
secondary amino compound;
sulfonamide		EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
ha 1004
N-(2-guanidinoethyl)-5-isoquinolinesulfonamide: structure given in first source		2.0310isoquinolines
fasudil
fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.		3.3560isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		4.7480aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		420phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
hexoprenaline
Hexoprenaline: Stimulant of adrenergic beta 2 receptors. It is used as a bronchodilator, antiasthmatic agent, and tocolytic agent.		2.0710
hexylresorcinol
[no description available]		2.610resorcinols
beta-thujaplicin
beta-thujaplicin: structure. beta-thujaplicin : A monoterpenoid that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2 and an isopropyl group at position 4. Isolated from Thuja plicata and Chamaecyparis obtusa, it exhibits antimicrobial activities.		2.610cyclic ketone;
enol;
monoterpenoid		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiplasmodial drug;
plant metabolite
hexamethylene bisacetamide
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208		2.0710acetamides
homochlorocyclizine
homochlorocyclizine: RN given refers to parent cpd		2.8930diarylmethane
hycanthone
Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.		2.5720thioxanthenesmutagen;
schistosomicide drug
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		3.620azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
hydrochlorothiazide
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.		4.1340benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
hydroflumethiazide
Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.		3.8830benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
hydroxychloroquine
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.		4.830aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
hydroxyurea
[no description available]		8.26181one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
hydroxyzine
Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.		5.0260hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		4.1340monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
phenelzine
Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.		3.620primary amine
lidocaine
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.		3.8730benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
ifenprodil
ifenprodil: NMDA receptor antagonist		3.1340piperidines
ifosfamide
[no description available]		3.6120ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		3.8730dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.		3.8830bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.		3.8830indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic
indirubin-3'-monoxime
indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.4620
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		4.4760aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
iodoquinol
Iodoquinol: One of the halogenated 8-quinolinols widely used as an intestinal antiseptic, especially as an antiamebic agent. It is also used topically in other infections and may cause CNS and eye damage. It is known by very many similar trade names world-wide.. iodoquinol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by iodine. It is considered the drug of choice for treating asymptomatic or moderate forms of amoebiasis.		2.0710monohydroxyquinoline;
organoiodine compound		antiamoebic agent;
antibacterial agent;
antiprotozoal drug;
antiseptic drug
iohexol
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.		2.0810benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
ioversol
[no description available]		3.2310amidobenzoic acid
iproniazid
[no description available]		3.8830carbohydrazide;
pyridines
avapro
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.		3.9530azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
irsogladine
irsogladine: RN given refers to parent cpd; MN 1695 refers to maleate salt		2.3110dichlorobenzene
isocarboxazid
Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)		3.2310benzenes
isoetharine
Isoetharine: Adrenergic beta-2 agonist used as bronchodilator for emphysema, bronchitis and asthma.		2.0710catecholamine
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		4.1140carbohydrazideantitubercular agent;
drug allergen
isoproterenol
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.		3.8930catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isoxsuprine
Isoxsuprine: A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.		3.620alkylbenzene
isradipine
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.		3.6120benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
itraconazole
[no description available]		4.7240piperazines
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline
WHI P131: a quinazoline derivative, inhibitor of glioblastoma cell adhesion and migration		2.1510
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone
ZM39923: structure in first source		2.8930naphthalenes
nsc 664704
kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).		4.0840indolobenzazepine;
lactam;
organobromine compound		cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector
ketamine
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.		4.3550cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketanserin
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.		2.0810aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		6.7561dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		4.3350benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
ketorolac
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.		3.2310amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate		analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
ketotifen
Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.		2.0710cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound		anti-asthmatic drug;
H1-receptor antagonist
khellin
Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024). khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.		2.610furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
kojic acid
[no description available]		2.6104-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
labetalol
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.		4.3250benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound
lamotrigine
[no description available]		3.94301,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
lansoprazole
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.		4.6540benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
lapachol
lapachol : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae.		2.610
lavendustin a
lavendustin A: from Streptomyces griseolavendus; structure given in first source		2.4420aromatic amine
2-hydroxy-5-(2,5-dihydrobenzyl)aminobenzoic acid
[no description available]		2.4420aromatic amine
leflunomide
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.		4.4660(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
letrozole
[no description available]		9.4460nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lg 100268
LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source		2.0810
lofepramine
Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.		2.0810aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound		antidepressant
lomefloxacin
lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.		3.2310fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent
lomustine
[no description available]		5.2731N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
loperamide
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.		4.5530monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
loratadine
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.		4.3150benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
lorazepam
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.		3.2310benzodiazepine
losartan
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position		4.7140biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
loxapine
Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.		3.2310dibenzooxazepineantipsychotic agent;
dopaminergic antagonist
ly 171883
LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity.		2.0710acetophenones;
aromatic ether;
phenols;
tetrazoles		anti-asthmatic drug;
leukotriene antagonist
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		5.6180chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide
4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide: structure in first source. 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide : A benzamide resulting from the formal condensation of the carboxy group of 4-(dimethylamino)benzoic acid with the amino group of 7-amino-N-hydroxyheptanamide. It is a potent inhibitor of histone deacetylases and induces cell cycle arrest and apoptosis in several human cancer cell lines.		2.610benzamides;
hydroxamic acid;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
mafenide
Mafenide: A sulfonamide that inhibits the enzyme CARBONIC ANHYDRASE and is used as a topical anti-bacterial agent, especially in burn therapy.		2.610aromatic amine
maprotiline
Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.		3.6120anthracenes
mebendazole
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.		4.560aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
mecamylamine
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.		3.2310primary aliphatic amine
mechlorethamine
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.		3.2310nitrogen mustard;
organochlorine compound		alkylating agent
meclizine
Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.		3.2310diarylmethane
meclofenamic acid
Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.		3.620aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
mefenamic acid
Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.		3.8930aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
mefloquine hydrochloride
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.		3.4110organofluorine compound;
piperidines;
quinolines;
secondary alcohol
memantine
[no description available]		3.620adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
mepenzolate
mepenzolic acid: anticholinergic, antispasmodic agent; RN given refers to parent cpd; structure		3.2310diarylmethane
meperidine
Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.		3.2310ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
mephenesin
Mephenesin: A centrally acting muscle relaxant with a short duration of action.. 1-(2-methylphenyl)glycerol : A glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage.		3.0640aromatic ether;
glycerol ether
mephenytoin
Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.		3.620imidazolidine-2,4-dioneanticonvulsant
mepivacaine
Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.		3.2310piperidinecarboxamidedrug allergen;
local anaesthetic
meprobamate
Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)		3.2310organic molecular entity
benzoic acid [2-methyl-2-(propylamino)propyl] ester
[no description available]		2.0710benzoate ester
mesalamine
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.		3.620amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
mesoridazine
Mesoridazine: A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.. mesoridazine : A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group.		3.2310phenothiazines;
sulfoxide;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic
metaproterenol
Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.		3.620aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		4.5970guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
methadone
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.		3.6120benzenes;
diarylmethane;
ketone;
tertiary amino compound
methapyrilene
Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.		2.0710ethylenediamine derivativeanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
methazolamide
Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.		3.7320sulfonamide;
thiadiazoles
methocarbamol
Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.		3.9430aromatic ether;
carbamate ester;
secondary alcohol
methoxsalen
Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.		3.2310aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
methyclothiazide
Methyclothiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)		3.2310benzothiadiazine
nocodazole
[no description available]		2.0810aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
methylphenidate
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.		3.2310beta-amino acid ester;
methyl ester;
piperidines
metoclopramide
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.		4.1840benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
metolazone
Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.		3.2310organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor
metoprolol
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.		3.8730aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		4.3150C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
metyrapone
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.		3.620aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.		3.6120aromatic ether;
primary amino compound		anti-arrhythmia drug
mianserin
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.		2.0710dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
miconazole
Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.		2.0710dichlorobenzene;
ether;
imidazoles
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		3.8730imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
midodrine
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.. midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.		3.2310amino acid amide;
aromatic ether;
secondary alcohol		alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent
milrinone
[no description available]		3.2310bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
minoxidil
Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.		4.1340dialkylarylamine;
tertiary amino compound
mirtazapine
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.		3.6120benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist
mitotane
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.		3.620diarylmethane
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		5.170dihydroxyanthraquinoneanalgesic;
antineoplastic agent
ml 7
ML-7 : An N-sulfonyldiazepane resullting from the formal condensation of 5-iodo-1-naphthylsulfonic acid with one of the nitrogens of 1,4-diazepane. It is a selective inhibitor of myosin light chain kinase (EC 2.7.11.18).		2.0310N-sulfonyldiazepane;
organoiodine compound		EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
ml 9
[no description available]		2.0310naphthalenes;
sulfonic acid derivative
moclobemide
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.		2.0810benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
modafinil
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.. modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.. 2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.		3.2310monocarboxylic acid amide;
sulfoxide
moxisylyte
Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)		3.6920monoterpenoid
entinostat
[no description available]		4.1940benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
acecainide
Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.		2.4820acetamides;
benzamides		anti-arrhythmia drug
ethylmaleimide
Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.		2.610maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
nabumetone
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.		3.7320methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
nadolol
[no description available]		3.8830tetralins
nafamostat
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic		2.610benzoic acids;
guanidines
nafronyl
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.		2.0710naphthalenes
naftopidil
[no description available]		2.0710piperazines
nalidixic acid
[no description available]		4.14401,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
naphazoline
Naphazoline: An adrenergic vasoconstrictor agent used as a decongestant.		2.0710naphthalenes
naratriptan
naratriptan: structure given in first source		3.2310heteroarylpiperidine;
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
nefazodone
nefazodone: may be useful as an opiate adjunct		4.6140aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
nefopam
Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.		2.0810benzoxazocine;
tertiary amino compound
neostigmine
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.		2.4820quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		4.350cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nialamide
Nialamide: An MAO inhibitor that is used as an antidepressive agent.		3.2310organonitrogen compound;
organooxygen compound
nicardipine
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.		4.8450benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
niclosamide
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.		9.3950benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		4.8250C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nilutamide
[no description available]		3.6120(trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone		androgen antagonist;
antineoplastic agent
nilvadipine
[no description available]		2.0710dihydropyridine;
isopropyl ester;
methyl ester;
nitrile
nimesulide
nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.		3.6120aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
nimodipine
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.		4.45302-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nisoldipine
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.		3.6120C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrazepam
Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).		2.08101,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
nitrendipine
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.		4.1140C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
nitroglycerin
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.		3.6620nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
nitromide
nitromide: antibacterial agent for prevention & treatment of Salmonella pullorum infections in chickens & turkeys & for fowl typhoid & paratyphoid; used in feed; structure		2.0710
nizatidine
[no description available]		3.23101,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist
nomifensine
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.		3.620isoquinolinesdopamine uptake inhibitor
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		3.6120fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
nortriptyline
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.		3.6120organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one
[no description available]		2.0710isoquinolines
nu6102
NU6102: structure in first source		2.0310
nylidrin
Nylidrin: A beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor.		2.0710alkylbenzene
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		3.88303-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
olomoucine
olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.		2.78302,6-diaminopurines;
ethanolamines		EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
olprinone
olprinone: RN refers to HCl; structure given in first source		2.0810bipyridines
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		5.0560aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
ondansetron
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.		3.6120carbazoles
orphenadrine
Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.. orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.		3.620ether;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
osalmide
osalmide: structure		2.610organic molecular entity
oxonic acid
Oxonic Acid: Antagonist of urate oxidase.		2.1101,3,5-triazines;
monocarboxylic acid
oxaprozin
Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.		3.93301,3-oxazoles;
monocarboxylic acid		analgesic;
non-steroidal anti-inflammatory drug
oxazepam
Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.		3.23101,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic
oxethazaine
[no description available]		2.5720amino acid amide
oxibendazole
oxibendazole: structure		3.0640benzimidazoles;
carbamate ester
oxprenolol
Oxprenolol: A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.		2.4620aromatic ether
benoxinate
benoxinate: RN given refers to parent cpd; structure. oxybuprocaine : A benzoate ester in which 4-amino-3-butoxybenzoic acid and 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester "caine") used especially in ophthalmology and otolaryngology.		2.0710amino acid ester;
benzoate ester;
substituted aniline;
tertiary amino compound		drug allergen;
local anaesthetic;
topical anaesthetic
oxybutynin
oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.		3.6120acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic
aminosalicylic acid
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.		3.6120aminobenzoic acid;
phenols		antitubercular agent
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine
4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine: a 5-HT(1A) ligand; structure in first source		2.8930
palmidrol
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.		2.610endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-(saturated fatty acyl)ethanolamine		anti-inflammatory drug;
anticonvulsant;
antihypertensive agent;
neuroprotective agent
pamidronate
[no description available]		4.120phosphonoacetic acid
pantoprazole
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.		4.2220aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
papaverine
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.		4.8650benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pargyline
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.		2.0710aromatic amine
pd 153035
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source. PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.		2.4420aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
pd 169316
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor		2.0310imidazoles
pd 98059
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.		2.4620aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
pemoline
Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.		3.61201,3-oxazolescentral nervous system stimulant
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		3.8830aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
pentobarbital
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		3.6120barbituratesGABAA receptor agonist
pentoxifylline
[no description available]		3.9530oxopurine
perhexiline
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.		3.9430piperidinescardiovascular drug
perphenazine
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.		4.4860N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
phenacemide
phenacemide: anti-epileptic drug; structure		2.0710acetamides
phenacetin
Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione		2.0810acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
phenazopyridine
Phenazopyridine: A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.. phenazopyridine : A diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.		2.5820diaminopyridine;
monoazo compound		anticoronaviral agent;
carcinogenic agent;
local anaesthetic;
non-narcotic analgesic
phenindione
Phenindione: An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)		3.1610aromatic ketone;
beta-diketone		anticoagulant
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		3.2310barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
phenoxybenzamine
Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.		3.2310aromatic amine
phentermine
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.		3.2310primary amineadrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent
4-phenylbutyric acid
4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.		3.7320monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
phenylmethylsulfonyl fluoride
Phenylmethylsulfonyl Fluoride: An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex.. phenylmethanesulfonyl fluoride : An acyl fluoride with phenylmethanesulfonyl as the acyl group.		2.610acyl fluorideserine proteinase inhibitor
1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate
[no description available]		2.0710pyrroloindole
3,3',4,5'-tetrahydroxystilbene
[no description available]		2.0610stilbenoid
pimobendan
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source		3.1640benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
pinacidil
Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)		2.0710pyridines
pindolol
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.		3.8730indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
pioglitazone
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.		4.140aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
piperazine
[no description available]		2.1510azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug
piracetam
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.		2.4820organonitrogen compound;
organooxygen compound
pirenzepine
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.		2.4620pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
piretanide
piretanide: potent inhibitor of chloride transport; structure		2.0710aromatic ether
piribedil
Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.		2.0810N-arylpiperazine
pj-34
PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties.		2.610phenanthridines;
secondary carboxamide;
tertiary amino compound		angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent
polythiazide
[no description available]		3.2310benzothiadiazine
1-NA-PP1
[no description available]		2.0310pyrazolopyrimidinetyrosine kinase inhibitor
ag 1879
3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor		4.35180aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine		beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
practolol
Practolol: A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS.. practolol : N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythmias.		2.4620acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist
duodote
duodote: consists of atropine and pralidoxime chloride; for treating those exposed to organophosphorus-containing nerve agents		3.620pyridinium ionantidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist		2.0810chromones
pyranoprofen
pyranoprofen: RN given refers to unlabled parent cpd; structure given in first source		2.0810pyridochromene
praziquantel
azinox: Russian drug		4.1440isoquinolines
prazosin
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.		4.350aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
primaquine
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.		3.8830aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
primidone
Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.		3.6120pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic
proadifen
Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.		2.0710diarylmethane
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		4.1440benzoic acids;
sulfonamide		uricosuric drug
probucol
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.		2.5720dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
procainamide
Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.		3.8930benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
procaine
Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).. procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.		2.0710benzoate ester;
substituted aniline;
tertiary amino compound		central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug
procarbazine
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.		3.6120benzamides;
hydrazines		antineoplastic agent
prochlorperazine
Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.		3.8830N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
procyclidine
Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.		3.6120pyrrolidines;
tertiary alcohol		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist
promazine
Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.		2.610phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
promethazine
Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.		4.8650phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
propafenone
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.		3.8830aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propantheline
Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.		3.2310xanthenes
propidium
Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.		2.0810phenanthridines;
quaternary ammonium ion		fluorochrome;
intercalator
propofol
Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.		3.2310phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		4.4760naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
protriptyline
Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.		3.620carbotricyclic compoundantidepressant
pyridostigmine
[no description available]		3.2310pyridinium ion
pyrilamine
Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.		2.0710aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
pyrimethamine
Maloprim: contains above 2 cpds		3.9330aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
sch 16134
quazepam: structure given in first source		3.2310benzodiazepine
quetiapine
[no description available]		3.2310dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
rabeprazole
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.		10.8531benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one
[no description available]		2.8330indoles
raloxifene
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.		4.39301-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
ranitidine
[no description available]		2.4720aralkylamine
riluzole
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.		4.850benzothiazoles
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		3.9530alkylamine
risperidone
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.		4.31501,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
rizatriptan
rizatriptan: structure given in first source; RN given refers to benzoate		3.2310tryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
ro 31-8220
Ro 31-8220: a protein kinase C inhibitor		2.8930imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor
rofecoxib
[no description available]		2.4820butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
rolipram
[no description available]		2.610pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
ropinirole
[no description available]		4.1940indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
roxarsone
Roxarsone: An arsenic derivative which has anticoccidial action and promotes growth in animals.. roxarsone : An organoarsonic acid where the organyl group is 4-hydroxy-3-nitrophenyl.		2.07102-nitrophenols;
organoarsonic acid		agrochemical;
animal growth promotant;
antibacterial drug;
coccidiostat
salicylamide
salamide: a major impurity of hydrochlorothiazide; structure in first source		2.0710phenols;
salicylamides		antirheumatic drug;
non-narcotic analgesic
salicylsalicylic acid
salicylsalicylic acid: structure. salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.		3.620benzoate ester;
benzoic acids;
phenols;
salicylates		antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
sb 206553
SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source		2.0810pyrroloindole
sb 220025
SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.		2.7530aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines		angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 239063
SB 239063: structure in first source. SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.		2.7730imidazoles
sb 202190
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase		4.8270imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
scriptaid
scriptide: provokes translocation of GLUT4 to increase glucose uptake; structure in first source		2.610isoquinolines
sebacic acid
sebacic acid : An alpha,omega-dicarboxylic acid that is the 1,8-dicarboxy derivative of octane.		2.610alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		human metabolite;
plant metabolite
secobarbital
Secobarbital: A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity.. secobarbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups.		3.2310barbituratesanaesthesia adjuvant;
GABA modulator;
sedative
sibutramine
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride		3.2310organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor
sulfadiazine
Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.		3.8830pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sk&f 86002
6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase		2.0810imidazoles
sodium fluoride
[no description available]		3.711fluoride saltmutagen
risedronic acid
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.		3.6920pyridines
sotalol
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.		3.8930ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
spiperone
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.		2.0710aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
fenofibrate
[no description available]		2.610benzochromenone;
delta-lactone;
naphtho-alpha-pyrone		platelet aggregation inhibitor;
Sir2 inhibitor
imatinib
[no description available]		9.82520aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		11.17150dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
succinylcholine
Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.. succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid.		3.2310quaternary ammonium ion;
succinate ester		drug allergen;
muscle relaxant;
neuromuscular agent
succinylsulfathiazole
succinylsulfathiazole: intestinal antimicrobial agent; structure		2.07101,3-thiazoles
sulfacetamide
Sulfacetamide: An anti-bacterial agent that is used topically to treat skin infections and orally for urinary tract infections.. sulfacetamide : A sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen.		2.0710N-sulfonylcarboxamide;
substituted aniline		antibacterial drug;
antiinfective agent;
antimicrobial agent;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfadimethoxine
Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position.		2.0710aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic
sulfamerazine
[no description available]		2.0710pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
sulfamethazine
Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.		2.0710pyrimidines;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic
sulfamethizole
Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.		3.620sulfonamide antibiotic;
sulfonamide;
thiadiazoles		antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.		2.4820isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfanitran
[no description available]		2.0810sulfonamide
sulfasalazine
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.		4.8150
sulfathiazole
Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.		3.23101,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sulfisoxazole
Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.		2.4820isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol
[no description available]		3.2310alkylbenzene
sulpiride
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.		2.4620benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
sumatriptan
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.		3.6120sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
suprofen
Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.		2.610aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
[no description available]		2.0810stilbenoid
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		2.4820N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene
tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.		2.0810acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane		keratolytic drug;
prodrug;
teratogenic agent
tegafur
[no description available]		2.110organohalogen compound;
pyrimidines
telenzepine
telenzepine: structure given in first source		2.0710benzodiazepine
temazepam
Temazepam: A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.		3.2310benzodiazepine
temozolomide
[no description available]		9.5770imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
terazosin
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia		3.6120furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
terbutaline
Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.		3.8730phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
terfenadine
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.		3.1750diarylmethane
tetracaine
Tetracaine: A potent local anesthetic of the ester type used for surface and spinal anesthesia.. tetracaine : A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.		2.0710benzoate ester;
tertiary amino compound		local anaesthetic
tetrahydroxy-1,4-quinone
tetrahydroxy-1,4-quinone: structure. tetrahydroxy-1,4-benzoquinone : A hydroxybenzoquinone in which all four protons of the benzoquinone structure are substituted by hydroxy groups. A systemic keratolytic, it is normally supplied as its hydrate (CHEBI:137471).		2.0710hydroxybenzoquinonekeratolytic drug
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		5.6690phthalimides;
piperidones
thiabendazole
Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate		3.6201,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
thiethylperazine
Thiethylperazine: A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457). thiethylperazine : A member of the class of phenothiazines that is perazine substituted by a ethylsulfanyl group at position 2.		3.4110N-methylpiperazine;
phenothiazines		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
2-thiosalicylic acid
2-thiosalicylic acid: a degradation product of thimerosal; RN given refers to parent cpd. thiosalicylic acid : A sulfanylbenzoic acid that is the 2-sulfanyl derivative of benzoic acid.		2.0710sulfanylbenzoic acidantipyretic;
non-narcotic analgesic
thioridazine
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.		4.6540phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
thiotepa
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).		3.8830aziridines
tiapride
[no description available]		2.0810benzamides
ticlopidine
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.		4.6540monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
tilorone
Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.		2.0810aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound		anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
tinidazole
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.		3.6120imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
tiopronin
Tiopronin: Sulfhydryl acylated derivative of GLYCINE.		3.2310N-acyl-amino acid
tizanidine
tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.		3.6120benzothiadiazole;
imidazoles		alpha-adrenergic agonist;
muscle relaxant
nikethamide
Nikethamide: A central nervous system stimulant. It was formerly used in the treatment of barbiturate overdose but is now considered to be of no value for such purposes and may be dangerous. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1229)		2.0810pyridinecarboxamide
tolazamide
Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.		3.620N-sulfonylureahypoglycemic agent;
potassium channel blocker
tolazoline
Tolazoline: A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.. tolazoline : A member of the class of imidazoles that is 4,5-dihydro-1H-imidazole substituted by a benzyl group.		2.0710imidazolesalpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		3.8830N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
tolmetin
Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.		3.2310aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
tolnaftate
[no description available]		2.4820monothiocarbamic esterantifungal drug
2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
[no description available]		2.5920stilbenoid
ultram
2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.		3.2310aromatic ether;
tertiary alcohol;
tertiary amino compound
tranexamic acid
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.		3.2310amino acid
trapidil
Trapidil: A coronary vasodilator agent.		2.0710triazolopyrimidines
trazodone
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.		4.3930monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
triamterene
Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.		3.9530pteridinesdiuretic;
sodium channel blocker
triazolam
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.		3.2310triazolobenzodiazepinesedative
trifluoperazine
[no description available]		3.9430N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
trifluperidol
Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)		2.5120aromatic ketone
triflupromazine
Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic.. triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position.		3.9930organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
trigonelline
trigonelline: in hydra among other organisms; RN given refers to hydroxide inner salt; structure. N-methylnicotinic acid : A pyridinium ion consisting of nicotinic acid having a methyl substituent on the pyridine nitrogen.. N-methylnicotinate : An iminium betaine that is the conjugate base of N-methylnicotinic acid, arising from deprotonation of the carboxy group.		2.610alkaloid;
iminium betaine		food component;
human urinary metabolite;
plant metabolite
trihexyphenidyl
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.		3.2310amine
trimebutine
Trimebutine: Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.		2.0710trihydroxybenzoic acid
trimeprazine
Trimeprazine: A phenothiazine derivative that is used as an antipruritic.		2.0710phenothiazines
trimethadione
Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.		3.2310oxazolidinoneanticonvulsant;
geroprotector
trimethobenzamide
trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.		3.7320benzamides;
tertiary amino compound		antiemetic
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		4.3550aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		3.2310
trimipramine
Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.		3.2310dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
trioxsalen
Trioxsalen: Pigmenting photosensitizing agent obtained from several plants, mainly Psoralea corylifolia. It is administered either topically or orally in conjunction with ultraviolet light in the treatment of vitiligo.. lactone : Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.. antipsoriatic : A drug used to treat psoriasis.. trioxsalen : 7H-Furo[3,2-g]chromen-7-one in which positions 2, 5, and 9 are substituted by methyl groups. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered orally in conjunction with UV-A for phototherapy treatment of vitiligo. After photoactivation it creates interstrand cross-links in DNA, inhibiting DNA synthesis and cell division, and can lead to cell injury; recovery from the cell injury may be followed by increased melanisation of the epidermis.		2.0710psoralensdermatologic drug;
photosensitizing agent
troglitazone
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.		4.140chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
tropicamide
Tropicamide: One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.		2.0710acetamides
thenoyltrifluoroacetone
Thenoyltrifluoroacetone: Chelating agent and inhibitor of cellular respiration.		2.0810
tulobuterol
[no description available]		2.0710organochlorine compound
tyramine
[no description available]		3.2310monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
tyrphostin a9
[no description available]		4.2530alkylbenzenegeroprotector
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		4.5730aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
undecylenic acid
undecylenic acid: a fatty acid with a terminal double bond. 10-undecenoic acid : An undecenoic acid having its double bond in the 10-position. It is derived from castor oil and is used for the treatment of skin problems.. undecenoic acid : A C11, straight-chain fatty acid carrying a C=C double bond at any position.		2.0810undecenoic acidantifungal drug;
plant metabolite
urapidil
[no description available]		2.4820piperazines
urethane
[no description available]		2.0710carbamate esterfungal metabolite;
mutagen
venlafaxine
venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.		3.8830cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
vesnarinone
[no description available]		2.610organic molecular entity
vigabatrin
[no description available]		3.6120gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
whi p180
[no description available]		2.0310
pirinixic acid
pirinixic acid: structure		2.0810aryl sulfide;
organochlorine compound;
pyrimidines
xylazine
Xylazine: An adrenergic alpha-2 agonist used as a sedative, analgesic and centrally acting muscle relaxant in VETERINARY MEDICINE.. xylazine : A methyl benzene that is 1,3-dimethylbenzene which is substituted by a 5,6-dihydro-4H-1,3-thiazin-2-ylnitrilo group at position 2. It is an alpha2 adrenergic receptor agonist and frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties.		2.07101,3-thiazine;
methylbenzene;
secondary amino compound		alpha-adrenergic agonist;
analgesic;
emetic;
muscle relaxant;
sedative
xylometazoline
xylometazoline: RN given refers to parent cpd; structure		2.0710alkylbenzene
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.		2.8930aromatic primary alcohol;
furans;
indazoles		antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
ici 204,219
zafirlukast: a leukotriene D4 receptor antagonist		3.9130carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
zaleplon
zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.		3.6120nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative
zm 336372
N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source		2.0310benzamides
zolpidem
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.		3.2310imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
zonisamide
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.		3.61201,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
zopiclone
zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.		3.5920monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
zotepine
zotepine: structure		2.8930dibenzothiepine;
tertiary amino compound		alpha-adrenergic drug;
second generation antipsychotic;
serotonergic drug
cortisone acetate
Cortisone Acetate: The acetate ester of cortisone that is used mainly for replacement therapy in adrenocortical insufficiency and in the treatment of many allergic and inflammatory disorders.		3.2310corticosteroid hormone
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		3.9230mitomycinalkylating agent;
antineoplastic agent
corticosterone
[no description available]		2.051011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		10.349011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
estriol
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.		2.071016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		4.8450alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
phentolamine
Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.		3.620imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
sorbitol
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).		3.2310glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
thymidine
[no description available]		2.0410pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
piperonyl butoxide
[no description available]		2.0710benzodioxolespesticide synergist
thyroxine
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.		3.23102-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
dextroamphetamine
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.		3.23101-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
spironolactone
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.		3.23103-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
penicillamine
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.		3.6120non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
cysteine
[no description available]		3.2310cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
prednisone
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.		8.3811211-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		3.62017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
oxandrolone
Oxandrolone: A synthetic hormone with anabolic and androgenic properties.		3.231017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen
dichlororibofuranosylbenzimidazole
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.		2.0310
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		3.620penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
idoxuridine
[no description available]		2.610organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
metaraminol
Metaraminol: A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.. metaraminol : A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.		2.0710phenylethanolaminesalpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent
pilocarpine
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.		3.2310pilocarpineantiglaucoma drug
pentylenetetrazole
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.		2.0710organic heterobicyclic compound;
organonitrogen heterocyclic compound
triiodothyronine
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.		3.23102-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
diethylnitrosamine
Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.		2.3110nitrosaminecarcinogenic agent;
hepatotoxic agent;
mutagen
carbon tetrachloride
Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.		2.0810chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		2.520alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		2.830L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		4.350C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		7.1710aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		3.2310amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		2.8530aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
vincristine
[no description available]		3.2310acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
physostigmine
Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.		3.2310carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
sucrose
Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.		2.0510glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
ethinyl estradiol
Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.		2.482017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
tubocurarine
Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.		2.0810bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		3.8830aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
aminopyrine
Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.		2.0510pyrazolone;
tertiary amino compound		antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
methyltestosterone
Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.		3.231017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
tetrabenazine
9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.		3.2310benzoquinolizine;
cyclic ketone;
tertiary amino compound
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		3.6120kanamycinsbacterial metabolite
ethopabate
Ethopabate: An inhibitor of folate metabolism. It is used as a coccidiostat in poultry.		2.0710amidobenzoic acid
galactose
galactopyranose : The pyranose form of galactose.		2.0410D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		3.9130monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		2.0810amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		3.2310ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
phenylethyl alcohol
Phenylethyl Alcohol: An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery.. 2-phenylethanol : A primary alcohol that is ethanol substituted by a phenyl group at position 2.		2.930benzenes;
primary alcohol		Aspergillus metabolite;
fragrance;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		4.27160amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
cysteamine
Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.		3.620amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
acetylcholine chloride
acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug.		3.2310quaternary ammonium salt
mepazine
mepazine: major descriptor (66-85); on-line search PHENOTHIAZINES (66-85); Index Medicus search MEPAZINE (66-85); RN given refers to parent cpd. pacatal : A phenothiazine derivative in which 10H-phenothiazine has an N-methylpiperidin-4-ylmethyl substituent at the N-10 position.		3.2310phenothiazines
acepromazine
Acepromazine: A phenothiazine that is used in the treatment of PSYCHOSES.. acepromazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by an acetyl group at position 2 and a 3-(dimethylamino)propyl group at position 10.		2.0710aromatic ketone;
methyl ketone;
phenothiazines;
tertiary amino compound		phenothiazine antipsychotic drug
methoxamine
Methoxamine: An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.. methoxamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group and the phenyl ring is 2- and 5-substituted with methoxy groups. It is an antihypotensive agent (pressor), an agonist acting directly at alpha-adrenoceptors with selectivity for the alpha-1 adrenoceptor subtype similar to phenylephrine .		2.0710amphetaminesalpha-adrenergic agonist;
antihypotensive agent
cloxacillin
Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.		3.620penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
zoxazolamine
Zoxazolamine: A uricosuric and muscle relaxant. Zoxazolamine acts centrally as a muscle relaxant, but the mechanism of its action is not understood.		2.5720benzoxazole
leucine
Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.		2.7430amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
berlition
berlition: antioxidant preparation containing alpha-lipoic acid, used in the neuroprotective therapy of chronic brain ischemia for correction of free-radical processes. (R)-lipoic acid : The (R)-enantiomer of lipoic acid. A vitamin-like, C8 thia fatty acid with anti-oxidant properties.. lipoic acid : A heterocyclic thia fatty acid comprising pentanoic acid with a 1,2-dithiolan-3-yl group at the 5-position.		2.4820dithiolanes;
heterocyclic fatty acid;
lipoic acid;
thia fatty acid		cofactor;
nutraceutical;
prosthetic group
calcium acetate
calcium acetate: a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer. calcium acetate : The calcium salt of acetic acid. It is used, commonly as a hydrate, to treat hyperphosphataemia (excess phosphate in the blood) in patients with kidney disease: the calcium ion combines with dietary phosphate to form (insoluble) calcium phosphate, which is excreted in the faeces.		3.2310calcium saltchelator
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		3.6920aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		2.9840amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
desoxycorticosterone
Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE		2.071020-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		5.2580alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
mebanazine
mebanazine: RN given refers to parent cpd without isomeric designation; structure		3.2310benzenes
oxacillin
Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.		3.2310penicillinantibacterial agent;
antibacterial drug
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		3.9220antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
ficusin
Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking.. psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia.		2.610psoralensplant metabolite
triamcinolone diacetate
triamcinolone diacetate: lysyl oxidase antagonist; Polcortolon may also refers to triamcinolone		2.0810corticosteroid hormone
norethindrone
Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.		2.071017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
cycloserine
Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).		3.6204-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
benziodarone
benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)		4.1940aromatic ketone
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		2.610antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		3.2310beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
mannitol
[no description available]		3.5820mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
cytarabine
[no description available]		9.76212beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
trifluridine
Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.		2.5720nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
medroxyprogesterone acetate
[no description available]		2.081020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		2.0310L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
threonine
Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.		2.7830amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
isoleucine
Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine.		2.0310aspartate family amino acid;
isoleucine;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		3.2310arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
perflutren
Definity: a fluorocarbon-filled ultrasonic contrast agent; Definity is tradename. octafluoropropane : A fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines.		3.2310fluoroalkane;
fluorocarbon
triamcinolone acetonide
Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.		2.081011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
fluoxymesterone
Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.		3.231011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid		anabolic agent;
antineoplastic agent
mepenzolate bromide
[no description available]		2.0710diarylmethane
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		2.0510benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
chlorphenoxamine
chlorphenoxamine: minor descriptor (66-84); on-line & Index Medicus search ETHYLAMINES (66-84); RN given refers to parent cpd		3.4110diarylmethaneanticoronaviral agent
methsuximide
methsuximide: anticonvulsant effective in petit mal & psychomotor epilepsy; has a number of unpleasant & toxic side effects; minor descriptor (75-86); on-line & INDEX MEDICUS search SUCCINIMIDES (75-86); RN given refers to parent cpd without isomeric designation		3.2310organic molecular entity
tromethamine
Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)		3.6120primary amino compound;
triol		buffer
triparanol
Triparanol: Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts.		3.4110stilbenoidanticoronaviral agent
chloroacetamide
[no description available]		2.4110
pantothenic acid
Pantothenic Acid: A butyryl-beta-alanine that can also be viewed as pantoic acid complexed with BETA ALANINE. It is incorporated into COENZYME A and protects cells against peroxidative damage by increasing the level of GLUTATHIONE.. pantothenic acid : A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.. vitamin B5 : Any member of a group of vitamers that belong to the chemical structural class called pantothenic acids that exhibit biological activity against vitamin B5 deficiency. Deficiency of vitamin B5 is rare due to its widespread distribution in whole grain cereals, legumes and meat. Symptoms associated with vitamin B5 deficiency are difficult to asses since they are subtle and resemble those of other B vitamin deficiencies. The vitamers include (R)-pantothenic acid and its ionized and salt forms.. (R)-pantothenate : A pantothenate that is the conjugate base of (R)-pantothenic acid, obtained by deprotonation of the carboxy group.. (R)-pantothenic acid : A pantothenic acid having R-configuration.		2.0710pantothenic acid;
vitamin B5		antidote to curare poisoning;
geroprotector;
human blood serum metabolite
sulfachlorpyridazine
Sulfachlorpyridazine: A sulfonamide antimicrobial used for urinary tract infections and in veterinary medicine.. sulfachloropyridazine : A sulfonamide antimicrobial used for urinary tract infections and in veterinary medicine.		2.0710organochlorine compound;
pyridazines;
sulfonamide		antibacterial drug;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
cyclizine
Cyclizine: A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935). cyclizine : An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.		2.2110N-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		9.1406-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
rotenone
Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.		2.0810organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
9,10-anthraquinone
9,10-anthraquinone : An anthraquinone that is anthracene in which positions 9 and 10 have been oxidised to carbonyls.		2.610anthraquinone
brompheniramine
Brompheniramine: Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.. brompheniramine : Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		3.2310organobromine compound;
pyridines		anti-allergic agent;
H1-receptor antagonist
phensuximide
phensuximide: major descriptor (73-84); on-line search SUCCINIMIDES (73-84); Index Medicus search PHENSUXIMIDE (73-84); RN given refers to cpd without isomeric designation		2.0710pyrrolidines
dimethisoquin
[no description available]		2.0710isoquinolines
penicillin v
Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.		3.2310penicillin allergen;
penicillin
salicylanilide
salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.		2.610benzanilide fungicide;
salicylamides;
salicylanilides
isosorbide dinitrate
Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.		3.2310glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
gramine
gramine : An aminoalkylindole that is indole carrying a dimethylaminomethyl substituent at postion 3.		2.610aminoalkylindole;
indole alkaloid;
tertiary amino compound		antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist
aminacrine
Aminacrine: A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.. 9-aminoacridine : An aminoacridine that is acridine in which the hydrogen at position 9 is replaced by an amino group. A fluorescent dyd and topical antiseptic agent, it is used (usually as the hydrochloride salt) in eye drops for the treatment of superficial eye infections.		2.610aminoacridines;
primary amino compound		acid-base indicator;
antiinfective agent;
antiseptic drug;
fluorescent dye;
MALDI matrix material;
mutagen
pseudoephedrine
Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.		3.2310phenylethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
diethylpropion
Diethylpropion: A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290). diethylpropion : An aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.		3.2310aromatic ketone;
tertiary amine		appetite depressant
phenothiazine
10H-phenothiazine : The 10H-tautomer of phenothiazine.		2.1110phenothiazineferroptosis inhibitor;
plant metabolite;
radical scavenger
synephrine
[no description available]		2.0710ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
benzothiazole
benzothiazole: structure. benzothiazole : An organic heterobicyclic compound that is a fusion product between benzene and thiazole. The parent of the class of benzothiazoles.		7.0810benzothiazolesenvironmental contaminant;
plant metabolite;
xenobiotic
trehalose
alpha,alpha-trehalose : A trehalose in which both glucose residues have alpha-configuration at the anomeric carbon.		2.8930trehaloseEscherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
methyl gallate
methyl gallate: has both immunosuppressive and phytogenic antineoplastic activities; isolated from Acer saccharinum. methyl 3,4,5-trihydroxybenzoate : A gallate ester obtained by the formal condensation of gallic acid with methanol. It exhibits anti-oxidant, anti-tumor, anti-microbial and anti-inflammatory properties.		2.610gallate esteranti-inflammatory agent;
antioxidant;
plant metabolite
triclocarban
triclocarban: bacteriostat; antiseptic in soaps & other cleansing solns; germicide; structure. triclocarban : A member of the class of phenylureas that is urea substituted by a 4-chlorophenyl group and a 3,4-dichlorophenyl group at positions 1 and 3 respectively.		2.8930dichlorobenzene;
monochlorobenzenes;
phenylureas		antimicrobial agent;
antiseptic drug;
disinfectant;
environmental contaminant;
xenobiotic
pyridostigmine bromide
Pyridostigmine Bromide: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.		2.0710pyridinium salt
1,3-diphenylurea
1,3-diphenylurea : A member of the class of phenylureas that is urea in which one of the hydrogens of each amino group is replaced by a phenyl group. It is present in coconut milk (Cocos nucifera).		2.0610phenylureascytokinin;
plant metabolite
monobenzone
monobenzone: structure. monobenzone : The monobenzyl ether of hydroquinone. It is used as a topical drug for medical depigmentation.		2.5820benzyl etherallergen;
dermatologic drug;
melanin synthesis inhibitor
benzonatate
benzonatate: structure in Merck Index, 9th ed, #1107. benzonatate : The ester obtained by formal condensation of 4-butylaminobenzoic acid with nonaethylene glycol monomethyl ether. Structurally related to procaine and benzocaine, it has an anaesthetic effect on the stretch sensors in the lungs, and is used as a non-narcotic cough suppressant.		3.620benzoate ester;
secondary amino compound;
substituted aniline		anaesthetic;
antitussive
melamine
melamine: RN given refers to parent cpd; structure. melamine : A trimer of cyanamide, with a 1,3,5-triazine skeleton.		3.1610triamino-1,3,5-triazinexenobiotic metabolite
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		10.26400pyrrole;
secondary amine
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.7730mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
methylergonovine
Methylergonovine: A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)		3.2310ergoline alkaloid
phenformin
Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.		2.4820biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
pyrazolanthrone
pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.		4.3250anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
1,4-naphthoquinone
naphthoquinone : A polycyclic aromatic ketone metabolite of naphthalene.. 1,4-naphthoquinone : The parent structure of the family of 1,4-naphthoquinones, in which the oxo groups of the quinone moiety are at positions 1 and 4 of the naphthalene ring. Derivatives have pharmacological properties.		2.03101,4-naphthoquinones
cinchophen
cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94		3.620quinolines
chloroprocaine
chloroprocaine: RN given refers to parent cpd; structure. chloroprocaine : Procaine in which one of the hydrogens ortho- to the carboxylic acid group is substituted by chlorine. It is used as its monohydrochloride salt as a local anaesthetic, particularly for oral surgery. It has the advantage over lidocaine of constricting blood vessels, so reducing bleeding.		2.0710benzoate ester;
monochlorobenzenes		central nervous system depressant;
local anaesthetic;
peripheral nervous system drug
4-tert-octylphenol
4-tert-octylphenol: structure given in first source		2.8930alkylbenzene
yohimbine
Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.		2.0710methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
nafcillin
Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.		3.2310penicillin allergen;
penicillin		antibacterial drug
ditiocarb
Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.		2.5720dithiocarbamic acidschelator;
copper chelator
methohexital
Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.		3.2310acetylenic compound;
barbiturates		drug allergen;
intravenous anaesthetic
catechin
Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.		2.7620catechinantioxidant;
plant metabolite
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		19.49599azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		3.1750acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		5.3150indazole
1,3-benzodioxole
1,3-benzodioxole : A benzodioxole consisting of a benzene ring substituted by a the methylenedioxy group.		3.5110benzodioxole
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		2.0810isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		2.13101,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazoles
[no description available]		25.751,2871401,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pyrimidine
pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.		2.1710diazine;
pyrimidines		Daphnia magna metabolite
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		7.22161diazine;
pyrazines		Daphnia magna metabolite
propantheline bromide
[no description available]		2.0710xanthenes
ephedrine
Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.		3.2310phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
hydrazine
diamine : Any polyamine that contains two amino groups.		3.5720azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
ethamivan
ethamivan: minor descriptor (65-72); major descriptor (73-86); on-line search BENZAMIDES (66-86); INDEX MEDICUS search BENZAMIDES (65-72); ETHAMIVAN (73-86). etamivan : Phenol substituted at C-2 and C-4 by a methoxy group and an N,N-diethylaminocarbonyl group respectively. A respiratory stimulant drug related to nikethamide, it has now fallen largely into disuse.		2.8930methoxybenzenes;
phenols
evans blue
Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.. Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.		2.610organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent
monocrotaline
Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.		2.0710pyrrolizidine alkaloid
aminophylline
Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.		3.6120mixturebronchodilator agent;
cardiotonic drug
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		11.0370N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
diazomethane
Diazomethane: A diazonium compound with the formula CH2N2.. diazomethane : The simplest diazo compound, in which a diazo group is attached to a methylene group.		2.3110diazo compoundalkylating agent;
antineoplastic agent;
carcinogenic agent;
poison
galantamine
Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.		3.6120benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
nandrolone decanoate
Nandrolone Decanoate: Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.		3.2310steroid ester
methysergide
Methysergide: An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.. methysergide : A synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD and used prophylactically to reduce the frequency and intensity of severe vascular headaches.		2.8930ergoline alkaloid
procarbazine hydrochloride
procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.		2.0810hydrochlorideantineoplastic agent
betamethasone
Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)		2.081011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
fluorometholone
Fluorometholone: A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluorometholone : A member of the class of glucocorticoids that is Delta(1)-progesterone substituted at positions 11beta and 17 by hydroxy groups, at position 6alpha by a methyl group and at position 9 by a fluoro group. Used for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.		2.071011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
dextropropoxyphene
Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.		3.23101-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoatemu-opioid receptor agonist;
opioid analgesic
chenodeoxycholic acid
Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.		3.2310bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
lucanthone
Lucanthone: One of the SCHISTOSOMICIDES, it has been replaced largely by HYCANTHONE and more recently PRAZIQUANTEL. (From Martindale The Extrapharmacopoeia, 30th ed., p46). lucanthone : A thioxanthen-9-one compound having a methyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. Formerly used for the treatment of schistosomiasis. It is a prodrug, being metabolised to hycanthone.		2.610thioxanthenesadjuvant;
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
mutagen;
photosensitizing agent;
prodrug;
schistosomicide drug
cepharanthine
cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.		2.610bisbenzylisoquinoline alkaloid;
isoquinolines
aloe emodin
aloe emodin: structure distinct from emodin; this does not mean emodin from aloe. Aloe emodin : A dihydroxyanthraquinone that is chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe.		2.610aromatic primary alcohol;
dihydroxyanthraquinone		antineoplastic agent;
plant metabolite
chrysophanic acid
chrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260. chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.		2.610dihydroxyanthraquinoneanti-inflammatory agent;
antiviral agent;
plant metabolite
emetine
Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.		4.5560isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
osthol
osthol: from Cnidium monnieri and Angelica pubescens (both Apiaceae); structure given in first source		2.610botanical anti-fungal agent;
coumarins		metabolite
dihydralazine
Dihydralazine: 1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)		2.5520phthalazines
flavanone
flavanone: RN given refers to cpd with unspecified isomeric designation; structure in first source. flavanone : The simplest member of the class of flavanones that consists of flavan bearing an oxo substituent at position 4.		2.610flavanones
phloretic acid
phloretic acid: structure. N-hydroxysuccinimide ester : An ester of N-hydroxysuccinimide.. phloretic acid : A hydroxy monocarboxylic acid consisting of propionic acid having a 4-hydroxyphenyl group at the 3-position.		2.610hydroxy monocarboxylic acidplant metabolite
4-hydroxybutyric acid
4-hydroxybutyric acid: was an entry term to Sodium Oxybate (74-98). 4-hydroxybutyric acid : A 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group.		3.23104-hydroxy monocarboxylic acid;
hydroxybutyric acid		general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		7.0781
oleanolic acid
[no description available]		2.610hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
dihydroergotamine
Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.		3.6520ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		3.0740furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
medroxyprogesterone
[no description available]		3.231017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
angelicin
angelicin: used as tranquillizer; sedative; or anticonvulsant; structure		2.610furanocoumarin
dimenhydrinate
gravinol: has antioxidant and ant-inflammatory activities; structure in first source		3.8830diarylmethane
gluconic acid
gluconic acid: zinc gluconate has anti-inflammatory activity; RN given refers to (D)-isomer; all RRs refers to (D)-isomer unless otherwise noted. ketogluconic acid : A gluconic acid that contains a ketonic carbonyl group.. D-gluconic acid : A gluconic acid having D-configuration.		2.110gluconic acidchelator;
Penicillium metabolite
copper gluconate
Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.		2.110organic molecular entity
4-(benzoylamino)-2-hydroxybenzoic acid
4-(benzoylamino)-2-hydroxybenzoic acid: Bepask is calcium salt		2.0710benzamides
perillyl alcohol
perillyl alcohol: inhibits geranylgeranyl transferase; structure in first source. perillyl alcohol : A limonene monoterpenoid consists of a cyclohexene ring substituted by a hydroxymethyl and a prop-1-en-2-yl group at positions 1 and 4 respectively. It is a constituent of a variety of essential oils including lavender.		2.1110limonene monoterpenoidplant metabolite;
volatile oil component
diperodon
diperodon: RN given refers to parent cpd; structure given in first source		2.610carbamate ester
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		3.2310amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
levocarnitine
(R)-carnitine : The (R)-enantiomer of carnitine.		3.2310carnitineantilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role)
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.1310dialdehydebiomarker
myristic acid
Myristic Acid: A saturated 14-carbon fatty acid occurring in most animal and vegetable fats, particularly butterfat and coconut, palm, and nutmeg oils. It is used to synthesize flavor and as an ingredient in soaps and cosmetics. (From Dorland, 28th ed). tetradecanoic acid : A straight-chain, fourteen-carbon, long-chain saturated fatty acid mostly found in milk fat.. tetradecanoate : A long-chain fatty acid anion that is the conjugate base of myristic acid; major species at pH 7.3.		3.4420long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite
sulfanilylurea
sulfanilylurea: antimicrobial agent; structure		3.2310benzenes;
sulfonamide
gentian violet
Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.		2.0210organic chloride saltanthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye
1-naphthylisothiocyanate
1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.		2.0810isothiocyanateinsecticide
formestane
[no description available]		2.081017-oxo steroid;
3-oxo-Delta(4) steroid;
enol;
hydroxy steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lactulose
[no description available]		3.2310glycosylfructosegastrointestinal drug;
laxative
3-hydroxyflavone
3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.		2.3110flavonols;
monohydroxyflavone
diphenylamine
Diphenylamine: In humans it may be irritating to mucous membranes. Methemoglobinemia has been produced experimentally. In veterinary use, it is one of active ingredients in topical agents for prevention and treatment of screwworm infestation. An indicator in tests for nitrate poisoning.. diphenylamine : An aromatic amine containing two phenyl substituents. It has been used as a fungicide for the treatment of superficial scald in apples and pears, but is no longer approved for this purpose within the European Union.		2.8230aromatic amine;
bridged diphenyl fungicide;
secondary amino compound		antifungal agrochemical;
antioxidant;
carotogenesis inhibitor;
EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor;
ferroptosis inhibitor;
radical scavenger
megestrol acetate
[no description available]		2.823020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
pamabrom
[no description available]		3.2310
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		4.1840acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
trimetozine
[no description available]		2.0710morpholines
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		3.8730cyclic ketone;
erythromycin
docosanol
Tadenan: from powdered bark of Pygaeum africanum (Rosaceae), see also heading for docosanol (a priciple ingredient of extract). docosan-1-ol : A long-chain primary fatty alcohol that is docosane substituted by a hydroxy group at position 1. It is a non-prescription medicine approved by the FDA to shorten healing time of cold sores.. docosanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of twenty-two carbon atoms.		2.0710docosanol;
long-chain primary fatty alcohol		antiviral drug;
plant metabolite
hydroxychloroquine sulfate
[no description available]		2.8330
ethylnitrosourea
Ethylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-ethyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.		2.0310N-nitrosoureasalkylating agent;
carcinogenic agent;
genotoxin;
mutagen
levonorgestrel
Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.		3.612017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
etonitazene
etonitazene: was heading 1979-94 (see under BENZIMIDAZOLES 1979-90); ETONITAZIN was see ETONITAZENE 1979-94; use BENZIMIDAZOLES to search ETONITAZENE 1979-94; narcotic analgesic similar to morphine in action; used mainly to study narcotic habituation, tolerance, and withdrawal in laboratory animals		2.8930
diphenoxylate
Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.		3.2310ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
deoxycytidine
[no description available]		7.6144pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ethambutol hydrochloride
ethambutol dihydrochloride : The dihydrchloride salt of ethambutol. A bacteriostatic antimycobacterial drug, it is effective against Mycobacterium tuberculosis and some other mycobacteria. It is used in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol dihydrochloride is used alone.		2.0810hydrochlorideantitubercular agent
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		3.9730ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
metformin hydrochloride
metformin hydrochloride : A hydrochloride resulting from the reaction of metformin with one molar equivalent of hydrogen chloride.		2.610hydrochlorideenvironmental contaminant;
hypoglycemic agent;
xenobiotic
tetramethylpyrazine
tetramethylpyrazine: found in Ligusticum chuanxiong. tetramethylpyrazine : A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii).		2.0710alkaloid;
pyrazines		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
arsenic trioxide
Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.		4.3430
antimycin a
[no description available]		2.5820benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		3.2310glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
d-alpha tocopherol
Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.		3.2310alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
tocopherols
[no description available]		2.1710
pregnenolone carbonitrile
Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage.		2.0810aliphatic nitrile
flurandrenolone
Flurandrenolone: A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)		2.071021-hydroxy steroid
ibufenac
ibufenac: used in the treatment of rheumatism; also possesses antipyretic properties; minor descriptor (75-84); on-line & Index Medicus search PHENYLACETATES (75-84); RN given refers to parent cpd. ibufenac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.		3.2310monocarboxylic acidEC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
metylperon
metylperon: RN given refers to parent cpd		2.0810aromatic ketone
metaxalone
[no description available]		3.2310aromatic ether
spectinomycin
Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.		3.2310cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
5,5'-dimethyl-2,2'-bipyridyl
5,5'-dimethyl-2,2'-bipyridyl: structure in first source		2.610bipyridines
dichlorobenzyl alcohol
2,4-dichlorobenzyl alcohol : A member of the class of benzyl alcohols that is benzyl alcohol in which the hydrogens at positions 2 and 4 are replaced by chlorines.		2.610benzyl alcohols;
dichlorobenzene		antiseptic drug
dronabinol
Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.		3.2310benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
amiloride hydrochloride, anhydrous
amiloride hydrochloride : A hydrochloride obtained by combining amiloride with one molar equivalent of hydrochloric acid.		2.0810hydrochloridediuretic;
sodium channel blocker
amiloride
Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.		3.8730aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
clothiapine
clothiapine: was heading 1975-94 (was see under DIBENZOTHIAZEPINES 1975-90); CLOTIAPINE was see CLOTHIAPINE 1978-94; use DIBENZOTHIAZEPINES to search CLOTHIAPINE 1975-94; antipsychotic similar to clozapine		2.8930dibenzothiazepine
pimozide
Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.		4.140benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
benperidol
Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)		2.8930aromatic ketone
7-hydroxychlorpromazine
7-hydroxychlorpromazine: RN given refers to parent cpd		2.8930phenothiazines
flumethasone
Flumethasone: An anti-inflammatory glucocorticoid used in veterinary practice.		2.071011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
guanoxan
guanoxan: was MH 1976-92 (see under GUANIDINES 1976-90); use GUANIDINES to search GUANOXAN 1976-92; antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage		2.0510benzodioxine
aminorex
Aminorex: An amphetamine-like anorectic agent. It may cause pulmonary hypertension.		2.0810benzenes
dexbrompheniramine
dexbrompheniramine : The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		3.2310brompheniramineanti-allergic agent;
H1-receptor antagonist
sulfadoxine
Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.		2.0710pyrimidines;
sulfonamide		antibacterial drug;
antimalarial
uridine diphosphate glucuronic acid
Uridine Diphosphate Glucuronic Acid: A nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis. It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones.. UDP-alpha-D-glucuronic acid : A UDP-sugar having alpha-D-glucuronic acid as the sugar component.		2.0410UDP-D-glucuronic acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
acadesine
[no description available]		2.08101-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor
sulfuryl fluoride
sulfuryl fluoride: fumigant		2.1510sulfuryl halidefumigant insecticide
acetophenazine
acetophenazine: major descriptor (73-85); minor descriptor (64-72); on-line search PHENOTHIAZINES (64-85); Index Medicus search PHENOTHIAZINES (64-72); ACETOPHENAZINE (73-85); RN given refers to parent cpd. acetophenazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the nitogen atom and an acetyl group at position 2.		3.4110N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
phenothiazines		phenothiazine antipsychotic drug
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		3.9530dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
dicloxacillin
Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.		3.8830dichlorobenzene;
penicillin		antibacterial drug
fluorescein-5-isothiocyanate
Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.		2.1510fluorescein isothiocyanate
palmatine
burasaine: structure in first source		3.1910berberine alkaloid;
organic heterotetracyclic compound		plant metabolite
megestrol
Megestrol: A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.. megestrol : A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.		3.231017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
tranylcypromine
Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.		2.07102-phenylcyclopropan-1-amine
streptomycin
[no description available]		3.2310antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
nitroxoline
nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.		2.0810C-nitro compound;
monohydroxyquinoline		antifungal agent;
antiinfective agent;
antimicrobial agent;
renal agent
dideoxyadenosine
Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.		2.610adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
cladribine
[no description available]		9.4360organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
beclomethasone
[no description available]		2.071011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug
carbenicillin
Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.		3.2310penicillin allergen;
penicillin		antibacterial drug
metocurine
metocurine: from Chinese herb Cyclea hainanensis Mrr		2.0810isoquinolines
floxacillin
Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.		2.0710penicillin allergen;
penicillin		antibacterial drug
clomacran
clomacran: RN given refers to parent cpd; structure		3.2310acridines
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		6.93121beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
methenamine hippurate
methenamine hippurate: both parts of molecule contribute to its antibacterial action		3.2310N-acylglycine
olsalazine
olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.		3.5820azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug
3-deazaadenosine
3-deazaadenosine: RN given refers to parent cpd.		2.610
terodiline
[no description available]		2.0810diarylmethane
etidronate disodium
etidronate disodium : An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions.		2.0810organic sodium saltantineoplastic agent;
bone density conservation agent;
chelator
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		2.1310elemental platinum;
nickel group element atom;
platinum group metal atom
terbium
Terbium: An element of the rare earth family of metals. It has the atomic symbol Tb, atomic number 65, and atomic weight 158.92.		2.1110f-block element atom;
lanthanoid atom
titanium
Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.		2.0810titanium group element atom
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		3.4360copper group element atom;
elemental gold
zirconium
Zirconium: A rather rare metallic element with atomic number 40, atomic weight 91.224, and symbol Zr.		2.6620titanium group element atom
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		2.5820pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		3.7490delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
tricalcium phosphate
tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.		2.3110calcium phosphate
sodium thiosulfate
sodium thiosulfate: do not confuse synonym sodium hyposulfite with sodium hyposulfite, synonym for di-Na salt of dithionous acid. sodium thiosulfate : An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.		3.2310inorganic sodium saltantidote to cyanide poisoning;
antifungal drug;
nephroprotective agent
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		2.4820dihydrogen
ancitabine
Ancitabine: Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.. ancitabine : An organic heterotricyclic compound resulting from the formal condensation of the oxo group of cytidine to the 2' position with loss of water to give the corresponding cyclic ether. A prodrug, it is metabolised to the antineoplastic agent cytarabine, so is used to maintain a more constant antineoplastic action.		2.610diol;
organic heterotricyclic compound		antimetabolite;
antineoplastic agent;
prodrug
trolamine salicylate
Arthritis: Acute or chronic inflammation of JOINTS.		2.1710
chloropyramine
chloropyramine: RN given refers to parent cpd; structure		2.610aminopyridine
mafenide acetate
[no description available]		2.0810carboxylic acid
titanium dioxide
titanium dioxide: used medically as protectant against externally caused irritation & sunlight; high concentrations of dust may cause irritation to respiratory tract; RN given refers to titanium oxide (TiO2); structure. titanium dioxide : A titanium oxide with the formula TiO2. A naturally occurring oxide sourced from ilmenite, rutile and anatase, it has a wide range of applications.		2.0810titanium oxidesfood colouring
(1S,2R)-tranylcypromine
(1S,2R)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1S,2R)-enantiomer of tranylcypromine.		2.07102-phenylcyclopropan-1-amine
diacerein
diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;		2.0810anthraquinone
parbendazole
parbendazole: anthelmintic used against a variety of gastrointestinal parasites; minor descriptor (75-86); on-line & INDEX MEDICUS search BENZIMIDAZOLES; RN given refers to parent cpd		2.0710benzimidazoles;
carbamate ester
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		3.2310selegiline;
terminal acetylenic compound		geroprotector
selegiline hydrochloride, (r)-isomer
[no description available]		2.0810hydrochloride;
terminal acetylenic compound		antiparkinson drug;
dopaminergic agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor
levamisole
Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.		2.57206-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
clemastine
Clemastine: A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.. clemastine : 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.		3.2310monochlorobenzenes;
N-alkylpyrrolidine		anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
thiamphenicol
[no description available]		2.0810monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
pancuronium bromide
pancuronium bromide : A bromide salt consisting of two bromide ions and one pancuronium dication.		2.0810bromide saltcholinergic antagonist;
muscle relaxant;
nicotinic antagonist
cephalexin
Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.		3.6920beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
thenalidine
thenalidine: antihistaminic, antipruritic; RN in Chemline for thenalidine calcium: 67250-62-8; structure		2.8930dialkylarylamine;
tertiary amino compound
n'-nitrosonornicotine
N'-nitrosonornicotine: structure; a potent carcinogen in laboratory animals		2.610pyridines;
pyrrolidines
ornidazole
Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.		2.0810C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope
fluorides
[no description available]		3.711halide anion;
monoatomic fluorine
danazol
Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.		4.094017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
metergoline
Metergoline: A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy.. metergoline : An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7.		2.0710carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
fenclozic acid
fenclozic acid: an analgesic & antipyretic with anti-inflammatory properties; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZOLES (75-86); RN given refers to parent cpd		3.620
laxagetten 4,4'-diacetoxydiphenylpyridylemethane
[no description available]		3.2310
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		12.92121aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
capobenic acid
[no description available]		2.0710benzamides
diftalone
[no description available]		2.0710
fludarabine phosphate
fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.		3.6120nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate		antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
phosphotyrosine
Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.. O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.		3.5680L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid;
O(4)-phosphotyrosine		Escherichia coli metabolite;
immunogen
alclofenac
alclofenac: was heading 1975-94 (was see under PHENYLACETATES 1975-90); use PHENYLACETATES to search ALCLOFENAC 1975-94; an anti-inflammatory agent used in the treatment of rheumatoid arthritis; acts also as an analgesic and an antipyretic. alclofenac : An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.		3.2310aromatic ether;
monocarboxylic acid;
monochlorobenzenes		drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
carbimazole
Carbimazole: An imidazole antithyroid agent. Carbimazole is metabolized to METHIMAZOLE, which is responsible for the antithyroid activity.. carbimazole : A member of the class of imidazoles that is methimazole in which the nitrogen bearing a hydrogen is converted into its ethoxycarbonyl derivative. A prodrug for methimazol, carbimazole is used for the treatment of hyperthyroidism.		2.07101,3-dihydroimidazole-2-thiones;
carbamate ester		antithyroid drug;
prodrug
bromocriptine
Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.		4.1940indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.0810benzenes;
phenyl acetates
cetylpyridinium chloride anhydrous
tserigel: according to first source contains polyvinylbutyral & cetylpyridinium chloride; UD only lists cetylpyridinium chloride as constituent. cetylpyridinium chloride : A pyridinium salt that has N-hexadecylpyridinium as the cation and chloride as the anion. It has antiseptic properties and is used in solutions or lozenges for the treatment of minor infections of the mouth and throat.		2.0510chloride salt;
organic chloride salt		antiseptic drug;
surfactant
oxyphenisatin
[no description available]		3.2310indoles
fludrocortisone
Fludrocortisone: A synthetic mineralocorticoid with anti-inflammatory activity.		3.231011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug
ursodeoxycholic acid
Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.		3.620bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.0810C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
bisbenzimidazole trihydrochloride
[no description available]		2.2510
rose bengal b disodium salt
[no description available]		2.0710
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.0710glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
dexchlorpheniramine
dexchlorpheniramine: RN given refers to parent cpd(S)-isomer		4.1940chlorphenamine
adenylyl imidodiphosphate
Adenylyl Imidodiphosphate: 5'-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation.		2.0510adenosine 5'-phosphate
clometacin
clometacin: structure		3.2310N-acylindole
cefazolin
Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.		3.2310beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
pivampicillin
Pivampicillin: Pivalate ester analog of AMPICILLIN.. pivampicillin : A penicillanic acid ester that is the pivaloyloxymethyl ester of ampicillin. It is a prodrug of ampicillin.		2.1710penicillanic acid ester;
pivaloyloxymethyl ester		prodrug
azides
Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.		2.6320pseudohalide anionmitochondrial respiratory-chain inhibitor
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		4.0940penicillin allergen;
penicillin		antibacterial drug
timolol
(S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.		3.8730timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
indoramin
Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.		2.4820tryptamines
penfluridol
Penfluridol: One of the long-acting ANTIPSYCHOTIC AGENTS used for maintenance or long-term therapy of SCHIZOPHRENIA and other PSYCHOTIC DISORDERS.		2.1110diarylmethane
dv 1006
[no description available]		2.8930
oxcarbazepine
Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.		3.6120cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen
carbidopa
carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.		3.8830catechols;
hydrazines;
monocarboxylic acid		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
moricizine
Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.		3.6420carbamate ester;
morpholines;
phenothiazines		anti-arrhythmia drug
amineptin
amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.		3.2310amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound		antidepressant;
dopamine uptake inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		4.350azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
feprazone
Feprazone: A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)		2.0810organic molecular entity
pirprofen
pirprofen: anti-inflammatory agent used in therapy of rheumatoid arthritis; prostaglandin synthetase inhibitor; more potent than indomethacin; structure		3.2310pyrroline
tobramycin
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.		2.0810amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		10.11305taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		4.8690beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
dobutamine
Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.		3.9330catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
halofantrine
halofantrine: used in treatment of mild to moderate acute malaria		2.0810phenanthrenes
penbutolol
Penbutolol: A nonselective beta-blocker used as an antihypertensive and an antianginal agent.		3.2310ethanolamines
ribavirin
Rebetron: Rebetron is tradename		6.051001-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
amikacin
Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.		3.6120alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
climbazole
1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one : A ketone that is butan-2-one substituted by a 4-chlorophenoxy and a 1H-imidazol-1-yl group at position 1 and 2 methyl groups at position 3.		2.8930aromatic ether;
hemiaminal ether;
imidazoles;
ketone;
monochlorobenzenes
cephradine
Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.		3.2310beta-lactam antibiotic allergen;
cephalosporin		antibacterial drug
ticrynafen
Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.. tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.		3.2310aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes		antihypertensive agent;
hepatotoxic agent;
loop diuretic
methyldopa
Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.		3.9430L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
pyridoxal phosphate
[no description available]		2.610pyridinecarbaldehyde
bezafibrate
[no description available]		2.5420aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
sq-11725
Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.		2.0510
diltiazem
Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.		4.79505-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
lonidamine
lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.		2.0810dichlorobenzene;
indazoles;
monocarboxylic acid		antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector
vecuronium bromide
Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.		2.0810organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent;
nicotinic antagonist
vecuronium
vecuronium : A 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidino- and 16beta-N-methylpiperidinium substituents.		3.2310acetate ester;
androstane;
quaternary ammonium ion		drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist
benoxaprofen
benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.		3.6201,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes		antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
exifone
[no description available]		3.2310benzophenones
mefloquine
(-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.		4.4530[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
vindesine
Vindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).		2.0810methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
primary carboxamide;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent
desogestrel
Desogestrel: A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents (ORAL CONTRACEPTIVES, COMBINED).		2.081017beta-hydroxy steroid;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
triadimenol
triadimenol : A member of the class of triazoles that is 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butane-1,2-diol substituted at position O1 by a 4-chlorophenyl group. A fungicide for cereals, beet and brassicas used to control a range of diseases including powdery mildew, rusts, bunts and smuts.		2.8930aromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite
nitazoxanide
nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug		3.9530benzamides;
carboxylic ester
sufentanil
Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.		3.2310anilide;
ether;
piperidines;
thiophenes		anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
acarbose
[no description available]		3.6120tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
torsemide
Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.		3.620aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic
epirubicin
Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.		3.6520aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
lorcainide
[no description available]		2.0810acetamides
idarubicin
Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.		4.140anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
propiconazole
Orbit: Bony cavity that holds the eyeball and its associated tissues and appendages.		2.5420conazole fungicide;
cyclic ketal;
dichlorobenzene;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		3.8830penicillin allergen;
penicillin		antibacterial drug
paroxetine
Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.		3.6120aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
triciribine phosphate
[no description available]		2.1510
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		4.1540alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone
Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.		3.2310cephalosporinantibacterial drug
staurosporine
[no description available]		5.32120indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
foscarnet sodium
trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		2.0810one-carbon compound;
organic sodium salt		antiviral drug
indalpine
indalpine: selective 5-hydroxytryptamine uptake inhibitor; RN given refers to parent cpd		2.0710indoles
oltipraz
oltipraz : A 1,2-dithiole that is 3H-1,2-dithiole-3-thione substituted at positions 4 and 5 by methyl and pyrazin-2-yl groups respectively.		2.6101,2-dithiole;
pyrazines		angiogenesis modulating agent;
antimutagen;
antineoplastic agent;
antioxidant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
neurotoxin;
protective agent;
schistosomicide drug
atracurium
Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.		3.2310diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
atracurium besylate
atracurium besylate : The bisbenzenesulfonate salt of atracurium.		2.0810organosulfonate salt;
quaternary ammonium salt		muscle relaxant;
nicotinic antagonist
lidamidine
lidamidine: synonym WHR-1142A refers to HCl; structure		2.0710ureas
nicorandil
Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.		2.0810nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent
pergolide
Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.		3.2310diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist
pergolide mesylate
pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.		2.0810methanesulfonate saltantiparkinson drug;
dopamine agonist;
geroprotector
colforsin
Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.		2.610acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
cefadroxil anhydrous
Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		3.6120cephalosporinantibacterial drug
talniflumate
talniflumate: an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma		2.4820benzofurans
fenoldopam mesylate
[no description available]		2.0810benzazepine
triclabendazole
[no description available]		2.3110aromatic ether
nedocromil
Nedocromil: A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with ASTHMA, including EOSINOPHILS; NEUTROPHILS; MACROPHAGES; MAST CELLS; MONOCYTES; AND PLATELETS.		2.5420dicarboxylic acid;
organic heterotricyclic compound		anti-allergic agent;
anti-asthmatic drug;
non-steroidal anti-inflammatory drug
fiacitabine
fiacitabine: anti-herpes virus agent which also inhibits growth of certain human tumor cell lines in vitro.		2.610
fialuridine
[no description available]		3.2310
amonafide
xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor		3.0440isoquinolines
cefaclor anhydrous
Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		3.6120cephalosporinantibacterial drug;
drug allergen
pefloxacin
Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.		2.0810fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor
alfentanil
Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.		3.2310monocarboxylic acid amide;
piperidines		central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug
miglustat
miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.		3.2310piperidines;
tertiary amino compound		anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
haloperidol decanoate
[no description available]		3.2310organic molecular entity
dazoxiben
dazoxiben: RN given refers to parent cpd		2.0710
cefotetan
Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.		3.6120
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		4.4130delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
flupirtine
flupirtine: RN given refers to parent cpd without isomeric designation		3.0740aminopyridine
chaetochromin
chaetochromin: from Chaetomium spp.; RN given refers to chaetochromin A		2.8930
tolrestat
tolrestat: RN & structure given in first source		3.620naphthalenesEC 1.1.1.21 (aldehyde reductase) inhibitor
enoximone
Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.		3.0740aromatic ketone
stepronin
[no description available]		2.0810N-acyl-amino acid
castanospermine
castanospermine: indolizidine alkaloid from seeds of Australian legume, Castanospermum australe. castanospermine : A tetrahydroxyindolizidine alkaloid that consists of octahydroindolizine having four hydroxy substituents located at positions 1, 6, 7 and 8 (the 1S,6S,7R,8R,8aR-diastereomer).		3.2310indolizidine alkaloidanti-HIV-1 agent;
anti-inflammatory agent;
EC 3.2.1.* (glycosidase) inhibitor;
metabolite
simvastatin
Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.		4.9860delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
idazoxan
Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.		2.0810benzodioxine;
imidazolines		alpha-adrenergic antagonist
remoxipride
Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.		2.4820dimethoxybenzene
balsalazide
balsalazide: a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine; structure in first source. balsalazide : A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.		3.2310
pravastatin
Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		8.71203-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
cabergoline
Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.		3.6120N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist
atomoxetine hydrochloride
Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.. atomoxetine hydrochloride : The hydrochloride salt of atomoxetine.		2.0810hydrochlorideadrenergic uptake inhibitor;
antidepressant
atomoxetine
atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.		3.2310aromatic ether;
secondary amino compound;
toluenes		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic
quinapril
Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.		3.8830dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
alpidem
[no description available]		3.620imidazoles
mifepristone
Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.		3.61203-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
itraconazole
Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.		2.5420aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
dopexamine
dopexamine: RN given refers to parent cpd; structure given in first source		2.0710catecholamine
lonapalene
RS 43179: used in treatment of psoriasis		2.0710naphthalenes;
organochlorine compound
fosphenytoin
fosphenytoin: structure given in first & second source		3.2310imidazolidine-2,4-dione
pravadoline
[no description available]		2.0810
salmeterol xinafoate
Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.		2.0810naphthoic acid
ranolazine
Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.		3.7320aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
ipsapirone
[no description available]		2.0710N-arylpiperazine
brequinar
brequinar : A quinolinemonocarboxylic acid that is quinoline substituted by 2'-fluoro[1,1'-biphenyl]-4-yl, methyl, carboxy and fluoro groups at positions 2, 3, 4, and 6, respectively. It is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis. The compound exhibits antineoplastic and antiviral properties.		2.610biphenyls;
monocarboxylic acid;
monofluorobenzenes;
quinolinemonocarboxylic acid		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor
finasteride
Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.		3.61203-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod
Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.		2.5820imidazoquinolineantineoplastic agent;
interferon inducer
sematilide
sematilide: RN refers to HCl; structure given in first source		2.0710
esmolol
methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.		3.2310aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound
sertindole
sertindole : A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.		2.4920heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole		alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist
adapalene
Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.		2.0810adamantanes;
monocarboxylic acid;
naphthoic acid		dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		3.73206-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
aromasil
[no description available]		3.612017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
sparfloxacin
[no description available]		2.4920fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
zileuton
[no description available]		4.1401-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
remacemide
remacemide: structure given in first source		2.0710stilbenoid
niguldipine
[no description available]		2.0810diarylmethane
clopidogrel
Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.		4.1120methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		3.9530phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
tiagabine
Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.		3.2310beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor
mibefradil
Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.		3.8630tetralinsT-type calcium channel blocker
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		9.1540pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
eliprodil
1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol : A member of the class of piperidines that is piperidine substituted by a 2-(4-chlorophenyl)-2-hydroxyethyl group at position 1 and by a 4-fluorobenzyl group at position 4.		2.0810monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary alcohol;
tertiary amino compound
bromfenac
bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.		3.9330aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
celgosivir
celgosivir: inhibits glycoprotein processing & the growth of HIVs		3.7320
gemcitabine hydrochloride
[no description available]		2.0810hydrochloride;
organofluorine compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		7.83162organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
temoporfin
temoporfin: used as PHOTOCHEMOTHERAPY		2.110
ibutilide
ibutilide: RN & structure in first source; RN refers to the fumarate salt		3.6120benzenes;
organic amino compound
aripiprazole
Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.		4.9960aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
remifentanil
Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.		3.2310alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
atorvastatin calcium anhydrous
[no description available]		2.0810organic calcium salt
atorvastatin
[no description available]		5.3730aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
lamivudine
[no description available]		4.1540monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
duloxetine hydrochloride
Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.		2.0810duloxetine hydrochlorideantidepressant
duloxetine
[no description available]		3.6120duloxetine
irinotecan
[no description available]		8.9730carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
valsartan
Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.		4.1440biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
ibandronic acid
Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.		3.2310
ziprasidone
ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.		3.23101,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
zanamivir
Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.		2.610guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan
zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.		3.9330oxazolidinone;
tryptamines		anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
adefovir dipivoxil
bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.		2.58206-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
emtricitabine
Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.		3.9530monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
tasosartan
tasosartan: angiotensin II antagonist; structure given in first source		3.2310biphenyls
tiludronic acid
tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source		3.2310organochlorine compound
tirofiban
Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.		3.2310L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
capecitabine
Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.		6.9542carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		4.0430adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
octyl gallate
[no description available]		2.610gallate esterfood antioxidant;
hypoglycemic agent;
plant metabolite
vanadates
Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects.. vanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms.		2.4920trivalent inorganic anion;
vanadium oxoanion		EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
paroxetine hydrochloride
paroxetine hydrochloride : The hydrochloride salt of paroxetine. It is an antidepressant drug.		2.4820hydrochlorideantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
bupropion hydrochloride
[no description available]		2.0810aromatic ketone
venlafaxine hydrochloride
Venlafaxine Hydrochloride: A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.		2.610hydrochloride
trazodone hydrochloride
Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.		2.0810hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
trovafloxacin
trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.		3.2310
verapamil hydrochloride
verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.		2.4820
cefprozil
[no description available]		3.2310cephalosporin;
semisynthetic derivative		antibacterial drug
doxazosin mesylate
Cardura: Trade name in United States.		2.0810methanesulfonate saltgeroprotector
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		4.8750acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nelfinavir
Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.		5.4870aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
mevastatin
mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.		3.61202-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
bupivacaine hydrochloride
bupivacaine hydrochloride (anhydrous) : A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride : A hydrochloride obtained by combining 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with one molar equivalent of hydrochloric acid.		2.0810hydrochloride;
racemate		adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic
fenofibric acid
fenofibric acid: RN given refers to parent cpd without isomeric designation; structure. fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.		3.6920aromatic ketone;
chlorobenzophenone;
monocarboxylic acid		drug metabolite;
marine xenobiotic metabolite
norharman
norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.		2.0610beta-carbolines;
mancude organic heterotricyclic parent		fungal metabolite;
marine metabolite
betulinic acid
[no description available]		3.6920hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
arctigenin
arctigenin: precursor to catechols; in many plants		2.5220lignan
baicalin
[no description available]		2.610dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative		antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug
plerixafor
plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.		4.8350azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
amprenavir
[no description available]		5.3760carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
oseltamivir
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.		4.0330acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
epigallocatechin gallate
epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.		2.7620flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose
pentagalloylglucose: pentahydroxy gallic acid ester of glucose; a phytogenic antineoplastic agent and antibacterial agent. 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose : A galloyl-beta-D-glucose compound having five galloyl groups in the 1-, 2-, 3-, 4- and 6-positions.		2.610gallate ester;
galloyl beta-D-glucose		anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger
cephalotaxine
[no description available]		2.610benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
cyclic acetal;
enol ether;
organic heteropentacyclic compound;
secondary alcohol;
tertiary amino compound
desipramine hydrochloride
desipramine hydrochloride : The hydrochloride salt of desipramine.		2.610hydrochloridedrug allergen
mefloquine hydrochloride
[no description available]		2.610hydrochloride
ticlopidine hydrochloride
[no description available]		2.0810hydrochloride
epirubicin hydrochloride
[no description available]		2.0810
fenclofenac
fenclofenac: RN given refers to parent cpd		2.0710aromatic ether
sinefungin
[no description available]		3.2310adenosines;
non-proteinogenic alpha-amino acid		antifungal agent;
antimicrobial agent
proxicromil
proxicromil: RN given refers to parent cpd; structure		2.0710
histamine phosphate
histamine phosphate : A phosphate salt that is the diphosphate salt of histamine.		3.2310phosphate salthistamine agonist
tilbroquinol
[no description available]		3.2310organohalogen compound;
quinolines
bendamustine
[no description available]		4.6940benzimidazoles
aloxistatin
aloxistatin: a membrane-permeable cysteine protease inhibitor. aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide.		2.7220epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide		anticoronaviral agent;
cathepsin B inhibitor
droxicam
droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.		3.2310organic heterotricyclic compound;
pyridines		cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug
propazole
propazole: RN given refers to parent cpd; structure		2.610benzimidazoles
caroverine
caroverine: structure		2.0810quinoxaline derivative
indocate
[no description available]		2.8930
etofibrate
etofibrate: analog of clofibrate with nicotinic acid substituted on the 2-carbon of the ethyl ester group; structure; RN given refers to parent cpd		2.3110monocarboxylic acid
ebrotidine
ebrotidine: an H2-receptor antagonist and gastric mucosa protector		3.2310sulfonamide
torbafylline
torbafylline: structure given in first source		2.0710
cgs 9343b
[no description available]		2.0810benzimidazoles
prulifloxacin
prulifloxacin: structure given in first source		2.610fluoroquinolone antibiotic;
quinolone antibiotic
pazufloxacin
[no description available]		2.0810quinolines
repaglinide
[no description available]		3.6120piperidines
telmisartan
Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.		5.1270benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
bergenin
bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure		2.610trihydroxybenzoic acidmetabolite
2-methoxyestradiol
2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.		2.572017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
naphthalimides
Naphthalimides: Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.		2.0410
N(4)-acetylsulfathiazole
N(4)-acetylsulfathiazole : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a 1,3-thiazol-2-yl group at the nitrogen atom. It is a metabolite of sulfathiazole.		2.89301,3-thiazoles;
acetamides;
sulfonamide		marine xenobiotic metabolite
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		5.011101,2,3-triazole
cyclizine hydrochloride
[no description available]		2.5920
diazobenzenesulfonic acid
diazobenzenesulfonic acid: RN given refers to parent cpd; structure		3.9911
2,3-trimethylene-4-quinazolone
2,3-trimethylene-4-quinazolone: structure in first source		2.8930quinazolines
miconazole nitrate
miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.		2.0810
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		2.13102-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
sertraline
Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.		3.620dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
zoledronic acid
Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.		11.52711,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.5820organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
brinzolamide
brinzolamide: an antiglaucoma agent		2.5820sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
drospirenone
drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source		2.08103-oxo-Delta(4) steroid;
steroid lactone		aldosterone antagonist;
contraceptive drug;
progestin
artemether
Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.0810artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
fluindione
fluindione: structure		3.1610cyclic ketone;
indanones
1,3-dimethyluric acid
1,3-dimethyluric acid : An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trionesubstituted by methyl groups at N-1 and N-3.		2.8930oxopurinemetabolite
dipropylacetamide
dipropylacetamide: structure. valpromide : A fatty amide derived from valproic acid.		2.610fatty amidegeroprotector;
metabolite;
teratogenic agent
acamprosate
Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.		3.2310acetamides;
organosulfonic acid		environmental contaminant;
neurotransmitter agent;
xenobiotic
isaxonine
isaxonine: promotes nerve growth		3.2310aminopyrimidine
oxprenolol hydrochloride
[no description available]		2.610
n-methylscopolamine
N-Methylscopolamine: A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.		2.0510
enrofloxacin
Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets.		2.0710cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
nebivolol
2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.		3.2310chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound
uk 68798
[no description available]		4.140aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
danofloxacin
[no description available]		2.8930quinolines
hp 873
iloperidone: an atypical, negative symptom antipsychotic agent. iloperidone : A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia.		3.61201,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
dexrazoxane
Dexrazoxane: The (+)-enantiomorph of razoxane.		3.2310razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
loxapine succinate
[no description available]		2.0810succinate saltgeroprotector
fenoxypropazine
[no description available]		3.2310aromatic ether
opipramol hydrochloride
[no description available]		2.610
voriconazole
Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.		4.1340conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
betamipron
[no description available]		2.0810organonitrogen compound;
organooxygen compound
moroxydine
[no description available]		2.610biguanides
mepindolol
mepindolol: 2-methyl deriv of pindolol; RN given refers to parent cpd; structure		2.0710indoles
fpl 52791
FPL 52791: also has anti-allergic properties; related to sodium cromoglycate; structure		2.0710
uroxatral
[no description available]		2.0810hydrochloride
buparvaquone
buparvaquone: used in therapy of theileriasis; structure given in first source		2.2110
aceclofenac
[no description available]		3.6120amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
nitrefazole
[no description available]		4.1940imidazoles
alacepril
[no description available]		2.0810dipeptide;
thioacetate ester		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
epanolol
epanolol: structure given in first source		2.0710acetamides
thiocolchicoside
[no description available]		2.0810glycoside
thioxolone
tioxolone : A 1,3-benzoxathiole having a hydroxy substituent at the 6-position.		2.610benzoxathioleantiseborrheic
ubenimex
ubenimex: growth inhibitor		2.0810
methotrimeprazine
Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.		4.3750phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
honokiol
[no description available]		3.1640biphenyls
chelerythrine chloride
[no description available]		2.0310
nobiletin
nobiletin : A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively.		2.610methoxyflavoneantineoplastic agent;
plant metabolite
lycorine
lycorine: from bulbs of LYCORIS & other plants; RN given refers to (1 alpha,2 beta)-isomer; structure in Merck Index, 9th ed, #5444. lycorine : An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity.		2.610indolizidine alkaloidanticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor
leupeptin
[no description available]		2.610aldehyde;
tripeptide		bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor
picropodophyllin
picropodophyllin: isolated from American May apple (Podophyllum); inhibits IGF-I autophosphorylation without interfering with tyrosine kinase activity. picropodophyllotoxin : An organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing 3,4,5-trimethoxyphenyl and hydroxy substituents.		2.1510furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antineoplastic agent;
insulin-like growth factor receptor 1 antagonist;
plant metabolite;
tyrosine kinase inhibitor
9-methoxyellipticine
9-methoxyellipticine: RN given refers to parent cpd		2.8930
3-aminophenoxazone
3-aminophenoxazone: also inhibits sulfatase; structure		2.8930phenoxazine
tetrandrine
tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity		2.610bisbenzylisoquinoline alkaloid;
isoquinolines
3-deazaneplanocin
3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist		2.8930
fascaplysine
fascaplysine: from tropic sea sponges		2.0310
doripenem
Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.		3.6120carbapenems
calpeptin
[no description available]		2.610amino acid amide
fangchinoline
[no description available]		2.610aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle		anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite
tryptanthrine
tryptanthrine: minor constituent of traditional Chinese medicine qing dai		2.8930alkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound
maslinic acid
(2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria		2.610dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
atovaquone
Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.		4.5730hydroxy-1,2-naphthoquinone
2-chlorodiazepam
[no description available]		2.8930
bendamustine hydrochloride
[no description available]		3.4311
Polycartine B
[no description available]		2.8930phenazines
rivastigmine
[no description available]		3.2310carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent
frovatriptan
[no description available]		3.2310carbazoles
eletriptan
eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.		3.2310indoles;
N-alkylpyrrolidine;
sulfone		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
rosiglitazone
[no description available]		4.1340aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
tamiflu
[no description available]		2.0810phosphate salt
aminoquinuride dihydrochloride
[no description available]		2.8930
bexarotene
[no description available]		3.6120benzoic acids;
naphthalenes;
retinoid		antineoplastic agent
s20098
[no description available]		2.0810acetamides
flunisolide
flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones		2.081011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent
ketorolac tromethamine
Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.		2.0810organoammonium saltanalgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		9.3150macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
loganin
[no description available]		2.610beta-D-glucoside;
cyclopentapyran;
enoate ester;
iridoid monoterpenoid;
methyl ester;
monosaccharide derivative;
secondary alcohol		anti-inflammatory agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor;
neuroprotective agent;
plant metabolite
gemfibrozil 1-o-acylglucuronide
gemfibrozil 1-O-acylglucuronide: urinary metabolite of gemfibrozil; structure in first source		3.1710
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		2.76303-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
moexipril
[no description available]		3.7320peptide
aucubin
[no description available]		2.610organic molecular entitymetabolite
catalpol
[no description available]		2.610organic molecular entitymetabolite
gliquidone
gliquidone: structure; RN given refers to parent cpd		2.0810isoquinolines
thioproperazine mesylate
[no description available]		2.8930phenothiazines
n(6)-(delta(2)-isopentenyl)adenine
N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group.		2.89306-isopentenylaminopurinecytokinin
lekoptin
(S)-verapamil : A 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile that has S configuration.		2.6102-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
mci 9038
[no description available]		3.2310peptide
lopinavir
[no description available]		5.0140amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
3 beta-hydroxy-delta 5-cholenic acid
[no description available]		2.1110steroid
levcromakalim
[no description available]		2.07101-benzopyran
4-methyl-N-(phenylmethyl)benzenesulfonamide
[no description available]		2.8930sulfonamide
eupatorin
eupatorin: a flavonoid from the East Asian medicinal plant Orthosiphon spicatus; prevents oxidative inactivation of 15-lipoxygenase; structure given in first source. eupatorin : A trimethoxyflavone that is 6-hydroxyluteolin in which the phenolic hydogens at positions 4', 6 and 7 have been replaced by methyl groups.		2.0610dihydroxyflavone;
polyphenol;
trimethoxyflavone		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
Brassica napus metabolite;
calcium channel blocker;
P450 inhibitor;
vasodilator agent
5-iodotubercidin
7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase		2.0310organoiodine compound
zpck
ZPCK: alkylates histidine residue at active center of bovine chymotrypsin		2.6320
moxifloxacin hydrochloride
moxifloxacin hydrochloride : A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.		2.0810hydrochlorideantibacterial drug
n-methyladenosine
N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.		2.920methyladenosine
hexylcaine hydrochloride
[no description available]		2.0710
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		4.325017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
mizoribine
[no description available]		2.0810imidazolesanticoronaviral agent
arginyl-glycyl-aspartic acid
arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system		2.0510oligopeptide
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.0710beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
sr141716
[no description available]		3.2350amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
bosentan anhydrous
Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.		4.2850primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
fpl 55712
FPL 55712: inhibitor of SRS-A and LTC4 and LTD4 receptors		2.0710aromatic ketone
paxilline
paxilline: structure given in first source; RN given refers to (2R-(2alpha,4bbeta,6aalpha,12bbeta,12calpha,14abeta))-isomer. paxilline : An indole diterpene alkaloid with formula C27H33NO4 isolated from Penicillium paxilli. It is a potent inhibitor of large conductance Ca2(+)- and voltage-activated K(+) (BK)-type channels.		3.79100diterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol		anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker
vinpocetine
[no description available]		2.0810
(6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide
[no description available]		2.5920aromatic ketone
sivelestat
sivelestat: inhibitor of neutrophil elastase; structure given in first source		2.5720N-acylglycine;
pivalate ester
racecadotril
racecadotril: parenterally active enkephalinase inhibitor		2.0810N-acyl-amino acid
pyronaridine
[no description available]		2.610aminoquinoline
saikosaponin d
[no description available]		2.610
n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide
[no description available]		3.4110
perindopril
Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline		3.2310alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
geniposide
[no description available]		2.610terpene glycoside
deguelin
deguelin: a natural product from Mundulea sericea; RN refers to (7aS-cis)-isomer; structure given in first source. deguelin : A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.		2.0810aromatic ether;
diether;
organic heteropentacyclic compound;
rotenones		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor;
plant metabolite
fingolimod hydrochloride
Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.. fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).		2.0310hydrochlorideimmunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
fingolimod
fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.		2.8930aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
daidzin
daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).		2.6107-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
triptolide
[no description available]		2.0810diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound		antispermatogenic agent;
plant metabolite
parthenolide
[no description available]		2.0410germacranolide
tryptoquivaline
tryptoquivaline: tremor-producing metabolite from Aspergillus clavatus; tetrapeptide derived from tryptophan, anthranilic acid, valine, & methylalanine; structure & N1 names previously assigned to tryptoquivaline C & tryptoquivaline D found to be incorrect & are revised in third source; see also record for tryptoquivalone; structure in third source		2.0510
tesmilifene
[no description available]		2.8930diarylmethane
tadalafil
[no description available]		3.6120benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
paliperidone
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one : A member of the class of pyridopyrimidines that is 9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.. paliperidone : A racemate comprising equimolar amounts of (R)- and (S)-paliperidone. Paliperidone is the primary active metabolite of the older antipsychotic risperidone and is used for treatment of schizophrenia.		3.93301,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol
sophocarpine
[no description available]		2.610
nitisinone
[no description available]		3.6920(trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione		EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
plavix
[no description available]		2.0810azaheterocycle sulfate salt;
organoammonium sulfate salt		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
marimastat
marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary. marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.		2.610hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor
clofarabine
[no description available]		9.2850adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent
sr 48692
SR 48692: structure in first source; a neurotensin receptor-1 antagonist		2.0810N-acyl-amino acid
elacridar
Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source		8.4870
pramipexole
Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.		3.6120benzothiazoles;
diamine		antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger
valdecoxib
[no description available]		3.6120isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid: structure given in first source. DOTA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 7 and 10 of a twelve-membered ring are each substituted with a carboxymethyl group.		2.0510azamacrocyclechelator;
copper chelator
fpl-52694
FPL-52694: mast cell stabilizer; RN given refers to parent cpd; FPL-52694 is mono-Na salt; structure given in first source		2.0710
sr 27897
SR 27897: structure given in first source; a CCK(A) receptor antagonist		2.8930indolyl carboxylic acid
celastrol
[no description available]		2.610monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		24.78854103methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
almotriptan
almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.		3.2310indoles;
sulfonamide;
tertiary amine		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
mk 0663
[no description available]		2.0810bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
gefitinib
[no description available]		11.31411aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine
N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer)		3.1640leucine derivative
bay x 1005
2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source;		2.0810
norketamine
norketamine: metabolite of ketamine; RN given refers to cpd without isomeric designation		2.8930organochlorine compound
ramatroban
[no description available]		2.0710organic molecular entity
vadimezan
vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.		2.610monocarboxylic acid;
xanthones		antineoplastic agent
e 64
E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)		2.610dicarboxylic acid monoamide;
epoxy monocarboxylic acid;
guanidines;
L-leucine derivative;
zwitterion		antimalarial;
antiparasitic agent;
protease inhibitor
desloratadine
desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.		3.9330benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
desvenlafaxine
O-desmethylvenlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.		3.2310cyclohexanols;
phenols;
tertiary amino compound		antidepressant;
drug metabolite;
marine xenobiotic metabolite
1,3-bis(tris(hydroxymethyl)methylamino)propane
bis-tris propane : A water-soluble buffer substance used for the preparation of the biochemical and biological buffer solutions; pKa = 6.8 at 20 degreeC.		2.0810hexolbuffer
indatraline
indatraline: RN given for (trans)-isomer; structure in first source		2.6320indanes
lestaurtinib
[no description available]		5.2180indolocarbazole
gyki 53655
GYKI 53655: an AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) receptor antagonist		2.0810
methotrexate
[no description available]		9.13191dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
salvinorin a
salvinorin A: from the herb, Salvia divinorum		2.2110organic heterotricyclic compound;
organooxygen compound		metabolite;
oneirogen
xaliproden
xaliproden : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine which is substituted on the nitrogen by a 2-(2-naphthyl)ethyl group and at position 4 by a m-trifluoromethylphenyl group.		2.0710(trifluoromethyl)benzenes;
naphthalenes;
tertiary amino compound;
tetrahydropyridine		serotonergic agonist
tamsulosin
[no description available]		3.23105-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
rufinamide
rufinamide: for treatment of Lennox-Gastaut syndrome; structure in first source		3.2310aromatic amide;
heteroarene
(hydroxy-2-naphthalenylmethyl)phosphonic acid
(hydroxy-2-naphthalenylmethyl)phosphonic acid: a protein-tyrosine kinase inhibitor; structure given in first source		2.1710
arginine-glycine-aspartate-o-methyltyrosine amide
arginine-glycine-aspartate-O-methyltyrosine amide: competes with fibrinogen for binding to platelet glycoprotein IIb/IIIa receptors		2.2510
n-isobutyrylcysteine
N-isobutyrylcysteine: RN given refers to L-isomer		2.0710
sulbactam
[no description available]		2.0810penicillanic acids
olmesartan medoxomil
Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.		3.6120biphenyls
dexpanthenol
dexpanthenol: The alcohol of pantothenic acid		3.620amino alcohol;
monocarboxylic acid amide		cholinergic drug;
provitamin
umifenovir
umifenovir: an antiviral agent		2.610indolyl carboxylic acid
fosamprenavir
fosamprenavir: a prodrug of the protease inhibitor amprenavir. fosamprenavir : A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir.		3.2310sulfonamideprodrug
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide
4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide: increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol		2.8930
safinamide
safinamide: short-acting inhibitor of MOA-B; FCE 26743 is (S)-isomer, FCE 28073 is (R)-isomer; structure in first source		2.610amino acid amide
quilostigmine
quilostigmine: RN given for (3aS,cis)-isomer; structure in first source		2.0710pyrroloindole
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide
N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide: binds with high affinity to glial mitochondrial diazepam binding inhibitor receptors & increases mitochondrial steroidogenesis		2.8930phenylindole
ilomastat
CS 610: matrix metalloproteinase inhibitor; structure in first source. ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor		2.610hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
abiraterone
[no description available]		8.64623beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
ml-3000
[no description available]		2.0810
ns 1608
NS 1608: a BK(Ca) channel opener		2.0610ureas
imiloxan
[no description available]		2.0710benzodioxine
l 741626
3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole: structure in first source		2.8930piperidines
febuxostat
Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.		4.45301,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile		EC 1.17.3.2 (xanthine oxidase) inhibitor
aspartame
[no description available]		2.0710carboxylic acid;
dipeptide zwitterion;
dipeptide;
methyl ester		apoptosis inhibitor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
environmental contaminant;
micronutrient;
nutraceutical;
sweetening agent;
xenobiotic
pomalidomide
3-aminophthalimidoglutarimide: structure in first source		2.3110aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
cd 437
CD 437: selective for retinoic acid receptors gamma. CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells.		2.0810adamantanes;
monocarboxylic acid;
naphthoic acid;
phenols		apoptosis inducer;
retinoic acid receptor gamma agonist
tempol
[no description available]		2.0710aminoxyls;
hydroxypiperidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
catalyst;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
radical scavenger
proline
Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.		2.0810amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
escitalopram
Escitalopram: S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.. escitalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram.		3.23101-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrileantidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
lexapro
Lexapro: Trade name of escitalopram, the active S-enantiomer of the racemic citalopram.		2.0810
10-propargyl-10-deazaaminopterin
10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.		3.2310N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		9.73143secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
perifosine
[no description available]		3.3760ammonium betaine;
phospholipid		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
atazanavir
atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).		4.5730carbohydrazideantiviral drug;
HIV protease inhibitor
lonafarnib
lonafarnib: inhibitor of farnesyl protein transferase. lonafarnib : A 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor.		3.51104-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamideantineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
tariquidar
[no description available]		2.2510benzamides
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		4.64409-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ezetimibe
Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).		3.6120azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite
ertapenem
Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.		3.2310carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
dx 8951
[no description available]		2.8930pyranoindolizinoquinoline
cox 189
lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.		3.6120amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
conivaptan
conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).		3.2310benzazepineaquaretic;
vasopressin receptor antagonist
mk 767
5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source		2.0810
vatalanib
[no description available]		5.33120monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		4.1140aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
vx 497
N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic acid tetrahydrofuran-3-yl ester: structure in first source		2.610
pralnacasan
pralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source		3.2310
clevidipine
clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source		3.620dihydropyridine
ruboxistaurin
ruboxistaurin: inhibits protein kinase C beta; structure in first source		4.760
solifenacin
[no description available]		3.6120isoquinolines
dexmethylphenidate
dexmethylphenidate : A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate.		3.2310methyl phenyl(piperidin-2-yl)acetateadrenergic agent
bcx 1812
[no description available]		2.6103-hydroxy monocarboxylic acid;
acetamides;
cyclopentanols;
guanidines		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
bazedoxifene acetate
[no description available]		2.0810
hyoscyamine
Hyoscyamine: The 3(S)-endo isomer of atropine.. (S)-atropine : An atropine with a 2S-configuration.		2.0710tropane alkaloid
xamoterol
Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.		2.0810morpholines
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		4.350methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
canertinib dihydrochloride
[no description available]		2.0610
canertinib
[no description available]		4.7260monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
cinacalcet
cinacalcet : A secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group.		3.2310(trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound		calcimimetic;
P450 inhibitor
birb 796
[no description available]		6.57140aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
lactitol
lactitol : A glycosyl alditol consisting of beta-D-galactopyranose and D-glucitol joined by a 1->4 glycosidic bond. It is used as a laxative, as an excipient, and as replacement bulk sweetener in some low-calorie foods.		2.0710glycosyl alditolcathartic;
excipient;
laxative
lubiprostone
[no description available]		3.2310
olmesartan
olmesartan: an active metabolite of CS 866		2.610biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent
telbivudine
[no description available]		4.1540pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
tipifarnib
[no description available]		3.0740imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
celastrol methyl ester
celastrol methyl ester: isolated from Tripterygium wilfordii; potent inhibitory activity on both Kir2.1 and ERG1 potassium channels, leading to LONG QT SYNDROME		2.610carboxylic ester
atrasentan
Atrasentan: A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.		5.4620pyrrolidines
resiquimod
S 28463: structure given in first source		2.610imidazoquinoline
cyc 202
seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.		6.551302,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fpl 52757
FPL 52757: FPL 52758 is Na salt of FPL 52757; structure in first source; RN given refers to parent cpd		2.0710
tanshinone ii a
tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source		3.9220abietane diterpenoid
paromomycin
Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.		3.620amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
anidulafungin
Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.		3.2310antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative
avasimibe
[no description available]		2.8930monoterpenoid
anacardic acid
anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor. anacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities.		2.610hydroxy monocarboxylic acid;
hydroxybenzoic acid		anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite
17 alpha-hydroxyprogesterone caproate
17 alpha-Hydroxyprogesterone Caproate: Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.		3.2310corticosteroid hormone
varenicline
Varenicline: A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.. varenicline : An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.		3.2310
fiduxosin
fiduxosin: fiduxosin (ABT-980) is the (3aR,9bR)-isomer; structure in first source		3.2310
fpl 59257
FPL 59257: abolishes cough response & partly inhibits bronchoconstriction produced by leukotrienes C & D		2.0710
atropine
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.		3.8830
ropivacaine
Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.		2.5220piperidinecarboxamide;
ropivacaine		local anaesthetic
migalastat
migalastat: a potent inhibitor of glycolipid biosynthesis		2.610piperidines
sb 203580
[no description available]		7.11140imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
sb 216763
[no description available]		2.4920indoles;
maleimides
enzastaurin
[no description available]		3.0140indoles;
maleimides
erlotinib
[no description available]		8.62250aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
erlotinib hydrochloride
[no description available]		12.31355hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
cilengitide
Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells		2.4820oligopeptide
piboserod
Serotonin 5-HT4 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT4 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN RECEPTOR AGONISTS.		2.0810
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		3.5520divalent inorganic anion;
phosphite ion
zeneca zd 6169
Zeneca ZD 6169: an ATP-sensitive potassium channel opener; structure given in first source		2.0710
l 163191
[no description available]		3.0740
limonin
[no description available]		2.610epoxide;
furans;
hexacyclic triterpenoid;
lactone;
limonoid;
organic heterohexacyclic compound		inhibitor;
metabolite;
volatile oil component
dizocilpine
[no description available]		2.8930secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
sibenadet
sibenadet: structure in first source		2.0710
scutellarin
scutellarin: see scutellarein for aglycone. scutellarin : The glycosyloxyflavone which is the 7-O-glucuronide of scutellarein.		2.610glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antineoplastic agent;
proteasome inhibitor
bd 1047
N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin: sigma receptor ligand; putative sigma receptor antagonist with antidystonic activity		2.0810primary amine
s-benzylcysteine
[no description available]		2.8930S-aryl-L-cysteine zwitterion
etravirine
[no description available]		3.7320aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
latrepirdine
latrepirdine: structure		2.0710methylpyridines;
pyridoindole		geroprotector
chelidonine
chelidonine: benzophenanthridine derived from scoulerine from Chelidonium majus; RN given refers to parent cpd (chelidonine, (5bR-(5balpha,6beta,12alpha))-isomer)		3.1640alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid
4-n-butylresorcinol
4-n-butylresorcinol: structure in first source		2.610resorcinols
orantinib
[no description available]		2.0610monocarboxylic acid;
oxindoles;
pyrroles		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
dronedarone
Dronedarone: A non-iodinated derivative of amiodarone that is used for the treatment of ARRHYTHMIA.. dronedarone : A member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias.		3.23101-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic
ramelteon
ramelteon: melatonin MT1/MT2 receptor agonist		3.8830indanes
lapatinib
[no description available]		11.17351furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
darunavir
Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.		3.7320carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
dapivirine
Dapivirine: effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission		2.610
deferasirox
Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.		9.3730benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
bms204352
BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source		2.0810
dabigatran
Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.. dabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism.		2.2110aromatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
pyridines		anticoagulant;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
EC 3.4.21.5 (thrombin) inhibitor
tbc-11251
sitaxsentan: endothelin A receptor antagonist; structure in first source		3.6120benzodioxoles
tolvaptan
[no description available]		8.9330benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist
sorafenib
[no description available]		10.96600(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
lenalidomide
[no description available]		10.75100aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
nutlin 3
[no description available]		3.4110stilbenoid
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
[no description available]		2.0810aminoquinoline
regadenoson
[no description available]		3.2310purine nucleoside
roxindole
[no description available]		2.8930indolesalpha-adrenergic antagonist;
serotonergic drug
sr 142806
[no description available]		2.0810
lacosamide
Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.		3.6120N-acyl-amino acid
1-methylpropyl-2-imidazolyl disulfide
1-methylpropyl-2-imidazolyl disulfide: a thioredoxin inhibitor with antineoplastic activity		3.4110imidazoles
conidendrin
[no description available]		2.8930
cortisone
[no description available]		2.462011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
vincaleukoblastine
[no description available]		3.6120acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
Porfiromycine
[no description available]		2.8930mitomycin
vincristine sulfate
[no description available]		2.0810organic sulfate saltantineoplastic agent;
geroprotector
nsc 74859
NSC 74859: inhibits Stat3 binding activity; structure in first source. S3I-201 : An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid.		2.610amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester		STAT3 inhibitor
anisomycin
Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.		3.7320monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.2510
benzarone
benzarone: antihemorrhagic agent; structure		3.23101-benzofurans
estramustine
Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.		3.231017beta-hydroxy steroid;
carbamate ester;
organochlorine compound		alkylating agent;
antineoplastic agent;
radiation protective agent
nsc 95397
[no description available]		2.89301,4-naphthoquinones
4-methyl-2-quinazolinamine
4-methyl-2-quinazolinamine: from Streptomyces of TCM plant; structure in first source		2.8930
phenethicillin
phenethicillin: minor descriptor (85); major descriptor (63-84); on-line search PENICILLIN, PHENOXYMETHYL/AA (66-85); Index Medicus search PHENETHICILLIN (63-84); RN given refers to (2S-(2alpha,5alpha,6beta))-isomer. phenethicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.		2.0710penicillin allergen;
penicillin
berbamine
[no description available]		420bisbenzylisoquinoline alkaloid;
isoquinolines
2-glycineamide-5-chlorophenyl-2-pyrryl ketone
[no description available]		2.8930
homoharringtonine
Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.		5.5860alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
elesclomol
[no description available]		2.0810carbohydrazide;
thiocarbonyl compound		antineoplastic agent;
apoptosis inducer
u-104
SLC-0111: a carbonic anhydrase inhibitor; structure in first source		2.610
wortmannin
[no description available]		5.0640acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
niguldipine hydrochloride
[no description available]		2.6320
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one
[no description available]		2.610glycoside
2,5-bis(5-hydroxymethyl-2-thienyl)furan
[no description available]		3.140thiophenes
nsc 663284
NSC 663284: structure in first source		2.0810quinolone
bortezomib
[no description available]		8.6181amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		5.15701,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
tizoxanide
tizoxanide: major metabolite of nitazoxanide; structure in first source		2.610salicylamides
bardoxolone methyl
methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source		2.5320cyclohexenones
5-iodoindirubin-3'-monoxime
5-iodoindirubin-3'-monoxime: inhibits GSK-3beta		2.0310
tryptoquivaline
fumitremorgin C : An organic heteropentacyclic compound that is a mycotoxic indole alkaloid produced by several fungi. A potent and specific inhibitor of the breast cancer resistance protein multidrug transporter.		3.5110aromatic ether;
indole alkaloid;
organic heteropentacyclic compound		breast cancer resistance protein inhibitor;
mycotoxin
nsc 23766
[no description available]		2.0810aminopyrimidine;
aminoquinoline;
primary amino compound;
secondary amino compound;
tertiary amino compound		antiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist
leupeptins
Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.		2.1110
carboplatin
[no description available]		6.4172
Destruxin B
[no description available]		2.8930cyclodepsipeptide
lithium chloride
Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.		2.3110inorganic chloride;
lithium salt		antimanic drug;
geroprotector
leptomycin b
[no description available]		2.1510
2H-pyrazolo[4,3-b]quinoxalin-3-amine
[no description available]		2.0310quinoxaline derivative
s-adenosylhomocysteine
S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions.. S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine.		3.2310adenosines;
amino acid zwitterion;
homocysteine derivative;
homocysteines;
organic sulfide		cofactor;
EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor;
EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor;
epitope;
fundamental metabolite
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		3.2310heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		2.071011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
salicin
[no description available]		2.0710aromatic primary alcohol;
aryl beta-D-glucoside;
benzyl alcohols		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
tosylphenylalanyl chloromethyl ketone
Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.		2.8930alpha-chloroketone;
sulfonamide		alkylating agent;
serine proteinase inhibitor
pentostatin
Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.		3.6120coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
arbutin
hydroquinone O-beta-D-glucopyranoside : A monosaccharide derivative that is hydroquinone attached to a beta-D-glucopyranosyl residue at position 4 via a glycosidic linkage.		2.610beta-D-glucoside;
monosaccharide derivative		Escherichia coli metabolite;
plant metabolite
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		4.4860cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
conessine
conessine : A steroid alkaloid that is con-5-enine substituted by a N,N-dimethylamino group at position 3. It has been isolated from the plant species of the family Apocynaceae.		2.610steroid alkaloid;
tertiary amino compound		antibacterial agent;
antimalarial;
H3-receptor antagonist;
plant metabolite
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		3.6120alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
griseofulvin
Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.		3.58201-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound		antibacterial agent;
Penicillium metabolite
cefoxitin
Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.		3.2310beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
digitoxin
Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.		2.4820cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		5.5880L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
pancuronium
Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.		3.2310acetate ester;
steroid ester		cholinergic antagonist;
muscle relaxant;
nicotinic antagonist
abacavir
abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.		4.57302,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
perindopril erbumine
[no description available]		2.0810addition compoundantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol
[no description available]		3.6120piperidines
metyrosine
alpha-methyl-L-tyrosine : An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.		3.2310L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
rocuronium bromide
rocuronium bromide : The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.		2.0810organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent
terconazole
terconazole: structure & RN for (cis)-isomer from first source. terconazole : A racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-terconazole. It has broad-spectrum antifungal activitiy and is used for the treatment of vaginal yeast infections (Candida).. (2R,4S)-terconazole : A 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine in which positions 2 and 4 of the 1,3-dioxolane moiety have R and S configuration, respectively.		3.41101-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine
linezolid
[no description available]		4.3150acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
(S)-bicalutamide
(S)-bicalutamide : A N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide that is the (S)-enantiomer of bicalutamide.		2.0710N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
ruscogenin
ruscogenin: basic sapogenin of Ruscus sp.; RN given refers to (1 beta,3 beta,25R)-isomer		7.610triterpenoid
ginsenoside rf
ginsenoside Rf: from ginseng. ginsenoside Rf : A ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy group at position 6 has been converted to the corresponding beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.		3.511012beta-hydroxy steroid;
20-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid		antineoplastic agent;
apoptosis inducer;
plant metabolite
cephaelin
cephaelin: do not confuse with cephalin of brain; after emetine this is the most important alkaloid of ipecac; protein synthesis inhibitor. cephaeline : A pyridoisoquinoline comprising emetam having a hydroxy group at the 6'-position and methoxy substituents at the 7'-, 10- and 11-positions.		2.610pyridoisoquinoline
(-)-usnic acid
(-)-usnic acid : The (-)-enantiomer of usnic acid.		2.610usnic acidEC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
lusianthridin
lusianthridin: from rhizome of Arundina graminifolia		2.2110dihydrophenanthrene
acetylleucyl-leucyl-norleucinal
acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.		2.610aldehyde;
tripeptide		cysteine protease inhibitor
6-prenylchrysin
6-prenylchrysin: structure in first source. 6-(3,3-dimethylallyl)chrysin : A dihydroxyflavone that is chrysin substituted by a prenyl group at position 6.		3.51107-hydroxyflavonol;
dihydroxyflavone
devazepide
Devazepide: A derivative of benzodiazepine that acts on the cholecystokinin A (CCKA) receptor to antagonize CCK-8's (SINCALIDE) physiological and behavioral effects, such as pancreatic stimulation and inhibition of feeding.. devazepide : An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders.		2.07101,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
clindamycin phosphate
[no description available]		3.2310
1-O-Acetyllycorine
1-acetyllycorine: has antiviral activity; structure in first source		3.2310alkaloid
pemirolast potassium salt
[no description available]		2.0810
eplerenone
Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.		3.61203-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent
tolterodine
[no description available]		3.2310tertiary amineantispasmodic drug;
muscarinic antagonist;
muscle relaxant
halcinonide
Halcinonide: A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.		2.0710organic molecular entitySMO receptor agonist
metrizamide
Metrizamide: A solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.		2.0710amino sugar
ao 128
AO 128: alpha-glucosidase inhibitor; structure given in first source		2.0810organic molecular entity
loteprednol etabonate
Loteprednol Etabonate: An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.		2.081011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
etabonate ester;
organochlorine compound;
steroid acid ester;
steroid ester		anti-inflammatory drug
darifenacin
darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.		3.23101-benzofurans;
monocarboxylic acid amide;
pyrrolidines		antispasmodic drug;
muscarinic antagonist
fluticasone propionate
fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.		2.081011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester		adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.1110cyclodextrin
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		3.9830antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
tretinoin
Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.		5.81110retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		2.610icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		3.1130resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
retinol
Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).		3.2310retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		5.270macrolide lactambacterial metabolite;
immunosuppressive agent
(3R,5S)-fluvastatin
(3R,5S)-fluvastatin : A (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid diastereoisomer in which the stereocentres beta- and delta- to the carboxy group have R and S configuration, respectively. The drug fluvastatin is an equimolar mixture of this compound and its enantiomer.		3.2310(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid;
statin (synthetic)
rosuvastatin
rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).		3.2310dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
mycophenolic acid
Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.		5.29602-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
mupirocin
Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.		2.0810alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
clindamycin
Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.		3.2310
lycopene
[no description available]		2.610acyclic caroteneantioxidant;
plant metabolite
fosfomycin
Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.		3.6120epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		4.1540macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
pd 173955
PD 173955: inhibits src family-selective tyrosine kinase; structure in first source		2.4920aryl sulfide;
dichlorobenzene;
methyl sulfide;
pyridopyrimidine		tyrosine kinase inhibitor
pd 166326
PD 166326: a pyrido(2,3-d)pyrimidine src tyrosine kinase inhibitor		3.8730
gw 3965
GW 3965: a liver X receptor ligand		2.0810diarylmethane
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea
N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source		2.4520
y 27632
Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.		2.4620aromatic amide
h 1152
(S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane : A member of the class of isoquinolines that is the sulfonamide formed by the formal condensation of the sulfo group of 4-methylisoquinoline-5-sulfonic acid with the 1-amino group of (S)-2-methyl-1,4-diazepane.		2.0310isoquinolines;
N-sulfonyldiazepane		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
bms 214662
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.		3.5420benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
octreotide
[no description available]		3.2310
epothilone a
Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).		5.4841epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
eptifibatide
[no description available]		3.2310homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine
[no description available]		2.0310
6-bromoindirubin-3'-oxime
6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.4620
purvalanol b
purvalanol B: protein kinase inhibitor; structure in first source		2.0810purvalanolprotein kinase inhibitor
y-700
[no description available]		2.0810
repsox
RepSox: inhibits TGF-beta signaling; structure in first source appears to be incorrect		2.0810pyrazolopyridine
roflumilast
[no description available]		2.610aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound		anti-asthmatic drug;
phosphodiesterase IV inhibitor
L-cycloserine
L-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has S configuration. An antibiotic isolated from Erwinia uredovora.		2.6104-amino-1,2-oxazolidin-3-oneanti-HIV agent;
anticonvulsant;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
h 89
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.		2.5220N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
decitabine
[no description available]		4.31502'-deoxyribonucleoside
teniposide
[no description available]		3.6120aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
valrubicin
[no description available]		2.0810anthracycline;
trifluoroacetamide
ketoconazole
(2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.		3.5110cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
purvalanol a
6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;		2.7830purvalanol
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		4.1320actinomycinmutagen
bevirimat
bevirimat: an HIV inhibitor; disrupts late step in processing HIV Major Core Protein p24, preventing the capsid precursor p25 from being converted to mature capsid p24. bevirimat : A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhibitors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems.		2.610dicarboxylic acid monoester;
monocarboxylic acid;
pentacyclic triterpenoid		HIV-1 maturation inhibitor;
metabolite
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		9.780L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
sitafloxacin
[no description available]		2.2110fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.		2.6120amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		4.4430nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
posaconazole
[no description available]		10.0860aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
gw 257406x
maribavir: has antiviral activity against human cytomegalovirus		2.610
rubitecan
rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor. rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.		2.0810C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
micafungin
Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.		4.2220antibiotic antifungal drug;
echinocandin		antiinfective agent
shikonin
shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities		2.610hydroxy-1,4-naphthoquinone
2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione
[no description available]		2.0310aminotoluene
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide
[no description available]		2.5820tropane alkaloid
cmx 001
[no description available]		2.610
amd 8664
[no description available]		2.610
bay 41-4109
BAY 41-4109: structure in first source		2.610
bay 57-1293
pritelivir: herpes simplex virus 1 helicase-primase inhibitor		2.610
riboflavin
vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).		3.2310flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
2'-c-methylcytidine
2'-C-methylcytidine: structure in first source		3.1640
n-nonyl-1-deoxynojirimycin
N-nonyldeoxynojirimycin : A hydroxypiperidine that is deoxynojirimycin (duvoglustat) in which the amino hydrogen is replaced by a nonyl group.		3.2310hydroxypiperidine;
tertiary amino compound		antiviral agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.2.1.45 (glucosylceramidase) inhibitor
isoxanthohumol
isoxanthohumol: structure in first source		2.610flavanones
1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide
[no description available]		3.4110indolecarboxamideanticoronaviral agent
sodium bicarbonate
Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.		3.2310one-carbon compound;
organic sodium salt		antacid;
food anticaking agent
arsenic trioxide
Tetraarsenic Oxide: A form of As2O3 that exists as As4O6 in the solid state. It dissociates to As2O3 upon heating to the vapor phase above 800 degrees Celsius.		3.2310arsenic oxideantineoplastic agent;
insecticide
jp-1302
[no description available]		2.8930
bromochloroacetic acid
Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.. bromochloroacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by bromine while a second is replaced by chlorine. A low-melting (27.5-31.5degreeC), hygroscopic crystalline solid, it can be formed during the disinfection (by chlorination) of water that contains bromide ions and organic matter, so can occur in drinking water as a byproduct of the disinfection process.		2.03102-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide
4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide: a c-FLIP inhibitor; structure in first source		2.610aromatic ether
mecarbinate
[no description available]		2.610
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one
[no description available]		2.8930benzodiazepine
sr 90107
fondaparinux sodium : An organic sodium salt, being the decasodium salt of fondaparinux.		3.2310
meglumine iodipamide
[no description available]		3.2310organoammonium saltradioopaque medium
tenatoprazole
Tenatoprazole: structure in first source		2.8930imidazopyridine
hirsutanone
hirsutanone: from methanolic extract of the aerial parts of Viscum cruciatum (Viscaceae)		3.4110diarylheptanoid
isomethyleugenol
Methylation: Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed)		2.5820isomethyleugenol
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		2.5320stilbene
thyrotropin-releasing hormone
PR 546: no other info available 9/89. protirelin : A tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence.		3.2310peptide hormone;
tripeptide		human metabolite
arginine vasopressin
Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.		3.6120vasopressincardiovascular drug;
hematologic agent;
mitogen
s 1033
[no description available]		22.353139(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
acetyl-aspartyl-glutamyl-valyl-aspartal
acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor. Ac-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7.		2.610tetrapeptideprotease inhibitor
5-[(2-fluoroanilino)methyl]-8-quinolinol
[no description available]		2.8930hydroxyquinoline
trilostane
trilostane: inhibits conversion of pregnenolone to progesterone; adrenal blocking agent used in treatment of Cushing's syndrome. trilostane : An epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions.		2.081017beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile		abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
lanatoside c
lanatoside C: RN given refers to (3beta,5beta,12beta)-isomer		3.2310
benidipine hydrochloride
[no description available]		2.5920
benidipine
benidipine: RN refers to (R*,R*)-(+-)-isomer		2.2110
leuprolide acetate
leuprolide acetate : An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.		2.0810acetate saltantineoplastic agent;
gonadotropin releasing hormone agonist
octotropine methylbromide
octotropine methylbromide: minor descriptor (65-86); on line & INDEX MEDICUS search TROPANES (69-86); RN given refers to endo-isomer. anisotropine methylbromide : A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide.		2.610
fludarabine
[no description available]		6.84111purine nucleoside
propylthiouracil
Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.		3.6120pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
r 59949
R 59949: diacylglycerol kinase inhibitor		2.0310diarylmethane
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one
[no description available]		2.8930quinazolines
sesquiterpenes
[no description available]		2.4520
chlorprothixene
(E)-chlorprothixene : A chlorprothixene in which the double bond adopts an (E)-configuration.		2.8930chlorprothixene
chlorprothixene
Chlorprothixene: A thioxanthine with effects similar to the phenothiazine antipsychotics.. (Z)-chlorprothixene : A chlorprothixene in which the double bond adopts a (Z)-configuration.		3.6520chlorprothixene
etomidate
Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.		3.620ethyl ester;
imidazoles		intravenous anaesthetic;
sedative
mercaptopurine
Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.		4.4760aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
methylthiouracil
Methylthiouracil: A thiourea antithyroid agent that inhibits the synthesis of thyroid hormone. It is used in the treatment of hyperthyroidism.		2.0710pyrimidone
3,3',4,5'-tetrahydroxystilbene
3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.		2.0310catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
jrf 12
N2,N4-dibenzylquinazoline-2,4-diamine: a selective, potent, reversible, and ATP-competitive p97 inhibitor		3.1640
crotamiton
[no description available]		2.0710
levosulpiride
(S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).		2.0810sulpirideantidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
3,4'-dihydroxyflavone
3,4'-dihydroxyflavone: an antioxidant; structure in first source		2.610
rg108
RG108: DNA methyltransferase inhibitor; structure in first source		2.0810indolyl carboxylic acid
pyrantel
Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920). pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'.		3.23101,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes		antinematodal drug
3-(3,4-dimethoxyphenyl)propenoic acid
3-(3,4-dimethoxyphenyl)propenoic acid: structure given in first source; RN given refers to parent cpd. 3,4-dimethoxycinnamic acid : A methoxycinnamic acid that is trans-cinnamic acid substituted by methoxy groups at positions 3' and 4' respectively.		2.610methoxycinnamic acid
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester
[no description available]		2.8930methoxybenzenes;
substituted aniline
stf 083010
[no description available]		2.0810
isoferulic acid
isoferulic acid: isomer of ferulic acid; structure. isoferulic acid : A ferulic acid consisting of trans-cinnamic acid bearing methoxy and hydroxy substituents at positions 4 and 3 respectively on the phenyl ring.		2.610ferulic acidsantioxidant;
biomarker;
metabolite
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol
[no description available]		3.9730substituted aniline
3-hydroxypyridine, sodium salt
[no description available]		2.8930
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide
[no description available]		3.0740naphthalenecarboxamide
cyclouridine
cyclouridine: structure given in third source		2.610
5-[(2-bromoanilino)methyl]-8-quinolinol
[no description available]		2.8930hydroxyquinoline
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide
3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide: structure in first source		3.0640
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline
[no description available]		2.8930aromatic amine
flunarizine
Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.		2.0710diarylmethane
thiothixene
[no description available]		4.4430N-methylpiperazineanticoronaviral agent
eszopiclone
Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.		3.6120zopiclonecentral nervous system depressant;
sedative
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		4.5860aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
cct018159
CCT018159: structure in first source. CCT-018159 : A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively.		2.4820benzodioxine;
pyrazoles;
resorcinols		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide
[no description available]		2.8930piperidinecarboxamide
secinh3
SecinH3: a small molecule antagonist of cytohesins; structure in first source		2.0810triazoles
jk184
JK184: structure in first source		2.0810
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol
[no description available]		2.8930hydroxyquinoline
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide
[no description available]		2.8930acetamides;
anilide
benztropine
Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.		4.4430diarylmethane
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide
[no description available]		2.8930aromatic amide;
thiophenes
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone
[no description available]		2.8930dimethoxybenzene
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide
[no description available]		2.8930aromatic amide
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide
[no description available]		2.8930aromatic ether
methimazole
Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.		3.88301,3-dihydroimidazole-2-thionesantithyroid drug
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione
[no description available]		2.8930maleimides
Src Inhibitor-1
Src Inhibitor-1 : A member of the class of quinazolines that is quinazoline which is substituted at position 4 by a p-phenoxyanilino group and at positions 6 and 7 by methoxy groups. It is a potent, competitive dual site (both the ATP- and peptide-binding) Src kinase inhibitor. Src Inhibitor-1 is one of the 'gold standards' for Src kinase inhibition that has been shown to use PP1 or PP2 in parallel with Src-I1 to inhbit Src family kinases.		3.0440aromatic ether;
polyether;
quinazolines;
secondary amino compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one
[no description available]		2.8930dimethoxybenzene
cinnarizine
Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.		2.0810diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
sulindac
Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.		3.8830monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
zucapsaicin
[no description available]		2.610methoxybenzenes;
phenols
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		2.0710capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
enclomiphene
Enclomiphene: The trans or (E)-isomer of clomiphene.		2.2510
terbinafine
[no description available]		3.2310acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
epalrestat
epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.		2.0810monocarboxylic acid;
thiazolidines		EC 1.1.1.21 (aldehyde reductase) inhibitor
nbd 556
[no description available]		2.610
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide
[no description available]		2.8930quinolines
oxazolone
Oxazolone: Immunologic adjuvant and sensitizing agent.		2.0810
drotaverin
drotaverin: Hungarian drug; RN given refers to parent cpd; structure		2.0810isoquinolines
tg 003
TG 003: a Clk inhibitor; structure in first source		2.0310
xl147
[no description available]		2.1510aromatic amine;
benzothiadiazole;
quinoxaline derivative;
sulfonamide		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
[no description available]		2.8930pyrroles
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		4.16402-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
thiourea
Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.		2.520one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
thioacetamide
Thioacetamide: A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.. thioacetamide : A thiocarboxamide consiting of acetamide having the oxygen replaced by sulfur.		7.4110thiocarboxamidehepatotoxic agent
succimer
Succimer: A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.. succimer : A sulfur-containing carboxylic acid that is succinic acid bearing two mercapto substituents at positions 2 and 3. A lead chelator used as an antedote to lead poisoning.		3.2310dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid		chelator
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		3.9330cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
4,5,6,7-tetrachloroindan-1,3-dione
4,5,6,7-tetrachloroindan-1,3-dione: inhibits ubiquitin C-terminal hydrolase L1		2.610
streptozocin
[no description available]		3.2310
tamoxifen citrate
[no description available]		2.0810citrate saltangiogenesis inhibitor;
anticoronaviral agent
tamoxifen
[no description available]		5.66130stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
1-butyl-3-methylimidazolium
1-butyl-3-methylimidazolium: structure in first source. 1-butyl-3-methylimidazolium : A 1-alkyl-3-methylimidazolium in which the alkyl substituent at C-1 is butyl.		7.13101-alkyl-3-methylimidazolium
hc-067047
HC-067047: a TRPA1 antagonist; structure in first source		2.0810
bi-78d3
[no description available]		3.0740aryl sulfide
ethionamide
Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.		3.620pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
stattic
[no description available]		2.58201-benzothiophenes;
C-nitro compound;
sulfone		antineoplastic agent;
radiosensitizing agent;
STAT3 inhibitor
srpin340
SRPIN340: Serine-Arginine-Rich Protein Kinase Inhibitor		2.610
gsk 3787
[no description available]		2.0810
pr-619
[no description available]		2.610
p5091
P5091: inhibits ubiquitin-specific protease 7; structure in first source		2.610
S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate
[no description available]		3.4110acetylenic compound;
furans;
organofluorine compound;
thioester;
triazoles
kartogenin
kartogenin: promotes chondrocyte differentiation; structure in first source		2.8930
cancidas
[no description available]		4.2220
methyl-thiohydantoin-tryptophan
methyl-thiohydantoin-tryptophan: structure in first source		2.0810organonitrogen compound;
organooxygen compound
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester
[no description available]		2.0810monocarboxylic acid
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide
[no description available]		2.0810sulfonamide
fusidic acid
Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.		3.662011alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester		EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor
scopolamine
[no description available]		2.07103-hydroxy carboxylic acid
lincomycin
Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.		3.2310carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
valinomycin
Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.		2.0810cyclodepsipeptide;
macrocycle		antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore
trovirdine
trovirdine: HIV-1 reverse transcriptase inhibitor		2.610
ranitidine
Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.		3.620C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
aplaviroc
aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source		3.2310
hmr 3647
[no description available]		3.6120
latoconazole
latoconazole: RN refers to cpd without isomeric designation; latoconazole is (E)-isomer; structure given in first source		2.0810conazole antifungal drug;
imidazole antifungal drug
maraviroc
[no description available]		3.6120tropane alkaloid
LSM-1318
[no description available]		2.0810oxa-steroid
fti 277
[no description available]		2.610
toremifene citrate
[no description available]		2.0810stilbenoidanticoronaviral agent
toremifene
Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.		4.530aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
u 0126
U 0126: protein kinase kinase inhibitor; structure in first source		6.38111aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
rwj 67657
RWJ 67657: inhibits p38 mitogen-activated protein kinase; structure in first source		2.0810
vicriviroc
vicriviroc: structure in first source		2.610(trifluoromethyl)benzenes
telaprevir
[no description available]		2.7620cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
nelarabine
nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).		3.6120beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor;
prodrug
6-methyl-2-(phenylethynyl)pyridine
6-methyl-2-(phenylethynyl)pyridine: an mGlu5 antagonist. 2-methyl-6-(phenylethynyl)pyridine : A methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.		2.0810acetylenic compound;
methylpyridines		anxiolytic drug;
metabotropic glutamate receptor antagonist
bms 387032
N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.		4.84701,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
dermatan sulfate
Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed). alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.. dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units.		3.2310amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate
nizatidine
Nizatidine: A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.. nizatidine : A member of the class of 1,3-thiazoles having a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl moiety at position 4.		2.0710
dolasetron
[no description available]		3.2310indolyl carboxylic acid
almokalant
almokalant: structure given in first source		2.0710
gestodene
Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer		2.0810steroidestrogen
orlistat
Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.		3.9530beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine
[no description available]		3.8830cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
sf 2370
SF 2370: indolocarbazole isolated from Actinomadura sp. SF-2370; structure given in first source. K-252a : A organic heterooctacyclic compound that is a potent inhibitor of protein kinase C and is isolated from Nocardiopsis sp K-252a		2.5220bridged compound;
gamma-lactam;
methyl ester;
organic heterooctacyclic compound		antimicrobial agent;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
tropomyosin-related kinase B receptor antagonist
ly335979
[no description available]		2.0510carbopolycyclic compound
fospropofol
[no description available]		3.2310alkylbenzene
tandutinib
[no description available]		4.9580aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745
[no description available]		5.35120aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
corlanor
ivabradine hydrochloride : A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure.		2.0810hydrochloridecardiotonic drug
azilect
[no description available]		2.0810
rasagiline
[no description available]		3.2310indanes;
secondary amine;
terminal acetylenic compound		EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent
deracoxib
SC 046: structure in first source. deracoxib : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3, and 5 by 4-sulfamoylphenyl, difluoromethyl and 3-fluoro-4-methoxyphenyl groups, respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs.		2.0710organofluorine compound;
pyrazoles;
sulfonamide		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ha 1100
HA 1100: intracellular calcium antagonist		2.1510
7-epi-hydroxystaurosporine
[no description available]		2.1510
2-aminohippuric acid
[no description available]		2.0710N-acylglycine
zd 6474
CH 331: structure in first source		10.68203aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
salinomycin
salinomycin: from Streptomyces albus; RN given refers to parent cpd; structure		7.2510polyketide;
spiroketal		animal growth promotant;
potassium ionophore
N-methyl-2-[[3-[2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide
[no description available]		2.0610aryl sulfide
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
[no description available]		2.8330indoles
compound 968
compound 968: a glutaminase inhibitor. 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one : A partially hydrogenated benzophenanthridine carrying an oxo group at C-4, geminal methyl groups at C-2 and a 3-bromo-4-(dimethylamino)phenyl group at C-5.		2.0810benzophenanthridineEC 3.5.1.2 (glutaminase) inhibitor
yya-021
YYA-021: an HIV entry inhibitor; structure in first source		2.610
N-(4-Butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-pyridin-3-ylethyl]furan-2-carboxamide
[no description available]		3.4110aromatic amide;
furans		anticoronaviral agent
nih-12848
NIH-12848: inhibits phosphatidylinositol 5-phosphate 4-kinase gamma; structure in first source		2.8930
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide
[no description available]		2.8930quinazolines
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone
[no description available]		2.8930benzimidazoles
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile
[no description available]		2.8930imidazopyridine
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
[no description available]		2.8930aromatic ketone
ovalbumin
Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.		3.0240
rs-130830
RS-130830: orally-active broad-spectrum matrix metalloproteinase inhibitor		2.0710
sb-224289
SB 224289 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid with the secondary amino group of 1'-methyl-6,7-dihydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine]. Selective 5-HT1B receptor antagonist (pKi = 8.2). Displays >60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. Centrally active following oral administration in vivo.		2.08101,2,4-oxadiazole;
azaspiro compound;
benzamides;
organic heterotetracyclic compound		serotonergic antagonist
1,8-dinitro-4,5-dihydroxyanthraquinone
1,8-dinitro-4,5-dihydroxyanthraquinone: structure in first source		3.1910
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester
[no description available]		2.8930oxopurine
gtp 14564
[no description available]		2.0310pyrazoles;
ring assembly
sb 218078
[no description available]		2.0310indolocarbazole
gw 7647
GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.		2.0810aryl sulfide;
monocarboxylic acid;
ureas		PPARalpha agonist
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester
[no description available]		2.8930organonitrogen compound;
organosulfur compound
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide
[no description available]		2.8930quinolines
8-(Trifluoromethyl)-9H-purin-6-amine
[no description available]		2.15106-aminopurinesanticoronaviral agent
l 663536
MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.		2.0810aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
LSM-1924
[no description available]		2.8930organic heterotricyclic compound;
organooxygen compound
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine
[no description available]		2.0810imidazoles
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine
[no description available]		2.0810aromatic amine;
tertiary amino compound
ferrostatin-1
ferrostatin-1: inhibits ferroptosis, an iron-dependent form of nonapoptotic cell death; structure in first source. ferrostatin-1 : An ethyl ester resulting from the formal condensation of the carboxy group of 3-amino-4-(cyclohexylamino)benzoic acid with ethanol. It is a potent inhibitor of ferroptosis, a distinct non-apoptotic form of cell death caused by lipid peroxidation. It is also a radical-trapping antioxidant and has the ability to reduce the accumulation of lipid peroxides and chain-carrying peroxyl radicals.		2.8930ethyl ester;
primary arylamine;
substituted aniline		antifungal agent;
antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radiation protective agent;
radical scavenger
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester
[no description available]		2.0810isoquinolines
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor. TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease.		3.2250benzenes;
thiadiazolidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
sb 415286
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source		2.5920C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline		antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		2.6320
4-methylene-2-octyl-5-oxo-3-oxolanecarboxylic acid
4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid : A tetrahydrofuranone that is tetrahydrofuran substituted by octyl, carboxy, methylidene, and oxo groups at positions 2, 3, 4 and 5, respectively.		3.2310gamma-lactone;
monocarboxylic acid;
tetrahydrofuranone
sch 79797
[no description available]		2.0810quinazolines
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine
[no description available]		2.8930C-nitro compound
sitagliptin
sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.		4.3150triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
ver-49009
VER-49009: inhibits heat shock protein 90 molecular chaperone; structure in first source. 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)pyrazole-3-carboxamide : An aromatic amide obtained by formal condensation of the carboxy group of 5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)pyrazole-3-carboxylic acid with the amino group of ethylamine.		2.0610aromatic amide;
monochlorobenzenes;
monomethoxybenzene;
pyrazoles;
resorcinols		Hsp90 inhibitor
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor		4.5450benzamides;
benzodioxoles;
imidazoles;
pyridines		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
rabeprazole(1-)
[no description available]		2.6320organic nitrogen anion
tolcapone
Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.		4.13402-nitrophenols;
benzophenones;
catechols		antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one
[no description available]		2.0810monobactam
alsterpaullone
alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.		4.8550C-nitro compound;
caprolactams;
organic heterotetracyclic compound		anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor
imd 0354
N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source		2.7830benzamides
ex 527
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.		2.0810carbazoles;
monocarboxylic acid amide;
organochlorine compound
ncgc00099374
[no description available]		2.8930
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide
[no description available]		2.8930benzamides
sq 109
N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine: has antitubercular activity		3.5110
tak-220
TAK-220: structure in first source		2.610
jtk-303
[no description available]		2.610aromatic ether;
monochlorobenzenes;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		HIV-1 integrase inhibitor
nbd 557
[no description available]		2.610
sphingosine
sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.		2.4620sphing-4-eninehuman metabolite;
mouse metabolite
quercetin
[no description available]		11.725727-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.0710prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
acacetin
5,7-dihydroxy-4'-methoxyflavone : A monomethoxyflavone that is the 4'-methyl ether derivative of apigenin.		2.0610dihydroxyflavone;
monomethoxyflavone		anticonvulsant;
plant metabolite
apigenin
Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.		8.9530trihydroxyflavoneantineoplastic agent;
metabolite
luteolin
[no description available]		4.23403'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
calcitriol
dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes		3.6120D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
quercitrin
[no description available]		3.1910alpha-L-rhamnoside;
monosaccharide derivative;
quercetin O-glycoside;
tetrahydroxyflavone		antileishmanial agent;
antioxidant;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
plant metabolite
vitamin k semiquinone radical
vitamin K semiquinone radical: found in active preparations of vitamin K-dependent carboxylase. vitamin K : Any member of a group of fat-soluble 2-methyl-1,4-napthoquinones that exhibit biological activity against vitamin K deficiency. Vitamin K is required for the synthesis of prothrombin and certain other blood coagulation factors.		2.0710
beta carotene
beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.		2.0710carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
daphnetin
[no description available]		2.0310hydroxycoumarin
5'-o-caffeoylquinic acid
trans-5-O-caffeoyl-D-quinic acid : A cinnamate ester obtained by formal condensation of the carboxy group of trans-caffeic acid with the 5-hydroxy group of quinic acid.		2.610cinnamate ester;
cyclitol carboxylic acid		plant metabolite
luteolin-7-glucoside
luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.610beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite
alprostadil
[no description available]		2.0810prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
cyclosporine
[no description available]		2.7220
vitamin d 2
Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.		3.6120hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide
cholecalciferol
Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.		3.4110D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
rutin
Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.		3.1910disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite
kaempferol
[no description available]		2.89307-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
alpha-linolenic acid
linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.. linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid.		2.0810linolenic acid;
omega-3 fatty acid		micronutrient;
mouse metabolite;
nutraceutical
harmine
Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.		2.610harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
genistein
[no description available]		4.64707-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		4.2220antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
pulmicort
Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.		3.612011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
oxymetholone
Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed). oxymetholone : A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.		3.6120
pyrvinium
pyrvinium: RN given refers to parent cpd; synonyms vanquin & vankin refer to pamoate[2:1]; structure in Merck Index, 9th ed, #7810. pyrvinium : A quinolinium ion that is 1-methylquinolinium substituted by dimethylamino group at position 6 and a (E)-2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl at position 2. It is a anthelminthic drug active against pinworms. The salts of pyrvinium can also be used as anticancer agents.		2.1110quinolinium ionanthelminthic drug;
antineoplastic agent
eprosartan
eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.		3.9530dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
montelukast
montelukast: a leukotriene D4 receptor antagonist		3.6120aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
mivacurium
Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.		3.2310isoquinolines
brompheniramine maleate
brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		2.0810maleate saltanti-allergic agent
dexchlorpheniramine maleate
[no description available]		2.0810organic molecular entity
olopatadine
[no description available]		2.0810
hemabate
carboprost tromethamine : The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.		3.2310
mycophenolate mofetil
mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.		4.5360carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
entacapone
entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.		3.95302-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol
[no description available]		3.2310hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug
bruceantin
[no description available]		2.8930triterpenoid
garcinol
garcinol: from stem bark of Garcinia huillensis; has chemotherapeutic activity against gram-positive & gram-negative cocci, mycobacteria & fungi		2.2510
amentoflavone
[no description available]		3.9220biflavonoid;
hydroxyflavone;
ring assembly		angiogenesis inhibitor;
antiviral agent;
cathepsin B inhibitor;
P450 inhibitor;
plant metabolite
baicalein
[no description available]		2.610trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
chrysin
chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.		2.89307-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
diosmetin
[no description available]		3.51103'-hydroxyflavonoid;
monomethoxyflavone;
trihydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
bone density conservation agent;
cardioprotective agent;
plant metabolite;
tropomyosin-related kinase B receptor agonist;
vasodilator agent
fisetin
[no description available]		7.82203'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
genkwanin
genkwanin: structure. genkwanin : A monomethoxyflavone that is apigenin in which the hydroxy group at position 7 is methylated.		2.610dihydroxyflavone;
monomethoxyflavone		metabolite
hyperoside
quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity.		3.6920beta-D-galactoside;
monosaccharide derivative;
quercetin O-glycoside;
tetrahydroxyflavone		hepatoprotective agent;
plant metabolite
mangostin
mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.		2.610aromatic ether;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite
3-methylquercetin
isorhamnetin : A monomethoxyflavone that is quercetin in which the hydroxy group at position 3' is replaced by a methoxy group.		2.6107-hydroxyflavonol;
monomethoxyflavone;
tetrahydroxyflavone		anticoagulant;
EC 1.14.18.1 (tyrosinase) inhibitor;
metabolite
kaempferide
kaempferide: structure in first source. kaempferide : A monomethoxyflavone that is the 4'-O-methyl derivative of kaempferol.		2.6107-hydroxyflavonol;
monomethoxyflavone;
trihydroxyflavone		antihypertensive agent;
metabolite
orientin
orientin: structure given in first source; RN given refers to the (D-glucopyranosyl)-isomer. orientin : A C-glycosyl compound that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 8.		2.6103'-hydroxyflavonoid;
C-glycosyl compound;
tetrahydroxyflavone		antioxidant;
metabolite
scutellarein
scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.		2.610tetrahydroxyflavonemetabolite
daidzein
[no description available]		2.89307-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
trans-2,3',4,5'-tetrahydroxystilbene
trans-2,3',4,5'-tetrahydroxystilbene: hydroxystilbene oxyresveratrol		2.610stilbenoid
polydatin
trans-piceid : A stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue.		2.610beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid		anti-arrhythmia drug;
antioxidant;
geroprotector;
hepatoprotective agent;
metabolite;
nephroprotective agent;
potassium channel modulator
chicoric acid
chicoric acid: inhibits HIV-1 integrase		2.610organooxygen compoundgeroprotector;
HIV-1 integrase inhibitor
gingerenone a
gingerenone A: has antineoplastic activity; isolated from Zingiber officinale; structure in first source		2.4110diarylheptanoid
caffeic acid phenethyl ester
phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.		2.5520alkyl caffeate esteranti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent
acteoside
acteoside: a protein kinase C inhibitor with hepatoprotective, anti-asthmatic, and analgesic activities; a phenylethanoid glycoside related to isoacteoside; from leaves of Lippia multiflora (Verbenaceae). acteoside : A glycoside that is the alpha-L-rhamnosyl-(1->3)-beta-D-glucoside of hydroxytyrosol in which the hydroxy group at position 4 of the glucopyranosyl moiety has undergone esterification by formal condensation with trans-caffeic acid.		2.610catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol		anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite
wedelolactone
wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source. wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3.		2.0310aromatic ether;
coumestans;
delta-lactone;
polyphenol		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
hepatoprotective agent;
metabolite
rottlerin
rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.		2.4110aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
savinin
savinin: a lignan from Pterocarpus santalinus inhibits tumor necrosis factor-alpha production and T cell proliferation; structure in first source. savinin : A lignan that is dihydrofuran-2(3H)-one (gamma-butyrolactone) substituted by a 1,3-benzodioxol-5-ylmethylidene group at position 3 and a 1,3-benzodioxol-5-ylmethyl group at position 4 (the 3E,4R-isomer). It exhibits antiviral activity against SARS-CoV-2.		3.4110benzodioxoles;
gamma-lactone;
lignan		anti-inflammatory agent;
anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
plant metabolite;
T-cell proliferation inhibitor
sdz psc 833
valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215		2.0510homodetic cyclic peptide
l 660,711
[no description available]		3.6620quinolines
tectochrysin
tectochrysin: structure in first source. tectochrysin : A monohydroxyflavone that is flavone substituted by a hydroxy group at position 4 and a methoxy group at position 7 respectively.		3.5110monohydroxyflavone;
monomethoxyflavone		antidiarrhoeal drug;
antineoplastic agent;
plant metabolite
pheniramine maleate
Naphcon A: tradename; contains above compounds; ophthalmic solution		2.0710organic molecular entity
travoprost
Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.. travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.		2.0810(trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha		antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist
tranilast
tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group.		2.5820amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide		anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent
7432 s
Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections.. ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections.		3.2310cephalosporin;
dicarboxylic acid		antibacterial drug
imipenem
[no description available]		2.0810carbapenems
etretinate
retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.		2.0810enoate ester;
ethyl ester;
retinoid		keratolytic drug
isotretinoin
Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.		3.6120retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
ketotifen fumarate
ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug.		2.0810organoammonium saltanti-asthmatic drug;
H1-receptor antagonist
epoprostenol
[no description available]		3.2310prostaglandins Imouse metabolite
indocyanine green
[no description available]		3.23101,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
dinoprost tromethamine
[no description available]		2.0810organic molecular entity
dothiepin hydrochloride
Dothiepin: A tricyclic antidepressant with some tranquilizing action.		3.4110dothiepin
neticonazole
neticonazole: RN refers to (E)-isomer. neticonazole : An enamine that is ethene which is substituted at positions 1, 1, and 2 by o-pentoxyphenyl, 1H-imidazol-1-yl, and methylthio groups, respectively (the E isomer). An inhibitor of P450-dependent C-14alpha-demethylation of lanosterol (preventing conversion to ergosterol and inhibiting cell wall synthesis in fungi), it is used in Japan (generally as the corresponding hydrochloride salt) as an antifungal drug for the treatment of superficial skin infections.		2.8930aromatic ether;
benzenes;
conazole antifungal drug;
enamine;
imidazole antifungal drug;
imidazoles;
methyl sulfide		antifungal drug;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
triprolidine
Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.		3.620N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
pitavastatin
pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.		3.2310cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant
rosuvastatin calcium
S 4522: structure in first source		2.0810N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt		anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor
terbinafine hydrochloride
terbinafine hydrochloride : A hydrochloride obtained by reaction of terbinafine with one molar equivalent of hydrogen chloride.		2.0810allylamine antifungal drug;
hydrochloride		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor
ethamolin
monoethanolamine oleate: used for treatment of pyogenic granuloma		3.2310long-chain fatty acid
alatrofloxacin mesylate
[no description available]		3.2310
homatropine
[no description available]		2.0710tropane alkaloid
4-hydroxy-2-nonenal
4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.		2.25104-hydroxynon-2-enal;
4-hydroxynonenal
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine
synaptamide: structurally similar to the endocannabinoid N-arachidonoylethanolamine (anandamide). N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine : An N-acylethanolamine 22:6 that is the ethanolamide of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid.		2.8930endocannabinoid;
N-acylethanolamine 22:6
n-oleoylethanolamine
N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.		2.8930endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1		EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist
codeine
[no description available]		3.2310morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		4.6540homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
natamycin
[no description available]		2.0810antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic		antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug
acitretin
Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.		3.6120acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid		keratolytic drug
dorzolamide
dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.		2.610sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
estropipate
estropipate: used therapeutically in menopausal patients		3.2310piperazinium salt;
steroid sulfate
hydromorphone
Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.		3.2310morphinane alkaloid;
organic heteropentacyclic compound		mu-opioid receptor agonist;
opioid analgesic
levetiracetam
Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.		3.8830pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
ly 163892
loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.		3.2310carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
nabilone
nabilone: cannabinol deriv; RN given refers to cpd without isomeric designation; structure		3.2310
nalmefene
nalmefene: RN given refers to 5-alpha isomer		2.0810morphinane alkaloid
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		3.8830morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
oxycodone
Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.		3.2310organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
oxymorphone
Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)		3.2310morphinane alkaloid
vitamin k 1
Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.		3.6920phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
proscillaridin
Proscillaridin: A cardiotonic glycoside isolated from Scilla maritima var. alba (Squill).		2.0510organic molecular entity
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		8.65221antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
topiramate
Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.		4.1440cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
trospium chloride
trospium chloride : An organic chloride salt of trospium. It is an antispasmodic drug used for the treatment of overactive bladder.		3.2310
alpha-zearalenol
[no description available]		2.8930macrolide
alvocidib
alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.		6.180dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fenretinide
Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.		3.6120monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
topiroxostat
FYX-051: xanthine oxidoreductase inhibitor		3.5110
geldanamycin
[no description available]		2.03101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound		antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: structure in first source. alvespimycin : A 19-membered macrocyle that is geldanamycin in which the methoxy group attached to the benzoquinone moiety has been replaced by a 2-(N,N-dimethylamino)ethylamino group.		3.45111,4-benzoquinones;
ansamycin;
carbamate ester;
secondary amino compound;
tertiary amino compound		Hsp90 inhibitor
morphine
Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.		3.7320morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
demycarosylturimycin h
[no description available]		2.0810
su 5402
SU 5402: structure given in first source. SU5402 : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 3-(2-carboxyethyl)-4-methyl-1H-pyrrol-2-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.		2.4920
su 9516
[no description available]		3.0440
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
[no description available]		2.8930triazolopyrimidines
ter 199
[no description available]		2.0810
ar c67085mx
PSB-0413: a selective antagonist radioligand for platelet P2Y12 receptors		2.0710
acipimox
acipimox: lipolysis inhibitor		2.0810pyrazinecarboxylic acid
arachidonylcyclopropylamide
arachidonylcyclopropylamide: a potent and selective agonist of neuronal cannabinoid receptor; structure in first source		2.0810
atosiban
[no description available]		2.0810oligopeptide
benzphetamine
Benzphetamine: A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222). benzphetamine : Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.		3.2310amphetamines;
tertiary amine		adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent
bimatoprost
Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.		2.0810monocarboxylic acid amideantiglaucoma drug;
antihypertensive agent
deamino arginine vasopressin
Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.		3.2310heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
desoximetasone
Desoximetasone: A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.. desoximetasone : Dexamethasone in which the hydroxy group at the 17alpha position is substituted by hydrogen. A synthetic corticosteroid with glucocorticoid activity, it is used as an anti-inflammatory and anti-pruritic in the treatment of various skin disorders, including skin allergies and psoriasis.		2.071011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
dexmedetomidine
[no description available]		3.2310medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
sb 277011
SB 277011: structure in first source		2.8930
fluticasone
Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.. fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.		2.61011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
pd 180970
PD 180970: inhibits p210(Bcr-Abl) tyrosine kinase; structure in first source		3.8330
goserelin
Goserelin: A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.		3.2310organic molecular entity
benzyloxycarbonyl-phe-ala-fluormethylketone
cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).		2.610
iloprost
Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.		2.0810carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
latanoprost
Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.		2.0810isopropyl ester;
prostaglandins Falpha;
triol		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug
ly 320135
LY 320135: cannabinoid receptor antagonist; structure in first source		2.0810benzofurans
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester
DAPT : A dipeptide consisting of alanylphenylglycine derivatised as a 3,5-difluorophenylacetamide at the amino terminal and a tert-butyl ester at the carboxy terminal. A gamma-secretase inhibitor.		2.610carboxylic ester;
difluorobenzene;
dipeptide;
tert-butyl ester		EC 3.4.23.46 (memapsin 2) inhibitor
nalbuphine
Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.		3.2310organic heteropentacyclic compoundmu-opioid receptor antagonist;
opioid analgesic
nateglinide
Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.		3.6120phenylalanine derivative
pd 166285
[no description available]		3.0140
sb 223412
SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source		3.0640
sr 59230a
[no description available]		2.8930tetralins
vinorelbine
[no description available]		3.2310acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide
[no description available]		3.460pyrimidines
kn 93
KN 93: reduces dopamine content in PC12h cells. KN-93 : A sulfonamide resulting from the formal condensation of p-methoxybenzenesulfonic acid with the anilino nitrogen of 2-(aminomethyl)-N-(2-hydroxyethyl)aniline in which the hydrogens of the primary amino group have been replaced by methyl and p-chlorocinnamyl groups. KN-93 is a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II.		2.0310monochlorobenzenes;
monomethoxybenzene;
primary alcohol;
sulfonamide;
tertiary amino compound		EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor;
geroprotector
silodosin
silodosin: an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source		3.2310indolecarboxamide
kn 62
KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II		3.0740piperazines
su 6656
SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.		4.5670
casticin
casticin: from fruit of Vitex rotundifolia; structure in second source. casticin : A tetramethoxyflavone that consists of quercetagetin in which the hydroxy groups at positions 3, 6, 7 and 4' have been replaced by methoxy groups. It has been isolated from Eremophila mitchellii.		2.610dihydroxyflavone;
tetramethoxyflavone		apoptosis inducer;
plant metabolite
MeJA
[no description available]		2.8930Jasmonate derivatives
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one: isolated from the Chinese herb Scutellariae radix. oroxylin A : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-6.		2.610dihydroxyflavone;
monomethoxyflavone		antineoplastic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor
spiraeoside
spiraeoside: from flowers of Filipendula ulmaria (L.); structure given in first source. quercetin 4'-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 4'.		3.1910beta-D-glucoside;
flavonols;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone		antineoplastic agent;
antioxidant;
plant metabolite
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside
2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside: Tyrosinase inhibitor from Polygonum multiflorum; structure in first source. (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside : A stilbenoid that is trans-stilbene which has been substituted by hydroxy groups at positions 2, 3, 5, and 4', and in which the hydroxy group at positon 2 has then been converted to the corresponding the beta-D-glucoside.		2.610beta-D-glucoside;
resorcinols;
stilbenoid		anti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
cyclooxygenase 2 inhibitor;
platelet aggregation inhibitor
fluvoxamine
Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.		3.2310(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
casein kinase ii
Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.		4.1740
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)-
1H-pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-: structure in first source		2.8930
pd 161570
PD 161570: structure in first source		2.8930
ag 538
AG 538: an IGF-1 receptor kinase inhibitor; structure in first source		2.0710
ag 99
tyrphostin A46: epidermal growth factor-urogastrone receptor antagonist		2.0310
tyrphostin ag 555
[no description available]		2.610
tyrphostin ag-494
AG 494: tyrphostin that blocks Cdk2 activation; structure in first source		2.0310
ag-490
[no description available]		2.0310catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide		anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor
bosutinib
4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile: a Src kinase inhibitor; structure in first source		15.081073aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
semaxinib
semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.		2.0810olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
orantinib
orantinib: an antiangiogenic agent. orantinib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.		2.1510
su 11248
[no description available]		13.44682monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
su 11652
SU 11652: a tyrosine kinase inhibitor; amino acid sequence in first source. SU11652 : A member of the class of pyrrolecarboxamides obtained by formal condensation of the carboxy group of 5-[(Z)-(5-chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethylpyrrole-3-carboxylic acid with the primary amino group of N(1),N(1)-diethylethane-1,2-diamine.		2.4420olefinic compound;
organochlorine compound;
oxindoles;
pyrrolecarboxamide;
tertiary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor
m475271
AZM475271: a Src family kinase inhibitor		2.2110
palbociclib
[no description available]		4.8690aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621
[no description available]		5.0890sulfonamide
fosbretabulin
fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source		2.5320
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.		3.6120dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
molsidomine
[no description available]		2.0810ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
pd 151746
[no description available]		2.610
levorphanol
Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.		3.2310morphinane alkaloid
arsenic
Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)		4.3430metalloid atom;
pnictogen		micronutrient
naltrexone
Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.		3.620cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
dextromethorphan
Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.		3.23106-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
butorphanol
Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.		3.6120morphinane alkaloidantitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
cefixime
[no description available]		3.8830cephalosporinantibacterial drug;
drug allergen
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		3.9530dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril
benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.		3.2310benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
ramipril
Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.		3.6120azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
verteporfin
(2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.		3.7320
batimastat
batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor. batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor.		2.610hydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide		angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		3.9530dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
sulfur
Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.		2.3110chalcogen;
nonmetal atom		macronutrient
geldanamycin
[no description available]		2.0510
zimeldine
Zimeldine: One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)		3.620styrenes
3,3',4,5'-tetramethoxy-trans-stilbene
(E)-3,4,3',5'-tetramethoxystilbene: from the leaves of Eugenia rigida; structure in first source		3.5110
virginiamycin factor s1
virginiamycin factor S1: a component of VIRGINIAMYCIN; was EP to VIRGINIAMYCIN 1992-2001. virginiamycin S1 : A cyclodepsipeptide that is N-(3-hydroxypicolinoyl)-L-threonyl-D-alpha-aminobutyryl-L-prolyl-N-methyl-L-phenylalanyl-4-oxo-L-pipecoloyl-L-2-phenylglycine in which the carboxy group of the 2-phenylglycine moiety has undergone formal intramolecular condensation with the hydroxy group of the N-(3-hydroxypicolinoyl)-L-threonyl to give the corresponding 19-membered ring lactone. It is one of the two major components of the antibacterial drug virginiamycin, produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others.		2.8930cyclodepsipeptide;
macrolide antibiotic		antibacterial drug;
bacterial metabolite
enalapril maleate
enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.		2.0810maleate saltantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
enalapril
Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).		3.5820dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
nitrofurazone
Nitrofurazone: A topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial WOUNDS AND INJURIES and skin infections. Nitrofurazone has also been administered orally in the treatment of TRYPANOSOMIASIS.. nitrofurazone : A semicarbazone resulting from the formal condensation of semicarbazide with 5-nitrofuraldehyde. A broad spectrum antibacterial drug, although with little activity against Pseudomonas species, it is used as a local application for burns, ulcers, wounds and skin infections.		2.0810
trientine hydrochloride
[no description available]		3.2310
n-methylscopolamine bromide
scopolamine methobromide : A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.		3.2310
cisplatin
[no description available]		2.0810diamminedichloroplatinumantineoplastic agent;
apoptosis inducer;
cross-linking reagent;
ferroptosis inducer;
genotoxin;
mutagen;
nephrotoxin;
photosensitizing agent
bleomycin
[no description available]		3.2310bleomycinantineoplastic agent;
metabolite
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		2.4110cysteiniumfundamental metabolite
enalaprilat anhydrous
Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.		3.8830dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
solanesol
solanesol : A nonaprenol that is hexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-ol substituted by 9 methyl groups at positions 3, 7, 11, 15, 19, 23, 27, 31 and 35 (the all-trans0stereoisomer).		2.610nonaprenol;
primary alcohol		plant metabolite
alanyl-alanyl-alanine
alanyl-alanyl-alanine: RN given refers to all (L)-isomer. Ala-Ala-Ala : A tripeptide composed of three L-alanine units joined by peptide linkages.		2.2110tripeptidemetabolite
pepstatin
pepstatin: inhibits the aspartic protease endothiapepsin		2.610pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
ximelagatran
ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.		3.2310amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor
cefuroxime
[no description available]		3.23103-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether		drug allergen
ceftriaxone
[no description available]		3.87301,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime
Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		3.2310cephalosporin;
oxime O-ether		antibacterial drug
l 685458
L 685458: a gamma-secretase inhibitor; structure in first source. L-685,458 : A peptide and carboxamide that is L-leucyl-L-phenylalaninamide, L-Leu-L-Phe-NH2, which has been acylated on the N-terminus by a Phe-Phe hydroxyethylene dipeptide isotere, 2R-benzyl-5S-tert-butoxycarbonylamino-4R-hydroxy-6-phenylhexanoic acid. Compounds based on the structure of L-685,458 are potent inhibitors of gamma-secretase, which mediates the final catalytic step that generates the amyloid beta-peptide (Abeta), which assembles into the neurotoxic aggregates in the brains of sufferers of Alzheimer's disease.		2.610carbamate ester;
monocarboxylic acid amide;
peptide;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor;
peptidomimetic
pafuramidine
pafuramidine: a prodrug of furamidine		3.2310
ceftazidime
[no description available]		3.2310cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril
trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.		3.6120dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
pregabalin
Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.		3.6120gamma-amino acidanticonvulsant;
calcium channel blocker
tiotropium
tiotropium : A quaternary ammonium ion obtained by methylation of the tertiary amino group of (1alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane. Used (in the form of the bromide hydrate) for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.		2.0710
alvimopan anhydrous
alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain		3.6120peptide
avicularin
avicularin: from Polygonum aviculare L.; RN given refers to L-isomer. avicularin : A quercetin O-glycoside in which an alpha-L-arabinofuranosyl residue is attached at position 3 of quercetin via a glycosidic linkage. It is isolated particularly from Juglans regia and Foeniculum vulgare.		3.1910alpha-L-arabinofuranoside;
monosaccharide derivative;
quercetin O-glycoside;
tetrahydroxyflavone		hepatoprotective agent;
plant metabolite
aliskiren
aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.		3.2310monocarboxylic acid amide;
monomethoxybenzene		antihypertensive agent
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one: a janus-activated kinase inhibitor. 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one : An organic heterotetracyclic compound that is 1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one bearing additional tert-butyl and fluoro substituents at positions 2 and 9 respectively.		2.7330organic heterotetracyclic compound;
organofluorine compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
vx680
[no description available]		8.09220N-arylpiperazine
bms 806
BMS 806: prevents entry of HIV into cells by binding HIV envelope protein gp120; no further info available 4/2002		2.610
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
[no description available]		2.610
guanabenz
Guanabenz: An alpha-2 selective adrenergic agonist used as an antihypertensive agent.		2.4620dichlorobenzene
famotidine
[no description available]		3.61201,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
fenoterol
fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.		2.6320hydrobromidebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
tulobuterol hydrochloride
[no description available]		2.610organic molecular entity
xib 4035
XIB 4035: a GFRalpha-1 agonist; structure in first source		2.8930
carbocyanines
Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.		2.6320cyanine dye;
organic iodide salt		fluorochrome
salubrinal
salubrinal: prevents dephosphorylation of eIF2alpha; structure in first source. salubrinal : A member of the class of quinolines that is a mixed aminal resulting from the formal condensation oftrichloroacetaldehyde with the amide nitrogen of trans-cinnamamide and the primary amino group of 1-quinolin-8-ylthiourea. It is a selective inhibitor of cellular complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit alpha (eIF2alpha).		2.610aminal;
organochlorine compound;
quinolines;
secondary carboxamide;
thioureas
cefotaxime
Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.		3.23101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
aztreonam
[no description available]		3.2310beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
nw 1029
Ralfinamide: Sodium Channel Blocker; structure in first source		2.0710
viroxime
[no description available]		2.4110
gw-5074
[no description available]		2.2110
st 638
[no description available]		2.0310
su 1498
SU 1498: structure in first source. SU1498 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2E)-2-cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]prop-2-enoic acid with the amino group of 3-phenylpropylamine.		2.0310enamide;
monocarboxylic acid amide;
nitrile;
phenols;
secondary carboxamide		vascular endothelial growth factor receptor antagonist
proguanil
Proguanil: A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.. proguanil : A biguanide compound which has isopropyl and p-chlorophenyl substituents on the terminal N atoms. A prophylactic antimalarial drug, it works by inhibiting the enzyme dihydrofolate reductase, which is involved in the reproduction of the malaria parasites Plasmodium falciparum and P. vivax within the red blood cells.		3.5110biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
cci 15641
[no description available]		2.0810cephalosporin
22,23-dihydroavermectin b(1)a
22,23-dihydroavermectin B(1)a: C48H74O14; major component of IVERMECTIN; MW 875.093; structure given in first source. 22,23-dihydroavermectin B1a : A macrocyclic lactone that is avermectin B1a in which the double bond present in the spirocyclic ring system has been reduced to a single bond. It is the major component of ivermectin.		3.5110macrocyclic lactone;
spiroketal
monorden
monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II		2.0310cyclic ketone;
enone;
epoxide;
macrolide antibiotic;
monochlorobenzenes;
phenols		antifungal agent;
metabolite;
tyrosine kinase inhibitor
ro 42-5892
remikiren : An L-histidine derivative that is L-histidine in which one of the amino hydrogens is replaced by a (2S)-2-[(2-methylpropane-2-sulfonyl)methyl]-3-phenylpropanoyl group and the carboxy group is replaced by a [(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino group. It is a renin inhibitor which was under development for the treatment of hypertension (now discontinued).		2.0510cyclopropanes;
diol;
L-histidine derivative;
secondary carboxamide;
sulfone		antihypertensive agent;
EC 3.4.23.15 (renin) inhibitor;
peptidomimetic;
vasodilator agent
radium
Radium: A radioactive element of the alkaline earth series of metals. It has the atomic symbol Ra and atomic number 88. Radium is the product of the disintegration of URANIUM and is present in pitchblende and all ores containing uranium. It is used clinically as a source of beta and gamma-rays in radiotherapy, particularly BRACHYTHERAPY.		4.1120alkaline earth metal atom
oxalates
Oxalates: Derivatives of OXALIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are derived from the ethanedioic acid structure.		3.1610
cefpodoxime
[no description available]		3.2310carboxylic acid;
cephalosporin		antibacterial drug
palonosetron
Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.		3.2310azabicycloalkane;
delta-lactam;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
tenofovir disoproxil fumarate
tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.		2.0810fumarate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
ml 3403
[no description available]		2.0310
d 4476
[no description available]		2.4620imidazoles
GSK3-XIII
GSK3-XIII : A member of the class of aromatic amines that is ammonia with two of the hydrogens replaced by 5-methylpyrazol-3-yl and 2-phenylquinazolin-4-yl groups.		2.0310aromatic amine;
pyrazoles;
quinazolines;
secondary amino compound		EC 2.7.11.26 (tau-protein kinase) inhibitor
cyc 116
4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: an aurora kinase inhibitor; structure in first source		3.0140
bay 19-8004
BAY 19-8004: a PDE4 inhibitor; structure in first source		2.0810
dexbrompheniramine maleate
dexbrompheniramine maleate : The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		2.0810brompheniramine maleateanti-allergic agent;
H1-receptor antagonist
tiacrilast
tiacrilast: structure given in first source		2.0510
rifaximin
[no description available]		3.6120acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative		antimicrobial agent;
gastrointestinal drug;
orphan drug
bafilomycin a1
bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.		2.0510cyclic hemiketal;
macrolide antibiotic;
oxanes		apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin
germacrone
germacrone: isolated from Curcuma wenyujin		2.610germacrane sesquiterpenoid;
olefinic compound		androgen antagonist;
anti-inflammatory agent;
antifeedant;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antioxidant;
antitussive;
antiviral agent;
apoptosis inducer;
autophagy inducer;
hepatoprotective agent;
insecticide;
neuroprotective agent;
plant metabolite;
volatile oil component
(2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid
(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid: an acyclic retinoid that suppresses hepatocellular carcinoma recurrence; structure in first source		2.610
squalestatin 1
squalestatin 1: structure given in first source; inhibits both mammalian and fungal squalene synthetase; from fungus Phoma sp (Coelomycetes). zaragozic acid A : A polyketide isolated from fungi that is a potent inhibitor of fungal and mammalian squalene synthase.		3.2310acetate ester;
cyclic ketal;
oxabicycloalkane;
polyketide;
tertiary alcohol;
tricarboxylic acid		EC 2.5.1.21 (squalene synthase) inhibitor;
fungal metabolite
broussochalcone a
broussochalcone A: RN given for (E)-isomer; inhibits neutrophil respiratory burst; structure in first source		3.4110
ici d1542
ICI D1542: redirects arachidonic acid metabolism; an inhibitor of thromboxane A2 synthetase and of thromboxane receptors		2.0710
rupintrivir
rupintrivir: a rhinovirus 3C protease inhibitor		3.4110
antibiotic 1233a
antibiotic 1233A: beta-lactone antibiotic from Cephalosporium; hydroxymethylglutaryl-CoA synthase & 3C protease, viral inhibitor; structure in first source		3.2310long-chain fatty acid
lithospermic acid
[no description available]		2.610
everolimus
[no description available]		8.1200cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
laq824
LAQ824: Histone deacetylase inhibitor		2.610
ixabepilone
[no description available]		11.35611,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
ekb 569
EKB 569: an EGF receptor kinase inhibitor		4.8770aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile		protein kinase inhibitor
gavestinel
[no description available]		2.0710
axitinib
[no description available]		3.84100aryl sulfide;
benzamides;
indazoles;
pyridines		antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
pai 039
tiplaxtinin: inhibitor of plasminogen activator inhibitor-1		2.0810indole-3-acetic acids
rilpivirine
[no description available]		420aminopyrimidine;
nitrile		EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor
belotecan
belotecan: structure in first source		2.8930pyranoindolizinoquinoline
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one
[no description available]		2.610germacranolide
4,5-di-O-caffeoylquinic acid
[no description available]		2.610quinic acid
indigo carmine
3,5-di-O-(E)-caffeoylquinic acid: from roots of Lychnophora ericoides; structure in first source. 3,5-di-O-caffeoyl quinic acid : A carboxylic ester that is the diester obtained by the condensation of the hydroxy groups at positions 3 and 5 of (-)-quinic acid with the carboxy group of trans-caffeic acid. Isolated from Brazilian propolis and Suaeda glauca, it exhibits hepatoprotective and cytotoxic activities.		2.610
tanespimycin
CP 127374: analog of herbimycin A		2.04101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
manzamine a
manzamine A: RN given refers to (1R-(1R*,9Z,13S*,13aR*,20aR*,21aR*)-isomer; RN for cpd without isomeric designation not avail 12/92. manzamine A : An alkaloid of the class of beta-carbolines isolated from Haliclona and Acanthostrongylophora. It exhibits inhibitory activity against Glycogen Synthase Kinase-3 (EC 2.7.11.26).		2.0710alkaloid;
beta-carbolines;
isoquinolines		animal metabolite;
anti-HSV-1 agent;
antimalarial;
antineoplastic agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
marine metabolite
cefpodoxime proxetil
cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.		2.0810carboxylic acid;
carboxylic ester;
cephalosporin		antibacterial drug;
prodrug
ceftizoxime
[no description available]		3.2310cephalosporinantibacterial drug
1-azakenpaullone
1-azakenpaullone : An organic heterotetracyclic compound that is 7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indole substituted at positions 6 and 9 by oxo and bromo groups respectively.		2.0610lactam;
organic heterotetracyclic compound;
organobromine compound;
organonitrogen heterocyclic compound		EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole
[no description available]		2.0310aryl sulfide
a 419259
[no description available]		2.0610
gdp 366
GDP 366: an antineoplastic agent; structure in first source		2.0610
1-methyl-d-lysergic acid butanolamide
[no description available]		3.620ergot alkaloid;
monocarboxylic acid amide		serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent
norgestimate
[no description available]		2.8930ketoxime;
steroid ester;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
fluphenazine
[no description available]		2.0810
b 43
RK-24466 : A member of the class of pyrrolopyrimidines that is 7H-pyrrolo[2,3-d]pyrimidine substituted by amino, 4-phenoxyphenyl, and cyclopentyl groups at positions 4, 5 and 7, respectively. It is a potent inhibitor of Lck that inhibits Lck (64-509) and LckCD isoforms (IC50 of less than 1 and 2 nM, respectively).		2.8930aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
gw2974
GW2974: quinazoline derivative, which is able to block the activation of both the EGFR and erbB2		2.0810pyridopyrimidine
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine
[no description available]		2.8930
nitrofurantoin
Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.		4.140imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
methiazole
methiazole: a parasitostatic agent		2.8930benzimidazoles;
carbamate ester
sb 218795
SB 218795: structure in first source		2.8930quinolines
aminopurvalanol a
aminopurvalanol A: casein kinase I alpha inhibitor; structure in first source		2.0310monochlorobenzenes;
purvalanol		protein kinase inhibitor
bvt.948
[no description available]		2.8930
2-[[6-[(phenylmethyl)amino]-9-propan-2-yl-2-purinyl]amino]ethanol
[no description available]		2.0610thiopurine
nifurtimox
Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.		3.1610nitrofuran antibiotic
ispinesib
[no description available]		2.0810benzamides
gsk5182
GSK5182: an estrogen-related receptor gamma inverse agonist		2.2510
dantrolene
[no description available]		3.620
fk 866
N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source		2.6120benzamides;
N-acylpiperidine
roxithromycin
(E)-roxithromycin : A major geometrical isomer of roxithromycin.		2.0810roxithromycinenvironmental contaminant;
xenobiotic
cefdinir
[no description available]		3.6120cephalosporin;
ketoxime		antibacterial drug
etonogestrel
[no description available]		3.231017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin
a 38503
[no description available]		2.8930
bisoprolol, fumarate (1:1) salt
[no description available]		2.0810
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		2.830artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
tipredane
[no description available]		2.07103-hydroxy steroidandrogen
etoposide phosphate
[no description available]		2.0810furonaphthodioxole
u 62840
U 62840: stereoisomeric benzindene prostaglandin analog; structure given in first source		2.0810carbotricyclic compound;
carboxylic acid		antihypertensive agent;
cardiovascular drug;
human blood serum metabolite;
platelet aggregation inhibitor;
vasodilator agent;
vitamin K antagonist
ciclesonide
ciclesonide: nasal spray approved for seasonal and perennial allergic rhinitis		2.0810organic molecular entity
temsirolimus
[no description available]		4.1240macrolide lactam
dutasteride
Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.		3.6120(trifluoromethyl)benzenes;
aza-steroid;
delta-lactam		antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone
[no description available]		2.610oligopeptide
cvt 313
CVT 313: a potent inhibitor of CDK2 that prevents neointimal proliferation; structure given in first source		2.0310
tekturna
[no description available]		2.0810fumarate saltantihypertensive agent
pd 184352
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source		5.9771aminobenzoic acid
prasugrel
5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate : A member of the class of thienopyridines that is 2-acetoxy-4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the amino hydrogen is replaced by a 2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl group.. prasugrel : A racemate comprising equal amounts of (R)- and (S)-prasugrel. Used (as its hydrochloride salt) to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.		3.1710acetate ester;
cyclopropanes;
ketone;
monofluorobenzenes;
tertiary amino compound;
thienopyridine
isavuconazole
isavuconazole : A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis.		3.51101,3-thiazoles;
conazole antifungal drug;
difluorobenzene;
nitrile;
tertiary alcohol;
triazole antifungal drug		EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor;
orphan drug
lu 208075
ambrisentan: an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension		3.6120diarylmethane
bibx 1382bs
BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001		4.1240substituted aniline
vildagliptin
[no description available]		2.5820amino acid amide
fesoterodine
fesoterodine: a muscarinic antagonist for treatment of overactive bladder		3.2310diarylmethane
belinostat
[no description available]		2.610hydroxamic acid;
olefinic compound;
sulfonamide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
on 01910
ON 01910: a Plk1 inhibitor with antineoplastic activity; structure in first source. N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine : A glycine derivative that is glycine in which one of the hydrogens of the amino group is substituted by a 2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl group.. rigosertib : An N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine in which the double bond has E-configuration. It is a non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM and exhibits anti-cancer properties.		2.1510N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycineantineoplastic agent;
apoptosis inducer;
EC 2.7.11.21 (polo kinase) inhibitor;
microtubule-destabilising agent
panobinostat
Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.		4.1440cinnamamides;
hydroxamic acid;
methylindole;
secondary amino compound		angiogenesis modulating agent;
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
hdac-42
HDAC-42: structure in first source		2.5820amidobenzoic acid
bentiromide
bentiromide: chymotrypsin labile peptide used diagnostically as an index of exocrine pancreas function. bentiromide : The dipeptide obtained by condensation of N-benzoyl-L-tyrosine with 4-aminobenzoic acid. Used as a noninvasive screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy, it is given by mouth: the amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas.		2.0710dipeptidediagnostic agent;
indicator;
reagent
staurosporine
staurosporinium : Conjugate acid of staurosporine.		10.87170ammonium ion derivative
5-Chloro-3-pyridinyl 2-furoate
[no description available]		3.4110carboxylic esteranticoronaviral agent
parthenolide
[no description available]		2.5820sesquiterpene lactonedrug allergen;
inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
3-methyl-n-(3-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)isoxazole-5-carboxamide
3-methyl-N-(3-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)isoxazole-5-carboxamide: a LIMK2 inhibitor; structure in first source		2.4110
a 770041
[no description available]		2.0610aromatic amide
sl 327
SL 327: a MEK inhibitor. SL-327 : A nitrile that is acrylonitrile in which the hydrogen attached to the same carbon as the cyano group has been replaced by an o-(trifluoromethyl)phenyl group, while the remaining hydrogens of the ethenyl group have been replaced by amino and (4-aminophenyl)sulfanyl groups. The configuration of the double bond is not specified. It is an inhibitor of MEK1 and MEK2.		2.0310
tws 119
[no description available]		2.0310pyrroles
krn 633
N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea: a VEGF receptor-2 tyrosine kinase inhibitor; structure in first source		3.0440
((3z)-n-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1h-pyrrol-2-yl)methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide)
[no description available]		2.4620sulfonamide
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone
[no description available]		2.0810benzamides;
N-acylpiperidine
c 1368
[no description available]		2.0310
pq 401
PQ 401: an IGF receptor type I antagonist; structure in first source		2.0310quinolines
chlorhexidine
Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.		2.610biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
sgd 301-76
[no description available]		2.0810conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt		antiinfective agent
fluvoxamine maleate
[no description available]		2.0810(trifluoromethyl)benzenes
thioacetazone
Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.		2.0810
gemifloxacin
Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.		3.6201,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor
gs-7340
tenofovir alafenamide: component of Biktarvy. tenofovir alafenamide : An L-alanine derivative that is isopropyl L-alaninate in which one of the amino hydrogens is replaced by an (S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl group. A prodrug for tenofovir, it is used (as the fumarate salt) in combination therapy for the treatment of HIV-1 infection.		2.6106-aminopurines;
ether;
isopropyl ester;
L-alanine derivative;
phosphoramidate ester		antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
dexlansoprazole
Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.		3.6120benzimidazoles;
sulfoxide
gemifloxacin mesylate
gemifloxacin mesylate : The mesylate salt of gemifloxacin.		2.0810methanesulfonate saltantimicrobial agent;
topoisomerase IV inhibitor
fosinopril
[no description available]		3.2310
vacuolin-1
vacuolin-1: inhibits Ca2-dependent lysosomal exocytosis		3.9220
armodafinil
armodafinil : A 2-[(diphenylmethyl)sulfinyl]acetamide that has R configuration at the sulfur atom. Like its racemate, modafinil, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. Peak concentration in the blood later occurs later following administration than with modafinil, so it is thought that armodafinil may be more effective than modafinil in treating people with excessive daytime sleepiness.		3.23102-[(diphenylmethyl)sulfinyl]acetamidecentral nervous system stimulant;
eugeroic
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid
[no description available]		2.8930organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
iniparib
[no description available]		2.5820carbonyl compound;
organohalogen compound
jnj 10198409
[no description available]		2.0310
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide
[no description available]		2.610
pri-2205
[no description available]		2.610
mk 0752
[no description available]		2.5820
utibapril
utibapril: structure given in first source; prodrug for FPL 63547 diacid		2.0710
gw 501516
GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.		3.07401,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound		carcinogenic agent;
PPARbeta/delta agonist
givinostat
[no description available]		2.610carbamate ester
av 412
[no description available]		2.5220
ag-041r
AG-041R: structure in first source		2.0810
telatinib
[no description available]		2.5220
y-39983
Y-39983: SNJ-1656 is an ophthalmic solution of Y-39983; ROCK (rho kinase) inhibitor, promotes regeneration of crushed axons of retinal ganglion cells; structure in first source		2.1510pyrrolopyridine
dolastatin 10
dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization.		2.89301,3-thiazoles;
tetrapeptide		animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent
cp 547632
3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source		3.0140
timcodar
timcodar: a mutlidrug resistance inhibitor; structure in first source		3.5110
bms345541
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline: structure in first source		2.4720quinoxaline derivative
pd 144418
[no description available]		2.610
spc-839
SPC-839: an inhibitor of activator protein 1; structure in first source		3.0740
bicyclol
bicyclol: an antihepatitis drug, on the metabolism and hepatotoxicity of aflatoxin B1 (AFB1) in rats.		2.610
abiraterone acetate
Abiraterone Acetate: An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.. abiraterone acetate : A sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer.		5.3331pyridines;
sterol ester		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor;
prodrug
lenvatinib
lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.		2.8530aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
andarine
[no description available]		2.0810acetamides;
anilide
adw 742
[no description available]		2.0610
gw843682x
[no description available]		2.4820(trifluoromethyl)benzenes
pd 0325901
mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).		3.3960difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound		antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin
midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.		7.6240benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
sincalide
Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.		3.2310oligopeptide
tapentadol
Tapentadol: An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.		3.2310alkylbenzene
ag 14361
[no description available]		2.0810benzimidazoles
sb 265610
[no description available]		2.0810
zd 9379
ZD 9379: structure given in first source		2.0710
ly 450139
[no description available]		2.5720peptide
px-866
PX-866: inhibitor of phosphoinositide-3-kinase signaling with antitumor activity; structure in first source. PX-866 : An organic heterotetracyclic compound that is obtained from wortmanin via aminolysis of its furan ring by diallyl amine.		2.1510acetate ester;
delta-lactone;
organic heterotetracyclic compound;
tertiary amino compound		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
valnemulin
[no description available]		2.6320
gambogic acid
gambogic acid: RN given refers to (1R-(1alpha,1(Z),3abeta,5alpha,11beta,14aS*))-isomer		3.5110pyranoxanthonesmetabolite
pentagastrin
Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid.		3.8930organic molecular entity
cangrelor
cangrelor: platelet P(2T) receptor antagonist. cangrelor : A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.		2.0710adenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound		P2Y12 receptor antagonist;
platelet aggregation inhibitor
cabazitaxel
cabazitaxel: an antineoplastic agent; structure in first source. cabazitaxel : A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly.		7.1360tetracyclic diterpenoidantineoplastic agent;
microtubule-stabilising agent
knk 437
KNK 437: inhibits thermotolerance acquisition and heat shock protein induction in colon carcinoma cells; structure in first source		2.0810
nu 7026
2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source		3.0440organic heterotricyclic compound;
organooxygen compound
sb 242235
SB 242235: p38 MAP kinase antagonist		2.0610
ripasudil
[no description available]		2.1510isoquinolines
fr 148083
5Z-7-oxozeaenol : A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB.		3.6620aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone		antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.8530aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
sch 527123
[no description available]		2.0710
osi 930
OSI 930: inhibits both receptor tyrosine kinase Kit and kinase insert domain receptor; structure in first source		3.2550aromatic amide
cgp 74588
CGP 74588: a metabolite of STI-571; structure in first source		2.110benzamides
ki 20227
[no description available]		2.4820
cefditoren
cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.		3.2310carboxylic acid;
cephalosporin		antibacterial drug
scio-469
SCIO-469: a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor for potential oral therapy for inflammatory disorders; in phase lib clinical trials for rheumatoid arthritis 4/2004. talmapimod : An indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties.		2.5220aromatic amide;
aromatic ketone;
chloroindole;
dicarboxylic acid diamide;
indolecarboxamide;
monofluorobenzenes;
N-acylpiperazine;
N-alkylpiperazine		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ticagrelor
Ticagrelor: An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.. ticagrelor : A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome.		2.8930aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines		P2Y12 receptor antagonist;
platelet aggregation inhibitor
ssr 69071
SSR 69071: structure in first source		2.0810pyridopyrimidine
l 692585
[no description available]		2.8930peptide
wp 744
WP 744: structure in first source; crosses BLOOD-BRAIN BARRIER and inhibits TOPOISOMERASE II		2.0310
cp 724714
2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide: CP-724714 is the ((2E)-isomer, 1:1.5 succinate); structure in first source		4.37402-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamideantineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
hepatotoxic agent
rivaroxaban
Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.		2.8830aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
sb 3ct compound
SB 3CT compound: a matrix metalloproteinase-2 inhibitor; structure in first source		2.610aromatic ether
pi103
PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce		5.33120aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
sb 210313
[no description available]		2.0810
hmn-214
(E)-4-(2-(2-(N-acetyl-N-(4-methoxybenzenesulfonyl)amino)stilbazole)) 1-oxide: an antineoplastic agent; structure in first source		2.1510
gw 4064
[no description available]		2.0810stilbenoid
nnc 26-9100
NNC 26-9100: structure in first source		2.8930aminopyridine
ginsenoside rb1
[no description available]		2.610ginsenoside;
glycoside;
tetracyclic triterpenoid		anti-inflammatory drug;
anti-obesity agent;
apoptosis inhibitor;
neuroprotective agent;
plant metabolite;
radical scavenger
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine
[no description available]		2.8930
y 27632, dihydrochloride, (4(r)-trans)-isomer
[no description available]		2.0310
tgx 221
TGX 221: a platelet aggregation inhibitor		2.0610pyridopyrimidine
sa 4503
[no description available]		2.0810
ic 87114
IC 87114: structure in first source		2.08106-aminopurines;
biaryl;
quinazolines		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zibotentan
ZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferation		2.0810phenylpyridine
tivozanib
N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source		4.6570aromatic ether
zm 447439
ZM447439 : A member of the class of quinazolines that is quinazoline which is substituted at positions 4, 6 and 7 by a (4-benzamidophenyl)nitrilo group, methoxy group and a 3-(morpholin-4-yl)propoxy group, respectively. It is an ATP-competitive inhibitor of Aurora A and Aurora B kinases with IC50 of 110 nM and 130 nM, respectively.		2.0610aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor
hki 272
[no description available]		3.3660nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
tofacitinib
tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.		6.46120N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bibr 1532
[no description available]		2.0810
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide
[no description available]		3.2350
olesoxime
olesoxime: drug candidate for amyotrophic lateral sclerosis; structure in first source		3.2310
rucaparib
AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source		2.8130azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound		antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cediranib
[no description available]		10.6561aromatic ether
tae226
TAE226: an adhesion kinase inhibitor, offers an attractive therapeutic approach in ovarian carcinoma; structure in first source		3.0640morpholines
gw0742
GW 610742: structure in first source		3.0740monocarboxylic acid
ap23464
AP23464: a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases		3.1310
melflufen
melflufen: structure in first source		2.1310
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-
[no description available]		2.610organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
ps1145
PS1145: IkappaB kinase inhibitor; structure in first source		2.0810beta-carbolines
cp 31398
CP 31398: structure in first source		2.2110
linaprazan
linaprazan: structure in first source		2.0710
tak-715
N-(4-(2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl)-2-pyridyl)benzamide: anti-rheumatoid arthritis agent; structure in first source		2.0610benzamides
cetilistat
cetilistat: lipase inhibitor in randomized, placebo-controlled study of weight reduction in obese patients (3/2007)		2.610benzoxazine
bay 41-8543
BAY 41-8543: structure in first source		2.0810pyrazolopyridine
u 18666a
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one: inhibits cycloartenol synthase. 3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride : A hydrochloride obtained by reaction of 3beta-(2-diethylaminoethoxy)androst-5-en-17-one with one equivalent of hydrochloric acid. It is a cholesterol synthesis and transport inhibitor.		4.1940hydrochlorideantiviral agent;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
Hedgehog signaling pathway inhibitor;
nicotinic antagonist;
sterol biosynthesis inhibitor
chir 99021
Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.		3.0540aminopyridine;
aminopyrimidine;
cyanopyridine;
diamine;
dichlorobenzene;
imidazoles;
secondary amino compound		EC 2.7.11.26 (tau-protein kinase) inhibitor
ym 201636
6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide: an antiviral agent; structure in first source		420aromatic amide
sb 525334
6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline: a TGF-betaR kinase inhibitor		3.0740quinoxaline derivative
way-362450
[no description available]		2.0810indoles
osu 03012
OSU 03012: a PDK-1 inhibitor; structure in first source		2.4110antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
ly2090314
LY-2090314 : A member of the class of diazepinoindoles that is 1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indole substituted by piperidin-1-ylcarbonyl, 4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl and fluoro groups at position 2, 7 and 9, respectively. It is a potent ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3alpha and GSK-3beta. The drug is in clinical development for the treatment of advanced/metastatic cancer.		2.0610diazepinoindole;
imidazopyridine;
maleimides;
monofluorobenzenes;
piperidinecarboxamide;
ureas		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator
masitinib
[no description available]		4.13401,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines		antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor
bx795
BX795: structure in first source		3.2850ureas
ly-2157299
LY-2157299: an orally active transforming growth factor beta receptor (TGF-beraR) kinase inhibitor. LY-2157299 : A pyrrolopyrazole that is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole which is substituted at positions 2 and 3 by 6-methylpyridin-2-yl and 6-(aminocarbonyl)quinolin-4-yl groups, respectively. A Transforming growth factor-betaRI (TGF-betaRI) kinase inhibitor, it blocks TGF-beta-mediated tumor growth in glioblastoma.		2.1510aromatic amide;
methylpyridines;
monocarboxylic acid amide;
pyrrolopyrazole;
quinolines		antineoplastic agent;
TGFbeta receptor antagonist
linagliptin
Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.. linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes.		2.610aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
pazopanib
pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.		12.91230aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
lecozotan
lecozotan: structure in first source		2.0710
sepantronium
sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.		2.0810organic cation
azd 6244
AZD 6244: a MEK inhibitor		5.27140benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
su 14813
5-((5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide: has both antineoplastic and antiangiogenic activities; structure in first source		4.5550
odanacatib
odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source		2.610
prasugrel hydrochloride
Prasugrel Hydrochloride: A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.. prasugrel hydrochloride : A racemate comprising equal amounts of (R)- and (S)-prasugrel hydrochloride. Used to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.		3.2310
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea: structure in first source		3.0740
a 443654
A 443654: an Akt kinase inhibitor; structure in first source		2.4110indoles
apilimod
[no description available]		4.9840
apixaban
[no description available]		2.610aromatic ether;
lactam;
piperidones;
pyrazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
bibw 2992
[no description available]		7.04211aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
bay 61-3606
[no description available]		3.0640pyrimidines
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide : A member of the class of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-4-carboxylic acid with the amino group of 3-cyanoaniline.		2.08101,3,4-oxadiazoles;
benzamides;
biphenyls;
nitrile		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ar c155858
AR C155858: an MCT1 inhibitor; structure in first source		2.4820
betrixaban
betrixaban: a highly potent, selective, and orally efficacious factor Xa inhibitor; structure in first source. betrixaban : A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade.		2.610benzamides;
guanidines;
monochloropyridine;
monomethoxybenzene;
secondary carboxamide		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
pik 75
PIK 75: structure in first source		2.4110
edoxaban
edoxaban : A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.		2.610chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor
binimetinib
binimetinib : A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib.		2.1510benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monofluorobenzenes;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sotrastaurin
sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source. sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients.		4.1340indoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines		anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent
aee 788
AEE 788: structure in first source		2.52206-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug
saracatinib
[no description available]		9.08310aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
sd-208
[no description available]		3.0740
on012380
ON012380: a non-ATP-competitive inhibitor of BCR-ABL; structure in first source		4.3430
ko 143
[no description available]		3.5110beta-carbolines;
tert-butyl ester
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.		2.610tripeptide;
ureas		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
2-acetylfuranonaphthoquinone
2-acetylfuranonaphthoquinone: has antineoplastic activity; structure in first source		2.2510
vx 702
VX 702: a p38 MAP kinase inhibitor		2.7830phenylpyridine
crenolanib
[no description available]		3.140aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
tg100-115
3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol: for treatment of ischemia reperfusion injury; structure in first source		2.520pteridines
cj 033466
CJ 033466: structure in first source		2.8930
cc 401
CC 401: an anthrapyrazolone		3.140pyrazoles;
ring assembly
ly 411575
[no description available]		2.610dibenzoazepine;
difluorobenzene;
lactam;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor
bms 599626
[no description available]		2.1510
galidesivir
[no description available]		2.610
exel-7647
tesevatinib : A member of the class of quinazolines that is quinazoline substituted by (3,4-dichloro-2-fluorophenyl)amino, methoxy, and [(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy groups at positions 4, 6 and 7, respectively. It is a multi-target tyrosine kinase inhibitor of EGFR, ErbB2, KDR, Flt4 and EphB4 and exhibits anti-cancer properties.		2.5420
volasertib
BI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source		2.5220
pha 665752
[no description available]		2.0610dichlorobenzene;
enamide;
indolones;
N-acylpyrrolidine;
pyrrolecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide		antineoplastic agent;
c-Met tyrosine kinase inhibitor
PB28
PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.		3.2850aromatic ether;
piperazines;
tetralins		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist
arterolane
arterolane: a trioxolane with antimalarial activity; structure in first source. arterolane : An oxaspiro compound that is dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.1(3,7)]decane] substituted by a 2-[(2-amino-2-methylpropyl)amino]-2-oxoethyl group at position 4s. Its maleic acid salt is used as an antimalarial drug in combination with piperaquine.		2.8930
amg 009
AMG 009: an anti-inflammatory agent; structure in first source		2.0810
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		2.5420
cefotaxime sodium
[no description available]		2.0810organic sodium salt
baci-im
[no description available]		3.2310homodetic cyclic peptide;
polypeptide;
zwitterion		antibacterial agent;
antimicrobial agent
tafamidis
tafamidis: may be effective in treating transthyretin amyloid polyneuropathy. tafamidis : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazole-6-carboxylic acid in which the hydrogen at position 2 is replaced by a 3,5-dichlorophenyl group. Used (as its meglumine salt) for the amelioration of transthyretin-related hereditary amyloidosis.		2.31101,3-benzoxazoles;
dichlorobenzene;
monocarboxylic acid		central nervous system drug
azd 7762
[no description available]		2.5220aromatic amide;
thiophenes
cariprazine
cariprazine: Structure in first source. cariprazine : An N-alkylpiperazine that is N,N-dimethyl-N'-{trans-4-[2-(piperazin-1-yl)ethyl]cyclohexyl}urea substituted at position 4 on the piperazine ring by a 2,3-dichlorophenyl group. Used (as the hydrochloride salt) for treatment of schizophrenia and bipolar disorder.		2.8930
krp-203
[no description available]		3.0740
mk 0354
[no description available]		2.0810
regorafenib
[no description available]		4.8890(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
at 7867
[no description available]		2.8930monochlorobenzenes;
piperidines;
pyrazoles		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester
[no description available]		3.0740pyrroloquinoline
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
[no description available]		3.1850methoxybenzenes;
substituted aniline
ptc 124
[no description available]		2.8930oxadiazole;
ring assembly
degrasyn
degrasyn: a JAK2 kinase inhibitor that induces rapid degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines; structure in first source		2.9830
epoxomicin
[no description available]		2.610morpholines;
tripeptide		proteasome inhibitor
abt-737
[no description available]		2.520aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
brivanib
[no description available]		3.0140aromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
icg 001
[no description available]		2.0810peptide
bms 477118
[no description available]		3.7320adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
pha 680632
PHA 680632: Aurora kinase inhibitor with potent antitumoral activity; structure in first source		2.930
tmc 353121
[no description available]		2.610
amd 070
mavorixafor: a derivative of AMD3100; a CXCR4 blocker		2.610aminoquinoline
cvt-6883
3-ethyl-1-propyl-8-(1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione: structure in first source		2.0610
mp470
[no description available]		2.5220N-arylpiperazine
rgb 286638
[no description available]		2.1510
danoprevir
[no description available]		2.610
nystatin a1
Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.		3.2310nystatins
bay 63-2521
riociguat: guanylate cyclase stimulator; structure in first source. riociguat : A carbamate ester that is the methyl ester of {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamic acid. It is used for treatment of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension		2.0810aminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine		antihypertensive agent;
soluble guanylate cyclase activator
np 031112
tideglusib: an NSAID and neuroprotective agent. tideglusib : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a naphthalen-1-yl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. Currently under clinical investigation for the treatment of Alzheimer's disease and progressive supranuclear palsy.		4.5530benzenes;
naphthalenes;
thiadiazolidine		anti-inflammatory agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
bms-626529
[no description available]		2.610
bms-663068
fostemsavir: an HIV-1 attachment inhibitor; structure in first source		2.610
nu 7441
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source		2.0810dibenzothiophenes
at 7519
4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide : A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine.		2.7830dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bms-690514
[no description available]		2.8130
cyt997
[no description available]		2.1510ureas
bi 2536
[no description available]		3.86100
inno-406
[no description available]		12.12140biaryl
amenamevir
ASP2151: a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes; structure in first source		2.610
vx 765
belnacasan: a NSAID		2.610dipeptide
r 1487
[no description available]		2.0610
nvp-ast487
NVP-AST487: antineoplastic; a RET kinase inhibitor that blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells		4.760
Dihydrotanshinone I
dihydrotanshinone I: extracted from Radix Salviae		2.610abietane diterpenoidanticoronaviral agent
kw 2449
KW 2449: has both multikinase inhibitory activity and antineoplastic activity; structure in first source		3.9330
nutlin-3a
nutlin 3: an MDM2 antagonist; structure in first source		2.0610stilbenoid
danusertib
[no description available]		2.7930piperazines
alogliptin
alogliptin: structure in first source. alogliptin : A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes.		2.610nitrile;
piperidines;
primary amino compound;
pyrimidines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide
[no description available]		2.0810benzamides
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide
[no description available]		2.0810benzamides
nvp-aew541
[no description available]		8.5270
abt 869
[no description available]		4.9680aromatic amine;
indazoles;
phenylureas		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
azd 8931
sapitinib : A member of the class of quinazolines that is 4-amino-7-methoxyquinazoline in which the amino group has been substituted by a 3-chloro-2-fluorophenyl group and in which position 6 of the quinoline ring has been substituted by a {1-[2-(methylamino)-2-oxoethyl]piperidin-4-yl}oxy group. Sapitinib is a dual tyrosine kinase inhibitor (TKI) of epithelial growth factor receptors (EGFR) HER2 and HER3.		2.1510aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
fr 180204
FR 180204: structure in first source		2.5220pyrazoles;
ring assembly
arq 197
[no description available]		2.1510indoles
azd 1152
AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.		3.2450anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor;
prodrug
pf 00299804
dacomitinib: a pan-ERBB inhibitor. dacomitinib : A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin-1-yl)but-2-enoyl group.		4.6640enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
ridaforolimus
[no description available]		2.1510macrolide lactam
dorsomorphin
dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.		3.6620aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
ac 261066
[no description available]		2.0810
quisinostat
[no description available]		2.610indoles
ch 4987655
[no description available]		2.1510
6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamide
[no description available]		2.6320phenylpyridine
carfilzomib
[no description available]		3.2850epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor
hcv 796
HCV 796: inhibits HCV RdRp; structure in first source		2.610
sitagliptin phosphate
Sitagliptin Phosphate: A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.		2.2510
gw9508
GW9508: structure in first source		2.0810aromatic amine
cc-930
[no description available]		2.1510
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine : A pyrazolylpiperidine that consists of 4-(pyrazol-1-yl)piperidine carrying a 2-amino-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-5-yl group at the 4-position of the pyrazole ring.. rac-crizotinib : A racemate comprising equimolar amounts of (R)- and (S)-crizotinib. The active (R)-enantiomer acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.		2.0610aminopyridine;
aromatic ether;
dichlorobenzene;
organofluorine compound;
pyrazolylpiperidine;
racemate		antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
jnj 26854165
[no description available]		2.0810
resminostat
resminostat: a histone deacetylase inhibitor; structure in first source		2.610
pf 573228
6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one: structure in first source		2.5220quinolines
gw 2580
5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source		4.8370
tak 285
N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide: also inhibits HER2; structure in first source		2.1510
milnacipran
[no description available]		3.2310acetamides
idelalisib
idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.		4.4960aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
crizotinib
Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)		5.882013-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile
[no description available]		2.0810benzimidazoles
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide
Vx-11e: ERK1-2 inhibitor		2.0810aromatic amide;
heteroarene
osi 906
[no description available]		2.7830cyclobutanes;
quinolines
cgp 57380
CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1		2.1710pyrazolopyrimidine
ly2109761
[no description available]		2.0810
chir-265
[no description available]		4.760aromatic ether
motesanib
[no description available]		5.0990pyridinecarboxamide
fostamatinib
fostamatinib: a spleen tyrosine kinase (Syk) inhibitor, metabolized to R406		4.7240
az-628
AZ-628: a multikinase inhibitor; structure in first source		2.0810benzamides
jnj 28312141
[no description available]		2.0610
zk 756326
2-(2-(4-(3-phenoxybenzyl)piperazin-1-yl)ethoxy)ethanol: a CC chemokine receptor CCR8 agonist; structure in first source		2.610aromatic ether
balapiravir
balapiravir: a prodrug of R1479; structure in first source		2.610
trametinib
[no description available]		5.35140acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
mln8054
[no description available]		5.0890benzazepine
pf-562,271
[no description available]		4.7280indoles
pha 767491
PHA 767491: a Cdc7 inhibitor; structure in first source		2.5420pyrrolopyridine
GDC-0879
[no description available]		2.0610indanes;
ketoxime;
primary alcohol;
pyrazoles;
pyridines		antineoplastic agent;
B-Raf inhibitor
gpi 15427
[no description available]		2.0610
gliocladin c
gliocladin C: structure in first source		2.8930
deoxyarbutin
4-((tetrahydro-2H-pyran-2-yl)oxy)phenol: has antineoplastic activity; structure in first source		2.610
abexinostat
abexinostat: structure in first source		2.610benzofurans
losartan potassium
Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.		2.4820
N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide
[no description available]		2.4110ureas
silvestrol
silvestrol: isolated from the fruit and twig of Aglaia silvestris. silvestrol : An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.		2.610dioxanes;
ether;
methyl ester;
organic heterotricyclic compound		antineoplastic agent;
metabolite
sb 706504
[no description available]		2.8930
narlaprevir
narlaprevir: an antiviral agent that inhibits hepatitis C virus NS3 protease. narlaprevir : An azabicyclohexane that is (1R,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane substituted by [(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]aminoacyl and N-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-L-valyl groups at positions 2S and 3, respectively. It is a hepatitis C virus (HCV) NS3/4A serine protease inhibitor (Ki = 6 nM) that is used for the treatment of chronic hepatitis C.		2.610azabicyclohexane;
cyclopropanes;
pyrrolidinecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide;
ureas		anticoronaviral agent;
antiviral drug;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
hepatitis C protease inhibitor
teneligliptin
[no description available]		2.610amino acid amide
jnj-26483327
JNJ-26483327: an orally active macrocyclic tyrosine kinase inhibitor for treatment of patients with advanced solid tumours; in Phase I trial, 9/2010		2.1510
ly2603618
[no description available]		2.1510ureas
dextrothyroxine
[no description available]		2.610
veliparib
[no description available]		7.8830benzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ku-0060648
[no description available]		3.0740dibenzothiophenes
sepharose
agarose : A linear polysaccharide made up from alternating D-galactose and 3,6-anhydro-alpha-L-galactopyranose residues joined by alpha-(1->3)- and beta-(1->4)-linkages.		2.2110
indocyanine green
Indocyanine Green: A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output.		7.31101,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
scopolamine hydrobromide
[no description available]		3.8730
tg100801
[no description available]		2.1510
dactolisib
dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.		8.83100imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
bgt226
BGT226 free base : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor.. BGT226 : The maleate salt of 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one. A dual PI3K/mTOR inhibitor.		3.140aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
pituitrin
Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).		2.2110
n4-(2,2-dimethyl-3-oxo-4h-pyrid(1,4)oxazin-6-yl)-5-fluoro-n2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine
N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine: a spleen tyrosine kinase (Syk) inhibitor; structure in first source		2.5220
palomid 529
[no description available]		2.0810
pf 03491390
[no description available]		2.610
chidamide
[no description available]		3.4110benzamides
alloin
[no description available]		2.610anthracenes;
C-glycosyl compound;
cyclic ketone;
phenols		laxative;
metabolite
n-desmethyldanofloxacin
N-desmethyldanofloxacin: structure given in first source		2.8930
rabeprazole sodium
[no description available]		2.5220organic sodium salt
a-484954
A-484954: eEF2K inhibitor; structure in first source		2.0610
tosedostat
[no description available]		2.0810carboxylic ester;
hydroxamic acid;
secondary carboxamide
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
[no description available]		3.9220organochlorine compound
mdv 3100
[no description available]		6.9460(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent
ku 60019
[no description available]		2.0810
Benzotriazol-1-yl 1H-indole-5-carboxylate
[no description available]		3.4110indolyl carboxylic acidanticoronaviral agent
gsk 461364
GSK 461364: an antineoplastic agent that inhibits polo-like kinase 1		3.0240(trifluoromethyl)benzenes
n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide: a MEK inhibitor; structure in first source		2.0810
macitentan
[no description available]		2.0810aromatic ether;
organobromine compound;
pyrimidines;
ring assembly;
sulfamides		antihypertensive agent;
endothelin receptor antagonist;
orphan drug
azd 1152-hqpa
AZD2811: has antineoplastic activity; structure in first source		5.18100anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor
CDN1163
CDN1163: a SERCA2 activator with antidiabetic activity; structure in first source. CDN1163 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-isopropoxybenzoic acid with the primary amino group of 2-methylquinolin-8-amine. An allosteric activator of sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA).		2.8930aromatic ether;
quinolines;
secondary carboxamide		SERCA activator
nvp-tae684
[no description available]		3.1850piperidines
enmd 2076
ENMD 2076: an antiangiogenic agent with aurora kinase inhibitory and antineoplastic activities		2.5720
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.1110
bms-650032
asunaprevir: an NS3 protease inhibitor against hepatitis C virus		2.610oligopeptide
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-N-(3-(trifluoromethyl)phenyl)benzamide: structure in first source		2.0810
gsk 269962a
[no description available]		3.2350
e 7050
[no description available]		2.5420aromatic ether
rg 7128
2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine: inhibits HCV polymerase; structure in first source		2.610
2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone
[no description available]		2.1510pyrazolopyridine
tak-901
[no description available]		2.5420
ceruletide
Ceruletide: A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.. ceruletide : A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction.		2.2110oligopeptidediagnostic agent;
gastrointestinal drug
bivalirudin
bivalirudin: designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition. bivalirudin : A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.		3.6120polypeptideanticoagulant;
EC 3.4.21.5 (thrombin) inhibitor
somatostatin
[no description available]		2.0810heterodetic cyclic peptide;
peptide hormone
enfuvirtide
Enfuvirtide: A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.. enfuvirtide : A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.		3.2310
ganirelix
[no description available]		3.2310polypeptide
teriparatide
[no description available]		3.2310polypeptide
salmon calcitonin
[no description available]		3.2310heterodetic cyclic peptide;
peptide hormone;
polypeptide		bone density conservation agent;
metabolite
oligonucleotides
[no description available]		3.5920
ly-146032
[no description available]		3.6120heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide: FE-200486 is the acetate salt		3.2310polypeptide
oritavancin
oritavancin : A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.		2.610disaccharide derivative;
glycopeptide;
semisynthetic derivative		antibacterial drug;
antimicrobial agent
c-peptide
C-Peptide: The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.		2.1110
exenatide
[no description available]		3.2310
5-Chloropyridin-3-yl 5-(4-chlorophenyl)furan-2-carboxylate
[no description available]		3.4110carboxylic esteranticoronaviral agent
(5-Chloropyridin-3-yl) 1H-indole-5-carboxylate
[no description available]		3.4110indolyl carboxylic acidanticoronaviral agent
5-Chloropyridin-3-yl 1H-indole-2-carboxylate
[no description available]		3.4110indolyl carboxylic acidanticoronaviral agent
warfarin sodium
warfarin sodium : A racemate comprising equal amounts of (R)- and (S)-warfarin sodium. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.		2.0810
endothelin-1
Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)		5.7730
a-83-01
A-83-01: an ALK-5 inhibitor; structure in first source		2.0810
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one
[no description available]		2.4820indoles
vx-770
ivacaftor: a CFTR potentiator; structure in first source. ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.		2.0810aromatic amide;
monocarboxylic acid amide;
phenols;
quinolone		CFTR potentiator;
orphan drug
gdc-0973
cobimetinib: has antineoplastic activity; structure in first source. cobimetinib : A member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma.		2.1510aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
buparlisib
NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source		4.1831aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
azd 1480
[no description available]		2.8430
azd8330
[no description available]		2.6320pyridinecarboxamide
vendex
Torque: The rotational force about an axis that is equal to the product of a force times the distance from the axis where the force is applied.		2.2110organotin acaricide
pha 848125
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide: a cyclin dependent kinase inhibitor		3.4260
ro5126766
RO5126766: a dual MEK/RAF kinase inhibitor. CH5126766 : A member of the class of coumarins that is 4-methyl-7-[(pyrimidin-2-yl)oxy]coumarin carrying an additional [2-[(methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl substituent at position 3.		3.7320aryloxypyrimidine;
coumarins;
organofluorine compound;
pyridines;
sulfamides		antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pevonedistat
pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.		2.610cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate		antineoplastic agent;
apoptosis inducer
tg101209
[no description available]		2.0610N-alkylpiperazine;
N-arylpiperazine;
pyrimidines;
secondary amino compound;
sulfonamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
fedratinib
fedratinib: a selective small-molecule inhibitor of JAK2		3.3560sulfonamide
gsk690693
[no description available]		2.78301,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024
[no description available]		2.08102-aminopurines;
aromatic ether;
organochlorine compound;
pyridines		antineoplastic agent;
Hsp90 inhibitor
ku 0063794
Ku 0063794: an mTOR inhibitor; structure in first source		2.0810benzyl alcohols;
monomethoxybenzene;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
mTOR inhibitor
uk 453,061
UK 453,061: a reverse transcriptase inhibitor/anti-HIV agent; structure in first source		2.610aromatic ether
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source		2.6320
azd 7545
AZD 7545: an anilide tertiary carbinol; a pyruvate dehydrogenase kinase 2 inhibitor. AZD7545 : A sulfone that is benzene substituted by [4-(dimethylcarbamoyl)phenyl]sulfonyl, chloro and [(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino groups at positions 1, 3 and 4, respectively. It is a potent and non-ATP-competitive inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2) with IC50 of 6.4 nM and exhibits glucose-lowering activity. Also inhibits PDHK1 at higher levels (IC50 = 36.8 nM).		2.4820benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide		EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent
nvp-bhg712
[no description available]		2.8930benzamides
azd5438
[no description available]		2.5820sulfonamide
nutlin-3b
[no description available]		2.0810Nutlin;
piperazinone		anticoronaviral agent
pravastatin sodium
pravastatin sodium : An organic sodium salt that is the sodium salt of pravastatin. A reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), it is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		2.0810organic sodium salt;
statin (semi-synthetic)		anticholesteremic drug
alendronate sodium
[no description available]		2.0810
sphingosine kinase
[no description available]		2.4920
N-(2-aminophenyl)-2-pyrazinecarboxamide
[no description available]		2.610aromatic amide
pf 04217903
[no description available]		3.5170quinolines
3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile
[no description available]		2.0610pyrrolopyrimidine
gdc 0941
pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.		4.9960indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
sm 164
SM 164: a bivalent Smac mimetic with antineoplastic activity; structure in first source		2.0810benzenes;
organic heterobicyclic compound;
secondary carboxamide;
triazoles		antineoplastic agent;
apoptosis inducer;
radiosensitizing agent
sl 80.0750
[no description available]		2.0810
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one
[no description available]		2.8930aromatic ketone
chitosan
[no description available]		3.0730
icotinib
[no description available]		3.6120
ph 797804
PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.		3.3860aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone		anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pha 408
PHA 408: an IKK-2 antagonist; structure in first source		2.0810
gsk 1016790a
GSK1016790A : A tertiary carboxamide that is piperazine in which one of the amino groups has undergone condensation with the carboxy group of N-[(2,4-dichlorophenyl)sulfonyl]-L-serine, while the other has undergone condensation with the carboxy group of N-(1-benzothiophen-2-ylcarbonyl)-L-leucine. It is a cell-permeable, potent and selective agonist of the TRPV4 (transient receptor potential vanilloid 4) channel.		2.08101-benzothiophenes;
aromatic primary alcohol;
dichlorobenzene;
N-acylpiperazine;
sulfonamide;
tertiary carboxamide		TRPV4 agonist
kx-01
[no description available]		3.3660
tegobuvir
tegobuvir: a non-structural protein 5B polymerase inhibitor		2.610
pf-429242
PF-429242: a subtilisin kexin isozyme-1/site-1 protease inhibitor		2.610
mesna
Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.		3.6120organosulfonic acid
clavulanate potassium
potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.		2.4820potassium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
cytomel
liothyronine sodium : The sodium salt of liothyronine. Thought to be more active than levothyroxine and with a rapid (few hours) onset and short duration of action, liothyronine sodium is used in the treatment of hypothyroidism, particularly in cases of hypothyroid coma.		2.0710organic sodium salt
sodium lactate
Sodium Lactate: The sodium salt of racemic or inactive lactic acid. It is a hygroscopic agent used intravenously as a systemic and urinary alkalizer.. sodium lactate : An organic sodium salt having lactate as the counterion.		3.2310lactate salt;
organic sodium salt		food acidity regulator;
food preservative
piperacillin sodium
[no description available]		2.0810organic sodium salt
sodium iothalamate
[no description available]		3.2310
oxacillin sodium
[no description available]		2.0810organic sodium salt
cefazolin sodium
cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.		2.0810organic sodium salt
azlocillin sodium
[no description available]		2.0810organic sodium salt
olaparib
[no description available]		8.4960cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
srt1720
[no description available]		3.0740
plx 4720
PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source		2.7730aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
lcl161
[no description available]		2.55201,3-thiazoles;
aromatic ketone;
L-alanine derivative;
monofluorobenzenes;
N-acylpyrrolidine		antineoplastic agent;
apoptosis inducer
mk 5108
[no description available]		2.8630aromatic ether
cx 4945
[no description available]		4.3750
pci 34051
PCI 34051: an HDAC8 inhibitor		2.610indolecarboxamide
cudc 101
7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide: a histone deacetylase inhibitor; structure in first source		4.6440
purfalcamine
purfalcamine: a PfCDPK-1 inhibitor; structure in first source		2.8930
arry-614
pexmetinib: inhibits both p38 mitogen-activated protein kinase and Tie2 protein		2.1510
tak 593
TAK 593: structure in first source		2.1510
mln 8237
MLN 8237: an aurora kinase A inhibitor		4.4560benzazepine
lde225
sonidegib: specific Smoothened/Smo antagonist. sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.		2.0810aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
gdc 0449
HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity		3.9130benzamides;
monochlorobenzenes;
pyridines;
sulfone		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
sgx 523
[no description available]		2.7830aryl sulfide;
biaryl;
pyrazoles;
quinolines;
triazolopyridazine		c-Met tyrosine kinase inhibitor;
nephrotoxic agent
bms 754807
BMS 754807: an IGR-1R kinase inhibitor; structure in first source		3.88100pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
gdc-0068
ipatasertib: an Akt kinase inhibitor; structure in first source		2.3110N-arylpiperazine
bms 777607
N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: a Met kinase inhibitor; structure in first source		2.5220aromatic amide
sgi 1776
SGI 1776: a Pim kinase inhibitor; structure in first source		2.5220imidazoles
lomibuvir
lomibuvir: an antiviral agent with polymerase NS5 inhibitory activity		2.610thiophenecarboxylic acid
delanzomib
[no description available]		2.610C-terminal boronic acid peptide;
phenylpyridine;
secondary alcohol;
threonine derivative		antineoplastic agent;
apoptosis inducer;
proteasome inhibitor
pci 32765
ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.		6.05120acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ponatinib
[no description available]		15.54918(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine		antineoplastic agent;
tyrosine kinase inhibitor
pitavastatin(1-)
pitavastatin(1-) : A hydroxy monocarboxylic acid anion that is the conjugate base of pitavastatin, obtained by deprotonation of the carboxy group.		2.610hydroxy monocarboxylic acid anion
amg 900
N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine: a pan-aurora kinase inhibitor; structure in first source		2.5220
mk-1775
adavosertib: a Wee1 kinase inhibitor; structure in first source		3.250piperazines
cgi 1746
CGI 1746: inhibits Bruton's protein kinase (Btk); structure in first source		3.1710
AMG-208
[no description available]		2.1510aromatic ether;
quinolines;
triazolopyridazine		antineoplastic agent;
c-Met tyrosine kinase inhibitor
bag956
BAG956: an imidazo[4,5-c]quinoline; dual PI3K/PDK-1 inhibitor, used in antileukemic therapies		2.0810
quizartinib
[no description available]		9.5680benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
PP121
[no description available]		4.4560aromatic amine;
cyclopentanes;
pyrazolopyrimidine;
pyrrolopyridine		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
tyrosine kinase inhibitor
at13148
[no description available]		2.1510
GRL-0617
GRL-0617 : A benzamide resulting from the formal condensation of the carboxy group of 5-amino-2-methylbenzoic acid with the amino group of (1R)-1-(naphthalen-1-yl)ethan-1-amine. It is a potent noncovalent inhibitor (IC50 = 600 nM) of severe acute respiratory syndrome-coronavirus papain-like protease (SARS-CoV PLpro).		3.9220benzamides;
naphthalenes;
secondary carboxamide;
substituted aniline		anticoronaviral agent;
protease inhibitor
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester
CAY10603: a HDAC6 inhibitor		2.5820carbamate ester
niraparib
niraparib: structure in first source. niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.		2.6102-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent
tak 733
[no description available]		2.8330
mk 2206
MK 2206: a protein kinase inhibitor and antineoplastic agent		4.6370organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax
[no description available]		8.9100aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
pervanadate
pervanadate: from a mixture of orthovanadate and hydrogen peroxide		2.0810
sns 314
SNS 314: an aurora kinase inhibitor; structure in first source		2.7830ureas
jzl 184
JZL 184: inhibits monoacylglycerol lipase; structure in first source		2.5820benzodioxoles
gsk 650394
[no description available]		3.1640phenylpyridine
lucitanib
E-3810: a multi-kinase inhibitor with antineoplastic activity; structure in first source. E-3810 : A hydrochloride salt obtained by reaction of 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-N-methyl-1-naphthamide with one equivalent of hydrochloric acid. E-3810 is a dual VEGFR and FGFR inhibitor. E-3810 free base : A naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine.		2.1510aromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines		antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist
pf-04691502
[no description available]		2.1510
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene
[no description available]		2.110BODIPY compound
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide: a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source. momelotinib : A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.		3.0640aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound		anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
dcc-2036
rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent		5.2680organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines		tyrosine kinase inhibitor
oprozomib
ONX 0912: antineoplastic; an orally active proteasome inhibitor; structure in first source		2.610
cetrorelix
cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.		3.2310oligopeptideantineoplastic agent;
GnRH antagonist
az 960
[no description available]		2.920
cabozantinib
cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.		7.85160aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
(5-Chloropyridin-3-yl) 1H-indole-4-carboxylate
[no description available]		3.4110indolyl carboxylic acidanticoronaviral agent
golgicide a
golgicide A: inhibits the cis-golgi ArfGEF GBF1; structure in first source. golgicide A : A diastereoisomeric mixture comprising racemic cis- and racemic trans-goglioside A in a 10:1 ratio. It is a potent and rapidly reversible GBF1 (Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1) inhibitor. The (3aS,4R,9bR) isomer is the most active (see Bioorg. Med. Chem. Lett., 2012, 22, 5177-5181).		2.610diastereoisomeric mixturecis-Golgi ArfGEF GBF inhibitor
defactinib
[no description available]		2.1510
ly2584702
[no description available]		2.1510
N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide
[no description available]		2.0810benzamides
incb-018424
[no description available]		6.89200nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
poziotinib
HM781-36B: antitumor irreversible Pan-HER inhibitor for treatment of gastric cancer		2.1510acrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline		antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist
asp3026
ASP3026: an anaplastic lymphoma receptor tyrosine kinase inhibitor; structure in first source. ASP-3026 : A member of the class of diamino-1,3,5-triazines that is 1,3,5-triazine-2,4-diamine in which the amino groups at positions 2 and 4 are respectively carrying 2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl and 2-(propan-2-ylsulfonyl)phenyl substituents. It is a potent inhibitor of anaplastic lymphoma kinase (ALK), Ack and ROS1 activity (IC50 values are 3.5, 5.8 and 8.9 nM respectively) and exhibits anti-cancer properties.		2.5420aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor
entrectinib
entrectinib: inhibits TRK, ROS1, and ALK receptor tyrosine kinases; structure in first source. entrectinib : A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours.		2.520benzamides;
difluorobenzene;
indazoles;
N-methylpiperazine;
oxanes;
secondary amino compound;
secondary carboxamide		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
bix 01294
[no description available]		2.0810piperidines
pexidartinib
pexidartinib: inhibits both CSF1R and c-kit receptor tyrosine kinase; structure in first source. pexidartinib : A pyrrolopyridine that is 5-chloro-1H-pyrrolo[2,3-b]pyridine which is substituted by a [6-({[6-(trifluoromethyl)pyridin-3-yl]methyl}amino)pyridin-3-yl]methyl group at position 3. It is a potent multi-targeted receptor tyrosine kinase inhibitor of CSF-1R, KIT, and FLT3 (IC50 of 20 nM, 10 nM and 160 nM, respectively). Approved by the FDA for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT).		2.5320aminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cobicistat
[no description available]		9.32301,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas		P450 inhibitor
bms-790052
daclatasvir: an HCV NS5A inhibitor. daclatasvir : A member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C.		2.610biphenyls;
carbamate ester;
carboxamide;
imidazoles;
valine derivative		antiviral drug;
nonstructural protein 5A inhibitor
pf 3845
PF 3845: inhibits fatty acid amide hydrolase		2.0810piperidines
TAK-580
MLN 2480: brain-penetrant RAF dimer antagonist. TAK-580 : A 1,3-thiazolecarboxamide that is 2-[(1R)-1-aminoethyl]-1,3-thiazole-5-carboxylic acid in which the carboxy group undergoes formal condensation with the amino group of 5-chloro-4-(trifluoromethyl)pyridin-2-amine and in which the amino group undergoes formal condensation with the carboxy group of 6-amino-5-chloropyrimidine-4-carboxylic acid. It is a pan-RAF kinase inhibitor which is currently in clinical development for the treatment of radiographically recurrent or progressive low-grade glioma in children and young adults.		3.27501,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
gsk 2126458
omipalisib: inhibitor of mTOR protein. omipalisib : A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.		3.9530aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent
emd1214063
tepotinib: MET inhibitor		2.1510
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one
[no description available]		2.8930chromones
gsk 1838705a
[no description available]		2.0610organonitrogen compound;
organooxygen compound
ixazomib
ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.		2.9130benzamides;
boronic acids;
dichlorobenzene;
glycine derivative		antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor
fit-039
FIT-039: CDK9 inhibitor; structure in first source		3.9220
ldn 193189
LDN 193189: inhibits bone morphogenetic protein signaling		2.4920pyrimidines
ucph 101
2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile: structure in first source		2.610
pf 3758309
PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first source		3.140organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
gdc 0980
[no description available]		2.1510
3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid
3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid: an SHP2 inhibitor; structure in first source		2.110
azd2014
vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source		2.9330
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol: a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity; structure in first source		2.8930benzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
plx4032
[no description available]		3.5370aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol
[no description available]		2.0810biphenyls
a 967079
A 967079: a TRPA1 channel antagonist; structure in first source		2.0710
gsk 1363089
GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source		4.4660aromatic ether
arry-334543
ARRY-334543: an antagonist of ATP-binding cassette subfamily G member 2 (ABCG2); structure in first source		2.1510
kin-193
[no description available]		2.5220pyridopyrimidine
mk 2461
[no description available]		2.520
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
[no description available]		2.8930aryl sulfide;
thienopyrimidine
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
[no description available]		3.1640aryl sulfide;
thienopyrimidine
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine
[no description available]		2.8930aryl sulfide;
thienopyrimidine
bay 869766
[no description available]		2.8530
as 703026
[no description available]		2.5920pyridinecarboxamide
ddd 85646
DDD 85646: a trypanocidal agent for treating African sleeping sickness; structure in first source		3.1710
baricitinib
[no description available]		5.3880azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester
WYE-354: an mTOR inhibitor; structure in first source		2.0810carbamate ester
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine
[no description available]		2.8930quinazolines
KOM70144
KOM70144 : A benzamide that is GRL-0617 in which one of the hydrogen's of the primary amino group is replaced by an acetyl group. It an inhibitor of SARS-CoV and SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 2.6 muM and 5.0 muM, respectively. It also inhibits SARS-CoV and SARS-CoV-2 infection of Vero E6 cells in vitro (EC50 values are 13.1 and 21 muM, respectively).		3.9220acetamides;
benzamides;
naphthalenes;
secondary carboxamide		anticoronaviral agent;
protease inhibitor
piperidines
Piperidines: A family of hexahydropyridines.		9.85213
pht 427
4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide: an antineoplastic agent; structure in first source		2.4620
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
ML-265: a small molecule activator of PKM2		3.0740organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
e-52862
[no description available]		2.610
ly2811376
[no description available]		2.610
thymosin
Thymosin: Thymosin. A family of heat-stable, polypeptide hormones secreted by the thymus gland. Their biological activities include lymphocytopoiesis, restoration of immunological competence and enhancement of expression of T-cell characteristics and function. They have therapeutic potential in patients having primary or secondary immunodeficiency diseases, cancer or diseases related to aging.		7.0510
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		4.8671
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide
[no description available]		2.8930hydroxyquinoline
p505-15
[no description available]		2.8930
dabrafenib
[no description available]		2.59201,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
mrt67307
MRT67307: IKK (IκB(inhibitor of NF-κB (nuclear factor κB)) kinase) family inhibitor; structure in first source		3.1440aromatic amine
anagliptin
anagliptin: anagliptin hydrochloride salt is the active compound		2.610amino acid amide
pki 587
gedatolisib: inhibits both phosphatidylinositol 3-kinase and mTOR; structure in first source		2.1510
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline
[no description available]		2.0810benzenes;
sulfonamide
cp 466722
[no description available]		2.0810quinazolines
gardiquimod
[no description available]		2.610
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide: a protein kinase inhibitor; structure in first source		2.4110
CAY10626
[no description available]		2.0810ureas
grazoprevir
grazoprevir: has antiviral activity; component of Zepatier. grazoprevir : An azamacrocyclic compound that is a hepatitis C protease inhibitor used in combination with elbasvir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.		2.610aromatic ether;
azamacrocycle;
carbamate ester;
cyclopropanes;
lactam;
N-sulfonylcarboxamide;
quinoxaline derivative		antiviral drug;
hepatitis C protease inhibitor;
hepatoprotective agent
n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
merestinib: in phase I clinical trials (2013); structure in first source		2.1510
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide
[no description available]		2.8930piperazines
thiopental sodium
[no description available]		2.0810organochlorine compound;
piperazines;
pyrimidines		antineoplastic agent;
tyrosine kinase inhibitor
ribociclib
ribociclib: inhibits both CDK4 and CDK6		3.140
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone
[no description available]		2.8930aromatic ketone;
thienopyrimidine
abt-450
paritaprevir: inhibits HCV NS3 protease. paritaprevir : An azamacrocycle which is used which is in combination with dasabuvir sodium hydrate, ombitasvir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2.610
letermovir
letermovir: has antiviral activity; structure in first source		2.610
mk-8033
1-(3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide: inhibits both Ron and c-Met kinases; structure in first source		2.1510
sofosbuvir
Sofosbuvir: A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.. sofosbuvir : A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.		2.9830isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine
sapanisertib: an mTOR inhibitor		2.610benzoxazole
3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol
3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol: inhibits ALK2 protein; structure in first source		2.110
blz 945
[no description available]		2.610
pha 793887
[no description available]		3.2550piperidinecarboxamide
azd3839
AZD3839: a BACE1 inhibitor; structure in first source		2.610
abt-348
ilorasertib: an antineoplastic agent and protein kinase inhibitor; structure in first source		2.0610
ly2784544
[no description available]		2.8220pyridazines
gsk 2334470
GSK 2334470: a PDK1 inhibitor; structure in first source		2.2110indazoles
sb 1518
[no description available]		2.6320
abemaciclib
[no description available]		5.1440
pf 3084014
nirogacestat: an antineoplastic agent. nirogacestat : A member of the class of imidazoles that is 1H-imidazole substituted by a 1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl group at position 1 and a {N-[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-L-norvalyl}amino group at position 4. It is a gamma-secretase inhibitor whose hydrobromide salt is indicated for adult patients with progressing desmoid tumours who require systemic treatment.		2.610
unc 0638
UNC 0638: inhibits lysine methyltransferases G9a and GLP; structure in first source		2.610quinazolines
mk-8776
[no description available]		2.1510
gs-9620
[no description available]		2.610
nvp-bsk805
[no description available]		2.0810
ml228 probe
ML228 probe: structure in first source. ML228 : A member of the class of 1,2,4-triazines in which the triazine ring is substituted at positions 3, 5, and 6 by pyridin-2-yl, ([biphenyl]-4-ylmethyl)amin, and methyl groups, respectively. It is an activator of the hypoxia inducible factor (HIF) pathway.		2.89301,2,4-triazines;
biphenyls;
pyridines;
secondary amino compound		hypoxia-inducible factor pathway activator
afuresertib
[no description available]		2.1510amphetamines
xmd 8-92
XMD8-92 : A dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a [2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino substituent. It is an inhibitor of the BMK1 kinase pathway.		2.0810pyrimidobenzodiazepineprotein kinase inhibitor
hh-gv678
flumatinib: an antineoplastic agent and tyrosine kinase inhibitor		3.5110
n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide
N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide: structure in first source		2.610
pf-03882845
[no description available]		2.8930
bms 708163
BMS 708163: structure in first source		2.610oxadiazole;
ring assembly
arry-371797
ARRY-371797: a p38 MAP kinase inhibitor		3.5110
gsk 1070916
GSK 1070916: an antineoplastic agent with aurora B/C kinase inhibitory activity		2.1510pyrazoles;
ring assembly
N-[(1R)-2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide
[no description available]		3.4110aromatic amide;
furans
jq1 compound
[no description available]		3.4460carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
rn486
RN486: a selective Bruton's tyrosine kinase inhibitor		3.1710
jnj38877605
[no description available]		2.5220quinolines
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide
[no description available]		2.0810benzothiazoles
dinaciclib
[no description available]		4.8240pyrazolopyrimidine
pf-04620110
PF-04620110: a DGAT1 inhibitor; structure in first source		2.8930
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone: a USP7 inhibitor; structure in first source		2.610
gsk525762a
molibresib: mimicks acetylated histones; structure in first source		3.1640benzodiazepine
gilteritinib
gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor. gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.		4.0630aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
alectinib
[no description available]		4.2740aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ML240
ML240 : A member of the class of quinazolines that is quinazoline which is substituted at positions 2, 5 and 8 by 2-amino-1H-benzimidazol-1-yl, benzylnitrilo and methoxy groups, respectively. It is a ATP-competetive inhibitor of AAA ATPase p97, also known as valosin-containing protein (VCP).		2.610aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound		antineoplastic agent
glpg0634
[no description available]		2.6320
birinapant
birinapant: a Smac mimetic with antineoplastic activity		2.7220dipeptide
torin 1
torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.		3.0740N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines		antineoplastic agent;
mTOR inhibitor
ly2886721
[no description available]		2.610
nms-p118
NMS-P118: a PARP-1 inhibitor; structure in first source		2.610
abt-199
venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.		7.33112aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
ly2940680
[no description available]		2.0810
tubastatin a
[no description available]		2.610hydroxamic acid;
pyridoindole;
tertiary amino compound		EC 3.5.1.98 (histone deacetylase) inhibitor
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea
[no description available]		3.0740ureas
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide
[no description available]		2.8930(trifluoromethyl)benzenes
pracinostat
pracinostat : A hydroxamic acid that is N-hydroxyacrylamide which is substituted at position 3 by a 2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl group (the E isomer). An orally available pan-histone deacetylase inhibitor with demonstrated activity in the treatment of advanced solid tumours.		2.610benzimidazole;
hydroxamic acid;
olefinic compound;
tertiary amino compound		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
ro 4929097
[no description available]		2.0810dibenzoazepine;
dicarboxylic acid diamide;
lactam;
organofluorine compound		EC 3.4.23.46 (memapsin 2) inhibitor
ncgc00242364
NCGC00242364: structure in first source		2.8930quinazolines
gsk4112
GSK4112: a Rev-erbalpha agonist; structure in first source		2.0810
delgocitinib
delgocitinib: a Janus kinase inhibitor. delgocitinib : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan.		2.4110azaspiro compound;
N-acylazetidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound;
tertiary carboxamide		anti-inflammatory drug;
antipsoriatic;
antiseborrheic;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
encorafenib
encorafenib: a BRAF inhibitor		2.1510
bms-911543
N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide: has antineoplastic activity; structure in first source		2.5220
spautin-1
[no description available]		2.610
azd4547
[no description available]		3.0540benzamides;
N-arylpiperazine;
pyrazoles		fibroblast growth factor receptor antagonist
gsk2141795
GSK2141795: an Akt inhibitor with antineoplastic activity; structure in first source		2.1510
torin 2
torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.		2.0810aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline		antineoplastic agent;
mTOR inhibitor
pf-4708671
[no description available]		2.0810
ldn 57444
LDN 57444: inhibitor of ubiquitin C-terminal hydrolase-L1; structure in first source		2.610
gsk1210151a
GSK1210151A: inhibitor of the BET family of proteins; structure in first source		3.1640imidazoquinoline
i-bet726
[no description available]		2.610
azd8186
[no description available]		2.1510
hs-173
[no description available]		2.8930
sr1664
[no description available]		2.8930indolecarboxamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide: inhibits phosphopantetheinyl transferase; structure in first source		2.8930
natriuretic peptide, brain
Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.		2.1710polypeptide
acy-1215
ricolinostat: an HDAC6 inhibitor; structure in first source		3.9220pyrimidinecarboxylic acid
incb039110
INCB039110: a JAK1 inhibitor; structure in first source		2.4110
chir 98014
[no description available]		2.4110aminopyrimidine;
C-nitro compound;
diaminopyridine;
dichlorobenzene;
imidazoles;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
hypoglycemic agent;
tau aggregation inhibitor;
Wnt signalling activator
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide
[no description available]		2.8330benzamides;
N-acylpiperidine
N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
[no description available]		2.5920aminoquinoline
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide : A member of the class of quinazolines that is quinazoline substituted by {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino and 3-(2-methoxyacetamido)prop-1-en-1-yl groups at positions 4 and 6, respectively.		2.0810aromatic ether;
methylpyridines;
olefinic compound;
quinazolines;
secondary amino compound;
secondary carboxamide;
toluenes
belinostat
[no description available]		2.0810olefinic compound
cudc-907
[no description available]		3.1640
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		3.9230ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
raltegravir
[no description available]		3.61201,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		3.6620carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		3.6120
oxytetracycline, anhydrous
Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.		3.2310
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		3.2310
methacycline
Methacycline: A broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.. methacycline : A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.		2.2110
dicumarol
Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.		2.0710hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
piroxicam
[no description available]		3.8730benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
roquinimex
roquinimex: structure in first source		2.0810aromatic amide
lfm a13
LFM-A13 : An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties.		3.5520aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		4.13401,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
mobiflex
tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.		2.0810heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
isoxicam
isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.		2.0810benzothiazine;
isoxazoles;
monocarboxylic acid amide		antirheumatic drug;
non-steroidal anti-inflammatory drug
ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate
ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate: RN & structure given in first source		2.0810carboxylic acid;
pyrroline
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		9.7280benzenes;
hydroxycoumarin;
methyl ketone
demeclocycline
Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.		3.2310
tipranavir
tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.		3.9530sulfonamideantiviral drug;
HIV protease inhibitor
tasquinimod
tasquinimod: a lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer; structure in first source		3.6620
methacycline monohydrochloride
[no description available]		2.5920
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid
[no description available]		2.8930quinolines
minocycline hydrochloride
[no description available]		2.0810
tigecycline
[no description available]		3.6120
lornoxicam
lornoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.		2.0810heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
a 769662
[no description available]		2.0810biphenyls
gsk1265744
[no description available]		2.610difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide		HIV-1 integrase inhibitor
s 1 (combination)
S 1 (combination): consists of tegafur, 5-chloro-2,4-dihydroxyuridine & potassium oxonate; an inhibitor of fluorouracil(5-FU) degradation; prolongs the blood 5-FU level as well as increases selective toxicity to tumor; used for the treatment of colon cancer		2.110
palinurin
palinurin: an NSAID with antibacterial activity; isolated from Ircinia species; structure in firs t source		2.4820
abt-267
ombitasvir: inhibits HCV NS5A protein, component of Viekirax. ombitasvir : A dipeptide derivative which is used which is in combination with dasabuvir sodium hydrate, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2.610aromatic amide;
carbamate ester;
dipeptide;
pyrrolidines		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor
abt-333
dasabuvir: an antiviral agent. dasabuvir : A member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2.610aromatic ether;
naphthalenes;
pyrimidone;
sulfonamide		antiviral drug;
nonnucleoside hepatitis C virus polymerase inhibitor
agi-5198
AGI-5198: inhibits isocitrate dehydrogenase 1; structure in first source		2.8930
byl719
[no description available]		2.1510proline derivative
rgfp966
[no description available]		2.610
rg2833
RG2833: a histone deacetylase inhibitor; structure in first source		2.610
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		2.4720
pf 3512676
ProMune: an anticancer adjuvant and immunostimulant		2.0810
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		3.6380
cep-32496
agerafenib: inhibitor of RAF family kinases; structure in first source		3.2750
pi-1840
PI-1840: has both antineoplastic and proteasome inhibitory activities; structure in first source		2.610
epz004777
[no description available]		2.8930N-glycosyl compound
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid
[no description available]		2.8930organonitrogen heterocyclic compound
LimKi 3
LIMKi3: LIMK inhibitor. LimKi 3 : A member of the class of pyrazoles that is 1-(2,6-dichlorophenyl)-1H-pyrazole which is substituted by a difluoromethyl group at position 3 and by a 2-(isobutyrylamino)-1,3-thiazol-5-yl group at position 5. It is a a potent cell-permeable inhibitor of LIM kinase 1 and 2.		2.57201,3-thiazoles;
dichlorobenzene;
organofluorine compound;
pyrazoles;
secondary carboxamide		LIM kinase inhibitor
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone
[no description available]		2.0810pyrroles
okadaic acid
Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.		7.4110ketal
rociletinib
rociletinib: inhibits epidermal growth factor receptor tyrosine kinase activity; structure in first source		2.1510
entecavir
[no description available]		2.8930benzamides;
N-acylpiperidine
2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole
[no description available]		2.0810dipyrrins
ceritinib
ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.		2.5820aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
acy-738
[no description available]		2.610
pelabresib
CPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source		2.610monochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide		antineoplastic agent;
bromodomain-containing protein 4 inhibitor
N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide
[no description available]		2.0810tryptamines
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione
[no description available]		2.0810pyrazines
gsk837149a
GSK837149A: structure in first source		2.0810
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
[no description available]		2.0810quinazolines
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
[no description available]		2.0810quinazolines
wnt-c59
2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamide: a PORCN acyltransferase inhibitor; structure in first source		2.0810
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime
[no description available]		2.0810indanes
gs-5806
presatovir: a respiratory syncytial virus entry inhibitor		2.610
cc214-2
CC214-2: an mTOR kinase inhibitor; structure in first source		2.1310
azd1208
[no description available]		2.1510
doravirine
[no description available]		2.610
gkt137831
setanaxib: NOX4/NOX1 inhibitor; a pyrazolopyridine dione derivative		2.8930
vx-509
[no description available]		3.140
vx-970
berzosertib: an ATR kinase inhibitor		4.4550sulfonamide
gs-9973
[no description available]		2.8930
ldn-212854
[no description available]		2.110
amg 925
AMG-925 : An organic heterotricyclic compound that is 9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine which is substituted by a [6-(hydroxyacetyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]nitrilo group at position 2 and by a trans-4-methylcyclohexyl group at position 9. It is a FLT3 and CDK4 dual kinase inhibitor that has antineoplastic activity. Currently under clinical investigation in patients with relapsed or refractory acute myeloid leukemia (AML).		2.8930
gn6958
GN6958: inhibits SUMO-sentrin specific protease 1 (SENP1); structure in first source		2.610
debio 1347
CH5183284: a fibroblast growth factor receptor antagonist; structure in first source		2.1510
gne-618
GNE-618: inhibits nicotinamide phosphoribosyl transferase; structure in first source		2.8930
vx-787
pimodivir: non‐nucleotide inhibitor of the polymerase basic protein 2 (PB2) subunit of the influenza A that is active against H1N1, H7N9 and H5N1, as well as influenza A strains with reduced susceptibility to NAIs		2.610
ledipasvir
ledipasvir : A benzimidazole derivative that is used in combination with sofosbuvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.		2.610azaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound		antiviral drug;
hepatitis C protease inhibitor
gs-5816
velpatasvir: an NS5A inhibitor used for treating hepatitis C infections. velpatasvir : A complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes.		2.610carbamate ester;
ether;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heteropentacyclic compound;
ring assembly		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor
g007-lk
G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source		3.1640
frax486
[no description available]		2.4110
volitinib
[no description available]		3.140
ML355
ML355: 12-Lipoxygenase inhibitor. ML355 : A sulfonamide resulting from the formal condensation of the amino group of 2-aminobenzothiazole with the sulfo group of 4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonic acid. It is an inhibitor of 12-lipoxygenase, being developed by Veralox Therapeutics for the treatment of heparin-induced thrombocytopenia and thrombosis.		2.8930benzothiazoles;
monomethoxybenzene;
phenols;
secondary amino compound;
substituted aniline;
sulfonamide		EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
platelet aggregation inhibitor
acp-196
acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity. acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.		2.8930aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gsk343
GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).		2.8930aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
agi-6780
AGI-6780: inhibits isocitrate dehydrogenases 1 and 2; structure in first source		2.8930
khs101
KHS101: a small molecule accelerates neuronal differentiation in the adult rat		2.8930
4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide
4-((1-butyl-3-phenylureido)methyl)-N-hydroxybenzamide: inhibits HDAC6; structure in first source		2.610
selinexor
selinexor: inhibits karyopherin XPO1		2.610
verdinexor
verdinexor: a selective inhibitor of nuclear export		2.610
osimertinib
osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.		4.9950acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
cb-839
[no description available]		3.1640
ivosidenib
ivosidenib: an inhibitor of isocitrate dehydrogenase 1 (IDH1) for treatment of acute myeloid leukemia (AML). ivosidenib : A tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation.		3.4110cyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
mk-8742
elbasvir: inhibits NS5A protein of hepatitis C virus. elbasvir : A complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.		2.610carbamate ester;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heterotetracyclic compound;
ring assembly		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor;
hepatoprotective agent
atglistatin
atglistatin: inhibits adipose triglyceride lipase; structure in first source. atglistatin : A biphenyl that is 1,1'-biphenyl substituted by (dimethylcarbamoyl)amino and dimethylamino groups at positions 3 and 4', respectively. It is a potent inhibitor of adipose triglyceride lipase activity (IC50 = 700nM).		2.610
gsk-j4
GSK-J4: a JMJD3 inhibitor; structure in first source		2.8930organonitrogen heterocyclic compound
pf-06463922
lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein. lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.		2.8220aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
pf-06424439
PF-06424439: an inhibitor of diacylglycerol acyltransferase 2; structure in first source		2.8930
etp-46464
ETP-46464: inhibits ATM and Rad3-related kinase; structure in first source		2.8930
xen445
[no description available]		2.610
DDR1-IN-1
DDR1-IN-1 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzoic acid with the amino group of 5-(5-amino-2-methylphenoxy)-1,3-dihydro-2H-indol-2-one. It is a potent inhibitor of discoidin domain receptor tyrosine kinase 1 and 2 (DDR1/2) with IC50 = 105 nM and 413 nM, respectively.		3.2110(trifluoromethyl)benzenes;
aromatic ether;
benzamides;
N-alkylpiperazine;
oxindoles;
secondary carboxamide		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
imetelstat
[no description available]		3.1310
santacruzamate a
santacruzamate A: HDAC2 inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.; structure in first source		2.610organonitrogen compound;
organooxygen compound
cyclin d1
Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.		2.7630
onc201
TIC10 compound: a TRAIL-dependent antitumor agent; structure in first source		2.8930
kai407
KAI407: an antimalarial; structure in first source		2.8930
fertinex
[no description available]		3.2310
ldc4297
LDC4297: a CDK7 inhibitor with antineoplastic activity; structure in first source. LDC4297 : A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity.		2.920aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound		antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source		2.8930
ap20187
AP20187: a nontoxic, cell-permeable analog, a wholly synthesized, cell-permeable dimeric FK506 derivative. AP20187 : A tertiary amino compound that is 2-(aminomethyl)-N,N-dimethylpropane-1,3-diamine in which the primary ammino groups have each been acylated by condensation with the carboxy group of 2-{3-[(1R)-3-(3,4-dimethoxyphenyl)-1-hydroxypropyl]phenoxy}acetic acid, the hydroxy groups of which have been esterified by condensation with the carboxy group of L-pipecolic acid, the nitrogen of which has been acylated by condensation with (2S)-2-(3,4,5-trimethoxyphenyl)butyric acid. It is a synthetic, cell-permeable ligand that can be used to induce homodimerization of fusion proteins containing the DmrB domain.		2.2110aromatic ether;
carboxylic ester;
N-acylpiperidine;
tertiary amino compound		ligand
hg-9-91-01
HG-9-91-01: inhibits salt-inducible kinases; structure in first source. HG-9-91-01 : A member of the class of phenylureas that is a potent inhibitor of salt-inducible kinase 2, a potential target protein for therapy in ovarian cancer.		2.110aminopyrimidine;
dimethoxybenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas;
secondary amino compound		antineoplastic agent;
salt-inducible kinase 2 inhibitor
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor		2.5120
nitrophenols
Nitrophenols: PHENOLS carrying nitro group substituents.		2.520
enasidenib
[no description available]		3.16401,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
oicr-9429
OICR-9429: antineoplastic; structure in first source		2.8930
lly-507
LLY-507: inhibits methyltransferase SMYD2; structure in first source. LLY-507 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-cyano-2'-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}[biphenyl]-3-carboxylic acid with the amino group of 3-(pyrrolidin-1-yl)propan-1-amine. It is a potent and selective inhibitor of SMYD2 and inhibits the ability of SMYD2 to methylate p53. It serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.		2.8930
unipr129
UniPR129: an antiangiogenic agent that disrupts the interaction between EphA2 and ephrin-A1; structure in first source		2.1110
epoetin alfa
Epoetin Alfa: A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients.		2.0610
s 8932
[no description available]		3.9220aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine		anticoronaviral agent;
antiviral drug;
prodrug
transforming growth factor alpha
Transforming Growth Factor alpha: An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.		3.4611
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		5.9571
lactoferrin
Lactoferrin: An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.		2.2110
myelin oligodendrocyte glycoprotein (35-55)
[no description available]		2.1110
exudates
Malaysia: A parliamentary democracy with a constitutional monarch in southeast Asia, consisting of 11 states (West Malaysia) on the Malay Peninsula and two states (East Malaysia) on the island of BORNEO. It is also called the Federation of Malaysia. Its capital is Kuala Lumpur. Before 1963 it was the Union of Malaya. It reorganized in 1948 as the Federation of Malaya, becoming independent from British Malaya in 1957 and becoming Malaysia in 1963 as a federation of Malaya, Sabah, Sarawak, and Singapore (which seceded in 1965). The form Malay- probably derives from the Tamil malay, mountain, with reference to its geography. (From Webster's New Geographical Dictionary, 1988, p715 & Room, Brewer's Dictionary of Names, 1992, p329)		2.4110
at 9283
[no description available]		4.5860
otssp167
OTS167: inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity		2.5920
akt-i-1,2 compound
Akt-I-1,2 compound: an aminopeptidase P inhibitor; structure in first source		3.1510
entecavir
entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.		3.95302-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
chir 258
[no description available]		6.1790
r 1530
[no description available]		2.0610
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		4.3502-aminopurines;
oxopurine		antimetabolite;
antiviral drug
osi 027
OSI 027: inhibits both mTORC1 and mTORC2; structure in first source		2.5220
nu 1025
NU 1064: structure in first source		2.610phenols;
quinazolines		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
levoleucovorin
Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.		2.15105-formyltetrahydrofolic acidantineoplastic agent;
metabolite
guanine
[no description available]		3.57202-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
hypoxanthine
[no description available]		2.8930nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite
folic acid
folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.		3.930folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		4.6740cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		4.6170benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		11.0681dacarbazine
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		3.9530purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ganciclovir
[no description available]		5.41602-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
valtrex
[no description available]		2.0810organic molecular entity
valacyclovir
Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.		3.7320L-valyl esterantiviral drug
sildenafil
sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.		3.930piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
olanzapine
Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.		3.8830benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
penciclovir
penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.		2.6102-aminopurines;
propane-1,3-diols		antiviral drug
raltitrexed
[no description available]		2.0810N-acyl-amino acid
vardenafil
vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.		3.2310imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		3.930nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
hli 373
[no description available]		2.0810
citrovorum factor
[no description available]		3.6120tetrahydrofolic acid
leucovorin
5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.		3.620formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
rifapentine
rifapentine: cyclopentyl derivative of rifampicin		3.6120N-alkylpiperazine;
N-iminopiperazine;
rifamycins		antitubercular agent;
leprostatic drug
4-hydroxyquinazoline
4-oxo-3,4-dihydroquinazoline: structure in first source		2.610quinazolines
bl 4162a
anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.		3.6420imidazoquinazolineanticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor
tegaserod
tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source		3.7320carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
norclozapine
norclozapine: structure given in first source. N-desmethylclozapine : A dibenzodoazepine substituted with chloro and piperazino groups which is a major metabolite of clozapine; a potent and selective 5-HT2C serotonin receptor antagonist.		2.610dibenzodiazepine;
organochlorine compound;
piperazines		delta-opioid receptor agonist;
metabolite;
serotonergic antagonist
pemetrexed
pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).		9.9860N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
1-hydroxyphenazine
1-hydroxyphenazine: a virulence factor of Pseudomonas aeruginosa. 1-hydroxyphenazine : A phenazine carrying a hydroxy substituent at the 1-position.		2.8930phenazines
sildenafil citrate
Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.		3.3460citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
valganciclovir
Valganciclovir: A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor.. valganciclovir : The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.		3.2310L-valyl ester;
purines		antiviral drug;
prodrug
aprepitant
Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.		4.1540(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
fosaprepitant
fosaprepitant: a pro-drug form of aprepitant. fosaprepitant : A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.		3.2310(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles		antiemetic;
neurokinin-1 receptor antagonist;
prodrug
tegaserod maleate
[no description available]		2.0810maleate saltserotonergic agonist
hymenialdisine
[no description available]		2.0310
rifabutin
[no description available]		3.6120
azilsartan
azilsartan: an angiotensin type 1 receptor blocker; receptor blocker. azilsartan : A benzimidazolecarboxylic acid that is benzimidazole-7-carboxylic acid substituted at position 2 by a methoxy group and at position 1 by a 2'-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl group. Used (as the prodrug, azilsartan medoxomil) for treatment of hypertension.		2.6101,2,4-oxadiazole;
aromatic ether;
benzimidazolecarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent
isogranulatimide
isogranulatimide: G2 checkpoint inhibitor; structure in first source		2.0310
xav939
XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source. XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.		2.0810(trifluoromethyl)benzenes;
thiopyranopyrimidine		tankyrase inhibitor
ag-879
AG-879: structure given in first source		3.9220
2-carboxyarabinitol 1-phosphate
[no description available]		2.0810
hesperadin
[no description available]		2.920
trypan blue
Trypan Blue: A diazo-naphthalene sulfonate that is widely used as a stain.. trypan blue : An organosulfonate salt that is the tetrasodium salt of 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonic acid).		2.0210
ro 24-7429
Ro 24-7429: blocks the action of the HIV tat protein; an analog of Ro 5-3335; Proc Natl Acad Sci U S A 1993 Jul 15;90(14):6395-9		2.8930benzodiazepine
nintedanib
nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.		5.06110
6-bromoindirubin-3'-acetoxime
6-bromoindirubin-3'-acetoxime: a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, protects cells from varicella infection		2.610
bms 536924
BMS 536924: inhibits insulin-like growth factor I receptor kinase; structure in first source		2.0810
amg531
[no description available]		4.1320
debromohymenialdisine
[no description available]		2.0310
carbadox
Carbadox: An antibacterial agent that has been used in veterinary practice for treating swine dysentery and enteritis and for promoting growth. However, its use has been prohibited in the UK following reports of carcinogenicity and mutagenicity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p125)		2.0710quinoxaline derivative
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide
[no description available]		3.1640catechols;
hydrazide;
hydrazone;
naphthols		EC 3.6.5.5 (dynamin GTPase) inhibitor
ver 52296
luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.		3.0740aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols		angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor
levomefolate calcium
levomefolate calcium: an ingredient in Contraceptives, Oral, Combined. levomefolate calcium : An organic calcium salt of (6S)-5-methyltetrahydrofolic acid.		3.2310organic calcium saltantidepressant
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile: structure in first source. AZD1080 : A member of the class of hydroxyindoles that is 1H-indole substituted by hydroxy, 5-(morpholin-4-ylmethyl)pyridin-2-yl, and cyano groups at positions 2, 3 and 5, respectively. It is a potent, brain permeable inhibitor of human GSK3alpha and GSK3beta with Ki of 6.9 nM and 31 nM, respectively. The drug was being developed by AstraZeneca for the treatment of Alzheimer's disease (clinical trial now discontinued).		2.520hydroxyindoles;
morpholines;
nitrile;
pyridines;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
tau aggregation inhibitor
sb-590885
N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine : A ketoxime that is the oxime of indan-1-one in which the hydrogen at position 5 has been replaced by an imidazol-5-yl group which has itself been substituted at positions 2 and 4 by p-[2-(dimethylamino)ethoxy]phenyl and pyridin-4-yl groups, respectively.		2.0810aromatic ether;
imidazoles;
ketoxime;
pyridines;
tertiary amino compound
XL413
XL413 : A benzofuropyrimidine that is 3,4-dihydro[1]benzofuro[3,2-d]pyrimidine substituted by (2S)-pyrrolidin-2-yl, oxo and chloro groups at positions 2, 4, and 8, respectively. It is a potent ATP competitive inhibitor of Cdc7 kinase (IC50 = 3.4 nM) and exhibits anticancer properties.		2.610benzofuropyrimidine;
organochlorine compound;
pyrrolidines		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
rvx 208
apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation		2.8930
bmn 673
talazoparib: inhibits both PARP1 and PARP2; structure in first source		2.8930
pf-477736
PF 00477736: a Chk1 inhibitor; structure in first source. PF-00477736 : A diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1).		2.8330
bay 80-6946
copanlisib: an antineoplastic agent with PI3K inhibitory activity; structure in first source. copanlisib : An imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies.		2.1510
pp242
torkinib : A member of the class of pyrazolopyrimidines that is 1H-pyrazolo[3,4-d]pyrimidine substituted by isopropyl, 5-hydroxyindol-2-yl and amino groups at positions 1, 3 and 4 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.		2.7830aromatic amine;
biaryl;
hydroxyindoles;
phenols;
primary amino compound;
pyrazolopyrimidine		antineoplastic agent;
mTOR inhibitor
me0328
ME0328: inhibits ARTD3; structure in first source		2.610
fenobam
fenobam: in USAN fenobam refers to monohydrate		2.4820ureas
cyanine dye 3
cyanine dye 3: structures of Cy3 derivatives given in first source		2.2510
nvp-tnks656
[no description available]		2.610
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-cyclohexyl-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-alaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.53 muM).		3.4110aldehyde;
indolecarboxamide;
oligopeptide;
pyrrolidin-2-ones;
secondary carboxamide		anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
molnupiravir
molnupiravir: prodrug that’s metabolized into N4-hydroxycytidine (NHC), a ribonucleoside analog. molnupiravir : A nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19.		3.4110isopropyl ester;
ketoxime;
nucleoside analogue		anticoronaviral agent;
antiviral drug;
prodrug
3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide
3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-fluoro-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.72 muM).		3.4110aldehyde;
indolecarboxamide;
monofluorobenzenes;
oligopeptide;
pyrrolidin-2-ones;
secondary carboxamide		anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		3.8190
phenanthrenes
Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.		2.2110
ConditionIndicatedRelationship StrengthStudiesTrials
Granulocytic Leukemia, Chronic
[description not available]		026.231,202162
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		128.231,202162
Benign Neoplasms
[description not available]		014.34798
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		120.5723724
Chronic Illness
[description not available]		07.78241
Adjuvant Arthritis
[description not available]		02.4920
Innate Inflammatory Response
[description not available]		08.01370
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		07.78241
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		08.01370
Leukemia, Myelogenous, Aggressive Phase
[description not available]		09.3163
Breast Cancer
[description not available]		010.976611
Breast Neoplasms
Tumors or cancer of the human BREAST.		116.7219833
Acute Liver Injury, Drug-Induced
[description not available]		05.5100
Adverse Drug Event
[description not available]		011.61179
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		05.5100
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		011.61179
B-Cell Leukemia
[description not available]		03.9640
Angiogenesis, Pathologic
[description not available]		03.94120
Torsade de Pointes
[description not available]		02.0810
Fibrodysplasia Ossificans Progressiva
[description not available]		02.110
Myositis Ossificans
A disease characterized by bony deposits or the ossification of muscle tissue.		02.110
Chickungunya Fever
[description not available]		03.0110
Break-Bone Fever
[description not available]		04.1930
Encephalitis, West Nile Fever
[description not available]		03.0110
Dengue
An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. SEVERE DENGUE is a more virulent form of dengue.		04.1930
West Nile Fever
A mosquito-borne viral illness caused by the WEST NILE VIRUS, a FLAVIVIRUS and endemic to regions of Africa, Asia, and Europe. Common clinical features include HEADACHE; FEVER; maculopapular rash; gastrointestinal symptoms; and lymphadenopathy. MENINGITIS; ENCEPHALITIS; and MYELITIS may also occur. The disease may occasionally be fatal or leave survivors with residual neurologic deficits. (From Joynt, Clinical Neurology, 1996, Ch26, p13; Lancet 1998 Sep 5;352(9130):767-71)		03.0110
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		15.1850
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
[description not available]		02.8330
Hepatitis C
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.		02.8330
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		04.57210
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		04.57210
Experimental Neoplasms
[description not available]		03.7690
Leucocythaemia
[description not available]		08.98271
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		110.98271
Infections, Staphylococcal
[description not available]		02.1510
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.1510
Cancer of Ovary
[description not available]		07.57183
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		19.57183
Carcinoma, Non-Small Cell Lung
[description not available]		010.85417
Cancer of Lung
[description not available]		012.67511
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		112.85417
Lung Neoplasms
Tumors or cancer of the LUNG.		114.67511
Acute Myelogenous Leukemia
[description not available]		014.386613
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		116.386613
Blast Phase
[description not available]		015.998023
Blast Crisis
An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.		015.998023
Lung Injury, Acute
[description not available]		02.1710
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		02.1710
Carcinoma, Epidermoid
[description not available]		010.47383
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		114.95766
Experimental Mammary Neoplasms
[description not available]		03.570
2019 Novel Coronavirus Disease
[description not available]		05.6890
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		012.19855
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Viral Diseases
[description not available]		03.7420
Virus Diseases
A general term for diseases caused by viruses.		03.7420
Acute Promyelocytic Leukemia
[description not available]		03.4220
Leukemia, Promyelocytic, Acute
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.		03.4220
Degenerative Diseases, Central Nervous System
[description not available]		04.0140
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		04.0140
Amyloid Neuropathy Type 1
[description not available]		02.3110
Amyloid Neuropathies, Familial
Inherited disorders of the peripheral nervous system associated with the deposition of AMYLOID in nerve tissue. The different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin (PREALBUMIN); APOLIPOPROTEIN A-I; and GELSOLIN.		02.3110
Tauopathies
Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.		08.0254
Cancer of Pancreas
[description not available]		07.8322
Carcinoma, Ductal, Pancreatic
[description not available]		05.34111
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		19.8322
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.		05.34111
Pleural Effusion
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.		014.86829
Degenerative Disc Disease
[description not available]		02.6620
Cirrhosis
[description not available]		05.89120
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		114.69270
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		05.89120
Intervertebral Disc Degeneration
Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.		07.6620
Myofibromatosis
A condition characterized by multiple formations of myofibromas (LEIOMYOMA).		02.4110
Acute Lymphoid Leukemia
[description not available]		019.8422944
Ph 1 Chromosome
[description not available]		016.9713613
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		126.21687132
Pulmonary Hypertension
[description not available]		09.41451
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.		09.41451
Recrudescence
[description not available]		014.866228
Acute Disease
Disease having a short and relatively severe course.		08.22211
Blood Clot
[description not available]		013.944036
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		013.944036
Granulocytic Leukemia, Chronic, Stable Phase
[description not available]		019.7717570
Hepatocellular Carcinoma
[description not available]		04.94300
Cancer of Liver
[description not available]		07.39361
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		16.94300
Liver Neoplasms
Tumors or cancer of the LIVER.		07.39361
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.		06.0681
Malignant Melanoma
[description not available]		014.56264
Cancer of Skin
[description not available]		07.94161
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		115.397812
Skin Neoplasms
Tumors or cancer of the SKIN.		07.94161
Graft-Versus-Host Disease
[description not available]		011.65181
Graft vs Host Disease
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.		06.65181
Chylopericardium
[description not available]		05.1190
Pericardial Effusion
Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.		05.1190
Bacteremia
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.		02.4110
HIV Coinfection
[description not available]		04.86110
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		04.86110
Brain Stem Neoplasms, Primary
[description not available]		06.8783
Local Neoplasm Recurrence
[description not available]		012.883817
Brain Stem Neoplasms
Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.		06.8783
Leukemia, Pre-B-Cell
[description not available]		05.1140
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.		05.1140
Diabetes Mellitus, Adult-Onset
[description not available]		03.3960
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		03.3960
Cancer of Prostate
[description not available]		012.6334
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		117.24668
Bone Diseases
Diseases of BONES.		02.5420
Aseptic Meningitis
[description not available]		07.5720
Paraneoplastic Syndromes
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.		02.3110
Chromosomal Translocation
[description not available]		08.28380
Meningitis, Aseptic
A syndrome characterized by headache, neck stiffness, low grade fever, and CSF lymphocytic pleocytosis in the absence of an acute bacterial pathogen. Viral meningitis is the most frequent cause although MYCOPLASMA INFECTIONS; RICKETTSIA INFECTIONS; diagnostic or therapeutic procedures; NEOPLASTIC PROCESSES; septic perimeningeal foci; and other conditions may result in this syndrome. (From Adams et al., Principles of Neurology, 6th ed, p745)		02.5720
Aseptic Necrosis of Bone
[description not available]		05.1631
Osteonecrosis
Death of a bone or part of a bone, either atraumatic or posttraumatic.		05.1631
Congenital Limb Deformities
[description not available]		02.4110
Acro-Osteolysis
A condition with congenital and acquired forms causing recurrent ulcers in the fingers and toes. The congenital form exhibits autosomal dominant inheritance; the acquired form is found in workers who handle VINYL CHLORIDE. When acro-osteolysis is accompanied by generalized OSTEOPOROSIS and skull deformations, it is called HAJDU-CHENEY SYNDROME.		02.4110
Hutchinson Gilford Progeria Syndrome
[description not available]		02.4110
Abnormalities, Skin
[description not available]		02.4110
Progeria
An abnormal congenital condition, associated with defects in the LAMIN TYPE A gene, which is characterized by premature aging in children, where all the changes of cell senescence occur. It is manifested by premature graying; hair loss; hearing loss (DEAFNESS); cataracts (CATARACT); ARTHRITIS; OSTEOPOROSIS; DIABETES MELLITUS; atrophy of subcutaneous fat; skeletal hypoplasia; elevated urinary HYALURONIC ACID; and accelerated ATHEROSCLEROSIS. Many affected individuals develop malignant tumors, especially SARCOMA.		02.4110
Skin Abnormalities
Congenital structural abnormalities of the skin.		02.4110
Cirrhosis, Liver
[description not available]		02.7220
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		02.7220
Cytomegalic Inclusion Disease
[description not available]		03.7390
Hematochezia
The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.		011.19111
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		05.34190
Cytomegalovirus Infections
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.		03.7390
Enterocolitis
Inflammation of the MUCOSA of both the SMALL INTESTINE and the LARGE INTESTINE. Etiology includes ISCHEMIA, infections, allergic, and immune responses.		07.5420
Gastrointestinal Hemorrhage
Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.		06.19111
Cardiovascular Stroke
[description not available]		03.0130
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		03.0130
Heritable Pulmonary Arterial Hypertension
[description not available]		05.19100
Familial Primary Pulmonary Hypertension
Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.		05.19100
Urogenital Prolapse
[description not available]		02.4110
Pelvic Organ Prolapse
Abnormal descent of a pelvic organ resulting in the protrusion of the organ beyond its normal anatomical confines. Symptoms often include vaginal discomfort, DYSPAREUNIA; URINARY STRESS INCONTINENCE; and FECAL INCONTINENCE.		02.4110
Anasarca
[description not available]		06.9452
Exanthem
[description not available]		04.840
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		06.9452
Exanthema
Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.		04.840
Acute Confusional Senile Dementia
[description not available]		09.73125
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		111.73125
Cardiac Toxicity
[description not available]		05.1380
Cardiotoxicity
Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.		05.1380
Debility
[description not available]		02.4110
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		09.350
Leukemia, Lymphoblastic, Acute, T Cell
[description not available]		05.71160
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.		05.71160
Bone Fractures
[description not available]		02.6620
Fractures, Bone
Breaks in bones.		02.6620
Infections, Soft Tissue
[description not available]		02.4110
Soft Tissue Infections
Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688)		07.4110
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		015.484836
Hospital-Acquired Condition
[description not available]		02.5320
Bleeding
[description not available]		03.7390
Hemorrhage
Bleeding or escape of blood from a vessel.		03.7390
B-Cell Chronic Lymphocytic Leukemia
[description not available]		014.03293
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.		111.03293
Anoxemia
[description not available]		05.0481
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		05.0481
Colitis Gravis
[description not available]		03.1840
Colitis, Granulomatous
[description not available]		02.610
Colitis, Ulcerative
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.		03.1840
Crohn Disease
A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.		02.610
Carcinoma, Squamous Cell of Head and Neck
[description not available]		07.57171
Cancer of Head
[description not available]		09.35282
Cancer of Mouth
[description not available]		03.1140
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		07.57171
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		111.35282
Mouth Neoplasms
Tumors or cancer of the MOUTH.		03.1140
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		04.5170
Achlorhydria
A lack of HYDROCHLORIC ACID in GASTRIC JUICE despite stimulation of gastric secretion.		04.2131
Epithelial Ovarian Cancer
[description not available]		09.4741
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		04.4741
Benign Neoplasms, Brain
[description not available]		010.17214
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		112.17214
Focal Segmental Glomerulosclerosis
[description not available]		07.7620
Glomerulosclerosis, Focal Segmental
A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.		02.7620
Nephrotic Syndrome
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.		04.7190
Insulin Sensitivity
[description not available]		09.3360
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		04.3360
Acute Lung Injury, Transfusion-Related
[description not available]		02.4110
Acute Hemolytic Transfusion Reaction
[description not available]		03.1340
Transfusion Reaction
Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.		03.1340
EBV Infections
[description not available]		04.1940
Diffuse Large B-Cell Lymphoma
[description not available]		05.0550
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.		17.0550
Epstein-Barr Virus Infections
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).		04.1940
Adenopathy
[description not available]		04.2550
Acute Hepatic Failure
[description not available]		02.6120
Acute Yellow Atrophy
[description not available]		02.4110
Hepatitis
INFLAMMATION of the LIVER.		07.4110
Liver Failure, Acute
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.		02.6120
Congenital Myotonic Dystrophy
[description not available]		02.4110
Myotonic Dystrophy
Neuromuscular disorder characterized by PROGRESSIVE MUSCULAR ATROPHY; MYOTONIA, and various multisystem atrophies. Mild INTELLECTUAL DISABILITY may also occur. Abnormal TRINUCLEOTIDE REPEAT EXPANSION in the 3' UNTRANSLATED REGIONS of DMPK PROTEIN gene is associated with Myotonic Dystrophy 1. DNA REPEAT EXPANSION of zinc finger protein-9 gene intron is associated with Myotonic Dystrophy 2.		02.4110
Lymphoma, Primary Effusion
A rare neoplasm of large B-cells usually presenting as serious effusions without detectable tumor masses. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. It is associated with HUMAN HERPESVIRUS 8, most often occurring in the setting of immunodeficiency.		03.2140
Germinoblastoma
[description not available]		04.1450
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		16.1450
Lymphocytosis
Excess of normal lymphocytes in the blood or in any effusion.		07.87151
Epithelial Neoplasms
[description not available]		04.2131
Fatty Liver, Nonalcoholic
[description not available]		03.450
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		03.450
Cardiac Remodeling, Ventricular
[description not available]		02.4110
Astrocytoma, Grade IV
[description not available]		09.93303
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		111.93303
Allergic Reaction
[description not available]		02.610
Atopic Hypersensitivity
[description not available]		02.6120
Hypersensitivity
Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.		02.610
Brill-Symmers Disease
[description not available]		03.0430
Hyperplasia
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.		04.1650
Lymphoma, Follicular
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.		15.0430
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		09.2130
Cardiac Failure
[description not available]		03.4160
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		08.4160
Cancer of Stomach
[description not available]		05.02130
Stomach Neoplasms
Tumors or cancer of the STOMACH.		05.02130
Mycosis Fungoides
A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.		19.610
Cholangiocellular Carcinoma
[description not available]		05.11120
Bile Duct Cancer
[description not available]		05.05110
Bile Duct Neoplasms
Tumors or cancer of the BILE DUCTS.		05.05110
Hepatoblastoma
A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)		04.0290
Cholangiocarcinoma
A malignant tumor arising from the epithelium of the BILE DUCTS.		112.11120
Chylothorax
The presence of chyle in the thoracic cavity. (Dorland, 27th ed)		06.69150
Cytokine Release Syndrome
A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.		03.4550
Skin Ulcer
An ULCER of the skin and underlying tissues.		07.4110
Ulcer
A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.		02.7930
Minimal Disease, Residual
[description not available]		010.74233
Keratoacanthoma
A benign, non-neoplastic, usually self-limiting epithelial lesion closely resembling squamous cell carcinoma clinically and histopathologically. It occurs in solitary, multiple, and eruptive forms. The solitary and multiple forms occur on sunlight exposed areas and are identical histologically; they affect primarily white males. The eruptive form usually involves both sexes and appears as a generalized papular eruption.		08.4620
Neurilemoma
[description not available]		02.9830
Neurilemmoma
A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)		02.9830
Myelomonocytic Leukemia, Chronic
[description not available]		02.610
Leukemia, Myelomonocytic, Chronic
A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.		02.610
Asthma, Bronchial
[description not available]		02.9130
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		07.9130
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		08.01280
Cryptogenic Fibrosing Alveolitis
[description not available]		06.7232
Idiopathic Pulmonary Fibrosis
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.		113.7232
Allodynia
[description not available]		02.610
Ache
[description not available]		02.6620
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		07.6620
Proliferative Vitreoretinopathy
[description not available]		03.140
Vitreoretinopathy, Proliferative
Vitreoretinal membrane shrinkage or contraction secondary to the proliferation of primarily retinal pigment epithelial cells and glial cells, particularly fibrous astrocytes, followed by membrane formation. The formation of fibrillar collagen and cellular proliferation appear to be the basis for the contractile properties of the epiretinal and vitreous membranes.		03.140
Angiitis
[description not available]		02.610
Vasculitis
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.		02.610
Colorectal Cancer
[description not available]		07.06152
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		19.06152
Cognitive Decline
[description not available]		02.610
Cognitive Dysfunction
Diminished or impaired mental and/or intellectual function.		02.610
Kaposi Sarcoma
[description not available]		02.610
Sarcoma, Kaposi
A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.		02.610
Keloid
A sharply elevated, irregularly shaped, progressively enlarging scar resulting from formation of excessive amounts of collagen in the dermis during connective tissue repair. It is differentiated from a hypertrophic scar (CICATRIX, HYPERTROPHIC) in that the former does not spread to surrounding tissues.		07.610
Eosinophilia, Tropical
[description not available]		0440
Eosinophilia
Abnormal increase of EOSINOPHILS in the blood, tissues or organs.		0940
Myeloproliferative Disorders
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.		06.94130
Short Bowel Syndrome
A malabsorption syndrome resulting from extensive operative resection of the SMALL INTESTINE, the absorptive region of the GASTROINTESTINAL TRACT.		07.610
African Lymphoma
[description not available]		03.2350
Burkitt Lymphoma
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.		110.2350
American Trypanosomiasis
[description not available]		02.610
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		02.610
Root Resorption
Resorption in which cementum or dentin is lost from the root of a tooth owing to cementoclastic or osteoclastic activity in conditions such as trauma of occlusion or neoplasms. (Dorland, 27th ed)		02.610
Chronic Insomnia
[description not available]		02.610
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		07.7220
Sleep Initiation and Maintenance Disorders
Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.		02.610
Albuminuria
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.		02.610
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		111.9742
Cancer of the Thyroid
[description not available]		04.6590
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		04.6590
Adenocarcinoma, Endometrioid
[description not available]		03.9911
Adenocarcinoma, Clear Cell
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)		04.0221
Carcinoma, Endometrioid
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.		03.9911
Granulocytic Leukemia
[description not available]		07.6111
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		19.6111
Acoustic Neurinoma, Bilateral
[description not available]		02.610
Neurofibromatosis 2
An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.		02.610
Edema, Pulmonary
[description not available]		02.610
Pulmonary Edema
Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.		02.610
Peripheral Nerve Injury
[description not available]		02.610
Nerve Pain
[description not available]		02.610
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		02.610
Peripheral Nerve Injuries
Injuries to the PERIPHERAL NERVES.		02.610
Alloxan Diabetes
[description not available]		02.6620
Thyroid Cancer, Anaplastic
[description not available]		02.610
Thyroid Carcinoma, Anaplastic
An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.		02.610
Anterior Optic Neuritis
[description not available]		02.7220
Optic Neuritis
Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).		07.7220
Choroid Neovascularization
[description not available]		07.6620
Itching
[description not available]		03.5210
Pruritus
An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.		03.5210
Enterocele
An intestinal HERNIA.		02.2510
Hernia
Protrusion of tissue, structure, or part of an organ through the bone, muscular tissue, or the membrane by which it is normally contained. Hernia may involve tissues such as the ABDOMINAL WALL or the respiratory DIAPHRAGM. Hernias may be internal, external, congenital, or acquired.		02.2510
T-Cell Lymphoma
[description not available]		09.2231
Lymphoma, T-Cell
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.		04.2231
Adenocarcinoma, Basal Cell
[description not available]		09.01193
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		09.01193
Edema-Proteinuria-Hypertension Gestosis
[description not available]		02.6620
Pre-Eclampsia
A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.		02.6620
Ewing Sarcoma
[description not available]		07.9940
Sarcoma, Ewing
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.		02.9940
Pleural Effusion, Malignant
Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.		05.362
Carcinoma, Small Cell Lung
[description not available]		03.8921
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		15.8921
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		06.24121
Pulmonary Arterial Hypertension
A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.		03.1740
Cancer of Testis
[description not available]		02.2110
Testicular Neoplasms
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.		02.2110
Thromboembolism
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.		02.2510
Invasiveness, Neoplasm
[description not available]		09.2441
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		02.5220
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		07.5220
Hypertriglyceridemia
A condition of elevated levels of TRIGLYCERIDES in the blood.		02.2110
Dilatation, Pathologic
The condition of an anatomical structure's being dilated beyond normal dimensions.		02.2510
Hemorrhage, Retinal
[description not available]		02.8330
Day Blindness
[description not available]		02.8330
Airflow Obstruction, Chronic
[description not available]		02.6120
Pulmonary Disease, Chronic Obstructive
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.		02.6120
Glaucoma, Suspect
[description not available]		02.2510
Ocular Hypertension
A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.		02.2510
Acute Kidney Failure
[description not available]		04.6150
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.		09.6150
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		010.1333
Stunted Growth
[description not available]		02.5220
Growth Disorders
Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.		02.5220
Endometrial Diseases
[description not available]		03.1710
Uterine Diseases
Pathological processes involving any part of the UTERUS.		03.1710
Chronic Kidney Failure
[description not available]		02.2510
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		02.2510
Angioimmunoblastic Lymphadenopathy
[description not available]		03.6411
Immunoblastic Lymphadenopathy
A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.		15.6411
Cardiac Diseases
[description not available]		06.2341
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		06.2341
Acoustic Neuroma
[description not available]		02.2510
Diathesis
[description not available]		02.6320
Enlarged Spleen
[description not available]		03.6930
Chronic Kidney Diseases
[description not available]		04.1950
Blood Pressure, High
[description not available]		04.4640
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		04.4640
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		16.1950
Bone Cancer
[description not available]		09.97185
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		09.97185
Glaucoma
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)		02.9330
Androgen-Independent Prostatic Cancer
[description not available]		09.57107
Prostatic Neoplasms, Castration-Resistant
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.		111.57107
B16 Melanoma
[description not available]		03.0240
Colon Cancer, Familial Nonpolyposis
[description not available]		02.2510
Cancer of the Thymus
[description not available]		02.4920
Colorectal Neoplasms, Hereditary Nonpolyposis
A group of autosomal-dominant inherited diseases in which COLON CANCER arises in discrete adenomas. Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. HNPCC has been associated with germline mutations in mismatch repair (MMR) genes. It has been subdivided into Lynch syndrome I or site-specific colonic cancer, and LYNCH SYNDROME II which includes extracolonic cancer.		02.2510
Thymus Neoplasms
Tumors or cancer of the THYMUS GLAND.		02.4920
Gastrointestinal Stromal Neoplasm
[description not available]		08.78153
Cancer of Gastrointestinal Tract
[description not available]		06.1352
Gastrointestinal Stromal Tumors
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).		110.78153
Biliary Tract Cancer
[description not available]		02.6920
Biliary Tract Neoplasms
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.		02.6920
Arteriosclerosis, Coronary
[description not available]		02.2510
Coronary Artery Disease
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.		02.2510
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		07.3953
Inflammatory Breast Cancer
[description not available]		02.2510
Inflammatory Breast Neoplasms
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.		02.2510
Diffuse Parenchymal Lung Disease
[description not available]		07.0961
Lung Diseases, Interstitial
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.		07.0961
Endotoxemia
A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.		02.2510
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		02.2510
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		06.4230
Neutrophilic Leukemia, Chronic
[description not available]		02.3110
Leukemia, Neutrophilic, Chronic
A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, EOSINOPHILIA, or basophilia is present, nor is there a PHILADELPHIA CHROMOSOME or bcr-abl fusion gene (GENES, ABL).		02.3110
Glial Cell Tumors
[description not available]		08134
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		110134
Nevoxanthoendothelioma
[description not available]		02.2510
Peripheral Nerve Diseases
[description not available]		02.6120
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		02.6120
HPV Infection
[description not available]		02.5920
Papillomavirus Infections
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.		02.5920
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		0340
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		0340
Lassitude
[description not available]		07.1754
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.		07.1754
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		08.3276
Duncan Disease
[description not available]		02.2510
Lymphoproliferative Disorders
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.		02.2510
Aggressive Natural Killer Cell Leukemia
[description not available]		04.4341
Leukemia, Large Granular Lymphocytic
A spectrum of disorders characterized by clonal expansions of the peripheral blood LYMPHOCYTE populations known as large granular lymphocytes which contain abundant cytoplasm and azurophilic granules. Subtypes develop from either CD3-negative NATURAL KILLER CELLS or CD3-positive T-CELLS. The clinical course of both subtypes can vary from spontaneous regression to progressive, malignant disease.		16.4341
Precordial Catch
[description not available]		02.4920
Breathlessness
[description not available]		03.0240
Chest Pain
Pressure, burning, or numbness in the chest.		02.4920
Dyspnea
Difficult or labored breathing.		03.0240
Sclerosis, Systemic
[description not available]		07.81101
Scleroderma, Systemic
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.		07.81101
Malignant Mesothelioma
[description not available]		04.2531
Benign Cerebellar Neoplasms
[description not available]		02.6320
Arachnoidal Cerebellar Sarcoma, Circumscribed
[description not available]		02.8630
Medulloblastoma
A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)		02.8630
Surgical Incision
[description not available]		02.2510
Injury, Ischemia-Reperfusion
[description not available]		02.2510
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		02.2510
Acute Edematous Pancreatitis
[description not available]		03.830
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		03.830
Blood Poisoning
[description not available]		02.8930
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.8930
Left Ventricular Dysfunction
[description not available]		02.8430
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		02.8430
B-Cell Lymphoma
[description not available]		04.1250
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		04.1250
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		07.11111
Injuries, Radiation
[description not available]		02.5820
Abnormalities, Multiple
Congenital abnormalities that affect more than one organ or body structure.		03.1710
Intraocular Pressure
The pressure of the fluids in the eye.		02.6320
Chloroma
[description not available]		03.0840
Aggressive Systemic Mastocytosis
A form of systemic mastocytosis in which patients have impaired organ functions due to multifocal infiltrates of pathological MAST CELLS in bone marrow, liver, spleen, gastrointestinal tract, or skeletal system. The cytomorphology shows a low to high grade.		07.53181
Sarcoma, Myeloid
An extramedullary tumor of immature MYELOID CELLS or MYELOBLASTS. Granulocytic sarcoma usually occurs with or follows the onset of ACUTE MYELOID LEUKEMIA.		03.0840
Mastocytosis, Systemic
A group of disorders caused by the abnormal proliferation of MAST CELLS in a variety of extracutaneous tissues including bone marrow, liver, spleen, lymph nodes, and gastrointestinal tract. Systemic mastocytosis is commonly seen in adults. These diseases are categorized on the basis of clinical features, pathologic findings, and prognosis.		19.53181
Skin Aging
The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.		02.3110
Injuries, Eye
[description not available]		02.3110
Eye Injuries
Damage or trauma inflicted to the eye by external means. The concept includes both surface injuries and intraocular injuries.		02.3110
Clostridioides difficile Infection
[description not available]		02.3110
Clostridium Infections
Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.		02.3110
Dermatitis Medicamentosa
[description not available]		05.66120
Cold Panniculitis
[description not available]		02.7730
Osteomyelitis
INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.		07.7220
Cells, Neoplasm Circulating
[description not available]		06.7254
Cancer of Endometrium
[description not available]		04.622
Endometrial Neoplasms
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.		16.622
Candida Infection
[description not available]		02.3110
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)		02.3110
Corneal Angiogenesis
[description not available]		02.3110
Corneal Neovascularization
New blood vessels originating from the corneal blood vessels and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION.		07.3110
Ureteral Obstruction
Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.		02.3110
Coronary Artery Stenosis
[description not available]		02.3110
Atherogenesis
[description not available]		02.5920
Coronary Stenosis
Narrowing or constriction of a coronary artery.		02.3110
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.5920
Cardiomyopathy, Hypertrophic Obstructive
[description not available]		02.4110
Cardio-Cutaneous Syndrome
[description not available]		02.4110
Cardiomyopathy, Hypertrophic
A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).		02.4110
Rheumatoid Arthritis
[description not available]		02.930
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.930
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.3110
Extravascular Hemolysis
[description not available]		02.3110
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.3110
Disease Exacerbation
[description not available]		016.977534
Liver Dysfunction
[description not available]		02.5920
Liver Diseases
Pathological processes of the LIVER.		02.5920
Acanthocytosis with Neurologic Disorder
[description not available]		02.7220
Adenocarcinoma Of Kidney
[description not available]		03.2350
Cancer of Kidney
[description not available]		02.7930
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		03.2350
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.7930
Pleurisy, Tuberculous
[description not available]		02.3110
Central Nervous System Tuberculosis
[description not available]		02.3110
Infections, Coronavirus
[description not available]		02.3110
Coronavirus Infections
Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).		02.3110
Acute Respiratory Distress Syndrome
[description not available]		02.5820
Respiratory Distress Syndrome
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.		02.5820
Anemia, Hypoplastic
[description not available]		02.4110
Pancytopenia
Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.		011.1432
Anemia, Aplastic
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.		02.4110
Infection Reactivation
[description not available]		02.3110
Cancer of Esophagus
[description not available]		03.0340
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		03.0340
Delayed Effects, Prenatal Exposure
[description not available]		02.3110
Cancer of the Uterus
[description not available]		02.5720
Uterine Neoplasms
Tumors or cancer of the UTERUS.		02.5720
MS (Multiple Sclerosis)
[description not available]		03.520
Idiopathic Parkinson Disease
[description not available]		03.2310
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)		08.520
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		03.2310
Metastase
[description not available]		016.873112
Cancer of the Vulva
[description not available]		04.4511
Cancer of the Vagina
[description not available]		04.4511
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		011.873112
Vaginal Neoplasms
Tumors or cancer of the VAGINA.		04.4511
Vulvar Neoplasms
Tumors or cancer of the VULVA.		04.4511
Tricuspid Incompetence
[description not available]		02.1510
Vascular Diseases
Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.		03.9940
Adrenal Gland Hypofunction
[description not available]		02.1510
Addison Disease and Cerebral Sclerosis
[description not available]		02.1510
Adrenal Insufficiency
Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.		02.1510
Adrenoleukodystrophy
An X-linked recessive disorder characterized by the accumulation of saturated very long chain fatty acids in the LYSOSOMES of ADRENAL CORTEX and the white matter of CENTRAL NERVOUS SYSTEM. This disease occurs almost exclusively in the males. Clinical features include the childhood onset of ATAXIA; NEUROBEHAVIORAL MANIFESTATIONS; HYPERPIGMENTATION; ADRENAL INSUFFICIENCY; SEIZURES; MUSCLE SPASTICITY; and DEMENTIA. The slowly progressive adult form is called adrenomyeloneuropathy. The defective gene ABCD1 is located at Xq28, and encodes the adrenoleukodystrophy protein (ATP-BINDING CASSETTE TRANSPORTERS).		02.1510
Ischemia
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.		02.1510
Liver Steatosis
[description not available]		02.1510
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		02.1510
Osteogenic Sarcoma
[description not available]		04.5651
Animal Mammary Carcinoma
[description not available]		02.8130
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		04.5651
Agnogenic Myeloid Metaplasia
[description not available]		04.2860
Primary Myelofibrosis
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.		09.2860
Hyperplasia, Reactive Lymphoid
[description not available]		02.1510
Lymphatic Diseases
Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.		02.5320
Histiocytic Sarcoma
Malignant neoplasms composed of MACROPHAGES or DENDRITIC CELLS. Most histiocytic sarcomas present as localized tumor masses without a leukemic phase. Though the biological behavior of these neoplasms resemble lymphomas, their cell lineage is histiocytic not lymphoid.		03.0640
Canine Diseases
[description not available]		03.3960
Alveolar Soft Part Sarcoma
[description not available]		08.9421
Sarcoma, Alveolar Soft Part
A variety of rare sarcoma having a reticulated fibrous stroma enclosing groups of sarcoma cells, which resemble epithelial cells and are enclosed in alveoli walled with connective tissue. It is a rare tumor, usually occurring between 15 and 35 years of age. It appears in the muscles of the extremities in adults and most commonly in the head and neck regions of children. Though slow-growing, it commonly metastasizes to the lungs, brain, bones, and lymph nodes. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1365)		03.9421
B Virus Infection
[description not available]		02.1510
Cancer, Second Primary
[description not available]		04.6390
Clinically Isolated CNS Demyelinating Syndrome
[description not available]		02.1710
Polyneuropathy, Acquired
[description not available]		02.1710
Demyelinating Diseases
Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.		02.1710
Polyneuropathies
Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.		02.1710
Dysmyelopoietic Syndromes
[description not available]		07.3361
Myelodysplastic Syndromes
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.		19.3361
Lymph Node Metastasis
[description not available]		02.7930
Hyperlipemia
[description not available]		02.1710
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		02.1710
Apoplexy
[description not available]		04.2631
CACH Syndrome
[description not available]		03.5311
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		09.2631
Chromosome Deletion
Actual loss of portion of a chromosome.		03.730
Genetic Predisposition
[description not available]		05.3141
Diseases in Twins
Disorders affecting TWINS, one or both, at any age.		02.5220
Abnormality, Heart
[description not available]		02.2110
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		03.4820
Heart Defects, Congenital
Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.		02.2110
Bisphosphonate Osteonecrosis
[description not available]		02.1710
Neovascularization, Optic Disc
[description not available]		02.5220
Retinal Neovascularization
Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.		02.5220
Atypical Chronic Myeloid Leukemia
[description not available]		04.5550
Hematologic Malignancies
[description not available]		012.9391
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.		07.9391
Mast-Cell Leukemia
[description not available]		02.4920
Leukemia, Mast-Cell
A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of		02.4920
Central Nervous System Neoplasm
[description not available]		08.97175
Neoplasms, Bone Marrow
[description not available]		02.1710
Central Nervous System Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.		110.97175
Bone Marrow Neoplasms
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.		02.1710
Embryopathies
[description not available]		03.0910
Neoplasms, Pleural
[description not available]		04.1631
Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)		17.74102
Desmoid
[description not available]		02.1710
Fibromatosis, Aggressive
A childhood counterpart of abdominal or extra-abdominal desmoid tumors, characterized by firm subcutaneous nodules that grow rapidly in any part of the body but do not metastasize. The adult form of abdominal fibromatosis is FIBROMATOSIS, ABDOMINAL. (Stedman, 25th ed)		02.1710
Acquired Autoimmune Hemolytic Anemia
[description not available]		03.0910
Anemia, Hemolytic, Autoimmune
Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.		03.0910
Experimental Hepatoma
[description not available]		02.8130
Latent Tuberculosis
The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.		03.0910
Hepatitis B Virus Infection
[description not available]		03.4620
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		05.551
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.		03.0910
Hepatitis B
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.		08.4620
Pneumonia
Infection of the lung often accompanied by inflammation.		05.551
Congenital Thrombotic Thrombocytopenic Purpura
[description not available]		02.1710
Purpura, Thrombotic Thrombocytopenic
An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.		02.1710
Sarcoma, Epithelioid
[description not available]		04.7661
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		04.7661
Lymphocytopenia
[description not available]		04.921
Benign Supratentorial Neoplasms
[description not available]		02.1710
Lymphopenia
Reduction in the number of lymphocytes.		04.921
Abnormal Karyotype
A variation from the normal set of chromosomes characteristic of a species.		02.8930
Abnormalities, Autosome
[description not available]		010.93215
Cancer, Radiation-Induced
[description not available]		02.1710
Eye Cancer, Retinoblastoma
[description not available]		02.1710
Multiple Primary Neoplasms
[description not available]		03.9240
Retinoblastoma
A malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. The tumor tends to occur in early childhood or infancy and may be present at birth. The majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. Histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. An abnormal pupil reflex (leukokoria); NYSTAGMUS, PATHOLOGIC; STRABISMUS; and visual loss represent common clinical characteristics of this condition. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2104)		02.1710
Heart Disease, Ischemic
[description not available]		02.1710
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		02.1710
Alveolitis, Fibrosing
[description not available]		04.2860
Pulmonary Fibrosis
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.		04.2860
Mandibular Diseases
Diseases involving the MANDIBLE.		03.0910
Cardiac Hypertrophy
Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.		07.1710
Cardiomegaly
Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.		02.1710
Juvenile Chronic Myelogenous Leukemia
[description not available]		02.830
Leukemia, Myelomonocytic, Juvenile
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.		02.830
Pulmonary Arterial Remodeling
[description not available]		02.5320
Complication, Postoperative
[description not available]		02.1710
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		02.1710
Astrocytosis
[description not available]		02.1710
Impaired Glucose Tolerance
[description not available]		02.1710
Compensatory Hyperinsulinemia
A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.		02.1710
Hyperinsulinism
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.		02.1710
Glucose Intolerance
A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.		02.1710
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.8130
Nerve Degeneration
Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.		02.1710
Ophthalmoplegia, Progressive Supranuclear
[description not available]		02.1710
Protein Aggregation, Pathological
A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.		02.1710
Atrophy
Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.		02.5220
Supranuclear Palsy, Progressive
A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)		02.1710
Amaurosis
[description not available]		02.1710
Hyphema
Bleeding in the anterior chamber of the eye.		07.1710
Blindness
The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.		07.1710
Infection
[description not available]		02.5220
Infections
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.		02.5220
Complications, Hematologic Pregnancy
[description not available]		02.1710
Complications, Neoplastic Pregnancy
[description not available]		05.1770
Coronary Artery Vasospasm
[description not available]		02.5920
Coronary Vasospasm
Spasm of the large- or medium-sized coronary arteries.		02.5920
Infections, Respiratory
[description not available]		02.5520
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		02.5520
Blood Diseases
[description not available]		08.1671
Orthopedic Disorders
[description not available]		03.1210
Hematologic Diseases
Disorders of the blood and blood forming tissues.		08.1671
Musculoskeletal Diseases
Diseases of the muscles and their associated ligaments and other connective tissue and of the bones and cartilage viewed collectively.		03.1210
Respiratory Tract Diseases
Diseases involving the RESPIRATORY SYSTEM.		03.1210
Kahler Disease
[description not available]		06.17111
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		18.17111
Acute Biphenotypic Leukemia
[description not available]		02.520
Leukemia, Biphenotypic, Acute
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.		02.520
MODS
[description not available]		02.5420
Multiple Organ Failure
A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.		02.5420
Chromosome Inversion
An aberration in which a chromosomal segment is deleted and reinserted in the same place but turned 180 degrees from its original orientation, so that the gene sequence for the segment is reversed with respect to that of the rest of the chromosome.		02.5220
Chromosomal Triplication
[description not available]		02.5220
Hyperoxia
An abnormal increase in the amount of oxygen in the tissues and organs.		02.5820
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		05.1231
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		17.1231
47,XX,+21
[description not available]		02.5820
Down Syndrome
A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)		07.5820
Polyarthritis
[description not available]		02.1710
Autoimmune Disease
[description not available]		03.6830
Arthritis
Acute or chronic inflammation of JOINTS.		07.1710
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.		03.6830
Congestive Ophthalmopathy
[description not available]		02.8330
Graves Ophthalmopathy
An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.		02.8330
ST Elevated Myocardial Infarction
[description not available]		02.2110
ST Elevation Myocardial Infarction
A clinical syndrome defined by MYOCARDIAL ISCHEMIA symptoms; persistent elevation in the ST segments of the ELECTROCARDIOGRAM; and release of BIOMARKERS of myocardial NECROSIS (e.g., elevated TROPONIN levels). ST segment elevation in the ECG is often used in determining the treatment protocol (see also NON-ST ELEVATION MYOCARDIAL INFARCTION).		02.2110
Actinic Keratosis
[description not available]		02.2110
Keratosis, Actinic
White or pink lesions on the arms, hands, face, or scalp that arise from sun-induced DNA DAMAGE to KERATINOCYTES in exposed areas. They are considered precursor lesions to superficial SQUAMOUS CELL CARCINOMA.		02.2110
Corridor Disease
[description not available]		02.2110
Pleural Diseases
Diseases involving the PLEURA.		07.6120
Carotid Artery Thrombosis
Blood clot formation in any part of the CAROTID ARTERIES. This may produce CAROTID STENOSIS or occlusion of the vessel, leading to TRANSIENT ISCHEMIC ATTACK; CEREBRAL INFARCTION; or AMAUROSIS FUGAX.		02.2110
Brain Hemorrhage, Cerebral
[description not available]		02.2110
Cerebral Ischemia
[description not available]		02.6120
Cerebral Hemorrhage
Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.		07.2110
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		02.6120
Auricular Fibrillation
[description not available]		02.2110
Atrial Fibrillation
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.		02.2110
DIPG Brain Tumors
[description not available]		02.6320
Diffuse Intrinsic Pontine Glioma
A rare, aggressive brain tumor that forms in the GLIAL CELLS in the PONS.		14.6320
Acute Febrile Neutrophilic Dermatosis
[description not available]		02.5720
Amyloid Deposits
[description not available]		02.5220
Angor Pectoris
[description not available]		02.5420
Diseases, Peripheral Vascular
[description not available]		02.5520
Angina Pectoris
The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.		02.5420
Peripheral Vascular Diseases
Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.		02.5520
Becker Muscular Dystrophy
[description not available]		02.5720
Muscular Dystrophy, Animal
MUSCULAR DYSTROPHY that occurs in VERTEBRATE animals.		02.5720
Muscular Dystrophy, Duchenne
An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)		02.5720
Allergy, Drug
[description not available]		02.2110
Delayed Hypersensitivity
[description not available]		02.2110
Drug Hypersensitivity
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.		02.2110
Demyelinative Myelitis
[description not available]		02.2110
Koch's Disease
[description not available]		02.2110
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		07.2110
Arrhythmia
[description not available]		02.2510
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		02.2510
Thyroiditis
Inflammatory diseases of the THYROID GLAND. Thyroiditis can be classified into acute (THYROIDITIS, SUPPURATIVE), subacute (granulomatous and lymphocytic), chronic fibrous (Riedel's), chronic lymphocytic (HASHIMOTO DISEASE), transient (POSTPARTUM THYROIDITIS), and other AUTOIMMUNE THYROIDITIS subtypes.		07.2510
De Quervain Thyroiditis
[description not available]		02.2510
Thyroiditis, Subacute
Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.		02.2510
Chronic Pancreatitis
[description not available]		07.2110
Pancreatitis, Chronic
INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.		02.2110
Libman-Sacks Disease
[description not available]		02.520
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.		02.520
Granuloma, Hodgkin
[description not available]		02.7930
Verruca
[description not available]		02.2110
Congenital Immunodeficiency Disease
[description not available]		02.2110
Primary Immunodeficiency Diseases
Genetic immunologic deficiency diseases and syndromes due to mutations in genes involved in IMMUNITY generally characterized by an increased susceptibility to infectious diseases. They are often associated with AUTOIMMUNE DISEASE manifestations.		02.2110
Hodgkin Disease
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.		14.7930
Warts
Benign epidermal proliferations or tumors; some are viral in origin.		02.2110
Cancer of Larynx
[description not available]		02.0810
Laryngeal Neoplasms
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.		02.0810
Cancer of Intestines
[description not available]		02.4820
Intestinal Neoplasms
Tumors or cancer of the INTESTINES.		02.4820
Erythremia
[description not available]		04.2660
Hemorrhagic Thrombocythemia
[description not available]		03.7130
Polycythemia Vera
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.		16.2660
Thrombocythemia, Essential
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.		03.7130
Incontinentia Pigmenti Achromians
[description not available]		0310
Synovioma
[description not available]		02.0810
Sarcoma, Synovial
A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)		02.0810
Sycosis
[description not available]		02.110
Folliculitis
Inflammation of follicles, primarily hair follicles.		02.110
Hair Diseases
Diseases affecting the orderly growth and persistence of hair.		02.4820
Bilateral Headache
[description not available]		04.3911
Emesis
[description not available]		04.3911
Headache
The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.		04.3911
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		05.3622
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		04.3911
Familial Nonmedullary Thyroid Cancer
[description not available]		02.110
Carcinoma, Anaplastic
[description not available]		05.48100
Carcinoma, Papillary
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)		02.110
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		05.48100
Germinoma
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)		08.4711
Thrombopenia
[description not available]		07.3392
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		07.3392
Chondrosarcoma
A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)		04.1631
Disease, Pulmonary
[description not available]		03.9440
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		03.420
Lung Diseases
Pathological processes involving any part of the LUNG.		03.9440
Abdominal Neoplasms
New abnormal growth of tissue in the ABDOMEN.		02.0810
Bone Loss, Osteoclastic
[description not available]		05.2941
Autosomal Chromosome Disorders
[description not available]		0310
Pemphigus Foliaceus
[description not available]		02.110
Pemphigus
Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.		07.110
Cardiac Cancer
[description not available]		02.110
Tuberculosis, Drug-Resistant
[description not available]		03.0410
Mast Cell Activation Disease
[description not available]		04.1830
Alastrim
[description not available]		03.0410
Mastocytosis
A rare neoplastic disorder characterized by a clonal proliferation of MAST CELLS, associated with KIT-D816 mutations, and accompanied by aberrant mast cell activation. The abnormal increase of MAST CELLS may occur in only the skin (MASTOCYTOSIS, CUTANEOUS), in extracutaneous tissues involving multiple organs (MASTOCYTOSIS, SYSTEMIC), or in solid tumors (MASTOCYTOMA).		04.1830
Smallpox
An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)		03.0410
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.		03.0410
Adenocarcinoma, Scirrhous
An adenocarcinoma with a hard (Greek skirrhos, hard) structure owing to the formation of dense connective tissue in the stroma. (From Dorland, 27th ed)		02.110
Pneumatosis Cystoides Intestinalis
A condition characterized by the presence of multiple gas-filled cysts in the intestinal wall, the submucosa and/or subserosa of the INTESTINE. The majority of the cysts are found in the JEJUNUM and the ILEUM.		02.110
Rhabdomyosarcoma 2
[description not available]		02.110
Rhabdomyosarcoma, Alveolar
A form of RHABDOMYOSARCOMA occurring mainly in adolescents and young adults, affecting muscles of the extremities, trunk, orbital region, etc. It is extremely malignant, metastasizing widely at an early stage. Few cures have been achieved and the prognosis is poor. Alveolar refers to its microscopic appearance simulating the cells of the respiratory alveolus. (Holland et al., Cancer Medicine, 3d ed, p2188)		02.110
Tumour Lysis Syndrome
[description not available]		02.110
Tumor Lysis Syndrome
A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.		07.110
Leukocytosis
A transient increase in the number of leukocytes in a body fluid.		04.1430
Cutaneous T-Cell Lymphoma
[description not available]		07.110
Lymphoma, T-Cell, Cutaneous
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.		02.110
P carinii Pneumonia
[description not available]		02.110
Pneumonia, Pneumocystis
A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.		02.110
Remission, Spontaneous
A spontaneous diminution or abatement of a disease over time, without formal treatment.		02.4920
Bone Marrow Diseases
Diseases involving the BONE MARROW.		02.4720
Hematoma, Subdural
Accumulation of blood in the SUBDURAL SPACE between the DURA MATER and the arachnoidal layer of the MENINGES. This condition primarily occurs over the surface of a CEREBRAL HEMISPHERE, but may develop in the spinal canal (HEMATOMA, SUBDURAL, SPINAL). Subdural hematoma can be classified as the acute or the chronic form, with immediate or delayed symptom onset, respectively. Symptoms may include loss of consciousness, severe HEADACHE, and deteriorating mental status.		02.1110
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.5220
Lung Adenocarcinoma
[description not available]		03.2250
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		03.2250
Bowel Diseases, Inflammatory
[description not available]		02.110
Inflammatory Bowel Diseases
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.		02.110
Agitation, Psychomotor
[description not available]		03.0110
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		010.0930
Psychomotor Agitation
A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.		03.0110
Acquired-Immune Deficiency Syndrome Dementia Complex
[description not available]		02.110
AIDS Dementia Complex
A neurologic condition associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME and characterized by impaired concentration and memory, slowness of hand movements, ATAXIA, incontinence, apathy, and gait difficulties associated with HIV-1 viral infection of the central nervous system. Pathologic examination of the brain reveals white matter rarefaction, perivascular infiltrates of lymphocytes, foamy macrophages, and multinucleated giant cells. (From Adams et al., Principles of Neurology, 6th ed, pp760-1; N Engl J Med, 1995 Apr 6;332(14):934-40)		02.110
Alveolar Proteinoses, Pulmonary
[description not available]		02.5220
Pulmonary Alveolar Proteinosis
A PULMONARY ALVEOLI-filling disease, characterized by dense phospholipoproteinaceous deposits in the alveoli, cough, and DYSPNEA. This disease is often related to, congenital or acquired, impaired processing of PULMONARY SURFACTANTS by alveolar macrophages, a process dependent on GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR.		02.5220
Carcinoma, Large Cell
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)		02.110
Spinal Neoplasms
New abnormal growth of tissue in the SPINE.		02.110
Neoplasms, Squamous Cell
Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.		02.7830
Cancer of Colon
[description not available]		03.3260
Colonic Neoplasms
Tumors or cancer of the COLON.		15.3260
Peritonitis, Tuberculous
A form of PERITONITIS seen in patients with TUBERCULOSIS, characterized by lesion either as a miliary form or as a pelvic mass on the peritoneal surfaces. Most patients have ASCITES, abdominal swelling, ABDOMINAL PAIN, and other systemic symptoms such as FEVER; WEIGHT LOSS; and ANEMIA.		02.1110
Brain Hemorrhage
[description not available]		02.1110
Intracranial Hemorrhages
Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.		02.1110
Age-Related Osteoporosis
[description not available]		02.1110
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		02.1110
Anaplastic Astrocytoma
[description not available]		02.1110
Anaplastic Ependymoma
[description not available]		02.1110
Astrocytoma
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)		02.1110
Ependymoma
Glioma derived from EPENDYMOGLIAL CELLS that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9)		02.1110
Antral Vascular Ectasia
[description not available]		07.1110
Allergic Encephalomyelitis
[description not available]		02.1110
Cancer of Oropharnyx
[description not available]		02.5120
Oropharyngeal Neoplasms
Tumors or cancer of the OROPHARYNX.		02.5120
Antidiuretic Hormone, Inappropriate Secretion
[description not available]		02.1310
Hyponatremia
Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)		02.1310
Inappropriate ADH Syndrome
A condition of HYPONATREMIA and renal salt loss attributed to overexpansion of BODY FLUIDS resulting from sustained release of ANTIDIURETIC HORMONES which stimulates renal resorption of water. It is characterized by normal KIDNEY function, high urine OSMOLALITY, low serum osmolality, and neurological dysfunction. Etiologies include ADH-producing neoplasms, injuries or diseases involving the HYPOTHALAMUS, the PITUITARY GLAND, and the LUNG. This syndrome can also be drug-induced.		02.1310
Leukostasis
Abnormal intravascular leukocyte aggregation and clumping often seen in leukemia patients. The brain and lungs are the two most commonly affected organs. This acute syndrome requires aggressive cytoreductive modalities including chemotherapy and/or leukophoresis. It is differentiated from LEUKEMIC INFILTRATION which is a neoplastic process where leukemic cells invade organs.		02.1110
Muscle Pain
[description not available]		02.1110
Myalgia
Painful sensation in the muscles.		02.1110
Age-Related Macular Degeneration
[description not available]		02.1110
Macular Degeneration
Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.		02.1110
Neoplasms, Bronchial
[description not available]		02.1110
Bronchial Neoplasms
Tumors or cancer of the BRONCHI.		02.1110
Nasopharyngeal Carcinoma
A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.		07.1110
Cancer of Nasopharynx
[description not available]		02.1110
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.		02.1110
Bladder Cancer
[description not available]		05.1231
Cancer of Muscle
[description not available]		04.8421
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		05.1231
Fibromatosis
[description not available]		03.0310
Angioma
A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.		03.0310
Papilloma, Squamous Cell
[description not available]		03.0310
Fibroma
A benign tumor of fibrous or fully developed connective tissue.		03.0310
Hemangioma
A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)		03.0310
Papilloma
A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)		03.0310
Inclusion Body Myopathy, Sporadic
[description not available]		02.1110
Myositis, Inclusion Body
Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)		02.1110
Facial Dermatoses
Skin diseases involving the FACE.		02.1310
Acneiform Eruptions
Visible efflorescent lesions of the skin caused by acne or resembling acne. (Dorland, 28th ed, p18, 575)		02.1310
Leukemic Infiltration
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.		04.2460
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
[description not available]		02.5220
Lymphoma, Mantle-Cell
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).		14.5220
FMR1-Related Primary Ovarian Insufficiency
[description not available]		02.1310
Primary Ovarian Insufficiency
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections. The most commonly known genetic cause is the expansion of a CGG repeat to 55 to 199 copies in the 5' untranslated region in the X-linked FMR1 gene.		02.1310
Adenocystic Carcinoma
[description not available]		03.5111
Cancer of Salivary Gland
[description not available]		03.5111
Carcinoma, Adenoid Cystic
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)		15.5111
Salivary Gland Neoplasms
Tumors or cancer of the SALIVARY GLANDS.		03.5111
Acute-Phase Reaction
An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma.		02.1310
Peripheral Arterial Diseases
[description not available]		02.1310
Peripheral Arterial Disease
Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.		07.1310
Leiomyosarcoma, Epithelioid
[description not available]		03.5111
Leiomyosarcoma
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)		03.5111
ALS - Amyotrophic Lateral Sclerosis
[description not available]		03.4220
Amyotrophic Lateral Sclerosis
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)		03.4220
Silicosis
A form of pneumoconiosis resulting from inhalation of dust containing crystalline form of SILICON DIOXIDE, usually in the form of quartz. Amorphous silica is relatively nontoxic.		07.1310
Weight Reduction
[description not available]		02.1310
Weight Loss
Decrease in existing BODY WEIGHT.		02.1310
Congenital Familial Lymphedema
[description not available]		02.1310
Morbid Obesity
[description not available]		02.1310
Lipedema
Disorder of adipose tissue characterized by symmetric and bilateral enlargement of the lower extremities due to abnormal deposition of SUBCUTANEOUS FAT often in obese women. It is associated with HEMATOMA, pain and may progress to secondary LYMPHEDEMA which is known as lipolymphedema.		02.1310
Lymphedema
Edema due to obstruction of lymph vessels or disorders of the lymph nodes.		07.1310
Obesity, Morbid
The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.		02.1310
Cancer of the Urinary Tract
[description not available]		02.4920
Elevated Cholesterol
[description not available]		03.420
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		03.420
Peritoneal Carcinomatosis
[description not available]		03.8921
Peritoneal Neoplasms
Tumors or cancer of the PERITONEUM.		15.8921
Airway Remodeling
The structural changes in the number, mass, size and/or composition of the airway tissues.		02.1310
Glucose Metabolic Disorder
[description not available]		03.0410
Diseases of Endocrine System
[description not available]		03.0410
Endocrine System Diseases
Pathological processes of the ENDOCRINE GLANDS, and diseases resulting from abnormal level of available HORMONES.		03.0410
Cancer of the Tongue
[description not available]		02.4920
Tongue Neoplasms
Tumors or cancer of the TONGUE.		02.4920
Sclerosis
A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve.		04.1631
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.		02.4920
Microsatellite Instability
The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.		02.1510
Diseases, Metabolic
[description not available]		03.0610
Metabolic Diseases
Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)		03.0610
Chordoma
A malignant tumor arising from the embryonic remains of the notochord. It is also called chordocarcinoma, chordoepithelioma, and notochordoma. (Dorland, 27th ed)		08.5311
Solitary Fibrous Tumors
Rare neoplasms of mesenchymal origin, usually benign, and most commonly involving the PLEURA (see SOLITARY FIBROUS TUMOR, PLEURAL). They also are found in extrapleural sites.		03.5311
Rhabdoid Tumor
A rare but highly lethal childhood tumor found almost exclusively in infants. Histopathologically, it resembles RHABDOMYOSARCOMA but the tumor cells are not of myogenic origin. Although it arises primarily in the kidney, it may be found in other parts of the body. The rhabdoid cytomorphology is believed to be the expression of a very primitive malignant cell. (From Holland et al., Cancer Medicine, 3d ed, p2210)		02.5320
Encephalopathy, Traumatic
[description not available]		02.1310
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.		02.1310
Brain Injuries, Traumatic
A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain.		02.1310
Bronchopulmonary Dysplasia
A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.		02.1510
Dysembryoma
[description not available]		02.1310
Teratoma
A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642)		02.1310
Diabetic Retinopathy
Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.		02.1510
Cough
A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.		02.4820
Cancer of Granulosa Cells
[description not available]		02.1510
Atypical Mycobacterial Infection, Disseminated
[description not available]		02.1510
Pulmonary Consumption
[description not available]		02.1510
Tuberculosis, Pulmonary
MYCOBACTERIUM infections of the lung.		02.1510
Leukemoid Reaction
A peripheral blood picture resembling that of leukemia or indistinguishable from it on the basis of morphologic appearance alone. (Dorland, 27th ed)		02.1510
Diseases of Immune System
[description not available]		03.3820
Immune System Diseases
Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.		03.3820
Anemia, Hemolytic, Acquired
[description not available]		02.9610
Purpura, Thrombopenic
[description not available]		02.9610
Anemia, Hemolytic
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).		02.9610
Purpura, Thrombocytopenic
Any form of purpura in which the PLATELET COUNT is decreased. Many forms are thought to be caused by immunological mechanisms.		02.9610
Endocarditis, Loeffler
[description not available]		02.4620
Hypereosinophilic Syndrome
A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.		02.4620
Di Guglielmo Disease
[description not available]		02.4420
Leukemia, Erythroblastic, Acute
A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.		02.4420
Ascites
Accumulation or retention of free fluid within the peritoneal cavity.		02.0510
Splenic Rupture
Rupture of the SPLEEN due to trauma or disease.		02.0510
Monosomy
The condition in which one chromosome of a pair is missing. In a normally diploid cell it is represented symbolically as 2N-1.		07.4620
Right Ventricular Dysfunction
[description not available]		02.4620
Jejunal Diseases
Pathological development in the JEJUNUM region of the SMALL INTESTINE.		02.0510
Hemorrhagic Diathesis
[description not available]		03.4311
Hemorrhagic Disorders
Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).		03.4311
Hormone-Dependent Neoplasms
[description not available]		03.3820
Pleurisy
INFLAMMATION of PLEURA, the lining of the LUNG. When PARIETAL PLEURA is involved, there is pleuritic CHEST PAIN.		02.0510
Hypomelanosis
[description not available]		02.4620
Hypopigmentation
A condition caused by a deficiency or a loss of melanin pigmentation in the epidermis, also known as hypomelanosis. Hypopigmentation can be localized or generalized, and may result from genetic defects, trauma, inflammation, or infections.		02.4620
Cholera Infantum
[description not available]		06.5232
Serositis
Inflammation of a serous membrane.		02.9610
Thrombocytopathy
[description not available]		02.0510
Blood Platelet Disorders
Disorders caused by abnormalities in platelet count or function.		02.0510
Cat Diseases
Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.		02.0510
Colicky Pain
[description not available]		02.0510
Abdominal Pain
Sensation of discomfort, distress, or agony in the abdominal region.		02.0510
Osteolysis
Dissolution of bone that particularly involves the removal or loss of calcium.		07.0510
Ear Diseases
Pathological processes of the ear, the hearing, and the equilibrium system of the body.		02.0510
Water-Electrolyte Imbalance
Disturbances in the body's WATER-ELECTROLYTE BALANCE.		02.9610
Experimental Leukemia
[description not available]		02.4520
Drug Withdrawal Symptoms
[description not available]		02.0510
Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.		02.0510
Genome Instability
[description not available]		02.4720
Colonic Diseases
Pathological processes in the COLON region of the large intestine (INTESTINE, LARGE).		02.0510
Anorectal Diseases
[description not available]		02.0510
Rectal Diseases
Pathological developments in the RECTUM region of the large intestine (INTESTINE, LARGE).		02.0510
Leukemia, Megakaryocytic
[description not available]		02.4520
Leukemia, Megakaryoblastic, Acute
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.		02.4520
Connective Tissue Disease, Mixed
[description not available]		02.0510
Adenoma, Basal Cell
[description not available]		02.0610
Adenoma
A benign epithelial tumor with a glandular organization.		02.0610
Benign Mastocytoma
[description not available]		02.7630
Fasting Hypoglycemia
HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.		02.0610
Hypoglycemia
A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.		02.0610
Neoplasms, Vascular
[description not available]		02.0510
Myxoid Liposarcoma
[description not available]		02.0510
Liposarcoma, Myxoid
A liposarcoma containing round mesenchymal cells and a myxoid extracellular matrix in stroma.		02.0510
Leukocytopenia
[description not available]		03.3820
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		03.3820
Thyroid Diseases
Pathological processes involving the THYROID GLAND.		02.0510
B-Cell Prolymphocytic Leukemia
[description not available]		02.0710
Leukemia, Prolymphocytic, B-Cell
A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.		02.0710
Breast Cancer, Male
[description not available]		03.4511
Breast Neoplasms, Male
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.		03.4511
Chromosomal Duplication
[description not available]		02.0610
Orbital Neoplasms
Neoplasms of the bony orbit and contents except the eyeball.		02.0610
Foreign-Body Granuloma
[description not available]		02.0710
Carcinoma, Colloid
[description not available]		02.0610
Adenocarcinoma, Mucinous
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)		02.0610
Anorexia
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.		03.4511
Preleukemia
Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.		02.0710
Dermatoses
[description not available]		04.7621
Skin Diseases
Diseases involving the DERMIS or EPIDERMIS.		04.7621
Mucositis, Oral
[description not available]		02.0710
Stomatitis
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.		02.0710
Cancer of Pituitary
[description not available]		02.0610
Pituitary Neoplasms
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.		02.0610
Anemia, Fanconi
[description not available]		02.0710
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.0710
Vitiligo
A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.		07.0710
Edema, Fetal
[description not available]		02.0710
Hypertrophy, Right Ventricular
Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.		02.0710
Adenocarcinoma, Papillary
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)		02.0710
Erythrocytosis
[description not available]		02.0710
Micrometastases, Neoplasm
[description not available]		02.0710
Nervous System Disorders
[description not available]		02.0710
Nervous System Diseases
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.		02.0710
Allergic Contact Dermatitis
[description not available]		07.0810
Dermatitis, Allergic Contact
A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.		02.0810
Barrett Epithelium
[description not available]		02.0810
Condition, Preneoplastic
[description not available]		02.0810
Barrett Esophagus
A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus.		02.0810
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		02.0810
Antibody Deficiency Syndrome
[description not available]		02.0810
DNA Virus Infections
Diseases caused by DNA VIRUSES.		02.0810
Immunologic Deficiency Syndromes
Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.		02.0810
Retinal Pigment Epithelial Detachment
[description not available]		02.0810
Retinal Detachment
Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).		02.0810
Carcinoma, Thymic
[description not available]		02.0310
Thymoma
A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)		07.0310
Anal Cancer
[description not available]		02.0310
Anus Neoplasms
Tumors or cancer of the ANAL CANAL.		02.0310
Enlarged Liver
[description not available]		02.9510
Basal Cell Cancer
[description not available]		02.0310
Infections, Parvoviridae
[description not available]		02.4420
Complications of Diabetes Mellitus
[description not available]		02.0410
ATLL
[description not available]		02.0410
Leukemia-Lymphoma, Adult T-Cell
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.		14.0410
Retinal Diseases
Diseases involving the RETINA.		02.0410
Adolescent Gynecomastia
[description not available]		02.0410
Gynecomastia
Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males.		07.0410